

UNCLASSIFIED

AD NUMBER: ADB148205

LIMITATION CHANGES

TO:

Approved for public release; distribution is unlimited.

FROM:

Distribution authorized to US Government agencies only; Proprietary Information and Test and Evaluation; 28 Jul 1988. Other requests shall be referred to Army Medical Research and Development Command, Fort Detrick, MD 21701-5012.

AUTHORITY

USAMRDC ltr dtd 28 Apr 1993

THIS PAGE IS UNCLASSIFIED

L2

AD-B148 205

RESEARCH IN DRUG DEVELOPMENT AGAINST VIRAL DISEASES
OF MILITARY IMPORTANCE (BIOLOGICAL TESTING)

Annual Report

W.M. Shannon, G. Arnett, A.D. Brazier,
E.A. Dulmage, M.G. Hollingshead, B. Roberts,
B.R. Toyer, L. Westbrook, and L.J. WilkoffDTIC
FLECTE
OCT 03 1990
S D

SRI-BIO-89-721-5975

December 15, 1988

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21701-5012

Contract No. DAMD17-86-C-6013

SOUTHERN RESEARCH INSTITUTE
2000 Ninth Avenue South
P. O. Box 55305
Birmingham, Alabama 35255-5305

Distribution authorized to U.S. Government agencies only; proprietary information and Test Evaluations, July 28, 1988. Other requests for this document must be referred to the Commander, U.S. Army Medical Research and Development Command (ATTN: SGRD-RMI-S) Fort Detrick, Frederick, Maryland 21701-5012.

90-10-02-052

REPORT DOCUMENTATION PAGE

1a. REPORT SECURITY CLASSIFICATION UNCLASSIFIED			1b. RESTRICTIVE MARKINGS		
2a. SECURITY CLASSIFICATION AUTHORITY			3. DISTRIBUTION/AVAILABILITY OF REPORT Distribution authorized to U.S. Gvt Agencies only; proprietary information & test evaluations July 28, 1988		
2b. DECLASSIFICATION/DOWNGRADING SCHEDULE			5. MONITORING ORGANIZATION REPORT NUMBER(S)		
4. PERFORMING ORGANIZATION REPORT NUMBER(S) SRI-BIO-89-721-5975			7a. NAME OF MONITORING ORGANIZATION		
6a. NAME OF PERFORMING ORGANIZATION Southern Research Insti.		6b. OFFICE SYMBOL (if applicable)	7b. ADDRESS (City, State, and ZIP Code)		
6c. ADDRESS (City, State, and ZIP Code) 2000 Ninth Avenue South P.O. Box 55305 Birmingham, AL 35255-5305		9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER Contract No. DAMD17-86-C-6013			
8a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Med. Research & Dev. Command		8b. OFFICE SYMBOL (if applicable) SGRDRME-S	10. SOURCE OF FUNDING NUMBERS		
8c. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012		PROGRAM ELEMENT NO. 603002A	PROJECT NO. 3M2-60002D807	TASK NO. AD	WORK UNIT ACCESSION NO. 056
11. TITLE (Include Security Classification) Research in Drug Development Against Viral Diseases of Military Importance (Biological Testing)					
12. PERSONAL AUTHOR(S) W.M. Shannon, G. Arnett, A.D. Brazier, M.G. Hollingshead, B. Roberts, B.R. Toyer and L. Westbrook					
13a. TYPE OF REPORT Annual Report		13b. TIME COVERED FROM 11/15/87 TO 11/4/88		14. DATE OF REPORT (Year, Month, Day) 15 December 1988	
15. PAGE COUNT 404					
16. SUPPLEMENTARY NOTATION					
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)		
FIELD	GROUP	SUB-GROUP	Antiviral Drugs In Vivo Exotic RNA viruses RA1 In Vitro		
06	13				
06	15				
19. ABSTRACT (Continue on reverse if necessary and identify by block number)					
The purpose of this program is to evaluate the efficacy of candidate antiviral compounds against a spectrum of viruses of military importance. This program involves (a) primary testing of chemical compounds and natural products for antiviral efficacy <i>in vitro</i> using CPE-inhibition and plaque-reduction assays, (b) primary testing of compounds for antiviral efficacy <i>in vivo</i> in animal model systems, and (c) secondary evaluation of the active candidate antiviral compounds. The target viruses for <i>in vitro</i> testing are Vaccinia Virus (VV), Adenovirus (AD2), Vesicular Stomatitis Virus (VSV), Punta Toro Virus (PT), Sandfly Fever Virus (SF), Yellow Fever Virus (YF), Venezuelan Equine Encephalomyelitis Virus (VEE), Japanese Encephalitis Virus (JE), Pichinde Virus (PIC), and Hantaan Virus (HTN). The current <i>in vivo</i> systems are Pichinde Virus infection of hamsters, Venezuelan Equine Encephalomyelitis Virus, Japanese Encephalitis Virus and Vaccinia Virus infections of mice. Over 2600 compounds have been received for <i>in vitro</i> evaluation and over 14,000 assays have been performed on this contract to date. Compounds have been identified in nearly all virus systems that have confirmed antiviral activity exceeding that of the various positive control					
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT ☐ UNCLASSIFIED/UNLIMITED ☒ SAME AS RPT. ☐ OTIC USERS			21. ABSTRACT SECURITY CLASSIFICATION		
22a. NAME OF RESPONSIBLE INDIVIDUAL Mary F. Bostian			22b. TELEPHONE (Include Area Code) 301-663-7325		22c. OFFICE SYMBOL SGRD-RMI-S

compounds (Ribavirin, Selenazole, and Ara-A). Many of these compounds represent potent and selective new antiviral agents. One compound (AVS-206), which showed broad-spectrum antiviral activity in the *in vitro* assays, has proven very effective in the *in vivo* treatment of hamsters infected with Pichinde Virus. This compound is as effective as Ribavirin in increasing survival following lethal virus challenge and it has the apparent advantage of being less toxic. In addition, four compounds have been identified with *in vivo* efficacy against JE virus challenge. These compounds include AVS 361, AVS 2811, AVS 2812 and AVS 2980. Four compounds (AVS 1985, AVS 1986, AVS 1987 and AVS 1988) were active against cutaneous VV lesions; however, they were ineffective in reducing mortality associated with intracranial VV challenge.

FOREWORD

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

In conducting the research described in this report, the investigators adhered to the "Guide for the Care and Use of Laboratory Animals", DHEW Publication No. (NIH) 86-23, Revised 1985.

In conducting the research described in this report, the investigators adhered to all safety, security, and biocontainment requirements specified in the contract, including all U.S. Public Health Service biosafety guidelines contained in "Biosafety in Microbiological and Biomedical Laboratories", DHHS Publication No. (CDC) 86-23 (March 1985).



Accession For	
NTIS CRA&I	☐
DTIC TAB	☒
Unannounced	☐
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
B-3	

TABLE OF CONTENTS

	Page
1. INTRODUCTION	7
2. CURRENT SCOPE OF WORK	10
2.1 Task 1: <i>In Vitro</i> Antiviral Evaluations	10
2.2 Task 2: <i>In Vivo</i> Antiviral Evaluations	11
2.3 Task 3: Secondary Evaluations	11
3. EXPERIMENTAL METHODS	11
3.1 Test Compounds	11
3.1.1 Receipt, Cataloging and Storage	11
3.1.2 Determination of Solubilities	11
3.1.3 Compound Preparation for Testing	12
3.2 <i>In Vitro</i> Antiviral Screening: DNA Viruses and Exotic RNA Viruses	12
3.2.1 Vaccinia Virus (VV)	15
3.2.2 Adenovirus Type 2 (AD2)	15
3.2.3 Vesicular Stomatitis Virus (VSV)	16
3.2.4 Punta Toro Virus (PT)	16
3.2.5 Sandfly Fever Virus (SF)	17
3.2.6 Pichinde Virus (PIC)	17
3.2.7 Venezuelan Equine Encephalomyelitis Virus (VEE)	18
3.2.8 Yellow Fever Virus (YF)	19
3.2.9 Japanese Encephalitis Virus (JE)	19
3.2.10 Hantaan Virus (HTN)	19
3.3 Assay Development	20
3.3.1 Vaccinia Virus (VV), Strain Lederle CA	20
3.3.2 Adenovirus Type 2 (AD2) Strain Adenoid 6	22
3.3.3 Exotic RNA Viruses (PT, VEE, YFV, JE, SF)	23
Pinchinde Virus (PIC) and Hantaan Virus (HTN)	24
Comparative Data - MTT vs. CPE-Inhibition Assay	26
3.4 Antiviral Evaluations <i>In Vivo</i>	30
3.4.1 Acute Toxicity Determinations	30
3.4.2 Pichinde Virus	30
3.4.3 Venezuelan Equine Encephalomyelitis Virus	31
3.4.4 Japanese Encephalitis Virus	32
3.4.5 Vaccinia Virus Intracranial Challenge	32
3.4.6 Vaccinia Virus Induced Tailpox Model	32
3.5 Data Analysis and Processing	33
4. RESULTS	33
4.1 Antiviral Screening <i>in Vitro</i> : DNA Viruses and Exotic RNA Viruses	33
4.1.1 Vaccinia Virus (VV)	33
4.1.2 Adenovirus Type 2 (AD2)	48
4.1.3 Vesicular Stomatitis Virus (VSV)	53
4.1.4 Punta Toro Virus (PT)	56
4.1.5 Sandfly Fever Virus (SF)	57
4.1.6 Pichinde Virus (PIC)	58
4.1.7 Venezuelan Equine Encephalomyelitis (VEE)	59
4.1.8 Yellow Fever Virus (YF)	60
4.1.9 Japanese Encephalitis Virus (JE)	61
4.1.10 Hantaan Virus (HTN)	63
4.2 Antiviral Evaluations <i>In Vivo</i>	64
4.2.1 Pichinde Virus in MHA Hamsters	65
4.2.2 Venezuelan Equine Encephalomyelitis Virus (VEE)	83

TABLE OF CONTENTS

	Page
4.2.3 Japanese Encephalitis Virus (JE) Challenge Model	90
Primary <i>In Vivo</i> Passage of <i>In Vitro</i> Virus Stock	90
Primary <i>In Vivo</i> Passage in C57Bl/6 Mice of <i>In Vivo</i> Virus Stock ..	90
Secondary <i>In Vivo</i> Passage	91
Preliminary Challenge Experiment	92
Confirmatory Challenge Experiment	94
Preparation of a Large Stock of Challenge Virus	94
<i>In Vivo</i> Titration of Challenge Virus Stocks	95
Titration of Challenge Prep 6 Virus Stock	97
Preparation of Challenge Prep 7 Virus Challenge Stock	97
Titration of Challenge Prep 7 Virus Stock	97
JE Virus Challenge of Older C57Bl/6 Mice	98
Antiviral Evaluations of AVS Compounds	99
Back Challenge of Surviving Mice Treated with AVS-361, AVS- 2563, AVS-2811 and AVS-2812	102
Evaluation of AVS-111 and AVS-257	104
Evaluation of AVS-360	106
Antiviral Testing of AVS-361, 2811, 2812, 2980 and 4113	107
4.2.4 Vaccinia Virus <i>In Vivo</i> Challenge	110
Model Development	110
Compound Evaluations Against Intracranial Vaccinia Virus Challenge	114
Compound Evaluations Against the Vaccinia Virus-Induced Tailpox Lesion Model	117
5. DISCUSSION	128
6. ACKNOWLEDGMENTS	131
7. LITERATURE CITED	131
APPENDICES	132

List of Tables

	Page
Table 1. <i>In Vitro</i> Antiviral Screening Models	14
Table 2. MTT Assay Vaccinia Virus in Vero Cells (Mean OD)	21
Table 3. MTT Assay Adenovirus (120 CCID ₅₀ /0.1 ml) in 293 Cells	23
Table 4. Primary <i>In Vitro</i> Antiviral Screen Target Viruses and Numbers of Compounds Tested Through November 14, 1988	34
Table 5. Compounds Most Active Against Vaccinia Virus	36
Table 6. Confirmatory Assays for Compounds Active Against Vaccinia Virus	43
Table 7. Plaque Reduction Assays for Compounds Active Against Vaccinia Virus	48
Table 8. Compounds Most Active Against Adenovirus Type 2	49
Table 9. Confirmatory Assays for Compounds Active Against Adenovirus Type 2	50
Table 10. Compounds Most Active Against Vesicular Stomatitis Virus	54
Table 11. Confirmatory Assays for Compounds Active Against Vesicular Stomatitis Virus	55
Table 12. Plaque Reduction Assay for a Compound Active Against Vesicular Stomatitis Virus	56
Table 13. Compounds Most Active Against Punta Toro Virus	56
Table 14. Confirmatory Assay for Compounds Active Against Punta Toro	57
Table 15. Compounds Most Active Against Sandfly Fever Virus	57
Table 16. Confirmatory Assays for Compounds Active Against Sandfly Fever Virus	58
Table 17. Compounds Most Active Against Pichinde Virus	58
Table 18. Confirmatory Assays for Compounds Active Against Pichinde Virus	59
Table 19. Compounds Most Active Against Venezuelan Equine Encephalomyelitis	59
Table 20. Compounds Most Active Against Yellow Fever Virus	60
Table 21. Confirmatory Assays for Compounds Active Against Yellow Fever Virus	61
Table 22. Compounds Most Active Against Japanese Encephalitis Virus	62
Table 23. Confirmatory Assays for Compounds Active Against Japanese Encephalitis Virus	63
Table 24. Compounds Active Against Hantaan Virus	64
Table 25. Primary <i>In Vivo</i> Antiviral Screen: Target Viruses and Numbers of Compounds Tested Through November 15, 1988	64
Table 26. Compounds Received for <i>In Vivo</i> Testing Against Pichinde Virus	65
Table 27. Antiviral Effects of AVS-272 and AVS-346 on Pichinde Virus	66
Table 28. Secondary <i>In Vivo</i> Testing of AVS-346	67
Table 29. Antiviral Efficacy of AVS-925 Against Pichinde Virus	68
Table 30. Secondary Testing of AVS-52 and AVS-148	70
Table 31. Antiviral Efficacy of Low-Dose Treatment with AVS-148	71
Table 32. Secondary <i>In Vivo</i> Testing of AVS-111	72
Table 33. Results of <i>In Vivo</i> Testing of AVS-215 Against Pichinde Virus Infection in MHA Hamsters	73
Table 34. Hematocrit Values for Animals Receiving AVS-206 or Ribavirin	75
Table 35. Antiviral Efficacy of AVS-206 and Ribavirin (AVS-01)	79
Table 36. Antiviral Efficacy of Ribavirin (AVS-01) Administered Through Day 7 Post Challenge	80
Table 37. Comparative Antiviral Efficacy of Ribavirin Administered Through Day 10 Post Challenge	81
Table 38. Antiviral Effect of Delay in Initiation of Ribavirin (AVS-01) Treatment	82
Table 39. <i>In Vivo</i> Titration of Pichinde Virus	83
Table 40. Antiviral Efficacy of AVS-79 and AVS-272	85
Table 41. Secondary Evaluations of AVS-79, AVS-272 and AVS-347	86
Table 42. Antiviral Efficacy of AVS-79 Against VEE in Mice	87
Table 43. Antiviral Evaluation of AVS-347	88
Table 44. Antiviral Efficacy of Ribavirin (AVS-01) Treatment	89
Table 45. <i>In Vivo</i> Passage of <i>In Vitro</i> Virus Stock	90

List of Tables

Page

Table 46. <i>In Vivo</i> Passage of Swiss Mouse <i>In Vivo</i> Virus Stock	91
Table 47. Secondary <i>In Vivo</i> Passage of JE Virus in C57Bl/6 Mice	92
Table 48. <i>In Vivo</i> Titration of JE Virus Challenge Stocks	93
Table 49. <i>In Vivo</i> Titration (JE Virus Challenge Preparations 4 and 5)	94
Table 50. <i>In Vivo</i> Titration of Challenge Preps No. 4 and No. 6	96
Table 51. Titration of Challenge Prep 6 Stock Virus (JE)	97
Table 52. Titration of Challenge Prep 7 Stock Virus (JE)	98
Table 53. Mortality of Old C57Bl/6 Mice Challenged with JE Virus	99
Table 54. Antiviral Efficacy of AVS-361, AVS-2563, AVS-2811 and AVS-2812	101
Table 55. Back Challenge of Mice Treated with AVS-361, AVS-2563, AVS-2811 and AVS-2812	103
Table 56. Antiviral Efficacy of AVS-111 and AVS-257 (JE Virus)	105
Table 57. Antiviral Evaluation of AVS-360 (JE Virus)	106
Table 58. Antiviral Efficacy of Selected AVS Compounds Against JE Virus	108
Table 59. Initial <i>In Vivo</i> Challenged with Vaccinia Virus by Different Routes	111
Table 60. <i>In Vivo</i> Titration of Vaccinia Virus Administered Intracranially	112
Table 61. Preliminary Tailpox Titration (Vaccinia Virus)	113
Table 62. Secondary Tailpox Titration (Vaccinia Virus)	114
Table 63. Antiviral Efficacy of AVS-1986 Against Lethal Vaccinia Virus Infection	115
Table 64. Antiviral Efficacy of AVS-1985 and AVS-1987	116
Table 65. Anti-Vaccinia Activity of AVS-1752 (Tailpox Model)	117
Table 66. Results of Testing AVS-1985 and AVS-1986 in Vaccinia Tailpox Model	118
Table 67. Square Root Transformation of Tailpox Counts for AVS-1985 and AVS-1986	119
Table 68. Secondary Testing of AVS-1985 and AVS-1986 (Numerical Counts)	121
Table 69. Secondary Testing of AVS-1985 and AVS-1986 (Transformed Counts)	122
Table 70. Raw Tailpox Counts for AVS-1985-Treated Vaccinia Challenged Mice	123
Table 71. Square Root Transformation of Tailpox Counts for AVS-1985-Treated Vaccinia Challenged Mice	124
Table 72. Raw Tailpox Counts for AVS-1986-Treated Vaccinia Challenged Mice	125
Table 73. Square Root Transformation of Tailpox Counts for AVS-1986-Treated Vaccinia Challenged Mice	126
Table 74. Antiviral Efficacy of AVS-1987 and AVS-1988 (Numerical Count)	127
Table 75. Antiviral Efficacy of AVS-1987 and AVS-1988 (Transformed Counts)	128

APPENDIX A

Table 1. Compounds Active Against Vaccinia Virus In Vero Cell Cultures Employing a CPE-Inhibition Assay Procedure	134
Table 2. Compounds Active Against Adenovirus Type 2 in HEp-2 Cell Cultures by CPE-Inhibition Assay	136
Table 3. Compounds Active Against Punta Toro Virus	137
Table 4. Compounds Active Against Sandfly Fever Virus	138
Table 5. Compounds Active Against Pichinde Virus	140
Table 6. Compounds Active Against Venezuelan Equine Encephalomyelitis Virus	142
Table 7. Compounds Active Against Yellow Fever Virus	143
Table 8. Compounds Active Against Japanese Encephalitis Virus	144

List of Figures

	Page
Figure 1. MTT Assay Plate Configuration	24
Figure 2. ELISA Experimental Plate Configuration	25
Figure 3. ELISA Toxicity Plate Configuration	25
Figure 4. AVS-4407 and AVS-4409 vs. Japanese Encephalitis	27
Figure 5. AVS-4408 and AVS-0001 vs. Japanese Encephalitis	28
Figure 6. AVS-253 and AVS-4407 vs. Japanese Encephalitis	29
Figure 7. Plaque Reduction Assay with Vaccinia Virus	37
Figure 8. Plaque Reduction Assay with Vaccinia Virus	38
Figure 9. Plaque Reduction Assay with Vaccinia Virus	39
Figure 10. Plaque Reduction Assay with Vaccinia Virus	40
Figure 11. Plaque Reduction Assay with Vaccinia Virus	41
Figure 12. Plaque Reduction Assay with Vaccinia Virus	42
Figure 13. Percentage of Compounds Tested Having Antiviral Activity for Each Primary <i>In Vitro</i> Screen	130

1. INTRODUCTION

This is the Third Annual Progress Report on SRI Project No. 5975, Contract No. DAMD17-86-C-6013. It covers the progress of the research program during the report period from November 15, 1987 to November 14, 1988.

The goal of this program is to implement testing systems in which to evaluate the efficacy of candidate antiviral compounds against a spectrum of viruses of military importance. The program consists of three major task areas: a) primary testing of chemical compounds and natural products for antiviral efficacy *in vitro*, b) primary testing of chemical compounds and immunopotentiators for antiviral efficacy *in vivo*, and c) secondary evaluation of compounds found active in the primary *in vitro* and *in vivo* screens.

One of the primary missions of the U.S. Army Medical Research and Development Command is to perform studies on the pathogenesis, diagnosis, epidemiology, prophylaxis, and treatment of infectious diseases of military importance. The Army's infectious disease research program, conducted by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick, is primarily concerned with medical defense against (a) naturally-occurring infectious diseases that could seriously interrupt U.S. military operations such as troop mobilization and deployment and (b) the threat of infectious diseases or toxic effects caused by the potential field use of biological warfare (BW) agents, either conventional BW agents or altered agents, by an unfriendly force.

The U.S. Army has a recognized need for new chemical compounds that will be useful as prophylactic or therapeutic antiviral drugs to treat U.S. military personnel who are at risk of exposure to, or who might become infected with, naturally-occurring viruses or altered viruses for which there exists no effective protection or therapy at the present time. The development of selective antiviral drugs for use in the successful treatment of infections with certain exotic RNA viruses (togaviruses, bunyaviruses, arenaviruses, rhabdoviruses, and other, unclassified RNA viruses) is of particular importance to the Army because there are no other research efforts being conducted, either by the government or by the private sector, which are directed toward the control of these virus diseases of military relevance.

In 1973, USAMRIID initiated a research and development program to identify and to pursue new compounds with activity against these exotic RNA viruses. Approximately 1500 compounds have already been screened *in vitro* for selective antiviral effects against these target viruses and a number of the compounds which were found active in cell culture have been evaluated for antiviral efficacy *in vivo*. Several of these compounds (e.g., Ribavirin, Selenazole, and Pyrazofurin) have been extensively tested for efficacy against lethal RNA virus infections in various animal model systems at USAMRIID. To date, the most promising antiviral drug with demonstrated, broad-spectrum activity against these viruses of military importance, both *in vitro* and *in vivo*, appears to be Ribavirin, its prodrug derivatives, and its carboxamidine derivative (AVS-206). Ribavirin has been evaluated in humans infected with Sandfly Fever (SF) Virus, Lassa Fever Virus, and Korean Hemorrhagic Fever (KHF) Virus and has demonstrated marked clinical efficacy against these particular virus infections. This drug will be further developed for general use in military personnel. There is a real need, however, for more potent and more selective antiviral drugs to combat these virus diseases which represent serious threats throughout the world.

Troops in the field are threatened not only by infectious diseases of natural origin, but also by the possibility of BW attack. The commercial development of antiviral drugs for the treatment of the more common respiratory virus, enteric virus, and herpesvirus infections may not solve the problems which are unique to the Armed Forces. These potential problems of encountering exotic viruses and BW agents will not be sufficiently addressed by depending solely on the possibility that antiviral drugs originally developed for the treatment of acute respiratory diseases, enterovirus infections, and herpesvirus infections might also be useful in the treatment of these virus diseases of military relevance. A more direct approach, and one which is clearly indicated, is to focus on antiviral drug development efforts designed to attack these particular virus disease threats that are unique to the Armed Forces.

The U.S. Army Medical Research Institute of Infectious Diseases has, for a number of years, been involved in conducting a unique and ambitious antiviral drug research and development program, primarily directed toward the chemical control of exotic RNA virus infections of military importance. Potential antiviral agents have been synthesized and evaluated against a number of target viruses both *in vitro* and *in vivo*. Program emphasis is currently on the development of antivirals for use in the treatment of infections with alphaviruses, flaviviruses, bunyaviruses, arenaviruses, and other viruses which are capable of eroding combat strength in troops deployed in overseas areas. In addition, current efforts are also being directed toward the development of antivirals for use in the treatment of AIDS through an Inter-Agency Agreement with the National Institutes of Health (NIH).

Members of the *Togaviridae* and *Flaviviridae* families (alphaviruses and flaviviruses) are capable of producing serious hemorrhagic or encephalitic diseases in humans. Infections with alphaviruses [Eastern equine encephalomyelitis (EEE), Western equine encephalitis (WEE), and Venezuelan equine encephalitis (VEE)] have occurred in epidemic proportions in the Americas. Chikungunya and O'nyong-nyong viruses also continue to cause epidemic disease on the African continent. The flaviviruses include several members which cause significant disease in humans. Dengue viruses types 1-4 are prevalent causes of acute illness in the tropics and subtropics of the world. Available vaccines are inadequate to control these infections effectively. Other members such as St. Louis encephalitis virus, Japanese B Encephalitis (JE) virus, and West Nile encephalitis virus cause mild to severe encephalitis diseases in humans. The tick-borne encephalitis virus group, represented by Russian Spring-Summer Encephalitis Virus, has caused widespread encephalitic disease in the U.S.S.R. and Northern Europe with high mortality rates. Yellow Fever (YF), in either the urban or jungle form, continues to be a threat, although the use of the 17-D vaccine is quite effective as a prophylactic measure against this disease. The Army's program is interested in controlling infections caused by the dengue viruses, Japanese encephalitis virus, Russian Spring-Summer encephalitis virus, Yellow Fever virus, and West Nile encephalitis virus.

A number of bunyaviruses have caused epidemic disease in many areas of the world: Rift Valley Fever virus was responsible for a major epizootic in Egypt in 1977-79 with considerable losses in domestic animals (sheep and cattle) and significant mortality among those humans infected with the virus. Sandfly fever virus has also been recognized as an important cause of epidemics in the Mediterranean area, in the Middle East, and in Central Europe. Oropouche, La Crosse, and California encephalitis viruses have all caused significant disease in the Americas. Oropouche virus, for example, has been associated with a number of large human epidemics in Brazil over the past twenty years. Hantaan virus, the causative agent of Korean hemorrhagic fever, causes appreciable mortality and is widely distributed in Asia. It has only recently been shown to belong to the *Bunyaviridae* family. Of the *Bunyaviridae* family, the USAMRIID program has initiated studies with Sandfly fever virus, Rift Valley fever virus, Korean hemorrhagic fever virus, and Punta Toro virus.

Of the *Arenaviridae* family, current interest includes Lassa fever virus, an agent which causes significant lethal disease among infected humans in Africa, especially in Sierra Leone. Other arenaviruses under current investigation include Junin and Machupo viruses, the causative agents of Argentine hemorrhagic fever and Bolivian hemorrhagic fever, respectively. These agents are found endemic in wide areas of South America. Pichinde (PIC) virus has been used in antiviral studies as a representative of this important family of viruses. Vesicular stomatitis virus is currently employed as a representative of the *Rhabdoviridae* family.

Other viruses which cause sporadic but severe hemorrhagic fever in Africa are Marburg and Ebola viruses. These two closely-related agents have been placed in a new family (*Filoviridae*).

The above viruses are those which might be encountered in exotic troop locations and against which troops would not be expected to have any pre-existing immunity. With few exceptions, specific vaccines do not exist for these agents and some of the agents encountered may be poorly classified or may even be unclassified viruses which have not been seen previously. The antiviral

chemoprophylaxis/chemotherapy approach may be the best modality to defend against this threat at the present time.

Another recurring problem with naturally-occurring virus infections exists in military boot camps where new recruits are assembled. These troops often develop infections with adenoviruses, influenza viruses, and parainfluenza viruses, sometimes in epidemic proportions. Infections with the adenoviruses have been a distinct military problem for years and multivalent vaccines have been prepared for use in new recruits. Nevertheless, an effective antiviral drug for treatment of adenovirus infections would be quite useful and therefore this virus group is also a target for antiviral chemotherapy in the Army's program.

A number of naturally-occurring viruses could be developed by an adversary into potent biological weapons for use in the field against U.S. forces. Many of the exotic RNA viruses are also potential BW agents, since their dissemination in an area where they are already indigenous could be employed as a means of disguising the source of the infection. In addition, other agents such as smallpox virus could be used very effectively against a susceptible civilian population prior to and during military operations to disrupt logistics and support activities and to create panic and chaos. The threat of BW attack poses some of the same problems as those to be addressed in the defense against naturally-occurring virus infections. Again, a broad-spectrum antiviral drug with selective activity against the RNA viruses could be the only real line of defense against such attack with those particular type of agents. The vaccine approach will only be effective in affording protection against a very limited group of these agents which number in the hundreds of different antigenic types.

With the advances made in the field of molecular genetics, it is now technically possible to genetically engineer altered viruses with enhanced virulence, communicability, drug resistance, and overall threat potential. An example of such misuse of advanced biotechnology would be the insertion of genes for highly toxic peptides such as snake venom toxins, potent bacterial toxins, or other low molecular weight toxins of military importance into the genome of a highly communicable virus such as influenza. The feasibility of inserting foreign genes into vaccinia virus and obtaining expression of those genes in the host cell has already been demonstrated. Recombinant DNA technology has made it possible to insert and express heterologous genes in a variety of different viruses. Effective defense against possible altered viruses used as BW agents may well depend upon the development of antiviral drugs active against the vector viruses.

The Department of Antiviral Studies at USAMRIID is responsible for the acquisition, identification, and development of potential new antiviral drugs which are effective against viruses of military relevance and which might be useful in the treatment of AIDS. The program is therefore, broad-based and involves the synthesis, primary and secondary testing, and further characterization of novel antiviral compounds with regard to their possible biochemical mechanisms of action, pharmacokinetics, metabolism, optimal formulation, optimal combination with other drugs, and safety in animal model systems. The Department also directs studies in support of IND applications to the FDA for clinical testing of active antiviral agents for use in man.

Since the establishment of its antiviral testing program, the Department of Antiviral Studies, USAMRIID, has evaluated approximately 3,000 compounds in its primary *in vitro* screen. Fewer compounds have been evaluated *in vivo*. Selenazole was reported to have broad-spectrum activity against the exotic RNA viruses *in vitro* and is significantly more potent than Ribavirin against the togaviruses (VEE, YF, JE), bunyaviruses (RVF, SF, KHF), and arenaviruses (PIC) *in vitro*. The activity of this compound against YF virus is most impressive with an ED₅₀ of 0.005 mg/ml in cell culture. The evaluation of Selenazole for therapeutic antiviral efficacy *in vivo*, however, yielded disappointing results and pharmacological problems may be responsible for the lack of efficacy in animal model systems. Ribavirin, on the other hand, has been shown in laboratory animal models to have significant antiviral efficacy against the bunyaviruses (RVF, Punta Toro and KHF) and the arenaviruses (PIC, Junin, Machupo, and Lassa Fever). Clinical trials with Ribavirin in patients with Lassa Fever virus or Hantavirus infections have yielded good results.

Ribavirin has also been shown to be effective in the treatment of Sandfly fever virus in human volunteers. Good progress has been made toward developing this particular antiviral drug for general clinical use by the Army, but new agents with higher potency and selectivity against the exotic RNA viruses will hopefully be identified in the expanded USAMRIID antiviral program. Because of the lag time in diagnosing viral disease, treatment with broad-spectrum antiviral agents offers the best hope to successfully defend against both naturally-occurring diseases and against possible BW agents in the field. It is unlikely, however, that a single drug will be found that is effective against all of these exotic RNA virus infections, so additional antiviral agents must be developed. There is also a need to explore the efficacy of immunopotentiators, biological response modifiers, interferons, combination chemotherapy, and new approaches to drug delivery to enhance the antiviral efficacy of these agents.

The present contract at Southern Research Institute was established to enable USAMRIID to evaluate approximately 1,500 compounds per year for efficacy against 10 different target viruses in a primary *in vitro* screen, 96 compounds per year for *in vivo* efficacy against a representative togavirus and arenavirus in appropriate animal model systems, and approximately 5 compounds per year in detailed *in vivo* studies. The basic contract also includes secondary testing studies with candidate antiviral agents that demonstrate promising activity both *in vitro* and *in vivo*. This report summarizes our progress in implementing the research program and includes summaries of antiviral test data collected up to November 14, 1988.

2. CURRENT SCOPE OF WORK

This section describes the research objectives and the scope of work for each of the three main tasks being performed by Southern Research Institute (SRI) on this contract. These tasks are: (a) Primary testing of compounds for antiviral efficacy *in vitro*, (b) Primary testing of compounds and immunopotentiators for antiviral efficacy *in vivo*, and (c) Secondary testing of compounds found active in primary testing.

2.1 Task 1: In Vitro Antiviral Evaluations

SRI is conducting the primary screening of chemical compounds which are furnished by the Department of Antiviral Studies, USAMRIID, through its repository contractor (Technassociates, Inc., Ijamsville, MD) for antiviral efficacy in cell culture against representative viruses from the Togaviridae, Flaviviridae, Bunyaviridae, Arenaviridae, Rhabdoviridae, Poxviridae, and Adenoviridae families. The test viruses consist of the following agents: (1) Venezuelan Equine Encephalomyelitis (VEE) Virus, (2) Yellow Fever (YF) Virus, (3) Japanese Encephalitis (JE) Virus, (4) Sandfly Fever (SF) Virus, (5) Punta Toro (PT) Virus, (6) Hantaan (HTN) Virus, (7) Pichinde (PIC) Virus, (8) Vesicular Stomatitis Virus (VSV), (9) Vaccinia Virus (VV), and (10) Adenovirus type 2 (AD2). SRI is scheduled to evaluate approximately 1500 compounds per year against each of these ten viruses *in vitro*, using standard CPE-inhibition and quantitative plaque-reduction assays, to determine the virus rating and the 50% minimal inhibitory concentration (MIC₅₀), or median inhibition dose (ID₅₀), of active compounds, respectively. Determinations are also being made of the cytotoxicity of each candidate compound for the host cells, expressed in terms of the minimum cytotoxic concentration of the compound. We are calculating an *in vitro* therapeutic index for each active compound against each susceptible test virus. All screening data are being reported to Technassociates, Inc. and to USAMRIID essentially as it is obtained in hardcopy form or on floppy diskettes.

Primary screening of compounds against human immunodeficiency virus (HIV) previously screened for USAMRIID under this contract is now conducted under a National Cooperative Drug Discovery Grant, Number UO1 AI/CA35617 (USAMRIID contract no. DAMD17-88-H-8003). Also, compounds furnished by the Developmental Therapeutics Program, NCI for HIV primary screening is now tested under Contract Number NO1-CM-87237.

2.2 Task 2: *In Vivo* Antiviral Evaluations

SRI is conducting the primary testing of chemical compounds and immunopotentiators, being furnished by the Department of Antiviral Studies, USAMRIID, for antiviral efficacy in rodent models and is conducting a preliminary assessment of acute toxicity with each material submitted. SRI is evaluating the compounds and immunopotentiators against representative viruses from the Togaviridae, Arenaviridae, and Flaviviridae and Poxviridae families in rodents. These challenge viruses consist of the following agents: (1) Pichinde Virus in the hamster, (2) Venezuelan Equine Encephalomyelitis Virus in the mouse, (3) Japanese Encephalitis Virus in the mouse, and (4) Vaccinia Virus in the mouse. Compounds are evaluated at the primary level against each of these viruses using parenteral routes of administration. Antiviral efficacy is being expressed in terms of the observed increase in the number of survivors, or in the average day of death, in the treated group compared with that of the control untreated group or the diluent control group.

2.3 Task 3: Secondary Evaluations

SRI is also conducting the secondary testing and further evaluation of compounds found active in the primary antiviral screen. Secondary testing includes an estimation of the *in vivo* therapeutic index of the candidate compound, the optimal dosage regimen, the optimal route of administration, the optimal treatment schedule, schedule dependency, the duration of antiviral effect, a determination of the utility of the candidate compound in combination with other drugs, and the influence of formulation on activity. SRI is expecting to evaluate approximately 5 compounds per year in extensive secondary *in vivo* testing to include determinations of dose-response relationships and antiviral efficacy. Data will be reported to USAMRIID essentially as it is obtained.

3. EXPERIMENTAL METHODS

3.1 Test Compounds

3.1.1 Receipt, Cataloging and Storage

The compounds submitted from USAMRIID for testing in the antiviral screening program were shipped to the SRI home site facility by Technassociates, Inc. The drugs were unpacked, checked against the enclosed shipping list, and recorded in a log book maintained in a bound SRI laboratory notebook. The drugs were then stored in numerical order under the appropriate conditions according to the storage information listed on each drug data sheet. Drugs to be used in the BL-3 facility were delivered to the building after they were logged in at the home site. Copies of the shipping list and drug data sheets were distributed to each task leader.

If the full amount of the drug was available, the sample was split by Technassociates into 25 and 45 mg samples. The 25 mg sample was retained at the home site for drug solubility determination and assay in 3 virus systems (VV, AD2, VSV). The 45 mg sample was used for the 7 virus systems (PT, VEE, YF, HTN, PIC, JE, SF) in the BL-3 facility. If less than 70 mg of drug was provided, the solubility was determined and the drug tested against as many viruses as possible according to the priority list provided by Technassociates, Inc.

Compounds submitted for *in vivo* testing were sent to the BL-3 facility as soon as they were logged-in at the home site.

3.1.2 Determination of Solubilities

If drug solubility information was included on the drug data sheet, then that information was used. If no information was available, solubility was determined at the home site and the information distributed to each task leader.

To determine the solubility of a drug, a 1-mg sample was weighed, placed in a homogenizer vessel, and the first solvent on the priority list was added. If the drug did not dissolve in the solvent, it was heated to 40 °C (unless it was known to be heat-unstable). If the drug was not in solution after heating, it was homogenized with a hand homogenizer. If the drug still was not in solution, another sample was weighed and this procedure used with the next solvent on the priority list. The priority list of solvents was as follows: H₂O, 1 N HCl or 1 N NaOH (used only if the drug was known to be stable in the presence of acid or base), ETOH, DMSO or acetone. If a compound was not soluble in any of the above listed solvents, then it was suspended in cell culture medium with the aid of a hand homogenizer or a vortex mixer.

3.1.3 Compound Preparation for Testing

For use in an experiment, the drugs were weighed in advance and stored under the appropriate conditions. Drugs were solubilized on the day of assay using the solvent which had previously been determined to be optimal for that drug. The drug solution was then diluted in serial half-log₁₀ dilutions in the appropriate cell culture medium.

Initial control experiments for each solvent in each virus, host-cell system were done to determine a noncytotoxic, inactive amount of solvent which could be used in each assay system. If a safe concentration could not be determined, then a solvent control was included with each experiment.

3.2 In Vitro Antiviral Screening: DNA Viruses and Exotic RNA Viruses

The viruses and host cell lines used in our *in vitro* assays are listed in Table 1. The antiviral activity of a compound was a measure of its ability to inhibit the cytopathogenic effect (CPE) of the virus on its host cell. Compounds were evaluated against most of the viruses in a standard CPE-inhibition assay. Mammalian cells were pregrown as monolayer cultures in 96-well tissue culture plates using suitable cell culture medium. Stock viruses were pretitered according to the method of Reed and Muench (1938) and diluted in cell culture medium to yield 32 TCID₅₀ (tissue culture infectious dose, 50%) units per 0.1 ml. Antiviral assays were designed to test seven 0.5-log₁₀ concentrations of each compound in triplicate against the challenge viruses. If drug cytotoxicity was provided, then drug concentrations were chosen to range from toxic to noncytotoxic. If no cytotoxicity information was available, testing began at 320 µg/ml. To each of the replicate host cell cultures were added 0.1 ml of the test drug solution and 0.1 ml of virus suspension. Cell controls containing medium alone, virus controls containing medium and virus, and drug cytotoxicity controls containing medium and each drug concentration were included on each plate. The covered plates were incubated at 37 °C until maximum virus-induced CPE were observed in the untreated, virus-infected control cell cultures. Positive control drugs (Table 1) were included in each antiviral assay to validate the test conditions used in the antiviral assays.

The degree of inhibition of virus-induced CPE and the degree of drug-induced cytotoxicity were observed microscopically. CPE were scored numerically from 0 (normal uninfected cells) to 4 (100% virus-induced cell destruction) for each individual culture as follows:

- 4 = Viral CPE observed in 100% of the cells
- 3 = Viral CPE observed in 75% of the cells
- 2 = Viral CPE observed in 50% of the cells
- 1 = Viral CPE observed in 25% of the cells
- 0 = No CPE; normal cell monolayer
- u = Unsatisfactory test, e.g., contamination or leakage
- t = Drug is toxic to cells, CPE not discernible
- p = Drug is partially toxic to cells, cell monolayer is intact
so that CPE may be discernible

Antiviral activity was determined by calculating the degree of inhibition of virus-induced CPE in drug-treated, virus-infected cell cultures by means of a virus rating (VR). The VR is a standard weighted measurement of antiviral activity taking into account both the degree of CPE inhibition and drug cytotoxicity, and was determined by a modification of the method of Ehrlich et al. (1965). The VR was calculated as 0.1 of the sum of the numerical differences between the recorded CPE grade of each test well and that of the corresponding virus control culture. Numerical differences between the reading of test wells containing a drug concentration which was partially cytotoxic (p) and their corresponding virus controls were halved. As requested by USAMRIID, the VR was also reported by the method of Sidwell and Huffman (1971). This virus rating (VR*) was calculated by dividing the VR obtained by the method of Ehrlich et al. (1965) by 3. The inhibitory drug concentration which reduced the CPE by 50% (ID₅₀) was calculated by using a regression analysis program for semilog curve fitting. A therapeutic index (TI) for each active test compound for each susceptible virus was determined by dividing the minimum cytotoxic concentration (MTC) of the test compound by the ID₅₀.

Compounds showing antiviral activity in the initial CPE-inhibition assay were retested in confirmatory CPE-inhibition assays. The most active of the compounds having confirmed antiviral activity were further tested in quantitative plaque-reduction assays. The details of the assay procedures for each virus are described below.

Table 1

In Vitro Antiviral Screening Models

<u>Virus</u>	<u>Strain</u>	<u>Classification</u>	<u>Cell Line</u>	<u>Positive Control Compound</u>
Vaccinia Virus	Lederle Chorio-allantoic	Poxviridae	Vero	Selenazole (AVS-0253), Arabinofuranosyladenine (AVS-1752)
Adenovirus Type 2	Adenoid 6	Adenoviridae	Hep-2	Ribavirin, (AVS-0001), Selenazole (AVS-0253)
Vesicular Stomatitis Virus	Indiana	Rhabdoviridae	L929	Carbocyclic-3-deaza-adenosine (AVS-0303), Adenosine dialdehyde (AVS-1160)
Punta Toro Virus	Adames	Bunyaviridae	Vero	Ribavirin (AVS-0001)
Sandfly Fever Virus	Sicilian	Bunyaviridae	Vero	Ribavirin (AVS-0001)
Pichinde Virus	4763	Arenaviridae	Vero	Ribavirin (AVS-0001)
Venezuelan Equine Encephalomyelitis Virus	Trinidad Donkey	Togaviridae	Vero	Selenazole (AVS-0253)
Yellow Fever Virus	Asibi	Flaviviridae	Vero	Selenazole (AVS-0253)
Japanese Encephalitis Virus	Nakayama	Flaviviridae	Vero	Selenazole (AVS-0253)
Hantaan Virus	76-118	Bunyaviridae	Vero (VSC-6)	Ribavirin (AVS-0001)

3.2.1 Vaccinia Virus (VV)

Vaccinia virus, strain Lederle CA, was obtained from Dr. Wilton Rightsel, formerly with Parke, Davis and Co., Detroit, Michigan. We have serially passed VV in HEp-2 (continuous-passage human carcinoma of the larynx) and Vero (continuous-passage African green monkey kidney) cell monolayer cultures. The VV used to screen compounds for USAMRIID was propagated and assayed in Vero cell monolayer cultures in Eagle's minimal essential medium (MEM) supplemented with 2% heat-inactivated fetal bovine serum (fbs) and 50 $\mu\text{g/ml}$ of gentamicin.

A CPE-inhibition assay procedure was employed to screen compounds for activity against VV in cell culture. Vero cells were seeded (40,000 cells/well in 0.2 ml volumes) into wells of 96-well plates. After a 24 hr. incubation period at 37 °C in a humidified atmosphere containing 2% CO₂, the growth medium was removed from the replicate cell monolayers. To each of triplicate cell cultures were added 0.1 ml of test compound (at 0 hr postvirus infection) and 0.1 ml of virus suspension. Test drugs and virus suspension were diluted in MEM containing 2% fbs shortly before use.

It has been our experience that a challenge dose of 32 TCID₅₀ of VV per microtiter plate well yielded only 30-60% CPE after 4 to 5 days of incubation. Therefore, for use in our CPE-inhibition assays, stock VV was diluted in medium to contain 100 TCID₅₀ units in 0.1 ml. The plates were incubated at 37 °C in the CO₂ incubator until maximum CPE were observed (4 days). The cell cultures were examined microscopically for virus-induced CPE and drug cytotoxicity.

Selenazole (AVS-253) and Ara-A (9- β -D-Arabinofuranosyladenine, AVS-1752) were utilized as positive control compounds.

3.2.2 Adenovirus Type 2 (AD2)

We obtained the Adenoid-6 strain of Adenovirus Type 2 from the American Type Culture Collection. In our laboratories, the virus was passaged in HEp-2 cell monolayer cultures in MEM supplemented with 0.4% lactalbumin hydrolysate and 2% heat-inactivated fbs.

An early "cytotoxicity" is frequently observed in adenovirus-infected cell cultures. This "cytotoxicity", the result of penton toxin following an accumulation of unassembled viral components within the cell, can mask the later-appearing CPE. To prevent the appearance of this early cytotoxicity, virus stocks were treated as follows: Adenovirus-infected HEp-2 cell cultures were subjected to three cycles of freeze-thawing to disrupt the cell membranes. The material from the cultures was centrifuged, and the pooled supernatant fluid was treated with 100 $\mu\text{g/ml}$ of purified trypsin (Worthington, TRL) for one hour at 37 °C. The enzyme action was then stopped by adding soybean trypsin inhibitor (Worthington; titrated for specific activity against trypsin) to the supernatant viral fluid. The trypsin-treated virus preparation, along with the untreated supernatant viral fluid was titrated for infectivity in HEp-2 cell cultures to make sure that the viral infectivity of the treated preparation was not diminished. Before the trypsin-treated stock adenovirus was used for antiviral screening, it was evaluated as the challenge virus against our positive control compounds Selenazole and Ribavirin.

Test compounds were screened for antiviral activity against Adenovirus using a CPE-inhibition assay procedure as described above for Vaccinia Virus. Stock AD2 was diluted in medium to 100 TCID₅₀ per 0.1 ml. We have found that a 32-TCID₅₀ challenge of AD2 per plate well resulted in only 50-70% CPE in four days. Because HEp-2 cells grow rapidly, the host cell cultures in the plate wells deteriorated significantly after four days post-virus infection. Therefore the stronger virus challenge allowed 100% CPE to develop in four days.

3.2.3 Vesicular Stomatitis Virus (VSV)

The VSV (Indiana strain) was obtained from Dr. Robert Sidwell, Utah State University, Logan, Utah in 1973. Dr. Sidwell had originally obtained the virus from the ATCC. Since the virus has been in this laboratory, it has been passaged 4 times in L929 cells.

The L929 cells were obtained from the ATCC and have been carried in continuous passage or stored frozen in liquid nitrogen. The medium used to maintain the L929 cells was Eagle's minimum essential medium supplemented with 10% or 5% heat-inactivated fetal bovine serum, 100 units penicillin per ml, and 100 μ g streptomycin per ml (EMEM + 10% or 5% heat-inactivated fbs).

The preliminary *in vitro* CPE-inhibition assay described above was used to assay the drugs against VSV. The L929 cells were seeded into the 96-well plates at a concentration of 4×10^4 cells per well in 0.2 ml medium. The cells were pregrown for 20 hrs. before the addition of drug and virus. Virus-induced CPE were scored on Day 3 post-virus infection. Carbocyclic 3-deaza-adenosine hydrochloride (C-3-deaza-AdO, AVS 303) and adenosine dialdehyde (AVS 1160) were included in each VSV experiment as positive control drugs.

Drugs which demonstrated confirmed activity in the CPE-inhibition assay were evaluated in a plaque reduction assay. For that assay L929 cells were seeded into 6 well tissue culture dishes at a density of 5×10^5 cells/well in EMEM + 10% heat-inactivated fbs and incubated at 37 °C in a humidified atmosphere containing 5% CO₂. The following day the medium was decanted and a virus inoculum of 0.5 ml was adsorbed for 1 hr. The virus was then removed and the cell layer rinsed with phosphate-buffered saline (PBS). An agarose overlay (2.5 ml) containing a final concentration of 0.5% agarose in EMEM + 5% heat-inactivated fbs was added to each well. Cell and virus control cultures received medium and agarose only. Test and drug control cultures received the appropriate drug concentration in the medium and agarose. The plates were incubated overnight. The following morning, neutral red was added to each well and the plaques were counted in the afternoon.

3.2.4 Punta Toro Virus (PT)

We obtained our original stock of Punta Toro virus (Adames strain) from Dr. Robert Sidwell of Utah State University. His virus stock originated from Dr. Dominique Pifat of USAMRIID.

To grow virus stocks, Vero cells (ATCC) were infected at a low multiplicity of infection (moi; ≤ 0.1) in MEM supplemented with 10% inactivated fbs. Culture fluid was collected at five days post-infection and clarified by centrifugation (5000 rpm, 15 minutes, 4 °C) in a Sorvall SA-600 rotor. The supernate was dispensed into 0.5-ml aliquots, then frozen and stored at -84 °C. One aliquot was used to determine a TCID₅₀ titer and a plaque forming unit (PFU) titer for the stock.

A CPE-inhibition assay was used to screen compounds for antiviral activity against PT virus. Vero cells were treated for 30 minutes at 37 °C with DEAE-dextran (25 μ g/ml) and 1% DMSO in 0.1 ml Hanks balanced salt solution. The pre-treatment solution was removed, and an 0.1 ml virus inoculum containing 32 TCID₅₀ of PT virus was added. Following a 30-minute adsorption period at 37 °C, 0.1 ml of compound or medium alone was added to the appropriate wells.

When virus control wells showed maximum CPE (6-8 days), the cells were fixed by addition of 100 μ l buffered formalin (at least 1 hr at room temperature). All liquid was removed and the cells were stained with 0.1% Coomassie Brilliant Blue R-250 (Sigma Chemicals, St. Louis, MO) for about 1 hour at room temperature. The plates were rinsed with deionized water, allowed to dry, and then observed microscopically for CPE and drug cytotoxicity.

Compounds showing good antiviral activity in the CPE-inhibition assays were further evaluated in a plaque-reduction assay. Vero cells, seeded into twelve-well culture trays at a density of 1.5×10^5 cells per

well, were incubated at 37 °C in a humidified atmosphere containing 5% CO₂. The following day, the medium was aspirated and cell monolayers were treated with a solution of 20 µg/ml DEAE Dextran-1% DMSO in Hanks Balanced Salt Solution. After a 30 minute incubation at 37 °C, the pretreatment solution was removed and 0.1 ml of PT virus diluted in medium to contain approximately 20 PFU/0.1 ml was added to 8 of the 12 cultures of each tray. To the remaining cultures, 0.1 ml MEM containing 10% fbs was added, and the cultures were reincubated for 30 min. After this virus adsorption period, 0.1 ml of the appropriate compound dilution was added to three of the infected cultures and one of the mock infected cultures (toxicity control) of each tray. Control and experimental compounds were serially diluted in half-log₁₀ increments in MEM containing 10% fetal bovine serum (final concentrations used were 320 µg/ml to 0.32 µg/ml). Two virus control and two cell control cultures received 0.1 ml of medium only. When all culture trays had received either compound or MEM, 0.8 ml of agarose overlay was added to each culture. The cultures were mixed by gentle swirling and set on a level surface until the overlay had solidified. The agarose overlay used in the assay contains Eagles' MEM, fetal bovine serum, glutamine, sodium bicarbonate, penicillin/streptomycin, and Seakem Agarose in final concentrations of 1x, 10%, 1 mM, 2.2 mg/ml, 100 units/ml, 100 µg/ml, and 0.7% respectively. The cultures were incubated 6 days, after which 1 ml of buffered formalin was added to inactivate the virus. Monolayers were stained with Coomassie Brilliant Blue and the plaques counted.

3.2.5 Sandfly Fever Virus (SF)

We obtained our original stock of Sandfly fever virus, Sicilian strain (TC adapted), from Dr. George R. French of the Salk Institute, Government Services Division, Swiftwater, PA.

To grow virus stocks, Vero-76 cells (Dr. French, Salk Inst.) or Vero cells (ATCC), depending on availability, were pre-treated with DEAE-dextran (25 µg/ml) and 1% DMSO in growth medium (MEM containing 10% inactivated fbs) for 30 minutes at 37 °C. This was removed and then the cells were infected with SF virus in growth medium at an moi of 0.1. Virus was allowed to adsorb for one hour at 37 °C. A minimal volume of growth medium was then added and the cells were incubated at 37 °C. The culture fluid was collected at four days post infection and clarified by centrifugation (5000 rpm, 15 min, 4 °C). The supernate was dispensed into 0.5 ml aliquots, then frozen and stored at -84 °C. One aliquot was used to determine TCID₅₀ and PFU titers for the stock.

Antiviral screening of compounds for activity against SF virus was performed on Vero cells in 96-well trays (Corning). Cells were pre-treated for 30 minutes at 37 °C with DEAE-dextran (25 µg/ml) and 1% DMSO in 0.1 ml Hanks balanced salt solution. This was removed and then 0.1 ml growth medium containing 32 TCID₅₀ of SF virus was added and allowed to adsorb for 30 minutes at 37 °C. 0.1 ml of test compound, control compound (Ribavirin or Selenazole), or growth medium was then added to appropriate wells.

When virus control wells showed maximum CPE (6-8 days), the cells were fixed by addition of 100 µl buffered formalin ($\leq$ 1 hour, 22°C). All liquid was removed and then the cells were stained with 0.1% Coomassie Brilliant Blue R-250 (Sigma Chemicals, St. Louis, MO) for $\geq$ 1 hour at 22°C. The plates were rinsed with deionized water, allowed to dry, and then observed microscopically for CPE.

A plaque-reduction assay was developed to further confirm the antiviral activity of compounds showing the greatest activity in the CPE-inhibition assays. The plaque-reduction assay procedure for SF is the same as described above for Punta Toro Virus, except that the agarose overlay additionally contains 1% DMSO and 0.002% DEAE-dextran. This allowed for an enhancement in plaque size.

3.2.6 Pichinde Virus (PIC)

Vero cells, obtained from Dr. George French of the Salk Institute, Swiftwater, PA, were maintained in Eagle's Minimal Essential Medium containing 10% fetal bovine serum. Baby hamster kidney (BHK-

21) cells were obtained from the American Type Culture Collection and maintained in MEM containing 10% newborn calf serum and 10% tryptose phosphate broth.

Pichinde virus strain 4763 was obtained from Dr. J. Gangemi of the University of South Carolina, School of Medicine. The virus preparation received was that of a guinea pig spleen homogenate from Pichinde virus infected guinea pigs. After amplifying this virus preparation in BHK-21 cells, a three-time plaque-purified virus preparation was generated in Vero cells. The plaque-purified virus was amplified twice in BHK-21 cell cultures and stored at -84°C as a virus seed stock. Several preparations of virus used for plaque-reduction assays were prepared by infecting BHK-21 cells with seed stock virus at a multiplicity of infection of 1 PFU/cell. Culture fluids collected three days post-infection were clarified by centrifugation at $600 \times g$ for 5 min., frozen rapidly in a dry ice/ethanol bath and stored at -84°C in small aliquots. These preparations had virus titers ranging from 6.4×10^7 to 1.2×10^9 PFU/ml.

Vero cells, seeded into six-well cell culture trays at a density of 8×10^5 cells per well, were incubated at 37°C in a humidified 5% CO_2 incubator. The following day the cultures were examined microscopically for confluency. Ribavirin and experimental antiviral drugs were serially diluted in half- $\log_{10}$ increments in MEM containing 10% fbs (final concentrations used were $320 \mu\text{g/ml}$ to $0.1 \mu\text{g/ml}$). Culture fluids were removed by aspiration and to four of the six cultures of each tray were added a 0.2 ml inocula of PIC virus diluted in MEM containing 10% fbs so as to contain 40 to 80 PFU. To the remaining cultures of each tray, 0.2 ml of culture medium alone was added. The cultures were reincubated as above and periodically shaken so that the inoculum was dispensed over the entire monolayer.

One hour later, 0.2 ml of the appropriate dilution of drug was added to three of the virus-infected cultures (virus-infected, treated) and to one of the mock infected cultures (toxicity control) on each tray. To the remaining mock infected (cell control) and virus-infected (virus control) cultures were added 0.2 ml of MEM containing 10% fbs. The culture fluids were mixed by shaking the culture trays, then 1.6 ml of agar overlay was added and each culture was thoroughly mixed as above. The cultures were set on a level surface until the agar overlay solidified and were then reincubated at 37°C . The agar overlay used in the assay contained Eagle's MEM, fetal bovine serum, glutamine, non-essential amino acids, sodium bicarbonate, and Noble agar in final concentrations of 1x, 2%, 1 mM, 1 mM, 2.2 mg/ml and 1% respectively.

Three days later, 2 ml of a sterily filtered neutral red solution (0.08 mg/ml in PBS) was added to each culture. Cultures were reincubated; then six to eight hours later plaques were examined and counted. With each daily assay, Ribavirin (positive control antiviral drug) was included in a parallel assay. Drug cytotoxicity was microscopically evaluated and rated as with CPE-inhibition assays.

3.2.7 Venezuelan Equine Encephalomyelitis Virus (VEE)

We obtained our original stock of Venezuelan Equine Encephalomyelitis Virus, Trinidad Donkey strain, from Dr. George R. French of The Salk Institute, Swiftwater, PA.

The virus was propagated in Vero cells (ATCC) by infection at a moi of <0.1 PFU/cell. Fluids from infected cultures were collected three days post infection and clarified by centrifugation (5000 rpm, 15 min, 4°C) in a Sorvall SA-600 rotor. The supernatant fluid was dispensed into 0.5-ml aliquots, quick frozen in a dry ice-ethanol bath and stored at -84°C . One aliquot was used to determine TCID_{50} and PFU titers of the stock.

We have been using a standard CPE-inhibition assay to screen test compounds for antiviral activity against VEE virus. Vero cells were seeded into wells of 96-well trays (1.5×10^4 cells per well) and incubated at 37°C in a humidified incubator with a 5% CO_2 atmosphere. On the following day, culture medium was removed and the cultures were inoculated with 0.1 ml of VEE virus stock containing 32 TCID_{50} . Cultures were incubated at 37°C for 30 minutes to allow virus to adsorb, then 0.1 ml of compound or medium alone was added to the appropriate cultures. Cultures were reincubated at 37°C until the virus control cultures (infected/untreated) exhibited maximum CPE (3 days post-infection). At this time all

cultures were fixed with buffered formalin and stained with Coomassie blue as described above for PT and SF. The cultures were washed three times with deionized water and allowed to air dry, then examined microscopically for CPE and drug cytotoxicity.

3.2.8 Yellow Fever Virus (YF)

We obtained our original stock of Yellow Fever Virus, Asibi strain, from Dr. Andrew J. Main, Jr., of the Yale Arbovirus Research Unit, New Haven, CT.

To grow virus stocks, Vero cells (ATCC) were infected at an moi of about 0.1 PFU/cell in MEM containing 10% inactivated fbs. Virus was allowed to adsorb for 1 hour, after which a minimal volume of growth medium was added and the cells were incubated at 37 °C. The culture fluid was collected at 5 days post infection and clarified by centrifugation (5000 rpm, 15 minutes, 4 °C) in a Sorvall SA-600 rotor. The supernate was dispensed into 0.5 ml aliquots and then frozen and stored at -84 °C. One aliquot was used to determine the TCID₅₀ and PFU titers for the stock.

We have used a standard CPE-inhibition assay to screen test compounds for antiviral activity against YF virus. Vero cells were seeded into wells of 96-well trays (1.5 x 10⁴ cells/well) and incubated overnight at 37 °C in a humidified incubator with a 5% CO₂ atmosphere. Culture medium was removed and the wells were inoculated with 0.1 ml of the YF virus stock containing 32 TCID₅₀. Cultures were incubated for 1 hr at 37 °C to allow virus to adsorb, then 0.1 ml of compound or medium alone was added to the appropriate cultures.

Virus control wells showed maximum CPE at 6-8 days post infection. The cells were fixed and stained as described above for PT and SF virus, and observed microscopically for CPE and drug cytotoxicity.

3.2.9 Japanese Encephalitis Virus (JE)

We obtained our original stock of Japanese Encephalitis Virus, Nakayama strain, from Dr. George R. French of the Salk Institute, Swiftwater, PA.

To grow virus stocks, Vero cells (ATCC) were infected at an moi of about 0.1 PFU/cell in MEM containing 5% fbs. Virus was allowed to adsorb for 1 hour, then a minimal volume of growth medium was added and the cells were incubated at 37 °C. The culture fluid was collected at 4-5 days post infection and clarified by centrifugation (5000 rpm, 15 minutes, 4 °C) in a Sorvall SA-600 rotor. The supernate was dispensed into 0.5 ml aliquots and then frozen and stored at -84 °C. One aliquot was used to determine TCID₅₀ and PFU titers of the stock.

We have used a standard CPE-inhibition assay to screen test compounds for antiviral activity against JE virus. The assay procedure was the same as described above for YF virus. The JE virus control wells showed maximum CPE at 6-8 days post-infection. The plates were rinsed with deionized water, allowed to dry, and then observed microscopically for CPE and drug cytotoxicity. Fixing with buffered formalin and staining with Coomassie blue were as described above.

3.2.10 Hantaan Virus (HTN)

We obtained several vials of Hantaan Virus, strain 76-118, (formerly referred to as Korean Hemorrhagic Fever Virus, KHF) from Dr. John W. Huggins and Mr. Orville Brand of USAMRIID. Initial attempts to plaque this virus in a routine plaque assay were unsuccessful. Discussions with Dr. Huggins and Mr. Brand indicated that the quality of the reagents used in the assay is critical. Mr. Brand graciously supplied us with a shipment of his tested cell culture supplies and fresh cultures of Vero VSC-6 cells to use in assaying KHF virus.

Six-well culture trays of VSC-6 cells were seeded at a density of 3.75×10^5 cells/well with MEM containing 5% horse serum, 5% Nu serum, 10 mM HEPES buffer, 2mM glutamine, 1mM sodium pyruvate, and penicillin/streptomycin (at 100 units and 100 μ g per ml, respectively) and incubated at 37 °C in a 5% CO₂ humidified atmosphere. As suggested by Mr. Brand, KHF virus was diluted tenfold in MEM with supplements and stored at 4 °C overnight prior to assay.

The following day, the culture medium was aspirated and 0.4 ml of virus dilution was added to duplicate cultures. Two cultures per tray were mock infected with 0.4 ml MEM. Culture trays were incubated for 1 hour at 37 °C and swirled every 15 minutes.

After 1 hour adsorption, 2.5 ml of overlay consisting of cell culture medium plus 0.6% agarose was added to each culture. The trays were reincubated at 37 °C. Seven days after infection, a 2.0 ml volume of overlay was added to each culture and the cultures reincubated. Twelve days after infection, 1 ml of overlay with neutral red was added to each well. Culture trays were reincubated and observed for plaques from day 13 to day 20 post infection.

3.3 Assay Development

3.3.1 Vaccinia Virus (VV), Strain Lederle CA

We have developed a more quantitative, objective method to measure VV-induced CPE inhibition in Vero (ATCC) cell cultures. Our procedure is a modification of the method of H. Tada *et al.* (1986), and is based on the reduction of the tetrazolium salt, 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) by mitochondrial enzymes of viable host cells to MTT formazan (T. Mosmann, 1983). The blue color of the MTT formazan is measured spectrophotometrically. Known active compounds such as AVS-1752 (Ara-A) and AVS-1986 were used in our experiments to determine the optimum host cell density and the appropriate volumes and concentrations of media and reagents needed to demonstrate suitable antiviral activity.

Vero cells are seeded into 96-well plates at a density of 4×10^4 cells in 0.2 ml per well in MEM + 5% bovine calf serum. The plates are incubated at 37 °C overnight. The next day our CPE-inhibition assay is set up, according to the format shown in Figure 1. MEM + 2% heat-inactivated fbs serves as experiment medium. To each of triplicate test wells containing replicate cell monolayers, 100 μ l of each test drug solution (or suspension) and 100 μ l of experiment virus are dispensed. Six 0.5 log₁₀ concentrations of each drug beginning with 320 μ g/ml are used. Cell controls containing 200 μ l of medium, virus controls containing cells, medium and virus, and duplicate drug cytotoxicity controls containing cells, medium and each drug concentration are included on each plate. Blank wells, medium control wells, and drug color controls (drug + medium + MTT + SDS - no cells) accompany each test. The covered plates are incubated at 37 °C in a humidified atmosphere containing 2% CO₂.

On the day the CPE would normally be graded microscopically, 20 μ l of MTT (a 5 mg/ml solution in cell culture medium) is added to each well. The plates are incubated at 37 °C for seven hours to allow reduction of the MTT to the formazan form. Then 60 μ l aliquots of a 20% solution of SDS in 0.02N HCl are added to the plate wells. The plates are incubated overnight to allow the SDS to lyse the cells and dissolve the MTT formazan crystals. The absorbance (570 nm) of the contents of each well is determined by a plate reader. A plate reader is interfaced with a computer programmed to capture the data from the reader and calculate the ID₅₀, MTC₅₀ and TI.

Data (mean OD's) from an assay set up 11/10/88 with Selenazole (AVS-253) and Ara-A (AVS-1752) are summarized in Table 2. The VV inoculum was 32 CCID₅₀/0.1 ml.

In December we will begin screening compounds in Shipment 42 by the MTT procedure. As we accumulate data and calculate the results, we will be able to determine if any minor adjustments in volumes,

virus doses, or incubation times are needed. We will select compounds that have previously shown activity for retest simultaneously by the MTT procedure and the original CPE-inhibition assay procedure.

Table 2

MTT Assay
Vaccinia Virus in Vero Cells (Mean OD)

MTT Day 4 p.i.

<u>μg/ml</u>	AVS-1752 + VV	AVS-1752		AVS-253 + VV	AVS-253	
		TC ^a	Drug Color Control		TC ^a	Drug Color Control
0.32	0.83	2.24	0.28	0.62	2.32	0.25
1.0	1.16	2.20	0.23	0.84	2.03	0.24
3.2	1.89	2.15	0.24	1.37	1.85	0.22
10.0	1.77	1.83	0.24	1.36	1.30	0.25
32.0	1.51	1.55	0.23	1.03	1.03	0.24
100.0	0.83	0.98	0.23	1.16	1.14	0.21
VC ^b	0.75			0.75		
CC ^c	2.27			2.27		
Med. C. ^d	0.26			0.26		

Differential (CC-VC) = 1.52

MTT Day 5 p.i.

<u>μg/ml</u>	AVS-1752 + VV	AVS-1752		AVS-253 + VV	AVS-253	
		TC ^a	Drug Color Control		TC ^a	Drug Color Control
0.32	0.53	2.51	0.26	0.47	2.39	0.28
1.0	0.68	2.47	0.24	0.47	2.29	0.25
3.2	1.58	2.37	0.25	0.75	2.33	0.24
10.0	2.13	2.12	0.25	1.59	1.73	0.26
32.0	1.80	1.52	0.24	1.21	1.21	0.25
100.0	0.81	0.87	0.22	1.28	1.28	0.24
VC ^b	0.44			0.44		
CC ^c	2.49			2.49		
Med. C. ^d	0.30			0.30		

Differential (CC-VC) = 2.05

^a TC = Toxicity Control

^b VC = Virus Control

^c CC = Cell Control

^d Med. C. = Medium Color Control

3.3.2 Adenovirus Type 2 (AD2) Strain Adenoid 6

We have developed a more quantitative, objective method to measure AD2-induced CPE inhibition in cell cultures. The procedure is similar to that described for VV and employs MTT.

Adenovirus has proven to be difficult to adapt to an MTT assay. Initial experiments indicated that AD2-infected HEP-2 cells which show 100% CPE on microscopic examination still convert a considerable amount of MTT to the blue MTT formazan. Holding the cultures another day before adding MTT decreased the optical density (OD) readings of the virus control cell cultures as desired, but the viability of the uninfected HEP-2 cell controls decreased. Thus we needed a host cell type with which cultures would remain viable for longer time periods. Next, we used A549 cells for our host cultures. Our experiments in which Ribavirin was evaluated for activity against AD2 in A549 cells indicate that a high cell density (4×10^4 cells/well) is needed to reduce the drug toxicity and to obtain high OD readings (e.g., 1.1-1.2) on uninfected cell controls. We have tested Ribavirin against varying AD2 concentrations to determine a virus challenge sufficient to yield a mean OD in the untreated virus controls of $\leq 50\%$ of the mean OD of the uninfected cell controls. The virus dose, on the other hand, must be low enough to permit demonstration of the normal, predicted antiviral activity of Ribavirin. On duplicate assays in A549 cells, the ID_{50} of Ribavirin was 25 and 28 $\mu\text{g/ml}$ which is consistent with ID_{50} 's obtained by our old CPE-inhibition assay in HEP-2. It was necessary to hold the plates ≥ 5 days p.i. for the virus-infected control cells to give OD readings of $\leq 50\%$ of the cell control OD's.

After seeing a recent paper (D.M. Perron-Henry *et al.* J. Chem. Microbiol. 26:1445-1447, Aug. 1988) in which 293 cells were used to isolate adenoviruses, we decided to switch to the 293 cell line. Frozen cells of 293, a continuous-passage cell line derived from human embryonic kidney cells transformed by DNA fragments of Adenovirus type 5 (F.L. Graham *et al.*, J. Gen. Virol. 36:59-72, 1977), were obtained and grown in monolayer cultures in MEM + 9% heat-inactivated fbs. For MTT assays, 4×10^4 293 cells are seeded/well in the 96-well plates. Preliminary experiments indicate that an increased serum content of 5% fbs is preferable. As with the A549 cells, it is necessary to incubate test plates at least 5 days p.i. before adding MTT to the system.

Mean OD's on some recent assays are listed on Table 3. As can be seen, the drug cytotoxicity has been reduced, the activity is dose-responsive, but the percent inhibition at each drug level can be quite low. Use of the 293 cells for the AD2 assay does not seem to be an improvement over the A549 cells.

MTT can be used as an indicator for anti-AD2 activity, but such an assay will be a more severe challenge for candidate antiviral compounds as compared to the original microscopically graded CPE-inhibition assay. Before we decide that an MTT assay is inappropriate for AD2, we should retest a number of active compounds by the MTT procedure.

As an alternative to MTT, an ELISA assay could be developed. Or, if the number of compounds to be evaluated against AD2 is to be reduced, the original CPE-inhibition screening assay might suffice.

Table 3
MTT Assay
Adenovirus (120 CCID₅₀/0.1 ml) in 293 Cells

Medium: MEM + 5% heat-inactivated fbs

MTT Day 5 p.i.

$\mu\text{g/ml}$	11/3/88		10/13/88		% Red.
	AVS 1+AD2	TC ^a	AVS 1+AD2	TC ^a	
	Mean OD	Mean OD	Mean OD	Mean OD	
320	1.16	1.12	1.08	1.01	54.8
100	1.26	1.57	1.08	1.19	54.8
32	1.09	1.78	0.69	1.53	23.4
10	0.70	1.86	0.42	1.50	1.6
3.2	0.75	1.77	0.38	1.53	0
1.0	0.70	1.77	0.38	1.54	0
0.32	0.75	1.86	0.37	1.59	0
VC ^b	0.75			0.40	
CC ^c	1.92			1.64	

Medium: MEM + 9% heat-inactivated fbs

MTT Day 5 p.i.

	11/10/88		11/17/88	
320	1.06	1.07	1.07	0.76
100	1.14	1.31	1.06	0.73
32	1.19	1.53	1.30	0.89
10	0.94	1.52	1.10	1.18
3.2	0.77	1.57	0.80	1.84
VC ^b	0.69			0.87
CC ^c	1.56			1.98

^aTC = Toxicity Control

^bVC = Virus Control

^cCC = Cell Control

3.3.3 Exotic RNA Viruses (PT, VEE, YFV, JE, SF)

Development of the MTT assay for screening of compounds against the five exotic RNA viruses PT, VEE, YF, JE and SF was completed during this reporting period. This assay will be implemented in the next reporting period.

The standard procedure utilizes Vero cells seeded at 1.5×10^4 cells/well one day prior to infecting with virus stock at a concentration of 32 TCID₅₀/well. For PT and SF assays, cells are pretreated prior to infection with 2.0 $\mu\text{g/ml}$ and 2.5 $\mu\text{g/ml}$, respectively, DEAE-Dextran in HBSS for 30 minutes. Viruses are adsorbed for 30 minutes at 37 °C. A 2X drug is added which is serially diluted in semilog fashion (from 1.0 $\mu\text{g/ml}$ to 320 $\mu\text{g/ml}$). Plates are incubated for a time period that is dependent upon the virus used, to maximum CPE, observed microscopically and then treated with 1.38 mg/ml MTT for 7-8 hours. Cells are lysed with 10% SDS/0.1N HCL overnight at 37 °C. MTT-plates are read spectrophotometrically at 570 nm. Data are collected and analyzed in Lotus 123. See Figure 1 for the MTT assay plate configuration.

	1	2	3	4	5	6	7	8	9	10	11	12
A	MEDIA BLANKS						FBS OR PLASTIC BLANKS					
B	CONTROL	CELL CTRL.				CONTROL	CONTROL				CELL CTRL.	CONTROL
C	TOXICITY	CELL CTRL.		DRUG A		TOXICITY	TOXICITY		DRUG B		CELL CTRL.	TOXICITY
D	TOXICITY	CELL CTRL.		EXP.		TOXICITY	TOXICITY		EXP.		CELL CTRL.	TOXICITY
E	TOXICITY	CELL CTRL.				TOXICITY	TOXICITY				CELL CTRL.	TOXICITY
F	DRUG A	VIRUS CTRL.				DRUG A	DRUG B				VIRUS CTRL.	DRUG B
G	DRUG A	VIRUS CTRL.		high conc.		DRUG A	DRUG B		high conc.		VIRUS CTRL.	DRUG B
H	high conc. Drug A	Colorimetric Control				high conc. Drug B	Colorimetric Control					

Figure 1. MTT Assay Plate Configuration

Pichinde Virus (PIC) and Hantaan Virus (HTN)

Development of the Pichinde ELISA with an incorporated MTT assay has been completed. Utilization of this assay in place of the PIC plaque reduction assay will be implemented in the near future. The ascites and monoclonal antibodies will be supplied to us by Dr. Bill Barnett, Utah State University.

The standard operating procedure (SOP) utilizes Vero cells at a density of 1.5×10^4 cells/ml seeded one day prior to infecting with Pichinde stock at an MOI of 0.1. Virus is allowed to adsorb for 1 hour at 37 °C/5% CO₂, then removed. Plates are rinsed 1x with PBS. Drug is then added to experimental and toxicity control wells at a 2x concentration. An equal volume of complete medium is added to the wells making the final concentration of the drug 1x. Plates are incubated 5 days at 37 °C/5% CO₂. On Day 5, plates are washed with 1x PBS and fixed with a cold mixture of 50% ethanol/50% acetone for 20 minutes at 4 °C. Fixative is removed and plates are air dried at room temperature. Plates are blocked with PBS + 2% fetal bovine serum at 37 °C CO₂ for 1 hour. Then a dilution of monoclonal antibody, Pichinde ascites PIC.8D4 is added for 1 hour at 37 °C. The dilution of monoclonal antibody needs to be adjusted from lot to lot. Plates are washed 5x with wash solution (PBS/0.1% Tween-20).

Conjugate, horseradish peroxidase/anti-mouse IgG, is added for 1 hour at 37 °C. Plates are rinsed 5x with wash solution. HRP substrate solution (ABTS) is added for 1 hour at 37 °C. Plates are read spectrophotometrically at 415 nm. Data is analyzed in Lotus 123. A diagram of the ELISA plate configuration is shown in Figure 2.

	1	2	3	4	5	6	7	8	9	10	11	12
A												
B	Conjugate ctrl. (virus)			DRUG A			DRUG B			DRUG C		
C	Monoclonal ctrl. (virus)			EXP.			EXP.			EXP.		
D	Virus ctrl.											
E	Cell ctrl.											
F	Monoclonal ctrl. (no virus)											
G	Conjugate ctrl. (no virus)			high conc.			high conc.			high conc.		
H												

Figure 2. ELISA Experimental Plate Configuration

To account for drug toxicity, a duplicate plate is assayed utilizing MTT. Plates are seeded at the same density as ELISA plates with Vero cells. Cells are treated with drug and are incubated 5 days at 37 °C/5%CO₂. On the 5th day a 1.38 mg/ml solution of MTT is added to the plate and incubated at 37 °C for 6-8 hours. The cells are lysed with 10% SDS/0.1N HCl overnight. Plates are scored spectrophotometrically at 570 nm. These data are merged with the ELISA data when they are collected and analyzed in Lotus 123 (plate layout, Figure 3).

	1	2	3	4	5	6	7	8	9	10	11	12
A												
B			DRUG A			DRUG B			DRUG C			
C			EXP.			EXP.			EXP.			
D	cells											
E		CELL CONTROL										
F	BLANK		TOX.	TOX.	COLOR CORRECTION	TOX.	TOX.	COLOR CORRECTION	TOX.	TOX.	COLOR CORRECTION	no cells
G			high conc.			high conc.			high conc.			
H												

Figure 3. ELISA Toxicity Plate (MTT) Configuration

The HTN ELISA development is now being pursued in collaboration with Dr. John Huggins and Dr. Z. Zhang, Ft. Detrick, Maryland. When we have established a standard operating procedure (SOP), we will include this assay protocol into our testing rotation. The titrated virus stocks and monoclonal antibody will be provided to us by Dr. Huggins.

Comparative Data - MTT vs. CPE-Inhibition Assay

When the development of the MTT assay was completed, a series of compounds was tested against the "exotic" RNA viruses. In these comparative trials both MTT- and CPE-inhibition assays were simultaneously executed. The data produced from these assays were examined and analyzed with different computer software (MTT - Lotus 123, CPE-inhibition - R-Base); however, the same parameters for analysis were implemented. The parameters include MTC, ID₅₀, and TI. The CPE data are available in Appendix B. The software of the MTT-generated data was modified before the assays were analyzed; therefore, data input is not in the proper format to yield TI and ID₅₀ values. In order to establish a more uniform reporting of these data, we selected to display graphs of percent reduction (of CPE) for both assays (Figures 4a,b through 6a,b). The determination of percent reduction CPE in the CPE-inhibition assay is referenced in the footnote to Table 5 (Sidwell and Huffman, Appl. Microbiol. 22:797, 1971). The percent reduction for the MTT is determined by the following formula:

$$\frac{\begin{array}{c} \text{(The average optical densities of the} \\ \text{experimental wells} \\ \text{at a given concentration of drug)} \\ \text{(Exp Values)} \end{array}}{\begin{array}{c} \text{(Operating Range, cc - vc)} \end{array}} \times 100$$

Where cc = cell control and vc = virus control optical densities.

After examining the data in this matter we made the observation that MTT assay utilization would be more beneficial than the CPE-inhibition technique for several reasons. First, the CPE-inhibition assay which yields VR, MTC, ID₅₀ and TI values from microscopic examination is a very subjective approach to analyzing antiviral screening tests. The method grossly underestimates the drugs' effects on the cellular metabolism. Very high concentrations of drug are necessary with most compounds in order to microscopically observe structural changes in the cells. In reality, drugs affect the metabolic activities of a cell, i.e., translation, transcription, glycosylation and cellular metabolite pool size before structural changes are microscopically apparent. On the contrary, the MTT assay is more reliable for depicting the activity of an experimental well than the CPE-inhibition assay because it can measure the metabolic events in the cells. Furthermore, the MTT assay overcomes the traditional problems of measuring the drug's effect on the cells. Secondly, by using the MTT assay, it removes the technicians' bias in quantitating numerical values when evaluating toxic drug effect on the cells and antiviral activity, and replaces experimental reading with spectrophotometric reading of the assays. Thirdly, an automated assay system which utilizes computer analysis yields reproducible results and allows for a more rapid turnover of compounds being tested.

These reasons primarily emphasize the cytotoxicity and automation aspects which benefit the antiviral screening program. There are also several reasons to convert to the MTT assay based on the drug antiviral effect analysis. When analyzing antiviral activity in CPE-inhibition assays, you can produce as much as a 25% error in measuring CPE (measuring criteria is defined in quarters of 100%; 0 = 0%, 1 = 25%, 2 = 50%, 3 = 75%, 4 = 100% CPE). Data points are extrapolated from estimates made visually when scoring assays. This is also subject to technicians' bias. The MTT assay, on the other hand, will identify the data points exactly, rather than estimating a percentage of structural change caused by virus (and drug). Also, viruses that are marginal CPE producers (i.e., SF and PT) are inherently more difficult to score microscopically; thus MTT assays should eliminate the difficulty in determining assay results.




Figure A. AVS-4407^a vs. Japanese Encephalitis (9/27/88).




Figure B. AVS-4409 vs. Japanese Encephalitis (9/27/88)




Figure A. AVS-4408 vs. Japanese Encephalitis (9/27/88).




Figure B. AVS-0001 vs. Japanese Encephalitis (9/27/88).

Figure 5.




Figure A. AVS-253 vs. Japanese Encephalitis (9/27/88).




Figure B. AVS-4406 vs. Japanese Encephalitis (9/27/88).

Figure 6.

In conclusion, we have observed similar trends of antiviral activity with other RNA viruses as depicted by the JE data in both assay methods. We have used ribavirin, selenazofurin and other more toxic compounds as standards in our assay comparison trials. The errors and biases of the CPE-inhibition (VR) assay were corrected by the MTT assay. The MTT method will yield more reliable and accurate data, reflecting the drugs' actual effect on the cells and viruses. The automation of the data analysis is an added improvement to our primary screening program and should expedite overall performance considerably in the future.

3.4 Antiviral Evaluations *In Vivo*

3.4.1 Acute Toxicity Determinations

To perform a complete acute toxicity assay, a minimum of 4 grams of compound was needed. Because most compounds supplied to us for *in vivo* testing were available in insufficient amounts to permit both preliminary acute toxicity determinations and antiviral evaluations, preliminary acute toxicity assays were not routinely performed. Instead, compounds were processed directly into antiviral screening assays in which acute toxicity drug control animals were included. Studies performed in murine systems were dosed once daily for 7 days at 320, 100, 32, and 10 mg/kg/day, while hamster systems were conducted similarly except that dosage levels were 100, 32, 10 and 3.2 mg/kg/day. With this format we were able to assess the toxicity of compounds available in as little as 2 gm quantities. In some cases toxicity information was already available; consequently, the dose levels were adjusted appropriately based on that information.

When sufficient compound was available to determine the 10% lethal dose (LD_{10}) of a potential antiviral compound, a two phase acute toxicity protocol was used. The first phase was a range finding procedure in which the test compound was administered on the desired route and frequency schedule at half- $\log_{10}$ dilutions starting at 1000 mg/kg. Body weights were recorded each day that compound was administered. Animals were monitored for mortality for 7 to 14 days after the last compound dose was administered. From this preliminary range-finding assay the LD_{10} dose was bracketed. Five dose levels of compound within the LD_{10} range were administered in groups of 10 mice on the desired route and frequency schedule. The animals were monitored as for the range finding assays and the LD_{10} dose was determined by plotting on probit paper.

3.4.2 Pichinde Virus

A therapeutic testing protocol was used for evaluating the antiviral activity of compounds against Pichinde virus infection of MHA hamsters. Soluble compounds were diluted in PBS (pH 7.2) while insoluble compounds were diluted and homogenized in 0.4% carboxymethylcellulose (CMC) in PBS. The compounds were prepared at concentrations appropriate for dosing animals at 0.1 ml of compound per 20 gm of body weight. If there were no stability problems noted on the compound data sheets then compound quantities adequate for the first half of the experiment were prepared on the first day of dosing. The remaining compound was prepared on experimental day 2 or 3. The prepared compounds were maintained sterily at 4 °C when not in use. The compounds are prepared at concentrations appropriate for dosing animals at 0.1 ml of compound per 20 gm of body weight. Hamsters (4-wk old, 60-80 gm) were infected intraperitoneally (IP) with 1×10^4 PFU of Pichinde virus strain An 4763 in a volume of 0.5 ml of MEM/2% FCS. Fifteen hamsters (5 uninfected, 10 infected) were treated subcutaneously (SC) at each compound dose level once daily for 7 days (q1d x 7) with the first dose administered 4 hours after virus challenge. The virus challenge, consisting of 1×10^4 pfu, is administered IP in a volume of 0.5 ml. The amount of compound administered per hamster is based on the average cage weight (5 hamsters/cage). Because of compound quantity limitations, the highest dose of compound generally tested was 100 mg/kg with 3-4 serial half- $\log_{10}$ dilutions below this level. Treatment groups included the test compound dilutions as well as the diluent used for compound preparation. Controls included (1) untreated, uninfected animals, (2) untreated, infected animals, (3) virus diluent-treated animals and (4) ribavirin (positive control) treated animals.

Compounds showing some indication of *in vivo* efficacy in the primary testing protocol are reevaluated when adequate quantities are available. The protocols for these retests vary with the compound being evaluated. Some compounds were retested on an extended treatment schedule. In such cases, the compound was administered on a q1d x 10 or a q1d x 12 schedule with the first compound dose administered on Day -1, and the second dose administered 2 hours prior to virus inoculation on the day of virus challenge (Day 0).

3.4.3 Venezuelan Equine Encephalomyelitis Virus

A prophylactic treatment protocol was used for evaluating the antiviral activity of compounds against Venezuelan Equine Encephalomyelitis virus infection of CD-1 outbred mice. Compounds submitted for *in vivo* evaluation were diluted in phosphate buffered saline (pH 7.2) if they were soluble or they were diluted and homogenized in 0.4% CMC in PBS if they were insoluble. Compounds were prepared at concentrations consistent with a dose volume of 0.1 ml of compound per 10 gm of body weight. Adequate compound was prepared for the entire treatment schedule unless the compound data sheet indicated that the compound was unstable. Unstable compounds were prepared immediately before administration. Diluted compounds are held at 4 °C when not in use. All compound administration was by the SC route on an individual animal weight basis. Mice are challenged IP with an LD₅₀ dose of virus in a volume of 0.5 ml of MEM/2% FCS. Fifteen female CD-1 mice (18-21 gm) were treated at each compound dose level on a q1d x 7 schedule starting day -1. Because of compound quantity limitations, the highest dose of compound generally tested was 320 mg/kg with 4 serial half-log dilutions below this level. Treatment groups included the test compound dilutions as well as the diluent used for compound preparation. Controls included (1) untreated, uninfected animals, (2) untreated, infected animals, and (3) virus diluent treated animals. No positive control drug was available for this model.

3.4.4 Japanese Encephalitis Virus

A prophylactic treatment protocol was used for evaluating the antiviral activity of compounds against Japanese Encephalitis virus infection of inbred C57Bl/6 mice. Compounds submitted for *in vivo* evaluation were diluted in PBS (pH 7.2) if they were soluble or they were diluted and homogenized in 0.4% CMC in PBS if they were insoluble. In some cases, compounds were solubilized in ethanol or DMSO prior to dilution in PBS or 0.4% CMC/PBS. Compounds were prepared at concentrations consistent with a dose volume of 0.1 ml of compound per 10 gm of body weight. If there were no stability problems noted on the compound data sheet then compound quantities adequate for the first half of the experiment were prepared on the first day of dosing. The remaining compound was prepared on experimental day 2. Unstable compounds were prepared immediately before administration. Diluted compounds were held at 4 °C when not in use. Compound administration was primarily by the SC route on an individual animal weight basis; however, in some cases IP route was used for comparative purposes. Mice were challenged IPly with an LD₅₀ dose of virus in a volume of 0.5 ml of MEM/2% FCS. Fifteen female C57Bl/6 mice were treated at each compound dose level on a qld x 7 schedule starting day -1. Because of compound quantity limitations, the highest dose of compound generally tested was 320 mg/kg with 4 serial half-log dilutions below this level. Treatment groups included the test compound dilutions as well as the diluent below this level. Treatment groups included the test compound dilutions as well as the diluent used for compound preparation. Controls included (1) untreated, uninfected animals, (2) untreated, infected animals, and (3) virus diluent treated animals. No positive control drug was available for this model. Mice were challenged with an LD₁₀ dose of virus given IP in a volume of 0.5 ml.

3.4.5 Vaccinia Virus Intracranial Challenge

A prophylactic treatment protocol was used for evaluating the antiviral activity of compounds against Vaccinia virus infection of CD-1 outbred mice. Compounds submitted for *in vivo* evaluation were diluted in PBS (pH 7.2) if they were soluble or they were diluted and homogenized in 0.4% CMC in PBS if they were insoluble. In some instances the compounds were solubilized in DMSO prior to dilution in PBS or 0.4% CMC/PBS. Compounds were prepared at concentrations consistent with a dose volume of 0.1 ml of compound per 10 gm of body weight. If there were no stability problems noted on the compound data sheet then compound quantities adequate for the first half of the experiment were prepared on the first day of dosing. The remaining compound was prepared on experimental day 2. Unstable compounds were prepared immediately before administration. Diluted compounds were held at 4 °C when not in use. Compound administration was by the SC or by the IP route on an individual animal weight basis. Mice were challenged intracranially with an LD₅₀ dose of virus in a volume of 0.03 ml of MEM/2% FCS. Fifteen female CD-1 mice (18-21 gm) were treated at each compound dose level on a qld x 7 schedule starting day -1. Because of compound quantity limitations, the highest dose of compound generally tested was 320 mg/kg with 4 serial half-log dilutions below this level. Treatment groups included the test compound dilutions as well as the diluent used for compound preparation. Controls included (1) untreated, uninfected animals, (2) untreated, infected animals, and (3) virus diluent treated animals. Ara-A was the positive control drug for this model.

3.4.6 Vaccinia Virus Induced Tailpox Model

The IHD strain of vaccinia virus, passed once in mouse brain and once in primary rabbit kidney cell culture, was used. Random-bred Swiss mice (CD-1TM, VAF+, Charles River Laboratories, Inc.), weighing 18-21 grams, were inoculated via the tail vein (1 cm from the base) with 0.2 ml of a 1:40 dilution of the virus suspension. Compounds were administered SC once daily for 7 days with the first dose given the day preceeding virus challenge. Uninfected drug-treated toxicity controls were included for each treatment administered. Animals were sacrificed on the sixth day and their tails were stained with a solution of 1% fluorescein-0.5% methylene blue in 70% methanol. Lesions were enumerated under ultraviolet light (354 nm) with the aid of a hand lens. The average number of lesions for each treatment group was calculated prior to, and following square root transformation of the individual tailpox counts. Tailpox

counts from each treatment group were statistically compared by Student's T-test. Ara-A was used as a positive control drug in this model.

3.5 Data Analysis and Processing

An R:Base 5000 data management program was supplied to us by Technassociates, Inc. All *in vitro* testing results generated at the BL-3 facility were entered into the data management program using a personal computer, then transferred via modem from the off-site containment laboratory to the central data office, located at the SRI home-site facilities, for further processing. Raw data from the home-site laboratories were directly submitted to this central data office for processing. Pertinent information, such as study identification, AVS number, drug concentrations, and individual test data, was entered into data forms within the data management program. Data were then cycled through a program that calculated the virus rating (VR), minimum toxic concentration (MTC), 50% inhibitory dose (ID_{50}), and therapeutic index (TI). Floppy diskettes containing these data were submitted to Technassociates, Inc. on a regular weekly basis for input into their VAX computer database. Periodically, an updated cumulative summary of all antiviral test results was routed internally to Task Leaders as well as to Technassociates, Inc.

Summaries of the raw *in vivo* data were sent to Technassociates, Inc. as they were produced. We are awaiting a program for entry of *in vivo* data into our computer so that we can transfer data directly to the VAX computer databank. Until this program is available, we will continue to submit copies of our raw data to Technassociates, Inc.

4. RESULTS

4.1 Antiviral Screening *in Vitro*: DNA Viruses and Exotic RNA Viruses

During the twelve-month reporting period from November 15, 1987 to November 14, 1988, a total of 1036 test compounds were received at SRI for evaluation in the primary *in vitro* antiviral screen. Compounds received in amounts too small for appropriate evaluation against all of the viruses were screened according to a priority list of the target viruses. During this reporting period compounds were evaluated *in vitro* against Vaccinia Virus (VV), Adenovirus (AD2), Vesicular Stomatitis Virus (VSV), Punta Tora Virus (PT), Sandfly Fever Virus (SF), Yellow Fever Virus (YF), Japanese Encephalitis Virus (JE), Venezuelan Equine Encephalomyelitis Virus (VEE) and Pichinde Virus (PIC) as they were received. Testing of antiviral compounds against Hantaan Korean Hemorrhagic Fever Virus (KHF) was temporarily suspended in order to develop an ELISA assay for evaluating the compounds. A cumulative summary of the compound shipments received, and the assays performed, is presented in Table 4.

Approximately 9000 *in vitro* antiviral assays were performed this reporting period. The results for compounds found to be active are summarized in the sections below for each virus: Also, we are retesting those compounds that demonstrated the greatest activity in the initial CPE-inhibition assays in confirmatory CPE-inhibition assays and plaque-reduction assays. These results are shown below. A cumulative summary presenting all of the *in vitro* antiviral tests results (both positive and negative) is included as Appendix B.

4.1.1 Vaccinia Virus (VV)

During the time period covered by this report 50 compounds demonstrated significant antiviral activity in the primary screen, as indicated by VR's of ≥ 1.0 and TI values > 1.0 (See Table 1 in Appendix A for a complete listing). Marked efficacy and selectivity against VV were shown by fifteen of the active compounds (Table 5) with VR's > 5.5 and TI's > 100 . The most active compounds were AVS numbers 3679, 1985, 4227, 4533, 4224, 4226, 3912, 3607, and 4225, all with VR's ≥ 7.9 . The potency and selectivity of these compounds are shown by ID_{50} 's $< 0.32 \mu\text{g/ml}$ and therapeutic indices > 1000 .

Table 4

Primary *In Vitro* Antiviral Screen
Target Viruses and Numbers of Compounds Tested Through November 14, 1988

Shipment Number	Compounds Per Shipment	Date Received	PT	VEE	YFV	HTN	PIC	JE	SF	VV	AD2	VSV
1	28	05/02/86	28	16	26	--	25	27	24	25	25	25
2	27	05/23/86	26	25	25	--	24	27	25	24	24	24
3	32	06/03/86	32	32	32	--	32	32	32	--	--	1
4	19	06/20/86	19	19	19	1	19	19	19	15	15	15
5	22	07/10/86	21	22	20	--	21	21	19	21	21	21
6	26	07/24/86	26	26	26	--	24	26	26	26	26	26
7	26	07/31/86	25	22	26	--	24	26	26	26	26	26
8	27	08/22/86	27	27	27	--	22	27	26	26	26	26
9	42	09/12/86	42	4	39	--	22	36	28	24	24	24
10	28	09/25/86	28	--	28	--	15	28	28	28	28	28
11	32	10/17/86	32	--	32	--	27	32	17	32	32	32
12	40	11/3-11/4/86	40	2	40	--	40	40	39	40	40	40
13	23	11/13/86	20	--	20	--	23	21	21	23	23	23
14	1	11/13/86	1	1	1	--	1	1	1	1	1	1
15	26	12/05/86	26	--	26	--	24	10	24	26	26	26
16	32	12/12/86	31	--	32	--	21	--	32	32	32	32
17	30	01/13/87	30	--	30	--	27	30	30	30	30	30
18	32	01/30/87	32	--	32	--	32	32	32	32	32	32
19	101	03/02/87	96	55	99	--	66	99	98	101	101	101
20	71	03/18/87	69	6	60	--	40	49	64	45	45	46
21	75	04/14/87	74	1	71	--	28	68	55	57	57	57
22	49	05/05/87	46	9	48	--	34	46	41	46	46	46
24	77	06/03/87	68	2	8	--	7	8	5	10	10	10
25	8	06/12/87	6	4	7	--	5	8	7	8	8	8
26	71	06/26/87	41	--	70	--	65	70	68	67	67	70
27	86	07/21/87	77	8	45	33	39	47	81	45	45	46

Table 4 (Cont'd.)

Shipment Number	Compounds Per Shipment	Date Received	PT	VEE	YFV	HTN	PIC	JE	SF	VV	AD2	VSV
28	102	08/10/87	22	9	96	1	76	11	26	11	11	11
29	116	08/19/87	40	22	103	--	82	39	35	7	7	7
30	75	09/03/87	60	60	57	1	27	71	60	30	30	30
31	86	09/11/87	66	66	23	0	0	63	70	70	68	70
32	123	10/09/87	42	19	4	1	20	60	19	109	109	109
33	107	11/03/87	6	6	58	--	4	32	3	24	24	24
34	49	11/25/87	34	49	49	--	--	45	39	19	19	19
35	80	12/22/87	32	79	64	--	1	64	46	28	28	28
36	65	01/29/88	62	62	50	--	--	62	62	58	58	60
37	48	02/09/88	40	40	40	--	--	40	40	36	36	38
38	5	03/15/88	4	3	4	--	4	4	4	4	4	4
39	68	03/23/88	68	68	37	--	1	66	68	67	67	68
40	57	04/26/88	55	47	15	--	--	55	40	29	29	29
41	30	05/13/88	29	20	28	--	26	29	28	29	29	29
41B	30	05/13/88	29	20	28	--	26	29	28	29	29	29
41C	4	05/13/88	4	4	4	--	4	4	4	3	3	3
42	66	05/13/88	65	53	64	--	--	65	64	37	37	37
43	140	07/08/88	112	66	49	--	--	126	138	32	33	31
44	89	08/10/88	34	29	29	--	--	32	25	33	34	33
45	76	09/13/88	--	--	--	--	--	--	--	34	36	27
46	126	10/06/88	15	6	15	--	10	17	15	80	80	18
47	2	10/20/88	1	--	1	--	--	1	--	1	1	1
48	101	11/02/88	15	13	14	--	9	14	11	14	16	13
Total	2676		1798	1022	1721	37	997	1759	1693	1594	1599	1534

Table 5

Compounds Most Active Against Vaccinia Virus^a


<u>AVS No.</u>	<u>Shipment</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
3679	32	≥9.8	3.3	≤0.01	100	10,000
1985	41b	10.2	3.4	0.006	32	5650
4227	42	8.7	2.9	0.08	320	3880
4533	42	9.2	3.1	0.1	>320	>3010
4224	42	8.4	2.8	0.2	>320	>1760
4226	42	8.3	2.8	0.2	>320	>1340
3912	34	7.9	2.6	0.3	>320	>1070
3607	32	8.0	2.7	<0.1	>320	>1000
4225	42	7.9	2.6	0.3	>320	>1000
3941	35	6.8	2.3	1.0	>320	>325
4530	42	5.9	2.0	1.2	320	263
4620	43	6.1	2.0	1.5	>320	>206
4619	43	6.0	2.0	1.8	>320	>180
4621	43	5.9	2.0	2.0	>320	>160
4622	43	5.6	1.9	2.8	>320	>114

^aCompounds identified by AVS number are listed in descending order of activity as measured by the therapeutic index (TI). The VR is a measurement of selective antiviral activity which takes into account the degree of inhibition of virus-induced CPE and the degree of cytotoxicity produced by the test compound, determined by a modification of the method of Ehrlich *et al.* (Ann. N.Y. Acad. Sci. 130:5, 1965). VR* is the designation for the virus rating calculated by the method of Sidwell and Huffman (Appl. Microbiol. 22:797, 1971). The drug concentration which reduced the CPE by 50% (50% inhibitory dose, ID₅₀) was calculated using a regression analysis program for semilog curve fitting and is expressed as $\mu\text{g/ml}$. The minimum cytotoxic drug concentration (MTC) is also expressed as $\mu\text{g/ml}$. The TI of a test compound was determined by dividing the MTC by the ID₅₀.


Confirmatory retests of active compounds were performed, employing the CPE-inhibition assay procedure in Vero cell monolayer cultures. The data from the retests which were carried out during the report period are summarized on Table 6. The results from the primary and the subsequent CPE-inhibition assays are listed chronologically for each compound. Of the 71 active compounds listed the antiviral activity observed in the original evaluation, in terms of inhibition (VR), potency (ID₅₀) and selectivity (TI), were confirmed for all except six of the drugs. The original activity of each of these six compounds was minimal (VR 1-1.6); differences in drug cytotoxicity (MTC) and <50% CPE-inhibition contributed to the variability of retests in which VR's were <1.0.

Two positive control drugs, Ara-A (AVS 1752) and Selenazole (AVS 253), were tested in each batch of VV CPE-inhibition assays. The inhibitory effects of Ara-A and Selenazole were fairly consistent. For Ara-A, the VR averaged 3.1, the ID₅₀ averaged 2.6 $\mu\text{g/ml}$, and the MTC was 32 or 10 $\mu\text{g/ml}$. For Selenazole, the VR averaged 2.3, the ID₅₀ 1.01 $\mu\text{g/ml}$, and the MTC was 32 or 10 $\mu\text{g/ml}$.


Nine of the more active candidate antiviral compounds were further evaluated for efficacy against VV by plaque reduction assays in Vero cells. The data obtained from the plaque reduction assays are summarized on Table 7. The potency and selectivity of each of the compounds were again confirmed. Ara-A served as the positive control. The actual plaque numbers and percent of control for each drug are plotted and displayed in Figures 7 through 12.




Plaque Reduction Assay with Vaccinia Virus
Figure 7




Plaque Reduction Assay with Vaccinia Virus
Figure 8




Plaque Reduction Assay with Vaccinia Virus
Figure 9



Plaque Reduction Assay with Vaccinia Virus
Figure 10



Plaque Reduction Assay with Vaccinia Virus
Figure 11



Plaque Reduction Assay with Vaccinia Virus
Figure 12

Table 6

Confirmatory Assays for
Compounds Active Against Vaccinia Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>Date Tested</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
71	2	07/24/86	1.7	0.6	81	320	3.9
	41b	05/26/88	1.9	0.6	58	320	5.6
79	1	07/17/86	1.7	0.6	32	100	3.1
	33	02/04/88	1.1	0.4	112	100	0.9
	41b	05/26/88	1.7	0.6	98	320	3.3
94	1	06/12/86 ^b	1.3	0.4	-	>320	-
		07/07/86	0	0	-	>320	-
		04/21/88	1.4	0.5	258	320	1.2
148	2	07/24/86	5.4	1.8	1.0	100	100
	41b	05/26/88	3.5	1.2	0.8	3.2	4.1
215	1	07/17/86	≥4.2	1.4	0.7	3.2	≥4.6
	41b	05/26/88	3.3	1.1	0.8	3.2	3.9
272	1	06/17/86	4.7	1.6	0.6	3.2	5.3
	41b	05/26/88	4.3	1.4	0.6	3.2	5.7
303	1	07/17/86	5.2	1.7	0.6	10	16
	46	10/27/88	5.5	1.8	0.3	32	100
	46	11/10/88	6.3	2.1	0.2	100	410
707	30	10/22/87	2.0	0.7	17	100	5.9
		11/12/87	0.7	0.2	24	32	1.3
		05/12/88	1.2	0.4	129	320	2.5
1159	27	08/13/87	1.5	0.5	22	100	4.5
		05/12/88	1.4	0.5	22	100	4.6
1160	27	08/07/86	5.5	1.9	0.6	100	166
		05/12/88	2.6	0.9	5.7	10	1.7
1392	33	02/04/88	1.5	0.5	123	320	2.6
		02/18/88	1.7	0.6	100	100	1.0
1654	46	10/13/88	3.9	1.3	2.0	10	5.0
	46	10/27/88	4.3	1.4	3.1	100	32
1947	28	08/27/87	1.5	0.5	7.8	32	4.1
		05/12/88	0.9	0.3	-	100	-
1985	2	07/24/86	≥7.2	≥2.4	<0.32	100	313
	41b	05/26/88	10.2	3.4	0.006	32	5650

Table 6 (Cont'd.)

Confirmatory Assays for
Compounds Active Against Vaccinia Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>Date Tested</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
1986	2	07/24/86	≥7.4	≥2.5	0.6	>320	>533
	41b	05/26/88	7.2	2.4	0.7	>320	>487
1987	2	07/24/86	6.8	2.3	1.7	>320	>188
	41b	05/26/88	5.6	1.9	2.8	>320	>114
1988	2	07/24/86	6.4	2.1	3.6	>320	>89
	41b	05/26/88	5.9	2.0	2.0	>320	>160
2170	8	10/16/86	4.7	1.6	1.3	10	7.7
	41c	06/16/88	5.0	1.7	0.9	32	37
2275	12	12/04/86	2.1	0.7	23	100	6.8
		01/21/88	1.9	0.6	16	100	6.2
2290	11	11/13/86	3.2	1.1	5.7	32	5.6
		05/12/88	2.7	0.9	16	100	6.1
2297	11	12/04/86	3.4	1.1	5.0	32	6.4
		01/21/88	4.0	1.3	3.6	100	27
2321	13	12/18/86	1.4	0.5	0.5	1	2.0
		04/21/88	1.1	0.4	0.8	3.2	4.2
2323	13	12/11/86	2.8	0.9	2.4	10	4.3
		05/12/88	4.5	1.5	2.7	100	37
2326	13	12/11/86	1.7	0.6	100	>320	>3.2
	41b	05/26/88	2.1	0.7	67	>320	>4.7
2336	13	12/11/86	1.5	0.5	88	320	3.6
		05/12/88	0.6	0.2	307	320	1.0
2449	18	02/12/87	1.5	0.5	88	320	3.6
		05/12/88	1.7	0.6	75	320	4.3
2568	21	05/14/87	1.9	0.6	38	320	8.5
		01/02/88	2.9	1.0	18	320	18
2688	22	06/25/87	1.4	0.5	3.1	10	3.3
	41b	05/26/88	0.90	0.3	5.1	10	1.8
2716	22	05/28/87	1.6	0.5	13	100	7.7
	22	01/21/88	0.8	0.3	20	10	0.5
	46	05/12/88	0.8	0.3	16	32	2.0
	46	10/13/88	0.6	0.2	18	10	0.6

Table 6 (Cont'd.)

Confirmatory Assays for
Compounds Active Against Vaccinia Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>Date Tested</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
2786	24	07/02/87	1.1	0.4	71	320	4.5
		05/12/88	1.3	0.4	100	320	3.2
2893	26	07/16/87	1.7	0.6	87	320	3.7
		05/12/88	1.1	0.4	115	100	0.9
2906	26	07/30/87	2.2	0.7	11	100	8.7
		01/21/88	3.2	1.1	9.8	320	33
2964	27	08/20/87	2.3	0.8	21	100	4.9
		01/21/88	2.3	0.8	21	100	4.9
2966	27	08/13/87	2.2	0.7	23	100	4.4
		05/12/87	1.6	0.5	40	100	2.5
2991	27 41b	08/20/87	1.6	0.5	0.8	3.2	4.1
		05/26/88	0.8	0.3	5.6	10	1.8
2992	27	08/20/87	2.1	0.7	34	320	9.5
		01/21/88	1.3	0.4	100	320	3.2
2994	27	09/04/87	7.1	2.4	0.1	100	917
	27	09/24/87	8.6	2.9	0.09	320	3564
	46	10/27/88	8.7	2.9	0.06	320	5815
3513	33	02/19/88	2.5	0.8	18	100	5.5
		03/03/88	2.9	1.0	18	320	18
3586	32	03/03/88	3.2	1.1	0.4	3.2	8.9
		03/17/88	3.4	1.1	0.4	1	2.7
3593	32	10/22/87	4.2	1.4	0.3	10	40
	32	11/12/87	4.1	1.4	<0.3	1	>3.1
	32	01/21/88	4.0	1.3	0.4	1	2.8
	41b	05/26/88	4.2	1.4	0.4	1	2.8
3607	32	01/14/88	8.0	2.7	<0.1	>320	>1000
		02/04/88	7.2	2.4	0.3	>100	>306
		02/18/88	7.2	2.4	0.3	320	992
3679	32	01/21/88	9.8	3.3	0.01	100	10,000
		02/04/88	9.1	3.0	0.01	32	3200
		02/18/88	8.5	2.8	0.01	32	3200
3705	32	01/14/88	1.4	0.5	35	100	2.9
		02/04/88	1.1	0.4	50	100	2.0
3912	34	03/10/88	7.9	2.6	0.3	>320	>1075
		03/31/88	8.3	2.8	0.2	>320	>1609

Table 6 (Cont'd.)

Confirmatory Assays for
Compounds Active Against Vaccinia Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>Date Tested</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
3913	34	02/25/88	2.1	0.7	67	>320	>4.8
		03/10/88	2.1	0.7	43	320	7.4
3940	35	03/03/88	5.0	1.7	5.0	>320	>64
		03/17/88	4.4	1.5	9.5	>320	>34
3941	35	03/03/88	6.8	2.3	1.0	>320	>325
		03/17/88	6.6	2.2	1.1	>320	>285
3944	35	03/03/88	2.1	0.7	88	>320	>3.6
		03/17/88	1.8	0.6	100	>320	>3.2
3963	35	03/03/88	2.1	0.7	51	320	6.3
		03/17/88	2.4	0.8	18	100	5.6
4050	37	04/14/88	1.0	0.3	3.2	10	3.1
	37	06/16/88	0.8	0.3	--	32	--
	37	06/30/88	0.4	0.1	--	10	--
4163	41	06/02/88	1.3	0.4	64	100	1.6
	41	06/16/88	1.5	0.5	118	320	2.7
4182	39	04/21/88	1.0	0.3	32	>100	>3.1
	39	06/16/88	1.5	0.5	50	>100	>2.0
4210	41	06/30/88	5.5	1.8	0.03	0.1	2.9
	41	07/21/88	5.6	1.9	0.03	0.1	3.2
4224	42	07/07/88	8.4	2.8	0.2	>320	>1760
	42	07/21/88	7.7	2.6	0.3	>320	>996
4225	42	07/07/88	7.9	2.6	0.3	>320	>1000
	42	07/21/88	7.5	2.5	0.5	>320	>707
4226	42	07/07/88	8.3	2.8	0.2	>320	>1340
	42	07/21/88	7.7	2.6	0.4	>320	>849
4227	42	07/07/88	8.7	2.9	0.08	320	3880
	42	07/21/88	8.7	2.9	0.07	320	4100
4229	42	06/23/88	1.5	0.5	4.7	10	2.1
	42	07/07/88	1.3	0.4	5.3	10	1.9
4230	42	06/23/88	1.2	0.4	8.1	3.2	0.4
	42	07/07/88	1.8	0.6	5.6	10	1.8

Table 6 (Cont'd.)

Confirmatory Assays for
Compounds Active Against Vaccinia Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>Date Tested</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
4232	42	06/23/88	1.5	0.5	202	>320	>1.6
	42	07/07/88	1.4	0.5	176	>320	>1.8
4275	39	04/21/88	5.3	1.8	0.02	0.32	19
		04/29/88	4.4	1.5	0.03	0.32	10.0
4530	42	06/23/88	5.9	2.0	1.2	320	263
	42	06/30/88	7.2	2.4	0.5	>320	>708
4531	42	06/23/88	1.4	0.5	110	>320	>2.9
	42	07/07/88	2.0	0.7	89	320	>3.6
4532	42	06/23/88	1.7	0.6	103	320	3.1
	42	07/07/88	1.4	0.5	100	320	3.2
4533	42	07/07/88	9.2	3.1	0.1	>320	>3010
	42	07/21/88	8.0	2.7	0.2	320	1930
4588	42	06/23/88	1.0	0.3	60	32	0.54
	42	07/07/88	1.1	0.4	96	100	1.0
4619	43	07/21/88	6.0	2.0	1.8	>320	>180
	43	08/18/88	6.0	2.0	1.8	>320	>180
4620	43	07/21/88	6.1	2.0	1.5	>320	>206
	43	08/18/88	6.1	2.0	1.8	>320	>174
4621	43	07/21/88	5.9	2.0	2.0	>320	>160
	43	08/18/88	6.0	2.0	1.8	>320	>180
4622	43	07/21/88	5.6	1.9	2.8	>320	>114
	43	08/18/88	6.0	2.0	1.8	>320	>180
4864	46	06/16/88	1.1	0.4	320	>320	>1.0
	46	06/30/88	1.0	0.3	--	>320	--
	46	10/13/88	2.1	0.7	32	320	10
	46	10/27/88	1.9	0.6	57	320	5.6

a. Compounds are listed in ascending numerical order by AVS number. The results from the primary and the subsequent confirmatory CPE-inhibition assays are listed chronologically for each compound. The abbreviations are defined in the footnote to Table 5.

b. Host Cells used on 6/12/86 were L929 instead of Vero.

Table 7

Plaque Reduction Assays for Compounds Active
Against Vaccinia Virus^a

AVS No.	Shipment	ID ₅₀ (μ g/ml)	MTC (μ g/ml)	TI	Date Tested
1985	2	0.005	10	2003	4/03/87
2964	27	6.8	>320	>46	9/23/88
3513	33	4.7	>320	68	9/23/88
3533	31	0.5	320	681	4/08/88
3607	32	0.4	>320	>800	4/08/88
3679	32	0.007	100	15,151	7/15/88
3912	34	0.05	100	2000	7/15/88
3940	35	0.5	>100	>207	9/23/88
3941	35	0.5	320	711	7/15/88
1752	(Ara-A)	<1.0	100	>100	4/08/88
1752	(Ara-A)	0.50	3.2	6	7/15/88
1752	(Ara-A)	0.39	32	81	9/23/88

^a Assay was done in Vero cells. The drug concentration which reduced the mean plaque number by 50% (50% inhibitory dose, ID₅₀) was calculated using a regression analysis program for semilog curve fitting and is expressed as μ g/ml. The minimum cytotoxic drug concentration (MTC) is the lowest drug concentration (μ g/ml) at which toxicity was observed. The therapeutic index (TI) was determined by dividing the MTC by the ID₅₀.

4.1.2 Adenovirus Type 2 (AD2)

A total of 28 compounds were identified during the report period as active against adenovirus type 2. Activity was defined as a VR of ≥ 1.0 and a therapeutic index (TI) greater than 1.0. Data from the primary evaluations of the active compounds are summarized in Appendix A, Table 2. The compounds are listed by AVS number in descending order of selectivity (TI). Marked efficacy and selectivity against AD2 were shown by 7 of the active drugs (Table 8). The most active compounds were AVS 4167 (VR 3.5, ID₅₀ 2.5 μ g/ml, TI 12.8) and AVS 4785 (VR 3.4, ID₅₀ 4.3 μ g/ml, TI 7.5). AVS 4530 is of particular interest because it also showed a marked inhibitory effect on VV replication (Table 5). This compound should be evaluated for its effect on other DNA viruses.

Table 8

Compounds Most Active Against Adenovirus Type 2*

AVS No.	Shipment	VR	VR*	ID ₅₀	MTC	TI
4167	41	3.5	1.2	2.5	32	12.8
4530	42	1.8	0.6	27	320	11.8
4871	46	2.1	0.7	32	320	10.0
4785	46	3.4	1.1	4.3	32	7.5
3910	34	1.2	0.4	56.5	320	5.7
4798	46	2.4	0.8	0.6	3.2	5.6
4796	46	2.4	0.8	17.9	100	5.6

a. Compounds identified by their AVS number are listed in descending order of activity as determined by selectivity (therapeutic index). An active compound is defined as having a therapeutic index (TI) of greater than 1.0 and a virus rating (VR) of 1.0 or greater. The VR is a measurement of selective antiviral activity which takes into account the degree of inhibition of virus-induced CPE and the degree of cytotoxicity produced by the test compound, determined by a modification of the method of Ehrlich *et al.* (Ann. N.Y. Acad. Sci. 130:5, 1965). VR* is the designation for the virus rating calculated by the method of Sidwell and Huffman (Appl. Microbiol. 22:797, 1971). The drug concentration which reduced the CPE by 50% (50% inhibitory dose, ID₅₀) was calculated using a regression analysis program for semilog curve fitting and is expressed as $\mu\text{g/ml}$. The minimum cytotoxic drug concentration (MTC) is also expressed as $\mu\text{g/ml}$. The therapeutic index of a test compound was determined by dividing the MTC by the ID₅₀.

Data obtained from confirmatory retests of compounds active against AD2 are summarized on Table 9. The retests were performed in HEP-2 cell monolayers utilizing the CPE-inhibition assay procedure. The activity of most of the compounds was confirmed. The reproducibility of the inhibitory effects of the active compounds was satisfactory considering the low levels of CPE-inhibition displayed by these drugs. Examination of the raw data indicates that the protective effect against AD2-induced CPE was frequently less than 100%.

Ribavirin (AVS 1) and Selenazole (AVS 253) were enlisted as positive control drugs for the AD2 assays. Data summaries show that Ribavirin averaged 2.2 (VR), 19.2 $\mu\text{g/ml}$ (ID₅₀), and 100 $\mu\text{g/ml}$ (MTC). Selenazole averaged a VR of 1.8, ID₅₀ of 31.1 $\mu\text{g/ml}$ and an MTC of 100 $\mu\text{g/ml}$.

Table 9
Confirmatory Assays for Compounds Active
Against Adenovirus Type 2*

<u>AVS No.</u>	<u>Shipment</u>	<u>Date Tested</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
79	1	09/11/86	1.3	0.4	2.3	10	4.4
		02/04/88	2.1	0.7	0.8	3.2	3.9
94	1	09/11/86	1.0	0.3	231.1	320	1.4
		04/21/88	1.0	0.3	222	>320	>1.4
136	4	09/25/86	1.3	0.4	96.9	320	3.3
	38	05/19/88	1.2	0.4	178.8	>320	>1.8
	41b	05/26/88	1.0	0.3	200	>320	>1.6
361	2	09/18/86	1.3	0.4	0.1	0.1	1.0
		10/30/86	0.6	0.2	0.3	0.1	0.3
		03/03/88	1.2	0.4	1.3	1.0	0.8
1215	27	08/13/87	1.1	0.4	62.9	320	5.1
		01/08/88	0.8	0.3	50.5	100	2.0
		01/21/88	1.3	0.4	53.7	320	6.0
		05/12/88	0.6	0.2	100	320	3.2
1337	33	02/04/88	1.5	0.5	88.4	320	3.6
		02/18/88	1.5	0.5	78.2	320	4.1
2247	12	11/20/86	1.3	0.4	-	>100	-
		01/08/88	0.0	0.0	-	>100	-
		01/21/88	0.7	0.2	-	>320	-
		05/12/88	0.0	0.0	-	>100	-
2296	11	12/04/86	1.2	0.4	10	32	3.2
		01/08/88	2.4	0.8	3.2	32	10.1
		01/21/88	2.0	0.7	10	100	10.0
2350 ^b	14	11/05/87	1.8	0.6	6.3	20	3.2
		02/04/88	0.6	0.2	-	20	-
		02/25/88	0.2	0.1	-	200	-
		05/26/88	0.6	0.2	63.1	200	3.2
2409	16	02/12/87	0.3	0.1	-	3.2	-
		04/10/87	1.5	0.5	2.8	10	3.6
		01/08/88	1.1	0.4	2	10	5.0
		05/12/88	0.3	0.1	-	10	-
	46	10/27/88	0.7	0.2	6.2	10	1.6
2563	21	01/14/88	1.1	0.4	46.8	100	2.1
		01/28/88	1.7	0.6	9.5	10	1.0
		03/03/88	1.7	0.6	20.6	100	4.9

Table 9 (Cont'd.)

Confirmatory Assays for Compounds Active
Against Adenovirus Type 2*

<u>AVS No.</u>	<u>Shipment</u>	<u>Date Tested</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MT₅₀</u>	<u>TI</u>
2716	22	05/28/87	1.1	0.4	12.6	32	2.5
		01/21/88	1.4	0.5	14.1	100	7.1
		05/12/88	1.3	0.5	9.6	32	3.3
2811	24	10/13/88	0.9	0.3	10.0	32	3.2
		01/21/88	1.7	0.6	0.4	0.3	0.9
		02/04/88	1.2	0.4	0.2	0.1	0.5
2812	24	02/25/88	1.1	0.4	0.1	0.1	0.7
		03/10/88	1.5	0.5	0.1	0.1	0.9
2960	27	08/13/87	1.2	0.4	44.4	100	2.3
		01/08/88	1.4	0.5	81.1	320	3.9
		05/12/88	0.8	0.3	-	320	-
2964	27	08/20/87	1.2	0.4	100.0	>320	>3.2
		05/12/88	0.7	0.2	-	>320	-
2979	25	07/09/87	1.7	0.6	11.4	32	2.8
	25	01/08/88	0.9	0.3	68.4	320	4.7
	25	01/21/88	1.8	0.6	35.3	100	2.8
	41b	05/26/88	1.3	0.4	10.0	32	3.2
2980	25	07/09/87	2.1	0.7	1.5	10	6.8
		10/29/87	2.0	0.7	1.0	3.2	3.3
		11/12/87	1.5	0.5	1.5	3.2	2.2
		05/12/88	1.2	0.4	5.0	10	2.0
2985	27	08/20/87	1.2	0.4	100	>320	>3.2
		05/12/88	0	0	-	>320	-
2986	27	08/20/87	1.7	0.6	100	320	3.2
		01/08/88	1.5	0.5	100	320	3.2
2988	27	08/20/87	1.0	0.3	70.9	320	4.5
		01/08/88	0.6	0.2	-	320	-
		01/21/88	0.5	0.2	-	320	-
		05/12/88	0.9	0.3	307	>320	>1.0
2994	27	08/20/87	1.5	0.5	25.5	25.5	3.9
		01/08/88	1.1	0.4	32.0	100	3.1
		01/21/88	0.7	0.2	64.1	100	1.6
3527	31	12/17/87	1.0	0.3	2.4	10	4.3
		05/12/88	0.4	0.1	-	100	-

Table 9 (Cont'd.)
Confirmatory Assays for Compounds Active
Against Adenovirus Type 2*

<u>AVS No.</u>	<u>Shipment</u>	<u>Date Tested</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
3529	31	01/28/88	1.3	0.5	1.6	3.2	2.0
		02/18/88	1.6	0.5	1.8	10	5.5
3577	32	01/28/88	1.4	0.5	96.4	320	3.3
		02/18/88	1.8	0.6	113.0	320	2.8
3593	30	10/22/87	2.7	0.9	3.7	10	2.7
		12/31/87	1.1	0.4	2.5	3.2	1.3
		01/21/88	1.2	0.4	1.8	3.2	1.8
		12/31/87	0.6	0.2	100	320	3.2
3610	32	05/12/88	1.3	0.4	50.7	320	6.3
3705	32	01/14/88	1.7	0.6	73.1	320	4.4
		02/04/88	1.1	0.4	118	320	2.7
		02/18/88	0.9	0.3	147	320	2.2
		05/12/88	0.6	0.2	320	>320	>1.0
3910	34	02/18/88	1.2	0.4	56.5	320	5.7
		03/10/88	1.1	0.4	204	>320	>1.6
4001	36	03/10/88	1.1	0.4	204	>320	>1.6
		03/31/88	1.0	0.3	320	>320	>1.0
4002	36	03/10/88	1.0	0.3	320	>320	>1.0
		03/31/88	0.8	0.3	-	>320	-
		04/14/88	0.3	0.1	-	>320	-
4004	36	03/10/88	1.2	0.4	193	>320	>1.7
		03/31/88	0.8	0.3	-	>320	-
		04/14/88	0.5	0.2	-	>320	-
4041	36	03/17/88	1.1	0.4	320	>320	>1.0
		04/21/88	1.1	0.4	320	>320	>1.0
4070	35	01/28/88	2.2	0.7	4.3	10	2.4
		02/18/88	2.3	0.8	3.8	32	8.5
4167	41	06/16/88	3.5	1.2	2.5	32	12.8
	41	06/30/88	2.3	0.8	6.6	32	4.8
4262	39	05/05/88	1.1	0.4	199	>320	1.6
	39	05/26/88	0.6	0.2	--	>320	--
	39	06/16/88	0.5	0.2	--	>320	--
4267	39	05/05/88	1.4	0.5	159	>320	2.0
	39	05/26/88	1.3	0.4	169	>320	1.9

Table 9 (Cont'd.)
Confirmatory Assays for Compounds Active
Against Adenovirus Type 2^a

<u>AVS No.</u>	<u>Shipment</u>	<u>Date Tested</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
4279	42	06/23/88	1.0	0.3	29.7	32	1.1
	42	07/27/88	1.0	0.3	40.3	100	2.5
4281	42	06/23/88	1.1	0.4	26.1	32	1.2
	42	07/07/88	1.1	0.4	37.6	100	2.7
4750	44	08/25/88	1.1	0.4	11.1	32	2.9
	44	09/01/88	0.4	0.1	8.4	10	1.2

a. Compounds are listed in ascending numerical order by AVS number. The results from the primary and the subsequent confirmatory CPE-inhibition assays are listed chronologically for each compound. Host cell were HEP-2. The abbreviations are defined in the footnote to Table 5

b. The ID₅₀ and MTC for AVS 2350 are expressed as units/ml.

4.1.3 Vesicular Stomatitis Virus (VSV)

Eight compounds of the 605 tested during this reporting period exhibited antiviral activity against vesicular stomatitis virus (VSV), strain Indiana, in L929 cells (Table 10). The two most active drugs tested and confirmed in the CPE-inhibition assay during this reporting period were AVS 3586 with a VR of 3.7 and 4.3 and a TI of 17.7 and 20.1, and AVS 4240 with a VR of 2.6 and 1.7 and a TI of 4.0 and 8.5 (Table 11).

AVS 2350 was retested twice during this reporting period. No activity was observed in the first retest and a VR of 2.0 and a TI of 31.7 were obtained in the second retest. The drug had previously been tested twice, once with negative and once with positive results. The data from all 4 tests are presented in Table 11.

The positive control drug AVS 303 was included in each assay. The VR ranged from 2.3 to 4.8, the ID₅₀ ranged from 0.6 to 3.9 $\mu\text{g/ml}$, and the TI ranged from 1.1 to 17.8. During the first 3 months of this reporting period, AVS 1 was used as a second positive control drug. The VR ranged from 0.5 to 1.9, the ID₅₀ ranged from 28.5 to 243 $\mu\text{g/ml}$ and the TI ranged from 0.1 to 3.5. Since March 1988, AVS 1160 has been used as the second positive control drug. The range of the VR has been 1.7 to 4.9, the range of the ID₅₀ has been 0.2 to 2.3 $\mu\text{g/ml}$, and the range of the TI has been 1.1 to 33.6.

Table 10

Compounds Most Active Against Vesicular Stomatitis Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
3586	32	3.7	1.2	1.8	32.0	17.7
4050	37	1.1	0.4	1.9	10.0	5.2
4275	39	3.6	1.2	0.2	1.0	4.5
4240	39	2.6	0.9	8.0	32.0	4.0
3968	36	1.3	0.4	89.5	320.0	3.6
3565	32	1.0	0.3	13.4	32.0	2.4
4239	39	1.8	0.6	17.9	32.0	1.8
4179	39	1.0	0.3	201.0	>320.0	>1.6

a. Compounds identified by their AVS number are listed in descending order from the most active to the least active. CPE-inhibition assays were done in L929 cells. An active compound is defined here as having a therapeutic index (TI) of greater than 1.0 and a virus rating (VR) of 1.0 or greater. The VR is a measurement of selective antiviral activity which takes into account the degree of inhibition of virus-induced CPE and the degree of cytotoxicity produced by the test compound, determined by a modification of the method of Ehrlich *et al.* (Ann. N.Y. Acad. Sci. 130:5, 1965). VR* is the designation for the virus rating calculated by the method of Sidwell and Huffman (Appl. Microbiol. 22:797, 1971). The drug concentration which reduced the CPE by 50% (50% inhibitory dose, ID₅₀) was calculated using a regression analysis program for semilog curve fitting and is expressed as $\mu\text{g/ml}$. The minimum cytotoxic drug concentration (MTC) is also expressed as $\mu\text{g/ml}$. The therapeutic index of a test compound was determined by dividing the MTC by the ID₅₀.

Table 11

Confirmatory Assays for Compounds Active
Against Vesicular Stomatitis Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>Date Tested</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
2350 ^b	14	11/06/87	1.1	0.4	-	>20,000	>0
		11/12/87	1.95	0.7	632	200,000	316.6
		02/04/88	0	0	-	200,000	0
		05/13/88	2.0	0.7	6317	>200,000	>31.7
3565	32	01/29/88	1.0	0.3	13.4	32	2.4
		03/11/88	0	0	-	32	0
3586	32	01/29/88	3.7	1.2	1.8	32	17.7
		02/23/88	4.3	1.4	1.6	32	20.1
4050	37	04/01/88	1.1	0.4	1.91	10	5.2
		05/03/88	0	0	-	<10	-
		05/10/88	0	0	-	<10	-
4240	39	04/05/88	2.6	0.9	8.0	32	4.0
		05/10/88	1.7	0.6	11.8	<100	<8.5
4275	39	04/08/88	3.6	1.2	0.2	1.0	4.5
		04/17/88	4.1	1.4	0.2	0.32	2.0

a. Compounds are listed in ascending numerical order by AVS number. The results of the primary and the subsequent confirmatory CPE-inhibition assays are listed chronologically for each compound. The abbreviations are defined in the footnote to Table 5.

b. The ID₅₀ and MTC for AVS 2350 are expressed as units/ml.

One drug, AVS 4240, which was confirmed active in the CPE-inhibition assay was further evaluated in a plaque reduction assay (Table 12). AVS 303 was used as a positive control drug in the plaque assay. AVS 4240 had an ID₅₀ of 18.9 µg/ml and a TI of 1.69. The positive control, AVS 303, had an ID₅₀ of 1.3 µg/ml and a TI >7.58.

AVS 3586, the drug with the highest confirmed TI in the CPE-inhibition assay, will be tested in the plaque reduction assay when sufficient drug is available.

Table 12

Plaque Reduction Assay for a Compound
Active Against Vesicular Stomatitis Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
4240	39	18.90	32	1.69
303 (Positive Control)	1	1.31	>10	>7.58

^a Assay was done in L929 cells. The drug concentration which reduced the mean plaque number by 50% (50% inhibitory dose, ID₅₀) was calculated using a regression analysis program for semilog curve fitting and is expressed as $\mu\text{g/ml}$. The minimum cytotoxic drug concentration (MTC) is the lowest drug concentration ($\mu\text{g/ml}$) at which toxicity was observed. The TI was determined by dividing the MTC by the ID₅₀.

4.1.4 Punta Toro Virus (PT)

A total of 38 compounds of the 912 tested exhibited significant antiviral efficacy against PT in Vero cells (Appendix A, Table 3). The 9 most active compounds are listed in Table 13. The most active compound against PT was AVS-2980. The compound was tested on separate occasions; 12/21/87, 3/01/88 and 5/25/88, and yielded VR's of 2.8, 1.5 and 1.7; ID₅₀'s of 0.3, 0.4 and 0.4 $\mu\text{g/ml}$ and TI values of 10.3, 7.7 and 2.7, respectively. Ribavirin was used as the positive control compound and yielded VR's ranging from 0.6 to 3.3, ID₅₀'s from 2.7 to 57 $\mu\text{g/ml}$ and TI values from 0.4 to 38.

Table 13

Compounds Most Active Against Punta Toro Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
2980	25	2.8	0.9	0.3	3.2	10.3
2980	25	1.5	0.5	0.4	<3.2	<7.7
2812	24	1.0	0.3	0.007	<0.032	<4.6
2991	27	1.0	0.3	2.2	<10	<4.5
4239	39	1.1	0.4	2.4	10	4.2
3048	28	1.6	0.5	78	320	4.1
4281	42	1.5	0.5	2.6	10	3.8
4240	39	1.4	0.5	8.5	32	3.7
2026	9	1.9	0.6	8.9	32	3.6
2902	26	2.0	0.7	29	100	3.4

^a Compounds identified by their AVS number are listed in descending order by activity. CPE-inhibition assays were done in Vero cells. The abbreviations are defined in the footnote to Table 5.

Several compounds were retested against Punta Toro to confirm their activity. Only one compound, AVS-2980, of the 4 retested was active in the subsequent screen. These compounds are listed in more detail in Table 14.

Table 14

Confirmatory Assay for Compounds Active Against Punta Toro^a

<u>AVS No.</u>	<u>Shipment</u>	<u>Date Tested</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
2902	26	12/16/87	2.0	0.7	29	100	3.4
2902	26	05/25/88	0.2	0.07	-	32	-
2980	25	12/21/87	2.8	0.9	0.3	3.2	10.3
2980	25	03/01/88	1.5	0.5	0.4	<3.2	<7.7
2980	25	05/25/88	1.7	0.6	0.4	1	2.7
2991	27	12/21/87	1.0	0.3	2.2	<10	<4.5
2991	27	06/01/88	0.1	0.03	-	3.2	-
4275	39	04/13/88	1.3	0.4	320	<0.32	-
4275	39	06/07/88	-	-	-	>32	-

^aCompounds are listed in ascending numerical order by AVS number. The results from the primary and subsequent confirmatory CPE-inhibition assays are listed chronologically for each compound. The abbreviations are defined in the footnote to Table 5.

4.1.5 Sandfly Fever Virus (SF)

Fifty-eight of the 885 compounds tested against SF exhibited anti-viral efficacy against the virus (Appendix A, Table 4). AVS-0253, Selenazole, was discontinued as a positive control compound at the end of the 5th semiannual reporting period (May 1988). AVS-0001, Ribavirin, was used as a positive control compound in this assay system and yielded VR's ranging from 1.1 to 4.4, ID₅₀'s from 1.1 to 26.1 µg/ml and TI values of 0.4 to 80. Table 15 lists the ten most active compounds against SF tested this past year.

Table 15
Compounds Most Active Against Sandfly Fever Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
2948	26	3.8	1.3	15	320	21.4
2563	21	2.6	0.9	0.8	10	12.7
4271	39	2.6	0.9	1.0	10	10.3
4391	43	1.8	0.6	31	320	<10.2
2992	27	2.0	0.7	10	100	10
3747	34	2.7	0.9	3.9	32	8.2
3980	36	1.9	0.6	18	100	5.4
4720	43	3.0	1.0	1.8	10	5.4
4044	37	2.2	0.7	20	100	4.9
4224	42	1.3	0.4	6.8	32	4.7

^aCompounds identified by their AVS number are listed in descending order by activity. CPE-inhibition assays were done in Vero cells. The abbreviations are defined in the footnote to Table 5.

Table 16 shows the results of confirmatory CPE-inhibition assays performed on compounds found active against SF. Two compounds were retested and one showed activity against SF, AVS-4720. The other compound, AVS-4113, was marginally active as its TI values and VR's were near 1.0.

Table 16

Confirmatory Assays for Compounds Active Against Sandfly Fever Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>Date Tested</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
4113	39	05/14/88	0.5	0.2	0.2	0.32	1.5
4113	39	06/14/88	0.8	0.3	0.4	<0.32	<0.9
4720	43	08/16/88	1.0	0.3	121	100	0.8
4720	43	09/13/88	3.0	1.0	1.8	10	5.4

^aCompounds are listed in ascending numerical order by AVS number. The results from the primary and subsequent confirmatory CPE-inhibition assays are listed chronologically for each compound. The abbreviations are defined in the footnote to Table 5.

4.1.6 Pichinde Virus (PIC)

The data summarized in Table 15 represent the results of compounds found to be most active against Pichinde virus in Vero cell cultures using a plaque-reduction assay. Seventy-six of the 943 compounds tested demonstrated significant antiviral efficacy against PIC (Appendix A, Table 5). Six compounds had TI values of >10. The compound which exhibited the most antiviral effect was AVS-2350 (human recombinant INF- γ) which had an ID₅₀ of 158 units/ml and a TI value of 126. Table 17 lists the 10 most active compounds tested.

Table 17

Compounds Most Active Against Pichinde Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
2350 ^b	14	158	>20,000	126
3189	29	0.9	100	106
2527	20	0.9	32	34
2581	19	5.9	100	16.6
2568	21	26	320	12.1
2585	19	8.3	100	11.9
2506	21	1.4	10	7.4
2503	21	0.1	1	6.9
2618	19	47	>320	6.8
2594	19	16	100	6.2

^aCompounds identified by their AVS number are listed in descending order by activity. Assays were done in Vero cells. The drug concentration which reduced the mean plaque number by 50% (50% inhibitory dose, ID₅₀) was calculated using a regression analysis program for semilog curve fitting and is expressed as μ g/ml. The minimum cytotoxic drug concentration (MTC) is the lowest drug concentration at which toxicity was observed. This is also expressed as μ g/ml. The therapeutic index of a test compound was determined by dividing the MTC by the ID₅₀.

^b The ID₅₀ and MTC are expressed in units/ml.

Four compounds were tested again for confirmation of activity. Two compounds, AVS-2506 and AVS-2980, were confirmed as active when retested. Table 18 lists these compounds and the dates they were tested.

Table 18

Confirmatory Assays for Compounds Active Against Pichinde Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>Date Tested</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
2350 ^b	14	12/04/87	158	>20,000	>126
2350	14	05/24/88	--	>20,000	--
2506	21	02/22/88	4.8	10	2.1
2506	21	07/29/88	1.4	10	7.4
2979	25	02/08/88	17	100	6.0
2979	25	09/16/88	--	10	--
2980	25	03/25/88	1.4	3.2	2.4
2980	25	09/09/88	4.0	3.2	0.8

^aCompounds identified by their AVS number are listed in descending order by activity. Assays were done in Vero cells. The drug concentration which reduced the mean plaque number by 50% (50% inhibitory dose, ID₅₀) was calculated using a regression analysis program for semilog curve fitting and is expressed as $\mu\text{g/ml}$. The minimum cytotoxic drug concentration (MTC) is the lowest drug concentration at which toxicity was observed. This is also expressed as $\mu\text{g/ml}$. The therapeutic index of a test compound was determined by dividing the MTC by the ID₅₀.

^bThe ID₅₀ and MTC are expressed in units/ml.

4.1.7 Venezuelan Equine Encephalomyelitis (VEE)

Five of the 866 compounds tested for CPE-inhibitory activity against VEE showed significant results (Appendix A, Table 6). The most active of these compounds was AVS-3800 with a VR of 2.3, an ID₅₀ of 0.96 $\mu\text{g/ml}$ and a TI value of 10.3. Selenazole was the positive control standard for this assay series and its activity ranged from VR's of 0.5 to 3.0, ID₅₀'s of 0.27 to 50 $\mu\text{g/ml}$ and TI values of 0 to 10.5. Table 19 lists the three most active compounds against VEE.

Table 19

Compounds Most Active Against Venezuelan Equine Encephalomyelitis^a

<u>AVS No.</u>	<u>Shipment</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
3800	35	2.3	0.8	0.96	10	10.3
2350	14	1.7	0.6	59	200	3.4
3802	35	1.9	0.6	1	3.2	3.2

^aCompounds identified by their AVS number are listed in descending order by activity. CPE-inhibition assays were done in Vero cells. The abbreviations are defined in the footnote to Table 5.

4.1.8 Yellow Fever Virus (YF)

Twenty-five of the 902 total compounds tested for antiviral efficacy against YF exhibited inhibition of virus-induced CPE (Appendix A, Table 7); the most active of these are listed in Table 20. The most active compound was AVS-4592 with a VR of 2.4, an ID_{50} of 3.2 $\mu\text{g/ml}$ and a TI value of 10.1. Selenazole, AVS-0253, was used as the positive control compound and exhibited VR's ranging from 1.3 to 3.4, ID_{50} 's from 0.47 to 8.3 $\mu\text{g/ml}$ and TI values ranging from 0.12 to 6.5.

Table 20

Compounds Most Active Against Yellow Fever Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
4592	42	2.4	0.8	3.2	32	10.1
4278	42	1.9	0.7	3.2	32	9.9
4281	42	1.7	0.6	1.9	10	5.3
2563	21	1.0	0.3	0.63	<3.2	<5.1
4280	42	1.9	0.6	2.7	10	3.6
4277	42	1.4	0.5	2.8	320	3.5
4533	42	1.8	0.6	95	100	3.4
0361	2	1.1	0.4	0.03	3.2	2.7
4020	36	1.6	0.5	1.2	0.32	2.6
2980	25	2.4	0.8	1.4	3.2	2.3

^aCompounds identified by their AVS number are listed in descending order by activity. CPE-inhibition assays were done in Vero cells. The abbreviations are defined in the footnote to Table 5.

Five compounds were tested again in the CPE-inhibition assay against YFV as a means of confirming previous data reported (Table 21). Four of the five compounds exhibited some degree of activity in the repeat assay.

Table 21

Confirmatory Assays for Compounds Active Against Yellow Fever Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>Date Tested</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
0140	4	02/04/88	1.4	0.5	0.48	1	0.2
0140	4	05/04/88	1.4	0.5	1.0	0.32	1.0
0140	4	05/18/88	0.3	0.03	-	0.1	-
0646	2	05/17/88	3.2	1.1	0.04	0.032	0.7
0646	2	12/14/88	1.7	0.6	0.08	0.10	1.2
1019	28	11/30/87	3.5	1.2	<0.32	0.32	>1.0
1019	28	02/02/88	1.1	0.4	0.26	0.10	0.4
1976	1	12/14/87	-	-	-	>100	-
1976	1	05/18/88	0.8	0.3	57	100	1.8
2563	21	03/01/88	1.0	0.3	0.63	<3.2	5.1
2563	21	05/25/88	1.6	0.5	0.13	0.32	2.4

^a Compounds are listed in ascending numerical order by AVS number. The results from the primary and the subsequent confirmatory CPE-inhibition assays are listed chronologically for each compound. The abbreviations are defined in the footnote to Table 5.

4.1.9 Japanese Encephalitis Virus (JE)

A total of 24 compounds of the 862 tested against JE exhibited significant antiviral effect against the virus tested in Vero cells (Appendix A, Table 8). The most active of these compounds are listed in Table 22. AVS-2350 was the most active compound against JE and yielded a VR of 2.6, an ID₅₀ of 128 units/ml, a MTC of 20,000 units/ml and a calculated TI of 156. Both AVS-0001 (Ribavirin) and AVS-0253 (Selenazole) were used as positive control compounds in the virus assay system. Ribavirin yielded VR's ranging from 0.5 to 3.3, ID₅₀'s ranging from 0.0 to 82 and calculated TI values from 0.0 to 29.8. Selenazole yielded VR's in a range from 1.4 to 3.7, ID₅₀'s from 0.3 to 23 µg/ml and TI values from 0.0 to 11.2. Selenazole and Ribavirin are not good candidate positive controls for JE but are the best we have at the present time.. The Sponsor is exploring the possibility of supplying some of the more active compounds for a positive control instead of Selenazole or Ribavirin.

Table 22

Compounds Most Active Against Japanese Encephalitis Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
2350 ^b	14	2.6	0.9	128	20,000	156
4592	42	2.1	0.7	3.4	32	9.4
4113	39	1.4	0.5	0.2	1	5.5
0094	1	2.8	0.9	18	100	5.5
0361	2	1.4	0.5	0.02	0.1	4.1
2563	21	1.5	0.5	0.8	3.2	3.9
4590	42	1.9	0.6	0.9	3.2	3.5
3731	34	1.5	0.5	28	100	3.1
2811	24	1.1	0.4	0.3	1	2.9
3734	34	2.6	0.9	3	10	2.6

^a Compounds identified by their AVS number are listed in descending order by activity. CPE-inhibition assays were done in Vero cells. The abbreviations are defined in the footnote to Table 5.

Table 23 shows the results of the confirmatory CPE-inhibition assays performed on compounds found active against JE. AVS-2563, AVS-2811 and AVS-4113 were confirmed as having activity against JE.

Table 23

Confirmatory Assays for Compounds Active Against Japanese Encephalitis Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>Date Tested</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
0079	1	01/27/87	0.5	0.2	16.7	1	0.06
0079	1	05/20/88	0.5	0.2	22.1	3.2	0.1
0094	1	05/20/88	2.8	0.9	18.2	100	5.5
0094	1	01/29/88	0.5	0.2	240.0	32	0.13
0094	1	05/04/88	0.6	0.2	56.4	10	0.18
0136	4	12/07/87	-	-	-	100	-
0136	4	01/29/88	-	-	-	>320	-
0136	4	05/04/88	0.7	0.2	121	86	0.7
0136	4	05/18/88	1.1	0.4	83	100	1.2
0347	2	03/01/88	0.9	0.3	-	1	-
0347	2	05/18/88	0.9	0.3	3.5	3.2	0.8
2563	21	03/01/88	1.0	0.3	0.4	1	2.6
2563	21	05/25/88	1.5	0.5	0.8	3.2	3.9
2811	24	12/04/87	1.2	0.4	0.6	0.32	0.6
2811	24	03/01/88	1.1	0.4	0.3	1	3.5
4113	39	05/04/88	1.1	0.4	0.3	0.1	0.4
4113	39	06/14/88	1.4	0.5	0.2	1	5.5
4275	39	04/13/88	2.8	0.9	0.5	<0.32	<0.7
4275	39	06/07/88	-	-	-	1	-

^aCompounds are listed in ascending numerical order by AVS number. The results from the primary and subsequent confirmatory CPE-inhibition assays are listed chronologically for each compound. The abbreviations are defined in the footnote to Table 5.

4.1.10 Hantaan Virus (HTN)

We continued to assay HTN by plaque reduction assay through April, 1988. During this time period, one compound, AVS-3593, showed antiviral activity against the virus. Ribavirin was our positive control compound and yielded ID₅₀'s ranging from 1 to 17 µg/ml and TI values from 6.3 to 57. Table 24 shows a comparison of AVS-3593 and Ribavirin tested 2/17/88.

Table 24

Compounds Active Against Hantaan Virus*

<u>AVS No.</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
0001	15.9	100	6.3
3593	0.9	1	1.1

*Plaque reduction assays were done in C1008 cells. The abbreviations are defined in the footnote to Table 5.

Due to variability in the Hantaan plaque reduction assay and problems of producing consistent results with this method, a new, less labor-intensive assay, ELISA, is being developed in collaboration with Drs. John Huggins and Z. Zhang, USAMRIID. We anticipate that this technique will give more accurate and consistent results. Our plan is to initiate this screening method in the coming year.

4.2 Antiviral Evaluations In Vivo

A total of 31 compounds have been received at SRI for evaluation in the primary *in vivo* antiviral screen. Some of these compounds were to be evaluated in more than one *in vivo* model and have been received in more than one shipment. Table 25 presents a cumulative summary of the number of compounds received for testing, and the number of compounds tested, in each *in vivo* antiviral model. Eighteen compounds have been evaluated in our *in vivo* models this reporting period. A cumulative summary presenting all of the *in vivo* antiviral test results is included in Appendix D.

Table 25

Primary *In Vivo* Antiviral Screen:
Target Viruses and Numbers of Compounds Tested
Through November 15, 1988*

<u>Shipment</u>	<u>Compounds Per Shipment</u>	<u>Date Received</u>	<u>PIC</u>	<u>VEE</u>	<u>JE</u>	<u>VV</u>
13	1	11/13/86	NS	1 (1)	1 (1)	NS
22	11	05/05/87	11 (11)	NS	NS	NS
26	1	06/26/87	1 (1)	NS	NS	NS
27	2	07/21/87	2 (2)	2 (2)	NS	NS
33	9	11/03/87	3 (3)	3 (3)	NS	4 (4)
35	3	12/22/87	NS	NS	3 (3)	NS
36	4	01/29/88	3 (3)	NS	1 (1)	NS
41C	1	05/13/88	NS	NS	1 (1)	NS
Fed EX	1	07/26/88	NS	NS	1 (1)	NS
47	8	10/20/88	NS	NS	8 (5)	NS
49	2	11/11/88	0 (2)	NS	NS	NS
Total	43		20 (22)	6 (6)	15 (12)	4 (4)

* The number of compounds specified for testing against each virus is shown in parentheses. NS indicates that compounds were not specified for testing against that virus.

4.2.1 Pichinde Virus in MHA Hamsters

The compounds received during this reporting period are listed in Table 26.

Table 26

Compounds Received for *In Vivo* Testing
Against Pichinde Virus
(11/15/87 to 11/15/88)

<u>AVS No.</u>	<u>Date Received</u>	<u>Shipment</u>	<u>Quantity Received (gm)</u>
94	11/11/88	49	2.0
347	11/11/88	49	1.5
111	1/29/88	36	2.0
206	1/29/88	36	30.0
346	1/29/88	36	0.3

During this reporting period, three compounds were tested in the initial *in vivo* screen. These include AVS-272, AVS-346 and AVS-925. AVS-272 dosed at 100 mg/kg resulted in 80% mortality in the toxicity controls while a dose level of 32 mg/kg resulted in weight loss in the toxicity controls. Toxicity controls receiving 10 mg/kg of AVS-272 failed to gain weight and sustained one death in the five treated animals. As shown in Table 27, no antiviral efficacy was associated with AVS-272 treatment.

The results of preliminary testing of AVS-346 are also shown in Table 27. Because of compound quantity limitations, the highest dose of AVS-346 tested was 60 mg/kg/day. Animals receiving 7.5 mg/kg/day of AVS-346 had a prolongation in the average day of death (ADD) compared to diluent-treated controls, however, it was not statistically significant. The higher dose levels of AVS-346 did not have antiviral activity. Further studies of this compound at low dose levels on a longer treatment schedule were conducted. AVS-346 was administered once daily for 10 days at dose levels of 7.5, 5.0, 2.5 or 1.0 mg/kg. As shown in Table 28, no antiviral activity was demonstrated at any of the dose levels tested. This variance from the initial test may be due to differences in the compound since the second assay was conducted with compound received in Shipment 36 while the first assay was conducted with compound received in Shipment 33.

As shown in Table 29, preliminary testing of AVS-925 did not provide evidence for antiviral efficacy. The ADD for AVS-925-treated animals was shorter than that obtained in the diluent-treated controls at all dose levels tested.

Table 27
Antiviral Effects of AVS-272 and AVS-346 on Pichinde Virus

Virus: Pichinde

Treatment: q1d x 7 starting 4 hours post-challenge, SC

	No. Uninfected Dead/ <u>No. Treated*</u>	No. Infected Dead/ <u>No. Treated*</u>	<u>GMTD</u>	<u>VR</u>
Untreated	0/5	10/10 (10.2 ± 1.6) ^a	10.1	NA
0.4% CMC in PBS	0/5	9/10 (11.4 ± 3.9)	12.1	1.0
100 mg/kg AVS-272	4/5 (10.5 ± 2.1)	10/10 (10.5 ± 1.8) ^b	10.3	0.9
32 mg/kg AVS-272	0/5	10/10 (9.8 ± 1.1) ^c	9.7	0.8
10 mg/kg AVS-272	1/5 (16.0 ± 0.0)	10/10 (11.6 ± 3.7) ^d	11.2	0.9
3.2 mg/kg AVS-272	0/5	10/10 (11.5 ± 3.0) ^e	11.2	0.9
60 mg/kg AVS-346	0/5	10/10 (11.1 ± 3.4) ^f	10.7	0.9
30 mg/kg AVS-346	0/5	10/10 (11.9 ± 3.8) ^g	11.4	0.9
15 mg/kg AVS-346	0/5	9/10 (11.8 ± 2.0) ^h	12.7	1.1
7.5 mg/kg AVS-346	0/5	8/10 (14.4 ± 5.1) ^{ij}	15.7	1.3
100 mg/kg Ribavirin	0/5	5/10 (16.2 ± 2.3) ^k	21.2	1.8
<u>Virus Titration</u>				
1 x 10 ⁶ pfu/hamster	NA	5/5 (9.2 ± 1.1)	9.2	NA
1 x 10 ⁵ pfu/hamster	NA	5/5 (9.4 ± 1.1)	9.3	NA
1 x 10 ⁴ pfu/hamster	NA	10/10 (10.0 ± 2.7)	9.7	NA
1 x 10 ³ pfu/hamster	NA	8/10 (12.5 ± 4.8)	14.0	NA
1 x 10 ² pfu/hamster	NA	4/5 (9.0 ± 1.4)	11.2	NA

*No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$ADD = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

GMTD = Geometric Mean Time to Death

$$GMTD = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where} \quad n = \text{day of death} \\ x = \text{total number of animals}$$

All survivors are calculated as dying on Day 28

VR = GMTD of Experimental/GMTD of Diluent-Treated Control

- | | |
|---------------------------------|---------------------------------------|
| a. T-test of ADD vs PBS p = .37 | g. T-test of ADD vs PBS p = .8 |
| b. T-test of ADD vs PBS p = .5 | h. T-test of ADD vs PBS p = .8 |
| c. T-test of ADD vs PBS p = .22 | i. T-test of ADD vs PBS p = .21 |
| d. T-test of ADD vs PBS p = .93 | j. T-test of ADD vs Ribavirin p = .43 |
| e. T-test of ADD vs PBS p = .97 | k. T-test of ADD vs PBS p = .03 |
| f. T-test of ADD vs PBS p = .84 | |

Table 28

Secondary *In Vivo* Testing of AVS-346

Virus: Pichinde

Treatment: q1d x 10 days starting 4 hours pre-challenge, SC

	<u>No. Dead/ No. Uninfected</u>	<u>No. Dead/ No. Infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
Untreated	0/5	7/10 (10.9 ± 3.3)	14.1	NA
0.4% CMC in PBS	0/5	10/10 (12.6 ± 2.1)	12.5	1.0
100 mg/kg AVS-01	0/5	2/10 (20.5 ± 7.8)	26.1	2.1
7.5 mg/kg AVS-346	0/5	10/10 (10.7 ± 1.8)	10.6	0.8
5.0 mg/kg AVS-346	0/5	9/10 (10.4 ± 1.6)	11.4	0.9
2.5 mg/kg AVS-346	0/5	10/10 (11.2 ± 2.1)	11.1	0.9
1.0 mg/kg AVS-346	0/5	9/10 (10.9 ± 5.0)	11.3	0.9

Virus Challenge

1 x 10 ⁷ pfu	NA	5/5 (7.6 ± 2.7)	8.8	NA
1 x 10 ⁶ pfu	NA	5/5 (8.6 ± 1.1)	8.5	NA
1 x 10 ⁵ pfu	NA	5/5 (9.0 ± 1.2)	8.9	NA
1 x 10 ⁴ pfu	NA	5/5 (10.6 ± 3.6)	10.2	NA
1 x 10 ³ pfu	NA	5/5 (9.7 ± 0.8)	9.8	NA
1 x 10 ² pfu	NA	4/5 (8.8 ± 0.5)	12.0	NA

a. No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$\text{ADD} = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

b. GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death}$$

x = total number of animals

All survivors are calculated as dying on Day 28

c. VR = GMTD of Experimental/GMTD of Diluent-Treated Control

Table 29

Antiviral Efficacy of AVS-925 Against Pichinde Virus

Virus: Pichinde

Treatment: 10 days x 7 days starting 4 hours post-challenge, SC

	<u>No. Dead/ No. Uninfected</u>	<u>No. Dead/ No. Infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
Untreated	0/5	10/10 (13.4 ± 6.0)	12.4	1.2
0.4% CMC in PBS	0/5	10/10 (11.3 ± 4.3)	10.7	1.0
100 mg/kg Ribavirin	0/5	7/10 (18.7 ± 6.2)	20.5	1.9
100 mg/kg AVS-925	0/5	10/10 (8.0 ± 3.2)	7.6	0.7
32 mg/kg AVS-925	0/5	10/10 (9.2 ± 1.3)	9.1	0.9
10 mg/kg AVS-925	0/5	10/10 (10.3 ± 1.5)	10.2	1.0
3.2 mg/kg AVS-925	0/5	10/10 (9.9 ± 1.7)	9.8	0.9

a. No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$ADD = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

b. GMTD = Geometric Mean Time to Death

$$GMTD = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death}$$

$$x = \text{total number of animals}$$

All survivors are calculated as dying on Day 28

c. VR = GMTD of Experimental/GMTD of Diluent-Treated Control

During this reporting period secondary testing was conducted with AVS-52, AVS-111, AVS-148 and AVS-206. Secondary testing of AVS-52 was conducted at dose levels of 3.2 and 1.0 mg/kg alone and in combination with Ribavirin (50 mg/kg/day). Compounds were administered once daily for 10 days with the first dose given on the day preceding virus challenge. At a dose level of 3.2 mg/kg, AVS-52 caused weight loss in the toxicity controls and significantly reduced the ADD in the virus-infected, drug-treated animals ($p=.002$). Toxicity controls receiving 1.0 mg/kg/day of AVS-52 failed to gain weight and infected, treated animals did not have a reduction in mortality or an increase in ADD. Administration of AVS-52 in conjunction with Ribavirin resulted in a slight but not significant increase in the ADD when compared to animals receiving Ribavirin (50 mg/kg) alone. As shown in Table 30, no significant antiviral efficacy was demonstrated for AVS-52.

Secondary testing of AVS-148 was conducted at dose levels of 3.2 and 1.0 mg/kg alone and in combination with Ribavirin (50 mg/kg/day). Compounds were administered once daily for 10 days with the first dose administered on the day preceding virus challenge. As shown in Table 30, no antiviral efficacy was demonstrated for AVS-148 alone or in combination with Ribavirin. Following this study, lower doses of AVS-148 were tested alone and in combination with Ribavirin. As shown in Table 31, treatment with

0.5 or 0.25 mg/kg/day of AVS-148 alone, or in combination with Ribavirin (50 mg/kg/day), on a 10 day treatment schedule did not demonstrate antiviral efficacy.

Secondary testing of AVS-111 was conducted on a 10-day treatment schedule with the first dose of compound administered 4 hours prior to virus challenge. Doses of 150, 32 and 10 mg/kg/day were evaluated. The 32 mg/kg/day dose was divided into doses of 16 mg/kg administered twice daily. Toxicity controls receiving 150 mg/kg/day failed to gain weight, however, there were no drug-associated deaths. As shown in Table 32, treatment with AVS-111 resulted in a slight but insignificant increase in the ADD at doses of 150 and 32 mg/kg/day. No significant antiviral efficacy was demonstrated for AVS-111.

Table 30
Secondary Testing of AVS-52 and AVS-148
in Combination with Ribavirin (AVS-000i)

Virus: Picliinde

Treatment: q1d x 10 days starting Day -1, SC

	No. Uninfected Dead/ No. Treated	No. Infected Dead/ No. Treated*	GMTD	VR
Untreated	0/5	10/10 (10.0 ± 0.9) ^a	NA	NA
PBS	0/5	10/10 (9.9 ± 1.8)	9.8	1.0
3.2 mg/kg AVS-52	0/5	10/10 (7.7 ± 0.7) ^b	7.7	0.8
1.0 mg/kg AVS-52	0/5	10/10 (10.5 ± 2.7) ^c	10.2	1.0
3.2 mg/kg AVS-148	0/5	10/10 (10.3 ± 0.9) ^d	10.3	1.1
1.0 mg/kg AVS-148	0/5	10/10 (11.3 ± 2.5) ^e	11.1	1.1
3.2 mg/kg AVS-52 + 50 mg/kg Ribavirin	0/5	10/10 (17.0 ± 1.8) ^{f,g}	16.9	1.7
1.0 mg/kg AVS-52 + 50 mg/kg Ribavirin	0/5	9/10 (17.6 ± 3.6) ^{h,i}	18.1	1.8
3.2 mg/kg AVS-148 + 50 mg/kg Ribavirin	0/5	10/10 (16.6 ± 2.5) ^{j,k}	16.5	1.7
1.0 mg/kg AVS-148 + 50 mg/kg Ribavirin	0/5	9/9 (16.2 ± 1.4) ^{l,m}	17.1	1.7
50 mg/kg Ribavirin	0/5	9/10 (16.4 ± 3.2) ⁿ	17.1	1.7

Virus Titration

1x10 ⁵ pfu	NA	5/5 (11.4 ± 3.7)	NA	NA
1x10 ⁴ pfu	NA	5/5 (10.0 ± 0.7)	NA	NA
1x10 ³ pfu	NA	5/5 (9.6 ± 0.9)	NA	NA

*No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$ADD = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

GMTD = Geometric Mean Time to Death

$$GMTD = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death} \\ x = \text{total number of animals}$$

All survivors are calculated as dying on Day 28

VR = GMTD of Experimental/GMTD of Diluent-Treated Control

- | | |
|---|---|
| a. T-test vs PBS control p = .88 | h. T-test vs PBS control p = .00002 |
| b. T-test vs PBS control p = .002 | i. T-test vs Ribavirin alone p = .5 |
| c. T-test vs PBS control p = .56 | j. T-test vs PBS control p = .000002 |
| d. T-test vs PBS control p = .54 | k. T-test vs Ribavirin alone p = .91 |
| e. T-test vs PBS control p = .16 | l. T-test vs PBS control p < 10 ⁻⁶ |
| f. T-test vs PBS control p < 10 ⁻⁶ | m. T-test vs Ribavirin alone p = .85 |
| g. T-test vs Ribavirin alone p = .64 | n. T-test vs PBS control p = .00003 |

Table 31

Antiviral Efficacy of Low-Dose-Treatment
with AVS-148

Virus: Pichinde

Treatment: q1d x 10 days starting on the day preceding virus challenge, SC

	<u>No. Dead/ No. Uninfected</u>	<u>No. Dead/ No. Infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
Untreated	3/5	8/10 (9.0 ± 1.2)	11.2	NA
PBS SC	0/5	10/10 (13.0 ± 4.8)	12.3	1.0
50 mg/kg Ribavirin	0/5	8/10 (14.5 ± 2.1)	16.4	1.3
0.5 mg/kg AVS-148	0/5	10/10 (12.2 ± 2.5)	12.0	1.0
0.25 mg/kg AVS-148	0/5	10/10 (12.1 ± 2.3)	11.9	1.0
0.5 mg/kg AVS-148 + 50 mg/kg Ribavirin	0/5	10/10 (16.5 ± 2.3)	16.3	1.3
0.25 mg/kg AVS-148 + 50 mg/kg Ribavirin	0/5	10/10 (16.5 ± 2.2)	16.4	1.3

Virus Challenge

1x10 ⁶ pfu	NA	5/5 (8.2 ± 0.4)	8.2	NA
1x10 ⁵ pfu	NA	5/5 (9.8 ± 1.1)	9.8	NA
1x10 ⁴ pfu	NA	10/10 (11.9 ± 5.2)	11.2	NA
1x10 ³ pfu	NA	10/10 (11.4 ± 3.0)	11.1	NA
1x10 ² pfu	NA	4/4 (10.0 ± 1.2)	9.9	NA

a. No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$\text{ADD} = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

b. GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } \bar{n} = \text{day of death}$$

$x = \text{total number of animals}$

All survivors are calculated as dying on Day 28

c. VR = GMTD of Experimental/GMTD of Diluent-Treated Control

Table 32

Secondary *In vivo* Testing of AVS-111

Virus: Pichinde

Treatment: q1d x 10 days starting 4 hours pre-challenge, SC

	No. Dead/ No. Uninfected	No. Dead/ No. Infected ^a	GMTD ^b	VR ^c
Untreated	0/5	7/10 (10.9 ± 3.3)	14.1	NA
0.4% CMC in PBS	0/5	10/10 (12.6 ± 2.1)	12.5	1.0
0.4% CMC in PBS (bid)	0/5	10/10 (10.7 ± 2.9)	10.4	1.0
100 mg/kg Ribavirin	0/5	2/10 (20.5 ± 7.8)	26.1	2.1
150 mg/kg AVS-111	0/3	5/5 (14.0 ± 1.0)	14.0	1.1
32 mg/kg AVS-111 (bid)	0/5	10/10 (13.0 ± 4.4)	12.3	1.2
10 mg/kg AVS-111	0/5	10/10 (10.8 ± 2.3)	10.6	0.8

Virus Challenge

1 x 10 ⁷ pfu	NA	5/5 (7.6 ± 2.7)	8.8	NA
1 x 10 ⁶ pfu	NA	5/5 (8.6 ± 1.1)	8.5	NA
1 x 10 ⁵ pfu	NA	5/5 (9.0 ± 1.2)	8.9	NA
1 x 10 ⁴ pfu	NA	5/5 (10.6 ± 3.6)	10.2	NA
1 x 10 ³ pfu	NA	5/5 (9.8 ± 0.8)	9.8	NA
1 x 10 ² pfu	NA	4/5 (9.8 ± 0.5)	12.0	NA

a. No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$\text{ADD} = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

b. GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death}$$

$$x = \text{total number of animals}$$

All survivors are calculated as dying on Day 28

c. VR = GMTD of Experimental/GMTD of Diluent-Treated Control

AVS-215 which had been previously evaluated at doses of 32 mg/kg/day and lower was retested at higher dose levels. AVS-215 was administered at doses of 100, 50 and 25 mg/kg/day by the subcutaneous route on a q1d x 7 day schedule. Two hours after the first dose of compound was administered, 10 animals were challenged intraperitoneally with 1 x 10⁴ pfu of Pichinde virus. Five uninfected toxicity controls were treated in parallel. AVS-215 administered to MHA hamsters at 100 mg/kg/day on a 7-day treatment schedule resulted in mortality in all 5 toxicity controls. At 50 mg/kg, AVS-215 was lethal for 3 of the 4 toxicity controls. The 25 mg/kg/day dose level did not result in mortality; however, the animals receiving this dose did suffer severe weight loss. None of the AVS-215-treated, virus-infected hamsters survived, nor

was there any increase in the average day to death or geometric mean time to death in compound-treated hamsters. The results are shown in Table 33.

Table 33

Results of *In Vivo* Testing of AVS-215
Against Pichinde Virus Infection
in MHA Hamsters

Virus: Pichinde

Treatment: qld x 7 starting 4 hours post-challenge, SC

Pichinde Expt #37

<u>Treatment</u>	<u>No. dead/ No. Uninfected^a</u>	<u>No. dead/ No. Infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
Untreated	0/5	10/10 (10.0 ± 1.7)	9.9	
PBS sc x 7	0/5	9/10 (9.7 ± 1.2)	10.7	
<u>AVS-215</u>				
100 mg/kg	5/5 (6.2 ± 0.5)	10/10 (6.0 ± 1.1)	5.9	0.6
50 mg/kg	3/4 (13.0 ± 1.7)	10/10 (10.4 ± 1.6)	10.3	1.0
25 mg/kg	0/5	10/10 (9.4 ± 1.8)	9.2	0.9

Virus Titration

1x10 ⁵ pfu	NA ^d	10/10 (9.7 ± 1.3)	9.6	NA
1x10 ⁴ pfu	NA	10/10 (9.9 ± 0.6)	9.9	NA
1x10 ³ pfu	NA	10/10 (11.7 ± 3.5)	11.3	NA
1x10 ² pfu	NA	10/10 (9.5 ± 1.0)	9.5	NA
10 pfu	NA	10/10 (12.4 ± 3.9)	11.9	NA
5 pfu	NA	10/10 (11.4 ± 3.6)	11.0	NA
1 pfu	NA	2/10 (12.0 ± 1.4)	23.6	NA
0.5 pfu	NA	5/10 (16.4 ± 5.9)	20.8	NA
0.1 pfu	NA	7/10 (19.6 ± 5.9)	21.0	NA
0.01 pfu	NA	0/10 NA		

^a No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$ADD = \frac{\sum [(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

^b GMTD = Geometric Mean Time to Death

$$GMTD = \sqrt[n]{n_1 \cdot n_2 \cdot n_3 \cdots n_x} \quad \text{where } n = \text{day of death} \\ x = \text{total number of animals}$$

All survivors are calculated as dying on Day 28

^c VR = GMTD of Experimental/GMTD of Diluent-Treated Control

^d NA = Not Applicable

Of the compounds tested against Pichinde virus to date, AVS-206 has shown the best *in vivo* antiviral efficacy. In order to compare the antiviral efficacy of AVS-206 and Ribavirin, a dose response study was conducted. Hamsters received AVS-206 or Ribavirin once daily for 10 days. Initially, drugs were administered by the subcutaneous (SC) route, however, the route of administration was changed to intraperitoneal (IP) on Day 3 post-infection due to skin lesions at the SC injection sites. AVS-206 was administered at dose levels of 1000, 500, 250 or 200 mg/kg/day. Ribavirin was administered to uninfected controls only, at doses of 1000 and 250 mg/kg/day, and to infected and uninfected animals at doses of 500, 200 or 100 mg/kg/day. In order to compare the severity of anemia induced by treatment with these two compounds hematocrits were determined for the toxicity control animals on Days -1, 3, 7, 13 and 28. For hematocrit determinations, three heparinized microhematocrit tubes of blood were collected from the retro-orbital sinus of each animal. The tubes were centrifuged in a standard microhematocrit centrifuge for 5 minutes and the hematocrits were determined for each tube using a Clay-Adams hematocrit reader. The hematocrit for each animal was determined by averaging the individual tube readings. The results are shown in Table 34. Treatment with AVS-206 did not induce as severe an anemia as did Ribavirin at any of the time points examined. Doses of 1000 and 500 mg/kg/day of AVS-206 were uniformly fatal in the toxicity controls. Doses of 1000, 500 and 250 mg/kg/day of Ribavirin were uniformly fatal in the toxicity controls. Three of the 5 toxicity controls receiving 200 mg/kg/day of Ribavirin died. Although treatment with 250 mg/kg/day of AVS-206 did result in weight loss, none of the toxicity controls died and the lowest average hematocrit for this group was 42 (Day 13). In contrast, treatment with 200 mg/kg/day of Ribavirin resulted in 60% mortality and produced an average hematocrit of 33.8 (on Day 13) in the 2 surviving toxicity controls. By Day 28, the hematocrits of drug-treated animals returned to the level present in untreated controls.

Table 34

Hematocrit Values for Animals Receiving AVS-206 or Ribavirin

<u>Treatment</u>	<u>Day 1</u>					<u>Group Avg</u>
	<u>Animal Number</u>					
	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	
Untreated Controls	54.5	53.0	52.5	54.5	51.0	53.1
PBS	54.0	52.5	54.0	56.5	55.5	54.5
PBS	55.5	51.5	54.5	58.5	57.0	55.4
1000 mg/kg AVS-206	54.0	54.0	58.0	57.0	52.0	55.0
500 mg/kg AVS-206	59.0	54.0	55.0	58.0	54.0	56.0
250 mg/kg AVS-206	54.0	54.0	54.0	55.5	54.5	54.4
200 mg/kg AVS-206	51.0	53.0	56.5	57.0	59.0	55.3
1000 mg/kg Ribavirin	55.0	54.5	57.0	55.5	51.0	54.6
500 mg/kg Ribavirin	53.0	53.0	53.0	57.0	56.0	54.4
250 mg/kg Ribavirin	53.0	57.0	55.0	56.0	54.0	55.0
200 mg/kg Ribavirin	54.5	53.5	57.0	55.0	56.0	55.2
100 mg/kg Ribavirin	50.0	55.0	57.0	56.0	55.5	54.7

<u>Treatment</u>	<u>Day 3</u>					<u>Group Avg</u>
	<u>Animal Number</u>					
	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	
Untreated Controls	51.0	55.5	49.5	54.0	47.5	51.5
PBS	49.0	51.0	52.0	56.0	51.0	51.8
PBS	53.5	51.0	50.0	55.0	54.5	52.8
1000 mg/kg AVS-206	56.0	53.0	55.0	53.5	53.5	54.2
500 mg/kg AVS-206	50.5	54.0	54.0	50.5	51.5	52.1
250 mg/kg AVS-206	49.0	46.0	46.0	48.5	48.0	47.5
200 mg/kg AVS-206	51.0	48.5	48.0	48.0	51.5	49.4
1000 mg/kg Ribavirin	41.0	35.5	*	37.0	30.0	35.9
500 mg/kg Ribavirin	51.5	48.0	48.5	52.5	51.5	50.4
250 mg/kg Ribavirin	49.5	53.5	48.0	51.5	49.5	50.4
200 mg/kg Ribavirin	51.0	51.0	47.5	47.5	47.5	48.9
100 mg/kg Ribavirin	44.5	47.5	51.0	48.5	53.5	49.0

a. Dead

Table 34 (cont'd)

Hematocrit Values for Animals Receiving AVS-206 or Ribavirin

Treatment	Day 7					Group Avg
	Animal Number					
	1	2	3	4	5	
Untreated Controls	54.0	52.5	52.0	50.5	51.0	52.0
PBS	52.5	52.0	50.0	53.5	50.0	51.6
PBS	56.0	50.5	50.0	52.5	53.5	52.5
1000 mg/kg AVS-206	a	a	a	a	a	
500 mg/kg AVS-206	58.5	48.0	53.5	31.0	45.5	47.3
250 mg/kg AVS-206	46.5	42.0	41.0	45.0	44.5	43.8
200 mg/kg AVS-206	43.5	44.0	40.0	45.0	50.0	44.5
1000 mg/kg Ribavirin	a	a	a	a	a	
500 mg/kg Ribavirin	a	a	a	a	a	
250 mg/kg Ribavirin	54.5	b	48.0	b	50.0	50.8
200 mg/kg Ribavirin	46.5	46.5	45.5	48.0	40.5	45.4
100 mg/kg Ribavirin	43.5	45.0	44.5	43.0	43.5	43.9

a. No samples available; all animals dead from treatment

b. Dead

Treatment	Day 13					Group Avg.
	Animal Number					
	1	2	3	4	5	
Untreated Controls	55.5	52.5	50.0	53.0	53.0	52.8
PBS	51.5	49.5	49.5	53.0	51.5	51.0
PBS	52.5	52.5	51.5	51.0	51.0	51.7
1000 mg/kg AVS-206	a	a	a	a	a	
500 mg/kg AVS-206	a	a	a	a	a	
250 mg/kg AVS-206	46.0	44.0	39.0	40.0	41.0	42.0
200 mg/kg AVS-206	42.0	45.5	44.0	42.5	45.5	43.9
1000 mg/kg Ribavirin	a	a	a	a	a	
500 mg/kg Ribavirin	a	a	a	a	a	
250 mg/kg Ribavirin	a	a	a	a	a	
200 mg/kg Ribavirin	b	37.0	b	b	30.5	33.8
100 mg/kg Ribavirin	45.0	44.0	43.0	43.5	46.5	44.4

a. No samples available; all animals dead from treatment

b. Dead

Table 34 (cont'd)

Hematocrit Values for Animals Receiving AVS-206 or Ribavirin

Treatment	Day 28					Group Avg.
	Animal Number					
	1	2	3	4	5	
Untreated Controls	58.0	55.5	52.0	54.0	53.0	54.5
PBS	51.5	52.0	51.0	55.0	52.5	52.4
PBS	55.5	51.5	52.5	53.0	56.5	53.8
1000 mg/kg AVS-206	a	a	a	a	a	
500 mg/kg AVS-206	a	a	a	a	a	
250 mg/kg AVS-206	53.0	51.0	52.5	50.5	50.0	51.4
200 mg/kg AVS-206	52.5	50.0	54.0	54.0	55.5	53.2
1000 mg/kg Ribavirin	a	a	a	a	a	
500 mg/kg Ribavirin	a	a	a	a	a	
250 mg/kg Ribavirin	a	a	a	a	a	
200 mg/kg Ribavirin	b	54.0	b	b	55.0	54.5
100 mg/kg Ribavirin	49.0	54.5	53.0	56.0	54.0	53.3

a. No sample available; all animals dead from treatment

b. Dead

As shown in Table 35, treatment with AVS-206 at 250 mg/kg/day significantly reduced mortality in the virus infected animals as compared to the diluent treated controls ($p = 5.9 \times 10^{-5}$). Similarly, treatment with AVS-206 at 200 mg/kg/day also significantly reduced virus-induced mortality ($p = 3.6 \times 10^{-4}$). In contrast, treatment with Ribavirin at 200 mg/kg/day did not significantly reduce mortality although it did significantly prolong the ADD ($p = .02$). However, this dose level was toxic in the uninfected controls and therefore a percentage of the infected animal deaths may be drug-toxicity associated. Administration of Ribavirin at 100 mg/kg/day did significantly reduce virus-related mortality ($p = 1.6 \times 10^{-3}$). The VR for AVS-206, administered at dose levels of 250 or 200 mg/kg/day was 3.1 while the VR for Ribavirin (100 mg/kg/day) was 2.7. These studies further document the antiviral efficacy of AVS-206 against Pichinde virus infection and provide evidence of the lower toxicity of AVS-206 in comparison to the parent compound Ribavirin.

In order to further delineate the antiviral activity of Ribavirin against Pichinde virus, several treatment schedules were compared. In the first experiment, the antiviral efficacy of Ribavirin, at doses of 150, 100, 50 and 25 mg/kg/day, was compared for two treatment schedules. The first treatment schedule was a once daily administration of Ribavirin for a total of 11 days with the first dose given 3 days prior to virus challenge. The second schedule was similar except that treatment was given for a total of 8 days beginning on the day of virus challenge. The purpose of this study was to determine whether pretreatment with Ribavirin would reduce the dose level necessary to produce antiviral efficacy.

Ribavirin administered at 150 mg/kg/day for 11 days resulted in the death of 1 of the 5 toxicity control animals while the same daily dose was tolerated on an 8-day treatment schedule. As shown in Table 36, treatment with 100 mg/kg/day beginning 3 days prior to virus challenge was as effective as treatment with 150 mg/kg/day beginning on Day 0. Pretreatment with 100 mg/kg/day beginning 3 days prior to challenge significantly decreased the mortality rates when compared to those obtained with treatment at 100 mg/kg/day

starting on the day of virus challenge ($p=.029$). Pretreatment with 50 mg/kg/day or 25 mg/kg/day did not significantly increase the percent survivors or the average day of death (ADD) compared to animal receiving these dose levels beginning on the day of virus challenge. The highest VR was obtained by treating with 100 mg/kg/day beginning 3 days prior to virus challenge.

In a second study (Table 37) hamsters were treated with 100 mg/kg/day or 50 mg/kg/day for 18 days or for 11 days. The 18-day treatment schedule began 7 days prior to virus challenge while the 11-day treatment schedule began on the day of virus challenge. No Ribavirin-related toxicities were evident in the toxicity control animals. Ribavirin did not demonstrate significant improvements when administered for 7 days prior to virus challenge as compared to treatment initiated on the day of virus challenge and continued for 11 days. These results are in contrast to the preceding experiment in which three days of pretreatment did enhance antiviral efficacy. However, in that experiment the last dose of compound was given on Day 7, while in the present experiment the final dose was given on Day 10 post-virus challenge. These results indicate that Ribavirin has greater antiviral efficacy against Pichinde virus infections when treatment is continued through Day 10 post-infection.

In a third experiment, the effects of delay in onset of Ribavirin treatment relative to the day of virus challenge was addressed. Animals were treated once daily for 7 days with 100 mg/kg/day of Ribavirin starting on Day -1, Day +4, Day +5 or Day +6. As shown in Table 38, a delay in initiating treatment beyond Day 4 post-virus challenge results in a loss of antiviral efficacy. Two of 6 virus-infected animals undergoing treatment with Ribavirin from Day-1 to +5 died, while there were no deaths in animals treated from Day +4 to +10. Although all of the virus-infected animals treated from Day +5 to +11 died, there was a prolongation in the ADD. Treatment initiated on Day 6 did not significantly reduce mortality nor increase the ADD. The results further confirm the value of treating Pichinde-infected hamsters early in the disease course and indicate that, when possible, treatment should be continued through Day 10 post-virus infection.

Table 35

Antiviral Efficacy of AVS-206 and Ribavirin (AVS-01)

Virus: Pichinde

Treatment: qld x 10 days starting on the day preceding virus challenge

	<u>No. Dead/ No. Uninfected^a</u>		<u>No. Dead/ No. Infected^a</u>		<u>GMTD^b</u>	<u>VR^c</u>
Untreated	0/10		10/10 (9.8 ± 0.9)		9.8	NA
PBS	0/10		10/10 (9.0 ± 1.3)		8.9	1.0
1000 mg/kg AVS-206	4/4	(5.0 ± 0.0)	10/10	(5.0 ± 0.8)	4.9	0.6
500 mg/kg AVS-206	4/4	(8.5 ± 0.6)	10/10	(8.4 ± 1.5)	8.3	0.9
250 mg/kg AVS-206	0/5		1/10 ^d	(23.0 ± 0.0) ^e	27.5	3.1
200 mg/kg AVS-206	0/5		2/10 ^f	(25.0 ± 2.8) ^g	27.4	3.1
1000 mg/kg AVS-01	5/5	(3.6 ± 0.5)	Not done			
500 mg/kg AVS-01	5/5	(5.2 ± 0.4)	10/10	(5.7 ± 1.3)	5.6	0.6
250 mg/kg AVS-01	5/5	(7.6 ± 2.4)	Not done			
200 mg/kg AVS-01	3/5	(10.7 ± 1.5)	8/10	(12.8 ± 4.4) ^h	14.4	1.6
100 mg/kg AVS-01	0/5		3/10 ⁱ	(18.7 ± 8.1) ^j	24.4	2.7

Virus challenge

1 x 10 ⁶ pfu	NA	5/5	(8.4 ± 0.9)	8.4	NA
1 x 10 ⁵ pfu	NA	5/5	(9.0 ± 1.2)	8.9	NA
1 x 10 ⁴ pfu	NA	5/5	(8.2 ± 0.4)	8.2	NA
1 x 10 ³ pfu	NA	5/5	(9.4 ± 0.5)	9.4	NA
1 x 10 ² pfu	NA	5/5	(9.0 ± 0.7)	9.0	NA
10 pfu	NA	5/5	(10.0 ± 1.6)	9.9	NA

a. No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$\text{ADD} = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

b. GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death}$$

$$x = \text{total number of animals}$$

All survivors are calculated as dying on Day 28

c. VR = GMTD of Experimental/GMTD of Diluent-Treated Control

d. Fisher's Exact Test comparing mortality of PBS-treated vs drug treated $p = 5.9 \times 10^{-5}$ e. Student's T-test comparing ADD of PBS-treated vs drug treated $p = 3.5 \times 10^{-6}$ f. Fisher's Exact Test comparing mortality of PBS-treated vs drug treated $p = 3.6 \times 10^{-4}$ g. Student's T-test comparing ADD of PBS-treated vs drug treated $p < 10^{-6}$ h. Student's T-test comparing ADD of PBS-treated vs drug treated $p = .02$ i. Fisher's Exact Test comparing mortality of PBS-treated vs drug treated $p = 1.6 \times 10^{-3}$ j. Student's T-test comparing ADD of PBS-treated vs drug treated $p = .002$

Table 36
Antiviral Efficacy of Ribavirin (AVS-01) Administered
Through Day 7 Post Challenge

Virus: Pichinde

	<u>No. Dead/ No. Uninfected*</u>	<u>No. Dead/ No. Infected*</u>	<u>GMTD</u>	<u>VR</u>
Untreated	0/5	10/10 (10.3 ± 1.7)	10.2	NA

Treatment: SC q1d x 11 days, Starting Day -3

PBS	0/5	10/10 (9.0 ± 1.1)	9.0	1.0
150 mg/kg AVS-01	1/5 (14.0 ± 0.0)	3/10 (16.0 ± 1.0) ^a	23.7	2.6
100 mg/kg AVS-01	0/5	1/10 (14.0 ± 0.0) ^b	26.1	2.9
50 mg/kg AVS-01	0/3	10/10 (16.2 ± 3.1) ^c	15.9	1.8
25 mg/kg AVS-01	0/5	10/10 (13.0 ± 1.6) ^d	13.0	1.4

Treatment: SC q1d x 8 days, Starting Day 0 (2 hr. pre-challenge)

PBS	0/5	10/10 (9.3 ± 1.1)	9.4	1.0
150 mg/kg AVS-01	0/5	1/10 (13.0 ± 0.0) ^e	25.9	2.8
100 mg/kg AVS-01	0/5	6/10 ^f (18.5 ± 4.4) ^g	21.5	2.3
50 mg/kg AVS-01	0/5	8/10 (14.5 ± 1.9) ^h	16.4	1.7
25 mg/kg AVS-01	0/5	10/10 (13.6 ± 1.3) ⁱ	13.6	1.4

Virus Challenge

1 x 10 ⁶ pfu	NA	5/5 (9.0 ± 0.0)	9.0	NA
1 x 10 ⁵ pfu	NA	5/5 (9.0 ± 1.0)	9.0	NA
1 x 10 ⁴ pfu	NA	5/5 (9.6 ± 0.9)	9.6	NA
1 x 10 ³ pfu	NA	4/5 (9.0 ± 0.0)	11.3	NA
1 x 10 ² pfu	NA	5/5 (9.0 ± 0.0)	9.0	NA

*No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$ADD = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

GMTD = Geometric Mean Time to Death

$$GMTD = \frac{x}{\sqrt{n_1 \cdot n_2 \cdot n_x}} \quad \text{where } n = \text{day of death} \\ x = \text{total number of animals}$$

All survivors are calculated as dying on Day 28

VR = GMTD of Experimental/GMTD of Diluent-Treated Control

- a. T-test vs PBS control $p < 10^{-6}$
- b. T-test vs PBS control $p = .001$
- c. T-test vs PBS control $p = 1.7 \times 10^{-6}$
- d. T-test vs PBS control $p = 2.8 \times 10^{-6}$
- e. T-test vs PBS control $p = .009$
- f. Fisher's Exact Test vs 8 day treatment with AVS-01 $p = 0.029$
- g. T-test vs PBS control $p = 1.6 \times 10^{-5}$
- h. T-test vs PBS control $p = 1.8 \times 10^{-6}$
- i. T-test vs PBS control $p < 10^{-6}$

Table 37

**Comparative Antiviral Efficacy of Ribavirin
Administered Through Day 10 Post Challenge**

Virus: Pichinde

	<u>No. Dead/ No. Uninfected</u>	<u>No. Dead/ No. Infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
Untreated	0/5	10/10 (10.1 ± 3.0)	9.8	NA
<u>Treatment: q1d x 18 starting Day -7</u>				
PBS SC	0/5	10/10 (10.5 ± 2.2)	10.3	1.0
100 mg/kg Ribavirin	0/5	3/10 (17.0 ± 1.0)	24.1	2.3
50 mg/kg Ribavirin	0/5	7/10 (18.3 ± 2.8)	20.7	2.0
<u>Treatment: q1d x 11 starting Day 0</u>				
PBS SC	0/5	10/10 (10.5 ± 1.4)	10.4	1.0
100 mg/kg Ribavirin	0/5	4/10 (20.8 ± 2.9)	24.8	2.4
50 mg/kg Ribavirin	0/5	9/10 (19.2 ± 4.7)	19.4	1.9
<u>Virus Challenge</u>				
1 x 10 ⁶ pfu	NA	5/5 (9.2 ± 0.8)	9.2	NA
1 x 10 ⁵ pfu	NA	5/5 (9.6 ± 0.9)	9.6	NA
1 x 10 ⁴ pfu	NA	5/5 (9.4 ± 0.9)	9.4	NA
1 x 10 ³ pfu	NA	5/5 (11.6 ± 4.7)	11.0	NA
1 x 10 ² pfu	NA	5/5 (9.4 ± 0.9)	9.4	NA
1 x 10 pfu	NA	5/5 (11.0 ± 4.5)	10.4	NA

a. No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$\text{ADD} = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

b. GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death}$$

x = total number of animals

All survivors are calculated as dying on Day 28

c. VR = GMTD of Experimental/GMTD of Diluent-Treated Control

Table 38

Antiviral Effect of Delay in Initiation of Ribavirin (AVS-01) Treatment

	No. Dead/No. <u>Uninfected</u>	No. Dead/ <u>No. Infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
Untreated	0/3	3/3 (9.7 ± 1.2)	9.6	NA
PBS, Day -1 to +5	0/3	3/3 (10.3 ± 1.5)	10.3	1.0
PBS, Day +4 to +10	0/3	3/3 (9.7 ± 1.5)	9.6	1.0
PBS, Day +5 to +11	0/3	3/3 (9.3 ± 0.6)	9.3	1.0
PBS, Day +6 to +12	0/3	3/3 (10.3 ± 1.2)	10.3	1.0
100 mg/kg AVS-01, Day -1 to +5	0/6	2/6 (13.5 ± 0.7)	22.2	2.2
100 mg/kg AVS-01, Day +4 to +10	0/6	0/6	28.0	2.9
100 mg/kg AVS-01, Day +5 to +11	0/6	6/6 (15.7 ± 3.3)	16.3	1.8
100 mg/kg AVS-01, Day +6 to +12	0/6	5/6 (11.2 ± 1.3)	13.0	1.3

a. No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$\text{ADD} = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

b. GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death}$$

$$x = \text{total number of animals}$$

All survivors are calculated as dying on Day 28

c. VR = GMTD of Experimental/GMTD of Diluent-Treated Control

The Pichinde virus stock was retitrated *in vivo*. Groups of hamsters were inoculated intraperitoneally with various challenge levels of Pichinde stock virus. In order to simulate the stress of compound treatment, the hamsters were treated with PBS subcutaneously on a qld x 7 day schedule beginning 2 hours prior to virus challenge.

As shown in Table 39, the LD₁₀ from this experiment is less than 1 pfu per animal. The LD₅₀ is between 1 and 5 pfu per hamster. This would indicate that we are challenging hamsters with approximately 2000 LD₅₀ of Pichinde virus.

Table 39

In Vivo Titration of Pichinde Virus

Challenge	No. dead/ No. infected	ADD $\pm$ SD ^a	GMTD ^b
5 x 10 ⁵ pfu	10/10	9.0 $\pm$ 1.3	8.9
1 x 10 ⁵ pfu	10/10	9.6 $\pm$ 0.8	9.6
5 x 10 ⁴ pfu	10/10	9.1 $\pm$ 1.1	9.0
1 x 10 ⁴ pfu	19/19	9.9 $\pm$ 1.1	9.8
5 x 10 ³ pfu	20/20	10.0 $\pm$ 0.8	9.9
1 x 10 ³ pfu	20/20	9.6 $\pm$ 0.9	9.5
5 x 10 ² pfu	20/20	10.2 $\pm$ 2.2	10.0
1 x 10 ² pfu	20/20	10.2 $\pm$ 1.1	10.2
50 pfu	20/20	10.2 $\pm$ 1.1	10.1
10 pfu	20/20	10.9 $\pm$ 3.1	10.5
5 pfu	10/10	11.4 $\pm$ 1.3	11.2
1 pfu	6/10	12.5 $\pm$ 3.3	16.0

^a ADD $\pm$ SD = average day of death $\pm$ 1 standard deviation

$$\text{ADD} = \frac{\sum [(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

^b GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x / \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where} \quad n = \text{day of death} \\ x = \text{total number of animals}$$

All survivors are calculated as dying on Day 24

4.2.2 Venezuelan Equine Encephalomyelitis Virus (VEE)

No compounds were received during the current reporting period for VEE; however, compounds received during the previous reporting periods were tested.

During this reporting period three compounds (AVS-79, AVS-272 and AVS-347) were assessed for antiviral activity against VEE. AVS-79 was uniformly toxic at the 320 mg/kg dose level. The 100 mg/kg dose level resulted in significant weight loss in the toxicity control mice; however, there were no deaths. Virus-infected mice receiving the 320 or 100 mg/kg dose levels of AVS-79 had a decrease in their ADD compared to the diluent-treated controls. No significant antiviral effects were seen with AVS-79 treatment (Table 40). Because of the slight increase in the ADD of animals receiving 32 mg/kg of AVS-79, this dose level was retested. As shown in Table 41, AVS-79 was administered on a 10-day schedule at doses of 32 and 16 mg/kg/day. The 16 mg/kg/day dose was divided, bid, such that the mice received 8 mg/kg of AVS-79 in the morning and in the evening. No antiviral effect was seen with AVS-79 dosed at 16 mg/kg/day (divided bid); however, there was a reduction in the mortality rate of animals receiving 32 mg/kg/day (60%) compared to the diluent-treated controls (90%). There was no significant increase in the ADD of animals receiving this dose level of AVS-79. AVS-79 was tested against VEE *in vivo* at doses of 32 mg/kg/day given once daily and 32 mg/kg/day split into two daily doses (16 mg/kg/day bid). The compound was administered subcutaneously on a 10-day treatment schedule beginning the day preceding virus challenge. Toxicity did not occur at the dose levels tested. As shown in Table 42, AVS-79 did not alter the outcome of VEE infection in mice.

AVS-272 was tested against VEE challenge at dose levels of 100 mg/kg/day and lower. As shown in Table 40, no significant antiviral effects were associated with AVS-272 treatment; however, there was a slight increase in the ADD at the 32 and 10 mg/kg/dose levels. Retesting of AVS-272 on a 10-day treatment schedule at doses of 10 mg/kg/day and 5 mg/kg/day (divided bid) did not indicate antiviral efficacy for this compound (Table 41).

AVS-347 was evaluated on a 7-day treatment schedule at dose levels of 32, 10, 3.2, 1.0 and 0.32 mg/kg/day. Animals receiving 10, 3.2 or 0.32 mg/kg/day had an increase in ADD compared to diluent-treated controls. The mortality rates were reduced at all dose levels, however, the reduction was not statistically significant. The greatest reduction in mortality occurred in animals receiving 0.32 mg/kg/day (Table 43). Retesting of AVS-347 on a 10-day treatment schedule at doses of 5 mg/kg/day (divided bid), 0.32 mg/kg/day and 0.16 mg/kg/day (divided bid) did not provide evidence of significant antiviral efficacy (Table 41).

The ability of Ribavirin pretreatment to alter the outcome of VEE challenge was assessed by pretreating mice for 7 days prior to virus challenge. As shown in Table 44, treatment with 150 or 100 mg/kg/day of Ribavirin for 18 days beginning 7 days prior to virus challenge did not significantly reduce mortality compared to diluent-treated mice nor to mice receiving Ribavirin for 11 days beginning on the day of virus challenge. No evidence of pretreatment-induced alterations in Ribavirin compartmentalization was observed in this experiment.

Table 40

Antiviral Efficacy of AVS-79 and AVS-272

Virus: VEE

Treatment: q1d x 7 days starting Day -1

Challenge: 0.13 pfu

VEE Expt. No. 18

	<u>No. Dead/ No. Uninfected^a</u>	<u>No. Dead/ No. Infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
Untreated	0/5	7/10 (7.7 ± 1.7)	11.2	0.9
PBS, SC	0/5	6/10 (7.3 ± 1.0)	12.5	1.0
320 mg/kg AVS-79	5/5 (3.0 ± 0.7)	10/10 (3.3 ± 0.5)	3.3	0.3
100 mg/kg AVS-79	0/5	8/10 (6.3 ± 1.5)	8.3	0.7
32 mg/kg AVS-79	0/5	9/10 (8.6 ± 1.3) ^d	9.5	0.8
10 mg/kg AVS-79	0/5	9/10 (7.0 ± 0.9)	8.0	0.6
3.2 mg/kg AVS-79	0/5	10/10 (8.0 ± 0.9)	7.9	0.6
100 mg/kg AVS-272	0/5	9/10 (6.9 ± 1.1)	7.8	0.6
32 mg/kg AVS-272	0/5	10/10 (8.6 ± 2.1) ^e	8.4	0.7
10 mg/kg AVS-272	0/5	7/10 (8.3 ± 0.8) ^f	11.9	1.0
3.2 mg/kg AVS-272	0/5	9/10 (7.9 ± 0.9)	8.9	0.7
1 mg/kg AVS-272	0/5	9/10 (8.1 ± 1.2)	9.1	0.7

Virus Challenge

10 pfu	NA	5/5 (7.2 ± 0.4)	7.2	NA
1 pfu	NA	5/5 (8.0 ± 1.7)	7.9	NA
0.13 pfu	NA	4/5 (8.0 ± 1.2)	10.2	NA
0.013 pfu	NA	2/5 (7.0 ± 0.0)	16.1	NA
0.0013 pfu	NA	0/5	28.0	NA

a. No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$\text{ADD} = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

b. GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death}$$

$$x = \text{total number of animals}$$

All survivors are calculated as dying on Day 28

c. VR = GMTD of Experimental/GMTD of Diluent-Treated Control

d. Student's T test vs PBS controls; p = 0.08.

e. Student's T test vs PBS controls; p = 0.2.

f. Student's T test vs PBS controls; p = 0.08.

Table 41

Secondary Evaluations of AVS-79, AVS-272 and AVS-347

Virus: VEE

Treatment: q1d x 10 days starting Day -1, SC

Challenge: 0.2 pfu

VEE Expt. No. 20

	<u>No. Dead/ No. Uninfected</u>	<u>No. Dead/ No. Infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
Untreated	0/5	9/9* (9.0 ± 1.6)	8.9	NA
PBS, div bid	0/5	9/10 (8.8 ± 1.0)	9.5	1.0
16 mg/kg AVS-79, div bid	0/5	5/5 (9.2 ± 2.9)	8.8	0.9
5 mg/kg AVS-272, div bid	0/5	10/10 (7.8 ± 1.2)	7.7	0.8
5 mg/kg AVS-347, div bid	0/5	10/10 (8.4 ± 1.4)	8.3	0.9
0.16 mg/kg AVS-347, div bid	0/5	8/10 (9.3 ± 2.3)	10.7	1.1
PBS, SC	0/5	9/10 (8.4 ± 0.9)	9.2	1.0
32 mg/kg AVS-79	0/5	6/10 (8.8 ± 1.6)	12.4	1.3
10 mg/kg AVS-272	0/5	10/10 (8.3 ± 0.9)	8.2	0.9
0.32 mg/kg AVS-347	0/5	10/10 (8.2 ± 1.3)	8.1	0.9
Virus challenge				
10 pfu	NA	5/5 (8.8 ± 1.6)	8.7	NA
1 pfu	NA	5/5 (9.4 ± 1.3)	9.3	NA
0.20 pfu	NA	5/5 (9.2 ± 1.8)	9.0	NA
0.02 pfu	NA	1/5 (10.0 ± 0.0)	18.1	NA
0.002 pfu	NA	0/5	21.0	NA

a. No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$ADD = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

b. GMTD = Geometric Mean Time to Death

$$GMTD = \sqrt[n]{n_1 \cdot n_2 \cdot n_3 \cdots n_x} \quad \text{where } n = \text{day of death}$$

x = total number of animals

All survivors are calculated as dying on Day 28

c. VR = GMTD of Experimental/GMTD of Diluent-Treated Control

* 1 animal died within 24 hours post-virus inoculation and is not included in the data

Table 42

Antiviral Efficacy of AVS-79 Against VEE in Mice
(VEE Experiment No. 22)

<u>Treatment</u>	<u>No. dead/ No. uninfected</u>	<u>No. dead/ No. Infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
Untreated	0/5	10/10 (7.7 ± 1.3)	7.6	NA ^d
PBS	0/5	9/10 (7.0 ± 0.9)	8.0	NA
PBS, bid	0/5	9/10 (7.4 ± 2.1)	8.2	NA
32 mg/kg AVS-79	0/5	9/10 (7.4 ± 0.5)	8.5	1.0
16 mg/kg AVS-79, bid	ND ^e	10/10 (7.8 ± 0.6)	7.8	1.0

^a ADD ± SD = average day of death ± 1 standard deviation

$$\text{ADD} = \frac{\sum [(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

^b GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death}$$

x = total number of animals

All survivors are calculated as dying on Day 28

^c VR = Virus Rating

$$\text{VR} = \text{GMTD of Experimental} / \text{GMTD of Diluent-Treated Control}$$

^d NA = Not applicable

^e ND = Not done

Table 43

Antiviral Evaluation of AVS-347

Virus: VEE

Treatment: q1d x 7 days starting Day -1, SC

Challenge: 0.13 pfu

	No. Dead/No. <u>Uninfected</u>	No. Dead/ <u>No. Infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
Untreated	0/5	6/10 (8.7 ± 1.5)	13.7	NA
0.4% CMC in PBS	0/5	10/10 (8.7 ± 1.8)	8.5	1.0
32 mg/kg AVS-347	0/4	8/10 (7.5 ± 2.9)	9.2	1.1
10 mg/kg AVS-347	0/5	9/10 (9.8 ± 2.8)	10.5	1.2
3.2 mg/kg AVS-347	0/5	9/10 (9.0 ± 0.9)	10.0	1.2
1 mg/kg AVS-347	0/5	9/10 (7.6 ± 1.3)	8.5	1.0
0.32 mg/kg AVS-347	0/5	7/10 (9.4 ± 1.0)	13.0	1.5
Virus Challenge				
10 pfu	NA	5/5 (8.2 ± 1.3)	8.1	NA
1 pfu	NA	5/5 (8.0 ± 1.0)	7.9	NA
0.13 pfu	NA	5/5 (8.8 ± 1.5)	8.7	NA
0.013 pfu	NA	2/5 (8.5 ± 0.7)	17.4	NA
0.0013 pfu	NA	0/5	28.0	NA

a. No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$\text{ADD} = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

b. GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death}$$

x = total number of animals

All survivors are calculated as dying on Day 28

c. VR = GMTD of Experimental/GMTD of Diluent-Treated Control

Table 44

Antiviral Efficacy of Ribavirin (AVS-01) Treatment

Virus: VEE

Challenge: 0.2 pfu

	<u>No. Dead/ No. Uninfected</u>	<u>No. Dead No. Infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
<u>Treatment: qid x 18 starting Day -7</u>				
PBS	0/5	9/10 (9.0 ± 1.4)	9.7	1.0
150 mg/kg AVS-01	0/5	9/10 (8.0 ± 1.0)	8.1	0.8
100 mg/kg AVS-01	0/5	7/10 (7.9 ± 2.0)	10.3	1.1
<u>Treatment: qid x 11 starting Day 0</u>				
PBS	0/5	10/10 (8.9 ± 1.7)	8.8	1.0
150 mg/kg AVS-01	0/5	9/10 (8.6 ± 1.0)	9.3	1.1
100 mg/kg AVS-01	0/5	10/10 (8.9 ± 1.8)	8.7	1.0
Untreated	0/5	8/10 (8.5 ± 1.3)	10.1	NA
<u>Virus Challenge</u>				
100 pfu	NA	5/5 (8.0 ± 1.4)	7.9	NA
10 pfu	NA	5/5 (7.8 ± 1.3)	7.7	NA
1 pfu	NA	5/5 (7.6 ± 0.9)	7.6	NA
0.2	NA	5/5 (9.4 ± 1.7)	9.3	NA
0.02	NA	2/5 (10.0 ± 2.8)	15.5	NA
0.002	NA	0/5	21.0	NA
0.0002	NA	0/5	21.0	NA

a. No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$\text{ADD} = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

b. GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death}$$

x = total number of animals

All survivors are calculated as dying on Day 28

c. VR = GMTD of Experimental/GMTD of Diluent-Treated Control

4.2.3 Japanese Encephalitis Virus (JE) Challenge Model

Attempts to establish an *in vivo* challenge model in outbred Swiss CD-1^R (Charles River Laboratories, Inc.) were unsuccessful. During this reporting period we have been working toward establishing a reproducible challenge model in C57Bl/6 mice. To generate a lethal stock virus for challenge experiments, serial *in vivo* passages of JE virus (Beijing strain) were performed.

Primary *In Vivo* Passage of *In Vitro* Virus Stock

Four-week-old female C57Bl/6 mice (Charles River Labs, Inc.) were challenged intracranially with JE virus (Beijing strain) to generate an initial *in vivo* passage pool. The virus used for challenge was the first Vero cell passage of JE virus which had been passaged in the C6/36 mosquito cell line (obtained from USAMRIID). Animals were administered one of three challenge levels [(7800 plaque forming units (pfu), 3900 pfu or 780 pfu)] intracranially and sacrificed when they became moribund. The brains were harvested from the sacrificed animals and from those which were found shortly after death. The brains were prepared as a 10% homogenate in phosphate-buffered saline (PBS).

The results of this experiment are shown in Table 45. Brain homogenates prepared from the animals challenged with 780 pfu will be subsequently referred to as Challenge Prep #1.

Table 45
In Vivo Passage of *In Vitro* Virus Stock

Challenge Dose ^a (pfu)	Number Infected	Number Dead	Number Sacrificed
7800	5	2	2
3900	10	4	4
780	17	2	14 ^b

a. Administered intracranially

b. Challenge Prep 1

Primary *In Vivo* Passage in C57Bl/6 Mice of *In Vivo* Virus Stock

A 10% brain homogenate generated from passage of JE virus (Beijing strain) in Swiss outbred mice (CD-1^R) was used as the challenge virus in this experiment. The brain preps were prepared from CNS tissues collected from moribund CD-1^R mice infected intraperitoneally with the Vero cell passage 2 stock of JE virus. Four-week-old female C57Bl/6 mice were challenged intraperitoneally or intracranially with one of several dilutions of the CD-1^R brain preps. Brains were collected from C57Bl/6 mice when they were moribund or recently dead. A 10% homogenate of the brains was prepared in PBS.

The results of this experiment are shown in Table 46. The brain homogenates prepared from animals receiving a 1:100 dilution of the CD-1^R brain homogenate prep 1 will be subsequently referred to as Challenge Prep 2 while brain homogenates prepared from animals receiving a 1:1000 dilution of the CD-1^R brain homogenate prep 1 will be referred to as Challenge Prep 3.

Table 46

In Vivo Passage of Swiss Mouse *In Vivo* Virus Stock

<u>Challenge</u>	<u>Dilution</u>	<u>Route</u>	<u>No. Infected</u>	<u>No. Dead</u>	<u>No. Sacrificed</u>
CD-1 ^R Prep 1	1:10000	IP	10	2	0
	1:1000	IP	10	3	6 ^a
	1:100	IP	10	2	7 ^b
CD-1 ^R Prep 2	1:10000	IP	10	1	4
	1:1000	IP	10	4	6
	1:100	IP	10	3	7
CD-1 ^R Prep 1	1:10000	IC	10	0	0
	1:1000	IC	10	0	6
	1:100	IC	10	1	8
CD-1 ^R Prep 2	1:10000	IC	10	1	3
	1:1000	IC	10	1	9
	1:100	IC	10	1	9

a. Challenge Prep 3

b. Challenge Prep 2

Secondary *In Vivo* Passage

The brain preps generated in the primary *in vivo* C57Bl/6 mouse passages were inoculated into four-week-old C57Bl/6 female mice by the intraperitoneal or intracranial routes. Brains were collected from these animals when they were moribund or recently dead. The brains were prepared as 10% homogenates in PBS for use in challenge studies.

The results of this experiment are shown in Table 47. The 10% homogenate prepared from the animals receiving the 1:100 dilution of Challenge Prep 1 are subsequently referred to as Challenge Prep 4. Challenge Prep 5 refers to the 10% homogenate prepared from animals receiving a 1:750 dilution of Challenge Prep 3.

Table 47

Secondary *In Vivo* Passage of JE Virus in C57Bl/6 Mice

	<u>Dilution</u>	<u>Route</u>	<u>No. Infected</u>	<u>No. Dead</u>	<u>No. Sacrificed</u>
Challenge Prep 1	1:100	IP	5	2	2 ^a
	1:500	IP	5	5	0
	1:750	IP	5	1	3
	1:1000	IP	5	5	0
	1:100	IC	5	1	4
	1:500	IC	5		5
	1:1000	IC	5	1	4
Challenge Prep 2	1:100	IP	5	1	3
	1:500	IP	5	4	0
	1:750	IP	5	5	0
	1:1000	IP	5	4	1
	1:500	IC	5	4	1
	1:1000	IC	5	4	1
Challenge Prep 3	1:100	IP	5	3	2
	1:500	IP	5	4	0
	1:750	IP	5	1	3 ^b
	1:1000	IP	5	3	0
	1:500	IC	5	2	3
	1:1000	IC	5	5	0

a. Challenge Prep 4

b. Challenge Prep 5

Preliminary Challenge Experiment

The brain homogenates generated in the preceding passage experiments were tested for lethality in four-week-old female C57Bl/6 mice. Mice were challenged by the intraperitoneal or intracranial route with various dilutions of the brain homogenates. Intraperitoneal challenge consisted of 0.5 ml of the inoculum while intracranial challenge consisted of 0.03 ml of the inoculum.

With few exceptions, all of the preparations assayed produced 100% mortality in the challenged mice by the intraperitoneal and intracranial routes. This experiment indicates that JE virus capable of producing significant mortality in C57Bl/6 mice was generated by serial *in vivo* passage. The results are shown in Table 48.

Table 48
In Vivo Titration of JE Virus Challenge Stocks

<u>Challenge Prep No.</u>	<u>Dilution</u>	<u>Route</u>	<u>No. Dead/ No. Infected</u>	<u>ADD $\pm$ SD^a</u>
1	1:100	IP	4/5	14.3 $\pm$ 2.1
1	1:500	IP	4/5	13.3 $\pm$ 4.0
1	1:750	IP	5/5	12.6 $\pm$ 2.1
1	1:1000	IP	5/5	14.0 $\pm$ 1.0
1	1:100	IC	5/5	6.0 $\pm$ 0.7
1	1:500	IC	5/5	6.0 $\pm$ 0.0
1	1:1000	IC	5/5	6.0 $\pm$ 0.7
2	1:100	IP	5/5	13.2 $\pm$ 2.4
2	1:500	IP	5/5	14.8 $\pm$ 1.6
2	1:750	IP	5/5	13.6 $\pm$ 2.8
2	1:1000	IP	5/5	13.8 $\pm$ 3.3
2	1:500	IC	5/5	7.2 $\pm$ 1.1
2	1:1000	IC	5/5	7.4 $\pm$ 1.1
3	1:100	IP	5/5	13.4 $\pm$ 1.5
3	1:500	IP	5/5	12.8 $\pm$ 0.4
3	1:750	IP	4/5	15.5 $\pm$ 2.6
3	1:1000	IP	5/5	13.8 $\pm$ 1.3
3	1:500	IC	5/5	7.4 $\pm$ 0.5
3	1:1000	IC	5/5	8.4 $\pm$ 1.7
4	1:100	IP	5/5	10.6 $\pm$ 4.3
4	1:500	IP	5/5	12.2 $\pm$ 2.2
4	1:750	IP	5/5	13.4 $\pm$ 1.7
4	1:1000	IP	3/5	14.0 $\pm$ 1.0
4	1:100	IC	5/5	6.4 $\pm$ 0.9
4	1:500	IC	5/5	6.8 $\pm$ 0.4
4	1:750	IC	5/5	7.0 $\pm$ 0.7
4	1:1000	IC	5/5	7.0 $\pm$ 0.0
5	1:100	IP	5/5	14.0 $\pm$ 1.0
5	1:500	IP	5/5	13.0 $\pm$ 2.6
5	1:750	IP	5/5	13.8 $\pm$ 2.5
5	1:1000	IP	5/5	15.0 $\pm$ 1.6
5	1:100	IC	4/5	6.8 $\pm$ 1.0
5	1:500	IC	5/5	7.0 $\pm$ 0.7
5	1:750	IC	5/5	6.2 $\pm$ 1.9
5	1:1000	IC	5/5	7.0 $\pm$ 0.7

a. ADD $\pm$ SD = Average Day of Death $\pm$ 1 Standard Deviation

$$\text{ADD} = \frac{\sum[(\text{day of death}) \times (\text{No. dead that day})]}{\text{total no. of dead}}$$

Confirmatory Challenge Experiment

To confirm the lethality of Challenge Preps 4 and 5 a second *in vivo* experiment was conducted. Four-week-old female C57Bl/6 mice were inoculated with 0.5 ml of one of several serial dilutions of Challenge Prep 4 or 5 by the intraperitoneal route. Dilutions of the Challenge Preps as high as 1:8000 produced significant mortality. The results, shown in Table 49, indicate that an acceptable challenge virus preparation has been obtained for use in young C57Bl/6 mice.

Table 49

In Vivo Titration (JE Virus Challenge Preparations 4 and 5)

<u>Challenge Prep No.^a</u>	<u>Dilution</u>	<u>No. Dead/ No. Infected</u>	<u>ADD $\pm$ SD^b</u>	<u>GMTD^c</u>
4	1:100	10/10	15.0 $\pm$ 1.8	14.9
4	1:500	10/10	12.8 $\pm$ 1.7	12.7
4	1:1000	10/10	12.0 $\pm$ 2.2	11.8
4	1:2000	9/10	11.7 $\pm$ 3.2	12.3
4	1:4000	9/10	13.9 $\pm$ 1.2	14.9
4	1:8000	9/10	12.7 $\pm$ 2.5	13.5
5	1:100	9/10	13.2 $\pm$ 2.8	14.0
5	1:500	9/10	14.2 $\pm$ 2.2	15.1
5	1:1000	9/10	14.3 $\pm$ 1.9	15.2
5	1:2000	7/10	14.6 $\pm$ 1.1	17.7
5	1:4000	8/10	12.1 $\pm$ 2.6	14.0
5	1:8000	8/10	13.0 $\pm$ 2.4	15.0

a. Administered intraperitoneally

b. ADD $\pm$ SD = Average Day of Death $\pm$ 1 Standard Deviation

$$\text{ADD} = \frac{\sum[(\text{day of death}) \times (\text{No. dead that day})]}{\text{total no. of dead}}$$

c. GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death} \\ x = \text{total number of animals}$$

Preparation of a Large Stock of Challenge Virus

A lethal challenge virus preparation was successfully generated (Challenge Prep 4) by serial *in vivo* passage of Beijing strain JE virus. Therefore, a large pool of challenge virus was produced by intraperitoneal injection of 60 C57Bl/6 female mice with JE Challenge Prep 1. Brains were collected from these animals when they were moribund or recently dead. The brains were prepared as a 10% homogenate in phosphate buffered saline (PBS, pH 7.2) for use in challenge studies. A total of 47 brains was collected and homogenized. This preparation is subsequently referred to as Challenge Prep 6.

In Vivo Titration of Challenge Virus Stocks

Challenge Preps 4 and 6 were assessed for lethality in four-week-old C57B1/6 mice. Mice were challenged intraperitoneally with 0.5 ml of serial dilutions of the brain homogenates prepared in PBS. Both preparations are able to produce 100% mortality in challenged mice; however, the titers are significantly different. As shown in Table 50, Challenge Prep 4 produced significant mortality at a dilution of 1:60,000. Challenge Prep 6 was associated with significant mortality only at dilutions of 1:5,000 or less. The theoretical LD₉₀, LD₅₀ and LD₁₀ for Challenge Prep 4 calculated by plotting on probit paper are 1:52,000, 1:70,000 and 1:95,000 dilutions, respectively. The theoretical LD₉₀, LD₅₀ and LD₁₀ for Challenge Prep 6 calculated by plotting on probit paper are 1:2,600, 1:13,000 and 1:60,000 dilutions, respectively. Since Challenge Prep 6 is significantly less lethal than Challenge Prep 4 a second attempt to generate a large pool of Prep 4-like material will be pursued. The *in vitro* pfu titers for both preparations will be determined.

Table 50

In Vivo Titration of Challenge Preps No. 4 and No. 6

<u>Dilution</u>	<u>No. Dead/ No. Infected</u>	<u>ADD $\pm$ SD^a</u>
Challenge Prep 4		
1:10,000	9/10	11.8 $\pm$ 3.6
1:20,000	9/10	12.3 $\pm$ 2.6
1:40,000	10/10	14.3 $\pm$ 1.8
1:60,000	8/10	14.1 $\pm$ 2.9
1:80,000	3/10	11.7 $\pm$ 3.1
1:100,000	0/10	NA
1:150,000	1/10	15.0 $\pm$ 0.0
1:200,000	0/10	NA
1:250,000	1/10	14.0 $\pm$ 0.0
1:300,000	0/10	NA
1:400,000	0/10	NA
1:500,000	2/10	13.0 $\pm$ 1.4
Challenge Prep 6		
1:1,000	10/10	12.0 $\pm$ 2.0
1:5,000	8/10	13.0 $\pm$ 2.1
1:10,000	1/10	14.0 $\pm$ 0.0
1:20,000	1/10	15.0 $\pm$ 0.0
1:40,000	2/10	16.5 $\pm$ 0.7
1:60,000	1/10	11.0 $\pm$ 0.0
1:80,000	0/10	NA
1:100,000	0/10	NA
1:150,000	0/10	NA
1:200,000	0/10	NA
1:250,000	0/10	NA
1:300,000	0/10	NA
1:350,000	0/10	NA
1:400,000	0/10	NA
1:450,000	0/10	NA
1:500,000	0/10	NA

a. ADD $\pm$ SD = Average Day of Death $\pm$ 1 Standard Deviation

$$= \frac{\sum[(\text{day of death}) \times (\text{No. dead that day})]}{\text{total no. of dead}}$$

Titration of Challenge Prep 6 Virus Stock

Four-week-old female C57Bl/6 mice were challenged intraperitoneally with the Challenge Prep 6 JE virus stock. Serial dilutions of the virus stock were prepared in PBS and administered intraperitoneally in a volume of 0.5 ml per mouse. The results of this titration indicate that a 1:4000 dilution of the virus stock should result in 90% mortality in four-week-old C57Bl/6 mice after intraperitoneal challenge with 0.5 ml of the virus inoculum. The results of the *in vivo* titration are shown in the Table 51.

Table 51

Titration of Challenge Prep 6 Stock Virus (JE)

<u>Challenge Dose</u>	<u>No. dead/ No. infected</u>	<u>ADD $\pm$ SD^a</u>	<u>GMTD^b</u>
1:1000 dilution	10/10	12.9 $\pm$ 1.3	12.8
1:2000 dilution	10/10	12.7 $\pm$ 1.6	12.6
1:4000 dilution	9/10	12.2 $\pm$ 1.5	13.2
1:6000 dilution	2/10	14.0 $\pm$ 2.8	24.3
1:8000 dilution	8/10	13.1 $\pm$ 1.4	15.2
1:10000 dilution	4/10	15.8 $\pm$ 1.0	22.2

^a ADD $\pm$ SD = average day of death $\pm$ 1 standard deviation

$$\text{ADD} = \frac{\sum [(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

^b GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death} \\ x = \text{total number of animals}$$

All survivors are calculated as dying on Day 28

Preparation of Challenge Prep 7 Virus Challenge Stock

Thirty-five female C57Bl/6 mice were infected intraperitoneally with 0.5 ml of a 1:8000 dilution of Challenge prep 4. The animals were sacrificed when moribund and the brains were collected and stored at -70 °C. A total of 31 brains were collected, pooled and prepared as a 10% homogenate in PBS for use in future challenge studies. This homogenate will be referred to as Challenge Prep 7.

Titration of Challenge Prep 7 Virus Stock

Four-week-old female C57Bl/6 mice were challenged intraperitoneally with the Challenge Prep 7 JE virus stock. Serial dilutions of the virus stock were prepared in PBS and administered intraperitoneally in a volume of 0.5 ml per mouse. The results of the *in vivo* titration are shown in the Table 52. Further titration will be performed in order to determine the LD₅₀ dose for Challenge Prep 7.

Table 52

Titration of Challenge Prep 7 Stock Virus (JE)

<u>Challenge Dose</u>	<u>No. dead/ No. infected</u>	<u>ADD $\pm$ SD^a</u>	<u>GMTD^b</u>
1:1000 dilution	10/10	11.6 $\pm$ 2.6	11.3
1:5000 dilution	10/10	13.7 $\pm$ 1.5	13.6
1:10000 dilution	4/10	14.3 $\pm$ 1.0	21.4
1:15000 dilution	1/5	14.0 $\pm$ 0.0	24.7

^a ADD $\pm$ SD = average day of death $\pm$ 1 standard deviation

$$\text{ADD} = \frac{\sum [(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

^b GMTD = Geometric Mean Time to Death

$$\text{GMTD} = \frac{x}{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death}$$

x = total number of animals

All survivors are calculated as dying on Day 28

JE Virus Challenge of Older C57Bl/6 Mice

The susceptibility of older C57Bl/6 mice to challenge with JE virus was assessed in 23-week-old mice. Mice were challenged intraperitoneally with Challenge Prep 6. Dilutions of virus, ranging from 1:10 to 1:1000, were prepared in PBS and 0.5 ml of the dilutions was administered intraperitoneally to mice. Mortality was monitored for 28 days. The results, shown in Table 53, indicate that older C57Bl/6 mice are more resistant to JE virus challenge than are young mice as the greatest mortality achieved with any challenge dose was 50%. Older C57Bl/6 mice are not a suitable host for *in vivo* testing of potential anti-JE virus compounds.

Table 53

Mortality of Old C57Bl/6 Mice Challenged with JE Virus

<u>Challenge</u>	<u>No. dead/ No. Infected</u>	<u>ADD $\pm$ SD^a</u>	<u>GMTD^b</u>
Uninfected Control	0/10	NA ^c	NA
<u>10% Brain from JE28</u>			
1:10 dilution IP	2/10	12.0 $\pm$ 1.4	23.6
1:20 dilution IP	1/9	17.0 $\pm$ 0.0	26.5
1:40 dilution IP	3/10	15.3 $\pm$ 0.6	23.4
1:60 dilution IP	5/10	15.6 $\pm$ 1.5	20.9
1:80 dilution IP	3/10	14.3 $\pm$ 0.6	22.9
1:100 dilution IP	4/10	15.3 $\pm$ 1.5	21.9
1:150 dilution IP	5/10	14.6 $\pm$ 0.6	20.2
1:200 dilution IP	5/10	13.8 $\pm$ 2.2	19.6
1:400 dilution IP	2/10	16.0 $\pm$ 2.8	25.0
1:800 dilution IP	5/10	16.8 $\pm$ 3.3	21.5
1:1000 dilution IP	4/9	14.5 $\pm$ 1.7	20.9
1:1600 dilution IP	3/10	16.7 $\pm$ 2.3	23.9
1:3200 dilution IP	4/10	16.3 $\pm$ 1.3	22.5
1:6400 dilution IP	2/10	17.0 $\pm$ 0.0	25.3
1:12800 dilution IP	2/10	15.0 $\pm$ 1.4	24.7

^a ADD $\pm$ SD average day of death $\pm$ 1 standard deviation

$$\text{ADD} = \frac{\sum [(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

^b GMTD = Geometric Mean Time to Death

$$\text{GMTD} = \frac{x}{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death} \\ x = \text{total number of animals}$$

All survivors are calculated as dying on Day 28

^c NA = Not Applicable

Antiviral Evaluations of AVS Compounds

During this reporting period four compounds (AVS Nos. 361, 2563, 2811, 2812) were evaluated for antiviral efficacy against JE virus challenge. Compounds were dissolved in ethanol and diluted with sterile saline to a final ethanol concentration of 2.0%. Compounds were administered subcutaneously on a 7-day treatment schedule starting on the day preceding virus challenge. Compounds were prepared at concentrations appropriate for dosing at 0.1 ml of compound/10 gm of body weight. Compounds were administered on an individual animal weight basis. Mice were challenged with approximately 9 LD₅₀ of Beijing strain JE virus (Challenge Prep 4).

AVS-361 was tested at 6, 4 and 2 mg/kg/day dose levels. AVS-2563 was tested at 12, 6 and 3 mg/kg/day dose levels. AVS-2811 was tested at 25, 12.5 and 6.25 mg/kg/day dose levels. AVS-2812 was tested at 6, 3 and 1 mg/kg/day dose levels. Diluent-treated controls (infected and uninfected) received 2% ethanol in saline. Untreated, uninfected and untreated, infected controls were included.

As shown in Table 54, significant antiviral efficacy was demonstrated for AVS-361 and for AVS-2812. AVS-361 was toxic at 6 mg/kg/day producing a 60% mortality rate in uninfected controls. At this dose level 70% of the infected, treated animals died. The ADD for the infected animals was 4 days which is significantly lower than the ADD for diluent-treated controls ($p < 10^{-6}$). These deaths are presumed to be related to drug toxicity since the ADD is low and the toxicity controls suffered a similar mortality rate. The 3 infected, treated mice which survive are presumed to represent antiviral drug efficacy since all virus-challenged control animals died (25/25). Mice receiving 4 mg/kg/day of AVS-361 did not present evidence of drug toxicity as the uninfected, treated controls continued to gain weight during treatment. At this dose level significant antiviral efficacy was demonstrated for AVS-361. No mortality occurred in the 10 infected mice receiving 4 mg/kg/day of AVS-361 in contrast to the 100% mortality occurring in the diluent-treated infected controls (Fisher's Exact Test, $p = 5 \times 10^{-6}$). The VR for this treatment group was 2.2. Virus-infected animals receiving 2 mg/kg/day of AVS-361 had an 80% mortality rate which is not significantly different from the 100% mortality occurring in diluent-treated controls. However, the ADD for mice receiving 2 mg/kg/day of AVS-361 was significantly prolonged as compared to the diluent-treated controls ($p = 0.00034$). These results indicate that AVS-361 has significant antiviral activity against JE virus challenge. Further studies are strongly suggested.

Testing of AVS-2563 did not indicate significant antiviral efficacy as the mortality rates and the ADD of compound-treated animals did not differ significantly from the diluent-treated controls (Table 54). However, the highest dose level tested, 12 mg/kg/day, was not a toxic dose as uninfected controls receiving this dose continued to gain weight and suffered no mortality. Further studies at higher dose levels may provide evidence for antiviral efficacy.

AVS-2811 administered at 25 mg/kg/day resulted in a mortality rate of 80% in toxicity control mice; however, the mortality rate in virus-infected animals was 40% (Table 54). A 40% mortality rate in virus-infected animals is significantly different from the diluent-treated, infected controls ($p = .0054$). This difference in mortality rate implies that the toxicity induced by AVS-2811 and the lethality induced by JE virus counteracted one another. The mortality rates in mice receiving 12.5 or 6.25 mg/kg/day of AVS-2811 were both 80% which are not significantly reduced when compared to diluent-treated controls. No significant prolongation in the ADD was present at either dose level. Further testing at dose levels between 12.5 and 25 mg/kg/day is suggested.

Table 54

Antiviral Efficacy of AVS-361, AVS-2563, AVS-2811 and AVS-2812

	No. Dead/ No. Uninfected ^a	GMTD ^b	No. Dead/ No. Infected ^a	GMTD ^b	VR ^c
Untreated	0/5		10/10 (14.0 ± 1.8)	13.9	NA
2% alc/saline	0/5		10/10 (12.8 ± 1.3)	12.7	1.0
<u>AVS-361</u>					
6 mg/kg	3/5 (2.7 ± 0.6)	6.8	7/10 (4.0 ± 2.4) ^d	6.5	0.5
4 mg/kg	0/5		0/10 ^e	28.0	2.2
2 mg/kg	0/5		8/10 (16.3 ± 1.9) ^f	18.0	1.4
<u>AVS-2563</u>					
12 mg/kg	0/5		10/10 (13.6 ± 2.4)	13.4	1.1
6 mg/kg	0/5		9/10 (13.7 ± 1.7)	14.6	1.2
3 mg/kg	0/5		9/10 (12.0 ± 2.7)	12.7	1.0
<u>AVS-2811</u>					
25 mg/kg	4/5 (4.8 ± 3.1)	6.0	4/10 ^g (10.5 ± 6.7)	16.1	1.3
12.5 mg/kg	0/5		8/10 (14.0 ± 1.8)	16.0	1.3
6.25 mg/kg	0/5		8/10 (13.5 ± 1.5)	15.6	1.2
<u>AVS-2812</u>					
6 mg/kg	4/5 (6.0 ± 1.4)	8.0	5/9 ^{h,i} (6.4 ± 3.1) ^j	15.8	1.2
3 mg/kg	0/5		2/10 ^k (17.5 ± 7.8) ^l	25.2	2.0
1 mg/kg	0/5		6/10 ^m (15.7 ± 3.4) ⁿ	19.5	1.5
Sham-infected	0/10				
4 x challenge	NA	NA	5/5 (13.4 ± 1.1)	13.4	NA
2 x challenge	NA	NA	5/5 (12.2 ± 1.1)	12.2	NA
1 x challenge	NA	NA	5/5 (12.4 ± 2.7)	12.1	NA
0.5 x challenge	NA	NA	5/5 (13.4 ± 1.1)	13.4	NA

a. No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$ADD = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

b. GMTD = Geometric Mean Time to Death

$$GMTD = x / \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death} \\ x = \text{total number of animals}$$

All survivors are calculated as dying on Day 28

c. VR = GMTD of Experimental/GMTD of Diluent-Treated Control

d. T-test of ADD vs. diluent-treated controls $p < 10^{-6}$

e. Fishers' Exact Test of exptal vs. control mortality $p = 5 \times 10^{-6}$

f. T-test of ADD vs. diluent-treated controls $p = 3.4 \times 10^{-4}$

g. Fishers' Exact Test of exptal vs. control mortality $p = 5.4 \times 10^{-3}$

h. One animal sacrificed day 28 due to head tilt not included in data

i. Fisher's Exact Test of exptal vs. control mortality $p = 0.047$

j. T-test of ADD vs. diluent-treated controls $p = 7 \times 10^{-5}$

k. Fishers' Exact Test of exptal vs. control mortality $p = 3.6 \times 10^{-4}$

l. T-test of ADD vs. diluent-treated controls $p = .052$

m. Fishers' Exact Test of exptal vs. control mortality $p = 0.04$

n. T-test of ADD vs. diluent-treated controls $p = .031$

AVS-2812 administered at 6 mg/kg/day produced an 80% mortality rate in toxicity control animals; however, virus-infected animals had a significantly lower mortality rate of 56% ($p = 0.047$) (Table 54). The ADD of virus-infected mice receiving 6 mg/kg/day of AVS-2812 was significantly reduced as compared to the diluent-treated control animals ($p = 0.00007$). The mortality occurring in virus-infected animals receiving this dose level of AVS-2812 is presumed to be due to drug toxicity effects since the ADD in virus-infected mice is comparable to the ADD of the toxicity controls. The reduction in mortality in the drug-treated, virus-infected mice compared to diluent-treated controls is presumed to be due to AVS-2812 antiviral activity. Virus-infected mice receiving 3 mg/kg/day of AVS-2812 had a 20% mortality rate which is significantly lower than that occurring in diluent-treated controls ($p = .00036$). Animals receiving 1 mg/kg/day of AVS-2812 had a significantly reduced mortality rate ($p = 0.04$) and a significantly increased ADD ($p = 0.031$) when compared to diluent-treated controls. Further studies with AVS-2812 are strongly suggested since it has demonstrated significant antiviral activity against JE virus challenge.

Back Challenge of Surviving Mice Treated with AVS-361, AVS-2563, AVS-2811 and AVS-2812

Mice which survived the previous challenge experiment assessing antiviral activity of potential anti-JE virus chemotherapeutic agents were back challenged intraperitoneally with 0.5 ml of a 1:1000 dilution of Challenge Prep 4 (approximately 70 LD₅₀). The results are shown in Table 55. At this dose level, 60 of the 69 JE virus naive toxicity controls succumbed to challenge producing an 87% mortality rate. Mice which had been previously challenged with JE virus varied in response to secondary challenge. Mice which had been previously challenged and treated with AVS-361 at 6 or 4 mg/kg/day succumbed to secondary challenge implying that no protective response had been generated during the first virus challenge. This may indicate that these dose levels of AVS-361 successfully aborted JE virus replication. This same circumstance appears to be true for animals previously challenged and treated with 25 mg/kg/day of AVS-2811 or 6 mg/kg/day of AVS-2812. In the other treatment groups the number of back challenged survivors is so low that interpretation is difficult except for those receiving 3 mg/kg of AVS-2812. There were 3 deaths in the 8 animals receiving a secondary challenge. This lower mortality rate could indicate that an immune response occurred at the time of primary challenge. These results indicate that animals surviving JE virus challenge during drug treatment did so due to drug antiviral efficacy and is not due to innate resistance to JE virus challenge.

Table 55

Back Challenge of Mice Treated with AVS-361, AVS-2563,
AVS-2811 and AVS-2812

<u>Original Treatment Group</u>	<u>No. Dead/ No. Challenged</u>	<u>ADD $\pm$ SD^a</u>
Uninfected (1st Expt)		
Untreated	4/5	14.3 $\pm$ 1.3
2% alcohol/saline	3/5	15.3 $\pm$ 1.2
6 mg/kg AVS-361	2/2	14.0 $\pm$ 0.0
4 mg/kg AVS-361	4/5	12.8 $\pm$ 2.6
2 mg/kg AVS-361	5/5	15.2 $\pm$ 0.4
12 mg/kg AVS-2563	3/5	13.7 $\pm$ 1.5
6 mg/kg AVS-2563	3/5	14.7 $\pm$ 1.5
3 mg/kg AVS-2563	3/5	15.7 $\pm$ 1.5
25 mg/kg AVS-2811	1/1	11.0 $\pm$ 0.0
12.5 mg/kg AVS-2811	4/5	13.5 $\pm$ 3.5
6.25 mg/kg AVS-2811	5/5	16.2 $\pm$ 1.1
6 mg/kg AVS-2812	1/1	13.0 $\pm$ 0.0
3 mg/kg AVS-2812	3/5	16.0 $\pm$ 1.7
1 mg/kg AVS-2812	5/5	15.0 $\pm$ 1.9
Sham-infected	5/10	12.0 $\pm$ 2.9
Infected (1st Expt)		
6 mg/kg AVS-361	3/3	14.0 $\pm$ 0.0
4 mg/kg AVS-361	9/10	14.2 $\pm$ 2.3
2 mg/kg AVS-361	0/2	NA
6 mg/kg AVS-2563	1/1	10.0 $\pm$ 0.0
3 mg/kg AVS-2563	0/1	NA
25 mg/kg AVS-2811	4/6	14.0 $\pm$ 1.4
12.5 mg/kg AVS-2811	0/2	NA
6.25 mg/kg AVS-2811	0/2	NA
6 mg/kg AVS-2812	3/4	14.0 $\pm$ 1.0
3 mg/kg AVS-2812	3/8	15.0 $\pm$ 1.7
1 mg/kg AVS-2812	0/3	NA

a. ADD $\pm$ SD = average day of death $\pm$ 1 standard deviation

$$\text{ADD} = \frac{\sum[(\text{day of death}) \times (\text{No. dead that day})]}{\text{total no. of dead}}$$

Evaluation of AVS-111 and AVS-257

Groups of 15 C57Bl/6 mice were treated with phosphate-buffered saline (PBS), AVS-111 or AVS-257 on a q1d X 7 day schedule with the first dose given on the day preceding virus challenge. Treatments were given by the subcutaneous route for PBS, AVS-111 and AVS-257 and by the intraperitoneal route for PBS and AVS-111. Ten of the 15 animals in each group were infected intraperitoneally with an LD₅₀ dose of JE (Beijing strain) 2 hours after the second dose of compound was administered (Day 0). Mortality was monitored for 28 days and the average day of death (ADD), geometric mean time to death (GMTD) and virus rating (VR) were calculated for each compound treatment.

AVS-111 administered by the subcutaneous route on a 7 day treatment schedule did not produce mortality in the toxicity controls; however, it did result in the animals failing to gain weight. The other dose levels of AVS-111 did not cause a failure to gain nor did AVS-257 result in a failure to gain in the toxicity controls.

Neither AVS-111 nor AVS-257 demonstrated antiviral efficacy against *in vivo* challenge with JE virus. The ADD and GMTD of animals receiving the AVS compounds was reduced compared to the PBS treated controls. The results are shown in Table 56.

Table 56

Antiviral Efficacy of AVS-111 and AVS-257 (JE Virus)

<u>Treatment</u>	<u>No. dead/ No. uninfected</u>	<u>No. dead/ No. infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
Untreated	0/5	7/10 (13.6 ± 2.6)	16.7	NA ^d
<u>Treatment: q1d x 7 days subcutaneously</u>				
PBS	0/5	10/10 (13.5 ± 2.1)	13.3	NA
<u>AVS-111</u>				
320 mg/kg	0/5	10/10 (10.5 ± 1.0)	10.5	0.8
100 mg/kg	0/5	10/10 (11.4 ± 1.2)	11.4	0.9
32 mg/kg	0/5	9/10 (12.1 ± 1.5)	13.1	1.0
<u>AVS-257</u>				
320 mg/kg	0/5	10/10 (10.9 ± 1.1)	10.9	0.8
100 mg/kg	0/5	10/10 (10.4 ± 0.8)	10.4	0.8
32 mg/kg	0/5	10/10 (12.9 ± 2.7)	12.7	1.0
<u>Treatment: q1d x 7 days intraperitoneally</u>				
PBS	ND	10/10 (13.7 ± 3.4)	13.1	NA
<u>AVS-111</u>				
320 mg/kg	0/5	10/10 (10.7 ± 0.8)	10.7	0.8
100 mg/kg	0/5	10/10 (10.5 ± 1.4)	10.4	0.8
32 mg/kg	0/5	10/10 (10.7 ± 2.0)	10.5	0.8
1 x Challenge	NA ^d	5/5 (13.0 ± 3.2)	12.6	NA
0.5 x Challenge	NA	9/10 (13.3 ± 1.9)	14.2	NA
0.25 x Challenge	NA	9/10 (13.7 ± 1.0)	14.7	NA

^a ADD ± SD = average day of death ± 1 standard deviation

$$\text{ADD} = \frac{\sum [(\text{day of death} \times (\text{number dead that day}))]}{\text{total number of dead}}$$

^b GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death} \\ x = \text{total number of animals}$$

All survivors are calculated as dying on Day 28

^c VR = Virus Rating

$$\text{VR} = \text{GMTD of Experimental} / \text{GMTD of Diluent-Treated Control}$$

^d NA = Not applicable

Evaluation of AVS-360

Groups of 15 C57Bl/6 mice were treated subcutaneously with PBS or AVS-360 on a q1d x 7 day schedule with the first dose given on the day preceding virus challenge. Ten of the 15 animals in each group were infected intraperitoneally with an LD₅₀ dose of JE (Beijing strain) 2 hours after the second dose of compound was administered (Day 0). Mortality was monitored for 28 days and the average day of death (ADD), geometric mean time to death (GMTD) and virus rating (VR) were calculated for each treatment group.

As can be seen in Table 57, AVS-360 demonstrated some antiviral efficacy as the mortality rate in treated mice was 70% compared to 100% in the diluent-treated controls. The ADD of AVS-360 treated mice was not prolonged compared to the diluent-treated controls. Further studies with alternate dose, route and treatment schedules may provide improved antiviral efficacy.

Table 57

Antiviral Evaluation of AVS-360 (JE Virus)

<u>Treatment</u>	<u>No. dead/ No. infected</u>	<u>No. dead/ No. infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
Untreated	0/5	10/10 (13.6 ± 1.5)	13.5	NA ^d
0.4% CMC in PBS	0/5	10/10 (12.3 ± 2.8)	12.1	NA
250 mg/kg AVS-360	0/5	7/10 (12.0 ± 2.5)	15.2	1.3

^a ADD ± SD = average day of death ± 1 standard deviation

$$ADD = \frac{\sum [(day\ of\ death) \times (number\ dead\ that\ day)]}{total\ number\ of\ dead}$$

^b GMTD = Geometric Mean Time to Death

$$GMTD = \frac{x}{n_1 \cdot n_2 \cdot n_3} \quad \text{where } n = \text{day of death}$$

$x = \text{total number of animals}$

All survivors are calculated as dying on Day 28

^c VR = Virus Rating

$$VR = \frac{GMTD\ of\ Experimental}{GMTD\ of\ Diluent-Treated\ Control}$$

^d NA = Not Applicable

Antiviral Testing of AVS-361, 2811, 2812, 2980 and 4113

Fifteen female C57Bl/6 mice were randomly assigned to one of the following treatment groups.

1. untreated control
2. 2% alcohol/saline diluent control
3. NCI HPC diluent control
4. 6 mg/kg/day AVS-361
5. 4 mg/kg/day AVS-361
6. 2 mg/kg/day AVS-361
7. 6 mg/kg/day AVS-2812
8. 3 mg/kg/day AVS-2812
9. 1 mg/kg/day AVS-2812
10. 32 mg/kg/day AVS-4113
11. 16 mg/kg/day AVS-4113
12. 8 mg/kg/day AVS-4113
13. 20 mg/kg/day AVS-2811
14. 10 mg/kg/day AVS-2811
15. 5 mg/kg/day AVS-2811
16. 40 mg/kg/day AVS-2980
17. 20 mg/kg/day AVS-2980
18. 10 mg/kg/day AVS-2980

AVS-361, AVS-2812 and AVS-4113 were prepared in 2% alcohol/saline at concentrations consistent with dosing at 0.1 ml of solution per 10 gm of body weight. AVS-2811 and AVS-2980 were prepared in NCI HPC diluent at concentrations consistent with dosing at 0.1 ml of solution per 10 gm of body weight. The compounds were administered on a q1d x 7 day schedule with the first dose given the day preceding virus challenge. Two hours after the second dose of compound was administered (Day 0), 10 of the 15 mice in each treatment group were challenged intraperitoneally with JE virus. The remaining 5 animals in each treatment group served as drug toxicity controls. Mortality was monitored for 28 days and the average day of death (ADD), geometric mean time to death (GMTD) and virus rating (VR) were calculated for each compound treatment. The results are shown in Table 58.

Table 58
Antiviral Efficacy of Selected AVS Compounds
Against JE Virus

<u>Treatment</u>	<u>No. dead/ No. uninfected^a</u>	<u>No. dead/ No. infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
Untreated	0/5	10/10 (12.2 ± 2.5)	11.9	NA ^d
2% alc/saline	0/5	10/10 (12.4 ± 2.6)	12.1	NA
<u>AVS-361</u>				
6 mg/kg	0/5	1/10 ^e (15.0 ± 0.0) ^f	26.3	2.2
4 mg/kg	0/5	7/10 ^g (15.4 ± 2.0) ^b	18.4	1.5
2 mg/kg	1/5 (28.0 ± 0.0)	9/10 (11.6 ± 1.4)	12.5	1.0
<u>AVS-2812</u>				
6 mg/kg	3/5 (7.0 ± 5.0)	10/10 (6.9 ± 2.8) ⁱ	6.3	0.5
3 mg/kg	0/5	1/10 ^j (15.0 ± 0.0) ^k	26.3	2.2
1 mg/kg	0/5	9/10 (15.1 ± 1.2) ^l	16.0	1.3
<u>AVS-4113</u>				
32 mg/kg	NA*	9/10 (13.6 ± 2.6)	14.4	1.2
16 mg/kg	0/5	9/10 (11.8 ± 2.6)	12.6	1.0
8 mg/kg	0/5	9/10 (13.3 ± 1.5)	13.2	1.1
<u>NCI/HPC</u>	0/5	10/10 (12.6 ± 1.2)	12.6	NA
<u>AVS-2811</u>				
20 mg/kg	5/5 (2.6 ± 1.3)	10/10 (3.5 ± 2.2) ^m	2.8	0.2
10 mg/kg	0/5	4/10 ⁿ (13.3 ± 1.0) ^o	20.7	1.6
5 mg/kg	0/5	9/10 (13.4 ± 1.9)	14.4	1.1
<u>AVS-2980</u>				
40 mg/kg	0/5	2/10 ^p (9.5 ± 4.9) ^q	22.2	1.8
20 mg/kg	0/5	4/10 ^r (15.0 ± 2.6) ^s	21.7	1.7
10 mg/kg	0/5	9/10 (13.6 ± 1.9)	14.4	1.1

* The animals in this cage died due to flooding by a ruptured water bottle.

^a The numbers in parentheses are the ADD ± SD = average day of death ± 1 standard deviation

$$ADD = \frac{\sum [(day\ of\ death) \times (number\ dead\ that\ day)]}{total\ number\ of\ dead}$$

^b GMTD = Geometric Mean Time to Death

$$GMTD = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death}$$

$$x = \text{total number of animals}$$

All survivors are calculated as dying on Day 28

^c VR = Virus Rating

$$VR = GMTD\ of\ Experimental / GMTD\ of\ Diluent-Treated\ Control$$

^d NA = Not Applicable

^e Fisher's Exact Test $p = 5.95 \times 10^{-5}$

^f Student's t-test $p = .36$

^g Fisher's Exact Test $p = .105$

^h Student's t-test $p = .02$

Table 58 (Cont'd.)

- ⁱ Student's t-test $p = 2.7 \times 10^{-4}$
- ^j Fisher's Exact Test $p = 5.95 \times 10^{-5}$
- ^k Student's t-test $p = .36$
- ^l Student's t-test $p = .01$
- ^m Student's t-test $p = <10^{-6}$
- ⁿ Fisher's Exact Test $p = 5.4 \times 10^{-3}$
- ^o Student's t-test $p = .35$
- ^p Fisher's Exact Test $p = 3.6 \times 10^{-4}$
- ^q Student's t-test $p = .06$
- ^r Fisher's Exact Test $p = 5.4 \times 10^{-3}$
- ^s Student's t-test $p = .03$

AVS-361 administered at 6 mg/kg/day significantly reduced mortality (10%) in JE virus challenged mice compared to the diluent treated controls (100%) ($p = 6 \times 10^{-5}$). No mortality occurred in the toxicity control animals. At 4 mg/kg/day, AVS-361 reduced mortality to 70% and significantly increased the ADD ($p = .02$). The 2 mg/kg/day dose level did not significantly alter the outcome of JE virus challenge. One of the 5 toxicity control animals receiving the 2 mg/kg/day dose level died on Day 28; however, this death is not believed to be drug-related as the animal suffered from malocclusion and was emaciated. The VR for AVS-361 at doses of 6 mg/kg/day and 4 mg/kg/day was 2.2 and 1.5, respectively. Toxicity control animals receiving AVS-361 at any of the three dose levels did not fail to gain or lose weight throughout the treatment period.

AVS-2811 administered at 20 mg/kg/day resulted in 100% mortality in toxicity control animals with an ADD of 2.6 days. Similarly, all of the virus-infected mice receiving AVS-2811 at 20 mg/kg/day died with an ADD of 3.5 days. At 10 mg/kg/day, AVS-2811 did not produce mortality in the toxicity controls although it did result in a failure to gain weight. At this dose level AVS-2811 reduced mortality in the virus-infected mice to 40% which is significantly reduced compared to the diluent-treated controls ($p = 5.4 \times 10^{-3}$). Administered at 5 mg/kg/day, AVS-2811 did not significantly reduce mortality nor increase the ADD in virus infected animals. At this dose level no evidence of toxicity was found in the toxicity control animals.

AVS-2812 administered at 6 mg/kg/day produced 60% mortality in the toxicity control animals. All of the virus-infected mice receiving AVS-2812 at 6 mg/kg/day died with an ADD which was significantly shorter than that present in the diluent-treated controls ($p = 2.7 \times 10^{-4}$). At 3 mg/kg/day AVS-2812 significantly reduced mortality (10%) in the virus-infected mice ($p = 5.95 \times 10^{-5}$) compared to the diluent-treated control animals. AVS-2812 administered at 1 mg/kg/day did not reduce mortality in the virus-infected animals; however, it did significantly prolong the ADD compared to diluent treated controls ($p = 0.01$). Neither the 3 mg/kg/day nor the 1 mg/kg/day dose levels resulted in toxicity in the toxicity control animals.

AVS-2980 administered at 40 mg/kg/day significantly reduced mortality (20%) in the virus infected mice compared to the diluent-treated control animals ($p = 3.6 \times 10^{-4}$). At 20 mg/kg/day AVS-2980 reduced mortality to 40% which is significantly reduced compared to the diluent-treated controls ($p = 5.4 \times 10^{-3}$). In addition, this dose level significantly prolonged the ADD ($p = 0.03$).

AVS-2980 administered at 10 mg/kg/day did not reduce mortality or increase the ADD compared to the diluent-treated control animals. Toxicity control animals receiving 40 mg/kg/day of AVS-2980 lost weight during the treatment period while animals receiving the 20 or the 10 mg/kg/day dose levels did not show evidence of toxicity.

AVS-4113 at dose levels of 32, 16 or 8 mg/kg/day did not significantly reduce mortality or increase the ADD in virus-infected mice. The 5 toxicity control animals receiving the 32 mg/kg/day dose level of

AVS-4113 died due to a flooded cage on day 13 post-infection. None of the remaining toxicity control animals receiving AVS-4113 showed evidence of toxicity.

4.2.4 Vaccinia Virus In Vivo Challenge

Due to an interest in developing agents for use against vaccinia virus, we have established two murine vaccinia virus challenge models. One is a lethal model in which mice are challenged intracerebrally with vaccinia virus (strain IHD). The second is a peripheral challenge model which produces ectodermal lesions on the mouse tail.

Model Development

Outbred Swiss mice (Charles River Labs, VAF, +, CD-1^R) weighing 14-16 gm, were challenged by one of several routes with serial ten-fold dilutions of a mouse brain-passaged vaccinia virus (strain IHD). Animals were challenged intranasally (IN) with 10 μ l of the virus inoculum, intrathoracically (IT) with 0.1 ml of the virus inoculum, intravenously (IV) with 0.2 ml of the virus inoculum or intracranially (IC) with 0.03 ml of the virus inoculum. Mortality was monitored for 28 days in the IN, IT and IC challenged animals. Animals receiving IV challenge were sacrificed on Day 8 post challenge and their tails were examined. Tailpox were visualized by staining with a 1% fluorescein-0.5% methylene blue solution which was prepared in 70% methanol. After staining, the tails were destained in 70% methanol and dried by rolling in absorbent paper. Lesions were visualized and enumerated under longwave UV (354nm) irradiation.

As shown in Table 59, the only route which produced significant mortality was intracranial. All animals challenged intracranially with 0.03 ml of the virus prep at the 10^{-3} and 10^{-4} dilutions died. Four of the 5 mice receiving the 10^{-5} dilution of the virus prep died. Of the 5 mice receiving the 10^{-6} dilution intracranially only 2 died. The ADD ranged from 4.4 to 9.3 days. Intranasal challenge did not result in any significant mortality. Five of 9 mice challenged intrathoracically with a 10^{-1} dilution died, however, 6 of the 9 died within 24 hours post-inoculation. These deaths are believed to be due to emboli associated with incomplete clarification of the virus inoculum. Tailpox were enumerated on mice receiving the 10^{-2} and 10^{-3} dilutions of the virus prep. The mice receiving the 10^{-2} dilution IV had a mean tailpox count of 21.7 while those receiving the 10^{-3} dilution had a mean pox count of 1.9.

A second experiment was conducted to determine the LD₅₀ and LD₉₀ of the vaccinia virus challenge prep. Four-week-old CD-1^R mice were challenged intracranially with 0.03 ml of various virus dilutions. To simulate drug treatment stress, the mice were treated with PBS subcutaneously on a qld x 7 day schedule beginning on the day preceding virus challenge.

The results (Table 60) indicate that the virus challenge prep produces significant mortality at dilutions as high as 1:500,000. The LD₅₀ for the virus prep is approximately a 10^{-5} dilution while the LD₉₀ is approximately a 10^{-4} dilution. The 10^{-4} dilution was chosen for intracranial challenge studies.

A new virus challenge preparation for use in the tailpox model was generated by passage of the brain passaged vaccinia virus (strain IHD) in primary rabbit kidney cells. This preparation has a 50% cell culture infective dose (CCID₅₀) of $\geq 10^{6.2}$ when titrated in Vero cells. This rabbit kidney cell-passaged virus was inoculated IV into groups of 10 mice at various dilutions. To simulate drug treatment stress, the mice were treated with PBS subcutaneously on a qld x 7 day schedule beginning on the day preceding virus challenge. Mice were sacrificed on Day 8 and the tailpox were counted under UV irradiation following staining with 1% fluorescein-0.5% methylene blue. Five of the ten mice receiving the higher virus dilutions were held until Day 11 to determine if there was a difference in tailpox counts.

Table 59
Initial *In Vivo* Challenged with Vaccinia Virus by Different Routes

<u>Challenge Dose</u>	<u>No. Dead/ No. Challenged</u>	<u>ADD $\pm$ SD^e</u>
Uninfected	0/10	NA
<u>Intranasal^a</u>		
10 ⁻¹ Dilution	1/10	12 $\pm$ 0.0
10 ⁻² Dilution	1/10	10 $\pm$ 0.0
10 ⁻³ Dilution	0/10	NA
10 ⁻⁴ Dilution	0/10	NA
10 ⁻⁵ Dilution	0/10	NA
10 ⁻⁶ Dilution	0/10	NA
<u>Intravenous^b</u>		
10 ⁻¹ Dilution	9/9	3.1 $\pm$ 3.3
10 ⁻² Dilution	0/10	NA
10 ⁻³ Dilution	1/9	7.0 $\pm$ 0.0
10 ⁻⁴ Dilution	1/10	8.0 $\pm$ 0.0
10 ⁻⁵ Dilution	0/10	NA
10 ⁻⁶ Dilution	0/10	NA
<u>Intrathoracic^c</u>		
10 ⁻¹ Dilution	5/9	5.0 $\pm$ 1.2
10 ⁻² Dilution	0/7	NA
10 ⁻³ Dilution	0/7	NA
10 ⁻⁴ Dilution	0/10	NA
10 ⁻⁵ Dilution	1/10	10 $\pm$ 0.0
10 ⁻⁶ Dilution	0/7	NA
<u>Intracranial^d</u>		
10 ⁻³ Dilution	5/5	4.4 $\pm$ 0.6
10 ⁻⁴ Dilution	5/5	6.2 $\pm$ 1.6
10 ⁻⁵ Dilution	4/5	9.3 $\pm$ 2.6
10 ⁻⁶ Dilution	2/5	9.0 $\pm$ 4.2

a. Each mouse was inoculated intranasally with 10 μ l of a 10% brain homogenate dilution.

b. Each mouse was inoculated intravenously with 0.2 ml of a 10% brain homogenate dilution and all surviving animals receiving the 10⁻² and 10⁻³ dilutions were sacrificed on day 8 and observed for tail lesions.

Tail Pox Counts on Day 8

10⁻² Dil IV: 3,3,4,9,12,29,33,52,60
Mean: 21.7/mouse

10⁻³ Dil IV: 0,0,1,2,1,2,5,4
Mean: 1.9/mouse

c. All animals inoculated intrathoracically 0.1 ml of a 10% brain homogenate dilution.

d. All animals inoculated intracranially 0.03 ml of a 10% brain homogenate dilution.

e. ADD $\pm$ SD = Average Day of Death $\pm$ 1 Standard Deviation

Table 60

In Vivo Titration of Vaccinia Virus Administered Intracranially

<u>Virus Challenge Dilution</u>	<u>No. Dead/ No. infected</u>	<u>ADD $\pm$ SD^a</u>	<u>GMTD^b</u>
21:100	10/10	4.3 $\pm$ 0.7	4.3
12:1000	10/10	4.7 $\pm$ 0.5	4.7
1:25000	9/9	6.6 $\pm$ 1.9	6.4
1:120,000	9/10	5.9 $\pm$ 0.6	6.7
1:122,000	9/10	7.0 $\pm$ 3.2	7.4
1:15,2000	8/10	6.9 $\pm$ 2.5	8.3
1:18,0200	9/10	6.7 $\pm$ 2.4	7.1
1:100,0200	5/10	8.4 $\pm$ 2.5	13.0
1:500,0020	4/10	7.3 $\pm$ 1.3	13.7
1:1,000,0200	1/10	10.0 $\pm$ 0.0	19.5

a. ADD $\pm$ SD = average day of death $\pm$ 1 standard deviation

b. GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where} \quad \begin{array}{l} n = \text{day of death} \\ x = \text{total number of animals} \end{array}$$

The results (Table 61) indicate a broad range of lesions occurring with all dilutions tested except 1:1000. Waiting until Day 11 post-infection did not appear to provide any advantage in reducing the range of lesions present. The 1:40, 1:50 and 1:60 dilutions were chosen for further studies.

Table 61
Preliminary Tailpox Titration (Vaccinia Virus)

Day 8				
<u>Virus Dilution</u>	<u>Range ^a</u>	<u>Median</u>	<u>Mean</u>	<u>Standard Deviation</u>
1:10	23 - tntc (74)	46.5	44.8	19.4
1:20	36 - tntc (91)	64.0	65.6	22.0
1:40	0 - 122	46.0	50.2	40.3
1:50	14 - 78	25.0	35.6	23.4
1:60	6 - 86	15.0	28.3	27.0
1:80	1 - tntc (20)	8.0	8.9	6.1
1:100	9 - 108	23.0	45.4	41.7
1:150	0 - 17	6.5	7.5	7.6
1:250	8 - 56	11.0	19.6	20.5
1:500	1 - 68	2.0	18.2	28.7
1:1000	3 - 10	6.0	6.3	3.3

Day 11				
<u>Virus Dilution</u>	<u>Range</u>	<u>Median</u>	<u>Mean</u>	<u>Standard Deviation</u>
1:100	24 - 50	39	38.0	11.2
1:150	8 - 57	15	22.6	19.6
1:250	13 - 66	18	28.6	22.1
1:500	5 - 55	11	17.8	21.0
1:1000	8 - 24	14	15.8	7.8

a. Range of tailpox count. tntc = too numerous to count
Number in parentheses is the highest countable number

Groups of 30 mice were inoculated intravenously with 0.2 ml of the 1:40, 1:50 or 1:60 dilution of the challenge virus preparation. The mice were treated with PES on a qld x 7 day schedule starting on Day -1 to simulate drug treatment stress. Ten mice from each group were sacrificed on Day 6, Day 7 and Day 8. However, only 5 animals receiving the 1:60 dilution were examined on Day 7 and only 3 animals at this dose were examined on Day 8.

The results of this experiment are shown in Table 62. For all three challenge doses, collection of tails for lesion enumeration was best done on Day 6 post-infection. As the time post-infection increases, the number of tails that have uncountable lesions increases. Lesions are uncountable when they coalesce and become large erosive lesions. Tails which have these types of lesions are recorded as too numerous to count (tntc) if epithelial destruction is extreme or they are reported as greater than (>) the number of

countable lesions. The Day 6 mean count for mice receiving the 1:40 dilution was 35.5. This mean is not significantly different from that obtained by challenge with a 1:50 or 1:60 dilution. However, the lowest tailpox count was 14 for mice receiving the 1:40 dilution and 5 and 1 for the 1:50 and 1:60 dilutions, respectively. Challenge with 0.2 ml of a 1:40 dilution of the virus preparation and tailpox enumeration on Day 6 was chosen for use in the tailpox challenge studies.

Table 62

Secondary Tailpox Titration (Vaccinia Virus)

Day 6				
<u>Virus Dilution</u>	<u>Range^a</u>	<u>Median</u>	<u>Mean</u>	<u>Standard Deviation</u>
1:40	14 - 97	26	35.5	27.5
1:50	5 - 78	23	31.8	22.6
1:60	1 - >50	32	29.5	18.4
Day 7				
<u>Virus Dilution</u>	<u>Range</u>	<u>Median</u>	<u>Mean</u>	<u>Standard Deviation</u>
1:40	33 - tntc (69)	69	>47.9	12.4
1:50	12 - >90	42	42.3	26.6
1:60	10 - 82	40	47.2	30.3
Day 8				
<u>Virus Dilution</u>	<u>Range</u>	<u>Median</u>	<u>Mean</u>	<u>Standard Deviation</u>
1:40	6 - tntc (47)	39	32.2	16.0
1:50	26 - tntc (>50)	>40	39.8	9.4
1:60	3 - >60	16	26.3	29.9

a. Range of tailpox count. tntc = too numerous to count
Number in parentheses is the highest countable number

Compound Evaluations Against Intracranial Vaccinia Virus Challenge

Three compounds (AVS-1985, AVS-1986, AVS-1987) have been evaluated for antiviral activity in the intracranial challenge model. In these studies, compounds were administered intraperitoneally on a q1d x 9 day schedule beginning on the day preceding virus challenge. The first dose of AVS-1986 was administered subcutaneously; however, mortality occurred and the route of administration was changed to the intraperitoneal route on the day of virus challenge. AVS-1752 (Ara-A) was included as a positive control. AVS-1986 was diluted in 0.9% saline/0.5% Tween-80. AVS-1985 and AVS-1987 were diluted in sterile water.

The results of testing of AVS-1986 are shown in Table 63. No significant antiviral activity was demonstrated for AVS-1986 at dose levels between 62.5 and 500 mg/kg/day. The first treatment for this

experiment was administered by the subcutaneous route; however, severe lesions occurred within 24 hours at the injection site of animals receiving 500 or 250 mg/kg/day. These animals were sacrificed and replacement animals were obtained. Thereafter compounds were administered by the IP route. Two of the five toxicity control mice receiving 500 mg/kg/day died. Dose levels below this were not lethal. The positive control compound, AVS-1752 (Ara-A), significantly reduced mortality at dose levels of 300 and 150 mg/kg/day.

AVS-1985 and AVS-1987 were tested for antiviral activity against the intracranial vaccinia virus model. As shown in Table 64, no significant antiviral activity was demonstrated for these compounds at any dose level tested. In contrast, the positive control compound, AVS-1752 (Ara-A) significantly reduced virus-induced mortality when administered by the SC or IP route at 150 mg/kg/day on a 7- or 9-day schedule, respectively.

Table 63
Antiviral Efficacy of AVS-1986 Against Lethal Vaccinia Virus Infection

	No. Dead/No. <u>Uninfected</u>	No. Dead/ <u>No. Infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
Untreated	0/5	8/10 (8.5 ± 6.6)	7.0	NA
0.9% saline /0.5% Tw 80	0/5	10/10 (5.2 ± 0.8)	5.1	1.0
500 mg/kg AVS-1986	2/5	6/06 (4.8 ± 0.4)	4.8	0.9
250 mg/kg AVS-1986	0/5	10/10 (4.6 ± 1.1)	4.4	0.9
125 mg/kg AVS-1986	0/4	9/10 (5.6 ± 1.0)	6.3	1.2
62.5 mg/kg AVS-1986	0/5	10/10 (5.6 ± 0.5)	5.6	1.1
300 mg/kg AVS-1752	0/5	1/10 (7.0 ± 0.0)	18.8	3.7
150 mg/kg AVS-1752	0/5	2/10 (7.0 ± 0.0)	16.9	3.3
Sham-infected	0/5	NA		

a. No. in parentheses = Average Day of Death ±1 Standard Deviation (ADD ± SD)

$$\text{ADD} = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

b. GMTD = Geometric Mean Time to Death

$$\text{GMTD} = x \sqrt{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death}$$

x = total number of animals

All survivors are calculated as dying on Day 28

c. VR = GMTD of Experimental/GMTD of Diluent-Treated Control

Table 64

Antiviral Efficacy of AVS-1985 and AVS-1987

Virus: Vaccinia

	<u>No. Dead/ No. Uninfected</u>	<u>No. Dead/ No. Infected^a</u>	<u>GMTD^b</u>	<u>VR^c</u>
<u>Intraperitoneal Route, q1d x 9</u>				
Untreated	0/5	9/10 (5.1 ± 0.6)	6.0	NA
Distilled water	0/5	10/10 (5.1 ± 0.9)	5.0	1.0
293 mg/kg AVS-1985	0/5	10/10 (5.2 ± 0.4)	5.2	1.0
146.5 mg/kg AVS-1985	0/5	10/10 (5.0 ± 0.7)	5.0	1.0
73.3 mg/kg AVS-1985	0/5	10/10 (5.0 ± 0.0)	5.0	1.0
320 mg/kg AVS-1987	0/5	10/10 (5.1 ± 0.3)	5.1	1.0
100 mg/kg AVS-1987	0/5	10/10 (5.1 ± 0.6)	5.1	1.0
32 mg/kg AVS-1987	0/5	10/10 (5.4 ± 0.7)	5.4	1.1
10 mg/kg AVS-1987	0/5	10/10 (5.2 ± 0.8)	5.2	1.0
150 mg/kg Ara-A	0/5	1/10 (8.0 ± 0.0)	24.7	4.9
<u>Subcutaneous Route, q1d x 7</u>				
PBS	0/5	9/10 (5.1 ± 0.3)	6.0	1.0
150 mg/kg Ara-A q1d x 7 SC	0/5	1/10 (8.0 ± 0.0)	24.7	4.1
Sham-infected	0/10	NA		

a. No. in parentheses = Average Day of Death ± 1 Standard Deviation (ADD ± SD)

$$ADD = \frac{\sum[(\text{day of death}) \times (\text{number dead that day})]}{\text{total number of dead}}$$

b. GMTD = Geometric Mean Time to Death

$$GMTD = \sqrt[n]{n_1 \cdot n_2 \cdot n_x} \quad \text{where } n = \text{day of death}$$

$$x = \text{total number of animals}$$

All survivors are calculated as dying on Day 28

c. VR = GMTD of Experimental/GMTD of Diluent-Treated Control

Compound Evaluations Against the Vaccinia Virus-Induced Tailpox Lesion Model

To assess the antiviral efficacy of the positive control compound, AVS-1752 (Ara-A), mice were treated subcutaneously with AVS-1752 at dose levels of 150, 75 and 37.5 mg/kg/day on a q1d x 7 day schedule. The first dose of compound was administered on the day preceding virus challenge. Mice were challenged IV with 0.2 ml of a 1:40 dilution of the challenge virus. Tailpox were enumerated on Day 6 post-inoculation. The numerical counts and the square root transformation of the counts are presented in Table 65. Boyle *et al.* (Antimicrob Agents Chemother. 1966: 536-539, 1967) recommended square root transformation in order to provide a more normal distribution since the tailpox counts vary widely within the same treatment group. As shown, the highest dose level of AVS-1752 (150 mg/kg) reduced the lesion counts; however, the efficacy at this dose level was not as significant as desired. Therefore, treatment with AVS-1752 was administered at a dose of 300 mg/kg/day in subsequent experiments.

Table 65

Anti-Vaccinia Activity of AVS-1752 (Tailpox Model)

<u>Treatment^a</u>	<u>Numerical Counts</u>			<u>Std. Deviation</u>
	<u>No.^b</u>	<u>Median</u>	<u>Mean</u>	
Saline	18	35.5	44.0	26.9
AVS-1752				
150 mg/kg	10	29.0	28.3	13.9
75 mg/kg	11	29.0	47.4	43.9
37.5 mg/kg	13	43.0	38.1	20.9

<u>Treatment^a</u>	<u>Square Root Transformation^c</u>			<u>Std. Deviation</u>
	<u>No.^b</u>	<u>Median</u>	<u>Mean</u>	
Saline	18	6.0	6.4	1.9
AVS-1752				
150 mg/kg	10	5.4	5.1	1.5
75 mg/kg	11	5.4	6.1	3.4
37.5 mg/kg	13	6.6	5.9	1.9

a. Treatment q1d x 7 days, SC

b. No. number of tails included in the data

c. Individual counts were square root transformed and then evaluated

AVS-1985 and AVS-1986 were subsequently tested in the tailpox model at dose levels of 293 mg/kg/day and 250 mg/kg/day, respectively. AVS-1752 was included as a positive control at a dose level of 300 mg/kg/day. All compounds were administered intraperitoneally on a q1d x 7 day schedule with the first dose administered on Day -1. The diluent-treated control mice had a mean tailpox count of 58.3 pox/mouse. In contrast, the tailpox counts of mice receiving AVS-1752, AVS-1985 and AVS-1986 were significantly lower. AVS-1752-treated mice had a mean tailpox count of 24.3 ($p = 6.01 \times 10^{-4}$). AVS-1985-treated mice were similar in that their mean tailpox count was 26.1 ($p = 1.27 \times 10^{-4}$). AVS-1986-treated mice had a somewhat higher mean count of 35.7 ($p = 0.03$). Because of the variation in counts obtained within groups,

the median count provides another method for comparing inter-treatment differences. The median for all three compound treatment groups was less than half of the diluent-treated group median. Treatment with Ara-A (300 mg/kg/day) resulted in a 58% reduction in the mean tailpox counts. Treatment with AVS-1985 and AVS-1986 resulted in 55% and 39% reductions, respectively. These results are shown in Tables 66 and 67.

Table 66

Results of Testing AVS-1985 and AVS-1986
in Vaccinia Tailpox Model

	Treatment			
<u>Water</u>	<u>Ara-A</u> <u>300 mg/kg</u>	<u>AVS-1985</u> <u>293 mg/kg</u>	<u>AVS-1986</u> <u>250 mg/kg</u>	
32	4	32	18	
87	4	30	20	
28	4	17	25	
80	10	0	26	
20	134	11	1	
52	32	7	8	
48	1	4	18	
70	12	41	21	
71	4	23	114	
54	0	35	>93	
62	42	2	30	
25	26	5	19	
65	70	52	>120	
>91	32	>100	21	
106	49	29	20	
>80	4	26	22	
54	5	40	5	
47	17	22	>61	
36	21	8	tntc ^a	
dead	14	37	dead	
Mean	58.3	26.1 ^{c,d}	35.7 ^{e,f}	
Median	54.0	24.5	21	
Std Dev	24.1	23.0	36.3	
Number	19	20	18	

a. tntc = too numerous to count - lesions coalesced

b. T-test vs. drug diluent-treated controls $p = 6.01 \times 10^{-4}$

c. T-test vs. drug diluent-treated controls $p = 1.27 \times 10^{-4}$

d. T-test vs. Ara-A-treated controls $p = 0.84$

e. T-test vs. drug diluent-treated controls $p = 0.03$

f. T-test vs. Ara-A-treated controls $p = 0.31$

Table 67

Square Root Transformation of Tailpox Counts
for AVS-1985 and AVS-1986

Treatment				
	Water	Ara-A 300 mg/kg	AVS-1985 293 mg/kg	AVS-1986 250 mg/kg
	5.66	2.0	5.66	4.24
	9.33	2.0	5.48	4.47
	5.29	2.0	4.12	5.0
	8.94	3.16	0	5.1
	4.47	11.58	3.32	1.0
	7.21	5.66	2.65	2.83
	6.93	1.0	2.0	4.24
	8.37	3.46	6.4	4.58
	8.43	2.0	4.8	10.68
	7.35	0	5.92	>9.64
	7.87	6.48	1.41	dead
	5.0	5.1	2.24	5.48
	8.06	8.37	7.21	4.36
	>9.54	5.66	>10.0	10.95
	10.3	7.0	5.39	4.58
	>8.94	2.0	5.1	4.47
	7.35	2.24	6.32	4.69
	6.86	4.12	4.69	2.24
	6.0	4.58	2.83	>7.81
	dead	3.74	6.08	tntc ^a
Mean	7.5	4.1 ^b	4.6 ^{c,d}	5.4 ^{e,f}
Median	7.4	3.6	5.0	4.6
Std Dev	1.6	2.8	2.3	2.7
Number	19	20	20	18

a. tntc = too numerous to count - lesions coalesced

b. T-test vs. drug diluent-treated controls $p = 5.492 \times 10^{-5}$

c. T-test vs. drug diluent-treated controls $p = 6.926 \times 10^{-5}$

d. T-test vs. Ara-A-treated controls $p = 0.56$

e. T-test vs. drug diluent-treated controls $p = 0.0067$

f. T-test vs. Ara-A-treated controls $p = 0.17$

The data were subjected to square root transformations prior to calculating the results as suggested by Boyle *et al.* Evaluation of Antiviral Compounds by Suppression of Tail Lesions in Vaccinia-infected Mice. (Antimicrob. Agents Chemother. 1966:536-539, 1967).

A retest of AVS-1985 was conducted at a higher dose level. AVS-1985 was dosed once daily at 325 mg/kg/day on Days -1 through +5. The compound was administered intraperitoneally after solubilization in water. Five of the 19 treated animals had pox counts of 60 or greater while the remaining 14 animals had pox counts of 36 or less (Tables 68 and 69). The mean for AVS-1985-treated mice was not significantly different from the mean for diluent-treated mice, however, the median for AVS-1985-treated mice was nearly

half the median for diluent-treated mice. Two of the AVS-1985-treated mice, both of which had high counts (180, >120), did not have the typical erosive lesion seen in diluent-treated controls, rather the lesions were pinpoint size fluorescence positive spots which demonstrated no loss of epithelium. These results are in contrast to the earlier tailpox study with AVS-1985 in which a significant reduction in tailpox counts occurred with AVS-1985 treatment. The virus inoculum for both experiments was from the same stock virus pool. In both experiments the compounds were administered intraperitoneally in water. In the first experiment AVS-1985 was from Lot No. E375-7-25 and was dosed at 293 mg/kg/day while in the second experiment the compound was prepared from two lots of AVS-1985 (E375-7-25 and E375-21-24) and was dosed at 325 mg/kg/day. Subjective observation of the tailpox lesions in the present experiment indicates a lower total epithelial surface area involvement in AVS-1985-treated mice than in diluent-treated controls. In addition, the median tailpox count approached 50% of that in the diluent-treated controls.

A retest of AVS-1986 was conducted at a higher dose level. Mice were treated intraperitoneally with AVS-1986 in water once daily on Days -1 through +5. Initially treatment was scheduled for dosing at 350 mg/kg/day, however, this dose proved to be rapidly fatal and was reduced to 300 mg/kg/day on day 0. The remaining 11 animals, which were treated at 300 mg/kg/day for the duration of the experiment had a significant reduction in tailpox counts. The reduction in tailpox counts obtained with AVS-1986 treatment was comparable to that obtained with Ara-A treatment (Tables 70 and 71).

A third evaluation of AVS-1985 was conducted at a dose level of 325 mg/kg/day on a 7-day schedule with the first dose administered on Day -1 (administered IP). This dose level was not lethal in the toxicity control animals although it approached a toxic dose based on the weight gain/loss patterns of the toxicity control animals. AVS-1985 demonstrated antiviral efficacy in this experiment in that the mean and median tailpox counts for drug-treated animals were significantly reduced as compared to diluent-treated control animals. Animals treated with the positive control compound, Ara-A, at a dose level of 400 mg/kg/day on the same treatment schedule did not demonstrate a significant reduction in tailpox count. However, one animal in the Ara-A-treated group had a pox count in excess of 230. These lesions were pinpoint size fluorescence positive, methylene blue negative spots rather than the more typical erosive lesion as is seen in the diluent-treated controls. If this single count of >230 pox is excluded from the data then the mean pox count for Ara-A-treated animals is 35.4 which is significantly different from the diluent-treated controls ($p = 0.02$). In both the Ara-A-treated animals and the AVS-1985-treated animals the median pox count is nearly 50% lower than the count for diluent-treated control mice. The results are shown in Tables 70 and 71. AVS-1985 demonstrated antiviral efficacy in this study and further testing is suggested including pharmacokinetic studies to assist in determining appropriate dose/route/schedule regimens.

AVS-1986 was administered to vaccinia virus-challenged mice at 100 mg/kg/day with the first dose given on Day -1 (administered SC). At this dose level, AVS-1986 significantly reduced the mean tailpox counts in treated mice as compared to diluent-treated controls. AVS-1986 administered subcutaneously at a dose level of 100 mg/kg/day had equal or greater efficacy in reducing tailpox counts as did the positive control compound, Ara-A, administered at 400 mg/kg/day. Of the five toxicity control animals receiving 100 mg/kg/day, one of the animals died on Day 5 and several of the toxicity as well as virus-challenged animals developed lesions at the site of compound injection. AVS-1986 demonstrated antiviral efficacy in this study and further testing is suggested including pharmacokinetic studies to assist in determining appropriate dose/route/schedule regimens. The results are shown in Tables 72 and 73. In this experiment, 400 mg/kg/day of AVS-1752 was effective in reducing the tailpox counts, however, it was administered SC in contrast to the preceding experiment. At this dose level, administered SC, the toxicity control animals did not suffer weight loss nor did they fail to gain.

AVS 1987 (320 mg/kg) and AVS-1988 (300 mg/kg) were evaluated for efficacy in the tailpox model. Both compounds as well as the positive control AVS-1752 (300 mg/kg) were administered IP on a q1d x 7 day schedule.

As shown in Tables 74 and 75, both AVS-1987 and AVS-1988 had some antiviral efficacy. AVS-1987 reduced the mean tailpox count in treated animals to 28.2 pox/mouse compared to the diluent-treated

control count of 46 pox/mouse ($p = 0.059$). These figures may under-represent AVS-1987 efficacy in that 2 of the diluent-treated controls had lesions which were too numerous to count. Additionally, 6 of the diluent-treated controls had pox counts in excess of what could be counted (lesions coalesce and become uncountable). The median pox count for AVS-1987-treated mice was 50% of that found in the diluent-treated mice. AVS-1987 does demonstrate some antiviral efficacy and should be evaluated at higher dose levels to achieve statistically significant pox count reductions.

AVS-1988 reduced the mean tailpox count in treated animals to 31.6 pox/mouse compared to the diluent-treated control count of 46 pox/mouse ($p = 0.268$). These figures may under-represent AVS-1988 efficacy in that the median count for treated animals was 14.5 pox/mouse compared to a median of 40 pox/mouse in the diluent-treated control animals. Eight of the 20 AVS-1988 mice had pox counts <10 while only 1 of 20 diluent-treated mice had pox counts <10 . Two of the 20 AVS-1988-treated mice had pox counts >100 . If these 2 counts are excluded from the data, then the mean count for AVS-1988-treated mice would be 18.9 pox/mouse which is significantly lower than the diluent-treated animals. AVS-1988 does demonstrate some antiviral efficacy and should be evaluated at higher dose levels to achieve significant pox count reductions.

Table 68

Secondary Testing of AVS-1985 and AVS-1986 (Numerical Counts)

Virus: Vaccinia (Tailpox Model)

Treatment: q1d x 7 starting Day -1 (administered intraperitoneally)

	<u>Water</u>	<u>Ara-A</u> <u>300 mg/kg</u>	<u>AVS-1985</u> <u>325 mg/kg</u>	<u>AVS-1986</u> <u>300 mg/kg</u>
	29	4	180	6
	16	>100	>120	5
	47	8	8	2
	19	30	20	59
	41	>80	1	1
	42	0	36	24
	>100	62	95	2
	96	7	>60	67
	42	19	>90	0
	36	0	32	0
	11	37	7	49
	5	2	6	
	24	4	5	
	28	2	6	
	20	17	18	
	61	2	31	
	>100	1	9	
		6	32	
		1	7	
No.	17	19	19	11
Mean	42.2	20.1	40.2	19.5
Median	36.0	6.0	20.0	5.0
Std Dev	30.4	29.5	48.5	26.1
p		0.03	0.88	0.05

Table 69

Secondary Testing of AVS-1985 and AVS-1986 (Transformed Counts)

Virus: Vaccinia (Tailpox Model)

Treatment: q1d x 7 starting Day -1 (administered intraperitoneally)

	<u>Water</u>	<u>Ara-A</u> <u>300 mg/kg</u>	<u>AVS-1985</u> <u>293 mg/kg</u>	<u>AVS-1986</u> <u>250 mg/kg</u>
	5.39	2.00	13.42	2.45
	4.00	10.00	10.95	2.24
	6.86	2.83	2.83	1.41
	4.36	5.48	4.47	7.68
	6.40	8.94	1.00	1.00
	6.48	0.00	6.00	4.90
	10.00	7.87	9.75	1.41
	9.80	2.65	7.75	8.19
	6.48	4.36	9.49	0.00
	6.00	0.00	5.66	0.00
	3.32	6.08	2.65	7.00
	2.24	1.41	2.45	
	4.90	2.00	2.24	
	5.29	1.41	2.45	
	4.47	4.12	4.24	
	7.81	1.41	5.57	
	10.00	1.00	3.00	
		2.45	5.66	
		1.00	2.65	
No.	17	19	19	11
Mean	6.1	3.4	5.4	3.3
Median	6.0	2.5	4.5	2.2
Std Dev	1.9	2.6	2.6	3.1
p		0.004	0.22	0.03

Table 70

Raw Tailpox Counts for AVS-1985-Treated
Vaccinia Challenged Mice

Treatment: q1d x 7 days starting Day -1 (administered IP)

	<u>Water</u>	<u>Ara-A 400 mg/kg</u>	<u>AVS-1985 325 mg/kg</u>
	>93	6	32
	38	>230	29
	>51	31	4
	62	>84	6
	>57	>31	>90 ^a
	>96	27	35
	39	26	30
	103	17	59
	85	>79	28
	7	34	25
	45	30	21
	>72	27	36
	>99	59	30
	26	13	47
	>67	35	>80
	>57	8	>63
	23	10	>49
	36	85	0
	35		19
No.	19	18	19
Mean	57.4	46.2 ^b	36.0 ^{cd}
Median	57.0	30.5	30.0
Std Dev	28.1	52.3	24.1
Range	7-103	6-230	0-90

a. This animal was suffering from posterior paralysis at the time of sacrifice

b. T-test vs diluent-treated controls $p = 0.42$

c. T-test vs diluent-treated controls $p = 0.02$

d. T-test vs Ara-A-treated controls $p = 0.44$

Table 71

Square Root Transformation of Tailpox Counts
for AVS-1985-Treated Vaccinia Challenged Mice

Treatment: q1d x 7 days starting Day -1 (administered IP)

	<u>Water</u>	<u>Ara-A</u> <u>400 mg/kg</u>	<u>AVS-1985</u> <u>325 mg/kg</u>
	>9.64	2.45	5.66
	5.16	>15.17	5.39
	>7.14	5.57	2.00
	7.87	>9.17	2.45
	>7.55	>5.57	>9.49 ^a
	>9.80	5.20	5.92
	6.24	5.10	5.48
	10.15	4.12	7.68
	9.22	>8.89	5.29
	2.65	5.83	5.00
	6.71	5.48	4.58
	>8.49	5.20	6.00
	>9.95	7.68	5.48
	5.10	3.61	6.86
	>8.19	5.92	>8.94
	>7.55	2.83	>7.94
	4.80	3.16	>7.00
	6.00	9.22	.00
	5.92		4.36
No.	19	18	19
Mean	7.32	6.12 ^b	5.55 ^{cd}
Median	7.55	5.53	5.48
Std Dev	2.00	3.05	2.32
Range	2.65-10.15	2.45-15.17	0.9-49

a. This animal was suffering from posterior paralysis at the time of sacrifice

b. T-test vs diluent-treated controls $p = 0.16$

c. T-test vs diluent-treated controls $p = 0.02$

d. T-test vs Ara-A-treated controls $p = 0.53$

Table 72

Raw Tailpox Counts for AVS-1986-Treated Vaccinia Challenged Mice

Treatment: q1d x 7 days starting Day -1 (administered SC)

	<u>Water</u>	<u>Ara-A 400 mg/kg</u>	<u>AVS-1986 100 mg/kg</u>
	35	3	0
	>71	2	24
	31	93	16
	75	0	17
	34	6	1
	35	2	7
	>90	56	72
	>98	21	9
	>46	4	3
	>90	15	38
	60	8	6
	>83	0	51
	32	14	16
	29	3	14
	>95	54	50
	tntc ^a	50	4
	tntc	7	23
	tntc	75	1
	tntc	>70	14
	tntc	5	3
No.	15	20	20
Mean	60.3	24.4 ^b	18.5 ^{cd}
Median	60.0	7.5	14.0
Std Dev	26.8	29.8	19.8
Range	29-98	0-93	0-72

a. tntc = too numerous to count--lesions coalesced

b. T-test vs. drug diluent-treated controls $p = 8.4 \times 10^{-4}$ c. T-test vs. drug diluent-treated controls $p = 7.2 \times 10^{-6}$ d. T-test vs. Ara-A-treated controls $p = 0.46$

Table 73

Square Root Transformation of Tailpox Counts
for AVS-1986-Treated Vaccinia Challenged Mice

Treatment: q1d x 7 days starting Day -1 (administered SC)

	<u>Water</u>	<u>Ara-A 400 mg/kg</u>	<u>AVS-1986 100 mg/kg</u>
	5.92	1.73	.00
	>8.43	1.41	4.90
	5.57	9.64	4.00
	8.66	.00	4.12
	5.83	2.45	1.00
	5.92	1.41	2.65
	>9.49	7.48	8.49
	>9.90	4.58	3.00
	>6.78	2.00	1.73
	>9.49	3.87	6.16
	7.75	2.83	2.45
	>9.11	.00	7.14
	5.66	3.74	4.00
	5.39	1.73	3.74
	>9.75	7.35	7.07
	tntc ^a	7.07	2.00
	tn.c	2.65	4.80
	tntc	8.66	1.00
	tntc	>8.37	3.74
	tntc	2.24	1.73
No.	15	20	20
Mean	7.58	3.96 ^b	3.87 ^{cd}
Median	7.75	2.74	3.74
Std Dev	1.76	3.03	2.26
Range	5.39-9.75	0-9.64	0-8.49

a. tntc = too numerous to count - lesions coalesced

b. T-test vs. drug diluent-treated controls $p = 2.4 \times 10^{-4}$

c. T-test vs. drug diluent-treated controls $p = 3.8 \times 10^{-6}$

d. T-test vs. Ara-A-treated controls $p = 0.75$

Table 74

Antiviral Efficacy of AVS-1987 and AVS-1988 (Numerical Count)

Virus: Vaccinia (Tailpox Model)

Treatment: q1d x 7 days IP starting Day -1

<u>Diluent</u>	<u>AVS-1987</u> <u>320 mg/kg</u>	<u>AVS-1988</u> <u>300 mg/kg</u>	<u>Ara-A</u> <u>300 mg/kg</u>
71	>73	51	3
tntc	33	11	9
tntc	56	3	1
1	19	18	9
>54	10	>137	14
45	18	15	3
>85	8	14	69
15	3	25	5
18	10	4	5
>51	73	85	6
31	39	6	31
35	7	2	2
10	20	4	2
19	22	16	4
>112	27	>156	25
>67	43	5	4
>97	15	8	3
12	60	22	12
20	9	7	6
85	19	42	1
Mean	46.0	28.2 ^a	10.7 ^c
Median	40.0	14.5	5.0
Std Dev	33.5	44.3	15.8

a. T-test vs diluent-treated controls $p = 0.6$ b. T-test vs diluent-treated controls $p = 0.27$ c. T-test vs diluent-treated controls $p = 1.6 \times 10^{-4}$

Table 75

Antiviral Efficacy of AVS-1987 and AVS-1988 (Transformed Counts)

Virus: Vaccinia (Tailpox Model)

Treatment: q1d x 7 days IP starting Day -1

Diluent	AVS-1987 320 mg/kg	AVS-1988 300 mg/kg	Ara-A 300 mg/kg
8.43	>8.54	7.14	1.73
tntc	5.74	3.32	3.00
tntc	7.48	1.73	1.00
1.00	4.36	4.24	3.00
>7.35	3.16	>11.70	3.74
6.71	4.24	3.87	1.73
>9.22	2.83	3.74	8.31
3.87	1.73	5.00	2.24
4.24	3.16	2.00	2.24
>7.14	8.54	9.22	2.45
5.57	6.24	2.45	5.57
5.92	2.65	1.41	1.41
3.16	4.47	2.00	1.41
4.36	4.69	4.00	2.00
>10.58	5.20	>12.49	5.00
>8.19	6.56	2.24	2.00
>9.85	3.87	2.83	1.73
3.46	7.75	4.69	3.46
4.47	3.00	2.65	2.45
9.22	4.36	6.48	1.00
Mean	6.26	4.93 ^a	2.77 ^c
Median	6.32	4.42	2.24
Std Dev	2.68	2.03	1.78

a. T-test vs diluent-treated controls $p = 0.09$ b. T-test vs diluent-treated controls $p = 0.11$ c. T-test vs diluent-treated controls $p = 3 \times 10^{-5}$ 5. DISCUSSION

A number of the submitted compounds exhibited highly selective activity against vaccinia virus (VV) *in vitro*. Marked efficacy and selectivity against VV were shown by fifteen of the active compounds (Table 5) with VR's >5.5 and TI's >100. The most active compounds were AVS numbers 3679, 1985, 4227, 4533, 4224, 4226, 3912, 3607 and 4225, all with VR's >7.9. The potency and selectivity of these compounds are shown by ID₅₀'s $\leq 0.32 \mu\text{g/ml}$ and TI's >1000. Confirmatory retests of these active compounds were performed, employing the CPE-inhibition assay procedure in Vero cell monolayer cultures (Table 6). The original antiviral activity was confirmed on all nine compounds.

Nine of the more active compounds from the previous reporting period (AVS-1985, 2964, 3513, 3533, 3607, 3679, 3912, 3940 and 3941) were further evaluated for efficacy against VV by plaque reduction

assays in Vero cells. The potency and selectivity of each of the compounds were again confirmed (Table 7).

Marked efficacy and selectivity against AD2 were shown by seven compounds (See Table 8). The most active compounds were AVS-4167 (VR 3.5, ID₅₀ 2.5 µg/ml, TI 12.8) and AVS-4785 (VR 3.4, ID₅₀ 4.3 µg/ml, TI 7.5). AVS-4530 is of particular interest because it showed a marked inhibitory effect on VV replication (Table 5). This compound should be evaluated for its effect on other DNA viruses.

A limited number of compounds have demonstrated significant antiviral activity against VSV (Table 10). The two most active drugs tested and confirmed in the CPE-inhibition assay during this reporting period were AVS-3586 with a VR of 3.7 and 4.3 and a TI of 17.7 and 20.1 and AVS-4240 with a VR of 2.6 and 1.7 and a TI of 4.0 and 8.5 (Table 11). These compounds should be evaluated for efficacy against VSV in mice.

Nine compounds were found to be active against the Punta Toro Virus in the initial CPE-inhibition assays (Table 13), but only one compound (AVS-2980) of the four retested was active in the confirmatory retest. We will consider changing the criteria for activity for this virus from a TI of >1.0 to a TI of >5.0 which will probably eliminate retesting of false actives.

Six compounds (AVS-2948, 2563, 4271, 4391 and 2992) were found to have a TI of ≥ 10 against the Sandfly virus (See Table 15). The activity of these compounds has not been confirmed in a repeat CPE inhibition assay.

Six compounds (AVS-2350, 3189, 2527, 2581, 2568 and 2585) had significant antiviral activity against the Pichinde Virus in the initial plaque reduction assay (See Table 17). If this activity is confirmed in a subsequent assay, these compounds should be pursued as candidate antivirals in *in vivo* testing in hamsters.

As shown in Table 19, AVS-3800 was the most active compound against *in vitro* VEE this reporting period (VR 2.3, ID₅₀ 0.96 µg/ml and TI of 10.3). If this activity is confirmed in a subsequent test, it would be a candidate for evaluation as an chemotherapeutic agent against VEE infections in mice.

Four compounds exhibited activity with a TI of ≥ 5.0 in the initial CPE inhibition assay (AVS-4592, 4278, 4281, 2563 and 4280) against the Yellow Fever Virus (Table 20). These compounds will be retested to confirm this activity.

Three compounds demonstrated reproducible activity against the Japanese encephalitis virus *in vitro* (Table 23). The compounds (AVS-2563, 2811 and 4113) should now be evaluated for their therapeutic efficacy against JE infections in mice.

During the first half of this reporting period, one compound, AVS-3593, showed marginal antiviral activity against the HTN virus using the plaque reduction assay (See Table 24). The TI was 1.1 as compared to 6.3 for the positive control, Ribavirin. Due to variability and inconsistency of results with this plaque assay, we plan to change over to the ELISA-based assay procedure. It will be a much more practical and useful type of method to employ for high-volume screening of compounds against HTN virus *in vitro* and will also be amenable to automated plate-reading.

The percentage of active compounds relative to the total number of compounds tested against the various viruses in the *in vitro* primary screen are presented in Figure 13. As can be seen, we are detecting activity at a rate of approximately 3-10% of the compounds against most of the challenge viruses.

In November 1988 we converted to an MTT microculture assay/automated plate reading system for PT, VEE, YFV, JE, SF, VV and VSV viruses. It is believed that this assay system will improve the efficiency of the primary screening program and that the automated plate-reading will improve the reliability, consistency and accuracy of the antiviral test data being collected.

Antiviral evaluations *in vivo* have been conducted with compounds tested against Pichinde (PIC) virus in MHA strain hamsters, Venezuelan Equine Encephalomyelitis virus (VEE) in CD-1 Swiss mice, Japanese Encephalitis Virus (JE) in C57BL/6 mice and Vaccinia Virus (intracranial and tailpox models) in CD-1 mice.

Three compounds were tested against PIC and showed no antiviral effect. Of the compounds tested to date against PIC, AVS-206 has shown the best *in vivo* antiviral efficacy.

To date, four compounds have been identified with antiviral activity against JE virus challenge. These include AVS 361, AVS 2811, AVS 2812, and AVS 2980. Although these compounds do significantly reduce JE virus induced mortality, there is a narrow window between dose levels with antiviral efficacy and dose levels which produce lethality in toxicity control mice.

During this reporting period two vaccinia virus models were developed. One produces mortality following intracranial challenge with VV and the second one produces pox lesions on the tails of mice following intravenous challenge with VV. AVS 1752 has significant antiviral activity in both challenge models. AVS 1985, AVS 1986, AVS 1987 and AVS 1988 all demonstrated activity against VV induced tailpox lesions; however, they were unable to reduce mortality in intracranially challenged mice.




Figure 13
Percentage of Compounds Tested Having Antiviral Activity
for Each Primary *In Vitro* Screen

6. ACKNOWLEDGMENTS

Mr. David Baggett (Associate Biologist), Ms. Cheri Campbell (Biological Technician), Ms. Sharon Chynoweth (Assistant Biologist), Ms. Joan Conway (Associate Biologist), Mr. Fred Davidson (Assistant Biologist), Ms. Carol Eldridge (Associate Biologist), Mr. James Gallespie (Assistant Biologist), Ms. Diane Horton (Assistant Biologist), Ms. Sandra Kooyer (Assistant Biologist), Mr. Richard Kirkman (Associate Microbiologist), Ms. Edith Mayomi (Assistant Biologist), Mr. Daniel C. Potts (Assistant Biologist), Ms. Karen Shelton (Assistant Biologist), Ms. Ellen Stringfellow (Assistant Biologist), performed the *in vitro* antiviral evaluations against the DNA viruses and exotic RNA viruses.

Ms. Joan Johnson (Assistant Statistician) performed statistical analysis on the data and set up the database on our VAX computer. Ms. Kimberly Page (Biological Technician), Ms. Judith Talley (Biological Technician) helped with data entry and processing.

Ms. Carrie Edwards (Biological Technician), Ms. Geraldine Jefferson (Assistant Biologist), Mr. Byron Lambert (Assistant Biologist), Mr. Frank Vance (Biological Technician) performed the *in vivo* antiviral evaluations.

Ms. Cecelia Griffin (Senior Secretary), Ms. Nancy Hamner (Senior Secretary), Ms. Barbara Hughes (Secretary), Ms. Reta Sisk (Senior Secretary) provided excellent secretarial assistance for this project.

7. LITERATURE CITED

Boyle, *et al.*, (1967). Evaluation of antiviral compounds by suppression of lesions in vaccinia-infected mice. *Antimicrobiol. Agents and Chemother.* 1966:536-539.

Ehrlich, J., Sloan, B. J., Miller, F. A., and Michamer, H.E. (1965). Searching for antiviral materials from microbial fermentations. *Ann. N.Y. Acad. Sci.* 130:5-16.

Mitsuya, H., Weinhold, K.J., Furman, P.A., St. Clair, M.H., Nusinoff-Lehrman, S., Gallo, R.C., Bolognesi, D., Barry, D.W. and Broder, S. (1985). 3'-AZT-3'-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus *in vitro*. *Proc. Natl. Acad. Sci. USA* 82:7096-7100

Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival-application to proliferation and cytotoxicity assays. *J. Immunol. Methods* 65:55-63.

Perron-Henry, D.M., Herrmann, John and Blacklow, Neil. (1988). Isolation and Propagation of Enteric Adenoviruses in HEp-2 Cells. *J. Chem. Microbiol.* 20:1445-1447.

Reed, L.J., and Muench, H.A. (1938). A simple method for estimating fifty percent end-points. *Amer. J. Hyg.* 27:493-497.

Sidwell, R.W., and Huffman, J. H. (1971). Use of disposable micro tissue culture plates for antiviral and interferon induction studies. *Appl. Microbiol.* 22:797-801.

Tada, H., Shiho, O., Kuroshima, K., Koyamu, M., Tsukamoto, K.J. (1986). An improved colorimetric assay for interleukin 2. *J. Immunol. Methods* 93:157-165.

APPENDICES

APPENDIX A

Complete Listing of Active Compounds

APPENDIX A

Table 1

Compounds Active Against Vaccinia Virus^a In Vero Cell Cultures
Employing a CPE-Inhibition Assay Procedure

<u>AVS No.</u>	<u>Shipment</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
3679	32	≥9.8	3.3	≤0.01	100	10,000
1985	41b	10.2	3.4	0.006	32	5650
4227	42	8.7	2.9	0.08	320	3880
4533	42	9.2	3.1	0.1	>320	>3010
4224	42	8.4	2.8	0.2	>320	>1760
4226	42	8.3	2.8	0.2	>320	>1340
3912	34	7.9	2.6	0.3	>320	>1070
3607	32	8.0	2.7	<0.1	>320	>1000
4225	42	7.9	2.6	0.3	>320	>1000
3941	35	6.8	2.3	1.0	>320	>325
4530	42	5.9	2.0	1.2	320	263
4620	43	6.1	2.0	1.5	>320	>206
4619	43	6.0	2.0	1.8	>320	>180
4621	43	5.9	2.0	2.0	>320	>160
4622	43	5.6	1.9	2.8	>320	>114
3940	35	5.0	1.7	5.0	>320	>64
4874	46	4.8	1.6	5.6	>320	>57
4275	39	5.3	1.8	0.02	0.32	19
4864	46	2.1	0.7	32	320	10
3586	32	3.3	1.1	0.4	3.2	8.9
4065	35	5.1	1.7	0.1	1	6.8
3963	35	2.1	0.7	51	320	6.3
3571	32	1.6	0.5	18	100	5.6
3513	33	2.5	0.8	18	100	5.5
1654	46	3.9	1.3	2	10	5.0
3913	34	2.1	0.7	67	>320	>4.8
4875	46	1.5	0.5	83	320	3.9
4235	42	1.5	0.5	83	320	3.9
3944	35	2.1	0.7	88	>320	>3.6
4871	46	1.7	0.5	100	320	3.2
4050	37	1.0	0.3	3.2	10	3.1
4182	39	1.0	0.3	32	100	3.1
4532	42	1.7	0.6	103	320	3.1
4210	41	5.5	1.8	0.03	0.1	2.9
4531	42	1.4	0.5	110	320	2.9
3705	32	1.5	0.5	35	100	2.9
4600	43	1.2	0.4	36	100	2.8
1392	33	1.5	0.5	123	320	2.6
4229	42	1.5	0.5	4.7	10	2.1
4343	43	1.9	0.6	4.8	10	2.1
4872	46	1.3	0.4	180	>320	>1.8
3622	32	1.2	0.4	57	>100	>1.8
3557	31	1.1	0.4	57	100	1.8
3968	36	1.7	0.6	57	100	1.8

Table 1 (Cont'd.)

Compounds Active Against Vaccinia Virus^a In Vero Cell Cultures
Employing a CPE-Inhibition Assay Procedure

<u>AVS No.</u>	<u>Shipment</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
4232	42	1.5	0.5	202	>320	>1.6
4163	41	1.3	0.4	64	100	1.6
4126	40	1.0	0.3	222	>320	>1.4
3677	32	1.5	0.5	2.6	3.2	1.2
4798	46	1.2	0.4	0.9	>1	>1.1
4864	46	1.1	0.4	320	>320	>1.0

^aCompounds identified by AVS number are listed in descending order of activity as measured by the therapeutic index (TI). The VR is a measurement of selective antiviral activity which takes into account the degree of inhibition of virus-induced CPE and the degree of cytotoxicity produced by the test compound, determined by a modification of the method of Ehrlich *et al.* (Ann. N.Y. Acad. Sci. 130:5, 1965). VR* is the designation for the virus rating calculated by the method of Sidwell and Huffman (Appl. Microbiol. 22:797, 1971). The drug concentration which reduced the CPE by 50% (50% inhibitory dose, ID₅₀) was calculated using a regression analysis program for semilog curve fitting and is expressed as $\mu\text{g/ml}$. The minimum cytotoxic drug concentration (MTC) is also expressed as $\mu\text{g/ml}$. The TI of a test compound was determined by dividing the MTC by the ID₅₀.

APPENDIX A

Table 2

Compounds Active^a Against Adenovirus Type 2
in HEp-2 Cell Cultures by CPE-Inhibition Assay

AVS No.	Shipment	VR	VR*	ID ₅₀	MTC	TI
4167	41	3.5	1.2	2.5	32	12.8
4530	42	1.8	0.6	27	320	11.8
4871	46	2.1	0.7	32	320	10.0
4785	46	3.4	1.1	4.3	32	7.5
3910	34	1.2	0.4	56.5	320	5.7
4798	46	2.4	0.8	0.6	3.2	5.6
4796	46	2.4	0.8	17.9	100	5.6
3705	32	1.7	0.6	73.1	320	4.4
3527	31	1.0	0.3	2.4	10	4.3
1337	33	1.5	0.5	88.4	320	3.6
3577	32	1.4	0.5	96.4	320	3.3
4750	44	1.1	0.4	11.1	32	2.9
4609	43	1.0	0.3	0.4	1	2.5
4070	35	2.2	0.7	4.3	10	2.4
2563	21	1.1	0.4	46.8	100	2.1
4267	39	1.4	0.5	159	>320	>2.0
3529	31	1.3	0.5	1.6	3.2	2.0
4199	39	1.0	0.3	166	320	1.9
3557	31	1.2	0.4	56.5	100	1.8
4004	36	1.2	0.4	193	>320	>1.7
4262	39	1.1	0.4	200	>320	>1.6
3617	32	1.1	0.4	204	>320	>1.6
4001	36	1.1	0.4	204	>320	>1.6
3561	31	1.0	0.3	243	>320	>1.3
4281	42	1.1	0.4	26.1	32	1.2
4279	42	1.0	0.3	29.7	32	1.1
4041	36	1.1	0.4	320	>320	>1.0
4002	36	1.0	0.3	320	>320	>1.0

a. Compounds identified by their AVS number are listed in descending order of activity as determined by selectivity (therapeutic index). An active compound is defined as having a therapeutic index (TI) of greater than 1.0 and a virus rating (VR) of 1.0 or greater. The VR is a measurement of selective antiviral activity which takes into account the degree of inhibition of virus-induced CPE and the degree of cytotoxicity produced by the test compound, determined by a modification of the method of Ehrlich *et al.* (Ann. N.Y. Acad. Sci. 130:5, 1965). VR* is the designation for the virus rating calculated by the method of Sidwell and Huffman (Appl. Microbiol. 22:797, 1971). The drug concentration which reduced the CPE by 50% (50% inhibitory dose, ID₅₀) was calculated using a regression analysis program for semilog curve fitting and is expressed as $\mu\text{g/ml}$. The minimum cytotoxic drug concentration (MTC) is also expressed as $\mu\text{g/ml}$. The therapeutic index of a test compound was determined by dividing the MTC by the ID₅₀.

APPENDIX A
Table 3
Compounds Active Against Punta Toro Virus^a

AVS No.	Shipment	VR	VR*	ID ₅₀	MTC	TI
2980	25	2.8,1.5	0.9,0.5	0.3,0.4	3.2, 3.2	10.3,7.7
2812	24	1.0	0.3	0.007	<0.032	<4.6
2991	27	1.0	0.3	2.2	<10	<4.5
4239	39	1.1	0.4	2.4	10	4.2
3048	28	1.6	0.5	78	320	4.1
4281	42	1.5	0.5	2.6	10	3.8
4240	39	1.4	0.5	8.5	32	3.7
2026	9	1.9	0.6	8.9	32	3.6
2902	26	2.0	0.7	29	100	3.4
2980	25	1.7	0.6	0.4	1	2.7
4050	37	1.1	0.4	4.0	10	2.5
4266	39	1.1	0.4	13	32	2.4
3866	41	1.5	0.5	13	32	2.4
4071	35	1.4	0.5	133	>320	>2.4
0197	5	1.5	0.5	134	>320	>2.4
4279	42	1.0	0.3	4.3	10	2.4
0361	2	1.0,1.1	0.3,0.4	0.04, 0.2	0.1, >0.32	2.4,1.6
1212	27	1.5	0.5	46	100	2.2
4070	35	1.9	0.6	1.5	3.2	2.1
2279	11	1.0	0.3	4.8	10	2.1
4241	39	1.5	0.5	4.9	10	2.0
0272	1	2.0	0.7	0.5	1.0	2.0
4576	43	1.7	0.6	17	32	1.9
3021	27	1.8	0.6	54	100	1.9
0070	1	1.2	0.4	19	32	1.7
4015	34	2.1	0.7	0.06	<0.1	1.6
4244	39	1.3	0.4	6.3	10	1.6
4424	44	1.1	0.4	69	100	1.5
4018	36	1.2	0.4	0.2	0.32	1.4
2716	22	1.0	0.3	7.2	10	1.4
2573	19	1.8	0.6	26	32	1.2
3800	35	1.6	0.5	2.6	3.2	1.2
2743	18	1.1	0.4	83	100	1.2
0148	2	2.3	0.8	0.8	1	1.2
4278	42	1.1	0.4	8.3	10	1.2
4600	43	1.0	0.3	28	32	1.1
3593	30	1.9,3.9	0.6,1.3	0.08,0.32	0.1,0.32	1.1,1.0
4611	43	2.1	0.7	8.9	10	1.1

a. Compounds identified by their AVS number are listed in descending order of activity as determined by selectivity (therapeutic index). An active compound is defined as having a therapeutic index (TI) of greater than 1.0 and a virus rating (VR) of 1.0 or greater. The VR is a measurement of selective antiviral activity which takes into account the degree of inhibition of virus-induced CPE and the degree of cytotoxicity produced by the test compound, determined by a modification of the method of Ehrlich *et al.* (Ann. N.Y. Acad. Sci. 130:5, 1965). VR* is the designation for the virus rating calculated by the method of Sidwell and Huffman (Appl. Microbiol. 22:797, 1971). The drug concentration which reduced the CPE by 50% (50% inhibitory dose, ID₅₀) was calculated using a regression analysis program for semilog curve fitting and is expressed as $\mu\text{g/ml}$. The minimum cytotoxic drug concentration (MTC) is also expressed as $\mu\text{g/ml}$. The therapeutic index of a test compound was determined by dividing the MTC by the ID₅₀.

APPENDIX A
Table 4
Compounds Active Against Sandfly Fever Virus^a

AVS No.	Shipment	VR	VR*	ID ₅₀	MTC	TI
2948	26	3.8	1.3	15	320	21.4
2563	21	2.6	0.9	0.8	10	12.7
4271	39	2.6	0.9	1.0	10	10.3
4391	43	1.8	0.6	31	<320	<10.2
2992	27	2.0	0.7	10	100	10.0
3747	34	2.7	0.9	3.9	32	8.2
3980	36	1.9	0.6	18	100	5.4
4720	43	3.0	1.0	1.8	10	5.4
4044	37	2.2	0.7	20	100	4.9
4244	42	1.3	0.4	6.8	32	4.7
2501	19	3.3	1.1	23	100	4.3
0347	2	2.0	0.7	0.2	1.0	4.2
2743	18	1.5	0.5	83	320	3.9
2318	13	2.6	0.9	8.3	32	3.9
3829	40	1.3	0.4	0.9	3.2	3.8
3247	30	1.9	0.6	2.7	100	3.8
4217	41	1.9	0.6	9.5	32	3.4
0148	2	4.8	1.6	0.3	1.0	3.2
3906	34	1.3	0.4	3.2	10	3.1
0215	1	3.8	1.3	0.3	1.0	3.0
4056	35	1.2	0.4	36	100	2.8
3252	30	1.7	0.6	12	32	2.7
0646	2	3.5	1.2	0.03	0.1	2.7
4339	42	1.6	0.5	13	32	2.4
4070	35	1.6	0.5	1.3	3.2	2.4
3229	29	1.8	0.6	14	32	2.2
3226	29	1.9	0.6	16	32	2.1
4600	43	1.6	0.5	5	10	2.0
4244	39	1.8	0.6	1.7	3.2	1.8
4255	39	1.1	0.4	1.7	3.2	1.8
4389	43	1.4	0.5	18	32	1.8
4272	39	1.4	0.5	5.6	10	1.8
4247	39	1.5	0.5	58	100	1.7
4314	42	1.3	0.4	0.6	1	1.7
4428	44	1.5	0.5	5.9	10	1.7
3593	30	2.2	0.7	0.2	0.32	1.6
4241	39	1.3	0.4	6.3	10	1.6
2627	19	2.7	0.9	64	100	1.6
0197	5	1.4	0.5	64	100	1.6
3734	34	1.4	0.5	6.4	10	1.5
4221	41	1.5	0.5	6.8	10	1.5
4254	39	1.3	0.4	23	32	1.4
3737	34	1.4	0.5	7.6	10	1.3
4273	39	1.3	0.4	2.5	3.2	1.3
4611	43	1.8	0.6	7.7	10	1.3
3762	35	1.1	0.4	7.7	10	1.3
3371	31	1.1	0.4	7.9	10	1.3
4281	42	1.1	0.4	2.6	3.2	1.2
4420	44	1.1	0.4	26	32	1.2
4219	41	1.3	0.4	8.3	10	1.2

Table 4 (Cont'd.)
Compounds Active Against Sandfly Fever Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
3742	34	2.5	0.8	85	100	1.2
4035	36	1.9	0.6	8.6	10	1.2
2274	12	1.0	0.3	28	32	1.1
4396	43	1.4	0.5	88	100	1.1
4032	36	1.6	0.5	29	32	1.1
3981	36	1.5	0.5	294	320	1.1
3251	30	1.4	0.5	9.3	10	1.1
3730	34	1.6	0.5	30	32	1.1

a. Compounds identified by their AVS number are listed in descending order of activity as determined by selectivity (therapeutic index). An active compound is defined as having a therapeutic index (TI) of greater than 1.0 and a virus rating (VR) of 1.0 or greater. The VR is a measurement of selective antiviral activity which takes into account the degree of inhibition of virus-induced CPE and the degree of cytotoxicity produced by the test compound, determined by a modification of the method of Ehrlich *et al.* (Ann. N.Y. Acad. Sci. 130:5, 1965). VR* is the designation for the virus rating calculated by the method of Sidwell and Huffman (Appl. Microbiol. 22:797, 1971). The drug concentration which reduced the CPE by 50% (50% inhibitory dose, ID₅₀) was calculated using a regression analysis program for semilog curve fitting and is expressed as $\mu\text{g/ml}$. The minimum cytotoxic drug concentration (MTC) is also expressed as $\mu\text{g/ml}$. The therapeutic index of a test compound was determined by dividing the MTC by the ID₅₀.

API'ENDIX A
Table 5
Compounds Active Against Pichinde Virus*

<u>AVS No.</u>	<u>Shipment</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
2350 ^b	14	158	>20000	>126
3189	29	0.9	100	106
2527	20	0.9	32	34
2581	19	5.9	100	17
2568	21	26	320	12
2585	19	8.3	100	12
2506	21	1.4,4.8	10,10	7.4,2.1
2503	21	0.14	1	6.9
2618	19	47	>320	>6.8
2594	19	16	100	6.2
2979	25	17	100	6.0
2582	19	17	100	5.8
2591	19	17	100	5.7
3038	28	0.06	0.32	4.7
0230	1	71	320	4.5
2868	20	2.2	<10	<4.5
2577	19	28	100	3.6
0094	1	30,56	>100,100	>3.3,1.8
2592	19	100	320	3.2
2576	19	38	100	2.6
2575	19	40	100	2.5
2125	7	13	32	2.5
2584	19	42	>100	>2.4
2980	25	1.4	3.2	2.4
2811	24	0.13	0.32	2.4
2089	6	4.3	10	2.3
2277	11	43	100	2.3
3190	29	14	32	2.3
2132	7	45	100	2.2
2589	19	48	100	2.1
2363	15	16	32	2.0
2172	8	16	32	2.0
2108	6	52	>100	>1.9
0084	1	172	320	1.9
2630	19	57	100	1.8
2863	20	1.8	3.2	1.8
2907	26	57	100	1.7
3141	29	5.7	10	1.7
2228	10	19	32	1.7
3073	28	1.9	3.2	1.7
1970	27	19	32	1.7
2862	20	19	32	1.6
2717	22	195	320	1.6
2167	8	64	100	1.6
2193	9	6.4	10	1.6
3691	32	64	>100	>1.6
2985	27	209	320	1.5
0140	4	0.2	0.32	1.5
2583	19	22	32	1.5
2487	19	223	320	1.4

APPENDIX A
Table 5 (Cont'd.)
Compounds Active Against Pichinde Virus^a

<u>AVS</u> <u>No.</u>	<u>Shipment</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
3204	29	2.3	3.2	1.4
2178	8	73	>100	>1.4
2615	19	74	100	1.3
2093	6	76	100	1.3
2212	10	7.6	10	1.3
2984	27	25	32	1.3
3695	32	248	320	1.3
2716	22	2.5	3.2	1.3
3689	32	82	100	1.2
2188	9	84	100	1.2
2232	10	84	100	1.2
2517	20	2.7	3.2	1.2
2138	5	270	320	1.2
2285	11	269	320	1.2
2812	24	0.02	0.032	1.2
3106	28	27	32	1.2
2739	22	28	32	1.2
3205	29	2.8	3.2	1.2
2718	22	279	320	1.1
2652	21	287	320	1.1
0065	2	29	32	1.1
2429	17	9.1	10	1.1
3131	28	9.2	10	1.1
2971	27	30	32	1.1
2189	9	303	320	1.1

a. Compounds identified by their AVS number are listed in descending order of activity as determined by selectivity (therapeutic index). An active compound is defined as having a therapeutic index (TI) of greater than 1.0. The drug concentration which reduced the mean plaque number by 50% (50% inhibitory dose, ID₅₀) was calculated using a regression analysis program for semilog curve fitting and is expressed as $\mu\text{g/ml}$. The minimum cytotoxic drug concentration (MTC) is the lowest drug concentration at which toxicity was observed and is also expressed as $\mu\text{g/ml}$. The therapeutic index of a test compound was determined by dividing the MTC by the ID₅₀.

b. The ID₅₀ and MTC are expressed in units/ml.

APPENDIX A
Table 6
Compounds Active Against Venezuelan Equine
Encephalomyelitis Virus^a

<u>AVS</u> <u>No.</u>	<u>Shipment</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
3800	35	2.3	0.8	0.96	10	10.3
2350 ^b	14	1.7	0.6	59	200	3.4
3802	35	1.9	0.6	1	3.2	3.2
3857	40	1.2	0.4	5.6	10	1.8
0646	2	2.8	0.9	0.08	0.1	1.2

a. Compounds identified by their AVS number are listed in descending order of activity as determined by selectivity (therapeutic index). An active compound is defined as having a therapeutic index (TI) of greater than 1.0 and a virus rating (VR) of 1.0 or greater. The VR is a measurement of selective antiviral activity which takes into account the degree of inhibition of virus-induced CPE and the degree of cytotoxicity produced by the test compound, determined by a modification of the method of Ehrlich *et al.* (Ann. N.Y. Acad. Sci. 130:5, 1965). VR* is the designation for the virus rating calculated by the method of Sidwell and Huffman (Appl. Microbiol. 22:797, 1971). The drug concentration which reduced the CPE by 50% (50% inhibitory dose, ID₅₀) was calculated using a regression analysis program for semilog curve fitting and is expressed as $\mu\text{g/ml}$. The minimum cytotoxic drug concentration (MTC) is also expressed as $\mu\text{g/ml}$. The therapeutic index of a test compound was determined by dividing the MTC by the ID₅₀.

b. The ID₅₀ and MTC are expressed in units/ml.

APPENDIX A
Table 7
Compounds Active Against Yellow Fever Virus*

AVS No.	Shipment	VR	VR*	ID ₅₀	MTC	TI
4592	42	2.4	0.8	3.2	32	10.1
4278	42	1.9	0.7	3.2	32	9.9
4281	42	1.7	0.6	1.9	10	5.3
2563	21	1.0,1.6	0.3,0.5	0.63,0.13	<3.2,0.32	<5.1,2.4
4280	42	1.9	0.6	2.7	10	3.6
4277	42	1.4	0.5	2.8	10	3.5
4533	42	1.8	0.6	95	320	3.4
0361	2	1.1	0.4	0.03	0.1	2.7
4020	36	1.6	0.5	1.2	3.2	2.6
2980	25	2.4	0.8	1.4	3.2	2.3
4590	42	1.9	0.6	1.4	3.2	2.3
4021	36	1.3	0.4	144	320	2.2
0111	9	1.5	0.5	48	100	2.1
4018	36	1.4	0.5	0.15	0.32	2.0
2318	13	3.2	1.1	1.6	3.2	2.0
0148	2	2.4	0.8	0.17	0.32	1.8
4070	35	1.4	0.5	1.8	3.2	1.8
3964	33	1.0	0.3	19	32	1.7
2631	19	1.8	0.6	2.2	3.2	1.4
2906	26	2.1	0.7	23	32	1.4
0646	2	1.7	0.6	0.08	0.1	1.2
0094	1	1.1	0.4	83	100	1.2
0215	1	2.9	1.0	0.83	1.0	1.2
4019	36	1.1	0.4	0.83	1.0	1.2
1089	5	1.6	0.5	2.8	3.2	1.1

a. Compounds identified by their AVS number are listed in descending order of activity as determined by selectivity (therapeutic index). An active compound is defined as having a therapeutic index (TI) of greater than 1.0 and a virus rating (VR) of 1.0 or greater. The VR is a measurement of selective antiviral activity which takes into account the degree of inhibition of virus-induced CPE and the degree of cytotoxicity produced by the test compound, determined by a modification of the method of Ehrlich *et al.* (Ann. N.Y. Acad. Sci. 130:5, 1965). VR* is the designation for the virus rating calculated by the method of Sidwell and Huffman (Appl. Microbiol. 22:797, 1971). The drug concentration which reduced the CPE by 50% (50% inhibitory dose, ID₅₀) was calculated using a regression analysis program for semilog curve fitting and is expressed as $\mu\text{g/ml}$. The minimum cytotoxic drug concentration (MTC) is also expressed as $\mu\text{g/ml}$. The therapeutic index of a test compound was determined by dividing the MTC by the ID₅₀.

APPENDIX A
Table 8
Compounds Active Against Japanese Encephalitis Virus^a

<u>AVS No.</u>	<u>Shipment</u>	<u>VR</u>	<u>VR*</u>	<u>ID₅₀</u>	<u>MTC</u>	<u>TI</u>
	2350 ^b	14	2.6	0.9	128	20000
156						
4592	42	2.1	0.7	3.4	32	9.4
4113	39	1.4	0.5	0.2	1	5.5
0094	1	2.8	0.9	18.2	100	5.5
0361	2	1.4	0.5	0.02	0.1	4.1
2563	21	1.5,1.0	0.5,0.3	0.8,0.4	3.2,1.0	3.9,2.6
4590	42	1.9	0.6	0.9	3.2	3.6
3731	34	1.5	0.5	28	100	3.5
2811	24	1.1	0.4	0.3	1	3.5
3734	34	2.6	0.9	3.2	10	3.1
1337	33	2.2	0.7	109	320	2.9
0230	1	1.6	0.5	39	100	2.5
3593	30	2.8	0.9	0.1	0.32	2.5
2925	32	1.0	0.3	133	320	2.4
4281	42	1.5	0.5	1.4	3.2	2.2
2503	21	1.2	0.4	1.8	3.2	1.8
4533	42	1.0	0.3	61	100	1.6
1089	5	1.8	0.6	2.0	3.2	1.6
4070	35	1.5	0.5	0.7	1	1.5
0646	2	3.5	1.2	0.02	0.032	1.2
2980	25	1.1	0.4	0.8	1	1.2
0136	4	1.1	0.4	83	100	1.2
0272	1	1.1	0.4	0.8	1	1.2
4276	42	1.1	0.4	2.8	3.2	1.1

a. Compounds identified by their AVS number are listed in descending order of activity as determined by selectivity (therapeutic index). An active compound is defined as having a therapeutic index (TI) of greater than 1.0 and a virus rating (VR) of 1.0 or greater. The VR is a measurement of selective antiviral activity which takes into account the degree of inhibition of virus-induced CPE and the degree of cytotoxicity produced by the test compound, determined by a modification of the method of Ehrlich *et al.* (Ann. N.Y. Acad. Sci. 130:5, 1965). VR* is the designation for the virus rating calculated by the method of Sidwell and Huffman (Appl. Microbiol. 22:797, 1971). The drug concentration which reduced the CPE by 50% (50% inhibitory dose, ID₅₀) was calculated using a regression analysis program for semilog curve fitting and is expressed as $\mu\text{g/ml}$. The minimum cytotoxic drug concentration (MTC) is also expressed as $\mu\text{g/ml}$. The therapeutic index of a test compound was determined by dividing the MTC by the ID₅₀.

b. The ID₅₀ and MTC for AVS-2350 are expressed in units/ml.

APPENDIX B

Cumulative Summary of *In Vitro* Antiviral Test Results

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0001	CPE	AD2	1.65	21.20	HEP2	32.00	1.51	9/18/86
AVS-0001	CPE	AD2	1.35	57.40	HEP2	100.00	1.74	9/25/86
AVS-0001	CPE	AD2	1.70	30.00	HEP2	100.00	3.33	10/ 2/86
AVS-0001	CPE	AD2	1.85	30.70	HEP2	100.00	3.26	10/ 9/86
AVS-0001	CPE	AD2	1.65	32.00	HEP2	100.00	3.12	10/16/86
AVS-0001	CPE	AD2	1.95	30.70	HEP2	100.00	3.25	10/23/86
AVS-0001	CPE	AD2	1.2	26.20	HEP2	32.00	1.22	10/30/86
AVS-0001	CPE	AD2	1.89	16.20	HEP2	100.00	6.17	11/ 6/86
AVS-0001	CPE	AD2	1.89	37.10	HEP2	100.00	2.69	11/13/86
AVS-0001	CPE	AD2	1.65	15.90	HEP2	100.00	6.27	11/20/86
AVS-0001	CPE	AD2	2.16	24.50	HEP2	320.00	13.00	12/ 4/86
AVS-0001	CPE	AD2	1.50	51.80	HEP2	100.00	1.92	12/11/86
AVS-0001	CPE	AD2	1.65	42.60	HEP2	100.00	2.34	12/18/86
AVS-0001	CPE	AD2	1.25	32.00	HEP2	100.00	3.13	1/ 8/87
AVS-0001	CPE	AD2	1.40	64.00	HEP2	100.00	1.55	1/29/87
AVS-0001	CPE	AD2	1.65	31.10	HEP2	100.00	3.22	2/ 5/87
AVS-0001	CPE	AD2	1.45	48.30	HEP2	100.00	2.06	2/12/87
AVS-0001	CPE	AD2	1.60	40.60	HEP2	100.00	2.46	2/19/87
AVS-0001	CPE	AD2	1.65	37.70	HEP2	100.00	2.65	3/12/87
AVS-0001	CPE	AD2	1.55	35.90	HEP2	100.00	2.76	4/10/87
AVS-0001	CPE	AD2	1.75	33.00	HEP2	100.00	3.02	4/24/87
AVS-0001	CPE	AD2	1.7	64.50	HEP2	320.00	4.95	5/ 7/87
AVS-0001	CPE	AD2	1.55	20.60	HEP2	100.00	4.84	5/14/87
AVS-0001	CPE	AD2	2.	25.60	HEP2	100.00	3.90	5/21/87
AVS-0001	CPE	AD2	1.35	31.10	HEP2	100.00	3.21	5/28/87
AVS-0001	CPE	AD2	1.45	47.70	HEP2	100.00	2.09	6/ 4/87
AVS-0001	CPE	AD2	1.8	29.60	HEP2	100.00	3.37	6/11/87
AVS-0001	CPE	AD2	2.	16.90	HEP2	100.00	5.90	6/18/87
AVS-0001	CPE	AD2	2.	15.90	HEP2	100.00	6.28	6/25/87
AVS-0001	CPE	AD2	2.	15.90	HEP2	100.00	6.28	7/ 2/87
AVS-0001	CPE	AD2	2.25	15.60	HEP2	100.00	6.40	7/ 9/87
AVS-0001	CPE	AD2	2.25	16.00	HEP2	100.00	6.24	7/16/87
AVS-0001	CPE	AD2	2.1	20.90	HEP2	100.00	4.77	7/30/87
AVS-0001	CPE	AD2	2.05	24.20	HEP2	100.00	4.12	8/ 6/87
AVS-0001	CPE	AD2	1.8	11.20	HEP2	32.00	2.84	8/13/87
AVS-0001	CPE	AD2	2.25	11.70	HEP2	32.00	2.73	8/20/87
AVS-0001	CPE	AD2	1.5	41.00	HEP2	320.00	7.79	8/27/87
AVS-0001	CPE	AD2	1.4	50.40	HEP2	100.00	1.98	9/ 4/87
AVS-0001	CPE	AD2	1.25	63.40	HEP2	100.00	1.57	9/24/87
AVS-0001	CPE	AD2	1.2	63.30	HEP2	100.00	1.57	9/24/87
AVS-0001	CPE	AD2	1.25	56.50	HEP2	100.00	1.76	9/24/87
AVS-0001	CPE	AD2	1.2	63.30	HEP2	100.00	1.57	9/24/87
AVS-0001	CPE	AD2	1.4	50.90	HEP2	100.00	1.96	9/24/87
AVS-0001	CPE	AD2	2.3	16.70	HEP2	100.00	5.95	10/ 8/87
AVS-0001	CPE	AD2	2.3	17.40	HEP2	100.00	5.72	10/ 8/87
AVS-0001	CPE	AD2	2.25	16.00	HEP2	100.00	6.24	10/ 8/87
AVS-0001	CPE	AD2	2.4	15.90	HEP2	100.00	6.27	10/ 8/87
AVS-0001	CPE	AD2	2.05	20.30	HEP2	100.00	4.92	10/ 8/87
AVS-0001	CPE	AD2	1.7	51.50	HEP2	100.00	1.94	10/22/87
AVS-0001	CPE	AD2	1.35	50.50	HEP2	100.00	1.97	10/29/87
AVS-0001	CPE	AD2	1.6	40.10	HEP2	100.00	2.49	10/29/87
AVS-0001	CPE	AD2	1.45	45.70	HEP2	100.00	2.18	10/29/87
AVS-0001	CPE	AD2	1.8	42.80	HEP2	100.00	2.33	10/29/87
AVS-0001	CPE	AD2	1.5	50.40	HEP2	100.00	1.98	10/29/87
AVS-0001	CPE	AD2	1.55	46.70	HEP2	100.00	2.13	10/29/87
AVS-0001	CPE	AD2	1.85	36.20	HEP2	100.00	2.75	11/12/87
AVS-0001	CPE	AD2	2.	27.90	HEP2	100.00	3.58	12/10/87
AVS-0001	CPE	AD2	2.2	22.20	HEP2	100.00	4.49	12/10/87
AVS-0001	CPE	AD2	2.1	24.80	HEP2	100.00	4.02	12/10/87
AVS-0001	CPE	AD2	2.15	21.60	HEP2	100.00	4.62	12/10/87
AVS-0001	CPE	AD2	2.2	22.20	HEP2	100.00	4.49	12/10/87
AVS-0001	CPE	AD2	2.	24.40	HEP2	100.00	4.08	12/17/87
AVS-0001	CPE	AD2	2.25	18.80	HEP2	100.00	5.30	12/31/87
AVS-0001	CPE	AD2	2.3	16.00	HEP2	100.00	6.24	1/ 8/88
AVS-0001	CPE	AD2	2.3	23.00	HEP2	100.00	4.33	1/14/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0001	CPE	AD2	2.5	15.90	HEP2	100.00	6.27	1/21/88
AVS-0001	CPE	AD2	1.8	31.70	HEP2	100.00	3.15	1/28/88
AVS-0001	CPE	AD2	2.8	13.30	HEP2	100.00	7.47	2/ 4/88
AVS-0001	CPE	AD2	2.45	15.60	HEP2	100.00	6.41	2/11/88
AVS-0001	CPE	AD2	2.35	17.80	HEP2	100.00	5.59	2/18/88
AVS-0001	CPE	AD2	2.1	14.70	HEP2	32.00	2.17	2/25/88
AVS-0001	CPE	AD2	2.35	17.40	HEP2	100.00	5.74	3/ 3/88
AVS-0001	CPE	AD2	2.2	19.10	HEP2	100.00	5.20	3/10/88
AVS-0001	CPE	AD2	2.15	24.50	HEP2	100.00	4.06	3/17/88
AVS-0001	CPE	AD2	2.4	17.80	HEP2	100.00	5.58	3/24/88
AVS-0001	CPE	AD2	2.4	17.80	HEP2	100.00	5.59	3/31/88
AVS-0001	CPE	AD2	1.45	45.70	HEP2	100.00	2.18	4/14/88
AVS-0001	CPE	AD2	2.05	26.10	HEP2	100.00	3.81	4/21/88
AVS-0001	CPE	AD2	2.3	16.00	HEP2	100.00	6.24	4/29/88
AVS-0001	CPE	AD2	2.1	46.70	HEP2	320.00	6.83	5/ 5/88
AVS-0001	CPE	AD2	2.25	19.60	HEP2	100.00	5.09	5/12/88
AVS-0001	CPE	AD2	2.3	16.60	HEP2	100.00	6.01	5/19/88
AVS-0001	CPE	AD2	2.2	24.50	HEP2	100.00	4.07	5/26/88
AVS-0001	CPE	AD2	2.3	23.00	HEP2	100.00	4.33	6/ 2/88
AVS-0001	CPE	AD2	2.2	22.20	HEP2	100.00	4.49	6/16/88
AVS-0001	CPE	AD2	2.2	22.20	HEP2	100.00	4.49	6/16/88
AVS-0001	CPE	AD2	2.	45.70	HEP2	320.00	6.99	6/23/88
AVS-0001	CPE	AD2	1.7	37.60	HEP2	100.00	2.65	6/30/88
AVS-0001	CPE	AD2	2.4	14.30	HEP2	100.00	6.94	7/ 7/88
AVS-0001	CPE	AD2	2.35	17.80	HEP2	100.00	5.59	7/21/88
AVS-0001	CPE	AD2	2.15	22.40	HEP2	100.00	4.45	8/18/88
AVS-0001	CPE	AD2	2.25	19.60	HEP2	100.00	5.09	8/25/88
AVS-0001	CPE	AD2	2.35	17.10	HEP2	100.00	5.84	9/ 1/88
AVS-0001	CPE	AD2	2.9	10.00	HEP2	100.00	9.97	10/ 6/88
AVS-0001	CPE	AD2	2.2	22.20	HEP2	100.00	4.49	10/13/88
AVS-0001	CPE	AD2	2.1	26.10	HEP2	100.00	3.81	10/27/88
AVS-0001	CPE	AD2	2.15	21.60	HEP2	100.00	4.61	11/ 3/88
AVS-0001	CPE	AD2	2.6	23.70	HEP2	320.00	13.40	11/10/88
AVS-0001	CPE	AD2	2.3	20.00	HEP2	100.00	4.98	11/17/88
AVS-0001	PR	HTN	N/A	1.69	VERC	96.00	56.60	1/13/88
AVS-0001	PR	HTN	N/A	3.93	VERC	100.00	25.30	2/ 1/88
AVS-0001	PR	HTN	N/A	5.10	VERC	100.00	19.30	2/12/88
AVS-0001	PR	HTN	N/A	15.90	VERC >	100.00 >	6.27	2/17/88
AVS-0001	PR	HTN	N/A	5.40	VERC >	100.00 >	18.30	2/25/88
AVS-0001	PR	HTN	N/A	16.70	VERC	100.00	5.95	2/29/88
AVS-0001	PR	HTN	N/A	15.00	VERC >	100.00 >	6.62	3/ 2/88
AVS-0001	PR	HTN	N/A	5.40	VERC	100.00	18.20	3/ 9/88
AVS-0001	PR	HTN	N/A	3.62	VERC	100.00	27.60	3/11/88
AVS-0001	PR	HTN	N/A	5.90	VERC >	100.00 >	16.70	3/15/88
AVS-0001	PR	HTN	N/A	9.40	VERC >	100.00 >	10.50	4/14/88
AVS-0001	PR	HTN	N/A	5.10	VERC >	100.00 >	19.40	4/21/88
AVS-0001	CPE	JE	1.3	32.10	VERO	100.00	3.11	3/20/87
AVS-0001	CPE	JE	1.5	26.30	VERO	100.00	3.79	5/18/87
AVS-0001	CPE	JE	2.5	20.30	VERO >	100.00 >	4.90	5/19/87
AVS-0001	CPE	JE	0.6	57.80	VERO	100.00	1.72	5/20/87
AVS-0001	CPE	JE	1.55	12.60	VERO	100.00	7.92	6/ 1/87
AVS-0001	CPE	JE	0.65	48.00	VERO	100.00	2.08	6/ 8/87
AVS-0001	CPE	JE	1.45	29.80	VERO >	100.00 >	3.34	9/30/87
AVS-0001	CPE	JE	1.7	36.90	VERO >	100.00 >	2.70	10/ 1/87
AVS-0001	CPE	JE	2.2	18.50	VERO >	100.00 >	5.38	10/ 2/87
AVS-0001	CPE	JE	1.9	15.90	VERO	100.00	6.27	10/ 6/87
AVS-0001	CPE	JE	1.4	28.10	VERO	100.00	3.55	10/ 9/87
AVS-0001	CPE	JE	1.1	43.70	VERO >	100.00 >	2.18	10/13/87
AVS-0001	CPE	JE	2.	27.90	VERO >	100.00 >	3.58	10/14/87
AVS-0001	CPE	JE	1.27	28.50	VERO	100.00	3.50	10/16/87
AVS-0001	CPE	JE	1.3	29.70	VERO	100.00	3.36	10/20/87
AVS-0001	CPE	JE	1.3	49.90	VERO >	100.00 >	2.00	10/21/87
AVS-0001	CPE	JE	0.9	81.90	VERO >	100.00 >	1.22	10/22/87
AVS-0001	CPE	JE	1.2	56.50	VERO >	100.00 >	1.76	10/23/87
AVS-0001	CPE	JE	1.	69.80	VERO >	100.00 >	1.43	10/26/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0001	CPE	JE	1.2	31.70	VERO	100.00	3.15	10/28/87
AVS-0001	CPE	JE	1.8	34.70	VERO >	100.00 >	2.87	10/29/87
AVS-0001	CPE	JE	1.05	50.30	VERO	100.00	1.98	11/ 2/87
AVS-0001	CPE	JE	1.45	28.10	VERO	100.00	3.55	11/ 3/87
AVS-0001	CPE	JE	1.7	23.80	VERO	100.00	4.20	11/ 5/87
AVS-0001	CPE	JE	1.3	31.60	VERO	100.00	3.15	11/19/87
AVS-0001	CPE	JE	2.1	8.10	VERO	32.00	3.90	12/ 1/87
AVS-0001	CPE	JE	1.2	22.80	VERO	32.00	1.40	12/ 2/87
AVS-0001	CPE	JE	1.5	52.00	VERO >	100.00 >	1.92	12/ 4/87
AVS-0001	CPE	JE	0.9	63.00	VERO	100.00	1.58	12/ 7/87
AVS-0001	CPE	JE	1.8	20.60	VERO	100.00	4.84	12/ 8/87
AVS-0001	CPE	JE	1.9	30.50	VERO >	100.00 >	3.27	12/11/87
AVS-0001	CPE	JE	1.4	33.30	VERO	100.00	3.00	12/14/87
AVS-0001	CPE	JE	1.4	34.30	VERO	100.00	2.90	12/22/87
AVS-0001	CPE	JE	1.5	26.30	VERO	100.00	3.79	12/29/87
AVS-0001	CPE	JE	1.65	23.60	VERO	100.00	4.23	12/30/87
AVS-0001	CPE	JE	1.4	30.70	VERO	100.00	3.24	1/ 4/88
AVS-0001	CPE	JE	0.75	76.40	VERO	100.00	1.30	1/ 4/88
AVS-0001	CPE	JE	1.05	42.50	VERO	100.00	2.34	1/ 4/88
AVS-0001	CPE	JE	0.85	64.60	VERO	100.00	1.54	1/ 4/88
AVS-0001	CPE	JE	1.5	49.80	VERO >	100.00 >	2.00	1/ 4/88
AVS-0001	CPE	JE	1.2	63.30	VERO >	100.00 >	1.57	1/ 4/88
AVS-0001	CPE	JE	1.5	26.30	VERO	100.00	3.79	1/ 6/88
AVS-0001	CPE	JE	1.3	32.10	VERO	100.00	3.11	1/ 6/88
AVS-0001	CPE	JE	1.2	35.90	VERO	100.00	2.77	1/ 6/88
AVS-0001	CPE	JE	1.3	32.10	VERO	100.00	3.11	1/ 6/88
AVS-0001	CPE	JE	1.6	23.90	VERO	100.00	4.18	1/ 6/88
AVS-0001	CPE	JE	0.9	51.10	VERO	100.00	1.95	1/ 6/88
AVS-0001	CPE	JE	1.	82.40	VERO >	100.00 >	1.21	1/ 7/88
AVS-0001	CPE	JE	1.5	31.10	VERO	100.00	3.21	1/ 7/88
AVS-0001	CPE	JE	0.7	----	VERO >	100.00	----	1/ 7/88
AVS-0001	CPE	JE	1.2	57.20	VERO >	100.00 >	1.74	1/11/88
AVS-0001	CPE	JE	1.45	28.10	VERO	100.00	3.55	1/11/88
AVS-0001	CPE	JE	1.5	26.30	VERO	100.00	3.79	1/11/88
AVS-0001	CPE	JE	1.35	33.30	VERO	100.00	2.99	1/11/88
AVS-0001	CPE	JE	1.3	56.40	VERO >	100.00 >	1.77	1/11/88
AVS-0001	CPE	JE	1.6	26.60	VERO	100.00	3.75	1/11/88
AVS-0001	CPE	JE	2.04	23.30	VERO	100.00	4.28	3/ 1/88
AVS-0001	CPE	JE	3.25	3.34	VERO	100.00	29.80	3/15/88
AVS-0001	CPE	JE	1.8	18.20	VERO	100.00	5.47	3/16/88
AVS-0001	CPE	JE	1.1	37.60	VERO	100.00	2.65	3/17/88
AVS-0001	CPE	JE	1.7	20.10	VERO	100.00	4.96	3/21/88
AVS-0001	CPE	JE	1.85	9.50	VERO	32.00	3.34	3/22/88
AVS-0001	CPE	JE	1.	27.90	VERO	32.00	1.14	3/30/88
AVS-0001	CPE	JE	1.05	22.60	VERO	32.00	1.41	3/31/88
AVS-0001	CPE	JE	1.05	26.10	VERO	32.00	1.22	4/ 5/88
AVS-0001	CPE	JE	1.7	20.10	VERO	100.00	4.96	4/12/88
AVS-0001	CPE	JE	2.	15.80	VERO	100.00	6.29	4/12/88
AVS-0001	CPE	JE	1.3	29.70	VERO	100.00	3.36	4/13/88
AVS-0001	CPE	JE	1.05	26.10	VERO	32.00	1.22	4/13/88
AVS-0001	CPE	JE	0.7	53.70	VERO	100.00	1.84	4/19/88
AVS-0001	CPE	JE	1.5	26.10	VERO	100.00	3.81	4/20/88
AVS-0001	CPE	JE	1.1	37.60	VERO	100.00	2.65	4/26/88
AVS-0001	CPE	JE	0.65	53.70	VERO	32.00	0.60	4/27/88
AVS-0001	CPE	JE	1.35	19.00	VERO	32.00	1.77	4/29/88
AVS-0001	CPE	JE	0.6	10.50	VERO	100.00	1.76	5/ 3/88
AVS-0001	CPE	JE	1.5	26.10	VERO	100.00	3.81	5/ 4/88
AVS-0001	CPE	JE	0.95	49.40	VERO	100.00	2.02	5/10/88
AVS-0001	CPE	JE	0.5	59.00	VERO	32.00	0.54	5/11/88
AVS-0001	CPE	JE	0.9	46.70	VERO	100.00	2.13	5/18/88
AVS-0001	CPE	JE	0.85	37.60	VERO	32.00	0.85	5/20/88
AVS-0001	CPE	JE	0.7	45.60	VERO	32.00	0.70	5/24/88
AVS-0001	CPE	JE	0.6	56.50	VERO	32.00	0.57	5/25/88
AVS-0001	CPE	JE	1.8	18.00	VERO	100.00	5.53	6/ 1/88
AVS-0001	CPE	JE	0.75	46.70	VERO	10.00	0.21	6/ 2/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0001	CPE	JE	1.15	22.20	VERO	32.00	1.43	6/ 7/88
AVS-0001	CPE	JE	0.9	50.40	VERO	100.00	1.98	6/ 8/88
AVS-0001	CPE	JE	0.6	56.50	VERO	32.00	0.57	6/14/88
AVS-0001	CPE	JE	0.75	56.40	VERO	100.00	1.77	6/15/88
AVS-0001	CPE	JE	0.6	56.50	VERO	10.00	0.18	6/21/88
AVS-0001	CPE	JE	0.6	55.10	VERO	32.00	0.58	6/22/88
AVS-0001	CPE	JE	1.4	28.10	VERO	100.00	3.55	6/30/88
AVS-0001	CPE	JE	0.7	53.70	VERO	100.00	1.86	7/ 5/88
AVS-0001	CPE	JE	1.05	26.10	VERO	32.00	1.22	7/ 6/88
AVS-0001	CPE	JE	1.3	33.70	VERO	100.00	2.96	7/19/88
AVS-0001	CPE	JE	0.65	53.70	VERO	32.00	0.60	7/20/88
AVS-0001	CPE	JE	0.65	49.90	VERO	10.00	0.20	7/21/88
AVS-0001	CPE	JE	1.75	12.10	VERO	32.00	2.63	7/26/88
AVS-0001	CPE	JE	1.52	19.10	VERO	100.00	5.22	7/27/88
AVS-0001	CPE	JE	0.75	56.40	VERO	100.00	1.77	7/28/88
AVS-0001	CPE	JE	0.85	35.80	VERO	32.00	0.89	8/ 2/88
AVS-0001	CPE	JE	0.5	77.40	VERO	100.00	1.29	8/ 3/88
AVS-0001	CPE	JE	1.2	19.30	VERO	32.00	1.65	8/ 4/88
AVS-0001	CPE	JE	0.8	39.20	VERO	3.20	0.08	8/ 9/88
AVS-0001	CPE	JE	0.5	69.80	VERO	32.00	0.46	8/10/88
AVS-0001	CPE	JE	0.45	68.30	VERO	100.00	1.46	8/11/88
AVS-0001	CPE	JE	0.75	56.40	VERO	100.00	1.77	8/16/88
AVS-0001	CPE	JE	1.3	41.30	VERO	100.00	2.42	8/17/88
AVS-0001	CPE	JE	0.75	57.50	VERO	100.00	1.73	8/18/88
AVS-0001	CPE	JE	1.1	37.60	VERO	100.00	2.65	8/23/88
AVS-0001	CPE	JE	0.55	69.80	VERO	100.00	1.43	8/24/88
AVS-0001	CPE	JE	0.6	56.40	VERO	32.00	0.57	8/25/88
AVS-0001	CPE	JE	0.55	51.20	VERO	32.00	0.62	9/21/88
AVS-0001	CPE	JE	0.35	56.80	VERO	10.00	0.18	9/22/88
AVS-0001	CPE	JE	0.80	39.20	VERO	32.00	0.82	9/27/88
AVS-0001	CPE	JE	0.55	48.00	VERO	32.00	0.67	9/28/88
AVS-0001	CPE	JE	0.15	----	VERO	32.00	----	10/ 4/88
AVS-0001	CPE	JE	0.55	62.90	VERO	32.00	0.51	10/ 5/88
AVS-0001	CPE	JE	----	----	VERO	32.00	----	10/11/88
AVS-0001	CPE	JE	0.55	62.90	VERO	32.00	0.51	10/12/88
AVS-0001	CPE	JE	0.6	56.40	VERO	10.00	0.18	10/13/88
AVS-0001	CPE	PIC	----	4.30	VERO >	100.00 >	23.20	12/ 5/86
AVS-0001	CPE	PIC	----	9.30	VERO >	100.00 >	10.70	12/12/86
AVS-0001	CPE	PIC	----	8.90	VERO >	100.00 >	11.20	12/12/86
AVS-0001	PR	PIC	N/A	8.00	VERO >	100.00 >	12.30	2/17/87
AVS-0001	PR	PIC	N/A	2.49	VERO >	100.00 >	40.10	2/23/87
AVS-0001	PR	PIC	N/A	4.29	VERO >	100.00 >	23.20	2/27/87
AVS-0001	PR	PIC	N/A	3.67	VERO	32.00	8.69	3/ 2/87
AVS-0001	PR	PIC	N/A	7.60	VERO >	100.00 >	13.10	3/20/87
AVS-0001	PR	PIC	N/A	5.00	VERO >	100.00 >	19.70	3/23/87
AVS-0001	PR	PIC	N/A	7.50	VERO >	100.00 >	13.10	3/27/87
AVS-0001	PR	PIC	N/A	6.10	VERO >	100.00 >	16.30	4/ 3/87
AVS-0001	PR	PIC	N/A	2.69	VERO >	100.00 >	37.00	4/21/87
AVS-0001	PR	PIC	N/A	55.20	VERO	100.00	1.81	10/26/87
AVS-0001	PR	PIC	N/A	24.20	VERO	100.00	4.12	11/13/87
AVS-0001	PR	PIC	N/A	31.50	VERO	100.00	3.16	11/13/87
AVS-0001	PR	PIC	N/A	22.80	VERO	100.00	4.36	11/13/87
AVS-0001	PR	PIC	N/A	5.60	VERO	32.00	5.66	12/ 4/87
AVS-0001	PR	PIC	N/A	43.80	VERO >	100.00 >	2.28	12/11/87
AVS-0001	PR	PIC	N/A	17.60	VERO	100.00	5.65	12/18/87
AVS-0001	PR	PIC	N/A	23.80	VERO	100.00	4.18	1/ 5/88
AVS-0001	PR	PIC	N/A	6.10	VERO	100.00	16.30	1/15/88
AVS-0001	PR	PIC	N/A	13.30	VERO	100.00	7.47	1/29/88
AVS-0001	PR	PIC	N/A	10.50	VERO	100.00	9.47	2/ 2/88
AVS-0001	PR	PIC	N/A	6.20	VERO	100.00	16.00	2/ 2/88
AVS-0001	PR	PIC	N/A	8.60	VERO	100.00	11.50	2/ 2/88
AVS-0001	PR	PIC	N/A	7.90	VERO	100.00	12.50	2/ 2/88
AVS-0001	PR	PIC	N/A	5.60	VERO	100.00	17.50	2/ 2/88
AVS-0001	PK	PIC	N/A	5.60	VERO	100.00	17.50	2/ 2/88
AVS-0001	PR	PIC	N/A	3.44	VERO	100.00	29.00	2/ 5/88

B-4

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0001	PR	PIC	N/A	5.20	VERO	100.00	19.10	2/ 8/88
AVS-0001	PR	PIC	N/A	6.40	VERO	100.00	15.50	2/ 9/88
AVS-0001	PR	PIC	N/A	6.80	VERO	100.00	14.50	2/12/88
AVS-0001	PR	PIC	N/A	7.90	VERO	100.00	12.50	2/15/88
AVS-0001	PR	PIC	N/A	6.30	VERO	100.00	15.80	2/22/88
AVS-0001	PR	PIC	N/A	4.90	VERO	100.00	20.30	3/18/88
AVS-0001	PR	PIC	N/A	10.10	VERO	100.00	9.89	3/21/88
AVS-0001	PR	PIC	N/A	2.36	VERO	100.00	42.30	3/22/88
AVS-0001	PR	PIC	N/A	7.30	VERO	100.00	13.60	3/25/88
AVS-0001	PR	PIC	N/A	4.77	VERO	100.00	20.90	3/28/88
AVS-0001	PR	PIC	N/A	11.20	VERO	100.00	8.90	4/ 1/88
AVS-0001	PR	PIC	N/A	4.00	VERO	100.00	24.90	4/ 8/88
AVS-0001	PR	PIC	N/A	4.59	VERO	100.00	21.70	4/11/88
AVS-0001	PR	PIC	N/A	8.70	VERO	100.00	11.30	4/12/88
AVS-0001	PR	PIC	N/A	8.10	VERO	100.00	12.20	4/15/88
AVS-0001	PR	PIC	N/A	5.90	VERO	100.00	16.80	4/18/88
AVS-0001	PR	PIC	N/A	6.50	VERO	100.00	15.30	4/19/88
AVS-0001	PR	PIC	N/A	4.56	VERO	100.00	21.90	4/22/88
AVS-0001	PR	PIC	N/A	7.10	VERO	100.00	13.90	4/25/88
AVS-0001	PR	PIC	N/A	6.50	VERO	100.00	15.10	4/29/88
AVS-0001	PR	PIC	N/A	8.60	VERO	100.00	11.40	5/ 2/88
AVS-0001	PR	PIC	N/A	15.10	VERO	100.00	6.60	5/ 3/88
AVS-0001	PR	PIC	N/A	6.90	VERO	100.00	14.30	5/ 6/88
AVS-0001	PR	PIC	N/A	6.40	VERO	100.00	15.40	5/10/88
AVS-0001	PR	PIC	N/A	5.50	VERO	100.00	17.90	5/13/88
AVS-0001	PR	PIC	N/A	7.10	VERO	100.00	13.90	5/16/88
AVS-0001	PR	PIC	N/A	30.40	VERO	32.00	1.05	5/17/88
AVS-0001	PR	PIC	N/A	7.00	VERO	100.00	14.20	5/20/88
AVS-0001	PR	PIC	N/A	5.50	VERO	32.00	5.76	5/23/88
AVS-0001	PR	PIC	N/A	6.50	VERO	100.00	15.30	5/24/88
AVS-0001	PR	PIC	N/A	8.80	VERO	32.00	3.63	5/27/88
AVS-0001	PR	PIC	N/A	7.80	VERO	32.00	4.10	6/ 3/88
AVS-0001	PR	PIC	N/A	13.50	VERO	32.00	2.36	6/ 6/88
AVS-0001	PR	PIC	N/A	2.31	VERO	100.00	43.10	6/ 7/88
AVS-0001	PR	PIC	N/A	10.70	VERO	100.00	9.32	6/10/88
AVS-0001	PR	PIC	N/A	10.60	VERO	100.00	9.40	6/13/88
AVS-0001	PR	PIC	N/A	7.20	VERO	100.00	13.80	6/14/88
AVS-0001	PR	PIC	N/A	7.50	VERO	32.00	4.24	6/20/88
AVS-0001	PR	PIC	N/A	9.30	VERO	32.00	3.42	6/21/88
AVS-0001	PR	PIC	N/A	9.70	VERO	32.00	3.29	6/24/88
AVS-0001	PR	PIC	N/A	6.00	VERO	32.00	5.32	6/27/88
AVS-0001	PR	PIC	N/A	8.00	VERO	32.00	3.99	6/28/88
AVS-0001	PR	PIC	N/A	34.00	VERO	100.00	2.93	7/ 1/88
AVS-0001	PR	PIC	N/A	9.00	VERO	32.00	3.54	7/ 5/88
AVS-0001	PR	PIC	N/A	8.10	VERO	100.00	12.30	7/ 8/88
AVS-0001	PR	PIC	N/A	5.80	VERO	32.00	5.50	7/11/88
AVS-0001	PR	PIC	N/A	5.10	VERO	32.00	6.18	7/12/88
AVS-0001	PR	PIC	N/A	6.30	VERO	32.00	5.04	7/15/88
AVS-0001	PR	PIC	N/A	8.30	VERO	32.00	3.81	7/18/88
AVS-0001	PR	PIC	N/A	6.50	VERO	100.00	15.30	7/22/88
AVS-0001	PR	PIC	N/A	4.40	VERO	10.00	2.26	7/25/88
AVS-0001	PR	PIC	N/A	5.50	VERO	32.00	5.78	7/26/88
AVS-0001	PR	PIC	N/A	3.78	VERO	100.00	26.30	7/29/88
AVS-0001	PR	PIC	N/A	9.30	VERO	32.00	3.40	8/ 2/88
AVS-0001	PR	PIC	N/A	7.80	VERO	100.00	12.70	8/ 5/88
AVS-0001	PR	PIC	N/A	5.40	VERO	100.00	18.30	8/12/88
AVS-0001	PR	PIC	N/A	5.90	VERO	100.00	16.80	8/16/88
AVS-0001	PR	PIC	N/A	7.70	VERO	100.00	12.80	8/19/88
AVS-0001	PR	PIC	N/A	9.40	VERO	100.00	10.50	8/23/88
AVS-0001	PR	PIC	N/A	6.00	VERO	100.00	16.40	8/23/88
AVS-0001	PR	PIC	N/A	10.90	VERO	100.00	9.09	8/26/88
AVS-0001	PR	PIC	N/A	8.70	VERO	10.00	1.14	8/29/88
AVS-0001	PR	PIC	N/A	11.90	VERO	32.00	2.68	8/30/88
AVS-0001	PR	PIC	N/A	7.00	VERO	100.00	14.10	9/ 2/88
AVS-0001	PR	PIC	N/A	6.30	VERO	32.00	5.05	9/ 9/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0001	PR	PIC	N/A	3.84	VERO	100.00	26.00	9/12/88
AVS-0001	PR	PIC	N/A	4.74	VERO	100.00	21.00	9/14/88
AVS-0001	PR	PIC	N/A	6.10	VERO	100.00	16.30	9/16/88
AVS-0001	PR	PIC	N/A	7.30	VERO	32.00	4.36	9/19/88
AVS-0001	PR	PIC	N/A	7.60	VERO	100.00	13.10	9/20/88
AVS-0001	PR	PIC	N/A	5.20	VERO	100.00	19.00	9/26/88
AVS-0001	PR	PIC	N/A	6.60	VERO	32.00	4.83	9/27/88
AVS-0001	PR	PIC	N/A	8.80	VERO	100.00	11.30	9/30/88
AVS-0001	PR	PIC	N/A	5.50	VERO	32.00	5.74	10/ 3/88
AVS-0001	PR	PIC	N/A	6.00	VERO	100.00	16.40	10/ 4/88
AVS-0001	PR	PIC	N/A	8.40	VERO	32.00	3.80	10/ 7/88
AVS-0001	PR	PIC	N/A	8.30	VERO	100.00	11.90	10/11/88
AVS-0001	PR	PIC	N/A	4.32	VERO	100.00	23.10	10/14/88
AVS-0001	PR	PIC	N/A	6.40	VERO	100.00	15.50	10/19/88
AVS-0001	PR	PIC	N/A	17.80	VERO	100.00	5.60	10/21/88
AVS-0001	PR	PIC	N/A	6.40	VERO	100.00	15.40	10/25/88
AVS-0001	PR	PIC	N/A	7.90	VERO	32.00	4.03	10/28/88
AVS-0001	PR	PIC	N/A	18.60	VERO	100.00	5.35	10/31/88
AVS-0001	PR	PIC	N/A	6.70	VERO	100.00	14.90	11/ 1/88
AVS-0001	PR	PIC	N/A	9.40	VERO	32.00	3.37	11/ 4/88
AVS-0001	PR	PIC	N/A	9.60	VERO	100.00	10.30	11/ 7/88
AVS-0001	PR	PIC	N/A	8.30	VERO	100.00	11.90	11/ 8/88
AVS-0001	PR	PIC	N/A	4.96	VERO	100.00	20.10	11/11/88
AVS-0001	PR	PIC	N/A	4.09	VERO	1.00	0.24	11/15/88
AVS-0001	PR	PIC	N/A	8.10	VERO	100.00	12.30	11/18/88
AVS-0001	CPE	PT	5.00	1.00	VERO	320.00	320.00	9/19/86
AVS-0001	CPE	PT	2.10	14.90	VERO >	100.00 >	6.71	10/22/86
AVS-0001	CPE	PT	2.31	20.60	VERO >	100.00 >	4.84	10/23/86
AVS-0001	CPE	PT	2.79	10.40	VERO >	100.00 >	9.54	10/24/86
AVS-0001	CPE	PT	3.21	10.00	VERO >	100.00 >	9.97	10/27/86
AVS-0001	CPE	PT	2.49	9.60	VERO	100.00	10.30	10/28/86
AVS-0001	CPE	PT	3.81	6.00	VERO >	100.00 >	6.60	10/28/86
AVS-0001	CPE	PT	2.40	9.00	VERO >	100.00 >	11.00	10/29/86
AVS-0001	CPE	PT	2.70	11.60	VERO >	100.00 >	8.57	10/29/86
AVS-0001	CPE	PT	1.50	28.00	VERO	100.00	3.56	10/30/86
AVS-0001	CPE	PT	2.49	8.60	VERO >	100.00 >	11.60	10/30/86
AVS-0001	CPE	PT	1.80	32.00	VERO >	100.00 >	3.13	10/31/86
AVS-0001	CPE	PT	2.49	9.40	VERO >	100.00 >	10.60	11/ 5/86
AVS-0001	CPE	PT	2.31	8.40	VERO >	100.00 >	11.80	11/ 7/86
AVS-0001	CPE	PT	2.43	14.50	VERO	100.00	6.87	11/ 7/86
AVS-0001	CPE	PT	2.76	11.10	VERO >	100.00 >	8.99	11/10/86
AVS-0001	CPE	PT	3.00	20.60	VERO >	100.00 >	4.84	11/12/86
AVS-0001	CPE	PT	2.70	15.50	VERO >	100.00 >	6.45	11/12/86
AVS-0001	CPE	PT	2.40	11.10	VERO	100.00	8.96	11/13/86
AVS-0001	CPE	PT	1.50	27.90	VERO	100.00	3.57	11/14/86
AVS-0001	CPE	PT	1.35	23.80	VERO	32.00	1.33	11/17/86
AVS-0001	CPE	PT	2.1	22.20	VERO	100.00	4.50	11/18/86
AVS-0001	CPE	PT	1.25	25.90	VERO	32.00	1.23	11/18/86
AVS-0001	CPE	PT	1.2	25.00	VERO	32.00	1.27	11/19/86
AVS-0001	CPE	PT	1.75	20.20	VERO	32.00	1.57	11/19/86
AVS-0001	CPE	PT	1.95	12.80	VERO	100.00	7.75	11/20/86
AVS-0001	CPE	PT	1.93	23.10	VERO	100.00	4.32	11/20/86
AVS-0001	CPE	PT	2.2	30.30	VERO >	100.00 >	3.30	11/20/86
AVS-0001	CPE	PT	2.1	25.40	VERO >	100.00 >	3.93	11/21/86
AVS-0001	CPE	PT	2.	24.10	VERO	100.00	4.14	11/21/86
AVS-0001	CPE	PT	3.	2.20	VERO	100.00	45.40	11/24/86
AVS-0001	CPE	PT	1.5	24.80	VERO	32.00	1.29	11/25/86
AVS-0001	CPE	PT	1.75	27.90	VERO	100.00	3.57	11/26/86
AVS-0001	CPE	PT	2.95	12.50	VERO	100.00	7.98	4/20/87
AVS-0001	CPE	PT	2.72	11.40	VERO	100.00	8.76	4/21/87
AVS-0001	CPE	PT	2.59	16.40	VERO	100.00	6.07	4/22/87
AVS-0001	CPE	PT	2.01	13.50	VERO	100.00	7.40	4/23/87
AVS-0001	CPE	PT	2.03	18.60	VERO	100.00	5.35	4/24/87
AVS-0001	CPE	PT	1.42	19.50	VERO	100.00	5.12	4/27/87
AVS-0001	CPE	PT	1.7	20.10	VERO	100.00	4.96	4/28/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0001	PR	PT	N/A	6.30	VERO	100.00	15.80	4/29/87
AVS-0001	PR	PT	N/A	11.30	VERO	100.00	8.80	5/12/87
AVS-0001	PR	PT	N/A	11.40	VERO >	32.00 >	2.78	5/12/87
AVS-0001	PR	PT	N/A	8.30	VERO >	32.00 >	3.82	5/14/87
AVS-0001	CPE	PT	2.74	7.00	VERO	100.00	14.20	5/15/87
AVS-0001	CPE	PT	2.25	10.90	VERO	100.00	9.17	5/18/87
AVS-0001	CPE	PT	1.7	23.10	VERO	100.00	4.32	5/19/87
AVS-0001	CPE	PT	2.94	8.40	VERO	100.00	11.80	5/20/87
AVS-0001	CPE	PT	2.65	5.30	VERO	100.00	18.70	5/21/87
AVS-0001	CPE	PT	2.64	24.30	VERO >	100.00 >	4.10	5/27/87
AVS-0001	CPE	PT	2.09	15.00	VERO	32.00	2.12	5/28/87
AVS-0001	CPE	PT	1.54	11.50	VERO	32.00	2.77	5/29/87
AVS-0001	CPE	PT	2.6	3.69	VERO	32.00	8.67	6/ 1/87
AVS-0001	CPE	PT	1.35	27.30	VERO	32.00	1.16	6/ 2/87
AVS-0001	CPE	PT	1.54	29.30	VERO >	100.00 >	3.41	6/ 4/87
AVS-0001	CPE	PT	2.72	11.50	VERO	100.00	8.64	6/ 5/87
AVS-0001	CPE	PT	2.3	10.30	VERO	32.00	3.10	6/ 8/87
AVS-0001	CPE	PT	2.2	9.70	VERO	32.00	3.29	6/10/87
AVS-0001	CPE	PT	2.1	12.90	VERO	100.00	7.70	6/11/87
AVS-0001	CPE	PT	2.31	7.30	VERO	100.00	13.50	6/12/87
AVS-0001	CPE	PT	2.34	9.00	VERO	100.00	11.00	6/16/87
AVS-0001	PR	PT	N/A	5.80	VERO	100.00	16.90	6/17/87
AVS-0001	CPE	PT	1.25	17.60	VERO	32.00	1.81	6/18/87
AVS-0001	CPE	PT	2.3	10.90	VERO	100.00	9.10	6/19/87
AVS-0001	CPE	PT	2.1	9.60	VERO	100.00	10.30	6/23/87
AVS-0001	CPE	PT	2.4	9.40	VERO	100.00	10.50	6/24/87
AVS-0001	CPE	PT	2.14	20.20	VERO	100.00	4.94	6/25/87
AVS-0001	CPE	PT	1.5	8.90	VERO	3.20	0.36	6/26/87
AVS-0001	CPE	PT	1.79	11.00	VERO	32.00	2.89	6/29/87
AVS-0001	CPE	PT	1.75	15.00	VERO	32.00	2.13	6/30/87
AVS-0001	CPE	PT	2.36	13.00	VERO	100.00	7.66	7/ 1/87
AVS-0001	CPE	PT	2.23	16.50	VERO	100.00	5.90	7/ 7/87
AVS-0001	CPE	PT	2.02	20.20	VERO	100.00	4.93	7/ 8/87
AVS-0001	CPE	PT	2.07	9.90	VERO	100.00	10.00	7/ 9/87
AVS-0001	CPE	PT	2.9	9.20	VERO	100.00	10.80	7/10/87
AVS-0001	CPE	PT	1.4	28.10	VERO	100.00	3.55	7/23/87
AVS-0001	CPE	PT	2.43	6.70	VERO	100.00	14.90	7/24/87
AVS-0001	CPE	PT	1.64	36.60	VERO	100.00	2.72	8/ 6/87
AVS-0001	CPE	PT	1.69	16.30	VERO	100.00	6.09	8/ 7/87
AVS-0001	CPE	PT	2.27	22.20	VERO	100.00	4.49	8/11/87
AVS-0001	CPE	PT	2.5	10.00	VERO	100.00	9.92	8/12/87
AVS-0001	CPE	PT	2.27	15.50	VERO	100.00	6.44	8/14/87
AVS-0001	CPE	PT	1.3	29.70	VERO	100.00	3.36	8/17/87
AVS-0001	CPE	PT	0.9	68.30	VERO >	100.00 >	1.46	8/18/87
AVS-0001	CPE	PT	1.2	31.70	VERO	100.00	3.15	8/19/87
AVS-0001	CPE	PT	1.2	31.70	VERO	100.00	3.15	8/20/87
AVS-0001	CPE	PT	1.2	31.70	VERO	100.00	3.15	8/21/87
AVS-0001	CPE	PT	1.5	24.90	VERO	100.00	4.01	8/25/87
AVS-0001	CPE	PT	0.9	18.30	VERO	32.00	1.74	8/26/87
AVS-0001	CPE	PT	1.2	31.70	VERO	100.00	3.15	8/27/87
AVS-0001	CPE	PT	1.6	70.10	VERO	320.00	4.56	8/28/87
AVS-0001	CPE	PT	1.2	22.80	VERO	32.00	1.40	8/31/87
AVS-0001	CPE	PT	0.9	30.10	VERO	32.00	1.06	9/ 1/87
AVS-0001	CPE	PT	1.5	26.10	VERO	100.00	3.81	9/ 3/87
AVS-0001	CPE	PT	0.85	45.60	VERO	100.00	2.18	9/ 4/87
AVS-0001	CPE	PT	1.9	18.40	VERO	100.00	5.40	9/11/87
AVS-0001	CPE	PT	2.54	10.70	VERO	100.00	9.29	9/11/87
AVS-0001	CPE	PT	1.27	30.10	VERO	100.00	3.31	9/15/87
AVS-0001	CPE	PT	1.4	30.70	VERO	100.00	3.24	9/18/87
AVS-0001	CPE	PT	1.7	20.10	VERO	100.00	4.96	9/21/87
AVS-0001	CPE	PT	1.82	30.50	VERO	100.00	3.26	9/23/87
AVS-0001	CPE	PT	1.5	37.40	VERO	100.00	2.66	9/24/87
AVS-0001	CPE	PT	0.9	46.70	VERO	100.00	2.13	9/28/87
AVS-0001	CPE	PT	0.7	84.90	VERO >	100.00 >	1.17	10/ 6/87
AVS-0001	CPE	PT	0.77	62.10	VERO	100.00	1.60	10/15/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0001	CPE	PT	1.25	28.50	VERO	100.00	3.50	10/21/87
AVS-0001	CPE	PT	1.2	9.00	VERO	10.00	1.10	10/28/87
AVS-0001	CPE	PT	1.45	20.00	VERO	100.00	4.97	10/28/87
AVS-0001	CPE	PT	1.35	21.70	VERO	100.00	4.60	10/29/87
AVS-0001	CPE	PT	1.25	24.60	VERO	100.00	4.06	11/ 2/87
AVS-0001	CPE	PT	1.8	6.10	VERO	32.00	5.21	11/ 4/87
AVS-0001	CPE	PT	1.2	16.00	VERO	32.00	2.00	11/ 5/87
AVS-0001	CPE	PT	0.9	21.70	VERO	32.00	1.47	11/11/87
AVS-0001	CPE	PT	1.	19.30	VERO	32.00	1.65	11/11/87
AVS-0001	CPE	PT	0.8	26.60	VERO	32.00	1.19	11/12/87
AVS-0001	CPE	PT	0.8	26.60	VERO	32.00	1.19	11/12/87
AVS-0001	CPE	PT	0.7	42.50	VERO	32.00	0.75	11/16/87
AVS-0001	CPE	PT	0.65	36.90	VERO	32.00	0.87	11/16/87
AVS-0001	CPE	PT	0.9	17.80	VERO	32.00	1.79	11/16/87
AVS-0001	CPE	PT	0.9	27.00	VERO	32.00	1.18	11/16/87
AVS-0001	CPE	PT	0.8	29.00	VERO	32.00	1.10	11/16/87
AVS-0001	CPE	PT	0.7	29.70	VERO	32.00	1.07	11/16/87
AVS-0001	CPE	PT	0.75	35.60	VERO	32.00	0.90	11/16/87
AVS-0001	CPE	PT	1.	16.20	VERO	32.00	1.96	11/17/87
AVS-0001	CPE	PT	1.15	22.20	VERO	32.00	1.43	11/25/87
AVS-0001	CPE	PT	1.2	17.80	VERO	32.00	1.78	11/25/87
AVS-0001	CPE	PT	1.8	10.00	VERO	32.00	3.17	11/25/87
AVS-0001	CPE	PT	1.75	10.00	VERO	32.00	3.19	11/25/87
AVS-0001	CPE	PT	2.	8.80	VERO	32.00	3.61	11/25/87
AVS-0001	CPE	PT	2.1	8.30	VERO	32.00	3.85	11/25/87
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	11/25/87
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	11/25/87
AVS-0001	CPE	PT	1.	25.60	VERO	10.00	0.39	11/30/87
AVS-0001	CPE	PT	2.1	26.30	VERO	100.00	3.79	12/14/87
AVS-0001	CPE	PT	1.9	15.90	VERO	100.00	6.27	12/16/87
AVS-0001	CPE	PT	1.6	22.20	VERO	100.00	4.48	12/17/87
AVS-0001	CPE	PT	1.5	26.10	VERO	100.00	3.81	12/17/87
AVS-0001	CPE	PT	1.95	9.10	VERO	32.00	3.49	12/21/87
AVS-0001	CPE	PT	1.9	15.90	VERO	100.00	6.27	12/22/87
AVS-0001	CPE	PT	1.65	13.10	VERO	32.00	2.43	12/29/87
AVS-0001	CPE	PT	1.5	26.10	VERO	100.00	3.81	12/30/87
AVS-0001	CPE	PT	2.1	14.70	VERO	100.00	6.78	3/ 1/88
AVS-0001	CPE	PT	1.22	18.50	VERO	100.00	5.39	3/15/88
AVS-0001	CPE	PT	1.	42.50	VERO	100.00	2.35	3/17/88
AVS-0001	CPE	PT	1.02	22.60	VERO	10.00	0.44	4/ 5/88
AVS-0001	CPE	PT	2.04	9.50	VERO	100.00	10.40	4/12/88
AVS-0001	CPE	PT	2.44	5.30	VERO	100.00	8.80	4/12/88
AVS-0001	CPE	PT	1.4	27.90	VERO	100.00	3.58	4/13/88
AVS-0001	CPE	PT	1.3	29.70	VERO	100.00	3.36	4/13/88
AVS-0001	CPE	PT	1.15	22.20	VERO	32.00	1.43	4/14/88
AVS-0001	CPE	PT	1.15	22.20	VERO	32.00	1.43	4/14/88
AVS-0001	CPE	PT	1.25	20.10	VERO	32.00	1.59	4/15/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	4/15/88
AVS-0001	CPE	PT	1.4	27.90	VERO	100.00	3.58	4/19/88
AVS-0001	CPE	PT	1.95	5.60	VERO	10.00	1.76	4/20/88
AVS-0001	CPE	PT	1.7	20.10	VERO	100.00	4.96	4/26/88
AVS-0001	CPE	PT	1.55	15.80	VERO	32.00	2.01	4/26/88
AVS-0001	CPE	PT	2.15	9.00	VERO	100.00	11.00	4/27/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	4/27/88
AVS-0001	CPE	PT	1.85	9.60	VERO	32.00	3.32	4/29/88
AVS-0001	CPE	PT	1.5	14.20	VERO	32.00	2.24	4/29/88
AVS-0001	CPE	PT	1.25	20.10	VERO	32.00	1.59	5/ 3/88
AVS-0001	CPE	PT	2.1	8.30	VERO	32.00	3.85	5/ 4/88
AVS-0001	CPE	PT	1.15	22.20	VERO	32.00	1.43	5/10/88
AVS-0001	CPE	PT	1.7	20.10	VERO	100.00	4.96	5/11/88
AVS-0001	CPE	PT	1.8	18.00	VERO	100.00	5.52	5/18/88
AVS-0001	CPE	PT	1.8	18.00	VERO	100.00	5.52	5/18/88
AVS-0001	CPE	PT	2.3	6.30	VERO	32.00	5.06	5/20/88
AVS-0001	CPE	PT	1.7	14.70	VERO	32.00	2.17	5/20/88
AVS-0001	CPE	PT	1.4	27.90	VERO	100.00	3.58	5/25/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0001	CPE	PT	1.5	26.10	VERO	100.00	3.81	5/25/88
AVS-0001	CPE	PT	2.3	7.10	VERO	32.00	4.44	6/ 1/88
AVS-0001	CPE	PT	2.2	7.10	VERO	32.00	4.48	6/ 1/88
AVS-0001	CPE	PT	1.45	15.90	VERO	32.00	2.00	6/ 2/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	6/ 7/88
AVS-0001	CPE	PT	1.6	22.20	VERO	100.00	4.48	6/ 7/88
AVS-0001	CPE	PT	1.9	16.00	VERO	100.00	6.22	6/ 8/88
AVS-0001	CPE	PT	1.5	26.10	VERO	100.00	3.81	6/ 8/88
AVS-0001	CPE	PT	1.2	31.70	VERO	100.00	3.15	6/14/88
AVS-0001	CPE	PT	1.15	22.20	VERO	32.00	1.43	6/14/88
AVS-0001	CPE	PT	1.5	26.10	VERO	100.00	3.81	6/15/88
AVS-0001	CPE	PT	0.8	50.40	VERO	100.00	1.98	6/15/88
AVS-0001	CPE	PT	1.6	22.20	VERO	100.00	4.48	6/21/88
AVS-0001	CPE	PT	1.6	22.20	VERO	100.00	4.48	6/21/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	6/22/88
AVS-0001	CPE	PT	1.15	22.20	VERO	32.00	1.43	6/22/88
AVS-0001	CPE	PT	1.5	26.10	VERO	100.00	3.81	6/30/88
AVS-0001	CPE	PT	0.92	44.10	VERO	100.00	2.26	6/30/88
AVS-0001	CPE	PT	1.7	20.10	VERO	100.00	4.96	7/ 5/88
AVS-0001	CPE	PT	1.15	22.20	VERO	32.00	1.43	7/ 5/88
AVS-0001	CPE	PT	3.3	2.66	VERO	100.00	37.40	7/ 6/88
AVS-0001	CPE	PT	2.4	5.60	VERO	32.00	5.61	7/ 6/88
AVS-0001	CPE	PT	1.9	15.90	VERO	100.00	6.27	7/ 7/88
AVS-0001	CPE	PT	2.05	7.50	VERO	32.00	4.21	7/ 7/88
AVS-0001	CPE	PT	1.8	17.90	VERO	100.00	5.57	7/19/88
AVS-0001	CPE	PT	1.8	17.90	VERO	100.00	5.57	7/19/88
AVS-0001	CPE	PT	2.	14.20	VERO	100.00	7.03	7/20/88
AVS-0001	CPE	PT	2.4	18.00	VERO >	100.00 >	5.52	7/20/88
AVS-0001	CPE	PT	1.6	22.20	VERO	100.00	4.48	7/21/88
AVS-0001	CPE	PT	2.2	22.20	VERO >	100.00 >	4.48	7/21/88
AVS-0001	CPE	PT	1.5	26.10	VERO	100.00	3.81	7/26/88
AVS-0001	CPE	PT	1.6	13.30	VERO	32.00	2.39	7/26/88
AVS-0001	CPE	PT	1.3	29.70	VERO	100.00	3.36	7/27/88
AVS-0001	CPE	PT	0.8	50.40	VERO	100.00	1.98	7/27/88
AVS-0001	CPE	PT	1.1	37.60	VERO	100.00	2.65	7/28/88
AVS-0001	CPE	PT	1.7	20.00	VERO	100.00	4.97	7/28/88
AVS-0001	CPE	PT	1.45	15.90	VERO	32.00	2.00	8/ 2/88
AVS-0001	CPE	PT	1.1	24.50	VERO	32.00	1.30	8/ 2/88
AVS-0001	CPE	PT	1.7	20.00	VERO	100.00	4.97	8/ 4/88
AVS-0001	CPE	PT	1.4	16.00	VERO	32.00	1.99	8/ 4/88
AVS-0001	CPE	PT	1.35	18.00	VERO	32.00	1.76	8/ 9/88
AVS-0001	CPE	PT	1.15	18.60	VERO	32.00	1.71	8/ 9/88
AVS-0001	CPE	PT	2.1	26.10	VERO >	100.00 >	3.81	8/10/88
AVS-0001	CPE	PT	1.7	20.10	VERO	100.00	4.96	8/10/88
AVS-0001	CPE	PT	1.1	37.60	VERO	100.00	2.65	8/11/88
AVS-0001	CPE	PT	0.9	46.70	VERO	100.00	2.13	8/11/88
AVS-0001	CPE	PT	1.2	56.50	VERO >	100.00 >	1.76	8/16/88
AVS-0001	CPE	PT	0.6	56.50	VERO	100.00	1.76	8/16/88
AVS-0001	CPE	PT	1.3	29.70	VERO	100.00	3.36	8/17/88
AVS-0001	CPE	PT	1.	27.90	VERO	32.00	1.14	8/17/88
AVS-0001	CPE	PT	1.5	26.10	VERO	100.00	3.81	8/18/88
AVS-0001	CPE	PT	0.95	29.70	VERO	32.00	1.07	8/18/88
AVS-0001	CPE	PT	1.5	26.10	VERO	100.00	3.81	8/23/88
AVS-0001	CPE	PT	1.5	26.10	VERO	100.00	3.81	8/23/88
AVS-0001	CPE	PT	1.2	56.50	VERO >	100.00 >	1.76	8/24/88
AVS-0001	CPE	PT	0.6	56.50	VERO	100.00	1.76	8/24/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	9/ 1/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	9/ 1/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	9/13/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	9/13/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	9/14/88
AVS-0001	CPE	PT	0.95	24.40	VERO	32.00	1.31	9/14/88
AVS-0001	CPE	PT	1.15	22.20	VERO	32.00	1.44	9/15/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	9/15/88
AVS-0001	CPE	PT	1.40	16.00	VERO	32.00	1.99	9/20/88

B-9

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND PROTOCOL VIRUS			VR	ID50	CELL	MTCSO	TI	DATE
AVS-0001	CPE	PT	0.85	37.60	VERO	32.00	0.85	9/21/88
AVS-0001	CPE	PT	1.05	23.10	VERO	22.90	1.00	9/21/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	9/22/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	9/22/88
AVS-0001	CPE	PT	1.60	13.30	VERO	32.00	2.39	9/27/88
AVS-0001	CPE	PT	2.00	8.80	VERO	32.00	3.61	9/27/88
AVS-0001	CPE	PT	1.90	9.40	VERO	32.00	3.39	9/28/88
AVS-0001	CPE	PT	2.00	8.80	VERO	32.00	3.61	9/28/88
AVS-0001	CPE	PT	1.40	15.90	VERO	32.00	2.01	9/29/88
AVS-0001	CPE	PT	1.25	20.10	VERO	32.00	1.59	9/29/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	10/ 4/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	10/ 4/88
AVS-0001	CPE	PT	1.	27.90	VERO	32.00	1.14	10/ 5/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	10/ 5/88
AVS-0001	CPE	PT	0.95	24.50	VERO	32.00	1.30	10/ 6/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	10/ 6/88
AVS-0001	CPE	PT	1.45	15.80	VERO	32.00	2.01	10/11/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	10/11/88
AVS-0001	CPE	PT	1.7	11.80	VERO	32.00	2.71	10/12/88
AVS-0001	CPE	PT	1.7	11.80	VERO	32.00	2.71	10/12/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	10/13/88
AVS-0001	CPE	PT	1.05	26.10	VERO	32.00	1.22	10/13/88
AVS-0001	CPE	SF	6.	1.00	VERO >	320.00 >	320.00	9/23/86
AVS-0001	CPE	SF	3.51	22.90	VERO >	100.00 >	4.36	10/22/86
AVS-0001	CPE	SF	4.35	1.71	VERO >	100.00 >	58.40	10/23/86
AVS-0001	CPE	SF	3.81	5.10	VERO >	100.00 >	19.40	10/24/86
AVS-0001	CPE	SF	2.70	14.70	VERO >	100.00 >	6.78	10/27/86
AVS-0001	CPE	SF	3.00	10.00	VERO >	100.00 >	9.97	10/27/86
AVS-0001	CPE	SF	5.10	1.32	VERO >	100.00 >	75.70	10/28/86
AVS-0001	CPE	SF	3.00	12.00	VERO >	100.00 >	8.29	10/28/86
AVS-0001	CPE	SF	4.41	3.31	VERO >	100.00 >	30.10	10/29/86
AVS-0001	CPE	SF	2.79	11.40	VERO >	100.00 >	8.77	10/30/86
AVS-0001	CPE	SF	3.24	11.90	VERO >	100.00 >	8.38	10/30/86
AVS-0001	CPE	SF	3.39	1.97	VERO >	100.00 >	50.80	10/31/86
AVS-0001	CPE	SF	2.31	11.60	VERO	100.00	8.62	11/ 3/86
AVS-0001	CPE	SF	2.40	6.70	VERO >	100.00 >	14.80	11/ 4/86
AVS-0001	CPE	SF	3.00	8.90	VERO >	100.00 >	11.10	11/ 4/86
AVS-0001	CPE	SF	2.91	14.30	VERO >	100.00 >	6.94	11/ 5/86
AVS-0001	CPE	SF	2.49	15.90	VERO >	100.00 >	6.27	11/ 5/86
AVS-0001	CPE	SF	2.94	6.70	VERO >	100.00 >	14.90	11/ 6/86
AVS-0001	CPE	SF	3.00	12.00	VERO >	100.00 >	8.27	11/ 7/86
AVS-0001	CPE	SF	4.41	2.13	VERO >	100.00 >	46.90	11/10/86
AVS-0001	CPE	SF	3.99	1.23	VERO >	100.00 >	81.40	11/12/86
AVS-0001	CPE	SF	3.39	7.40	VERO >	100.00 >	13.40	11/12/86
AVS-0001	CPE	SF	4.41	3.02	VERO >	100.00 >	33.00	11/13/86
AVS-0001	CPE	SF	3.99	3.71	VERO >	100.00 >	26.90	11/13/86
AVS-0001	CPE	SF	3.00	10.00	VERO >	100.00 >	10.00	11/13/86
AVS-0001	CPE	SF	2.10	21.00	VERO	100.00	4.76	11/17/86
AVS-0001	CPE	SF	2.40	18.10	VERO >	100.00 >	5.50	11/17/86
AVS-0001	CPE	SF	3.20	8.70	VERO >	100.00 >	11.30	11/18/86
AVS-0001	CPE	SF	2.60	13.50	VERO >	100.00 >	7.38	11/18/86
AVS-0001	CPE	SF	3.50	6.50	VERO >	100.00 >	15.10	11/19/86
AVS-0001	CPE	SF	2.90	9.40	VERO	100.00	10.60	11/19/86
AVS-0001	CPE	SF	2.40	23.70	VERO >	100.00 >	4.21	11/20/86
AVS-0001	CPE	SF	2.90	14.30	VERO >	100.00	6.94	11/20/86
AVS-0001	CPE	SF	2.40	10.00	VERO	100.00	10.00	11/21/86
AVS-0001	CPE	SF	3.50	6.60	VERO >	100.00 >	15.00	11/24/86
AVS-0001	CPE	SF	4.00	5.60	VERO >	100.00	17.50	11/24/86
AVS-0001	CPE	SF	3.30	7.50	VERO >	100.00 >	13.20	11/25/86
AVS-0001	CPE	SF	2.40	17.30	VERO >	100.00	5.78	11/25/86
AVS-0001	CPE	SF	3.20	8.00	VERO >	100.00 >	12.40	11/26/86
AVS-0001	PR	SF	N/A	19.60	VERO	100.00	5.08	5/13/87
AVS-0001	CPE		2.95	4.15	VERO	32.00	7.70	5/18/87
AVS-0001	CPE		3.	3.97	VERO	32.00	8.04	6/ 1/87
AVS-0001	CPE		2.3	3.76	VERO	32.00	8.49	6/ 2/87

B-10

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0001	CPE	SF	2.3	3.82	VERO	10.00	2.61	6/ 3/87
AVS-0001	CPE	SF	2.6	15.90	VERO >	100.00 >	6.27	6/ 4/87
AVS-0001	CPE	SF	2.8	4.25	VERO	32.00	7.52	6/ 5/87
AVS-0001	CPE	SF	3.	5.60	VERO	100.00	17.60	6/ 8/87
AVS-0001	CPE	SF	3.	5.60	VERO	100.00	17.60	6/10/87
AVS-0001	CPE	SF	3.5	5.10	VERO >	100.00 >	19.50	6/11/87
AVS-0001	CPE	SF	1.4	13.30	VERO	3.20	0.24	6/16/87
AVS-0001	CPE	SF	3.9	2.61	VERO	100.00	38.10	6/19/87
AVS-0001	CPE	SF	2.9	11.80	VERO >	100.00 >	8.46	6/23/87
AVS-0001	CPE	SF	1.9	5.30	VERO	10.00	1.86	6/24/87
AVS-0001	CPE	SF	1.9	16.90	VERO	100.00	5.89	6/25/87
AVS-0001	CPE	SF	3.3	4.67	VERO	100.00	21.30	6/29/87
AVS-0001	CPE	SF	2.3	4.43	VERO	32.00	7.21	7/ 6/87
AVS-0001	CPE	SF	3.19	2.91	VERO	32.00	10.90	7/ 7/87
AVS-0001	CPE	SF	3.9	4.89	VERO >	100.00 >	20.40	7/14/87
AVS-0001	CPE	SF	2.9	6.30	VERO	100.00	15.80	7/15/87
AVS-0001	CPE	SF	3.4	2.32	VERO	32.00	13.70	7/16/87
AVS-0001	CPE	SF	3.2	5.90	VERO	100.00	16.90	7/17/87
AVS-0001	CPE	SF	2.69	3.76	VERO	32.00	8.50	7/20/87
AVS-0001	CPE	SF	3.37	4.41	VERO	100.00	22.60	7/21/87
AVS-0001	CPE	SF	3.2	15.90	VERO	320.00	20.00	7/22/87
AVS-0001	CPE	SF	2.35	3.21	VERO	10.00	3.11	7/23/87
AVS-0001	CPE	SF	3.55	5.20	VERO >	100.00 >	19.00	7/27/87
AVS-0001	CPE	SF	3.49	1.94	VERO	32.00	16.40	7/28/87
AVS-0001	CPE	SF	2.7	4.67	VERO	32.00	6.83	8/ 3/87
AVS-0001	CPE	SF	2.1	8.30	VERO	32.00	3.85	8/ 4/87
AVS-0001	CPE	SF	2.1	7.70	VERO	32.00	4.10	8/ 5/87
AVS-0001	CPE	SF	3.7	3.77	VERO	100.00	26.40	8/ 6/87
AVS-0001	CPE	SF	3.1	5.00	VERO	100.00	19.70	8/ 7/87
AVS-0001	CPE	SF	3.5	3.21	VERO	100.00	31.10	8/11/87
AVS-0001	CPE	SF	2.4	10.00	VERO	100.00	9.92	8/12/87
AVS-0001	CPE	SF	2.5	5.00	VERO	32.00	6.32	8/13/87
AVS-0001	CPE	SF	3.	5.60	VERO	100.00	17.60	8/14/87
AVS-0001	CPE	SF	3.2	5.00	VERO	100.00	19.80	8/18/87
AVS-0001	CPE	SF	2.1	8.30	VERO	32.00	3.85	8/25/87
AVS-0001	CPE	SF	2.2	7.00	VERO	32.00	4.56	8/26/87
AVS-0001	CPE	SF	2.1	8.30	VERO	32.00	3.85	8/31/87
AVS-0001	CPE	SF	2.	15.90	VERO	100.00	6.27	9/ 1/87
AVS-0001	CPE	SF	2.1	14.70	VERO	100.00	6.78	9/ 2/87
AVS-0001	CPE	SF	2.59	4.09	VERO	32.00	7.82	9/ 3/87
AVS-0001	CPE	SF	2.4	5.60	VERO	32.00	5.66	9/ 4/87
AVS-0001	CPE	SF	2.1	7.70	VERO	32.00	4.10	9/ 8/87
AVS-0001	CPE	SF	2.8	7.10	VERO	100.00	14.00	9/ 9/87
AVS-0001	CPE	SF	2.1	7.80	VERO	32.00	4.08	9/10/87
AVS-0001	CPE	SF	2.8	7.10	VERO	100.00	14.00	9/14/87
AVS-0001	CPE	SF	2.52	7.90	VERO	100.00	12.60	9/15/87
AVS-0001	CPE	SF	2.3	11.80	VERO	100.00	8.46	9/16/87
AVS-0001	CPE	SF	2.1	7.70	VERO	32.00	4.10	9/17/87
AVS-0001	CPE	SF	3.	7.40	VERO	100.00	13.40	9/18/87
AVS-0001	CPE	SF	2.62	8.80	VERO	100.00	11.30	9/23/87
AVS-0001	CPE	SF	2.4	6.40	VERO	32.00	4.98	9/24/87
AVS-0001	CPE	SF	3.1	5.30	VERO	100.00	18.60	9/28/87
AVS-0001	CPE	SF	2.2	7.00	VERO	32.00	4.56	9/29/87
AVS-0001	CPE	SF	2.3	11.80	VERO	100.00	8.46	9/30/87
AVS-0001	CPE	SF	2.1	14.70	VERO	100.00	6.78	10/ 1/87
AVS-0001	CPE	SF	2.25	5.70	VERO	32.00	5.54	10/ 2/87
AVS-0001	CPE	SF	2.1	11.70	VERO	100.00	8.53	10/ 6/87
AVS-0001	CPE	SF	2.2	7.70	VERO	32.00	4.10	10/30/87
AVS-0001	CPE	SF	1.4	27.90	VERO	100.00	3.58	11/ 2/87
AVS-0001	CPE	SF	2.1	14.70	VERO	100.00	6.78	11/ 3/87
AVS-0001	CPE	SF	3.	5.60	VERO	100.00	17.60	11/11/87
AVS-0001	CPE	SF	1.4	27.90	VERO	100.00	3.58	11/11/87
AVS-0001	CPE	SF	2.2	13.30	VERO	100.00	7.47	11/11/87
AVS-0001	CPE	SF	2.	15.90	VERO	100.00	6.27	11/11/87
AVS-0001	CPE	SF	3.1	5.00	VERO	100.00	19.90	11/11/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-0001	CPE	SF	3.	5.60	VERO	100.00	17.50	11/11/87
AVS-0001	CPE	SF	2.5	11.20	VERO	100.00	8.92	11/11/87
AVS-0001	CPE	SF	2.65	1.18	VERO	1.00	0.85	11/30/87
AVS-0001	CPE	SF	1.6	13.30	VERO	32.00	2.39	12/15/87
AVS-0001	CPE	SF	2.8	7.00	VERO	100.00	14.20	12/16/87
AVS-0001	CPE	SF	2.1	8.30	VERO	32.00	3.85	12/17/87
AVS-0001	CPE	SF	1.9	9.40	VERO	32.00	3.38	12/18/87
AVS-0001	CPE	SF	2.1	14.70	VERO	100.00	6.78	12/22/87
AVS-0001	CPE	SF	1.5	26.10	VERO	100.00	3.81	1/ 4/88
AVS-0001	CPE	SF	1.5	26.10	VERO	100.00	3.81	1/ 4/88
AVS-0001	CPE	SF	1.5	26.10	VERO	100.00	3.81	1/ 4/88
AVS-0001	CPE	SF	2.1	12.90	VERO	100.00	7.74	1/ 4/88
AVS-0001	CPE	SF	2.1	26.10	VERO >	100.00 >	3.81	1/ 4/88
AVS-0001	CPE	SF	2.1	26.10	VERO >	100.00 >	3.81	1/ 4/88
AVS-0001	CPE	SF	2.6	8.80	VERO	100.00	11.20	1/ 5/88
AVS-0001	CPE	SF	1.7	23.00	VERO	100.00	4.33	1/ 5/88
AVS-0001	CPE	SF	1.8	17.80	VERO	100.00	5.58	1/ 5/88
AVS-0001	CPE	SF	2.1	12.90	VERO	100.00	7.74	1/ 5/88
AVS-0001	CPE	SF	2.3	11.80	VERO	100.00	8.46	1/ 5/88
AVS-0001	CPE	SF	2.1	14.70	VERO	100.00	6.78	1/ 5/88
AVS-0001	CPE	SF	2.1	14.70	VERO	100.00	6.78	1/ 6/88
AVS-0001	CPE	SF	1.6	24.50	VERO	100.00	4.07	1/ 6/88
AVS-0001	CPE	SF	1.6	22.20	VERO	100.00	4.48	1/ 6/88
AVS-0001	CPE	SF	2.5	9.40	VERO	100.00	10.50	1/ 6/88
AVS-0001	CPE	SF	2.1	8.30	VERO	32.00	3.85	1/ 6/88
AVS-0001	CPE	SF	2.1	8.30	VERO	32.00	3.55	1/ 6/88
AVS-0001	CPE	SF	2.9	6.30	VERO	100.00	15.80	1/11/88
AVS-0001	CPE	SF	3.3	2.61	VERO	32.00	12.20	1/11/88
AVS-0001	CPE	SF	2.6	8.80	VERO	100.00	11.20	1/11/88
AVS-0001	CPE	SF	2.8	7.00	VERO	100.00	14.20	1/11/88
AVS-0001	CPE	SF	2.8	7.00	VERO	100.00	14.20	1/11/88
AVS-0001	CPE	SF	2.6	8.80	VERO	100.00	11.20	1/11/88
AVS-0001	CPE	SF	1.8	18.00	VERO	100.00	5.52	1/12/88
AVS-0001	CPE	SF	2.7	8.30	VERO	100.00	12.00	1/12/88
AVS-0001	CPE	SF	2.1	14.70	VERO	100.00	6.78	1/12/88
AVS-0001	CPE	SF	1.9	16.00	VERO	100.00	6.22	1/12/88
AVS-0001	CPE	SF	2.5	9.40	VERO	100.00	10.50	1/12/88
AVS-0001	CPE	SF	2.7	8.30	VERO	100.00	12.00	1/12/88
AVS-0001	CPE	SF	1.5	26.10	VERO	100.00	3.81	1/18/88
AVS-0001	CPE	SF	2.1	8.30	VERO	32.00	3.85	1/18/88
AVS-0001	CPE	SF	1.5	26.10	VERO	100.00	3.81	1/18/88
AVS-0001	CPE	SF	2.1	8.30	VERO	32.00	3.85	1/18/88
AVS-0001	CPE	SF	2.7	8.30	VERO	100.00	12.00	1/18/88
AVS-0001	CPE	SF	2.2	13.30	VERO	100.00	7.47	1/18/88
AVS-0001	CPE	SF	4.65	1.58	VERO	100.00	63.00	2/ 2/88
AVS-0001	CPE	SF	4.05	2.93	VERO	100.00	34.00	2/ 5/88
AVS-0001	CPE	SF	4.35	2.36	VERO	100.00	42.20	2/ 9/88
AVS-0001	CPE	SF	3.17	6.20	VERO	100.00	15.90	2/18/88
AVS-0001	CPE	SF	3.9	2.04	VERO	100.00	49.00	3/15/88
AVS-0001	CPE	SF	3.94	1.24	VERO	100.00	80.40	3/16/88
AVS-0001	CPE	SF	3.3	5.30	VERO	100.00	18.60	3/17/88
AVS-0001	CPE	SF	2.	8.80	VERO	32.00	3.61	3/21/88
AVS-0001	CPE	SF	2.2	7.00	VERO	32.00	4.56	3/22/88
AVS-0001	CPE	SF	2.5	12.80	VERO	100.00	7.76	3/31/88
AVS-0001	CPE	SF	3.1	5.00	VERO	100.00	19.90	4/ 6/88
AVS-0001	CPE	SF	2.6	5.90	VERO	100.00	16.90	4/12/88
AVS-0001	CPE	SF	3.	5.60	VERO	100.00	17.60	4/12/88
AVS-0001	CPE	SF	3.47	2.77	VERO	100.00	36.00	4/13/88
AVS-0001	CPE	SF	4.	1.71	VERO	100.00	58.30	4/13/88
AVS-0001	CPE	SF	2.4	10.10	VERO	100.00	9.85	4/19/88
AVS-0001	CPE	SF	3.6	2.89	VERO	100.00	34.50	4/20/88
AVS-0001	CPE	SF	4.	1.87	VERO	100.00	53.40	4/26/88
AVS-0001	CPE	SF	3.6	2.50	VERO	100.00	39.80	4/26/88
AVS-0001	CPE	SF	3.1	4.29	VERO	100.00	23.20	4/27/88
AVS-0001	CPE	SF	2.8	6.10	VERO	100.00	16.10	4/27/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-0001	CPE	SF	3.9	1.13	VERO	32.00	28.20	4/29/88
AVS-0001	CPE	SF	3.8	4.14	VERO	100.00	24.10	4/29/88
AVS-0001	CPE	SF	2.	15.90	VERO	100.00	6.27	5/ 3/88
AVS-0001	CPE	SF	2.6	4.36	VERO	32.00	7.33	5/ 4/88
AVS-0001	CPE	SF	2.3	6.10	VERO	32.00	5.19	5/10/88
AVS-0001	CPE	SF	2.2	9.30	VERO	100.00	10.60	5/11/88
AVS-0001	CPE	SF	4.2	2.66	VERO	100.00	37.40	5/17/88
AVS-0001	CPE	SF	4.2	2.37	VERO	100.00	42.00	5/17/88
AVS-0001	CPE	SF	2.7	7.70	VERO	100.00	12.80	5/18/88
AVS-0001	CPE	SF	1.05	26.10	VERO	32.00	1.22	5/24/88
AVS-0001	CPE	SF	1.2	18.00	VERO	10.00	0.55	5/25/88
AVS-0001	CPE	SF	1.65	11.40	VERO	32.00	2.80	5/25/88
AVS-0001	CPE	SF	1.05	26.10	VERO	32.00	1.22	5/26/88
AVS-0001	CPE	SF	1.25	20.10	VERO	32.00	1.59	5/26/88
AVS-0001	CPE	SF	2.7	6.00	VERO	100.00	16.50	6/ 1/88
AVS-0001	CPE	SF	3.8	2.50	VERO	100.00	39.80	6/ 1/88
AVS-0001	CPE	SF	2.2	7.00	VERO	32.00	4.56	6/ 2/88
AVS-0001	CPE	SF	2.8	7.00	VERO	100.00	14.20	6/ 2/88
AVS-0001	CPE	SF	1.9	8.80	VERO	32.00	3.60	6/ 7/88
AVS-0001	CPE	SF	3.2	5.50	VERO	100.00	18.10	6/ 7/88
AVS-0001	CPE	SF	2.9	5.20	VERO	100.00	19.10	6/14/88
AVS-0001	CPE	SF	3.5	3.83	VERO	100.00	26.00	6/14/88
AVS-0001	CPE	SF	2.15	9.60	VERO	32.00	3.31	6/15/88
AVS-0001	CPE	SF	2.55	5.60	VERO	32.00	5.69	6/15/88
AVS-0001	CPE	SF	2.3	6.30	VERO	32.00	5.06	6/21/88
AVS-0001	CPE	SF	2.6	8.00	VERO	100.00	12.40	6/21/88
AVS-0001	CPE	SF	3.85	2.99	VERO	100.00	33.40	6/22/88
AVS-0001	CPE	SF	3.	4.94	VERO	100.00	20.20	6/22/88
AVS-0001	CPE	SF	2.9	6.30	VERO	100.00	15.80	6/28/88
AVS-0001	CPE	SF	2.1	8.30	VERO	32.00	3.85	6/28/88
AVS-0001	CPE	SF	1.8	18.00	VERO	100.00	5.52	6/29/88
AVS-0001	CPE	SF	2.7	8.30	VERO	100.00	12.00	6/29/88
AVS-0001	CPE	SF	2.2	5.00	VERO	32.00	6.35	6/30/88
AVS-0001	CPE	SF	1.45	15.90	VERO	32.00	2.00	6/30/88
AVS-0001	CPE	SF	1.65	7.10	VERO	32.00	4.50	7/ 5/88
AVS-0001	CPE	SF	2.5	3.26	VERO	10.00	3.06	7/ 5/88
AVS-0001	CPE	SF	3.	2.36	VERO	32.00	13.50	7/ 6/88
AVS-0001	CPE	SF	2.35	3.10	VERO	10.00	3.22	7/ 6/88
AVS-0001	CPE	SF	2.35	5.70	VERO	32.00	5.56	7/ 7/88
AVS-0001	CPE	SF	2.1	11.70	VERO	100.00	8.53	7/19/88
AVS-0001	CPE	SF	1.35	11.70	VERO	10.00	0.85	7/19/88
AVS-0001	CPE	SF	1.65	11.70	VERO	32.00	2.72	7/20/88
AVS-0001	CPE	SF	1.75	6.90	VERO	10.00	1.44	7/20/88
AVS-0001	CPE	SF	1.15	22.20	VERO	32.00	1.43	7/21/88
AVS-0001	CPE	SF	1.05	26.10	VERO	32.00	1.22	7/21/88
AVS-0001	CPE	SF	2.9	3.46	VERO	32.00	9.24	7/26/88
AVS-0001	CPE	SF	2.5	5.80	VERO	32.00	5.44	7/26/88
AVS-0001	CPE	SF	1.8	18.00	VERO	100.00	5.52	7/27/88
AVS-0001	CPE	SF	1.03	26.10	VERO	32.00	1.22	7/27/88
AVS-0001	CPE	SF	2.4	10.10	VERO	100.00	9.85	8/ 2/88
AVS-0001	CPE	SF	1.45	15.90	VERO	32.00	2.00	8/ 2/88
AVS-0001	CPE	SF	2.4	10.10	VERO	100.00	9.85	8/ 3/88
AVS-0001	CPE	SF	2.15	10.00	VERO	100.00	9.96	8/ 3/88
AVS-0001	CPE	SF	2.8	3.64	VERO	32.00	8.78	8/ 4/88
AVS-0001	CPE	SF	1.75	6.40	VERO	10.00	1.54	8/ 4/88
AVS-0001	CPE	SF	2.4	8.90	VERO	100.00	11.10	8/ 9/88
AVS-0001	CPE	SF	1.75	9.30	VERO	32.00	3.40	8/ 9/88
AVS-0001	CPE	SF	2.2	6.00	VERO	32.00	5.30	8/10/88
AVS-0001	CPE	SF	2.1	6.50	VERO	32.00	4.84	8/10/88
AVS-0001	CPE	SF	1.8	18.00	VERO	100.00	5.52	8/11/88
AVS-0001	CPE	SF	1.8	18.00	VERO	100.00	5.52	8/11/88
AVS-0001	CPE	SF	1.55	21.30	VERO	100.00	4.68	8/16/88
AVS-0001	CPE	SF	1.8	18.00	VERO	100.00	5.52	8/16/88
AVS-0001	CPE	SF	1.65	11.70	VERO	32.00	2.72	8/17/88
AVS-0001	CPE	SF	1.35	18.00	VERO	32.00	1.76	8/17/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0001	CPE	SF	2.2	11.50	VERO	100.00	8.66	8/18/88
AVS-0001	CPE	SF	2.	13.80	VERO	100.00	7.23	8/18/88
AVS-0001	CPE	SF	1.75	9.30	VERO	32.00	3.40	8/23/88
AVS-0001	CPE	SF	1.35	18.00	VERO	32.00	1.76	8/23/88
AVS-0001	CPE	SF	1.5	26.10	VERO	100.00	3.81	8/24/88
AVS-0001	CPE	SF	1.6	22.20	VERO	100.00	4.48	8/24/88
AVS-0001	CPE	SF	1.05	26.10	VERO	32.00	1.22	8/25/88
AVS-0001	CPE	SF	1.05	26.10	VERO	32.00	1.22	8/25/88
AVS-0001	CPE	SF	1.7	20.10	VERO	100.00	4.97	8/30/88
AVS-0001	CPE	SF	1.05	26.10	VERO	32.00	1.22	8/30/88
AVS-0001	CPE	SF	1.05	26.10	VERO	32.00	1.22	8/31/88
AVS-0001	CPE	SF	1.05	26.10	VERO	32.00	1.22	8/31/88
AVS-0001	CPE	SF	1.95	7.50	VERO	32.00	4.25	9/ 1/88
AVS-0001	CPE	SF	1.75	9.30	VERO	32.00	3.42	9/ 1/88
AVS-0001	CPE	SF	1.5	7.50	VERO	10.00	1.33	9/ 7/88
AVS-0001	CPE	SF	1.5	7.50	VERO	10.00	1.33	9/ 7/88
AVS-0001	CPE	SF	1.6	6.40	VERO	10.00	1.56	9/ 8/88
AVS-0001	CPE	SF	1.5	7.50	VERO	10.00	1.32	9/ 8/88
AVS-0001	CPE	SF	2.35	4.12	VERO	10.00	2.42	9/13/88
AVS-0001	CPE	SF	2.05	6.60	VERO	10.00	1.49	9/13/88
AVS-0001	CPE	SF	2.65	4.20	VERO	32.00	7.61	9/20/88
AVS-0001	CPE	SF	1.35	18.00	VERO	32.00	1.78	9/21/88
AVS-0001	CPE	SF	1.65	13.50	VERO	32.00	2.35	9/21/88
AVS-0001	CPE	SF	2.40	7.40	VERO	100.00	13.30	9/22/88
AVS-0001	CPE	SF	2.15	5.90	VERO	32.00	5.41	9/22/88
AVS-0001	CPE	SF	2.80	4.12	VERO	32.00	7.75	9/28/88
AVS-0001	CPE	SF	3.00	2.58	VERO	32.00	12.30	9/28/88
AVS-0001	CPE	SF	2.55	5.10	VERO	32.00	6.23	9/29/88
AVS-0001	CPE	SF	2.70	4.50	VERO	32.00	7.11	9/29/88
AVS-0001	CPE	SF	1.5	26.10	VERO	100.00	3.81	10/ 4/88
AVS-0001	CPE	SF	1.05	26.10	VERO	32.00	1.22	10/ 4/88
AVS-0001	CPE	SF	1.05	26.10	VERO	32.00	1.22	10/ 5/88
AVS-0001	CPE	SF	1.4	16.00	VERO	32.00	1.99	10/ 5/88
AVS-0001	CPE	SF	1.05	26.10	VERO	32.00	1.22	10/ 6/88
AVS-0001	CPE	SF	1.05	26.10	VERO	10.00	0.38	10/ 6/88
AVS-0001	CPE	SF	1.5	14.70	VERO	32.00	2.17	10/12/88
AVS-0001	CPE	SF	2.2	7.10	VERO	32.00	4.48	10/12/88
AVS-0001	CPE	SF	1.80	7.80	VERO	32.00	4.10	10/13/88
AVS-0001	CPE	SF	1.65	8.30	VERO	10.00	1.20	10/13/88
AVS-0001	CPE	VEE	1.2	23.80	VERO	10.00	0.42	4/13/87
AVS-0001	CPE	VEE	3.45	0.26	VERO	1.00	3.80	4/29/87
AVS-0001	CPE	VEE	1.95	7.40	VERO	3.20	0.43	5/ 5/87
AVS-0001	CPE	VEE	2.35	3.06	VERO	3.20	1.04	5/ 6/87
AVS-0001	CPE	VEE	2.35	4.04	VERO	10.00	2.46	5/ 7/87
AVS-0001	CPE	VEE	2.15	4.94	VERO	10.00	2.02	5/ 8/87
AVS-0001	CPE	VEE	2.	7.30	VERO	10.00	1.36	5/11/87
AVS-0001	CPE	VEE	2.2	4.49	VERO	10.00	2.22	5/12/87
AVS-0001	CPE	VEE	2.1	28.00	VERO	100.00	3.56	5/13/87
AVS-0001	CPE	VEE	1.35	17.80	VERO	32.00	1.79	5/14/87
AVS-0001	CPE	VEE	2.05	8.80	VERO	32.00	3.62	5/15/87
AVS-0001	CPE	VEE	2.5	5.70	VERO	32.00	5.54	5/18/87
AVS-0001	CPE	VEE	2.5	11.20	VERO	100.00	8.88	5/19/87
AVS-0001	CPE	VEE	1.5	19.90	VERO	32.00	1.60	5/20/87
AVS-0001	CPE	VEE	2.15	8.80	VERO	32.00	3.62	5/21/87
AVS-0001	CPE	VEE	1.3	22.60	VERO	32.00	1.41	5/27/87
AVS-0001	CPE	VEE	2.9	11.80	VERO	100.00	8.46	5/28/87
AVS-0001	CPE	VEE	0.65	49.80	VERO	32.00	0.64	11/11/87
AVS-0001	CPE	VEE	1.	28.20	VERO	32.00	1.13	11/12/87
AVS-0001	CPE	VEE	0.45	77.40	VERO	32.00	0.47	11/13/87
AVS-0001	CPE	VEE	0.45	68.30	VERO	32.00	0.47	11/13/87
AVS-0001	CPE	VEE	0.5	69.30	VERO	32.00	0.46	11/13/87
AVS-0001	CPE	VEE	0.5	69.80	VERO	32.00	0.46	11/13/87
AVS-0001	CPE	VEE	0.4	75.10	VERO	32.00	0.43	11/13/87
AVS-0001	CPE	VEE	0.6	57.20	VERO	32.00	0.56	11/13/87
AVS-0001	CPE	VEE	0.45	68.30	VERO	32.00	0.47	11/19/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0001	CPE	VEE	0.5	70.90	VERO	10.00	0.14	11/25/87
AVS-0001	CPE	VEE	0.8	26.60	VERO	10.00	0.37	11/25/87
AVS-0001	CPE	VEE	0.9	21.70	VERO	10.00	0.46	11/25/87
AVS-0001	CPE	VEE	0.45	68.30	VERO	32.00	0.47	11/25/87
AVS-0001	CPE	VEE	0.7	43.20	VERO	10.00	0.23	11/25/87
AVS-0001	CPE	VEE	0.2	----	VERO	10.00	----	11/25/87
AVS-0001	CPE	VEE	0.2	----	VERO	32.00	----	12/ 1/87
AVS-0001	CPE	VEE	0.65	50.50	VERO	32.00	0.63	12/ 2/87
AVS-0001	CPE	VEE	0.6	56.50	VERO	32.00	0.57	12/ 3/87
AVS-0001	CPE	VEE	0.05	----	VERO	32.00	----	12/ 3/87
AVS-0001	CPE	VEE	0.65	53.70	VERO	32.00	0.60	12/ 3/87
AVS-0001	CPE	VEE	0.6	56.50	VERO	32.00	0.56	12/ 3/87
AVS-0001	CPE	VEE	----	----	VERO	32.00	----	12/ 3/87
AVS-0001	CPE	VEE	0.7	50.40	VERO	32.00	0.63	12/ 3/87
AVS-0001	CPE	VEE	1.05	26.10	VERO	32.00	1.22	12/ 7/87
AVS-0001	CPE	VEE	1.	42.50	VERO	100.00	2.35	12/30/87
AVS-0001	CPE	VEE	1.05	26.10	VERO	32.00	1.22	12/30/87
AVS-0001	CPE	VEE	1.	25.50	VERO	32.00	1.25	12/30/87
AVS-0001	CPE	VEE	1.1	24.50	VERO	32.00	1.30	12/30/87
AVS-0001	CPE	VEE	1.05	26.10	VERO	32.00	1.22	12/30/87
AVS-0001	CPE	VEE	1.15	22.20	VERO	32.00	1.43	12/30/87
AVS-0001	CPE	VEE	0.55	63.20	VERO	32.00	0.50	1/ 4/88
AVS-0001	CPE	VEE	0.75	35.90	VERO	10.00	0.28	1/18/88
AVS-0001	CPE	VEE	1.05	24.90	VERO	10.00	0.40	3/15/88
AVS-0001	CPE	VEE	0.95	34.10	VERO	32.00	0.94	3/16/88
AVS-0001	CPE	VEE	1.15	20.60	VERO	10.00	0.48	3/17/88
AVS-0001	CPE	VEE	0.45	86.80	VERO	100.00	1.15	3/21/88
AVS-0001	CPE	VEE	0.7	43.00	VERO	10.00	0.23	3/22/88
AVS-0001	CPE	VEE	1.4	44.80	VERO	100.00	2.22	3/30/88
AVS-0001	CPE	VEE	0.2	----	VERO	32.00	----	3/31/88
AVS-0001	CPE	VEE	0.55	64.20	VERO	3.20	0.05	4/ 5/88
AVS-0001	CPE	VEE	----	----	VERO	32.00	----	4/ 6/88
AVS-0001	CPE	VEE	0.15	----	VERO	32.00	----	4/12/88
AVS-0001	CPE	VEE	0.35	84.90	VERO	32.00	0.38	4/12/88
AVS-0001	CPE	VEE	0.4	86.80	VERO	32.00	0.37	4/13/88
AVS-0001	CPE	VEE	0.15	----	VERO	10.00	----	4/13/88
AVS-0001	CPE	VEE	0.35	84.90	VERO	32.00	0.38	4/19/88
AVS-0001	CPE	VEE	0.75	36.00	VERO	10.00	0.28	4/20/88
AVS-0001	CPE	VEE	0.4	75.10	VERO	100.00	1.33	4/26/88
AVS-0001	CPE	VEE	0.25	----	VERO	32.00	----	4/27/88
AVS-0001	CPE	VEE	0.45	68.30	VERO	32.00	0.47	4/29/88
AVS-0001	CPE	VEE	0.15	----	VERO	100.00	----	5/ 3/88
AVS-0001	CPE	VEE	0.6	56.40	VERO	32.00	0.57	5/ 4/88
AVS-0001	CPE	VEE	0.1	----	VERO	32.00	----	5/10/88
AVS-0001	CPE	VEE	0.1	----	VERO	32.00	----	5/11/88
AVS-0001	CPE	VEE	0.45	68.30	VERO	32.00	0.47	5/17/88
AVS-0001	CPE	VEE	0.45	68.30	VERO	10.00	0.15	5/18/88
AVS-0001	CPE	VEE	0.55	64.20	VERO	32.00	0.50	5/24/88
AVS-0001	CPE	VSV	1.25	77.10	L929	32.00	0.41	6/24/86
AVS-0001	CPE	VSV	1.3	53.70	L929	100.00	1.86	10/13/87
AVS-0001	CPE	VSV	1.1	77.90	L929	10.00	0.13	11/ 6/87
AVS-0001	CPE	VSV	1.3	53.70	L929	100.00	1.86	11/13/87
AVS-0001	CPE	VSV	1.2	56.50	L929	32.00	0.57	11/17/87
AVS-0001	CPE	VSV	1.2	56.50	L929	32.00	0.57	11/17/87
AVS-0001	CPE	VSV	1.15	73.00	L929	100.00	1.36	11/17/87
AVS-0001	CPE	VSV	1.15	73.00	L929	10.00	0.14	11/17/87
AVS-0001	CPE	VSV	1.25	56.50	L929	100.00	1.76	11/17/87
AVS-0001	CPE	VSV	1.35	53.70	L929	32.00	0.60	11/20/87
AVS-0001	CPE	VSV	1.1	77.90	L929	32.00	0.41	12/ 1/87
AVS-0001	CPE	VSV	1.3	50.40	L929	32.00	0.63	12/ 1/87
AVS-0001	CPE	VSV	1.25	53.70	L929	32.00	0.60	12/ 1/87
AVS-0001	CPE	VSV	1.2	56.50	L929	32.00	0.57	12/ 1/87
AVS-0001	CPE	VSV	1.25	53.70	L929	32.00	0.60	12/ 1/87
AVS-0001	CPE	VSV	1.15	73.00	L929	100.00	1.36	12/ 4/87
AVS-0001	CPE	VSV	1.1	77.90	L929	32.00	0.41	12/ 4/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0001	CPE	VSV	1.25	56.50	L929	100.00	1.76	12/ 4/87
AVS-0001	CPE	VSV	1.05	83.00	L929	32.00	0.38	12/ 4/87
AVS-0001	CPE	VSV	1.2	56.50	L929	32.00	0.57	12/ 4/87
AVS-0001	CPE	VSV	1.15	73.00	L929	100.00	1.36	12/18/87
AVS-0001	CPE	VSV	0.9	80.70	L929	100.00	1.23	12/18/87
AVS-0001	CPE	VSV	1.05	83.00	L929	32.00	0.38	12/18/87
AVS-0001	CPE	VSV	1.2	56.50	L929	100.00	1.76	12/18/87
AVS-0001	CPE	VSV	1.2	56.50	L929	100.00	1.76	12/18/87
AVS-0001	CPE	VSV	1.9	29.70	L929	100.00	3.36	1/ 5/88
AVS-0001	CPE	VSV	1.6	28.50	L929	100.00	3.50	1/ 5/88
AVS-0001	CPE	VSV	1.4	50.40	L929	100.00	1.98	1/ 5/88
AVS-0001	CPE	VSV	1.6	42.50	L929	100.00	2.35	1/ 5/88
AVS-0001	CPE	VSV	1.7	35.10	L929	100.00	2.84	1/ 5/88
AVS-0001	CPE	VSV	1.2	56.50	L929	32.00	0.57	1/19/88
AVS-0001	CPE	VSV	1.1	77.90	L929	100.00	1.28	1/22/88
AVS-0001	CPE	VSV	1.1	77.90	L929	100.00	1.28	1/29/88
AVS-0001	CPE	VSV	1.15	73.00	L929	32.00	0.44	2/ 2/88
AVS-0001	CPE	VSV	1.25	53.70	L929	32.00	0.60	2/ 5/88
AVS-0001	CPE	VSV	0.8	113.00	L929	100.00	0.88	2/12/88
AVS-0001	CPE	VSV	0.5	242.00	L929	100.00	0.41	2/16/88
AVS-0001	CPE	VSV	1.2	56.50	L929	32.00	0.56	2/19/88
AVS-0001	CPE	VSV	1.2	56.50	L929	32.00	0.57	2/23/88
AVS-0001	CPE	VV	2.1	150.00	VERO >	320.00 >	2.12	7/31/86
AVS-0001	CPE	YFV	0.8	73.40	VERO	100.00	1.36	5/13/87
AVS-0001	CPE	YFV	0.7	81.30	VERO	100.00	1.22	5/18/87
AVS-0001	CPE	YFV	0.6	93.10	VERO	100.00	1.07	5/19/87
AVS-0001	CPE	YFV	0.75	50.50	VERO	100.00	1.97	10/ 6/87
AVS-0001	CPE	YFV	1.2	31.70	VERO	100.00	3.15	3/15/88
AVS-0001	CPE	YFV	0.65	50.70	VERO	32.00	0.63	3/16/88
AVS-0001	CPE	YFV	0.7	56.40	VERO	32.00	0.57	3/17/88
AVS-0001	CPE	YFV	0.75	46.70	VERO	32.00	0.68	3/21/88
AVS-0001	CPE	YFV	0.7	50.40	VERO	32.00	0.63	3/22/88
AVS-0001	CPE	YFV	0.7	50.40	VERO	32.00	0.63	3/30/88
AVS-0001	CPE	YFV	0.75	46.70	VERO	32.00	0.68	3/31/88
AVS-0001	CPE	YFV	0.65	35.80	VERO	32.00	0.89	4/ 5/88
AVS-0001	CPE	YFV	0.75	56.40	VERO	100.00	1.77	4/12/88
AVS-0001	CPE	YFV	1.05	26.10	VERO	32.00	1.22	4/12/88
AVS-0001	CPE	YFV	0.5	69.80	VERO	32.00	0.46	4/13/88
AVS-0001	CPE	YFV	0.75	46.70	VERO	10.00	0.21	4/13/88
AVS-0001	CPE	YFV	1.4	15.90	VERO	32.00	2.00	4/20/88
AVS-0001	CPE	YFV	0.45	68.30	VERO	100.00	1.46	4/26/88
AVS-0001	CPE	YFV	0.55	69.80	VERO	100.00	1.43	4/27/88
AVS-0001	CPE	YFV	0.7	50.40	VERO	32.00	0.63	4/29/88
AVS-0001	CPE	YFV	0.45	68.30	VERO	100.00	1.46	5/ 3/88
AVS-0001	CPE	YFV	1.05	26.10	VERO	32.00	1.22	5/ 4/88
AVS-0001	CPE	YFV	0.65	62.90	VERO	100.00	1.58	5/10/88
AVS-0001	CPE	YFV	0.75	56.40	VERO	100.00	1.77	5/11/88
AVS-0001	CPE	YFV	0.45	68.30	VERO	32.00	0.47	5/17/88
AVS-0001	CPE	YFV	0.5	69.80	VERO	32.00	0.46	5/18/88
AVS-0001	CPE	YFV	0.45	68.30	VERO	32.00	0.47	5/24/88
AVS-0002	CPE	AD2	0.7	----	HEP2 >	320.00	----	10/13/88
AVS-0002	CPE	VSV	----	----	L929 >	320.00	----	11/18/88
AVS-0002	CPE	VV	0.3	----	VERO >	320.00	----	10/13/88
AVS-0015	CPE	PT	4.25	18.20	VERO >	320.00 >	17.50	9/19/86
AVS-0015	PR	PT	N/A	37.90	VERO	100.00	2.63	5/12/87
AVS-0033	CPE	AD2	0.30	----	HEP2 <	100.00	----	9/18/86
AVS-0033	CPE	JE	0.25	----	VERO	32.00	----	3/12/87
AVS-0033	CPE	PIC	----	240.00	VERO <	100.00	0.42	1/ 9/87
AVS-0033	PR	PIC	N/A	----	VERO	3.20	----	1/16/87
AVS-0033	CPE	PT	1.20	32.00	VERO	100.00	3.13	10/17/86
AVS-0033	CPE	PT	0.3	----	VERO <	32.00	----	5/20/88
AVS-0033	CPE	SF	3.36	13.30	VERO	32.00	2.41	10/28/86
AVS-0033	CPE	SF	1.30	----	VERO	10.00	----	12/ 1/86
AVS-0033	CPE	VEE	----	----	VERO	10.00	----	5/ 6/87
AVS-0033	CPE	VV	0.6	100.00	VERO <	320.00 <	3.20	7/24/86

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0033	CPE	YFV	0.10	----	VERO <	32.00	----	1/20/87
AVS-0052	CPE	AD2	0.15	----	HEP2	1.00	----	9/25/86
AVS-0052	CPE	JE	0.95	77.40	VERO	100.00	1.29	3/20/87
AVS-0052	PR	PIC	N/A	----	VERO >	100.00	----	3/ 2/ 87
AVS-0052	PR	PIC	N/A	----	VERO	100.00	----	5/16/88
AVS-0052	CPE	PT	0.54	262.00	VERO	100.00	0.38	10/29/86
AVS-0052	CPE	PT	1.25	57.30	VERO	10.00	0.17	5/20/88
AVS-0052	CPE	SF	0.75	----	VERO	32.00	----	11/24/86
AVS-0052	CPE	VEE	----	----	VERO	100.00	----	5/14/87
AVS-0052	CPE	VSV	0.35	----	L929	32.00	----	6/24/86
AVS-0052	CPE	VV	0.4	----	VERO	100.00	----	7/31/86
AVS-0052	CPE	YFV	----	----	VERO	32.00	----	1/29/87
AVS-0052	CPE	YFV	0.6	32.00	VERO	3.20	0.10	5/17/88
AVS-0064	CPE	AD2	0.30	----	HEP2 >	320.00	----	9/11/86
AVS-0064	CPE	JE	----	----	VERO >	320.00	----	3/27/87
AVS-0064	CPE	PIC	----	----	VERO	10.00	----	12/ 5/86
AVS-0064	PR	PIC	N/A	----	VERO >	100.00	----	5/16/88
AVS-0064	CPE	PT	1.95	68.00	VERO	320.00	4.70	9/19/86
AVS-0064	CPE	SF	1.4	----	VERO >	320.00	----	10/ 8/86
AVS-0064	CPE	SF	0.84	----	VERO >	100.00	----	11/24/86
AVS-0064	CPE	VEE	----	----	VERO >	100.00	----	4/13/87
AVS-0064	CPE	VSV	----	----	L929 >	320.00	----	6/13/86
AVS-0064	CPE	VV	----	----	L929 >	320.00	----	6/12/86
AVS-0064	CPE	VV	----	----	VERO >	320.00	----	7/17/86
AVS-0064	CPE	YFV	0.24	----	VERO >	320.00	----	1/13/87
AVS-0065	CPE	AD2	0.65	----	HEP2	10.00	----	9/18/86
AVS-0065	CPE	JE	1.20	3.10	VERO	3.20	1.03	3/12/87
AVS-0065	CPE	JE	----	----	VERO	3.20	----	5/20/88
AVS-0065	CPE	PIC	----	16.60	VERO	3.20	0.19	1/ 9/87
AVS-0065	PR	PIC	N/A	29.30	VERO	32.00	1.09	5/16/88
AVS-0065	CPE	PT	2.01	15.90	VERO	32.00	2.01	10/23/86
AVS-0065	CPE	SF	2.61	0.98	VERO	3.20	3.27	10/28/86
AVS-0065	CPE	SF	0.60	----	VERO >	1.00	----	12/ 1/86
AVS-0065	CPE	SF	1.4	5.70	VERO	3.20	0.56	5/17/88
AVS-0065	CPE	VEE	----	----	VERO	10.00	----	5/ 6/87
AVS-0065	CPE	VSV	----	----	L929	320.00	----	6/20/86
AVS-0065	CPE	VV	0.4	100.00	VERO	10.00	0.10	7/24/86
AVS-0065	CPE	YFV	0.55	29.70	VERO	10.00	0.34	1/20/87
AVS-0068	CPE	AD2	----	----	HEP2	100.00	----	9/11/86
AVS-0068	CPE	JE	0.75	72.00	VERO	100.00	1.39	3/ 9/87
AVS-0068	CPE	JE	----	----	VERO	100.00	----	5/24/88
AVS-0068	CPE	PIC	----	112.00	VERO >	320.00 >	2.85	1/ 5/87
AVS-0068	CPE	PT	2.4	2.40	VERO <	32.00 <	13.30	9/19/86
AVS-0068	CPE	PT	0.3	----	VERO >	10.00	----	11/18/86
AVS-0068	CPE	PT	----	----	VERO >	10.00	----	8/21/87
AVS-0068	CPE	PT	0.1	----	VERO >	10.00	----	9/21/87
AVS-0068	CPE	SF	1.6 <	0.32	VERO -	0.32 -	1.00	10/ 8/86
AVS-0068	CPE	VEE	0.15	30.60	VERO	32.00	1.04	4/13/87
AVS-0068	CPE	VSV	----	----	L929	320.00	----	6/13/86
AVS-0068	CPE	VV	0.6	82.10	L929	100.00	1.21	6/12/86
AVS-0068	CPE	VV	----	----	VERO	320.00	----	7/17/86
AVS-0068	CPE	YFV	0.07	----	VERO	10.00	----	1/13/87
AVS-0070	CPE	AD2	1.30 <	0.32	HEP2 -	0.32 >	1.00	9/11/86
AVS-0070	CPE	AD2	2.35	0.05	HEP2	0.32	5.33	9/25/86
AVS-0070	CPE	JE	2.74	1.41	VERO	3.20	2.25	7/ 9/87
AVS-0070	CPE	JE	1.05	5.80	VERO	1.00	0.17	5/20/88
AVS-0070	PR	PIC	N/A	----	VERO	32.00	----	12/11/87
AVS-0070	PR	PIC	N/A	----	VERO	32.00	----	5/16/88
AVS-0070	CPE	PT	1.2	19.30	VERO	32.00	1.65	12/17/87
AVS-0070	CPE	VSV	----	----	L929	1.00	----	6/13/86
AVS-0070	CPE	VV	0.55 <	0.32	L929 -	0.32 >	1.00	6/12/86
AVS-0070	CPE	VV	0.3	100.00	VERO	100.00	1.00	7/17/86
AVS-0071	CPE	AD2	0.25	----	HEP2	100.00	----	9/18/86
AVS-0071	CPE	JE	----	----	VERO	100.00	----	3/12/87
AVS-0071	CPE	PIC	----	173.00	VERO	100.00	0.57	1/ 9/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0071	PR	PIC	N/A	----	VERO	32.00	----	1/16/87
AVS-0071	CPE	PT	0.60	32.00	VERO <	100.00 <	3.13	10/23/86
AVS-0071	CPE	PT	0.5	70.80	VERO	10.00	0.14	5/20/88
AVS-0071	CPE	SF	3.69	15.90	VERO >	100.00 >	6.28	10/28/86
AVS-0071	CPE	SF	1.95	1.43	VERO <	0.32 <	0.22	5/17/88
AVS-0071	CPE	VEE	----	----	VERO >	1.00	----	5/ 6/87
AVS-0071	CPE	VSV	----	----	L929 <	320.00	----	6/20/86
AVS-0071	CPE	VV	1.7	81.40	VERO	320.00	3.93	7/24/86
AVS-0071	CPE	VV	1.9	57.50	VERO	320.00	5.56	5/26/88
AVS-0071	CPE	YFV	----	----	VERO	100.00	----	1/21/87
AVS-0078	CPE	AD2	----	----	HEP2	10.00	----	9/18/86
AVS-0078	CPE	JE	1.00	3.10	VERO	3.20	1.03	3/12/87
AVS-0078	CPE	JE	----	----	VERO	0.32	----	5/20/88
AVS-0078	CPE	PIC	----	23.80	VERO	0.32	0.01	1/ 9/87
AVS-0078	CPE	PT	0.51	7.50	VERO	10.00	1.05	10/23/86
AVS-0078	CPE	SF	1.74	3.21	VERO	1.00	0.31	10/28/86
AVS-0078	CPE	SF	----	----	VERO	1.00	----	5/17/88
AVS-0078	CPE	VEE	----	----	VERO	3.20	----	5/ 6/87
AVS-0078	CPE	VSV	0.6	29.80	L929	32.00	1.07	6/20/86
AVS-0078	CPE	VV	0.6	8.50	VERO	10.00	1.17	7/24/86
AVS-0078	CPE	YFV	----	----	VERO	0.32	----	1/21/87
AVS-0078	CPE	YFV	0.5	1.00	VERO	1.00	1.00	5/17/88
AVS-0079	CPE	AD2	1.30	2.30	HEP2 <	10.00 <	4.35	9/11/86
AVS-0079	CPE	AD2	2.1	0.83	HEP2	3.20	3.85	2/ 4/88
AVS-0079	CPE	JE	0.65	23.80	VERO	3.20	0.13	3/ 9/87
AVS-0079	CPE	JE	0.52	16.70	VERO	1.00	0.06	1/27/88
AVS-0079	CPE	JE	0.5	22.10	VERO	3.20	0.14	5/20/88
AVS-0079	CPE	PIC	----	----	VERO	0.10	----	1/ 5/87
AVS-0079	PR	PIC	N/A	----	VERO >	0.10	----	2/12/88
AVS-0079	PR	PIC	N/A	8.30	VERO	3.20	0.38	5/17/88
AVS-0079	CPE	PT	1.7	----	VERO >	100.00	----	9/19/86
AVS-0079	CPE	PT	1.1	23.80	VERO	10.00	0.42	11/18/86
AVS-0079	CPE	SF	5.45	0.70	VERO >	100.00 >	101.00	10/ 8/86
AVS-0079	CPE	SF	1.05	72.20	VERO	10.00	0.14	7/27/87
AVS-0079	CPE	SF	2.05	3.83	VERO	1.00	0.26	5/17/88
AVS-0079	CPE	VEE	0.6	100.00	VERO	3.20	0.03	4/13/87
AVS-0079	CPE	VEE	----	----	VERO	10.00	----	1/29/88
AVS-0079	CPE	VSV	0.75	9.80	L929	10.00	1.02	6/13/86
AVS-0079	CPE	VSV	0.1	----	L929	10.00	----	1/29/88
AVS-0079	CPE	VV	1.4	1.00	L929	3.20	3.18	6/12/86
AVS-0079	CPE	VV	1.7	32.00	VERO	100.00	3.12	7/17/86
AVS-0079	CPE	VV	1.05	112.00	VERO	100.00	0.89	2/ 4/88
AVS-0079	CPE	VV	1.65	98.00	VERO	320.00	3.25	5/26/88
AVS-0079	CPE	YFV	2.06	15.20	VERO	100.00	6.54	1/13/87
AVS-0079	CPE	YFV	0.3	----	VERO	10.00	----	2/ 4/88
AVS-0084	CPE	AD2	----	----	HEP2	32.00	----	9/11/86
AVS-0084	CPE	JE	2.20	7.70	VERO	32.00	4.13	3/ 9/87
AVS-0084	CPE	JE	1.5	21.70	VERO	10.00	0.46	6/ 1/88
AVS-0084	CPE	PIC	----	----	VERO	100.00	----	1/ 5/87
AVS-0084	PR	PIC	N/A	172.00	VERO	320.00	1.86	6/ 3/88
AVS-0084	CPE	PT	1.9	66.40	VERO <	320.00 <	4.81	9/19/86
AVS-0084	CPE	SF	4.4	2.03	VERO <	320.00 <	157.00	10/ 7/86
AVS-0084	CPE	SF	0.22	80.90	VERO	100.00	1.24	11/20/86
AVS-0084	CPE	SF	1.15	17.10	VERO	1.00	0.06	7/27/87
AVS-0084	CPE	SF	1.85	15.80	VERO	10.00	0.63	6/ 1/88
AVS-0084	CPE	VEE	0.3	320.00	VERO	320.00	1.00	4/13/87
AVS-0084	CPE	VSV	0.4	----	L929	100.00	----	6/13/86
AVS-0084	CPE	VV	0.2	----	L929	32.00	----	6/12/86
AVS-0084	CPE	VV	0.6	298.00	VERO	320.00	1.07	7/17/86
AVS-0084	CPE	YFV	1.20	25.60	VERO	100.00	3.90	1/13/87
AVS-0087	CPE	AD2	0.30	----	HEP2	320.00	----	9/18/86
AVS-0087	CPE	JE	0.13	----	VERO	100.00	----	3/12/87
AVS-0087	CPE	JE	0.05	----	VERO	32.00	----	5/20/88
AVS-0087	CPE	PIC	----	35.30	VERO	32.00	0.90	1/ 9/87
AVS-0087	PR	PIC	N/A	----	VERO	32.00	----	5/17/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0087	CPE	PT	1.05	36.40	VERO	100.00	2.74	10/23/86
AVS-0087	CPE	SF	0.60	9.30	VERO	10.00	1.08	10/28/86
AVS-0087	CPE	VEE	0.75	----	VERO	10.00	----	5/ 6/87
AVS-0087	CPE	VSV	----	----	L929	100.00	----	6/20/86
AVS-0087	CPE	VV	----	----	VERO	320.00	----	7/24/86
AVS-0087	CPE	YFV	0.75	100.00	VERO	100.00	1.00	1/21/87
AVS-0087	CPE	YFV	----	----	VERO	32.00	----	5/17/88
AVS-0094	CPE	AD2	1.10	231.00	HEP2	320.00	1.38	9/11/86
AVS-0094	CPE	AD2	1.	222.00	HEP2 >	320.00 >	1.44	4/21/88
AVS-0094	CPE	JE	1.80	19.30	VERO >	100.00 >	5.18	3/ 9/87
AVS-0094	CPE	JE	2.8	18.20	VERO	100.00	5.48	1/29/88
AVS-0094	CPE	JE	0.45	246.00	VERO	32.00	0.13	5/ 4/88
AVS-0094	CPE	JE	0.6	56.40	VERO	10.00	0.18	5/20/88
AVS-0094	CPE	PIC	----	43.50	VERO	100.00	2.29	1/ 6/87
AVS-0094	PR	PIC	N/A	30.20	VERO >	100.00 >	3.30	2/12/88
AVS-0094	PR	PIC	N/A	56.30	VERO	100.00	1.77	5/17/88
AVS-0094	CPE	PT	3.	10.00	VERO >	320.00 >	32.00	9/19/86
AVS-0094	CPE	PT	0.7	----	VERO	100.00	----	11/10/86
AVS-0094	PR	PT	N/A	130.00	VERO	320.00	2.46	5/12/87
AVS-0094	CPE	PT	0.15	----	VERO	100.00	----	8/21/87
AVS-0094	CPE	PT	----	----	VERO	320.00	----	9/18/87
AVS-0094	CPE	PT	----	----	VERO	32.00	----	5/ 4/88
AVS-0094	CPE	PT	----	----	VERO	32.00	----	5/20/88
AVS-0094	CPE	SF	4.65	1.00	VERO >	320.00 >	320.00	10/ 8/86
AVS-0094	CPE	SF	0.4	----	VERO	32.00	----	8/18/87
AVS-0094	CPE	SF	----	----	VERO	100.00	----	5/ 4/88
AVS-0094	CPE	SF	1.6	99.00	VERO >	100.00 >	1.00	5/17/88
AVS-0094	CPE	VEE	0.9	32.00	VERO	10.00	0.31	4/13/87
AVS-0094	CPE	VEE	0.6	57.00	VERO	10.00	0.17	1/29/88
AVS-0094	CPE	VEE	----	----	VERO	10.00	----	5/ 4/88
AVS-0094	CPE	VSV	----	----	L929	10.00	----	6/13/86
AVS-0094	CPE	VSV	----	----	L929 >	320.00	----	3/18/88
AVS-0094	CPE	VV	1.3	----	L929 >	320.00	----	6/12/86
AVS-0094	CPE	VV	----	----	VERO >	320.00	----	7/17/86
AVS-0094	CPE	VV	1.4	257.00	VERO	320.00	1.24	4/21/88
AVS-0094	CPE	YFV	2.03	37.80	VERO	320.00	8.44	1/13/87
AVS-0094	CPE	YFV	1.05	83.00	VERO	100.00	1.20	2/ 4/88
AVS-0094	CPE	YFV	0.15	----	VERO	10.00	----	5/ 4/88
AVS-0094	CPE	YFV	0.6	178.00	VERO	32.00	0.18	5/17/88
AVS-0095	CPE	AD2	0.80	----	HEP2	320.00	----	9/18/86
AVS-0095	CPE	AD2	0.1	----	HEP2 >	320.00	----	10/27/88
AVS-0095	CPE	JE	----	----	VERO >	100.00	----	3/12/87
AVS-0095	PR	PIC	N/A	9.10	VERO >	100.00 >	10.90	1/13/87
AVS-0095	PR	PIC	N/A	----	VERO	100.00	----	5/16/88
AVS-0095	CPE	PT	1.89	16.00	VERO	100.00	6.23	10/23/86
AVS-0095	CPE	PT	----	----	VERO	10.00	----	5/20/88
AVS-0095	CPE	SF	1.15	12.90	VERO	100.00	7.73	12/15/86
AVS-0095	CPE	VEE	0.1	----	VERO >	100.00	----	5/ 6/87
AVS-0095	CPE	VSV	----	----	L929 >	320.00	----	6/20/86
AVS-0095	CPE	VSV	----	----	L929 >	320.00	----	11/18/88
AVS-0095	CPE	VV	----	----	VERO	100.00	----	7/24/86
AVS-0095	CPE	VV	0.1	----	VERO	100.00	----	10/27/88
AVS-0095	CPE	YFV	----	----	VERO	100.00	----	1/21/87
AVS-0096	CPE	AD2	----	----	HEP2 <	10.00	----	9/18/86
AVS-0096	CPE	JE	----	----	VERO >	100.00	----	3/12/87
AVS-0096	PR	PIC	N/A	----	VERO	0.32	----	1/13/87
AVS-0096	CPE	PT	0.96	410.00	VERO	32.00	0.08	10/21/86
AVS-0096	CPE	SF	0.09	206.00	VERO <	100.00 <	0.48	10/14/86
AVS-0096	CPE	VEE	0.52	----	VERO	100.00	----	5/ 6/87
AVS-0096	CPE	VSV	----	----	L929	100.00	----	6/20/86
AVS-0096	CPE	VV	----	----	VERO <	320.00	----	7/24/86
AVS-0096	CPE	YFV	----	----	VERO	32.00	----	1/21/87
AVS-0103	CPE	AD2	----	----	HEP2 >	320.00	----	9/25/86
AVS-0103	CPE	JE	----	----	VERO >	320.00	----	3/20/87
AVS-0103	PR	PIC	N/A	----	VERO >	320.00	----	3/ 2/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MT50	TI	DATE
AVS-0103	CPE	SF	----	----	VERO >	320.00	----	11/25/86
AVS-0103	CPE	VEE	----	----	VERO >	320.00	----	5/14/87
AVS-0103	CPE	VSV	----	----	L929	100.00	----	6/24/86
AVS-0103	CPE	VV	----	----	VERO >	320.00	----	7/31/86
AVS-0103	CPE	YFV	----	----	VERO	320.00	----	1/29/87
AVS-0105	CPE	AD2	----	----	HEP2	3.20	----	9/25/86
AVS-0105	CPE	JE	----	----	VERO	10.00	----	3/20/87
AVS-0105	PR	PIC	N/A	----	VERO <	10.00	----	3/ 2/87
AVS-0105	CPE	PT	0.75	66.00	VERO	32.00	0.48	10/29/86
AVS-0105	CPE	SF	0.90	29.80	VERO	32.00	1.07	11/24/86
AVS-0105	CPE	VEE	----	----	VERO	32.00	----	5/14/87
AVS-0105	CPE	VSV	0.03	----	L929	100.00	----	6/24/86
AVS-0105	CPE	VV	----	----	VERO <	320.00	----	7/31/86
AVS-0105	CPE	YFV	----	----	VERO	32.00	----	1/29/87
AVS-0111	CPE	AD2	0.6	320.00	HEP2 >	320.00 >	1.00	6/30/88
AVS-0111	CPE	JE	1.05	83.00	VERO	32.00	0.38	7/ 6/88
AVS-0111	CPE	PT	0.5	222.00	VERO	32.00	0.14	7/ 6/88
AVS-0111	CPE	SF	1.75	72.50	VERO	32.00	0.44	7/ 6/88
AVS-0111	CPE	VSV	1.5	80.60	L929	3.20	0.04	6/22/88
AVS-0111	CPE	VV	0.8	320.00	VERO	320.00	1.00	6/30/88
AVS-0111	CPE	YFV	1.54	48.40	VERO	100.00	2.06	7/ 6/88
AVS-0113	CPE	AD2	0.20	----	HEP2 <	100.00	----	9/11/86
AVS-0113	CPE	JE	----	----	VERO	100.00	----	3/ 9/87
AVS-0113	CPE	PIC	----	45.10	VERO	100.00	2.22	1/ 6/87
AVS-0113	CPE	PT	2.	3.20	VERO <	32.00 <	10.00	9/19/86
AVS-0113	CPE	PT	----	----	VERO <	100.00	----	8/21/87
AVS-0113	CPE	PT	0.2	----	VERO <	100.00	----	9/21/87
AVS-0113	CPE	PT	----	----	VERO	32.00	----	6/ 1/88
AVS-0113	CPE	SF	1.98	39.80	VERO	10.00	0.25	10/21/86
AVS-0113	CPE	SF	----	----	VERO	32.00	----	11/26/86
AVS-0113	CPE	VSV	----	----	L929	320.00	----	6/13/86
AVS-0113	CPE	VV	0.7	97.00	L929 >	100.00	1.02	6/12/86
AVS-0113	CPE	VV	----	----	VERO <	100.00	----	7/17/86
AVS-0113	CPE	YFV	1.20	27.00	VERO <	100.00 <	3.70	1/14/87
AVS-0122	CPE	AD2	1.65	1.73	HEP2	3.20	1.84	9/25/86
AVS-0122	CPE	JE	3.	2.00	VERO	3.20	1.59	3/20/87
AVS-0122	CPE	JE	1.45	9.50	VERO	1.00	0.10	5/24/88
AVS-0122	PR	PIC	N/A	----	VERO	3.20	----	3/ 2/87
AVS-0122	CPE	PT	0.60	182.00	VERO	100.00	0.55	10/27/86
AVS-0122	CPE	VEE	----	----	VERO	10.00	----	5/14/87
AVS-0122	CPE	VSV	1.3	75.10	L929	3.20	0.04	6/24/86
AVS-0122	CPE	VV	2.05	10.00	VERO	32.00	3.20	7/31/86
AVS-0122	CPE	YFV	1.00	58.00	VERO	1.00	0.17	1/29/87
AVS-0132	CPE	AD2	----	----	HEP2	100.00	----	9/25/86
AVS-0132	CPE	JE	----	----	VERO >	320.00	----	3/20/87
AVS-0132	PR	PIC	N/A	----	VERO >	100.00	----	3/20/87
AVS-0132	CPE	SF	0.80	6.90	VERO	3.20	0.46	11/24/86
AVS-0132	CPE	VEE	----	----	VERO >	100.00	----	5/14/87
AVS-0132	CPE	VSV	----	----	L929	32.00	----	6/27/86
AVS-0132	CPE	VV	----	----	VERO	320.00	----	7/31/86
AVS-0132	CPE	YFV	----	----	VERO	100.00	----	1/29/87
AVS-0136	CPE	AD2	1.25	96.00	HEP2	320.00	3.29	9/25/86
AVS-0136	CPE	AD2	1.2	178.00	HEP2 >	320.00 >	1.78	5/19/88
AVS-0136	CPE	AD2	1.	200.00	HEP2 >	320.00 >	1.59	5/26/88
AVS-0136	CPE	JE	2.1	30.60	VERO	320.00	10.40	3/20/87
AVS-0136	CPE	JE	1.9	94.40	VERO >	320.00 >	3.38	7/28/87
AVS-0136	CPE	JE	----	----	VERO	100.00	----	12/ 7/87
AVS-0136	CPE	JE	----	----	VERO >	320.00	----	1/29/88
AVS-0136	CPE	JE	0.7	121.00	VERO	86.00	0.71	5/ 4/88
AVS-0136	CPE	JE	1.05	83.00	VERO	100.00	1.20	5/18/88
AVS-0136	PR	PIC	N/A	198.00	VERO >	320.00 >	1.61	3/20/87
AVS-0136	CPE	PT	1.50	83.50	VERO >	320.00 >	3.83	10/27/86
AVS-0136	CPE	PT	0.55	171.00	VERO	86.00	0.50	5/ 4/88
AVS-0136	CPE	PT	0.1	----	VERO	26.00	----	5/20/88
AVS-0136	CPE	SF	----	----	VERO >	320.00	----	11/18/86

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0136	CPE	SF	----	----	VERO >	100.00	----	11/21/86
AVS-0136	CPE	SF	0.45	186.00	VERO	86.00	0.46	5/ 4/88
AVS-0136	CPE	VEE	0.15	----	VERO	32.00	----	5/14/87
AVS-0136	CPE	VEE	----	----	VERO	32.00	----	1/29/88
AVS-0136	CPE	VEE	0.1	----	VERO	86.00	----	5/ 4/88
AVS-0136	CPE	VSV	0.2	----	L929	320.00	----	6/27/86
AVS-0136	CPE	VSV	0.3	----	L929	100.00	----	3/18/88
AVS-0136	CPE	VV	0.15	----	VERO	320.00	----	7/31/86
AVS-0136	CPE	VV	0.9	306.00	VERO >	320.00 >	1.04	5/19/88
AVS-0136	CPE	YFV	1.20	66.80	VERO	100.00	1.50	1/29/87
AVS-0136	CPE	YFV	----	----	VERO >	100.00	----	2/ 4/88
AVS-0136	CPE	YFV	0.65	145.00	VERO	86.00	0.59	5/ 4/88
AVS-0138	CPE	AD2	1.05	95.00	HEP2	100.00	1.03	9/11/86
AVS-0138	CPE	JE	----	----	VERO	32.00	----	3/ 9/87
AVS-0138	CPE	PIC	----	----	VERO >	320.00	----	12/12/86
AVS-0138	CPE	PT	1.1	----	VERO >	320.00	----	9/19/86
AVS-0138	CPE	PT	----	----	VERO	320.00	----	11/18/86
AVS-0138	CPE	VSV	----	----	L929	32.00	----	6/13/86
AVS-0138	CPE	VV	3.1	8.80	L929	100.00	11.30	6/12/86
AVS-0138	CPE	VV	3.8	19.90	VERO >	320.00 >	16.00	7/17/86
AVS-0138	CPE	YFV	3.65	38.90	VERO >	320.00 >	8.22	1/14/87
AVS-0138	CPE	YFV	----	----	VERO >	100.00	----	11/30/87
AVS-0138	CPE	YFV	----	----	VERO >	100.00	----	12/ 2/87
AVS-0138	CPE	YFV	----	----	VERO	100.00	----	12/ 4/87
AVS-0138	CPE	YFV	----	----	VERO	100.00	----	12/ 8/87
AVS-0138	CPE	YFV	----	----	VERO	10.00	----	5/18/88
AVS-0139	CPE	AD2	----	----	HEP2 <	0.32	----	9/11/86
AVS-0139	CPE	JE	0.6	0.09	VERO	0.10	1.03	4/ 1/87
AVS-0139	CPE	PIC	----	15.40	VERO >	320.00 >	20.70	12/12/86
AVS-0139	CPE	PIC	----	3.17	VERO >	32.00 >	10.20	1/ 6/87
AVS-0139	CPE	PT	1.63	0.70	VERO	0.32	0.46	9/19/86
AVS-0139	CPE	SF	1.80 <	----	VERO	1.00	1000.00	10/ 8/86
AVS-0139	CPE	SF	1.30	0.97	VERO	0.32	0.33	11/24/86
AVS-0139	CPE	SF	0.25	----	VERO	0.32	----	8/18/87
AVS-0139	CPE	SF	0.4	0.86	VERO	0.10	0.12	5/18/88
AVS-0139	CPE	VSV	1.55	31.50	L929	3.20	0.10	6/13/86
AVS-0139	CPE	VV	1.3	1.80	L929	3.20	1.77	6/12/86
AVS-0139	CPE	VV	2.7	1.04	VERO	1.00	0.96	7/17/86
AVS-0139	CPE	YFV	2.15	0.12	VERO	0.32	2.49	1/14/87
AVS-0139	CPE	YFV	0.95	1.16	VERO	0.32	0.28	5/18/88
AVS-0140	CPE	AD2	----	----	HEP2 <	0.01	----	6/16/88
AVS-0140	CPE	JE	0.7	0.09	VERO	0.10	1.04	4/ 9/87
AVS-0140	CPE	JE	0.15	----	VERO	0.32	----	1/29/88
AVS-0140	CPE	JE	----	----	VERO <	0.03	----	5/ 4/88
AVS-0140	CPE	JE	0.3	----	VERO	0.10	----	5/20/88
AVS-0140	PR	PIC	N/A	0.48	VERO >	100.00 >	108.00	3/20/87
AVS-0140	PR	PIC	N/A	1.17	VERO	1.00	0.85	2/12/88
AVS-0140	PR	PIC	N/A	0.21	VERO	0.32	1.45	5/17/88
AVS-0140	CPE	PT	0.30	1.00	VERO	1.00	1.00	10/27/86
AVS-0140	CPE	PT	0.95	0.84	VERO	0.32	0.38	5/ 4/88
AVS-0140	CPE	SF	0.51	0.08	VERO	1.00	12.50	10/29/86
AVS-0140	CPE	SF	1.25	2.02	VERO	0.32	0.16	5/ 4/88
AVS-0140	CPE	VEE	----	----	VERO	0.32	----	5/14/87
AVS-0140	CPE	VEE	----	----	VERO <	0.32	----	1/29/88
AVS-0140	CPE	VEE	----	----	VERO <	0.03	----	5/ 4/88
AVS-0140	CPE	VSV	0.15	----	L929	10.00	----	3/18/88
AVS-0140	CPE	VV	1.8	1.77	VERO	1.00	0.56	5/19/88
AVS-0140	CPE	YFV	0.35	20.50	VERO	10.00	0.49	1/29/87
AVS-0140	CPE	YFV	0.25	----	VERO	0.10	----	2/ 4/88
AVS-0140	CPE	YFV	1.4	0.48	VERO	0.10	0.21	5/ 4/88
AVS-0140	CPE	YFV	1.4	1.01	VERO	1.00	0.99	5/17/88
AVS-0142	CPE	AD2	----	----	HEP2	320.00	----	9/25/86
AVS-0142	CPE	JE	----	----	VERO >	320.00	----	3/20/87
AVS-0142	CPE	JE	0.05	----	VERO	320.00	----	5/24/88
AVS-0142	PR	PIC	N/A	----	VERO >	320.00	----	3/20/87

8-21

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0142	CPE	SF	----	----	VERO >	100.00	----	11/19/86
AVS-0142	CPE	VEE	----	----	VERO	100.00	----	5/14/87
AVS-0142	CPE	VSV	----	----	L929	320.00	----	6/27/86
AVS-0142	CPE	VV	----	----	VERO >	320.00	----	7/31/86
AVS-0142	CPE	YFV	0.08	----	VERO	100.00	----	1/29/87
AVS-0147	CPE	AD2	----	----	HEP2	32.00	----	9/25/86
AVS-0147	CPE	JE	----	----	VERO	32.00	----	3/20/87
AVS-0147	PR	PIC	N/A	----	VERO	32.00	----	3/20/87
AVS-0147	PR	PIC	N/A	----	VERO	10.00	----	5/17/88
AVS-0147	CPE	SF	0.99	258.00	VERO	100.00	0.39	10/29/86
AVS-0147	CPE	VEE	----	----	VERO	32.00	----	12/ 1/87
AVS-0147	CPE	VSV	----	----	L929	10.00	----	6/27/86
AVS-0147	CPE	VV	0.3	----	VERO	10.00	----	7/31/86
AVS-0147	CPE	YFV	----	----	VERO	10.00	----	1/30/87
AVS-0148	CPE	AD2	0.90	0.09	HEP2	0.10	1.11	9/25/86
AVS-0148	CPE	JE	2.91	0.72	VERO	1.00	1.39	3/12/87
AVS-0148	PR	PIC	N/A	0.66	VERO >	100.00	150.00	1/13/87
AVS-0148	PR	PIC	N/A	0.17	VERO	100.00	588.00	1/30/87
AVS-0148	CPE	PT	6.30	0.32	VERO <	320.00	1000.00	10/21/86
AVS-0148	PR	PT	N/A	0.10	VERO	100.00	1000.00	5/12/87
AVS-0148	PR	PT	N/A	0.37	VERO >	1.00	2.66	6/17/87
AVS-0148	CPE	PT	1.2	0.31	VERO	1.00	3.15	8/21/87
AVS-0148	CPE	PT	2.25	0.83	VERO	1.00	1.20	5/20/88
AVS-0148	CPE	SF	3.78	1.34	VERO	32.00	23.70	10/14/86
AVS-0148	CPE	SF	4.05	0.24	VERO	3.20	12.90	11/18/86
AVS-0148	CPE	SF	3.90	0.29	VERO	1.00	3.36	12/15/86
AVS-0148	CPE	SF	0.55	0.69	VERO	1.00	1.43	8/18/87
AVS-0148	CPE	SF	4.8	0.31	VERO	1.00	3.15	5/17/88
AVS-0148	CPE	VEE	----	----	VERO	1.00	----	5/ 6/87
AVS-0148	CPE	VEE	1.35	16.70	VERO <	0.10	0.01	5/17/88
AVS-0148	CPE	VSV	2.6	0.32	L929	0.32	1.00	6/20/86
AVS-0148	CPE	VSV	2.7	2.20	L929	1.00	0.45	8/15/86
AVS-0148	CPE	VV	5.4	1.00	VERO	100.00	100.00	7/24/86
AVS-0148	CPE	VV	3.5	0.79	VERO	3.20	4.05	5/26/88
AVS-0148	CPE	YFV	3.30	0.88	VERO	3.20	3.59	1/22/87
AVS-0148	CPE	YFV	2.4	0.17	VERO	0.32	1.78	5/17/88
AVS-0181	CPE	AD2	----	----	HEP2 >	320.00	----	9/18/86
AVS-0181	CPE	JE	----	----	VERO >	100.00	----	3/12/87
AVS-0181	CPE	JE	----	----	VERO	320.00	----	5/24/88
AVS-0181	PR	PIC	N/A	----	VERO >	320.00	----	1/13/87
AVS-0181	PR	PIC	N/A	----	VERO >	1.00	----	2/ 3/87
AVS-0181	CPE	PT	0.39	788.00	VERO >	320.00	0.41	10/21/86
AVS-0181	CPE	SF	----	----	VERO	320.00	----	11/18/86
AVS-0181	CPE	SF	----	----	VERO >	320.00	----	11/21/86
AVS-0181	CPE	SF	----	----	VERO >	320.00	----	11/24/86
AVS-0181	CPE	VEE	----	----	VERO	320.00	----	5/ 6/87
AVS-0181	CPE	VSV	----	----	L929	32.00	----	6/20/86
AVS-0181	CPE	VV	----	----	VERO >	320.00	----	7/24/86
AVS-0181	CPE	YFV	----	----	VERO >	320.00	----	1/22/87
AVS-0195	CPE	AD2	1.40	217.00	HEP2 >	320.00	1.47	9/25/86
AVS-0195	CPE	JE	----	----	VERO	320.00	----	3/20/87
AVS-0195	PR	PIC	N/A	----	VERO >	100.00	----	3/23/87
AVS-0195	CPE	PT	0.51	351.00	VERO >	100.00	0.28	10/28/86
AVS-0195	CPE	SF	----	----	VERO >	32.00	----	11/19/86
AVS-0195	CPE	VEE	----	----	VERO	100.00	----	12/ 1/87
AVS-0195	CPE	VSV	----	----	L929	100.00	----	6/27/86
AVS-0195	CPE	VV	----	----	VERO	100.00	----	7/31/86
AVS-0195	CPE	YFV	----	----	VERO	100.00	----	1/30/87
AVS-0197	CPE	AD2	----	----	HEP2 >	320.00	----	9/25/86
AVS-0197	PR	PIC	N/A	----	VERO	100.00	----	12/ 4/87
AVS-0197	CPE	PT	1.71	61.00	VERO >	320.00	5.24	10/30/86
AVS-0197	CPE	PT	1.5	134.00	VERO >	320.00	2.37	5/18/88
AVS-0197	CPE	SF	3.39	59.00	VERO >	320.00	5.42	10/29/86
AVS-0197	CPE	SF	1.35	64.10	VERO	100.00	1.55	5/18/88
AVS-0197	CPE	VEE	0.8	----	VERO >	320.00	----	5/14/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0197	CPE	VSV	----	----	L929	100.00	----	8/ 1/86
AVS-0197	CPE	VV	----	----	VERO >	320.00	----	8/ 7/86
AVS-0197	CPE	YFV	0.10	----	VERO	320.00	----	2/ 2/87
AVS-0199	CPE	JE	1.28	102.00	VERO	320.00	3.12	3/23/87
AVS-0199	CPE	JE	----	----	VERO	100.00	----	8/ 3/87
AVS-0199	CPE	PT	1.44	25.50	VERO	100.00	3.92	10/21/86
AVS-0199	CPE	SF	0.1	-	VERO	3.20	----	8/ 3/87
AVS-0199	CPE	YFV	----	----	VERO	10.00	----	8/ 3/87
AVS-0200	CPE	AD2	0.20	----	HEP2 <	32.00	----	9/18/86
AVS-0200	CPE	JE	----	----	VERO	100.00	----	3/12/87
AVS-0200	CPE	JE	----	----	VERO	100.00	----	5/20/88
AVS-0200	PR	PIC	N/A	----	VERO <	100.00	----	1/13/87
AVS-0200	PR	PIC	N/A	----	VERO	1.00	----	5/17/88
AVS-0200	CPE	PT	2.10	12.30	VERO	100.00	8.10	10/21/86
AVS-0200	CPE	PT	0.35	84.90	VERO	32.00	0.38	5/20/88
AVS-0200	CPE	SF	1.14	12.50	VERO >	100.00 >	7.98	10/14/86
AVS-0200	CPE	SF	0.15	----	VERO	100.00	----	11/17/86
AVS-0200	CPE	SF	----	----	VERO >	100.00	----	5/17/88
AVS-0200	CPE	VEE	0.15	----	VERO	10.00	----	5/ 6/87
AVS-0200	CPE	VSV	0.1	----	L929	100.00	----	6/20/86
AVS-0200	CPE	VV	0.95	52.40	VERO	100.00	1.90	7/24/86
AVS-0200	CPE	YFV	----	----	VERO >	100.00	----	1/22/87
AVS-0202	CPE	AD2	----	----	HEP2	320.00	----	9/25/86
AVS-0202	CPE	JE	1.1	122.00	VERO	320.00	2.62	3/23/87
AVS-0202	PR	PIC	N/A	297.00	VERO >	320.00 >	1.07	3/23/87
AVS-0202	CPE	PT	1.89	72.40	VERO	320.00	4.42	10/28/86
AVS-0202	CPE	PT	----	----	VERO >	320.00	----	5/20/88
AVS-0202	CPE	VEE	----	----	VERO	100.00	----	12/ 1/87
AVS-0202	CPE	VSV	----	----	L929	100.00	----	6/27/86
AVS-0202	CPE	VV	0.45	306.00	VERO	320.00	1.04	7/31/86
AVS-0202	CPE	YFV	0.69	82.10	VERO <	0.32	----	1/30/87
AVS-0206	CPE	AD2	0.75	238.00	HEP2	320.00	1.34	9/25/86
AVS-0206	CPE	JE	1.75	108.00	VERO >	320.00 >	2.95	3/23/87
AVS-0206	CPE	JE	0.6	178.00	VERO	100.00	0.56	5/24/88
AVS-0206	CPE	PT	2.70	43.00	VERO >	320.00 >	7.43	10/28/86
AVS-0206	CPE	PT	1.44	56.50	VERO	320.00	5.66	10/30/86
AVS-0206	CPE	SF	3.69	8.60	VERO	320.00	36.90	10/29/86
AVS-0206	CPE	SF	2.2	21.60	VERO	100.00	4.62	8/ 7/87
AVS-0206	CPE	VEE	0.95	135.00	VERO	320.00	2.35	5/14/87
AVS-0206	CPE	VSV	0.55	295.00	L929	100.00	0.34	7/18/86
AVS-0206	CPE	VV	1.2	85.30	VERO	100.00	1.17	8/ 7/86
AVS-0206	CPE	YFV	1.35	115.00	VERO	320.00	2.75	1/30/87
AVS-0206	CPE	YFV	0.60	297.00	VERO	320.00	1.07	2/ 2/87
AVS-0206	CPE	YFV	0.45	217.00	VERO	100.00	0.46	5/24/88
AVS-0215	CPE	AD2	2.25	9.50	HEP2	10.00	1.05	9/11/86
AVS-0215	CPE	JE	3.40	0.57	VERO	3.20	5.55	3/ 9/87
AVS-0215	CPE	JE	1.05	26.10	VERO	10.00	0.38	8/31/87
AVS-0215	CPE	JE	1.05	1.59	VERO	1.00	0.63	5/20/88
AVS-0215	CPE	PIC	----	2.20	VERO >	100.00 >	45.40	12/12/86
AVS-0215	PR	PIC	N/A	1.19	VERO	1.00	0.83	5/17/88
AVS-0215	CPE	PT	2.65	2.20	VERO	3.20	1.45	10/ 3/86
AVS-0215	CPE	PT	2.35	0.70	VERO	1.00	1.42	9/24/87
AVS-0215	CPE	SF	2.04	1.08	VERO	1.00	0.93	10/10/86
AVS-0215	CPE	SF	3.75	0.33	VERO	1.00	3.03	5/17/88
AVS-0215	CPE	VSV	2.1	10.00	L929	3.20	0.32	6/13/86
AVS-0215	CPE	VSV	1.05	21.10	L929	1.00	0.05	5/24/88
AVS-0215	CPE	VV	2.95	2.80	L929	10.00	3.57	6/12/86
AVS-0215	CPE	VV	4.2	0.70	VERO	3.20	4.57	7/17/86
AVS-0215	CPE	VV	3.25	0.83	VERO	3.20	3.84	5/26/88
AVS-0215	CPE	YFV	2.31	2.59	VERO	3.20	1.23	1/14/87
AVS-0215	CPE	YFV	2.85	0.83	VERO	1.00	1.20	5/17/88
AVS-0222	CPE	AD2	----	----	HEP2 <	100.00	----	9/25/86
AVS-0222	CPE	JE	----	----	VERO	320.00	----	3/23/87
AVS-0222	PR	PIC	N/A	----	VERO >	100.00	----	4/ 3/87
AVS-0222	CPE	VEE	----	----	VERO >	100.00	----	5/14/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0222	CPE	VSV	----	----	L929	100.00	----	7/18/86
AVS-0222	CPE	VV	----	----	VERO	100.00	----	8/ 7/86
AVS-0222	CPE	YFV	----	----	VERO	100.00	----	2/ 2/87
AVS-0222	CPE	YFV	----	----	VERO	100.00	----	5/18/88
AVS-0225	CPE	AD2	0.1	----	HEP2 >	320.00	----	10/27/88
AVS-0225	CPE	VSV	----	----	L929 >	320.00	----	11/18/88
AVS-0225	CPE	VV	----	----	VERO >	320.00	----	10/27/88
AVS-0228	CPE	AD2	0.20	----	HEP2	10.00	----	9/11/86
AVS-0228	CPE	JE	0.15	----	VERO	100.00	----	3/ 9/87
AVS-0228	CPE	PIC	----	28.40	VERO	32.00	1.13	12/12/86
AVS-0228	CPE	PT	----	----	VERO <	32.00	----	10/ 3/86
AVS-0228	CPE	SF	0.39	31.90	VERO	32.00	1.00	10/10/86
AVS-0228	CPE	SF	0.30	----	VERO	32.00	----	11/24/86
AVS-0228	CPE	VSV	----	----	L929	32.00	----	6/13/86
AVS-0228	CPE	VV	0.25	----	L929	100.00	----	6/12/86
AVS-0228	CPE	VV	----	----	VERO	32.00	----	7/17/86
AVS-0228	CPE	YFV	0.88	67.40	VERO	32.00	0.47	1/14/87
AVS-0230	CPE	AD2	1.30	66.40	HEP2 >	100.00 >	1.51	9/11/86
AVS-0230	CPE	AD2	0.80	----	HEP2	320.00	----	9/18/86
AVS-0230	CPE	JE	2.10	6.40	VERO	32.00	4.92	3/ 9/87
AVS-0230	CPE	JE	1.6	39.30	VERO	100.00	2.53	5/18/88
AVS-0230	CPE	PIC	----	9.80	VERO	320.00	32.60	12/12/86
AVS-0230	PR	PIC	N/A	71.00	VERO	320.00	4.50	5/17/88
AVS-0230	CPE	PT	1.45	100.00	VERO	100.00	1.00	10/ 3/86
AVS-0230	CPE	SF	2.19	34.10	VERO	100.00	2.93	10/10/86
AVS-0230	CPE	SF	0.40	31.90	VERO	32.00	1.00	11/24/86
AVS-0230	CPE	VSV	2.05	9.10	L929	3.20	0.35	6/13/86
AVS-0230	CPE	VV	0.4	0.79	L929	1.00	1.25	6/12/86
AVS-0230	CPE	VV	0.85	66.40	VERO	100.00	1.05	7/17/86
AVS-0230	CPE	YFV	2.03	27.90	VERO	100.00	3.57	1/15/87
AVS-0230	CPE	YFV	1.95	11.70	VERO	10.00	0.85	5/17/88
AVS-0245	CPE	AD2	----	----	HEP2	320.00	----	9/25/86
AVS-0245	CPE	JE	0.23	----	VERO	320.00	----	3/23/87
AVS-0245	CPE	JE	----	----	VERO	320.00	----	1/29/88
AVS-0245	CPE	JE	----	----	VERO	320.00	----	5/25/88
AVS-0245	PR	PIC	N/A	----	VERO	100.00	----	4/ 3/87
AVS-0245	CPE	SF	1.41	1245.00	VERO >	100.00 >	0.08	10/29/86
AVS-0245	CPE	SF	0.95	98.00	VERO	100.00	1.02	12/ 1/86
AVS-0245	CPE	VEE	0.6	297.00	VERO	32.00	0.11	5/15/87
AVS-0245	CPE	VSV	----	----	L929	100.00	----	7/18/86
AVS-0245	CPE	VV	0.25	----	VERO	320.00	----	8/ 7/86
AVS-0245	CPE	YFV	0.52	229.00	VERO	320.00	1.39	2/ 2/87
AVS-0253	CPE	AD2	1.55	8.10	HEP2	32.00	3.95	9/11/86
AVS-0253	CPE	AD2	1.35	7.50	HEP2	10.00	1.33	9/18/86
AVS-0253	CPE	AD2	1.70	9.70	HEP2	32.00	3.29	9/25/86
AVS-0253	CPE	AD2	1.50	9.60	HEP2	32.00	3.33	10/ 2/86
AVS-0253	CPE	AD2	1.35	9.60	HEP2	32.00	3.33	10/ 9/86
AVS-0253	CPE	AD2	1.95	8.10	HEP2	32.00	3.95	10/16/86
AVS-0253	CPE	AD2	1.25	9.70	HEP2	32.00	3.29	10/23/86
AVS-0253	CPE	AD2	1.4	50.70	HEP2	32.00	0.63	10/30/86
AVS-0253	CPE	AD2	1.59	7.80	HEP2	32.00	4.06	11/ 6/86
AVS-0253	CPE	AD2	0.84	12.70	HEP2	10.00	0.78	11/13/86
AVS-0253	CPE	AD2	1.44	7.50	HEP2	32.00	4.23	11/20/86
AVS-0253	CPE	AD2	1.86	10.30	HEP2	32.00	3.10	12/ 4/86
AVS-0253	CPE	AD2	1.20	30.60	HEP2	32.00	1.03	12/11/86
AVS-0253	CPE	AD2	1.20	31.80	HEP2	32.00	1.00	12/18/86
AVS-0253	CPE	AD2	1.10	9.60	HEP2	10.00	1.03	1/ 8/87
AVS-0253	CPE	AD2	1.40	10.20	HEP2	32.00	3.11	1/29/87
AVS-0253	CPE	AD2	1.40	35.60	HEP2	100.00	2.80	2/ 5/87
AVS-0253	CPE	AD2	1.40	14.40	HEP2	32.00	2.21	2/12/87
AVS-0253	CPE	AD2	1.10	32.10	HEP2	32.00	1.00	3/12/87
AVS-0253	CPE	AD2	1.15	30.80	HEP2	32.00	1.03	4/10/87
AVS-0253	CPE	AD2	1.4	20.20	HEP2	32.00	1.57	4/24/87
AVS-0253	CPE	AD2	1.35	33.30	HEP2	32.00	0.96	5/ 7/87
AVS-0253	CPE	AD2	2.05	14.90	HEP2	32.00	2.14	5/14/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MT50	TI	DATE
AVS-0253	CPE	AD2	1.45	38.30	HEP2	32.00	0.83	5/21/87
AVS-0253	CPE	AD2	1.33	18.40	HEP2	32.00	1.73	5/28/87
AVS-0253	CPE	AD2	0.95	56.10	HEP2	100.00	1.78	6/ 4/87
AVS-0253	CPE	AD2	1.4	17.40	HEP2	32.00	1.83	6/11/87
AVS-0253	CPE	AD2	1.5	19.70	HEP2	32.00	1.62	6/18/87
AVS-0253	CPE	AD2	1.25	21.10	HEP2	32.00	1.51	6/25/87
AVS-0253	CPE	AD2	1.45	36.70	HEP2	32.00	0.87	7/ 2/87
AVS-0253	CPE	AD2	1.7	15.00	HEP2	32.00	2.12	7/ 9/87
AVS-0253	CPE	AD2	1.75	14.20	HEP2	100.00	7.03	7/16/87
AVS-0253	CPE	AD2	1.4	53.20	HEP2	32.00	0.60	7/30/87
AVS-0253	CPE	AD2	1.3	16.90	HEP2	32.00	1.88	8/ 6/87
AVS-0253	CPE	AD2	1.45	13.50	HEP2	32.00	2.36	8/13/87
AVS-0253	CPE	AD2	1.65	4.47	HEP2	10.00	2.23	8/20/87
AVS-0253	CPE	AD2	1.5	20.30	HEP2	100.00	4.92	8/27/87
AVS-0253	CPE	AD2	1.1	46.70	HEP2	100.00	2.13	9/ 4/87
AVS-0253	CPE	AD2	1.05	100.00	HEP2	32.00	0.32	9/24/87
AVS-0253	CPE	AD2	0.85	100.00	HEP2	32.00	0.32	9/24/87
AVS-0253	CPE	AD2	0.8	157.00	HEP2	32.00	0.20	9/24/87
AVS-0253	CPE	AD2	0.85	133.00	HEP2	32.00	0.24	9/24/87
AVS-0253	CPE	AD2	0.9	109.00	HEP2	32.00	0.29	9/24/87
AVS-0253	CPE	AD2	1.15	18.40	HEP2	32.00	1.73	10/ 8/87
AVS-0253	CPE	AD2	1.45	14.30	HEP2	32.00	2.22	10/ 8/87
AVS-0253	CPE	AD2	1.3	17.30	HEP2	32.00	1.84	10/ 8/87
AVS-0253	CPE	AD2	1.5	55.40	HEP2	100.00	1.80	10/22/87
AVS-0253	CPE	AD2	1.75	40.50	HEP2	100.00	2.46	10/22/87
AVS-0253	CPE	AD2	1.55	57.30	HEP2	100.00	1.74	10/22/87
AVS-0253	CPE	AD2	1.65	46.70	HEP2	100.00	2.13	10/22/87
AVS-0253	CPE	AD2	1.85	34.10	HEP2	100.00	2.92	10/22/87
AVS-0253	CPE	AD2	1.9	27.70	HEP2	32.00	1.15	10/29/87
AVS-0253	CPE	AD2	1.8	31.00	HEP2	32.00	1.03	10/29/87
AVS-0253	CPE	AD2	1.65	30.60	HEP2	32.00	1.04	10/29/87
AVS-0253	CPE	AD2	1.5	55.90	HEP2	32.00	0.57	10/29/87
AVS-0253	CPE	AD2	1.7	37.00	HEP2	32.00	0.86	10/29/87
AVS-0253	CPE	AD2	2.05	14.30	HEP2	32.00	2.22	11/ 5/87
AVS-0253	CPE	AD2	1.4	17.40	HEP2	32.00	1.83	11/12/87
AVS-0253	CPE	AD2	1.85	13.10	HEP2	100.00	7.63	12/10/87
AVS-0253	CPE	AD2	2.3	20.00	HEP2	100.00	4.98	12/17/87
AVS-0253	CPE	AD2	1.6	24.50	HEP2	100.00	4.07	12/31/87
AVS-0253	CPE	AD2	2.	15.90	HEP2	100.00	6.27	1/ 8/88
AVS-0253	CPE	AD2	2.5	15.90	HEP2	100.00	6.27	1/14/88
AVS-0253	CPE	AD2	2.35	17.10	HEP2	100.00	5.84	1/21/88
AVS-0253	CPE	AD2	1.6	25.60	HEP2	100.00	3.90	1/28/88
AVS-0253	CPE	AD2	2.	14.30	HEP2	100.00	6.95	2/ 4/88
AVS-0253	CPE	AD2	1.8	17.80	HEP2	100.00	5.58	2/11/88
AVS-0253	CPE	AD2	1.95	21.70	HEP2	100.00	4.60	2/18/88
AVS-0253	CPE	AD2	1.55	41.10	HEP2	100.00	2.43	2/25/88
AVS-0253	CPE	AD2	1.95	13.10	HEP2	32.00	2.43	3/ 3/88
AVS-0253	CPE	AD2	1.75	22.40	HEP2	32.00	1.42	3/10/88
AVS-0253	CPE	AD2	1.45	45.70	HEP2	100.00	2.18	3/17/88
AVS-0253	CPE	AD2	2.05	26.10	HEP2	100.00	3.81	3/24/88
AVS-0253	CPE	AD2	1.55	43.80	HEP2	100.00	2.27	3/31/88
AVS-0253	CPE	AD2	1.4	50.90	HEP2	100.00	1.96	4/14/88
AVS-0253	CPE	AD2	1.75	30.30	HEP2	100.00	3.29	4/21/88
AVS-0253	CPE	AD2	2.1	20.90	HEP2	100.00	4.77	4/29/88
AVS-0253	CPE	AD2	2.05	20.30	HEP2	100.00	4.91	5/ 5/88
AVS-0253	CPE	AD2	2.1	26.10	HEP2	100.00	3.81	5/12/88
AVS-0253	CPE	AD2	2.	45.70	HEP2	320.00	6.99	5/19/88
AVS-0253	CPE	AD2	1.9	25.50	HEP2	100.00	3.91	5/26/88
AVS-0253	CPE	AD2	2.05	20.30	HEP2	100.00	4.92	6/ 2/88
AVS-0253	CPE	AD2	1.35	57.10	HEP2	100.00	1.74	6/16/88
AVS-0253	CPE	AD2	1.35	57.10	HEP2	100.00	1.74	6/16/88
AVS-0253	CPE	AD2	1.75	36.60	HEP2	100.00	2.72	6/23/88
AVS-0253	CPE	AD2	1.45	49.40	HEP2	100.00	2.02	6/30/88
AVS-0253	CPE	AD2	1.8	12.40	HEP2	100.00	8.02	7/ 7/88
AVS-0253	CPE	AD2	1.95	24.00	HEP2	100.00	4.15	7/21/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0253	CPE	AD2	1.45	57.50	HEP2	100.00	1.73	8/18/88
AVS-0253	CPE	AD2	1.7	30.00	HEP2	100.00	3.32	8/25/88
AVS-0253	CPE	AD2	2.1	20.90	HEP2	100.00	4.77	9/ 1/88
AVS-0253	CPE	AD2	2.15	21.60	HEP2	100.00	4.61	10/ 6/88
AVS-0253	CPE	AD2	1.65	32.00	HEP2	100.00	3.12	10/13/88
AVS-0253	CPE	AD2	1.9	32.00	HEP2	320.00	10.00	10/27/88
AVS-0253	CPE	AD2	1.45	50.60	HEP2	100.00	1.97	11/ 3/88
AVS-0253	CPE	AD2	1.45	60.80	HEP2	320.00	5.25	11/10/88
AVS-0253	CPE	AD2	1.45	32.00	HEP2	100.00	3.12	11/17/88
AVS-0253	CPE	JE	3.85	0.23	VERO	3.20	13.40	3/ 9/87
AVS-0253	CPE	JE	3.19	2.03	VERO	10.00	4.91	3/11/87
AVS-0253	CPE	JE	3.60	1.00	VERO	10.00	9.98	3/12/87
AVS-0253	CPE	JE	4.25	0.21	VERO	10.00	47.30	3/12/87
AVS-0253	CPE	JE	3.3	1.22	VERO	10.00	8.15	3/17/87
AVS-0253	CPE	JE	3.8	0.70	VERO	10.00	14.20	3/18/87
AVS-0253	CPE	JE	2.45	1.32	VERO	10.00	7.53	3/19/87
AVS-0253	CPE	JE	4.6	0.29	VERO	10.00	33.60	3/20/87
AVS-0253	CPE	JE	4.1	0.65	VERO	10.00	15.20	3/23/87
AVS-0253	CPE	JE	2.19	2.06	VERO	32.00	15.50	3/24/87
AVS-0253	CPE	JE	0.26	2.72	VERO	10.00	3.66	3/25/87
AVS-0253	CPE	JE	2.87	2.19	VERO	10.00	4.55	3/26/87
AVS-0253	CPE	JE	2.87	1.50	VERO	10.00	6.65	3/27/87
AVS-0253	CPE	JE	2.4	1.95	VERO	10.00	5.11	4/ 1/87
AVS-0253	CPE	JE	2.65	1.03	VERO	3.20	3.08	4/ 2/87
AVS-0253	CPE	JE	2.9	2.00	VERO	10.00	4.98	4/ 3/87
AVS-0253	CPE	JE	3.	1.79	VERO	10.00	5.56	4/ 6/87
AVS-0253	CPE	JE	2.12	2.22	VERO	10.00	4.49	4/ 7/87
AVS-0253	CPE	JE	2.7	1.60	VERO	10.00	6.21	4/ 8/87
AVS-0253	CPE	JE	3.77	0.60	VERO	10.00	16.40	4/ 9/87
AVS-0253	CPE	JE	4.5	0.43	VERO	10.00	23.20	4/10/87
AVS-0253	CPE	JE	3.02	0.93	VERO	10.00	10.60	4/13/87
AVS-0253	CPE	JE	3.37	0.94	VERO	10.00	10.50	4/14/87
AVS-0253	CPE	JE	3.3	1.22	VERO	10.00	8.15	4/15/87
AVS-0253	CPE	JE	3.44	0.83	VERO	10.00	12.00	4/16/87
AVS-0253	CPE	JE	2.5	1.07	VERO	3.20	2.97	4/20/87
AVS-0253	CPE	JE	3.4	0.62	VERO	3.20	5.15	4/21/87
AVS-0253	CPE	JE	3.1	0.80	VERO	3.20	3.95	4/22/87
AVS-0253	CPE	JE	2.95	1.05	VERO	3.20	3.03	4/23/87
AVS-0253	CPE	JE	2.6	1.59	VERO	3.20	2.00	4/24/87
AVS-0253	CPE	JE	3.1	2.12	VERO	10.00	4.70	4/27/87
AVS-0253	CPE	JE	2.1	1.68	VERO	3.20	1.89	4/28/87
AVS-0253	CPE	JE	2.75	1.32	VERO	3.20	2.41	4/30/87
AVS-0253	CPE	JE	2.07	3.09	VERO	10.00	3.22	5/ 1/87
AVS-0253	CPE	JE	1.95	3.10	VERO	10.00	3.22	5/ 4/87
AVS-0253	CPE	JE	2.15	2.18	VERO	10.00	4.58	5/ 5/87
AVS-0253	CPE	JE	1.95	2.89	VERO	10.00	3.45	5/ 6/87
AVS-0253	CPE	JE	2.15	0.89	VERO	3.20	3.55	5/ 7/87
AVS-0253	CPE	JE	2.65	5.70	VERO	10.00	1.75	5/ 8/87
AVS-0253	CPE	JE	1.95	1.88	VERO	3.20	1.69	5/11/87
AVS-0253	CPE	JE	2.59	1.68	VERO	3.20	1.90	5/12/87
AVS-0253	CPE	JE	3.24	0.66	VERO	3.20	4.85	5/13/87
AVS-0253	CPE	JE	2.95	1.16	VERO	3.20	2.75	5/14/87
AVS-0253	CPE	JE	1.9	2.50	VERO	3.20	1.27	5/15/87
AVS-0253	CPE	JE	2.25	2.55	VERO	3.20	1.25	5/21/87
AVS-0253	CPE	JE	3.2	0.81	VERO	3.20	3.91	5/22/87
AVS-0253	CPE	JE	3.23	0.74	VERO	3.20	4.27	5/22/87
AVS-0253	CPE	JE	3.9	0.38	VERO	3.20	8.28	5/26/87
AVS-0253	CPE	JE	3.14	0.58	VERO	3.20	5.44	5/27/87
AVS-0253	CPE	JE	3.02	0.44	VERO	3.20	7.16	5/28/87
AVS-0253	CPE	JE	3.54	0.69	VERO	10.00	14.30	5/29/87
AVS-0253	CPE	JE	2.4	1.45	VERO	3.20	2.20	6/ 9/87
AVS-0253	CPE	JE	3.09	0.78	VERO	3.20	4.04	6/10/87
AVS-0253	CPE	JE	1.65	2.79	VERO	3.20	1.14	6/11/87
AVS-0253	CPE	JE	1.85	1.51	VERO	3.20	2.11	6/16/87
AVS-0253	CPE	JE	2.75	4.29	VERO	10.00	2.32	6/17/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0253	CPE	JE	2.3	2.04	VERO	3.20	1.56	6/18/87
AVS-0253	CPE	JE	2.54	1.19	VERO	3.20	2.67	6/19/87
AVS-0253	CPE	JE	1.7	2.53	VERO	3.20	1.24	6/24/87
AVS-0253	CPE	JE	1.95	2.69	VERO	3.20	1.18	6/25/87
AVS-0253	CPE	JE	2.05	2.32	VERO	3.20	1.37	6/29/87
AVS-0253	CPE	JE	3.17	1.87	VERO	10.00	5.32	6/30/87
AVS-0253	CPE	JE	2.69	0.97	VERO	3.20	3.27	7/ 1/87
AVS-0253	CPE	JE	2.65	1.43	VERO	3.20	2.22	7/ 2/87
AVS-0253	CPE	JE	3.7	0.58	VERO	3.20	5.50	7/ 6/87
AVS-0253	CPE	JE	3.1	0.80	VERO	3.20	3.99	7/ 7/87
AVS-0253	CPE	JE	2.6	2.80	VERO	10.00	3.56	7/ 8/87
AVS-0253	CPE	JE	3.79	0.25	VERO	3.20	12.30	7/ 9/87
AVS-0253	CPE	JE	3.49	0.48	VERO	3.20	6.55	7/10/87
AVS-0253	CPE	JE	2.45	1.33	VERO	3.20	2.39	7/13/87
AVS-0253	CPE	JE	2.05	3.76	VERO	3.20	0.85	7/14/87
AVS-0253	CPE	JE	2.1	1.92	VERO	3.20	1.66	7/15/87
AVS-0253	CPE	JE	2.7	1.41	VERO	3.20	2.26	7/16/87
AVS-0253	CPE	JE	2.15	2.97	VERO	3.20	1.07	7/17/87
AVS-0253	CPE	JE	2.25	1.32	VERO	3.20	2.40	7/20/87
AVS-0253	CPE	JE	2.5	1.78	VERO	3.20	1.78	7/20/87
AVS-0253	CPE	JE	3.	0.63	VERO	3.20	5.07	7/22/87
AVS-0253	CPE	JE	2.8	0.83	VERO	3.20	3.82	7/23/87
AVS-0253	CPE	JE	2.6	1.59	VERO	3.20	2.00	7/24/87
AVS-0253	CPE	JE	2.7	1.53	VERO	3.20	2.08	7/28/87
AVS-0253	CPE	JE	2.29	1.66	VERO	3.20	1.92	8/ 3/87
AVS-0253	CPE	JE	3.4	0.70	VERO	3.20	4.51	8/ 4/87
AVS-0253	CPE	JE	2.85	1.15	VERO	3.20	2.76	8/ 5/87
AVS-0253	CPE	JE	2.39	2.43	VERO	3.20	1.31	8/ 6/87
AVS-0253	CPE	JE	2.4	1.03	VERO	3.20	3.10	8/ 7/87
AVS-0253	CPE	JE	2.	2.85	VERO	3.20	1.11	8/11/87
AVS-0253	CPE	JE	2.19	1.29	VERO	3.20	2.46	8/11/87
AVS-0253	CPE	JE	2.	2.36	VERO	3.20	1.35	8/13/87
AVS-0253	CPE	JE	2.45	1.99	VERO	3.20	1.60	8/14/87
AVS-0253	CPE	JE	2.3	2.04	VERO	3.20	1.56	8/17/87
AVS-0253	CPE	JE	1.7	3.87	VERO	3.20	0.83	8/18/87
AVS-0253	CPE	JE	2.25	2.80	VERO	3.20	1.14	8/19/87
AVS-0253	CPE	JE	2.1	1.60	VERO	3.20	1.99	8/19/87
AVS-0253	CPE	JE	2.15	1.65	VERO	3.20	1.93	8/21/87
AVS-0253	CPE	JE	3.3	0.81	VERO	3.20	3.93	8/24/87
AVS-0253	CPE	JE	2.65	1.56	VERO	3.20	2.04	8/25/87
AVS-0253	CPE	JE	2.09	2.85	VERO	3.20	1.11	8/26/87
AVS-0253	CPE	JE	2.6	0.99	VERO	3.20	3.21	8/26/87
AVS-0253	CPE	JE	3.9	0.26	VERO	1.00	3.80	8/28/87
AVS-0253	CPE	JE	2.1	4.30	VERO	10.00	2.22	8/31/87
AVS-0253	CPE	JE	1.69	5.80	VERO	10.00	1.69	9/ 3/87
AVS-0253	CPE	JE	2.24	2.02	VERO	3.20	1.57	9/ 4/87
AVS-0253	CPE	JE	2.55	1.44	VERO	3.20	2.22	9/ 8/87
AVS-0253	CPE	JE	2.3	3.02	VERO	3.20	1.05	9/ 9/87
AVS-0253	CPE	JE	2.8	1.42	VERO	3.20	2.24	9/10/87
AVS-0253	CPE	JE	1.99	3.21	VERO	3.20	1.00	9/11/87
AVS-0253	CPE	JE	2.35	2.22	VERO	3.20	1.43	9/14/87
AVS-0253	CPE	JE	2.39	1.57	VERO	3.20	2.02	9/15/87
AVS-0253	CPE	JE	2.8	1.70	VERO	3.20	1.87	9/17/87
AVS-0253	CPE	JE	3.69	0.29	VERO	3.20	10.70	9/18/87
AVS-0253	CPE	JE	2.36	2.21	VERO	10.00	4.51	9/21/87
AVS-0253	CPE	JE	2.47	2.01	VERO	10.00	4.96	9/30/87
AVS-0253	CPE	JE	3.1	1.56	VERO	10.00	6.38	10/ 1/87
AVS-0253	CPE	JE	3.1	1.56	VERO	10.00	6.38	10/ 6/87
AVS-0253	CPE	JE	2.6	1.59	VERO	3.20	2.00	10/ 9/87
AVS-0253	CPE	JE	2.9	0.69	VERO	3.20	4.57	10/13/87
AVS-0253	CPE	JE	3.6	0.78	VERO	10.00	12.70	10/14/87
AVS-0253	CPE	JE	2.95	1.18	VERO	3.20	2.69	10/16/87
AVS-0253	CPE	JE	2.8	2.25	VERO	10.00	4.42	10/20/87
AVS-0253	CPE	JE	2.6	3.02	VERO	10.00	3.30	10/21/87
AVS-0253	CPE	JE	2.75	1.97	VERO	3.20	1.61	10/22/87

B-27

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0253	CPE	JE	2.35	2.22	VERO	3.20	1.43	10/23/87
AVS-0253	CPE	JE	3.2	0.88	VERO	3.20	3.61	10/26/87
AVS-0253	CPE	JE	3.3	0.81	VERO	3.20	3.93	10/28/87
AVS-0253	CPE	JE	3.4	0.91	VERO	3.20	3.49	10/29/87
AVS-0253	CPE	JE	3.15	0.95	VERO	3.20	3.35	11/ 2/87
AVS-0253	CPE	JE	2.65	1.56	VERO	3.20	2.04	11/ 3/87
AVS-0253	CPE	JE	3.	1.76	VERO	3.20	1.81	11/ 5/87
AVS-0253	CPE	JE	4.1	0.34	VERO	3.20	9.41	11/12/87
AVS-0253	CPE	JE	3.45	1.11	VERO	3.20	2.87	11/12/87
AVS-0253	CPE	JE	3.6	0.82	VERO	3.20	3.87	11/12/87
AVS-0253	CPE	JE	3.75	0.59	VERO	3.20	5.39	11/12/87
AVS-0253	CPE	JE	2.35	2.09	VERO	3.20	1.53	11/12/87
AVS-0253	CPE	JE	3.55	0.93	VERO	3.20	3.44	11/12/87
AVS-0253	CPE	JE	3.05	1.35	VERO	3.20	2.35	11/18/87
AVS-0253	CPE	JE	2.95	1.45	VERO	3.20	2.19	11/18/87
AVS-0253	CPE	JE	3.1	1.09	VERO	3.20	2.91	11/18/87
AVS-0253	CPE	JE	2.85	1.53	VERO	3.20	2.08	11/18/87
AVS-0253	CPE	JE	3.5	0.67	VERO	3.20	6.77	11/18/87
AVS-0253	CPE	JE	3.05	1.07	VERO	3.20	2.97	11/18/87
AVS-0253	CPE	JE	2.85	1.53	VERO	3.20	2.08	11/19/87
AVS-0253	CPE	JE	2.55	1.78	VERO	3.20	1.79	12/ 1/87
AVS-0253	CPE	JE	2.45	1.99	VERO	3.20	1.60	12/ 2/87
AVS-0253	CPE	JE	3.2	1.04	VERO	3.20	3.06	12/ 4/87
AVS-0253	CPE	JE	2.35	3.57	VERO	3.20	0.90	12/ 7/87
AVS-0253	CPE	JE	2.85	1.13	VERO	1.00	0.88	12/ 8/87
AVS-0253	CPE	JE	2.95	1.45	VERO	3.20	2.19	12/14/87
AVS-0253	CPE	JE	2.4	3.98	VERO	3.20	0.80	12/14/87
AVS-0253	CPE	JE	3.8	0.60	VERO	3.20	5.26	12/22/87
AVS-0253	CPE	JE	3.	1.26	VERO	3.20	2.53	12/29/87
AVS-0253	CPE	JE	3.5	0.76	VERO	3.20	4.17	12/30/87
AVS-0253	CPE	JE	2.25	3.90	VERO	3.20	0.82	1/ 4/88
AVS-0253	CPE	JE	2.9	1.59	VERO	3.20	2.00	1/ 4/88
AVS-0253	CPE	JE	2.95	1.45	VERO	3.20	2.19	1/ 4/88
AVS-0253	CPE	JE	2.55	2.04	VERO	3.20	1.56	1/ 4/88
AVS-0253	CPE	JE	2.75	1.83	VERO	3.20	1.74	1/ 4/88
AVS-0253	CPE	JE	3.05	1.33	VERO	3.20	2.40	1/ 4/88
AVS-0253	CPE	JE	2.6	1.42	VERO	1.00	0.70	1/ 6/88
AVS-0253	CPE	JE	2.8	1.42	VERO	3.20	2.24	1/ 6/88
AVS-0253	CPE	JE	2.55	1.56	VERO	1.00	0.64	1/ 6/88
AVS-0253	CPE	JE	2.3	3.98	VERO	3.20	0.80	1/ 6/88
AVS-0253	CPE	JE	2.6	1.59	VERO	3.20	2.00	1/ 6/88
AVS-0253	CPE	JE	2.7	1.76	VERO	3.20	1.81	1/ 7/88
AVS-0253	CPE	JE	2.75	1.83	VERO	3.20	1.74	1/ 7/88
AVS-0253	CPE	JE	2.75	1.56	VERO	3.20	2.04	1/ 7/88
AVS-0253	CPE	JE	2.75	1.82	VERO	3.20	1.75	1/ 7/88
AVS-0253	CPE	JE	2.4	4.12	VERO	3.20	0.78	1/ 7/88
AVS-0253	CPE	JE	2.75	1.83	VERO	3.20	1.74	1/ 7/88
AVS-0253	CPE	JE	3.3	0.81	VERO	3.20	3.93	1/11/88
AVS-0253	CPE	JE	2.55	1.78	VERO	3.20	1.79	1/11/88
AVS-0253	CPE	JE	3.6	0.55	VERO	3.20	5.74	1/11/88
AVS-0253	CPE	JE	3.	1.11	VERO	3.20	2.85	1/11/88
AVS-0253	CPE	JE	2.75	1.35	VERO	3.20	2.36	1/11/88
AVS-0253	CPE	JE	3.2	0.95	VERO	3.20	3.35	1/11/88
AVS-0253	CPE	JE	2.78	1.65	VERO	10.00	6.05	1/13/88
AVS-0253	CPE	JE	2.55	1.20	VERO	3.20	2.66	1/18/88
AVS-0253	CPE	JE	3.5	1.19	VERO	10.00	8.34	1/22/88
AVS-0253	CPE	JE	2.13	1.54	VERO	3.20	2.07	1/27/88
AVS-0253	CPE	JE	3.6	0.99	VERO	10.00	10.00	1/29/88
AVS-0253	CPE	JE	3.29	2.83	VERO	32.00	11.20	3/ 1/88
AVS-0253	CPE	JE	3.04	1.62	VERO	10.00	6.15	3/ 7/88
AVS-0253	CPE	JE	2.3	1.61	VERO	3.20	1.97	3/ 9/88
AVS-0253	CPE	JE	1.85	4.29	VERO	3.20	0.74	3/10/88
AVS-0253	CPE	JE	2.	4.25	VERO	1.00	0.23	3/11/88
AVS-0253	CPE	JE	1.4	11.80	VERO	3.20	0.27	3/15/88
AVS-0253	CPE	JE	1.85	4.29	VERO	3.20	0.74	3/16/88

B-28

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0253	CPE	JE	1.8	4.26	VERO	3.20	0.75	3/17/88
AVS-0253	CPE	JE	2.	4.29	VERO	3.20	0.75	3/21/88
AVS-0253	CPE	JE	2.55	1.33	VERO	1.00	0.75	3/22/88
AVS-0253	CPE	JE	2.35	2.22	VERO	3.20	1.43	3/30/88
AVS-0253	CPE	JE	2.12	2.15	VERO	1.00	0.46	3/31/88
AVS-0253	CPE	JE	1.65	8.30	VERO	1.00	0.12	4/ 5/88
AVS-0253	CPE	JE	2.05	2.17	VERO	1.00	0.46	4/12/88
AVS-0253	CPE	JE	2.4	1.81	VERO	3.20	1.76	4/13/88
AVS-0253	CPE	JE	1.8	5.60	VERO	3.20	0.56	4/19/88
AVS-0253	CPE	JE	1.8	5.60	VERO	1.00	0.18	4/20/88
AVS-0253	CPE	JE	1.95	5.30	VERO	3.20	0.60	4/26/88
AVS-0253	CPE	JE	1.9	4.57	VERO	3.20	0.70	4/27/88
AVS-0253	CPE	JE	2.4	1.81	VERO	3.20	1.76	4/29/88
AVS-0253	CPE	JE	2.15	2.65	VERO	1.00	0.38	5/ 3/88
AVS-0253	CPE	JE	1.65	8.30	VERO	3.20	0.38	5/ 4/88
AVS-0253	CPE	JE	1.75	6.30	VERO	3.20	0.51	5/10/88
AVS-0253	CPE	JE	1.57	8.30	VERO	1.00	0.12	5/11/88
AVS-0253	CPE	JE	1.85	5.00	VERO	1.00	0.20	5/18/88
AVS-0253	CPE	JE	1.75	6.30	VERO	3.20	0.51	5/20/88
AVS-0253	CPE	JE	1.65	8.30	VERO	3.20	0.38	5/24/88
AVS-0253	CPE	JE	1.8	5.60	VERO	1.00	0.18	5/25/88
AVS-0253	CPE	JE	2.7	1.35	VERO	3.20	2.36	6/ 1/88
AVS-0253	CPE	JE	1.75	5.50	VERO	1.00	0.18	6/ 2/88
AVS-0253	CPE	JE	1.95	5.60	VERO	1.00	0.18	6/ 7/88
AVS-0253	CPE	JE	2.15	2.07	VERO	1.00	0.48	6/ 8/88
AVS-0253	CPE	JE	1.8	5.60	VERO	3.20	0.56	6/14/88
AVS-0253	CPE	JE	1.75	5.50	VERO	1.00	0.18	6/15/88
AVS-0253	CPE	JE	1.7	6.10	VERO	0.32	0.05	6/21/88
AVS-0253	CPE	JE	1.65	5.50	VERO	3.20	0.58	6/22/88
AVS-0253	CPE	JE	2.1	3.17	VERO	3.20	1.00	6/30/88
AVS-0253	CPE	JE	2.05	2.93	VERO	3.20	1.09	7/ 5/88
AVS-0253	CPE	JE	1.75	4.68	VERO	1.00	0.21	7/ 6/88
AVS-0253	CPE	JE	1.65	8.30	VERO	1.00	0.12	7/ 7/88
AVS-0253	CPE	JE	2.3	2.93	VERO	3.20	1.09	7/19/88
AVS-0253	CPE	JE	1.9	4.36	VERO	3.20	0.73	7/20/88
AVS-0253	CPE	JE	1.85	3.70	VERO	1.00	0.27	7/21/88
AVS-0253	CPE	JE	3.19	0.30	VERO	1.00	3.29	7/26/88
AVS-0253	CPE	JE	3.65	0.57	VERO	1.00	1.73	7/27/88
AVS-0253	CPE	JE	2.4	1.78	VERO	1.00	0.56	7/28/88
AVS-0253	CPE	JE	----	1.95	VERO	1.00	0.51	8/ 2/88
AVS-0253	CPE	JE	1.15	22.70	VERO	1.00	0.04	8/ 3/88
AVS-0253	CPE	JE	2.2	2.28	VERO	1.00	0.44	8/ 4/88
AVS-0253	CPE	JE	2.05	1.67	VERO	1.00	0.60	8/ 9/88
AVS-0253	CPE	JE	2.05	2.47	VERO	3.20	1.29	8/10/88
AVS-0253	CPE	JE	1.8	5.60	VERO	1.00	0.18	8/11/88
AVS-0253	CPE	JE	1.8	5.60	VERO	3.20	0.56	8/16/88
AVS-0253	CPE	JE	2.15	3.77	VERO	3.20	0.85	8/17/88
AVS-0253	CPE	JE	2.2	2.89	VERO	3.20	1.10	8/18/88
AVS-0253	CPE	JE	1.8	5.60	VERO	3.20	0.57	8/23/88
AVS-0253	CPE	JE	1.65	5.50	VERO	1.00	0.18	8/24/88
AVS-0253	CPE	JE	1.7	4.95	VERO	1.00	0.20	8/25/88
AVS-0253	CPE	JE	1.75	7.30	VERO	3.20	0.44	9/20/88
AVS-0253	CPE	JE	2.07	4.12	VERO	1.00	0.24	9/21/88
AVS-0253	CPE	JE	1.15	7.50	VERO	1.00	0.13	9/22/88
AVS-0253	CPE	JE	2.50	2.64	VERO	1.00	0.38	9/27/88
AVS-0253	CPE	JE	2.30	2.64	VERO	1.00	0.38	9/28/88
AVS-0253	CPE	JE	1.63	6.40	VERO	3.20	0.49	10/ 4/88
AVS-0253	CPE	JE	1.95	3.71	VERO	0.32	0.09	10/ 5/88
AVS-0253	CPE	JE	1.8	5.60	VERO	1.00	0.18	10/11/88
AVS-0253	CPE	JE	2.1	4.83	VERO	3.20	0.66	10/12/88
AVS-0253	CPE	JE	1.95	4.67	VERO	1.00	0.21	10/13/88
AVS-0253	CPE	PIC	----	2.00	VERO	32.00	16.00	12/ 5/86
AVS-0253	CPE	PIC	----	0.85	VERO	32.00	37.60	1/ 5/87
AVS-0253	CPE	PIC	----	0.70	VERO	0.10	0.14	1/ 6/87
AVS-0253	CPE	PIC	----	2.10	VERO	10.00	4.76	1/ 9/87

B-29

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MT50	TI	DATE
AVS-0253	PR	PIC	N/A	11.60	VERO >	100.00 >	8.61	1/13/87
AVS-0253	PR	PIC	N/A	2.46	VERO >	100.00 >	40.40	1/16/87
AVS-0253	PR	PIC	N/A	1.72	VERO	100.00	57.90	1/23/87
AVS-0253	PR	PIC	N/A	1.04	VERO	32.00	30.50	1/27/87
AVS-0253	PR	PIC	N/A	1.91	VERO	100.00	52.20	1/30/87
AVS-0253	PR	PIC	N/A	1.08	VERO >	100.00 >	92.50	2/ 3/87
AVS-0253	PR	PIC	N/A	0.19	VERO >	100.00 >	517.00	2/ 6/87
AVS-0253	PR	PIC	N/A	1.22	VERO	32.00	26.00	2/10/87
AVS-0253	PR	PIC	N/A	8.90	VERO	10.00	1.11	10/26/87
AVS-0253	PR	PIC	N/A	5.60	VERO	10.00	1.76	11/ 3/87
AVS-0253	CPE	PT	4.22	2.30	VERO	32.00	13.90	9/19/86
AVS-0253	CPE	PT	3.35	4.41	VERO	32.00	7.24	9/19/86
AVS-0253	CPE	PT	1.55	18.30	VERO	32.00	1.74	10/ 3/86
AVS-0253	CPE	PT	1.20	32.00	VERO	100.00	3.13	10/17/86
AVS-0253	CPE	PT	2.91	1.89	VERO	32.00	16.90	10/21/86
AVS-0253	CPE	PT	1.89	10.40	VERO	100.00	9.58	10/21/86
AVS-0253	CPE	PT	1.05	29.70	VERO	32.00	1.06	10/22/86
AVS-0253	CPE	PT	1.50	9.10	VERO	10.00	1.10	12/ 1/86
AVS-0253	CPE	PT	1.10	16.20	VERO	3.20	0.20	12/ 2/86
AVS-0253	CPE	PT	1.33	3.30	VERO	3.20	0.97	12/11/86
AVS-0253	CPE	PT	2.69	2.58	VERO	10.00	3.85	12/12/86
AVS-0253	CPE	PT	1.30	12.70	VERO	10.00	0.79	12/15/86
AVS-0253	CPE	PT	1.40	10.30	VERO	3.20	0.31	12/16/86
AVS-0253	CPE	PT	1.55	6.40	VERO	3.20	0.50	12/17/86
AVS-0253	CPE	PT	1.00	32.00	VERO	3.20	0.10	12/18/86
AVS-0253	CPE	PT	1.80	7.70	VERO	3.20	0.41	12/22/86
AVS-0253	CPE	PT	1.90	4.95	VERO	3.20	0.65	12/23/86
AVS-0253	CPE	PT	1.57	8.10	VERO	10.00	1.23	12/30/86
AVS-0253	CPE	PT	1.55	19.50	VERO	3.20	0.16	12/31/86
AVS-0253	CPE	PT	1.48	5.10	VERO	10.00	1.95	1/ 2/87
AVS-0253	CPE	PT	1.75	7.00	VERO	3.20	0.45	1/ 5/87
AVS-0253	CPE	PT	1.99	8.60	VERO	10.00	1.14	1/ 6/87
AVS-0253	CPE	PT	1.65	5.00	VERO	3.20	0.64	1/ 7/87
AVS-0253	CPE	PT	1.39	7.60	VERO	10.00	1.31	1/ 8/87
AVS-0253	CPE	PT	1.55	16.60	VERO	3.20	0.19	1/ 9/87
AVS-0253	CPE	PT	0.75	66.50	VERO	3.20	0.05	1/12/87
AVS-0253	CPE	PT	1.05	18.20	VERO	3.20	0.18	1/13/87
AVS-0253	CPE	PT	0.85	47.70	VERO	10.00	0.21	1/14/87
AVS-0253	CPE	PT	0.82	12.00	VERO	10.00	0.83	1/15/87
AVS-0253	CPE	PT	1.60	9.30	VERO	3.20	0.34	1/20/87
AVS-0253	CPE	PT	1.30	19.20	VERO	3.20	0.17	1/21/87
AVS-0253	CPE	PT	0.52	50.00	VERO	10.00	0.33	1/22/87
AVS-0253	CPE	PT	1.05	13.30	VERO	10.00	0.75	1/23/87
AVS-0253	CPE	PT	1.52	6.30	VERO	10.00	1.57	1/26/87
AVS-0253	CPE	PT	1.1	18.50	VERO	10.00	0.54	1/27/87
AVS-0253	CPE	PT	1.35	10.00	VERO	3.20	0.32	1/28/87
AVS-0253	CPE	PT	2.63	1.69	VERO	10.00	5.90	1/29/87
AVS-0253	CPE	PT	2.48	3.73	VERO	10.00	2.68	1/30/87
AVS-0253	CPE	PT	1.85	7.60	VERO	10.00	1.30	2/ 2/87
AVS-0253	CPE	PT	1.28	7.50	VERO	10.00	1.33	2/ 4/87
AVS-0253	CPE	PT	1.80	61.40	VERO	10.00	0.16	2/ 5/87
AVS-0253	CPE	PT	1.55	28.50	VERO	32.00	1.12	2/ 9/87
AVS-0253	CPE	PT	2.40	2.70	VERO	10.00	3.70	2/10/87
AVS-0253	CPE	PT	1.67	6.20	VERO	10.00	1.60	2/11/87
AVS-0253	CPE	PT	1.52	10.40	VERO	10.00	0.95	2/12/87
AVS-0253	CPE	PT	2.05	6.90	VERO	10.00	1.44	2/13/87
AVS-0253	CPE	PT	1.67	7.10	VERO	10.00	1.40	2/17/87
AVS-0253	CPE	PT	2.20	5.00	VERO	10.00	1.97	2/18/87
AVS-0253	CPE	PT	2.03	4.24	VERO	10.00	2.35	2/23/87
AVS-0253	CPE	PT	1.72	6.20	VERO	10.00	1.59	2/24/87
AVS-0253	CPE	PT	2.30	7.60	VERO	3.20	0.42	2/26/87
AVS-0253	CPE	PT	1.30	12.70	VERO	10.00	0.79	2/27/87
AVS-0253	CPE	PT	1.78	7.20	VERO	10.00	1.38	3/ 2/87
AVS-0253	CPE	PT	1.1	35.50	VERO	10.00	0.28	3/16/87
AVS-0253	CPE	PT	0.95	5.80	VERO	3.20	0.55	3/17/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	LD50	CELL	MTCSO	TI	DATE
AVS-0253	CPE	PT	0.8	33.30	VERO	10.00	0.30	3/19/87
AVS-0253	CPE	PT	1.64	25.40	VERO	10.00	0.39	3/20/87
AVS-0253	CPE	PT	1.42	13.30	VERO	10.00	0.75	4/ 6/87
AVS-0253	CPE	PT	2.3	1.78	VERO	3.20	1.79	4/ 7/87
AVS-0253	CPE	PT	1.27	23.10	VERO	3.20	0.14	4/ 8/87
AVS-0253	CPE	PT	1.52	9.60	VERO	3.20	0.33	4/ 9/87
AVS-0253	CPE	PT	2.14	2.31	VERO	3.20	1.38	4/10/87
AVS-0253	CPE	PT	1.32	21.00	VERO	10.00	0.47	4/14/87
AVS-0253	CPE	PT	1.45	6.20	VERO	3.20	0.51	4/15/87
AVS-0253	CPE	PT	1.3	23.30	VERO	3.20	0.14	4/16/87
AVS-0253	CPE	PT	1.35	30.40	VERO	3.20	0.10	4/17/87
AVS-0253	CPE	PT	1.35	11.70	VERO	10.00	0.85	9/28/87
AVS-0253	CPE	PT	1.1	14.30	VERO	10.00	0.70	10/ 6/87
AVS-0253	CPE	PT	1.4	14.00	VERO	10.00	0.71	10/15/87
AVS-0253	CPE	PT	1.05	16.00	VERO	10.00	0.63	10/21/87
AVS-0253	CPE	PT	0.75	42.00	VERO	3.20	0.08	10/28/87
AVS-0253	CPE	PT	0.67	221.00	VERO	10.00	0.05	10/28/87
AVS-0253	CPE	PT	1.15	18.60	VERO	3.20	0.17	10/29/87
AVS-0253	CPE	PT	1.6	3.95	VERO	1.00	0.25	11/ 2/87
AVS-0253	CPE	PT	0.85	0.75	VERO	1.00	1.33	11/ 4/87
AVS-0253	CPE	PT	1.45	5.30	VERO	1.00	0.19	11/ 5/87
AVS-0253	CPE	PT	1.2	12.80	VERO	1.00	0.08	11/11/87
AVS-0253	CPE	PT	1.25	4.93	VERO	1.00	0.20	11/11/87
AVS-0253	CPE	PT	0.9	14.80	VERO	3.20	0.22	11/12/87
AVS-0253	CPE	PT	1.15	11.90	VERO	1.00	0.08	11/12/87
AVS-0253	CPE	PT	1.1	12.30	VERO	0.32	0.03	11/16/87
AVS-0253	CPE	PT	1.	11.60	VERO	1.00	0.09	11/17/87
AVS-0253	CPE	PT	2.1	2.59	VERO	1.00	0.38	11/25/87
AVS-0253	CPE	PT	2.35	1.99	VERO	1.00	0.50	11/25/87
AVS-0253	CPE	PT	1.9	4.36	VERO	1.00	0.23	11/30/87
AVS-0253	CPE	PT	1.35	5.50	VERO	1.00	0.18	12/14/87
AVS-0253	CPE	PT	1.95	3.59	VERO	1.00	0.28	12/16/87
AVS-0253	CPE	PT	1.6	6.50	VERO	1.00	0.15	12/17/87
AVS-0253	CPE	PT	1.25	10.10	VERO	1.00	0.10	12/17/87
AVS-0253	CPE	PT	1.4	13.60	VERO	10.00	0.74	12/21/87
AVS-0253	CPE	PT	2.2	2.28	VERO	1.00	0.44	12/22/87
AVS-0253	CPE	PT	2.1	3.19	VERO	1.00	0.31	12/29/87
AVS-0253	CPE	PT	2.25	4.77	VERO	3.20	0.67	3/ 1/88
AVS-0253	CPE	PT	----	----	VERO	10.00	----	3/15/88
AVS-0253	CPE	PT	0.2	----	VERO	10.00	----	3/17/88
AVS-0253	CPE	PT	0.05	----	VERO	3.20	----	4/ 5/88
AVS-0253	CPE	PT	0.75	42.50	VERO	3.20	0.08	4/19/88
AVS-0253	CPE	PT	0.45	----	VERO	3.20	----	4/20/88
AVS-0253	CPE	PT	0.75	42.50	VERO	3.20	0.08	5/ 3/88
AVS-0253	CPE	PT	0.45	77.40	VERO	3.20	0.04	5/ 4/88
AVS-0253	CPE	PT	0.55	71.10	VERO	3.20	0.04	5/10/88
AVS-0253	CPE	PT	0.2	----	VERO	3.20	----	5/11/88
AVS-0253	CPE	SF	6.1	1.00	VERO >	320.00 >	320.00	9/23/86
AVS-0253	CPE	SF	5.95	0.60	VERO >	100.00 >	166.00	10/ 8/86
AVS-0253	CPE	SF	5.46	0.59	VERO >	100.00 >	168.00	10/ 8/86
AVS-0253	CPE	SF	5.01	1.58	VERO	100.00	63.40	10/10/86
AVS-0253	CPE	SF	- .24	100.00	VERO	100.00	1.00	10/14/86
AVS-0253	CPE	SF	3.09	0.33	VERO	32.00	96.50	10/15/86
AVS-0253	CPE	SF	5.85	0.21	VERO >	100.00 >	461.00	10/18/86
AVS-0253	CPE	SF	3.21	6.80	VERO	32.00	4.66	10/21/86
AVS-0253	CPE	SF	0.10	----	VERO <	10.00	----	11/26/86
AVS-0253	CPE	SF	2.48	3.81	VERO	10.00	2.62	12/ 1/86
AVS-0253	CPE	SF	2.40	9.30	VERO	32.00	3.43	12/ 2/86
AVS-0253	CPE	SF	1.80	6.20	VERO	10.00	1.59	12/ 2/86
AVS-0253	CPE	SF	3.35	1.31	VERO	10.00	7.60	12/ 2/86
AVS-0253	CPE	SF	2.30	3.27	VERO	10.00	3.05	12/ 4/86
AVS-0253	CPE	SF	2.60	3.10	VERO	10.00	3.22	12/ 4/86
AVS-0253	CPE	SF	2.25	2.18	VERO	10.00	4.58	12/ 5/86
AVS-0253	CPE	SF	3.09	1.77	VERO	10.00	5.65	12/15/86
AVS-0253	CPE	SF	2.80	3.85	VERO	10.00	2.60	12/15/86

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	LD50	CELL	MTC50	TI	DATE
AVS-0253	CPE	SF	2.30	4.56	VERO	10.00	2.19	12/16/86
AVS-0253	CPE	SF	2.25	3.55	VERO	10.00	2.82	12/16/86
AVS-0253	CPE	SF	2.70	7.30	VERO	3.20	0.44	12/23/86
AVS-0253	CPE	SF	1.70	7.70	VERO	3.20	0.41	12/29/86
AVS-0253	CPE	SF	1.65	12.70	VERO	10.00	0.79	12/30/86
AVS-0253	CPE	SF	1.95	3.20	VERO	3.20	1.00	12/31/86
AVS-0253	CPE	SF	2.75	4.48	VERO	10.00	2.23	12/31/86
AVS-0253	CPE	SF	2.45	11.00	VERO	3.20	0.29	1/ 2/87
AVS-0253	CPE	SF	2.45	3.63	VERO	10.00	2.75	1/ 2/87
AVS-0253	CPE	SF	2.50	4.19	VERO	10.00	2.39	1/ 5/87
AVS-0253	CPE	SF	2.95	1.14	VERO	3.20	2.78	1/ 5/87
AVS-0253	CPE	SF	2.90	2.67	VERO	10.00	3.73	1/ 6/87
AVS-0253	CPE	SF	2.45	2.42	VERO	3.20	1.32	1/ 6/87
AVS-0253	CPE	SF	2.00	7.60	VERO	10.00	1.31	1/ 7/87
AVS-0253	CPE	SF	1.85	5.60	VERO	10.00	1.77	1/ 7/87
AVS-0253	CPE	SF	1.55	9.70	VERO	10.00	1.03	1/ 8/87
AVS-0253	CPE	SF	1.75	9.40	VERO	10.00	1.05	1/ 8/87
AVS-0253	CPE	SF	2.45	4.11	VERO	3.20	0.78	1/10/87
AVS-0253	CPE	SF	1.80	6.30	VERO	10.00	1.58	1/12/87
AVS-0253	CPE	SF	1.30	18.30	VERO	10.00	0.55	1/12/87
AVS-0253	CPE	SF	1.70	6.90	VERO	10.00	1.42	1/13/87
AVS-0253	CPE	SF	1.45	14.30	VERO	10.00	0.69	1/13/87
AVS-0253	CPE	SF	2.60	1.77	VERO	3.20	1.81	1/14/87
AVS-0253	CPE	SF	1.65	6.90	VERO	10.00	1.42	1/14/87
AVS-0253	CPE	SF	2.05	6.60	VERO	10.00	1.50	1/15/87
AVS-0253	CPE	SF	2.70	2.81	VERO	10.00	3.56	1/16/87
AVS-0253	CPE	SF	1.90	6.80	VERO	3.20	0.47	1/19/87
AVS-0253	CPE	SF	2.55	0.91	VERO	3.20	3.48	2/25/87
AVS-0253	CPE	SF	2.10	3.20	VERO	3.20	1.00	2/26/87
AVS-0253	CPE	SF	1.80	9.30	VERO	10.00	1.07	2/27/87
AVS-0253	CPE	SF	1.00	22.90	VERO	1.00	0.04	3/ 2/87
AVS-0253	CPE	SF	2.30	9.70	VERO	10.00	1.02	3/ 3/87
AVS-0253	CPE	SF	0.9	21.80	VERO	3.20	0.15	3/ 9/87
AVS-0253	CPE	SF	1.65	9.50	VERO	10.00	1.04	3/11/87
AVS-0253	CPE	SF	1.45	14.40	VERO	3.20	0.22	3/18/87
AVS-0253	CPE	SF	1.9	5.60	VERO	10.00	1.78	3/20/87
AVS-0253	CPE	SF	1.45	18.20	VERO	1.00	0.05	4/ 6/87
AVS-0253	CPE	SF	1.15	24.90	VERO	1.00	0.04	4/ 7/87
AVS-0253	CPE	SF	1.2	23.70	VERO	1.00	0.04	4/ 8/87
AVS-0253	CPE	SF	1.95	6.60	VERO	3.20	0.48	4/ 9/87
AVS-0253	CPE	SF	2.25	3.06	VERO	3.20	1.04	4/10/87
AVS-0253	CPE	SF	2.4	2.97	VERO	1.00	0.34	4/13/87
AVS-0253	CPE	SF	1.8	9.30	VERO	3.20	0.34	4/14/87
AVS-0253	CPE	SF	2.15	3.14	VERO	1.00	0.32	4/15/87
AVS-0253	CPE	SF	1.95	6.60	VERO	1.00	0.15	4/16/87
AVS-0253	CPE	SF	1.8	8.90	VERO	3.20	0.36	4/20/87
AVS-0253	CPE	SF	2.05	4.56	VERO	3.20	0.70	4/21/87
AVS-0253	CPE	SF	1.65	7.70	VERO	3.20	0.41	4/22/87
AVS-0253	CPE	SF	1.8	7.40	VERO	1.00	0.14	4/23/87
AVS-0253	CPE	SF	1.3	----	VERO	1.00	----	4/24/87
AVS-0253	CPE	SF	1.55	32.00	VERO	1.00	0.03	5/20/87
AVS-0253	CPE	SF	1.75	2.80	VERO	1.00	0.36	5/21/87
AVS-0253	CPE	SF	1.9	7.30	VERO	3.20	0.44	5/29/87
AVS-0253	CPE	SF	2.25	4.12	VERO	1.00	0.24	9/29/87
AVS-0253	CPE	SF	1.2	17.80	VERO	3.20	0.18	9/30/87
AVS-0253	CPE	SF	1.95	4.11	VERO	1.00	0.24	10/ 1/87
AVS-0253	CPE	SF	2.05	9.50	VERO	3.20	0.33	10/ 2/87
AVS-0253	CPE	SF	1.55	8.30	VERO	10.00	1.19	10/ 6/87
AVS-0253	CPE	SF	2.15	2.97	VERO	1.00	0.34	10/30/87
AVS-0253	CPE	SF	1.95	4.67	VERO	3.20	0.68	11/ 2/87
AVS-0253	CPE	SF	2.2	2.79	VERO	1.00	0.36	11/ 3/87
AVS-0253	CPE	SF	1.3	15.90	VERO	3.20	0.20	11/11/87
AVS-0253	CPE	SF	1.85	5.00	VERO	3.20	0.64	11/30/87
AVS-0253	CPE	SF	1.2	17.80	VERO	3.20	0.18	12/15/87
AVS-0253	CPE	SF	2.05	3.76	VERO	1.00	0.26	12/16/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-0253	CPE	SF	2.	4.25	VERO	3.20	0.75	1/ 4/88
AVS-0253	CPE	SF	1.8	5.60	VERO	3.20	0.57	1/ 4/88
AVS-0253	CPE	SF	1.9	5.00	VERO	3.20	0.63	1/ 4/88
AVS-0253	CPE	SF	1.55	9.40	VERO	3.20	0.34	1/ 4/88
AVS-0253	CPE	SF	1.75	6.30	VERO	3.20	0.51	1/ 4/88
AVS-0253	CPE	SF	1.7	7.70	VERO	3.20	0.41	1/ 4/88
AVS-0253	CPE	SF	1.9	5.00	VERO	3.20	0.63	1/ 5/88
AVS-0253	CPE	SF	1.8	5.60	VERO	3.20	0.57	1/ 5/88
AVS-0253	CPE	SF	1.8	5.60	VERO	3.20	0.57	1/ 5/88
AVS-0253	CPE	SF	1.95	4.67	VERO	1.00	0.21	1/ 5/88
AVS-0253	CPE	SF	2.3	2.45	VERO	1.00	0.41	1/ 5/88
AVS-0253	CPE	SF	1.5	10.00	VERO	3.20	0.32	1/ 5/88
AVS-0253	CPE	SF	2.15	2.97	VERO	3.20	1.07	1/ 6/88
AVS-0253	CPE	SF	2.	4.25	VERO	3.20	0.75	1/ 6/88
AVS-0253	CPE	SF	2.15	2.97	VERO	1.00	0.34	1/ 6/88
AVS-0253	CPE	SF	1.2	17.80	VERO	3.20	0.18	1/ 6/88
AVS-0253	CPE	SF	2.05	3.76	VERO	1.00	0.26	1/ 6/88
AVS-0253	CPE	SF	1.9	5.00	VERO	3.20	0.63	1/ 6/88
AVS-0253	CPE	SF	2.35	2.66	VERO	1.00	0.38	1/11/88
AVS-0253	CPE	SF	2.35	1.99	VERO	1.00	0.50	1/11/88
AVS-0253	CPE	SF	2.45	1.59	VERO	1.00	0.63	1/11/88
AVS-0253	CPE	SF	2.5	1.43	VERO	1.00	0.69	1/11/88
AVS-0253	CPE	SF	2.85	0.83	VERO	1.00	1.20	1/11/88
AVS-0253	CPE	SF	1.2	17.80	VERO	3.20	0.18	1/11/88
AVS-0253	CPE	SF	2.55	1.78	VERO	3.20	1.79	1/12/88
AVS-0253	CPE	SF	2.75	1.56	VERO	3.20	2.04	1/12/88
AVS-0253	CPE	SF	2.4	2.25	VERO	3.20	1.41	1/12/88
AVS-0253	CPE	SF	2.35	1.99	VERO	1.00	0.50	1/12/88
AVS-0253	CPE	SF	2.45	1.99	VERO	3.20	1.60	1/12/88
AVS-0253	CPE	SF	2.65	1.56	VERO	3.20	2.04	1/12/88
AVS-0253	CPE	SF	1.6	8.80	VERO	3.20	0.36	1/18/88
AVS-0253	CPE	SF	1.65	8.30	VERO	3.20	0.38	1/18/88
AVS-0253	CPE	SF	1.9	5.00	VERO	3.20	0.63	1/18/88
AVS-0253	CPE	SF	2.05	3.76	VERO	1.00	0.26	1/18/88
AVS-0253	CPE	SF	2.	4.25	VERO	3.20	0.75	1/18/88
AVS-0253	CPE	SF	1.65	8.30	VERO	3.20	0.38	1/18/88
AVS-0253	CPE	SF	4.3	0.23	VERO	3.20	13.60	2/ 2/88
AVS-0253	CPE	SF	2.75	1.14	VERO	1.00	0.87	2/ 5/88
AVS-0253	CPE	SF	3.05	1.05	VERO	1.00	0.94	2/ 9/88
AVS-0253	CPE	SF	2.75	4.11	VERO	3.20	0.78	2/18/88
AVS-0253	CPE	SF	2.27	2.86	VERO	1.00	0.35	3/ 8/88
AVS-0253	CPE	SF	1.9	4.88	VERO	3.20	0.65	3/11/88
AVS-0253	CPE	SF	1.75	9.10	VERO	3.20	0.35	3/15/88
AVS-0253	CPE	SF	1.97	12.70	VERO	3.20	0.25	3/16/88
AVS-0253	CPE	SF	1.6	9.20	VERO	3.20	0.34	3/17/88
AVS-0253	CPE	SF	1.1	22.20	VERO	3.20	0.14	3/21/88
AVS-0253	CPE	SF	0.85	37.60	VERO	1.00	0.03	3/22/88
AVS-0253	CPE	SF	1.	37.60	VERO	3.20	0.09	3/31/88
AVS-0253	CPE	SF	----	20.10	VERO	3.20	0.16	4/ 6/88
AVS-0253	CPE	SF	1.05	26.10	VERO	1.00	0.04	4/12/88
AVS-0253	CPE	SF	1.65	7.60	VERO	3.20	0.42	4/13/88
AVS-0253	CPE	SF	1.2	15.40	VERO	3.20	0.21	4/19/88
AVS-0253	CPE	SF	2.05	11.70	VERO	3.20	0.27	4/20/88
AVS-0253	CPE	SF	1.1	19.30	VERO	3.20	0.17	5/ 3/88
AVS-0253	CPE	SF	0.5	200.60	VERO	100.00	0.50	5/10/88
AVS-0253	CPE	SF	1.45	23.70	VERO	1.00	0.04	5/11/88
AVS-0253	CPE	SF	1.8	6.30	VERO	3.20	0.50	5/18/88
AVS-0253	CPE	SF	1.45	14.30	VERO	32.00	2.22	5/24/88
AVS-0253	CPE	VEE	2.8	0.30	VERO	0.32	1.04	4/28/87
AVS-0253	CPE	VEE	2.25	0.73	VERO	0.32	0.43	11/11/87
AVS-0253	CPE	VEE	2.4	0.41	VERO	0.32	0.77	11/12/87
AVS-0253	CPE	VEE	1.2	2.90	VERO	1.00	0.34	11/13/87
AVS-0253	CPE	VEE	1.7	2.56	VERO	1.00	0.39	11/13/87
AVS-0253	CPE	VEE	1.85	1.72	VERO	1.00	0.58	11/13/87
AVS-0253	CPE	VEE	1.7	3.45	VERO	1.00	0.29	11/13/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCS ₅₀	TI	DATE
AVS-0253	CPE	VEE	1.75	2.17	VERO	0.32	0.15	11/13/87
AVS-0253	CPE	VEE	1.85	1.46	VERO	1.00	0.69	11/13/87
AVS-0253	CPE	VEE	1.25	4.28	VERO	1.00	0.23	11/19/87
AVS-0253	CPE	VEE	1.35	3.62	VERO	1.00	0.28	11/25/87
AVS-0253	CPE	VEE	1.5	2.84	VERO	1.00	0.35	11/25/87
AVS-0253	CPE	VEE	1.25	6.10	VERO	1.00	0.16	11/25/87
AVS-0253	CPE	VEE	1.65	1.23	VERO	1.00	0.81	11/25/87
AVS-0253	CPE	VEE	1.5	2.84	VERO	1.00	0.35	11/25/87
AVS-0253	CPE	VEE	1.8	1.12	VERO	1.00	0.89	11/25/87
AVS-0253	CPE	VEE	2.95	0.70	VERO	1.00	1.42	12/ 1/87
AVS-0253	CPE	VEE	2.05	3.21	VERO	1.00	0.31	12/ 2/87
AVS-0253	CPE	VEE	1.8	4.82	VERO	1.00	0.21	12/ 3/87
AVS-0253	CPE	VEE	2.25	2.61	VERO	1.00	0.38	12/ 3/87
AVS-0253	CPE	VEE	2.25	2.18	VERO	1.00	0.46	12/ 3/87
AVS-0253	CPE	VEE	2.05	2.85	VERO	1.00	0.35	12/ 3/87
AVS-0253	CPE	VEE	2.5	1.18	VERO	1.00	0.84	12/ 3/87
AVS-0253	CPE	VEE	1.8	4.96	VERO	1.00	0.20	12/ 3/87
AVS-0253	CPE	VEE	2.25	2.61	VERO	1.00	0.38	12/ 7/87
AVS-0253	CPE	VEE	2.3	2.22	VERO	1.00	0.45	12/31/87
AVS-0253	CPE	VEE	2.25	2.61	VERO	1.00	0.38	12/31/87
AVS-0253	CPE	VEE	2.3	2.22	VERO	1.00	0.45	12/31/87
AVS-0253	CPE	VEE	1.7	7.10	VERO	1.00	0.14	12/31/87
AVS-0253	CPE	VEE	1.75	6.30	VERO	1.00	0.16	12/31/87
AVS-0253	CPE	VEE	2.25	2.61	VERO	1.00	0.38	12/31/87
AVS-0253	CPE	VEE	3.2	0.50	VERO	1.00	1.97	1/ 4/88
AVS-0253	CPE	VEE	2.4	1.78	VERO	1.00	0.56	1/18/88
AVS-0253	CPE	VEE	2.8	1.09	VERO	3.20	2.91	1/25/88
AVS-0253	CPE	VEE	1.5	4.69	VERO	3.20	0.68	1/29/88
AVS-0253	CPE	VEE	3.8	0.27	VERO	1.00	3.58	3/ 1/88
AVS-0253	CPE	VEE	2.45	1.56	VERO	1.00	0.64	3/ 7/88
AVS-0253	CPE	VEE	2.35	1.61	VERO	1.00	0.62	3/ 9/88
AVS-0253	CPE	VEE	2.5	1.35	VERO	1.00	0.74	3/10/88
AVS-0253	CPE	VEE	2.25	3.04	VERO	3.20	1.04	3/15/88
AVS-0253	CPE	VEE	2.35	2.24	VERO	3.20	1.42	3/16/88
AVS-0253	CPE	VEE	2.05	3.34	VERO	1.00	0.30	3/17/88
AVS-0253	CPE	VEE	1.45	5.30	VERO	3.20	0.60	3/21/88
AVS-0253	CPE	VEE	1.9	4.50	VERO	0.32	0.07	3/22/88
AVS-0253	CPE	VEE	2.05	2.47	VERO	1.00	0.40	3/30/88
AVS-0253	CPE	VEE	1.3	7.70	VERO	1.00	0.13	3/31/88
AVS-0253	CPE	VEE	1.35	10.20	VERO	3.20	0.31	4/ 5/88
AVS-0253	CPE	VEE	0.95	23.00	VERO	3.20	0.14	4/ 6/88
AVS-0253	CPE	VEE	1.5	5.30	VERO	3.20	0.60	4/12/88
AVS-0253	CPE	VEE	1.9	3.65	VERO	1.00	0.27	4/13/88
AVS-0253	CPE	VEE	1.6	8.00	VERO	10.00	1.24	4/19/88
AVS-0253	CPE	VEE	1.85	5.00	VERO	1.00	0.20	4/20/88
AVS-0253	CPE	VEE	1.75	6.30	VERO	1.00	0.16	4/26/88
AVS-0253	CPE	VEE	1.95	3.93	VERO	1.00	0.25	4/27/88
AVS-0253	CPE	VEE	1.75	5.50	VERO	1.00	0.18	4/29/88
AVS-0253	CPE	VEE	1.85	5.00	VERO	3.20	0.64	5/ 3/88
AVS-0253	CPE	VEE	1.55	6.40	VERO	1.00	0.16	5/ 4/88
AVS-0253	CPE	VEE	1.75	6.30	VERO	1.00	0.16	5/10/88
AVS-0253	CPE	VEE	1.8	5.60	VERO	1.00	0.18	5/11/88
AVS-0253	CPE	VEE	2.1	2.84	VERO	1.00	0.35	5/17/88
AVS-0253	CPE	VEE	1.8	4.94	VERO	1.00	0.20	5/18/88
AVS-0253	CPE	VEE	2.4	2.36	VERO	3.20	1.35	5/24/88
AVS-0253	CPE	VEE	1.65	5.10	VERO	0.32	0.06	6/ 1/88
AVS-0253	CPE	VEE	1.4	17.90	VERO	3.20	0.18	6/ 1/88
AVS-0253	CPE	VEE	1.4	6.70	VERO	1.00	0.15	6/ 2/88
AVS-0253	CPE	VEE	1.4	5.60	VERO	1.00	0.17	6/ 2/88
AVS-0253	CPE	VEE	1.6	3.27	VERO	1.00	0.31	6/ 7/88
AVS-0253	CPE	VEE	1.5	4.46	VERO	1.00	0.22	6/ 7/88
AVS-0253	CPE	VEE	1.5	4.46	VERO	1.00	0.22	6/ 8/88
AVS-0253	CPE	VEE	2.1	1.53	VERO	0.32	0.21	6/ 8/88
AVS-0253	CPE	VEE	1.5	14.10	VERO	10.00	0.70	6/14/88
AVS-0253	CPE	VEE	1.5	16.20	VERO	10.00	0.61	6/14/88

B-34

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0253	CPE	VEE	1.2	9.00	VERO	1.00	0.11	6/15/88
AVS-0253	CPE	VEE	1.15	11.90	VERO	1.00	0.08	6/15/88
AVS-0253	CPE	VEE	0.65	49.50	VERO	1.00	0.02	6/22/88
AVS-0253	CPE	VEE	0.5	----	VERO	3.20	----	6/22/88
AVS-0253	CPE	VEE	1.6	3.26	VERO	1.00	0.31	6/28/88
AVS-0253	CPE	VEE	1.5	5.20	VERO	0.32	0.06	6/28/88
AVS-0253	CPE	VEE	2.	2.25	VERO	1.00	0.44	6/29/88
AVS-0253	CPE	VEE	2.	1.40	VERO	1.00	0.71	6/29/88
AVS-0253	CPE	VEE	1.2	9.00	VERO	3.20	0.35	6/30/88
AVS-0253	CPE	VEE	1.6	3.95	VERO	1.00	0.25	6/30/88
AVS-0253	CPE	VEE	1.75	6.40	VERO	1.00	0.16	7/ 5/88
AVS-0253	CPE	VEE	1.75	5.70	VERO	3.20	0.56	7/ 5/88
AVS-0253	CPE	VEE	1.5	4.46	VERO	1.00	0.22	7/19/88
AVS-0253	CPE	VEE	1.45	5.00	VERO	1.00	0.20	7/20/88
AVS-0253	CPE	VEE	1.35	6.40	VERO	1.00	0.15	7/20/88
AVS-0253	CPE	VEE	2.3	2.32	VERO	1.00	0.43	7/21/88
AVS-0253	CPE	VEE	2.3	3.33	VERO	3.20	0.96	7/21/88
AVS-0253	CPE	VEE	2.65	1.00	VERO	1.00	1.00	7/26/88
AVS-0253	CPE	VEE	3.3	0.44	VERO	1.00	2.24	7/26/88
AVS-0253	CPE	VEE	2.35	2.02	VERO	1.00	0.50	7/27/88
AVS-0253	CPE	VEE	2.2	3.29	VERO	1.00	0.30	7/27/88
AVS-0253	CPE	VEE	1.65	7.50	VERO	1.00	0.13	7/28/88
AVS-0253	CPE	VEE	2.25	2.83	VERO	1.00	0.35	7/28/88
AVS-0253	CPE	VEE	1.7	6.60	VERO	1.00	0.15	8/ 2/88
AVS-0253	CPE	VEE	1.8	6.40	VERO	1.00	0.15	8/ 2/88
AVS-0253	CPE	VEE	1.5	11.10	VERO	1.00	0.09	8/ 3/88
AVS-0253	CPE	VEE	1.55	9.00	VERO	1.00	0.11	8/ 3/88
AVS-0253	CPE	VEE	1.95	4.84	VERO	3.20	0.66	8/ 4/88
AVS-0253	CPE	VEE	1.95	3.93	VERO	3.20	0.81	8/ 4/88
AVS-0253	CPE	VEE	2.3	2.93	VERO	3.20	1.09	8/10/88
AVS-0253	CPE	VEE	2.45	2.32	VERO	3.20	1.37	8/10/88
AVS-0253	CPE	VEE	1.5	8.00	VERO	3.20	0.40	8/11/88
AVS-0253	CPE	VEE	1.8	5.60	VERO	1.00	0.18	8/11/88
AVS-0253	CPE	VEE	1.6	7.00	VERO	3.20	0.45	8/16/88
AVS-0253	CPE	VEE	1.6	7.80	VERO	3.20	0.41	8/16/88
AVS-0253	CPE	VEE	1.7	6.40	VERO	1.00	0.16	8/18/88
AVS-0253	CPE	VEE	1.9	4.36	VERO	3.20	0.73	8/18/88
AVS-0253	CPE	VEE	2.65	0.99	VERO	1.00	1.00	9/ 1/88
AVS-0253	CPE	VEE	2.75	0.72	VERO	1.00	1.37	9/ 1/88
AVS-0253	CPE	VEE	2.4	1.56	VERO	1.00	0.64	9/ 8/88
AVS-0253	CPE	VEE	2.4	1.78	VERO	1.00	0.56	9/ 8/88
AVS-0253	CPE	VEE	2.55	1.14	VERO	1.00	0.88	9/13/88
AVS-0253	CPE	VEE	2.6	0.95	VERO	1.00	1.04	9/13/88
AVS-0253	CPE	VEE	2.3	2.45	VERO	1.00	0.41	9/14/88
AVS-0253	CPE	VEE	2.85	0.88	VERO	1.00	1.12	9/14/88
AVS-0253	CPE	VEE	2.4	1.90	VERO	1.00	0.52	9/15/88
AVS-0253	CPE	VEE	2.3	2.22	VERO	1.00	0.45	9/15/88
AVS-0253	CPE	VEE	2.55	1.15	VERO	1.00	0.87	9/20/88
AVS-0253	CPE	VEE	2.85	0.87	VERO	1.00	1.14	9/21/88
AVS-0253	CPE	VEE	2.97	0.52	VERO	1.00	1.91	9/21/88
AVS-0253	CPE	VEE	2.55	1.16	VERO	1.00	0.86	9/22/88
AVS-0253	CPE	VEE	2.44	1.39	VERO	1.00	0.72	9/22/88
AVS-0253	CPE	VEE	2.85	0.83	VERO	1.00	1.20	9/28/88
AVS-0253	CPE	VEE	2.85	0.83	VERO	1.00	1.20	9/28/88
AVS-0253	CPE	VEE	2.25	2.61	VERO	3.20	1.22	9/29/88
AVS-0253	CPE	VEE	2.25	2.61	VERO	3.20	1.22	9/29/88
AVS-0253	CPE	VEE	2.15	2.42	VERO	1.00	0.41	10/ 4/88
AVS-0253	CPE	VEE	1.4	2.98	VERO	0.32	0.11	10/ 4/88
AVS-0253	CPE	VEE	2.25	2.61	VERO	1.00	0.38	10/ 5/88
AVS-0253	CPE	VEE	1.6	8.00	VERO	1.00	0.12	10/ 5/88
AVS-0253	CPE	VEE	2.8	0.94	VERO	10.00	10.50	10/11/88
AVS-0253	CPE	VEE	2.25	2.61	VERO	1.00	0.38	10/11/88
AVS-0253	CPE	VEE	2.25	2.61	VERO	1.00	0.38	10/12/88
AVS-0253	CPE	VEE	2.25	2.61	VERO	1.00	0.38	10/12/88
AVS-0253	CPE	VEE	2.5	1.35	VERO	1.00	0.74	10/13/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0253	CPE	VEE	2.6	0.96	VERO	0.32	0.33	10/13/88
AVS-0253	CPE	VSV	2.	21.20	L929	1.00	0.05	6/13/86
AVS-0253	CPE	VV	0.45 <	0.32	L929	0.32 >	1.00	6/12/86
AVS-0253	CPE	VV	2.6	6.90	VERO	3.20	0.46	7/17/86
AVS-0253	CPE	VV	2.45	6.40	VERO	10.00	1.56	7/24/86
AVS-0253	CPE	VV	2.6	10.00	VERO	32.00	3.20	7/31/86
AVS-0253	CPE	VV	3.	7.50	VERO	32.00	4.26	8/ 7/86
AVS-0253	CPE	VV	2.45	6.40	VERO	10.00	1.56	8/20/86
AVS-0253	CPE	VV	2.7	4.27	VERO	10.00	2.33	8/28/86
AVS-0253	CPE	VV	2.15	18.70	VERO	10.00	0.53	10/16/86
AVS-0253	CPE	VV	2.45	5.50	VERO	10.00	1.79	10/23/86
AVS-0253	CPE	VV	2.2	17.40	VERO	10.00	0.57	10/30/86
AVS-0253	CPE	VV	2.64	5.70	VERO	10.00	1.75	11/ 6/86
AVS-0253	CPE	VV	2.76	3.29	VERO	3.20	0.97	11/13/86
AVS-0253	CPE	VV	2.55	3.07	VERO	3.20	1.03	11/20/86
AVS-0253	CPE	VV	2.46	15.30	VERO	3.20	0.21	12/ 4/86
AVS-0253	CPE	VV	2.61	3.83	VERO	3.20	0.84	12/11/86
AVS-0253	CPE	VV	2.49	11.80	VERO	3.20	0.27	12/18/86
AVS-0253	CPE	VV	2.95	3.82	VERO	3.20	0.84	1/ 8/87
AVS-0253	CPE	VV	2.55	3.19	VERO	3.20	1.00	1/29/87
AVS-0253	CPE	VV	2.35	6.40	VERO	10.00	1.55	2/ 5/87
AVS-0253	CPE	VV	2.55	5.60	VERO	10.00	1.78	2/12/87
AVS-0253	CPE	VV	2.55	10.50	VERO	10.00	0.95	3/12/87
AVS-0253	CPE	VV	1.85	15.80	VERO	10.00	0.63	4/10/87
AVS-0253	CPE	VV	2.6	5.00	VERO	10.00	1.99	4/24/87
AVS-0253	CPE	VV	3.05	2.78	VERO	10.00	3.59	5/ 7/87
AVS-0253	CPE	VV	1.85	9.10	VERO	10.00	1.08	5/14/87
AVS-0253	CPE	VV	2.8	8.00	VERO	32.00	3.99	5/21/87
AVS-0253	CPE	VV	2.3	9.40	VERO	10.00	1.05	5/28/87
AVS-0253	CPE	VV	2.2	7.70	VERO	10.00	1.28	6/ 4/87
AVS-0253	CPE	VV	1.8	10.20	VERO	3.20	0.31	6/11/87
AVS-0253	CPE	VV	2.	10.00	VERO	10.00	0.99	6/18/87
AVS-0253	CPE	VV	2.1	10.50	VERO	10.00	0.95	6/25/87
AVS-0253	CPE	VV	2.	12.60	VERO	10.00	0.79	7/ 2/87
AVS-0253	CPE	VV	2.15	14.20	VERO	10.00	0.70	7/ 9/87
AVS-0253	CPE	VV	2.5	10.90	VERO	32.00	2.93	7/16/87
AVS-0253	CPE	VV	2.2	14.90	VERO	10.00	0.67	7/30/87
AVS-0253	CPE	VV	1.5	27.10	VERO	10.00	0.37	8/ 6/87
AVS-0253	CPE	VV	1.95	17.80	VERO	10.00	0.56	8/13/87
AVS-0253	CPE	VV	1.5	35.00	VERO	10.00	0.28	8/20/87
AVS-0253	CPE	VV	1.85	31.90	VERO	32.00	1.00	8/27/87
AVS-0253	CPE	VV	1.9	10.00	VERO	32.00	3.20	9/ 4/87
AVS-0253	CPE	VV	1.55	38.10	VERO	32.00	0.84	9/24/87
AVS-0253	CPE	VV	1.65	38.40	VERO	32.00	0.83	9/24/87
AVS-0253	CPE	VV	1.85	20.70	VERO	32.00	1.54	9/24/87
AVS-0253	CPE	VV	1.7	27.10	VERO	32.00	1.17	9/24/87
AVS-0253	CPE	VV	1.55	22.80	VERO	32.00	1.40	9/24/87
AVS-0253	CPE	VV	1.9	12.80	VERO	10.00	0.78	10/ 8/87
AVS-0253	CPE	VV	1.65	18.60	VERO	10.00	0.54	10/ 8/87
AVS-0253	CPE	VV	2.35	14.10	VERO	10.00	0.71	10/ 8/87
AVS-0253	CPE	VV	2.45	6.80	VERO	32.00	4.64	10/22/87
AVS-0253	CPE	VV	2.3	8.40	VERO	32.00	3.77	10/22/87
AVS-0253	CPE	VV	2.35	9.10	VERO	32.00	3.50	10/22/87
AVS-0253	CPE	VV	2.35	9.10	VERO	32.00	3.50	10/22/87
AVS-0253	CPE	VV	2.9	9.20	VERO	100.00	10.80	10/22/87
AVS-0253	CPE	VV	2.3	7.60	VERO	10.00	1.30	10/29/87
AVS-0253	CPE	VV	2.	11.30	VERO	10.00	0.88	10/29/87
AVS-0253	CPE	VV	2.35	6.00	VERO	10.00	1.65	10/29/87
AVS-0253	CPE	VV	2.15	8.90	VERO	10.00	1.11	10/29/87
AVS-0253	CPE	VV	2.35	8.70	VERO	10.00	1.13	10/29/87
AVS-0253	CPE	VV	2.45	6.40	VERO	10.00	1.56	11/ 5/87
AVS-0253	CPE	VV	2.4	5.60	VERO	10.00	1.75	11/12/87
AVS-0253	CPE	VV	2.2	7.50	VERO	10.00	1.33	12/10/87
AVS-0253	CPE	VV	1.75	12.00	VERO	10.00	0.83	12/17/87
AVS-0253	CPE	VV	2.45	10.90	VERO	32.00	2.93	12/31/87

R-36

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0253	CPE	VV	2.75	6.90	VERO	32.00	4.61	1/14/88
AVS-0253	CPE	VV	2.25	10.00	VERO	10.00	1.00	1/21/88
AVS-0253	CPE	VV	2.6	10.00	VERO	32.00	3.18	1/28/88
AVS-0253	CPE	VV	2.	9.30	VERO	10.00	1.06	2/ 4/88
AVS-0253	CPE	VV	2.25	7.40	VERO	10.00	1.33	2/11/88
AVS-0253	CPE	VV	2.1	12.40	VERO	10.00	0.80	2/18/88
AVS-0253	CPE	VV	1.5	29.60	VERO	32.00	1.08	2/25/88
AVS-0253	CPE	VV	2.25	11.40	VERO	32.00	2.80	3/ 3/88
AVS-0253	CPE	VV	2.55	10.00	VERO	32.00	3.18	3/10/88
AVS-0253	CPE	VV	2.3	14.50	VERO	32.00	2.19	3/17/88
AVS-0253	CPE	VV	2.4	10.10	VERO	32.00	3.14	3/24/88
AVS-0253	CPE	VV	2.65	10.10	VERO	32.00	3.14	3/31/88
AVS-0253	CPE	VV	2.75	3.43	VERO	32.00	9.32	4/14/88
AVS-0253	CPE	VV	2.5	10.50	VERO	32.00	3.03	4/21/88
AVS-0253	CPE	VV	2.9	9.40	VERO	32.00	3.40	4/29/88
AVS-0253	CPE	VV	2.5	10.00	VERO	32.00	3.20	5/ 5/88
AVS-0253	CPE	VV	2.55	8.20	VERO	32.00	3.87	5/12/88
AVS-0253	CPE	VV	2.25	7.40	VERO	32.00	4.31	5/19/88
AVS-0253	CPE	VV	2.5	10.30	VERO	32.00	3.08	5/26/88
AVS-0253	CPE	VV	2.35	10.00	VERO	32.00	3.18	6/ 2/88
AVS-0253	CPE	VV	2.25	9.90	VERO	32.00	3.20	6/16/88
AVS-0253	CPE	VV	2.25	9.90	VERO	32.00	3.20	6/16/88
AVS-0253	CPE	VV	2.45	6.80	VERO	32.00	4.64	6/23/88
AVS-0253	CPE	VV	1.85	14.60	VERO	32.00	2.18	6/30/88
AVS-0253	CPE	VV	1.85	14.60	VERO	32.00	2.18	6/30/88
AVS-0253	CPE	VV	2.25	7.40	VERO	32.00	4.31	7/ 7/88
AVS-0253	CPE	VV	1.75	8.40	VERO	10.00	1.18	7/21/88
AVS-0253	CPE	VV	2.4	10.00	VERO	32.00	3.17	8/18/88
AVS-0253	CPE	VV	2.2	9.30	VERO	32.00	3.41	8/25/88
AVS-0253	CPE	VV	2.35	10.00	VERO	32.00	3.20	9/ 1/88
AVS-0253	CPE	VV	2.35	7.70	VERO	10.00	1.28	10/ 6/88
AVS-0253	CPE	VV	2.45	5.50	VERO	10.00	1.79	10/13/88
AVS-0253	CPE	VV	2.35	7.70	VERO	10.00	1.28	10/27/88
AVS-0253	CPE	VV	2.45	9.70	VERO	32.00	3.27	11/ 3/88
AVS-0253	CPE	VV	2.3	11.00	VERO	32.00	2.89	11/10/88
AVS-0253	CPE	VV	2.75	7.00	VERO	32.00	4.53	11/17/88
AVS-0253	CPE	YFV	2.75	3.00	VERO	10.00	3.33	1/13/87
AVS-0253	CPE	YFV	2.87	1.98	VERO	10.00	5.05	1/14/87
AVS-0253	CPE	YFV	2.94	1.01	VERO	10.00	9.89	1/15/87
AVS-0253	CPE	YFV	3.47	0.95	VERO	10.00	10.40	1/16/87
AVS-0253	CPE	YFV	3.20	2.57	VERO	10.00	3.88	1/20/87
AVS-0253	CPE	YFV	2.60	3.10	VERO	10.00	3.22	1/21/87
AVS-0253	CPE	YFV	2.10	3.20	VERO	3.20	1.00	1/22/87
AVS-0253	CPE	YFV	3.10	2.63	VERO	32.00	12.10	1/22/87
AVS-0253	CPE	YFV	2.25	3.06	VERO	3.20	1.03	1/23/87
AVS-0253	CPE	YFV	3.80	1.09	VERO	10.00	9.16	1/23/87
AVS-0253	CPE	YFV	2.00	7.10	VERO	10.00	1.39	1/26/87
AVS-0253	CPE	YFV	2.90	0.88	VERO	3.20	3.59	1/27/87
AVS-0253	CPE	YFV	2.05	2.28	VERO	1.00	0.04	1/27/87
AVS-0253	CPE	YFV	1.95	2.00	VERO	3.20	1.60	1/28/87
AVS-0253	CPE	YFV	1.95	3.03	VERO	3.20	1.05	1/28/87
AVS-0253	CPE	YFV	2.40	2.40	VERO	1.00	0.42	1/29/87
AVS-0253	CPE	YFV	2.65	2.49	VERO	10.00	4.01	1/29/87
AVS-0253	CPE	YFV	2.68	3.03	VERO	10.00	3.29	1/30/87
AVS-0253	CPE	YFV	3.25	1.82	VERO	10.00	5.48	1/30/87
AVS-0253	CPE	YFV	2.25	2.21	VERO	3.20	1.44	2/ 2/87
AVS-0253	CPE	YFV	2.95	0.74	VERO	3.20	4.31	2/ 2/87
AVS-0253	CPE	YFV	2.50	2.86	VERO	10.00	3.49	2/ 3/87
AVS-0253	CPE	YFV	2.00	57.90	VERO	10.00	0.89	2/ 3/87
AVS-0253	CPE	YFV	2.55	1.77	VERO	3.20	1.79	2/ 4/87
AVS-0253	CPE	YFV	3.20	1.37	VERO	3.20	2.32	2/ 4/87
AVS-0253	CPE	YFV	2.25	0.96	VERO	3.20	3.32	2/ 5/87
AVS-0253	CPE	YFV	2.10	1.67	VERO	3.20	1.91	2/ 5/87
AVS-0253	CPE	YFV	2.25	3.03	VERO	3.20	1.05	2/ 6/87
AVS-0253	CPE	YFV	2.10	3.03	VERO	3.20	1.05	2/ 6/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0253	CPE	YFV	2.40	4.06	VERO	10.00	2.46	2/ 9/87
AVS-0253	CPE	YFV	2.50	3.14	VERO	10.00	3.18	2/10/87
AVS-0253	CPE	YFV	2.45	2.30	VERO	3.20	1.39	2/12/87
AVS-0253	CPE	YFV	2.85	1.05	VERO	3.20	3.02	2/13/87
AVS-0253	CPE	YFV	2.90	2.00	VERO	10.00	4.98	2/16/87
AVS-0253	CPE	YFV	3.50	0.52	VERO	3.20	6.13	2/17/87
AVS-0253	CPE	YFV	3.10	0.95	VERO	3.20	3.36	2/19/87
AVS-0253	CPE	YFV	1.30	7.80	VERO	10.00	1.27	2/20/87
AVS-0253	CPE	YFV	2.90	2.00	VERO	10.00	4.98	3/ 6/87
AVS-0253	CPE	YFV	2.57	2.61	VERO	10.00	3.81	3/13/87
AVS-0253	CPE	YFV	2.1	6.60	VERO	10.00	1.51	3/17/87
AVS-0253	CPE	YFV	3.2	2.28	VERO	10.00	4.45	3/18/87
AVS-0253	CPE	YFV	3.3	0.95	VERO	3.20	3.33	3/19/87
AVS-0253	CPE	YFV	3.9	0.51	VERO	3.20	6.18	3/19/87
AVS-0253	CPE	YFV	3.	1.13	VERO	3.20	2.82	3/20/87
AVS-0253	CPE	YFV	3.77	0.72	VERO	10.00	13.70	3/23/87
AVS-0253	CPE	YFV	3.3	2.10	VERO	10.00	4.76	3/24/87
AVS-0253	CPE	YFV	2.5	1.78	VERO	3.20	1.79	3/25/87
AVS-0253	CPE	YFV	3.1	1.60	VERO	10.00	6.24	3/26/87
AVS-0253	CPE	YFV	3.6	0.56	VERO	3.20	5.65	3/27/87
AVS-0253	CPE	YFV	2.8	2.22	VERO	10.00	4.48	3/31/87
AVS-0253	CPE	YFV	3.1	0.98	VERO	3.20	3.25	4/ 1/87
AVS-0253	CPE	YFV	2.5	1.43	VERO	3.20	2.22	4/ 2/87
AVS-0253	CPE	YFV	2.25	3.06	VERO	1.00	0.33	4/ 6/87
AVS-0253	CPE	YFV	2.25	1.01	VERO	3.20	3.14	4/ 7/87
AVS-0253	CPE	YFV	2.65	1.54	VERO	3.20	2.06	4/ 8/87
AVS-0253	CPE	YFV	3.2	0.97	VERO	3.20	3.28	4/ 9/87
AVS-0253	CPE	YFV	3.3	0.74	VERO	3.20	4.28	4/10/87
AVS-0253	CPE	YFV	2.75	1.48	VERO	3.20	2.15	4/14/87
AVS-0253	CPE	YFV	3.15	0.55	VERO	1.00	1.79	4/15/87
AVS-0253	CPE	YFV	2.4	2.54	VERO	1.00	0.39	4/17/87
AVS-0253	CPE	YFV	3.2	0.96	VERO	3.20	3.30	4/20/87
AVS-0253	CPE	YFV	2.2	2.97	VERO	3.20	1.07	4/21/87
AVS-0253	CPE	YFV	2.35	3.00	VERO	1.00	0.33	4/22/87
AVS-0253	CPE	YFV	2.4	2.97	VERO	3.20	1.07	4/23/87
AVS-0253	CPE	YFV	2.4	2.97	VERO	3.20	1.07	4/24/87
AVS-0253	CPE	YFV	1.2	0.86	VERO	1.00	1.15	4/27/87
AVS-0253	CPE	YFV	2.75	0.95	VERO	1.00	1.04	4/28/87
AVS-0253	CPE	YFV	2.45	2.59	VERO	1.00	0.38	4/29/87
AVS-0253	CPE	YFV	2.55	2.10	VERO	1.00	0.48	5/ 1/87
AVS-0253	CPE	YFV	2.85	0.95	VERO	1.00	1.04	5/ 4/87
AVS-0253	CPE	YFV	3.	0.70	VERO	1.00	1.41	5/ 5/87
AVS-0253	CPE	YFV	2.55	1.59	VERO	3.20	2.00	5/ 6/87
AVS-0253	CPE	YFV	1.75	7.30	VERO	1.00	0.14	5/ 7/87
AVS-0253	CPE	YFV	2.7	2.10	VERO	3.20	1.52	5/ 8/87
AVS-0253	CPE	YFV	3.35	0.93	VERO	3.20	3.43	5/11/87
AVS-0253	CPE	YFV	2.45	0.56	VERO	1.00	1.76	5/20/87
AVS-0253	CPE	YFV	2.35	0.55	VERO	1.00	1.79	5/21/87
AVS-0253	CPE	YFV	2.6	2.19	VERO	3.20	1.45	5/27/87
AVS-0253	CPE	YFV	1.4	0.73	VERO	1.00	1.36	5/28/87
AVS-0253	CPE	YFV	2.6	1.59	VERO	3.20	2.00	5/29/87
AVS-0253	CPE	YFV	3.	1.00	VERO	3.20	3.17	6/ 1/87
AVS-0253	CPE	YFV	0.85	0.16	VERO	0.32	1.92	6/ 2/87
AVS-0253	CPE	YFV	1.3	1.59	VERO	1.00	0.63	6/ 3/87
AVS-0253	CPE	YFV	2.1	3.29	VERO	3.20	0.97	6/ 4/87
AVS-0253	CPE	YFV	2.4	5.60	VERO	10.00	1.76	6/ 5/87
AVS-0253	CPE	YFV	1.9	1.59	VERO	1.00	0.63	6/ 8/87
AVS-0253	CPE	YFV	1.94	5.30	VERO	3.20	0.60	6/10/87
AVS-0253	CPE	YFV	3.2	1.08	VERO	3.20	2.95	6/11/87
AVS-0253	CPE	YFV	3.2	0.53	VERO	1.00	1.86	6/24/87
AVS-0253	CPE	YFV	3.7	0.50	VERO	3.20	6.33	6/25/87
AVS-0253	CPE	YFV	2.2	1.78	VERO	1.00	0.56	6/29/87
AVS-0253	CPE	YFV	2.4	1.74	VERO	3.20	1.83	7/ 6/87
AVS-0253	CPE	YFV	2.44	4.09	VERO	3.20	0.78	7/ 7/87
AVS-0253	CPE	YFV	2.5	1.59	VERO	1.00	0.63	7/ 9/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0253	CPE	YFV	2.45	1.69	VERO	1.00	0.59	7/10/87
AVS-0253	CPE	YFV	2.29	1.69	VERO	3.20	1.89	7/14/87
AVS-0253	CPE	YFV	2.5	1.59	VERO	1.00	0.63	7/15/87
AVS-0253	CPE	YFV	2.5	1.69	VERO	3.20	1.88	7/16/87
AVS-0253	CPE	YFV	2.55	5.90	VERO	10.00	1.69	7/17/87
AVS-0253	CPE	YFV	2.2	1.78	VERO	3.20	1.78	7/20/87
AVS-0253	CPE	YFV	1.9	1.69	VERO	3.20	1.88	7/21/87
AVS-0253	CPE	YFV	2.44	1.10	VERO	1.00	0.90	7/22/87
AVS-0253	CPE	YFV	2.4	1.78	VERO	1.00	0.56	7/23/87
AVS-0253	CPE	YFV	2.39	1.57	VERO	3.20	2.03	7/29/87
AVS-0253	CPE	YFV	2.	4.25	VERO	1.00	0.23	8/ 3/87
AVS-0253	CPE	YFV	2.65	1.18	VERO	1.00	0.85	8/ 4/87
AVS-0253	CPE	YFV	2.32	1.74	VERO	1.00	0.57	8/ 5/87
AVS-0253	CPE	YFV	2.5	1.69	VERO	3.20	1.88	8/ 6/87
AVS-0253	CPE	YFV	2.4	1.78	VERO	3.20	1.78	8/ 7/87
AVS-0253	CPE	YFV	2.4	1.78	VERO	1.00	0.56	8/12/87
AVS-0253	CPE	YFV	2.45	1.69	VERO	1.00	0.59	8/13/87
AVS-0253	CPE	YFV	2.5	1.69	VERO	3.20	1.88	8/14/87
AVS-0253	CPE	YFV	1.83	4.86	VERO	1.00	0.20	8/19/87
AVS-0253	CPE	YFV	2.4	1.78	VERO	3.20	1.78	8/31/87
AVS-0253	CPE	YFV	2.4	1.78	VERO	1.00	0.56	9/ 1/87
AVS-0253	CPE	YFV	2.35	2.30	VERO	1.00	0.43	9/ 2/87
AVS-0253	CPE	YFV	2.1	1.78	VERO	1.00	0.56	9/ 3/87
AVS-0253	CPE	YFV	2.4	1.78	VERO	3.20	1.78	9/ 4/87
AVS-0253	CPE	YFV	2.5	1.59	VERO	1.00	0.63	9/ 8/87
AVS-0253	CPE	YFV	2.45	1.69	VERO	1.00	0.59	9/ 9/87
AVS-0253	CPE	YFV	1.85	5.30	VERO	1.00	0.19	9/10/87
AVS-0253	CPE	YFV	2.	4.25	VERO	1.00	0.23	9/14/87
AVS-0253	CPE	YFV	2.18	1.73	VERO	1.00	0.57	9/16/87
AVS-0253	CPE	YFV	1.8	5.60	VERO	3.20	0.57	9/17/87
AVS-0253	CPE	YFV	1.9	5.00	VERO	3.20	0.63	9/18/87
AVS-0253	CPE	YFV	2.45	1.69	VERO	1.00	0.59	9/23/87
AVS-0253	CPE	YFV	2.35	2.22	VERO	3.20	1.43	9/24/87
AVS-0253	CPE	YFV	2.05	3.76	VERO	1.00	0.26	9/28/87
AVS-0253	CPE	YFV	2.35	2.30	VERO	3.20	1.38	9/29/87
AVS-0253	CPE	YFV	1.8	5.60	VERO	10.00	1.76	9/30/87
AVS-0253	CPE	YFV	2.6	2.79	VERO	10.00	3.58	10/ 1/87
AVS-0253	CPE	YFV	2.1	4.67	VERO	10.00	2.13	10/ 2/87
AVS-0253	CPE	YFV	2.6	2.79	VERO	10.00	3.58	10/ 6/87
AVS-0253	CPE	YFV	2.25	2.61	VERO	3.20	1.22	11/30/87
AVS-0253	CPE	YFV	2.7	1.47	VERO	3.20	2.17	12/ 1/87
AVS-0253	CPE	YFV	2.55	1.78	VERO	3.20	1.79	12/ 2/87
AVS-0253	CPE	YFV	2.	4.25	VERO	3.20	0.75	12/ 3/87
AVS-0253	CPE	YFV	2.45	1.99	VERO	3.20	1.60	12/ 4/87
AVS-0253	CPE	YFV	1.95	4.67	VERO	3.20	0.68	12/ 7/87
AVS-0253	CPE	YFV	2.	4.25	VERO	1.00	0.23	12/ 8/87
AVS-0253	CPE	YFV	2.7	1.00	VERO	1.00	0.99	12/ 9/87
AVS-0253	CPE	YFV	2.2	2.79	VERO	3.20	1.14	12/10/87
AVS-0253	CPE	YFV	2.65	1.18	VERO	1.00	0.85	12/10/87
AVS-0253	CPE	YFV	2.25	2.61	VERO	1.00	0.38	12/10/87
AVS-0253	CPE	YFV	2.25	2.61	VERO	1.00	0.38	12/10/87
AVS-0253	CPE	YFV	2.35	2.22	VERO	3.20	1.43	12/10/87
AVS-0253	CPE	YFV	2.25	2.61	VERO	1.00	0.38	12/10/87
AVS-0253	CPE	YFV	2.25	2.61	VERO	3.20	1.22	12/14/87
AVS-0253	CPE	YFV	2.25	2.61	VERO	1.00	0.38	12/15/87
AVS-0253	CPE	YFV	2.3	2.45	VERO	3.20	1.30	12/16/87
AVS-0253	CPE	YFV	2.3	2.22	VERO	1.00	0.45	12/17/87
AVS-0253	CPE	YFV	2.6	0.88	VERO	3.20	3.61	12/18/87
AVS-0253	CPE	YFV	2.45	1.99	VERO	3.20	1.60	12/21/87
AVS-0253	CPE	YFV	2.25	2.61	VERO	3.20	1.22	12/22/87
AVS-0253	CPE	YFV	2.5	1.69	VERO	3.20	1.88	1/ 4/88
AVS-0253	CPE	YFV	2.3	2.22	VERO	10.00	4.49	1/ 4/88
AVS-0253	CPE	YFV	2.7	1.47	VERO	3.20	2.17	1/ 4/88
AVS-0253	CPE	YFV	2.35	2.22	VERO	3.20	1.43	1/ 4/88
AVS-0253	CPE	YFV	2.55	1.78	VERO	3.20	1.79	1/ 4/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-0253	CPE	YFV	2.6	1.59	VERO	3.20	2.00	1/ 4/88
AVS-0253	CPE	YFV	2.35	1.99	VERO	1.00	0.50	1/ 5/88
AVS-0253	CPE	YFV	2.55	1.78	VERO	3.20	1.79	1/ 5/88
AVS-0253	CPE	YFV	2.65	1.56	VERO	3.20	2.04	1/ 5/88
AVS-0253	CPE	YFV	3.05	0.62	VERO	1.00	1.59	1/ 5/88
AVS-0253	CPE	YFV	2.35	2.22	VERO	3.20	1.43	1/ 5/88
AVS-0253	CPE	YFV	2.4	1.78	VERO	1.00	0.56	1/ 5/88
AVS-0253	CPE	YFV	2.95	0.70	VERO	1.00	1.42	1/ 6/88
AVS-0253	CPE	YFV	2.65	0.83	VERO	1.00	1.20	1/ 6/88
AVS-0253	CPE	YFV	2.95	0.70	VERO	1.00	1.42	1/ 6/88
AVS-0253	CPE	YFV	3.1	0.56	VERO	1.00	1.77	1/ 6/88
AVS-0253	CPE	YFV	2.7	1.47	VERO	3.20	2.17	1/ 6/88
AVS-0253	CPE	YFV	2.	4.25	VERO	3.20	0.75	1/ 6/88
AVS-0253	CPE	YFV	2.85	0.83	VERO	1.00	1.20	1/11/88
AVS-0253	CPE	YFV	2.55	1.78	VERO	3.20	1.79	1/11/88
AVS-0253	CPE	YFV	2.55	1.78	VERO	3.20	1.79	1/11/88
AVS-0253	CPE	YFV	2.45	2.66	VERO	3.20	1.20	1/11/88
AVS-0253	CPE	YFV	1.8	5.60	VERO	3.20	0.56	1/11/88
AVS-0253	CPE	YFV	2.5	2.02	VERO	3.20	1.58	1/11/88
AVS-0253	CPE	YFV	2.85	0.83	VERO	1.00	1.20	1/12/88
AVS-0253	CPE	YFV	2.85	0.83	VERO	1.00	1.20	1/12/88
AVS-0253	CPE	YFV	2.55	1.78	VERO	3.20	1.79	1/12/88
AVS-0253	CPE	YFV	2.55	1.78	VERO	3.20	1.79	1/12/88
AVS-0253	CPE	YFV	2.55	1.47	VERO	1.00	0.68	1/12/88
AVS-0253	CPE	YFV	2.4	2.25	VERO	3.20	1.41	1/12/88
AVS-0253	CPE	YFV	2.45	1.99	VERO	3.20	1.60	1/18/88
AVS-0253	CPE	YFV	2.9	1.18	VERO	3.20	2.71	1/18/88
AVS-0253	CPE	YFV	2.2	3.19	VERO	3.20	1.00	1/18/88
AVS-0253	CPE	YFV	3.	1.00	VERO	3.20	3.17	1/18/88
AVS-0253	CPE	YFV	2.8	0.99	VERO	1.00	1.00	1/18/88
AVS-0253	CPE	YFV	2.2	3.19	VERO	3.20	1.00	1/18/88
AVS-0253	CPE	YFV	2.7	1.00	VERO	1.00	0.99	1/21/88
AVS-0253	CPE	YFV	2.55	1.78	VERO	3.20	1.79	1/22/88
AVS-0253	CPE	YFV	2.85	1.15	VERO	3.20	2.76	1/25/88
AVS-0253	CPE	YFV	2.4	1.78	VERO	1.00	0.56	2/ 2/88
AVS-0253	CPE	YFV	3.6	0.56	VERO	3.20	5.71	2/ 4/88
AVS-0253	CPE	YFV	3.	1.00	VERO	3.20	3.17	2/ 9/88
AVS-0253	CPE	YFV	3.7	0.50	VERO	3.20	6.34	2/10/88
AVS-0253	CPE	YFV	3.15	0.56	VERO	1.00	1.78	2/11/88
AVS-0253	CPE	YFV	3.05	0.62	VERO	1.00	1.59	2/12/88
AVS-0253	CPE	YFV	3.4	0.47	VERO	1.00	2.11	2/15/88
AVS-0253	CPE	YFV	3.15	0.56	VERO	1.00	1.78	3/ 1/88
AVS-0253	CPE	YFV	3.05	0.62	VERO	1.00	1.59	3/ 2/88
AVS-0253	CPE	YFV	3.05	0.62	VERO	1.00	1.59	3/ 3/88
AVS-0253	CPE	YFV	2.95	0.70	VERO	1.00	1.42	3/ 4/88
AVS-0253	CPE	YFV	2.85	1.47	VERO	1.00	0.68	3/ 7/88
AVS-0253	CPE	YFV	2.25	2.83	VERO	1.00	0.35	3/ 8/88
AVS-0253	CPE	YFV	2.4	1.77	VERO	1.00	0.56	3/ 9/88
AVS-0253	CPE	YFV	2.85	0.99	VERO	1.00	1.00	3/10/88
AVS-0253	CPE	YFV	2.1	4.08	VERO	1.00	0.24	3/11/88
AVS-0253	CPE	YFV	2.5	2.79	VERO	3.20	1.14	3/15/88
AVS-0253	CPE	YFV	2.2	4.10	VERO	3.20	0.78	3/16/88
AVS-0253	CPE	YFV	2.3	4.10	VERO	3.20	0.78	3/17/88
AVS-0253	CPE	YFV	2.2	3.83	VERO	3.20	0.83	3/21/88
AVS-0253	CPE	YFV	2.3	2.32	VERO	1.00	0.43	3/22/88
AVS-0253	CPE	YFV	2.65	2.38	VERO	3.20	1.34	3/30/88
AVS-0253	CPE	YFV	2.25	3.60	VERO	3.20	0.89	3/31/88
AVS-0253	CPE	YFV	1.65	2.87	VERO	1.00	0.35	4/ 5/88
AVS-0253	CPE	YFV	2.3	4.14	VERO	10.00	2.41	4/12/88
AVS-0253	CPE	YFV	2.35	3.29	VERO	3.20	0.97	4/13/88
AVS-0253	CPE	YFV	2.3	2.22	VERO	1.00	0.45	4/20/88
AVS-0253	CPE	YFV	1.9	5.70	VERO	3.20	0.56	4/26/88
AVS-0253	CPE	YFV	2.3	4.10	VERO	3.20	0.78	4/27/88
AVS-0253	CPE	YFV	2.45	2.21	VERO	3.20	1.38	4/29/88
AVS-0253	CPE	YFV	2.6	2.37	VERO	3.20	1.34	5/ 3/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0360	CPE	SF	1.65	0.08	VERO	0.01	0.12	8/18/87
AVS-0360	CPE	SF	----	----	VERO >	10.00	----	5/18/88
AVS-0360	CPE	VEE	1.85	0.20	VERO	0.10	0.49	5/ 7/87
AVS-0360	CPE	VEE	0.8	0.11	VERO <	0.01 <	0.09	5/18/88
AVS-0360	CPE	VSV	0.9	1.00	L929 -	0.32 -	0.32	6/20/86
AVS-0360	CPE	VV	0.6	3.00	VERO	1.00	0.33	7/24/86
AVS-0360	CPE	YFV	1.60	0.07	VERO	0.32	4.56	3/ 6/87
AVS-0360	CPE	YFV	----	----	VERO >	10.00	----	5/18/88
AVS-0361	CPE	AD2	1.30	0.05	HEP2	0.10	1.86	9/18/86
AVS-0361	CPE	AD2	0.55	0.30	HEP2	0.10	0.33	10/30/86
AVS-0361	CPE	AD2	1.2	1.31	HEP2	1.00	0.76	3/ 3/88
AVS-0361	CPE	JE	1.5	0.02	VERO	0.10	3.81	7/24/87
AVS-0361	CPE	JE	1.4	0.02	VERO	0.10	4.11	5/24/88
AVS-0361	PR	PIC	N/A	----	VERO	0.10	----	12/ 4/87
AVS-0361	PR	PIC	N/A	----	VERO	0.03	----	5/23/88
AVS-0361	CPE	PT	0.45 <	0.32	VERO -	0.32 >	1.00	11/12/87
AVS-0361	CPE	PT	1.1	0.19	VERO >	0.32 >	1.60	12/21/87
AVS-0361	CPE	PT	1.	0.04	VERO	0.10	2.35	3/ 1/88
AVS-0361	CPE	VEE	----	----	VERO	0.32	----	11/19/87
AVS-0361	CPE	VEE	0.05	----	VERO	0.03	----	5/24/88
AVS-0361	CPE	VSV	1.2 <	0.32	L929 -	0.32 -	1.00	6/20/86
AVS-0361	CPE	VSV	1.6	0.30	L929	0.10	0.32	8/15/86
AVS-0361	CPE	VV	0.45	0.46	VERO -	0.32 -	0.68	7/24/86
AVS-0361	CPE	VV	0.45	0.30	VERO	0.10	0.33	10/30/86
AVS-0361	CPE	YFV	1.1	0.03	VERO	0.10	2.65	3/ 1/88
AVS-0580	CPE	AD2	0.1	----	HEP2	320.00	----	9/24/87
AVS-0580	CPE	JE	----	----	VERO	100.00	----	7/21/88
AVS-0580	PR	PIC	N/A	----	VERO	100.00	----	11/ 8/88
AVS-0580	CPE	PT	----	----	VERO	320.00	----	7/21/88
AVS-0580	CPE	SF	----	----	VERO	100.00	----	7/21/88
AVS-0580	CPE	VEE	----	----	VERO	100.00	----	7/21/88
AVS-0580	CPE	VSV	----	----	L929	320.00	----	9/29/87
AVS-0580	CPE	VV	----	----	VERO	320.00	----	9/24/87
AVS-0580	CPE	YFV	----	----	VERO	100.00	----	7/21/88
AVS-0581	CPE	AD2	----	----	HEP2	320.00	----	9/24/87
AVS-0581	CPE	JE	----	----	VERO <	0.32	----	7/21/88
AVS-0581	PR	PIC	N/A	----	VERO	100.00	----	11/ 8/88
AVS-0581	CPE	PT	----	----	VERO	10.00	----	7/21/88
AVS-0581	CPE	SF	----	----	VERO	3.20	----	7/21/88
AVS-0581	CPE	VEE	----	----	VERO	32.00	----	7/21/88
AVS-0581	CPE	VSV	----	----	L929	10.00	----	9/29/87
AVS-0581	CPE	VV	----	----	VERO	320.00	----	9/24/87
AVS-0581	CPE	YFV	----	----	VERO	3.20	----	7/21/88
AVS-0582	CPE	AD2	0.3	----	HEP2 >	320.00	----	10/ 8/87
AVS-0582	CPE	JE	----	----	VERO	32.00	----	7/21/88
AVS-0582	PR	PIC	N/A	----	VERO	320.00	----	11/ 8/88
AVS-0582	CPE	PT	----	----	VERO	320.00	----	7/21/88
AVS-0582	CPE	SF	----	----	VERO	32.00	----	7/21/88
AVS-0582	CPE	VEE	----	----	VERO >	320.00	----	7/21/88
AVS-0582	CPE	VSV	----	----	L929 >	320.00	----	9/29/87
AVS-0582	CPE	VV	----	----	VERO >	320.00	----	10/ 8/87
AVS-0582	CPE	YFV	0.1	----	VERO >	320.00	----	7/21/88
AVS-0583	CPE	AD2	0.3	----	HEP2 >	320.00	----	9/24/87
AVS-0583	CPE	JE	----	----	VERO >	320.00	----	7/28/88
AVS-0583	PR	PIC	N/A	----	VERO	320.00	----	11/ 8/88
AVS-0583	CPE	PT	----	----	VERO	320.00	----	7/28/88
AVS-0583	CPE	VEE	----	----	VERO	320.00	----	7/28/88
AVS-0583	CPE	VSV	----	----	L929	100.00	----	9/29/87
AVS-0583	CPE	VV	----	----	VERO >	320.00	----	9/24/87
AVS-0583	CPE	YFV	----	----	VERO >	320.00	----	7/28/88
AVS-0584	CPE	AD2	0.1	----	HEP2 >	320.00	----	9/24/87
AVS-0584	CPE	JE	----	----	VERO >	320.00	----	7/28/88
AVS-0584	PR	PIC	N/A	----	VERO	320.00	----	11/ 8/88
AVS-0584	CPE	PT	----	----	VERO	320.00	----	7/28/88
AVS-0584	CPE	VEE	----	----	VERO	320.00	----	7/28/88

B-46

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0253	CPE	YFV	1.95	4.67	VERO	3.20	0.68	5/ 4/88
AVS-0253	CPE	YFV	2.05	4.67	VERO	3.20	0.68	5/10/88
AVS-0253	CPE	YFV	2.05	3.76	VERO	3.20	0.85	5/11/88
AVS-0253	CPE	YFV	2.55	1.78	VERO	3.20	1.79	5/17/88
AVS-0253	CPE	YFV	2.	4.25	VERO	1.00	0.23	5/18/88
AVS-0253	CPE	YFV	1.9	5.00	VERO	3.20	0.63	5/24/88
AVS-0253	CPE	YFV	2.5	2.77	VERO	3.20	1.15	5/25/88
AVS-0253	CPE	YFV	2.3	3.45	VERO	3.20	0.93	5/25/88
AVS-0253	CPE	YFV	1.75	6.30	VERO	3.20	0.51	6/15/88
AVS-0253	CPE	YFV	1.8	5.60	VERO	3.20	0.56	6/15/88
AVS-0253	CPE	YFV	1.9	5.30	VERO	1.00	0.19	6/22/88
AVS-0253	CPE	YFV	2.1	3.18	VERO	1.00	0.31	6/22/88
AVS-0253	CPE	YFV	1.35	8.60	VERO	10.00	1.15	6/30/88
AVS-0253	CPE	YFV	1.85	2.72	VERO	3.20	1.17	6/30/88
AVS-0253	CPE	YFV	2.35	2.18	VERO	3.20	1.46	7/ 5/88
AVS-0253	CPE	YFV	2.5	1.86	VERO	3.20	1.71	7/ 5/88
AVS-0253	CPE	YFV	2.25	2.61	VERO	3.20	1.22	7/ 6/88
AVS-0253	CPE	YFV	2.35	1.94	VERO	3.20	1.64	7/ 6/88
AVS-0253	CPE	YFV	2.55	2.61	VERO	3.20	1.22	7/ 7/88
AVS-0253	CPE	YFV	2.65	2.15	VERO	3.20	1.48	7/ 7/88
AVS-0253	CPE	YFV	2.25	2.61	VERO	3.20	1.22	7/19/88
AVS-0253	CPE	YFV	1.75	6.30	VERO	3.20	0.50	7/19/88
AVS-0253	CPE	YFV	2.1	4.67	VERO	10.00	2.13	7/20/88
AVS-0253	CPE	YFV	2.15	2.97	VERO	3.20	1.07	7/20/88
AVS-0253	CPE	YFV	2.6	2.79	VERO	10.00	3.57	7/21/88
AVS-0253	CPE	YFV	2.3	2.48	VERO	3.20	1.29	7/21/88
AVS-0253	CPE	YFV	3.7	0.49	VERO	3.20	6.49	7/26/88
AVS-0253	CPE	YFV	3.35	0.42	VERO	1.00	2.34	7/26/88
AVS-0253	CPE	YFV	3.02	0.60	VERO	1.00	1.64	7/27/88
AVS-0253	CPE	YFV	2.55	2.08	VERO	3.20	1.53	7/27/88
AVS-0253	CPE	YFV	1.3	7.10	VERO	3.20	0.45	7/28/88
AVS-0253	CPE	YFV	2.25	1.23	VERO	1.00	0.81	7/28/88
AVS-0253	CPE	YFV	2.35	3.29	VERO	3.20	0.97	8/ 2/88
AVS-0253	CPE	YFV	2.45	2.83	VERO	3.20	1.12	8/ 2/88
AVS-0253	CPE	YFV	2.25	2.61	VERO	3.20	1.22	8/ 4/88
AVS-0253	CPE	YFV	2.45	2.31	VERO	3.20	1.38	8/ 4/88
AVS-0253	CPE	YFV	2.25	1.51	VERO	3.20	2.11	8/10/88
AVS-0253	CPE	YFV	1.75	2.16	VERO	1.00	0.46	8/10/88
AVS-0253	CPE	YFV	2.55	1.89	VERO	3.20	1.68	8/11/88
AVS-0253	CPE	YFV	2.25	2.61	VERO	3.20	1.22	8/11/88
AVS-0253	CPE	YFV	2.3	3.35	VERO	3.20	0.95	8/16/88
AVS-0253	CPE	YFV	2.	4.29	VERO	3.20	0.75	8/16/88
AVS-0253	CPE	YFV	1.67	5.40	VERO	1.00	0.18	8/25/88
AVS-0253	CPE	YFV	2.3	4.10	VERO	3.20	0.78	8/25/88
AVS-0253	CPE	YFV	2.25	5.00	VERO	1.00	0.20	9/20/88
AVS-0253	CPE	YFV	2.13	5.00	VERO	1.00	0.20	9/21/88
AVS-0253	CPE	YFV	1.70	4.90	VERO	3.20	0.65	9/21/88
AVS-0253	CPE	YFV	2.17	6.50	VERO	1.00	0.14	9/22/88
AVS-0253	CPE	YFV	1.69	7.30	VERO	1.00	0.14	9/22/88
AVS-0253	CPE	YFV	2.0	2.49	VERO	3.20	1.27	9/27/88
AVS-0253	CPE	YFV	2.30	2.22	VERO	1.00	0.45	9/27/88
AVS-0253	CPE	YFV	2.00	4.25	VERO	1.00	0.24	9/28/88
AVS-0253	CPE	YFV	2.25	2.61	VERO	1.00	0.38	9/28/88
AVS-0253	CPE	YFV	1.65	8.30	VERO	1.00	0.12	9/29/88
AVS-0253	CPE	YFV	1.65	8.30	VERO	1.00	0.12	9/29/88
AVS-0253	CPE	YFV	1.6	4.94	VERO	3.20	0.65	10/ 4/88
AVS-0253	CPE	YFV	1.67	7.30	VERO	1.00	0.14	10/ 4/88
AVS-0253	CPE	YFV	1.85	5.30	VERO	1.00	0.19	10/ 5/88
AVS-0253	CPE	YFV	1.95	4.67	VERO	1.00	0.21	10/ 5/88
AVS-0253	CPE	YFV	2.	3.90	VERO	1.00	0.26	10/11/88
AVS-0253	CPE	YFV	1.52	7.30	VERO	3.20	0.43	10/11/88
AVS-0257	CPE	AD2	0.65	259.00	HEP2	320.00	1.23	9/25/86
AVS-0257	CPE	JE	1.9	23.70	VERO	100.00	4.20	3/24/87
AVS-0257	CPE	JE	0.45	217.00	VERO	320.00	1.47	5/18/88
AVS-0257	PR	PIC	N/A	174.00	VERO	100.00	0.57	4/ 3/87

B-41

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0257	CPE	PT	0.60	181.00	VERO	320.00	1.77	10/30/86
AVS-0257	CPE	SF	1.20	93.50	VERO	100.00	1.07	10/30/86
AVS-0257	CPE	VEE	3.7	3.21	VERO	32.00	9.96	5/15/87
AVS-0257	CPE	VEE	0.05	----	VERO	32.00	----	5/17/88
AVS-0257	CPE	VSV	1.6	60.90	L929	3.20	0.05	8/ 1/86
AVS-0257	CPE	VV	1.35	174.00	VERO	320.00	1.83	8/ 7/86
AVS-0257	CPE	VV	0.6	306.00	VERO	320.00	1.04	5/26/88
AVS-0257	CPE	YFV	1.31	74.10	VERO	320.00	4.32	2/ 2/87
AVS-0257	CPE	YFV	1.1	70.10	VERO	32.00	0.46	5/17/88
AVS-0272	CPE	AD2	2.10	8.10	HEP2	3.20	0.40	9/11/86
AVS-0272	CPE	JE	2.45	1.25	VERO	3.20	2.54	3/11/87
AVS-0272	CPE	JE	1.05	0.83	VERO	1.00	1.20	6/ 1/88
AVS-0272	CPE	PIC	----	2.00	VERO	32.00	16.00	12/12/86
AVS-0272	PR	PIC	N/A	----	VERO	0.32	----	6/ 3/88
AVS-0272	CPE	PT	2.25	1.01	VERO	3.20	3.15	10/ 3/86
AVS-0272	CPE	PT	2.	0.50	VERO	1.00	1.96	6/ 1/88
AVS-0272	CPE	SF	2.25	1.17	VERO	3.20	2.73	10/10/86
AVS-0272	CPE	SF	0.55	0.62	VERO	0.32	0.51	6/ 1/88
AVS-0272	CPE	VSV	2.05	7.50	L929	3.20	0.43	6/17/86
AVS-0272	CPE	VSV	0.75	66.90	L929	3.20	0.05	5/24/88
AVS-0272	CPE	VV	3.4	0.50	L929	3.20	6.40	6/12/86
AVS-0272	CPE	VV	4.7	0.60	VERO	3.20	5.33	7/17/86
AVS-0272	CPE	VV	4.25	0.56	VERO	3.20	5.70	5/26/88
AVS-0272	CPE	YFV	2.24	2.97	VERO	1.00	0.34	1/15/87
AVS-0286	CPE	AD2	----	----	HEP2	0.03	----	9/25/86
AVS-0286	CPE	JE	0.5	30.30	VERO	32.00	1.05	4/10/87
AVS-0286	CPE	JE	0.45	0.06	VERO <	0.03 <	0.47	5/25/88
AVS-0286	PR	PIC	N/A	----	VERO	1.00	----	12/ 4/87
AVS-0286	CPE	VEE	1.3	6.60	VERO -	0.01	----	5/15/87
AVS-0286	CPE	VSV	2.6	0.88	L929 -	0.32 -	0.36	7/18/86
AVS-0286	CPE	VV	1.85	1.00	VERO -	0.32 -	0.32	8/ 7/86
AVS-0286	CPE	VV	1.45	0.05	VERO	0.10	1.72	10/16/86
AVS-0286	CPE	YFV	0.15	----	VERO	0.01	----	3/ 6/87
AVS-0302	CPE	AD2	----	----	HEP2 <	0.32	----	9/11/86
AVS-0302	CPE	JE	0.4	0.01	VERO <	0.03 <	2.98	4/ 1/87
AVS-0302	CPE	PIC	----	0.30	VERO	0.32	1.07	12/12/86
AVS-0302	PR	PIC	N/A	----	VERO	0.10	----	5/16/88
AVS-0302	CPE	PT	0.6 <	0.01	VERO -	0.01	1.00	10/ 3/86
AVS-0302	CPE	SF	0.40	----	VERO <	0.32	----	11/24/86
AVS-0302	CPE	VSV	0.2	----	L929 <	1.00	----	6/17/86
AVS-0302	CPE	VV	0.2	----	L929	0.10	----	6/12/86
AVS-0302	CPE	VV	0.7	2.60	VERO	3.20	1.23	7/17/86
AVS-0302	CPE	YFV	0.20	----	VERO <	0.10	----	3/ 6/87
AVS-0303	CPE	AD2	1.20	----	HEP2 >	320.00	----	9/11/86
AVS-0303	CPE	AD2	0.15	----	HEP2	320.00	----	10/27/88
AVS-0303	CPE	JE	1.19	9.70	VERO	10.00	1.03	3/11/87
AVS-0303	CPE	PIC	----	----	VERO >	32.00	----	12/12/86
AVS-0303	CPE	PIC	----	----	VERO >	320.00	----	1/ 6/87
AVS-0303	CPE	PT	0.8	----	VERO	32.00 0	----	10/ 9/86
AVS-0303	CPE	VEE	----	----	VERO	3.20	----	12/ 2/87
AVS-0303	CPE	VSV	2.8	4.90	L929	10.00	2.04	6/13/86
AVS-0303	CPE	VSV	2.75	3.10	L929	10.00	3.22	6/17/86
AVS-0303	CPE	VSV	3.2	1.88	L929	10.00	5.30	6/20/86
AVS-0303	CPE	VSV	2.45	2.60	L929	3.20	1.23	6/24/86
AVS-0303	CPE	VSV	1.65	25.00	L929	10.00	0.40	6/27/86
AVS-0303	CPE	VSV	3.	3.10	L929	10.00	3.22	7/18/86
AVS-0303	CPE	VSV	2.25	6.80	L929	10.00	1.47	8/ 1/86
AVS-0303	CPE	VSV	2.1	8.20	L929	10.00	1.21	8/ 8/86
AVS-0303	CPE	VSV	2.4	3.10	L929	10.00	3.22	8/12/86
AVS-0303	CPE	VSV	3.25	3.10	L929	32.00	10.30	8/15/86
AVS-0303	CPE	VSV	1.8	7.40	L929	3.20	0.43	8/29/86
AVS-0303	CPE	VSV	2.	3.20	L929	3.20	1.00	9/ 5/86
AVS-0303	CPE	VSV	1.95	6.90	L929	3.20	0.46	9/19/86
AVS-0303	CPE	VSV	2.75	3.10	L929	32.00	10.30	10/ 3/86
AVS-0303	CPE	VSV	1.30	18.40	L929	3.20	0.17	1/16/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0303	CPE	VSV	2.20	4.93	L929	10.00	2.03	1/20/87
AVS-0303	PR	VSV	N/A	6.00	L929	10.00	1.65	2/ 3/87
AVS-0303	CPE	VSV	2.05	5.60	L929	10.00	1.78	2/ 6/87
AVS-0303	CPE	VSV	2.	5.50	L929	10.00	1.78	3/17/87
AVS-0303	CPE	VSV	4.25	0.62	L929	10.00	15.90	4/10/87
AVS-0303	CPE	VSV	3.1	2.54	L929	10.00	3.93	4/24/87
AVS-0303	CPE	VSV	3.15	2.43	L929	10.00	4.11	5/ 1/87
AVS-0303	CPE	VSV	1.9	8.60	L929	10.00	1.15	5/ 5/87
AVS-0303	CPE	VSV	2.35	8.90	L929	32.00	3.58	5/ 8/87
AVS-0303	CPE	VSV	3.05	2.79	L929	10.00	3.58	6/ 2/87
AVS-0303	CPE	VSV	3.55	1.45	L929	10.00	6.86	6/ 5/87
AVS-0303	CPE	VSV	3.2	2.61	L929	10.00	3.81	6/ 9/87
AVS-0303	CPE	VSV	3.2	2.45	L929	10.00	4.07	6/12/87
AVS-0303	CPE	VSV	2.8	2.52	L929	3.20	1.26	6/23/87
AVS-0303	CPE	VSV	2.4	2.00	L929	3.20	1.59	6/26/87
AVS-0303	CPE	VSV	2.8	3.13	L929	10.00	3.18	7/10/87
AVS-0303	CPE	VSV	3.	2.69	L929	10.00	3.70	7/14/87
AVS-0303	CPE	VSV	3.95	1.68	L929	10.00	5.94	7/17/87
AVS-0303	CPE	VSV	2.95	1.68	L929	3.20	1.89	7/21/87
AVS-0303	CPE	VSV	3.05	2.97	L929	10.00	3.36	7/28/87
AVS-0303	CPE	VSV	3.05	2.79	L929	10.00	3.58	7/31/87
AVS-0303	CPE	VSV	2.95	1.67	L929	3.20	1.90	8/ 4/87
AVS-0303	CPE	VSV	2.2	4.25	L929	10.00	2.35	8/21/87
AVS-0303	CPE	VSV	3.05	1.99	L929	3.20	1.60	8/25/87
AVS-0303	PR	VSV	N/A	1.35	L929	10.00	7.38	9/23/87
AVS-0303	CPE	VSV	3.2	2.79	L929	10.00	3.58	9/29/87
AVS-0303	CPE	VSV	4.1	1.18	L929	10.00	8.46	10/13/87
AVS-0303	PR	VSV	N/A	1.57	L929	3.20	2.02	10/28/87
AVS-0303	PR	VSV	N/A	1.08	L929	10.00	9.19	11/ 4/87
AVS-0303	CPE	VSV	4.2	1.78	L929	32.00	17.80	11/ 6/87
AVS-0303	CPE	VSV	4.25	0.82	L929	10.00	12.00	11/13/87
AVS-0303	CPE	VSV	3.85	0.97	L929	3.20	3.28	11/17/87
AVS-0303	CPE	VSV	4.1	0.54	L929	3.20	5.82	11/17/87
AVS-0303	CPE	VSV	4.1	0.88	L929	10.00	11.20	11/17/87
AVS-0303	CPE	VSV	4.4	0.88	L929	10.00	11.30	11/17/87
AVS-0303	CPE	VSV	4.6	0.36	L929	3.20	8.68	11/17/87
AVS-0303	CPE	VSV	3.35	2.30	L929	10.00	4.33	11/20/87
AVS-0303	CPE	VSV	3.25	1.18	L929	3.20	2.71	12/ 1/87
AVS-0303	CPE	VSV	3.6	1.00	L929	3.20	3.17	12/ 1/87
AVS-0303	CPE	VSV	3.1	1.59	L929	3.20	2.00	12/ 1/87
AVS-0303	CPE	VSV	3.5	1.18	L929	3.20	2.71	12/ 1/87
AVS-0303	CPE	VSV	3.9	0.83	L929	3.20	3.85	12/ 1/87
AVS-0303	CPE	VSV	4.15	1.00	L929	10.00	9.92	12/ 4/87
AVS-0303	CPE	VSV	4.8	0.56	L929	10.00	17.60	12/ 4/87
AVS-0303	CPE	VSV	3.9	1.21	L929	10.00	8.24	12/ 4/87
AVS-0303	CPE	VSV	3.8	1.60	L929	10.00	6.22	12/ 4/87
AVS-0303	CPE	VSV	4.4	0.79	L929	10.00	12.60	12/ 4/87
AVS-0303	CPE	VSV	3.55	0.99	L929	3.20	3.21	12/18/87
AVS-0303	CPE	VSV	3.75	1.47	L929	10.00	6.78	12/18/87
AVS-0303	CPE	VSV	3.4	2.30	L929	10.00	4.33	12/18/87
AVS-0303	CPE	VSV	4.25	0.94	L929	10.00	10.50	12/18/87
AVS-0303	CPE	VSV	3.45	1.13	L929	3.20	2.81	12/18/87
AVS-0303	CPE	VSV	4.	1.33	L929	10.00	7.47	1/ 5/88
AVS-0303	CPE	VSV	4.2	1.78	L929	32.00	17.80	1/19/88
AVS-0303	CPE	VSV	3.85	2.45	L929	32.00	13.00	1/19/88
AVS-0303	CPE	VSV	3.35	2.45	L929	10.00	4.07	1/19/88
AVS-0303	CPE	VSV	3.75	1.19	L929	10.00	8.39	1/19/88
AVS-0303	CPE	VSV	3.55	1.49	L929	10.00	6.68	1/19/88
AVS-0303	CPE	VSV	2.85	1.32	L929	3.20	2.41	1/22/88
AVS-0303	CPE	VSV	2.65	2.45	L929	3.20	1.30	1/29/88
AVS-0303	CPE	VSV	2.8	2.61	L929	3.20	1.22	2/ 2/88
AVS-0303	CPE	VSV	2.85	2.00	L929	10.00	4.97	2/ 5/88
AVS-0303	CPE	VSV	2.3	2.76	L929	10.00	3.62	2/12/88
AVS-0303	CPE	VSV	3.	1.31	L929	10.00	7.60	2/16/88
AVS-0303	CPE	VSV	2.6	3.88	L929	10.00	2.57	2/19/88

B-43

ACCUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

CD#		VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS	E	VSX	3.7	1.15	L929	10.00	8.64	2/23/88
AVS	PE	VSX	3.1	2.57	L929	10.00	3.88	3/11/88
AVS	PE	VSX	2.3	2.41	L929	3.20	1.32	3/18/88
AVS-0301	CPE	VSX	3.3	2.15	L929	10.00	4.63	3/25/88
AVS-0303	CPE	VSX	3.6	1.21	L929	10.00	8.23	3/29/88
AVS-0303	CPE	VSX	3.2	2.30	L929	10.00	4.33	4/ 1/88
AVS-0303	CPE	VSX	2.95	1.40	L929	3.20	2.27	4/ 5/88
AVS-0303	CPE	VSX	3.5	1.39	L929	10.00	7.17	4/ 8/88
AVS-0303	CPE	VSX	3.1	1.51	L929	3.20	2.11	4/12/88
AVS-0303	CPE	VSX	2.35	2.86	L929	3.20	1.11	4/15/88
AVS-0303	CPE	VSX	3.2	0.84	L929	3.20	3.78	4/19/88
AVS-0303	CPE	VSX	3.05	1.26	L929	3.20	2.53	5/ 3/88
AVS-0303	CPE	VSX	4.05	1.00	L929	10.00	9.92	5/10/88
AVS-0303	CPE	VSX	3.35	1.88	L929	10.00	5.30	5/13/88
AVS-0303	CPE	VSX	2.35	2.25	L929	3.20	1.42	5/24/88
AVS-0303	CPE	VSX	2.85	1.47	L929	3.20	2.17	6/ 7/88
AVS-0303	CPE	VSX	2.7	2.01	L929	3.20	1.58	6/22/88
AVS-0303	CPE	VSX	2.7	2.01	L929	3.20	1.58	6/22/88
AVS-0303	CPE	VSX	3.	2.69	L929	10.00	3.70	6/28/88
AVS-0303	CPE	VSX	2.25	2.78	L929	3.20	1.14	7/20/88
AVS-0303	CPE	VSX	2.85	2.33	L929	10.00	4.27	8/30/88
AVS-0303	CPE	VSX	3.35	2.30	L929	10.00	4.33	10/18/88
AVS-0303	CPE	VSX	N/A	1.31	L929	10.00	7.58	10/26/88
AVS-0303	CPE	VSX	2.95	1.78	L929	3.20	1.78	11/16/88
AVS-0303	CPE	VSX	3.1	2.61	L929	10.00	3.83	11/18/88
AVS-0303	CPE	VSX	2.9	1.00	L929	3.20	3.20	11/18/88
AVS-0303	CPE	VV	3.5	0.40	L929	10.00	24.50	6/12/86
AVS-0303	CPE	VV	5.2	0.63	VERO	10.00	15.80	7/17/86
AVS-0303	CPE	VV	5.45	0.32	VERO	32.00	100.00	10/27/88
AVS-0303	CPE	VV	6.3	0.24	VERO	100.00	409.00	11/10/88
AVS-0303	CPE	YFV	2.57	9.90	VERO	100.00	10.00	1/15/87
AVS-0303	CPE	YFV	1.1	100.00	VERO	0.32	----	8/19/87
AVS-0303	CPE	YFV	----	----	VERO	0.10	----	12/14/87
AVS-0332	CPE	AD2	0.40	----	HEP2	3.20	----	9/25/86
AVS-0332	CPE	JE	----	----	VERO	32.00	----	3/23/87
AVS-0332	CPE	JE	----	----	VERO	10.00	----	5/25/88
AVS-0332	CPE	PT	0.39	39.20	VERO	32.00	0.81	10/29/86
AVS-0332	CPE	SF	0.90	40.70	VERO	32.00	0.78	10/30/86
AVS-0332	CPE	VEE	1.05	10.00	VERO	3.20	0.32	5/15/87
AVS-0332	CPE	VEE	----	----	VERO	32.00	----	5/24/88
AVS-0332	CPE	VSX	0.3	----	L929	10.00	----	7/18/86
AVS-0332	CPE	VV	0.15	----	VERO	10.00	----	8/ 7/86
AVS-0332	CPE	YFV	----	----	VERO	0.32	----	1/30/87
AVS-0332	CPE	YFV	1.14	41.80	VERO	10.00	0.24	2/ 2/87
AVS-0343	CPE	AD2	----	----	HEP2	320.00	----	2/25/88
AVS-0343	CPE	JE	0.2	----	VERO	32.00	----	1/18/88
AVS-0343	CPE	VSX	----	----	L929	10.00	----	2/12/88
AVS-0343	CPE	VV	0.8	159.00	VERO	320.00	2.00	2/25/88
AVS-0345	CPE	AD2	----	----	HEP2	10.00	----	9/25/86
AVS-0345	CPE	JE	----	----	VERO	100.00	----	4/ 9/87
AVS-0345	PR	PIC	N/A	----	VERO	320.00	----	4/13/87
AVS-0345	PR	PIC	N/A	----	VERO	32.00	----	5/16/88
AVS-0345	CPE	SF	0.96	77.40	VERO	100.00	1.29	10/30/86
AVS-0345	CPE	VEE	0.55	93.90	VERO	10.00	0.11	5/15/87
AVS-0345	CPE	VSX	----	----	L929	10.00	----	7/18/86
AVS-0345	CPE	VV	0.9	100.00	VERO	100.00	1.00	5/28/87
AVS-0345	CPE	YFV	2.91	44.50	VERO	100.00	2.24	2/ 2/87
AVS-0346	CPE	AD2	----	----	HEP2	1.00	----	7/ 9/87
AVS-0346	CPE	JE	0.25	----	VERO	0.32	----	8/ 3/87
AVS-0346	CPE	JE	0.2	----	VERO	10.00	----	9/ 4/87
AVS-0346	CPE	JE	0.45	2.17	VERO	3.20	1.47	6/ 1/88
AVS-0346	CPE	PT	0.9	6.60	VERO	10.00	1.51	11/18/86
AVS-0346	CPE	PT	0.77	7.20	VERO	10.00	1.38	9/23/87
AVS-0346	CPE	SF	2.72	0.06	VERO	0.32	4.90	8/ 3/87
AVS-0346	CPE	SF	1.6	0.23	VERO	1.00	4.20	8/31/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0346	CPE	VEE	0.45	21.77	VERO	32.00	1.47	3/ 9/88
AVS-0346	CPE	VSV	0.95	0.41	L929	1.00	2.42	7/10/87
AVS-0346	CPE	VSV	1.4	0.08	L929	0.32	3.61	7/28/87
AVS-0346	CPE	VSV	0.6	----	L929	100.00	----	5/24/88
AVS-0346	CPE	VV	----	----	VERO	1.00	----	7/ 9/87
AVS-0346	CPE	YFV	0.7	0.84	VERO	1.00	1.18	6/ 3/87
AVS-0346	CPE	YFV	1.2	1.78	VERO	1.00	0.56	8/13/87
AVS-0347	CPE	AD2	0.80	0.07	HEP2 <	0.32 <	4.26	9/18/86
AVS-0347	CPE	AD2	----	----	HEP2	0.32	----	5/26/88
AVS-0347	CPE	JE	1.05	2.58	VERO	10.00	3.85	3/13/87
AVS-0347	CPE	JE	0.94	----	VERO	1.00	----	3/ 1/88
AVS-0347	CPE	JE	0.9	3.86	VERO	3.20	0.83	5/18/88
AVS-0347	PR	PIC	N/A	0.44	VERO	1.00	2.22	1/16/87
AVS-0347	PR	PIC	N/A	----	VERO <	0.10	----	2/ 3/87
AVS-0347	PR	PIC	N/A	----	VERO >	0.10	----	2/12/88
AVS-0347	PR	PIC	N/A	0.11	VERO	0.10	0.88	5/17/88
AVS-0347	CPE	PT	1.50	1.00	VERO	1.00	1.00	10/28/86
AVS-0347	CPE	SF	1.41	2.98	VERO	10.00	3.36	10/17/86
AVS-0347	CPE	SF	0.65	0.13	VERO	0.03	0.23	11/25/86
AVS-0347	CPE	SF	1.95	0.23	VERO	1.00	4.24	5/17/88
AVS-0347	CPE	VEE	1.5	2.75	VERO	1.00	0.36	5/ 6/87
AVS-0347	CPE	VEE	----	----	VERO	0.32	----	5/17/88
AVS-0347	CPE	VSV	0.6	1.78	L929	1.00	0.56	6/20/86
AVS-0347	CPE	VV	0.6	7.50	VERO	3.20	0.43	7/24/86
AVS-0347	CPE	YFV	0.75	5.00	VERO	10.00	1.98	1/22/87
AVS-0349	CPE	AD2	1.00	0.07	HEP2 <	0.32 <	4.58	9/18/86
AVS-0349	CPE	JE	0.20	5.00	VERO	10.00	1.97	3/13/87
AVS-0349	CPE	JE	0.5	6.30	VERO	3.20	0.50	5/18/88
AVS-0349	PR	PIC	N/A	1.63	VERO	3.20	1.95	1/16/87
AVS-0349	PR	PIC	N/A	----	VERO	0.32	----	5/17/88
AVS-0349	CPE	PT	0.45	3.10	VERO	3.20	1.03	10/28/86
AVS-0349	CPE	SF	1.71	2.48	VERO	3.20	1.29	10/17/86
AVS-0349	CPE	SF	0.55	----	VERO	3.20	----	11/25/86
AVS-0349	CPE	VEE	1.15	5.20	VERO	10.00	1.89	5/ 7/87
AVS-0349	CPE	VEE	----	----	VERO	1.00	----	5/17/88
AVS-0349	CPE	VSV	----	----	L929	1.00	----	6/20/86
AVS-0349	CPE	VV	0.45	----	VERO	10.00	----	7/24/86
AVS-0349	CPE	YFV	0.95	4.10	VERO	10.00	2.44	1/22/87
AVS-0351	CPE	JE	0.9	2.17	VERO <	10.00 <	4.60	8/ 4/87
AVS-0351	CPE	JE	0.25	----	VERO	0.32	----	7/21/88
AVS-0351	PR	PIC	N/A	----	VERO <	100.00	----	1/16/87
AVS-0351	PR	PIC	N/A	----	VERO <	320.00	----	3/27/87
AVS-0351	CPE	PT	0.60	9.30	VERO	10.00	1.08	10/28/86
AVS-0351	CPE	SF	----	----	VERO	3.20	----	8/ 4/87
AVS-0351	CPE	VEE	1.1	----	VERO >	10.00	----	5/ 7/87
AVS-0352	CPE	JE	0.6	5.60	VERO	10.00	1.76	8/ 4/87
AVS-0352	CPE	YFV	----	----	VERO	3.20	----	8/ 4/87
AVS-0353	CPE	AD2	----	----	HEP2 <	0.03	----	7/ 9/87
AVS-0353	CPE	JE	----	----	VERO -	0.32	----	9/ 4/87
AVS-0353	CPE	JE	----	----	VERO	0.01	----	5/25/88
AVS-0353	PR	PIC	N/A	----	VERO	0.03	----	8/23/88
AVS-0353	CPE	PT	----	----	VERO -	100.00	----	11/11/87
AVS-0353	CPE	SF	0.4	0.07	VERO	0.03	0.43	8/31/87
AVS-0353	CPE	VSV	----	----	L929 -	0.32	----	7/10/87
AVS-0353	CPE	VV	----	----	VERO	0.10	----	7/ 9/87
AVS-0353	CPE	YFV	----	----	VERO	0.03	----	8/31/87
AVS-0353	CPE	YFV	0.3	----	VERO	0.03	----	2/ 2/88
AVS-0360	CPE	AD2	1.50	0.10	HEP2	0.10	0.99	9/18/86
AVS-0360	CPE	JE	1.18	----	VERO	0.03	3.43	3/27/87
AVS-0360	CPE	JE	----	----	VERO >	10.00	----	5/18/88
AVS-0360	PR	PIC	N/A	0.18	VERO	1.00	5.46	1/23/87
AVS-0360	PR	PIC	N/A	----	VERO	0.32	----	5/23/88
AVS-0360	CPE	SF	2.49	0.01	VERO	0.32	18.40	10/17/86
AVS-0360	CPE	SF	1.80	0.32	VERO	1.00	3.13	11/ 5/86
AVS-0360	CPE	SF	1.05	----	VERO	0.03	----	11/25/86

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0584	CPE	VSV	----	----	L929	320.00	----	9/29/87
AVS-0584	CPE	VV	----	----	VERO >	320.00	----	9/24/87
AVS-0584	CPE	YFV	----	----	VERO >	320.00	----	7/28/88
AVS-0585	CPE	AD2	----	----	HEP2	320.00	----	9/24/87
AVS-0585	CPE	JE	----	----	VERO <	320.00	----	10/20/87
AVS-0585	PR	PIC	N/A	----	VERO	32.00	----	11/ 7/88
AVS-0585	CPE	PT	----	----	VERO >	320.00	----	7/28/88
AVS-0585	CPE	VEE	----	----	VERO	100.00	----	7/28/88
AVS-0585	CPE	VSV	----	----	L929	100.00	----	9/29/87
AVS-0585	CPE	VV	0.1	----	VERO	100.00	----	9/24/87
AVS-0585	CPE	YFV	----	----	VERO >	320.00	----	7/28/88
AVS-0586	CPE	AD2	----	----	HEP2	320.00	----	9/24/87
AVS-0586	CPE	JE	----	----	VERO	320.00	----	10/20/87
AVS-0586	PR	PIC	N/A	----	VERO	320.00	----	11/11/88
AVS-0586	CPE	PT	----	----	VERO	100.00	----	7/28/88
AVS-0586	CPE	VEE	----	----	VERO	100.00	----	7/28/88
AVS-0586	CPE	VSV	----	----	L929	320.00	----	9/29/87
AVS-0586	CPE	VV	----	----	VERO >	320.00	----	9/24/87
AVS-0586	CPE	YFV	0.4	----	VERO >	320.00	----	7/28/88
AVS-0587	CPE	AD2	0.3	----	HEP2 >	320.00	----	10/ 8/87
AVS-0587	CPE	JE	----	----	VERO	320.00	----	10/20/87
AVS-0587	PR	PIC	N/A	----	VERO >	320.00	----	11/11/88
AVS-0587	CPE	PT	----	----	VERO >	320.00	----	7/28/88
AVS-0587	CPF	SF	0.8	----	VERO	320.00	----	2/18/88
AVS-0587	CPE	VEE	----	----	VERO	100.00	----	7/28/88
AVS-0587	CPE	VSV	----	----	L929	320.00	----	9/29/87
AVS-0587	CPE	VV	----	----	VERO >	320.00	----	10/ 8/87
AVS-0587	CPE	YFV	----	----	VERO >	320.00	----	7/28/88
AVS-0588	CPE	AD2	0.1	----	HEP2 >	320.00	----	10/ 8/87
AVS-0588	CPE	JE	----	----	VERO	320.00	----	10/20/87
AVS-0588	PR	PIC	N/A	----	VERO	320.00	----	11/11/88
AVS-0588	CPE	PT	----	----	VERO	320.00	----	7/28/88
AVS-0588	CPE	VEE	----	----	VERO >	320.00	----	7/28/88
AVS-0588	CPE	VSV	0.15	----	L929	320.00	----	9/29/87
AVS-0588	CPE	VV	----	----	VERO >	320.00	----	10/ 8/87
AVS-0588	CPE	YFV	0.4	----	VERO >	320.00	----	7/28/88
AVS-0593	CPE	AD2	----	----	HEP2 >	320.00	----	9/25/86
AVS-0593	CPE	JE	----	----	VERO >	320.00	----	3/23/87
AVS-0593	CPE	JE	----	----	VERO	32.00	----	5/20/88
AVS-0593	PR	PIC	N/A	----	VERO >	100.00	----	3/23/87
AVS-0593	PR	PIC	N/A	----	VERO	320.00	----	5/16/88
AVS-0593	CPE	SF	----	----	VERO >	100.00	----	11/19/86
AVS-0593	CPE	VEE	----	----	VERO	32.00	----	12/ 1/87
AVS-0593	CPE	VSV	----	----	L929	320.00	----	6/27/86
AVS-0593	CPE	VV	----	----	VERO	320.00	----	7/31/86
AVS-0593	CPE	YFV	0.73	261.00	VERO	320.00	1.22	1/30/87
AVS-0598	CPE	AD2	----	----	HEP2 >	320.00	----	10/ 8/87
AVS-0598	CPE	JE	----	----	VERO	3.20	----	11/ 5/87
AVS-0598	PR	PIC	N/A	234.00	VERO	100.00	0.43	11/11/88
AVS-0598	CPE	PT	----	----	VERO	32.00	----	7/28/88
AVS-0598	CPE	VEE	----	----	VERO	32.00	----	7/28/88
AVS-0598	CPE	VSV	----	----	L929	100.00	----	9/29/87
AVS-0598	CPE	VV	----	----	VERO <	320.00	----	10/ 8/87
AVS-0598	CPE	YFV	0.2	----	VERO >	320.00	----	7/28/88
AVS-0599	CPE	AD2	0.3	----	HEP2 >	320.00	----	10/ 8/87
AVS-0599	CPE	JE	----	----	VERO	320.00	----	11/ 5/87
AVS-0599	PR	PIC	N/A	----	VERO	320.00	----	11/11/88
AVS-0599	CPE	PT	----	----	VERO >	320.00	----	7/28/88
AVS-0599	CPE	VEE	----	----	VERO	100.00	----	7/28/88
AVS-0599	CPE	VSV	----	----	L929 <	320.00	----	9/29/87
AVS-0599	CPE	VV	0.2	----	VERO >	320.00	----	10/ 8/87
AVS-0599	CPE	YFV	----	----	VERO >	320.00	----	7/28/88
AVS-0600	CPE	AD2	0.1	----	HEP2 >	320.00	----	10/ 8/87
AVS-0600	CPE	JE	0.45	----	VERO	320.00	----	11/ 5/87
AVS-0600	PR	PIC	N/A	----	VERO >	320.00	----	11/11/88

B-47

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0600	CPE	PT	----	----	VERO	320.00	----	7/25/88
AVS-0600	CPE	VEE	----	----	VERO	100.00	----	7/28/88
AVS-0600	CPE	VSV	----	----	L929 <	320.00	----	9/29/87
AVS-0600	CPE	VV	----	----	VERO >	320.00	----	10/ 8/87
AVS-0600	CPE	YFV	0.3	----	VERO >	320.00	----	7/28/88
AVS-0646	CPE	AD2	1.45	1.56	HEP2	3.20	2.04	9/18/86
AVS-0646	CPE	JE	2.9	----	VERO	0.03	4.57	3/27/87
AVS-0646	CPE	JE	3.45	0.02	VERO	0.03	1.22	5/18/88
AVS-0646	PR	PIC	N/A	0.14	VERO >	100.00 >	680.00	1/23/87
AVS-0646	PR	PIC	N/A	0.37	VERO >	10.00 >	26.90	2/ 3/87
AVS-0646	CPE	PT	1.59	13.20	VERO	0.32	0.02	10/31/86
AVS-0646	CPE	SF	4.20	0.10	VERO	3.20	32.00	10/17/86
AVS-0646	CPE	SF	4.41	0.46	VERO	10.00	21.80	11/ 5/86
AVS-0646	CPE	SF	0.8	0.42	VERO	0.32	0.75	8/18/87
AVS-0646	CPE	SF	3.45	0.03	VERO	0.10	2.65	5/17/88
AVS-0646	CPE	VEE	3.15	0.05	VERO	0.10	1.96	5/ 7/87
AVS-0646	CPE	VEE	2.75	0.08	VERO	0.10	1.20	5/17/88
AVS-0646	CPE	VSV	----	----	L929	100.00	----	6/24/86
AVS-0646	CPE	VV	3.95	0.60	VERO	1.00	1.66	7/24/86
AVS-0646	CPE	YFV	3.10	0.24	VERO	3.20	13.00	3/ 6/87
AVS-0646	CPE	YFV	0.65	0.52	VERO	0.03	0.06	8/19/87
AVS-0646	CPE	YFV	1.65	0.08	VERO	0.10	1.20	12/14/87
AVS-0646	CPE	YFV	3.15	0.04	VERO	0.03	0.68	5/17/88
AVS-0697	CPE	AD2	0.2	----	HEP2 >	320.00	----	10/ 8/87
AVS-0697	CPE	JE	----	----	VERO >	320.00	----	11/ 5/87
AVS-0697	CPE	JE	----	----	VERO	320.00	----	5/25/88
AVS-0697	PR	PIC	N/A	----	VERG >	320.00	----	11/11/88
AVS-0697	CPE	PT	----	----	VERO	100.00	----	7/28/88
AVS-0697	CPE	VEE	----	----	VERO >	320.00	----	7/28/88
AVS-0697	CPE	VSV	----	----	L929 >	320.00	----	9/29/87
AVS-0697	CPE	VV	----	----	VERO >	320.00	----	10/ 8/87
AVS-0697	CPE	YFV	----	----	VERO >	320.00	----	7/28/88
AVS-0698	CPE	AD2	0.3	----	HEP2 >	320.00	----	10/ 8/87
AVS-0698	CPE	JE	----	----	VERO	320.00	----	10/ 9/87
AVS-0698	PR	PIC	N/A	----	VERO	100.00	----	11/11/88
AVS-0698	CPE	PT	----	----	VERO >	320.00	----	7/28/88
AVS-0698	CPE	VEE	----	----	VERO	32.00	----	7/28/88
AVS-0698	CPE	VSV	----	----	L929	320.00	----	9/29/87
AVS-0698	CPE	VV	0.4	----	VERO >	320.00	----	10/ 8/87
AVS-0698	CPE	YFV	0.1	----	VERO >	320.00	----	7/28/88
AVS-0700	CPE	AD2	----	----	HEP2 >	320.00	----	10/ 8/87
AVS-0700	CPE	JE	----	----	VERO	100.00	----	10/ 9/87
AVS-0700	PR	PIC	N/A	----	VERG	100.00	----	11/11/88
AVS-0700	CPE	PT	----	----	VERO	32.00	----	7/23/88
AVS-0700	CPE	SF	0.6	----	VERO	32.00	----	2/18/88
AVS-0700	CPE	VEE	----	----	VERO	32.00	----	7/28/88
AVS-0700	CPE	VSV	----	----	L929	100.00	----	10/13/87
AVS-0700	CPE	VV	0.1	----	VERO	320.00	----	10/ 8/87
AVS-0700	CPE	YFV	----	----	VERO <	100.00	----	7/28/88
AVS-0701	CPE	AD2	----	----	HEP2 <	10.00	----	9/25/86
AVS-0701	CPE	JE	0.6	24.30	VERO	10.00	0.41	4/ 9/87
AVS-0701	CPE	JE	0.4	23.90	VERO	10.00	0.42	5/18/88
AVS-0701	PR	PIC	N/A	----	VERO <	32.00	----	4/13/87
AVS-0701	CPE	SF	1.11	26.20	VERO	32.00	1.22	10/30/86
AVS-0701	CPE	VEE	0.9	7.10	VERO	1.00	0.14	5/15/87
AVS-0701	CPE	VEE	----	----	VERO	1.00	----	5/17/88
AVS-0701	CPE	VSV	----	----	L929	32.00	----	7/18/86
AVS-0701	CPE	VV	----	----	VERO	3.20	----	8/ 7/86
AVS-0701	CPE	YFV	0.28	----	VERO	32.00	----	2/ 2/87
AVS-0702	CPE	AD2	----	----	HEP2 >	320.00	----	10/ 8/87
AVS-0702	CPE	JE	----	----	VERO >	320.00	----	10/ 9/87
AVS-0702	PR	PIC	N/A	----	VERO	320.00	----	11/11/88
AVS-0702	CPE	PT	0.3	320.00	VERO	320.00	1.00	7/28/88
AVS-0702	CPE	VEE	----	----	VERO	32.00	----	7/28/88
AVS-0702	CPE	VSV	----	----	L929	320.00	----	10/13/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0702	CPE	VV	----	----	VERO >	320.00	----	10/ 8/87
AVS-0702	CPE	YFV	0.4	222.00	VERO	320.00	1.43	7/28/88
AVS-0703	CPE	AD2	0.20	----	HEP2	100.00	----	9/25/86
AVS-0703	CPE	JE	0.85	98.00	VERO	32.00	0.32	4/ 9/87
AVS-0703	CPE	JE	----	----	VERO	3.20	----	5/24/88
AVS-0703	PR	PIC	N/A	----	VERO >	100.00	----	5/23/88
AVS-0703	CPE	SF	1.59	51.30	VERO	32.00	0.62	11/ 3/86
AVS-0703	CPE	VEE	1.35	20.90	VERO	32.00	1.53	5/15/87
AVS-0703	CPE	VEE	----	----	VERO	100.00	----	5/24/88
AVS-0703	CPE	VSV	----	----	L929	32.00	----	7/18/86
AVS-0703	CPE	VV	----	----	VERO	10.00	----	8/ 7/86
AVS-0703	CPE	YFV	3.00	2.46	VERO	32.00	12.90	2/ 2/87
AVS-0703	CPE	YFV	1.33	17.40	VERO	10.00	0.57	7/29/87
AVS-0703	CPE	YFV	0.45	68.30	VERO	100.00	1.46	12/14/87
AVS-0704	CPE	AD2	----	----	HEP2 <	10.00	----	10/ 8/87
AVS-0704	CPE	JE	----	----	VERO	1.00	----	10/ 9/87
AVS-0704	CPE	JE	----	----	VERO <	10.00	----	5/25/88
AVS-0704	CPE	PT	----	----	VERO	10.00	----	8/ 4/88
AVS-0704	CPE	SF	1.8	4.35	VERO	3.20	0.74	2/18/88
AVS-0704	CPE	VEE	----	----	VERO	1.00	----	8/ 4/88
AVS-0704	CPE	VSV	----	----	L929	10.00	----	10/13/87
AVS-0704	CPE	VV	----	----	VERO	3.20	----	10/ 8/87
AVS-0704	CPE	YFV	0.15	----	VERO	3.20	----	8/ 4/88
AVS-0705	CPE	AD2	0.3	----	HEP2 >	320.00	----	10/ 8/87
AVS-0705	CPE	JE	----	----	VERO	320.00	----	10/13/87
AVS-0705	CPE	JE	----	----	VERO	100.00	----	6/ 1/88
AVS-0705	CPE	PT	----	----	VERO	320.00	----	8/ 4/88
AVS-0705	CPE	SF	----	----	VERO	320.00	----	8/ 4/88
AVS-0705	CPE	VEE	----	----	VERO	320.00	----	8/ 4/88
AVS-0705	CPE	VSV	----	----	L929	100.00	----	10/13/87
AVS-0705	CPE	VV	----	----	VERO >	320.00	----	10/ 8/87
AVS-0705	CPE	YFV	----	----	VERO	320.00	----	8/ 4/88
AVS-0706	CPE	AD2	----	----	HEP2	32.00	----	10/ 8/87
AVS-0706	CPE	JE	----	----	VERO <	10.00	----	10/13/87
AVS-0706	CPE	PT	----	----	VERO	10.00	----	8/ 4/88
AVS-0706	CPE	SF	0.55	22.10	VERO	32.00	1.44	8/ 4/88
AVS-0706	CPE	VEE	----	----	VERO	10.00	----	8/ 4/88
AVS-0706	CPE	VSV	----	----	L929	10.00	----	10/13/87
AVS-0706	CPE	VV	----	----	VERO <	10.00	----	10/ 8/87
AVS-0706	CPE	YFV	----	----	VERO	32.00	----	8/ 4/88
AVS-0707	CPE	AD2	----	----	HEP2 <	10.00	----	10/22/87
AVS-0707	CPE	JE	0.28	94.90	VERO	100.00	1.05	10/13/87
AVS-0707	CPE	PT	----	----	VERO	32.00	----	8/ 4/88
AVS-0707	CPE	SF	----	----	VERO	32.00	----	8/ 4/88
AVS-0707	CPE	VEE	----	----	VERO	10.00	----	8/ 4/88
AVS-0707	CPE	VSV	----	----	L929	32.00	----	10/13/87
AVS-0707	CPE	VV	1.95	16.90	VERO	100.00	5.90	10/22/87
AVS-0707	CPE	VV	0.65	24.10	VERO	32.00	1.32	11/12/87
AVS-0707	CPE	VV	1.15	129.00	VERO	320.00	2.47	5/12/88
AVS-0707	CPE	YFV	0.1	----	VERO	10.00	----	8/ 4/88
AVS-0708	CPE	AD2	0.5	----	HEP2 <	320.00	----	10/22/87
AVS-0708	CPE	JE	0.23	----	VERO	100.00	----	10/13/87
AVS-0708	CPE	PT	0.5	63.30	VERO	32.00	0.50	8/ 4/88
AVS-0708	CPE	SF	0.75	35.90	VERO	10.00	0.28	8/ 4/88
AVS-0708	CPE	VEE	----	----	VERO	32.00	----	8/ 4/88
AVS-0708	CPE	VSV	----	----	L929	32.00	----	10/13/87
AVS-0708	CPE	VV	----	----	VERO	32.00	----	10/22/87
AVS-0708	CPE	YFV	0.55	59.30	VERO	32.00	0.34	8/ 4/88
AVS-0709	CPE	AD2	0.3	----	HEP2 >	320.00	----	10/ 8/87
AVS-0709	CPE	JE	----	----	VERO >	320.00	----	10/14/87
AVS-0709	CPE	PT	----	----	VERO	10.00	----	8/ 4/88
AVS-0709	CPE	SF	----	----	VERO	32.00	----	8/ 4/88
AVS-0709	CPE	VEE	----	----	VERO	100.00	----	8/ 4/88
AVS-0709	CPE	VSV	0.35	270.00	L929	320.00	1.18	10/13/87
AVS-0709	CPE	VV	0.1	----	VERO >	320.00	----	10/ 8/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-0709	CPE	YFV	0.25	----	VERO	32.00	----	8/ 4/88
AVS-0710	CPE	AD2	----	----	HEP2 <	100.00	----	10/ 8/87
AVS-0710	CPE	JE	----	----	VERO	100.00	----	10/14/87
AVS-0710	CPE	PT	----	----	VERO	10.00	----	8/ 4/88
AVS-0710	CPE	SF	0.4	23.90	VERO	10.00	0.42	8/ 4/88
AVS-0710	CPE	VEE	----	----	VERO	10.00	----	8/ 4/88
AVS-0710	CPE	VSV	----	----	L929	32.00	----	10/13/87
AVS-0710	CPE	VV	----	----	VERO <	100.00	----	10/ 8/87
AVS-0710	CPE	YFV	----	----	VERO	10.00	----	8/ 4/88
AVS-0712	CPE	AD2	----	----	HEP2 <	320.00	----	10/22/87
AVS-0712	CPE	JE	2.05	12.70	VERO	100.00	7.84	10/14/87
AVS-0712	CPE	JE	0.4	320.00	VERO	100.00	0.31	6/ 1/88
AVS-0712	CPE	PT	----	----	VERO	320.00	----	8/ 4/88
AVS-0712	CPE	SF	0.05	----	VERO	100.00	----	8/ 4/88
AVS-0712	CPE	VEE	----	----	VERO	32.00	----	8/ 4/88
AVS-0712	CPE	VSV	----	----	L929	10.00	----	10/13/87
AVS-0712	CPE	VV	----	----	VERO	100.00	----	10/22/87
AVS-0712	CPE	YFV	0.8	----	VERO	320.00	----	8/ 4/88
AVS-0713	CPE	AD2	----	----	HEP2	32.00	----	10/22/87
AVS-0713	CPE	JE	----	----	VERO <	32.00	----	10/14/87
AVS-0713	CPE	JE	----	----	VERO	10.00	----	6/ 1/88
AVS-0713	CPE	PT	----	----	VERO	32.00	----	8/ 4/88
AVS-0713	CPE	SF	0.1	----	VERO	3.20	----	8/ 4/88
AVS-0713	CPE	VEE	----	----	VERO	32.00	----	8/ 4/88
AVS-0713	CPE	VSV	----	----	L929	32.00	----	10/13/87
AVS-0713	CPE	VV	----	----	VERO	32.00	----	10/22/87
AVS-0713	CPE	YFV	----	----	VERO	10.00	----	8/ 4/88
AVS-0714	CPE	AD2	0.15	----	HEP2	320.00	----	10/22/87
AVS-0714	CPE	JE	----	----	VERO >	320.00	----	10/16/87
AVS-0714	CPE	PT	0.45	217.00	VERO	32.00	0.15	8/ 4/88
AVS-0714	CPE	SF	1.3	58.60	VERO	32.00	0.55	8/ 4/88
AVS-0714	CPE	VEE	----	----	VERO	10.00	----	8/ 4/88
AVS-0714	CPE	VSV	----	----	L929	100.00	----	11/ 6/87
AVS-0714	CPE	VV	----	----	VERO	32.00	----	10/22/87
AVS-0714	CPE	YFV	0.65	174.00	VERO	32.00	0.18	8/ 4/88
AVS-0715	CPE	AD2	0.3	100.00	HEP2	100.00	1.00	10/22/87
AVS-0715	CPE	JE	----	----	VERO >	320.00	----	10/16/87
AVS-0715	PR	PIC	N/A	----	VERO	32.00	----	11/15/88
AVS-0715	CPE	PT	----	----	VERO	32.00	----	8/ 4/88
AVS-0715	CPE	SF	0.6	56.30	VERO	10.00	0.18	8/ 4/88
AVS-0715	CPE	VEE	----	----	VERO	32.00	----	8/ 4/88
AVS-0715	CPE	VSV	----	----	L929 <	320.00	----	11/ 6/87
AVS-0715	CPE	VV	----	----	VERO	100.00	----	10/22/87
AVS-0715	CPE	YFV	0.4	70.00	VERO	32.00	0.46	8/ 4/88
AVS-0716	CPE	AD2	0.3	----	HEP2 >	320.00	----	10/22/87
AVS-0716	CPE	JE	0.5	----	VERO	320.00	----	10/16/87
AVS-0716	PR	PIC	N/A	----	VERO	320.00	----	11/15/88
AVS-0716	CPE	PT	----	----	VERO	100.00	----	8/ 4/88
AVS-0716	CPE	SF	0.75	112.00	VERO	100.00	0.89	8/ 4/88
AVS-0716	CPE	VEE	----	----	VERO >	320.00	----	8/ 4/88
AVS-0716	CPE	VSV	0.05	----	L929	320.00	----	11/ 6/87
AVS-0716	CPE	VV	----	----	VERO	320.00	----	10/22/87
AVS-0716	CPE	YFV	0.05	----	VERO	320.00	----	8/ 4/88
AVS-0801	CPE	JE	----	----	VERO	32.00	----	5/ 5/87
AVS-0801	PR	PIC	N/A	14.10	VERO	10.00	0.71	5/23/88
AVS-0801	CPE	PT	0.08	----	VERO	32.00	----	12/30/86
AVS-0801	CPE	SF	0.98	----	VERO	10.00	----	12/15/86
AVS-0801	CPE	YFV	0.75	9.70	VERO	10.00	1.03	2/19/87
AVS-0866	CPE	AD2	----	----	HEP2	100.00	----	10/16/86
AVS-0866	CPE	JE	1.1	46.40	VERO	100.00	2.15	7/10/87
AVS-0866	CPE	PT	0.02	----	VERO	10.00	----	7/24/87
AVS-0866	CPE	VEE	----	----	VERO >	100.00	----	5/15/87
AVS-0866	CPE	VSV	----	----	L929	10.00	----	7/18/86
AVS-0866	CPE	VV	----	----	VERO	100.00	----	10/16/86
AVS-0890	CPE	VEE	----	----	VERO	100.00	----	4/29/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-0913	CPE	AD2	0.4	----	HEP2 >	320.00	----	2/ 4/88
AVS-0913	CPE	JE	----	----	VERO "	0.32	----	1/18/88
AVS-0913	CPE	VSV	----	----	L929	100.00	----	2/12/88
AVS-0913	CPE	VV	----	----	VERO >	320.00	----	2/ 4/88
AVS-0968	CPE	AD2	----	----	HEP2 >	320.00	----	7/ 9/87
AVS-0968	CPE	JE	0.2	----	VERO >	320.00	----	8/26/87
AVS-0968	CPE	SF	----	----	VERO	100.00	----	9/23/87
AVS-0968	CPE	SF	0.3	320.00	VERO	320.00	1.00	5/18/88
AVS-0968	CPE	VSV	----	----	L929	320.00	----	7/28/87
AVS-0968	CPE	VSV	----	----	L929	100.00	----	5/10/88
AVS-0968	CPE	VV	----	----	VERO >	320.00	----	7/ 9/87
AVS-0968	CPE	YFV	0.1	----	VERO	32.00	----	9/23/87
AVS-0999	CPE	AD2	----	----	HEP2	100.00	----	9/25/86
AVS-0999	CPE	JE	----	----	VERO	100.00	----	3/24/87
AVS-0999	PR	PIC	N/A	----	VERO <	320.00	----	4/13/87
AVS-0999	CPE	VEE	----	----	VERO	320.00	----	5/15/87
AVS-0999	CPE	VEE	----	----	VERO	100.00	----	6/ 1/88
AVS-0999	CPE	VSV	----	----	L929	100.00	----	8/ 1/86
AVS-0999	CPE	VV	----	----	VERO	320.00	----	8/ 7/86
AVS-0999	CPE	YFV	----	----	VERO	100.00	----	2/ 3/87
AVS-1019	CPE	AD2	----	----	HEP2	0.32	----	9/ 4/87
AVS-1019	PR	HTN	N/A	----	VERC	0.32	----	2/12/88
AVS-1019	CPE	JE	2.45	1.33	VERO	3.20	2.39	9/21/87
AVS-1019	CPE	PT	2.55	0.56	VERO "	0.32 "	0.56	11/30/87
AVS-1019	CPE	SF	2.9	0.56	VERO "	0.32 "	0.56	11/30/87
AVS-1019	CPE	VSV	2.45	0.53	L929	0.32	0.60	8/21/87
AVS-1019	CPE	VV	3.	3.32	VERO	10.00	3.00	8/27/87
AVS-1019	CPE	YFV	3.45 <	0.32	VERO "	0.32 >	1.00	11/30/87
AVS-1019	CPE	YFV	1.05	0.26	VERO	0.10	0.38	2/ 2/88
AVS-1052	CPE	VEE	----	----	VERO	100.00	----	4/29/88
AVS-1089	CPE	AD2	1.00	3.20	HEP2	10.00	3.13	9/25/86
AVS-1089	CPE	JE	4.18	0.45	VERO	3.20	7.07	4/ 9/87
AVS-1089	CPE	JE	1.8	1.96	VERO	3.20	1.63	5/18/88
AVS-1089	PR	PIC	N/A	0.94	VERO	1.00	1.05	4/13/87
AVS-1089	CPE	PT	3.39	0.73	VERO	3.20	4.40	11/14/86
AVS-1089	CPE	PT	1.9	1.41	VERO	0.32	0.22	5/18/88
AVS-1089	CPE	SF	5.19	1.04	VERO >	100.00 >	96.30	11/ 3/86
AVS-1089	CPE	SF	3.42	1.05	VERO	3.20	3.04	7/27/87
AVS-1089	CPE	VEE	3.35	2.84	VERO	100.00	35.10	5/15/87
AVS-1089	CPE	VEE	0.95	6.00	VERO	3.20	0.52	5/18/88
AVS-1089	CPE	VSV	2.15	7.70	L929 "	1.00 "	0.13	8/ 1/86
AVS-1089	CPE	VV	1.65	81.40	VERO	320.00	3.93	8/ 7/86
AVS-1089	CPE	YFV	2.50	3.07	VERO	3.20	1.03	2/ 3/87
AVS-1089	CPE	YFV	1.6	2.79	VERO	3.20	1.14	5/18/88
AVS-1159	CPE	AD2	1.2	18.00	HEP2	10.00	0.55	8/13/87
AVS-1159	CPE	JE	----	----	VERO >	320.00	----	9/ 8/87
AVS-1159	PR	PIC	N/A	----	VERO	100.00	----	9/12/88
AVS-1159	CPE	SF	1.54	14.40	VERO	32.00	2.21	9/28/87
AVS-1159	CPE	VSV	1.9	15.90	L929	100.00	6.26	7/28/87
AVS-1159	CPE	VSV	2.6	8.80	L929	100.00	11.20	10/13/87
AVS-1159	PR	VSV	N/A	10.60	L929	32.00	2.99	11/ 4/87
AVS-1159	CPE	VV	1.45	22.10	VERO	100.00	4.50	8/13/87
AVS-1159	CPE	VV	1.33	21.70	VERO	100.00	4.60	5/12/88
AVS-1159	CPE	YFV	1.	21.70	VERO	32.00	1.47	9/28/87
AVS-1160	CPE	AD2	0.70	3.14	HEP2	3.20	1.02	9/25/86
AVS-1160	CPE	JE	0.55	3.00	VERC	3.20	1.06	3/24/87
AVS-1160	PR	PIC	N/A	----	VERO	3.20	----	4/21/87
AVS-1160	CPE	PT	0.84	51.40	VERO	0.70	0.01	11/14/86
AVS-1160	CPE	SF	1.26	49.40	VERO	100.00	2.01	11/ 3/86
AVS-1160	CPE	VEE	3.35	5.80	VERO	32.00	5.48	5/15/87
AVS-1160	CPE	VEE	----	----	VERO	10.00	----	5/17/88
AVS-1160	CPE	VSV	3.15 <	0.32	L929	1.00 >	3.12	7/18/86
AVS-1160	CPE	VSV	2.6	1.00	L929	3.20	3.20	8/15/86
AVS-1160	CPE	VSV	2.8	0.21	L929	1.00	4.63	3/18/88
AVS-116	CPE	VSV	2.8	0.26	L929	1.00	3.77	3/25/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-1160	CPE	VSF	3.05	0.24	L929	1.00	4.14	3/29/88
AVS-1160	CPE	VSF	1.85	0.63	L929	1.00	1.57	4/ 1/88
AVS-1160	CPE	VSF	3.	0.29	L929	1.00	3.36	4/ 5/88
AVS-1160	CPE	VSF	2.3	0.42	L929	1.00	2.37	4/ 8/88
AVS-1160	CPE	VSF	2.45	0.38	L929	1.00	2.58	4/12/88
AVS-1160	CPE	VSF	2.1	0.92	L929	1.00	1.08	4/15/88
AVS-1160	CPE	VSF	2.9	0.29	L929	1.00	3.38	4/19/88
AVS-1160	CPE	VSF	2.65	0.59	L929	3.20	5.37	5/ 3/88
AVS-1160	CPE	VSF	4.85	0.29	L929	10.00	33.60	5/10/88
AVS-1160	CPE	VSF	3.65	0.26	L929	3.20	12.10	5/13/88
AVS-1160	CPE	VSF	2.55	0.46	L929	1.00	2.13	5/24/88
AVS-1160	CPE	VSF	2.9	0.31	L929	1.00	3.15	6/ 7/88
AVS-1160	CPE	VSF	1.8	0.63	L929	1.00	1.57	6/22/88
AVS-1160	CPE	VSF	1.8	0.63	L929	1.00	1.57	6/22/88
AVS-1160	CPE	VSF	1.75	2.30	L929	3.20	1.38	6/28/88
AVS-1160	CPE	VSF	2.15	0.44	L929	1.00	2.25	7/20/88
AVS-1160	CPE	VSF	2.05	1.00	L929	3.20	3.17	8/30/88
AVS-1160	CPE	VSF	1.65	1.39	L929	3.20	2.29	10/18/88
AVS-1160	CPE	VSF	2.25	0.83	L929	1.00	1.20	11/16/88
AVS-1160	CPE	VSF	2.9	0.32	L929	1.00	3.12	11/18/88
AVS-1160	CPE	VV	5.6	0.60	VERO	100.00	166.00	8/ 7/86
AVS-1160	CPE	VV	2.55	5.70	VERO	10.00	1.73	5/12/88
AVS-1160	CPE	YFV	1.33	25.00	VERO	32.00	1.27	2/ 6/87
AVS-1176	CPE	AD2	0.2	----	HEP2 >	320.00	----	10/13/88
AVS-1176	CPE	VSF	----	----	L929 >	320.00	----	11/18/88
AVS-1176	CPE	VV	----	----	VERO >	320.00	----	10/13/88
AVS-1192	CPE	JE	----	----	VERO <	1.00	----	3/24/87
AVS-1192	PR	PIC	N/A	----	VERO	100.00	0.68	4/21/87
AVS-1192	CPE	SF	0.30	----	VERO <	0.01	----	12/ 2/86
AVS-1192	CPE	VEE	----	----	VERO	0.03	----	5/18/87
AVS-1192	CPE	YFV	----	----	VERO <	0.32	----	2/ 3/87
AVS-1207	CPE	AD2	----	----	HEP2	100.00	----	2/25/88
AVS-1207	CPE	JE	0.6	178.00	VERO	100.00	0.56	3/22/88
AVS-1207	CPE	PT	----	----	VERO	32.00	----	4/15/88
AVS-1207	CPE	SF	0.85	118.00	VERO	100.00	0.85	3/22/88
AVS-1207	CPE	VEE	----	----	VERO <	100.00	----	3/22/88
AVS-1207	CPE	VSF	----	----	L929	100.00	----	2/19/88
AVS-1207	CPE	VV	----	----	VERO <	320.00	----	2/25/88
AVS-1207	CPE	YFV	0.35	270.00	VERO	100.00	0.37	3/22/88
AVS-1210	CPE	AD2	1.1	19.90	HEP2 <	100.00 <	5.01	8/20/87
AVS-1210	CPE	JE	0.4	----	VERO <	320.00	----	10/ 1/87
AVS-1210	CPE	PT	----	----	VERO	320.00	----	8/28/87
AVS-1210	CPE	SF	2.9	27.90	VERO	320.00	11.40	9/28/87
AVS-1210	CPE	SF	0.5	221.00	VERO	100.00	0.45	5/18/88
AVS-1210	CPE	VV	0.05	----	VERO	100.00	----	8/20/87
AVS-1210	CPE	YFV	0.35	270.00	VERO	320.00	1.18	9/28/87
AVS-1210	CPE	YFV	0.15	----	VERO	320.00	----	5/18/88
AVS-1211	CPE	AD2	1.3	4.91	HEP2 <	32.00 <	6.51	8/20/87
AVS-1211	CPE	JE	0.3	----	VERO >	320.00	----	10/ 1/87
AVS-1211	CPE	PT	----	----	VERO >	320.00	----	8/28/87
AVS-1211	CPE	SF	1.34	13.20	VERO	32.00	2.41	9/28/87
AVS-1211	CPE	VV	1.5	62.10	VERO	320.00	5.15	8/20/87
AVS-1211	CPE	YFV	----	----	VERO	32.00	----	9/28/87
AVS-1212	CPE	AD2	0.9	24.60	HEP2 <	100.00 <	4.05	8/13/87
AVS-1212	CPE	AD2	0.3	----	HEP2 <	100.00	----	5/12/88
AVS-1212	CPE	JE	----	----	VERO >	320.00	----	9/ 8/87
AVS-1212	PR	PIC	N/A	----	VERO	100.00	----	9/12/88
AVS-1212	CPE	PT	0.4	----	VERO >	320.00	----	8/28/87
AVS-1212	CPE	PT	1.45	45.70	VERO	100.00	2.18	5/20/88
AVS-1212	CPE	SF	1.95	14.10	VERO	32.00	2.25	9/29/87
AVS-1212	CPE	VSF	----	----	L929 <	320.00	----	7/28/87
AVS-1212	CPE	VV	0.15	----	VERO	100.00	----	8/13/87
AVS-1212	CPE	YFV	0.25	----	VERO	10.00	----	9/29/87
AVS-1213	CPE	AD2	0.55	69.80	HEP2	100.00	1.43	8/13/87
AVS-1213	CPE	JE	0.8	277.00	VERO >	320.00 >	1.15	9/ 8/87

B-52

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NT500	TI	DATE
AVS-1213	PR	PIC	N/A	----	VERO >	3.20	----	9/12/88
AVS-1213	CPE	PT	0.35	270.00	VERO	320.00	1.18	8/28/87
AVS-1213	CPE	PT	----	----	VERO >	320.00	----	10/29/87
AVS-1213	CPE	SF	2.	53.70	VERO	320.00	5.95	9/29/87
AVS-1213	CPE	SF	0.95	99.00	VERO	100.00	1.00	5/18/88
AVS-1213	CPE	VSV	1.4	42.50	L929	1.00	0.02	7/28/87
AVS-1213	CPE	VV	0.5	----	VERO <	320.00	----	8/13/87
AVS-1213	CPE	YFV	1.05	77.80	VERO	100.00	1.28	9/29/87
AVS-1215	CPE	AD2	1.1	62.90	HEP2 <	320.00 <	5.08	8/13/87
AVS-1215	CPE	AD2	0.8	50.40	HEP2	100.00	1.98	1/ 8/88
AVS-1215	CPE	AD2	1.3	53.70	HEP2 <	320.00 <	5.95	1/21/88
AVS-1215	CPE	AD2	0.6	100.00	HEP2 <	320.00 <	3.20	5/12/88
AVS-1215	CPE	JE	0.25	----	VERO	320.00	----	9/ 8/87
AVS-1215	PR	PIC	N/A	----	VERO >	3.20	----	9/12/88
AVS-1215	CPE	PT	0.95	69.10	VERO	100.00	1.44	8/28/87
AVS-1215	CPE	SF	1.45	65.90	VERO	100.00	1.51	9/29/87
AVS-1215	CPE	VSV	0.4	----	L929 <	320.00	----	7/28/87
AVS-1215	CPE	VV	0.65	242.00	VERO	320.00	1.31	8/13/87
AVS-1215	CPE	YFV	0.6	320.00	VERO	320.00	1.00	9/29/87
AVS-1234	CPE	AD2	0.35	100.00	HEP2	100.00	1.00	8/20/87
AVS-1234	CPE	JE	----	----	VERO >	320.00	----	10/ 1/87
AVS-1234	CPE	PT	----	----	VERO >	320.00	----	8/28/87
AVS-1234	CPE	PT	----	----	VERO >	320.00	----	10/29/87
AVS-1234	CPE	SF	----	----	VERO	320.00	----	9/29/87
AVS-1234	CPE	VV	----	----	VERO	320.00	----	8/20/87
AVS-1234	CPE	YFV	----	----	VERO	100.00	----	9/29/87
AVS-1250	CPE	AD2	2.00	0.73	HEP2	3.20	4.36	9/25/86
AVS-1250	CPE	AD2	----	----	HEP2 <	10.00	----	10/16/86
AVS-1250	CPE	JE	0.3	29.00	VERO	32.00	1.10	7/ 9/87
AVS-1250	CPE	JE	----	----	VERO	1.00	----	5/14/88
AVS-1250	PR	PIC	N/A	----	VERO	10.00	----	10/26/87
AVS-1250	PR	PIC	N/A	6.40	VERO	3.20	0.50	5/23/88
AVS-1250	CPE	PT	0.02	----	VERO	10.00	----	7/24/87
AVS-1250	CPE	VEE	----	----	VERO	1.00	----	5/18/87
AVS-1250	CPE	VEE	----	----	VERO	1.00	----	5/24/88
AVS-1250	CPE	VSV	----	----	L929	3.20	----	7/18/86
AVS-1250	CPE	VV	0.75	21.00	VERO	10.00	0.48	8/ 7/86
AVS-1307	CPE	AD2	----	----	HEP2 <	32.00	----	2/ 4/88
AVS-1307	CPE	JE	0.44	----	VERO	10.00	----	3/ 7/88
AVS-1307	CPE	VSV	----	----	L929	10.00	----	2/12/88
AVS-1307	CPE	VV	----	----	VERO	10.00	----	2/ 4/88
AVS-1308	CPE	AD2	----	----	HEP2 <	100.00	----	2/ 4/88
AVS-1308	CPE	JE	0.05	----	VERO	32.00	----	1/18/88
AVS-1308	CPE	VSV	----	----	L929	10.00	----	2/12/88
AVS-1308	CPE	VV	0.1	----	VERO	32.00	----	2/ 4/88
AVS-1312	CPE	AD2	----	----	HEP2	320.00	----	2/ 4/88
AVS-1312	CPE	JE	0.49	----	VERO >	320.00	----	3/ 7/88
AVS-1312	CPE	VSV	----	----	L929 >	320.00	----	2/12/88
AVS-1312	CPE	VV	----	----	VERO <	320.00	----	2/ 4/88
AVS-1315	CPE	AD2	0.1	----	HEP2 >	320.00	----	2/ 4/88
AVS-1315	CPE	JE	0.5	----	VERO <	100.00	----	3/ 7/88
AVS-1315	CPE	VSV	----	----	L929 <	320.00	----	2/12/88
AVS-1315	CPE	VV	0.2	----	VERO	320.00	----	2/ 4/88
AVS-1337	CPE	AD2	1.5	88.40	HEP2	320.00	3.61	2/ 4/88
AVS-1337	CPE	AD2	1.5	78.10	HEP2	320.00	4.09	2/18/88
AVS-1337	CPE	JE	2.15	109.00	VERO	320.00	2.93	3/ 7/88
AVS-1337	CPE	VSV	----	----	L929	100.00	----	2/12/88
AVS-1337	CPE	VV	0.2	----	VERO	320.00	----	2/ 4/88
AVS-1371	CPE	AD2	0.15	----	HEP2	320.00	----	10/ 6/88
AVS-1371	CPE	VSV	----	----	L929 >	320.00	----	10/18/88
AVS-1371	CPE	VV	0.15	----	VERO	320.00	----	10/ 6/88
AVS-1372	CPE	AD2	0.6	5.60	HEP2	10.00	1.76	10/13/88
AVS-1372	CPE	VSV	----	----	L929 >	320.00	----	10/18/88
AVS-1372	CPE	VV	0.6	17.80	VERO	32.00	1.78	10/13/88
AVS-1378	CPE	AD2	0.3	----	HEP2 >	320.00	----	10/13/88

B-53

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MYC50	TI	DATE
AVS-1378	CPE	VSV	0.3	----	L929 >	320.00	----	10/18/88
AVS-1378	CPE	VV	----	----	VERO <	320.00	----	10/13/88
AVS-1380	CPE	AD2	----	----	HEP2 <	320.00	----	10/ 6/88
AVS-1380	CPE	VSV	----	----	L929	100.00	----	10/18/88
AVS-1380	CPE	VV	----	----	VERO	32.00	----	10/ 6/88
AVS-1381	CPE	AD2	----	----	HEP2	100.00	----	10/13/88
AVS-1392	CPE	AD2	0.4	----	HEP2 <	100.00	----	2/ 4/88
AVS-1392	CPE	JE	0.35	----	VERO	100.00	----	3/ 7/88
AVS-1392	CPE	VSV	----	----	L929	10.00	----	2/12/88
AVS-1392	CPE	VV	1.5	122.00	VERO	320.00	2.60	2/ 4/88
AVS-1392	CPE	VV	1.75	100.00	VERO	100.00	1.00	2/18/88
AVS-1569	CPE	AD2	----	----	HEP2 <	10.00	----	1/29/87
AVS-1569	CPE	JE	----	----	VERO	100.00	----	5/ 7/87
AVS-1569	PR	PIC	N/A	----	VERO >	320.00	----	6/20/88
AVS-1569	CPE	PT	0.77	576.00	VERO	320.00	0.56	2/17/87
AVS-1569	CPE	SF	1.40	22.70	VERO	32.00	1.41	2/25/87
AVS-1569	CPE	VSV	----	----	L929	32.00	----	1/20/87
AVS-1569	CPE	VV	0.15	----	VERO	100.00	----	1/29/87
AVS-1569	CPE	YFV	----	----	VERO	100.00	----	5/ 4/87
AVS-1645	CPE	AD2	----	----	HEP2 <	32.00	----	2/ 4/88
AVS-1645	CPE	JE	----	----	VERO <	320.00	----	1/22/88
AVS-1645	CPE	VSV	----	----	L929	32.00	----	2/12/88
AVS-1645	CPE	VV	----	----	VERO	10.00	----	2/ 4/88
AVS-1654	CPE	AD2	0.25	----	HEP2	100.00	----	10/13/88
AVS-1654	CPE	VSV	2.8	10.00	L929	100.00	10.00	11/18/88
AVS-1654	CPE	VV	3.9	2.00	VERO	10.00	4.99	10/13/88
AVS-1654	CPE	VV	4.25	3.10	VERO	100.00	32.20	10/27/88
AVS-1704	CPE	AD2	0.15	----	HEP2	10.00	----	2/ 4/88
AVS-1704	CPE	JE	0.55	22.10	VERO	32.00	1.44	1/22/88
AVS-1704	CPE	VSV	----	----	L929	100.00	----	2/12/88
AVS-1704	CPE	VV	----	----	VERO	32.00	----	2/ 4/88
AVS-1725	CPE	AD2	----	----	HEP2 >	320.00	----	10/ 6/88
AVS-1725	CPE	VSV	0.4	75.10	L929	100.00	1.33	10/18/88
AVS-1725	CPE	VV	----	----	VERO	320.00	----	10/ 6/88
AVS-1727	CPE	AD2	----	----	HEP2 >	320.00	----	10/ 6/88
AVS-1727	CPE	VSV	----	----	L929 >	320.00	----	10/18/88
AVS-1727	CPE	VV	----	----	VERO >	320.00	----	10/ 6/88
AVS-1728	CPE	AD2	----	----	HEP2 <	100.00	----	10/ 6/88
AVS-1728	CPE	VSV	----	----	L929	32.00	----	10/18/88
AVS-1728	CPE	VV	----	----	VERO	32.00	----	10/ 6/88
AVS-1729	CPE	AD2	----	----	HEP2	100.00	----	10/ 6/88
AVS-1729	CPE	VSV	0.4	----	L929	100.00	----	10/18/88
AVS-1729	CPE	VV	0.35	84.90	VERO	100.00	1.17	10/ 6/88
AVS-1730	CPE	AD2	----	----	HEP2 >	320.00	----	10/ 6/88
AVS-1730	CPE	VSV	0.5	----	L929 <	100.00	----	10/ 3/88
AVS-1730	CPE	VV	----	----	VERO	100.00	----	10/ 6/88
AVS-1731	CPE	AD2	----	----	HEP2 <	320.00	----	10/ 6/88
AVS-1731	CPE	VSV	0.2	----	L929 >	320.00	----	10/18/88
AVS-1731	CPE	VV	0.3	----	VERO	320.00	----	10/ 6/88
AVS-1732	CPE	AD2	----	----	HEP2 <	32.00	----	10/ 6/88
AVS-1732	CPE	VSV	0.85	100.00	L929	32.00	0.32	11/16/88
AVS-1732	CPE	VV	0.15	----	VERO	10.00	----	10/ 6/88
AVS-1733	CPE	AD2	----	----	HEP2 >	320.00	----	10/ 6/88
AVS-1733	CPE	VSV	0.4	----	L929 >	320.00	----	10/18/88
AVS-1733	CPE	VV	----	----	VERO >	320.00	----	10/ 6/88
AVS-1734	CPE	AD2	----	----	HEP2 >	320.00	----	10/ 6/88
AVS-1734	CPE	VSV	0.2	----	L929	320.00	----	10/18/88
AVS-1734	CPE	VV	----	----	VERO <	320.00	----	10/ 6/88
AVS-1735	CPE	AD2	----	----	HEP2	100.00	----	10/13/88
AVS-1735	CPE	VSV	0.2	----	L929	100.00	----	10/18/88
AVS-1735	CPE	VV	0.3	----	VERO >	320.00	----	10/13/88
AVS-1736	CPE	AD2	----	----	HEP2 >	320.00	----	10/13/88
AVS-1736	CPE	VSV	----	----	L929	100.00	----	10/18/88
AVS-1736	CPE	VV	----	----	VERO	320.00	----	10/ 6/88
AVS-1737	CPE	AD2	----	----	HEP2 <	320.00	----	10/ 6/88

B-54

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MT50	TI	DATE
AVS-1737	CPE	VSV	----	----	L929	32.00	----	10/18/88
AVS-1737	CPE	VV	----	----	VERO	100.00	----	10/ 6/88
AVS-1738	CPE	AD2	0.6	----	HEP2 <	320.00	----	10/ 6/88
AVS-1738	CPE	VSV	0.6	32.00	L929	32.00	1.00	10/18/88
AVS-1738	CPE	VV	0.3	----	VERO	32.00	----	10/ 6/88
AVS-1739	CPE	AD2	----	----	HEP2 >	320.00	----	10/ 6/88
AVS-1739	CPE	VSV	----	----	L929 <	320.00	----	10/18/88
AVS-1739	CPE	VV	----	----	VERO >	320.00	----	10/ 6/88
AVS-1740	CPE	AD2	0.2	----	HEP2 >	320.00	----	10/ 6/88
AVS-1740	CPE	VSV	0.5	239.00	L929	320.00	1.33	10/18/88
AVS-1740	CPE	VV	0.15	----	VERO	100.00	----	10/ 6/88
AVS-1741	CPE	AD2	0.4	----	HEP2	32.00	----	10/ 6/88
AVS-1741	CPE	VSV	0.3	----	L929	10.00	----	10/18/88
AVS-1741	CPE	VV	0.4	----	VERO	100.00	----	10/ 6/88
AVS-1742	CPE	AD2	----	----	HEP2	3.20	----	10/ 6/88
AVS-1742	CPE	VSV	0.5	----	L929	1.00	----	10/18/88
AVS-1742	CPE	VV	1.45	16.90	VERO	10.00	0.59	10/ 6/88
AVS-1743	CPE	AD2	0.15	----	HEP2	3.20	----	10/ 6/88
AVS-1743	CPE	VSV	0.2	----	L929	1.00	----	10/18/88
AVS-1743	CPE	VV	1.3	11.10	VERO	3.20	0.29	10/ 6/88
AVS-1744	CPE	AD2	----	----	HEP2	10.00	----	10/ 6/88
AVS-1744	CPE	VSV	----	----	L929 >	10.00	----	10/18/88
AVS-1744	CPE	VV	0.9	69.10	VERO	32.00	0.46	10/ 6/88
AVS-1745	CPE	AD2	----	----	HEP2	32.00	----	10/27/88
AVS-1745	CPE	VSV	0.15	----	L929	3.20	----	11/16/88
AVS-1745	CPE	VV	----	----	VERO	32.00	----	10/27/88
AVS-1746	CPE	AD2	----	----	HEP2	32.00	----	10/27/88
AVS-1746	CPE	VSV	----	----	L929	10.00	----	11/16/88
AVS-1746	CPE	VV	----	----	VERO	32.00	----	10/27/88
AVS-1747	CPE	AD2	----	----	HEP2	100.00	----	10/27/88
AVS-1747	CPE	VSV	----	----	L929	3.20	----	11/16/88
AVS-1747	CPE	VV	----	----	VERO	100.00	----	10/27/88
AVS-1748	CPE	AD2	----	----	HEP2 >	320.00	----	10/27/88
AVS-1748	CPE	VSV	----	----	L929	10.00	----	11/16/88
AVS-1748	CPE	VV	0.3	----	VERO >	320.00	----	10/27/88
AVS-1749	CPE	AD2	----	----	HEP2 <	100.00	----	10/27/88
AVS-1749	CPE	VSV	0.1	----	L929	32.00	----	11/16/88
AVS-1749	CPE	VV	----	----	VERO <	100.00	----	10/27/88
AVS-1750	CPE	AD2	----	----	HEP2 >	320.00	----	10/ 6/88
AVS-1750	CPE	VSV	----	----	L929 >	320.00	----	10/18/88
AVS-1750	CPE	VV	----	----	VERO	320.00	----	10/ 6/88
AVS-1751	CPE	AD2	0.3	----	HEP2 >	320.00	----	10/27/88
AVS-1751	CPE	VSV	1.	88.60	L929	32.00	0.36	11/16/88
AVS-1751	CPE	VV	0.1	----	VERO >	320.00	----	10/27/88
AVS-1752	CPE	AD2	0.2	----	HEP2	100.00	----	10/13/88
AVS-1752	CPE	VSV	----	----	L929	100.00	----	11/18/88
AVS-1752	CPE	VV	2.55	1.90	L929	32.00	16.80	6/12/86
AVS-1752	CPE	VV	3.6	10.00	VERO	320.00	31.70	7/17/86
AVS-1752	CPE	VV	3.1	9.80	VERO <	320.00 <	32.60	7/24/86
AVS-1752	CPE	VV	2.4	10.00	VERO	32.00	3.21	7/31/86
AVS-1752	CPE	VV	2.6	17.00	VERO	100.00	5.88	8/ 7/86
AVS-1752	CPE	VV	2.9	8.10	VERO	100.00	12.30	8/20/86
AVS-1752	CPE	VV	2.1	7.70	VERO	32.00	4.10	8/28/86
AVS-1752	CPE	VV	3.2	2.70	VERO	32.00	11.80	10/16/86
AVS-1752	CPE	VV	2.5	5.60	VERO	10.00	1.75	10/23/86
AVS-1752	CPE	VV	2.35	3.20	VERO	10.00	3.12	10/30/86
AVS-1752	CPE	VV	3.21	2.40	VERO	32.00	13.30	11/ 6/86
AVS-1752	CPE	VV	3.39	2.02	VERO	32.00	15.80	11/13/86
AVS-1752	CPE	VV	3.00	3.15	VERO	32.00	10.10	11/20/86
AVS-1752	CPE	VV	3.09	3.46	VERO	32.00	9.23	12/ 4/86
AVS-1752	CPE	VV	3.09	2.82	VERO	32.00	11.30	12/11/86
AVS-1752	CPE	VV	3.00	1.05	VERO	32.00	10.50	12/18/86
AVS-1752	CPE	VV	3.70	1.86	VERO	32.00	17.10	1/ 8/87
AVS-1752	CPE	VV	3.20	2.82	VERO	32.00	11.30	1/29/87
AVS-1752	CPE	VV	3.20	3.23	VERO	32.00	9.89	2/ 5/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-1752	CPE	VV	2.80	6.10	VERO	100.00	16.20	2/12/87
AVS-1752	CPE	VV	3.10	2.47	VERO	26.70	10.80	2/19/87
AVS-1752	CPE	VV	3.20	2.60	VERO	32.00	12.30	3/12/87
AVS-1752	CPE	VV	3.2	1.34	VERO	10.00	7.42	4/10/87
AVS-1752	CPE	VV	3.15	0.97	VERO	3.20	3.27	4/24/87
AVS-1752	CPE	VV	3.7	1.25	VERO	32.00	25.40	5/ 7/87
AVS-1752	CPE	VV	3.	1.78	VERO	10.00	5.59	5/14/87
AVS-1752	CPE	VV	4.1	1.06	VERO	26.70	25.10	5/21/87
AVS-1752	CPE	VV	3.85	1.08	VERO	32.00	29.40	5/28/87
AVS-1752	CPE	VV	3.	1.00	VERO	10.00	10.00	6/ 4/87
AVS-1752	CPE	VV	3.95	1.06	VERO	32.00	29.90	6/11/87
AVS-1752	CPE	VV	3.25	1.13	VERO	10.00	8.81	6/18/87
AVS-1752	CPE	VV	2.75	1.13	VERO	10.00	8.80	6/25/87
AVS-1752	CPE	VV	3.25	0.97	VERO	8.50	8.71	7/ 2/87
AVS-1752	CPE	VV	2.7	0.66	VERO	3.20	4.80	7/ 9/87
AVS-1752	CPE	VV	2.8	1.50	VERO	10.00	6.63	7/16/87
AVS-1752	CPE	VV	2.65	1.21	VERO	3.20	2.62	7/30/87
AVS-1752	CPE	VV	3.1	0.92	VERO	10.00	10.80	8/ 6/87
AVS-1752	CPE	VV	2.35	1.13	VERO	3.20	2.81	8/13/87
AVS-1752	CPE	VV	2.95	1.13	VERO	3.20	2.82	8/20/87
AVS-1752	CPE	VV	3.2	1.35	VERO	10.00	7.38	8/27/87
AVS-1752	CPE	VV	2.8	0.71	VERO	3.20	4.50	9/ 4/87
AVS-1752	CPE	VV	2.4	2.38	VERO	10.00	4.19	9/24/87
AVS-1752	CPE	VV	3.5	0.63	VERO	10.00	15.70	9/24/87
AVS-1752	CPE	VV	3.	1.00	VERO	10.00	9.99	9/24/87
AVS-1752	CPE	VV	3.2	0.87	VERO	10.00	11.30	9/24/87
AVS-1752	CPE	VV	3.5	0.55	VERO	10.00	17.90	9/24/87
AVS-1752	CPE	VV	2.6	0.92	VERO	3.20	3.46	10/ 8/87
AVS-1752	CPE	VV	2.7	0.77	VERO	3.20	4.14	10/ 8/87
AVS-1752	CPE	VV	2.95	0.65	VERO	3.20	4.89	10/ 8/87
AVS-1752	CPE	VV	2.9	0.63	VERO	3.20	5.03	10/ 8/87
AVS-1752	CPE	VV	2.85	0.76	VERO	3.20	4.17	10/ 8/87
AVS-1752	CPE	VV	4.2	0.56	VERO	10.00	17.80	10/22/87
AVS-1752	CPE	VV	4.	0.70	VERO	10.00	14.10	10/22/87
AVS-1752	CPE	VV	3.9	0.81	VERO	10.00	12.30	10/22/87
AVS-1752	CPE	VV	4.2	0.56	VERO	10.00	17.80	10/22/87
AVS-1752	CPE	VV	4.	0.70	VERO	10.00	14.10	10/22/87
AVS-1752	CPE	VV	2.95	3.26	L929	32.00	9.81	10/22/87
AVS-1752	CPE	VV	2.8	3.10	VERO	32.00	10.30	10/29/87
AVS-1752	CPE	VV	3.	2.89	VERO	32.00	11.00	10/29/87
AVS-1752	CPE	VV	3.1	2.40	VERO	32.00	13.30	10/29/87
AVS-1752	CPE	VV	2.7	3.71	VERO	32.00	8.60	10/29/87
AVS-1752	CPE	VV	2.85	2.99	VERO	32.00	10.60	10/29/87
AVS-1752	CPE	VV	2.9	3.02	VERO	32.00	10.50	11/ 5/87
AVS-1752	CPE	VV	3.3	1.62	VERO	32.00	19.60	11/12/87
AVS-1752	CPE	VV	3.2	3.02	VERO	32.00	10.50	12/10/87
AVS-1752	CPE	VV	3.1	8.40	VERO	100.00	11.70	12/17/87
AVS-1752	CPE	VV	3.	2.50	VERO	32.00	12.70	12/31/87
AVS-1752	CPE	VV	3.	3.19	VERO	32.00	10.00	1/14/88
AVS-1752	CPE	VV	3.2	3.58	VERO	100.00	27.80	1/21/88
AVS-1752	CPE	VV	2.6	3.57	VERO	32.00	8.95	1/28/88
AVS-1752	CPE	VV	1.1	46.70	L929	100.00	2.13	2/ 4/88
AVS-1752	CPE	VV	2.6	3.17	VERO	32.00	10.00	2/ 4/88
AVS-1752	CPE	VV	2.5	3.87	VERO	32.00	8.25	2/11/88
AVS-1752	CPE	VV	2.15	4.36	VERO	10.00	2.29	2/25/88
AVS-1752	CPE	VV	3.6	1.60	VERO	32.00	19.90	3/ 3/88
AVS-1752	CPE	VV	2.9	1.84	VERO	10.00	5.40	3/10/88
AVS-1752	CPE	VV	3.1	2.93	VERO	32.00	10.80	3/17/88
AVS-1752	CPE	VV	2.8	2.09	VERO	10.00	4.78	3/24/88
AVS-1752	CPE	VV	3.1	3.22	VERO	32.00	9.91	3/31/88
AVS-1752	PR	VV	N/A	0.38	VERO	100.00	256.00	4/ 8/88
AVS-1752	CPE	VV	3.5	1.63	VERO	32.00	19.50	4/14/88
AVS-1752	CPE	VV	4.2	0.99	VERO	32.00	32.10	4/21/88
AVS-1752	CPE	VV	3.6	1.78	VERO	32.00	17.90	4/29/88
AVS-1752	CPE	VV	3.3	3.20	VERO	32.00	10.00	5/ 5/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-1752	CPE	VV	3.8	1.35	VERO	32.00	23.60	5/12/88
AVS-1752	CPE	VV	3.2	2.46	VERO	32.00	12.90	5/19/88
AVS-1752	CPE	VV	3.1	2.40	VERO	32.00	13.30	5/26/88
AVS-1752	CPE	VV	3.	1.78	VERO	32.00	17.80	6/ 2/88
AVS-1752	CPE	VV	3.5	2.53	VERO	32.00	12.60	6/16/88
AVS-1752	CPE	VV	3.1	1.76	VERO	10.00	5.68	6/23/88
AVS-1752	CPE	VV	3.4	1.77	VERO	32.00	18.00	6/30/88
AVS-1752	CPE	VV	3.7	1.35	VERO	32.00	23.60	7/ 7/88
AVS-1752	PR	VV	N/A	0.50	VERO	3.20	6.40	7/15/88
AVS-1752	CPE	VV	3.25	1.33	VERO	10.00	7.48	7/21/88
AVS-1752	CPE	VV	3.4	2.37	VERO	32.00	13.40	8/18/88
AVS-1752	CPE	VV	3.2	2.28	VERO	32.00	14.00	8/25/88
AVS-1752	CPE	VV	3.6	1.26	VERO	10.00	7.93	9/ 1/88
AVS-1752	PR	VV	N/A	0.39	VERO	32.00	81.20	9/23/88
AVS-1752	CPE	VV	2.5	5.00	VERO	32.00	6.37	10/ 6/88
AVS-1752	CPE	VV	2.5	4.98	VERO	32.00	6.42	10/13/88
AVS-1752	CPE	VV	2.7	4.27	VERO	32.00	7.48	10/13/88
AVS-1752	CPE	VV	2.6	4.50	VERO	32.00	7.10	10/27/88
AVS-1752	CPE	VV	2.7	3.93	VERO	32.00	8.14	11/ 3/88
AVS-1752	CPE	VV	3.6	1.79	VERO	32.00	17.80	11/10/88
AVS-1752	CPE	VV	----	3.18	VERO	32.00	10.00	11/17/88
AVS-1753	CPE	VSV	2.49	2.55	L929	10.00	3.91	10/24/86
AVS-1753	CPE	VSV	2.46	2.81	L929	10.00	3.56	11/ 4/86
AVS-1753	CPE	VSV	1.74	3.10	L929	3.20	1.03	12/ 5/86
AVS-1753	CPE	VSV	2.01	2.90	L929	10.00	3.45	12/ 9/86
AVS-1753	CPE	VSV	2.01	5.20	L929	3.20	0.62	12/12/86
AVS-1753	CPE	VSV	2.31	4.13	L929	10.00	2.42	12/30/86
AVS-1764	CPE	AD2	0.2	----	HEP2	320.00	----	6/25/87
AVS-1764	CPE	JE	0.04	----	VERO	320.00	----	6/30/87
AVS-1764	CPE	PT	0.2	----	VERO	100.00	----	6/19/87
AVS-1764	CPE	SF	----	----	VERO	320.00	----	6/19/87
AVS-1764	CPE	VSV	----	----	L929	320.00	----	6/ 2/87
AVS-1764	CPE	VV	0.3	320.00	VERO	320.00	1.00	6/25/87
AVS-1764	CPE	YFV	----	----	VERO	320.00	----	3/ 4/88
AVS-1777	CPE	AD2	----	----	HEP2	100.00	----	7/ 9/87
AVS-1777	CPE	JE	----	----	VERO	100.00	----	7/24/87
AVS-1777	PR	PIC	N/A	----	VERO	100.00	----	8/12/88
AVS-1777	CPE	PT	----	----	VERO	100.00	----	6/19/87
AVS-1777	CPE	SF	----	----	VERO	100.00	----	6/19/87
AVS-1777	CPE	VSV	----	----	L929	0.10	----	6/ 9/87
AVS-1777	CPE	VV	----	----	VERO	100.00	----	7/ 9/87
AVS-1777	CPE	YFV	0.3	----	VERO	100.00	----	7/ 9/87
AVS-1795	CPE	AD2	0.3	----	HEP2	100.00	----	6/25/87
AVS-1795	CPE	JE	----	----	VERO	32.00	----	6/30/87
AVS-1795	PR	PIC	N/A	----	VERO	10.00	----	8/12/88
AVS-1795	CPE	PT	----	----	VERO	32.00	----	6/19/87
AVS-1795	CPE	SF	----	----	VERO	320.00	----	6/19/87
AVS-1795	CPE	VSV	----	----	L929	32.00	----	6/ 2/87
AVS-1795	CPE	VV	0.15	----	VERO	100.00	----	6/25/87
AVS-1795	CPE	YFV	0.6	56.50	VERO	3.20	0.06	7/ 9/87
AVS-1796	CPE	AD2	----	----	HEP2	320.00	----	6/25/87
AVS-1796	CPE	JE	----	----	VERO	32.00	----	6/30/87
AVS-1796	PR	PIC	N/A	----	VERO	10.00	----	8/12/88
AVS-1796	CPE	PT	0.05	----	VERO	32.00	----	6/19/87
AVS-1796	CPE	SF	----	----	VERO	320.00	----	6/19/87
AVS-1796	CPE	VSV	----	----	L929	320.00	----	6/ 2/87
AVS-1796	CPE	VV	1.3	65.10	VERO	100.00	1.53	6/25/87
AVS-1796	CPE	YFV	----	----	VERO	10.00	----	7/ 9/87
AVS-1801	CPE	AD2	----	----	HEP2	320.00	----	12/31/87
AVS-1801	CPE	JE	0.15	----	VERO	3.20	----	12/ 4/87
AVS-1801	CPE	PT	1.05	80.00	VERO	32.00	0.38	10/13/88
AVS-1801	CPE	SF	----	----	VERO	10.00	----	10/13/88
AVS-1801	CPE	VEE	----	----	VERO	10.00	----	10/13/88
AVS-1801	CPE	VSV	0.3	----	L929	320.00	----	1/22/88
AVS-1801	CPE	VV	----	----	VERO	320.00	----	12/31/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-1811	CPE	AD2	0.3	----	HEP2 >	320.00	----	10/13/88
AVS-1811	CPE	VSV	----	----	L929 <	320.00	----	10/18/88
AVS-1811	CPE	VV	----	----	VERO >	320.00	----	10/13/88
AVS-1820	CPE	AD2	----	----	HEP2	320.00	----	2/18/88
AVS-1820	CPE	JE	0.15	----	VERO	3.20	----	1/22/88
AVS-1820	CPE	VSV	----	----	L929	100.00	----	2/12/88
AVS-1820	CPE	VV	0.45	217.00	VERO	320.00	1.47	2/18/88
AVS-1829	CPE	AD2	----	----	HEP2 >	320.00	----	12/31/87
AVS-1829	CPE	JE	----	----	VERO	320.00	----	12/ 4/87
AVS-1829	CPE	PT	----	----	VERO	32.00	----	10/13/88
AVS-1829	CPE	SF	----	----	VERO	100.00	----	10/13/88
AVS-1829	CPE	VEE	----	----	VERO	32.00	----	10/13/88
AVS-1829	CPE	VSV	----	----	L929	100.00	----	1/22/88
AVS-1829	CPE	VV	----	----	VERO >	320.00	----	12/31/87
AVS-1835	CPE	AD2	0.2	----	HEP2	320.00	----	1/28/88
AVS-1835	CPE	JE	----	----	VERO	100.00	----	12/ 4/87
AVS-1835	CPE	PT	----	----	VERO	100.00	----	10/13/88
AVS-1835	CPE	SF	----	----	VERO	32.00	----	10/13/88
AVS-1835	CPE	VEE	----	----	VERO	320.00	----	10/13/88
AVS-1835	CPE	VSV	0.1	----	L929	320.00	----	1/22/88
AVS-1835	CPE	VV	----	----	VERO >	320.00	----	1/28/88
AVS-1841	CPE	AD2	----	----	HEP2	10.00	----	2/18/88
AVS-1841	CPE	JE	----	----	VERO	0.32	----	1/22/88
AVS-1841	CPE	VSV	----	----	L929	10.00	----	2/12/88
AVS-1841	CPE	VV	----	----	VERO	32.00	----	2/18/88
AVS-1843	CPE	AD2	----	----	HEP2	100.00	----	2/18/88
AVS-1843	CPE	JE	----	----	VERO	32.00	----	3/ 9/88
AVS-1843	CPE	VSV	----	----	L929	10.00	----	2/12/88
AVS-1843	CPE	VV	0.1	----	VERO >	320.00	----	2/18/88
AVS-1846	CPE	AD2	----	----	HEP2	320.00	----	2/18/88
AVS-1846	CPE	JE	----	----	VERO	0.32	----	3/ 9/88
AVS-1846	CPE	VSV	----	----	L929 <	320.00	----	2/12/88
AVS-1846	CPE	VV	----	----	VERO >	320.00	----	2/18/88
AVS-1850	CPE	AD2	----	----	HEP2	320.00	----	12/31/87
AVS-1850	CPE	AD2	----	----	HEP2	100.00	----	2/18/88
AVS-1850	CPE	JE	----	----	VERO >	320.00	----	12/ 4/87
AVS-1850	CPE	JE	----	----	VERO	32.00	----	3/ 9/88
AVS-1850	CPE	PT	1.25	15.90	VERO	10.00	0.63	10/13/88
AVS-1850	CPE	SF	0.8	26.60	VERO	3.20	0.12	10/13/88
AVS-1850	CPE	VEE	----	----	VERO	3.20	----	10/13/88
AVS-1850	CPE	VSV	----	----	L929	10.00	----	1/22/88
AVS-1850	CPE	VSV	----	----	L929	32.00	----	11/18/88
AVS-1850	CPE	VV	----	----	VERO	100.00	----	12/31/87
AVS-1850	CPE	VV	----	----	VERO	320.00	----	2/18/88
AVS-1899	CPE	AD2	----	----	HEP2	100.00	----	2/18/88
AVS-1899	CPE	JE	0.1	----	VERO	32.00	----	3/ 9/88
AVS-1899	CPE	VSV	----	----	L929	100.00	----	2/12/88
AVS-1899	CPE	VV	----	----	VERO <	100.00	----	2/18/88
AVS-1900	CPE	AD2	----	----	HEP2	100.00	----	2/18/88
AVS-1900	CPE	JE	0.45	68.30	VERO	10.00	0.15	3/ 9/88
AVS-1900	CPE	VSV	----	----	L929	32.00	----	2/12/88
AVS-1900	CPE	VV	----	----	VERO	100.00	----	2/18/88
AVS-1901	CPE	AD2	----	----	HEP2	32.00	----	2/18/88
AVS-1901	CPE	JE	----	----	VERO	32.00	----	3/10/88
AVS-1901	CPE	VSV	----	----	L929	32.00	----	2/12/88
AVS-1901	CPE	VV	----	----	VERO	320.00	----	2/18/88
AVS-1902	CPE	AD2	----	----	HEP2	320.00	----	2/18/88
AVS-1902	CPE	JE	----	----	VERO	32.00	----	3/10/88
AVS-1902	CPE	VSV	----	----	L929	100.00	----	2/12/88
AVS-1902	CPE	VV	0.1	----	VERO >	320.00	----	2/18/88
AVS-1915	CPE	AD2	0.7	31.90	HEP2 <	100.00 <	3.12	8/13/87
AVS-1915	CPE	AD2	0.1	----	HEP2 <	100.00	----	5/12/88
AVS-1915	PR	HTN	N/A	----	VERC >	320.00	----	4/14/88
AVS-1915	CPE	JE	----	----	VERO >	320.00	----	9/ 8/87
AVS-1915	PR	PIC	N/A	172.00	VERO	100.00	0.58	9/12/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

CONFOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-1915	CPE	PT	0.1	----	VERO >	320.00	----	8/28/87
AVS-1915	CPE	PT	----	----	VERO	320.00	----	10/29/87
AVS-1915	CPE	SF	1.05	26.10	VERO	32.00	1.22	9/29/87
AVS-1915	CPE	VSV	----	----	L929	100.00	----	7/28/87
AVS-1915	CPE	VV	0.7	320.00	VERO	320.00	1.00	8/13/87
AVS-1915	CPE	YFV	0.3	----	VERO	100.00	----	9/29/87
AVS-1947	CPE	AD2	----	----	HEP2	32.00	----	8/27/87
AVS-1947	CPE	JE	----	----	VERO	320.00	----	9/21/87
AVS-1947	PR	PIC	N/A	----	VERO	3.20	----	9/20/88
AVS-1947	CPE	PT	0.55	188.00	VERO	32.00	0.17	11/30/87
AVS-1947	CPE	VSV	----	----	L929	100.00	----	8/21/87
AVS-1947	CPE	VV	1.5	7.70	VERO	32.00	4.12	8/27/87
AVS-1947	CPE	VV	0.9	----	VERO	100.00	----	5/12/88
AVS-1947	CPE	YFV	----	----	VERO	10.00	----	11/30/87
AVS-1968	CPE	AD2	----	----	HEP2	1.00	----	9/24/87
AVS-1968	CPE	AD2	----	----	HEP2	1.00	----	9/24/87
AVS-1968	CPE	JE	----	----	VERO	10.00	----	9/ 3/87
AVS-1968	CPE	SF	0.25	----	VERO	1.00	----	9/ 1/87
AVS-1968	CPE	VSV	----	----	L929 <	10.00	----	7/17/87
AVS-1968	CPE	VSV	----	----	VERO <	10.00	----	11/ 5/87
AVS-1968	CPE	VSV	----	----	VERO <	10.00	----	11/ 6/87
AVS-1968	CPE	VV	0.15	----	VERO	3.20	----	9/24/87
AVS-1968	PR	VV	N/A	----	VERO	1.00	----	9/24/87
AVS-1968	CPE	YFV	----	----	VERO	3.20	----	9/ 1/87
AVS-1970	CPE	AD2	0.3	----	HEP2 <	10.00	----	8/13/87
AVS-1970	PR	HTN	N/A	----	VERC <	100.00	----	4/14/88
AVS-1970	CPE	JE	0.3	32.00	VERO	32.00	1.00	9/ 9/87
AVS-1970	PR	PIC	N/A	18.80	VERO	32.00	1.69	9/12/88
AVS-1970	CPE	PT	0.1	----	VERO >	320.00	----	8/28/87
AVS-1970	CPE	PT	----	----	VERO >	320.00	----	10/29/87
AVS-1970	CPE	SF	----	----	VERO >	320.00	----	9/30/87
AVS-1970	CPE	VSV	0.6	17.80	L929	32.00	1.78	7/28/87
AVS-1970	CPE	VV	----	----	VERO	32.00	----	8/13/87
AVS-1970	CPE	YFV	----	----	VERO >	320.00	----	9/30/87
AVS-1972	CPE	AD2	0.60	----	HEP2 >	320.00	----	9/11/86
AVS-1972	CPE	JE	----	----	VERO <	32.00	----	3/11/87
AVS-1972	CPE	PIC	----	79.30	VERO	100.00	1.26	12/12/86
AVS-1972	CPE	VEE	----	----	VERO	100.00	----	12/ 2/87
AVS-1972	CPE	VSV	----	----	L929 <	32.00	----	6/17/86
AVS-1972	CPE	VV	1.2	32.00	L929 <	100.00 <	3.12	6/12/86
AVS-1972	CPE	VV	----	----	VERC	32.00	----	7/17/86
AVS-1972	CPE	YFV	1.75	3.67	VERO <	32.00 <	8.70	1/15/87
AVS-1972	CPE	YFV	----	----	VERO	32.00	----	5/18/88
AVS-1973	CPE	AD2	0.30	----	HEP2 <	100.00	----	9/11/86
AVS-1973	CPE	JE	----	----	VERO	32.00	----	3/11/87
AVS-1973	CPE	PIC	----	25.00	VERO	32.00	1.27	12/12/86
AVS-1973	CPE	PT	1.6	19.20	VERO	10.00	5.20	10/ 9/86
AVS-1973	CPE	VEE	----	----	VERO	10.00	----	12/ 2/87
AVS-1973	CPE	VSV	----	----	L929 <	100.00	----	6/17/86
AVS-1973	CPE	VV	0.55	93.20	L929	100.00	1.07	6/12/86
AVS-1973	CPE	VV	----	----	VERO	32.00	----	7/17/86
AVS-1973	CPE	YFV	1.55	19.20	VERO <	100.00 <	5.19	1/16/87
AVS-1973	CPE	YFV	----	----	VERO	32.00	----	5/18/88
AVS-1974	CPE	AD2	----	----	HEP2 <	32.00	----	9/11/86
AVS-1974	CPE	JE	----	----	VERO	32.00	----	3/11/87
AVS-1974	CPE	PT	1.7	14.20	VERO	10.00	7.00	10/ 9/86
AVS-1974	CPE	SF	----	----	VERO	32.00	----	11/25/86
AVS-1974	CPE	VEE	----	----	VERO	32.00	----	12/ 2/87
AVS-1974	CPE	VSV	----	----	L929 <	100.00	----	6/17/86
AVS-1974	CPE	VV	0.75	72.50	L929	100.00	1.37	6/12/86
AVS-1974	CPE	VV	----	----	VERO	32.00	----	7/17/86
AVS-1974	CPE	YFV	1.75	10.30	VERO <	100.00 <	9.69	1/16/87
AVS-1974	CPE	YFV	----	----	VERO	3.20	----	5/18/88
AVS-1975	CPE	AD2	0.30	----	HEP2 >	100.00	----	9/11/86
AVS-1975	CPE	JE	0.3	----	VERO	320.00	----	3/27/87

B-59

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-1975	PR	PIC	N/A	120.00	VERO >	320.00 >	2.65	12/19/86
AVS-1975	PR	PT	N/A	312.00	VERO	320.00	1.02	5/14/87
AVS-1975	CPE	PT	----	----	VERO	32.00	----	8/21/87
AVS-1975	CPE	SF	0.80	295.00	VERO	320.00	1.08	11/25/86
AVS-1975	CPE	VEE	----	----	VERO	100.00	----	12/ 2/87
AVS-1975	CPE	VSV	----	----	L929 <	100.00	----	6/17/86
AVS-1975	CPE	VV	----	----	L929	100.00	----	6/12/86
AVS-1975	CPE	VV	----	----	VERO <	320.00	----	7/17/86
AVS-1975	CPE	YFV	2.28	24.20	VERO <	320.00 <	13.20	1/16/87
AVS-1975	CPE	YFV	1.64	19.70	VERO	32.00	1.62	7/29/87
AVS-1976	CPE	AD2	0.60	----	HEP2	32.00	----	9/11/86
AVS-1976	CPE	JE	1.00	70.90	VERO >	100.00 >	1.41	3/11/87
AVS-1976	CPE	PIC	----	66.90	VERO >	100.00 >	1.49	1/ 6/87
AVS-1976	CPE	PT	----	----	VERO >	320.00	----	10/29/87
AVS-1976	CPE	SF	2.40	16.40	VERO >	100.00 >	6.08	10/27/86
AVS-1976	CPE	SF	0.85	----	VERO	32.00	----	5/18/88
AVS-1976	CPE	VEE	----	----	VERO	100.00	----	12/ 7/87
AVS-1976	CPE	VSV	0.6	93.20	L929	100.00	1.07	6/17/86
AVS-1976	CPE	VV	0.5	29.00	L929	32.00	1.10	6/12/86
AVS-1976	CPE	VV	----	----	VERO	100.00	----	7/17/86
AVS-1976	CPE	YFV	2.85	18.00	VERO	320.00	17.70	1/16/87
AVS-1976	CPE	YFV	0.39	----	VERO	3.20	----	8/19/87
AVS-1976	CPE	YFV	----	----	VERO >	100.00	----	12/14/87
AVS-1976	CPE	YFV	0.8	57.00	VERO	100.00	1.75	5/18/88
AVS-1977	CPE	AD2	0.60	----	HEP2 >	320.00	----	9/11/86
AVS-1977	CPE	JE	----	----	VERO	32.00	----	3/11/87
AVS-1977	PR	PIC	N/A	----	VERO	32.00	----	12/19/86
AVS-1977	CPE	PT	----	----	VERO	32.00	----	10/15/86
AVS-1977	CPE	VEE	----	----	VERO	100.00	----	12/ 7/87
AVS-1977	CPE	VSV	----	----	L929	32.00	----	6/17/86
AVS-1977	CPE	VV	0.15	----	L929	10.00	----	6/12/86
AVS-1977	CPE	VV	----	----	VERO	320.00	----	7/17/86
AVS-1977	CPE	YFV	----	----	VERO >	320.00	----	1/16/87
AVS-1978	CPE	AD2	0.30	----	HEP2	100.00	----	9/11/86
AVS-1978	CPE	JE	----	----	VERO	32.00	----	3/11/87
AVS-1978	PR	PIC	N/A	----	VERO	0.32	----	12/19/86
AVS-1978	CPE	PT	0.7	79.80	VERO	10.00	1.30	10/15/86
AVS-1978	CPE	SF	1.14	32.00	VERO	32.00	1.00	10/27/86
AVS-1978	CPE	VEE	----	----	VERO	32.00	----	12/ 7/87
AVS-1978	CPE	VSV	----	----	L929	320.00	----	6/17/86
AVS-1978	CPE	VV	----	----	L929	320.00	----	6/12/86
AVS-1978	CPE	VV	----	----	VERO	100.00	----	7/17/86
AVS-1978	CPE	YFV	1.90	31.40	VERO <	320.00 <	10.10	1/20/87
AVS-1978	CPE	YFV	----	----	VERO	3.20	----	8/19/87
AVS-1978	CPE	YFV	----	----	VERO >	100.00	----	12/14/87
AVS-1978	CPE	YFV	----	----	VERO	3.20	----	5/24/88
AVS-1979	CPE	AD2	----	----	HEP2 <	3.20	----	9/11/86
AVS-1979	CPE	JE	----	----	VERO	3.20	----	3/11/87
AVS-1979	CPE	PIC	----	----	VERO	0.32	----	1/ 5/87
AVS-1979	CPE	VEE	----	----	VERO	100.00	----	12/ 7/87
AVS-1979	CPE	VSV	----	----	L929	1.00	----	6/17/86
AVS-1979	CPE	VV	0.05	----	L929	1.00	----	6/12/86
AVS-1979	CPE	VV	----	----	VERO	3.20	----	7/17/86
AVS-1979	CPE	YFV	0.30	----	VERO	1.00	----	1/20/87
AVS-1980	CPE	JE	0.55	56.50	VERO	32.00	0.57	8/ 3/87
AVS-1980	CPE	PT	1.71	150.00	VERO >	320.00 >	2.11	10/17/86
AVS-1980	CPE	PT	----	----	VERO >	320.00	----	10/29/87
AVS-1980	CPE	SF	0.8	42.50	VERO	10.00	0.23	8/ 3/87
AVS-1980	CPE	YFV	0.6	56.50	VERO	10.00	0.18	8/ 3/87
AVS-1981	CPE	JE	0.85	30.50	VERO	32.00	1.04	8/ 3/87
AVS-1981	CPE	SF	0.85	37.60	VERO	32.00	0.85	8/ 3/87
AVS-1981	CPE	YFV	0.3	100.00	VERO	10.00	0.10	8/ 3/87
AVS-1982	CPE	AD2	----	----	HEP2	32.00	----	9/11/86
AVS-1982	CPE	JE	----	----	VERO >	320.00	----	3/17/87
AVS-1982	CPE	PIC	----	141.00	VERO	100.00	0.71	1/ 5/87

B-60

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-1982	CPE	SF	0.81	98.00	VERO >	100.00 >	1.00	10/27/86
AVS-1982	CPE	VEE	----	----	VERO	320.00	----	12/ 7/87
AVS-1982	CPE	VSV	----	----	L929 <	320.00	----	6/17/86
AVS-1982	CPE	VV	1.	----	L929 <	320.00	----	6/12/86
AVS-1982	CPE	VV	----	----	VERO <	320.00	----	7/17/86
AVS-1982	CPE	YFV	0.35	----	VERO >	100.00	----	1/20/87
AVS-1982	CPE	AD2	0.90	100.00	HEP2 <	320.00 <	3.20	9/18/86
AVS-1983	CPE	JE	----	----	VERO	320.00	----	3/27/87
AVS-1983	PR	PIC	N/A	----	VERO >	320.00	----	1/23/87
AVS-1983	PR	PIC	N/A	----	VERO	320.00	----	4/21/87
AVS-1983	CPE	SF	2.94	0.32	VERO	32.00	100.00	10/22/86
AVS-1983	CPE	SF	----	----	VERO >	10.00	----	11/26/86
AVS-1983	CPE	SF	----	----	VERO	100.00	----	8/18/87
AVS-1983	CPE	SF	----	----	VERO	32.00	----	5/24/88
AVS-1983	CPE	VEE	0.85	----	VERO	0.10	----	5/ 7/87
AVS-1983	CPE	VEE	----	----	VERO	32.00	----	1/29/88
AVS-1983	CPE	VSV	0.05	----	L929	100.00	----	6/24/86
AVS-1983	CPE	VV	----	----	VERO	320.00	----	7/24/86
AVS-1983	CPE	YFV	3.20	7.40	VERO	320.00	42.90	1/23/87
AVS-1983	CPE	YFV	0.15	----	VERO	32.00	----	8/19/87
AVS-1983	CPE	YFV	----	----	VERO	100.00	----	12/14/87
AVS-1983	CPE	YFV	----	----	VERO >	32.00	----	2/ 4/88
AVS-1983	CPE	YFV	----	----	VERO	32.00	----	5/24/88
AVS-1984	CPE	AD2	1.90	88.00	HEP2 >	320.00 >	3.64	9/18/86
AVS-1984	CPE	AD2	0.7	----	HEP2 >	320.00	----	5/26/88
AVS-1984	CPE	JE	----	----	VERO	320.00	----	3/27/87
AVS-1984	PR	PIC	N/A	----	VERO >	320.00	----	1/23/87
AVS-1984	CPE	SF	2.85	1.00	VERO	32.00	32.00	10/22/86
AVS-1984	CPE	SF	----	----	VERO >	100.00	----	11/26/86
AVS-1984	CPE	SF	----	----	VERO	32.00	----	8/18/87
AVS-1984	CPE	SF	0.3	----	VERO	32.00	----	5/18/88
AVS-1984	CPE	VEE	----	----	VERO	100.00	----	5/ 7/87
AVS-1984	CPE	VSV	----	----	L929	320.00	----	6/24/86
AVS-1984	CPE	VV	----	----	VERO >	320.00	----	7/24/86
AVS-1985	CPE	AD2	0.30	----	HEP2 <	3.20	----	9/18/86
AVS-1985	CPE	JE	2.64	3.95	VERO	32.00	8.08	3/27/87
AVS-1985	CPE	JE	0.95	2.97	VERO	3.20	1.0	5/24/88
AVS-1985	PR	PIC	N/A	4.65	VERO	32.00	6.87	1/23/87
AVS-1985	PR	PIC	N/A	----	VERO	10.00	----	2/ 3/87
AVS-1985	PR	PIC	N/A	----	VERO	3.20	----	5/23/88
AVS-1985	CPE	PT	0.45	100.00	VERO	10.00	0.10	10/31/86
AVS-1985	CPE	SF	2.85	7.30	VERO >	100.00 >	13.60	10/22/86
AVS-1985	CPE	SF	2.55	4.57	VERO	10.00	2.18	7/28/87
AVS-1985	CPE	SF	0.9	14.80	VERO	32.00	2.15	5/24/88
AVS-1985	CPE	VEE	----	----	VERO	3.20	----	5/ 7/87
AVS-1985	CPE	VSV	----	----	L929	3.20	----	6/24/86
AVS-1985	CPE	VV	7.2 <	0.32	VERO	100.00 >	312.00	7/24/86
AVS-1985	PR	VV	N/A	----	VERO	32.00	29400.00	4/ 3/87
AVS-1985	PR	VV	N/A	----	VERO	10.00	2740.00	4/ 3/87
AVS-1985	CPE	VV	10.2	----	VERO	32.00	5640.00	5/26/88
AVS-1985	CPE	YFV	3.80	1.21	VERO	32.00	26.20	1/23/87
AVS-1985	CPE	YFV	2.69	3.90	VERO	10.00	2.56	7/29/87
AVS-1985	CPE	YFV	----	----	VERO	32.00	----	12/14/87
AVS-1985	CPE	YFV	----	----	VERO	100.00	----	5/24/88
AVS-1986	CPE	AD2	----	----	HEP2 >	320.00	----	9/18/86
AVS-1986	CPE	JE	----	----	VERO >	100.00	----	12/ 7/87
AVS-1986	PR	PIC	N/A	----	VERO >	320.00	----	1/23/87
AVS-1986	PR	PIC	N/A	----	VERO <	0.32	----	2/ 3/87
AVS-1986	CPE	VEE	----	----	VERO	320.00	----	5/ 7/87
AVS-1986	CPE	VSV	----	----	L929	320.00	----	6/24/86
AVS-1986	CPE	VV	7.4	0.60	VERO >	320.00 >	533.00	7/24/86
AVS-1986	CPE	VV	7.2	0.65	VERO >	320.00 >	487.00	5/26/88
AVS-1986	CPE	YFV	----	----	VERO	320.00	----	1/22/87
AVS-1987	CPE	AD2	----	----	HEP2 >	320.00	----	9/18/86
AVS-1987	CPE	JE	----	----	VERO	320.00	----	3/27/87

B-61

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-1987	PR	PIC	N/A	----	VERO >	320.00	----	1/23/87
AVS-1987	CPE	SF	2.49	19.00	VERO <	100.00 <	5.26	10/22/86
AVS-1987	CPE	SF	0.25	----	VERO	100.00	----	5/18/88
AVS-1987	CPE	VEE	----	----	VERO >	320.00	----	5/ 7/87
AVS-1987	CPE	VSV	----	----	L929 >	320.00	----	6/24/86
AVS-1987	CPE	VV	6.8	1.70	VERO >	320.00 >	188.00	7/24/86
AVS-1987	CPE	VV	5.6	2.79	VERO >	320.00 >	114.00	5/26/88
AVS-1987	CPE	YFV	----	----	VERO >	320.00	----	1/22/87
AVS-1988	CPE	AD2	----	----	HEP2	320.00	----	9/18/86
AVS-1988	CPE	JE	----	----	VERO >	320.00	----	3/27/87
AVS-1988	PR	PIC	N/A	----	VERO	100.00	----	1/27/87
AVS-1988	CPE	VEE	----	----	VERO	320.00	----	5/ 7/87
AVS-1988	CPE	VSV	----	----	L929 >	320.00	----	6/24/86
AVS-1988	CPE	VV	6.4	3.60	VERO >	320.00 >	88.80	7/24/86
AVS-1988	CPE	VV	5.9	1.99	VERO >	320.00 >	160.00	5/26/88
AVS-1988	CPE	YFV	----	----	VERO	320.00	----	1/22/87
AVS-1989	CPE	AD2	----	----	HEP2	100.00	----	9/18/86
AVS-1989	CPE	JE	----	----	VERO >	320.00	----	3/27/87
AVS-1989	PR	PIC	N/A	----	VERO	320.00	----	1/27/87
AVS-1989	CPE	SF	----	----	VERO	32.00	----	11/25/86
AVS-1989	CPE	VEE	----	----	VERO	32.00	----	5/ 7/87
AVS-1989	CPE	VSV	----	----	L929	10.00	----	6/24/86
AVS-1989	CPE	VV	----	----	VERO	32.00	----	7/24/86
AVS-1989	CPE	YFV	----	----	VERO	32.00	----	1/22/87
AVS-1990	CPE	AD2	----	----	HEP2	32.00	----	9/18/86
AVS-1990	CPE	JE	0.15	----	VERO	32.00	----	3/17/87
AVS-1990	PR	PIC	N/A	----	VERO	1.00	----	1/27/87
AVS-1990	CPE	SF	1.75	15.60	VERO	10.00	0.64	11/25/86
AVS-1990	CPE	VEE	----	----	VERO	100.00	----	5/ 8/87
AVS-1990	CPE	VSV	----	----	L929	32.00	----	6/24/86
AVS-1990	CPE	VV	----	----	VERO	320.00	----	7/24/86
AVS-1990	CPE	YFV	----	----	VERO	32.00	----	1/22/87
AVS-1991	CPE	JE	0.1	----	VERO <	10.00	----	3/17/87
AVS-1991	PR	PIC	N/A	2.65	VERO	3.20	1.20	1/30/87
AVS-1991	CPE	PT	0.60	298.00	VERO	320.00	1.07	10/17/86
AVS-1991	CPE	SF	1.11	0.83	VERO	3.20	3.84	10/17/86
AVS-1991	CPE	SF	0.65	1.99	VERO	3.20	1.60	5/18/88
AVS-1991	CPE	VEE	1.	0.73	VERO	1.00	1.36	5/ 8/87
AVS-1991	CPE	YFV	----	----	VERO <	0.32	----	1/23/87
AVS-1992	CPE	JE	----	----	VERO	100.00	----	3/17/87
AVS-1992	PR	PIC	N/A	94.90	VERO	320.00	3.37	1/30/87
AVS-1992	PR	PIC	N/A	----	VERO	100.00	----	5/16/88
AVS-1992	CPE	PT	1.50	43.20	VERO	100.00	2.30	10/21/86
AVS-1992	CPE	SF	0.90	94.80	VERO	32.00	0.34	10/27/86
AVS-1992	CPE	SF	0.55	----	VERO	32.00	----	11/17/86
AVS-1992	CPE	VEE	----	----	VERO	100.00	----	5/13/87
AVS-1992	CPE	YFV	----	----	VERO	100.00	----	1/23/87
AVS-1993	CPE	JE	----	----	VERO	100.00	----	3/17/87
AVS-1993	PR	PIC	N/A	----	VERO	320.00	----	1/30/87
AVS-1993	CPE	VEE	0.35	----	VERO	10.00	----	5/ 8/87
AVS-1993	CPE	YFV	----	----	VERO	320.00	----	1/23/87
AVS-1994	CPE	JE	0.1	----	VERO	100.00	----	3/17/87
AVS-1994	PR	PIC	N/A	----	VERO	320.00	----	2/ 6/87
AVS-1994	CPE	PT	0.75	66.00	VERO	32.00	0.48	10/21/86
AVS-1994	CPE	VEE	----	----	VERO	100.00	----	5/ 8/87
AVS-1994	CPE	YFV	----	----	VERO	100.00	----	1/23/87
AVS-1995	CPE	JE	0.35	----	VERO	100.00	----	4/ 1/87
AVS-1995	PR	PIC	N/A	----	VERO >	320.00	----	2/ 6/87
AVS-1995	CPE	PT	1.11	69.00	VERO	100.00	1.45	10/21/86
AVS-1995	CPE	SF	2.64	9.70	VERO	100.00	10.20	10/21/86
AVS-1995	CPE	SF	----	----	VERO	10.00	----	11/17/86
AVS-1995	CPE	SF	0.45	----	VERO	100.00	----	11/25/86
AVS-1995	CPE	SF	----	----	VERO	10.00	----	5/24/88
AVS-1995	CPE	VEE	----	----	VERO	100.00	----	5/ 8/87
AVS-1995	CPE	YFV	----	----	VERO	10.00	----	1/23/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	HTC50	TI	DATE
AVS-1996	CPE	JE	----	----	VERO	100.00	----	3/17/87
AVS-1996	PR	PIC	N/A	66.00	VERO	100.00	1.51	2/ 6/87
AVS-1996	CPE	SF	1.65	46.30	VERO <	100.00 <	2.16	10/21/86
AVS-1996	CPE	SF	----	----	VERO	100.00	----	11/25/86
AVS-1996	CPF	VEE	0.5	100.00	VERO	10.00	0.10	5/ 8/87
AVS-1996	CP	YFV	----	----	VERO	100.00	----	1/26/87
AVS-1997	CPE	JE	----	----	VERO >	100.00	----	3/17/87
AVS-1997	PR	PIC	N/A	----	VERO >	320.00	----	2/ 6/87
AVS-1997	CPE	SF	2.01	96.00	VERO	320.00	3.32	10/24/86
AVS-1997	CPE	SF	----	----	VERO	320.00	----	5/24/88
AVS-1997	CPE	VEE	----	----	VERO	320.00	----	5/ 8/87
AVS-1997	CPE	YFV	----	----	VERO >	320.00	----	1/26/87
AVS-1998	CPE	JE	----	----	VERO	100.00	----	3/17/87
AVS-1998	PR	PIC	N/A	----	VERO >	320.00	----	2/ 6/87
AVS-1998	CPE	PT	0.75	56.20	VERO	100.00	1.78	10/22/86
AVS-1998	CPE	SF	1.56	18.40	VERO	32.00	1.74	10/24/86
AVS-1998	CPE	VEE	----	----	VERO	100.00	----	5/ 8/87
AVS-1998	CPE	YFV	0.10	----	VERO	32.00	----	1/26/87
AVS-1999	CPE	JE	0.35	----	VERO >	320.00	----	4/ 1/87
AVS-1999	PR	PIC	N/A	----	VERO >	320.00	----	2/10/87
AVS-1999	CPE	VEE	----	----	VERO	100.00	----	5/ 8/87
AVS-1999	CPE	YFV	0.20	----	VERO >	320.00	----	1/26/87
AVS-2001	CPE	JE	0.1	----	VERO	32.00	----	3/17/87
AVS-2001	PR	PIC	N/A	----	VERO >	320.00	----	2/10/87
AVS-2001	CPE	PT	0.75	66.00	VERO	32.00	0.48	10/22/86
AVS-2001	CPE	SF	2.25	30.70	VERO	32.00	1.03	10/24/86
AVS-2001	CPE	VEE	----	----	VERO	100.00	----	5/ 8/87
AVS-2001	CPE	YFV	----	----	VERO	320.00	----	1/26/87
AVS-2002	CPE	JE	0.2	----	VERO >	320.00	----	3/18/87
AVS-2002	PR	PIC	N/A	----	VERO >	320.00	----	12/11/87
AVS-2002	CPE	SF	----	----	VERO >	100.00	----	11/26/86
AVS-2002	CPE	VEE	----	----	VERO	320.00	----	5/ 8/87
AVS-2002	CPE	YFV	----	----	VERO >	320.00	----	1/27/87
AVS-2003	CPE	JE	0.05	----	VERO	320.00	----	3/18/87
AVS-2003	PR	PIC	N/A	----	VERO >	320.00	----	2/10/87
AVS-2003	CPE	PT	0.48	61.90	VERO	100.00	1.61	10/22/86
AVS-2003	CPE	SF	1.92	102.00	VERO	100.00	0.97	10/23/86
AVS-2003	CPE	SF	----	536.00	VERO >	100.00 >	0.19	11/10/86
AVS-2003	CPE	VEE	----	----	VERO	32.00	----	5/11/87
AVS-2003	CPE	YFV	0.80	96.00	VERO	320.00	3.29	1/27/87
AVS-2003	CPE	YFV	----	----	VERO	100.00	----	5/24/88
AVS-2004	CPE	JE	0.15	421.00	VERO >	320.00 >	0.76	4/ 1/87
AVS-2004	PR	PIC	N/A	----	VERO >	320.00	----	2/10/87
AVS-2004	CPE	VEE	0.6	281.00	VERO	32.00	0.11	5/11/87
AVS-2004	CPE	YFV	2.00	96.00	VERO >	320.00	3.29	1/27/87
AVS-2004	CPE	YFV	----	----	VERO	100.00	----	5/24/88
AVS-2005	CPE	JE	0.02	----	VERO	320.00	----	4/ 1/87
AVS-2005	PR	PIC	N/A	----	VERO	100.00	----	2/23/87
AVS-2005	CPE	PT	0.96	34.20	VERO	100.00	2.92	10/22/86
AVS-2005	CPE	SF	1.86	93.20	VERO	32.00	0.34	10/23/86
AVS-2005	CPE	SF	----	----	VERO >	10.00	----	11/26/86
AVS-2005	CPE	VEE	----	----	VERO	10.00	----	5/11/87
AVS-2005	CPE	YFV	----	----	VERO	100.00	----	1/27/87
AVS-2006	CPE	JE	0.85	95.00	VERO	32.00	0.34	4/ 1/87
AVS-2006	PR	PIC	N/A	----	VERO >	320.00	----	2/10/87
AVS-2006	CPE	PT	1.29	49.60	VERO	100.00	2.01	10/22/86
AVS-2006	CPE	SF	2.79	30.90	VERO	32.00	1.03	10/23/86
AVS-2006	CPE	SF	1.20	----	VERO >	10.00	----	12/ 1/86
AVS-2006	CPE	VEE	----	----	VERO	10.00	----	5/11/87
AVS-2006	CPE	YFV	1.70	85.40	VERO	32.00	0.37	1/27/87
AVS-2007	CPE	JE	----	----	VERO >	320.00	----	3/18/87
AVS-2007	PR	PIC	N/A	----	VERO	100.00	----	2/10/87
AVS-2007	CPE	PT	0.81	317.00	VERO >	320.00 >	1.00	10/24/86
AVS-2007	CPE	SF	0.80	----	VERO >	32.00	----	12/ 1/86
AVS-2007	CPE	VEE	----	----	VERO	10.00	----	5/11/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MYC50	TI	DATE
AVS-2007	CPE	YFV	----	----	VERO	320.00	----	1/27/87
AVS-2008	CPE	JE	2.15	3.79	VERO	10.00	2.63	3/18/87
AVS-2008	PR	PIC	N/A	----	VERO	100.00	----	2/17/87
AVS-2008	CPE	VEE	----	----	VERO	100.00	----	5/11/87
AVS-2008	CPE	YFV	1.65	15.90	VERO	32.00	2.01	1/27/87
AVS-2009	CPE	JE	0.4	----	VERO >	320.00	----	3/18/87
AVS-2009	PR	PIC	N/A	----	VERO <	320.00	----	2/17/87
AVS-2009	CPE	VEE	----	----	VERO -	0.32	----	5/11/87
AVS-2009	CPE	YFV	0.20	----	VERO	100.00	----	1/27/87
AVS-2010	CPE	JE	----	----	VERO <	320.00	----	3/18/87
AVS-2010	PR	PIC	N/A	----	VERO >	320.00	----	2/17/87
AVS-2010	CPE	PT	0.60	93.00	VERO	100.00	1.08	10/24/86
AVS-2010	CPE	SF	0.10	----	VERO	100.00	----	11/21/86
AVS-2010	CPE	VEE	----	----	VERO -	0.10	----	5/11/87
AVS-2010	CPE	YFV	----	----	VERO	100.00	----	1/27/87
AVS-2011	CPE	JE	----	----	VERO	320.00	----	3/18/87
AVS-2011	PR	PIC	N/A	----	VERO >	320.00	----	2/17/87
AVS-2011	CPE	PT	0.75	50.50	VERO	100.00	1.98	10/24/86
AVS-2011	CPE	SF	----	----	VERO >	100.00	----	11/21/86
AVS-2011	CPE	VEE	----	----	VERO	32.00	----	5/11/87
AVS-2011	CPE	YFV	----	----	VERO >	320.00	----	1/27/87
AVS-2012	CPE	JE	----	----	VERO	32.00	----	3/18/87
AVS-2012	PR	PIC	N/A	----	VERO <	100.00	----	2/17/87
AVS-2012	CPE	PT	0.15	----	VERO	10.00	----	11/18/86
AVS-2012	CPE	SF	----	----	VERO	32.00	----	11/21/86
AVS-2012	CPE	VEE	----	----	VERO	10.00	----	5/11/87
AVS-2012	CPE	YFV	----	----	VERO <	100.00	----	1/28/87
AVS-2013	CPE	JE	----	----	VERO	320.00	----	3/19/87
AVS-2013	PR	PIC	N/A	----	VERO >	320.00	----	2/27/87
AVS-2013	CPE	PT	0.65	81.30	VERO	10.00	0.12	11/18/86
AVS-2013	CPE	SF	3.21	24.80	VERO >	320.00 >	12.80	11/12/86
AVS-2013	CPE	SF	----	----	VERO	100.00	----	5/24/88
AVS-2013	CPE	VEE	----	----	VERO -	0.10	----	5/11/87
AVS-2013	CPE	YFV	0.30	3.20	VERO	1.00	0.31	1/28/87
AVS-2014	CPE	JE	----	----	VERO	320.00	----	3/19/87
AVS-2014	PR	PIC	N/A	----	VERO >	320.00	----	2/23/87
AVS-2014	CPE	PT	0.6	93.20	VERO	10.00	0.11	11/18/86
AVS-2014	CPE	VEE	----	----	VERO	320.00	----	5/13/87
AVS-2014	CPE	YFV	0.20	----	VERO	100.00	----	1/28/87
AVS-2015	CPE	JE	----	----	VERO	320.00	----	3/19/87
AVS-2015	PR	PIC	N/A	----	VERO	100.00	----	2/23/87
AVS-2015	CPE	PT	0.6	94.80	VERO	10.00	0.10	11/18/86
AVS-2015	CPE	VEE	----	----	VERO	320.00	----	5/13/87
AVS-2015	CPE	YFV	----	----	VERO	320.00	----	1/28/87
AVS-2016	CPE	JE	----	----	VERO	320.00	----	3/19/87
AVS-2016	PR	PIC	N/A	----	VERO	320.00	----	2/23/87
AVS-2016	CPE	PT	0.2	----	VERO	32.00	----	11/18/86
AVS-2016	CPE	VEE	----	----	VERO >	320.00	----	5/13/87
AVS-2016	CPE	YFV	0.25	----	VERO	100.00	----	1/28/87
AVS-2017	CPE	JE	----	----	VERO	100.00	----	3/19/87
AVS-2017	PR	PIC	N/A	----	VERO	320.00	----	2/23/87
AVS-2017	CPE	PT	1.50	35.70	VERO	32.00	0.90	10/27/86
AVS-2017	CPE	SF	0.36	496.00	VERO	320.00	0.64	11/12/86
AVS-2017	CPE	VEE	----	----	VERO	32.00	----	5/13/87
AVS-2017	CPE	YFV	0.20	----	VERO	10.00	----	1/28/87
AVS-2018	CPE	JE	----	----	VERO	320.00	----	3/19/87
AVS-2018	PR	PIC	N/A	----	VERO <	320.00	----	2/23/87
AVS-2018	CPE	PT	1.29	54.00	VERO	100.00	1.85	10/27/86
AVS-2018	CPE	VEE	----	----	VERO	100.00	----	5/13/87
AVS-2018	CPE	YFV	0.15	----	VERO	100.00	----	1/28/87
AVS-2019	CPE	JE	----	----	VERO	10.00	----	3/19/87
AVS-2019	PR	PIC	N/A	3.13	VERO -	0.32	0.10	2/27/87
AVS-2019	CPE	PT	0.69	1.59	VERO	3.20	1.99	10/27/86
AVS-2019	CPE	SF	----	----	VERO <	3.20	----	12/23/86
AVS-2019	CPE	VEE	----	----	VERO	3.20	----	5/13/87

B-64

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2019	CPE	YFV	0.20	----	VERO	320.00	----	1/28/87
AVS-2020	CPE	JE	----	----	VERO >	320.00	----	3/19/87
AVS-2020	PR	PIC	N/A	----	VERO >	320.00	----	2/27/87
AVS-2020	CPE	PT	1.59	13.50	VERO	32.00	2.35	10/27/86
AVS-2020	CPE	VEE	----	----	VERO	100.00	----	5/13/87
AVS-2020	CPE	YFV	0.10	----	VERO	320.00	----	1/28/87
AVS-2021	CPE	JE	----	----	VERO >	320.00	----	3/19/87
AVS-2021	PR	PIC	N/A	----	VERO >	320.00	----	2/27/87
AVS-2021	CPE	PT	0.99	36.50	VERO	32.00	0.87	10/27/86
AVS-2021	CPE	VEE	----	----	VERO	100.00	----	5/13/87
AVS-2021	CPE	YFV	----	----	VERO	320.00	----	1/28/87
AVS-2022	CPE	JE	----	----	VERO	320.00	----	3/19/87
AVS-2022	PR	PIC	N/A	----	VERO	320.00	----	2/ 6/87
AVS-2022	CPE	VEE	----	----	VERO	320.00	----	5/13/87
AVS-2022	CPE	YFV	----	----	VERO	320.00	----	1/29/87
AVS-2023	CPE	JE	1.4	40.70	VERO	32.00	0.78	3/19/87
AVS-2023	PR	PIC	N/A	335.00	VERO >	320.00 >	0.95	2/27/87
AVS-2023	CPE	VEE	----	----	VERO	32.00	----	5/13/87
AVS-2023	CPE	VSV	----	----	L929	32.00	----	6/24/86
AVS-2023	CPE	YFV	0.90	91.70	VERO	32.00	0.35	1/29/87
AVS-2024	CPE	PT	----	----	VERO <	0.32	----	8/ 6/87
AVS-2024	CPE	YFV	----	----	VERO <	0.32	----	8/ 4/87
AVS-2025	CPE	PT	----	----	VERO <	0.32	----	8/ 6/87
AVS-2025	CPE	SF	----	----	VERO <	0.32	----	8/ 5/87
AVS-2025	CPE	YFV	----	----	VERO <	0.32	----	8/ 5/87
AVS-2026	CPE	JE	0.05	----	VERO	32.00	----	7/28/87
AVS-2026	CPE	PT	1.89	11.80	VERO <	100.00 <	8.47	11/ 7/86
AVS-2026	CPE	PT	1.9	8.90	VERO	32.00	3.57	6/ 1/88
AVS-2026	CPE	SF	0.85	100.00	VERO	32.00	0.32	8/ 7/87
AVS-2026	CPE	VEE	----	----	VERO	3.20	----	4/29/88
AVS-2026	CPE	YFV	----	----	VERO	100.00	----	8/ 7/87
AVS-2027	CPE	JE	----	----	VERO <	100.00	----	8/ 5/87
AVS-2027	CPE	SF	----	----	VERO	1.00	----	8/ 5/87
AVS-2027	CPE	YFV	----	----	VERO	1.00	----	8/ 5/87
AVS-2028	CPE	JE	----	----	VERO	50.00	----	8/ 5/87
AVS-2028	CPE	SF	0.1	----	VERO	10.00	----	8/ 5/87
AVS-2028	CPE	VEE	----	----	VERO	100.00	----	5/18/88
AVS-2028	CPE	YFV	0.22	----	VERO	10.00	----	8/ 5/87
AVS-2029	CPE	JE	----	----	VERO	10.00	----	8/ 5/87
AVS-2029	CPE	PT	0.21	30.70	VERO	3.20	0.10	11/10/86
AVS-2029	CPE	SF	----	----	VERO	3.20	----	8/ 5/87
AVS-2029	CPE	YFV	----	----	VERO	0.10	----	8/ 5/87
AVS-2030	CPE	JE	----	----	VERO <	160.00	----	8/ 5/87
AVS-2030	CPE	SF	----	----	VERO	10.00	----	8/ 5/87
AVS-2030	CPE	YFV	0.1	----	VERO	10.00	----	8/ 5/87
AVS-2031	CPE	JE	----	----	VERO	10.00	----	8/ 6/87
AVS-2031	CPE	SF	0.4	0.23	VERO	0.03	0.13	8/ 6/87
AVS-2031	CPE	YFV	----	----	VERO	0.03	----	8/ 6/87
AVS-2032	CPE	JE	----	----	VERO	3.20	----	8/ 6/87
AVS-2032	CPE	SF	----	----	VERO	0.03	----	8/ 6/87
AVS-2032	CPE	YFV	----	----	VERO <	100.00	----	8/ 6/87
AVS-2034	CPE	PT	2.07	4.15	VERO	10.00	2.41	11/ 5/86
AVS-2034	CPE	SF	0.25	----	VERO	0.32	----	8/ 7/87
AVS-2034	CPE	YFV	0.85	0.53	VERO	0.32	0.60	8/ 7/87
AVS-2035	CPE	JE	----	----	VERO	10.00	----	8/ 6/87
AVS-2035	CPE	SF	0.25	----	VERO	0.01	----	8/ 6/87
AVS-2035	CPE	YFV	----	----	VERO	0.10	----	8/ 6/87
AVS-2036	CPE	JE	----	----	VERO	100.00	----	8/ 6/87
AVS-2036	CPE	SF	0.8	----	VERO	1.00	----	8/ 6/87
AVS-2036	CPE	YFV	----	----	VERO	3.20	----	8/ 6/87
AVS-2037	CPE	JE	----	----	VERO >	320.00	----	8/ 7/87
AVS-2037	CPE	SF	----	----	VERO	0.32	----	8/ 7/87
AVS-2037	CPE	YFV	----	----	VERO	0.32	----	8/ 7/87
AVS-2038	CPE	JE	----	----	VERO	320.00	----	8/ 7/87
AVS-2038	CPE	SF	----	----	VERO	1.00	----	8/ 7/87

B-65

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MT50	TI	DATE
AVS-2038	CPE	YFV	----	----	VERO	1.00	----	8/ 7/87
AVS-2039	CPE	JE	----	----	VERO <	100.00	----	3/23/87
AVS-2039	PR	PIC	N/A	----	VERO -	0.32	----	3/27/87
AVS-2039	CPE	SF	----	----	VERO <	32.00	----	11/19/86
AVS-2039	CPE	VEE	----	----	VERO	320.00	----	12/ 1/87
AVS-2039	CPE	YFV	----	----	VERO	10.00	----	1/30/87
AVS-2040	CPE	JE	----	----	VERO	32.00	----	3/23/87
AVS-2040	PR	PIC	N/A	254.00	VERO -	0.32	----	3/27/87
AVS-2040	CPE	PT	0.60	298.00	VERO	32.00	0.11	10/29/86
AVS-2040	CPE	SF	0.25	----	VERO	10.00	----	11/19/86
AVS-2040	CPE	SF	----	----	VERO	3.20	----	12/23/86
AVS-2040	CPE	VEE	----	----	VERO	100.00	----	12/ 1/87
AVS-2040	CPE	YFV	0.23	----	VERO	32.00	----	1/30/87
AVS-2041	CPE	JE	0.1	----	VERO <	100.00	----	3/23/87
AVS-2041	PR	PIC	N/A	----	VERO -	0.32	----	3/27/87
AVS-2041	CPE	VEE	----	----	VERO	10.00	----	12/ 1/87
AVS-2041	CPE	YFV	----	----	VERO	10.00	----	1/30/87
AVS-2042	CPE	JE	0.17	----	VERO	1.00	----	3/23/87
AVS-2042	PR	PIC	N/A	----	VERO <	3.20	----	3/27/87
AVS-2042	CPE	SF	0.54	6.10	VERO	1.00	0.16	10/29/86
AVS-2042	CPE	SF	0.60	9.20	VERO	3.20	0.35	12/ 2/86
AVS-2042	CPE	VEE	----	----	VERO	32.00	----	12/ 2/87
AVS-2042	CPE	YFV	----	----	VERO <	0.32	----	1/30/87
AVS-2043	CPE	JE	----	----	VERO	3.20	----	6/10/87
AVS-2043	CPE	PT	0.05	----	VERO	3.20	----	6/10/87
AVS-2043	CPE	SF	----	----	VERO	1.00	----	6/10/87
AVS-2043	CPE	YFV	0.25	----	VERO	1.00	----	6/10/87
AVS-2044	CPE	JE	----	----	VERO	320.00	----	6/10/87
AVS-2044	CPE	FT	0.27	----	VERO	10.00	----	6/10/87
AVS-2044	CPE	SF	0.3	100.00	VERO	100.00	1.00	6/10/87
AVS-2044	CPE	YFV	0.4	----	VERO	32.00	----	6/10/87
AVS-2045	CPE	JE	0.05	----	VERO >	320.00	----	6/10/87
AVS-2045	CPE	PT	0.9	----	VERO	320.00	----	6/10/87
AVS-2045	CPE	SF	----	----	VERO >	100.00	----	6/10/87
AVS-2045	CPE	YFV	----	----	VERO >	100.00	----	6/10/87
AVS-2046	CPE	JE	0.05	----	VERO	100.00	----	6/10/87
AVS-2046	CPE	PT	0.5	----	VERO	3.20	----	6/10/87
AVS-2046	CPE	SF	----	----	VERO	32.00	----	6/10/87
AVS-2046	CPE	YFV	----	----	VERO	10.00	----	6/10/87
AVS-2047	CPE	JE	0.05	----	VERO	100.00	----	6/10/87
AVS-2047	CPE	PT	0.5	----	VERO	100.00	----	6/10/87
AVS-2047	CPE	SF	----	----	VERO	32.00	----	6/10/87
AVS-2047	CPE	YFV	----	----	VERO	100.00	----	6/10/87
AVS-2048	CPE	JE	----	----	VERO <	100.00	----	6/10/87
AVS-2048	CPE	PT	0.15	----	VERO	10.00	----	6/10/87
AVS-2048	CPE	SF	0.2	----	VERO	10.00	----	6/10/87
AVS-2048	CPE	YFV	----	----	VERO	10.00	----	6/10/87
AVS-2049	CPE	JE	----	----	VERO	320.00	----	6/10/87
AVS-2049	CPE	PT	----	----	VERO	320.00	----	6/10/87
AVS-2049	CPE	SF	----	----	VERO >	100.00	----	6/10/87
AVS-2049	CPE	YFV	0.15	----	VERO	32.00	----	6/10/87
AVS-2050	CPE	JE	----	----	VERO	320.00	----	6/10/87
AVS-2050	CPE	PT	0.3	----	VERO	32.00	----	6/10/87
AVS-2050	CPE	SF	0.6	178.00	VERO	100.00	0.56	6/10/87
AVS-2050	CPE	YFV	0.5	----	VERO	32.00	----	6/10/87
AVS-2051	CPE	JE	----	----	VERO	10.00	----	6/11/87
AVS-2051	CPE	PT	----	----	VERO	10.00	----	6/11/87
AVS-2051	CPE	SF	----	----	VERO	3.20	----	6/11/87
AVS-2051	CPE	YFV	0.65	23.30	VERO	3.20	0.14	6/11/87
AVS-2052	CPE	JE	----	----	VERO	10.00	----	6/11/87
AVS-2052	CPE	PT	0.05	----	VERO	3.20	----	6/11/87
AVS-2052	CPE	SF	0.07	----	VERO	3.20	----	6/11/87
AVS-2052	CPE	YFV	1.	33.10	VERO	3.20	0.10	6/11/87
AVS-2053	CPE	JE	----	----	VERO <	32.00	----	6/11/87
AVS-2053	CPE	PT	0.05	----	VERO	3.20	----	6/11/87

B-66

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2053	CPE	SF	0.2	----	VERO	3.20	----	6/11/87
AVS-2053	CPE	YFV	0.08	----	VERO <	32.00	----	6/11/87
AVS-2054	CPE	JE	----	----	VERO >	320.00	----	6/11/87
AVS-2054	CPE	PT	0.45	284.00	VERO	100.00	0.35	6/11/87
AVS-2054	CPE	SF	0.85	118.00	VERO	100.00	0.85	6/11/87
AVS-2054	CPE	YFV	0.94	281.00	VERO	320.00	1.13	6/11/87
AVS-2055	CPE	JE	----	----	VERO	100.00	----	6/11/87
AVS-2055	CPE	PT	0.1	----	VERO	100.00	----	6/11/87
AVS-2055	CPE	SF	0.95	94.40	VERO	100.00	1.05	6/11/87
AVS-2055	CPE	YFV	----	----	VERO	100.00	----	6/11/87
AVS-2056	CPE	JE	----	----	VERO	10.00	----	6/11/87
AVS-2056	CPE	PT	0.25	----	VERO	10.00	----	6/11/87
AVS-2056	CPE	SF	0.55	18.80	VERO	32.00	1.69	6/11/87
AVS-2056	CPE	YFV	0.3	----	VERO	32.00	----	6/11/87
AVS-2057	CPE	JE	----	----	VERO	100.00	----	6/11/87
AVS-2057	CPE	PT	0.5	----	VERO	100.00	----	6/11/87
AVS-2057	CPE	SF	0.6	178.00	VERO	100.00	0.56	6/11/87
AVS-2057	CPE	YFV	1.54	295.00	VERO	100.00	0.34	6/11/87
AVS-2058	CPE	JE	----	----	VERO	10.00	----	6/11/87
AVS-2058	CPE	PT	0.4	----	VERO <	10.00	----	6/11/87
AVS-2058	CPE	SF	0.25	----	VERO	10.00	----	6/11/87
AVS-2058	CPE	YFV	0.29	----	VERO	10.00	----	6/11/87
AVS-2059	CPE	JE	----	----	VERO	3.20	----	6/16/87
AVS-2059	CPE	PT	0.25	----	VERO	10.00	----	6/16/87
AVS-2059	CPE	SF	0.2	----	VERO	10.00	----	6/16/87
AVS-2060	CPE	JE	----	----	VERO <	10.00	----	6/16/87
AVS-2060	CPE	PT	0.1	----	VERO <	10.00	----	6/16/87
AVS-2060	CPE	SF	----	----	VERO <	10.00	----	6/16/87
AVS-2061	CPE	JE	----	----	VERO	100.00	----	6/16/87
AVS-2061	CPE	PT	0.5	----	VERO <	320.00	----	6/16/87
AVS-2061	CPE	SF	0.6	178.00	VERO	32.00	0.18	6/16/87
AVS-2062	CPE	JE	----	----	VERO >	320.00	----	6/16/87
AVS-2062	CPE	PT	0.6	----	VERO	320.00	----	6/16/87
AVS-2062	CPE	SF	----	----	VERO	100.00	----	6/16/87
AVS-2063	CPE	JE	----	----	VERO	32.00	----	6/16/87
AVS-2063	CPE	PT	0.55	----	VERO	32.00	----	6/16/87
AVS-2063	CPE	SF	0.3	32.00	VERO	10.00	0.31	6/16/87
AVS-2064	CPE	JE	----	----	VERO	100.00	----	6/16/87
AVS-2064	CPE	PT	0.1	----	VERO	3.20	----	6/16/87
AVS-2064	CPE	SF	0.6	178.00	VERO	32.00	0.18	6/16/87
AVS-2065	CPE	JE	----	----	VERO	10.00	----	6/16/87
AVS-2065	CPE	PT	----	----	VERO	0.32	----	6/16/87
AVS-2065	CPE	SF	----	----	VERO	1.00	----	6/16/87
AVS-2066	CPE	JE	----	----	VERO <	10.00	----	6/16/87
AVS-2066	CPE	PT	----	----	VERO	3.20	----	6/16/87
AVS-2066	CPE	SF	----	----	VERO <	10.00	----	6/16/87
AVS-2067	CPE	JE	----	----	VERO	100.00	----	6/16/87
AVS-2067	CPE	PT	0.17	----	VERO	100.00	----	6/16/87
AVS-2067	CPE	SF	0.65	169.00	VERO	32.00	0.19	6/16/87
AVS-2068	CPE	JE	0.05	----	VERO	100.00	----	4/29/88
AVS-2068	PR	PIC	N/A	----	VERO	32.00	----	6/ 6/88
AVS-2068	CPE	PT	1.70	----	VERO >	320.00	----	1/29/87
AVS-2068	CPE	SF	----	----	VERO	3.20	----	1/15/87
AVS-2068	CPE	YFV	----	----	VERO	320.00	----	3/31/87
AVS-2069	CPE	JE	----	----	VERO	100.00	----	4/29/88
AVS-2069	CPE	PT	0.60	----	VERO	320.00	----	1/29/87
AVS-2069	CPE	SF	----	----	VERO >	100.00	----	1/15/87
AVS-2069	CPE	YFV	0.15	----	VERO	320.00	----	3/31/87
AVS-2087	CPE	AD2	----	----	HEP2	320.00	----	10/ 2/86
AVS-2087	CPE	JE	----	----	VERO >	320.00	----	3/25/87
AVS-2087	PR	PIC	N/A	----	VERO >	320.00	----	3/25/88
AVS-2087	CPE	PT	0.86	----	VERO >	320.00	----	1/ 6/87
AVS-2087	CPE	SF	----	----	VERO	100.00	----	12/31/86
AVS-2087	CPE	VEE	----	----	VERO >	320.00	----	5/18/87
AVS-2087	CPE	VSV	----	----	L929	100.00	----	8/ 1/86

8-67

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2087	CPE	VV	----	----	VERO	320.00	----	8/20/86
AVS-2087	CPE	YFV	0.4	9.60	VERO	3.20	0.33	3/13/87
AVS-2088	CPE	AD2	----	----	HEP2	32.00	----	10/ 2/86
AVS-2088	CPE	JE	----	----	VERO	10.00	----	3/25/87
AVS-2088	-R	PIC	N/A	----	VERO	10.00	----	4/18/88
AVS-2088	CPE	PT	----	----	VERO	10.00	----	1/ 6/87
AVS-2088	CPE	SF	----	----	VERO	3.20	----	12/31/86
AVS-2088	CPE	VEE	0.15	----	VERO	32.00	----	5/18/87
AVS-2088	CPE	VSV	----	----	L929	10.00	----	8/ 1/86
AVS-2088	CPE	VV	----	----	VERO <	32.00	----	8/20/86
AVS-2088	CPE	YFV	----	----	VERO	10.00	----	3/13/87
AVS-2089	CPE	AD2	----	----	HEP2	1.00	----	10/ 2/86
AVS-2089	CPE	JE	----	----	VERO	10.00	----	3/25/87
AVS-2089	PR	PIC	N/A	4.28	VERO	10.00	2.33	3/25/88
AVS-2089	CPE	PT	1.27	3.30	VERO	10.00	3.02	1/ 6/87
AVS-2089	CPE	SF	0.85	4.56	VERO	3.20	0.70	12/31/86
AVS-2089	CPE	VEE	----	----	VERO	10.00	----	5/18/87
AVS-2089	CPE	VSV	----	----	L929	10.00	----	8/ 1/86
AVS-2089	CPE	VV	0.1	----	VERO	10.00	----	8/20/86
AVS-2089	CPE	YFV	0.4	32.00	VERO	10.00	0.31	3/13/87
AVS-2090	CPE	AD2	----	----	HEP2	320.00	----	10/ 2/86
AVS-2090	CPE	JE	----	----	VERO	100.00	----	3/25/87
AVS-2090	CPE	PT	1.04	31.90	VERO	100.00	3.13	1/ 6/87
AVS-2090	CPE	SF	----	----	VERO	32.00	----	12/31/86
AVS-2090	CPE	VEE	----	----	VERO	32.00	----	12/ 7/87
AVS-2090	CPE	VSV	----	----	L929	100.00	----	8/ 1/86
AVS-2090	CPE	VV	0.45	320.00	VERO	100.00	0.31	8/20/86
AVS-2090	CPE	YFV	0.3	----	VERO	32.00	----	3/13/87
AVS-2091	CPE	AD2	----	----	HEP2 >	320.00	----	10/ 2/86
AVS-2091	CPE	JE	0.1	----	VERO >	320.00	----	3/25/87
AVS-2091	PR	PIC	N/A	----	VERO >	320.00	----	3/25/88
AVS-2091	CPE	PT	----	----	VERO >	320.00	----	1/ 7/87
AVS-2091	CPE	SF	----	----	VERO	32.00	----	12/31/86
AVS-2091	CPE	VEE	----	----	VERO >	320.00	----	12/ 7/87
AVS-2091	CPE	VSV	----	----	L929 >	320.00	----	8/ 1/86
AVS-2091	CPE	VV	----	----	VERO >	320.00	----	8/20/86
AVS-2091	CPE	YFV	----	----	VERO >	320.00	----	3/13/87
AVS-2092	CPE	AD2	0.70	319.00	HEP2 >	320.00 >	1.00	10/ 2/86
AVS-2092	CPE	JE	0.2	----	VERO	320.00	----	3/25/87
AVS-2092	PR	PIC	N/A	----	VERO	320.00	----	3/25/88
AVS-2092	CPE	PT	----	----	VERO	32.00	----	1/ 7/87
AVS-2092	CPE	SF	0.10	----	VERO	100.00	----	1/ 2/87
AVS-2092	CPE	VEE	----	----	VERO	100.00	----	12/ 7/87
AVS-2092	CPE	VSV	----	----	L929	32.00	----	8/ 8/86
AVS-2092	CPE	VV	----	----	VERO	320.00	----	8/20/86
AVS-2092	CPE	YFV	0.2	----	VERO	100.00	----	3/13/87
AVS-2093	CPE	AD2	----	----	HEP2 <	320.00	----	10/ 2/86
AVS-2093	CPE	JE	0.58	190.00	VERO	320.00	1.67	3/25/87
AVS-2093	PR	PIC	N/A	76.40	VERO	100.00	1.30	3/25/88
AVS-2093	CPE	PT	0.25	735.00	VERO	320.00	0.43	1/ 7/87
AVS-2093	CPE	SF	1.60	55.80	VERO >	100.00 >	1.78	1/ 2/87
AVS-2093	CPE	VEE	----	----	VERO >	320.00	----	1/18/88
AVS-2093	CPE	VSV	----	----	L929	320.00	----	8/ 8/86
AVS-2093	CPE	VV	----	----	VERO	320.00	----	8/20/86
AVS-2093	CPE	YFV	0.7	----	VERO >	320.00	----	3/13/87
AVS-2094	CPE	AD2	0.10	----	HEP2 <	100.00	----	10/ 2/86
AVS-2094	CPE	JE	0.05	----	VERO	320.00	----	3/26/87
AVS-2094	PR	PIC	N/A	----	VERO	10.00	----	3/25/88
AVS-2094	CPE	PT	----	----	VERO	100.00	----	1/ 7/87
AVS-2094	CPE	SF	0.30	----	VERO	10.00	----	1/ 2/87
AVS-2094	CPE	VEE	----	----	VERO >	320.00	----	1/18/88
AVS-2094	CPE	VSV	----	----	L929 >	320.00	----	8/ 8/86
AVS-2094	CPE	VV	----	----	VERO >	100.00	----	8/20/86
AVS-2094	CPE	YFV	----	----	VERO	320.00	----	3/17/87
AVS-2095	CPE	AD2	0.20	----	HEP2 >	320.00	----	10/ 2/86

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2095	CPE	JE	0.05	----	VERO	320.00	----	3/26/87
AVS-2095	PR	PIC	N/A	----	VERO	320.00	----	3/25/88
AVS-2095	CPE	PT	0.05	----	VERO	100.00	----	1/ 7/87
AVS-2095	CPE	SF	0.30	----	VERO	10.00	----	1/ 2/87
AVS-2095	CPE	VEE	----	----	VERO	10.00	----	1/18/88
AVS-2095	CPE	VSV	----	----	L929	320.00	----	8/ 8/86
AVS-2095	CPE	VV	----	----	VERO	320.00	----	8/20/86
AVS-2095	CPE	YFV	0.2	----	VERO	100.00	----	3/17/87
AVS-2096	CPE	AD2	----	----	HEP2	32.00	----	10/ 2/86
AVS-2096	CPE	JE	0.1	----	VERO	10.00	2.23	3/26/87
AVS-2096	PR	PIC	N/A	----	VERO	3.20	----	3/25/88
AVS-2096	CPE	PT	----	----	VERO	3.20	----	1/ 8/87
AVS-2096	CPE	SF	0.25	107.00	VERO	3.20	0.03	1/ 2/87
AVS-2096	CPE	VEE	----	----	VERO	3.20	----	1/18/88
AVS-2096	CPE	VSV	----	----	L929	10.00	----	8/ 8/86
AVS-2096	CPE	VV	0.5	6.30	VERO	10.00	1.57	8/20/86
AVS-2096	CPE	YFV	----	----	VERO	3.20	----	3/17/87
AVS-2097	CPE	AD2	----	----	HEP2	320.00	----	10/ 2/86
AVS-2097	CPE	JE	----	----	VERO	320.00	----	3/26/87
AVS-2097	PR	PIC	N/A	----	VERO	320.00	----	3/28/88
AVS-2097	CPE	PT	----	----	VERO	320.00	----	1/ 8/87
AVS-2097	CPE	SF	----	----	VERO	100.00	----	1/ 2/87
AVS-2097	CPE	VEE	----	----	VERO	32.00	----	1/18/88
AVS-2097	CPE	VSV	----	----	L929	320.00	----	8/ 8/86
AVS-2097	CPE	VV	----	----	VERO	320.00	----	8/20/86
AVS-2097	CPE	YFV	0.1	----	VERO	100.00	----	3/17/87
AVS-2098	CPE	AD2	0.50	----	HEP2	320.00	----	10/ 2/86
AVS-2098	CPE	JE	----	----	VERO	320.00	----	3/26/87
AVS-2098	PR	PIC	N/A	----	VERO	32.00	----	3/28/88
AVS-2098	CPE	PT	0.12	----	VERO	320.00	----	1/ 8/87
AVS-2098	CPE	SF	----	----	VERO	32.00	----	1/ 2/87
AVS-2098	CPE	VEE	----	----	VERO	320.00	----	1/25/88
AVS-2098	CPE	VSV	----	----	L929	320.00	----	8/ 8/86
AVS-2098	CPE	VV	----	----	VERO	320.00	----	8/20/86
AVS-2098	CPE	YFV	----	----	VERO	100.00	----	3/17/87
AVS-2099	CPE	AD2	----	----	HEP2	100.00	----	10/ 2/86
AVS-2099	CPE	JE	----	----	VERO	320.00	----	3/26/87
AVS-2099	PR	PIC	N/A	----	VERO	320.00	----	3/28/88
AVS-2099	CPE	PT	0.38	----	VERO	320.00	----	1/ 8/87
AVS-2099	CPE	SF	----	----	VERO	32.00	----	1/ 2/87
AVS-2099	CPE	VEE	----	----	VERO	100.00	----	1/25/88
AVS-2099	CPE	VSV	----	----	L929	100.00	----	8/ 8/86
AVS-2099	CPE	VV	----	----	VERO	100.00	----	8/20/86
AVS-2099	CPE	YFV	----	----	VERO	32.00	----	3/17/87
AVS-2100	CPE	AD2	----	----	HEP2	320.00	----	10/ 2/86
AVS-2100	CPE	JE	----	----	VERO	32.00	----	3/26/87
AVS-2100	PR	PIC	N/A	57.80	VERO	32.00	0.55	7/15/88
AVS-2100	CPE	PT	0.43	61.30	VERO	32.00	0.52	1/ 8/87
AVS-2100	CPE	SF	1.00	190.00	VERO	32.00	0.17	1/ 5/87
AVS-2100	CPE	VEE	----	----	VERO	320.00	----	1/25/88
AVS-2100	CPE	VSV	----	----	L929	32.00	----	8/ 8/86
AVS-2100	CPE	VV	0.4	319.00	VERO	320.00	1.00	8/20/86
AVS-2100	CPE	YFV	----	----	VERO	32.00	----	3/17/87
AVS-2101	CPE	AD2	0.30	----	HEP2	320.00	----	10/ 2/86
AVS-2101	CPE	JE	----	----	VERO	100.00	----	3/26/87
AVS-2101	PR	PIC	N/A	----	VERO	100.00	----	3/28/88
AVS-2101	CPE	PT	0.07	----	VERO	100.00	----	1/ 9/87
AVS-2101	CPE	SF	0.50	37.20	VERO	100.00	2.68	1/ 5/87
AVS-2101	CPE	VEE	----	----	VERO	320.00	----	1/25/88
AVS-2101	CPE	VSV	----	----	L929	100.00	----	8/ 1/86
AVS-2101	CPE	VV	----	----	VERO	320.00	----	8/20/86
AVS-2101	CPE	YFV	----	----	VERO	10.00	----	3/17/87
AVS-2102	CPE	AD2	----	----	HEP2	320.00	----	10/ 2/86
AVS-2102	CPE	JE	0.1	----	VERO	100.00	----	3/26/87
AVS-2102	PR	PIC	N/A	----	VERO	100.00	----	3/28/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2102	CPE	PT	0.40	----	VERO	3.20	----	1/ 9/87
AVS-2102	CPE	SF	0.95	36.30	VERO	32.00	0.88	1/ 5/87
AVS-2102	CPE	VEE	----	----	VERO	100.00	----	1/25/88
AVS-2102	CPE	VSV	----	----	L929	10.00	----	8/ 8/86
AVS-2102	CPE	VV	0.75	57.80	VERO	10.00	0.17	8/20/86
AVS-2102	CPE	YFV	----	----	VERO	32.00	----	3/19/87
AVS-2103	CPE	AD2	----	----	HEP2	32.00	----	10/ 2/86
AVS-2103	CPE	AD2	----	----	HEP2	320.00	----	10/16/86
AVS-2103	CPE	JE	----	----	VERO	3.20	----	3/26/87
AVS-2103	PR	PIC	N/A	----	VERO	3.20	----	3/28/88
AVS-2103	CPE	PT	0.17	12.60	VERO	10.00	0.79	1/ 9/87
AVS-2103	CPE	SF	0.60	3.25	VERO	3.20	0.98	1/ 5/87
AVS-2103	CPE	VEE	----	----	VERO	10.00	----	1/ 4/88
AVS-2103	CPE	VSV	----	----	L929	32.00	----	8/ 8/86
AVS-2103	CPE	VV	----	----	VERO	3.20	----	8/20/86
AVS-2103	CPE	YFV	0.3	10.00	VERO	3.20	3.12	3/19/87
AVS-2103	CPE	YFV	0.15	----	VERO	1.00	----	5/24/88
AVS-2104	CPE	AD2	----	----	HEP2	0.32	----	10/ 2/86
AVS-2104	CPE	AD2	----	----	HEP2	0.03	----	10/16/86
AVS-2104	CPE	JE	0.1	----	VERO	3.20	----	3/26/87
AVS-2104	CPE	PT	0.40	----	VERO	10.00	----	1/ 9/87
AVS-2104	CPE	SF	0.09	----	VERO	3.20	----	1/ 5/87
AVS-2104	CPE	VEE	----	----	VERO	1.00	----	1/ 4/88
AVS-2104	CPE	VSV	----	----	L929	3.20	----	8/ 8/86
AVS-2104	CPE	VV	0.15	----	VERO	1.00	----	8/20/86
AVS-2104	CPE	YFV	0.6	1.58	VERO	1.00	0.63	3/19/87
AVS-2105	CPE	AD2	----	----	HEP2	320.00	----	10/ 2/86
AVS-2105	CPE	JE	----	----	VERO	320.00	----	4/ 1/87
AVS-2105	PR	PIC	N/A	----	VERO	320.00	----	3/28/88
AVS-2105	CPE	PT	0.40	----	VERO	320.00	----	1/ 9/87
AVS-2105	CPE	SF	0.40	----	VERO	100.00	----	1/ 5/87
AVS-2105	CPE	VEE	----	----	VERO	320.00	----	1/ 4/88
AVS-2105	CPE	VSV	----	----	L929	10.00	----	8/ 8/86
AVS-2105	CPE	VV	----	----	VERO	320.00	----	8/20/86
AVS-2105	CPE	YFV	0.75	----	VERO	320.00	----	3/19/87
AVS-2106	CPE	AD2	----	----	HEP2	320.00	----	10/ 2/86
AVS-2106	CPE	JE	0.2	----	VERO	320.00	----	4/ 1/87
AVS-2106	PR	PIC	N/A	----	VERO	320.00	----	4/ 1/88
AVS-2106	CPE	PT	0.10	----	VERO	320.00	----	1/12/87
AVS-2106	CPE	SF	0.70	----	VERO	32.00	----	1/ 5/87
AVS-2106	CPE	VEE	----	----	VERO	320.00	----	1/ 4/88
AVS-2106	CPE	VSV	----	----	L929	100.00	----	8/ 8/86
AVS-2106	CPE	VV	----	----	VERO	320.00	----	8/20/86
AVS-2106	CPE	YFV	0.1	----	VERO	320.00	----	3/19/87
AVS-2107	CPE	AD2	0.30	----	HEP2	320.00	----	10/ 2/86
AVS-2107	CPE	JE	0.4	----	VERO	100.00	----	4/ 1/87
AVS-2107	PR	PIC	N/A	----	VERO	100.00	----	4/ 1/88
AVS-2107	CPE	PT	----	----	VERO	320.00	----	1/12/87
AVS-2107	CPE	SF	----	----	VERO	100.00	----	1/ 5/87
AVS-2107	CPE	VEE	----	----	VERO	320.00	----	1/ 4/88
AVS-2107	CPE	VSV	----	----	L929	320.00	----	8/ 1/86
AVS-2107	CPE	VV	----	----	VERO	320.00	----	8/20/86
AVS-2107	CPE	YFV	0.55	----	VERO	320.00	----	3/19/87
AVS-2108	CPE	AD2	----	----	HEP2	10.00	----	10/ 2/86
AVS-2108	CPE	JE	----	----	VERO	32.00	----	4/ 1/87
AVS-2108	PR	PIC	N/A	51.80	VERO	100.00	1.92	4/ 1/88
AVS-2108	CPE	PT	----	----	VERO	320.00	----	1/12/87
AVS-2108	CPE	SF	----	----	VERO	32.00	----	1/ 6/87
AVS-2108	CPE	VEE	----	----	VERO	100.00	----	1/ 4/88
AVS-2108	CPE	VSV	----	----	L929	100.00	----	8/ 8/86
AVS-2108	CPE	VV	----	----	VERO	100.00	----	8/20/86
AVS-2108	CPE	YFV	----	----	VERO	32.00	----	3/19/87
AVS-2109	CPE	AD2	0.30	----	HEP2	320.00	----	10/ 2/86
AVS-2109	CPE	JE	0.2	----	VERO	100.00	----	4/ 2/87
AVS-2109	PR	PIC	N/A	----	VERO	320.00	----	4/ 1/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2109	CPE	PT	----	----	VERO	320.00	----	1/12/87
AVS-2109	CPE	SF	----	----	VERO	100.00	----	1/ 6/87
AVS-2109	CPE	VEE	----	----	VERO	32.00	----	1/ 4/88
AVS-2109	CPE	VSV	----	----	L929	100.00	----	8/ 8/86
AVS-2109	CPE	VV	0.4	320.00	VERO	100.00	0.31	8/20/86
AVS-2109	CPE	YFV	----	----	VERO	100.00	----	3/19/87
AVS-2110	CPE	AD2	----	----	HEP2	100.00	----	10/ 2/86
AVS-2110	CPE	JE	0.4	268.00	VERO	320.00	1.19	4/ 2/87
AVS-2110	PR	PIC	N/A	----	VERO	320.00	----	4/ 1/88
AVS-2110	CPE	PT	----	----	VERO	100.00	----	1/12/87
AVS-2110	CPE	SF	----	----	VERO >	100.00	----	1/ 6/87
AVS-2110	CPE	VEE	----	----	VERO	320.00	----	1/ 4/88
AVS-2110	CPE	VSV	----	----	L929	100.00	----	8/ 8/86
AVS-2110	CPE	VV	----	----	VERO >	320.00	----	8/20/86
AVS-2110	CPE	YFV	----	----	VERO	32.00	----	3/18/87
AVS-2111	CPE	AD2	----	----	HEP2	10.00	----	10/ 2/86
AVS-2111	CPE	JE	0.5	----	VERO <	32.00	----	4/ 2/87
AVS-2111	PR	PIC	N/A	----	VERO	10.00	----	4/ 1/88
AVS-2111	CPE	PT	0.50	32.40	VERO	32.00	0.99	1/13/87
AVS-2111	CPE	SF	0.05	----	VERO	10.00	----	1/ 6/87
AVS-2111	CPE	VEE	----	----	VERO	32.00	----	1/ 4/88
AVS-2111	CPE	VSV	----	----	L929	32.00	----	8/ 8/86
AVS-2111	CPE	VV	----	----	VERO	10.00	----	8/20/86
AVS-2111	CPE	YFV	----	----	VERO	3.20	----	3/18/87
AVS-2112	CPE	AD2	----	----	HEP2	100.00	----	10/ 2/86
AVS-2112	CPE	JE	0.95	87.50	VERO	100.00	1.13	4/ 2/87
AVS-2112	PR	PIC	N/A	----	VERO	32.00	----	4/ 1/88
AVS-2112	CPE	PT	0.40	----	VERO	100.00	----	1/13/87
AVS-2112	CPE	SF	0.20	----	VERO	100.00	----	1/ 6/87
AVS-2112	CPE	VEE	----	----	VERO	32.00	----	1/ 4/88
AVS-2112	CPE	VSV	----	----	L929	100.00	----	8/12/86
AVS-2112	CPE	VV	----	----	VERO >	320.00	----	8/20/86
AVS-2112	CPE	YFV	0.85	91.30	VERO	100.00	1.09	3/18/87
AVS-2113	CPE	AD2	0.30	----	HEP2 >	320.00	----	10/ 9/86
AVS-2113	CPE	JE	0.1	----	VERO	320.00	----	4/ 2/87
AVS-2113	PR	PIC	N/A	----	VERO >	320.00	----	4/ 1/88
AVS-2113	CPE	PT	0.20	----	VERO	320.00	----	1/13/87
AVS-2113	CPE	SF	----	----	VERO	100.00	----	12/31/86
AVS-2113	CPE	VEE	----	----	VERO	32.00	----	3/ 7/88
AVS-2113	CPE	VSV	----	----	L929	320.00	----	8/12/86
AVS-2113	CPE	VV	----	----	VERO	320.00	----	8/28/86
AVS-2113	CPE	YFV	----	----	VERO	100.00	----	3/18/87
AVS-2114	CPE	AD2	----	----	HEP2	10.00	----	10/ 9/86
AVS-2114	CPE	JE	----	----	VERO	32.00	----	4/ 2/87
AVS-2114	PR	PIC	N/A	----	VERO >	320.00	----	4/ 1/88
AVS-2114	CPE	PT	0.30	156.00	VERO	100.00	0.64	1/13/87
AVS-2114	CPE	SF	----	----	VERO	10.00	----	12/31/86
AVS-2114	CPE	VEE	----	----	VERO	10.00	----	3/ 7/88
AVS-2114	CPE	VSV	----	----	L929	32.00	----	8/12/86
AVS-2114	CPE	VV	----	----	VERO	32.00	----	8/28/86
AVS-2114	CPE	YFV	0.25	----	VERO	320.00	----	3/18/87
AVS-2115	CPE	AD2	----	----	HEP2	320.00	----	10/ 9/86
AVS-2115	CPE	JE	0.3	----	VERO >	320.00	----	4/ 2/87
AVS-2115	PR	PIC	N/A	----	VERO >	320.00	----	4/ 1/88
AVS-2115	CPE	PT	0.20	----	VERO >	320.00	----	1/13/87
AVS-2115	CPE	SF	----	----	VERO	100.00	----	12/31/86
AVS-2115	CPE	VEE	----	----	VERO	3.20	----	3/ 7/88
AVS-2115	CPE	VSV	----	----	L929	32.00	----	8/12/86
AVS-2115	CPE	VV	----	----	VERO	320.00	----	8/28/86
AVS-2115	CPE	YFV	----	----	VERO	100.00	----	3/18/87
AVS-2116	CPE	AD2	0.25	----	HEP2	32.00	----	10/ 9/86
AVS-2116	CPE	JE	0.1	----	VERO	32.00	----	4/ 2/87
AVS-2116	PR	PIC	N/A	----	VERO >	320.00	----	4/ 8/88
AVS-2116	CPE	PT	0.50	552.00	VERO >	320.00 >	0.58	1/14/87
AVS-2116	CPE	SF	----	----	VERO	100.00	----	12/31/86

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2116	CPE	VEE	0.15	----	VERO	3.20	----	3/ 7/88
AVS-2116	CPE	VSV	----	----	L929	32.00	----	8/12/86
AVS-2116	CPE	VV	----	----	VERO	320.00	----	8/28/86
AVS-2116	CPE	YFV	0.5	281.00	VERO	100.00	0.35	3/18/87
AVS-2117	CPE	AD2	0.60	----	HEP2 >	320.00	----	10/ 9/86
AVS-2117	CPE	JE	0.05	----	VERO	320.00	----	4/ 2/87
AVS-2117	PR	PIC	N/A	----	VERO >	320.00	----	4/ 8/88
AVS-2117	CPE	SF	----	----	VERO >	100.00	----	12/31/86
AVS-2117	CPE	VEE	----	----	VERO	10.00	----	3/ 7/88
AVS-2117	CPE	VSV	----	----	L929	320.00	----	8/12/86
AVS-2117	CPE	VV	----	----	VERO >	320.00	----	8/28/86
AVS-2117	CPE	YFV	0.3	32.00	VERO	10.00	3.20	3/18/87
AVS-2117	CPE	YFV	----	----	VERO	100.00	----	5/24/88
AVS-2118	CPE	AD2	----	----	HEP2	320.00	----	10/ 9/86
AVS-2118	CPE	JE	0.05	----	VERO	320.00	----	4/ 2/87
AVS-2118	PR	PIC	N/A	----	VERO >	320.00	----	4/ 8/88
AVS-2118	CPE	PT	----	----	VERO >	320.00	----	1/14/87
AVS-2118	CPE	SF	----	----	VERO	100.00	----	1/ 2/87
AVS-2118	CPE	VEE	----	----	VERO	3.20	----	3/ 7/88
AVS-2118	CPE	VSV	----	----	L929	100.00	----	8/12/86
AVS-2118	CPE	VV	0.15	----	VERO	100.00	----	8/28/86
AVS-2118	CPE	YFV	----	----	VERO >	320.00	----	3/19/87
AVS-2119	CPE	AD2	----	----	HEP2 >	320.00	----	10/ 9/86
AVS-2119	CPE	JE	0.05	----	VERO >	320.00	----	4/ 2/87
AVS-2119	PR	PIC	N/A	----	VERO	320.00	----	4/ 8/88
AVS-2119	CPE	PT	0.10	----	VERO >	320.00	----	1/14/87
AVS-2119	CPE	SF	----	----	VERO >	100.00	----	1/ 2/87
AVS-2119	CPE	VEE	----	----	VERO	3.20	----	3/ 7/88
AVS-2119	CPE	VSV	----	----	L929 >	320.00	----	8/12/86
AVS-2119	CPE	VV	----	----	VERO	320.00	----	8/28/86
AVS-2119	CPE	YFV	----	----	VERO >	320.00	----	3/19/87
AVS-2120	CPE	AD2	----	----	HEP2	32.00	----	10/ 9/86
AVS-2120	CPE	JE	----	----	VERO	100.00	----	4/ 3/87
AVS-2120	PR	PIC	N/A	----	VERO >	320.00	----	4/ 8/88
AVS-2120	CPE	PT	----	----	VERO <	320.00	----	1/14/87
AVS-2120	CPE	SF	----	----	VERO	100.00	----	1/ 2/87
AVS-2120	CPE	VEE	----	----	VERO	0.32	----	3/ 7/88
AVS-2120	CPE	VSV	----	----	L929	10.00	----	8/12/86
AVS-2120	CPE	VV	1.2	56.50	VERO	100.00	1.76	8/28/86
AVS-2120	CPE	YFV	----	----	VERO	100.00	----	3/19/87
AVS-2121	CPE	AD2	0.15	----	HEP2	100.00	----	10/ 9/86
AVS-2121	CPE	JE	0.1	----	VERO	320.00	----	4/ 3/87
AVS-2121	CPE	PT	1.42	32.10	VERO	100.00	3.11	1/15/87
AVS-2121	CPE	SF	0.65	78.20	VERO	100.00	1.27	1/ 2/87
AVS-2121	CPE	VEE	----	----	VERO	10.00	----	3/ 9/88
AVS-2121	CPE	VSV	----	----	L929	100.00	----	8/12/86
AVS-2121	CPE	VV	----	----	VERO <	100.00	----	8/28/86
AVS-2121	CPE	YFV	1.	127.00	VERO	100.00	0.78	3/19/87
AVS-2122	CPE	AD2	----	----	HEP2	320.00	----	10/ 9/86
AVS-2122	CPE	JE	----	----	VERO	320.00	----	4/ 3/87
AVS-2122	PR	PIC	N/A	----	VERO >	320.00	----	4/ 8/88
AVS-2122	CPE	PT	2.18	79.90	VERO >	320.00 >	4.00	1/15/87
AVS-2122	CPE	SF	2.80	18.20	VERO >	100.00	5.48	1/ 2/87
AVS-2122	CPE	SF	0.6	56.40	VERO	32.00	0.57	5/24/88
AVS-2122	CPE	VEE	----	----	VERO	10.00	----	3/ 9/88
AVS-2122	CPE	VSV	----	----	L929	32.00	----	8/12/86
AVS-2122	CPE	VV	0.4	317.00	VERO	100.00	0.31	8/28/86
AVS-2122	CPE	YFV	0.5	----	VERO	100.00	----	3/19/87
AVS-2123	CPE	AD2	0.30	----	HEP2 >	320.00	----	10/ 9/86
AVS-2123	CPE	JE	----	----	VERO	100.00	----	4/ 3/87
AVS-2123	PR	PIC	N/A	----	VERO	100.00	----	7/15/88
AVS-2123	CPE	PT	0.10	----	VERO	320.00	----	1/15/87
AVS-2123	CPE	SF	----	----	VERO	100.00	----	1/ 7/87
AVS-2123	CPE	VEE	----	----	VERO	3.20	----	3/ 9/88
AVS-2123	CPE	VSV	----	----	L929	320.00	----	8/12/86

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2123	CPE	VV	0.25	----	VERO	320.00	----	8/28/86
AVS-2123	CPE	YFV	----	----	VERO	320.00	----	3/19/87
AVS-2124	CPE	AD2	----	----	HEP2	100.00	----	10/ 9/86
AVS-2124	CPE	JE	0.05	----	VERO >	320.00	----	4/ 3/87
AVS-2124	PR	PIC	N/A	----	VERO >	320.00	----	4/ 8/88
AVS-2124	CPE	PT	----	----	VERO >	320.00	----	1/15/87
AVS-2124	CPE	SF	----	----	VERO	10.00	----	1/ 7/87
AVS-2124	CPE	VEE	----	----	VERO	10.00	----	3/ 9/88
AVS-2124	CPE	VSV	----	----	L929	32.00	----	8/12/86
AVS-2124	CPE	VV	----	----	VERO	320.00	----	8/28/86
AVS-2124	CPE	YFV	----	----	VERO	320.00	----	3/19/87
AVS-2125	CPE	AD2	----	----	HEP2	10.00	----	10/ 9/86
AVS-2125	CPE	JE	----	----	VERO	32.00	----	4/ 3/87
AVS-2125	PR	PIC	N/A	12.80	VERO	32.00	2.48	4/ 8/88
AVS-2125	CPE	PT	----	----	VERO	32.00	----	1/15/87
AVS-2125	CPE	SF	0.60	29.80	VERO	10.00	0.34	1/ 7/87
AVS-2125	CPE	VEE	0.3	10.00	VERO	0.32	0.03	3/ 9/88
AVS-2125	CPE	VSV	----	----	L929	10.00	----	8/12/86
AVS-2125	CPE	VV	----	----	VERO	100.00	----	8/28/86
AVS-2125	CPE	YFV	0.5	27.30	VERO	10.00	0.37	3/19/87
AVS-2126	CPE	AD2	----	----	HEP2 <	320.00	----	10/ 9/86
AVS-2126	CPE	JE	----	----	VERO	100.00	----	4/ 3/87
AVS-2126	PR	PIC	N/A	----	VERO >	32.00	----	4/ 8/88
AVS-2126	CPE	PT	0.15	----	VERO	32.00	----	2/13/87
AVS-2126	CPE	PT	0.94	0.87	VERO	3.20	3.66	3/17/87
AVS-2126	CPE	PT	0.25	----	VERO	10.00	----	5/18/88
AVS-2126	CPE	SF	----	----	VERO	100.00	----	1/ 7/87
AVS-2126	CPE	VEE	----	----	VERO	32.00	----	3/ 9/88
AVS-2126	CPE	VSV	----	----	L929	32.00	----	8/12/86
AVS-2126	CPE	VV	----	----	VERO >	320.00	----	8/28/86
AVS-2126	CPE	YFV	0.5	----	VERO	32.00	----	3/20/87
AVS-2127	CPE	AD2	0.15	----	HEP2	32.00	----	10/ 9/86
AVS-2127	CPE	JE	----	----	VERO	100.00	----	4/ 3/87
AVS-2127	PR	PIC	N/A	----	VERO	100.00	----	4/18/88
AVS-2127	CPE	PT	2.30	79.70	VERO	100.00	1.25	2/13/87
AVS-2127	CPE	PT	0.77	----	VERO	10.00	----	3/17/87
AVS-2127	CPE	SF	0.60	93.20	VERO	100.00	1.07	1/ 7/87
AVS-2127	CPE	VEE	----	----	VERO	10.00	----	3/ 9/88
AVS-2127	CPE	VSV	1.4	23.30	L929 <	100.00 <	4.27	8/15/86
AVS-2127	CPE	VSV	----	----	L929	32.00	----	5/24/88
AVS-2127	CPE	VV	0.4	99.00	VERO	100.00	1.00	8/28/86
AVS-2127	CPE	YFV	0.85	57.30	VERO	10.00	0.17	3/20/87
AVS-2128	CPE	AD2	0.80	10.00	HEP2	32.00	0.32	10/ 9/86
AVS-2128	CPE	JE	0.1	----	VERO	10.00	----	4/ 3/87
AVS-2128	PR	PIC	N/A	----	VERO	1.00	----	4/18/88
AVS-2128	CPE	PT	0.97	4.69	VERO	10.00	2.13	2/13/87
AVS-2128	CPE	PT	0.13	----	VERO	10.00	----	3/17/87
AVS-2128	CPE	SF	0.60	7.50	VERO	3.20	0.43	1/ 5/87
AVS-2128	CPE	VEE	----	----	VERO	10.00	----	3/10/88
AVS-2128	CPE	VSV	0.4	30.90	L929	32.00	1.03	8/15/86
AVS-2128	CPE	VV	0.6	----	VERO	10.00	----	8/28/86
AVS-2128	CPE	YFV	0.35	----	VERO	10.00	----	3/20/87
AVS-2129	CPE	AD2	----	----	HEP2	100.00	----	10/ 9/86
AVS-2129	CPE	JE	----	----	VERO >	320.00	----	4/ 3/87
AVS-2129	PR	PIC	N/A	----	VERO >	320.00	----	4/18/88
AVS-2129	CPE	PT	1.95	----	VERO >	320.00	----	2/13/87
AVS-2129	CPE	PT	0.9	----	VERO >	320.00	----	3/17/87
AVS-2129	CPE	SF	0.25	240.00	VERO	100.00	0.42	1/ 5/87
AVS-2129	CPE	VEE	----	----	VERO >	320.00	----	3/10/88
AVS-2129	CPE	VSV	----	----	L929	320.00	----	8/15/86
AVS-2129	CPE	VV	----	----	VERO >	320.00	----	8/28/86
AVS-2129	CPE	YFV	----	----	VERO >	320.00	----	3/20/87
AVS-2130	CPE	AD2	----	----	HEP2	320.00	----	10/ 9/86
AVS-2130	CPE	JE	----	----	VERO >	320.00	----	4/ 3/87
AVS-2130	PR	PIC	N/A	----	VERO >	320.00	----	4/18/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2130	CPE	PT	1.65	----	VERO >	320.00	----	2/13/87
AVS-2130	CPE	PT	0.35	----	VERO >	320.00	----	3/17/87
AVS-2130	CPE	SF	----	----	VERO .	0.10	----	1/ 5/87
AVS-2130	CPE	VEE	----	----	VERO >	320.00	----	3/10/88
AVS-2130	CPE	VSV	----	----	L929 >	320.00	----	8/15/86
AVS-2130	CPE	VV	----	----	VERO >	320.00	----	8/28/86
AVS-2130	CPE	YFV	----	----	VERO	320.00	----	3/20/87
AVS-2131	CPE	AD2	0.30	----	HEP2 >	320.00	----	10/ 9/86
AVS-2131	CPE	JE	----	----	VERO	320.00	----	4/10/87
AVS-2131	PR	PIC	N/A	----	VERO	320.00	----	4/11/88
AVS-2131	CPE	PT	0.58	----	VERO >	320.00	----	1/20/87
AVS-2131	CPE	SF	----	----	VERO	32.00	----	1/ 5/87
AVS-2131	CPE	VEE	----	----	VERO	100.00	----	3/10/88
AVS-2131	CPE	VSV	----	----	L929 >	320.00	----	8/15/86
AVS-2131	CPE	VV	----	----	VERO >	320.00	----	8/28/86
AVS-2131	CPE	YFV	----	----	VERO >	320.00	----	3/20/87
AVS-2132	CPE	AD2	----	----	HEP2	320.00	----	10/ 9/86
AVS-2132	CPE	JE	0.4	96.00	VERO	100.00	1.03	4/10/87
AVS-2132	PR	PIC	N/A	45.20	VERO	100.00	2.21	4/11/88
AVS-2132	CPE	PT	0.67	103.00	VERO	100.00	0.97	1/20/87
AVS-2132	CPE	SF	0.30	32.00	VERO	10.00	0.31	1/ 5/87
AVS-2132	CPE	VEE	----	----	VERO	32.00	----	3/10/88
AVS-2132	CPE	VSV	----	----	L929	320.00	----	8/15/86
AVS-2132	CPE	VV	0.5	98.00	VERO	100.00	1.01	8/28/86
AVS-2132	CPE	YFV	0.5	----	VERO	32.00	----	3/20/87
AVS-2133	CPE	AD2	----	----	HEP2	100.00	----	10/23/86
AVS-2133	CPE	JE	0.15	----	VERO	32.00	----	4/10/87
AVS-2133	PR	PIC	N/A	----	VERO	320.00	----	4/11/88
AVS-2133	CPE	PT	1.18	67.50	VERO	100.00	1.48	1/20/87
AVS-2133	CPE	SF	----	----	VERO	32.00	----	1/ 8/87
AVS-2133	CPE	VEE	----	----	VERO	320.00	----	3/10/88
AVS-2133	CPE	VSV	----	----	L929	100.00	----	8/15/86
AVS-2133	CPE	VV	----	----	VERO >	320.00	----	8/28/86
AVS-2133	CPE	VV	0.1	----	VERO	100.00	----	10/23/86
AVS-2133	CPE	YFV	1.75	37.20	VERO	10.00	0.27	3/20/87
AVS-2134	CPE	AD2	----	----	HEP2 >	320.00	----	10/ 9/86
AVS-2134	CPE	JE	0.1	----	VERO	100.00	----	4/10/87
AVS-2134	PR	PIC	N/A	----	VERO >	320.00	----	4/12/88
AVS-2134	CPE	PT	0.08	----	VERO >	320.00	----	1/20/87
AVS-2134	CPE	SF	----	----	VERO	100.00	----	1/ 8/87
AVS-2134	CPE	VEE	----	----	VERO	10.00	----	3/10/88
AVS-2134	CPE	VSV	----	----	L929	320.00	----	8/15/86
AVS-2134	CPE	VV	----	----	VERO >	320.00	----	8/28/86
AVS-2134	CPE	YFV	0.1	----	VERO	32.00	----	3/25/87
AVS-2135	CPE	AD2	0.30	----	HEP2 >	320.00	----	9/25/86
AVS-2135	CPE	JE	0.05	----	VERO >	320.00	----	4/ 9/87
AVS-2135	PR	PIC	N/A	----	VERO >	320.00	----	4/21/87
AVS-2135	CPE	VEE	----	----	VERO >	320.00	----	5/18/87
AVS-2135	CPE	VSV	----	----	L929	320.00	----	7/18/86
AVS-2135	CPE	VV	----	----	VERO >	320.00	----	8/ 7/86
AVS-2135	CPE	YFV	----	----	VERO >	320.00	----	2/ 3/87
AVS-2136	CPE	AD2	----	----	HEP2 >	320.00	----	9/25/86
AVS-2136	CPE	JE	----	----	VERO	32.00	----	3/24/87
AVS-2136	PR	PIC	N/A	----	VERO >	320.00	----	4/21/87
AVS-2136	CPE	SF	1.29	113.00	VERO	320.00	2.83	11/ 4/86
AVS-2136	CPE	VEE	----	----	VERO	32.00	----	5/18/87
AVS-2136	CPE	VSV	----	----	L929	10.00	----	7/18/86
AVS-2136	CPE	VV	1.7	144.00	VERO >	320.00 >	2.21	8/ 7/86
AVS-2136	CPE	YFV	----	----	VERO	32.00	----	2/ 3/87
AVS-2137	CPE	AD2	----	----	HEP2	32.00	----	9/25/86
AVS-2137	CPE	JE	0.05	----	VERO >	320.00	----	3/25/87
AVS-2137	PR	PIC	N/A	----	VERO	320.00	----	11/ 3/87
AVS-2137	CPE	PT	1.11	313.00	VERO	100.00	0.32	11/ 7/86
AVS-2137	CPE	VEE	----	----	VERO	320.00	----	5/18/87
AVS-2137	CPE	VSV	----	----	L929	100.00	----	7/18/86

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2137	CPE	VV	----	----	VERO <	100.00	----	8/ 7/86
AVS-2137	CPE	YFV	0.40	----	VERO >	320.00	----	2/ 3/87
AVS-2138	CPE	AD2	----	----	HEP2	320.00	----	9/25/86
AVS-2138	CPE	JE	0.05	----	VERO >	320.00	----	3/25/87
AVS-2138	PR	PIC	N/A	270.00	VERO	320.00	1.18	1/ 5/88
AVS-2138	CPE	PT	1.41	191.00	VERO >	320.00 >	1.67	11/ 7/86
AVS-2138	CPE	SF	0.90	82.80	VERO <	320.00 <	3.85	11/ 4/86
AVS-2138	CPE	SF	0.8	82.90	VERO	32.00	0.38	5/24/88
AVS-2138	CPE	VEE	----	----	VERO	100.00	----	5/18/87
AVS-2138	CPE	VSV	----	----	L929	32.00	----	7/18/86
AVS-2138	CPE	VV	----	----	VERO	100.00	----	8/ 7/86
AVS-2138	CPE	YFV	----	----	VERO >	32.00	----	2/ 3/87
AVS-2139	CPE	AD2	----	----	HEP2	32.00	----	9/25/86
AVS-2139	CPE	JE	0.38	----	VERO	320.00	----	3/25/87
AVS-2139	PR	PIC	N/A	----	VERO	100.00	----	12/18/87
AVS-2139	CPE	SF	0.69	262.00	VERO	32.00	0.12	11/ 4/86
AVS-2139	CPE	VEE	----	----	VERO >	320.00	----	5/18/87
AVS-2139	CPE	VSV	----	----	L929	100.00	----	7/18/86
AVS-2139	CPE	VV	----	----	VERO	100.00	----	8/ 7/86
AVS-2139	CPE	YFV	0.25	----	VERO	100.00	----	2/ 3/87
AVS-2140	CPE	AD2	----	----	HEP2	320.00	----	9/25/86
AVS-2140	CPE	JE	----	----	VERO >	320.00	----	3/25/87
AVS-2140	PR	PIC	N/A	----	VERO	320.00	----	12/18/87
AVS-2140	CPE	VEE	----	----	VERO	320.00	----	5/18/87
AVS-2140	CPE	VSV	----	----	L929 >	320.00	----	7/18/86
AVS-2140	CPE	VV	----	----	VERO >	320.00	----	8/ 7/86
AVS-2140	CPE	YFV	----	----	VERO >	320.00	----	2/ 3/87
AVS-2145	CPE	AD2	----	----	HEP2 >	320.00	----	10/16/86
AVS-2145	CPE	JE	0.4	----	VERO >	320.00	----	5/11/87
AVS-2145	CPE	PT	----	----	VERO >	320.00	----	1/28/87
AVS-2145	CPE	VEE	----	----	VERO	100.00	----	4/29/88
AVS-2145	CPE	VSV	----	----	L929 >	320.00	----	8/29/86
AVS-2145	CPE	VV	----	----	VERO >	320.00	----	10/16/86
AVS-2145	CPE	YFV	----	----	VERO <	320.00	----	3/27/87
AVS-2146	CPE	AD2	----	----	HEP2 >	320.00	----	10/16/86
AVS-2146	CPE	JE	0.5	----	VERO >	320.00	----	5/11/87
AVS-2146	PR	PIC	N/A	----	VERO >	320.00	----	4/11/88
AVS-2146	CPE	PT	----	----	VERO	320.00	----	1/28/87
AVS-2146	CPE	SF	0.10	----	VERO >	100.00	----	1/12/87
AVS-2146	CPE	VEE	----	----	VERO	320.00	----	4/29/88
AVS-2146	CPE	VSV	----	----	L929 >	320.00	----	8/29/86
AVS-2146	CPE	VV	----	----	VERO >	320.00	----	10/16/86
AVS-2146	CPE	YFV	----	----	VERO >	320.00	----	3/27/87
AVS-2147	CPE	AD2	----	----	HEP2	320.00	----	10/ 9/86
AVS-2147	CPE	JE	----	----	VERO	100.00	----	4/10/87
AVS-2147	PR	PIC	N/A	----	VERO >	320.00	----	4/11/88
AVS-2147	CPE	PT	0.08	----	VERO >	320.00	----	1/20/87
AVS-2147	CPE	SF	----	----	VERO	32.00	----	1/ 8/87
AVS-2147	CPE	VSV	----	----	L929	100.00	----	8/15/86
AVS-2147	CPE	VV	----	----	VERO >	320.00	----	8/28/86
AVS-2147	CPE	YFV	----	----	VERO	10.00	----	3/25/87
AVS-2148	CPE	AD2	----	----	HEP2	32.00	----	10/ 9/86
AVS-2148	CPE	JE	----	----	VERO <	100.00	----	4/13/87
AVS-2148	CPE	PT	----	----	VERO	100.00	----	1/21/87
AVS-2148	CPE	SF	0.60	----	VERO	10.00	----	1/ 8/87
AVS-2148	CPE	VSV	----	----	L929 <	100.00	----	8/15/86
AVS-2148	CPE	VV	----	----	VERO	100.00	----	8/28/86
AVS-2148	CPE	YFV	0.1	----	VERO	32.00	----	3/25/87
AVS-2150	CPE	AD2	----	----	HEP2	100.00	----	10/ 9/86
AVS-2150	CPE	JE	0.2	----	VERO	100.00	----	4/13/87
AVS-2150	PR	PIC	N/A	----	VERO >	32.00	----	4/11/88
AVS-2150	CPE	PT	0.05	----	VERO	100.00	----	1/21/87
AVS-2150	CPE	SF	----	----	VERO	100.00	----	1/ 8/87
AVS-2150	CPE	VSV	----	----	L929	100.00	----	7/15/86
AVS-2150	CPE	VV	0.25	----	VERO	100.00	----	8/28/86

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2150	CPE	YFV	0.15	----	VERO	10.00	----	3/25/87
AVS-2152	CPE	AD2	----	----	HEP2 >	320.00	----	10/ 9/86
AVS-2152	CPE	JE	----	----	VERO	100.00	----	4/13/87
AVS-2152	PR	PIC	N/A	----	VERO >	320.00	----	4/11/88
AVS-2152	CPE	PT	0.20	----	VERO >	320.00	----	1/21/87
AVS-2152	CPE	SF	----	----	VERO	32.00	----	1/15/87
AVS-2152	CPE	VSV	----	----	L929	100.00	----	8/15/86
AVS-2152	CPE	VV	----	----	VERO	100.00	----	8/28/86
AVS-2152	CPE	YFV	0.1	----	VERO	32.00	----	3/25/87
AVS-2159	CPE	AD2	0.5	----	HEP2 >	320.00	----	10/23/86
AVS-2159	CPE	JE	----	----	VERO >	320.00	----	4/20/87
AVS-2159	PR	PIC	N/A	----	VERO	320.00	----	4/19/88
AVS-2159	CPE	SF	3.66	0.32	VERO >	320.00 >	1000.00	10/31/86
AVS-2159	CPE	SF	----	----	VERO	320.00	----	5/ 4/88
AVS-2159	CPE	SF	----	----	VERO	320.00	----	6/ 1/88
AVS-2159	CPE	VSV	0.4	----	L929	100.00	----	9/19/86
AVS-2159	CPE	VV	----	----	VERO >	320.00	----	10/23/86
AVS-2159	CPE	YFV	0.90	----	VERO >	100.00	----	2/ 4/87
AVS-2160	CPE	AD2	0.3	32.00	HEP2	32.00	1.00	10/23/86
AVS-2160	CPE	JE	----	----	VERO	10.00	----	4/20/87
AVS-2160	PR	PIC	N/A	----	VERO >	32.00	----	4/19/88
AVS-2160	CPE	PT	0.45	12.60	VERO	10.00	0.79	11/12/86
AVS-2160	CPE	SF	3.12	0.36	VERO	32.00	89.60	10/31/86
AVS-2160	CPE	SF	1.7	3.27	VERO	1.00	0.31	7/27/87
AVS-2160	CPE	SF	1.75	1.47	VERO	1.00	0.68	5/24/88
AVS-2160	CPE	VSV	----	----	L929	100.00	----	9/19/86
AVS-2160	CPE	VV	0.2	----	VERO <	32.00	----	10/23/86
AVS-2160	CPE	YFV	0.85	9.80	VERO	1.00	0.11	2/ 4/87
AVS-2161	CPE	AD2	0.35	----	HEP2	100.00	----	10/23/86
AVS-2161	CPE	JE	----	----	VERO	32.00	----	4/20/87
AVS-2161	PR	PIC	N/A	----	VERO	32.00	----	4/18/88
AVS-2161	CPE	VSV	----	----	L929	32.00	----	9/19/86
AVS-2161	CPE	VV	1.2	47.30	VERO	32.00	0.68	10/23/86
AVS-2161	CPE	YFV	0.02	37.40	VERO	32.00	0.86	2/ 4/87
AVS-2162	CPE	AD2	----	----	HEP2 <	320.00	----	10/23/86
AVS-2162	CPE	JE	----	----	VERO <	100.00	----	4/20/87
AVS-2162	PR	PIC	N/A	----	VERO	320.00	----	4/19/88
AVS-2162	CPE	SF	2.79	5.70	VERO <	320.00 <	55.20	10/31/86
AVS-2162	CPE	SF	0.55	59.50	VERO	32.00	0.54	5/24/88
AVS-2162	CPE	VSV	----	----	L929	100.00	----	9/19/86
AVS-2162	CPE	VV	0.6	100.00	VERO <	320.00 <	3.20	10/23/86
AVS-2162	CPE	VV	0.6	100.00	VERO <	320.00 <	3.20	5/26/88
AVS-2162	CPE	YFV	----	----	VERO	32.00	----	2/ 4/87
AVS-2163	CPE	AD2	----	----	HEP2 >	100.00	----	10/23/86
AVS-2163	CPE	JE	----	----	VERO	32.00	----	4/13/87
AVS-2163	PR	PIC	N/A	----	VERO >	100.00	----	4/12/88
AVS-2163	CPE	PT	0.15	----	VERO	100.00	----	1/21/87
AVS-2163	CPE	SF	----	----	VERO	32.00	----	1/ 7/87
AVS-2163	CPE	VEE	----	----	VERO	320.00	----	3/10/88
AVS-2163	CPE	VSV	----	----	L929	32.00	----	8/29/86
AVS-2163	CPE	VV	0.3	----	VERO >	100.00	----	10/23/86
AVS-2163	CPE	YFV	0.5	31.40	VERO	10.00	0.32	3/25/87
AVS-2164	CPE	AD2	----	----	HEP2 <	1.00	----	10/23/86
AVS-2164	CPE	JE	0.1	----	VERO	32.00	----	4/13/87
AVS-2164	PR	PIC	N/A	----	VERO >	320.00	----	4/15/88
AVS-2164	CPE	PT	----	----	VERO >	320.00	----	1/21/87
AVS-2164	CPE	SF	0.75	----	VERO	100.00	----	1/ 7/87
AVS-2164	CPE	VEE	----	----	VERO	100.00	----	3/10/88
AVS-2164	CPE	VSV	----	----	L929	32.00	----	8/29/86
AVS-2164	CPE	VV	----	----	VERO	320.00	----	10/23/86
AVS-2164	CPE	YFV	0.15	----	VERO	10.00	----	3/25/87
AVS-2165	CPE	AD2	----	----	HEP2 <	320.00	----	10/16/86
AVS-2165	CPE	JE	----	----	VERO <	320.00	----	4/13/87
AVS-2165	PR	PIC	N/A	----	VERO	100.00	----	4/12/88
AVS-2165	CPE	PT	0.04	----	VERO >	320.00	----	1/22/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2165	CPE	SF	0.85	----	VERO	32.00	----	1/ 7/87
AVS-2165	CPE	VEE	----	----	VERO	1.00	----	3/10/88
AVS-2165	CPE	VSV	----	----	L929	100.00	----	8/29/86
AVS-2165	CPE	VV	----	----	VERO	100.00	----	10/16/86
AVS-2165	CPE	YFV	0.25	----	VERO	320.00	----	5/13/87
AVS-2166	CPE	AD2	----	----	HEP2 <	10.00	----	10/16/86
AVS-2166	CPE	JE	----	----	VERO <	32.00	----	4/14/87
AVS-2166	PR	PIC	N/A	5.40	VERO	3.20	0.59	4/12/88
AVS-2166	CPE	PT	----	----	VERO <	32.00	----	1/22/87
AVS-2166	CPE	SF	1.20	193.00	VERO	10.00	0.05	1/ 7/87
AVS-2166	CPE	VEE	----	----	VERO	100.00	----	3/10/88
AVS-2166	CPE	VSV	----	----	L929	1.00	----	8/29/86
AVS-2166	CPE	VV	0.5	----	VERO <	10.00	----	10/16/86
AVS-2166	CPE	YFV	----	----	VERO	32.00	----	5/13/87
AVS-2167	CPE	AD2	0.3	----	HEP2 <	320.00	----	10/23/86
AVS-2167	CPE	JE	----	----	VERO	100.00	----	4/14/87
AVS-2167	PR	PIC	N/A	63.50	VERO	100.00	1.57	4/12/88
AVS-2167	CPE	PT	----	----	VERO <	320.00	----	1/22/87
AVS-2167	CPE	SF	0.80	----	VERO	10.00	----	1/ 7/87
AVS-2167	CPE	VEE	----	----	VERO >	320.00	----	3/10/88
AVS-2167	CPE	VSV	----	----	L929	32.00	----	8/29/86
AVS-2167	CPE	VV	0.55	87.60	VERO	100.00	1.14	10/23/86
AVS-2167	CPE	YFV	0.2	----	VERO	32.00	----	3/25/87
AVS-2168	CPE	AD2	----	----	HEP2	100.00	----	10/23/86
AVS-2168	CPE	JE	0.05	----	VERO	320.00	----	4/14/87
AVS-2168	PR	PIC	N/A	----	VERO	100.00	----	4/12/88
AVS-2168	CPE	PT	0.05	----	VERO	320.00	----	1/22/87
AVS-2168	CPE	SF	0.50	----	VERO	100.00	----	1/ 7/87
AVS-2168	CPE	VEE	----	----	VERO	10.00	----	3/10/88
AVS-2168	CPE	VSV	----	----	L929	100.00	----	8/29/86
AVS-2168	CPE	VV	----	----	VERO	100.00	----	10/23/86
AVS-2168	CPE	YFV	0.1	----	VERO	32.00	----	3/25/87
AVS-2169	CPE	AD2	----	----	HEP2 >	320.00	----	10/16/86
AVS-2169	CPE	JE	0.2	----	VERO	100.00	----	4/14/87
AVS-2169	PR	PIC	N/A	----	VERO	320.00	----	4/12/88
AVS-2169	CPE	PT	----	----	VERO >	320.00	----	1/22/87
AVS-2169	CPE	SF	0.50	----	VERO	10.00	----	1/ 7/87
AVS-2169	CPE	VEE	----	----	VERO	32.00	----	3/10/88
AVS-2169	CPE	VSV	----	----	L929	100.00	----	9/ 5/86
AVS-2169	CPE	VV	0.4	----	VERO >	320.00	----	10/16/86
AVS-2169	CPE	YFV	----	----	VERO	0.32	----	3/26/87
AVS-2170	CPE	AD2	0.45	----	HEP2	32.00	----	10/16/86
AVS-2170	CPE	JE	----	----	VERO	32.00	----	4/14/87
AVS-2170	PR	PIC	N/A	----	VERO >	32.00	----	4/12/88
AVS-2170	CPE	PT	----	----	VERO	10.00	----	1/23/87
AVS-2170	CPE	SF	0.50	299.00	VERO <	10.00 <	0.03	1/ 7/87
AVS-2170	CPE	VEE	----	----	VERO	32.00	----	3/17/88
AVS-2170	CPE	VSV	----	----	L929	3.20	----	9/ 5/86
AVS-2170	CPE	VV	4.7	1.30	VERO	10.00	7.69	10/16/86
AVS-2170	CPE	VV	5.	0.87	VERO	32.00	36.50	6/16/88
AVS-2170	CPE	YFV	0.15	----	VERO	1.00	----	3/26/87
AVS-2171	CPE	AD2	----	----	HEP2 >	320.00	----	10/16/86
AVS-2171	CPE	JE	0.3	----	VERO >	320.00	----	4/14/87
AVS-2171	PR	PIC	N/A	----	VERO >	320.00	----	4/12/88
AVS-2171	CPE	PT	0.2	----	VERO >	320.00	----	1/23/87
AVS-2171	CPE	SF	----	----	VERO >	100.00	----	1/ 8/87
AVS-2171	CPE	VEE	----	----	VERO	100.00	----	3/17/88
AVS-2171	CPE	VSV	----	----	L929	320.00	----	9/ 5/86
AVS-2171	CPE	VV	----	----	VERO >	320.00	----	10/16/86
AVS-2171	CPE	YFV	----	----	VERO >	320.00	----	3/26/87
AVS-2172	CPE	AD2	----	----	HEP2 <	32.00	----	10/23/86
AVS-2172	CPE	JE	----	----	VERO <	32.00	----	4/15/87
AVS-2172	PR	PIC	N/A	16.00	VERO	32.00	1.99	4/12/88
AVS-2172	CPE	PT	----	----	VERO	10.00	----	1/23/87
AVS-2172	CPE	SF	----	----	VERO	10.00	----	1/ 8/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2172	CPE	VEE	----	----	VERO	0.10	----	3/17/88
AVS-2172	CPE	VSV	----	----	L929	10.00	----	9/ 5/86
AVS-2172	CPE	VV	----	----	VERO <	32.00	----	10/23/86
AVS-2172	CPE	YFV	----	----	VERO	1.00	----	3/26/87
AVS-2173	CPE	AD2	1.15	27.30	HEP2	100.00	3.66	10/23/86
AVS-2173	CPE	JE	----	----	VERO	32.00	----	4/15/87
AVS-2173	CPE	PT	1.18	15.70	VERO	10.00	0.64	1/23/87
AVS-2173	CPE	SF	0.45	----	VERO	32.00	----	1/ 8/87
AVS-2173	CPE	VEE	----	----	VERO	10.00	----	3/17/88
AVS-2173	CPE	VSV	----	----	L929	32.00	----	9/ 5/86
AVS-2173	CPE	VV	0.5	100.00	VERO	32.00	0.32	10/23/86
AVS-2173	CPE	YFV	0.2	----	VERO	10.00	----	3/26/87
AVS-2174	CPE	AD2	----	----	HEP2 <	320.00	----	10/16/86
AVS-2174	CPE	JE	1.75	41.70	VERO	10.00	0.24	4/15/87
AVS-2174	PR	PIC	N/A	210.00	VERO	100.00	0.48	4/15/88
AVS-2174	CPE	PT	1.59	57.00	VERO	100.00	1.75	1/23/87
AVS-2174	CPE	SF	----	----	VERO	100.00	----	1/ 8/87
AVS-2174	CPE	VEE	----	----	VERO	10.00	----	3/17/88
AVS-2174	CPE	VSV	----	----	L929	100.00	----	9/ 5/86
AVS-2174	CPE	VV	0.6	100.00	VERO	100.00	1.00	10/16/86
AVS-2174	CPE	YFV	0.3	----	VERO	10.00	----	3/26/87
AVS-2175	CPE	AD2	0.1	----	HEP2	32.00	----	10/23/86
AVS-2175	CPE	JE	----	----	VERO	32.00	----	4/15/87
AVS-2175	PR	PIC	N/A	31.40	VERO	32.00	1.01	4/15/88
AVS-2175	CPE	PT	0.13	119.00	VERO	32.00	0.27	1/26/87
AVS-2175	CPE	SF	----	----	VERO <	100.00	----	1/ 8/87
AVS-2175	CPE	VEE	0.15	----	VERO	32.00	----	3/17/88
AVS-2175	CPE	VSV	----	----	L929 <	32.00	----	9/ 5/86
AVS-2175	CPE	VV	0.2	----	VERO	100.00	----	10/23/86
AVS-2175	CPE	YFV	----	----	VERO	10.00	----	3/26/87
AVS-2176	CPE	AD2	----	----	HEP2	320.00	----	10/16/86
AVS-2176	CPE	JE	0.55	261.00	VERO	320.00	1.22	4/15/87
AVS-2176	PR	PIC	N/A	----	VERO	32.00	----	4/15/88
AVS-2176	CPE	PT	0.90	147.00	VERO >	320.00 >	2.17	1/26/87
AVS-2176	CPE	SF	----	----	VERO >	100.00	----	1/ 8/87
AVS-2176	CPE	VEE	----	----	VERO >	320.00	----	3/17/88
AVS-2176	CPE	VSV	----	----	L929	320.00	----	9/ 5/86
AVS-2176	CPE	VV	0.25	----	VERO	100.00	----	10/16/86
AVS-2176	CPE	YFV	0.7	----	VERO >	320.00	----	3/26/87
AVS-2177	CPE	AD2	0.5	----	HEP2 >	320.00	----	10/16/86
AVS-2177	CPE	JE	----	----	VERO >	320.00	----	4/15/87
AVS-2177	CPE	PT	0.20	----	VERO >	320.00	----	1/26/87
AVS-2177	CPE	SF	----	----	VERO >	100.00	----	1/ 8/87
AVS-2177	CPE	VEE	----	----	VERO	100.00	----	3/17/88
AVS-2177	CPE	VSV	----	----	L929	320.00	----	9/ 5/86
AVS-2177	CPE	VV	----	----	VERO >	320.00	----	10/16/86
AVS-2177	CPE	YFV	----	----	VERO	320.00	----	3/26/87
AVS-2178	CPE	AD2	----	----	HEP2 <	100.00	----	10/23/86
AVS-2178	CPE	JE	----	----	VERO	32.00	----	4/16/87
AVS-2178	PR	PIC	N/A	73.30	VERO >	100.00 >	1.36	4/15/88
AVS-2178	CPE	PT	0.10	----	VERO	100.00	----	1/26/87
AVS-2178	CPE	SF	0.42	----	VERO	100.00	----	1/ 8/87
AVS-2178	CPE	VEE	----	----	VERO	1.00	----	3/17/88
AVS-2178	CPE	VSV	----	----	L929	10.00	----	9/ 5/86
AVS-2178	CPE	VV	0.55	93.90	VERO	32.00	0.34	10/23/86
AVS-2178	CPE	YFV	0.15	----	VERO	10.00	----	3/26/87
AVS-2179	CPE	AD2	0.3	----	HEP2 >	320.00	----	10/16/86
AVS-2179	CPE	JE	----	----	VERO	320.00	----	4/16/87
AVS-2179	PR	PIC	N/A	49.70	VERO	32.00	0.64	4/15/88
AVS-2179	CPE	PT	0.05	----	VERO	320.00	----	1/26/87
AVS-2179	CPE	SF	0.10	----	VERO	32.00	----	1/10/87
AVS-2179	CPE	VEE	----	----	VERO	320.00	----	3/17/88
AVS-2179	CPE	VSV	----	----	L929	32.00	----	9/ 5/86
AVS-2179	CPE	VV	0.3	----	VERO >	320.00	----	10/16/86
AVS-2179	CPE	YFV	0.35	314.00	VERO	320.00	1.01	3/26/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2180	CPE	AD2	----	----	HEP2 <	3.20	----	10/16/86
AVS-2180	CPE	JE	----	----	VERO	100.00	----	4/16/87
AVS-2180	PR	PIC	N/A	----	VERO <	100.00	----	4/15/88
AVS-2180	CPE	PT	----	----	VERO <	320.00	----	1/27/87
AVS-2180	CPE	SF	0.50	----	VERO <	10.00	----	1/10/87
AVS-2180	CPE	VEE	----	----	VERO	10.00	----	3/17/88
AVS-2180	CPE	VSV	----	----	L929	1.00	----	9/ 5/86
AVS-2180	CPE	VV	0.05	----	VERO	10.00	----	10/16/86
AVS-2180	CPE	YFV	0.7	88.00	VERO	10.00	0.11	3/27/87
AVS-2181	CPE	AD2	----	----	HEP2	100.00	----	10/23/86
AVS-2181	CPE	JE	0.2	----	VERO >	320.00	----	4/16/87
AVS-2181	PR	PIC	N/A	----	VERO	100.00	----	4/15/88
AVS-2181	CPE	PT	0.15	----	VERO	32.00	----	1/27/87
AVS-2181	CPE	SF	0.09	----	VERO	32.00	----	1/10/87
AVS-2181	CPE	VEE	----	----	VERO	32.00	----	3/17/88
AVS-2181	CPE	VSV	----	----	L929	0.32	----	9/ 5/86
AVS-2181	CPE	VV	----	----	VERO	100.00	----	10/23/86
AVS-2181	CPE	YFV	----	----	VERO >	320.00	----	3/27/87
AVS-2182	CPE	AD2	0.2	----	HEP2 >	320.00	----	10/23/86
AVS-2182	CPE	JE	0.1	----	VERO	320.00	----	4/16/87
AVS-2182	PR	PIC	N/A	----	VERO	320.00	----	4/15/88
AVS-2182	CPE	PT	0.15	----	VERO	320.00	----	1/27/87
AVS-2182	CPE	SF	0.10	----	VERO >	100.00	----	1/10/87
AVS-2182	CPE	VEE	----	----	VERO	1.00	----	3/17/88
AVS-2182	CPE	VSV	----	----	L929	100.00	----	9/ 5/86
AVS-2182	CPE	VV	----	----	VERO >	320.00	----	10/23/86
AVS-2182	CPE	YFV	0.5	----	VERO	100.00	----	3/27/87
AVS-2183	CPE	JE	----	----	VERO >	320.00	----	4/16/87
AVS-2183	PR	PIC	N/A	----	VERO >	100.00	----	7/15/88
AVS-2183	CPE	PT	----	----	VERO >	320.00	----	1/27/87
AVS-2183	CPE	SF	----	----	VERO	100.00	----	1/10/87
AVS-2183	CPE	VEE	----	----	VERO	3.20	----	3/17/88
AVS-2183	CPE	YFV	----	----	VERO	10.00	----	3/27/87
AVS-2184	CPE	AD2	0.3	----	HEP2 <	320.00	----	10/16/86
AVS-2184	CPE	JE	----	----	VERO	320.00	----	5/11/87
AVS-2184	PR	PIC	N/A	----	VERO	320.00	----	4/18/88
AVS-2184	CPE	PT	0.15	----	VERO	100.00	----	1/27/87
AVS-2184	CPE	SF	0.20	----	VERO >	100.00	----	1/10/87
AVS-2184	CPE	VEE	----	----	VERO	32.00	----	4/29/88
AVS-2184	CPE	VSV	----	----	L929	100.00	----	9/ 5/86
AVS-2184	CPE	VV	0.9	210.00	VERO	320.00	1.52	10/16/86
AVS-2184	CPE	YFV	----	----	VERO	100.00	----	3/27/87
AVS-2185	CPE	AD2	0.51	0.34	HEP2 >	0.10 >	0.29	11/ 6/86
AVS-2185	CPE	JE	0.7	98.00	VERO	10.00	0.10	5/11/87
AVS-2185	CPE	PT	----	----	VERO	100.00	----	1/28/87
AVS-2185	CPE	SF	0.20	----	VERO	10.00	----	1/10/87
AVS-2185	CPE	SF	----	----	VERO	100.00	----	1/12/87
AVS-2185	CPE	VEE	----	----	VERO	100.00	----	4/29/88
AVS-2185	CPE	VSV	----	----	L929	32.00	----	9/ 5/86
AVS-2185	CPE	VV	----	----	VERO <	320.00	----	10/16/86
AVS-2185	CPE	YFV	----	----	VERO	100.00	----	3/27/87
AVS-2186	CPE	AD2	0.3	----	HEP2 >	320.00	----	10/23/86
AVS-2186	CPE	JE	----	----	VERO >	320.00	----	5/11/87
AVS-2186	PR	PIC	N/A	----	VERO	100.00	----	4/18/88
AVS-2186	CPE	PT	----	----	VERO	320.00	----	1/28/87
AVS-2186	CPE	SF	0.10	----	VERO	32.00	----	1/10/87
AVS-2186	CPE	VEE	----	----	VERO	100.00	----	4/29/88
AVS-2186	CPE	VSV	----	----	L929 >	320.00	----	9/ 5/86
AVS-2186	CPE	VV	----	----	VERO >	320.00	----	10/23/86
AVS-2186	CPE	YFV	----	----	VERO	100.00	----	3/27/87
AVS-2187	CPE	AD2	0.4	9.90	HEP2	10.00	1.00	10/16/86
AVS-2187	CPE	JE	----	----	VERO <	10.00	----	5/11/87
AVS-2187	CPE	PT	----	----	VERO	10.00	----	1/28/87
AVS-2187	CPE	SF	----	----	VERO	10.00	----	1/12/87
AVS-2187	CPE	VEE	----	----	VERO	100.00	----	4/29/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2187	CPE	VSV	----	----	L929	10.00	----	9/ 5/86
AVS-2187	CPE	VV	0.4	9.90	VERO	10.00	1.00	10/16/86
AVS-2187	CPE	YFV	----	----	VERO	10.00	----	3/27/87
AVS-2188	CPE	AD2	----	----	HEP2	3.20	----	10/23/86
AVS-2188	CPE	JE	----	----	VERO <	32.00	----	4/20/87
AVS-2188	PR	PIC	N/A	83.90	VERO	100.00	1.19	4/19/88
AVS-2188	CPE	SF	2.46	0.86	VERO	32.00	37.30	10/31/86
AVS-2188	CPE	SF	0.25	----	VERO	1.00	----	8/18/87
AVS-2188	CPE	SF	0.45	6.80	VERO	1.00	0.15	5/25/88
AVS-2188	CPE	VSV	0.45	----	L929	100.00	----	9/19/86
AVS-2188	CPE	VV	0.5	----	VERO	3.20	----	10/23/86
AVS-2188	CPE	YFV	----	----	VERO	3.20	----	2/ 4/87
AVS-2189	CPE	AD2	----	----	HEP2	3.20	----	10/23/86
AVS-2189	CPE	JE	----	----	VERO	320.00	----	4/20/87
AVS-2189	PR	PIC	N/A	303.00	VERO	320.00	1.05	4/19/88
AVS-2189	CPE	SF	0.20	----	VERO	10.00	----	11/20/86
AVS-2189	CPE	VSV	----	----	L929	32.00	----	9/19/86
AVS-2189	CPE	VV	----	----	VERO	320.00	----	10/23/86
AVS-2189	CPE	YFV	0.35	120.00	VERO	100.00	0.83	2/ 4/87
AVS-2190	CPE	AD2	----	----	HEP2	32.00	----	10/23/86
AVS-2190	CPE	JE	----	----	VERO <	320.00	----	4/20/87
AVS-2190	PR	PIC	N/A	----	VERO >	320.00	----	4/19/88
AVS-2190	CPE	VSV	----	----	L929	100.00	----	9/19/86
AVS-2190	CPE	VV	0.1	----	VERO	100.00	----	10/23/86
AVS-2190	CPE	YFV	----	----	VERO	32.00	----	2/ 4/87
AVS-2191	CPE	AD2	----	----	HEP2 <	1.00	----	10/23/86
AVS-2191	CPE	JE	----	----	VERO	10.00	----	4/20/87
AVS-2191	PR	PIC	N/A	9.70	VERO	10.00	1.02	4/19/88
AVS-2191	CPE	SF	0.15	26.10	VERO	32.00	1.23	11/ 4/86
AVS-2191	CPE	VSV	----	----	L929	3.20	----	9/19/86
AVS-2191	CPE	VV	0.45	----	VERO	10.00	----	10/23/86
AVS-2191	CPE	YFV	----	----	VERO	3.20	----	2/ 4/87
AVS-2192	CPE	AD2	----	----	HEP2	100.00	----	10/30/86
AVS-2192	CPE	JE	0.2	----	VERO	320.00	----	4/20/87
AVS-2192	PR	PIC	N/A	----	VERO	320.00	----	4/19/88
AVS-2192	CPE	PT	----	----	VERO	32.00	----	11/17/86
AVS-2192	CPE	VSV	----	----	L929	10.00	----	9/19/86
AVS-2192	CPE	VV	----	----	VERO	100.00	----	10/30/86
AVS-2192	CPE	YFV	0.25	----	VERO	100.00	----	2/ 4/87
AVS-2193	CPE	AD2	----	----	HEP2	32.00	----	10/30/86
AVS-2193	CPE	JE	0.1	----	VERO	10.00	----	4/20/87
AVS-2193	PR	PIC	N/A	6.40	VERO	10.00	1.56	4/18/88
AVS-2193	CPE	PT	----	----	VERO	1.00	----	11/17/86
AVS-2193	CPE	SF	-.81	33.00	VERO	32.00	0.97	11/ 4/86
AVS-2193	CPE	VSV	----	----	L929	3.20	----	9/19/86
AVS-2193	CPE	VV	0.15	----	VERO	100.00	----	10/30/86
AVS-2193	CPE	YFV	0.65	24.50	VERO	10.00	0.41	2/ 4/87
AVS-2194	CPE	AD2	----	----	HEP2 >	320.00	----	10/23/86
AVS-2194	CPE	JE	----	----	VERO <	320.00	----	4/21/87
AVS-2194	PR	PIC	N/A	----	VERO >	320.00	----	4/19/88
AVS-2194	CPE	PT	----	----	VERO >	320.00	----	11/17/86
AVS-2194	CPE	VSV	----	----	L929 >	320.00	----	9/19/86
AVS-2194	CPE	VV	----	----	VERO >	320.00	----	10/23/86
AVS-2194	CPE	YFV	0.10	----	VERO	320.00	----	2/ 5/87
AVS-2195	CPE	AD2	----	----	HEP2	320.00	----	10/30/86
AVS-2195	CPE	JE	0.05	----	VERO	320.00	----	4/21/87
AVS-2195	PR	PIC	N/A	----	VERO	320.00	----	4/22/88
AVS-2195	CPE	PT	----	----	VERO	32.00	----	11/17/86
AVS-2195	CPE	VSV	----	----	L929	32.00	----	9/19/86
AVS-2195	CPE	VV	----	----	VERO	320.00	----	10/30/86
AVS-2195	CPE	YFV	0.15	----	VERO	32.00	----	2/ 5/87
AVS-2196	CPE	AD2	----	----	HEP2	32.00	----	10/30/86
AVS-2196	CPE	JE	----	----	VERO	320.00	----	4/21/87
AVS-2196	PR	PIC	N/A	----	VERO	320.00	----	4/22/88
AVS-2196	CPE	PT	----	----	VERO	100.00	----	11/17/86

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2196	CPE	VSV	----	----	L929	320.00	----	9/19/86
AVS-2196	CPE	VV	----	----	VERO	320.00	----	10/30/86
AVS-2196	CPE	YFV	----	----	VERO	100.00	----	2/ 5/87
AVS-2197	CPE	AD2	----	----	HEP2	32.00	----	10/30/86
AVS-2197	CPE	JE	0.35	314.00	VERO	100.00	0.32	4/21/87
AVS-2197	PR	PIC	N/A	----	VERO	32.00	----	4/22/88
AVS-2197	CPE	PT	0.1	----	VERO	100.00	----	11/19/86
AVS-2197	CPE	VSV	----	----	L929	100.00	----	9/19/86
AVS-2197	CPE	VV	----	----	VERO >	320.00	----	10/30/86
AVS-2197	CPE	YFV	----	----	VERO >	100.00	----	3/ 6/87
AVS-2198	CPE	AD2	0.4	----	HEP2 <	320.00	----	10/30/86
AVS-2198	CPE	JE	----	----	VERO	320.00	----	4/21/87
AVS-2198	PR	PIC	N/A	----	VERO >	100.00	----	4/22/88
AVS-2198	CPE	PT	0.9	----	VERO >	100.00	----	11/19/86
AVS-2198	CPE	VSV	----	----	L929	32.00	----	9/19/86
AVS-2198	CPE	VV	0.15	----	VERO	320.00	----	10/30/86
AVS-2198	CPE	YFV	0.30	98.00	VERO	32.00	0.33	2/ 5/87
AVS-2199	CPE	AD2	----	----	HEP2	320.00	----	10/30/86
AVS-2199	CPE	JE	0.08	----	VERO	320.00	----	4/21/87
AVS-2199	PR	PIC	N/A	----	VERO >	320.00	----	4/22/88
AVS-2199	CPE	PT	0.23	----	VERO	32.00	----	11/19/86
AVS-2199	CPE	VSV	----	----	L929	320.00	----	9/19/86
AVS-2199	CPE	VV	0.35	270.00	VERO	100.00	0.37	10/30/86
AVS-2199	CPE	YFV	----	----	VERO >	100.00	----	3/ 6/87
AVS-2200	CPE	AD2	----	----	HEP2 >	320.00	----	10/30/86
AVS-2200	CPE	JE	----	----	VERO >	320.00	----	4/21/87
AVS-2200	PR	PIC	N/A	----	VERO >	320.00	----	4/22/88
AVS-2200	CPE	PT	0.3	----	VERO >	320.00	----	11/19/86
AVS-2200	CPE	VSV	----	----	L929	320.00	----	9/19/86
AVS-2200	CPE	VV	----	----	VERO >	320.00	----	10/30/86
AVS-2200	CPE	YFV	----	----	VERO	32.00	----	2/ 5/87
AVS-2201	CPE	AD2	0.3	320.00	HEP2	320.00	1.00	10/30/86
AVS-2201	CPE	JE	0.52	64.30	VERO	100.00	1.55	4/21/87
AVS-2201	PR	PIC	N/A	18.90	VERO	10.00	0.53	4/22/88
AVS-2201	CPE	PT	0.32	----	VERO	10.00	----	11/19/86
AVS-2201	CPE	VSV	----	----	L929	10.00	----	9/19/86
AVS-2201	CPE	VV	----	----	VERO >	320.00	----	10/30/86
AVS-2201	CPE	YFV	----	----	VERO	32.00	----	2/ 5/87
AVS-2202	CPE	AD2	----	----	HEP2 <	320.00	----	10/30/86
AVS-2202	CPE	JE	----	----	VERO	320.00	----	4/21/87
AVS-2202	PR	PIC	N/A	----	VERO >	320.00	----	4/22/88
AVS-2202	CPE	PT	0.05	----	VERO	100.00	----	11/19/86
AVS-2202	CPE	VSV	----	----	L929	320.00	----	9/19/86
AVS-2202	CPE	VV	0.1	----	VERO	320.00	----	10/30/86
AVS-2202	CPE	YFV	----	----	VERO	32.00	----	2/ 5/87
AVS-2203	CPE	AD2	----	----	HEP2	320.00	----	10/30/86
AVS-2203	CPE	JE	----	----	VERO	32.00	----	4/21/87
AVS-2203	CPE	PT	----	----	VERO	32.00	----	11/19/86
AVS-2203	CPE	VSV	----	----	L929 <	100.00	----	9/19/86
AVS-2203	CPE	VV	----	----	VERO	100.00	----	10/30/86
AVS-2203	CPE	YFV	1.80	18.60	VERO	32.00	1.71	2/ 5/87
AVS-2204	CPE	AD2	0.15	----	HEP2	100.00	----	10/30/86
AVS-2204	CPE	JE	0.1	----	VERO <	100.00	----	4/21/87
AVS-2204	PR	PIC	N/A	----	VERO	32.00	----	4/22/88
AVS-2204	CPE	PT	----	----	VERO	32.00	----	11/19/86
AVS-2204	CPE	VSV	----	----	L929 <	320.00	----	9/19/86
AVS-2204	CPE	VV	----	----	VERO	100.00	----	10/30/86
AVS-2204	CPE	YFV	0.10	----	VERO	32.00	----	2/ 6/87
AVS-2205	CPE	AD2	----	----	HEP2 <	320.00	----	10/30/86
AVS-2205	CPE	JE	----	----	VERO	10.00	----	4/22/87
AVS-2205	PR	PIC	N/A	----	VERO	320.00	----	4/25/88
AVS-2205	CPE	PT	0.1	----	VERO	320.00	----	11/19/86
AVS-2205	CPE	VSV	----	----	L929	32.00	----	9/19/86
AVS-2205	CPE	VV	----	----	VERO <	320.00	----	10/30/86
AVS-2205	CPE	YFV	0.17	----	VERO	32.00	----	2/ 6/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2206	CPE	AD2	----	----	HEP2 <	1.00	----	10/30/86
AVS-2206	CPE	JE	----	----	VERO	100.00	----	4/22/87
AVS-2206	PR	PIC	N/A	----	VERO	100.00	----	4/25/88
AVS-2206	CPE	PT	----	----	VERO	32.00	----	11/19/86
AVS-2206	CPE	VSV	----	----	L929	32.00	----	9/19/86
AVS-2206	CPE	VV	----	----	VERO	320.00	----	10/30/86
AVS-2206	CPE	YFV	0.30	100.00	VERO	1.00	0.01	2/ 6/87
AVS-2207	CPE	JE	0.05	----	VERO >	320.00	----	4/22/87
AVS-2207	CPE	PT	0.42	95.00	VERO	100.00	1.04	11/18/86
AVS-2207	CPE	YFV	----	----	VERO >	320.00	----	2/ 3/87
AVS-2208	CPE	AD2	----	----	HEP2	100.00	----	10/30/86
AVS-2208	CPE	JE	0.05	----	VERO	100.00	----	4/22/87
AVS-2208	CPE	PT	0.1	----	VERO	32.00	----	11/18/86
AVS-2208	CPE	VSV	----	----	L929	100.00	----	9/19/86
AVS-2208	CPE	VV	0.3	320.00	VERO	100.00	0.31	10/30/86
AVS-2208	CPE	YFV	0.45	95.00	VERO	10.00	0.10	2/ 6/87
AVS-2209	CPE	AD2	----	----	HEP2	100.00	----	10/30/86
AVS-2209	CPE	JE	----	----	VERO	320.00	----	4/22/87
AVS-2209	CPE	PT	0.1	----	VERO	320.00	----	11/20/86
AVS-2209	CPE	SF	0.15	----	VERO	100.00	----	11/20/86
AVS-2209	CPE	VSV	----	----	L929	32.00	----	10/ 3/86
AVS-2209	CPE	VV	----	----	VERO	320.00	----	10/30/86
AVS-2209	CPE	YFV	0.25	----	VERO	32.00	----	2/ 6/87
AVS-2210	CPE	JE	0.55	93.90	VERO	100.00	1.06	4/22/87
AVS-2210	PR	PIC	N/A	----	VERO	32.00	----	4/25/88
AVS-2210	CPE	PT	0.1	----	VERO	32.00	----	11/20/86
AVS-2210	CPE	VSV	----	----	L929	32.00	----	10/ 3/86
AVS-2210	CPE	VV	----	----	VERO	100.00	----	10/30/86
AVS-2210	CPE	YFV	----	----	VERO	3.20	----	2/ 6/87
AVS-2211	CPE	JE	----	----	VERO <	32.00	----	4/22/87
AVS-2211	PR	PIC	N/A	----	VERO	10.00	----	4/25/88
AVS-2211	CPE	PT	0.1	----	VERO	32.00	----	11/20/86
AVS-2211	CPE	SF	----	----	VERO <	32.00	----	11/20/86
AVS-2211	CPE	VSV	----	----	L929	0.32	----	10/ 3/86
AVS-2211	CPE	YFV	----	----	VERO	10.00	----	2/ 6/87
AVS-2212	CPE	JE	----	----	VERO	32.00	----	4/22/87
AVS-2212	PR	PIC	N/A	7.60	VERO	10.00	1.29	4/25/88
AVS-2212	CPE	PT	0.3	----	VERO	32.00	----	11/20/86
AVS-2212	CPE	SF	0.15	----	VERO	10.00	----	11/20/86
AVS-2212	CPE	VSV	----	----	L929	32.00	----	10/ 3/86
AVS-2212	CPE	YFV	0.35	----	VERO	10.00	----	2/ 6/87
AVS-2213	CPE	JE	----	----	VERO	32.00	----	4/22/87
AVS-2213	PR	PIC	N/A	----	VERO	10.00	----	4/25/88
AVS-2213	CPE	PT	0.1	----	VERO	32.00	----	11/20/86
AVS-2213	CPE	SF	----	----	VERO	32.00	----	11/20/86
AVS-2213	CPE	VSV	----	----	L929	100.00	----	10/ 3/86
AVS-2213	CPE	YFV	0.05	----	VERO	3.20	----	2/ 6/87
AVS-2214	CPE	JE	----	----	VERO	10.00	----	4/22/87
AVS-2214	CPE	PT	0.05	----	VERO <	10.00	----	12/22/86
AVS-2214	CPE	SF	1.14	13.10	VERO	10.00	0.76	11/10/86
AVS-2214	CPE	VSV	----	----	L929	10.00	----	10/ 3/86
AVS-2214	CPE	YFV	0.45	8.60	VERO	10.00	1.14	2/ 9/87
AVS-2215	CPE	JE	0.38	311.00	VERO	320.00	1.02	4/22/87
AVS-2215	CPE	PT	0.35	290.00	VERO	100.00	0.34	12/22/86
AVS-2215	CPE	SF	1.26	797.00	VERO	320.00	0.40	11/10/86
AVS-2215	CPE	VSV	----	----	L929	320.00	----	10/ 3/86
AVS-2215	CPE	YFV	----	----	VERO	320.00	----	2/ 9/87
AVS-2216	CPE	JE	0.1	----	VERO <	320.00	----	4/23/87
AVS-2216	CPE	PT	0.28	----	VERO	320.00	----	12/22/86
AVS-2216	CPE	SF	1.05	112.00	VERO	100.00	0.89	11/10/86
AVS-2216	CPE	VSV	----	----	L929	100.00	----	10/ 3/86
AVS-2216	CPE	YFV	----	----	VERO	320.00	----	2/ 9/87
AVS-2217	CPE	JE	0.35	9.80	VERO	10.00	1.01	4/23/87
AVS-2217	CPE	PT	0.05	----	VERO	10.00	----	11/21/86
AVS-2217	CPE	SF	1.20	1.23	VERO	3.20	2.60	11/12/86

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2217	CPE	VSV	----	----	L929	10.00	----	10/ 3/86
AVS-2217	CPE	YFV	----	----	VERO	3.20	----	2/ 9/87
AVS-2218	CPE	JE	0.5	----	VERO	3.20	----	4/23/87
AVS-2218	CPE	PT	0.35	----	VERO	3.20	----	11/21/86
AVS-2218	CPE	SF	0.81	21.20	VERO	3.20	0.15	11/12/86
AVS-2218	CPE	VSV	----	----	L929	32.00	----	10/ 3/86
AVS-2218	CPE	VV	0.84	15.40	VERO	32.00	2.07	11/ 6/86
AVS-2218	CPE	YFV	----	----	VERO	1.00	----	2/ 9/87
AVS-2219	CPE	JE	1.78	8.50	VERO	32.00	3.74	4/23/87
AVS-2219	CPE	PT	0.2	----	VERO	32.00	----	11/21/86
AVS-2219	CPE	SF	2.52	3.33	VERO	32.00	9.60	11/12/86
AVS-2219	CPE	SF	1.05	8.20	VERO	3.20	0.39	7/28/87
AVS-2219	CPE	SF	0.55	19.90	VERO	3.20	0.16	5/25/88
AVS-2219	CPE	VSV	----	----	L929 <	100.00	----	10/ 3/86
AVS-2219	CPE	VV	0.81	65.10	VERO	100.00	1.54	11/ 6/86
AVS-2219	CPE	YFV	0.65	77.00	VERO	32.00	0.42	2/ 9/87
AVS-2220	CPE	JE	0.45	----	VERO <	100.00	----	4/23/87
AVS-2220	CPE	PT	0.3	----	VERO	32.00	----	11/21/86
AVS-2220	CPE	PT	----	----	VERO	32.00	----	5/25/88
AVS-2220	CPE	SF	3.12	0.88	VERO	32.00	36.20	11/12/86
AVS-2220	CPE	SF	0.25	----	VERO	10.00	----	12/ 2/86
AVS-2220	CPE	SF	1.	26.40	VERO	10.00	0.38	7/27/87
AVS-2220	CPE	SF	0.5	22.10	VERO	10.00	0.45	5/25/88
AVS-2220	CPE	VSV	----	----	L929 <	100.00	----	10/ 3/86
AVS-2220	CPE	YFV	0.05	----	VERO	10.00	----	2/ 9/87
AVS-2221	CPE	JE	0.45	3.00	VERO	1.00	0.33	4/23/87
AVS-2221	CPE	PT	----	----	VERO	3.20	----	11/21/86
AVS-2221	CPE	SF	1.17	1.82	VERO	3.20	1.76	11/12/86
AVS-2221	CPE	SF	0.15	----	VERO	3.20	----	12/ 2/86
AVS-2221	CPE	VSV	----	----	L929	10.00	----	10/ 3/86
AVS-2221	CPE	YFV	----	----	VERO	3.20	----	2/ 9/87
AVS-2222	CPE	JE	0.5	----	VERO <	32.00	----	4/23/87
AVS-2222	CPE	PT	----	----	VERO	32.00	----	11/20/86
AVS-2222	CPE	SF	0.45	13.90	VERO	10.00	0.72	11/13/86
AVS-2222	CPE	VSV	----	----	L929	32.00	----	10/ 3/86
AVS-2222	CPE	YFV	----	----	VERO	32.00	----	2/ 9/87
AVS-2223	CPE	JE	0.1	----	VERO <	320.00	----	4/23/87
AVS-2223	CPE	PT	0.1	----	VERO	100.00	----	11/20/86
AVS-2223	CPE	SF	1.11	62.80	VERO	100.00	1.59	11/13/86
AVS-2223	CPE	VSV	----	----	L929 <	100.00	----	10/ 3/86
AVS-2223	CPE	YFV	----	----	VERO	100.00	----	2/ 9/87
AVS-2224	CPE	JE	1.65	8.70	VERO	10.00	1.14	4/23/87
AVS-2224	PR	PIC	N/A	----	VERO >	32.00	----	4/29/88
AVS-2224	CPE	PT	1.5	30.70	VERO	100.00	3.25	11/20/86
AVS-2224	CPE	PT	0.1	----	VERO	100.00	----	5/18/88
AVS-2224	CPE	VSV	----	----	L929	1.00	----	10/ 3/86
AVS-2224	CPE	YFV	1.55	15.70	VERO	32.00	2.03	2/ 9/87
AVS-2225	CPE	JE	----	----	VERO <	3.20	----	4/23/87
AVS-2225	PR	PIC	N/A	----	VERO	10.00	----	5/ 2/88
AVS-2225	CPE	PT	0.2	----	VERO	10.00	----	11/20/86
AVS-2225	CPE	SF	0.84	4.38	VERO	3.20	0.73	11/13/86
AVS-2225	CPE	VSV	----	----	L929	32.00	----	10/ 3/86
AVS-2225	CPE	VV	0.60	9.20	VERO	10.00	1.08	11/ 6/86
AVS-2225	CPE	YFV	----	----	VERO	3.20	----	2/10/87
AVS-2226	CPE	JE	0.2	----	VERO	10.00	----	4/23/87
AVS-2226	PR	PIC	N/A	----	VERO	10.00	----	4/29/88
AVS-2226	CPE	PT	0.1	----	VERO	32.00	----	11/20/86
AVS-2226	CPE	SF	1.41	9.60	VERO <	32.00 <	3.31	11/13/86
AVS-2226	CPE	SF	0.3	10.00	VERO	10.00	1.00	5/25/88
AVS-2226	CPE	VSV	----	----	L929	32.00	----	10/ 3/86
AVS-2226	CPE	VV	0.30	50.60	VERO	32.00	0.63	11/ 6/86
AVS-2226	CPE	YFV	----	----	VERO <	32.00	----	2/10/87
AVS-2227	CPE	JE	----	----	VERO	10.00	----	4/24/87
AVS-2227	CPE	PT	----	----	VERO	32.00	----	11/21/86
AVS-2227	CPE	VSV	----	----	L929 <	10.00	----	10/ 3/86

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2227	CPE	YFV	----	----	VERO	3.20	----	2/10/87
AVS-2228	CPE	JE	----	----	VERO	10.00	----	4/24/87
AVS-2228	PR	PIC	N/A	18.10	VERO	32.00	1.71	4/29/88
AVS-2228	CPE	PT	----	----	VERO	32.00	----	11/21/86
AVS-2228	CPE	SF	1.41	10.00	VERO	10.00	1.00	11/13/86
AVS-2228	CPE	VSV	----	----	L929	32.00	----	10/ 3/86
AVS-2228	CPE	YFV	----	----	VERO	10.00	----	2/10/87
AVS-2229	CPE	JE	----	----	VERO	100.00	----	4/24/87
AVS-2229	PR	PIC	N/A	95.00	VERO	100.00	1.04	4/29/88
AVS-2229	CPE	PT	0.1	----	VERO	100.00	----	11/21/86
AVS-2229	CPE	VSV	----	----	L929	32.00	----	10/ 3/86
AVS-2229	CPE	YFV	0.30	----	VERO	5.20	----	2/10/87
AVS-2230	CPE	JE	----	----	VERO	100.00	----	4/24/87
AVS-2230	CPE	PT	1.7	177.00	VERO	320.00	1.79	11/21/86
AVS-2230	CPE	VSV	----	----	L929	100.00	----	10/ 3/86
AVS-2230	CPE	YFV	0.30	320.00	VERO	320.00	1.00	2/10/87
AVS-2231	CPE	JE	----	----	VERO	32.00	----	4/24/87
AVS-2231	PR	PIC	N/A	79.90	VERO	10.00	0.13	4/29/88
AVS-2231	CPE	PT	0.6	----	VERO	100.00	----	11/21/86
AVS-2231	CPE	VSV	----	----	L929	100.00	----	10/ 3/86
AVS-2231	CPE	YFV	0.35	259.00	VERO	32.00	0.12	2/10/87
AVS-2232	CPE	JE	----	----	VERO	100.00	----	4/24/87
AVS-2232	PR	PIC	N/A	83.90	VERO	100.00	1.19	4/29/88
AVS-2232	CPE	PT	1.05	----	VERO	100.00	----	11/24/86
AVS-2232	CPE	SF	----	----	VERO	320.00	----	11/17/86
AVS-2232	CPE	VSV	----	----	L929	32.00	----	10/ 3/86
AVS-2232	CPE	YFV	0.25	237.00	VERO	100.00	0.42	2/10/87
AVS-2233	CPE	JE	----	----	VERO	320.00	----	4/24/87
AVS-2233	PR	PIC	N/A	----	VERO	100.00	----	4/29/88
AVS-2233	CPE	PT	1.2	----	VERO	100.00	----	11/24/86
AVS-2233	CPE	SF	----	----	VERO	100.00	----	11/17/86
AVS-2233	CPE	VSV	----	----	L929	100.00	----	10/ 3/86
AVS-2233	CPE	YFV	----	----	VERO	100.00	----	2/10/87
AVS-2234	CPE	JE	----	----	VERO	10.00	----	4/24/87
AVS-2234	PR	PIC	N/A	0.82	VERO	0.32	0.39	4/29/88
AVS-2234	CPE	PT	0.95	2.60	VERO	3.20	1.23	11/24/86
AVS-2234	CPE	SF	0.35	11.90	VERO	10.00	0.83	11/17/86
AVS-2234	CPE	VSV	----	----	L929	10.00	----	10/ 3/86
AVS-2234	CPE	YFV	----	----	VERO	10.00	----	2/10/87
AVS-2235	CPE	JE	----	----	VERO	32.00	----	4/24/87
AVS-2235	PR	PIC	N/A	----	VERO	32.00	----	5/ 2/88
AVS-2235	CPE	PT	0.7	----	VERO	3.20	----	11/24/86
AVS-2235	CPE	SF	0.95	42.90	VERO	100.00	2.33	11/17/86
AVS-2235	CPE	VSV	----	----	L929	32.00	----	10/ 3/86
AVS-2235	CPE	VV	1.35	17.70	VERO	32.00	1.81	11/ 6/86
AVS-2235	CPE	YFV	0.20	----	VERO	1.00	----	2/10/87
AVS-2236	CPE	JE	----	----	VERO	100.00	----	4/24/87
AVS-2236	PR	PIC	N/A	280.00	VERO	100.00	0.36	5/ 2/88
AVS-2236	CPE	PT	1.5	----	VERO	100.00	----	11/24/86
AVS-2236	CPE	SF	----	----	VERO	320.00	----	11/17/86
AVS-2236	CPE	VSV	----	----	L929	32.00	----	10/ 3/86
AVS-2236	CPE	YFV	----	----	VERO	32.00	----	3/24/87
AVS-2237	CPE	JE	----	----	VERO	32.00	----	5/21/87
AVS-2237	PR	PIC	N/A	----	VERO	32.00	----	5/10/88
AVS-2237	CPE	PT	----	----	VERO	32.00	----	3/ 2/87
AVS-2237	CPE	SF	0.15	----	VERO	100.00	----	11/26/86
AVS-2237	CPE	YFV	----	----	VERO	10.00	----	2/16/87
AVS-2238	CPE	JE	----	----	VERO	100.00	----	4/30/87
AVS-2238	PR	PIC	N/A	----	VERO	320.00	----	5/10/88
AVS-2238	CPE	PT	0.15	----	VERO	320.00	----	3/ 2/87
AVS-2238	CPE	SF	----	----	VERO	3.20	----	11/26/86
AVS-2238	CPE	SF	1.75	212.00	VERO	320.00	1.51	12/15/86
AVS-2238	CPE	YFV	----	----	VERO	320.00	----	2/16/87
AVS-2239	CPE	JE	----	----	VERO	100.00	----	4/30/87
AVS-2239	PR	PIC	N/A	----	VERO	10.00	----	5/10/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2230	CPE	PT	----	----	VERO	32.00	----	3/ 2/87
AVS-2230	CPE	SF	0.60	----	VERO	100.00	----	11/26/86
AVS-2230	CPE	VV	0.21	1325.00	VERO	320.00	0.24	11/20/86
AVS-2230	CPE	YFV	----	----	VERO	10.00	----	2/16/87
AVS-2240	CPE	JE	0.7	----	VERO	100.00	----	4/30/87
AVS-2240	PR	PIC	N/A	----	VERO	32.00	----	5/10/88
AVS-2240	CPE	PT	0.47	----	VERO	3.20	----	12/23/86
AVS-2240	CPE	SF	0.30	----	VERO	100.00	----	11/26/86
AVS-2240	CPE	YFV	----	----	VERO	32.00	----	2/16/87
AVS-2241	CPE	JE	0.1	----	VERO	320.00	----	4/30/87
AVS-2241	PR	PIC	N/A	----	VERO	320.00	----	5/10/88
AVS-2241	CPE	PT	0.67	----	VERO	320.00	----	12/23/86
AVS-2241	CPE	SF	----	----	VERO	320.00	----	11/26/86
AVS-2241	CPE	YFV	----	----	VERO	32.00	----	2/16/87
AVS-2242	CPE	JE	----	----	VERO	320.00	----	4/30/87
AVS-2242	PR	PIC	N/A	----	VERO	320.00	----	5/10/88
AVS-2242	CPE	PT	0.05	----	VERO	32.00	----	12/23/86
AVS-2242	CPE	SF	1.77	222.00	VERO	320.00	1.44	12/ 1/86
AVS-2242	CPE	SF	0.23	----	VERO	320.00	----	12/15/86
AVS-2242	CPE	YFV	0.38	311.00	VERO	100.00	0.32	2/16/87
AVS-2243	CPE	JE	0.3	----	VERO	100.00	----	4/30/87
AVS-2243	PR	PIC	N/A	----	VERO	320.00	----	5/13/88
AVS-2243	CPE	PT	1.33	191.00	VERO	32.00	0.17	12/23/86
AVS-2243	CPE	SF	0.40	104.00	VERO	100.00	0.96	12/ 1/86
AVS-2243	CPE	YFV	----	----	VERO	32.00	----	2/16/87
AVS-2244	CPE	JE	----	----	VERO	10.00	----	4/30/87
AVS-2244	PR	PIC	N/A	----	VERO	3.20	----	5/13/88
AVS-2244	CPE	PT	0.17	----	VERO	3.20	----	12/23/86
AVS-2244	CPE	SF	0.40	----	VERO	10.00	----	12/ 1/86
AVS-2244	CPE	SF	0.47	9.50	VERO	10.00	1.05	12/15/86
AVS-2244	CPE	VV	0.51	9.50	VERO	10.00	1.05	11/20/86
AVS-2244	CPE	YFV	----	----	VERO	10.00	----	2/16/87
AVS-2245	CPE	JE	----	----	VERO	320.00	----	4/30/87
AVS-2245	PR	PIC	N/A	----	VERO	100.00	----	5/13/88
AVS-2245	CPE	PT	0.10	----	VERO	100.00	----	3/ 2/87
AVS-2245	CPE	SF	1.10	----	VERO	320.00	----	12/ 1/86
AVS-2245	CPE	YFV	----	----	VERO	320.00	----	2/16/87
AVS-2246	CPE	JE	0.75	9.90	VERO	10.00	1.00	4/30/87
AVS-2246	PR	PIC	N/A	----	VERO	100.00	----	5/13/88
AVS-2246	CPE	PT	0.30	----	VERO	10.00	----	12/11/86
AVS-2246	CPE	SF	0.65	22.10	VERO	32.00	1.44	12/ 1/86
AVS-2246	CPE	YFV	----	----	VERO	10.00	----	2/16/87
AVS-2247	CPE	AD2	1.29	49.70	HEP2	320.00	6.43	11/20/86
AVS-2247	CPE	AD2	----	----	HEP2	100.00	----	1/ 8/88
AVS-2247	CPE	AD2	0.7	----	HEP2	320.00	----	1/21/88
AVS-2247	CPE	AD2	----	----	HEP2	100.00	----	5/12/88
AVS-2247	CPE	JE	----	----	VERO	100.00	----	4/30/87
AVS-2247	PR	PIC	N/A	----	VERO	100.00	----	5/13/88
AVS-2247	CPE	PT	1.95	11.30	VERO	32.00	2.81	12/11/86
AVS-2247	CPE	SF	0.55	293.00	VERO	100.00	0.34	12/ 2/86
AVS-2247	CPE	YFV	0.40	----	VERO	10.00	----	2/16/87
AVS-2248	CPE	JE	----	----	VERO	10.00	----	4/30/87
AVS-2248	PR	PIC	N/A	----	VERO	3.20	----	5/13/88
AVS-2248	CPE	PT	0.16	2.12	VERO	1.00	0.47	12/11/86
AVS-2248	CPE	SF	0.65	8.50	VERO	10.00	1.17	12/ 2/86
AVS-2248	CPE	VV	0.50	----	VERO	10.00	----	3/12/87
AVS-2248	CPE	YFV	0.15	----	VERO	3.20	----	2/17/87
AVS-2249	CPE	JE	----	----	VERO	320.00	----	5/ 1/87
AVS-2249	PR	PIC	N/A	----	VERO	320.00	----	5/13/88
AVS-2249	CPE	PT	0.41	----	VERO	320.00	----	12/11/86
AVS-2249	CPE	SF	----	----	VERO	320.00	----	12/ 2/86
AVS-2249	CPE	YFV	0.10	----	VERO	32.00	----	2/17/87
AVS-2250	CPE	JE	----	----	VERO	32.00	----	5/ 1/87
AVS-2250	PR	PIC	N/A	----	VERO	3.20	----	5/13/88
AVS-2250	CPE	PT	0.60	64.60	VERO	100.00	1.55	3/ 2/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2250	CPE	SF	----	----	VERO	100.00	----	12/ 2/86
AVS-2250	CPE	VV	0.90	49.00	VERO	100.00	2.04	11/20/86
AVS-2250	CPE	YFV	----	----	VERC	10.00	----	2/17/87
AVS-2251	CPE	JE	----	----	VERO	100.00	----	5/ 1/87
AVS-2251	PR	PIC	N/A	----	VERO	100.00	----	5/13/88
AVS-2251	CPE	PT	0.87	184.00	VERO	320.00	1.73	12/12/86
AVS-2251	CPE	SF	0.15	----	VERO	32.00	----	12/ 2/86
AVS-2251	CPE	YFV	0.15	----	VERO	10.00	----	2/17/87
AVS-2252	CPE	JE	----	----	VERO	10.00	----	5/ 1/87
AVS-2252	PR	PIC	N/A	----	VERO	320.00	----	5/13/88
AVS-2252	CPE	PT	1.74	66.00	VERO	100.00	1.51	12/12/86
AVS-2252	CPE	SF	----	----	VERO	100.00	----	12/ 4/86
AVS-2252	CPE	VV	0.60	242.00	VERO	320.00	1.32	12/ 4/86
AVS-2252	CPE	YFV	----	----	VERO	100.00	----	2/17/87
AVS-2253	CPE	JE	----	----	VERO	10.00	----	5/ 1/87
AVS-2253	PR	PIC	N/A	65.50	VERO	32.00	0.49	5/20/88
AVS-2253	CPE	PT	0.45	100.00	VERO	10.00	0.10	3/ 2/87
AVS-2253	CPE	SF	0.60	297.00	VERO	32.00	0.11	12/ 4/86
AVS-2253	CPE	YFV	----	----	VERO	10.00	----	2/17/87
AVS-2254	CPE	JE	----	----	VERO	100.00	----	5/ 1/87
AVS-2254	PR	PIC	N/A	----	VERO	100.00	----	5/20/88
AVS-2254	CPE	PT	1.50	134.00	VERO	100.00	0.75	12/12/86
AVS-2254	CPE	SF	----	----	VERO	100.00	----	12/ 4/86
AVS-2254	CPE	YFV	0.05	----	VERO	10.00	----	2/17/87
AVS-2255	CPE	JE	----	----	VERO	320.00	----	5/ 1/87
AVS-2255	PR	PIC	N/A	----	VERO	100.00	----	5/20/88
AVS-2255	CPE	PT	0.40	----	VERO	320.00	----	12/15/86
AVS-2255	CPE	SF	----	----	VERO	100.00	----	12/ 4/86
AVS-2255	CPE	YFV	----	----	VERO	3.20	----	2/17/87
AVS-2256	CPE	JE	----	----	VERO	72.00	----	5/ 1/87
AVS-2256	PR	PIC	N/A	----	VERO	100.00	----	5/20/88
AVS-2256	CPE	PT	0.20	----	VERO	320.00	----	12/15/86
AVS-2256	CPE	SF	0.20	----	VERO	32.00	----	12/ 4/86
AVS-2256	CPE	YFV	----	----	VERO	10.00	----	2/17/87
AVS-2257	CPE	AD2	0.61	57.50	HEP2	32.00	0.56	12/ 4/86
AVS-2257	CPE	JE	----	----	VERO	32.00	----	5/ 1/87
AVS-2257	PR	PIC	N/A	69.10	VERO	10.00	0.14	5/20/88
AVS-2257	CPE	PT	0.30	----	VERO	100.00	----	12/15/86
AVS-2257	CPE	SF	0.10	----	VERO	32.00	----	12/ 5/86
AVS-2257	CPE	VV	0.75	87.90	VERO	32.00	0.36	12/ 4/86
AVS-2257	CPE	YFV	----	----	VERO	10.00	----	2/17/87
AVS-2258	CPE	JE	----	----	VERO	320.00	----	5/ 1/87
AVS-2258	PR	PIC	N/A	----	VERO	320.00	----	5/20/88
AVS-2258	CPE	PT	0.40	----	VERO	320.00	----	12/15/86
AVS-2258	CPE	SF	0.10	----	VERO	320.00	----	12/ 5/86
AVS-2258	CPE	YFV	0.30	320.00	VERO	100.00	0.31	2/17/87
AVS-2259	CPE	JE	----	----	VERO	320.00	----	5/ 1/87
AVS-2259	PR	PIC	N/A	----	VERO	320.00	----	5/20/88
AVS-2259	CPE	PT	0.40	----	VERO	320.00	----	12/15/86
AVS-2259	CPE	SF	0.18	----	VERO	320.00	----	12/ 5/86
AVS-2259	CPE	YFV	0.35	----	VERO	100.00	----	3/23/87
AVS-2260	CPE	JE	----	----	VERO	320.00	----	5/ 4/87
AVS-2260	PR	PIC	N/A	----	VERO	320.00	----	5/20/88
AVS-2260	CPE	PT	----	----	VERO	320.00	----	12/16/86
AVS-2260	CPE	SF	0.53	----	VERO	320.00	----	12/ 5/86
AVS-2260	CPE	YFV	----	----	VERO	320.00	----	3/23/87
AVS-2261	CPE	JE	----	----	VERO	320.00	----	5/ 4/87
AVS-2261	PR	PIC	N/A	----	VERO	320.00	----	5/20/88
AVS-2261	CPE	PT	0.08	----	VERO	320.00	----	12/16/86
AVS-2261	CPE	SF	0.14	----	VERO	32.00	----	12/ 5/86
AVS-2261	CPE	YFV	----	----	VERO	320.00	----	3/23/87
AVS-2262	CPE	JE	0.15	----	VERO	32.00	----	5/20/87
AVS-2262	PR	PIC	N/A	----	VERO	320.00	----	5/20/88
AVS-2262	CPE	SF	----	----	VERO	320.00	----	12/16/86
AVS-2262	CPE	YFV	----	----	VERO	100.00	----	3/23/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2263	CPE	JE	0.6	----	VERO >	320.00	----	5/21/87
AVS-2263	PR	PIC	N/A	----	VERO	70.00	----	5/23/88
AVS-2263	CPE	PT	0.30	----	VERO >	320.00	----	12/16/86
AVS-2263	CPE	SF	----	----	VERO >	320.00	----	12/16/86
AVS-2263	CPE	YFV	----	----	VERO	320.00	----	3/23/87
AVS-2264	CPE	JE	----	----	VERO	100.00	----	5/21/87
AVS-2264	PR	PIC	N/A	----	VERO	320.00	----	5/23/88
AVS-2264	CPE	PT	0.10	----	VERO >	320.00	----	12/16/86
AVS-2264	CPE	SF	----	----	VERO >	320.00	----	12/16/86
AVS-2264	CPE	YFV	----	----	VERO	100.00	----	3/23/87
AVS-2265	CPE	JE	----	----	VERO <	100.00	----	5/21/87
AVS-2265	PR	PIC	N/A	----	VERO	32.00	----	5/24/88
AVS-2265	CPE	PT	3.25	----	VERO <	100.00	----	12/17/86
AVS-2265	CPE	SF	0.30	----	VERO <	100.00	----	12/16/86
AVS-2265	CPE	VV	0.75	210.00	VERO	100.00	0.48	12/ 4/86
AVS-2265	CPE	YFV	----	----	VERO	32.00	----	3/23/87
AVS-2266	CPE	JE	----	----	VERO	32.00	----	5/21/87
AVS-2266	PR	PIC	N/A	----	VERO	32.00	----	5/24/88
AVS-2266	CPE	PT	0.20	----	VERO	32.00	----	12/17/86
AVS-2266	CPE	SF	0.65	----	VERO	32.00	----	12/16/86
AVS-2266	CPE	YFV	----	----	VERO	32.00	----	3/23/87
AVS-2267	CPE	JE	----	----	VERO	10.00	----	5/21/87
AVS-2267	PR	PIC	N/A	----	VERO	32.00	----	5/24/88
AVS-2267	CPE	PT	0.55	685.00	VERO	100.00	0.15	12/17/86
AVS-2267	CPE	SF	0.25	----	VERO	100.00	----	12/ 2/86
AVS-2267	CPE	YFV	----	----	VERO	32.00	----	3/23/87
AVS-2268	CPE	JE	----	----	VERO	32.00	----	5/21/87
AVS-2268	PR	PIC	N/A	----	VERO	32.00	----	5/24/88
AVS-2268	CPE	PT	1.00	111.00	VERO	100.00	0.90	12/17/86
AVS-2268	CPE	SF	1.45	----	VERO	32.00	----	12/ 4/86
AVS-2268	CPE	YFV	----	----	VERO	100.00	----	3/23/87
AVS-2269	CPE	AD2	0.1	----	HEP2 >	1.00	----	11/ 5/87
AVS-2269	CPE	AD2	0.2	----	HEP2 >	1.00	----	11/ 5/87
AVS-2269	CPE	JE	----	----	VERO >	1.00	----	10/ 6/87
AVS-2269	PR	PIC	N/A	----	VERO	0.03	----	11/13/87
AVS-2269	CPE	PT	2.5	0.03	VERO >	1.00 >	31.20	10/ 6/87
AVS-2269	CPE	PT	----	----	VERO	0.01	----	5/18/88
AVS-2269	CPE	SF	0.2	----	VERO >	1.00	----	10/ 6/87
AVS-2269	CPE	VEE	----	----	VERO	6.40	----	11/12/87
AVS-2269	CPE	VSV	0.45	0.07	L929	0.03	0.44	11/ 5/87
AVS-2269	CPE	VSV	0.9	----	L929	0.03	----	11/ 5/87
AVS-2269	CPE	VSV	0.15	----	L929	0.10	----	11/ 6/87
AVS-2269	CPE	VSV	----	----	L929 >	1.00	----	11/ 6/87
AVS-2269	CPE	VV	----	----	VERO >	1.00	----	11/ 5/87
AVS-2269	CPE	VV	----	----	VERO >	1.00	----	11/ 5/87
AVS-2269	CPE	YFV	0.2	----	VERO >	1.00	----	10/ 6/87
AVS-2270	CPE	JE	0.6	200.00	VERO	320.00	1.59	5/22/87
AVS-2270	PR	PIC	N/A	47.70	VERO	32.00	0.67	5/23/88
AVS-2270	CPE	PT	0.10	----	VERO	100.00	----	12/17/86
AVS-2270	CPE	SF	0.92	25.50	VERO	3.20	0.13	12/ 4/86
AVS-2270	CPE	SF	----	----	VERO >	10.00	----	12/29/86
AVS-2270	CPE	VSV	0.36	30.90	L929	32.00	1.03	12/ 5/86
AVS-2270	CPE	YFV	0.28	----	VERO	32.00	----	3/23/87
AVS-2271	CPE	JE	----	----	VERO <	320.00	----	5/22/87
AVS-2271	PR	PIC	N/A	97.00	VERO	100.00	1.02	5/24/88
AVS-2271	CPE	PT	----	----	VERO <	320.00	----	12/18/86
AVS-2271	CPE	SF	0.30	----	VERO	32.00	----	12/ 4/86
AVS-2271	CPE	YFV	----	----	VERO	10.00	----	2/19/87
AVS-2272	CPE	AD2	0.60	9.30	HEP2	10.00	1.08	12/ 4/86
AVS-2272	CPE	JE	0.35	----	VERO	100.00	----	5/ 5/87
AVS-2272	PR	PIC	N/A	----	VERO	32.00	----	5/23/88
AVS-2272	CPE	PT	----	----	VERO <	320.00	----	12/18/86
AVS-2272	CPE	SF	0.85	14.10	VERO	10.00	0.70	12/ 4/86
AVS-2272	CPE	VV	0.24	779.00	VERO	320.00	0.41	12/ 4/86
AVS-2272	CPE	YFV	----	----	VERO	32.00	----	2/19/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2273	CPE	JE	----	----	VERO	10.00	----	5/ 5/87
AVS-2273	PR	PIC	N/A	----	VERO	100.00	----	5/24/88
AVS-2273	CPE	PT	0.40	----	VERO	100.00	----	12/18/86
AVS-2273	CPE	YFV	0.78	98.00	VERO	10.00	0.10	2/19/87
AVS-2274	CPE	JE	0.85	91.70	VERO	100.00	1.08	5/ 5/87
AVS-2274	PR	PIC	N/A	----	VERO	100.00	----	5/24/88
AVS-2274	CPE	PT	1.50	55.90	VERO	100.00	1.78	12/18/86
AVS-2274	CPE	SF	2.00	15.80	VERO	100.00	6.30	12/23/86
AVS-2274	CPE	SF	1.	27.90	VERO	32.00	1.14	5/25/88
AVS-2274	CPE	YFV	1.25	22.30	VERO	3.20	0.14	2/19/87
AVS-2275	CPE	AD2	1.59	57.50	HEP2	100.00	1.74	12/ 4/86
AVS-2275	CPE	JE	0.5	61.60	VERO	100.00	1.62	5/ 5/87
AVS-2275	PR	PIC	N/A	----	VERO	100.00	----	5/24/88
AVS-2275	CPE	PT	2.10	41.00	VERO	320.00	7.80	12/18/86
AVS-2275	CPE	SF	2.10	13.50	VERO	100.00	7.38	12/23/86
AVS-2275	CPE	SF	0.95	77.70	VERO	100.00	1.28	5/24/88
AVS-2275	CPE	VSV	0.39	30.90	L929	10.00	0.32	12/ 9/86
AVS-2275	CPE	VV	2.10	14.80	VERO	100.00	6.75	12/ 4/86
AVS-2275	CPE	VV	1.9	16.00	VERO	100.00	6.23	1/21/88
AVS-2275	CPE	YFV	3.23	13.10	VERO	320.00	24.30	2/19/87
AVS-2275	CPE	YFV	0.51	79.50	VERO	10.00	0.13	8/19/87
AVS-2275	CPE	YFV	----	----	VERO >	100.00	----	12/14/87
AVS-2275	CPE	YFV	----	----	VERO >	320.00	----	5/24/88
AVS-2276	CPE	JE	----	----	VERO <	100.00	----	4/24/87
AVS-2276	PR	PIC	N/A	----	VERO >	100.00	----	5/ 3/88
AVS-2276	CPE	PT	0.9	----	VERO	100.00	----	11/25/86
AVS-2276	CPE	SF	----	----	VERO	32.00	----	11/18/86
AVS-2276	CPE	YFV	----	----	VERO	10.00	----	3/24/87
AVS-2277	CPE	AD2	1.05	88.50	HEP2	320.00	3.62	11/13/86
AVS-2277	CPE	AD2	0.35	----	HEP2	320.00	----	5/12/88
AVS-2277	CPE	JE	----	----	VERO	100.00	----	4/27/87
AVS-2277	PR	PIC	N/A	42.90	VERO	100.00	2.32	5/ 3/88
AVS-2277	CPE	PT	1.	29.80	VERO	32.00	1.07	11/25/86
AVS-2277	CPE	SF	1.40	20.20	VERO	32.00	1.58	11/18/86
AVS-2277	CPE	VV	0.84	143.00	VERO	320.00	2.22	11/13/86
AVS-2277	CPE	YFV	----	----	VERO	3.20	----	3/24/87
AVS-2278	CPE	JE	----	----	VERO <	10.00	----	4/27/87
AVS-2278	CPE	PT	----	----	VERO	100.00	----	11/25/86
AVS-2278	CPE	SF	----	----	VERO	100.00	----	11/18/86
AVS-2278	CPE	YFV	----	----	VERO <	32.00	----	3/24/87
AVS-2279	CPE	AD2	0.69	9.90	HEP2 >	10.00 >	1.00	11/13/86
AVS-2279	CPE	JE	----	----	VERO <	32.00	----	4/27/87
AVS-2279	CPE	PT	1.4	3.16	VERO	32.00	10.10	11/25/86
AVS-2279	CPE	PT	1.	4.81	VERO	10.00	2.07	5/18/88
AVS-2279	CPE	SF	0.35	38.50	VERO	32.00	0.83	11/18/86
AVS-2279	CPE	YFV	0.3	----	VERO	10.00	----	3/24/87
AVS-2280	CPE	AD2	0.51	505.00	HEP2 >	320.00 >	0.63	11/13/86
AVS-2280	CPE	JE	----	----	VERO <	320.00	----	4/27/87
AVS-2280	PR	PIC	N/A	----	VERO	320.00	----	5/ 2/88
AVS-2280	CPE	PT	0.15	----	VERO	320.00	----	11/25/86
AVS-2280	CPE	SF	----	----	VERO	320.00	----	11/18/86
AVS-2280	CPE	YFV	----	----	VERO	32.00	----	3/24/87
AVS-2281	CPE	AD2	0.60	905.00	HEP2 >	320.00 >	0.35	11/13/86
AVS-2281	CPE	JE	----	----	VERO	320.00	----	4/27/87
AVS-2281	PR	PIC	N/A	----	VERO >	320.00	----	5/ 2/88
AVS-2281	CPE	PT	0.4	----	VERO >	320.00	----	11/26/86
AVS-2281	CPE	SF	----	----	VERO >	320.00	----	11/19/86
AVS-2281	CPE	YFV	----	----	VERO	320.00	----	3/24/87
AVS-2282	CPE	JE	----	----	VERO	100.00	----	4/27/87
AVS-2282	CPE	PT	0.6	78.10	VERO	100.00	1.27	11/26/86
AVS-2282	CPE	SF	0.70	100.00	VERO <	320.00 <	3.19	11/19/86
AVS-2282	CPE	YFV	0.15	----	VERO	32.00	----	3/24/87
AVS-2283	CPE	AD2	0.60	121.00	HEP2 >	100.00 >	0.82	11/13/86
AVS-2283	CPE	JE	----	----	VERO	32.00	----	4/27/87
AVS-2283	PR	PIC	N/A	----	VERO	10.00	----	5/ 2/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2283	CPE	PT	0.5	----	VERO	100.00	----	11/26/86
AVS-2283	CPE	SF	1.30	1155.00	VERO	100.00	0.09	11/19/86
AVS-2283	CPE	YFV	----	----	VERO	32.00	----	3/24/87
AVS-2284	CPE	JE	----	----	VERO	320.00	----	4/27/87
AVS-2284	PR	PIC	N/A	----	VERO >	320.00	----	5/ 3/88
AVS-2284	CPE	PT	0.95	----	VERO >	320.00	----	11/26/86
AVS-2284	CPE	SF	0.50	504.00	VERO >	320.00 >	0.63	11/19/86
AVS-2284	CPE	YFV	----	----	VERO	100.00	----	3/24/87
AVS-2285	CPE	JE	----	----	VERO	100.00	----	4/27/87
AVS-2285	PR	PIC	N/A	269.00	VERO	320.00	1.18	5/ 3/88
AVS-2285	CPE	PT	0.67	----	VERO	320.00	----	11/26/86
AVS-2285	CPE	SF	1.85	96.00	VERO	320.00	3.31	11/19/86
AVS-2285	CPE	YFV	0.4	----	VERO	100.00	----	3/24/87
AVS-2286	CPE	JE	----	----	VERO <	10.00	----	4/27/87
AVS-2286	PR	PIC	N/A	----	VERO	100.00	----	5/ 3/88
AVS-2286	CPE	PT	0.60	----	VERO	100.00	----	12/ 1/86
AVS-2286	CPE	SF	0.65	120.00	VERO	100.00	0.83	11/20/86
AVS-2286	CPE	YFV	0.05	----	VERO	32.00	----	2/12/87
AVS-2287	CPE	JE	----	----	VERO <	32.00	----	4/27/87
AVS-2287	PR	PIC	N/A	----	VERO	32.00	----	5/ 3/88
AVS-2287	CPE	PT	0.30	----	VERO	100.00	----	12/ 1/86
AVS-2287	CPE	SF	0.10	----	VERO	32.00	----	11/20/86
AVS-2287	CPE	YFV	----	----	VERO <	320.00	----	2/12/87
AVS-2288	CPE	AD2	0.39	100.00	HEP2	100.00	1.00	11/13/86
AVS-2288	CPE	JE	----	----	VERO <	100.00	----	4/23/87
AVS-2288	PR	PIC	N/A	----	VERO	10.00	----	5/ 3/88
AVS-2288	CPE	PT	0.40	----	VERO	100.00	----	12/ 1/86
AVS-2288	CPE	SF	----	----	VERO <	100.00	----	11/20/86
AVS-2288	CPE	YFV	----	----	VERO	10.00	----	2/12/87
AVS-2289	CPE	AD2	0.75	271.00	HEP2	320.00	1.17	11/13/86
AVS-2289	CPE	JE	----	----	VERO	32.00	----	4/28/87
AVS-2289	PR	PIC	N/A	----	VERO	32.00	----	5/ 3/88
AVS-2289	CPE	PT	1.70	28.60	VERO	32.00	1.12	12/ 1/86
AVS-2289	CPE	SF	0.95	31.40	VERO	32.00	1.02	11/20/86
AVS-2289	CPE	VV	0.69	64.60	VERO	100.00	1.55	11/13/86
AVS-2289	CPE	YFV	----	----	VERO	10.00	----	2/12/87
AVS-2290	CPE	AD2	0.96	21.80	HEP2	32.00	1.47	11/13/86
AVS-2290	CPE	JE	0.4	----	VERO <	320.00	----	5/20/87
AVS-2290	PR	PIC	N/A	10.80	VERO	3.20	0.30	5/ 3/88
AVS-2290	CPE	PT	3.00	4.13	VERO	100.00	24.10	12/ 1/86
AVS-2290	CPE	PT	0.8	133.00	VERO	100.00	0.75	8/21/87
AVS-2290	CPE	PT	1.7	80.40	VERO	100.00	1.24	9/21/87
AVS-2290	CPE	SF	1.25	29.10	VERO	100.00	3.43	11/20/86
AVS-2290	CPE	VV	3.15	3.79	VERO	32.00	8.44	11/13/86
AVS-2290	CPE	VV	2.7	16.30	VERO	100.00	6.13	5/12/88
AVS-2290	CPE	YFV	0.15	----	VERO	100.00	----	2/12/87
AVS-2291	CPE	JE	0.1	----	VERO	10.00	----	5/20/87
AVS-2291	PR	PIC	N/A	----	VERO	0.32	----	5/ 3/88
AVS-2291	CPE	PT	0.20	----	VERO	10.00	----	12/ 2/86
AVS-2291	CPE	PT	1.70	8.00	VERO <	32.00 <	3.95	12/22/86
AVS-2291	CPE	VV	1.86	2.25	VERO	10.00	4.44	11/13/86
AVS-2291	CPE	VV	0.9	----	VERO <	10.00	----	5/12/88
AVS-2291	CPE	YFV	0.05	----	VERO	10.00	----	2/12/87
AVS-2292	CPE	JE	----	----	VERO	3.20	----	5/20/87
AVS-2292	CPE	PT	0.20	----	VERO	320.00	----	12/ 2/86
AVS-2292	CPE	PT	1.30	----	VERO >	100.00	----	12/22/86
AVS-2292	CPE	YFV	----	----	VERO	32.00	----	2/12/87
AVS-2293	CPE	JE	----	----	VERO	320.00	----	5/21/87
AVS-2293	PR	PIC	N/A	----	VERO	100.00	----	5/ 6/88
AVS-2293	CPE	PT	1.00	----	VERO	320.00	----	12/ 2/86
AVS-2293	CPE	YFV	0.10	----	VERO	100.00	----	2/12/87
AVS-2295	CPE	JE	----	----	VERO <	1.00	----	5/20/87
AVS-2295	PR	PIC	N/A	----	VERO	1.00	----	5/ 6/88
AVS-2295	CPE	PT	0.70	----	VERO	10.00	----	12/ 2/86
AVS-2295	CPE	YFV	----	----	VERO	3.20	----	2/12/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2296	CPE	AD2	1.14	10.90	HEP2	32.00	2.92	12/ 4/86
AVS-2296	CPE	AD2	2.4	3.17	HEP2	32.00	10.00	1/ 8/88
AVS-2296	CPE	AD2	1.95	10.00	HEP2	100.00	10.00	1/21/88
AVS-2296	CPE	JE	0.2	----	VERO	32.00	----	4/28/87
AVS-2296	PR	PIC	N/A	----	VERO	100.00	----	5/ 6/88
AVS-2296	CPE	PT	1.00	91.20	VERO	100.00	1.10	12/ 2/86
AVS-2296	CPE	YFV	0.15	----	VERO	10.00	----	2/12/87
AVS-2297	CPE	JE	0.05	----	VERO	10.00	----	4/28/87
AVS-2297	PR	PIC	N/A	----	VERO	10.00	----	5/ 6/88
AVS-2297	CPE	PT	----	----	VERO	10.00	----	12/ 4/86
AVS-2297	CPE	VV	3.39	5.00	VERO	32.00	6.36	12/ 4/86
AVS-2297	CPE	VV	3.95	3.64	VERO	100.00	27.40	1/21/88
AVS-2297	CPE	YFV	----	----	VERO	3.20	----	2/12/87
AVS-2298	CPE	AD2	----	----	HEP2	1.00	----	11/13/86
AVS-2298	CPE	JE	----	----	VERO	0.32	----	4/28/87
AVS-2298	CPE	PT	0.32	----	VERO	1.00	----	12/ 4/86
AVS-2298	CPE	YFV	0.19	----	VERO	0.32	----	2/13/87
AVS-2299	CPE	JE	----	----	VERO	10.00	----	5/21/87
AVS-2299	PR	PIC	N/A	53.30	VERO	32.00	0.60	5/ 6/88
AVS-2299	CPE	PT	----	----	VERO	0.32	----	12/ 4/86
AVS-2299	CPE	YFV	1.07	75.10	VERO	10.00	0.13	2/13/87
AVS-2301	CPE	JE	0.05	----	VERO	32.00	----	5/21/87
AVS-2301	PR	PIC	N/A	----	VERO	3.20	----	5/ 6/88
AVS-2301	CPE	PT	0.35	----	VERO	32.00	----	12/ 4/86
AVS-2301	CPE	VV	0.66	241.00	VERO	32.00	0.13	11/20/86
AVS-2301	CPE	YFV	1.55	77.70	VERO	32.00	0.41	2/13/87
AVS-2302	CPE	JE	----	----	VERO	1.00	----	5/18/87
AVS-2302	PR	PIC	N/A	----	VERO	3.20	----	5/ 6/88
AVS-2302	CPE	PT	----	----	VERO	1.00	----	12/ 4/86
AVS-2302	CPE	VV	2.61	2.60	VERO	3.20	1.23	11/20/86
AVS-2302	CPE	YFV	----	----	VERO	1.00	----	2/13/87
AVS-2303	CPE	AD2	1.29	308.00	HEP2	320.00	1.03	11/20/86
AVS-2303	CPE	JE	----	----	VERO	32.00	----	5/18/87
AVS-2303	PR	PIC	N/A	----	VERO	100.00	----	5/ 6/88
AVS-2303	CPE	PT	1.55	133.00	VERO	320.00	2.41	12/ 5/86
AVS-2303	CPE	YFV	0.08	----	VERO	100.00	----	2/13/87
AVS-2304	CPE	AD2	0.39	788.00	HEP2	320.00	0.41	11/20/86
AVS-2304	CPE	JE	----	----	VERO	32.00	----	5/18/87
AVS-2304	PR	PIC	N/A	----	VERO	320.00	----	5/ 6/88
AVS-2304	CPE	PT	0.70	----	VERO	320.00	----	12/ 5/86
AVS-2304	CPE	YFV	0.55	----	VERO	320.00	----	2/13/87
AVS-2305	CPE	AD2	0.39	788.00	HEP2	320.00	0.41	11/20/86
AVS-2305	CPE	JE	----	----	VERO	100.00	----	5/18/87
AVS-2305	PR	PIC	N/A	----	VERO	320.00	----	5/ 6/88
AVS-2305	CPE	PT	0.58	----	VERO	320.00	----	12/ 5/86
AVS-2305	CPE	YFV	2.45	2.72	VERO	100.00	36.70	2/13/87
AVS-2305	CPE	YFV	0.15	----	VERO	100.00	----	5/13/87
AVS-2305	CPE	YFV	0.25	----	VERO	32.00	----	8/19/87
AVS-2305	CPE	YFV	----	----	VERO	100.00	----	12/14/87
AVS-2305	CPE	YFV	0.15	----	VERO	100.00	----	5/25/88
AVS-2307	CPE	JE	0.25	----	VERO	10.00	----	5/18/87
AVS-2307	PR	PIC	N/A	----	VERO	320.00	----	5/10/88
AVS-2307	CPE	PT	0.34	----	VERO	100.00	----	12/ 5/86
AVS-2307	CPE	YFV	0.40	310.00	VERO	32.00	0.10	2/13/87
AVS-2308	CPE	JE	----	----	VERO	0.32	----	5/18/87
AVS-2308	PR	PIC	N/A	2.74	VERO	0.03	0.01	5/10/88
AVS-2308	CPE	PT	1.10	93.10	VERO	0.32	----	12/ 5/86
AVS-2308	CPE	VV	1.35	3.06	VERO	1.00	0.33	3/12/87
AVS-2308	CPE	YFV	----	----	VERO	0.32	----	2/13/87
AVS-2309	CPE	JE	1.1	----	VERO	320.00	----	5/21/87
AVS-2309	PR	PIC	N/A	----	VERO	100.00	----	5/10/88
AVS-2309	CPE	PT	3.25	8.20	VERO	100.00	12.10	3/ 2/87
AVS-2309	CPE	PT	2.9	8.90	VERO	320.00	35.80	8/21/87
AVS-2309	CPE	SF	0.45	----	VERO	100.00	----	11/18/86
AVS-2309	CPE	YFV	0.95	81.90	VERO	320.00	3.91	2/13/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MYC50	TI	DATE
AVS-2309	CPE	YFV	1.15	53.20	VERO	32.00	0.60	5/25/88
AVS-2310	CPE	JE	----	----	VERO	320.00	----	5/21/87
AVS-2310	PR	PIC	N/A	----	VERO	100.00	----	5/10/88
AVS-2310	CPE	PT	1.03	----	VERO	100.00	----	3/ 2/87
AVS-2310	CPE	SF	0.35	----	VERO	100.00	----	11/18/86
AVS-2310	CPE	YFV	0.20	----	VERO	100.00	----	2/13/87
AVS-2311	CPE	JE	----	----	VERO >	320.00	----	5/ 5/87
AVS-2311	PR	PIC	N/A	----	VERO	320.00	----	5/24/88
AVS-2311	CPE	PT	0.98	----	VERO >	320.00	----	12/30/86
AVS-2311	CPE	SF	2.22	----	VERO	320.00	----	12/15/86
AVS-2311	CPE	SF	----	----	VERO >	100.00	----	12/29/86
AVS-2313	PR	PIC	N/A	----	VERO	1.00	----	5/27/88
AVS-2313	CPE	VV	1.80	7.50	VERO	3.20	0.43	12/11/86
AVS-2315	PR	PIC	N/A	----	VERO	100.00	----	5/27/88
AVS-2316	CPE	JE	----	----	VERO	10.00	----	5/ 5/87
AVS-2316	PR	PIC	N/A	----	VERO	320.00	----	5/27/88
AVS-2316	CPE	PT	0.45	----	VERO	100.00	----	12/30/86
AVS-2316	CPE	SF	1.48	111.00	VERO <	320.00 <	2.88	12/15/86
AVS-2316	CPE	YFV	0.75	297.00	VERO	100.00	0.34	2/19/87
AVS-2317	CPE	AD2	0.51	206.00	HEP2	100.00	0.48	12/11/86
AVS-2317	CPE	JE	0.25	----	VERO	100.00	----	5/ 5/87
AVS-2317	PR	PIC	N/A	----	VERO >	100.00	----	5/27/88
AVS-2317	CPE	PT	1.00	----	VERO	320.00	----	12/30/86
AVS-2317	CPE	SF	1.12	18.70	VERO	320.00	17.10	12/15/86
AVS-2317	CPE	SF	----	----	VERO	100.00	----	8/18/87
AVS-2317	CPE	YFV	----	----	VERO	100.00	----	2/19/87
AVS-2318	CPE	AD2	1.65	0.32	HEP2	3.20	10.00	12/18/86
AVS-2318	CPE	AD2	1.8	3.59	HEP2	10.00	2.78	9/ 4/87
AVS-2318	CPE	AD2	0.3	----	HEP2	10.00	----	9/24/87
AVS-2318	CPE	JE	3.3	0.73	VERO	10.00	13.50	5/ 5/87
AVS-2318	CPE	JE	2.5	0.50	VERO	3.20	6.32	7/28/87
AVS-2318	PR	PIC	N/A	2.95	VERO	1.00	0.34	5/27/88
AVS-2318	CPE	PT	4.40	0.73	VERO	3.20	4.36	12/30/86
AVS-2318	CPE	SF	4.56	0.32	VERO	3.20	10.00	12/15/86
AVS-2318	CPE	SF	----	----	VERO >	1.00	----	12/29/86
AVS-2318	CPE	SF	2.5	0.31	VERO	1.00	3.13	7/28/87
AVS-2318	CPE	SF	2.55	8.30	VERO	32.00	3.85	5/25/88
AVS-2318	CPE	VSV	2.10	1.98	L929	3.20	1.62	12/12/86
AVS-2318	CPE	VV	3.06	1.80	VERO	1.00	0.56	12/11/86
AVS-2318	CPE	YFV	3.15	1.59	VERO	3.20	2.00	3/ 4/88
AVS-2319	CPE	JE	1.1	----	VERO	320.00	----	5/ 5/87
AVS-2319	PR	PIC	N/A	----	VERO	32.00	----	5/27/88
AVS-2319	CPE	PT	0.30	----	VERO	100.00	----	12/31/86
AVS-2319	CPE	SF	0.36	----	VERO	32.00	----	12/15/86
AVS-2319	CPE	SF	----	----	VERO >	10.00	----	12/30/86
AVS-2319	CPE	VV	0.99	498.00	VERO >	320.00 >	0.64	12/11/86
AVS-2319	CPE	YFV	0.23	----	VERO <	0.32	----	2/19/87
AVS-2320	CPE	AD2	0.43	140.00	HEP2	32.00	0.23	12/11/86
AVS-2320	CPE	JE	0.05	----	VERO	100.00	----	5/ 5/87
AVS-2320	PR	PIC	N/A	----	VERO	10.00	----	5/27/88
AVS-2320	CPE	PT	1.80	17.70	VERO	32.00	1.81	12/31/86
AVS-2320	CPE	SF	3.49	2.06	VERO	100.00	48.50	12/15/86
AVS-2320	CPE	SF	3.4	0.75	VERO	3.20	4.26	7/28/87
AVS-2320	CPE	VV	1.80	148.00	VERO	10.00	0.07	12/11/86
AVS-2320	CPE	YFV	0.31	29.70	VERO	10.00	0.34	2/20/87
AVS-2321	CPE	JE	0.25	0.32	VERO	0.32	1.00	6/ 9/87
AVS-2321	PR	PIC	N/A	----	VERO	0.32	----	5/27/88
AVS-2321	CPE	PT	0.1	----	VERO	0.32	----	3/16/87
AVS-2321	CPE	SF	1.50	----	VERO <	0.32	----	12/15/86
AVS-2321	CPE	VV	1.41	0.31	VERO	32.00	103.00	12/18/86
AVS-2321	CPE	VV	1.1	0.76	VERO <	3.20 <	4.20	1/21/88
AVS-2321	CPE	YFV	0.5	0.03	VERO	0.01	0.34	3/27/87
AVS-2321	CPE	YFV	0.4	0.31	VERO	0.32	1.03	5/13/87
AVS-2322	CPE	JE	0.6	----	VERO	320.00	----	5/ 6/87
AVS-2322	PR	PIC	N/A	----	VERO >	320.00	----	5/27/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2322	CPE	PT	0.90	----	VERO	320.00	----	12/31/86
AVS-2322	CPE	SF	4.00	42.00	VERO >	320.00 >	7.60	12/15/86
AVS-2322	CPE	SF	----	----	VERO >	100.00	----	12/30/86
AVS-2322	CPE	SF	----	----	VERO	100.00	----	5/26/88
AVS-2322	CPE	YFV	----	----	VERO	320.00	----	2/20/87
AVS-2323	CPE	AD2	0.69	32.00	HEP2	10.00	0.31	12/11/86
AVS-2323	CPE	JE	0.7	----	VERO	10.00	----	5/ 6/87
AVS-2323	PR	PIC	N/A	----	VERO	10.00	----	5/27/88
AVS-2323	CPE	PT	0.10	----	VERO	3.20	----	12/31/86
AVS-2323	CPE	SF	0.99	92.90	VERO	3.20	0.03	12/15/86
AVS-2323	CPE	SF	----	----	VERO	1.00	----	12/29/86
AVS-2323	CPE	VV	2.79	2.35	VERO	10.00	4.25	12/11/86
AVS-2323	CPE	VV	4.5	2.73	VERO	100.00	36.60	5/12/88
AVS-2323	CPE	YFV	0.15	----	VERO <	0.32	----	2/20/87
AVS-2325	CPE	JE	0.5	----	VERO >	320.00	----	5/ 6/87
AVS-2325	PR	PIC	N/A	----	VERO >	320.00	----	6/ 3/88
AVS-2325	CPE	PT	0.15	----	VERO >	320.00	----	1/ 2/87
AVS-2325	CPE	SF	2.40	1.00	VERO	100.00	100.00	12/15/86
AVS-2325	CPE	SF	----	----	VERO >	32.00	----	12/30/86
AVS-2325	CPE	SF	----	----	VERO	320.00	----	8/18/87
AVS-2325	CPE	YFV	0.10	----	VERO	32.00	----	2/20/87
AVS-2326	CPE	JE	1.	----	VERO	320.00	----	5/ 6/87
AVS-2326	PR	PIC	N/A	----	VERO	320.00	----	6/ 3/88
AVS-2326	CPE	PT	0.13	----	VERO	320.00	----	1/ 2/87
AVS-2326	CPE	SF	0.10	----	VERO	100.00	----	12/16/86
AVS-2326	CPE	VV	1.71	103.00	VERO >	320.00 >	3.10	12/11/86
AVS-2326	CPE	VV	2.1	67.30	VERO >	320.00 >	4.75	5/26/88
AVS-2326	CPE	YFV	0.25	----	VERO	100.00	----	2/20/87
AVS-2327	CPE	JE	----	----	VERO	100.00	----	5/ 6/87
AVS-2327	PR	PIC	N/A	----	VERO	100.00	----	6/ 3/88
AVS-2327	CPE	PT	2.00	100.00	VERO	320.00	3.17	1/ 2/87
AVS-2327	CPE	SF	0.25	----	VERO	320.00	----	12/16/86
AVS-2327	CPE	VSV	0.60	298.00	L929	100.00	0.34	12/12/86
AVS-2327	CPE	VV	0.24	779.00	VERO	320.00	0.41	12/11/86
AVS-2327	CPE	YFV	0.95	----	VERO	100.00	----	2/20/87
AVS-2328	CPE	JE	0.2	----	VERO	320.00	----	5/ 6/87
AVS-2328	PR	PIC	N/A	----	VERO	100.00	----	6/ 3/88
AVS-2328	CPE	PT	0.90	----	VERO	320.00	----	1/ 2/87
AVS-2328	CPE	SF	----	----	VERO	100.00	----	12/16/86
AVS-2328	CPE	VV	----	----	VERO	320.00	----	12/11/86
AVS-2328	CPE	YFV	----	----	VERO	100.00	----	2/20/87
AVS-2329	CPE	JE	----	----	VERO	1.00	----	5/ 6/87
AVS-2329	PR	PIC	N/A	----	VERO	0.32	----	6/ 3/88
AVS-2329	CPE	PT	----	----	VERO	1.00	----	1/ 2/87
AVS-2329	CPE	SF	----	----	VERO	100.00	----	12/16/86
AVS-2329	CPE	VV	----	----	L929	0.10	----	1/16/87
AVS-2329	CPE	YFV	0.75	3.20	VERO	1.00	0.31	12/11/86
AVS-2329	CPE	YFV	----	----	VERO <	0.32	----	2/20/87
AVS-2331	CPE	JE	----	----	VERO	10.00	----	5/ 6/87
AVS-2331	PR	PIC	N/A	----	VERO	10.00	----	6/ 3/88
AVS-2331	CPE	PT	0.50	----	VERO	1.00	----	1/ 5/87
AVS-2331	CPE	SF	0.40	30.30	VERO	10.00	0.33	12/16/86
AVS-2331	CPE	VV	0.45	140.00	VERO	32.00	0.23	12/11/86
AVS-2331	CPE	YFV	----	----	VERO	32.00	----	2/20/87
AVS-2335	CPE	JE	----	----	VERO	320.00	----	5/ 6/87
AVS-2335	PR	PIC	N/A	271.00	VERO	32.00	0.12	6/ 3/88
AVS-2335	CPE	PT	1.60	179.00	VERO	32.00	0.18	1/ 5/87
AVS-2335	CPE	SF	0.75	156.00	VERO	100.00	0.64	12/16/86
AVS-2335	CPE	YFV	0.15	----	VERO	32.00	----	2/20/87
AVS-2336	CPE	JE	0.2	----	VERO	100.00	----	5/ 6/87
AVS-2336	PR	PIC	N/A	----	VERO	320.00	----	6/ 3/88
AVS-2336	CPE	PT	0.11	----	VERO	1.00	----	1/ 5/87
AVS-2336	CPE	SF	----	----	VERO	100.00	----	12/16/86
AVS-2336	CPE	VV	1.50	88.40	VERO	320.00	3.62	12/11/86
AVS-2336	CPE	VV	0.6	306.00	VERO	320.00	1.04	5/12/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2336	CPE	YFV	0.15	----	VERO	32.00	----	3/13/87
AVS-2340	CPE	JE	----	----	VERO	100.00	----	5/ 7/87
AVS-2340	PR	PIC	N/A	----	VERO	100.00	----	6/ 6/88
AVS-2340	CPE	PT	0.51	----	VERO	1.00	----	1/ 5/87
AVS-2340	CPE	SF	----	----	VERO	100.00	----	12/16/86
AVS-2340	CPE	YFV	----	----	VERO	100.00	----	3/13/87
AVS-2344	CPE	JE	----	----	VERO <	0.03	----	6/ 9/87
AVS-2344	PR	PIC	N/A	----	VERO	1.00	----	6/ 6/88
AVS-2344	CPE	SF	----	----	VERO	3.20	----	12/16/86
AVS-2344	CPE	VSV	2.40 <	0.32	L929 <	0.32 <	1.00	12/12/86
AVS-2344	CPE	VSV	1.40	1.31	L929	0.10	0.32	1/20/87
AVS-2344	CPE	YFV	0.35	1.03	VERO	0.01	0.32	5/13/87
AVS-2350	CPE	AD2	1.8	6.30	HEP2	320.00	3.16	11/ 5/87
AVS-2350	CPE	AD2	0.55	----	HEP2	320.00	----	2/ 4/88
AVS-2350	CPE	AD2	0.15	----	HEP2	200.00	----	2/25/88
AVS-2350	CPE	AD2	0.6	63.10	HEP2	200.00	3.16	5/26/88
AVS-2350	CPE	JE	6.6	0.35	VERO >	20000.00	>56100.00	10/ 6/87
AVS-2350	CPE	JE	2.6	128.00	VERO	20000.00	156.00	5/24/88
AVS-2350	PR	PIC	N/A	158.00	VERO >	20000.00	> 126.00	12/ 4/87
AVS-2350	PR	PIC	N/A	----	VERO >	20000.00	----	5/24/88
AVS-2350	CPE	PT	1.9	581.00	VERO	20000.00	34.30	10/ 6/87
AVS-2350	CPE	SF	2.7	139.00	VERO >	20000.00	> 143.00	10/ 6/87
AVS-2350	CPE	VEE	2.95	2.80	VERO	300.00	71.20	11/12/87
AVS-2350	CPE	VEE	1.65	59.20	VERO	200.00	3.37	5/24/88
AVS-2350	CPE	VSV	1.1	----	VERO >	20000.00	----	11/ 5/87
AVS-2350	CPE	VSV	1.95	631.00	VERO	200000.00	316.00	11/12/87
AVS-2350	CPE	VSV	----	----	VERO	200000.00	----	2/ 4/88
AVS-2350	CPE	VSV	2.	6315.00	VERO >	200000.00	> 31.60	5/13/88
AVS-2350	CPE	VV	0.3	----	VERO >	20000.00	----	11/ 5/87
AVS-2350	CPE	YFV	3.5	84.30	VERO >	20000.00	> 237.00	10/ 6/87
AVS-2352	CPE	JE	0.1	----	VERO >	320.00	----	5/ 7/87
AVS-2352	PR	PIC	N/A	----	VERO	3.20	----	6/ 6/88
AVS-2352	CPE	PT	1.06	----	VERO >	320.00	----	1/ 6/87
AVS-2352	CPE	SF	----	----	VERO	320.00	----	12/16/86
AVS-2352	CPE	YFV	0.45	236.00	VERO	320.00	1.35	3/13/87
AVS-2355	CPE	JE	0.65	199.00	VERO	320.00	1.60	4/29/88
AVS-2355	PR	PIC	N/A	----	VERO	320.00	----	6/ 6/88
AVS-2355	CPE	PT	1.10	----	VERO >	320.00	----	1/29/87
AVS-2355	CPE	YFV	0.5	281.00	VERO	100.00	0.35	3/31/87
AVS-2356	CPE	JE	----	----	VERO	32.00	----	4/29/88
AVS-2356	PR	PIC	N/A	18.20	VERO	10.00	0.55	6/ 6/88
AVS-2356	CPE	PT	1.85	42.60	VERO	32.00	0.75	1/29/87
AVS-2356	CPE	PT	0.50	----	VERO >	320.00	----	2/10/87
AVS-2356	CPE	PT	0.4	94.70	VERO	32.00	0.34	3/16/87
AVS-2356	CPE	SF	----	----	VERO	100.00	----	1/15/87
AVS-2356	CPE	VSV	0.39	97.00	L929	32.00	0.33	12/30/86
AVS-2356	CPE	YFV	0.6	93.10	VERO	100.00	1.07	3/31/87
AVS-2357	CPE	JE	0.3	32.00	VERO	10.00	0.31	4/29/88
AVS-2357	PR	PIC	N/A	----	VERO	10.00	----	6/ 6/88
AVS-2357	CPE	PT	1.50	320.00	VERO	100.00	0.31	1/29/87
AVS-2357	CPE	PT	0.47	224.00	VERO	320.00	1.42	3/16/87
AVS-2357	CPE	SF	----	----	VERO	100.00	----	1/ 6/87
AVS-2357	CPE	YFV	0.25	----	VERO	100.00	----	3/31/87
AVS-2358	CPE	JE	0.25	----	VERO	32.00	----	4/29/88
AVS-2358	PR	PIC	N/A	36.60	VERO	32.00	0.87	6/ 6/88
AVS-2358	CPE	PT	1.97	247.00	VERO	32.00	0.13	1/30/87
AVS-2358	CPE	PT	----	----	VERO	100.00	----	5/18/88
AVS-2358	CPE	SF	0.10	----	VERO	32.00	----	1/ 6/87
AVS-2358	CPE	VV	0.90	21.00	VERO	32.00	1.52	12/18/86
AVS-2358	CPE	YFV	0.6	93.10	VERO	32.00	0.34	3/31/87
AVS-2359	CPE	JE	0.05	----	VERO	10.00	----	4/29/88
AVS-2359	PR	PIC	N/A	12.20	VERO	10.00	0.82	6/ 6/88
AVS-2359	CPE	PT	1.82	----	VERO	32.00	----	1/30/87
AVS-2359	CPE	PT	0.15	----	VERO	10.00	----	3/16/87
AVS-2359	CPE	SF	----	----	VERO <	0.10	----	1/ 6/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2359	CPE	YFV	0.25	----	VERO	10.00	----	3/31/87
AVS-2360	CPE	JE	----	----	VERO	100.00	----	4/29/88
AVS-2360	PR	PIC	N/A	----	VERO >	320.00	----	6/ 7/88
AVS-2360	CPE	PT	0.65	----	VERO	100.00	----	1/30/87
AVS-2360	CPE	YFV	----	----	VERO >	100.00	----	1/ 6/87
AVS-2360	CPE	YFV	0.3	----	VERO	32.00	----	3/31/87
AVS-2361	CPE	AD2	0.30	----	HEP2 >	320.00	----	1/ 8/87
AVS-2361	PR	PIC	N/A	----	VERO >	320.00	----	6/10/88
AVS-2361	CPE	PT	0.10	----	VERO >	320.00	----	2/12/87
AVS-2361	CPE	SF	----	----	VERO >	100.00	----	1/19/87
AVS-2361	CPE	VSV	----	----	L929	320.00	----	1/ 6/87
AVS-2361	CPE	VV	0.25	----	VERO	320.00	----	1/ 8/87
AVS-2361	CPE	YFV	----	----	VERO >	320.00	----	5/ 4/87
AVS-2362	CPE	AD2	----	----	HEP2 >	320.00	----	1/ 8/87
AVS-2362	PR	PIC	N/A	----	VERO	320.00	----	6/13/88
AVS-2362	CPE	PT	----	----	VERO >	320.00	----	2/12/87
AVS-2362	CPE	SF	----	----	VERO >	100.00	----	1/19/87
AVS-2362	CPE	VSV	----	----	L929	320.00	----	1/ 6/87
AVS-2362	CPE	VV	----	----	VERO >	320.00	----	1/ 8/87
AVS-2362	CPE	YFV	----	----	VERO >	100.00	----	5/ 4/87
AVS-2363	CPE	JE	0.15	----	VERO	3.20	----	4/29/88
AVS-2363	PR	PIC	N/A	15.80	VERO	32.00	2.01	6/ 7/88
AVS-2363	CPE	PT	1.80	4.22	VERO	32.00	7.58	1/30/87
AVS-2363	CPE	PT	0.5	2.25	VERO <	0.03 <	0.01	5/18/88
AVS-2363	CPE	SF	1.10	7.70	VERO	10.00	1.29	1/ 6/87
AVS-2363	CPE	YFV	0.35	31.40	VERO	10.00	0.32	3/31/87
AVS-2364	CPE	JE	0.05	----	VERO	32.00	----	4/29/88
AVS-2364	PR	PIC	N/A	----	VERO	100.00	----	6/ 7/88
AVS-2364	CPE	PT	1.1	----	VERO <	100.00	----	1/30/87
AVS-2364	CPE	PT	0.1	----	VERO	32.00	----	3/16/87
AVS-2364	CPE	SF	----	----	VERO	3.20	----	1/12/87
AVS-2364	CPE	VV	0.45	306.00	VERO	320.00	1.03	12/18/86
AVS-2364	CPE	YFV	----	----	VERO	32.00	----	3/31/87
AVS-2365	PR	PIC	N/A	----	VERO >	320.00	----	6/ 7/88
AVS-2365	CPE	PT	0.80	----	VERO >	320.00	----	2/ 2/87
AVS-2365	CPE	SF	----	----	VERO >	100.00	----	1/12/87
AVS-2365	CPE	YFV	----	----	VERO >	320.00	----	3/31/87
AVS-2366	PR	PIC	N/A	----	VERO	320.00	----	6/ 7/88
AVS-2366	CPE	PT	0.60	----	VERO	320.00	----	2/ 2/87
AVS-2366	CPE	SF	----	----	VERO	100.00	----	1/12/87
AVS-2366	CPE	VV	0.69	159.00	VERO	320.00	2.01	12/18/86
AVS-2366	CPE	YFV	0.2	----	VERO >	320.00	----	4/ 1/87
AVS-2367	PR	PIC	N/A	----	VERO	3.20	----	6/ 7/88
AVS-2367	CPE	PT	2.00	----	VERO <	3.20	----	2/ 2/87
AVS-2367	CPE	SF	----	----	VERO <	3.20	----	1/12/87
AVS-2367	CPE	YFV	----	----	VERO	10.00	----	4/ 1/87
AVS-2368	PR	PIC	N/A	----	VERO >	10.00	----	6/ 7/88
AVS-2368	CPE	PT	0.30	----	VERO	3.20	----	2/ 2/87
AVS-2368	CPE	SF	----	----	VERO	3.20	----	1/12/87
AVS-2368	CPE	VV	1.05	47.30	VERO	1.00	0.02	12/18/86
AVS-2368	CPE	YFV	0.7	7.90	VERO	3.20	0.40	4/ 1/87
AVS-2369	PR	PIC	N/A	----	VERO	320.00	----	6/ 7/88
AVS-2369	CPE	PT	2.00	----	VERO	100.00	----	2/ 2/87
AVS-2369	CPE	SF	----	----	VERO	32.00	----	1/13/87
AVS-2369	CPE	YFV	----	----	VERO	100.00	----	4/ 1/87
AVS-2370	PR	PIC	N/A	----	VERO >	32.00	----	6/ 7/88
AVS-2370	CPE	PT	0.70	----	VERO	100.00	----	2/ 3/87
AVS-2370	CPE	SF	0.15	----	VERO	32.00	----	1/13/87
AVS-2370	CPE	YFV	----	----	VERO	32.00	----	4/ 1/87
AVS-2371	CPE	PT	0.40	----	VERO	32.00	----	2/ 3/87
AVS-2371	CPE	SF	0.15	----	VERO	10.00	----	1/13/87
AVS-2371	CPE	YFV	----	----	VERO	10.00	----	4/ 1/87
AVS-2372	PR	PIC	N/A	----	VERO	10.00	----	6/10/88
AVS-2372	CPE	PT	0.40	----	VERO	100.00	----	2/ 3/87
AVS-2372	CPE	SF	----	----	VERO	32.00	----	1/13/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2372	CPE	YFV	0.35	314.00	VERO	100.00	0.32	4/ 1/87
AVS-2373	PR	PIC	N/A	----	VERO	32.00	----	6/10/88
AVS-2373	CPE	PT	0.80	----	VERO	100.00	----	2/ 3/87
AVS-2373	CPE	SF	----	----	VERO <	0.10	----	1/13/87
AVS-2373	CPE	VV	0.15	241.00	VERO	100.00	0.41	12/18/86
AVS-2373	CPE	YFV	----	----	VERO	32.00	----	4/ 1/87
AVS-2374	PR	PIC	N/A	----	VERO	32.00	----	6/10/88
AVS-2374	CPE	PT	0.50	288.00	VERO	100.00	0.35	2/ 3/87
AVS-2374	CPE	SF	----	----	VERO	32.00	----	1/14/87
AVS-2374	CPE	VSV	0.30	320.00	L929	100.00	0.31	12/30/86
AVS-2374	CPE	YFV	0.1	----	VERO <	320.00	----	4/ 1/87
AVS-2375	PR	PIC	N/A	----	VERO	10.00	----	6/10/88
AVS-2375	CPE	PT	0.47	120.00	VERO	10.00	0.08	2/ 4/87
AVS-2375	CPE	SF	0.05	----	VERO <	0.10	----	1/14/87
AVS-2375	CPE	YFV	----	----	VERO	3.20	----	4/ 1/87
AVS-2376	PR	PIC	N/A	7.30	VERO	3.20	0.43	6/10/88
AVS-2376	CPE	PT	0.47	275.00	VERO	10.00	0.04	2/ 4/87
AVS-2376	CPE	SF	----	----	VERO <	0.10	----	1/14/87
AVS-2376	CPE	YFV	----	----	VERO	3.20	----	4/ 1/87
AVS-2377	PR	PIC	N/A	33.20	VERO	32.00	0.96	6/10/88
AVS-2377	CPE	PT	----	----	VERO	10.00	----	2/ 4/87
AVS-2377	CPE	SF	0.15	----	VERO <	0.10	----	1/14/87
AVS-2377	CPE	YFV	1.05	30.60	VERO	3.20	0.10	4/ 2/87
AVS-2378	PR	PIC	N/A	----	VERO	32.00	----	6/10/88
AVS-2378	CPE	PT	0.10	----	VERO	320.00	----	2/ 4/87
AVS-2378	CPE	SF	----	----	VERO <	0.10	----	1/14/87
AVS-2378	CPE	YFV	0.35	314.00	VERO	100.00	0.32	4/ 2/87
AVS-2379	PR	PIC	N/A	----	VERO	320.00	----	6/10/88
AVS-2379	CPE	PT	0.10	----	VERO >	320.00	----	2/ 4/87
AVS-2379	CPE	SF	----	----	VERO >	100.00	----	1/16/87
AVS-2379	CPE	YFV	0.5	326.00	VERO	100.00	0.31	4/ 2/87
AVS-2380	PR	PIC	N/A	----	VERO	10.00	----	6/10/88
AVS-2380	CPE	PT	0.80	----	VERO	100.00	----	2/ 5/87
AVS-2380	CPE	SF	0.15	----	VERO	10.00	----	1/16/87
AVS-2380	CPE	YFV	----	----	VERO	10.00	----	4/ 2/87
AVS-2381	CPE	AD2	0.25	----	HEP2	100.00	----	1/ 8/87
AVS-2381	PR	PIC	N/A	----	VERO	32.00	----	6/13/88
AVS-2381	CPE	PT	1.00	----	VERO	32.00	----	2/ 5/87
AVS-2381	CPE	SF	0.20	----	VERO	10.00	----	1/12/87
AVS-2381	CPE	VSV	----	----	L929	100.00	----	1/ 6/87
AVS-2381	CPE	VV	0.25	----	VERO	32.00	----	1/ 8/87
AVS-2381	CPE	YFV	0.5	94.80	VERO	10.00	0.10	4/ 2/87
AVS-2382	CPE	AD2	----	----	HEP2	32.00	----	1/ 8/87
AVS-2382	PR	PIC	N/A	----	VERO	1.00	----	6/13/88
AVS-2382	CPE	PT	----	----	VERO <	10.00	----	2/ 5/87
AVS-2382	CPE	SF	0.10	----	VERO	3.20	----	1/12/87
AVS-2382	CPE	VSV	----	----	L929	3.20	----	1/ 6/87
AVS-2382	CPE	VV	0.10	----	VERO	3.20	----	1/ 8/87
AVS-2382	CPE	YFV	0.6	2.97	VERO	0.32	0.11	4/ 2/87
AVS-2383	CPE	AD2	----	----	HEP2	3.20	----	1/ 8/87
AVS-2383	PR	PIC	N/A	----	VERO	32.00	----	6/13/88
AVS-2383	CPE	PT	0.40	0	VERO <	100.00	----	2/ 5/87
AVS-2383	CPE	SF	----	----	VERO <	100.00	----	1/12/87
AVS-2383	CPE	VSV	----	----	L929	10.00	----	1/ 6/87
AVS-2383	CPE	VV	----	----	VERO	100.00	----	1/ 8/87
AVS-2383	CPE	YFV	----	----	VERO	10.00	----	4/ 2/87
AVS-2384	CPE	AD2	----	----	HEP2	320.00	----	1/ 8/87
AVS-2384	PR	PIC	N/A	----	VERO	100.00	----	6/13/88
AVS-2384	CPE	PT	1.10	104.00	VERO <	320.00 <	3.06	2/ 5/87
AVS-2384	CPE	PT	0.8	42.40	VERO	32.00	0.75	5/18/88
AVS-2384	CPE	SF	0.4	94.00	VERO	32.00	0.33	3/18/87
AVS-2384	CPE	VSV	----	----	L929	100.00	----	1/ 6/87
AVS-2384	CPE	VV	0.65	320.00	VERO	100.00	0.31	1/ 8/87
AVS-2384	CPE	YFV	0.2	----	VERO	32.00	----	4/ 2/87
AVS-2385	CPE	AD2	----	----	HEP2 >	320.00	----	1/29/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2385	PR	PIC	N/A	----	VERO	100.00	----	6/13/88
AVS-2385	CPE	PT	0.4	----	VERO >	320.00	----	3/17/87
AVS-2385	CPE	SF	----	----	VERO >	100.00	----	1/12/87
AVS-2385	CPE	VSV	----	----	L929	100.00	----	1/ 6/87
AVS-2385	CPE	VV	----	----	VERO >	320.00	----	1/29/87
AVS-2385	CPE	YFV	----	----	VERO >	320.00	----	4/ 2/87
AVS-2386	CPE	AD2	----	----	HEP2	32.00	----	1/ 8/87
AVS-2386	PR	PIC	N/A	----	VERO	100.00	----	6/13/88
AVS-2386	CPE	PT	1.	68.70	VERO	32.00	0.47	3/17/87
AVS-2386	CPE	SF	0.40	96.00	VERO	100.00	1.03	1/13/87
AVS-2386	CPE	VSV	----	----	L929	32.00	----	1/ 6/87
AVS-2386	CPE	VV	----	----	VERO	32.00	----	1/ 8/87
AVS-2386	CPE	YFV	0.75	59.50	VERO	10.00	0.17	4/ 2/87
AVS-2387	CPE	AD2	----	----	HEP2	100.00	----	1/ 8/87
AVS-2387	PR	PIC	N/A	----	VERO >	100.00	----	6/13/88
AVS-2387	CPE	PT	0.23	----	VERO	32.00	----	3/17/87
AVS-2387	CPE	SF	0.30	----	VERO <	100.00	----	1/13/87
AVS-2387	CPE	VSV	----	----	L929	10.00	----	1/ 6/87
AVS-2387	CPE	VV	0.75	----	VERO	100.00	----	1/29/87
AVS-2387	CPE	YFV	0.35	----	VERO	10.00	----	4/ 2/87
AVS-2388	CPE	AD2	----	----	HEP2	320.00	----	1/ 8/87
AVS-2388	PR	PIC	N/A	272.00	VERO	100.00	0.37	6/13/88
AVS-2388	CPE	PT	0.88	269.00	VERO	320.00	1.18	3/17/87
AVS-2388	CPE	SF	----	----	VERO	100.00	----	1/13/87
AVS-2388	CPE	VSV	----	----	L929 >	320.00	----	1/ 6/87
AVS-2388	CPE	VV	0.10	----	VERO	100.00	----	1/ 8/87
AVS-2388	CPE	YFV	----	----	VERO >	320.00	----	4/29/87
AVS-2389	CPE	AD2	0.30	----	HEP2 >	320.00	----	1/ 8/87
AVS-2389	CPE	PT	0.7	----	VERO <	320.00	----	3/17/87
AVS-2389	CPE	SF	----	----	VERO	100.00	----	1/13/87
AVS-2389	CPE	VSV	0.05	----	L929	320.00	----	1/ 6/87
AVS-2389	CPE	VV	0.05	----	VERO	320.00	----	1/ 8/87
AVS-2389	CPE	YFV	----	----	VERO	100.00	----	4/29/87
AVS-2390	CPE	AD2	0.15	----	HEP2	10.00	----	1/ 8/87
AVS-2390	PR	PIC	N/A	----	VERO	10.00	----	6/14/88
AVS-2390	CPE	PT	1.20	----	VERO	100.00	----	2/ 9/87
AVS-2390	CPE	SF	0.43	90.60	VERO	10.00	0.11	1/13/87
AVS-2390	CPE	VSV	0.21	----	L929 <	0.32	----	1/ 6/87
AVS-2390	CPE	VSV	----	----	L929	0.10	----	1/16/87
AVS-2390	CPE	VV	----	----	VERO	10.00	----	1/ 8/87
AVS-2390	CPE	YFV	0.15	----	VERO	10.00	----	4/29/87
AVS-2391	CPE	AD2	----	----	HEP2	32.00	----	1/ 8/87
AVS-2391	PR	PIC	N/A	----	VERO	100.00	----	6/14/88
AVS-2391	CPE	PT	0.50	----	VERO	320.00	----	2/ 9/87
AVS-2391	CPE	SF	0.25	----	VERO	10.00	----	1/13/87
AVS-2391	CPE	VSV	----	----	L929	32.00	----	1/ 6/87
AVS-2391	CPE	VV	0.20	----	VERO	32.00	----	1/ 8/87
AVS-2391	CPE	YFV	----	----	VERO	32.00	----	4/29/87
AVS-2392	CPE	AD2	----	----	HEP2 >	320.00	----	1/ 8/87
AVS-2392	PR	PIC	N/A	----	VERO	320.00	----	6/14/88
AVS-2392	CPE	PT	0.58	----	VERO	320.00	----	2/ 9/87
AVS-2392	CPE	SF	----	----	VERO >	100.00	----	1/13/87
AVS-2392	CPE	VSV	----	----	L929	100.00	----	1/ 6/87
AVS-2392	CPE	VV	----	----	VERO	320.00	----	1/ 8/87
AVS-2392	CPE	YFV	----	----	VERO	100.00	----	4/29/87
AVS-2393	CPE	AD2	----	----	HEP2 >	320.00	----	1/ 8/87
AVS-2393	PR	PIC	N/A	----	VERO	320.00	----	6/14/88
AVS-2393	CPE	PT	1.	----	VERO	320.00	----	2/ 9/87
AVS-2393	CPE	PT	0.5	205.00	VERO	100.00	0.49	3/16/87
AVS-2393	CPE	SF	----	----	VERO >	100.00	----	1/13/87
AVS-2393	CPE	VSV	----	----	L929 >	320.00	----	1/ 6/87
AVS-2393	CPE	VV	0.10	----	VERO	320.00	----	1/ 8/87
AVS-2393	CPE	YFV	----	----	VERO	320.00	----	4/29/87
AVS-2394	CPE	AD2	----	----	HEP2	100.00	----	1/ 8/87
AVS-2394	PR	PIC	N/A	----	VERO	10.00	----	6/14/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2394	CPE	PT	0.65	----	VERO <	10.00	----	2/ 9/87
AVS-2394	CPE	PT	----	----	VERO	1.00	----	3/16/87
AVS-2394	CPE	SF	----	----	VERO <	3.20	----	1/14/87
AVS-2394	CPE	VSV	----	----	L929	320.00	----	1/ 6/87
AVS-2394	CPE	VV	0.85	----	VERO	3.20	----	1/ 8/87
AVS-2394	CPE	YFV	----	----	VERO	10.00	----	4/29/87
AVS-2395	CPE	AD2	----	----	HEP2	32.00	----	1/ 8/87
AVS-2395	PR	PIC	N/A	----	VERO	10.00	----	6/14/88
AVS-2395	CPE	PT	----	----	VERO	10.00	----	3/16/87
AVS-2395	CPE	SF	0.30	----	VERO <	10.00	----	1/14/87
AVS-2395	CPE	VSV	0.05	----	L929	32.00	----	1/ 6/87
AVS-2395	CPE	VV	0.10	----	VERO	32.00	----	1/ 8/87
AVS-2395	CPE	YFV	----	----	VERO	10.00	----	4/29/87
AVS-2396	CPE	AD2	0.20	----	HEP2 >	320.00	----	1/ 8/87
AVS-2396	PR	PIC	N/A	----	VERO >	320.00	----	6/14/88
AVS-2396	CPE	SF	----	----	VERO >	100.00	----	1/14/87
AVS-2396	CPE	VSV	----	----	L929 >	320.00	----	1/ 6/87
AVS-2396	CPE	VV	----	----	VERO >	320.00	----	1/ 8/87
AVS-2396	CPE	YFV	----	----	VERO	320.00	----	4/29/87
AVS-2397	CPE	AD2	----	----	HEP2	100.00	----	1/ 8/87
AVS-2397	PR	PIC	N/A	----	VERO	320.00	----	6/14/88
AVS-2397	CPE	PT	0.70	----	VERO >	100.00	----	2/10/87
AVS-2397	CPE	SF	----	----	VERO >	100.00	----	1/14/87
AVS-2397	CPE	VSV	----	----	L929	32.00	----	1/ 6/87
AVS-2397	CPE	VV	----	----	VERO	320.00	----	1/ 8/87
AVS-2397	CPE	YFV	0.4	31.00	VERO	10.00	0.32	4/29/87
AVS-2398	CPE	AD2	----	----	HEP2	100.00	----	1/ 8/87
AVS-2398	PR	PIC	N/A	----	VERO	100.00	----	6/14/88
AVS-2398	CPE	PT	0.70	310.00	VERO	100.00	0.32	2/10/87
AVS-2398	CPE	SF	0.15	----	VERO	100.00	----	1/14/87
AVS-2398	CPE	VSV	----	----	L929	320.00	----	1/ 6/87
AVS-2398	CPE	VV	0.10	----	VERO	320.00	----	1/ 8/87
AVS-2398	CPE	YFV	----	----	VERO >	320.00	----	4/29/87
AVS-2399	CPE	AD2	----	----	HEP2 >	320.00	----	1/ 8/87
AVS-2399	PR	PIC	N/A	----	VERO	320.00	----	6/14/88
AVS-2399	CPE	PT	----	----	VERO	320.00	----	2/10/87
AVS-2399	CPE	SF	----	----	VERO >	100.00	----	1/14/87
AVS-2399	CPE	VSV	----	----	L929 >	320.00	----	1/ 6/87
AVS-2399	CPE	VV	0.50	----	VERO >	320.00	----	1/ 8/87
AVS-2399	CPE	YFV	----	----	VERO >	320.00	----	5/ 1/87
AVS-2400	CPE	AD2	----	----	HEP2 >	320.00	----	1/29/87
AVS-2400	CPE	PT	0.30	4.00	VERO >	320.00 >	----	2/11/87
AVS-2400	CPE	SF	----	----	VERO	100.00	----	1/14/87
AVS-2400	CPE	VSV	----	----	L929	320.00	----	1/ 6/87
AVS-2400	CPE	VV	----	----	VERO >	320.00	----	1/29/87
AVS-2400	CPE	YFV	----	----	VERO >	320.00	----	5/ 1/87
AVS-2401	CPE	AD2	----	----	HEP2	1.00	----	1/ 8/87
AVS-2401	CPE	PT	0.45	----	VERO	10.00	----	2/11/87
AVS-2401	CPE	SF	----	----	VERO	1.00	----	1/14/87
AVS-2401	CPE	VSV	----	----	L929	3.20	----	1/ 6/87
AVS-2401	CPE	VV	----	----	VERO	1.00	----	1/ 8/87
AVS-2401	CPE	YFV	1.2	----	VERO	10.00	----	5/ 1/87
AVS-2402	CPE	AD2	----	----	HEP2 <	32.00	----	2/ 5/87
AVS-2402	CPE	PT	0.70	9.10	VERO <	32.00 <	3.50	2/11/87
AVS-2402	CPE	PT	----	----	VERO	10.00	----	5/18/88
AVS-2402	CPE	SF	0.15	----	VERO	10.00	----	1/16/87
AVS-2402	CPE	VSV	----	----	L929	10.00	----	1/ 6/87
AVS-2402	CPE	VV	----	----	VERO	10.00	----	2/ 5/87
AVS-2402	CPE	YFV	0.3	3.20	VERO	1.00	0.31	5/ 1/87
AVS-2403	CPE	AD2	----	----	HEP2 <	100.00	----	1/ 8/87
AVS-2403	CPE	PT	0.70	----	VERO <	100.00	----	2/11/87
AVS-2403	CPE	SF	----	----	VERO	10.00	----	1/16/87
AVS-2403	CPE	VSV	----	----	L929	100.00	----	1/ 6/87
AVS-2403	CPE	VV	1.10	69.40	VERO	100.00	1.44	1/ 8/87
AVS-2403	CPE	YFV	----	----	VERO	100.00	----	5/ 1/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2404	CPE	AD2	----	----	HEP2	10.00	----	1/ 8/87
AVS-2404	CPE	PT	----	----	VERO	32.00	----	4/28/87
AVS-2404	CPE	SF	----	----	VERO <	10.00	----	1/16/87
AVS-2404	CPE	VSV	----	----	L929	32.00	----	1/ 6/87
AVS-2404	CPE	VV	----	----	VERO	10.00	----	1/ 8/87
AVS-2404	CPE	YFV	----	----	VERO	32.00	----	5/ 1/87
AVS-2405	CPE	AD2	0.15	----	HEP2	10.00	----	1/29/87
AVS-2405	CPE	PT	0.55	----	VERO	10.00	----	2/12/87
AVS-2405	CPE	SF	0.55	6.90	VERO	10.00	1.42	1/19/87
AVS-2405	CPE	VSV	----	----	L929	3.20	----	1/ 6/87
AVS-2405	CPE	VV	0.65	6.20	VERO	10.00	1.59	1/29/87
AVS-2405	CPE	YFV	----	----	VERO	3.20	----	5/ 1/87
AVS-2406	CPE	AD2	----	----	HEP2	32.00	----	1/ 8/87
AVS-2406	CPE	PT	0.50	----	VERO >	320.00	----	2/12/87
AVS-2406	CPE	SF	----	----	VERO	100.00	----	1/19/87
AVS-2406	CPE	VSV	----	----	L929	1.00	----	1/ 6/87
AVS-2406	CPE	VV	0.30	----	VERO	100.00	----	1/ 8/87
AVS-2406	CPE	YFV	----	----	VERO	100.00	----	5/ 1/87
AVS-2407	CPE	AD2	0.30	3.20	HEP2	3.20	1.00	1/29/87
AVS-2407	CPE	PT	0.15	140.00	VERO	10.00	0.07	2/12/87
AVS-2407	CPE	SF	0.30	3.20	VERO	3.20	1.00	1/19/87
AVS-2407	CPE	VSV	----	----	L929	3.20	----	1/ 6/87
AVS-2407	CPE	VV	0.40	9.90	VERO	10.00	1.00	1/29/87
AVS-2407	CPE	YFV	----	----	VERO <	32.00	----	5/ 1/87
AVS-2408	CPE	AD2	0.25	----	HEP2	320.00	----	1/29/87
AVS-2408	CPE	PT	1.30	----	VERO	320.00	----	2/12/87
AVS-2408	CPE	SF	0.30	100.00	VERO	100.00	1.00	1/19/87
AVS-2408	CPE	VSV	0.20	----	L929	100.00	----	1/ 6/87
AVS-2408	CPE	VV	0.55	300.00	VERO	320.00	1.07	1/29/87
AVS-2408	CPE	YFV	----	----	VERO	320.00	----	5/ 1/87
AVS-2409	CPE	AD2	0.30	----	HEP2	3.20	----	2/12/87
AVS-2409	CPE	AD2	1.45	2.78	HEP2	10.00	3.59	4/10/87
AVS-2409	CPE	AD2	1.1	1.98	HEP2 <	10.00 <	5.04	1/ 8/88
AVS-2409	CPE	AD2	0.3	----	HEP2 <	10.00	----	5/12/88
AVS-2409	CPE	AD2	0.65	6.20	HEP2	10.00	1.59	10/27/88
AVS-2409	CPE	PT	0.65	8.70	VERO	10.00	1.14	2/12/87
AVS-2409	CPE	SF	0.60	9.20	VERO	10.00	1.08	1/19/87
AVS-2409	CPE	VSV	----	----	L929	10.00	----	1/ 6/87
AVS-2409	CPE	VV	0.60	20.00	VERO	32.00	1.60	1/29/87
AVS-2409	CPE	YFV	----	----	VERO	3.20	----	5/ 1/87
AVS-2410	CPE	AD2	----	----	HEP2	10.00	----	1/29/87
AVS-2410	PR	PIC	N/A	----	VERO	3.20	----	6/20/88
AVS-2410	CPE	PT	0.10	----	VERO <	100.00	----	2/12/87
AVS-2410	CPE	SF	----	----	VERO	10.00	----	1/19/87
AVS-2410	CPE	VSV	----	----	L929 <	32.00	----	1/ 6/87
AVS-2410	CPE	VV	0.10	----	VERO <	32.00	----	1/29/87
AVS-2410	CPE	YFV	0.1	----	VERO	10.00	----	5/ 4/87
AVS-2411	CPE	AD2	0.05	----	HEP2	10.00	----	1/29/87
AVS-2411	CPE	JE	----	----	VERO <	32.00	----	5/ 7/87
AVS-2411	PR	PIC	N/A	----	VERO	3.20	----	6/20/88
AVS-2411	CPE	PT	0.77	----	VERO	32.00	----	2/17/87
AVS-2411	CPE	SF	----	----	VERO	32.00	----	2/25/87
AVS-2411	CPE	VSV	0.60	239.00	L929	100.00	0.42	1/20/87
AVS-2411	CPE	VV	----	----	VERO <	32.00	----	1/29/87
AVS-2411	CPE	YFV	----	----	VERO	32.00	----	5/ 4/87
AVS-2412	CPE	AD2	----	----	HEP2	32.00	----	1/29/87
AVS-2412	CPE	JE	----	----	VERO	100.00	----	5/ 7/87
AVS-2412	PR	PIC	N/A	----	VERO	32.00	----	6/20/88
AVS-2412	CPE	PT	0.80	147.00	VERO	100.00	0.68	2/17/87
AVS-2412	CPE	SF	0.90	29.40	VERO	32.00	1.09	2/25/87
AVS-2412	CPE	VSV	----	----	L929 <	320.00	----	1/20/87
AVS-2412	CPE	VV	----	----	VERO	100.00	----	1/29/87
AVS-2412	CPE	YFV	----	----	VERO	10.00	----	5/ 4/87
AVS-2413	CPE	AD2	----	----	HEP2	100.00	----	1/29/87
AVS-2413	CPE	JE	----	----	VERO	32.00	----	5/ 7/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2413	PR	PIC	N/A	----	VERO	10.00	----	6/20/88
AVS-2413	CPE	PT	0.50	94.60	VERO	10.00	0.11	2/17/87
AVS-2413	CPE	SF	0.95	21.80	VERO	3.20	0.15	2/25/87
AVS-2413	CPE	VSV	----	----	L929	32.00	----	1/20/87
AVS-2413	CPE	VV	0.35	----	VERO	10.00	----	1/29/87
AVS-2413	CPE	YFV	----	----	VERO	3.20	----	5/ 4/87
AVS-2414	CPE	AD2	0.25	----	HEP2	100.00	----	1/29/87
AVS-2414	CPE	JE	----	----	VERO	100.00	----	5/ 7/87
AVS-2414	PR	PIC	N/A	----	VERO	10.00	----	6/20/88
AVS-2414	CPE	PT	0.10	----	VERO <	100.00	----	2/17/87
AVS-2414	CPE	SF	0.25	----	VERO	10.00	----	2/25/87
AVS-2414	CPE	VSV	0.15	----	L929	32.00	----	1/20/87
AVS-2414	CPE	VV	0.25	----	VERO	32.00	----	1/29/87
AVS-2414	CPE	YFV	----	----	VERO	100.00	----	5/ 4/87
AVS-2415	CPE	AD2	----	----	HEP2	320.00	----	1/29/87
AVS-2415	CPE	JE	----	----	VERO	100.00	----	5/ 7/87
AVS-2415	PR	PIC	N/A	----	VERO	100.00	----	6/20/88
AVS-2415	CPE	PT	0.50	----	VERO	100.00	----	2/18/87
AVS-2415	CPE	SF	----	----	VERO	100.00	----	2/26/87
AVS-2415	CPE	VSV	----	----	L929 <	320.00	----	1/20/87
AVS-2415	CPE	VV	----	----	VERO	100.00	----	1/29/87
AVS-2415	CPE	YFV	----	----	VERO	320.00	----	5/ 4/87
AVS-2416	CPE	AD2	----	----	HEP2	32.00	----	1/29/87
AVS-2416	CPE	JE	----	----	VERO <	32.00	----	5/ 7/87
AVS-2416	PR	PIC	N/A	----	VERO	3.20	----	6/20/88
AVS-2416	CPE	PT	0.30	----	VERO	10.00	----	2/18/87
AVS-2416	CPE	SF	----	----	VERO	3.20	----	2/26/87
AVS-2416	CPE	VSV	----	----	L929 <	100.00	----	1/20/87
AVS-2416	CPE	VV	----	----	VERO <	32.00	----	1/29/87
AVS-2416	CPE	YFV	----	----	VERO	1.00	----	5/ 4/87
AVS-2417	CPE	AD2	----	----	HEP2	100.00	----	2/ 5/87
AVS-2417	CPE	JE	----	----	VERO	100.00	----	5/ 7/87
AVS-2417	PR	PIC	N/A	----	VERO	10.00	----	6/20/88
AVS-2417	CPE	PT	0.34	----	VERO	100.00	----	5/15/87
AVS-2417	CPE	SF	----	----	VERO	100.00	----	2/26/87
AVS-2417	CPE	VSV	----	----	L929	320.00	----	1/20/87
AVS-2417	CPE	VV	0.05	----	VERO	320.00	----	2/ 5/87
AVS-2417	CPE	YFV	0.4	310.00	VERO	100.00	0.32	5/ 4/87
AVS-2418	CPE	AD2	0.10	----	HEP2	10.00	----	2/ 5/87
AVS-2418	CPE	JE	----	----	VERO	100.00	----	5/ 8/87
AVS-2418	PR	PIC	N/A	----	VERO >	100.00	----	6/20/88
AVS-2418	CPE	PT	0.6	----	VERO	100.00	----	5/15/87
AVS-2418	CPE	SF	----	----	VERO	320.00	----	2/26/87
AVS-2418	CPE	VSV	----	----	L929 <	320.00	----	1/20/87
AVS-2418	CPE	VV	----	----	VERO <	320.00	----	2/ 5/87
AVS-2418	CPE	YFV	----	----	VERO	100.00	----	5/ 5/87
AVS-2419	CPE	AD2	0.50	----	HEP2 >	320.00	----	2/ 5/87
AVS-2419	CPE	JE	----	----	VERO >	320.00	----	5/ 8/87
AVS-2419	PR	PIC	N/A	----	VERO >	100.00	----	6/21/88
AVS-2419	CPE	PT	1.07	293.00	VERO	320.00	1.09	2/18/87
AVS-2419	CPE	SF	----	----	VERO	100.00	----	2/26/87
AVS-2419	CPE	VSV	----	----	L929	320.00	----	1/20/87
AVS-2419	CPE	VV	----	----	VERO >	320.00	----	2/ 5/87
AVS-2419	CPE	YFV	0.2	----	VERO	100.00	----	5/ 5/87
AVS-2420	CPE	AD2	----	----	HEP2 >	320.00	----	2/ 5/87
AVS-2420	CPE	JE	0.1	----	VERO	100.00	----	5/ 8/87
AVS-2420	PR	PIC	N/A	----	VERO	100.00	----	6/21/88
AVS-2420	CPE	PT	1.2	----	VERO	100.00	----	5/15/87
AVS-2420	CPE	SF	----	----	VERO	100.00	----	2/26/87
AVS-2420	CPE	VSV	----	----	L929	320.00	----	1/20/87
AVS-2420	CPE	VV	----	----	VERO	320.00	----	2/ 5/87
AVS-2420	CPE	YFV	0.75	178.00	VERO	320.00	1.79	5/ 5/87
AVS-2421	CPE	AD2	----	----	HEP2	32.00	----	1/29/87
AVS-2421	CPE	JE	----	----	VERO	32.00	----	5/ 8/87
AVS-2421	PR	PIC	N/A	----	VERO <	100.00	----	6/21/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	T1	DATE
AVS-2421	CPE	PT	1.03	164.00	VERO	10.00	0.06	2/18/87
AVS-2421	CPE	SF	----	----	VERO	10.00	----	2/26/87
AVS-2421	CPE	VSV	----	----	L929	10.00	----	1/20/87
AVS-2421	CPE	VV	----	----	VERO	32.00	----	1/29/87
AVS-2421	CPE	YFV	0.6	29.70	VERO	3.20	0.11	5/ 5/87
AVS-2422	CPE	AD2	----	----	HEP2	32.00	----	2/ 5/87
AVS-2422	CPE	JE	----	----	VERO	100.00	----	5/ 8/87
AVS-2422	PR	PIC	N/A	----	VERO	100.00	----	6/21/88
AVS-2422	CPE	PT	0.58	----	VERO	100.00	----	2/18/87
AVS-2422	CPE	SF	----	----	VERO	100.00	----	2/26/87
AVS-2422	CPE	VSV	----	----	L929	100.00	----	1/20/87
AVS-2422	CPE	VV	----	----	VERO	100.00	----	2/ 5/87
AVS-2422	CPE	YFV	----	----	VERO	32.00	----	5/ 5/87
AVS-2423	CPE	AD2	----	----	HEP2	32.00	----	2/ 5/87
AVS-2423	CPE	JE	0.25	----	VERO	320.00	----	5/ 8/87
AVS-2423	PR	PIC	N/A	----	VERO	320.00	----	6/21/88
AVS-2423	CPE	PT	1.64	219.00	VERO	100.00	0.46	3/20/87
AVS-2423	CPE	SF	----	----	VERO	10.00	----	2/27/87
AVS-2423	CPE	VSV	----	----	L929	32.00	----	1/20/87
AVS-2423	CPE	VV	----	----	VERO	32.00	----	2/ 5/87
AVS-2423	CPE	YFV	0.95	135.00	VERO	320.00	2.35	5/ 5/87
AVS-2424	CPE	AD2	----	----	HEP2	320.00	----	2/ 5/87
AVS-2424	CPE	JE	----	----	VERO	100.00	----	5/ 8/87
AVS-2424	PR	PIC	N/A	----	VERO	32.00	----	6/21/88
AVS-2424	CPE	PT	1.45	298.00	VERO	100.00	0.34	3/20/87
AVS-2424	CPE	SF	0.40	96.00	VERO	32.00	0.33	2/27/87
AVS-2424	CPE	VSV	0.45	307.00	L929	320.00	1.03	1/20/87
AVS-2424	CPE	VV	0.20	----	VERO	320.00	----	2/ 5/87
AVS-2424	CPE	YFV	0.1	----	VERO	100.00	----	5/ 5/87
AVS-2425	CPE	AD2	----	----	HEP2	320.00	----	2/ 5/87
AVS-2425	CPE	JE	----	----	VERO	100.00	----	5/ 8/87
AVS-2425	PR	PIC	N/A	98.00	VERO	10.00	0.10	6/21/88
AVS-2425	CPE	PT	0.68	----	VERO	10.00	----	3/20/87
AVS-2425	CPE	SF	1.05	77.00	VERO	10.00	.13	2/27/87
AVS-2425	CPE	VSV	----	----	L929	320.00	----	1/20/87
AVS-2425	CPE	VV	0.45	95.00	VERO	32.00	0.33	2/ 5/87
AVS-2425	CPE	YFV	----	----	VERO	32.00	----	5/ 5/87
AVS-2426	CPE	AD2	0.20	----	HEP2	10.00	----	2/ 5/87
AVS-2426	CPE	JE	----	----	VERO	10.00	----	5/ 8/87
AVS-2426	PR	PIC	N/A	----	VERO	10.00	----	6/21/88
AVS-2426	CPE	PT	0.87	7.10	VERO	10.00	1.39	3/20/87
AVS-2426	CPE	SF	0.30	32.00	VERO	10.00	3.13	2/27/87
AVS-2426	CPE	SF	0.2	----	VERO	3.20	----	5/26/88
AVS-2426	CPE	VSV	----	----	L929	32.00	----	1/20/87
AVS-2426	CPE	VV	----	----	VERO	10.00	----	2/ 5/87
AVS-2426	CPE	YFV	0.3	----	VERO	10.00	----	5/ 5/87
AVS-2427	CPE	AD2	0.40	3.19	HEP2	3.20	1.00	2/ 5/87
AVS-2427	CPE	JE	----	----	VERO	10.00	----	5/ 8/87
AVS-2427	PR	PIC	N/A	----	VERO	3.20	----	6/21/88
AVS-2427	CPE	PT	0.53	----	VERO	3.20	----	3/20/87
AVS-2427	CPE	SF	----	----	VERO	10.00	----	2/27/87
AVS-2427	CPE	VV	0.05	----	VERO	3.20	----	2/ 5/87
AVS-2427	CPE	YFV	----	----	VERO	3.20	----	5/ 5/87
AVS-2428	CPE	AD2	0.15	----	HEP2	10.00	----	1/29/87
AVS-2428	CPE	JE	----	----	VERO	100.00	----	5/12/87
AVS-2428	PR	PIC	N/A	----	VERO	3.20	----	6/21/88
AVS-2428	CPE	PT	0.37	----	VERO	100.00	----	3/20/87
AVS-2428	CPE	SF	0.25	----	VERO	10.00	----	2/27/87
AVS-2428	CPE	VSV	1.00	57.50	L929	100.00	1.74	1/20/87
AVS-2428	CPE	VV	0.70	78.20	VERO	32.00	0.41	1/29/87
AVS-2428	CPE	YFV	----	----	VERO	32.00	----	5/ 5/87
AVS-2429	CPE	AD2	0.15	----	HEP2	10.00	----	2/ 5/87
AVS-2429	CPE	JE	----	----	VERO	32.00	----	5/12/87
AVS-2429	PR	PIC	N/A	9.10	VERO	10.00	1.08	6/24/88
AVS-2429	CPE	PT	0.32	----	VERO	10.00	----	3/20/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

CONC	NO	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	YI	DATE
AVS-2429	CPE	SF	0.15	----	VERO	3.20	----	2/27/87	
AVS-2429	CPE	VSV	----	----	L929 <	32.00	----	1/20/87	
AVS-2429	CPE	VV	0.05	----	VERO	10.00	----	2/ 5/87	
AVS-2429	CPE	YFV	----	----	VERO	3.20	----	5/ 6/87	
AVS-2430	CPE	AD2	0.15	----	HEP2	10.00	----	2/ 5/87	
AVS-2430	CPE	JE	0.2	----	VERO	32.00	----	5/12/87	
AVS-2430	PR	PIC	N/A	----	VERO	10.00	----	6/24/88	
AVS-2430	CPE	PT	0.58	----	VERO <	100.00	----	3/20/87	
AVS-2430	CPE	SF	----	----	VERO	100.00	----	2/27/87	
AVS-2430	CPE	VSV	----	----	L929	32.00	----	1/20/87	
AVS-2430	CPE	VV	----	----	VERO	10.00	----	2/ 5/87	
AVS-2430	CPE	YFV	----	----	VERO	32.00	----	5/ 6/87	
AVS-2431	CPE	AD2	----	----	HEP2	100.00	----	2/ 5/87	
AVS-2431	CPE	JE	----	----	VERO	100.00	----	5/12/87	
AVS-2431	PR	PIC	N/A	----	VERO	10.00	----	6/24/88	
AVS-2431	CPE	PT	0.52	----	VERO <	100.00	----	3/19/87	
AVS-2431	CPE	SF	0.35	----	VERO	32.00	----	3/ 2/87	
AVS-2431	CPE	VSV	0.80	298.00	L929	320.00	1.07	1/20/87	
AVS-2431	CPE	VV	0.15	----	VERC	100.00	----	2/ 5/87	
AVS-2431	CPE	YFV	----	----	VERO	32.00	----	5/ 6/87	
AVS-2433	CPE	AD2	----	----	HEP2	100.00	----	1/29/87	
AVS-2433	CPE	JE	1.5	93.10	VERO	320.00	3.43	5/12/87	
AVS-2433	CPE	JE	----	----	VERO	32.00	----	5/25/88	
AVS-2433	CPE	PT	0.12	----	VERO >	100.00	----	3/19/87	
AVS-2433	CPE	SF	----	----	VERO >	320.00	----	3/ 2/87	
AVS-2433	CPE	VSV	0.25	----	L929	100.00	----	1/20/87	
AVS-2433	CPE	VV	----	----	VERO	100.00	----	1/29/87	
AVS-2433	CPE	YFV	----	----	VERO	100.00	----	5/ 6/87	
AVS-2434	CPE	AD2	----	----	HEP2 >	320.00	----	1/29/87	
AVS-2434	CPE	JE	0.5	----	VERO >	320.00	----	5/12/87	
AVS-2434	CPE	PT	0.76	----	VERO	320.00	----	3/19/87	
AVS-2434	CPE	SF	----	----	VERO	32.00	----	3/ 2/87	
AVS-2434	CPE	VSV	0.30	----	L929 <	320.00	----	1/20/87	
AVS-2434	CPE	VV	----	----	VERO >	320.00	----	1/29/87	
AVS-2434	CPE	YFV	----	----	VERO	320.00	----	5/ 6/87	
AVS-2435	CPE	AD2	0.35	----	HEP2	32.00	----	2/ 5/87	
AVS-2435	CPE	JE	0.05	----	VERO <	100.00	----	5/12/87	
AVS-2435	PR	PIC	N/A	----	VERO	3.20	----	6/24/88	
AVS-2435	CPE	PT	0.61	----	VERO	100.00	----	3/19/87	
AVS-2435	CPE	SF	----	----	VERO	10.00	----	3/ 2/87	
AVS-2435	CPE	VSV	0.60	93.00	L929	32.00	0.34	1/20/87	
AVS-2435	CPE	VV	----	----	VERO <	320.00	----	2/ 5/87	
AVS-2435	CPE	YFV	----	----	VERO	32.00	----	5/ 6/87	
AVS-2436	CPE	AD2	----	----	HEP2	10.00	----	1/29/87	
AVS-2436	CPE	AD2	----	----	HEP2	32.00	----	2/ 5/87	
AVS-2436	CPE	JE	----	----	VERO	32.00	----	5/12/87	
AVS-2436	PR	PIC	N/A	----	VERO	10.00	----	6/24/88	
AVS-2436	CPE	PT	0.6	----	VERO	32.00	----	3/19/87	
AVS-2436	CPE	SF	0.15	----	VERO	10.00	----	3/ 2/87	
AVS-2436	CPE	VSV	----	----	L929 <	32.00	----	1/20/87	
AVS-2436	CPE	VV	0.25	----	VERO	10.00	----	1/29/87	
AVS-2436	CPE	VV	0.20	----	VERO	10.00	----	2/ 5/87	
AVS-2436	CPE	YFV	----	----	VERO >	320.00	----	5/ 6/87	
AVS-2437	CPE	AD2	0.60	----	HEP2	320.00	----	2/ 5/87	
AVS-2437	CPE	JE	0.3	----	VERO	100.00	----	5/12/87	
AVS-2437	CPE	PT	1.3	----	VERO	100.00	----	3/19/87	
AVS-2437	CPE	PT	0.42	----	VERO	100.00	----	5/15/87	
AVS-2437	CPE	SF	----	----	VERO	32.00	----	3/ 2/87	
AVS-2437	CPE	VSV	----	----	L929	320.00	----	1/20/87	
AVS-2437	CPE	VV	0.10	----	VERO	320.00	----	2/ 5/87	
AVS-2437	CPE	YFV	0.15	----	VERO	100.00	----	5/ 6/87	
AVS-2438	CPE	AD2	----	----	HEP2	1.00	----	2/ 5/87	
AVS-2438	CPE	JE	----	----	VERO	320.00	----	5/12/87	
AVS-2438	PR	PIC	N/A	----	VERO	320.00	----	6/27/88	
AVS-2438	CPE	PT	0.65	----	VERO	10.00	----	3/19/87	

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2438	CPE	SF	----	----	VERO	10.00	----	3/ 2/87
AVS-2438	CPE	VS	----	----	L929	32.00	----	1/20/87
AVS-2438	CPE	VV	----	----	VERO	100.00	----	2/ 5/87
AVS-2438	CPE	YFV	----	----	VERO	100.00	----	5/ 6/87
AVS-2439	CPE	AD2	----	----	HEP2	10.00	----	2/ 5/87
AVS-2439	CPE	JE	----	----	VERO	32.00	----	5/12/87
AVS-2439	PR	PIC	N/A	----	VERO	32.00	----	6/27/88
AVS-2439	CPE	PT	0.55	----	VERO	32.00	----	3/19/87
AVS-2439	CPE	SF	----	----	VERO	10.00	----	3/ 2/87
AVS-2439	CPE	VSV	0.60	93.00	L929	100.00	1.08	1/20/87
AVS-2439	CPE	VV	0.30	----	VERO	32.00	----	2/ 5/87
AVS-2439	CPE	YFV	----	----	VERO	32.00	----	5/ 6/87
AVS-2440	CPE	AD2	0.45	95.00	HEP2	100.00	1.03	2/ 5/87
AVS-2440	CPE	JE	----	----	VERO <	100.00	----	5/13/87
AVS-2440	PR	PIC	N/A	----	VERO	32.00	----	6/27/88
AVS-2440	CPE	PT	1.03	----	VERO	100.00	----	2/23/87
AVS-2440	CPE	SF	----	----	VERO <	100.00	----	3/ 3/87
AVS-2440	CPE	VSV	0.75	17.70	L929	32.00	1.79	1/20/87
AVS-2440	PR	VSV	N/A	4.92	L929	3.20	0.65	2/18/87
AVS-2440	CPE	VV	0.15	----	VERO	100.00	----	2/ 5/87
AVS-2440	CPE	YFV	----	----	VERO <	100.00	----	5/ 6/87
AVS-2441	CPE	AD2	----	----	HEP2	320.00	----	2/12/87
AVS-2441	CPE	JE	0.8	79.50	VERO	100.00	1.25	5/13/87
AVS-2441	PR	PIC	N/A	----	VERO	100.00	----	6/27/88
AVS-2441	CPE	PT	0.50	----	VERO	100.00	----	2/23/87
AVS-2441	CPE	SF	----	----	VERO	100.00	----	3/ 3/87
AVS-2441	CPE	VSV	----	----	L929	100.00	----	2/ 6/87
AVS-2441	CPE	VV	----	----	VERO	320.00	----	2/12/87
AVS-2441	CPE	YFV	0.4	303.00	VERO	32.00	0.10	5/ 7/87
AVS-2442	CPE	AD2	----	----	HEP2	100.00	----	2/12/87
AVS-2442	CPE	JE	0.1	----	VERO	100.00	----	5/13/87
AVS-2442	PR	PIC	N/A	----	VERO	10.00	----	6/27/88
AVS-2442	CPE	PT	0.25	----	VERO	100.00	----	2/23/87
AVS-2442	CPE	SF	----	----	VERO	100.00	----	3/ 3/87
AVS-2442	CPE	VSV	----	----	L929 <	100.00	----	2/ 6/87
AVS-2442	CPE	VV	----	----	VERO	32.00	----	2/12/87
AVS-2442	CPE	YFV	0.15	----	VERO	100.00	----	5/ 7/87
AVS-2443	CPE	AD2	0.10	----	HEP2	320.00	----	2/12/87
AVS-2443	CPE	JE	----	----	VERO	100.00	----	5/13/87
AVS-2443	PR	PIC	N/A	----	VERO	320.00	----	6/27/88
AVS-2443	CPE	PT	0.23	316.00	VERO	100.00	0.32	2/23/87
AVS-2443	CPE	SF	----	----	VERO	320.00	----	3/ 3/87
AVS-2443	CPE	VSV	----	----	L929	320.00	----	2/ 6/87
AVS-2443	CPE	VV	0.30	----	VERO	320.00	----	2/12/87
AVS-2443	CPE	YFV	----	----	VERO	1.00	----	5/ 7/87
AVS-2444	CPE	AD2	----	----	HEP2	100.00	----	2/12/87
AVS-2444	CPE	JE	----	----	VERO	320.00	----	5/13/87
AVS-2444	PR	PIC	N/A	----	VERO >	320.00	----	6/27/88
AVS-2444	CPE	PT	----	----	VERO	10.00	----	2/23/87
AVS-2444	CPE	SF	----	----	VERO	100.00	----	3/ 3/87
AVS-2444	CPE	VSV	----	----	L929	32.00	----	2/ 6/87
AVS-2444	CPE	VV	----	----	VERO	320.00	----	2/12/87
AVS-2444	CPE	YFV	----	----	VERO	32.00	----	5/ 7/87
AVS-2445	CPE	AD2	----	----	HEP2 <	100.00	----	3/12/87
AVS-2445	CPE	JE	----	----	VERO <	320.00	----	5/13/87
AVS-2445	PR	PIC	N/A	----	VERO	32.00	----	6/27/88
AVS-2445	CPE	PT	0.52	----	VERO	320.00	----	2/23/87
AVS-2445	CPE	SF	----	----	VERO	32.00	----	3/ 3/87
AVS-2445	CPE	VSV	----	----	L929 <	100.00	----	2/ 6/87
AVS-2445	CPE	VV	----	----	VERO	100.00	----	3/12/87
AVS-2445	CPE	YFV	----	----	VERO	32.00	----	5/ 7/87
AVS-2447	CPE	AD2	----	----	HEP2	320.00	----	2/12/87
AVS-2447	CPE	JE	0.49	----	VERO	100.00	----	5/13/87
AVS-2447	PR	PIC	N/A	----	VERO	320.00	----	6/27/88
AVS-2447	CPE	PT	0.45	----	VERO <	3	----	2/23/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2447	CPE	SF	----	----	VERO	320.00	----	3/ 3/87
AVS-2447	CPE	VSV	----	----	L929	32.00	----	2/ 6/87
AVS-2447	CPE	VV	0.70	319.00	VERO >	320.00 >	1.00	2/12/87
AVS-2447	CPE	YFV	0.3	----	VERO	100.00	----	5/ 7/87
AVS-2448	CPE	AD2	----	----	HEP2	320.00	----	2/12/87
AVS-2448	CPE	JE	0.5	----	VERO >	320.00	----	5/13/87
AVS-2448	PR	PIC	N/A	----	VERO	320.00	----	6/27/88
AVS-2448	CPE	PT	1.25	----	VERO	32.00	----	2/23/87
AVS-2448	CPE	SF	----	----	VERO	320.00	----	3/ 3/87
AVS-2448	CPE	VSV	----	----	L929 >	320.00	----	2/ 6/87
AVS-2448	CPE	VV	----	----	VERO >	320.00	----	2/12/87
AVS-2448	CPE	YFV	0.3	----	VERO	100.00	----	5/ 7/87
AVS-2449	CPE	AD2	----	----	HEP2 <	320.00	----	2/12/87
AVS-2449	CPE	JE	0.1	----	VERO	100.00	----	5/13/87
AVS-2449	PR	PIC	N/A	----	VERO	100.00	----	6/28/88
AVS-2449	CPE	PT	1.00	----	VERO	100.00	----	2/24/87
AVS-2449	CPE	SF	1.75	24.90	VERO	100.00	4.01	3/ 9/87
AVS-2449	CPE	SF	0.8	42.50	VERO	3.20	0.08	5/26/88
AVS-2449	CPE	VSV	----	----	L929	100.00	----	2/ 6/87
AVS-2449	CPE	VV	1.50	88.40	VERO	320.00	3.62	2/12/87
AVS-2449	CPE	VV	1.7	75.10	VERO	320.00	4.25	5/12/88
AVS-2449	CPE	YFV	----	----	VERO	32.00	----	5/ 7/87
AVS-2450	CPE	AD2	0.25	----	HEP2	100.00	----	2/12/87
AVS-2450	CPE	JE	----	----	VERO	100.00	----	5/13/87
AVS-2450	PR	PIC	N/A	----	VERO	100.00	----	6/28/88
AVS-2450	CPE	PT	0.50	230.00	VERO	32.00	0.14	2/24/87
AVS-2450	CPE	SF	1.25	28.40	VERO	100.00	3.51	3/ 9/87
AVS-2450	CPE	SF	----	----	VERO	10.00	----	5/26/88
AVS-2450	CPE	VSV	----	----	L929	100.00	----	2/ 6/87
AVS-2450	CPE	VV	0.65	62.90	VERO	100.00	1.59	2/12/87
AVS-2450	CPE	YFV	----	----	VERO	10.00	----	5/ 7/87
AVS-2451	CPE	JE	.7	56.00	VERO	32.00	0.57	5/13/87
AVS-2451	PR	PIC	N/A	----	VERO	32.00	----	6/28/88
AVS-2451	CPE	PT	2.75	----	VERO	32.00	----	2/24/87
AVS-2451	CPE	SF	0.1	----	VERO	32.00	----	3/ 9/87
AVS-2451	CPE	VSV	----	----	L929	32.00	----	2/ 6/87
AVS-2451	CPE	VV	0.30	----	VERO	320.00	----	2/12/87
AVS-2451	CPE	YFV	----	----	VERO	10.00	----	5/ 7/87
AVS-2452	CPE	AD2	----	----	HEP2	100.00	----	2/12/87
AVS-2452	CPE	JE	----	----	VERO	32.00	----	5/14/87
AVS-2452	PR	PIC	N/A	----	VERO	32.00	----	6/28/88
AVS-2452	CPE	PT	0.23	19.80	VERO	10.00	0.50	2/24/87
AVS-2452	CPE	SF	0.2	----	VERO	10.00	----	3/ 9/87
AVS-2452	CPE	VSV	----	----	L929	32.00	----	2/ 6/87
AVS-2452	CPE	VV	0.55	93.90	VERO	100.00	1.05	2/12/87
AVS-2452	CPE	YFV	----	----	VERO	10.00	----	5/ 7/87
AVS-2453	CPE	AD2	0.10	----	HEP2	3.20	----	2/12/87
AVS-2453	CPE	JE	----	----	VERO <	32.00	----	5/14/87
AVS-2453	PR	PIC	N/A	----	VERO	3.20	----	6/28/88
AVS-2453	CPE	PT	0.38	----	VERO	10.00	----	2/24/87
AVS-2453	CPE	SF	1.1	9.30	VERO <	32.00	3.40	3/ 9/87
AVS-2453	CPE	SF	0.55	18.80	VERO	10.00	0.53	5/26/88
AVS-2453	CPE	VSV	----	----	L929 <	10.00	----	2/ 6/87
AVS-2453	CPE	VV	----	----	VERO	10.00	----	2/12/87
AVS-2453	CPE	YFV	----	----	VERO	10.00	----	5/ 8/87
AVS-2454	CPE	AD2	0.25	----	HEP2	320.00	----	2/12/87
AVS-2454	CPE	JE	0.1	----	VERO	320.00	----	5/14/87
AVS-2454	PR	PIC	N/A	----	VERO >	320.00	----	6/28/88
AVS-2454	CPE	PT	2.03	95.00	VERO	32.00	0.34	2/24/87
AVS-2454	CPE	SF	0.2	----	VERO <	320.00	----	3/ 9/87
AVS-2454	CPE	VSV	----	----	L929 <	320.00	----	2/ 6/87
AVS-2454	CPE	VV	0.20	----	VERO	100.00	----	2/12/87
AVS-2454	CPE	YFV	----	----	VERO	100.00	----	5/ 8/87
AVS-2455	CPE	AD2	----	----	HEP2 <	32.00	----	2/12/87
AVS-2455	CPE	JE	----	----	VERO	10.00	----	5/14/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2455	PR	PIC	N/A	----	VERO	32.00	----	6/28/88
AVS-2455	CPE	PT	1.60	22.80	VERO	10.00	0.44	2/24/87
AVS-2455	CPE	SF	0.3	50.30	VERO	32.00	0.64	3/ 9/87
AVS-2455	CPE	VSV	----	----	L929	3.20	----	2/ 6/87
AVS-2455	CPE	VV	0.10	----	VERO	10.00	----	2/12/87
AVS-2455	CPE	YFV	0.2	----	VERO	0.32	----	5/ 8/87
AVS-2456	CPE	AD2	0.40	----	HEP2	320.00	----	2/12/87
AVS-2456	CPE	JE	0.15	----	VERO	320.00	----	5/14/87
AVS-2456	PR	PIC	N/A	----	VERO	100.00	----	6/28/88
AVS-2456	CPE	PT	1.42	53.80	VERO	10.00	0.19	2/24/87
AVS-2456	CPE	SF	----	----	VERO	320.00	----	3/ 9/87
AVS-2456	CPE	VSV	----	----	L929	320.00	----	2/ 6/87
AVS-2456	CPE	VV	0.25	----	VERO	320.00	----	2/12/87
AVS-2456	CPE	YFV	----	----	VERO	100.00	----	5/ 8/87
AVS-2457	CPE	AD2	----	----	HEP2	320.00	----	2/12/87
AVS-2457	CPE	JE	----	----	VERO	320.00	----	5/14/87
AVS-2457	PR	PIC	N/A	----	VERO	320.00	----	6/28/88
AVS-2457	CPE	PT	0.70	327.00	VERO	320.00	0.98	2/26/87
AVS-2457	CPE	SF	0.15	----	VERO	320.00	----	3/11/87
AVS-2457	CPE	VSV	----	----	L929	100.00	----	2/ 6/87
AVS-2457	CPE	VV	----	----	VERO	320.00	----	2/12/87
AVS-2457	CPE	YFV	----	----	VERO	320.00	----	5/ 8/87
AVS-2458	CPE	AD2	----	----	HEP2	10.00	----	2/12/87
AVS-2458	CPE	JE	----	----	VERO	10.00	----	5/14/87
AVS-2458	PR	PIC	N/A	4.57	VERO	3.20	0.70	6/28/88
AVS-2458	CPE	PT	----	----	VERO	10.00	----	2/26/87
AVS-2458	CPE	SF	----	----	VERO	10.00	----	3/11/87
AVS-2458	CPE	VSV	----	----	L929	10.00	----	2/ 6/87
AVS-2458	CPE	VV	----	----	VERO	10.00	----	2/12/87
AVS-2458	CPE	YFV	----	----	VERO	10.00	----	5/ 8/87
AVS-2459	CPE	AD2	----	----	HEP2	320.00	----	2/12/87
AVS-2459	CPE	JE	----	----	VERO	320.00	----	5/14/87
AVS-2459	PR	PIC	N/A	----	VERO	320.00	----	7/ 1/88
AVS-2459	CPE	PT	0.10	----	VERO	100.00	----	2/26/87
AVS-2459	CPE	SF	----	----	VERO	320.00	----	3/11/87
AVS-2459	CPE	VSV	----	----	L929	320.00	----	2/ 6/87
AVS-2459	CPE	VV	----	----	VERO	320.00	----	2/12/87
AVS-2459	CPE	YFV	0.15	----	VERO	100.00	----	5/ 8/87
AVS-2460	CPE	AD2	----	----	HEP2	320.00	----	2/19/87
AVS-2460	CPE	JE	----	----	VERO	320.00	----	5/14/87
AVS-2460	PR	PIC	N/A	----	VERO	100.00	----	7/ 1/88
AVS-2460	CPE	PT	0.60	304.00	VERO	100.00	0.33	2/26/87
AVS-2460	CPE	SF	----	----	VERO	100.00	----	3/11/87
AVS-2460	CPE	VSV	----	----	L929	320.00	----	2/ 6/87
AVS-2460	CPE	VV	0.50	----	VERO	320.00	----	2/19/87
AVS-2460	CPE	YFV	----	----	VERO	320.00	----	5/ 8/87
AVS-2461	CPE	AD2	0.30	32.00	HEP2	32.00	1.00	2/19/87
AVS-2461	CPE	JE	----	----	VERO	100.00	----	5/14/87
AVS-2461	PR	PIC	N/A	243.00	VERO	100.00	0.41	7/ 1/88
AVS-2461	CPE	PT	0.45	123.00	VERO	100.00	0.81	2/26/87
AVS-2461	CPE	SF	0.15	----	VERO	32.00	----	3/11/87
AVS-2461	CPE	VSV	----	----	L929	100.00	----	2/ 6/87
AVS-2461	CPE	VV	0.20	----	VERO	32.00	----	2/19/87
AVS-2461	CPE	YFV	0.6	93.10	VERO	32.00	0.34	5/ 8/87
AVS-2462	CPE	AD2	0.15	----	HEP2	100.00	----	2/19/87
AVS-2462	CPE	JE	----	----	VERO	100.00	----	5/14/87
AVS-2462	PR	PIC	N/A	----	VERO	320.00	----	7/ 1/88
AVS-2462	CPE	PT	0.50	----	VERO	100.00	----	2/26/87
AVS-2462	CPE	SF	----	----	VERO	32.00	----	3/11/87
AVS-2462	CPE	VSV	----	----	L929	100.00	----	2/ 6/87
AVS-2462	CPE	VV	0.30	----	VERO	100.00	----	2/19/87
AVS-2462	CPE	YFV	0.05	----	VERO	32.00	----	5/ 8/87
AVS-2463	CPE	AD2	0.25	----	HEP2	3.20	----	4/10/87
AVS-2463	CPE	JE	----	----	VERO	10.00	----	5/15/87
AVS-2463	PR	PIC	N/A	----	VERO	10.00	----	7/ 1/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2463	CPE	PT	0.60	11.70	VERO <	32.00 <	2.73	2/26/87
AVS-2463	CPE	SF	----	----	VERO <	32.00	----	3/11/87
AVS-2463	CPE	VSV	2.15	9.30	L929	10.00	1.07	2/ 6/87
AVS-2463	CPE	VV	0.25	----	VERO	3.20	----	2/19/87
AVS-2463	CPE	YFV	----	----	VERO <	32.00	----	5/ 8/87
AVS-2464	CPE	AD2	----	----	HEP2	32.00	----	2/19/87
AVS-2464	CPE	JE	----	----	VERO	100.00	----	5/15/87
AVS-2464	PR	PIC	N/A	----	VERO	100.00	----	7/ 1/88
AVS-2464	CPE	PT	0.40	313.00	VERO	100.00	0.32	2/26/87
AVS-2464	CPE	SF	----	----	VERO	100.00	----	3/11/87
AVS-2464	CPE	VSV	----	----	L929	320.00	----	2/ 6/87
AVS-2464	CPE	VV	0.65	259.00	VERO	100.00	0.39	2/19/87
AVS-2464	CPE	YFV	----	----	VERO	100.00	----	5/11/87
AVS-2465	CPE	AD2	----	----	HEP2	3.20	----	2/19/87
AVS-2465	CPE	JE	0.35	----	VERO	3.20	----	5/15/87
AVS-2465	PR	PIC	N/A	----	VERO	32.00	----	7/ 1'88
AVS-2465	CPE	PT	0.10	----	VERO	10.00	----	2/27/87
AVS-2465	CPE	SF	----	----	VERO	10.00	----	3/20/87
AVS-2465	CPE	VSV	----	----	L929 <	10.00	----	2/ 6/87
AVS-2465	CPE	VV	----	----	VERO <	10.00	----	2/19/87
AVS-2465	CPE	YFV	0.3	10.00	VERO	10.00	1.00	5/11/87
AVS-2466	CPE	AD2	----	----	HEP2 <	320.00	----	2/19/87
AVS-2466	CPE	JE	----	----	VERO	32.00	----	5/15/87
AVS-2466	PR	PIC	N/A	----	VERO	32.00	----	7/ 1/88
AVS-2466	CPE	PT	----	----	VERO <	100.00	----	2/27/87
AVS-2466	CPE	SF	0.25	----	VERO	32.00	----	3/20/87
AVS-2466	CPE	VSV	0.60	297.00	L929	100.00	0.34	2/ 6/87
AVS-2466	CPE	VV	0.75	210.00	VERO	100.00	0.48	2/19/87
AVS-2466	CPE	YFV	----	----	VERO <	100.00	----	5/11/87
AVS-2467	CPE	AD2	0.30	----	HEP2 <	100.00	----	2/19/87
AVS-2467	CPE	JE	----	----	VERO >	320.00	----	5/15/87
AVS-2467	PR	PIC	N/A	----	VERO	100.00	----	7/ 1/88
AVS-2467	CPE	PT	0.30	----	VERO <	320.00	----	2/27/87
AVS-2467	CPE	SF	0.2	----	VERO <	320.00	----	3/20/87
AVS-2467	CPE	VSV	0.30	100.00	L929	100.00	1.00	2/ 6/87
AVS-2467	CPE	VV	0.85	56.50	VERO	100.00	1.77	2/19/87
AVS-2467	CPE	YFV	----	----	VERO	32.00	----	5/11/87
AVS-2468	CPE	AD2	----	----	HEP2	100.00	----	2/19/87
AVS-2468	CPE	JE	----	----	VERO	32.00	----	5/15/87
AVS-2468	PR	PIC	N/A	----	VERO	100.00	----	7/ 8/88
AVS-2468	CPE	PT	0.40	111.00	VERO	100.00	0.90	2/27/87
AVS-2468	CPE	SF	0.1	----	VERO	100.00	----	3/20/87
AVS-2468	CPE	VSV	0.60	297.00	L929	100.00	0.34	2/ 6/87
AVS-2468	CPE	VV	0.30	----	VERO	320.00	----	2/19/87
AVS-2468	CPE	YFV	0.75	68.00	VERO	100.00	1.46	5/11/87
AVS-2469	CPE	AD2	0.50	----	HEP2 >	320.00	----	2/19/87
AVS-2469	CPE	JE	----	----	VERO	320.00	----	5/15/87
AVS-2469	PR	PIC	N/A	----	VERO	100.00	----	7/ 5/88
AVS-2469	CPE	PT	0.20	----	VERO <	320.00	----	2/27/87
AVS-2469	CPE	SF	----	----	VERO	320.00	----	3/20/87
AVS-2469	CPE	VSV	0.25	----	L929	320.00	----	2/ 6/87
AVS-2469	CPE	VV	0.30	----	VERO	320.00	----	2/19/87
AVS-2469	CPE	YFV	----	----	VERO	100.00	----	5/11/87
AVS-2470	CPE	AD2	----	----	HEP2	100.00	----	2/19/87
AVS-2470	CPE	JE	----	----	VERO	32.00	----	5/15/87
AVS-2470	PR	PIC	N/A	----	VERO	100.00	----	7/ 5/88
AVS-2470	CPE	PT	2.18	69.80	VERO	32.00	0.46	2/27/87
AVS-2470	CPE	SF	0.35	314.00	VERO	32.00	0.10	3/18/87
AVS-2470	CPE	VSV	----	----	L929	32.00	----	2/ 6/87
AVS-2470	CPE	VV	----	----	VERO	320.00	----	2/19/87
AVS-2470	CPE	YFV	0.25	----	VERO	10.00	----	5/11/87
AVS-2471	CPE	AD2	----	----	HEP2 <	320.00	----	3/12/87
AVS-2471	CPE	JE	0.2	----	VERO	320.00	----	5/22/87
AVS-2471	PR	PIC	N/A	----	VERO	100.00	----	7/ 5/88
AVS-2471	CPE	PT	3.7	297.00	VERO	10.00	0.03	4/20/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2471	CPE	SF	0.55	300.00	VERO	320.00	1.06	4/20/87
AVS-2471	CPE	VSV	----	----	L929	100.00	----	3/17/87
AVS-2471	CPE	VV	----	----	VERO	100.00	----	3/12/87
AVS-2471	CPE	YFV	----	----	VERO	320.00	----	4/20/87
AVS-2472	CPE	AD2	0.20	----	HEP2 >	320.00	----	3/12/87
AVS-2472	CPE	JE	----	----	VERO >	320.00	----	5/22/87
AVS-2472	PR	PIC	N/A	----	VERO	320.00	----	7/ 5/88
AVS-2472	CPE	PT	0.89	----	VERO	100.00	----	4/20/87
AVS-2472	CPE	SF	----	----	VERO	320.00	----	4/20/87
AVS-2472	CPE	VSV	----	----	L929	100.00	----	3/17/87
AVS-2472	CPE	VV	0.45	----	VERO	320.00	----	3/12/87
AVS-2472	CPE	YFV	----	----	VERO	320.00	----	4/20/87
AVS-2473	CPE	AD2	----	----	HEP2 >	320.00	----	3/12/87
AVS-2473	CPE	JE	----	----	VERO <	320.00	----	5/22/87
AVS-2473	PR	PIC	N/A	----	VERO	320.00	----	7/ 5/88
AVS-2473	CPE	PT	0.64	----	VERO	100.00	----	4/20/87
AVS-2473	CPE	SF	----	----	VERO	320.00	----	4/20/87
AVS-2473	CPE	VSV	----	----	L929	320.00	----	3/17/87
AVS-2473	CPE	VV	----	----	VERO	320.00	----	3/12/87
AVS-2473	CPE	YFV	0.1	----	VERO	320.00	----	4/20/87
AVS-2474	CPE	AD2	----	----	HEP2	10.00	----	3/12/87
AVS-2474	CPE	JE	----	----	VERO <	32.00	----	5/22/87
AVS-2474	CPE	PT	0.32	----	VERO <	10.00	----	4/20/87
AVS-2474	CPE	SF	0.1	----	VERO <	100.00	----	4/20/87
AVS-2474	CPE	VSV	----	----	L929 <	32.00	----	3/17/87
AVS-2474	CPE	VV	----	----	VERO	3.20	----	3/12/87
AVS-2474	CPE	YFV	----	----	VERO <	100.00	----	4/20/87
AVS-2475	CPE	AD2	----	----	HEP2 <	32.00	----	3/12/87
AVS-2475	CPE	JE	----	----	VERO	10.00	----	5/26/87
AVS-2475	PR	PIC	N/A	----	VERO	10.00	----	7/ 5/88
AVS-2475	CPE	PT	1.03	3.99	VERO	10.00	2.50	4/24/87
AVS-2475	CPE	SF	0.8	3.14	VERO	3.20	1.01	4/21/87
AVS-2475	CPE	VSV	----	----	L929 <	32.00	----	3/17/87
AVS-2475	CPE	VV	0.20	----	VERO <	32.00	----	3/12/87
AVS-2475	CPE	YFV	0.32	----	VERO	10.00	----	4/21/87
AVS-2476	CPE	AD2	----	----	HEP2 <	100.00	----	3/12/87
AVS-2476	CPE	JE	----	----	VERO	100.00	----	5/26/87
AVS-2476	PR	PIC	N/A	----	VERO	32.00	----	7/ 8/88
AVS-2476	CPE	PT	0.05	----	VERO <	100.00	----	4/24/87
AVS-2476	CPE	SF	0.6	297.00	VERO	32.00	0.11	4/21/87
AVS-2476	CPE	VSV	----	----	L929	100.00	----	3/17/87
AVS-2476	CPE	VV	0.45	320.00	VERO	100.00	0.31	3/12/87
AVS-2476	CPE	YFV	----	----	VERO	32.00	----	4/21/87
AVS-2477	CPE	AD2	----	----	HEP2 >	320.00	----	3/12/87
AVS-2477	CPE	JE	----	----	VERO >	320.00	----	5/26/87
AVS-2477	PR	PIC	N/A	----	VERO	100.00	----	7/ 8/88
AVS-2477	CPE	PT	0.1	----	VERO >	100.00	----	4/27/87
AVS-2477	CPE	SF	----	----	VERO >	320.00	----	4/21/87
AVS-2477	CPE	VSV	----	----	L929	32.00	----	3/17/87
AVS-2477	CPE	VV	----	----	VERO >	100.00	----	3/12/87
AVS-2477	CPE	YFV	0.3	----	VERO >	320.00	----	4/21/87
AVS-2478	CPE	AD2	0.20	----	HEP2 <	100.00	----	3/12/87
AVS-2478	CPE	JE	----	----	VERO	32.00	----	5/26/87
AVS-2478	PR	PIC	N/A	----	VERO	10.00	----	7/ 8/88
AVS-2478	CPE	PT	0.23	----	VERO	10.00	----	4/27/87
AVS-2478	CPE	SF	----	----	VERO <	10.00	----	4/21/87
AVS-2478	CPE	VEE	0.12	----	VERO	320.00	----	5/ 5/87
AVS-2478	CPE	VSV	----	----	L929	100.00	----	3/17/87
AVS-2478	CPE	VV	0.40	100.00	VERO	32.00	0.32	3/12/87
AVS-2478	CPE	YFV	----	----	VERO <	10.00	----	4/21/87
AVS-2479	CPE	AD2	0.15	----	HEP2	32.00	----	3/12/87
AVS-2479	CPE	JE	1.15	30.00	VERO	32.00	1.06	5/26/87
AVS-2479	PR	PIC	N/A	----	VERO	100.00	----	7/ 8/88
AVS-2479	CPE	PT	0.1	----	VERO	3.20	----	4/27/87
AVS-2479	CPE	SF	1.0	1.70	VERO	32.00	1.07	4/21/87

CLMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIPUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2479	CPE	VSV	----	----	L929	10.00	----	3/17/87
AVS-2479	CPE	VV	----	----	VERO	10.00	----	3/12/87
AVS-2479	CPE	YFV	1.05	29.70	VERO	3.20	0.11	4/21/87
AVS-2480	CPE	AD2	0.20	----	HEP2 <	32.00	----	3/12/87
AVS-2480	CPE	JE	----	----	VERO <	32.00	----	5/26/87
AVS-2480	PR	PIC	N/A	----	VERO	10.00	----	7/ 8/88
AVS-2480	CPE	PT	0.65	8.30	VERO	10.00	1.20	4/27/87
AVS-2480	CPE	SF	0.75	4.94	VERO	3.20	0.65	2/ 5/88
AVS-2480	CPE	VSV	0.05	----	L929	10.00	----	3/17/87
AVS-2480	CPE	VV	0.50	----	VERO	10.00	----	3/12/87
AVS-2480	CPE	YFV	0.9	3.20	VERO	3.20	1.00	4/28/87
AVS-2481	CPE	AD2	0.10	----	HEP2 >	320.00	----	3/12/87
AVS-2481	CPE	JE	----	----	VERO	320.00	----	5/26/87
AVS-2481	CPE	PT	0.5	----	VERO <	100.00	----	4/27/87
AVS-2481	CPE	SF	0.15	----	VERO	100.00	----	4/22/87
AVS-2481	CPE	VSV	----	----	L929 <	100.00	----	3/17/87
AVS-2481	CPE	VV	1.05	320.00	VERO	100.00	0.31	3/12/87
AVS-2481	CPE	YFV	----	----	VERO	100.00	----	4/22/87
AVS-2482	CPE	AD2	----	----	HEP2	100.00	----	3/12/87
AVS-2482	CPE	JE	----	----	VERO <	320.00	----	5/26/87
AVS-2482	PR	PIC	N/A	----	VERO	32.00	----	7/ 8/88
AVS-2482	CPE	PT	0.05	----	VERO	100.00	----	4/28/87
AVS-2482	CPE	SF	0.45	95.00	VERO	32.00	0.33	4/22/87
AVS-2482	CPE	VSV	----	----	L929	100.00	----	3/17/87
AVS-2482	CPE	VV	0.20	----	VERO	32.00	----	3/12/87
AVS-2482	CPE	YFV	----	----	VERO	100.00	----	4/22/87
AVS-2483	CPE	AD2	----	----	HEP2 >	100.00	----	3/12/87
AVS-2483	CPE	JE	----	----	VERO	320.00	----	5/26/87
AVS-2483	PR	PIC	N/A	----	VERO	100.00	----	7/ 8/88
AVS-2483	CPE	PT	0.1	----	VERO >	100.00	----	4/28/87
AVS-2483	CPE	SF	----	----	VERO	320.00	----	4/22/87
AVS-2483	CPE	VSV	----	----	L929	32.00	----	3/17/87
AVS-2483	CPE	VV	----	----	VERO	100.00	----	3/12/87
AVS-2483	CPE	YFV	----	----	VERO	10.00	----	4/22/87
AVS-2484	CPE	AD2	----	----	HEP2 >	320.00	----	3/12/87
AVS-2484	PR	PIC	N/A	----	VERO	100.00	----	7/ 8/88
AVS-2484	CPE	PT	0.05	----	VERO	320.00	----	4/28/87
AVS-2484	CPE	SF	----	----	VERO	320.00	----	4/22/87
AVS-2484	CPE	VSV	----	----	L929	32.00	----	3/17/87
AVS-2484	CPE	VV	0.30	----	VERO >	320.00	----	3/12/87
AVS-2484	CPE	YFV	0.1	----	VERO	100.00	----	4/22/87
AVS-2485	CPE	AD2	.3	320.00	HEP2	320.00	1.00	5/ 7/87
AVS-2485	CPE	JE	----	----	VERO	100.00	----	4/ 6/87
AVS-2485	PR	PIC	N/A	----	VERO	32.00	----	7/ 8/88
AVS-2485	CPE	PT	0.83	----	VERO	320.00	----	4/21/87
AVS-2485	CPE	SF	----	----	VERO	320.00	----	4/22/87
AVS-2485	CPE	VSV	----	----	L929	320.00	----	5/ 1/87
AVS-2485	CPE	VV	----	----	VERO	320.00	----	5/ 7/87
AVS-2485	CPE	YFV	----	----	VERO	32.00	----	4/22/87
AVS-2485	CPE	AD2	----	----	HEP2	100.00	----	5/ 7/87
AVS-2486	CPE	JE	0.2	----	VERO	3.20	----	4/ 6/87
AVS-2486	PR	PIC	N/A	----	VERO	32.00	----	7/11/88
AVS-2486	CPE	PT	0.35	31.40	VERO	10.00	0.32	4/21/87
AVS-2486	CPE	SF	0.05	----	VERO	3.20	----	4/23/87
AVS-2486	CPE	VSV	----	----	L929	32.00	----	5/ 1/87
AVS-2486	CPE	VV	0.5	72.00	VERO	32.00	0.44	5/ 7/87
AVS-2486	CPE	YFV	0.55	----	VERO	10.00	----	4/23/87
AVS-2487	CPE	AD2	0.35	----	HEP2	320.00	----	5/ 7/87
AVS-2487	CPE	JE	0.3	----	VERO	320.00	----	4/ 6/87
AVS-2487	PR	PIC	N/A	223.00	VERO	320.00	1.43	7/11/88
AVS-2487	CPE	PT	----	----	VERO	100.00	----	4/21/87
AVS-2487	CPE	SF	0.75	210.00	VERO	100.00	0.48	4/23/87
AVS-2487	CPE	VEE	0.97	123.00	VERO	320.00	2.58	5/ 5/87
AVS-2487	CPE	VSV	----	----	L929	320.00	----	5/ 1/87
AVS-2487	CPE	VV	0.1	----	VERO	320.00	----	5/ 7/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2487	CPE	YFV	----	----	VERO	100.00	----	4/23/87
AVS-2488	CPE	AD2	----	----	HEP2	320.00	----	5/ 7/87
AVS-2488	CPE	JE	----	----	VERO	320.00	----	4/ 6/87
AVS-2488	PR	PIC	N/A	----	VERO >	320.00	----	7/11/88
AVS-2488	CPE	PT	0.1	----	VERO	320.00	----	4/21/87
AVS-2488	CPE	SF	----	----	VERO	1.00	----	4/23/87
AVS-2488	CPE	VSV	----	----	L929 >	320.00	----	5/ 1/87
AVS-2488	CPE	VV	----	----	VERO >	320.00	----	5/ 7/87
AVS-2488	CPE	YFV	0.05	----	VERO	3.20	----	4/23/87
AVS-2489	CPE	AD2	----	----	HEP2	1.00	----	5/ 7/87
AVS-2489	PR	PIC	N/A	----	VERO	1.00	----	7/11/88
AVS-2489	CPE	PT	----	----	VERO	0.32	----	4/21/87
AVS-2489	CPE	SF	----	----	VERO	0.32	----	4/23/87
AVS-2489	CPE	VSV	----	----	L929	0.32	----	5/ 1/87
AVS-2489	CPE	VV	1.45	3.97	VERO	1.00	0.25	5/ 7/87
AVS-2489	CPE	YFV	----	----	VERO	0.32	----	4/23/87
AVS-2490	CPE	AD2	0.15	----	HEP2	320.00	----	5/ 7/87
AVS-2490	CPE	JE	0.2	----	VERO	100.00	----	4/ 6/87
AVS-2490	PR	PIC	N/A	----	VERO	320.00	----	7/11/88
AVS-2490	CPE	PT	0.1	----	VERO	320.00	----	4/22/87
AVS-2490	CPE	SF	----	----	VERO	10.00	----	4/23/87
AVS-2490	CPE	VSV	----	----	L929	100.00	----	5/ 1/87
AVS-2490	CPE	VV	0.7	----	VERO >	320.00	----	5/ 7/87
AVS-2490	CPE	YFV	----	----	VERO	320.00	----	4/23/87
AVS-2491	CPE	AD2	----	----	HEP2	100.00	----	5/ 7/87
AVS-2491	CPE	JE	0.1	----	VERO	32.00	----	4/ 7/87
AVS-2491	PR	PIC	N/A	----	VERO	32.00	----	7/11/88
AVS-2491	CPE	PT	0.4	----	VERO	100.00	----	4/22/87
AVS-2491	CPE	SF	----	----	VERO	10.00	----	4/24/87
AVS-2491	CPE	VSV	----	----	L929	100.00	----	5/ 1/87
AVS-2491	CPE	VV	0.6	----	VERO	100.00	----	5/ 7/87
AVS-2491	CPE	YFV	----	----	VERO	100.00	----	4/24/87
AVS-2492	CPE	AD2	0.3	320.00	HEP2	320.00	1.00	5/ 7/87
AVS-2492	CPE	JE	----	----	VERO	100.00	----	4/ 7/87
AVS-2492	PR	PIC	N/A	----	VERO >	100.00	----	7/11/88
AVS-2492	CPE	PT	1.15	248.00	VERO	100.00	0.40	4/22/87
AVS-2492	CPE	SF	0.05	----	VERO	100.00	----	4/24/87
AVS-2492	CPE	VSV	----	----	L929	100.00	----	5/ 1/87
AVS-2492	CPE	VV	0.5	219.00	VERO	100.00	0.46	5/ 7/87
AVS-2492	CPE	YFV	----	----	VERO	100.00	----	4/24/87
AVS-2493	CPE	AD2	----	----	HEP2 >	320.00	----	5/ 7/87
AVS-2493	CPE	JE	----	----	VERO	320.00	----	4/ 7/87
AVS-2493	PR	PIC	N/A	----	VERO >	320.00	----	7/11/88
AVS-2493	CPE	PT	0.47	----	VERO	320.00	----	4/22/87
AVS-2493	CPE	SF	----	----	VERO	100.00	----	4/24/87
AVS-2493	CPE	VSV	----	----	L929 >	320.00	----	5/ 1/87
AVS-2493	CPE	VV	0.2	----	VERO >	320.00	----	5/ 7/87
AVS-2493	CPE	YFV	0.05	----	VERO	100.00	----	4/24/87
AVS-2494	CPE	AD2	----	----	HEP2	100.00	----	5/ 7/87
AVS-2494	CPE	JE	0.1	----	VERO	100.00	----	4/ 7/87
AVS-2494	PR	PIC	N/A	----	VERO	320.00	----	7/11/88
AVS-2494	CPE	PT	0.28	----	VERO	320.00	----	4/22/87
AVS-2494	CPE	SF	0.2	----	VERO	32.00	----	4/24/87
AVS-2494	CPE	VSV	0.15	----	L929	100.00	----	5/ 1/87
AVS-2494	CPE	VV	0.2	----	VERO	320.00	----	5/ 7/87
AVS-2494	CPE	YFV	----	----	VERO	100.00	----	4/24/87
AVS-2495	CPE	AD2	----	----	HEP2	10.00	----	5/ 7/87
AVS-2495	CPE	JE	0.45	----	VERO	32.00	----	4/ 7/87
AVS-2495	PR	PIC	N/A	----	VERO	10.00	----	7/11/88
AVS-2495	CPE	PT	0.08	----	VERO	10.00	----	4/23/87
AVS-2495	CPE	SF	----	----	VERO	10.00	----	4/24/87
AVS-2495	CPE	VSV	----	----	L929	32.00	----	5/ 1/87
AVS-2495	CPE	VV	----	----	VERO	320.00	----	5/ 7/87
AVS-2495	CPE	YFV	----	----	VERO	3.20	----	4/24/87
AVS-2496	CPE	AD2	----	----	HEP2 >	320.00	----	5/ 7/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2496	CPE	JE	0.1	----	VERO	32.00	----	4/ 7/87
AVS-2496	PR	PIC	N/A	----	VERO	320.00	----	7/12/88
AVS-2496	CPE	PT	0.46	96.00	VERO	100.00	1.03	4/23/87
AVS-2496	CPE	SF	1.75	47.90	VERO	32.00	0.67	4/29/88
AVS-2496	CPE	VSV	----	----	L929	32.00	----	5/ 1/87
AVS-2496	CPE	VV	----	----	VERO	320.00	----	5/ 7/87
AVS-2496	CPE	YFV	----	----	VERO	100.00	----	4/27/87
AVS-2497	CPE	AD2	0.3	----	HEP2 >	320.00	----	5/ 7/87
AVS-2497	CPE	JE	----	----	VERO	100.00	----	4/ 8/87
AVS-2497	PR	PIC	N/A	----	VERO	320.00	----	7/12/88
AVS-2497	CPE	PT	0.3	----	VERO	100.00	----	4/23/87
AVS-2497	CPE	SF	0.8	----	VERO	100.00	----	4/29/88
AVS-2497	CPE	VSV	0.2	----	L929	320.00	----	5/ 1/87
AVS-2497	CPE	VV	----	----	VERO >	320.00	----	5/ 7/87
AVS-2497	CPE	YFV	----	----	VERO	100.00	----	4/27/87
AVS-2498	CPE	AD2	----	----	HEP2	100.00	----	5/ 7/87
AVS-2498	CPE	JE	----	----	VERO	32.00	----	4/ 8/87
AVS-2498	PR	PIC	N/A	----	VERO	100.00	----	7/12/88
AVS-2498	CPE	PT	0.48	----	VERO	100.00	----	4/23/87
AVS-2498	CPE	SF	1.27	61.60	VERO	10.00	0.16	4/29/88
AVS-2498	CPE	VSV	----	----	L929	100.00	----	5/ 1/87
AVS-2498	CPE	VV	----	----	VERO <	320.00	----	5/ 7/87
AVS-2498	CPE	YFV	----	----	VERO	32.00	----	4/27/87
AVS-2499	CPE	AD2	0.1	----	HEP2	320.00	----	5/ 7/87
AVS-2499	CPE	JE	----	----	VERO	100.00	----	4/ 8/87
AVS-2499	PR	PIC	N/A	----	VERO >	320.00	----	7/12/88
AVS-2499	CPE	PT	0.36	----	VERO	100.00	----	4/23/87
AVS-2499	CPE	SF	0.97	----	VERO	100.00	----	4/29/88
AVS-2499	CPE	VSV	----	----	L929	320.00	----	5/ 1/87
AVS-2499	CPE	VV	----	----	VERO >	320.00	----	5/ 7/87
AVS-2499	CPE	YFV	0.2	----	VERO	320.00	----	4/27/87
AVS-2500	CPE	AD2	0.3	----	HEP2 >	320.00	----	5/14/87
AVS-2500	CPE	JE	0.1	----	VERO	320.00	----	4/ 8/87
AVS-2500	PR	PIC	N/A	----	VERO	320.00	----	7/12/88
AVS-2500	CPE	PT	0.05	----	VERO	320.00	----	4/24/87
AVS-2500	CPE	SF	0.75	----	VERO	32.00	----	4/29/88
AVS-2500	CPE	VSV	0.1	----	L929	320.00	----	5/ 1/87
AVS-2500	CPE	VV	0.2	----	VERO	320.00	----	5/14/87
AVS-2500	CPE	YFV	----	----	VERO	100.00	----	4/27/87
AVS-2501	CPE	AD2	----	----	HEP2	100.00	----	5/14/87
AVS-2501	CPE	JE	0.55	----	VERO	320.00	----	4/ 8/87
AVS-2501	PR	PIC	N/A	----	VERO	320.00	----	7/12/88
AVS-2501	CPE	PT	----	----	VERO	320.00	----	4/24/87
AVS-2501	CPE	SF	3.3	23.40	VERO	100.00	4.27	4/29/88
AVS-2501	CPE	VSV	----	----	L929	32.00	----	5/ 1/87
AVS-2501	CPE	VV	----	----	VERO >	320.00	----	5/14/87
AVS-2501	CPE	YFV	----	----	VERO	320.00	----	4/28/87
AVS-2502	CPE	AD2	0.4	----	HEP2 >	320.00	----	5/14/87
AVS-2502	CPE	JE	----	----	VERO	320.00	----	4/ 3/87
AVS-2502	PR	PIC	N/A	----	VERO	320.00	----	7/12/88
AVS-2502	CPE	PT	0.35	----	VERO	100.00	----	4/24/87
AVS-2502	CPE	SF	1.4	----	VERO	100.00	----	4/29/88
AVS-2502	CPE	VSV	----	----	L929	320.00	----	5/ 1/87
AVS-2502	CPE	VV	----	----	VERO >	320.00	----	5/14/87
AVS-2502	CPE	YFV	0.2	----	VERO	320.00	----	4/28/87
AVS-2503	CPE	AD2	0.75	----	HEP2	1.00	----	5/14/87
AVS-2503	CPE	AD2	0.75	----	HEP2	1.00	----	5/28/87
AVS-2503	CPE	JE	3.62	0.19	VERO	1.00	5.13	6/18/87
AVS-2503	CPE	JE	1.2	1.78	VERO	3.20	1.78	5/25/88
AVS-2503	PR	PIC	N/A	0.14	VERO	1.00	6.93	7/25/88
AVS-2503	CPE	PT	2.17	1.45	VERO	3.20	2.19	7/ 9/87
AVS-2503	CPE	SF	4.1	0.37	VERO	1.00	2.65	7/16/87
AVS-2503	CPE	VSV	4.1	2.17	L929	100.00	46.00	5/ 3/87
AVS-2503	CPE	VSV	4.75	1.32	L929	100.00	75.30	6/12/87
AVS-2503	PR	VSV	N/A	7.30	L929	100.00	13.50	10/28/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2503	CPE	VV	2.85	1.31	VERO	3.20	2.44	5/14/87
AVS-2503	CPE	YFV	3.6	0.56	VERO	1.00	1.76	7/16/87
AVS-2504	CPE	AD2	-0-	----	HEP2	0.32	----	5/14/87
AVS-2504	CPE	AD2	----	----	HEP2	0.10	----	5/28/87
AVS-2504	CPE	JE	----	----	VERO	0.32	----	6/19/87
AVS-2504	PR	PIC	N/A	----	VERO	1.00	----	2/22/88
AVS-2504	PR	PIC	N/A	----	VERO	10.00	----	7/26/88
AVS-2504	CPE	PT	0.05	----	VERO	0.32	----	7/ 9/87
AVS-2504	CPE	SF	0.05	----	VERO	1.00	----	7/16/87
AVS-2504	CPE	VSV	0.5	----	L929	0.32	----	5/ 5/87
AVS-2504	CPE	VV	----	----	VERO	1.00	----	5/14/87
AVS-2504	CPE	YFV	----	----	VERO	1.00	----	7/16/87
AVS-2505	CPE	AD2	0.3	----	HEP2	320.00	----	5/14/87
AVS-2505	CPE	JE	----	----	VERO	320.00	----	6/19/87
AVS-2505	PR	PIC	N/A	----	VERO	320.00	----	2/22/88
AVS-2505	PR	PIC	N/A	----	VERO	100.00	----	7/29/88
AVS-2505	CPE	PT	0.69	----	VERO	100.00	----	7/ 9/87
AVS-2505	CPE	SF	0.6	178.00	VERO	32.00	0.18	7/16/87
AVS-2505	CPE	VSV	----	----	L929	320.00	----	5/ 5/87
AVS-2505	CPE	VV	----	----	VERO	320.00	----	5/14/87
AVS-2505	CPE	YFV	----	----	VERO	32.00	----	7/16/87
AVS-2506	CPE	AD2	1.35	1.00	HEP2	3.20	0.31	5/14/87
AVS-2506	CPE	JE	2.05	12.80	VERO	32.00	2.48	6/19/87
AVS-2506	PR	PIC	N/A	4.83	VERO	10.00	2.06	2/22/88
AVS-2506	PR	PIC	N/A	1.35	VERO	10.00	7.38	7/29/88
AVS-2506	CPE	PT	2.64	3.69	VERO	3.20	0.87	7/ 9/87
AVS-2506	CPE	SF	3.15	2.90	VERO	3.20	1.10	7/16/87
AVS-2506	CPE	VSV	----	----	L929	100.00	----	5/ 5/87
AVS-2506	CPE	VV	1.75	16.60	VERO	10.00	0.60	5/14/87
AVS-2506	CPE	YFV	2.1	10.00	VERO	10.00	0.99	7/16/87
AVS-2507	CPE	AD2	0.2	----	HEP2	320.00	----	4/24/87
AVS-2507	CPE	AD2	0.3	----	HEP2	320.00	----	5/14/87
AVS-2507	CPE	JE	----	----	VERO	320.00	----	5/29/87
AVS-2507	PR	PIC	N/A	----	VERO	320.00	----	2/22/88
AVS-2507	CPE	PT	0.82	----	VERO	320.00	----	5/29/87
AVS-2507	CPE	SF	----	----	VERO	320.00	----	5/29/87
AVS-2507	CPE	VSV	0.1	----	L929	320.00	----	4/10/87
AVS-2507	CPE	VV	0.2	----	VERO	320.00	----	4/24/87
AVS-2507	CPE	VV	----	----	VERO	320.00	----	5/14/87
AVS-2507	CPE	YFV	----	----	VERO	320.00	----	5/29/87
AVS-2508	CPE	AD2	----	----	HEP2	32.00	----	4/10/87
AVS-2508	CPE	JE	----	----	VERO	320.00	----	6/ 1/87
AVS-2508	PR	PIC	N/A	----	VERO	100.00	----	7/22/88
AVS-2508	CPE	PT	1.5	----	VERO	320.00	----	6/ 1/87
AVS-2508	CPE	SF	0.5	----	VERO	320.00	----	6/ 1/87
AVS-2508	CPE	VSV	----	----	L929	32.00	----	4/10/87
AVS-2508	CPE	VV	----	----	VERO	32.00	----	4/10/87
AVS-2508	CPE	YFV	----	----	VERO	320.00	----	6/ 1/87
AVS-2509	CPE	AD2	----	----	HEP2	0.10	----	4/10/87
AVS-2509	CPE	JE	----	----	VERO	0.32	----	6/ 1/87
AVS-2509	CPE	PT	----	----	VERO	0.32	----	6/ 1/87
AVS-2509	CPE	SF	----	----	VERO	0.32	----	6/ 1/87
AVS-2509	CPE	VSV	2.15	0.94	L929	0.32	0.34	4/10/87
AVS-2509	CPE	VV	-0-	----	VERO	0.10	----	4/10/87
AVS-2509	CPE	VV	----	----	VERO	0.03	----	5/28/87
AVS-2509	CPE	YFV	----	----	VERO	0.32	----	6/ 1/87
AVS-2510	CPE	AD2	----	----	HEP2	32.00	----	4/10/87
AVS-2510	CPE	JE	0.8	----	VERO	100.00	----	6/ 1/87
AVS-2510	PR	PIC	N/A	----	VERO	100.00	----	7/29/88
AVS-2510	CPE	PT	0.65	----	VERO	32.00	----	6/ 1/87
AVS-2510	CPE	SF	----	----	VERO	100.00	----	4/10/87
AVS-2510	CPE	VSV	0.1	----	L929	32.00	----	4/10/87
AVS-2510	CPE	VV	----	----	VERO	10.00	----	4/10/87
AVS-2510	CPE	YFV	----	----	VERO	100.00	----	6/ 1/87
AVS-2511	CPE	AD2	----	----	HEP2	3.20	----	4/10/87

B-110

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2511	CPE	JE	----	----	VERO <	32.00	----	6/ 1/87
AVS-2511	PR	PIC	N/A	----	VERO	3.20	----	7/22/88
AVS-2511	CPE	PT	0.45	----	VERO	10.00	----	6/ 1/87
AVS-2511	CPE	SF	0.85	12.90	VERO	3.20	0.25	6/ 1/87
AVS-2511	CPE	VSV	----	----	L929	3.20	----	4/10/87
AVS-2511	CPE	VV	0.85	11.20	VERO	3.20	0.28	4/10/87
AVS-2511	CPE	YFV	----	----	VERO	3.20	----	6/ 1/87
AVS-2512	CPE	AD2	----	----	HEP2 >	32.00	----	4/10/87
AVS-2512	CPE	JE	----	----	VERO	320.00	----	6/ 1/87
AVS-2512	PR	PIC	N/A	----	VERO	32.00	----	7/22/88
AVS-2512	CPE	PT	0.7	----	VERO	320.00	----	6/ 1/87
AVS-2512	CPE	SF	0.6	178.00	VERO	320.00	1.78	6/ 1/87
AVS-2512	CPE	VSV	----	----	L929 >	32.00	----	4/10/87
AVS-2512	CPE	VV	2.1	8.60	VERO >	32.00 >	3.67	4/10/87
AVS-2512	CPE	YFV	----	----	VERO	320.00	----	6/ 1/87
AVS-2513	CPE	AD2	0.8	----	HEP2	0.32	----	4/10/87
AVS-2513	PR	PIC	N/A	----	VERO	1.00	----	7/22/88
AVS-2513	CPE	PT	0.46	----	VERO	1.00	----	6/ 2/87
AVS-2513	CPE	SF	----	----	VERO	0.32	----	6/ 2/87
AVS-2513	CPE	VSV	0.4	31.00	L929	10.00	0.32	4/10/87
AVS-2513	CPE	VV	----	----	VERO	0.10	----	4/10/87
AVS-2513	CPE	YFV	0.15	----	VERO	1.00	----	6/ 2/87
AVS-2514	CPE	AD2	1.2	----	HEP2 >	32.00	----	4/10/87
AVS-2514	CPE	PT	0.66	109.00	VERO	3.20	0.03	6/ 2/87
AVS-2514	CPE	SF	0.15	----	VERO	3.20	----	6/ 2/87
AVS-2514	CPE	VSV	0.4	31.00	L929	10.00	0.32	4/10/87
AVS-2514	CPE	VV	0.75	10.00	VERO	3.20	0.32	4/10/87
AVS-2514	CPE	YFV	0.1	----	VERO	1.00	----	6/ 2/87
AVS-2515	CPE	AD2	----	----	HEP2 >	32.00	----	4/10/87
AVS-2515	PR	PIC	N/A	----	VERO	32.00	----	7/25/88
AVS-2515	CPE	PT	0.43	----	VERO	100.00	----	6/ 2/87
AVS-2515	CPE	SF	----	----	VERO	100.00	----	6/ 2/87
AVS-2515	CPE	VSV	----	----	L929 >	32.00	----	4/10/87
AVS-2515	CPE	VV	0.1	----	VERO >	32.00	----	4/10/87
AVS-2515	CPE	YFV	0.45	----	VERO	100.00	----	6/ 2/87
AVS-2516	CPE	AD2	----	----	HEP2	32.00	----	4/10/87
AVS-2516	PR	PIC	N/A	----	VERO >	32.00	----	7/25/88
AVS-2516	CPE	PT	0.52	----	VERO	100.00	----	6/ 2/87
AVS-2516	CPE	SF	----	----	VERO	320.00	----	6/ 2/87
AVS-2516	CPE	VSV	----	----	L929 >	32.00	----	4/10/87
AVS-2516	CPE	VV	----	----	VERO >	32.00	----	4/10/87
AVS-2516	CPE	YFV	0.1	----	VERO	100.00	----	6/ 2/87
AVS-2517	CPE	AD2	0.2	----	HEP2 <	10.00	----	4/10/87
AVS-2517	PR	PIC	N/A	2.69	VERO	3.20	1.18	7/25/88
AVS-2517	CPE	PT	0.16	----	VERO <	10.00	----	6/ 2/87
AVS-2517	CPE	SF	1.05	3.54	VERO	10.00	2.82	6/ 2/87
AVS-2517	CPE	VSV	0.2	----	L929	3.20	----	4/10/87
AVS-2517	CPE	VV	0.15	----	VERO	3.20	----	4/10/87
AVS-2517	CPE	YFV	0.8	----	VERO	3.20	----	6/ 2/87
AVS-2518	CPE	AD2	0.3	----	HEP2 <	32.00	----	4/10/87
AVS-2518	CPE	PT	0.45	6.80	VERO	10.00	1.46	6/26/87
AVS-2518	CPE	SF	1.1	2.39	VERO	10.00	4.18	6/ 3/87
AVS-2518	CPE	VSV	----	----	L929 <	10.00	----	4/10/87
AVS-2518	CPE	VV	0.4	----	VERO	10.00	----	4/10/87
AVS-2518	CPE	YFV	0.2	----	VERO	10.00	----	6/ 3/87
AVS-2519	CPE	AD2	0.1	----	HEP2	1.00	----	4/10/87
AVS-2519	PR	PIC	N/A	----	VERO	1.00	----	7/25/88
AVS-2519	CPE	PT	----	----	VERO	1.00	----	6/26/87
AVS-2519	CPE	SF	----	----	VERO	1.00	----	6/ 3/87
AVS-2519	CPE	VSV	----	----	L929 <	3.20	----	4/10/87
AVS-2519	CPE	VV	0.1	----	VERO	1.00	----	4/10/87
AVS-2519	CPE	YFV	0.85	0.50	VERO	1.00	2.00	6/ 3/87
AVS-2520	CPE	AD2	----	----	HEP2	10.00	----	4/10/87
AVS-2520	PR	PIC	N/A	----	VERO	10.00	----	7/25/88
AVS-2520	CPE	PT	0.05	----	VERO	1.00	----	6/26/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2520	CPE	SF	1.05	2.61	VERO	3.20	1.22	6/ 3/87
AVS-2520	CPE	VSV	----	----	L929	32.00	----	4/10/87
AVS-2520	CPE	VV	0.7	9.60	VERO	10.00	1.03	4/10/87
AVS-2520	CPE	YFV	0.15	----	VERO	10.00	----	6/ 3/87
AVS-2521	CPE	AD2	----	----	HEP2 <	0.10	----	4/10/87
AVS-2521	PR	PIC	N/A	2.05	VERO	1.00	0.49	7/25/88
AVS-2521	CPE	PT	----	----	VERO	1.00	----	6/26/87
AVS-2521	CPE	SF	----	----	VERO	1.00	----	6/ 3/87
AVS-2521	CPE	VSV	----	----	L929	0.10	----	4/10/87
AVS-2521	CPE	VV	----	----	VERO	1.00	----	4/10/87
AVS-2521	CPE	YFV	----	----	VERO	1.00	----	6/ 3/87
AVS-2522	CPE	AD2	0.4	----	HEP2 <	3.20	----	4/10/87
AVS-2522	PR	PIC	N/A	----	VERO	1.00	----	7/25/88
AVS-2522	CPE	PT	0.1	----	VERO	1.00	----	6/26/87
AVS-2522	CPE	SF	0.4	----	VERO	1.00	----	6/ 3/87
AVS-2522	CPE	VSV	----	----	L929 <	3.20	----	4/10/87
AVS-2522	CPE	VV	----	----	VERO	0.32	----	4/10/87
AVS-2522	CPE	YFV	0.45	2.17	VERO	1.00	0.46	6/ 3/87
AVS-2523	CPE	AD2	----	----	HEP2 >	32.00	----	4/10/87
AVS-2523	PR	PIC	N/A	----	VERO	100.00	----	7/25/88
AVS-2523	CPE	PT	0.1	----	VERO >	320.00	----	6/ 4/87
AVS-2523	CPE	SF	----	----	VERO >	320.00	----	6/ 4/87
AVS-2523	CPE	VSV	----	----	L929 >	32.00	----	4/10/87
AVS-2523	CPE	VV	----	----	VERO >	32.00	----	4/10/87
AVS-2523	CPE	YFV	----	----	VERO >	320.00	----	6/ 4/87
AVS-2524	CPE	AD2	----	----	HEP2 <	10.00	----	4/10/87
AVS-2524	PR	PIC	N/A	----	VERO	10.00	----	7/26/88
AVS-2524	CPE	PT	0.12	----	VERO	32.00	----	6/ 4/87
AVS-2524	CPE	SF	----	----	VERO <	100.00	----	6/ 4/87
AVS-2524	CPE	VSV	----	----	L929	10.00	----	4/10/87
AVS-2524	CPE	VV	0.6	6.60	VERO	10.00	1.51	4/10/87
AVS-2524	CPE	YFV	----	----	VERO	32.00	----	6/ 4/87
AVS-2525	CPE	AD2	----	----	HEP2 >	32.00	----	4/10/87
AVS-2525	CPE	PT	0.32	----	VERO	103.00	----	6/ 4/87
AVS-2525	CPE	SF	----	----	VERO	320.00	----	6/ 4/87
AVS-2525	CPE	VSV	----	----	L929 >	32.00	----	4/10/87
AVS-2525	CPE	VV	----	----	VERO	32.00	----	4/10/87
AVS-2525	CPE	YFV	----	----	VERO	320.00	----	6/ 4/87
AVS-2526	CPE	AD2	----	----	HEP2 >	32.00	----	4/10/87
AVS-2526	PR	PIC	N/A	----	VERO	100.00	----	7/26/88
AVS-2526	CPE	PT	0.5	----	VERO	320.00	----	6/ 4/87
AVS-2526	CPE	SF	----	----	VERO >	320.00	----	6/ 4/87
AVS-2526	CPE	VSV	----	----	L929 >	32.00	----	4/24/87
AVS-2526	CPE	VV	0.9	----	VERO >	32.00	----	4/24/87
AVS-2526	CPE	YFV	----	----	VERO >	320.00	----	6/ 4/87
AVS-2527	CPE	AD2	----	----	HEP2 >	32.00	----	4/24/87
AVS-2527	PR	PIC	N/A	0.93	VERO	32.00	34.00	7/26/88
AVS-2527	CPE	PT	0.83	----	VERO	320.00	----	6/ 4/87
AVS-2527	CPE	SF	----	----	VERO	320.00	----	6/ 4/87
AVS-2527	CPE	VEE	1.4	96.00	VERO	320.00	3.30	5/12/87
AVS-2527	CPE	VEE	----	----	VERO	100.00	----	5/17/88
AVS-2527	CPE	VSV	----	----	L929 >	32.00	----	4/24/87
AVS-2527	CPE	VV	----	----	VERO >	32.00	----	4/24/87
AVS-2527	CPE	YFV	----	----	VERO	320.00	----	6/ 4/87
AVS-2528	CPE	AD2	----	----	HEP2	32.00	----	4/24/87
AVS-2528	PR	PIC	N/A	----	VERO	100.00	----	7/26/88
AVS-2528	CPE	PT	0.77	----	VERO	100.00	----	6/ 5/87
AVS-2528	CPE	SF	0.6	56.50	VERO	32.00	0.57	6/ 5/87
AVS-2528	CPE	VSV	0.4	----	L929 >	32.00	----	4/24/87
AVS-2528	CPE	VV	0.25	----	VERO	32.00	----	4/24/87
AVS-2528	CPE	YFV	0.6	56.50	VERO	32.00	0.57	6/ 5/87
AVS-2529	CPE	AD2	1.4 <	0.03	HEP2	0.10 >	3.12	4/24/87
AVS-2529	PR	PIC	N/A	----	VERO	0.10	----	7/26/88
AVS-2529	CPE	SF	----	----	VERO <	0.32	----	6/ 5/87
AVS-2529	CPE	VSV	1.65	0.09	L929 "	0.03 "	0.34	4/24/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMP	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2529	CPE	VV	----	----	VERO <	0.32	----	4/24/87
AVS-2529	CPE	YFV	----	----	VERO <	0.32	----	6/ 5/87
AVS-2530	CPE	AD2	----	----	HEP2 >	32.00	----	4/24/87
AVS-2530	PR	PIC	N/A	----	VERO >	100.00	----	7/26/88
AVS-2530	CPE	PT	0.09	----	VERO	100.00	----	6/ 5/87
AVS-2530	CPE	SF	0.1	----	VERO <	320.00	----	5/ 5/87
AVS-2530	CPE	VSV	----	----	L929 >	32.00	----	4/24/87
AVS-2530	CPE	VV	----	----	VERO >	32.00	----	4/24/87
AVS-2530	CPE	YFV	0.2	----	VERO <	320.00	----	6/ 5/87
AVS-2531	CPE	AD2	----	----	HEP2 <	3.20	----	4/24/87
AVS-2531	PR	PIC	N/A	----	VERO	10.00	----	7/26/88
AVS-2531	CPE	PT	0.48	----	VERO	3.20	----	6/ 5/87
AVS-2531	CPE	SF	1.35	4.85	VERO	10.00	2.05	6/ 5/87
AVS-2531	CPE	VSV	0.1	----	L929	3.20	----	4/24/87
AVS-2531	CPE	VV	0.8	----	VERO	32.00	----	4/24/87
AVS-2531	CPE	YFV	0.6	17.80	VERO	10.00	0.56	6/ 5/87
AVS-2532	CPE	AD2	0.3	----	HEP2	1.00	----	4/24/87
AVS-2532	PR	PIC	N/A	----	VERO	0.32	----	7/26/88
AVS-2532	CPE	PT	----	----	VERO	1.00	----	6/ 5/87
AVS-2532	CPE	SF	----	----	VERO	3.20	----	5/ 5/87
AVS-2532	CPE	VSV	0.1	----	L929 <	10.00	----	4/24/87
AVS-2532	CPE	VV	0.15	----	VERO	1.00	----	4/24/87
AVS-2532	CPE	YFV	----	----	VERO	3.20	----	6/ 5/87
AVS-2533	CPE	AD2	----	----	HEP2 <	0.10	----	4/24/87
AVS-2533	CPE	JE	----	----	VERO <	0.32	----	6/ 8/87
AVS-2533	CPE	SF	----	----	VERO <	0.32	----	6/ 8/87
AVS-2533	CPE	VSV	1.35	3.06	L929	0.10	0.03	4/24/87
AVS-2533	CPE	YFV	0-	----	VERO <	0.32	----	6/ 8/87
AVS-2534	CPE	AD2	0.55	3.15	HEP2	0.32	0.10	4/24/87
AVS-2534	CPE	JE	----	----	VERO	1.00	----	6/ 8/87
AVS-2534	PR	PIC	N/A	----	VERO >	3.20	----	7/26/88
AVS-2534	CPE	PT	0.2	----	VERO	0.32	----	6/ 8/87
AVS-2534	CPE	SF	0.05	----	VERO	3.20	----	6/ 8/87
AVS-2534	CPE	VSV	0.1	----	L929	1.00	----	4/24/87
AVS-2534	CPE	VV	1.3	1.82	VERO	0.32	0.18	4/24/87
AVS-2534	CPE	YFV	0.4	----	VERO	3.20	----	6/ 8/87
AVS-2535	CPE	AD2	----	----	HEP2 >	32.00	----	4/24/87
AVS-2535	CPE	JE	----	----	VERO >	320.00	----	6/ 8/87
AVS-2535	PR	PIC	N/A	----	VERO	100.00	----	7/29/88
AVS-2535	CPE	PT	1.35	----	VERO >	320.00	----	6/ 8/87
AVS-2535	CPE	SF	----	----	VERO >	320.00	----	6/ 8/87
AVS-2535	CPE	VSV	----	----	L929 >	32.00	----	4/24/87
AVS-2535	CPE	VV	----	----	VERO >	32.00	----	4/24/87
AVS-2535	CPE	YFV	0.9	----	VERO >	320.00	----	6/ 8/87
AVS-2536	CPE	AD2	----	----	HEP2 >	32.00	----	4/24/87
AVS-2536	CPE	JE	----	----	VERO >	320.00	----	6/ 8/87
AVS-2536	PR	PIC	N/A	----	VERO	100.00	----	7/29/88
AVS-2536	CPE	PT	1.54	5.00	VERO	10.00	1.96	12/ 4/86
AVS-2536	CPE	PT	1.6	----	VERO >	320.00	----	6/ 8/87
AVS-2536	CPE	SF	----	----	VERO >	320.00	----	6/ 8/87
AVS-2536	CPE	VSV	----	----	L929 >	32.00	----	4/24/87
AVS-2536	CPE	VV	----	----	VERO >	32.00	----	4/24/87
AVS-2536	CPE	YFV	----	----	VERO >	320.00	----	6/ 8/87
AVS-2537	CPE	AD2	----	----	HEP2 >	32.00	----	4/24/87
AVS-2537	CPE	JE	----	----	VERO <	100.00	----	6/ 8/87
AVS-2537	PR	PIC	N/A	----	VERO	10.00	----	7/29/88
AVS-2537	CPE	PT	0.47	----	VERO	32.00	----	6/ 8/87
AVS-2537	CPE	SF	0.4	100.00	VERO	32.00	0.32	6/ 8/87
AVS-2537	CPE	VSV	0.2	----	L929 >	32.00	----	4/24/87
AVS-2537	CPE	VV	----	----	VERO	32.00	----	4/24/87
AVS-2537	CPE	YFV	0.05	----	VERO	32.00	----	6/ 8/87
AVS-2538	CPE	AD2	----	----	HEP2 >	320.00	----	4/24/87
AVS-2538	CPE	JE	----	----	VERO	320.00	----	6/18/87
AVS-2538	PR	PIC	N/A	----	VERO >	320.00	----	2/15/88
AVS-2538	PR	PIC	N/A	----	VERO	320.00	----	7/29/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2538	CPE	PT	0.05	----	VERO	100.00	----	6/18/87
AVS-2538	CPE	SF	0.57	----	VERO	320.00	----	7/ 7/87
AVS-2538	CPE	VSV	----	----	L929 >	320.00	----	4/10/87
AVS-2538	CPE	VV	----	----	VERO >	320.00	----	4/24/87
AVS-2538	CPE	YFV	1.39	----	VERO >	320.00	----	7/ 7/87
AVS-2540	CPE	AD2	----	----	HEP2 >	320.00	----	4/24/87
AVS-2540	CPE	JE	0.12	----	VERO	320.00	----	6/18/87
AVS-2540	PR	PIC	N/A	----	VERO >	320.00	----	2/15/88
AVS-2540	PR	PIC	N/A	----	VERO	100.00	----	7/29/88
AVS-2540	CPE	PT	0.05	----	VERO	320.00	----	6/18/87
AVS-2540	CPE	SF	0.34	----	VERO >	320.00	----	7/ 7/87
AVS-2540	CPE	VSV	----	----	L929 >	320.00	----	4/10/87
AVS-2540	CPE	VV	----	----	VERO >	320.00	----	4/24/87
AVS-2540	CPE	YFV	0.79	----	VERO >	320.00	----	7/ 7/87
AVS-2541	CPE	JE	----	----	VERO	0.32	----	6/18/87
AVS-2541	PR	PIC	N/A	----	VERO	10.00	----	2/15/88
AVS-2541	PR	PIC	N/A	----	VERO	10.00	----	7/29/88
AVS-2541	CPE	PT	0.8	116.00	VERO	10.00	0.09	6/18/87
AVS-2541	CPE	SF	----	----	VERO	3.20	----	7/ 7/87
AVS-2541	CPE	VSV	----	----	L929	3.20	----	4/10/87
AVS-2541	CPE	VV	0.1	----	VERO	10.00	----	4/24/87
AVS-2541	CPE	YFV	0.1	----	VERO	10.00	----	7/ 7/87
AVS-2542	CPE	AD2	----	----	HEP2	10.00	----	4/24/87
AVS-2542	CPE	JE	0.6	0.60	VERO	0.32	0.52	6/18/87
AVS-2542	PR	PIC	N/A	----	VERO	10.00	----	7/29/88
AVS-2542	CPE	PT	0.1	----	VERO	1.00	----	6/18/87
AVS-2542	CPE	SF	----	----	VERO	3.20	----	7/ 7/87
AVS-2542	CPE	VSV	0.3	----	L929	32.00	----	4/10/87
AVS-2542	CPE	VV	0.9	6.30	VERO	10.00	1.57	4/24/87
AVS-2542	CPE	YFV	0.1	----	VERO	1.00	----	7/ 7/87
AVS-2543	CPE	AD2	0.4	----	HEP2 <	32.00	----	5/ 4/87
AVS-2543	CPE	JE	----	----	VERO	32.00	----	6/18/87
AVS-2543	CPE	PT	0.85	59.80	VERO	100.00	1.67	7/10/87
AVS-2543	CPE	SF	1.5	10.30	VERO	32.00	3.09	7/16/87
AVS-2543	CPE	SF	0.1	----	VERO	100.00	----	5/26/88
AVS-2543	CPE	VSV	0.4	31.00	L929	32.00	1.03	5/ 5/87
AVS-2543	CPE	VV	----	----	VERO	32.00	----	5/14/87
AVS-2543	CPE	YFV	0.05	----	VERO	32.00	----	7/16/87
AVS-2544	CPE	AD2	----	----	HEP2 <	3.20	----	4/24/87
AVS-2544	PR	PIC	N/A	----	VERO	3.20	----	7/25/88
AVS-2544	CPE	VSV	----	----	L929	3.20	----	4/24/87
AVS-2544	CPE	VV	----	----	VERO <	10.00	----	4/24/87
AVS-2545	CPE	JE	----	----	VERO <	10.00	----	6/24/87
AVS-2545	CPE	PT	0.8	3.13	VERO	3.20	1.02	6/24/87
AVS-2545	CPE	SF	0.85	1.53	VERO	3.20	2.08	6/24/87
AVS-2545	CPE	YFV	0.1	----	VERO	1.00	----	6/24/87
AVS-2546	CPE	JE	----	----	VERO	3.20	----	6/24/87
AVS-2546	CPE	PT	0.3	----	VERO	1.00	----	6/24/87
AVS-2546	CPE	SF	----	----	VERO	0.32	----	6/24/87
AVS-2546	CPE	YFV	0.45	----	VERO	3.20	----	6/24/87
AVS-2547	CPE	PT	0.72	13.50	VERO	1.00	0.07	6/24/87
AVS-2548	CPE	JE	----	----	VERO	3.20	----	6/24/87
AVS-2548	CPE	PT	----	----	VERO	1.00	----	6/24/87
AVS-2548	CPE	SF	----	----	VERO	1.00	----	6/24/87
AVS-2548	CPE	YFV	----	----	VERO	1.00	----	6/24/87
AVS-2549	CPE	JE	----	----	VERO	10.00	----	6/24/87
AVS-2549	CPE	PT	----	----	VERO	3.20	----	6/24/87
AVS-2549	CPE	SF	----	----	VERO	1.00	----	6/24/87
AVS-2549	CPE	YFV	----	----	VERO	3.20	----	6/24/87
AVS-2550	CPE	JE	----	----	VERO	0.32	----	6/24/87
AVS-2550	CPE	SF	-0-	----	VERO <	0.32	----	6/24/87
AVS-2550	CPE	YFV	-0-	----	VERO <	0.32	----	6/24/87
AVS-2551	CPE	PT	0.08	----	VERO	1.00	----	6/24/87
AVS-2552	CPE	JE	----	----	VERO	0.32	----	6/24/87
AVS-2552	CPE	PT	----	----	VERO	0.32	----	6/24/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2552	CPE	YFV	0.35	----	VERO	0.32	----	6/24/87
AVS-2553	CPE	YFV	----	----	VERO	0.32	----	6/24/87
AVS-2554	CPF		----	----	VERO	10.00	----	6/25/87
AVS-2554	CF		0.2	----	VERO	3.20	----	6/24/87
AVS-2554	CI		----	----	VERO	1.00	----	6/25/87
AVS-2554	CPE	YFV	0.25	----	VERO	10.00	----	6/25/87
AVS-2555	CPE	PT	----	----	VERO	3.20	----	6/25/87
AVS-2555	CPE	YFV	----	----	VERO	3.20	----	6/25/87
AVS-2556	CPE	JE	----	----	VERO	0.32	----	6/25/87
AVS-2556	CPE	PT	----	----	VERO	0.32	----	6/25/87
AVS-2556	CPE	SF	----	----	VERO	0.32	----	6/25/87
AVS-2556	CPE	YFV	----	----	VERO	0.32	----	6/25/87
AVS-2557	CPE	JE	----	----	VERO	3.20	----	6/25/87
AVS-2557	CPE	PT	----	----	VERO	0.32	----	6/25/87
AVS-2557	CPE	SF	----	----	VERO	0.32	----	6/25/87
AVS-2557	CPE	YFV	0.15	----	VERO	0.32	----	6/25/87
AVS-2558	CPE	PT	----	----	VERO	0.32	----	6/25/87
AVS-2559	CPE	PT	----	----	VERO	0.32	----	6/25/87
AVS-2560	CPE	JE	----	----	VERO	10.00	----	6/25/87
AVS-2560	CPE	PT	0.6	5.60	VERO	0.32	0.06	6/25/87
AVS-2560	CPE	SF	0.1	----	VERO	0.32	----	6/25/87
AVS-2560	CPE	YFV	0.55	6.30	VERO	1.00	0.16	6/25/87
AVS-2561	CPE	JE	----	----	VERO	0.32	----	6/25/87
AVS-2561	CPE	PT	----	----	VERO	0.32	----	6/25/87
AVS-2561	CPE	SF	----	----	VERO	0.32	----	6/25/87
AVS-2561	CPE	YFV	-0-	----	VERO	0.32	----	6/25/87
AVS-2562	CPE	PT	----	----	VERO	32.00	----	6/25/87
AVS-2562	CPE	YFV	----	----	VERO	10.00	----	6/25/87
AVS-2563	CPE	AD2	1.1	46.70	HEP2	100.00	2.13	1/14/88
AVS-2563	CPE	AD2	1.7	9.50	HEP2	10.00	1.04	1/28/88
AVS-2563	CPE	AD2	1.7	20.60	HEP2	100.00	4.85	3/ 3/88
AVS-2563	CPE	JE	1.	0.64	VERO	3.20	5.00	6/25/87
AVS-2563	CPE	JE	1.	0.38	VERO	1.00	2.58	1/ 1/88
AVS-2563	CPE	JE	1.5	0.83	VERO	3.20	3.85	5/25/88
AVS-2563	PR	PIC	N/A	----	VERO	3.20	----	2/ 8/88
AVS-2563	CPE	PT	1.25	0.44	VERO	1.00	2.26	6/25/87
AVS-2563	CPE	SF	2.55	0.78	VERO	10.00	12.70	2/ 9/88
AVS-2563	CPE	VEE	----	----	VERO	0.32	----	3/ 1/88
AVS-2563	CPE	VSV	1.25	5.30	L929	3.20	0.60	1/29/88
AVS-2563	CPE	VV	0.5	6.30	VERO	3.20	0.50	11/ 5/87
AVS-2563	CPE	YFV	2.3	0.32	VERO	3.20	10.00	6/25/87
AVS-2563	CPE	YFV	1.	0.63	VERO	3.20	5.05	3/ 1/88
AVS-2563	CPE	YFV	1.6	0.13	VERO	0.32	2.39	5/25/88
AVS-2564	CPE	VSV	----	----	L929	32.00	----	4/24/87
AVS-2565	CPE	AD2	0.3	----	HEP2	320.00	----	5/14/87
AVS-2565	CPE	JE	----	----	VERO	32.00	----	6/19/87
AVS-2565	CPE	PT	0.7	----	VERO	100.00	----	7/10/87
AVS-2565	CPE	SF	2.1	30.10	VERO	100.00	3.31	7/17/87
AVS-2565	CPE	SF	----	----	VERO	100.00	----	5/26/88
AVS-2565	CPE	VSV	----	----	L929	320.00	----	5/ 5/87
AVS-2565	CPE	VV	----	----	VERO	100.00	----	5/14/87
AVS-2565	CPE	YFV	0.2	----	VERO	100.00	----	7/17/87
AVS-2566	CPE	AD2	----	----	HEP2	320.00	----	5/14/87
AVS-2566	CPE	JE	0.74	177.00	VERO	320.00	1.80	7/10/87
AVS-2566	CPE	PT	0.05	----	VERO	320.00	----	7/10/87
AVS-2566	CPE	SF	1.3	32.00	VERO	32.00	1.00	7/17/87
AVS-2566	CPE	VSV	----	----	L929	320.00	----	5/ 5/87
AVS-2566	CPE	VV	0.1	----	VERO	320.00	----	5/14/87
AVS-2566	CPE	YFV	----	----	VERO	100.00	----	7/17/87
AVS-2567	CPE	AD2	----	----	HEP2	320.00	----	5/14/87
AVS-2567	CPE	JE	----	----	VERO	320.00	----	7/10/87
AVS-2567	PR	PIC	N/A	----	VERO	320.00	----	2/22/88
AVS-2567	CPE	PT	0.25	----	VERO	320.00	----	7/10/87
AVS-2567	CPE	SF	0.25	----	VERO	320.00	----	7/17/87
AVS-2567	CPE	VSV	----	----	L929	320.00	----	5/ 5/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2567	CPE	VV	----	----	VERO >	320.00	----	5/14/87
AVS-2567	CPE	YFV	----	----	VERO	320.00	----	7/17/87
AVS-2568	CPE	AD2	----	----	HEP2	320.00	----	5/14/87
AVS-2568	CPE	JE	0.35	229.00	VERO	320.00	1.39	7/10/87
AVS-2568	PR	PIC	N/A	26.30	VERO	320.00	12.10	2/22/88
AVS-2568	CPE	PT	0.05	----	VERO	100.00	----	7/10/87
AVS-2568	CPE	SF	----	----	VERO	32.00	----	7/17/87
AVS-2568	CPE	VSV	0.85	98.00	L929	100.00	1.01	5/ 5/87
AVS-2568	CPE	VV	1.85	37.60	VERO	320.00	8.50	5/14/87
AVS-2568	CPE	VV	2.9	17.60	VERO	320.00	18.10	1/21/88
AVS-2568	CPE	YFV	0.85	----	VERO	32.00	----	7/17/87
AVS-2569	CPE	AD2	----	----	HEP2 <	320.00	----	5/28/87
AVS-2569	CPE	JE	0.3	263.00	VERO	100.00	0.38	7/10/87
AVS-2569	PR	PIC	N/A	----	VERO	320.00	----	2/22/88
AVS-2569	CPE	SF	0.57	59.60	VERO	100.00	1.67	7/17/87
AVS-2569	CPE	VSV	----	----	L929	100.00	----	5/ 5/87
AVS-2569	CPE	VV	----	----	VERO <	320.00	----	5/28/87
AVS-2569	CPE	YFV	----	----	VERO	10.00	----	7/17/87
AVS-2570	CPE	AD2	----	----	HEP2	100.00	----	6/ 4/87
AVS-2570	CPE	JE	----	----	VERO	100.00	----	5/18/87
AVS-2570	CPE	PT	0.7	----	VERO <	100.00	----	5/18/87
AVS-2570	CPE	SF	1.05	8.00	VERO	32.00	3.98	5/18/87
AVS-2570	CPE	VEE	----	----	VERO	100.00	----	5/18/87
AVS-2570	CPE	VSV	----	----	L929	10.00	----	6/ 5/87
AVS-2570	CPE	VV	0.15	----	VERO	32.00	----	6/ 4/87
AVS-2570	CPE	YFV	----	----	VERO	10.00	----	5/18/87
AVS-2571	CPE	AD2	----	----	HEP2	32.00	----	6/ 4/87
AVS-2571	CPE	JE	0.5	303.00	VERO	320.00	1.05	4/ 5/87
AVS-2571	CPE	PT	1.82	24.80	VERO	32.00	1.28	4/ 6/87
AVS-2571	CPE	SF	0.3	320.00	VERO	3.20	0.01	4/ 6/87
AVS-2571	CPE	VEE	1.	188.00	VERO	100.00	0.53	5/12/87
AVS-2571	CPE	VSV	0.15	----	L929	10.00	----	6/ 5/87
AVS-2571	CPE	VV	0.8	178.00	VERO	320.00	1.78	6/ 4/87
AVS-2571	CPE	YFV	1.7	30.30	VERO	3.20	0.10	4/ 6/87
AVS-2572	CPE	AD2	----	----	HEP2	100.00	----	6/ 4/87
AVS-2572	CPE	JE	----	----	VERO	32.00	----	4/ 6/87
AVS-2572	CPE	PT	1.4	54.10	VERO <	320.00 <	5.90	4/ 6/87
AVS-2572	CPE	SF	----	----	VERO	32.00	----	4/ 6/87
AVS-2572	CPE	VEE	1.15	128.00	VERO	100.00	0.78	5/ 5/87
AVS-2572	CPE	VSV	----	----	L929	32.00	----	6/ 5/87
AVS-2572	CPE	VV	0.3	----	VERO <	320.00	----	6/ 4/87
AVS-2572	CPE	YFV	1.05	30.60	VERO	32.00	1.04	4/ 6/87
AVS-2573	CPE	AD2	----	----	HEP2	100.00	----	6/ 4/87
AVS-2573	CPE	JE	0.75	120.00	VERO	100.00	0.83	4/ 6/87
AVS-2573	CPE	PT	1.09	33.50	VERO >	320.00 >	9.54	4/ 6/87
AVS-2573	CPE	PT	1.75	26.00	VERO	32.00	1.22	12/14/87
AVS-2573	CPE	SF	0.45	306.00	VERO	32.00	0.10	4/ 6/87
AVS-2573	CPE	VEE	1.35	313.00	VERO	100.00	0.32	5/ 5/87
AVS-2573	CPE	VSV	----	----	L929	10.00	----	6/ 5/87
AVS-2573	CPE	VV	0.5	197.00	VERO	100.00	0.51	6/ 4/87
AVS-2573	CPE	YFV	1.15	93.90	VERO	100.00	1.06	4/ 6/87
AVS-2574	CPE	AD2	----	----	HEP2	100.00	----	6/ 4/87
AVS-2574	CPE	JE	----	----	VERO	100.00	----	4/ 6/87
AVS-2574	PR	PIC	N/A	----	VERO	32.00	----	7/12/88
AVS-2574	CPE	PT	0.07	----	VERO	32.00	----	4/ 6/87
AVS-2574	CPE	SF	----	----	VERO	32.00	----	4/ 6/87
AVS-2574	CPE	VEE	----	----	VERO	0.32	----	5/ 5/87
AVS-2574	CPE	VSV	----	----	L929	10.00	----	6/ 5/87
AVS-2574	CPE	VV	----	----	VERO <	100.00	----	6/ 4/87
AVS-2574	CPE	YFV	0.65	66.40	VERO	32.00	0.48	4/ 6/87
AVS-2574	CPE	YFV	0.79	----	VERO	100.00	----	7/ 7/87
AVS-2575	CPE	AD2	----	----	HEP2	10.00	----	6/ 4/87
AVS-2575	CPE	JE	0.65	178.00	VERO	320.00	1.78	4/ 6/87
AVS-2575	PR	PIC	N/A	39.50	VERO	100.00	2.52	3/18/88
AVS-2575	CPE	PT	0.75	98.00	VERO	32.00	0.32	4/ 6/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2575	CPE	SF	0.6	297.00	VERO	1.00	----	4/ 6/87
AVS-2575	CPE	VEE	1.6	113.00	VERO >	320.00 >	2.83	5/ 5/87
AVS-2575	CPE	VSV	----	----	L929	32.00	----	6/ 5/87
AVS-2575	CPE	VV	----	----	VERO	100.00	----	6/ 4/87
AVS-2575	CPE	YFV	1.6	31.00	VERO	32.00	1.03	4/ 6/87
AVS-2576	CPE	AD2	----	----	HEP2	32.00	----	6/ 4/87
AVS-2576	CPE	JE	0.32	309.00	VERO	32.00	0.10	4/ 7/87
AVS-2576	PR	PIC	N/A	38.10	VERO	100.00	2.62	3/18/88
AVS-2576	CPE	PT	-1.4	150.00	VERO	10.00	0.07	4/ 7/87
AVS-2576	CPE	SF	0.6	297.00	VERO	10.00	0.03	4/ 7/87
AVS-2576	CPE	VEE	1.5	78.10	VERO	320.00	4.09	5/ 5/87
AVS-2576	CPE	VEE	----	----	VERO >	320.00	----	5/24/88
AVS-2576	CPE	VSV	----	----	L929	32.00	----	6/ 5/87
AVS-2576	CPE	VV	----	----	VERO	100.00	----	6/ 4/87
AVS-2576	CPE	YFV	2.9	2.53	VERO	10.00	3.94	4/ 7/87
AVS-2576	CPE	YFV	2.	19.20	VERO	10.00	0.52	5/25/88
AVS-2577	CPE	AD2	----	----	HEP2 <	320.00	----	6/ 4/87
AVS-2577	CPE	JE	0.05	----	VERO <	32.00	----	4/ 7/87
AVS-2577	PR	PIC	N/A	28.00	VERO	100.00	3.56	3/18/88
AVS-2577	CPE	PT	1.25	7.80	VERO	10.00	1.27	4/ 7/87
AVS-2577	CPE	SF	----	----	VERO	3.20	----	4/ 7/87
AVS-2577	CPE	VEE	0.75	100.00	VERO	10.00	0.10	5/ 5/87
AVS-2577	CPE	VSV	----	----	L929	10.00	----	6/ 5/87
AVS-2577	CPE	VV	----	----	VERO	32.00	----	6/ 4/87
AVS-2577	CPE	YFV	0.6	----	VERO	10.00	----	4/ 7/87
AVS-2578	CPE	AD2	0.3	----	HEP2 >	320.00	----	6/ 4/87
AVS-2578	CPE	JE	0.1	----	VERO >	320.00	----	4/ 7/87
AVS-2578	CPE	PT	0.95	----	VERO >	320.00	----	4/ 7/87
AVS-2578	CPE	SF	----	----	VERO	320.00	----	4/ 7/87
AVS-2578	CPE	VEE	0.3	----	VERO	100.00	----	5/ 5/87
AVS-2578	CPE	VSV	----	----	L929 >	320.00	----	6/ 5/87
AVS-2578	CPE	VV	----	----	VERO >	320.00	----	6/ 4/87
AVS-2579	CPE	AD2	0.6	320.00	HEP2 >	320.00 >	1.00	6/ 4/87
AVS-2579	CPE	JE	----	----	VERO >	320.00	----	5/18/87
AVS-2579	PR	PIC	N/A	----	VERO >	320.00	----	3/18/88
AVS-2579	CPE	PT	0.7	----	VERO >	320.00	----	5/18/87
AVS-2579	CPE	SF	2.05	26.60	VERO >	320.00 >	11.90	5/18/87
AVS-2579	CPE	VEE	----	----	VERO	100.00	----	5/18/87
AVS-2579	CPE	VSV	----	----	L929	320.00	----	6/ 5/87
AVS-2579	CPE	VV	----	----	VERO >	320.00	----	6/ 4/87
AVS-2579	CPE	YFV	----	----	VERO >	320.00	----	5/18/87
AVS-2580	CPE	AD2	0.35	----	HEP2	100.00	----	6/ 4/87
AVS-2580	CPE	JE	----	----	VERO	10.00	----	4/ 7/87
AVS-2580	CPE	PT	1.6	2.20	VERO	10.00	4.53	4/ 7/87
AVS-2580	CPE	SF	0.35	9.80	VERO	3.20	0.32	4/ 7/87
AVS-2580	CPE	VEE	1.95	1.75	VERO	3.20	1.82	5/ 5/87
AVS-2580	CPE	VSV	----	----	L929	100.00	----	6/ 5/87
AVS-2580	CPE	VV	1.3	56.10	VERO	32.00	0.57	6/ 4/87
AVS-2581	CPE	AD2	----	----	HEP2 <	100.00	----	6/ 4/87
AVS-2581	CPE	JE	0.65	297.00	VERO	320.00	1.07	4/ 7/87
AVS-2581	PR	PIC	N/A	5.90	VERO	100.00	16.60	3/21/88
AVS-2581	CPE	PT	1.07	29.60	VERO	32.00	1.07	4/ 7/87
AVS-2581	CPE	SF	0.6	297.00	VERO	10.00	0.03	4/ 7/87
AVS-2581	CPE	VEE	0.45	----	VERO	100.00	----	5/ 5/87
AVS-2581	CPE	VSV	----	----	L929	32.00	----	6/ 5/87
AVS-2581	CPE	VV	----	----	VERO	10.00	----	6/ 4/87
AVS-2581	CPE	YFV	1.8	17.90	VERO	3.20	0.18	2/ 2/88
AVS-2582	CPE	AD2	----	----	HEP2	32.00	----	6/ 4/87
AVS-2582	CPE	JE	0.4	307.00	VERO	320.00	1.04	4/ 8/87
AVS-2582	PR	PIC	N/A	17.30	VERO	100.00	5.78	7/12/88
AVS-2582	CPE	PT	1.32	29.60	VERO	100.00	3.36	4/ 8/87
AVS-2582	CPE	PT	0.8	133.00	VERO	10.00	0.07	5/25/88
AVS-2582	CPE	SF	0.45	306.00	VERO	3.20	0.01	4/ 8/87
AVS-2582	CPE	VSV	----	----	L929	100.00	----	6/ 5/87
AVS-2582	CPE	VV	0.1	----	VERO	32.00	----	6/ 4/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2582	CPE	YFV	1.8	44.20	VERO	10.00	0.22	4/ 8/87
AVS-2583	CPE	AD2	----	----	HEP2	100.00	----	6/ 4/87
AVS-2583	CPE	JE	0.6	260.00	VERO	320.00	1.22	4/ 8/87
AVS-2583	PR	PIC	N/A	21.90	VERO	32.00	1.45	3/21/88
AVS-2583	CPE	PT	0.85	31.50	VERO	32.00	1.01	4/ 8/87
AVS-2583	CPE	SF	0.6	297.00	VERO	32.00	0.11	4/ 8/87
AVS-2583	CPE	VSV	----	----	L929	32.00	----	6/ 5/87
AVS-2583	CPE	VV	----	----	VERO	320.00	----	6/ 4/87
AVS-2583	CPE	YFV	1.7	30.30	VERO	32.00	1.05	4/ 8/87
AVS-2584	CPE	AD2	0.15	----	HEP2	100.00	----	6/ 4/87
AVS-2584	CPE	JE	----	----	VERO	32.00	----	4/ 8/87
AVS-2584	PR	PIC	N/A	41.70	VERO >	100.00 >	2.39	3/21/88
AVS-2584	CPE	PT	----	----	VERO	32.00	----	4/ 8/87
AVS-2584	CPE	SF	----	----	VERO	32.00	----	4/ 8/87
AVS-2584	CPE	VSV	0.2	----	L929	10.00	----	6/ 5/87
AVS-2584	CPE	VV	----	----	VERO <	100.00	----	6/ 4/87
AVS-2584	CPE	YFV	0.1	----	VERO	32.00	----	4/ 8/87
AVS-2585	CPE	AD2	----	----	HEP2 <	100.00	----	6/ 4/87
AVS-2585	CPE	JE	1.6	98.00	VERO >	320.00	3.23	4/ 8/87
AVS-2585	CPE	JE	0.6	178.00	VERO	3.20	0.02	5/25/88
AVS-2585	PR	PIC	N/A	8.30	VERO	100.00	11.90	3/21/88
AVS-2585	CPE	PT	1.27	94.20	VERO	320.00	3.39	4/ 8/87
AVS-2585	CPE	PT	1.2	56.50	VERO	10.00	0.18	5/25/88
AVS-2585	CPE	SF	0.6	297.00	VERO	3.20	0.01	4/ 8/87
AVS-2585	CPE	VSV	0.05	----	L929	100.00	----	6/ 5/87
AVS-2585	CPE	VV	0.25	----	VERO	100.00	----	6/ 4/87
AVS-2585	CPE	YFV	1.75	30.00	VERO	32.00	1.06	4/ 8/87
AVS-2586	CPE	AD2	0.2	----	HEP2 >	320.00	----	6/ 4/87
AVS-2586	CPE	JE	----	----	VERO >	320.00	----	4/ 8/87
AVS-2586	PR	PIC	N/A	----	VERO	320.00	----	3/21/88
AVS-2586	CPE	PT	0.05	----	VERO >	320.00	----	4/ 8/87
AVS-2586	CPE	SF	----	----	VERO >	320.00	----	4/ 8/87
AVS-2586	CPE	VSV	----	----	L929	320.00	----	6/ 5/87
AVS-2586	CPE	VV	----	----	VERO	320.00	----	6/ 4/87
AVS-2586	CPE	YFV	1.6	71.80	VERO	320.00	4.45	4/ 8/87
AVS-2587	CPE	AD2	0.3	----	HEP2	320.00	----	6/ 4/87
AVS-2587	CPE	JE	----	----	VERO	10.00	----	4/ 9/87
AVS-2587	PR	PIC	N/A	----	VERO	32.00	----	7/12/88
AVS-2587	CPE	PT	1.3	28.50	VERO	32.00	1.12	4/ 9/87
AVS-2587	CPE	SF	1.5	9.60	VERO	10.00	1.03	4/ 9/87
AVS-2587	CPE	VSV	----	----	L929	100.00	----	6/ 5/87
AVS-2587	CPE	VV	1.7	55.10	VERO	100.00	1.81	6/ 4/87
AVS-2587	CPE	YFV	1.95	7.30	VERO	3.20	0.44	4/ 9/87
AVS-2588	CPE	AD2	----	----	HEP2	32.00	----	6/ 4/87
AVS-2588	CPE	JE	0.52	203.00	VERO	320.00	1.57	4/ 9/87
AVS-2588	CPE	PT	2.9	42.80	VERO >	320.00 >	7.46	4/ 9/87
AVS-2588	CPE	PT	0.5	222.00	VERO	10.00	0.04	5/15/88
AVS-2588	CPE	SF	0.9	297.00	VERO	10.00	0.03	4/ 9/87
AVS-2588	CPE	VSV	----	----	L929	32.00	----	6/ 5/87
AVS-2588	CPE	VV	0.7	----	VERO <	320.00	----	6/ 4/87
AVS-2588	CPE	YFV	1.6	31.00	VERO	32.00	1.03	4/ 9/87
AVS-2589	CPE	AD2	0.6	306.00	HEP2	320.00	1.04	6/11/87
AVS-2589	CPE	JE	0.25	----	VERO	320.00	----	4/ 9/87
AVS-2589	PR	PIC	N/A	48.10	VERO	100.00	2.07	3/21/88
AVS-2589	CPE	PT	1.18	80.30	VERO	100.00	1.24	4/ 9/87
AVS-2589	CPE	SF	----	----	VERO	32.00	----	4/ 9/87
AVS-2589	CPE	VSV	0.15	----	L929	32.00	----	6/12/87
AVS-2589	CPE	VV	----	----	VERO	320.00	----	6/11/87
AVS-2589	CPE	YFV	1.4	37.20	VERO	10.00	0.27	4/ 9/87
AVS-2590	CPE	AD2	0.3	----	HEP2 <	320.00	----	6/11/87
AVS-2590	CPE	JE	1.2	100.00	VERO	320.00	3.20	4/ 9/87
AVS-2590	CPE	PT	2.3	21.60	VERO <	320.00 <	14.80	4/ 9/87
AVS-2590	CPE	PT	0.85	132.00	VERO	100.00	0.76	8/21/87
AVS-2590	CPE	SF	0.05	----	VERO	32.00	----	4/ 9/87
AVS-2590	CPE	VSV	0.25	----	L929	100.00	----	6/12/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2590	CPE	VV	0.5	----	VERO >	320.00	----	6/11/87
AVS-2590	CPE	YFV	1.55	31.40	VERO	32.00	1.01	4/ 9/87
AVS-2591	CPE	AD2	----	----	HEP2	100.00	----	6/11/87
AVS-2591	CPE	JE	2.	96.00	VERO >	320.00	3.37	4/ 9/87
AVS-2591	CPE	JE	1.05	83.00	VERO	10.00	0.12	5/25/88
AVS-2591	PR	PIC	N/A	17.40	VERO	100.00	5.73	3/21/88
AVS-2591	CPE	PT	1.57	30.40	VER	10.00	0.33	4/ 9/87
AVS-2591	CPE	SF	1.2	93.10	VERO	10.00	0.11	4/ 9/87
AVS-2591	CPE	VSV	----	----	L929	32.00	----	6/12/87
AVS-2591	CPE	VV	0.05	----	VERO	320.00	----	6/11/87
AVS-2591	CPE	YFV	1.9	29.70	VERO	32.00	1.07	4/ 9/87
AVS-2592		AD2	0.4	319.00	HEP2	320.00	1.00	6/11/87
AVS-2592	CPE	JE	----	----	VERO >	320.00	----	4/10/87
AVS-2592	PR	PIC	N/A	100.00	VERO	320.00	3.17	3/22/88
AVS-2592	CPE	PT	1.39	202.00	VERO	100.00	0.49	4/10/87
AVS-2592	CPE	SF	0.15	----	VERO	32.00	----	4/10/87
AVS-2592	CPE	VSV	----	----	L929	100.00	----	6/12/87
AVS-2592	CPE	VV	0.2	----	VERO	320.00	----	6/11/87
AVS-2592	CPE	YFV	2.25	29.10	VERO	32.00	1.09	4/10/87
AVS-2593	CPE	AD2	----	----	HEP2 >	320.00	----	6/11/87
AVS-2593	CPE	JE	----	----	VERO >	320.00	----	4/10/87
AVS-2593	PR	PIC	N/A	----	VERO	100.00	----	7/15/88
AVS-2593	CPE	PT	0.5	----	VERO >	320.00	----	4/10/87
AVS-2593	CPE	SF	----	----	VERO	320.00	----	4/10/87
AVS-2593	CPE	VSV	----	----	L929	320.00	----	6/12/87
AVS-2593	CPE	VV	----	----	VERO >	320.00	----	6/11/87
AVS-2593	CPE	YFV	----	----	VERO >	320.00	----	4/10/87
AVS-2594	CPE	AD2	----	----	HEP2 >	320.00	----	6/11/87
AVS-2594	CPE	JE	----	----	VERO >	320.00	----	4/10/87
AVS-2594	PR	PIC	N/A	16.00	VERO	100.00	6.21	7/15/88
AVS-2594	CPE	PT	0.44	----	VERO >	320.00	----	4/10/87
AVS-2594	CPE	SF	----	----	VERO >	320.00	----	4/10/87
AVS-2594	CPE	VSV	----	----	L929 >	320.00	----	6/12/87
AVS-2594	CPE	VV	----	----	VERO >	320.00	----	6/11/87
AVS-2594	CPE	YFV	0.2	----	VERO >	320.00	----	4/10/87
AVS-2595	CPE	AD2	----	----	HEP2	1.00	----	6/11/87
AVS-2595	CPE	JE	----	----	VERO	100.00	----	5/18/87
AVS-2595	PR	PIC	N/A	----	VERO	32.00	----	7/15/88
AVS-2595	CPE	PT	0.5	----	VERO	100.00	----	5/18/87
AVS-2595	CPE	SF	----	----	VERO	32.00	----	5/18/87
AVS-2595	CPE	VEE	----	----	VERO	320.00	----	5/18/87
AVS-2595	CPE	VSV	----	----	L929	1.00	----	6/12/87
AVS-2595	CPE	VV	----	----	VERO <	100.00	----	6/11/87
AVS-2595	CPE	YFV	----	----	VERO	32.00	----	5/18/87
AVS-2596	CPE	AD2	----	----	HEP2 <	32.00	----	6/11/87
AVS-2596	CPE	JE	----	----	VERO	100.00	----	5/18/87
AVS-2596	PR	PIC	N/A	----	VERO	32.00	----	7/15/88
AVS-2596	CPE	PT	0.35	----	VERO	100.00	----	5/18/87
AVS-2596	CPE	SF	----	----	VERO	32.00	----	5/18/87
AVS-2596	CPE	VEE	----	----	VERO	320.00	----	5/18/87
AVS-2596	CPE	VSV	----	----	L929	10.00	----	6/12/87
AVS-2596	CPE	VV	----	----	VERO	100.00	----	6/11/87
AVS-2596	CPE	YFV	----	----	VERO	32.00	----	5/18/87
AVS-2597	CPE	AD2	0.15	----	HEP2	100.00	----	6/11/87
AVS-2597	CPE	JE	----	----	VERO >	320.00	----	5/18/87
AVS-2597	PR	PIC	N/A	----	VERO >	32.00	----	7/15/88
AVS-2597	CPE	PT	0.9	----	VERO	320.00	----	5/18/87
AVS-2597	CPE	SF	1.25	103.00	VERO	100.00	0.97	5/18/87
AVS-2597	CPE	VEE	1.25	73.40	VERO	320.00	4.35	5/18/87
AVS-2597	CPE	VEE	----	----	VERO	32.00	----	5/17/88
AVS-2597	CPE	VSV	----	----	L929	100.00	----	6/12/87
AVS-2597	CPE	VV	----	----	VERO	320.00	----	6/11/87
AVS-2597	CPE	YFV	----	----	VERO	32.00	----	5/18/87
AVS-2598	CPE	AD2	0.5	----	HEP2 <	320.00	----	6/11/87
AVS-2598	CPE	JE	----	----	VERO	320.00	----	5/19/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2598	PR	PIC	N/A	----	VERO	32.00	----	7/15/88
AVS-2598	CPE	PT	----	----	VERO	320.00	----	5/19/87
AVS-2598	CPE	SF	0.95	133.00	VERO	32.00	0.24	8/11/87
AVS-2598	CPE	VEE	----	----	VERO	320.00	----	5/19/87
AVS-2598	CPE	VSV	----	----	L929	100.00	----	6/12/87
AVS-2598	CPE	VV	----	----	VERO <	320.00	----	6/11/87
AVS-2598	CPE	YFV	0.1	----	VERO	32.00	----	5/19/87
AVS-2599	CPE	AD2	----	----	HEP2 <	10.00	----	6/11/87
AVS-2599	CPE	JE	----	----	VERO	10.00	----	5/19/87
AVS-2599	PR	PIC	N/A	----	VERO <	32.00	----	7/15/88
AVS-2599	CPE	PT	----	----	VERO	10.00	----	5/19/87
AVS-2599	CPE	SF	----	----	VERO	10.00	----	8/11/87
AVS-2599	CPE	VEE	----	----	VERO	32.00	----	5/19/87
AVS-2599	CPE	VSV	----	----	L929	3.20	----	6/12/87
AVS-2599	CPE	VV	----	----	VERO	32.00	----	6/11/87
AVS-2599	CPE	YFV	----	----	VERO	10.00	----	5/19/87
AVS-2600	CPE	AD2	----	----	HEP2 <	100.00	----	6/11/87
AVS-2600	CPE	JE	0.35	314.00	VERO	100.00	0.32	4/10/87
AVS-2600	CPE	PT	1.09	98.00	VERO	10.00	0.10	4/10/87
AVS-2600	CPE	SF	0.6	297.00	VERO	32.00	0.11	4/10/87
AVS-2600	CPE	VSV	----	----	L929	100.00	----	6/12/87
AVS-2600	CPE	VV	0.3	320.00	VERO	320.00	1.00	6/11/87
AVS-2600	CPE	YFV	1.9	30.30	VERO	10.00	0.33	4/10/87
AVS-2601	CPE	AD2	0.75	178.00	HEP2	320.00	1.79	6/11/87
AVS-2601	CPE	JE	----	----	VERO	320.00	----	5/19/87
AVS-2601	PR	PIC	N/A	----	VERO	100.00	----	7/18/88
AVS-2601	CPE	PT	0.22	----	VERO	320.00	----	5/19/87
AVS-2601	CPE	SF	1.1	118.00	VERO	320.00	2.71	8/11/87
AVS-2601	CPE	VEE	0.15	----	VERO	100.00	----	5/19/87
AVS-2601	CPE	VSV	----	----	L929 >	320.00	----	6/12/87
AVS-2601	CPE	VV	0.5	----	VERO >	320.00	----	6/11/87
AVS-2601	CPE	YFV	----	----	VERO	320.00	----	5/19/87
AVS-2602	CPE	AD2	----	----	HEP2 <	320.00	----	6/11/87
AVS-2602	CPE	JE	----	----	VERO	320.00	----	5/19/87
AVS-2602	CPE	PT	0.25	----	VERO	32.00	----	5/19/87
AVS-2602	CPE	SF	0.1	----	VERO	32.00	----	8/11/87
AVS-2602	CPE	VEE	0.6	----	VERO >	320.00	----	5/19/87
AVS-2602	CPE	VSV	----	----	L929	100.00	----	6/12/87
AVS-2602	CPE	VV	0.1	----	VERO <	320.00	----	6/11/87
AVS-2602	CPE	YFV	0.75	210.00	VERO	32.00	0.15	5/19/87
AVS-2603	CPE	AD2	0.7	178.00	HEP2	320.00	1.79	6/11/87
AVS-2603	CPE	JE	----	----	VERO	32.00	----	4/10/87
AVS-2603	CPE	PT	0.54	----	VERO	100.00	----	4/10/87
AVS-2603	CPE	SF	----	----	VERO <	320.00	----	4/10/87
AVS-2603	CPE	VSV	----	----	L929 <	320.00	----	6/12/87
AVS-2603	CPE	VV	0.4	----	VERO <	320.00	----	6/11/87
AVS-2603	CPE	YFV	----	----	VERO	32.00	----	4/10/87
AVS-2604	CPE	AD2	1.15	129.00	HEP2	320.00	2.47	6/11/87
AVS-2604	CPE	JE	----	----	VERO	10.00	----	4/13/87
AVS-2604	PR	PIC	N/A	----	VERO	100.00	----	7/18/88
AVS-2604	CPE	SF	0.25	----	VERO	32.00	----	4/13/87
AVS-2604	CPE	VEE	0.3	32.00	VERO	32.00	1.00	4/28/87
AVS-2604	CPE	VSV	----	----	L929	100.00	----	6/12/87
AVS-2604	CPE	VV	0.55	----	VERO	100.00	----	6/11/87
AVS-2604	CPE	YFV	----	----	VERO >	320.00	----	3/ 7/88
AVS-2605	CPE	AD2	0.55	222.00	HEP2	320.00	1.44	6/11/87
AVS-2605	CPE	JE	----	----	VERO	100.00	----	4/13/87
AVS-2605	PR	PIC	N/A	----	VERO	100.00	----	7/18/88
AVS-2605	CPE	SF	1.2	320.00	VERO	320.00	1.00	4/13/87
AVS-2605	CPE	VEE	----	----	VERO	320.00	----	4/28/87
AVS-2605	CPE	VV	0.15	----	VERO	320.00	----	6/11/87
AVS-2605	CPE	YFV	0.1	----	VERO	3.20	----	3/ 7/88
AVS-2606	CPE	AD2	0.6	178.00	HEP2	320.00	1.78	6/11/87
AVS-2606	CPE	JE	----	----	VERO	10.00	----	4/13/87
AVS-2606	CPE	SF	0.65	14.30	VERO	32.00	2.22	4/13/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2606	CPE	VEE	----	----	VERO	32.00	----	4/28/87
AVS-2606	CPE	VSV	----	----	L929	100.00	----	5/19/87
AVS-2606	CPE	VV	0.6	320.00	VERO	320.00	1.00	6/11/87
AVS-2606	CPE	YFV	0.35	8.40	VERO	3.20	0.38	3/ 7/88
AVS-2607	CPE	AD2	0.3	----	HEP2 <	3.20	----	6/11/87
AVS-2607	CPE	JE	----	----	VERO <	100.00	----	5/19/87
AVS-2607	CPE	PT	----	----	VERO	32.00	----	5/19/87
AVS-2607	CPE	SF	----	----	VERO	3.20	----	8/11/87
AVS-2607	CPE	VEE	----	----	VERO	100.00	----	5/19/87
AVS-2607	CPE	VSV	----	----	L929	10.00	----	5/19/87
AVS-2607	CPE	VV	----	----	VERO	100.00	----	6/11/87
AVS-2607	CPE	YFV	----	----	VERO	32.00	----	5/19/87
AVS-2608	CPE	AD2	0.7	169.00	HEP2	320.00	1.88	6/11/87
AVS-2608	CPE	JE	----	----	VERO	320.00	----	4/13/87
AVS-2608	CPE	SF	0.45	----	VERO	320.00	----	4/13/87
AVS-2608	CPE	VEE	----	----	VERO	320.00	----	4/28/87
AVS-2608	CPE	VSV	----	----	L929	100.00	----	5/19/87
AVS-2608	CPE	VV	----	----	VERO <	320.00	----	6/11/87
AVS-2608	CPE	YFV	----	----	VERO	10.00	----	3/ 7/88
AVS-2609	CPE	AD2	0.2	----	HEP2 <	320.00	----	6/11/87
AVS-2609	CPE	JE	----	----	VERO	100.00	----	4/13/87
AVS-2609	CPE	SF	0.45	320.00	VERO	100.00	3.20	4/13/87
AVS-2609	CPE	VEE	----	----	VERO	320.00	----	4/28/87
AVS-2609	CPE	VSV	----	----	L929	320.00	----	5/19/87
AVS-2609	CPE	VV	0.2	----	VERO	320.00	----	6/11/87
AVS-2609	CPE	YFV	----	----	VERO	10.00	----	3/ 7/88
AVS-2610	CPE	AD2	0.7	169.00	HEP2	320.00	1.88	6/11/87
AVS-2610	CPE	JE	----	----	VERO	320.00	----	4/14/87
AVS-2610	CPE	PT	1 12	----	VERO	100.00	----	4/14/87
AVS-2610	CPE	SF	0.7	320.00	VERO	320.00	1.00	4/14/87
AVS-2610	CPE	VEE	0.15	----	VERO	320.00	----	4/28/87
AVS-2610	CPE	VSV	----	----	L929	100.00	----	5/19/87
AVS-2610	CPE	VV	----	----	VERO	320.00	----	6/11/87
AVS-2610	CPE	YFV	0.25	----	VERO	100.00	----	4/14/87
AVS-2611	CPE	AD2	----	----	HEP2	32.00	----	6/11/87
AVS-2611	CPE	JE	----	----	VERO <	320.00	----	4/14/87
AVS-2611	PR	PIC	N/A	----	VERO	320.00	----	7/18/88
AVS-2611	CPE	PT	0.75	75.20	VERO	10.00	0.13	4/14/87
AVS-2611	CPE	SF	0.25	----	VERO	100.00	----	4/14/87
AVS-2611	CPE	VEE	----	----	VERO	100.00	----	4/28/87
AVS-2611	CPE	VSV	----	----	L929	32.00	----	5/19/87
AVS-2611	CPE	VV	0.4	99.00	VERO	100.00	1.00	6/11/87
AVS-2611	CPE	YFV	0.2	----	VERO	100.00	----	4/14/87
AVS-2612	CPE	AD2	0.8	64.00	HEP2	100.00	1.56	6/11/87
AVS-2612	CPE	JE	0.05	----	VERO	320.00	----	4/14/87
AVS-2612	CPE	PT	1.57	9.70	VERO	100.00	10.20	4/14/87
AVS-2612	CPE	PT	0.2	----	VERO	100.00	----	8/21/87
AVS-2612	CPE	PT	0.95	77.70	VERO	32.00	0.41	5/25/88
AVS-2612	CPE	SF	1.6	71.80	VERO	320.00	4.45	4/14/87
AVS-2612	CPE	SF	0.9	75.50	VERO	32.00	0.42	5/25/88
AVS-2612	CPE	VEE	----	----	VERO	320.00	----	4/28/87
AVS-2612	CPE	VSV	----	----	L929	32.00	----	5/19/87
AVS-2612	CPE	VV	0.25	----	VERO	100.00	----	6/11/87
AVS-2612	CPE	YFV	0.9	210.00	VERO	320.00	1.52	4/14/87
AVS-2613	CPE	AD2	0.35	----	HEP2	100.00	----	6/11/87
AVS-2613	CPE	JE	----	----	VERO <	320.00	----	4/14/87
AVS-2613	PR	PIC	N/A	----	VERO	32.00	----	7/18/88
AVS-2613	CPE	PT	0.85	----	VERO <	320.00	----	4/14/87
AVS-2613	CPE	SF	----	----	VERO <	320.00	----	4/14/87
AVS-2613	CPE	VEE	0.95	59.00	VERO	100.00	1.69	4/29/87
AVS-2613	CPE	VSV	----	----	L929	320.00	----	5/19/87
AVS-2613	CPE	VV	0.2	----	VERO	320.00	----	6/11/87
AVS-2613	CPE	YFV	----	----	VERO <	320.00	----	4/14/87
AVS-2614	CPE	AD2	0.25	----	HEP2	320.00	----	6/18/87
AVS-2614	CPE	JE	----	----	VERO	320.00	----	4/14/87

B-121

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2614	PR	PIC	N/A	42.20	VERO	32.00	0.76	7/18/88
AVS-2614	CPE	PT	1.4	67.60	VERO	10.00	0.15	4/14/87
AVS-2614	CPE	SF	0.6	297.00	VERO	100.00	0.34	4/14/87
AVS-2614	CPE	VEE	0.75	233.00	VERO	32.00	0.14	4/29/87
AVS-2614	CPE	VSV	----	----	L929	10.00	----	5/19/87
AVS-2614	CPE	VV	0.4	----	VERO	320.00	----	6/18/87
AVS-2614	CPE	YFV	1.2	93.10	VERO	32.00	0.34	4/14/87
AVS-2615	CPE	AD2	0.15	----	HEP2	320.00	----	6/18/87
AVS-2615	CPE	JE	----	----	VERO	320.00	----	4/15/87
AVS-2615	PR	PIC	N/A	74.30	VERO	100.00	1.34	7/18/88
AVS-2615	CPE	PT	0.7	98.00	VERO	32.00	0.32	4/15/87
AVS-2615	CPE	SF	0.6	297.00	VERO	100.00	0.34	4/15/87
AVS-2615	CPE	VEE	0.25	----	VERO	320.00	----	4/29/87
AVS-2615	CPE	VSV	0.15	----	L929	32.00	----	5/19/87
AVS-2615	CPE	VV	1.1	295.00	VERO >	320.00 >	1.08	6/18/87
AVS-2615	CPE	YFV	1.2	93.10	VERO	32.00	0.34	4/15/87
AVS-2616	CPE	AD2	0.6	178.00	HEP2	320.00	1.78	6/18/87
AVS-2616	CPE	JE	----	----	VERO	320.00	----	4/15/87
AVS-2616	PR	PIC	N/A	----	VERO	32.00	----	7/18/88
AVS-2616	CPE	PT	0.6	----	VERO	320.00	----	4/15/87
AVS-2616	CPE	SF	0.25	----	VERO	100.00	----	4/15/87
AVS-2616	CPE	VEE	0.6	----	VERO >	320.00	----	4/29/87
AVS-2616	CPE	VSV	----	----	L929	100.00	----	5/19/87
AVS-2616	CPE	VV	----	----	VERO	320.00	----	6/18/87
AVS-2616	CPE	YFV	0.15	----	VERO	320.00	----	4/15/87
AVS-2617	CPE	AD2	0.25	----	HEP2	100.00	----	6/18/87
AVS-2617	CPE	JE	0.35	314.00	VERO	320.00	1.01	4/15/87
AVS-2617	PR	PIC	N/A	77.20	VERO	3.20	0.04	7/18/88
AVS-2617	CPE	PT	0.45	----	VERO	32.00	----	4/15/87
AVS-2617	CPE	SF	0.05	----	VERO	100.00	----	4/15/87
AVS-2617	CPE	VEE	0.45	91.70	VERO	32.00	0.35	4/29/87
AVS-2617	CPE	VSV	----	----	L929	100.00	----	5/19/87
AVS-2617	CPE	VV	0.3	----	VERO <	320.00	----	6/18/87
AVS-2617	CPE	YFV	1.3	144.00	VERO	320.00	2.21	4/15/87
AVS-2618	CPE	AD2	0.3	----	HEP2	320.00	----	6/18/87
AVS-2618	CPE	JE	0.15	----	VERO	100.00	----	4/15/87
AVS-2618	PR	PIC	N/A	47.20	VERO >	320.00 >	6.76	7/18/88
AVS-2618	CPE	PT	0.3	----	VERO	10.00	----	4/15/87
AVS-2618	CPE	SF	----	----	VERO	32.00	----	4/15/87
AVS-2618	CPE	VEE	----	----	VERO	32.00	----	4/29/87
AVS-2618	CPE	VSV	0.15	----	L929	100.00	----	5/19/87
AVS-2618	CPE	VV	0.35	----	VERO	320.00	----	6/18/87
AVS-2618	CPE	YFV	1.1	85.40	VERO	32.00	0.37	4/15/87
AVS-2619	CPE	AD2	0.1	----	HEP2 <	100.00	----	6/18/87
AVS-2619	CPE	JE	0.05	----	VERO	100.00	----	4/15/87
AVS-2619	CPE	PT	1.1	92.80	VERO	100.00	1.07	4/15/87
AVS-2619	CPE	SF	0.7	217.00	VERO	100.00	0.46	4/15/87
AVS-2619	CPE	VEE	0.15	----	VERO	320.00	----	4/29/87
AVS-2619	CPE	VSV	----	----	L929	32.00	----	5/19/87
AVS-2619	CPE	VV	0.15	----	VERO	100.00	----	6/18/87
AVS-2619	CPE	YFV	1.1	98.00	VERO	100.00	1.01	4/15/87
AVS-2620	CPE	AD2	----	----	HEP2 <	100.00	----	6/18/87
AVS-2620	CPE	JE	----	----	VERO	100.00	----	4/16/87
AVS-2620	CPE	PT	0.73	82.80	VERO	100.00	1.20	4/16/87
AVS-2620	CPE	SF	0.3	----	VERO	100.00	----	4/16/87
AVS-2620	CPE	VEE	0.25	----	VERO	100.00	----	4/29/87
AVS-2620	CPE	VSV	----	----	L929	32.00	----	5/19/87
AVS-2620	CPE	VV	0.25	----	VERO	100.00	----	6/18/87
AVS-2620	CPE	YFV	----	----	VERO	32.00	----	3/ 7/88
AVS-2621	CPE	AD2	----	----	HEP2	320.00	----	6/18/87
AVS-2621	CPE	JE	----	----	VERO	320.00	----	4/16/87
AVS-2621	CPE	PT	0.45	----	VERO	32.00	----	4/16/87
AVS-2621	CPE	SF	----	----	VERO	100.00	----	4/16/87
AVS-2621	CPE	VEE	0.92	151.00	VERO	320.00	2.11	5/12/87
AVS-2621	CPE	VSV	----	----	L929	320.00	----	5/19/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2621	CPE	VV	0.35	----	VERO	320.00	----	6/18/87
AVS-2621	CPE	YFV	0.7	135.00	VERO	32.00	0.23	3/ 7/88
AVS-2622	CPE	AD2	0.6	178.00	HEP2	320.00	1.78	6/18/87
AVS-2622	CPE	JE	0.3	----	VERO	320.00	----	4/16/87
AVS-2622	CPE	PT	0.28	----	VERO	320.00	----	4/16/87
AVS-2622	CPE	SF	0.7	178.00	VERO	320.00	1.79	4/16/87
AVS-2622	CPE	VEE	0.55	----	VERO	100.00	----	5/12/87
AVS-2622	CPE	VSV	----	----	L929	100.00	----	5/19/87
AVS-2622	CPE	VV	----	----	VERO	320.00	----	6/18/87
AVS-2622	CPE	YFV	----	----	VERO	100.00	----	3/ 7/88
AVS-2623	CPE	AD2	0.1	----	HEP2 <	320.00	----	6/18/87
AVS-2623	CPE	JE	0.1	----	VERO	320.00	----	4/16/87
AVS-2623	CPE	PT	0.4	----	VERO	320.00	----	4/16/87
AVS-2623	CPE	SF	0.5	303.00	VERO	100.00	0.33	4/16/87
AVS-2623	CPE	VEE	----	----	VERO	0.32	----	5/12/87
AVS-2623	CPE	VSV	----	----	L929	100.00	----	5/19/87
AVS-2623	CPE	VV	----	----	VERO	320.00	----	6/18/87
AVS-2623	CPE	YFV	----	----	VERO	320.00	----	3/ 7/88
AVS-2624	CPE	AD2	0.65	199.00	HEP2	320.00	1.60	6/18/87
AVS-2624	CPE	JE	----	----	VERO	320.00	----	4/16/87
AVS-2624	CPE	PT	0.55	----	VERO	320.00	----	4/16/87
AVS-2624	CPE	SF	0.55	300.00	VERO	320.00	1.06	4/16/87
AVS-2624	CPE	VEE	1.2	256.00	VERO	100.00	0.39	5/12/87
AVS-2624	CPE	VSV	----	----	L929	320.00	----	5/19/87
AVS-2624	CPE	VV	0.45	----	VERO	320.00	----	6/18/87
AVS-2624	CPE	YFV	----	----	VERO	320.00	----	3/ 7/88
AVS-2625	CPE	AD2	1.3	178.00	HEP2 >	320.00 >	1.79	6/18/87
AVS-2625	CPE	JE	0.95	31.60	VERO	320.00	10.10	5/11/87
AVS-2625	CPE	JE	----	----	VERO	100.00	----	7/28/87
AVS-2625	CPE	JE	0.5	200.00	VERO	320.00	1.59	12/ 7/87
AVS-2625	CPE	PT	1.	64.00	VERO	32.00	0.50	4/17/87
AVS-2625	CPE	VEE	0.1	----	VERO	320.00	----	5/12/87
AVS-2625	CPE	VSV	----	----	L929	32.00	----	5/19/87
AVS-2625	CPE	VV	0.75	178.00	VERO	320.00	1.79	6/18/87
AVS-2625	CPE	YFV	1.	31.00	VERO	10.00	0.32	4/17/87
AVS-2626	CPE	AD2	0.45	217.00	HEP2	320.00	1.47	6/18/87
AVS-2626	CPE	JE	----	----	VERO >	320.00	----	5/20/87
AVS-2626	CPE	PT	1.34	----	VERO	320.00	----	5/20/87
AVS-2626	CPE	SF	----	----	VERO >	320.00	----	5/20/87
AVS-2626	CPE	VEE	----	----	VERO	320.00	----	5/20/87
AVS-2626	CPE	VSV	----	----	L929	100.00	----	5/19/87
AVS-2626	CPE	VV	----	----	VERO	320.00	----	6/18/87
AVS-2626	CPE	YFV	----	----	VERO >	320.00	----	5/20/87
AVS-2627	CPE	AD2	0.45	217.00	HEP2	320.00	1.47	6/18/87
AVS-2627	CPE	JE	----	----	VERO <	320.00	----	5/11/87
AVS-2627	CPE	PT	0.8	----	VERO <	320.00	----	4/17/87
AVS-2627	CPE	SF	2.65	63.90	VERO	100.00	1.56	4/29/88
AVS-2627	CPE	VSV	----	----	L929	320.00	----	5/19/87
AVS-2627	CPE	VV	----	----	VERO	320.00	----	6/18/87
AVS-2627	CPE	YFV	0.1	----	VERO	100.00	----	4/17/87
AVS-2628	CPE	AD2	----	----	HEP2 <	320.00	----	6/18/87
AVS-2628	CPE	JE	0.3	----	VERO	100.00	----	5/11/87
AVS-2628	CPE	PT	1.3	----	VERO <	320.00	----	4/17/87
AVS-2628	CPE	SF	1.97	85.00	VERO	10.00	0.12	4/29/88
AVS-2628	CPE	VEE	1.85	----	VERO	320.00	----	5/12/87
AVS-2628	CPE	VSV	----	----	L929	32.00	----	5/19/87
AVS-2628	CPE	VV	----	----	VERO <	320.00	----	6/18/87
AVS-2628	CPE	YFV	----	----	VERO <	320.00	----	4/17/87
AVS-2629	CPE	AD2	----	----	HEP2	32.00	----	6/18/87
AVS-2629	CPE	JE	----	----	VERO	32.00	----	5/11/87
AVS-2629	CPE	PT	1.6	----	VERO	100.00	----	4/17/87
AVS-2629	CPE	VEE	1.2	----	VERO	100.00	----	5/12/87
AVS-2629	CPE	VSV	----	----	L929	32.00	----	5/19/87
AVS-2629	CPE	VV	0.3	----	VERO	100.00	----	6/18/87
AVS-2629	CPE	YFV	1.	196.00	VERO	3.20	0.02	4/17/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2630	CPE	AD2	0.6	----	HEP2 <	320.00	----	6/18/87
AVS-2630	CPE	JE	0.65	219.00	VERO	100.00	0.46	5/11/87
AVS-2630	PR	PIC	N/A	56.50	VERO	100.00	1.76	7/22/88
AVS-2630	CPE	PT	0.95	86.70	VERO	100.00	1.15	4/17/87
AVS-2630	CPE	VEE	0.75	100.00	VERO	0.32	----	5/12/87
AVS-2630	CPE	VSV	0.9	210.00	L929	320.00	1.52	5/19/87
AVS-2630	CPE	VV	0.55	----	VERO	320.00	----	6/18/87
AVS-2630	CPE	YFV	3.75	6.40	VERO	320.00	49.70	4/17/87
AVS-2630	CPE	YFV	3.79	2.60	VERO	100.00	38.30	7/29/87
AVS-2631	CPE	AD2	----	----	HEP2 <	320.00	----	6/18/87
AVS-2631	CPE	JE	2.3	104.00	VERO >	320.00 >	3.07	4/20/87
AVS-2631	CPE	JE	0.2	----	VERO	32.00	----	5/25/88
AVS-2631	PR	PIC	N/A	40.70	VERO	32.00	0.79	7/22/88
AVS-2631	CPE	PT	1.8	48.10	VERO	100.00	2.07	4/20/87
AVS-2631	CPE	SF	1.	96.00	VERO	100.00	1.03	4/20/87
AVS-2631	CPE	VEE	1.8	56.60	VERO	320.00	5.64	5/12/87
AVS-2631	CPE	VEE	0.15	----	VERO	320.00	----	5/24/88
AVS-2631	CPE	VSV	0.75	210.00	L929	100.00	0.48	5/19/87
AVS-2631	CPE	VV	1.05	----	VERO	320.00	----	6/18/87
AVS-2631	CPE	YFV	2.8	16.50	VERO	100.00	6.05	4/20/87
AVS-2631	CPE	YFV	1.73	2.22	VERO	3.20	1.43	5/25/88
AVS-2632	CPE	AD2	0.3	----	HEP2	100.00	----	6/18/87
AVS-2632	CPE	JE	----	----	VERO <	100.00	----	5/20/87
AVS-2632	PR	PIC	N/A	----	VERO	32.00	----	7/22/88
AVS-2632	CPE	PT	1.09	----	VERO <	32.00	----	5/20/87
AVS-2632	CPE	SF	0.25	----	VERO	32.00	----	5/20/87
AVS-2632	CPE	VEE	----	----	VERO	0.32	----	5/20/87
AVS-2632	CPE	VSV	----	----	L929	32.00	----	5/19/87
AVS-2632	CPE	VV	0.1	----	VERO <	32.00	----	6/18/87
AVS-2632	CPE	YFV	----	----	VERO	10.00	----	5/20/87
AVS-2633	CPE	AD2	0.75	56.30	HEP2	100.00	1.77	6/18/87
AVS-2633	CPE	JE	----	----	VERO <	100.00	----	5/20/87
AVS-2633	PR	PIC	N/A	----	VERO	100.00	----	7/22/88
AVS-2633	CPE	PT	0.92	----	VERO	32.00	----	5/20/87
AVS-2633	CPE	SF	0.2	----	VERO	32.00	----	5/20/87
AVS-2633	CPE	VEE	----	----	VERO	32.00	----	5/20/87
AVS-2633	CPE	VSV	----	----	L929	100.00	----	5/19/87
AVS-2633	CPE	VV	0.3	----	VERO <	100.00	----	6/18/87
AVS-2633	CPE	YFV	----	----	VERO	3.20	----	5/20/87
AVS-2634	CPE	AD2	----	----	HEP2 <	10.00	----	6/18/87
AVS-2634	CPE	JE	----	----	VERO	32.00	----	5/20/87
AVS-2634	CPE	PT	0.26	----	VERO <	32.00	----	5/20/87
AVS-2634	CPE	SF	0.5	100.00	VERO	32.00	0.32	5/20/87
AVS-2634	CPE	VEE	0.6	93.10	VERO	0.32 <	----	5/20/87
AVS-2634	CPE	VSV	----	----	L929 <	32.00	----	5/19/87
AVS-2634	CPE	VV	----	----	VERO <	10.00	----	6/18/87
AVS-2634	CPE	YFV	----	----	VERO	10.00	----	5/20/87
AVS-2635	CPE	AD2	----	----	HEP2 <	32.00	----	6/18/87
AVS-2635	CPE	JE	----	----	VERO <	100.00	----	5/20/87
AVS-2635	CPE	PT	0.52	----	VERO	10.00	----	5/20/87
AVS-2635	CPE	SF	0.3	32.00	VERO	32.00	1.00	5/20/87
AVS-2635	CPE	VEE	0.5	88.00	VERO	32.00	0.36	5/20/87
AVS-2635	CPE	VSV	----	----	L929	32.00	----	5/19/87
AVS-2635	CPE	VV	0.6	17.80	VERO	32.00	1.78	6/18/87
AVS-2635	CPE	YFV	----	----	VERO	32.00	----	5/20/87
AVS-2636	CPE	AD2	----	----	HEP2	10.00	----	6/18/87
AVS-2636	CPE	JE	----	----	VERO	10.00	----	5/21/87
AVS-2636	CPE	PT	0.15	----	VERO	10.00	----	5/21/87
AVS-2636	CPE	SF	0.65	21.10	VERO	10.00	0.47	5/21/87
AVS-2636	CPE	VEE	0.65	22.70	VERO	10.00	0.44	5/21/87
AVS-2636	CPE	VSV	----	----	L929 <	32.00	----	5/19/87
AVS-2636	CPE	VV	----	----	VERO	10.00	----	6/18/87
AVS-2636	CPE	YFV	----	----	VERO	10.00	----	5/21/87
AVS-2637	CPE	AD2	----	----	HEP2 <	10.00	----	6/18/87
AVS-2637	CPE	JE	----	----	VERO	10.00	----	5/21/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MYC50	TI	DATE
AVS-2637	CPE	PT	0.45	----	VERO	10.00	----	5/21/87
AVS-2637	CPE	SF	0.75	66.00	VERO	10.00	0.15	5/21/87
AVS-2637	CPE	VEE	----	----	VERO	0.32	----	5/21/87
AVS-2637	CPE	VSV	----	----	L929	10.00	----	5/19/87
AVS-2637	CPE	VV	0.4	7.50	VERO	10.00	1.33	6/18/87
AVS-2637	CPE	YFV	----	----	VERO	10.00	----	5/21/87
AVS-2638	CPE	AD2	0.3	10.00	HEP2	10.00	1.00	6/18/87
AVS-2638	CPE	JE	----	----	VERO	32.00	----	5/21/87
AVS-2638	CPE	PT	0.1	----	VERO	10.00	----	5/21/87
AVS-2638	CPE	SF	0.5	30.30	VERO	10.00	0.33	5/21/87
AVS-2638	CPE	VEE	0.6	25.10	VERO	32.00	1.27	5/21/87
AVS-2638	CPE	VSV	----	----	L929	10.00	----	5/19/87
AVS-2638	CPE	VV	----	----	VERO	10.00	----	6/18/87
AVS-2638	CPE	YFV	----	----	VERO	10.00	----	5/21/87
AVS-2640	CPE	AD2	----	----	HEP2	320.00	----	5/28/87
AVS-2640	CPE	JE	0.05	----	VERO	320.00	----	7/13/87
AVS-2640	CPE	PT	0.74	----	VERO	100.00	----	6/23/87
AVS-2640	CPE	SF	----	----	VERO	320.00	----	6/23/87
AVS-2640	CPE	VSV	----	----	L929	320.00	----	5/ 5/87
AVS-2640	CPE	VV	----	----	VERO	320.00	----	5/28/87
AVS-2640	CPE	YFV	0.55	----	VERO	100.00	----	7/10/87
AVS-2641	CPE	AD2	----	----	HEP2	320.00	----	5/14/87
AVS-2641	CPE	JE	----	----	VERO	320.00	----	7/13/87
AVS-2641	CPE	PT	0.5	----	VERO	320.00	----	6/23/87
AVS-2641	CPE	SF	----	----	VERO	320.00	----	6/23/87
AVS-2641	CPE	VSV	----	----	L929	320.00	----	5/ 5/87
AVS-2641	CPE	VV	----	----	VERO	320.00	----	5/14/87
AVS-2641	CPE	YFV	----	----	VERO	320.00	----	7/10/87
AVS-2642	CPE	AD2	----	----	HEP2	320.00	----	5/14/87
AVS-2642	CPE	JE	----	----	VERO	320.00	----	7/13/87
AVS-2642	CPE	PT	0.1	----	VERO	320.00	----	6/23/87
AVS-2642	CPE	SF	----	----	VERO	320.00	----	6/23/87
AVS-2642	CPE	VSV	----	----	L929	320.00	----	5/ 5/87
AVS-2642	CPE	VV	----	----	VERO	320.00	----	5/14/87
AVS-2642	CPE	YFV	----	----	VERO	320.00	----	7/10/87
AVS-2643	CPE	AD2	----	----	HEP2	320.00	----	5/14/87
AVS-2643	CPE	JE	----	----	VERO	320.00	----	7/13/87
AVS-2643	CPE	PT	0.39	----	VERO	320.00	----	6/23/87
AVS-2643	CPE	SF	----	----	VERO	320.00	----	6/23/87
AVS-2643	CPE	VSV	----	----	L929	320.00	----	5/ 5/87
AVS-2643	CPE	VV	----	----	VERO	320.00	----	5/14/87
AVS-2643	CPE	YFV	----	----	VERO	320.00	----	7/10/87
AVS-2644	CPE	AD2	0.1	----	HEP2	320.00	----	5/21/87
AVS-2644	CPE	JE	----	----	VERO	320.00	----	7/13/87
AVS-2644	PR	PIC	N/A	----	VERO	320.00	----	8/ 2/88
AVS-2644	CPE	PT	0.14	----	VERO	320.00	----	6/23/87
AVS-2644	CPE	SF	----	----	VERO	320.00	----	6/23/87
AVS-2644	CPE	VSV	----	----	L929	320.00	----	5/ 5/87
AVS-2644	CPE	VV	0.3	----	VERO	320.00	----	5/21/87
AVS-2644	CPE	YFV	----	----	VERO	320.00	----	7/10/87
AVS-2645	CPE	AD2	----	----	HEP2	320.00	----	5/21/87
AVS-2645	CPE	JE	----	----	VERO	320.00	----	7/14/87
AVS-2645	PR	PIC	N/A	----	VERO	320.00	----	8/ 2/88
AVS-2645	CPE	PT	0.5	----	VERO	320.00	----	8/ 7/87
AVS-2645	CPE	SF	----	----	VERO	320.00	----	7/20/87
AVS-2645	CPE	VSV	----	----	L929	320.00	----	5/ 5/87
AVS-2645	CPE	VV	----	----	VERO	320.00	----	5/21/87
AVS-2645	CPE	YFV	----	----	VERO	100.00	----	7/20/87
AVS-2646	CPE	AD2	0.4	----	HEP2	320.00	----	5/21/87
AVS-2646	CPE	JE	----	----	VERO	320.00	----	7/14/87
AVS-2646	PR	PIC	N/A	----	VERO	320.00	----	8/ 2/88
AVS-2646	CPE	PT	0.4	----	VERO	320.00	----	8/ 7/87
AVS-2646	CPE	SF	----	----	VERO	320.00	----	7/20/87
AVS-2646	CPE	VSV	----	----	L929	320.00	----	5/ 5/87
AVS-2646	CPE	VV	----	----	VERO	320.00	----	5/21/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	T:	DATE
AVS-2646	CPE	YFV	----	----	VERO	32.00	----	7/20/87
AVS-2647	CPE	AD2	----	----	HEP2 >	320.00	----	5/21/87
AVS-2647	CPE	JE	----	----	VERO >	320.00	----	7/14/87
AVS-2647	PR	PIC	N/A	----	VERO	320.00	----	8/ 2/88
AVS-2647	CPE	PT	0.4	----	VERO	320.00	----	8/ 7/87
AVS-2647	CPE	SF	0.1	----	VERO >	320.00	----	7/20/87
AVS-2647	CPE	VSV	----	----	L929 >	320.00	----	5/ 5/87
AVS-2647	CPE	VV	----	----	VERO >	320.00	----	5/21/87
AVS-2647	CPE	YFV	----	----	VERO >	320.00	----	7/20/87
AVS-2648	CPE	AD2	0.2	----	HEP2 >	320.00	----	5/21/87
AVS-2648	CPE	JE	----	----	VERO >	320.00	----	7/14/87
AVS-2648	PR	PIC	N/A	----	VERO >	320.00	----	8/ 2/88
AVS-2648	CPE	PT	0.5	----	VERO >	320.00	----	8/ 7/87
AVS-2648	CPE	SF	0.02	----	VERO	10.00	----	7/20/87
AVS-2648	CPE	VSV	----	----	L929 >	320.00	----	5/ 5/87
AVS-2648	CPE	VV	0.1	----	VERO >	320.00	----	5/21/87
AVS-2648	CPE	YFV	----	----	VERO >	320.00	----	7/20/87
AVS-2649	CPE	AD2	0.3	----	HEP2 >	320.00	----	5/28/87
AVS-2649	CPE	JE	----	----	VERO <	320.00	----	7/14/87
AVS-2649	CPE	PT	0.2	----	VERO	10.00	----	8/ 7/87
AVS-2649	CPE	SF	0.17	----	VERO	3.20	----	7/20/87
AVS-2649	CPE	VSV	----	----	L929	320.00	----	5/ 5/87
AVS-2649	CPE	VV	0.05	----	VERO	320.00	----	5/28/87
AVS-2649	CPE	YFV	----	----	VERO	10.00	----	7/20/87
AVS-2650	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87
AVS-2650	CPE	JE	0.02	----	VERO	100.00	----	7/15/87
AVS-2650	CPE	PT	0.64	----	VERO	320.00	----	8/11/87
AVS-2650	CPE	SF	----	----	VERO >	320.00	----	7/21/87
AVS-2650	CPE	VSV	----	----	L929	320.00	----	5/ 5/87
AVS-2650	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2650	CPE	YFV	----	----	VERO	100.00	----	7/21/87
AVS-2651	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87
AVS-2651	CPE	JE	----	----	VERO >	320.00	----	7/15/87
AVS-2651	CPE	PT	0.4	----	VERO	100.00	----	8/11/87
AVS-2651	CPE	SF	0.15	----	VERO	10.00	----	7/21/87
AVS-2651	CPE	VSV	----	----	L929	320.00	----	5/ 5/87
AVS-2651	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2651	CPE	YFV	0.1	----	VERO	10.00	----	7/21/87
AVS-2652	CPE	AD2	0.1	----	HEP2 >	320.00	----	5/21/87
AVS-2652	CPE	JE	1.45	68.60	VERO	320.00	4.66	7/15/87
AVS-2652	CPE	JE	----	----	VERO	320.00	----	5/25/88
AVS-2652	PR	PIC	N/A	287.00	VERO	320.00	1.11	8/ 2/88
AVS-2652	CPE	PT	0.25	----	VERO >	320.00	----	8/11/87
AVS-2652	CPE	SF	----	----	VERO >	320.00	----	7/21/87
AVS-2652	CPE	VSV	----	----	L929 >	320.00	----	5/ 5/87
AVS-2652	CPE	VV	----	----	VERO >	320.00	----	5/21/87
AVS-2652	CPE	YFV	----	----	VERO	100.00	----	7/21/87
AVS-2653	CPE	AD2	----	----	HEP2 >	320.00	----	5/21/87
AVS-2653	CPE	JE	0.2	----	VERO >	320.00	----	7/15/87
AVS-2653	PR	PIC	N/A	----	VERO >	320.00	----	8/ 2/88
AVS-2653	CPE	PT	0.74	----	VERO >	320.00	----	8/11/87
AVS-2653	CPE	SF	----	----	VERO >	320.00	----	7/21/87
AVS-2653	CPE	VSV	----	----	L929 >	320.00	----	5/ 5/87
AVS-2653	CPE	VV	0.1	----	VERO >	320.00	----	5/21/87
AVS-2653	CPE	YFV	----	----	VERO >	320.00	----	7/21/87
AVS-2654	CPE	AD2	0.2	----	HEP2 >	320.00	----	5/21/87
AVS-2654	CPE	JE	----	----	VERO >	320.00	----	7/15/87
AVS-2654	PR	PIC	N/A	----	VERO	320.00	----	8/ 5/88
AVS-2654	CPE	PT	0.44	----	VERO >	320.00	----	8/11/87
AVS-2654	CPE	SF	----	----	VERO >	320.00	----	7/21/87
AVS-2654	CPE	VSV	----	----	L929	320.00	----	5/ 5/87
AVS-2654	CPE	VV	----	----	VERO >	320.00	----	5/21/87
AVS-2654	CPE	YFV	----	----	VERO	320.00	----	7/21/87
AVS-2655	CPE	AD2	0.2	----	HEP2 >	320.00	----	5/21/87
AVS-2655	CPE	JE	0.4	----	VERO >	320.00	----	7/16/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2655	PR	PIC	N/A	----	VERO >	320.00	----	8/ 5/88
AVS-2655	CPE	PT	----	----	VERO	320.00	----	8/12/87
AVS-2655	CPE	SF	0.2	----	VERO	100.00	----	7/22/87
AVS-2655	CPE	VSV	----	----	L929 >	320.00	----	5/ 5/87
AVS-2655	CPE	VV	0.3	----	VERO >	320.00	----	5/21/87
AVS-2655	CPE	YFV	0.2	----	VERO	320.00	----	7/22/87
AVS-2656	CPE	AD2	----	----	HEP2 >	320.00	----	5/21/87
AVS-2656	CPE	JE	1.1	118.00	VERO	320.00	2.71	7/16/87
AVS-2656	PR	PIC	N/A	----	VERO	320.00	----	8/ 5/88
AVS-2656	CPE	PT	----	----	VERO >	320.00	----	8/12/87
AVS-2656	CPE	SF	0.15	----	VERO	100.00	----	7/22/87
AVS-2656	CPE	VSV	----	----	L929 >	320.00	----	5/ 5/87
AVS-2656	CPE	VV	----	----	VERO >	320.00	----	5/21/87
AVS-2656	CPE	YFV	0.2	----	VERO	100.00	----	7/22/87
AVS-2657	CPE	AD2	0.3	----	HEP2 >	320.00	----	5/21/87
AVS-2657	CPE	JE	----	----	VERO >	320.00	----	7/16/87
AVS-2657	PR	PIC	N/A	----	VERO >	320.00	----	8/ 5/88
AVS-2657	CPE	PT	0.35	----	VERO	320.00	----	8/12/87
AVS-2657	CPE	SF	0.2	----	VERO	320.00	----	7/22/87
AVS-2657	CPE	VSV	----	----	L929 >	320.00	----	5/ 5/87
AVS-2657	CPE	VV	----	----	VERO >	320.00	----	5/21/87
AVS-2657	CPE	YFV	0.05	----	VERO	320.00	----	7/22/87
AVS-2658	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87
AVS-2658	CPE	JE	----	----	VERO >	320.00	----	7/16/87
AVS-2658	PR	PIC	N/A	----	VERO >	320.00	----	8/ 5/88
AVS-2658	CPE	PT	----	----	VERO	320.00	----	8/12/87
AVS-2658	CPE	SF	0.1	----	VERO	32.00	----	7/22/87
AVS-2658	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2658	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2658	CPE	YFV	0.15	----	VERO	100.00	----	7/22/87
AVS-2659	CPE	AD2	----	----	HEP2 >	320.00	----	5/21/87
AVS-2659	CPE	JE	----	----	VERO >	320.00	----	7.16/87
AVS-2659	PR	PIC	N/A	----	VERO	320.00	----	8/ 5/88
AVS-2659	CPE	PT	0.1	----	VERO	320.00	----	8/12/87
AVS-2659	CPE	SF	----	----	VERO	100.00	----	7/22/87
AVS-2659	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2659	CPE	VV	----	----	VERO >	320.00	----	5/21/87
AVS-2659	CPE	YFV	0.25	----	VERO	10.00	----	7/22/87
AVS-2660	CPE	AD2	----	----	HEP2 >	320.00	----	5/21/87
AVS-2660	CPE	JE	----	----	VERO >	320.00	----	7/17/87
AVS-2660	PR	PIC	N/A	----	VERO >	320.00	----	8/ 2/88
AVS-2660	CPE	PT	----	----	VERO >	320.00	----	8/17/87
AVS-2660	CPE	SF	1.	88.10	VERO	32.00	0.36	7/23/87
AVS-2660	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2660	CPE	VV	----	----	VERO >	320.00	----	5/21/87
AVS-2660	CPE	YFV	0.45	----	VERO	32.00	----	7/23/87
AVS-2661	CPE	AD2	0.2	----	HEP2 >	320.00	----	5/21/87
AVS-2661	CPE	JE	----	----	VERO >	320.00	----	7/17/87
AVS-2661	PR	PIC	N/A	----	VERO	320.00	----	8/ 2/88
AVS-2661	CPE	PT	0.1	----	VERO >	320.00	----	8/17/87
AVS-2661	CPE	SF	----	----	VERO	320.00	----	7/23/87
AVS-2661	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2661	CPE	VV	0.4	----	VERO >	320.00	----	5/21/87
AVS-2661	CPE	YFV	0.2	----	VERO	320.00	----	7/23/87
AVS-2662	CPE	AD2	----	----	HEP2 >	320.00	----	5/21/87
AVS-2662	CPE	JE	----	----	VERO >	320.00	----	7/17/87
AVS-2662	PR	PIC	N/A	----	VERO	320.00	----	8/ 2/88
AVS-2662	CPE	PT	----	----	VERO >	320.00	----	8/17/87
AVS-2662	CPE	SF	----	----	VERO >	320.00	----	7/23/87
AVS-2662	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2662	CPE	VV	----	----	VERO >	320.00	----	5/21/87
AVS-2662	CPE	YFV	0.25	----	VERO	320.00	----	7/23/87
AVS-2663	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87
AVS-2663	CPE	JE	----	----	VERO >	320.00	----	7/17/87
AVS-2663	CPE	PT	----	----	VERO	100.00	----	8/17/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2663	CPE	SF	----	----	VERO	320.00	----	7/23/87
AVS-2663	CPE	VSV	----	----	L929	32.00	----	5/ 8/87
AVS-2663	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2663	CPE	YFV	0.22	----	VERO	32.00	----	7/23/87
AVS-2664	CPE	AD2	----	----	HEP2 >	320.00	----	5/21/87
AVS-2664	CPE	JE	----	----	VERO >	320.00	----	7/17/87
AVS-2664	PR	PIC	N/A	----	VERO	320.00	----	8/ 5/88
AVS-2664	CPE	PT	----	----	VERO >	320.00	----	8/17/87
AVS-2664	CPE	SF	----	----	VERO	100.00	----	7/23/87
AVS-2664	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2664	CPE	VV	0.2	----	VERO >	320.00	----	5/21/87
AVS-2664	CPE	YFV	0.1	----	VERO	100.00	----	7/23/87
AVS-2665	CPE	AD2	----	----	HEP2 >	320.00	----	5/21/87
AVS-2665	CPE	JE	----	----	VERO >	320.00	----	7/20/87
AVS-2665	PR	PIC	N/A	----	VERO	320.00	----	8/ 5/88
AVS-2665	CPE	PT	----	----	VERO >	320.00	----	8/18/87
AVS-2665	CPE	SF	0.1	----	VERO >	320.00	----	3/ 8/88
AVS-2665	CPE	VSV	----	----	L929	320.00	----	5/ 8/87
AVS-2665	CPE	VV	----	----	VERO >	320.00	----	5/21/87
AVS-2665	CPE	YFV	----	----	VERO	320.00	----	3/ 2/88
AVS-2666	CPE	AD2	----	----	HEP2 >	320.00	----	5/21/87
AVS-2666	CPE	JE	----	----	VERO >	320.00	----	7/20/87
AVS-2666	PR	PIC	N/A	----	VERO	320.00	----	8/ 5/88
AVS-2666	CPE	PT	----	----	VERO >	320.00	----	8/18/87
AVS-2666	CPE	SF	----	----	VERO	320.00	----	3/11/88
AVS-2666	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2666	CPE	VV	----	----	VERO >	320.00	----	5/21/87
AVS-2666	CPE	YFV	----	----	VERO	100.00	----	3/ 2/88
AVS-2667	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87
AVS-2667	CPE	JE	----	----	VERO >	320.00	----	7/20/87
AVS-2667	PR	PIC	N/A	----	VERO	320.00	----	8/ 5/88
AVS-2667	CPE	PT	----	----	VERO >	320.00	----	8/18/87
AVS-2667	CPE	SF	----	----	VERO	320.00	----	3/11/88
AVS-2667	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2667	CPE	VV	0.1	----	VERO >	320.00	----	5/28/87
AVS-2667	CPE	YFV	----	----	VERO	320.00	----	3/ 2/88
AVS-2668	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87
AVS-2668	CPE	JE	0.2	----	VERO >	320.00	----	7/20/87
AVS-2668	CPE	PT	----	----	VERO	320.00	----	8/18/87
AVS-2668	CPE	SF	----	----	VERO >	320.00	----	3/11/88
AVS-2668	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2668	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2668	CPE	YFV	----	----	VERO	100.00	----	3/ 2/88
AVS-2669	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87
AVS-2669	CPE	JE	----	----	VERO >	320.00	----	7/20/87
AVS-2669	CPE	PT	----	----	VERO >	320.00	----	8/18/87
AVS-2669	CPE	SF	0.15	----	VERO >	320.00	----	3/ 8/88
AVS-2669	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2669	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2669	CPE	YFV	----	----	VERO	320.00	----	3/ 2/88
AVS-2670	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87
AVS-2670	CPE	JE	0.05	----	VERO	32.00	----	7/20/87
AVS-2670	CPE	PT	----	----	VERO	100.00	----	8/19/87
AVS-2670	CPE	SF	0.47	219.00	VERO	100.00	0.46	3/ 8/88
AVS-2670	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2670	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2670	CPE	YFV	----	----	VERO	100.00	----	3/ 3/88
AVS-2671	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87
AVS-2671	CPE	JE	----	----	VERO	320.00	----	7/20/87
AVS-2671	CPE	PT	----	----	VERO	100.00	----	8/19/87
AVS-2671	CPE	SF	0.62	219.00	VERO	100.00	0.46	3/ 8/88
AVS-2671	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2671	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2671	CPE	YFV	----	----	VERC	100.00	----	3/ 3/88
AVS-2672	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2672	CPE	JE	1.	100.00	VERO	320.00	3.19	7/20/87
AVS-2672	CPE	JE	----	----	VERO	320.00	----	5/25/88
AVS-2672	CPE	PT	----	----	VERO >	320.00	----	8/19/87
AVS-2672	CPE	SF	0.25	----	VERO >	320.00	----	3/ 8/88
AVS-2672	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2672	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2672	CPE	YFV	----	----	VERO	320.00	----	3/ 3/88
AVS-2673	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87
AVS-2673	CPE	JE	0.3	263.00	VERO	320.00	1.21	7/20/87
AVS-2673	CPE	PT	----	----	VERO >	320.00	----	8/19/87
AVS-2673	CPE	SF	----	----	VERO	32.00	----	3/11/88
AVS-2673	CPE	VSV	----	----	L929	320.00	----	5/ 8/87
AVS-2673	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2673	CPE	YFV	----	----	VERO	320.00	----	3/ 3/88
AVS-2674	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87
AVS-2674	CPE	JE	0.5	200.00	VERO	320.00	1.59	7/20/87
AVS-2674	CPE	PT	----	----	VERO	320.00	----	8/19/87
AVS-2674	CPE	VSV	----	----	L929	320.00	----	5/ 8/87
AVS-2674	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2674	CPE	YFV	----	----	VERO	320.00	----	3/ 3/88
AVS-2674	CPE	YFV	----	----	VERO >	320.00	----	3/11/88
AVS-2675	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87
AVS-2675	CPE	JE	0.4	----	VERO >	320.00	----	7/22/87
AVS-2675	CPE	PT	----	----	VERO >	320.00	----	8/20/87
AVS-2675	CPE	VSV	----	----	L929	320.00	----	5/ 8/87
AVS-2675	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2675	CPE	YFV	----	----	VERO	320.00	----	3/ 3/88
AVS-2676	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87
AVS-2676	CPE	JE	0.05	----	VERO >	320.00	----	7/22/87
AVS-2676	CPE	PT	----	----	VERO >	320.00	----	8/20/87
AVS-2676	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2676	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2676	CPE	YFV	----	----	VERO	320.00	----	3/ 3/88
AVS-2677	CPE	AD2	----	----	HEP2 >	320.00	----	6/ 4/87
AVS-2677	CPE	JE	----	----	VERO >	320.00	----	7/22/87
AVS-2677	CPE	PT	----	----	VERO >	320.00	----	8/20/87
AVS-2677	CPE	VSV	----	----	L929	320.00	----	5/ 8/87
AVS-2677	CPE	VV	----	----	VERO >	320.00	----	6/ 4/87
AVS-2677	CPE	YFV	----	----	VERO	320.00	----	3/ 3/88
AVS-2678	CPE	AD2	----	----	HEP2 >	320.00	----	6/ 4/87
AVS-2678	CPE	JE	1.35	84.50	VERO	320.00	3.78	7/22/87
AVS-2678	CPE	JE	----	----	VERO >	320.00	----	5/25/88
AVS-2678	CPE	PT	----	----	VERO >	320.00	----	8/20/87
AVS-2678	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2678	CPE	VV	----	----	VERO >	320.00	----	6/ 4/87
AVS-2678	CPE	YFV	----	----	VERO	320.00	----	3/ 3/88
AVS-2679	CPE	AD2	----	----	HEP2 >	320.00	----	6/ 4/87
AVS-2679	CPE	JE	----	----	VERO >	320.00	----	7/22/87
AVS-2679	CPE	PT	----	----	VERO >	320.00	----	8/20/87
AVS-2679	CPE	VSV	----	----	L929	320.00	----	5/ 8/87
AVS-2679	CPE	VV	----	----	VERO >	320.00	----	6/ 4/87
AVS-2679	CPE	YFV	----	----	VERO	320.00	----	3/ 3/88
AVS-2680	CPE	AD2	----	----	HEP2 >	320.00	----	6/ 4/87
AVS-2680	CPE	JE	1.7	28.90	VERO	100.00	3.45	7/23/87
AVS-2680	CPE	JE	----	----	VERO	320.00	----	5/25/88
AVS-2680	CPE	PT	----	----	VERO >	320.00	----	7/23/87
AVS-2680	CPE	VSV	----	----	L929	10.00	----	5/ 8/87
AVS-2680	CPE	VV	----	----	VERO >	320.00	----	6/ 4/87
AVS-2680	CPE	YFV	----	----	VERO	100.00	----	3/ 3/88
AVS-2681	CPE	AD2	----	----	HEP2 >	320.00	----	6/ 4/87
AVS-2681	CPE	JE	0.38	225.00	VERO	320.00	1.41	7/23/87
AVS-2681	CPE	PT	----	----	VERO	320.00	----	7/23/87
AVS-2681	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2681	CPE	VV	----	----	VERO >	320.00	----	6/ 4/87
AVS-2681	CPE	YFV	----	----	VERO	320.00	----	3/ 4/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2682	CPE	AD2	0.15	----	HEP2	320.00	----	6/ 4/87
AVS-2682	CPE	JE	0.7	229.00	VERO >	320.00 >	1.39	7/23/87
AVS-2682	CPE	PT	----	----	VERO	320.00	----	7/23/87
AVS-2682	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2682	CPE	VV	----	----	VERO	320.00	----	6/ 4/87
AVS-2682	CPE	YFV	----	----	VERO <	320.00	----	3/ 4/88
AVS-2683	CPE	AD2	----	----	HEP2 >	320.00	----	6/ 4/87
AVS-2683	CPE	JE	----	----	VERO >	320.00	----	7/23/87
AVS-2683	CPE	PT	----	----	VERO >	320.00	----	7/23/87
AVS-2683	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2683	CPE	VV	----	----	VERO >	320.00	----	6/ 4/87
AVS-2683	CPE	YFV	----	----	VERO	320.00	----	3/ 4/88
AVS-2684	CPE	AD2	----	----	HEP2 >	320.00	----	6/ 4/87
AVS-2684	CPE	JE	0.1	----	VERO >	320.00	----	7/23/87
AVS-2684	CPE	PT	----	----	VERO >	320.00	----	7/23/87
AVS-2684	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2684	CPE	VV	----	----	VERC >	320.00	----	6/ 4/87
AVS-2684	CPE	YFV	----	----	VERO	320.00	----	3/ 4/88
AVS-2685	CPE	AD2	----	----	HEP2	320.00	----	6/25/87
AVS-2685	CPE	JE	0.1	----	VERO	32.00	----	6/30/87
AVS-2685	PR	PIC	N/A	----	VERO	320.00	----	8/12/88
AVS-2685	CPE	PT	----	----	VERO	100.00	----	6/19/87
AVS-2685	CPE	SF	----	----	VERO >	320.00	----	6/19/87
AVS-2685	CPE	VSV	----	----	L929 >	320.00	----	6/ 2/87
AVS-2685	CPE	VV	0.5	317.00	VERO	320.00	1.00	6/25/87
AVS-2685	CPE	YFV	0.15	----	VERO	100.00	----	7/ 9/87
AVS-2686	CPE	AD2	0.3	----	HEP2 >	320.00	----	6/25/87
AVS-2686	CPE	JE	----	----	VERO	320.00	----	7/ 1/87
AVS-2686	PR	PIC	N/A	----	VERO >	320.00	----	8/12/88
AVS-2686	CPE	PT	0.3	----	VERO >	320.00	----	6/19/87
AVS-2686	CPE	SF	----	----	VERO >	320.00	----	6/19/87
AVS-2686	CPE	VSV	----	----	L929 >	320.00	----	6/ 2/87
AVS-2686	CPE	VV	0.6	305.00	VERO	320.00	1.04	6/25/87
AVS-2686	CPE	YFV	----	----	VERO >	320.00	----	7/ 9/87
AVS-2687	CPE	AD2	0.5	----	HEP2 >	320.00	----	6/25/87
AVS-2687	CPE	JE	0.2	----	VERO >	320.00	----	7/ 1/87
AVS-2687	PR	PIC	N/A	----	VERO	320.00	----	8/12/88
AVS-2687	CPE	PT	0.1	----	VERO >	320.00	----	6/19/87
AVS-2687	CPE	SF	----	----	VERO >	320.00	----	6/19/87
AVS-2687	CPE	VSV	----	----	L929	320.00	----	6/ 2/87
AVS-2687	CPE	VV	----	----	VERO >	320.00	----	6/25/87
AVS-2687	CPE	YFV	----	----	VERO >	320.00	----	7/ 9/87
AVS-2688	CPE	AD2	----	----	HEP2	1.00	----	6/25/87
AVS-2688	CPE	JE	----	----	VERO	32.00	----	6/29/87
AVS-2688	PR	PIC	N/A	----	VERO	3.20	----	8/12/88
AVS-2688	CPE	PT	0.1	----	VERO	10.00	----	6/29/87
AVS-2688	CPE	SF	----	----	VERO	3.20	----	6/29/87
AVS-2688	CPE	VSV	----	----	L929	10.00	----	6/23/87
AVS-2688	CPE	VV	1.35	3.05	VERO	10.00	3.27	6/25/87
AVS-2688	CPE	VV	0.9	5.60	VERO	10.00	1.78	5/26/88
AVS-2688	CPE	YFV	0.2	----	VERO	1.00	----	6/29/87
AVS-2689	CPE	AD2	0.15	----	HEP2	10.00	----	6/25/87
AVS-2689	CPE	JE	----	----	VERO	100.00	----	6/29/87
AVS-2689	PR	PIC	N/A	----	VERO	32.00	----	8/12/88
AVS-2689	CPE	PT	----	----	VERO	32.00	----	6/29/87
AVS-2689	CPE	SF	----	----	VERO	32.00	----	6/29/87
AVS-2689	CPE	VSV	----	----	L929	100.00	----	6/23/87
AVS-2689	CPE	VV	1.5	57.80	VERO <	320.00 <	5.52	6/25/87
AVS-2689	CPE	YFV	0.2	----	VERO	10.00	----	6/29/87
AVS-2690	CPE	AD2	----	----	HEP2 <	32.00	----	6/25/87
AVS-2690	CPE	JE	----	----	VERO	32.00	----	6/29/87
AVS-2690	PR	PIC	N/A	----	VERO	10.00	----	8/12/88
AVS-2690	CPE	PT	----	----	VERO	10.00	----	6/29/87
AVS-2690	CPE	SF	----	----	VERO	10.00	----	6/29/87
AVS-2690	CPE	VSV	----	----	L929	10.00	----	6/23/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2690	CPE	VV	1.3	60.60	VERO	100.00	1.64	6/25/87
AVS-2690	CPE	YFV	----	----	VERO	10.00	----	6/29/87
AVS-2691	CPE	AD2	0.05	----	HEP2	3.20	----	6/25/87
AVS-2691	CPE	JE	1.65	9.90	VERO	32.00	3.20	6/29/87
AVS-2691	CPE	JE	----	----	VERO	10.00	----	5/25/88
AVS-2691	PR	PTC	N/A	----	VERO	32.00	----	8/12/88
AVS-2691	CPE	PT	0.05	----	VERO	32.00	----	6/29/87
AVS-2691	CPE	SF	0.1	----	VERO	10.00	----	6/29/87
AVS-2691	CPE	VSV	----	----	L929	10.00	----	6/23/87
AVS-2691	CPE	VV	0.4	99.00	VERO	100.00	1.00	6/25/87
AVS-2691	CPE	YFV	0.37	----	VERO	3.20	----	6/29/87
AVS-2692	CPE	AD2	----	----	HEP2	10.00	----	6/25/87
AVS-2692	CPE	JE	0.15	----	VERO	100.00	----	6/29/87
AVS-2692	CPE	PT	0.2	----	VERO	100.00	----	6/29/87
AVS-2692	CPE	SF	----	----	VERO	100.00	----	6/29/87
AVS-2692	CPE	VSV	----	----	L929	32.00	----	6/23/87
AVS-2692	CPE	VV	----	----	VERO	32.00	----	6/25/87
AVS-2692	CPE	YFV	0.12	----	VERO	32.00	----	6/29/87
AVS-2693	CPE	AD2	----	----	HEP2	10.00	----	6/25/87
AVS-2693	CPE	JE	0.05	----	VERO	100.00	----	6/29/87
AVS-2693	CPE	PT	----	----	VERO	100.00	----	6/29/87
AVS-2693	CPE	SF	----	----	VERO	100.00	----	6/29/87
AVS-2693	CPE	VSV	----	----	L929	32.00	----	6/23/87
AVS-2693	CPE	VV	----	----	VERO	32.00	----	6/25/87
AVS-2693	CPE	YFV	0.2	----	VERO	32.00	----	6/29/87
AVS-2694	CPE	AD2	0.3	----	HEP2	320.00	----	6/25/87
AVS-2694	CPE	JE	----	----	VERO	1.00	----	7/ 1/87
AVS-2694	CPE	PT	----	----	VERO	320.00	----	6/19/87
AVS-2694	CPE	SF	----	----	VERO	320.00	----	6/19/87
AVS-2694	CPE	VSV	----	----	L929	320.00	----	6/ 2/87
AVS-2694	CPE	VV	----	----	VERO	320.00	----	6/25/87
AVS-2694	CPE	YFV	0.3	320.00	VERO	10.00	0.03	3/ 4/88
AVS-2695	CPE	AD2	0.3	----	HEP2	320.00	----	6/25/87
AVS-2695	CPE	JE	----	----	VERO	10.00	----	7/ 1/87
AVS-2695	CPE	PT	0.05	----	VERO	3.20	----	6/30/87
AVS-2695	CPE	SF	----	----	VERO	320.00	----	7/14/87
AVS-2695	CPE	VSV	----	----	L929	320.00	----	6/ 2/87
AVS-2695	CPE	VV	----	----	VERO	320.00	----	6/25/87
AVS-2695	CPE	YFV	----	----	VERO	32.00	----	7/14/87
AVS-2696	CPE	AD2	0.6	3.20	HEP2	3.20	1.00	6/25/87
AVS-2696	CPE	JE	----	----	VERO	1.00	----	7/ 1/87
AVS-2696	CPE	PT	----	----	VERO	1.00	----	6/30/87
AVS-2696	CPE	SF	----	----	VERO	1.00	----	7/14/87
AVS-2696	CPE	VSV	----	----	L929	10.00	----	6/ 2/87
AVS-2696	CPE	VV	0.55	7.20	VERO	3.20	0.44	6/25/87
AVS-2696	CPE	YFV	----	----	VERO	1.00	----	7/14/87
AVS-2697	CPE	AD2	----	----	HEP2	100.00	----	6/25/87
AVS-2697	CPE	JE	----	----	VERO	10.00	----	7/ 2/87
AVS-2697	CPE	PT	0.85	----	VERO	100.00	----	6/30/87
AVS-2697	CPE	SF	0.1	----	VERO	32.00	----	7/14/87
AVS-2697	CPE	VSV	0.25	----	L929	320.00	----	6/ 2/87
AVS-2697	CPE	VV	0.1	----	VERO	100.00	----	6/25/87
AVS-2697	CPE	YFV	0.1	----	VERO	10.00	----	7/14/87
AVS-2698	CPE	AD2	----	----	HEP2	100.00	----	6/25/87
AVS-2698	CPE	JE	----	----	VERO	32.00	----	7/ 2/87
AVS-2698	CPE	PT	0.3	----	VERO	100.00	----	6/30/87
AVS-2698	CPE	SF	0.55	----	VERO	10.00	----	7/14/87
AVS-2698	CPE	VSV	----	----	L929	32.00	----	6/ 2/87
AVS-2698	CPE	VV	----	----	VERO	100.00	----	6/25/87
AVS-2698	CPE	YFV	0.22	----	VERO	32.00	----	7/14/87
AVS-2699	CPE	AD2	----	----	HEP2	100.00	----	6/25/87
AVS-2699	CPE	JE	0.1	----	VERO	320.00	----	7/ 2/87
AVS-2699	CPE	PT	0.15	----	VERO	320.00	----	6/30/87
AVS-2699	CPE	SF	----	----	VERO	100.00	----	7/14/87
AVS-2699	CPE	VSV	----	----	L929	320.00	----	6/ 2/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2699	CPE	VV	0.75	----	VERO	100.00	----	6/25/87
AVS-2699	CPE	YFV	----	----	VERO	320.00	----	7/14/87
AVS-2700	CPE	AD2	2.7	0.32	HEP2	1.00	3.12	6/23/87
AVS-2700	CPE	AD2	3.7	0.21	HEP2	3.20	15.20	7/ 9/87
AVS-2700	CPE	AD2	3.6	0.44	HEP2	10.00	22.20	9/ 4/87
AVS-2700	CPE	AD2	1.75	0.44	HEP2	1.00	2.23	9/24/87
AVS-2700	CPE	JE	2.99	3.39	VERO	10.00	2.94	7/ 2/87
AVS-2700	CPE	JE	1.85	1.69	VERO	1.00	0.59	5/25/88
AVS-2700	CPE	PT	0.79	----	VERO	3.20	----	6/30/87
AVS-2700	CPE	SF	2.1	7.90	VERO	1.00	0.13	7/15/87
AVS-2700	CPE	VSV	----	----	L929	10.00	----	6/ 2/87
AVS-2700	CPE	VV	3.25	1.05	VERO	3.20	3.03	6/25/87
AVS-2700	CPE	VV	3.6	1.76	VERO	10.00	5.65	8/27/87
AVS-2700	CPE	YFV	2.65	3.76	VERO	3.20	0.85	7/15/87
AVS-2701	CPE	AD2	----	----	HEP2 <	320.00	----	6/25/87
AVS-2701	CPE	JE	----	----	VERO	32.00	----	7/ 2/87
AVS-2701	CPE	PT	0.1	----	VERO	10.00	----	6/30/87
AVS-2701	CPE	SF	0.05	----	VERO	100.00	----	7/15/87
AVS-2701	CPE	VSV	----	----	L929	320.00	----	6/ 2/87
AVS-2701	CPE	VV	----	----	VERO	100.00	----	6/25/87
AVS-2701	CPE	YFV	----	----	VERO	32.00	----	7/15/87
AVS-2702	CPE	AD2	----	----	HEP2 <	100.00	----	6/25/87
AVS-2702	CPE	AD2	0.2	----	HEP2	32.00	----	10/29/87
AVS-2702	CPE	JE	----	----	VERO	320.00	----	7/ 6/87
AVS-2702	PR	PIC	N/A	----	VERO	100.00	----	2/ 2/88
AVS-2702	CPE	PT	0.29	----	VERO	10.00	----	6/30/87
AVS-2702	CPE	SF	0.35	319.00	VERO	10.00	0.03	7/15/87
AVS-2702	CPE	VEE	----	----	VERO	320.00	----	11/19/87
AVS-2702	CPE	VSV	----	----	L929	320.00	----	6/ 2/87
AVS-2702	CPE	VV	----	----	VERO	320.00	----	6/25/87
AVS-2702	CPE	YFV	----	----	VERO	3.20	----	7/15/87
AVS-2703	CPE	AD2	0.8	100.00	HEP2	320.00	3.20	7/ 2/87
AVS-2703	CPE	AD2	0.3	----	HEP2 >	320.00	----	5/26/88
AVS-2703	CPE	JE	----	----	VERO >	320.00	----	7/ 6/87
AVS-2703	PR	PIC	N/A	----	VERO	320.00	----	3/22/88
AVS-2703	CPE	PT	0.44	----	VERO	320.00	----	7/ 1/87
AVS-2703	CPE	SF	0.85	118.00	VERO	100.00	0.85	7/15/87
AVS-2703	CPE	VEE	----	----	VERO >	320.00	----	11/19/87
AVS-2703	CPE	VSV	----	----	L929	320.00	----	6/ 2/87
AVS-2703	CPE	VV	0.1	----	VERO	320.00	----	7/ 2/87
AVS-2703	CPE	YFV	----	----	VERO	32.00	----	7/15/87
AVS-2704	CPE	AD2	0.6	----	HEP2 >	320.00	----	7/ 2/87
AVS-2704	PR	PIC	N/A	----	VERO >	320.00	----	3/19/88
AVS-2704	CPE	PT	----	----	VERO	10.00	----	7/ 1/87
AVS-2704	CPE	VSV	----	----	L929 >	320.00	----	6/23/87
AVS-2704	CPE	VV	----	----	VERO >	320.00	----	7/ 2/87
AVS-2704	CPE	YFV	----	----	VERO	100.00	----	3/ 4/88
AVS-2705	CPE	AD2	----	----	HEP2 >	320.00	----	7/ 2/87
AVS-2705	CPE	JE	----	----	VERO >	320.00	----	7/ 6/87
AVS-2705	PR	PIC	N/A	----	VERO	32.00	----	8/16/88
AVS-2705	CPE	PT	0.2	----	VERO >	320.00	----	7/ 1/87
AVS-2705	CPE	SF	----	----	VERO	320.00	----	7/15/87
AVS-2705	CPE	VSV	----	----	L929 >	320.00	----	6/ 2/87
AVS-2705	CPE	VV	0.1	----	VERO >	320.00	----	7/ 2/87
AVS-2705	CPE	YFV	----	----	VERO	320.00	----	7/15/87
AVS-2707	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87
AVS-2707	CPE	JE	----	----	VERO	320.00	----	7/24/87
AVS-2707	CPE	PT	0.43	----	VERO	100.00	----	7/24/87
AVS-2707	CPE	VSV	----	----	L929 >	320.00	----	5/ 8/87
AVS-2707	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2707	CPE	YFV	----	----	VERO	100.00	----	3/ 4/88
AVS-2709	CPE	AD2	0.3	----	HEP2 >	320.00	----	7/ 2/87
AVS-2709	CPE	JE	----	----	VERO	320.00	----	7/ 6/87
AVS-2709	PR	PIC	N/A	----	VERO	32.00	----	8/16/88
AVS-2709	CPE	PT	0.3	----	VERO >	320.00	----	7/ 1/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2709	CPE	SF	----	----	VERO >	320.00	----	7/15/87
AVS-2709	CPE	VSV	----	----	L929 >	320.00	----	6/ 2/87
AVS-2709	CPE	VV	0.2	----	VERO >	320.00	----	7/ 2/87
AVS-2709	CPE	YFV	----	----	VERO >	320.00	----	7/15/87
AVS-2710	CPE	AD2	0.7	319.00	HEP2 >	320.00 >	1.00	7/ 2/87
AVS-2710	CPE	JE	----	----	VERO >	320.00	----	7/ 6/87
AVS-2710	PR	PIC	N/A	----	VERO	32.00	----	8/16/88
AVS-2710	CPE	PT	0.4	----	VERO >	320.00	----	7/ 1/87
AVS-2710	CPE	SF	----	----	VERO	320.00	----	7/15/87
AVS-2710	CPE	VSV	----	----	L929 >	320.00	----	6/ 2/87
AVS-2710	CPE	VV	0.5	----	VERO >	320.00	----	7/ 2/87
AVS-2710	CPE	YFV	----	----	VERO >	320.00	----	7/15/87
AVS-2711	CPE	AD2	0.5	----	HEP2 >	320.00	----	7/ 2/87
AVS-2711	CPE	JE	2.2	50.40	VERO >	320.00 >	6.34	7/ 7/87
AVS-2711	CPE	JE	----	----	VERO >	320.00	----	5/25/88
AVS-2711	PR	PIC	N/A	----	VERO	32.00	----	8/16/88
AVS-2711	CPE	PT	----	----	VERO >	320.00	----	7/ 1/87
AVS-2711	CPE	SF	----	----	VERO >	320.00	----	7/15/87
AVS-2711	CPE	VSV	----	----	L929	320.00	----	6/ 2/87
AVS-2711	CPE	VV	----	----	VERO >	320.00	----	7/ 2/87
AVS-2711	CPE	YFV	----	----	VERO >	320.00	----	7/15/87
AVS-2712	CPE	PT	2.32	0.05	VERO	1.00	19.40	8/14/87
AVS-2712	CPE	SF	----	----	VERO >	1.00	----	8/14/87
AVS-2712	CPE	VEE	----	----	VERO	0.32	----	11/11/87
AVS-2712	CPE	YFV	----	----	VERO >	1.00	----	8/14/87
AVS-2713	CPE	JE	----	----	VERO >	1.00	----	8/14/87
AVS-2713	CPE	PT	1.84	----	VERO >	1.00	----	8/14/87
AVS-2713	CPE	SF	----	----	VERO >	1.00	----	8/14/87
AVS-2713	CPE	VEE	----	----	VERO	1.00	----	11/11/87
AVS-2713	CPE	YFV	----	----	VERO >	1.00	----	8/14/87
AVS-2714	CPE	AD2	0.3	----	HEP2 <	32.00	----	7/ 2/87
AVS-2714	CPE	JE	----	----	VERO >	320.00	----	7/ 7/87
AVS-2714	PR	PIC	N/A	----	VERO >	3.20	----	8/16/88
AVS-2714	CPE	PT	1.3	0.57	VERO	3.20	5.54	7/ 1/87
AVS-2714	CPE	PT	0.95	1.92	VERO	1.00	0.52	5/25/88
AVS-2714	CPE	SF	1.65	0.49	VERO	1.00	2.03	7/ 6/87
AVS-2714	CPE	VSV	----	----	L929	32.00	----	6/26/87
AVS-2714	CPE	VV	1.05	15.60	VERO	32.00	2.04	7/ 2/87
AVS-2714	CPE	YFV	0.65	5.50	VERO	3.20	0.58	7/ 6/87
AVS-2715	CPE	JE	----	----	VERO	100.00	----	8/14/87
AVS-2715	CPE	PT	1.94	----	VERO	100.00	----	8/14/87
AVS-2715	CPE	SF	----	----	VERO	100.00	----	8/14/87
AVS-2715	CPE	VEE	----	----	VERO	100.00	----	11/11/87
AVS-2715	CPE	YFV	----	----	VERO	100.00	----	8/14/87
AVS-2716	CPE	AD2	1.1	12.60	HEP2	32.00	2.53	5/28/87
AVS-2716	CPE	AD2	1.4	14.00	HEP2 <	100.00 <	7.11	1/21/88
AVS-2716	CPE	AD2	1.35	9.60	HEP2	32.00	3.32	5/12/88
AVS-2716	CPE	AD2	0.9	10.00	HEP2	32.00	3.20	10/13/88
AVS-2716	CPE	JE	1.64	3.10	VERO	10.00	3.15	5/27/87
AVS-2716	CPE	JE	0.5	----	VERO	3.20	----	5/25/88
AVS-2716	PR	PIC	N/A	2.51	VERO	3.20	1.27	1/15/88
AVS-2716	CPE	PT	2.	2.70	VERO	10.00	3.69	5/27/87
AVS-2716	CPE	PT	1.	7.20	VERO	10.00	1.38	5/25/88
AVS-2716	CPE	VEE	1.75	3.00	VERO -	0.32 <	0.11	5/27/87
AVS-2716	CPE	VSV	----	----	L929	32.00	----	6/ 2/87
AVS-2716	CPE	VSV	----	----	L929	10.00	----	11/18/88
AVS-2716	CPE	VV	1.6	13.00	VERO <	100.00 <	7.66	5/28/87
AVS-2716	CPE	VV	0.75	19.90	VERO	10.00	0.50	1/21/88
AVS-2716	CPE	VV	0.8	15.90	VERO	32.00	2.00	5/12/88
AVS-2716	CPE	VV	0.6	17.70	VERO	10.00	0.56	10/13/88
AVS-2716	CPE	YFV	1.15	7.60	VERO	10.00	1.30	5/27/87
AVS-2717	CPE	AD2	0.6	----	HEP2 >	320.00	----	5/28/87
AVS-2717	CPE	JE	----	----	VERO	320.00	----	5/27/87
AVS-2717	PR	PIC	N/A	195.00	VERO	320.00	1.63	1/15/88
AVS-2717	CPE	PT	0.2	----	VERO	100.00	----	5/27/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2717	CPE	VEE	----	----	VERO	320.00	----	5/27/87
AVS-2717	CPE	VSV	----	----	L929	320.00	----	6/ 2/87
AVS-2717	CPE	VV	0.1	----	VERO >	320.00	----	5/28/87
AVS-2717	CPE	YFV	----	----	VERO >	320.00	----	5/27/87
AVS-2718	CPE	AD2	----	----	HEP2 <	320.00	----	5/28/87
AVS-2718	CPE	JE	----	----	VERO	320.00	----	5/27/87
AVS-2718	PR	PIC	N/A	279.00	VERO	320.00	1.14	1/15/88
AVS-2718	CPE	PT	0.05	----	VERO	100.00	----	5/27/87
AVS-2718	CPE	VEE	----	----	VERO	320.00	----	5/27/87
AVS-2718	CPE	VSV	----	----	L929	100.00	----	6/ 2/87
AVS-2718	CPE	VV	0.8	317.00	VERO >	320.00 >	1.00	5/28/87
AVS-2718	CPE	YFV	----	----	VERO	320.00	----	5/27/87
AVS-2720	CPE	AD2	0.3	----	HEP2 >	320.00	----	5/28/87
AVS-2720	PR	PIC	N/A	----	VERO >	320.00	----	3/22/88
AVS-2720	CPE	VSV	----	----	L929 >	320.00	----	6/ 2/87
AVS-2720	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2720	CPE	YFV	----	----	VERO	100.00	----	3/ 7/88
AVS-2721	CPE	AD2	0.3	----	HEP2 >	320.00	----	5/28/87
AVS-2721	PR	PIC	N/A	----	VERO >	320.00	----	3/22/88
AVS-2721	CPE	VSV	----	----	L929 >	320.00	----	6/ 2/87
AVS-2721	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2721	CPE	YFV	----	----	VERO	100.00	----	3/ 7/88
AVS-2722	CPE	AD2	0.15	----	HEP2	320.00	----	5/28/87
AVS-2722	PR	PIC	N/A	----	VERO	100.00	----	2/ 9/88
AVS-2722	CPE	VSV	----	----	L929	320.00	----	6/ 2/87
AVS-2722	CPE	VV	0.1	----	VERO	320.00	----	5/28/87
AVS-2722	CPE	YFV	----	----	VERO	32.00	----	3/ 7/88
AVS-2723	CPE	AD2	----	----	HEP2 >	320.00	----	5/28/87
AVS-2723	CPE	JE	----	----	VERO >	320.00	----	5/27/87
AVS-2723	PR	PIC	N/A	----	VERO	100.00	----	8/16/88
AVS-2723	CPE	PT	----	----	VERO >	320.00	----	5/27/87
AVS-2723	CPE	VSV	----	----	L929 >	320.00	----	6/ 2/87
AVS-2723	CPE	VV	----	----	VERO >	320.00	----	5/28/87
AVS-2723	CPE	YFV	----	----	VERO >	320.00	----	5/27/87
AVS-2739	CPE	AD2	----	----	HEP2	32.00	----	7/ 2/87
AVS-2739	CPE	JE	----	----	VERO	100.00	----	7/ 7/87
AVS-2739	PR	PIC	N/A	27.50	VERO	32.00	1.16	8/16/88
AVS-2739	CPE	PT	0.58	----	VERO	32.00	----	7/ 7/87
AVS-2739	CPE	SF	1.15	64.40	VERO	100.00	1.55	7/ 6/87
AVS-2739	CPE	VSV	0.25	----	L929	100.00	----	6/26/87
AVS-2739	CPE	VV	----	----	VERO	100.00	----	7/ 2/87
AVS-2739	CPE	YFV	----	----	VERO	100.00	----	7/ 6/87
AVS-2740	CPE	AD2	0.2	----	HEP2 >	320.00	----	7/ 2/87
AVS-2740	CPE	JE	----	----	VERO >	320.00	----	7/ 7/87
AVS-2740	PR	PIC	N/A	----	VERO >	100.00	----	8/16/88
AVS-2740	CPE	PT	0.2	----	VERO	100.00	----	7/ 7/87
AVS-2740	CPE	SF	----	----	VERO	100.00	----	7/ 6/87
AVS-2740	CPE	VSV	0.1	----	L929 >	320.00	----	6/26/87
AVS-2740	CPE	VV	----	----	VERO >	320.00	----	7/ 2/87
AVS-2740	CPE	YFV	----	----	VERO	320.00	----	7/ 6/87
AVS-2741	CPE	AD2	----	----	HEP2 >	320.00	----	2/19/87
AVS-2741	CPE	JE	1.2	144.00	VERO	320.00	2.21	5/15/87
AVS-2741	PR	PIC	N/A	----	VERO >	320.00	----	7/ 5/88
AVS-2741	CPE	PT	0.70	----	VERO >	320.00	----	2/27/87
AVS-2741	CPE	SF	----	----	VERO >	320.00	----	3/18/87
AVS-2741	CPE	VSV	----	----	L929 >	320.00	----	2/ 6/87
AVS-2741	CPE	VV	----	----	VERO >	320.00	----	2/19/87
AVS-2741	CPE	YFV	----	----	VERO >	100.00	----	5/11/87
AVS-2742	CPE	AD2	----	----	HEP2 >	320.00	----	2/19/87
AVS-2742	CPE	JE	0.1	----	VERO	320.00	----	5/15/87
AVS-2742	PR	PIC	N/A	----	VERO	100.00	----	7/ 5/88
AVS-2742	CPE	PT	0.70	----	VERO >	320.00	----	2/27/87
AVS-2742	CPE	SF	----	----	VERO >	320.00	----	3/18/87
AVS-2742	CPE	VSV	----	----	L929 >	320.00	----	2/ 6/87
AVS-2742	CPE	VV	----	----	VERO >	320.00	----	2/19/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2742	CPE	YFV	----	----	VERO >	100.00	----	5/11/87
AVS-2743	CPE	AD2	0.75	178.00	HEP2	320.00	1.78	2/19/87
AVS-2743	CPE	JE	0.85	94.20	VERO	100.00	1.06	5/15/87
AVS-2743	PR	PIC	N/A	307.00	VERO	320.00	1.04	7/ 5/88
AVS-2743	CPE	PT	2.4	32.00	VERO	320.00	10.00	4/28/87
AVS-2743	CPE	PT	1.1	118.00	VERO	320.00	2.71	3/21/87
AVS-2743	CPE	PT	1.05	83.00	VERO	100.00	1.20	5/25/88
AVS-2743	CPE	SF	1.95	47.10	VERO	320.00	6.78	3/18/87
AVS-2743	CPE	SF	1.5	83.00	VERO	320.00	3.85	5/25/88
AVS-2743	CPE	VSV	0.20	----	L929	100.00	----	2/ 6/87
AVS-2743	CPE	VV	1.50	88.40	VERO	320.00	3.62	2/19/87
AVS-2743	CPE	VV	0.2	----	VERO >	320.00	----	5/26/88
AVS-2743	CPE	YFV	0.55	93.90	VERO	100.00	1.06	5/11/87
AVS-2744	CPE	AD2	0.4	----	HEP2 >	320.00	----	7/ 2/87
AVS-2744	CPE	JE	----	----	VERO >	320.00	----	7/ 7/87
AVS-2744	PR	PIC	N/A	----	VERO >	100.00	----	8/16/88
AVS-2744	CPE	PT	0.74	----	VERO >	320.00	----	7/ 7/87
AVS-2744	CPE	SF	0.2	----	VERO >	100.00	----	7/ 6/87
AVS-2744	CPE	VSV	0.1	----	L929 >	320.00	----	6/26/87
AVS-2744	CPE	VV	3.7	----	VERO >	320.00	----	7/ 2/87
AVS-2744	CPE	YFV	----	----	VERO >	100.00	----	7/ 6/87
AVS-2745	CPE	AD2	----	----	HEP2 >	320.00	----	7/ 2/87
AVS-2745	CPE	JE	0.2	----	VERO >	320.00	----	7/ 8/87
AVS-2745	PR	PIC	N/A	----	VERO	100.00	----	8/16/88
AVS-2745	CPE	PT	0.77	----	VERO	320.00	----	7/ 7/87
AVS-2745	CPE	SF	----	----	VERO >	100.00	----	7/ 6/87
AVS-2745	CPE	VSV	0.4	----	L929 >	320.00	----	6/26/87
AVS-2745	CPE	VV	0.1	----	VERO >	320.00	----	7/ 2/87
AVS-2745	CPE	YFV	----	----	VERO >	100.00	----	7/ 6/87
AVS-2765	CPE	AD2	0.9	93.90	HEP2 <	320.00	3.40	5/28/87
AVS-2765	CPE	JE	----	----	VERO <	320.00	----	5/27/87
AVS-2765	CPE	PT	----	----	VERO <	100.00	----	5/27/87
AVS-2765	CPE	VEE	0.	----	VERO	100.00	----	5/27/87
AVS-2765	CPE	VSV	0.25	----	L929	100.00	----	6/ 2/87
AVS-2765	CPE	VV	1.65	47.60	VERO	100.00	2.09	5/28/87
AVS-2765	CPE	YFV	----	----	VERO	32.00	----	5/27/87
AVS-2769	CPE	AD2	0.3	----	HEP2 >	320.00	----	7/ 2/87
AVS-2769	PR	PIC	N/A	----	VERO	320.00	----	8/19/88
AVS-2769	CPE	PT	0.12	----	VERO	3.20	----	7/ 7/87
AVS-2769	CPE	VSV	0.1	----	L929 >	320.00	----	6/23/87
AVS-2769	CPE	VV	----	----	VERO >	320.00	----	7/ 2/87
AVS-2770	CPE	AD2	1.15	32.00	HEP2	32.00	1.00	7/ 9/87
AVS-2770	CPE	JE	----	----	VERO	3.20	----	7/ 8/87
AVS-2770	PR	PIC	N/A	----	VERO	10.00	----	8/19/88
AVS-2770	CPE	PT	----	----	VERO	3.20	----	7/ 3/87
AVS-2770	CPE	SF	0.05	----	VERO	10.00	----	7/ 6/87
AVS-2770	CPE	VSV	----	----	L929	10.00	----	6/26/87
AVS-2770	CPE	VV	----	----	VERO	100.00	----	7/ 9/87
AVS-2770	CPE	YFV	0.12	----	VERO	10.00	----	7/ 6/87
AVS-2771	CPE	AD2	0.3	----	HEP2	100.00	----	7/ 9/87
AVS-2771	CPE	JE	----	----	VERO	10.00	----	7/ 8/87
AVS-2771	PR	PIC	N/A	7.50	VERO	3.20	0.42	8/19/88
AVS-2771	CPE	PT	0.05	----	VERO	10.00	----	7/ 3/87
AVS-2771	CPE	SF	0.15	----	VERO	3.20	----	7/ 6/87
AVS-2771	CPE	VSV	----	----	L929	32.00	----	6/26/87
AVS-2771	CPE	VV	----	----	VERO	32.00	----	7/ 9/87
AVS-2771	CPE	YFV	----	----	VERO	3.20	----	7/ 6/87
AVS-2772	CPE	AD2	0.5	----	HEP2 >	320.00	----	7/ 9/87
AVS-2772	CPE	JE	----	----	VERO	10.00	----	7/ 8/87
AVS-2772	PR	PIC	N/A	----	VERO >	10.00	----	8/19/88
AVS-2772	CPE	PT	----	----	VERO	10.00	----	7/ 8/87
AVS-2772	CPE	SF	----	----	VERO	10.00	----	7/ 7/87
AVS-2772	CPE	VSV	0.1	----	L929	320.00	----	6/26/87
AVS-2772	CPE	VV	----	----	VERO >	320.00	----	7/ 9/87
AVS-2772	CPE	YFV	0.25	----	VERO	3.20	----	7/ 7/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2773	CPE	AD2	0.5	----	HEP2 >	320.00	----	7/ 9/87
AVS-2773	CPE	JE	----	----	VERO	32.00	----	7/ 8/87
AVS-2773	PR	PIC	N/A	----	VERO >	10.00	----	8/19/88
AVS-2773	CPE	PT	----	----	VERO	10.00	----	7/ 8/87
AVS-2773	CPE	SF	----	----	VERO	10.00	----	7/ 7/87
AVS-2773	CPE	VSV	0.6	320.00	L929 >	320.00 >	1.00	6/26/87
AVS-2773	CPE	VV	0.2	----	VERO	320.00	----	7/ 9/87
AVS-2773	CPE	YFV	0.69	----	VERO	10.00	----	7/ 7/87
AVS-2774	CPE	AD2	----	----	HEP2 <	100.00	----	7/ 9/87
AVS-2774	CPE	JE	----	----	VERO	100.00	----	7/ 9/87
AVS-2774	PR	PIC	N/A	----	VERO	32.00	----	8/19/88
AVS-2774	CPE	PT	----	----	VERO	320.00	----	7/ 8/87
AVS-2774	CPE	SF	1.35	83.80	VERO	32.00	0.38	7/ 7/87
AVS-2774	CPE	VSV	----	----	L929	320.00	----	6/26/87
AVS-2774	CPE	VV	----	----	VERO	320.00	----	7/ 9/87
AVS-2775	CPE	AD2	----	----	HEP2 >	320.00	----	7/ 9/87
AVS-2775	CPE	JE	----	----	VERO	320.00	----	7/ 9/87
AVS-2775	PR	PIC	N/A	----	VERO >	320.00	----	8/19/88
AVS-2775	CPE	PT	0.17	----	VERO	100.00	----	7/ 9/87
AVS-2775	CPE	SF	----	----	VERO	100.00	----	7/ 7/87
AVS-2775	CPE	VSV	----	----	L929 >	320.00	----	6/26/87
AVS-2775	CPE	VV	0.1	----	VERO	320.00	----	7/ 9/87
AVS-2775	CPE	YFV	0.35	----	VERO	32.00	----	7/ 7/87
AVS-2786	CPE	AD2	0.2	----	HEP2 <	100.00	----	7/ 2/87
AVS-2786	CPE	JE	----	----	VERO	100.00	----	6/17/87
AVS-2786	PR	PIC	N/A	99.00	VERO >	100.00 >	1.00	8/19/88
AVS-2786	CPE	PT	0.92	57.80	VERO	100.00	1.72	6/12/87
AVS-2786	CPE	SF	1.3	50.40	VERO	32.00	0.63	8/12/87
AVS-2786	CPE	VSV	----	----	L929	32.00	----	6/23/87
AVS-2786	CPE	VV	1.1	71.00	VERO <	320.00 <	4.50	7/ 2/87
AVS-2786	CPE	VV	1.3	100.00	VERO	320.00	3.18	5/12/88
AVS-2786	CPE	YFV	----	----	VERO	32.00	----	8/12/87
AVS-2787	CPE	AD2	1.2	179.00	HEP2 >	320.00 >	1.78	7/ 2/87
AVS-2787	CPE	JE	0.35	270.00	VERO	320.00	1.18	6/17/87
AVS-2787	PR	PIC	N/A	----	VERO	320.00	----	8/19/88
AVS-2787	CPE	PT	0.34	----	VERO >	320.00	----	6/12/87
AVS-2787	CPE	SF	----	----	VERO >	320.00	----	8/12/87
AVS-2787	CPE	VSV	----	----	L929 >	320.00	----	6/23/87
AVS-2787	CPE	VV	0.6	----	VERO >	320.00	----	7/ 2/87
AVS-2787	CPE	YFV	0.1	----	VERO >	320.00	----	8/12/87
AVS-2788	CPE	AD2	----	----	HEP2 >	320.00	----	7/ 2/87
AVS-2788	CPE	JE	0.6	225.00	VERO	320.00	1.41	6/17/87
AVS-2788	CPE	PT	0.24	----	VERO >	320.00	----	6/12/87
AVS-2788	CPE	SF	----	----	VERO >	320.00	----	8/12/87
AVS-2788	CPE	VSV	----	----	L929 >	320.00	----	6/23/87
AVS-2788	CPE	VV	0.1	----	VERO >	320.00	----	7/ 2/87
AVS-2788	CPE	YFV	0.1	----	VERO >	320.00	----	8/12/87
AVS-2789	CPE	AD2	0.4	----	HEP2 >	320.00	----	7/ 2/87
AVS-2789	CPE	JE	----	----	VERO >	320.00	----	6/17/87
AVS-2789	CPE	PT	0.49	----	VERO >	320.00	----	6/12/87
AVS-2789	CPE	SF	----	----	VERO >	320.00	----	8/12/87
AVS-2789	CPE	VSV	----	----	L929 >	320.00	----	6/23/87
AVS-2789	CPE	VV	----	----	VERO >	320.00	----	7/ 2/87
AVS-2789	CPE	YFV	----	----	VERO >	320.00	----	8/12/87
AVS-2790	CPE	AD2	----	----	HEP2 >	320.00	----	7/ 2/87
AVS-2790	CPE	JE	0.4	239.00	VERO	100.00	0.42	6/17/87
AVS-2790	PR	PIC	N/A	----	VERO >	320.00	----	8/23/88
AVS-2790	CPE	PT	0.05	----	VERO >	320.00	----	6/12/87
AVS-2790	CPE	SF	----	----	VERO	320.00	----	8/12/87
AVS-2790	CPE	VSV	----	----	L929 >	320.00	----	6/23/87
AVS-2790	CPE	VV	0.1	----	VERO >	320.00	----	7/ 2/87
AVS-2790	CPE	YFV	----	----	VERO	320.00	----	8/12/87
AVS-2791	CPE	PT	----	----	VERO	10.00	----	9/ 4/87
AVS-2792	CPE	PT	0.2	----	VERO	0.10	----	9/21/87
AVS-2793	CPE	PT	----	----	VERO <	320.00	----	9/ 4/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2794	CPE	PT	0.05	----	VERO	1.00	----	9/ 4/87
AVS-2795	CPE	PT	----	----	VERO	1.00	----	9/ 4/87
AVS-2796	CPE	PT	----	----	VERO	0.32	----	9/ 4/87
AVS-2797	CPE	PT	----	----	VERO	100.00	----	9/ 4/87
AVS-2798	CPE	PT	----	----	VERO	100.00	----	9/ 4/87
AVS-2799	CPE	PT	----	----	VERO	320.00	----	9/ 4/87
AVS-2800	CPE	PT	----	----	VERO	32.00	----	9/ 4/87
AVS-2801	CPE	PT	----	----	VERO	10.00	----	9/ 4/87
AVS-2802	CPE	PT	1.	88.60	VERO	32.00	0.36	11/25/87
AVS-2803	CPE	PT	----	----	VERO	32.00	----	11/25/87
AVS-2804	CPE	PT	----	----	VERO	320.00	----	11/25/87
AVS-2806	CPE	PT	----	----	VERO	32.00	----	10/28/87
AVS-2807	CPE	PT	----	----	VERO	320.00	----	11/25/87
AVS-2808	CPE	PT	----	----	VERO	10.00	----	11/25/87
AVS-2809	CPE	PT	0.1	----	VERO	100.00	----	10/28/87
AVS-2810	CPE	PT	0.55	188.00	VERO	100.00	0.53	12/14/87
AVS-2811	CPE	AD2	1.65	0.35	HEP2	0.32	0.90	1/21/88
AVS-2811	CPE	AD2	1.2	0.18	HEP2	0.10	0.55	2/ 4/88
AVS-2811	CPE	JE	1.2	0.56	VERO	0.32	0.56	12/ 4/87
AVS-2811	CPE	JE	1.1	0.28	VERO	1.00	3.50	3/ 1/88
AVS-2811	PR	PIC	N/A	0.13	VERO	0.32	2.36	3/22/88
AVS-2811	CPE	PT	0.8	0.50	VERO	1.00	1.98	3/ 1/88
AVS-2811	CPE	VEE	0.15	----	VERO	0.32	----	3/ 1/88
AVS-2811	CPE	VSV	2.	0.42	L929	0.32	0.75	1/22/88
AVS-2811	CPE	VSV	1.4	1.33	L929	0.32	0.24	1/29/88
AVS-2811	CPE	VV	----	----	VERO	0.32	----	1/21/88
AVS-2811	CPE	YFV	0.55	0.69	VERO	1.00	1.43	3/ 1/88
AVS-2812	CPE	AD2	1.05	0.13	HEP2	0.10	0.72	2/25/88
AVS-2812	CPE	AD2	1.45	0.11	HEP2	0.10	0.91	3/10/88
AVS-2812	CPE	JE	0.9	----	VERO	0.03	5.41	3/ 1/88
AVS-2812	PR	PIC	N/A	0.02	VERO	0.03	1.18	3/22/88
AVS-2812	CPE	PT	1.	----	VERO	0.03	4.57	3/ 1/88
AVS-2812	CPE	VEE	----	----	VERO	0.03	----	3/ 1/88
AVS-2812	CPE	VSV	0.05	----	L929	0.03	----	2/12/88
AVS-2812	CPE	VV	----	----	VERO	0.10	----	2/25/88
AVS-2812	CPE	YFV	0.45	----	VERO	0.01	1.46	3/ 1/88
AVS-2813	CPE	AD2	----	----	HEP2	0.01	----	7/30/87
AVS-2813	CPE	JE	-0-	----	VERO	0.32	----	7/24/87
AVS-2813	CPE	VSV	----	----	L929	0.32	----	7/10/87
AVS-2813	CPE	VV	----	----	VERO	0.01	----	8/13/87
AVS-2814	CPE	PT	----	----	VERO	1.00	----	9/11/87
AVS-2815	CPE	PT	0.45	23.90	VERO	3.20	0.13	9/11/87
AVS-2816	CPE	PT	0.2	----	VERO	100.00	----	9/11/87
AVS-2817	CPE	PT	0.4	23.90	VERO	3.20	0.13	9/11/87
AVS-2818	CPE	PT	----	----	VERO	100.00	----	9/11/87
AVS-2819	CPE	PT	----	----	VERO	10.00	----	9/11/87
AVS-2820	CPE	PT	----	----	VERO	10.00	----	9/11/87
AVS-2821	CPE	PT	0.05	----	VERO	3.20	----	9/11/87
AVS-2822	CPE	PT	0.05	----	VERO	3.20	----	9/14/87
AVS-2823	CPE	PT	0.2	----	VERO	10.00	----	9/14/87
AVS-2824	CPE	PT	0.1	----	VERO	10.00	----	9/11/87
AVS-2827	CPE	PT	----	----	VERO	100.00	----	12/16/87
AVS-2829	CPE	PT	0.55	----	VERO	10.00	----	9/14/87
AVS-2830	CPE	PT	1.02	----	VERO	100.00	----	9/14/87
AVS-2832	CPE	PT	0.05	----	VERO	100.00	----	9/15/87
AVS-2833	CPE	PT	0.22	----	VERO	10.00	----	9/14/87
AVS-2834	CPE	PT	0.17	----	VERO	1.00	----	9/14/87
AVS-2835	CPE	PT	0.3	----	VERO	3.20	----	9/14/87
AVS-2836	CPE	PT	0.92	1.69	VERO	3.20	1.89	9/14/87
AVS-2837	CPE	PT	0.5	7.50	VERO	3.20	0.43	9/15/87
AVS-2838	CPE	PT	0.52	67.30	VERO	3.20	0.05	9/15/87
AVS-2839	CPE	PT	0.07	----	VERO	0.32	----	9/15/87
AVS-2841	CPE	PT	0.77	12.70	VERO	10.00	0.78	9/15/87
AVS-2842	CPE	PT	----	----	VERO	320.00	----	9/15/87
AVS-2843	CPE	PT	----	----	VERO	320.00	----	9/15/87

B-137

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2844	CPE	PT	0.07	----	VERO	1.00	----	9/15/87
AVS-2845	CPE	PT	0.12	----	VERO	0.32	----	9/15/87
AVS-2846	CPE	PT	0.07	----	VERO	320.00	----	9/15/87
AVS-2848	CPE	PT	----	----	VERO	320.00	----	12/14/87
AVS-2849	CPE	PT	0.05	----	VERO	100.00	----	12/14/87
AVS-2850	CPE	PT	0.1	----	VERO	320.00	----	12/14/87
AVS-2851	CPE	PT	----	----	VERO	100.00	----	12/14/87
AVS-2852	CPE	PT	0.15	----	VERO	320.00	----	12/14/87
AVS-2853	CPE	PT	0.05	----	VERO	100.00	----	12/14/87
AVS-2855	CPE	PT	----	----	VERO	100.00	----	11/25/87
AVS-2856	CPE	PT	----	----	VERO	100.00	----	10/15/87
AVS-2857	CPE	PT	----	----	VERO	3.20	----	9/18/87
AVS-2858	CPE	PT	0.05	----	VERO	3.20	----	10/15/87
AVS-2859	CPE	PT	----	----	VERO	10.00	----	9/18/87
AVS-2860	CPE	AD2	0.7	9.60	HEP2	10.00	1.03	5/ 7/87
AVS-2860	CPE	JE	0.52	----	VERO	32.00	----	5/28/87
AVS-2860	PR	PIC	N/A	----	VERO	32.00	----	2/ 8/88
AVS-2860	CPE	PT	0.05	----	VERO	10.00	----	5/28/87
AVS-2860	CPE	VEE	0.8	----	VERO	32.00	----	5/28/87
AVS-2860	CPE	VSV	0.05	----	L929	32.00	----	5/ 1/87
AVS-2860	CPE	VV	2.45	3.20	VERO	32.00	10.00	5/ 7/87
AVS-2860	CPE	YFV	0.15	----	VERO	3.20	----	5/28/87
AVS-2861	CPE	AD2	0.45	----	HEP2	320.00	----	5/ 7/87
AVS-2861	CPE	JE	1.63	94.10	VERO	100.00	1.06	5/28/87
AVS-2861	PR	PIC	N/A	----	VERO	100.00	----	7/29/88
AVS-2861	CPE	PT	0.15	----	VERO	32.00	----	5/28/87
AVS-2861	CPE	VEE	0.1	----	VERO	100.00	----	5/28/87
AVS-2861	CPE	VSV	----	----	L929	32.00	----	5/ 1/87
AVS-2861	CPE	VV	----	----	VERO	320.00	----	5/ 7/87
AVS-2861	CPE	YFV	0.05	----	VERO	3.20	----	5/28/87
AVS-2862	CPE	AD2	0.6	2.23	HEP2	3.20	1.43	5/ 7/87
AVS-2862	CPE	JE	----	----	VERO	3.20	----	5/28/87
AVS-2862	PR	PIC	N/A	19.40	VERO	32.00	1.64	2/ 8/88
AVS-2862	CPE	PT	0.04	----	VERO	3.20	----	5/28/87
AVS-2862	CPE	VEE	----	----	VERO	100.00	----	5/28/87
AVS-2862	CPE	VSV	----	----	L929	3.20	----	5/ 1/87
AVS-2862	CPE	VV	0.55	58.10	VERO	100.00	1.72	5/ 7/87
AVS-2862	CPE	YFV	----	----	VERO	3.20	----	5/28/87
AVS-2863	CPE	AD2	0.25	----	HEP2	1.00	----	5/ 7/87
AVS-2863	CPE	JE	----	----	VERO	3.20	----	5/29/87
AVS-2863	PR	PIC	N/A	1.82	VERO	3.20	1.75	2/ 8/88
AVS-2863	CPE	PT	0.16	----	VERO	1.00	----	5/28/87
AVS-2863	CPE	VEE	0.2	----	VERO	32.00	----	5/28/87
AVS-2863	CPE	VSV	----	----	L929	3.20	----	5/ 1/87
AVS-2863	CPE	VV	0.1	----	VERO	3.20	----	5/ 7/87
AVS-2863	CPE	YFV	----	----	VERO	1.00	----	5/28/87
AVS-2864	CPE	AD2	0.3	100.00	HEP2	100.00	1.00	5/ 7/87
AVS-2864	CPE	JE	0.25	----	VERO	320.00	----	5/28/87
AVS-2864	PR	PIC	N/A	----	VERO	32.00	----	2/ 9/88
AVS-2864	CPE	PT	0.36	----	VERO	100.00	----	5/28/87
AVS-2864	CPE	VEE	0.3	----	VERO	320.00	----	5/28/87
AVS-2864	CPE	VSV	----	----	L929	100.00	----	5/ 1/87
AVS-2864	CPE	VV	0.1	----	VERO	320.00	----	5/ 7/87
AVS-2864	CPE	YFV	0.15	----	VERO	32.00	----	5/28/87
AVS-2865	CPE	AD2	0.55	----	HEP2	100.00	----	5/ 7/87
AVS-2865	CPE	JE	----	----	VERO	100.00	----	5/29/87
AVS-2865	PR	PIC	N/A	----	VERO	32.00	----	2/ 9/88
AVS-2865	CPE	PT	0.48	----	VERO	32.00	----	5/29/87
AVS-2865	CPE	SF	----	----	VERO	10.00	----	5/29/87
AVS-2865	CPE	VSV	----	----	L929	320.00	----	5/ 1/87
AVS-2865	CPE	VV	0.05	----	VERO	320.00	----	5/ 7/87
AVS-2865	CPE	YFV	----	----	VERO	10.00	----	5/29/87
AVS-2866	CPE	AD2	0.15	----	HEP2	100.00	----	5/ 7/87
AVS-2866	CPE	JE	----	----	VERO	320.00	----	5/29/87
AVS-2866	PR	PIC	N/A	----	VERO	32.00	----	2/ 9/88

B-138

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2866	CPE	PT	0.4	----	VERO	320.00	----	5/29/87
AVS-2866	CPE	SF	----	----	VERO	100.00	----	5/29/87
AVS-2866	CPE	VSV	----	----	L929	320.00	----	5/ 1/87
AVS-2866	CPE	VV	1.8	100.00	VERO >	320.00 >	3.18	5/ 7/87
AVS-2866	CPE	YFV	0.1	----	VERO	100.00	----	5/29/87
AVS-2867	CPE	AD2	0.15	----	HEP2	1.00	----	5/ 7/87
AVS-2867	CPE	JE	----	----	VERO <	10.00	----	5/29/87
AVS-2867	PR	PIC	N/A	----	VERO	1.00	----	2/ 9/88
AVS-2867	CPE	PT	0.06	----	VERO	0.32	----	5/29/87
AVS-2867	CPE	SF	----	----	VERO	0.32	----	5/29/87
AVS-2867	CPE	VSV	----	----	L929	1.00	----	5/ 1/87
AVS-2867	CPE	VV	----	----	VERO	3.20	----	5/ 7/87
AVS-2867	CPE	YFV	----	----	VERO	0.32	----	5/29/87
AVS-2868	CPE	AD2	0.3	----	HEP2 <	3.20	----	5/ 7/87
AVS-2868	CPE	JE	----	----	VERO <	10.00	----	5/29/87
AVS-2868	PR	PIC	N/A	2.22	VERO <	10.00 <	4.49	2/ 9/88
AVS-2868	CPE	PT	0.14	----	VERO	3.20	----	5/29/87
AVS-2868	CPE	SF	----	----	VERO	1.00	----	5/29/87
AVS-2868	CPE	VSV	----	----	L929	10.00	----	5/ 1/87
AVS-2868	CPE	VV	----	----	VERO <	10.00	----	5/ 7/87
AVS-2868	CPE	YFV	----	----	VERO	1.00	----	5/29/87
AVS-2869	CPE	AD2	----	----	HEP2	320.00	----	7/ 9/87
AVS-2869	CPE	JE	----	----	VERO	320.00	----	8/11/87
AVS-2869	PR	PIC	N/A	----	VERO >	100.00	----	8/23/88
AVS-2869	CPE	PT	0.25	----	VERO	100.00	----	9/24/87
AVS-2869	CPE	SF	0.15	----	VERO	32.00	----	9/ 2/87
AVS-2869	CPE	VSV	----	----	L929 >	320.00	----	7/10/87
AVS-2869	CPE	VV	----	----	VERO >	320.00	----	7/ 9/87
AVS-2869	CPE	YFV	0.15	----	VERO	320.00	----	9/ 2/87
AVS-2870	CPE	AD2	----	----	HEP2	0.03	----	9/ 4/87
AVS-2870	CPE	JE	----	----	VERO	32.00	----	8/11/87
AVS-2870	PR	PIC	N/A	----	VERO	0.10	----	8/23/85
AVS-2870	CPE	PT	0.35	----	VERO	0.32	----	9/24/87
AVS-2870	CPE	SF	0.05	----	VERO	0.32	----	9/ 2/87
AVS-2870	CPE	VSV	----	----	L929	0.10	----	7/10/87
AVS-2870	CPE	VV	----	----	VERO	0.10	----	7/16/87
AVS-2870	CPE	YFV	----	----	VERO	0.32	----	9/ 2/87
AVS-2871	CPE	AD2	----	----	HEP2	0.03	----	9/ 4/87
AVS-2871	CPE	JE	----	----	VERO	100.00	----	8/13/87
AVS-2871	CPE	PT	----	----	VERO	0.32	----	11/11/87
AVS-2871	CPE	SF	----	----	VERO	10.00	----	9/ 2/87
AVS-2871	CPE	VSV	----	----	L929	0.03	----	7/10/87
AVS-2871	CPE	VV	----	----	VERO	0.01	----	9/ 4/87
AVS-2871	CPE	YFV	----	----	VERO	32.00	----	9/ 2/87
AVS-2872	CPE	AD2	----	----	HEP2	10.00	----	7/16/87
AVS-2872	CPE	JE	----	----	VERO	10.00	----	8/11/87
AVS-2872	CPE	PT	0.17	----	VERO	100.00	----	9/24/87
AVS-2872	CPE	SF	0.15	----	VERO	10.00	----	9/ 2/87
AVS-2872	CPE	VSV	----	----	L929 <	100.00	----	7/28/87
AVS-2872	CPE	VV	----	----	VERO >	32.00	----	7/16/87
AVS-2872	CPE	YFV	0.3	----	VERO	32.00	----	9/ 2/87
AVS-2873	CPE	AD2	0.15	----	HEP2	32.00	----	7/16/87
AVS-2873	CPE	JE	----	----	VERO >	320.00	----	8/11/87
AVS-2873	PR	PIC	N/A	----	VERO	320.00	----	8/23/88
AVS-2873	CPE	PT	0.1	----	VERO >	320.00	----	9/24/87
AVS-2873	CPE	SF	----	----	VERO >	320.00	----	9/ 2/87
AVS-2873	CPE	VSV	----	----	L929 >	320.00	----	7/10/87
AVS-2873	CPE	VV	3.3	10.60	VERO >	320.00 >	29.90	7/16/87
AVS-2873	CPE	VV	3.6	10.00	VERO >	320.00 >	32.00	8/27/87
AVS-2873	CPE	YFV	----	----	VERO >	320.00	----	9/ 2/87
AVS-2874	CPE	AD2	0.2	----	HEP2 >	320.00	----	7/16/87
AVS-2874	CPE	JE	----	----	VERO	320.00	----	8/11/87
AVS-2874	PR	PIC	N/A	----	VERO >	320.00	----	8/23/88
AVS-2874	CPE	PT	0.1	----	VERO >	320.00	----	9/24/87
AVS-2874	CPE	SF	----	----	VERO	320.00	----	9/ 3/87

B-139

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2874	CPE	VSV	----	----	L929 >	320.00	----	7/10/87
AVS-2874	CPE	VV	5.2	2.34	VERO >	320.00 >	136.00	7/16/87
AVS-2874	CPE	VV	5.	3.58	VERO >	320.00 >	89.10	8/27/87
AVS-2875	CPE	AD2	0.85	178.00	HEP2	320.00	1.79	7/16/87
AVS-2875	CPE	JE	0.17	----	VERO	320.00	----	8/11/87
AVS-2875	PR	PIC	N/A	----	VERO	320.00	----	8/23/88
AVS-2875	CPE	PT	----	----	VERO	320.00	----	9/24/87
AVS-2875	CPE	SF	----	----	VERO	100.00	----	9/ 3/87
AVS-2875	CPE	VSV	----	----	L929	320.00	----	7/10/87
AVS-2875	CPE	VV	7.3 <	0.32	VERO >	320.00 >	1000.00	7/16/87
AVS-2875	CPE	VV	7.1	0.40	VERO >	320.00 >	786.00	9/24/87
AVS-2875	CPE	YFV	----	----	VERO	100.00	----	9/ 3/87
AVS-2876	CPE	AD2	0.4	----	HEP2 >	320.00	----	7/30/87
AVS-2876	CPE	JE	----	----	VERO	320.00	----	8/11/87
AVS-2876	PR	PIC	N/A	----	VERO	320.00	----	8/23/88
AVS-2876	CPE	PT	----	----	VERO	100.00	----	9/28/87
AVS-2876	CPE	SF	0.6	162.00	VERO	32.00	0.20	9/ 3/87
AVS-2876	CPE	VSV	----	----	L929 >	320.00	----	7/17/87
AVS-2876	CPE	VV	0.1	----	VERO >	320.00	----	7/30/87
AVS-2876	CPE	YFV	----	----	VERO	320.00	----	9/ 3/87
AVS-2877	CPE	AD2	0.5	----	HEP2 <	100.00	----	7/16/87
AVS-2877	PR	PIC	N/A	----	VERO	10.00	----	8/23/88
AVS-2877	CPE	PT	0.1	----	VERO	100.00	----	9/28/87
AVS-2877	CPE	SF	0.23	----	VERO	100.00	----	9/ 3/87
AVS-2877	CPE	VSV	----	----	L929	100.00	----	7/14/87
AVS-2877	CPE	VV	0.45	----	VERO <	100.00	----	7/16/87
AVS-2877	CPE	YFV	----	----	VERO	32.00	----	9/ 3/87
AVS-2878	CPE	AD2	----	----	HEP2	100.00	----	7/16/87
AVS-2878	CPE	JE	----	----	VERO	100.00	----	8/13/87
AVS-2878	PR	PIC	N/A	----	VERO	32.00	----	8/23/88
AVS-2878	CPE	PT	----	----	VERO	32.00	----	9/28/87
AVS-2878	CPE	SF	0.32	80.20	VERO	10.00	0.12	9/ 3/87
AVS-2878	CPE	VSV	----	----	L929 <	320.00	----	7/14/87
AVS-2878	CPE	VV	0.6	93.90	VERO	100.00	1.06	7/16/87
AVS-2878	CPE	YFV	----	----	VERO	32.00	----	9/ 3/87
AVS-2879	CPE	AD2	----	----	HEP2 >	320.00	----	7/16/87
AVS-2879	CPE	JE	----	----	VERO >	320.00	----	8/13/87
AVS-2879	PR	PIC	N/A	----	VERO >	320.00	----	8/23/88
AVS-2879	CPE	PT	----	----	VERO >	320.00	----	9/28/87
AVS-2879	CPE	SF	----	----	VERO >	320.00	----	9/ 4/87
AVS-2879	CPE	VSV	----	----	L929	320.00	----	7/14/87
AVS-2879	CPE	VV	5.1	2.39	VERO >	320.00 >	133.00	7/16/87
AVS-2879	CPE	VV	5.4	3.20	VERO >	320.00 >	100.00	8/27/87
AVS-2879	CPE	YFV	----	----	VERO >	320.00	----	9/ 4/87
AVS-2880	CPE	AD2	----	----	HEP2	100.00	----	9/24/87
AVS-2880	CPE	AD2	----	----	HEP2	100.00	----	9/24/87
AVS-2880	CPE	JE	----	----	VERO >	320.00	----	9/ 3/87
AVS-2880	PR	PIC	N/A	----	VERO	320.00	----	8/23/88
AVS-2880	CPE	SF	----	----	VERO	320.00	----	9/ 4/87
AVS-2880	CPE	VSV	----	----	L929	100.00	----	7/13/87
AVS-2880	CPE	VSV	----	----	L929	320.00	----	7/14/87
AVS-2880	CPE	VV	----	----	VERO	320.00	----	9/24/87
AVS-2880	CPE	VV	----	----	VERO	100.00	----	9/24/87
AVS-2880	CPE	VV	0.2	----	L929	320.00	----	10/22/87
AVS-2880	CPE	VV	----	----	L929	320.00	----	10/22/87
AVS-2880	CPE	YFV	----	----	VERO	320.00	----	9/ 4/87
AVS-2883	CPE	AD2	0.3	----	HEP2 >	320.00	----	7/30/87
AVS-2883	CPE	JE	----	----	VERO	320.00	----	8/13/87
AVS-2883	PR	PIC	N/A	----	VERO >	320.00	----	8/23/88
AVS-2883	CPE	PT	0.05	----	VERO	320.00	----	9/28/87
AVS-2883	CPE	SF	----	----	VERO	100.00	----	9/ 4/87
AVS-2883	CPE	VSV	----	----	L929 >	320.00	----	7/14/87
AVS-2883	CPE	VV	----	----	VERO >	320.00	----	7/30/87
AVS-2883	CPE	YFV	0.1	----	VERO	100.00	----	9/ 4/87
AVS-2884	CPE	AD2	0.1	----	HEP2	320.00	----	7/30/87

B-140

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2884	CPE	JE	----	----	VERO	320.00	----	8/13/87
AVS-2884	PR	PIC	N/A	----	VERO	320.00	----	8/23/88
AVS-2884	CPE	PT	0.05	----	VERO	320.00	----	9/28/87
AVS-2884	CPE	SF	0.05	----	VERO	100.00	----	9/ 4/87
AVS-2884	CPE	VSV	----	----	L929 >	320.00	----	7/14/87
AVS-2884	CPE	VV	----	----	VERO >	320.00	----	7/30/87
AVS-2884	CPE	YFV	0.1	----	VERO	32.00	----	9/ 4/87
AVS-2885	CPE	AD2	----	----	HEP2	10.00	----	7/16/87
AVS-2885	CPE	JE	----	----	VERO	32.00	----	8/14/87
AVS-2885	PR	PIC	N/A	----	VERO	100.00	----	8/23/88
AVS-2885	CPE	PT	----	----	VERO <	320.00	----	9/28/87
AVS-2885	CPE	SF	0.7	159.00	VERO	100.00	0.63	9/ 4/87
AVS-2885	CPE	VSV	----	----	L929	10.00	----	7/14/87
AVS-2885	CPE	VV	0.1	----	VERO	100.00	----	7/16/87
AVS-2885	CPE	YFV	0.15	----	VERO	100.00	----	9/ 4/87
AVS-2886	CPE	AD2	----	----	HEP2	1.00	----	7/16/87
AVS-2886	CPE	JE	----	----	VERO	32.00	----	8/14/87
AVS-2886	PR	PIC	N/A	----	VERO	32.00	----	8/23/88
AVS-2886	CPE	SF	0.3	320.00	VERO	32.00	0.10	9/ 3/87
AVS-2886	CPE	VSV	----	----	L929 <	100.00	----	7/14/87
AVS-2886	CPE	VV	----	----	VERO	10.00	----	7/16/87
AVS-2886	CPE	YFV	----	----	VERO	320.00	----	9/ 8/87
AVS-2887	CPE	AD2	0.15	----	HEP2	320.00	----	7/16/87
AVS-2887	CPE	JE	----	----	VERO >	320.00	----	8/14/87
AVS-2887	PR	PIC	N/A	----	VERO >	320.00	----	8/26/88
AVS-2887	CPE	SF	----	----	VERO	100.00	----	9/ 8/87
AVS-2887	CPE	VSV	----	----	L929	320.00	----	7/14/87
AVS-2887	CPE	VV	0.35	----	VERO	320.00	----	7/16/87
AVS-2887	CPE	YFV	----	----	VERO	100.00	----	9/ 8/87
AVS-2888	CPE	AD2	----	----	HEP2 >	320.00	----	7/16/87
AVS-2888	CPE	JE	----	----	VERO >	320.00	----	8/14/87
AVS-2888	CPE	SF	----	----	VERO	320.00	----	9/ 8/87
AVS-2888	CPE	VSV	----	----	L929	100.00	----	7/14/87
AVS-2888	CPE	VV	5.3	2.30	VERO >	320.00 >	139.00	7/16/87
AVS-2888	CPE	VV	6.	1.55	VERO >	320.00 >	206.00	8/27/87
AVS-2888	CPE	YFV	----	----	VERO >	320.00	----	9/ 8/87
AVS-2889	CPE	AD2	0.2	----	HEP2 >	320.00	----	7/16/87
AVS-2889	CPE	JE	----	----	VERO >	320.00	----	8/14/87
AVS-2889	PR	PIC	N/A	----	VERO >	320.00	----	8/26/88
AVS-2889	CPE	PT	----	----	VERO	320.00	----	12/17/87
AVS-2889	CPE	SF	----	----	VERO >	320.00	----	9/ 8/87
AVS-2889	CPE	VSV	----	----	L929	100.00	----	7/14/87
AVS-2889	CPE	VV	4.3	6.30	VERO >	320.00 >	50.20	7/16/87
AVS-2889	CPE	VV	6.1	1.54	VERO >	320.00 >	206.00	8/27/87
AVS-2889	CPE	YFV	----	----	VERO >	320.00	----	9/ 8/87
AVS-2890	CPE	AD2	0.3	----	HEP2 >	320.00	----	7/16/87
AVS-2890	CPE	JE	0.05	----	VERO >	320.00	----	8/17/87
AVS-2890	PR	PIC	N/A	----	VERO >	320.00	----	8/26/88
AVS-2890	CPE	PT	----	----	VERO	320.00	----	12/17/87
AVS-2890	CPE	SF	----	----	VERO >	320.00	----	9/ 8/87
AVS-2890	CPE	VSV	----	----	L929 >	320.00	----	7/14/87
AVS-2890	CPE	VV	5.3	2.38	VERO >	320.00 >	134.00	7/16/87
AVS-2890	CPE	VV	5.9	1.76	VERO >	320.00 >	181.00	8/27/87
AVS-2890	CPE	YFV	----	----	VERO >	320.00	----	9/ 8/87
AVS-2891	CPE	AD2	----	----	HEP2 >	320.00	----	7/16/87
AVS-2891	CPE	JE	----	----	VERO >	320.00	----	8/17/87
AVS-2891	PR	PIC	N/A	----	VERO	320.00	----	8/26/88
AVS-2891	CPE	PT	----	----	VERO	320.00	----	12/17/87
AVS-2891	CPE	SF	----	----	VERO	320.00	----	9/ 9/87
AVS-2891	CPE	VSV	----	----	L929	320.00	----	7/14/87
AVS-2891	CPE	VV	4.7	3.68	VERO >	320.00 >	86.90	7/16/87
AVS-2891	CPE	VV	5.9	2.00	VERO >	320.00 >	159.00	8/27/87
AVS-2891	CPE	YFV	----	----	VERO	320.00	----	9/ 9/87
AVS-2892	CPE	PT	----	----	VERO	320.00	----	9/18/87
AVS-2893	CPE	AD2	----	----	HEP2 <	100.00	----	7/16/87

R-141

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2893	CPE	JE	0.1	----	VERO	100.00	----	8/17/87
AVS-2893	PR	PIC	N/A	----	VERO	32.00	----	8/26/88
AVS-2893	CPE	SF	----	----	VERO	32.00	----	9/ 9/87
AVS-2893	CPE	VSV	0.9	147.00	L929	320.00	2.17	7/14/87
AVS-2893	CPE	VV	1.65	86.70	VERO	320.00	3.68	7/16/87
AVS-2893	CPE	VV	1.15	114.00	VERO	100.00	0.87	5/12/88
AVS-2893	CPE	YFV	0.25	----	VERO	100.00	----	9/ 9/87
AVS-2894	CPE	AD2	----	----	HEP2	32.00	----	7/16/87
AVS-2894	CPE	JE	----	----	VERO	32.00	----	8/17/87
AVS-2894	PR	PIC	N/A	----	VERO	32.00	----	8/26/88
AVS-2894	CPE	SF	0.25	----	VERO	32.00	----	9/ 9/87
AVS-2894	CPE	VSV	----	----	L929 <	320.00	----	7/14/87
AVS-2894	CPE	VV	----	----	VERO	32.00	----	7/16/87
AVS-2894	CPE	YFV	----	----	VERO	100.00	----	9/ 9/87
AVS-2895	CPE	AD2	----	----	HEP2	320.00	----	7/16/87
AVS-2895	CPE	JE	----	----	VERO >	320.00	----	8/17/87
AVS-2895	PR	PIC	N/A	----	VERO	320.00	----	8/26/88
AVS-2895	CPE	SF	0.2	----	VERO	320.00	----	9/ 9/87
AVS-2895	CPE	VSV	----	----	L929 >	320.00	----	7/14/87
AVS-2895	CPE	VV	5.8	1.27	VERO >	320.00 >	251.00	7/16/87
AVS-2895	CPE	VV	6.6	1.00	VERO >	320.00 >	317.00	8/27/87
AVS-2895	CPE	YFV	----	----	VERO	320.00	----	9/ 9/87
AVS-2896	CPE	AD2	----	----	HEP2	320.00	----	7/30/87
AVS-2896	CPE	JE	----	----	VERO	320.00	----	8/18/87
AVS-2896	PR	PIC	N/A	----	VERO	320.00	----	8/26/88
AVS-2896	CPE	SF	0.1	----	VERO	100.00	----	9/ 9/87
AVS-2896	CPE	VSV	----	----	L929	320.00	----	7/14/87
AVS-2896	CPE	VV	6.	1.08	VERO >	320.00 >	295.00	7/30/87
AVS-2896	CPE	VV	5.6	1.66	VERO >	320.00 >	192.00	8/27/87
AVS-2896	CPE	YFV	----	----	VERO	100.00	----	9/ 9/87
AVS-2898	CPE	AD2	----	----	HEP2	10.00	----	7/30/87
AVS-2898	CPE	JE	----	----	VERO	3.20	----	8/18/87
AVS-2898	PR	PIC	N/A	----	VERO	1.00	----	8/26/88
AVS-2898	CPE	SF	0.35	----	VERO	3.20	----	9/10/87
AVS-2898	CPE	VSV	----	----	L929 <	10.00	----	7/17/87
AVS-2898	CPE	VV	----	----	VERO	10.00	----	7/30/87
AVS-2898	CPE	YFV	----	----	VERO	3.20	----	9/10/87
AVS-2899	CPE	AD2	----	----	HEP2	3.20	----	7/30/87
AVS-2899	CPE	JE	----	----	VERO	3.20	----	8/18/87
AVS-2899	PR	PIC	N/A	7.60	VERO	3.20	0.42	8/26/88
AVS-2899	CPE	SF	0.25	----	VERO	3.20	----	9/10/87
AVS-2899	CPE	VSV	----	----	L929	10.00	----	7/17/87
AVS-2899	CPE	VV	----	----	VERO	10.00	----	7/30/87
AVS-2899	CPE	YFV	----	----	VERO	3.20	----	9/10/87
AVS-2900	CPE	AD2	----	----	HEP2 <	32.00	----	7/30/87
AVS-2900	CPE	JE	----	----	VERO	10.00	----	8/18/87
AVS-2900	PR	PIC	N/A	----	VERO	1.00	----	8/29/88
AVS-2900	CPE	SF	0.75	3.86	VERO	3.20	0.83	9/10/87
AVS-2900	CPE	VSV	----	----	L929 <	32.00	----	7/17/87
AVS-2900	CPE	VV	----	----	VERO	10.00	----	7/30/87
AVS-2900	CPE	YFV	----	----	VERO	3.20	----	9/10/87
AVS-2901	CPE	AD2	----	----	HEP2	32.00	----	7/30/87
AVS-2901	CPE	JE	----	----	VERO	3.20	----	8/18/87
AVS-2901	PR	PIC	N/A	----	VERO	3.20	----	8/29/88
AVS-2901	CPE	PT	----	----	VERO	3.20	----	12/16/87
AVS-2901	CPE	SF	----	----	VERO >	320.00	----	9/10/87
AVS-2901	CPE	VSV	----	----	L929	32.00	----	7/17/87
AVS-2901	CPE	VV	----	----	VERO	32.00	----	7/30/87
AVS-2901	CPE	YFV	----	----	VERO >	320.00	----	9/10/87
AVS-2902	CPE	AD2	0.3	----	HEP2 <	100.00	----	7/30/87
AVS-2902	CPE	JE	----	----	VERO	32.00	----	8/19/87
AVS-2902	PR	PIC	N/A	----	VERO	32.00	----	8/29/88
AVS-2902	CPE	PT	1.95	29.10	VERO	100.00	3.42	12/16/87
AVS-2902	CPE	PT	0.2	----	VERO	32.00	----	5/25/88
AVS-2902	CPE	SF	0.3	----	VERO	32.00	----	9/10/87

8-142

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2902	CPE	VSV	----	----	L929	32.00	----	7/17/87
AVS-2902	CPE	VV	3.75	0.32	VERO	32.00	100.00	7/30/87
AVS-2902	CPE	VV	4.85	0.08	VERO	32.00	367.00	9/24/87
AVS-2902	CPE	YFV	----	----	VERO	100.00	----	9/10/87
AVS-2903	CPE	AD2	0.2	----	HEP2 >	320.00	----	7/30/87
AVS-2903	CPE	JE	----	----	VERO >	320.00	----	8/19/87
AVS-2903	PR	PIC	N/A	----	VERO >	100.00	----	8/29/88
AVS-2903	CPE	PT	----	----	VERO	100.00	----	12/16/87
AVS-2903	CPE	SF	----	----	VERO >	320.00	----	9/14/87
AVS-2903	CPE	VSV	----	----	L929	320.00	----	7/17/87
AVS-2903	CPE	VV	4.4	4.99	VERO >	320.00 >	64.00	7/30/87
AVS-2903	CPE	VV	3.4	12.20	VERO >	320.00 >	26.00	8/27/87
AVS-2903	CPE	YFV	----	----	VERO >	320.00	----	9/14/87
AVS-2904	CPE	AD2	----	----	HEP2 >	320.00	----	7/30/87
AVS-2904	CPE	JE	----	----	VERO	320.00	----	8/19/87
AVS-2904	PR	PIC	N/A	----	VERO >	32.00	----	8/29/88
AVS-2904	CPE	PT	0.35	319.00	VERO	100.00	0.31	12/22/87
AVS-2904	CPE	SF	0.57	178.00	VERO	100.00	0.56	9/14/87
AVS-2904	CPE	VSV	0.05	----	L929	320.00	----	7/17/87
AVS-2904	CPE	VV	4.	3.20	VERO	320.00	100.00	7/30/87
AVS-2904	CPE	VV	4.5	3.20	VERO >	320.00 >	100.00	8/27/87
AVS-2904	CPE	YFV	----	----	VERO	100.00	----	9/14/87
AVS-2905	CPE	AD2	----	----	HEP2 <	32.00	----	7/30/87
AVS-2905	CPE	JE	----	----	VERO <	100.00	----	8/19/87
AVS-2905	PR	PIC	N/A	----	VERO <	32.00	----	8/30/88
AVS-2905	CPE	PT	----	----	VERO	100.00	----	12/17/87
AVS-2905	CPE	SF	----	----	VERO <	100.00	----	9/14/87
AVS-2905	CPE	VSV	----	----	L929	32.00	----	7/17/87
AVS-2905	CPE	VV	----	----	VERO <	32.00	----	7/30/87
AVS-2905	CPE	YFV	----	----	VERO <	100.00	----	9/14/87
AVS-2906	CPE	AD2	0.6	57.00	HEP2	32.00	0.56	7/30/87
AVS-2906	CPE	JE	----	----	VERO	100.00	----	8/19/87
AVS-2906	PR	PIC	N/A	59.80	VERO	32.00	0.54	8/29/88
AVS-2906	CPE	PT	----	----	VERO	100.00	----	12/17/87
AVS-2906	CPE	SF	2.1	24.80	VERO	100.00	4.02	9/14/87
AVS-2906	CPE	SF	0.55	69.80	VERO	100.00	1.43	5/25/88
AVS-2906	CPE	VSV	2.1	7.80	L929 <	100.00 <	12.80	7/17/87
AVS-2906	CPE	VSV	2.6	8.80	L929	100.00	11.20	7/28/87
AVS-2906	PR	VSV	N/A	1.92	L929	32.00	16.50	9/23/87
AVS-2906	CPE	VV	2.2	11.40	VERO	100.00	8.73	7/30/87
AVS-2906	CPE	VV	3.2	9.80	VERO	320.00	32.60	1/21/88
AVS-2906	CPE	YFV	2.3	24.60	VERO	320.00	12.90	9/14/87
AVS-2906	CPE	YFV	2.05	23.10	VERO	32.00	1.38	5/25/88
AVS-2907	CPE	AD2	0.75	17.70	HEP2	32.00	1.80	7/30/87
AVS-2907	CPE	JE	----	----	VERO	100.00	----	8/19/87
AVS-2907	PR	PIC	N/A	57.10	VERO	100.00	1.74	8/29/88
AVS-2907	CPE	PT	----	----	VERO	100.00	----	12/17/87
AVS-2907	CPE	SF	2.82	16.30	VERO	320.00	19.50	9/14/87
AVS-2907	CPE	SF	0.95	43.10	VERO	100.00	2.31	5/25/88
AVS-2907	CPE	VSV	0.4	23.90	L929	32.00	1.33	7/17/87
AVS-2907	CPE	VV	0.05	----	VERO	100.00	----	7/30/87
AVS-2907	CPE	YFV	0.75	199.00	VERO	320.00	1.60	9/14/87
AVS-2908	CPE	AD2	0.35	----	HEP2	100.00	----	7/30/87
AVS-2908	CPE	JE	----	----	VERO	32.00	----	8/19/87
AVS-2908	PR	PIC	N/A	----	VERO	32.00	----	8/29/88
AVS-2908	CPE	SF	0.55	59.50	VERO	32.00	0.54	9/16/87
AVS-2908	CPE	VSV	0.05	----	L929	100.00	----	7/17/87
AVS-2908	CPE	VV	0.25	----	VERO	100.00	----	7/30/87
AVS-2908	CPE	YFV	----	----	VERO	100.00	----	9/16/87
AVS-2909	CPE	AD2	0.95	135.00	HEP2	320.00	2.35	7/30/87
AVS-2909	CPE	JE	----	----	VERO	100.00	----	8/19/87
AVS-2909	PR	PIC	N/A	----	VERO >	100.00	----	8/29/88
AVS-2909	CPE	PT	----	----	VERO	100.00	----	11/12/87
AVS-2909	CPE	PT	----	----	VERO >	10.00	----	12/21/87
AVS-2909	CPE	SF	0.55	200.00	VERO	32.00	0.16	9/16/87

B-143

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	T1	DATE
AVS-2909	CPE	VSV	----	----	L929 >	320.00	----	7/17/87
AVS-2909	CPE	VV	----	----	VERO	320.00	----	7/30/87
AVS-2909	CPE	YFV	----	----	VERO	320.00	----	9/16/87
AVS-2910	CPE	AD2	0.3	----	HEP2 <	320.00	----	7/30/87
AVS-2910	CPE	JE	----	----	VERO	100.00	----	8/19/87
AVS-2910	PR	PIC	N/A	----	VERO <	100.00	----	8/29/88
AVS-2910	CPE	PT	----	----	VERO	100.00	----	11/12/87
AVS-2910	CPE	SF	----	----	VERO	32.00	----	9/16/87
AVS-2910	CPE	VSV	----	----	L929	320.00	----	7/17/87
AVS-2910	CPE	VV	----	----	VERO <	320.00	----	7/30/87
AVS-2910	CPE	YFV	----	----	VERO	32.00	----	9/16/87
AVS-2911	CPE	AD2	0.3	----	HEP2 >	320.00	----	7/30/87
AVS-2911	CPE	JE	----	----	VERO	320.00	----	8/19/87
AVS-2911	PR	PIC	N/A	----	VERO >	100.00	----	8/30/88
AVS-2911	CPE	PT	----	----	VERO	100.00	----	12/17/87
AVS-2911	CPE	SF	0.15	----	VERO	320.00	----	9/16/87
AVS-2911	CPE	VSV	----	----	L929 >	320.00	----	7/17/87
AVS-2911	CPE	VV	6.2	1.03	VERO >	320.00 >	309.00	7/30/87
AVS-2911	CPE	VV	5.8	1.77	VERO >	320.00 >	180.00	8/27/87
AVS-2911	CPE	YFV	----	----	VERO	100.00	----	9/16/87
AVS-2912	CPE	AD2	----	----	HEP2 <	100.00	----	7/30/87
AVS-2912	CPE	JE	----	----	VERO	320.00	----	8/21/87
AVS-2912	PR	PIC	N/A	----	VERO	100.00	----	8/30/88
AVS-2912	CPE	PT	----	----	VERO	100.00	----	12/17/87
AVS-2912	CPE	SF	----	----	VERO	100.00	----	9/16/87
AVS-2912	CPE	VSV	----	----	L929	320.00	----	7/17/87
AVS-2912	CPE	VV	5.9	1.44	VERO >	320.00 >	220.00	7/30/87
AVS-2912	CPE	VV	5.8	1.77	VERO >	320.00 >	180.00	8/27/87
AVS-2912	CPE	YFV	----	----	VERO	320.00	----	9/16/87
AVS-2913	CPE	AD2	----	----	HEP2 <	320.00	----	7/30/87
AVS-2913	CPE	JE	----	----	VERO	100.00	----	8/21/87
AVS-2913	PR	PIC	N/A	----	VERO >	100.00	----	8/30/88
AVS-2913	CPE	PT	----	----	VERO	100.00	----	12/17/87
AVS-2913	CPE	SF	----	----	VERO	100.00	----	9/17/87
AVS-2913	CPE	VSV	----	----	L929	320.00	----	7/17/87
AVS-2913	CPE	VV	6.1	1.02	VERO >	320.00 >	313.00	7/30/87
AVS-2913	CPE	VV	6.3	1.02	VERO >	320.00 >	311.00	8/27/87
AVS-2913	CPE	YFV	----	----	VERO	100.00	----	9/17/87
AVS-2914	CPE	AD2	----	----	HEP2	100.00	----	7/30/87
AVS-2914	CPE	JE	----	----	VERO	100.00	----	8/21/87
AVS-2914	PR	PIC	N/A	----	VERO	32.00	----	8/30/88
AVS-2914	CPE	PT	0.9	137.00	VERO	100.00	0.73	12/29/87
AVS-2914	CPE	SF	0.15	----	VERO	100.00	----	9/17/87
AVS-2914	CPE	VSV	----	----	L929 <	320.00	----	7/17/87
AVS-2914	CPE	VV	1.3	128.00	VERO	320.00	2.48	7/30/87
AVS-2914	CPE	YFV	----	----	VERO	100.00	----	9/17/87
AVS-2915	CPE	AD2	0.3	----	HEP2 <	100.00	----	7/30/87
AVS-2915	CPE	JE	----	----	VERO <	100.00	----	8/21/87
AVS-2915	PR	PIC	N/A	----	VERO	32.00	----	8/30/88
AVS-2915	CPE	PT	----	----	VERO	32.00	----	10/21/87
AVS-2915	CPE	SF	----	----	VERO	320.00	----	9/17/87
AVS-2915	CPE	VSV	0.15	----	L929	100.00	----	7/17/87
AVS-2915	CPE	VV	0.6	60.10	VERO	32.00	0.53	7/30/87
AVS-2915	CPE	YFV	----	----	VERO	100.00	----	9/17/87
AVS-2916	CPE	AD2	----	----	HEP2	3.20	----	8/ 6/87
AVS-2916	CPE	JE	----	----	VERO	10.00	----	8/21/87
AVS-2916	PR	PIC	N/A	----	VERO	10.00	----	8/30/88
AVS-2916	CPE	SF	0.5	200.00	VERO	32.00	0.16	9/17/87
AVS-2916	CPE	VSV	----	----	L929	100.00	----	7/17/87
AVS-2916	CPE	VV	----	----	VERO	100.00	----	8/ 6/87
AVS-2916	CPE	YFV	----	----	VERO	100.00	----	9/17/87
AVS-2917	CPE	AD2	----	----	HEP2	32.00	----	8/ 6/87
AVS-2917	CPE	JE	----	----	VERO	32.00	----	8/24/87
AVS-2917	PR	PIC	N/A	----	VERO	32.00	----	8/30/88
AVS-2917	CPE	SF	0.1	----	VERO	100.00	----	9/17/87

B-144

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2917	CPE	VSV	----	----	L929	32.00	----	7/17/87
AVS-2917	CPE	VV	1.	46.70	VERO	10.00	0.21	8/ 6/87
AVS-2917	CPE	YFV	----	----	VERO	100.00	----	9/17/87
AVS-2918	CPE	AD2	----	----	HEP2	100.00	----	8/ 6/87
AVS-2918	CPE	JE	----	----	VERO	320.00	----	8/24/87
AVS-2918	PR	PIC	N/A	----	VERO	100.00	----	8/30/88
AVS-2918	CPE	PT	----	----	VERO	100.00	----	10/21/87
AVS-2918	CPE	SF	----	----	VERO	32.00	----	9/18/87
AVS-2918	CPE	VSV	----	----	L929 <	320.00	----	7/17/87
AVS-2918	CPE	VV	0.35	319.00	VERO	100.00	0.31	8/ 6/87
AVS-2918	CPE	YFV	----	----	VERO	100.00	----	9/18/87
AVS-2919	CPE	AD2	----	----	HEP2 <	32.00	----	8/ 6/87
AVS-2919	CPE	JE	----	----	VERO <	100.00	----	8/24/87
AVS-2919	PR	PIC	N/A	----	VERO <	32.00	----	8/30/88
AVS-2919	CPE	PT	----	----	VERO	100.00	----	10/21/87
AVS-2919	CPE	SF	0.45	27.70	VERO	32.00	1.15	9/18/87
AVS-2919	CPE	VSV	----	----	L929	10.00	----	7/21/87
AVS-2919	CPE	VV	----	----	VERO	32.00	----	8/ 6/87
AVS-2919	CPE	YFV	----	----	VERO	10.00	----	9/18/87
AVS-2920	CPE	AD2	0.3	----	HEP2 >	320.00	----	11/ 5/87
AVS-2920	CPE	JE	0.25	----	VERO	320.00	----	12/22/87
AVS-2920	CPE	PT	----	----	VERO	10.00	----	12/14/87
AVS-2920	CPE	PT	----	----	VERO >	320.00	----	12/29/87
AVS-2920	CPE	SF	0.45	217.00	VERO	100.00	0.46	10/13/88
AVS-2920	CPE	VEE	----	----	VERO	32.00	----	10/13/88
AVS-2920	CPE	VSV	----	----	L929	32.00	----	11/13/87
AVS-2920	CPE	VV	----	----	VERO	320.00	----	11/ 5/87
AVS-2921	CPE	AD2	0.8	317.00	HEP2 >	320.00 >	1.00	11/ 5/87
AVS-2921	CPE	JE	0.3	----	VERO	320.00	----	12/22/87
AVS-2921	CPE	PT	----	----	VERO	320.00	----	12/14/87
AVS-2921	CPE	SF	0.45	217.00	VERO	100.00	0.46	10/13/88
AVS-2921	CPE	VEE	----	----	VERO	32.00	----	10/13/88
AVS-2921	CPE	VSV	----	----	L929	100.00	----	11/13/87
AVS-2921	CPE	VV	----	----	VERO	320.00	----	11/ 5/87
AVS-2922	CPE	AD2	0.4	----	HEP2 >	320.00	----	11/ 5/87
AVS-2922	CPE	JE	0.2	----	VERO >	320.00	----	12/22/87
AVS-2922	CPE	PT	----	----	VERO	320.00	----	12/14/87
AVS-2922	CPE	SF	----	----	VERO	32.00	----	10/13/88
AVS-2922	CPE	VEE	----	----	VERO	100.00	----	10/13/88
AVS-2922	CPE	VSV	0.05	----	L929	100.00	----	11/13/87
AVS-2922	CPE	VV	0.45	----	VERO	320.00	----	11/ 5/87
AVS-2923	CPE	AD2	----	----	HEP2	100.00	----	11/ 5/87
AVS-2923	CPE	JE	----	----	VERO	32.00	----	12/22/87
AVS-2923	CPE	PT	0.05	----	VERO	320.00	----	12/14/87
AVS-2923	CPE	SF	----	----	VERO	10.00	----	10/13/88
AVS-2923	CPE	VEE	----	----	VERO	100.00	----	10/13/88
AVS-2923	CPE	VSV	----	----	L929 <	320.00	----	11/13/87
AVS-2923	CPE	VV	----	----	VERO	100.00	----	11/ 5/87
AVS-2924	CPE	AD2	0.5	----	HEP2 >	320.00	----	11/ 5/87
AVS-2924	CPE	JE	----	----	VERO >	320.00	----	12/29/87
AVS-2924	CPE	PT	----	----	VERO	320.00	----	12/14/87
AVS-2924	CPE	SF	----	----	VERO	100.00	----	10/13/88
AVS-2924	CPE	VEE	----	----	VERO	100.00	----	10/13/88
AVS-2924	CPE	VSV	----	----	L929	320.00	----	11/13/87
AVS-2924	CPE	VV	----	----	VERO >	320.00	----	11/ 5/87
AVS-2925	CPE	AD2	0.4	----	HEP2 >	320.00	----	11/ 5/87
AVS-2925	CPE	JE	1.	133.00	VERO	320.00	2.39	12/29/87
AVS-2925	CPE	PT	----	----	VERO	320.00	----	12/14/87
AVS-2925	CPE	SF	----	----	VERO	100.00	----	10/13/88
AVS-2925	CPE	VEE	----	----	VERO	320.00	----	10/13/88
AVS-2925	CPE	VSV	----	----	L929 >	320.00	----	11/13/87
AVS-2925	CPE	VV	----	----	VERO >	320.00	----	11/ 5/87
AVS-2926	CPE	AD2	----	----	HEP2	320.00	----	8/ 6/87
AVS-2926	CPE	JE	----	----	VERO	320.00	----	8/24/87
AVS-2926	PR	PIC	N/A	----	VERO >	100.00	----	9/ 2/88

B-145

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2926	CPE	SF	----	----	VERO	320.00	----	9/18/87
AVS-2926	CPE	VSV	----	----	L929	320.00	----	7/21/87
AVS-2926	CPE	VV	----	----	VERO	320.00	----	8/ 6/87
AVS-2926	CPE	YFV	----	----	VERO	320.00	----	9/18/87
AVS-2927	CPE	AD2	----	----	HEP2 >	320.00	----	8/ 6/87
AVS-2927	CPE	JE	----	----	VERO	320.00	----	8/24/87
AVS-2927	PR	PIC	N/A	----	VERO	320.00	----	9/ 2/88
AVS-2927	CPE	SF	0.05	----	VERO	320.00	----	9/18/87
AVS-2927	CPE	VSV	----	----	L929 >	320.00	----	7/21/87
AVS-2927	CPE	VV	----	----	VERO >	320.00	----	8/ 6/87
AVS-2927	CPE	YFV	----	----	VERO >	320.00	----	9/18/87
AVS-2928	CPE	AD2	0.15	----	HEP2	320.00	----	8/ 6/87
AVS-2928	CPE	JE	----	----	VERO	100.00	----	8/25/87
AVS-2928	PR	PIC	N/A	----	VERO >	100.00	----	9/ 2/88
AVS-2928	CPE	SF	2.44	7.70	VERO	32.00	4.12	9/18/87
AVS-2928	CPE	SF	----	----	VERO	100.00	----	5/26/88
AVS-2928	CPE	VSV	----	----	L929	320.00	----	7/21/87
AVS-2928	CPE	VV	----	----	VERO >	320.00	----	8/ 6/87
AVS-2928	CPE	YFV	0.35	----	VERO	100.00	----	9/18/87
AVS-2929	CPE	AD2	----	----	HEP2	320.00	----	8/ 6/87
AVS-2929	CPE	JE	----	----	VERO >	320.00	----	8/25/87
AVS-2929	PR	PIC	N/A	----	VERO >	10.00	----	9/ 2/88
AVS-2929	CPE	SF	0.82	13.90	VERO	3.20	0.23	9/23/87
AVS-2929	CPE	VSV	----	----	L929 >	320.00	----	7/21/87
AVS-2929	CPE	VV	----	----	VERO	320.00	----	8/ 6/87
AVS-2929	CPE	YFV	0.15	----	VERO	3.20	----	9/23/87
AVS-2930	CPE	AD2	----	----	HEP2 >	320.00	----	8/ 6/87
AVS-2930	CPE	JE	----	----	VERO >	320.00	----	8/25/87
AVS-2930	PR	PIC	N/A	----	VERO	10.00	----	9/ 2/88
AVS-2930	CPE	SF	0.32	8.70	VERO	3.20	0.36	9/23/87
AVS-2930	CPE	VSV	----	----	L929 >	320.00	----	7/21/87
AVS-2930	CPE	VV	----	----	VERO	320.00	----	8/ 6/87
AVS-2930	CPE	YFV	----	----	VERO	3.20	----	9/23/87
AVS-2931	CPE	AD2	----	----	HEP2	100.00	----	8/ 6/87
AVS-2931	CPE	JE	----	----	VERO	100.00	----	8/25/87
AVS-2931	PR	PIC	N/A	----	VERO >	10.00	----	9/ 2/88
AVS-2931	CPE	SF	----	----	VERO	0.32	----	9/23/87
AVS-2931	CPE	VSV	----	----	L929	320.00	----	7/21/87
AVS-2931	CPE	VV	1.	100.00	VERO	100.00	1.00	8/ 6/87
AVS-2931	CPE	YFV	----	----	VERO	0.32	----	9/23/87
AVS-2932	CPE	AD2	----	----	HEP2	320.00	----	8/ 6/87
AVS-2932	CPE	JE	----	----	VERO >	320.00	----	8/25/87
AVS-2932	PR	PIC	N/A	----	VERO >	10.00	----	9/ 2/88
AVS-2932	CPE	SF	----	----	VERO	0.32	----	9/23/87
AVS-2932	CPE	VSV	----	----	L929 >	320.00	----	7/21/87
AVS-2932	CPE	VV	----	----	VERO	320.00	----	8/ 6/87
AVS-2932	CPE	YFV	0.2	----	VERO	0.32	----	9/23/87
AVS-2934	CPE	AD2	----	----	HEP2	100.00	----	7/30/87
AVS-2934	CPE	JE	----	----	VERO	0.32	----	8/26/87
AVS-2934	CPE	JE	----	----	VERO	1.00	----	9/ 4/87
AVS-2934	PR	PIC	N/A	----	VERO	0.10	----	8/23/88
AVS-2934	PR	PIC	N/A	2.21	VERO <	0.32 <	0.14	9/ 2/88
AVS-2934	CPE	PT	----	----	VERO	100.00	----	11/11/87
AVS-2934	CPE	SF	0.1	----	VERO	0.10	----	8/31/87
AVS-2934	CPE	SF	0.15	----	VERO	3.20	----	9/23/87
AVS-2934	CPE	VSV	----	----	L929	0.32	----	7/10/87
AVS-2934	CPE	VSV	----	----	L929	0.01	----	7/28/87
AVS-2934	CPE	VV	0.1	----	VERO	0.32	----	7/30/87
AVS-2934	CPE	YFV	----	----	VERO	0.10	----	8/31/87
AVS-2934	CPE	YFV	----	----	VERO	3.20	----	9/23/87
AVS-2934	CPE	YFV	----	----	VERO	0.32	----	2/ 2/88
AVS-2935	CPE	AD2	----	----	HEP2 <	1.00	----	8/13/87
AVS-2935	CPE	JE	----	----	VERO	10.00	----	8/26/87
AVS-2935	PR	PIC	N/A	----	VERO	3.20	----	9/ 2/88
AVS-2935	CPE	SF	0.4	75.10	VERO	10.00	0.13	9/24/87

B-146

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2935	CPE	VSV	----	----	L929	10.00	----	7/21/87
AVS-2935	CPE	VV	----	----	VERO	1.00	----	8/13/87
AVS-2935	CPE	YFV	1.1	22.80	VERO	10.00	0.44	9/24/87
AVS-2937	CPE	JE	----	----	VERO	100.00	----	8/26/87
AVS-2937	PR	PIC	N/A	----	VERO	320.00	----	9/ 2/88
AVS-2937	CPE	SF	----	----	VERO	100.00	----	9/23/87
AVS-2937	CPE	VSV	----	----	L929	320.00	----	7/28/87
AVS-2937	CPE	YFV	0.05	----	VERO	320.00	----	9/23/87
AVS-2938	CPE	JE	----	----	VERO	100.00	----	8/26/87
AVS-2938	CPE	SF	0.34	----	VERO	100.00	----	9/23/87
AVS-2938	CPE	VSV	----	----	L929	10.00	----	7/28/87
AVS-2938	CPE	YFV	----	----	VERO	100.00	----	9/23/87
AVS-2939	CPL	AD2	----	----	HEP2	320.00	----	8/ 6/87
AVS-2939	CPE	JE	----	----	VERO >	320.00	----	8/26/87
AVS-2939	PR	PIC	N/A	----	VERO >	320.00	----	9/ 9/88
AVS-2939	CPE	SF	1.	73.40	VERO	32.00	0.44	9/23/87
AVS-2939	CPE	VSV	----	----	L929 >	320.00	----	7/28/87
AVS-2939	CPE	VV	----	----	VERO	320.00	----	8/ 6/87
AVS-2939	CPE	YFV	----	----	VERO	100.00	----	9/23/87
AVS-2940	CPE	AD2	----	----	HEP2	100.00	----	8/ 6/87
AVS-2940	CPE	JE	0.2	----	VERO	100.00	----	8/26/87
AVS-2940	PR	PIC	N/A	----	VERO >	100.00	----	9/ 9/88
AVS-2940	CPE	SF	0.4	222.00	VERO	32.00	0.14	9/23/87
AVS-2940	CPE	VSV	----	----	L929	320.00	----	7/28/87
AVS-2940	CPE	VV	----	----	VERO <	320.00	----	8/ 6/87
AVS-2940	CPE	YFV	0.4	----	VERO	32.00	----	9/23/87
AVS-2941	CPE	AD2	0.4	----	HEP2 <	100.00	----	8/ 6/87
AVS-2941	CPE	JE	----	----	VERO	32.00	----	8/26/87
AVS-2941	PR	PIC	N/A	----	VERO	10.00	----	9/ 9/88
AVS-2941	CPE	SF	----	----	VERO	32.00	----	9/24/87
AVS-2941	CPE	VSV	----	----	L929	100.00	----	7/21/87
AVS-2941	CPE	VV	0.65	----	VERO	100.00	----	8/ 6/87
AVS-2941	CPE	YFV	0.15	----	VERO	10.00	----	9/24/87
AVS-2942	CPE	AD2	0.2	----	HEP2 <	32.00	----	8/ 6/87
AVS-2942	CPE	JE	0.2	----	VERO	32.00	----	8/26/87
AVS-2942	PR	PIC	N/A	----	VERO	10.00	----	9/ 9/88
AVS-2942	CPE	SF	----	----	VERO	3.20	----	9/24/87
AVS-2942	CPE	VSV	----	----	L929 <	100.00	----	7/21/87
AVS-2942	CPE	VV	0.7	64.10	VERO	100.00	1.55	8/ 6/87
AVS-2942	CPE	YFV	0.15	----	VERO	3.20	----	9/24/87
AVS-2943	CPE	AD2	0.6	----	HEP2 <	320.00	----	8/ 6/87
AVS-2943	CPE	JE	0.05	----	VERO	320.00	----	8/26/87
AVS-2943	PR	PIC	N/A	----	VERO >	32.00	----	9/ 9/88
AVS-2943	CPE	PT	----	----	VERO	32.00	----	11/25/87
AVS-2943	CPE	SF	----	----	VERO	32.00	----	9/24/87
AVS-2943	CPE	VSV	----	----	L929	100.00	----	7/21/87
AVS-2943	CPE	VV	1.4	244.00	VERO	320.00	1.31	8/ 6/87
AVS-2943	CPE	YFV	----	----	VERO	10.00	----	9/24/87
AVS-2944	CPE	AD2	0.2	----	HEP2 <	32.00	----	8/ 6/87
AVS-2944	CPE	JE	0.9	40.60	VERO	32.00	0.79	8/28/87
AVS-2944	PR	PIC	N/A	----	VERO	32.00	----	9/ 9/88
AVS-2944	CPE	PT	0.6	225.00	VERO	32.00	0.14	12/29/87
AVS-2944	CPE	SF	----	----	VERO	3.20	----	9/24/87
AVS-2944	CPE	VSV	----	----	L929	32.00	----	7/21/87
AVS-2944	CPE	VV	0.7	98.00	VERO	100.00	1.02	8/ 6/87
AVS-2944	CPE	YFV	----	----	VERO	3.20	----	9/24/87
AVS-2945	CPE	JE	----	----	VERO	100.00	----	8/28/87
AVS-2945	CPE	PT	0.55	188.00	VERO	32.00	0.17	11/25/87
AVS-2945	CPE	YFV	----	----	VERO	100.00	----	1/22/88
AVS-2946	CPE	AD2	0.4	----	HEP2 <	100.00	----	8/ 6/87
AVS-2946	CPE	JE	0.1	----	VERO >	320.00	----	8/28/87
AVS-2946	PR	PIC	N/A	----	VERO	10.00	----	9/ 9/88
AVS-2946	CPE	PT	0.5	200.00	VERO	32.00	0.16	12/29/87
AVS-2946	CPE	SF	0.8	----	VERO	3.20	----	2/ 2/88
AVS-2946	CPE	VSV	----	----	L929	1.00	----	7/21/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2946	CPE	VV	1.2	57.80	VERO	100.00	1.72	8/ 6/87
AVS-2946	CPE	YFV	0.25	----	VERO	32.00	----	1/22/88
AVS-2947	CPE	AD2	0.2	----	HEP2 <	100.00	----	8/ 6/87
AVS-2947	CPE	JE	----	----	VERO	100.00	----	8/28/87
AVS-2947	PR	PIC	N/A	----	VERO	100.00	----	9/ 9/88
AVS-2947	CPE	PT	0.35	----	VERO	100.00	----	12/29/87
AVS-2947	CPE	VSV	----	----	L929	100.00	----	7/21/87
AVS-2947	CPE	VV	----	----	VERO <	100.00	----	8/ 6/87
AVS-2947	CPE	YFV	----	----	VERO	32.00	----	1/22/88
AVS-2948	CPE	AD2	----	----	HEP2 <	100.00	----	8/ 6/87
AVS-2948	CPE	JE	----	----	VERO	100.00	----	8/28/87
AVS-2948	PR	PIC	N/A	----	VERO	100.00	----	9/12/88
AVS-2948	CPE	SF	3.82	14.80	VERO	320.00	21.40	2/ 2/88
AVS-2948	CPE	VSV	----	----	L929	100.00	----	7/21/87
AVS-2948	CPE	VV	----	----	VERO	32.00	----	8/ 6/87
AVS-2948	CPE	YFV	----	----	VERO	10.00	----	1/22/88
AVS-2949	CPE	AD2	----	----	HEP2	1.00	----	8/ 6/87
AVS-2949	CPE	JE	----	----	VERO	10.00	----	8/31/87
AVS-2949	PR	PIC	N/A	----	VERO	1.00	----	9/12/88
AVS-2949	CPE	PT	----	----	VERO	0.32	----	10/28/87
AVS-2949	CPE	VSV	----	----	L929	1.00	----	7/21/87
AVS-2949	CPE	VV	----	----	VERO <	10.00	----	8/ 6/87
AVS-2949	CPE	YFV	----	----	VERO	3.20	----	1/22/88
AVS-2950	CPE	JE	----	----	VERO	320.00	----	8/31/87
AVS-2950	PR	PIC	N/A	----	VERO	1.00	----	9/12/88
AVS-2950	CPE	PT	----	----	VERO	10.00	----	10/28/87
AVS-2950	CPE	SF	0.35	0.92	VERO	0.32	0.35	9/28/87
AVS-2950	CPE	VSV	----	----	L929	10.00	----	10/13/87
AVS-2950	CPE	YFV	----	----	VERO	1.00	----	9/28/87
AVS-2951	CPE	AD2	----	----	HEP2	10.00	----	8/ 6/87
AVS-2951	CPE	JE	----	----	VERO	10.00	----	8/31/87
AVS-2951	PR	PIC	N/A	----	VERO	100.00	----	9/12/88
AVS-2951	CPE	PT	----	----	VERO	100.00	----	10/28/87
AVS-2951	CPE	SF	2.1	10.30	VERO	32.00	3.08	9/28/87
AVS-2951	CPE	SF	0.25	----	VERO	3.20	----	5/26/88
AVS-2951	CPE	VSV	----	----	L929	100.00	----	7/21/87
AVS-2951	CPE	VV	0.1	----	VERO	32.00	----	8/ 6/87
AVS-2951	CPE	YFV	0.45	----	VERO	100.00	----	9/28/87
AVS-2956	CPE	AD2	0.5	----	HEP2	100.00	----	8/13/87
AVS-2956	PR	HTN	N/A	----	VERC >	100.00	----	4/14/88
AVS-2956	CPE	JE	----	----	VERO >	100.00	----	9/ 9/87
AVS-2956	PR	PIC	N/A	----	VERO	100.00	----	9/14/88
AVS-2956	CPE	PT	----	----	VERO	320.00	----	8/28/87
AVS-2956	CPE	SF	----	----	VERO	10.00	----	9/30/87
AVS-2956	CPE	VSV	----	----	L929	320.00	----	7/28/87
AVS-2956	CPE	VV	0.3	----	VERO <	320.00	----	8/13/87
AVS-2956	CPE	YFV	----	----	VERO <	320.00	----	9/30/87
AVS-2957	CPE	AD2	0.7	----	HEP2 <	3.20	----	8/13/87
AVS-2957	PR	HTN	N/A	----	VERC >	100.00	----	4/14/88
AVS-2957	CPE	JE	----	----	VERO	100.00	----	9/ 9/87
AVS-2957	CPE	PT	0.25	----	VERO	100.00	----	8/28/87
AVS-2957	CPE	PT	0.2	----	VERO	32.00	----	11/ 2/87
AVS-2957	CPE	SF	0.4	75.10	VERO	10.00	0.13	9/30/87
AVS-2957	CPE	VSV	----	----	L929	100.00	----	7/28/87
AVS-2957	CPE	VV	----	----	VERO	100.00	----	8/13/87
AVS-2957	CPE	YFV	0.1	----	VERO	320.00	----	9/30/87
AVS-2958	CPE	AD2	0.4	----	HEP2 <	3.20	----	8/13/87
AVS-2958	PR	HTN	N/A	----	VERC >	32.00	----	4/14/88
AVS-2958	CPE	JE	----	----	VERO	32.00	----	9/ 9/87
AVS-2958	CPE	PT	0.1	----	VERO	32.00	----	8/28/87
AVS-2958	CPE	PT	0.15	----	VERO	10.00	----	11/ 2/87
AVS-2958	CPE	SF	0.55	199.00	VERO	10.00	0.05	9/30/87
AVS-2958	CPE	VSV	----	----	L929 <	320.00	----	7/31/87
AVS-2958	CPE	VV	----	----	VERO >	32.00	----	8/13/87
AVS-2958	CPE	YFV	0.2	----	VERO	320.00	----	9/30/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2959	CPE	AD2	0.4	----	HEP2 <	3.20	----	8/13/87
AVS-2959	PR	HTN	N/A	----	VERC	32.00	----	4/14/88
AVS-2959	CPE	JE	----	----	VERO	32.00	----	9/10/87
AVS-2959	PR	PIC	N/A	----	VERO	32.00	----	9/14/88
AVS-2959	CPE	PT	0.6	----	VERO	32.00	----	8/31/87
AVS-2959	CPE	SF	0.55	225.00	VERO	3.20	0.01	9/30/87
AVS-2959	CPE	VSV	----	----	L929 <	100.00	----	7/31/87
AVS-2959	CPE	VV	----	----	VERO	100.00	----	8/13/87
AVS-2959	CPE	YFV	----	----	VERO >	320.00	----	9/30/87
AVS-2960	CPE	AD2	1.15	44.30	HEP2	100.00	2.25	8/13/87
AVS-2960	CPE	AD2	1.45	81.10	HEP2	320.00	3.94	1/ 8/88
AVS-2960	CPE	AD2	0.85	----	HEP2	320.00	----	5/12/88
AVS-2960	PR	HTN	N/A	----	VERC <	32.00	----	4/14/88
AVS-2960	CPE	JE	0.85	11.10	VERO	10.00	0.90	9/10/87
AVS-2960	PR	PIC	N/A	----	VERO	32.00	----	9/14/88
AVS-2960	CPE	PT	0.15	----	VERO	32.00	----	8/31/87
AVS-2960	CPE	SF	1.5	10.00	VERO	10.00	0.99	10/ 1/87
AVS-2960	CPE	VSV	----	----	L929	100.00	----	7/31/87
AVS-2960	CPE	VV	0.75	46.70	VERO	32.00	0.68	8/13/87
AVS-2960	CPE	YFV	0.25	----	VERO	10.00	----	10/ 1/87
AVS-2961	CPE	JE	----	----	VERO	100.00	----	9/10/87
AVS-2961	CPE	PT	0.05	----	VERO	320.00	----	8/31/87
AVS-2961	CPE	SF	0.35	84.90	VERO	32.00	0.38	10/ 1/87
AVS-2961	CPE	VSV	----	----	L929	100.00	----	7/31/87
AVS-2961	CPE	YFV	----	----	VERO	32.00	----	10/ 1/87
AVS-2962	CPE	AD2	0.2	----	HEP2 >	320.00	----	8/13/87
AVS-2962	CPE	JE	----	----	VERO >	320.00	----	9/10/87
AVS-2962	PR	PIC	N/A	----	VERO >	320.00	----	9/14/88
AVS-2962	CPE	PT	0.52	290.00	VERO	320.00	1.09	8/31/87
AVS-2962	CPE	VSV	----	----	L929 >	320.00	----	7/31/87
AVS-2962	CPE	VV	----	----	VERO >	320.00	----	8/13/87
AVS-2962	CPE	YFV	----	----	VERO	320.00	----	10/ 1/87
AVS-2963	CPE	AD2	----	----	HEP2 >	320.00	----	8/13/87
AVS-2963	CPE	JE	----	----	VERO	100.00	----	9/10/87
AVS-2963	PR	PIC	N/A	----	VERO >	100.00	----	9/14/88
AVS-2963	CPE	PT	0.05	----	VERO	32.00	----	8/31/87
AVS-2963	CPE	VSV	----	----	L929 >	320.00	----	7/31/87
AVS-2963	CPE	VV	----	----	VERO	320.00	----	8/13/87
AVS-2963	CPE	YFV	----	----	VERO	100.00	----	3/ 7/88
AVS-2964	CPE	AD2	1.2	100.00	HEP2 >	320.00 >	3.20	8/20/87
AVS-2964	CPE	AD2	0.7	----	HEP2 >	320.00	----	5/12/88
AVS-2964	CPE	JE	----	----	VERO <	320.00	----	9/11/87
AVS-2964	PR	PIC	N/A	----	VERO	100.00	----	9/14/88
AVS-2964	CPE	PT	0.1	----	VERO	320.00	----	8/31/87
AVS-2964	CPE	PT	0.45	----	VERO	320.00	----	11/ 4/87
AVS-2964	CPE	SF	----	----	VERO	100.00	----	10/ 1/87
AVS-2964	CPE	VSV	----	----	L929	320.00	----	7/31/87
AVS-2964	CPE	VV	2.3	20.40	VERO	100.00	4.89	8/20/87
AVS-2964	CPE	VV	2.3	20.40	VERO	100.00	4.89	5/12/88
AVS-2964	PR	VV	N/A	6.80	VERO >	320.00 >	46.30	9/23/88
AVS-2964	CPE	YFV	0.15	----	VERO	320.00	----	10/ 1/87
AVS-2965	CPE	AD2	0.5	----	HEP2 <	320.00	----	8/20/87
AVS-2965	CPE	JE	----	----	VERO	32.00	----	9/11/87
AVS-2965	PR	PIC	N/A	----	VERO	32.00	----	9/14/88
AVS-2965	CPE	PT	----	----	VERO <	320.00	----	8/31/87
AVS-2965	CPE	SF	----	----	VERO	100.00	----	10/ 2/87
AVS-2965	CPE	VSV	----	----	L929	100.00	----	7/31/87
AVS-2965	CPE	VV	0.8	31.40	VERO <	100.00 <	3.18	8/20/87
AVS-2965	CPE	YFV	----	----	VERO	320.00	----	10/ 2/87
AVS-2966	CPE	AD2	0.15	----	HEP2	3.20	----	8/13/87
AVS-2966	CPE	JE	----	----	VERO <	100.00	----	9/11/87
AVS-2966	PR	PIC	N/A	----	VERO >	100.00	----	9/14/88
AVS-2966	CPE	PT	----	----	VERO <	320.00	----	8/31/87
AVS-2966	CPE	PT	0.15	----	VERO	0.32	----	11/ 4/87
AVS-2966	CPE	SF	0.05	----	VERO	0.32	----	10/ 2/87

B-149

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2966	CPE	VSV	----	----	L929 <	320.00	----	7/31/87
AVS-2966	CPE	VV	2.2	22.60	VERO	100.00	4.41	8/13/87
AVS-2966	CPE	VV	1.6	39.50	VERO	100.00	2.52	5/12/88
AVS-2966	CPE	YFV	----	----	VERO >	320.00	----	10/ 2/87
AVS-2967	CPE	AD2	----	----	HEP2	3.20	----	8/13/87
AVS-2967	CPE	JE	----	----	VERO <	320.00	----	9/11/87
AVS-2967	PR	PIC	N/A	----	VERO	32.00	----	9/14/88
AVS-2967	CPE	PT	0.1	----	VERO	320.00	----	8/31/87
AVS-2967	CPE	SF	----	----	VERO	100.00	----	10/ 2/87
AVS-2967	CPE	VSV	----	----	L929	320.00	----	7/31/87
AVS-2967	CPE	VV	1.35	----	VERO	100.00	----	8/13/87
AVS-2967	CPE	YFV	----	----	VERO	320.00	----	10/ 2/87
AVS-2968	CPE	AD2	----	----	HEP2	3.20	----	9/ 4/87
AVS-2968	CPE	JE	----	----	VERO <	32.00	----	9/11/87
AVS-2968	CPE	VSV	0.35	----	L929	32.00	----	8/21/87
AVS-2968	CPE	VV	----	----	VERO	100.00	----	9/ 4/87
AVS-2969	CPE	AD2	----	----	HEP2 <	0.32	----	8/13/87
AVS-2969	CPE	AD2	0.2	----	HEP2 <	1.00	----	8/27/87
AVS-2969	CPE	JE	----	----	VERO	320.00	----	9/14/87
AVS-2969	PR	PIC	N/A	----	VERO	100.00	----	9/16/88
AVS-2969	CPE	PT	0.1	----	VERO	320.00	----	8/31/87
AVS-2969	CPE	SF	----	----	VERO	32.00	----	10/ 2/87
AVS-2969	CPE	VSV	----	----	L929	100.00	----	7/31/87
AVS-2969	CPE	VV	2.	----	VERO	100.00	----	8/13/87
AVS-2969	CPE	YFV	----	----	VERO >	320.00	----	10/ 2/87
AVS-2970	CPE	AD2	----	----	HEP2 <	1.00	----	8/13/87
AVS-2970	CPE	JE	----	----	VERO	100.00	----	9/14/87
AVS-2970	PR	PIC	N/A	----	VERO	100.00	----	9/16/88
AVS-2970	CPE	PT	0.2	----	VERO	100.00	----	8/31/87
AVS-2970	CPE	PT	----	----	VERO >	320.00	----	11/ 5/87
AVS-2970	CPE	SF	1.	154.00	VERO	32.00	0.21	10/ 2/87
AVS-2970	CPE	VSV	----	----	L929	320.00	----	7/31/87
AVS-2970	CPE	VV	1.65	----	VERO	100.00	----	8/13/87
AVS-2970	CPE	YFV	----	----	VERO	320.00	----	10/ 2/87
AVS-2971	CPE	AD2	0.3	----	HEP2 <	32.00	----	8/13/87
AVS-2971	CPE	JE	----	----	VERO	100.00	----	9/14/87
AVS-2971	PR	PIC	N/A	29.80	VERO	32.00	1.07	9/16/88
AVS-2971	CPE	PT	----	----	VERO <	100.00	----	9/ 1/87
AVS-2971	CPE	PT	----	----	VERO	100.00	----	11/ 5/87
AVS-2971	CPE	SF	----	----	VERO	32.00	----	10/30/87
AVS-2971	CPE	VSV	----	----	L929	32.00	----	7/31/87
AVS-2971	CPE	VV	----	----	VERO	32.00	----	8/13/87
AVS-2971	CPE	YFV	----	----	VERO	10.00	----	1/21/88
AVS-2972	CPE	AD2	0.2	----	HEP2	10.00	----	8/13/87
AVS-2972	CPE	JE	----	----	VERO <	32.00	----	9/14/87
AVS-2972	PR	PIC	N/A	7.50	VERO	3.20	0.42	9/16/88
AVS-2972	CPE	PT	----	----	VERO	10.00	----	9/ 1/87
AVS-2972	CPE	SF	----	----	VERO	32.00	----	10/30/87
AVS-2972	CPE	VSV	----	----	L929 <	100.00	----	7/31/87
AVS-2972	CPE	VV	0.6	20.00	VERO	32.00	1.59	8/13/87
AVS-2972	CPE	YFV	----	----	VERO	10.00	----	1/21/88
AVS-2973	CPE	AD2	0.35	----	HEP2	32.00	----	8/20/87
AVS-2973	CPE	JE	----	----	VERO	100.00	----	9/14/87
AVS-2973	CPE	PT	----	----	VERO	32.00	----	9/ 1/87
AVS-2973	CPE	SF	0.1	----	VERO	100.00	----	10/30/87
AVS-2973	CPE	VSV	----	----	L929	100.00	----	7/31/87
AVS-2973	CPE	VV	----	----	VERO	320.00	----	8/20/87
AVS-2973	CPE	YFV	----	----	VERO	10.00	----	1/21/88
AVS-2974	CPE	AD2	0.45	----	HEP2	10.00	----	8/20/87
AVS-2974	CPE	JE	----	----	VERO >	320.00	----	9/15/87
AVS-2974	PR	PIC	N/A	----	VERO >	320.00	----	9/16/88
AVS-2974	CPE	PT	----	----	VERO >	320.00	----	9/ 1/87
AVS-2974	CPE	SF	----	----	VERO	100.00	----	10/30/87
AVS-2974	CPE	VSV	----	----	L929 >	320.00	----	7/31/87
AVS-2974	CPE	VV	----	----	VERO	100.00	----	8/20/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-2974	CPE	YFV	----	----	VERO	320.00	----	1/21/88
AVS-2974	CPE	YFV	----	----	VERO	320.00	----	3/ 4/88
AVS-2975	CPE	AD2	0.6	320.00	HEP2 >	320.00 >	1.00	8/20/87
AVS-2975	CPE	JE	----	----	VERO >	320.00	----	9/15/87
AVS-2975	PR	PIC	N/A	----	VERO	100.00	----	9/16/88
AVS-2975	CPE	PT	----	----	VERO	320.00	----	9/ 1/87
AVS-2975	CPE	PT	----	----	VERO	320.00	----	11/ 5/87
AVS-2975	CPE	SF	----	----	VERO	100.00	----	10/30/87
AVS-2975	CPE	VSV	----	----	L929	320.00	----	7/31/87
AVS-2975	CPE	VV	0.3	320.00	VERO	320.00	1.00	8/20/87
AVS-2975	CPE	YFV	0.1	----	VERO	320.00	----	1/21/88
AVS-2976	CPE	AD2	0.65	199.00	HEP2	320.00	1.60	8/20/87
AVS-2976	CPE	JE	----	----	VERO >	320.00	----	9/15/87
AVS-2976	CPE	PT	----	----	VERO >	320.00	----	9/ 1/87
AVS-2976	CPE	PT	----	----	VERO >	320.00	----	11/ 5/87
AVS-2976	CPE	SF	----	----	VERO	32.00	----	11/ 2/87
AVS-2976	CPE	VSV	----	----	L929 >	320.00	----	8/ 4/87
AVS-2976	CPE	VV	0.3	----	VERO >	320.00	----	8/20/87
AVS-2977	CPE	PT	----	----	VERO	32.00	----	11/11/87
AVS-2978	CPE	AD2	0.4	----	HEP2	320.00	----	7/ 9/87
AVS-2978	CPE	JE	----	----	VERO	100.00	----	9/ 4/87
AVS-2978	PR	PIC	N/A	----	VERO >	320.00	----	2/ 8/88
AVS-2978	PR	PIC	N/A	----	VERO	320.00	----	9/16/88
AVS-2978	CPE	PT	0.2	----	VERO	320.00	----	9/23/87
AVS-2978	CPE	SF	----	----	VERO	100.00	----	8/13/87
AVS-2978	CPE	VEE	----	----	VERO	100.00	----	11/19/87
AVS-2978	CPE	VSV	----	----	L929	320.00	----	7/10/87
AVS-2978	CPE	VSV	----	----	L929	320.00	----	8/ 4/87
AVS-2978	CPE	VV	----	----	VERO >	320.00	----	7/ 9/87
AVS-2978	CPE	YFV	----	----	VERO	100.00	----	8/13/87
AVS-2979	CPE	AD2	1.65	11.40	HEP2	32.00	2.79	7/ 9/87
AVS-2979	CPE	AD2	0.9	68.30	HEP2 <	320.00 <	4.68	1/ 8/88
AVS-2979	CPE	AD2	1.8	35.80	HEP2	100.00	2.79	1/21/88
AVS-2979	CPE	AD2	1.3	10.00	HEP2	32.00	3.18	5/26/88
AVS-2979	CPE	JE	1.47	6.20	VERO	32.00	5.11	8/11/87
AVS-2979	CPE	JE	0.35	8.40	VERO	10.00	1.17	5/25/88
AVS-2979	PR	PIC	N/A	16.80	VERO	100.00	5.95	2/ 8/88
AVS-2979	PR	PIC	N/A	----	VERO	10.00	----	9/16/88
AVS-2979	CPE	PT	1.37	97.00	VERO	100.00	1.02	9/23/87
AVS-2979	CPE	SF	0.7	5.30	VERO	10.00	1.86	9/ 1/87
AVS-2979	CPE	VEE	----	----	VERO	1.00	----	11/19/87
AVS-2979	CPE	VSV	1.6	8.10	L929	3.20	0.39	7/10/87
AVS-2979	CPE	VSV	0.7	5.00	L929	3.20	0.63	8/ 4/87
AVS-2979	CPE	VV	0.25	----	VERO	32.00	----	7/ 9/87
AVS-2979	CPE	YFV	0.9	4.67	VERO	10.00	2.13	9/ 1/87
AVS-2980	CPE	AD2	2.1	1.47	HEP2	10.00	6.78	7/ 9/87
AVS-2980	CPE	AD2	2.	0.96	HEP2	3.20	3.31	10/29/87
AVS-2980	CPE	AD2	1.5	1.47	HEP2	3.20	2.17	11/12/87
AVS-2980	CPE	AD2	1.2	5.00	HEP2	10.00	1.98	5/12/88
AVS-2980	CPE	JE	2.32	0.62	VERO	10.00	15.90	8/11/87
AVS-2980	CPE	JE	1.05	0.81	VERO	1.00	1.22	5/25/88
AVS-2980	PR	PIC	N/A	----	VERO	3.20	----	3/25/88
AVS-2980	PR	PIC	N/A	1.35	VERO	3.20	2.36	9/ 9/88
AVS-2980	PR	PIC	N/A	4.03	VERO	3.20	0.79	9/16/88
AVS-2980	CPE	PT	2.8	0.30	VERO	3.20	10.30	12/21/87
AVS-2980	CPE	PT	1.5	0.41	VERO <	3.20 <	7.71	3/ 1/88
AVS-2980	CPE	PT	1.7	0.37	VERO	1.00	2.65	5/25/88
AVS-2980	CPE	SF	1.7	1.18	VERO	3.20	2.71	9/ 1/87
AVS-2980	CPE	VEE	----	----	VERO	0.32	----	4/ 5/88
AVS-2980	CPE	VSV	----	----	L929	3.20	----	7/10/87
AVS-2980	CPE	VSV	0.7	4.56	L929	3.20	0.70	8/ 4/87
AVS-2980	CPE	VV	0.6	5.60	VERO	10.00	1.76	7/ 9/87
AVS-2980	CPE	VV	0.15	----	VERO	3.20	----	11/12/87
AVS-2980	CPE	VV	0.7	5.30	VERO	10.00	1.86	1/28/88
AVS-2980	CPE	YFV	2.3	0.63	VERO	3.20	5.05	9/ 1/87

B-151

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-2980	CPE	YFV	2.35	1.36	VERO	3.20	2.34	5/25/88
AVS-2981	CPE	AD2	1.05	53.60	HEP2	100.00	1.86	8/20/87
AVS-2981	CPE	JE	----	----	VERO >	320.00	----	9/15/87
AVS-2981	PR	PIC	N/A	----	VERO	100.00	----	9/ 9/88
AVS-2981	PR	PIC	N/A	----	VERO	100.00	----	9/16/88
AVS-2981	CPE	PT	----	----	VERO	100.00	----	9/ 1/87
AVS-2981	CPE	PT	----	----	VERO	100.00	----	11/11/87
AVS-2981	CPE	SF	----	----	VERO	100.00	----	11/ 2/87
AVS-2981	CPE	VSV	----	----	L929	320.00	----	8/ 4/87
AVS-2981	CPE	VV	----	----	VERO <	320.00	----	8/20/87
AVS-2981	CPE	YFV	0.2	----	VERO	100.00	----	1/25/88
AVS-2982	CPE	AD2	0.3	----	HEP2	100.00	----	8/20/87
AVS-2982	CPE	JE	----	----	VERO	100.00	----	9/15/87
AVS-2982	PR	PIC	N/A	----	VERO	32.00	----	9/19/88
AVS-2982	CPE	PT	----	----	VERO	32.00	----	9/ 1/87
AVS-2982	CPE	SF	----	----	VERO	32.00	----	11/ 2/87
AVS-2982	CPE	VSV	----	----	L929	32.00	----	8/ 4/87
AVS-2982	CPE	VV	----	----	VERO	32.00	----	8/20/87
AVS-2982	CPE	YFV	0.3	32.00	VERO	10.00	0.31	1/25/88
AVS-2983	CPE	AD2	0.25	----	HEP2	320.00	----	8/20/87
AVS-2983	CPE	JE	----	----	VERO >	320.00	----	9/30/87
AVS-2983	PR	PIC	-0-	----	VERO	320.00	----	9/19/88
AVS-2983	CPE	PT	----	----	VERO	320.00	----	9/ 1/87
AVS-2983	CPE	SF	----	----	VERO >	320.00	----	11/ 2/87
AVS-2983	CPE	VSV	----	----	L929 >	320.00	----	8/ 4/87
AVS-2983	CPE	VV	0.1	----	VERO >	320.00	----	8/20/87
AVS-2983	CPE	YFV	0.15	----	VERO	320.00	----	1/25/88
AVS-2984	CPE	AD2	0.6	----	HEP2	32.00	----	8/20/87
AVS-2984	CPE	JE	----	----	VERO	100.00	----	9/30/87
AVS-2984	PR	PIC	N/A	24.70	VERO	32.00	1.29	9/19/88
AVS-2984	CPE	PT	----	----	VERO	10.00	----	9/ 1/87
AVS-2984	CPE	SF	----	----	VERO	10.00	----	11/ 2/87
AVS-2984	CPE	VSV	----	----	L929	100.00	----	8/ 4/87
AVS-2984	CPE	VV	----	----	VERO	32.00	----	8/20/87
AVS-2984	CPE	YFV	0.45	21.70	VERO	32.00	1.47	1/25/88
AVS-2985	CPE	AD2	1.2	100.00	HEP2 >	320.00 >	3.20	8/20/87
AVS-2985	CPE	AD2	----	----	HEP2 >	320.00	----	5/12/88
AVS-2985	CPE	JE	0.3	290.00	VERO	320.00	1.10	9/30/87
AVS-2985	PR	PIC	N/A	209.00	VERO	320.00	1.52	9/19/88
AVS-2985	CPE	PT	----	----	VERO	100.00	----	9/ 1/87
AVS-2985	CPE	PT	----	----	VERO	320.00	----	11/11/87
AVS-2985	CPE	SF	----	----	VERO	100.00	----	11/ 3/87
AVS-2985	CPE	VSV	----	----	L929 >	320.00	----	8/ 4/87
AVS-2985	CPE	VV	----	----	VERO <	320.00	----	8/20/87
AVS-2985	CPE	YFV	0.15	----	VERO	32.00	----	1/25/88
AVS-2986	CPE	AD2	1.65	100.00	HEP2	320.00	3.20	8/20/87
AVS-2986	CPE	AD2	1.5	100.00	HEP2	320.00	3.20	1/ 8/88
AVS-2986	CPE	JE	----	----	VERO >	320.00	----	9/30/87
AVS-2986	PR	PIC	N/A	----	VERO >	320.00	----	9/19/88
AVS-2986	CPE	PT	----	----	VERO >	320.00	----	9/ 3/87
AVS-2986	CPE	SF	0.07	----	VERO	320.00	----	11/ 3/87
AVS-2986	CPE	VSV	----	----	L929 >	320.00	----	8/ 4/87
AVS-2986	CPE	VV	----	----	VERO	320.00	----	8/20/87
AVS-2986	CPE	YFV	----	----	VERO	320.00	----	1/25/88
AVS-2987	CPE	AD2	----	----	HEP2	32.00	----	8/20/87
AVS-2987	CPE	JE	----	----	VERO	32.00	----	10/ 1/87
AVS-2987	PR	PIC	N/A	----	VERO >	10.00	----	9/19/88
AVS-2987	CPE	PT	----	----	VERO	10.00	----	9/ 3/87
AVS-2987	CPE	SF	0.9	10.10	VERO	10.00	0.98	11/ 3/87
AVS-2987	CPE	VSV	----	----	L929	32.00	----	8/ 4/87
AVS-2987	CPE	VV	----	----	VERO	32.00	----	8/20/87
AVS-2987	CPE	YFV	----	----	VERO	10.00	----	1/25/88
AVS-2988	CPE	AD2	1.	70.80	HEP2 <	320.00 <	4.51	8/20/87
AVS-2988	CPE	AD2	0.6	----	HEP2 <	320.00	----	1/ 8/88
AVS-2988	CPE	AD2	0.5	----	HEP2	320.00	----	1/21/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-2988	CPE	AD2	0.9	306.00	HEP2 >	320.00 >	1.04	5/12/88
AVS-2988	CPE	JE	----	----	VERO <	320.00	----	9/17/87
AVS-2988	PR	PIC	N/A	----	VERO	100.00	----	9/19/88
AVS-2988	CPE	PT	----	----	VERO	100.00	----	9/ 3/87
AVS-2988	CPE	PT	----	----	VERO	100.00	----	11/12/87
AVS-2988	CPE	SF	----	----	VERO	320.00	----	11/ 3/87
AVS-2988	CPE	VSV	----	----	L929 <	320.00	----	8/ 4/87
AVS-2988	CPE	VV	0.2	----	VERO	320.00	----	8/20/87
AVS-2988	CPE	YFV	----	----	VERO	32.00	----	1/25/88
AVS-2989	CPE	AD2	----	----	HEP2	32.00	----	8/20/87
AVS-2989	CPE	JE	----	----	VERO <	10.00	----	9/17/87
AVS-2989	PR	PIC	N/A	----	VERO	3.20	----	9/19/88
AVS-2989	CPE	PT	0.15	----	VERO	3.20	----	9/ 3/87
AVS-2989	CPE	SF	0.4	2.39	VERO	1.00	0.42	11/ 3/87
AVS-2989	CPE	VSV	----	----	L929	10.00	----	8/ 4/87
AVS-2989	CPE	VV	----	----	VERO	32.00	----	8/20/87
AVS-2989	CPE	YFV	----	----	VERO	3.20	----	1/25/88
AVS-2990	CPE	AD2	0.2	----	HEP2 <	32.00	----	8/20/87
AVS-2990	CPE	JE	----	----	VERO <	32.00	----	9/17/87
AVS-2990	PR	PIC	N/A	----	VERO	10.00	----	9/19/88
AVS-2990	CPE	PT	----	----	VERO >	320.00	----	9/ 3/87
AVS-2990	CPE	PT	----	----	VERO	100.00	----	11/12/87
AVS-2990	CPE	SF	0.5	----	VERO	32.00	----	2/ 5/88
AVS-2990	CPE	VSV	----	----	L929 <	100.00	----	8/ 4/87
AVS-2990	CPE	VV	0.3	----	VERO <	32.00	----	8/20/87
AVS-2990	CPE	YFV	----	----	VERO	10.00	----	1/21/88
AVS-2991	CPE	AD2	----	----	HEP2 <	3.20	----	8/20/87
AVS-2991	CPE	JE	----	----	VERO <	10.00	----	9/17/87
AVS-2991	PR	PIC	N/A	----	VERO	3.20	----	9/19/88
AVS-2991	CPE	PT	0.9	2.58	VERO <	10.00 <	3.86	9/ 3/87
AVS-2991	CPE	PT	1.	2.21	VERO <	10.00 <	4.50	12/21/87
AVS-2991	CPE	PT	0.1	----	VERO	3.20	----	6/ 1/88
AVS-2991	CPE	SF	0.45	6.80	VERO	10.00	1.46	2/ 5/88
AVS-2991	CPE	VSV	0.7	2.70	L929 <	10.00 <	3.69	8/ 4/87
AVS-2991	CPE	VSV	----	----	L929 <	10.00	----	5/24/88
AVS-2991	CPE	VV	1.6	0.77	VERO	3.20	4.13	8/20/87
AVS-2991	CPE	VV	0.75	5.60	VERO	10.00	1.77	5/26/88
AVS-2991	CPE	YFV	----	----	VERO	3.20	----	1/21/88
AVS-2992	CPE	AD2	0.3	100.00	HEP2	100.00	1.00	8/20/87
AVS-2992	CPE	JE	----	----	VERO	320.00	----	9/17/87
AVS-2992	PR	PIC	N/A	----	VERO	32.00	----	9/20/88
AVS-2992	CPE	PT	1.05	----	VERO	100.00	----	9/ 3/87
AVS-2992	CPE	PT	0.3	320.00	VERO	100.00	0.31	11/12/87
AVS-2992	CPE	PT	1.05	133.00	VERO	100.00	0.75	12/21/87
AVS-2992	CPE	SF	1.96	10.00	VERO	100.00	10.00	2/ 5/88
AVS-2992	CPE	VSV	----	----	L929 >	320.00	----	8/ 4/87
AVS-2992	CPE	VV	2.1	33.60	VERO	320.00	9.50	8/20/87
AVS-2992	CPE	VV	1.3	99.00	VERO	320.00	3.21	1/21/88
AVS-2992	CPE	YFV	0.15	----	VERO	10.00	----	1/21/88
AVS-2993	CPE	AD2	0.6	----	HEP2 <	320.00	----	8/20/87
AVS-2993	CPE	JE	----	----	VERO >	320.00	----	9/18/87
AVS-2993	PR	PIC	N/A	----	VERO >	320.00	----	9/20/88
AVS-2993	CPE	PT	----	----	VERO >	320.00	----	9/ 3/87
AVS-2993	CPE	PT	----	----	VERO	320.00	----	11/12/87
AVS-2993	CPE	PT	0.4	----	VERO >	320.00	----	12/21/87
AVS-2993	CPE	SF	----	----	VERO	100.00	----	2/ 5/88
AVS-2993	CPE	VSV	----	----	L929	100.00	----	8/ 4/87
AVS-2993	CPE	VV	0.1	----	VERO	100.00	----	8/20/87
AVS-2993	CPE	YFV	----	----	VERO >	320.00	----	1/21/88
AVS-2994	CPE	AD2	1.5	25.40	HEP2	100.00	3.92	8/20/87
AVS-2994	CPE	AD2	1.15	32.00	HEP2	100.00	3.12	1/ 8/88
AVS-2994	CPE	AD2	0.7	64.10	HEP2	100.00	1.55	1/21/88
AVS-2994	CPE	AD2	0.3	----	HEP2 <	320.00	----	5/26/88
AVS-2994	CPE	JE	0.74	184.00	VERO	320.00	1.73	9/18/87
AVS-2994	PR	PIC	N/A	----	VERO >	100.00	----	9/20/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	ITC50	TI	DATE
AVS-2994	CPE	PT	----	----	VERO	100.00	----	9/ 3/87
AVS-2994	CPE	SF	----	----	VERO	100.00	----	2/ 5/88
AVS-2994	CPE	VSV	----	----	L929	32.00	----	8/ 4/87
AVS-2994	CPE	VV	7.1	0.10	VERO	100.00	916.00	9/ 4/87
AVS-2994	CPE	VV	8.6	0.09	VERO	320.00	3560.00	9/24/87
AVS-2994	CPE	VV	8.7	0.05	VERO	320.00	5810.00	10/27/88
AVS-2994	CPE	YFV	----	----	VERO	32.00	----	1/21/88
AVS-2995	CPE	AD2	1.1	199.00	HEP2 >	320.00 >	1.60	8/20/87
AVS-2995	CPE	JE	0.5	----	VERO >	320.00	----	9/18/87
AVS-2995	PR	PIC	N/A	----	VERO >	320.00	----	9/20/88
AVS-2995	CPE	PT	----	----	VERO >	320.00	----	9/ 3/87
AVS-2995	CPE	PT	----	----	VERO >	320.00	----	11/16/87
AVS-2995	CPE	SF	0.15	----	VERO	100.00	----	11/30/87
AVS-2995	CPE	VSV	----	----	L929	320.00	----	8/ 4/87
AVS-2995	CPE	VV	5.2	3.06	VERO >	320.00 >	104.00	8/20/87
AVS-2995	CPE	VV	4.5	6.80	VERO >	320.00 >	46.80	9/24/87
AVS-2995	CPE	YFV	----	----	VERO	100.00	----	11/30/87
AVS-2996	CPE	AD2	----	----	HEP2 >	320.00	----	8/20/87
AVS-2996	CPE	JE	----	----	VERO	320.00	----	9/18/87
AVS-2996	CPE	PT	----	----	VERO >	320.00	----	9/ 3/87
AVS-2996	CPE	VSV	0.4	239.00	L929	320.00	1.33	8/ 4/87
AVS-2996	CPE	VV	0.4	----	VERO	100.00	----	8/20/87
AVS-2996	CPE	YFV	----	----	VERO	32.00	----	11/30/87
AVS-2997	PR	HTN	N/A	----	VERC	320.00	----	2/25/88
AVS-2997	CPE	PT	----	----	VERO	32.00	----	11/16/87
AVS-2997	CPE	SF	----	----	VERO	32.00	----	8/25/87
AVS-2998	PR	HTN	N/A	----	VERC <	320.00	----	2/25/88
AVS-2998	CPE	PT	0.23	----	VERO	32.00	----	11/16/87
AVS-2998	CPE	SF	----	----	VERO	100.00	----	8/25/87
AVS-2999	PR	HTN	N/A	----	VERC <	32.00	----	2/25/88
AVS-2999	CPE	PT	----	----	VERO	3.20	----	11/16/87
AVS-2999	CPE	SF	----	----	VERO	10.00	----	8/25/87
AVS-3000	PR	HTN	N/A	----	VERC	100.00	----	2/29/88
AVS-3000	CPE	PT	----	----	VERO	1.00	----	11/16/87
AVS-3000	CPE	SF	----	----	VERO	10.00	----	8/25/87
AVS-3001	PR	HTN	N/A	----	VERC <	100.00	----	2/29/88
AVS-3001	CPE	SF	----	----	VERO	10.00	----	8/25/87
AVS-3002	PR	HTN	N/A	4.00	VERC	32.00	----	2/29/88
AVS-3002	CPE	SF	----	----	VERO	10.00	----	3/25/87
AVS-3003	PR	HTN	N/A	----	VERC	32.00	----	3/ 2/88
AVS-3003	CPE	SF	0.2	----	VERO	1.00	----	8/25/87
AVS-3004	PR	HTN	N/A	----	VERC	32.00	----	3/ 2/88
AVS-3004	CPE	SF	----	----	VERO	10.00	----	8/25/87
AVS-3005	CPE	SF	----	----	VERO	3.20	----	8/25/87
AVS-3006	PR	HTN	N/A	----	VERC <	320.00	----	3/ 9/88
AVS-3006	CPE	SF	----	----	VERO	32.00	----	8/25/87
AVS-3007	PR	HTN	N/A	----	VERC	100.00	----	3/ 9/88
AVS-3007	CPE	SF	----	----	VERO	1.00	----	8/25/87
AVS-3008	PR	HTN	N/A	----	VERC >	320.00	----	3/ 9/88
AVS-3008	CPE	PT	----	----	VERO	320.00	----	8/25/87
AVS-3008	CPE	SF	----	----	VERO	3.20	----	8/25/87
AVS-3009	PR	HTN	N/A	----	VERC <	32.00	----	3/11/88
AVS-3009	CPE	PT	----	----	VERO <	32.00	----	8/25/87
AVS-3009	CPE	PT	----	----	VERO >	320.00	----	11/19/87
AVS-3009	CPE	SF	----	----	VERO	3.20	----	8/25/87
AVS-3010	PR	HTN	N/A	----	VERC >	320.00	----	3/11/88
AVS-3010	CPE	PT	----	----	VERO >	320.00	----	8/25/87
AVS-3010	CPE	SF	----	----	VERO	100.00	----	8/25/87
AVS-3011	PR	HTN	N/A	----	VERC >	320.00	----	3/11/88
AVS-3011	CPE	PT	0.1	----	VERO >	320.00	----	8/25/87
AVS-3011	CPE	SF	----	----	VERO	100.00	----	8/25/87
AVS-3012	PR	HTN	N/A	----	VERC <	1.00	----	4/21/88
AVS-3012	CPE	PT	----	----	VERO <	10.00	----	8/25/87
AVS-3012	CPE	SF	0.35	3.19	VERO	0.32	0.10	8/25/87
AVS-3013	PR	HTN	N/A	----	VERC	10.00	----	3/15/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

CONFOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3013	CPE	PT	----	----	VERO	32.00	----	8/25/87
AVS-3013	CPE	SF	----	----	VERO	10.00	----	8/25/87
AVS-3014	PR	HTM	N/A	----	VERC <	320.00	----	3/15/88
AVS-3014	CPE	PT	----	----	VERO	320.00	----	8/25/87
AVS-3014	CPE	SF	0.35	119.00	VERC	320.00	2.67	8/26/87
AVS-3015	PR	HTM	N/A	----	VERC >	320.00	----	3/15/88
AVS-3015	CPE	PT	----	----	VERO >	320.00	----	8/25/87
AVS-3015	CPE	PT	----	----	VERO	320.00	----	12/14/87
AVS-3015	CPE	SF	----	----	VERO	32.00	----	8/26/87
AVS-3016	PR	HTM	N/A	----	VERC	100.00	----	3/15/88
AVS-3016	CPE	PT	----	----	VERO	100.00	----	8/25/87
AVS-3016	CPE	PT	0.05	----	VERO	100.00	----	12/22/87
AVS-3016	CPE	SF	1.2	23.80	VERO	10.00	0.42	8/26/87
AVS-3017	PR	HTM	N/A	----	VERC	100.00	----	3/15/88
AVS-3017	CPE	PT	----	----	VERO	100.00	----	8/25/87
AVS-3017	CPE	PT	0.35	----	VERO	100.00	----	12/16/87
AVS-3017	CPE	SF	0.85	118.00	VERO	10.00	0.08	8/26/87
AVS-3018	PR	HTM	N/A	----	VERC <	100.00	----	4/21/88
AVS-3018	CPE	PT	----	----	VERO	10.00	----	8/25/87
AVS-3018	CPE	PT	0.5	----	VERO	32.00	----	12/16/87
AVS-3018	CPE	SF	0.2	----	VERO	3.20	----	8/26/87
AVS-3019	PR	HTM	N/A	----	VERC >	100.00	----	4/21/88
AVS-3019	CPE	PT	0.1	----	VERO	100.00	----	8/26/87
AVS-3019	CPE	PT	1.9	14.00	VERO	10.00	0.71	12/16/87
AVS-3019	CPE	SF	0.25	----	VERO	10.00	----	8/26/87
AVS-3020	PR	HTM	N/A	----	VERC >	100.00	----	4/21/88
AVS-3020	CPE	PT	0.2	----	VERO	320.00	----	8/26/87
AVS-3020	CPE	PT	0.8	129.00	VERO	32.00	0.25	12/16/87
AVS-3020	CPE	SF	0.15	----	VERO	32.00	----	8/26/87
AVS-3021	PR	HTM	N/A	88.90	VERC	32.00	0.36	4/21/88
AVS-3021	CPE	PT	0.41	----	VERO	100.00	----	8/26/87
AVS-3021	CPE	PT	1.75	53.50	VERO	100.00	1.86	12/16/87
AVS-3021	CPE	SF	0.15	----	VERO	100.00	----	8/26/87
AVS-3022	CPE	PT	0.06	----	VERO	32.00	----	8/26/87
AVS-3022	CPE	PT	0.65	217.00	VERO	100.00	0.46	12/29/87
AVS-3022	CPE	SF	0.05	----	VERO	32.00	----	8/26/87
AVS-3023	CPE	PT	0.2	----	VERO	100.00	----	8/26/87
AVS-3023	CPE	SF	0.35	319.00	VERO	100.00	0.31	8/26/87
AVS-3024	CPE	PT	0.59	----	VERO	32.00	----	8/26/87
AVS-3024	CPE	PT	----	----	VERO	100.00	----	12/29/87
AVS-3024	CPE	SF	0.25	----	VERO	32.00	----	9/15/87
AVS-3025	CPE	PT	0.39	----	VERC	100.00	----	8/26/87
AVS-3025	CPE	PT	0.35	270.00	VERO	100.00	0.37	12/29/87
AVS-3025	CPE	SF	0.1	----	VERO	100.00	----	9/15/87
AVS-3026	CPE	PT	0.49	----	VERO	320.00	----	8/26/87
AVS-3026	CPE	SF	----	----	VERO	320.00	----	9/15/87
AVS-3027	CPE	PT	----	----	VERO	32.00	----	8/26/87
AVS-3027	CPE	SF	0.6	56.50	VERO	10.00	0.18	9/15/87
AVS-3028	CPE	PT	0.1	----	VERO	10.00	----	8/26/87
AVS-3028	CPE	SF	----	----	VERO	10.00	----	9/15/87
AVS-3029	CPE	PT	----	----	VERO	3.20	----	8/26/87
AVS-3029	CPE	PT	----	----	VERO	3.20	----	11/25/87
AVS-3029	CPE	SF	0.15	----	VERO	3.20	----	9/15/87
AVS-3030	CPE	PT	----	----	VERO	10.00	----	8/27/87
AVS-3030	CPE	PT	----	----	VERO	32.00	----	11/25/87
AVS-3030	CPE	SF	0.15	----	VERO	10.00	----	9/15/87
AVS-3031	PR	HTM	N/A	----	VERC <	1.00	----	4/21/88
AVS-3031	CPE	PT	----	----	VERO	0.32	----	8/27/87
AVS-3031	CPE	PT	----	----	VERO	0.32	----	11/25/87
AVS-3031	CPE	SF	----	----	VERO	0.32	----	9/15/87
AVS-3032	CPE	PT	0.05	----	VERO	0.32	----	8/27/87
AVS-3032	CPE	PT	----	----	VERO	1.00	----	11/25/87
AVS-3032	CPE	SF	----	----	VERO	0.32	----	9/15/87
AVS-3033	PR	HTM	N/A	----	VERC >	3.20	----	4/21/88
AVS-3033	CPE	PT	----	----	VERO	32.00	----	8/27/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMP	NO	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3033	CPE	PT	----	----	----	VERO	320.00	----	11/25/87
AVS-3033	CPE	SF	0.4	23.90	----	VERO	10.00	0.42	9/15/87
AVS-3034	CPE	PT	----	----	----	VERO <	3.20	----	8/27/87
AVS-3034	CPE	PT	----	----	----	VERO -	0.32	----	11/25/87
AVS-3034	CPE	SF	----	----	----	VERO	1.00	----	9/15/87
AVS-3035	CPE	AD2	----	----	----	HEP2 <	1.00	----	8/27/87
AVS-3035	CPE	JE	----	----	----	VERO	1.00	----	9/21/87
AVS-3035	PR	PIC	N/A	----	----	VERO	1.00	----	9/20/88
AVS-3035	CPE	PT	----	----	----	VERO -	0.32	----	11/30/87
AVS-3035	CPE	SF	----	----	----	VERO -	0.32	----	11/30/87
AVS-3035	CPE	VSV	----	----	----	L929 <	1.00	----	8/21/87
AVS-3035	CPE	VV	----	----	----	VERO <	1.00	----	8/27/87
AVS-3035	CPE	YFV	----	----	----	VERO -	0.32	----	11/30/87
AVS-3036	CPE	AD2	----	----	----	HEP2 <	10.00	----	8/27/87
AVS-3036	CPE	JE	----	----	----	VERO <	10.00	----	9/21/87
AVS-3036	PR	PIC	N/A	9.30	----	VERO	3.20	0.34	9/20/88
AVS-3036	CPE	PT	----	----	----	VERO	10.00	----	11/30/87
AVS-3036	CPE	SF	0.6	2.84	----	VERO	1.00	0.35	2/ 9/88
AVS-3036	CPE	VSV	----	----	----	L929	3.20	----	8/21/87
AVS-3036	CPE	VV	1.3	5.30	----	VERO	10.00	1.86	8/27/87
AVS-3036	CPE	YFV	----	----	----	VERO	10.00	----	1/22/88
AVS-3037	CPE	AD2	----	----	----	HEP2	320.00	----	8/27/87
AVS-3037	CPE	JE	----	----	----	VERO >	320.00	----	9/21/87
AVS-3037	CPE	PT	----	----	----	VERO	320.00	----	11/30/87
AVS-3037	CPE	VSV	----	----	----	L929 >	320.00	----	8/21/87
AVS-3037	CPE	VV	----	----	----	VERO >	320.00	----	8/27/87
AVS-3037	CPE	YFV	----	----	----	VERO	32.00	----	1/22/88
AVS-3038	CPE	AD2	----	----	----	HEP2	0.03	----	9/ 4/87
AVS-3038	CPE	JE	2.25	0.10	----	VERO -	0.32 -	3.12	9/ 9/87
AVS-3038	CPE	JE	0.85	0.31	----	VERO	0.01	0.03	5/25/88
AVS-3038	PR	PIC	N/A	0.06	----	VERO	0.32	4.70	2/12/88
AVS-3038	CPE	PT	1.6	1.01	----	VERO -	0.32 -	0.32	9/21/87
AVS-3038	CPE	PT	0.9	1.03	----	VERO -	0.32 -	0.31	11/30/87
AVS-3038	CPE	SF	3.45 <	0.32	----	VERO -	0.32 >	1.00	2/ 2/88
AVS-3038	CPE	VSV	2.4	0.56	----	L929 -	0.32 -	0.56	8/21/87
AVS-3038	CPE	VSV	2.9	0.24	----	L929	0.10	0.41	8/25/87
AVS-3038	CPE	VV	1.9	3.20	----	VERO	0.03	0.01	9/ 4/87
AVS-3038	CPE	YFV	0.85	5.00	----	VERO -	0.32 -	0.06	9/ 1/87
AVS-3038	CPE	YFV	0.65	----	----	VERO	0.01	----	1/22/88
AVS-3039	CPE	AD2	----	----	----	HEP2 >	320.00	----	8/27/87
AVS-3039	CPE	JE	0.05	----	----	VERO >	320.00	----	9/23/87
AVS-3039	CPE	PT	0.4	239.00	----	VERO	100.00	0.42	11/30/87
AVS-3039	CPE	VSV	----	----	----	L929	320.00	----	8/21/87
AVS-3039	CPE	VV	----	----	----	VERO >	320.00	----	8/27/87
AVS-3039	CPE	YFV	----	----	----	VERO >	320.00	----	1/25/88
AVS-3040	CPE	AD2	0.3	----	----	HEP2 <	100.00	----	8/27/87
AVS-3040	CPE	JE	0.15	----	----	VERO <	10.00	----	9/23/87
AVS-3040	CPE	PT	----	----	----	VERO	3.20	----	12/30/87
AVS-3040	CPE	SF	0.65	6.80	----	VERO	10.00	1.46	2/ 5/88
AVS-3040	CPE	VEE	----	----	----	VERO	32.00	----	12/ 1/87
AVS-3040	CPE	VSV	----	----	----	L929	100.00	----	8/21/87
AVS-3040	CPE	VV	0.75	56.30	----	VERO	100.00	1.77	8/27/87
AVS-3040	CPE	YFV	----	----	----	VERO	10.00	----	1/22/88
AVS-3041	CPE	AD2	----	----	----	HEP2 >	320.00	----	8/27/87
AVS-3041	CPE	JE	0.35	----	----	VERO >	320.00	----	9/23/87
AVS-3041	CPE	PT	----	----	----	VERO	100.00	----	12/30/87
AVS-3041	CPE	SF	0.3	----	----	VERO	32.00	----	11/11/87
AVS-3041	CPE	VEE	----	----	----	VERO	100.00	----	12/ 1/87
AVS-3041	CPE	VSV	----	----	----	L929	100.00	----	8/21/87
AVS-3041	CPE	VV	----	----	----	VERO >	320.00	----	8/27/87
AVS-3041	CPE	YFV	0.1	----	----	VERO	100.00	----	1/22/88
AVS-3042	CPE	AD2	----	----	----	HEP2 <	1.00	----	8/27/87
AVS-3042	CPE	JE	----	----	----	VERO	3.20	----	9/23/87
AVS-3042	CPE	PT	0.6	17.80	----	VERO	1.00	0.06	12/30/87
AVS-3042	CPE	SF	0.1	----	----	VERO	1.00	----	11/11/87

B-156

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3042	CPE	VEE	----	----	VERO	0.32	----	12/ 1/87
AVS-3042	CPE	VSV	0.6	56.50	L929	100.00	1.76	8/25/87
AVS-3042	CPE	VV	0.4	32.00	VERO	10.00	0.31	8/27/87
AVS-3042	CPE	YFV	----	----	VERO	1.00	----	1/25/88
AVS-3043	CPE	AD2	----	----	HEP2	1.00	----	8/27/87
AVS-3043	CPE	JE	----	----	VERO	3.20	----	9/23/87
AVS-3043	CPE	PT	----	----	VERO	3.20	----	4/29/88
AVS-3043	CPE	VSV	0.35	27.00	L929	10.00	0.37	8/25/87
AVS-3043	CPE	VV	0.25	----	VERO	10.00	----	8/27/87
AVS-3044	CPE	PT	0.9	4.92	VERO	10.00	2.03	4/29/88
AVS-3044	CPE	SF	----	----	VERO	32.00	----	12/15/87
AVS-3044	CPE	YFV	----	----	VERO	10.00	----	12/15/87
AVS-3045	CPE	PT	0.45	24.60	VERO	10.00	0.41	4/29/88
AVS-3045	CPE	SF	----	----	VERO	32.00	----	12/15/87
AVS-3045	CPE	YFV	----	----	VERO	32.00	----	12/15/87
AVS-3047	CPE	PT	0.5	200.00	VERO	100.00	0.50	12/30/87
AVS-3047	CPE	SF	----	----	VERO	32.00	----	12/16/87
AVS-3047	CPE	VEE	----	----	VERO	10.00	----	12/ 2/87
AVS-3047	CPE	YFV	----	----	VERO	32.00	----	12/16/87
AVS-3048	CPE	PT	1.6	77.90	VERO	320.00	4.10	12/30/87
AVS-3048	CPE	SF	0.4	75.10	VERO	100.00	1.33	12/16/87
AVS-3048	CPE	VEE	0.05	----	VERO	32.00	----	12/ 2/87
AVS-3048	CPE	YFV	----	----	VERO	100.00	----	12/16/87
AVS-3049	CPE	PT	0.2	----	VERO	10.00	----	4/29/88
AVS-3049	CPE	VEE	----	----	VERO	32.00	----	12/ 2/87
AVS-3050	CPE	PT	0.8	4.25	VERO	1.00	0.23	4/29/88
AVS-3050	CPE	SF	0.4	23.90	VERO	10.00	0.42	12/16/87
AVS-3050	CPE	YFV	----	----	VERO	10.00	----	12/16/87
AVS-3051	CPE	PT	----	----	VERO	100.00	----	4/29/88
AVS-3051	CPE	SF	----	----	VERO	100.00	----	12/17/87
AVS-3051	CPE	YFV	----	----	VERO	32.00	----	12/17/87
AVS-3052	PR	PIC	N/A	----	VERO	32.00	----	9/26/88
AVS-3052	CPE	PT	----	----	VERO	100.00	----	4/29/88
AVS-3052	CPE	SF	----	----	VERO	100.00	----	12/17/87
AVS-3052	CPE	YFV	----	----	VERO	32.00	----	12/17/87
AVS-3053	CPE	PT	0.05	----	VERO	100.00	----	4/29/88
AVS-3053	CPE	SF	----	----	VERO	32.00	----	12/17/87
AVS-3053	CPE	YFV	----	----	VERO	100.00	----	12/17/87
AVS-3054	PR	PIC	N/A	----	VERO	10.00	----	9/26/88
AVS-3054	CPE	PT	----	----	VERO	32.00	----	4/29/88
AVS-3054	CPE	SF	0.45	68.30	VERO	32.00	0.47	12/17/87
AVS-3054	CPE	YFV	----	----	VERO	32.00	----	12/17/87
AVS-3055	PR	PIC	N/A	----	VERO	10.00	----	9/26/88
AVS-3055	CPE	SF	----	----	VERO	10.00	----	12/17/87
AVS-3055	CPE	YFV	----	----	VERO	32.00	----	12/17/87
AVS-3056	PR	PIC	N/A	----	VERO	3.20	----	9/26/88
AVS-3056	CPE	SF	0.55	6.20	VERO	3.20	0.51	12/18/87
AVS-3056	CPE	YFV	0.15	----	VERO	3.20	----	12/18/87
AVS-3057	PR	PIC	N/A	----	VERO	3.20	----	9/26/88
AVS-3057	CPE	SF	0.55	6.20	VERO	3.20	0.51	12/18/87
AVS-3057	CPE	YFV	0.2	----	VERO	1.00	----	12/18/87
AVS-3058	PR	PIC	N/A	----	VERO	3.20	----	9/26/88
AVS-3058	CPE	SF	0.2	----	VERO	32.00	----	12/18/87
AVS-3058	CPE	YFV	----	----	VERO	32.00	----	12/18/87
AVS-3059	PR	PIC	N/A	----	VERO	32.00	----	9/26/88
AVS-3059	CPE	SF	0.4	86.80	VERO	32.00	0.37	12/18/87
AVS-3059	CPE	YFV	0.15	----	VERO	32.00	----	12/18/87
AVS-3060	PR	PIC	N/A	----	VERO	10.00	----	9/26/88
AVS-3060	CPE	SF	0.15	----	VERO	10.00	----	12/18/87
AVS-3060	CPE	YFV	----	----	VERO	10.00	----	12/18/87
AVS-3061	CPE	YFV	----	----	VERO	100.00	----	12/21/87
AVS-3062	PR	PIC	N/A	----	VERO	0.32	----	9/27/88
AVS-3062	CPE	YFV	----	----	VERO	0.10	----	2/ 2/88
AVS-3063	CPE	YFV	----	----	VERO	10.00	----	12/21/87
AVS-3064	PR	PIC	N/A	----	VERO	10.00	----	9/27/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3064	CPE	YFV	----	----	VERO	10.00	----	12/21/87
AVS-3065	PR	PIC	N/A	----	VERO >	10.00	----	9/27/88
AVS-3065	CPE	YFV	----	----	VERO	10.00	----	12/21/87
AVS-3066	PR	PIC	N/A	----	VERO >	3.20	----	9/27/88
AVS-3066	CPE	SF	----	----	VERO	3.20	----	12/22/87
AVS-3066	CPE	YFV	----	----	VERC	3.20	----	12/22/87
AVS-3067	PR	PIC	N/A	----	VERO >	1.00	----	9/27/88
AVS-3067	CPE	SF	0.15	----	VERO	1.00	----	12/22/87
AVS-3067	CPE	YFV	----	----	VERO	1.00	----	12/22/87
AVS-3068	PR	PIC	N/A	----	VERO	32.00	----	9/27/88
AVS-3068	CPE	SF	0.1	----	VERO	32.00	----	12/22/87
AVS-3068	CPE	YFV	----	----	VERO	32.00	----	12/22/87
AVS-3070	PR	PIC	N/A	----	VERO <	32.00	----	9/27/88
AVS-3070	CPE	SF	0.2	----	VERO	32.00	----	12/22/87
AVS-3070	CPE	YFV	----	----	VERO	100.00	----	12/22/87
AVS-3071	PR	PIC	N/A	----	VERO >	10.00	----	9/27/88
AVS-3071	CPE	YFV	0.15	----	VERO	10.00	----	2/11/88
AVS-3072	PR	PIC	N/A	----	VERO	100.00	----	9/26/88
AVS-3072	CPE	YFV	----	----	VERO	100.00	----	2/11/88
AVS-3073	PR	PIC	N/A	1.87	VERO	3.20	1.70	9/26/88
AVS-3073	CPE	YFV	0.15	----	VERO	32.00	----	2/11/88
AVS-3074	CPE	YFV	----	----	VERO	100.00	----	2/11/88
AVS-3075	PR	PIC	N/A	----	VERO	10.00	----	9/27/88
AVS-3075	CPE	YFV	----	----	VERO	10.00	----	2/11/88
AVS-3076	PR	PIC	N/A	----	VERO <	10.00	----	9/27/88
AVS-3076	CPE	YFV	----	----	VERO	10.00	----	2/11/88
AVS-3077	PR	PIC	N/A	----	VERO	10.00	----	9/30/88
AVS-3077	CPE	YFV	0.05	----	VERO	10.00	----	2/11/88
AVS-3078	CPE	YFV	----	----	VERO	10.00	----	2/11/88
AVS-3079	CPE	YFV	0.15	----	VERO	10.00	----	2/11/88
AVS-3080	PR	PIC	N/A	----	VERO	100.00	----	9/30/88
AVS-3080	CPE	PT	----	----	VERO	100.00	----	12/30/87
AVS-3080	CPE	VEE	----	----	VERO	100.00	----	12/ 2/87
AVS-3080	CPE	YFV	----	----	VERO	32.00	----	2/11/88
AVS-3081	PR	PIC	N/A	----	VERC	32.00	----	9/30/88
AVS-3081	CPE	VEE	----	----	VERO	100.00	----	12/ 2/87
AVS-3081	CPE	YFV	0.35	----	VERO	10.00	----	2/11/88
AVS-3082	PR	PIC	N/A	----	VERO >	10.00	----	9/30/88
AVS-3082	CPE	VEE	----	----	VERO	10.00	----	12/ 2/87
AVS-3082	CPE	YFV	0.05	----	VERO	32.00	----	2/11/88
AVS-3083	PR	PIC	N/A	----	VERO	32.00	----	9/30/88
AVS-3083	CPE	YFV	----	----	VERO	32.00	----	2/11/88
AVS-3084	CPE	YFV	----	----	VERO	100.00	----	2/11/88
AVS-3085	PR	PIC	N/A	----	VERC	32.00	----	9/30/88
AVS-3085	CPE	YFV	----	----	VERO	32.00	----	2/11/88
AVS-3086	CPE	YFV	----	----	VERO	10.00	----	2/11/88
AVS-3087	PR	PIC	N/A	----	VERO	10.00	----	10/ 3/88
AVS-3087	CPE	YFV	----	----	VERO	32.00	----	2/11/88
AVS-3088	PR	PIC	N/A	----	VERO	32.00	----	10/ 3/88
AVS-3088	CPE	YFV	----	----	VERO	100.00	----	2/11/88
AVS-3089	PR	PIC	N/A	----	VERO <	10.00	----	10/ 3/88
AVS-3089	CPE	YFV	----	----	VERO	32.00	----	2/11/88
AVS-3090	PR	PIC	N/A	----	VERO	32.00	----	10/ 3/88
AVS-3090	CPE	YFV	----	----	VERO	32.00	----	2/11/88
AVS-3091	PR	PIC	N/A	----	VERO	32.00	----	10/ 3/88
AVS-3091	CPE	YFV	----	----	VERO	32.00	----	2/11/88
AVS-3092	PR	PIC	N/A	----	VERO	100.00	----	10/ 3/88
AVS-3092	CPE	YFV	----	----	VERO	100.00	----	2/11/88
AVS-3093	PR	PIC	N/A	----	VERO >	3.20	----	10/ 3/88
AVS-3093	CPE	YFV	----	----	VERO	3.20	----	2/11/88
AVS-3095	PR	PIC	N/A	----	VERO	32.00	----	10/ 3/88
AVS-3095	CPE	YFV	----	----	VERO	100.00	----	2/10/88
AVS-3096	PR	PIC	N/A	----	VERO <	10.00	----	10/ 3/88
AVS-3096	CPE	YFV	0.2	----	VERO	32.00	----	2/10/88
AVS-3098	PR	PIC	N/A	----	VERO	32.00	----	10/ 4/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3098	CPE	YFV	----	----	VERO	32.00	----	2/10/88
AVS-3099	PR	PIC	N/A	----	VERO	32.00	----	10/ 4/88
AVS-3099	CPE	YFV	----	----	VERO	32.00	----	2/10/88
AVS-3100	P	PIC	N/A	----	VERO <	100.00	----	10/ 4/88
AVS-3100		YFV	----	----	VERO	100.00	----	2/10/88
AVS-3101	PR	PIC	N/A	----	VERO	32.00	----	10/ 4/88
AVS-3101	CPE	YFV	----	----	VERO	32.00	----	2/10/88
AVS-3102	PR	PIC	N/A	----	VERO	32.00	----	10/ 4/88
AVS-3102	CPE	YFV	----	----	VERO	32.00	----	2/10/88
AVS-3103	PR	PIC	N/A	----	VERO	32.00	----	10/ 4/88
AVS-3103	CPE	YFV	0.25	----	VERO	100.00	----	2/10/88
AVS-3104	PR	PIC	N/A	----	VERO	32.00	----	10/ 4/88
AVS-3104	CPE	YFV	----	----	VERO	32.00	----	2/10/88
AVS-3105	PR	PIC	N/A	----	VERO	100.00	----	10/ 4/88
AVS-3105	CPE	YFV	----	----	VERO	100.00	----	2/ 9/88
AVS-3106	PR	PIC	N/A	27.30	VERO	32.00	1.16	10/ 4/88
AVS-3106	CPE	YFV	----	----	VERO	32.00	----	2/ 9/88
AVS-3107	PR	PIC	N/A	----	VERO >	32.00	----	10/ 7/88
AVS-3107	CPE	YFV	----	----	VERO	32.00	----	2/ 9/88
AVS-3108	PR	PIC	N/A	----	VERO	100.00	----	10/ 7/88
AVS-3108	CPE	YFV	----	----	VERO	100.00	----	2/ 9/88
AVS-3109	PR	PIC	N/A	4.18	VERO	3.20	0.76	10/ 7/88
AVS-3109	CPE	YFV	0.15	----	VERO	32.00	----	2/ 9/88
AVS-3110	PR	PIC	N/A	----	VERO	100.00	----	10/ 7/88
AVS-3110	CPE	YFV	----	----	VERO	100.00	----	2/ 9/88
AVS-3111	PR	PIC	N/A	----	VERO	32.00	----	10/ 7/88
AVS-3111	CPE	YFV	----	----	VERO	100.00	----	2/ 9/88
AVS-3112	PR	PIC	N/A	----	VERO	10.00	----	10/ 7/88
AVS-3112	CPE	YFV	0.15	----	VERO	10.00	----	2/ 9/88
AVS-3113	PR	PIC	N/A	----	VERO	32.00	----	10/ 7/88
AVS-3113	CPE	YFV	----	----	VERO	32.00	----	2/ 9/88
AVS-3114	PR	PIC	N/A	----	VERO >	10.00	----	10/ 7/88
AVS-3114	CPE	YFV	----	----	VERO	10.00	----	2/ 9/88
AVS-3115	PR	PIC	N/A	----	VERO	32.00	----	10/ 7/88
AVS-3115	CPE	YFV	----	----	VERO <	32.00	----	2/ 9/88
AVS-3116	PR	PIC	N/A	----	VERO	3.20	----	10/ 7/88
AVS-3116	CPE	YFV	0.6	17.80	VERO	10.00	0.56	2/12/88
AVS-3117	PR	PIC	N/A	1.25	VERO	1.00	0.80	10/ 3/88
AVS-3117	CPE	YFV	----	----	VERO	10.00	----	2/12/88
AVS-3118	PR	PIC	N/A	----	VERO	32.00	----	9/30/88
AVS-3118	CPE	YFV	0.1	----	VERO	32.00	----	2/12/88
AVS-3119	PR	PIC	N/A	----	VERO	10.00	----	9/30/88
AVS-3119	CPE	YFV	0.7	50.40	VERO	32.00	0.63	2/12/88
AVS-3120	PR	PIC	N/A	----	VERO	10.00	----	9/30/88
AVS-3120	CPE	YFV	0.5	75.60	VERO	10.00	0.13	2/12/88
AVS-3121	PR	PIC	N/A	----	VERO	3.20	----	10/ 4/88
AVS-3121	CPE	YFV	0.15	----	VERO	32.00	----	2/12/88
AVS-3122	PR	PIC	N/A	----	VERO	10.00	----	10/11/88
AVS-3122	CPE	YFV	0.15	----	VERO	10.00	----	2/12/88
AVS-3123	PR	PIC	N/A	----	VERO	3.20	----	10/11/88
AVS-3123	CPE	YFV	----	----	VERO	3.20	----	2/12/88
AVS-3124	PR	PIC	N/A	----	VERO	10.00	----	10/11/88
AVS-3124	CPE	YFV	0.15	----	VERO	100.00	----	2/12/88
AVS-3125	PR	PIC	N/A	6.20	VERO	3.20	0.51	10/11/88
AVS-3125	CPE	YFV	0.15	----	VERO	10.00	----	2/12/88
AVS-3126	PR	PIC	N/A	----	VERO	10.00	----	10/11/88
AVS-3126	CPE	YFV	0.3	320.00	VERO	10.00	0.03	2/12/88
AVS-3127	PR	PIC	N/A	----	VERO	10.00	----	10/11/88
AVS-3127	CPE	YFV	----	----	VERO	32.00	----	2/12/88
AVS-3128	PR	PIC	N/A	----	VERO	32.00	----	10/11/88
AVS-3128	CPE	YFV	----	----	VERO	100.00	----	2/12/88
AVS-3129	PR	PIC	N/A	----	VERO >	3.20	----	10/11/88
AVS-3129	CPE	YFV	0.6	17.80	VERO	3.20	0.18	2/12/88
AVS-3130	PR	PIC	N/A	----	VERO	10.00	----	10/11/88
AVS-3130	CPE	YFV	0.55	188.00	VERO	100.00	0.53	2/12/88

B-159

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3131	PR	PIC	N/A	9.20	VERO	10.00	1.08	10/11/88
AVS-3131	CPE	YFV	0.7	50.40	VERO	32.00	0.63	2/12/88
AVS-3132	PR	PIC	N/A	----	VERO	32.00	----	10/14/88
AVS-3132	CPE	YFV	----	----	VERO	100.00	----	2/12/88
AVS-3133	PR	PIC	N/A	----	VERO	100.00	----	10/14/88
AVS-3133	CPE	YFV	----	----	VERO	100.00	----	2/12/88
AVS-3134	PR	PIC	N/A	----	VERO	3.20	----	10/14/88
AVS-3134	CPE	YFV	----	----	VERO	100.00	----	2/12/88
AVS-3135	PR	PIC	N/A	----	VERO >	3.20	----	10/14/88
AVS-3135	CPE	YFV	----	----	VERO	3.20	----	2/12/88
AVS-3136	PR	PIC	N/A	----	VERO <	10.00	----	10/14/88
AVS-3136	CPE	YFV	----	----	VERO	32.00	----	2/12/88
AVS-3137	PR	PIC	N/A	----	VERO >	32.00	----	10/14/88
AVS-3137	CPE	YFV	0.3	100.00	VERO	32.00	0.32	2/12/88
AVS-3138	PR	PIC	N/A	----	VERO >	3.20	----	10/14/88
AVS-3138	CPE	YFV	0.3	100.00	VERO	3.20	0.03	2/12/88
AVS-3139	PR	PIC	N/A	----	VERO	32.00	----	10/14/88
AVS-3139	CPE	YFV	----	----	VERO	32.00	----	3/ 8/88
AVS-3140	PR	PIC	N/A	----	VERO >	100.00	----	10/14/88
AVS-3140	CPE	YFV	----	----	VERO	100.00	----	3/ 8/88
AVS-3141	PR	PIC	N/A	5.70	VERO	10.00	1.74	10/14/88
AVS-3141	CPE	YFV	----	----	VERO	10.00	----	3/ 8/88
AVS-3142	CPE	YFV	----	----	VERO	32.00	----	3/ 8/88
AVS-3143	CPE	YFV	----	----	VERO	10.00	----	3/ 8/88
AVS-3144	CPE	YFV	----	----	VERO	32.00	----	3/ 8/88
AVS-3145	CPE	YFV	----	----	VERO	3.20	----	3/ 8/88
AVS-3146	CPE	YFV	----	----	VERO	32.00	----	3/ 8/88
AVS-3147	CPE	YFV	----	----	VERO	3.20	----	3/ 8/88
AVS-3148	CPE	YFV	----	----	VERO	32.00	----	3/ 8/88
AVS-3149	CPE	YFV	----	----	VERO	10.00	----	3/ 8/88
AVS-3152	PR	PIC	N/A	----	VERO	100.00	----	10/19/88
AVS-3153	PR	PIC	N/A	----	VERO	100.00	----	10/19/88
AVS-3153	CPE	YFV	----	----	VERO	100.00	----	3/ 9/88
AVS-3154	PR	PIC	N/A	----	VERO >	32.00	----	10/19/88
AVS-3154	CPE	YFV	----	----	VERO	32.00	----	3/ 9/88
AVS-3155	PR	PIC	N/A	----	VERO	100.00	----	10/19/88
AVS-3155	CPE	YFV	----	----	VERO	100.00	----	3/ 9/88
AVS-3156	PR	PIC	N/A	----	VERO >	100.00	----	10/19/88
AVS-3156	CPE	YFV	----	----	VERO	100.00	----	3/ 9/88
AVS-3158	PR	PIC	N/A	----	VERO	32.00	----	10/19/88
AVS-3158	CPE	YFV	----	----	VERO	32.00	----	3/ 9/88
AVS-3159	PR	PIC	N/A	31.20	VERO	32.00	1.02	10/19/88
AVS-3159	CPE	YFV	----	----	VERO	100.00	----	3/ 9/88
AVS-3160	PR	PIC	N/A	----	VERO >	10.00	----	10/19/88
AVS-3160	CPE	YFV	----	----	VERO	10.00	----	3/ 9/88
AVS-3161	PR	PIC	N/A	----	VERO >	10.00	----	10/19/88
AVS-3161	CPE	YFV	0.15	----	VERO	10.00	----	3/10/88
AVS-3162	CPE	YFV	0.15	----	VERO	10.00	----	3/10/88
AVS-3163	CPE	YFV	----	----	VERO	10.00	----	3/10/88
AVS-3164	PR	PIC	N/A	----	VERO	3.20	----	10/19/88
AVS-3164	CPE	YFV	0.05	----	VERO	3.20	----	3/10/88
AVS-3165	PR	PIC	N/A	----	VERO	100.00	----	10/21/88
AVS-3165	CPE	YFV	----	----	VERO	100.00	----	3/10/88
AVS-3166	CPE	YFV	----	----	VERO	32.00	----	3/10/88
AVS-3167	PR	PIC	N/A	----	VERO >	3.20	----	10/21/88
AVS-3167	CPE	YFV	----	----	VERO	3.20	----	3/10/88
AVS-3168	PR	PIC	N/A	----	VERO	32.00	----	10/21/88
AVS-3168	CPE	YFV	----	----	VERO	32.00	----	3/10/88
AVS-3169	PR	PIC	N/A	----	VERO >	100.00	----	10/21/88
AVS-3169	CPE	YFV	----	----	VERO	100.00	----	3/10/88
AVS-3170	PR	PIC	N/A	----	VERO >	10.00	----	10/21/88
AVS-3170	CPE	YFV	----	----	VERO	10.00	----	3/10/88
AVS-3171	PR	PIC	N/A	----	VERO	10.00	----	10/21/88
AVS-3171	CPE	YFV	----	----	VERO	32.00	----	3/10/88
AVS-3172	PR	PIC	N/A	----	VERO >	10.00	----	10/21/88

B-160

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3172	CPE	YFV	----	----	VERO	10.00	----	3/11/88
AVS-3173	PR	PIC	N/A	----	VERO	32.00	----	10/21/88
AVS-3174	PR	PIC	N/A	----	VERO	10.00	----	10/21/88
AVS-3174	CPE	YFV	----	----	VERO	32.00	----	3/11/88
AVS-3175	PR	PIC	N/A	----	VERO	32.00	----	10/21/88
AVS-3175	CPE	YFV	----	----	VERO	100.00	----	3/11/88
AVS-3176	CPE	YFV	----	----	VERO	32.00	----	3/11/88
AVS-3177	CPE	YFV	0.15	----	VERO	10.00	----	3/11/88
AVS-3178	CPE	YFV	----	----	VERO	100.00	----	3/11/88
AVS-3179	CPE	YFV	----	----	VERO	100.00	----	3/11/88
AVS-3180	CPE	YFV	----	----	VERO	32.00	----	3/11/88
AVS-3181	CPE	YFV	----	----	VERO	32.00	----	3/11/88
AVS-3183	CPE	YFV	----	----	VERO	10.00	----	3/11/88
AVS-3184	CPE	YFV	----	----	VERO	100.00	----	3/11/88
AVS-3185	CPE	YFV	----	----	VERO	10.00	----	3/11/88
AVS-3186	CPE	YFV	----	----	VERO	10.00	----	3/11/88
AVS-3187	CPE	YFV	----	----	VERO	100.00	----	3/11/88
AVS-3188	PR	PIC	N/A	----	VERO	100.00	----	10/25/88
AVS-3188	CPE	YFV	----	----	VERO	100.00	----	3/11/88
AVS-3189	PR	PIC	N/A	0.93	VERO	100.00	106.00	10/25/88
AVS-3189	CPE	YFV	----	----	VERO	100.00	----	3/11/88
AVS-3190	PR	PIC	N/A	13.80	VERO	32.00	2.31	10/25/88
AVS-3190	CPE	YFV	----	----	VERO	100.00	----	3/11/88
AVS-3191	PR	PIC	N/A	----	VERO	100.00	----	10/25/88
AVS-3191	CPE	YFV	----	----	VERO	100.00	----	3/11/88
AVS-3193	PR	PIC	N/A	----	VERO	32.00	----	10/25/88
AVS-3193	CPE	YFV	0.15	----	VERO	100.00	----	3/11/88
AVS-3194	CPE	JE	----	----	VERO	10.00	----	3/17/88
AVS-3194	PR	PIC	N/A	----	VERO	100.00	----	10/25/88
AVS-3194	CPE	PT	0.15	----	VERO	1.00	----	3/17/88
AVS-3194	CPE	SF	0.5	----	VERO	1.00	----	3/17/88
AVS-3194	CPE	YFV	----	----	VERO	100.00	----	3/17/88
AVS-3195	CPE	JE	----	----	VERO	0.10	----	3/17/88
AVS-3195	PR	PIC	N/A	----	VERO	3.20	----	10/25/88
AVS-3195	CPE	PT	0.3	----	VERO	1.00	----	3/17/88
AVS-3195	CPE	SF	1.47	0.89	VERO	0.10	0.11	3/17/88
AVS-3195	CPE	YFV	0.15	----	VERO	1.00	----	3/17/88
AVS-3196	CPE	JE	----	----	VERO	3.20	----	3/17/88
AVS-3196	PR	PIC	N/A	----	VERO	100.00	----	10/25/88
AVS-3196	CPE	SF	1.62	55.30	VERO	0.10	----	3/17/88
AVS-3196	CPE	YFV	0.05	----	VERO	100.00	----	3/17/88
AVS-3197	CPE	JE	0.15	----	VERO	0.10	----	3/17/88
AVS-3197	PR	PIC	N/A	----	VERO	1.00	----	10/25/88
AVS-3197	CPE	PT	----	----	VERO	0.10	----	3/17/88
AVS-3197	CPE	SF	1.	8.40	VERO	0.10	0.01	3/17/88
AVS-3197	CPE	YFV	----	----	VERO	1.00	----	3/17/88
AVS-3199	PR	PIC	N/A	----	VERO	10.00	----	10/25/88
AVS-3199	CPE	YFV	----	----	VERO	32.00	----	4/29/88
AVS-3200	PR	PIC	N/A	----	VERO	32.00	----	10/28/88
AVS-3200	CPE	YFV	----	----	VERO	32.00	----	4/29/88
AVS-3202	PR	PIC	N/A	----	VERO	100.00	----	10/28/88
AVS-3202	CPE	YFV	----	----	VERO	100.00	----	4/29/88
AVS-3203	PR	PIC	N/A	----	VERO	32.00	----	10/28/88
AVS-3203	CPE	YFV	----	----	VERO	32.00	----	4/29/88
AVS-3204	PR	PIC	N/A	2.32	VERO	3.20	1.37	10/28/88
AVS-3204	CPE	YFV	0.25	----	VERO	3.20	----	4/29/88
AVS-3205	CPE	JE	----	----	VERO	100.00	----	8/25/88
AVS-3205	PR	PIC	N/A	2.77	VERO	3.20	1.15	10/28/88
AVS-3205	CPE	YFV	----	----	VERO	3.20	----	4/29/88
AVS-3205	CPE	YFV	0.1	----	VERO	100.00	----	8/25/88
AVS-3206	CPE	YFV	0.5	2.00	VERO	3.20	1.59	4/29/88
AVS-3207	PR	PIC	N/A	----	VERO	32.00	----	10/28/88
AVS-3207	CPE	YFV	----	----	VERO	100.00	----	4/29/88
AVS-3208	PR	PIC	N/A	----	VERO	32.00	----	10/31/88
AVS-3208	CPE	YFV	----	----	VERO	32.00	----	4/29/88

B-161

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3209	CPE	JE	----	----	VERO	32.00	----	6/30/88
AVS-3209	PR	PIC	N/A	----	VERO	32.00	----	10/31/88
AVS-3209	CPE	PT	0.1	----	VERO	32.00	----	6/30/88
AVS-3209	CPE	SF	0.27	----	VERO	10.00	----	6/30/88
AVS-3209	CPE	VEE	----	----	VERO	32.00	----	6/30/88
AVS-3209	CPE	YFV	----	----	VERO	100.00	----	6/30/88
AVS-3211	CPE	JE	----	----	VERO	32.00	----	6/30/88
AVS-3211	PR	PIC	N/A	----	VERO	320.00	----	10/31/88
AVS-3211	CPE	PT	----	----	VERO	100.00	----	6/30/88
AVS-3211	CPE	SF	0.1	----	VERO	32.00	----	6/30/88
AVS-3211	CPE	VEE	----	----	VERO	100.00	----	6/30/88
AVS-3211	CPE	YFV	----	----	VERO	100.00	----	6/30/88
AVS-3213	CPE	JE	----	----	VERO	1.00	----	6/30/88
AVS-3213	PR	PIC	N/A	----	VERO	10.00	----	10/31/88
AVS-3213	CPE	PT	0.2	----	VERO	1.00	----	6/30/88
AVS-3213	CPE	SF	1.05	1.52	VERO	0.32	0.21	6/30/88
AVS-3213	CPE	VEE	----	----	VERO	3.20	----	6/30/88
AVS-3213	CPE	YFV	0.1	----	VERO	1.00	----	6/30/88
AVS-3215	CPE	JE	0.3	----	VERO	100.00	----	6/30/88
AVS-3215	PR	PIC	N/A	----	VERO	32.00	----	10/31/88
AVS-3215	CPE	PT	0.15	----	VERO	32.00	----	6/30/88
AVS-3215	CPE	SF	0.27	----	VERO	32.00	----	6/30/88
AVS-3215	CPE	VEE	----	----	VERO	32.00	----	6/30/88
AVS-3215	CPE	YFV	0.22	----	VERO	100.00	----	6/30/88
AVS-3216	CPE	JE	----	----	VERO	10.00	----	6/30/88
AVS-3216	PR	PIC	N/A	----	VERO	3.20	----	11/ 1/88
AVS-3216	CPE	PT	0.85	56.40	VERO	100.00	1.77	6/30/88
AVS-3216	CPE	SF	0.12	----	VERO	10.00	----	6/30/88
AVS-3216	CPE	VEE	----	----	VERO	32.00	----	6/30/88
AVS-3216	CPE	YFV	0.05	----	VERO	32.00	----	6/30/88
AVS-3217	CPE	JE	0.15	----	VERO	3.20	----	6/30/88
AVS-3217	PR	PIC	N/A	----	VERO	1.00	----	11/ 1/88
AVS-3217	CPE	PT	0.25	----	VERO	10.00	----	6/30/88
AVS-3217	CPE	SF	0.65	6.80	VERO	3.20	0.47	6/30/88
AVS-3217	CPE	VEE	----	----	VERO	3.20	----	6/30/88
AVS-3217	CPE	YFV	----	----	VERO	10.00	----	6/30/88
AVS-3218	CPE	JE	0.12	----	VERO	10.00	----	6/30/88
AVS-3218	PR	PIC	N/A	23.00	VERO	10.00	0.43	11/ 1/88
AVS-3218	CPE	PT	0.65	15.70	VERO	10.00	0.64	6/30/88
AVS-3218	CPE	SF	0.65	20.10	VERO	10.00	0.50	6/30/88
AVS-3218	CPE	VEE	----	----	VERO	32.00	----	6/30/88
AVS-3218	CPE	YFV	----	----	VERO	10.00	----	6/30/88
AVS-3219	CPE	JE	0.22	----	VERO	3.20	----	6/30/88
AVS-3219	PR	PIC	N/A	----	VERO	10.00	----	11/ 1/88
AVS-3219	CPE	PT	0.2	----	VERO	32.00	----	6/30/88
AVS-3219	CPE	SF	0.4	23.90	VERO	10.00	0.42	6/30/88
AVS-3219	CPE	VEE	----	----	VERO	10.00	----	6/30/88
AVS-3219	CPE	YFV	----	----	VERO	32.00	----	6/30/88
AVS-3221	CPE	JE	----	----	VERO	10.00	----	6/30/88
AVS-3221	PR	PIC	N/A	----	VERO	1.00	----	11/ 1/88
AVS-3221	CPE	PT	0.35	----	VERO	10.00	----	6/30/88
AVS-3221	CPE	SF	1.05	26.10	VERO	10.00	0.38	6/30/88
AVS-3221	CPE	VEE	----	----	VERO	32.00	----	6/30/88
AVS-3221	CPE	YFV	----	----	VERO	32.00	----	6/30/88
AVS-3222	CPE	JE	0.12	----	VERO	100.00	----	6/30/88
AVS-3222	PR	PIC	N/A	----	VERO	3.20	----	11/ 1/88
AVS-3222	CPE	PT	0.05	----	VERO	100.00	----	6/30/88
AVS-3222	CPE	SF	----	----	VERO	10.00	----	6/30/88
AVS-3222	CPE	VEE	----	----	VERO	32.00	----	6/30/88
AVS-3222	CPE	YFV	----	----	VERO	32.00	----	6/30/88
AVS-3223	CPE	JE	0.05	----	VERO	100.00	----	6/30/88
AVS-3223	PR	PIC	N/A	----	VERO	320.00	----	11/ 1/88
AVS-3223	CPE	PT	0.1	----	VERO	100.00	----	6/30/88
AVS-3223	CPE	SF	----	----	VERO	32.00	----	6/30/88
AVS-3223	CPE	VEE	----	----	VERO	10.00	----	6/30/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3223	CPE	YFV	----	----	VERO	100.00	----	6/30/88
AVS-3224	CPE	JE	----	----	VERO	10.00	----	7/ 7/88
AVS-3224	PR	PIC	N/A	----	VERO	32.00	----	11/ 1/88
AVS-3224	CPE	PT	0.55	71.10	VERO	3.20	0.04	7/ 7/88
AVS-3224	CPE	SF	1.35	21.80	VERO	10.00	0.46	7/ 7/88
AVS-3224	CPE	YFV	0.2	----	VERO	10.00	----	7/ 7/88
AVS-3225	CPE	JE	----	----	VERO	10.00	----	7/ 7/88
AVS-3225	PR	PIC	N/A	----	VERO	100.00	----	11/ 1/88
AVS-3225	CPE	PT	0.05	----	VERO	32.00	----	7/ 7/88
AVS-3225	CPE	SF	0.35	----	VERO	32.00	----	7/ 7/88
AVS-3225	CPE	YFV	0.1	----	VERO	32.00	----	7/ 7/88
AVS-3226	CPE	JE	----	----	VERO	10.00	----	7/ 7/88
AVS-3226	PR	PIC	N/A	----	VERO	100.00	----	11/ 1/88
AVS-3226	CPE	PT	0.37	28.50	VERO	1.00	0.04	7/ 7/88
AVS-3226	CPE	SF	1.85	15.50	VERO	32.00	2.05	7/ 7/88
AVS-3226	CPE	YFV	----	----	VERO	3.20	----	7/ 7/88
AVS-3227	CPE	JE	----	----	VERO	32.00	----	7/ 7/88
AVS-3227	PR	PIC	N/A	----	VERO	320.00	----	10/31/88
AVS-3227	PR	PIC	N/A	----	VERO	100.00	----	11/ 4/88
AVS-3227	CPE	PT	0.05	----	VERO	32.00	----	7/ 7/88
AVS-3227	CPE	SF	1.35	37.00	VERO	32.00	0.86	7/ 7/88
AVS-3227	CPE	YFV	----	----	VERO	32.00	----	7/ 7/88
AVS-3228	CPE	JE	----	----	VERO	32.00	----	7/ 7/88
AVS-3228	PR	PIC	N/A	----	VERO	32.00	----	10/31/88
AVS-3228	PR	PIC	N/A	----	VERO	32.00	----	11/ 4/88
AVS-3228	CPE	PT	0.42	69.10	VERO	10.00	0.14	7/ 7/88
AVS-3228	CPE	SF	1.3	98.00	VERO	100.00	1.01	7/ 7/88
AVS-3228	CPE	YFV	0.2	----	VERO	32.00	----	7/ 7/88
AVS-3229	CPE	JE	----	----	VERO	10.00	----	7/ 7/88
AVS-3229	PR	PIC	N/A	----	VERO	100.00	----	10/31/88
AVS-3229	PR	PIC	N/A	----	VERO	100.00	----	11/ 4/88
AVS-3229	CPE	PT	0.95	53.40	VERO	32.00	0.60	7/ 7/88
AVS-3229	CPE	SF	1.75	14.20	VERO	32.00	2.24	7/ 7/88
AVS-3229	CPE	YFV	0.2	----	VERO	32.00	----	7/ 7/88
AVS-3230	CPE	JE	----	----	VERO	32.00	----	7/ 7/88
AVS-3230	PR	PIC	N/A	----	VERO	100.00	----	11/ 4/88
AVS-3230	CPE	PT	0.4	75.10	VERO	3.20	0.04	7/ 7/88
AVS-3230	CPE	SF	1.2	18.70	VERO	10.00	0.53	7/ 7/88
AVS-3230	CPE	YFV	0.35	----	VERO	32.00	----	7/ 7/88
AVS-3231	CPE	JE	----	----	VERO	32.00	----	7/ 7/88
AVS-3231	PR	PIC	N/A	----	VERO	320.00	----	11/ 4/88
AVS-3231	CPE	PT	0.15	----	VERO	32.00	----	7/ 7/88
AVS-3231	CPE	SF	1.	----	VERO	32.00	----	7/ 7/88
AVS-3231	CPE	YFV	0.2	----	VERO	100.00	----	7/ 7/88
AVS-3232	CPE	JE	----	----	VERO	10.00	----	7/ 7/88
AVS-3232	PR	PIC	N/A	----	VERO	100.00	----	11/ 4/88
AVS-3232	CPE	PT	0.89	40.00	VERO	32.00	0.80	7/ 7/88
AVS-3232	CPE	YFV	0.3	----	VERO	32.00	----	7/ 7/88
AVS-3233	CPE	JE	----	----	VERO	10.00	----	7/ 7/88
AVS-3233	PR	PIC	N/A	30.00	VERO	10.00	0.33	11/ 4/88
AVS-3233	CPE	PT	0.05	----	VERO	10.00	----	7/ 7/88
AVS-3233	CPE	YFV	0.1	----	VERO	10.00	----	7/ 7/88
AVS-3234	CPE	AD2	----	----	HEP2	3.20	----	9/ 4/87
AVS-3234	CPE	JE	----	----	VERO	320.00	----	10/ 2/87
AVS-3234	PR	PIC	N/A	----	VERO	32.00	----	11/ 4/88
AVS-3234	CPE	SF	----	----	VERO	320.00	----	11/11/87
AVS-3234	CPE	VSV	----	----	L929	32.00	----	8/25/87
AVS-3234	CPE	VV	----	----	VERO	100.00	----	9/ 4/87
AVS-3234	CPE	YFV	----	----	VERO	10.00	----	1/22/88
AVS-3235	CPE	JE	----	----	VERO	32.00	----	7/ 7/88
AVS-3235	PR	PIC	N/A	----	VERO	320.00	----	11/ 4/88
AVS-3235	CPE	PT	0.02	----	VERO	3.20	----	7/ 7/88
AVS-3235	CPE	YFV	0.1	----	VERO	100.00	----	7/ 7/88
AVS-3236	PR	PIC	N/A	----	VERO	32.00	----	10/31/88
AVS-3236	PR	PIC	N/A	----	VERO	10.00	----	11/ 4/88

B-163

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3236	CPE	PT	0.85	38.60	VERO	3.20	0.08	7/ 7/88
AVS-3236	CPE	YFV	----	----	VERO	32.00	----	7/ 7/88
AVS-3237	PR	PIC	N/A	----	VERO	100.00	----	10/31/88
AVS-3237	PR	PIC	N/A	----	VERO	32.00	----	11/ 7/88
AVS-3237	CPE	PT	----	----	VERO	3.20	----	7/ 7/88
AVS-3237	CPE	YFV	0.15	----	VERO	100.00	----	7/ 7/88
AVS-3238	PR	PIC	N/A	----	VERO	100.00	----	11/ 7/88
AVS-3238	CPE	PT	----	----	VERO	32.00	----	7/ 7/88
AVS-3238	CPE	YFV	----	----	VERO	100.00	----	7/ 7/88
AVS-3239	PR	PIC	N/A	----	VERO	100.00	----	11/ 7/88
AVS-3239	CPE	PT	0.17	----	VERO	1.00	----	7/ 7/88
AVS-3239	CPE	YFV	----	----	VERO >	100.00	----	7/ 7/88
AVS-3240	CPE	JE	----	----	VERO	10.00	----	7/21/88
AVS-3240	PR	PIC	N/A	----	VERO	320.00	----	11/ 7/88
AVS-3240	CPE	PT	----	----	VERO >	100.00	----	7/21/88
AVS-3240	CPE	SF	----	----	VERO	10.00	----	7/21/88
AVS-3240	CPE	VEE	----	----	VERO	32.00	----	7/21/88
AVS-3240	CPE	YFV	----	----	VERO >	100.00	----	7/21/88
AVS-3241	CPE	JE	----	----	VERO	100.00	----	7/21/88
AVS-3241	PR	PIC	N/A	----	VERO	32.00	----	11/ 7/88
AVS-3241	CPE	PT	----	----	VERO >	100.00	----	7/21/88
AVS-3241	CPE	SF	0.15	----	VERO	3.20	----	7/21/88
AVS-3241	CPE	VEE	----	----	VERO	32.00	----	7/21/88
AVS-3241	CPE	YFV	----	----	VERO	32.00	----	7/21/88
AVS-3242	CPE	JE	----	----	VERO	100.00	----	7/21/88
AVS-3242	PR	PIC	N/A	----	VERO	32.00	----	11/ 7/88
AVS-3242	CPE	PT	----	----	VERO	100.00	----	7/21/88
AVS-3242	CPE	SF	----	----	VERO	100.00	----	7/21/88
AVS-3242	CPE	VEE	----	----	VERO	32.00	----	7/21/88
AVS-3242	CPE	YFV	----	----	VERO >	100.00	----	7/21/88
AVS-3243	CPE	JE	----	----	VERO	1.00	----	7/21/88
AVS-3243	PR	PIC	N/A	----	VERO	3.20	----	11/ 7/88
AVS-3243	CPE	PT	----	----	VERO	3.20	----	7/21/88
AVS-3243	CPE	SF	0.6	5.60	VERO	10.00	1.76	7/21/88
AVS-3243	CPE	VEE	----	----	VERO	3.20	----	7/21/88
AVS-3243	CPE	YFV	----	----	VERO	3.20	----	7/21/88
AVS-3244	CPE	JE	----	----	VERO	32.00	----	7/21/88
AVS-3244	PR	PIC	N/A	----	VERO	32.00	----	11/ 7/88
AVS-3244	CPE	PT	----	----	VERO	32.00	----	7/21/88
AVS-3244	CPE	SF	0.15	----	VERO	3.20	----	7/21/88
AVS-3244	CPE	VEE	----	----	VERO	32.00	----	7/21/88
AVS-3244	CPE	YFV	----	----	VERO >	100.00	----	7/21/88
AVS-3245	CPE	AD2	0.2	----	HEP2 >	320.00	----	9/ 4/87
AVS-3245	CPE	JE	----	----	VERO	320.00	----	7/21/88
AVS-3245	PR	PIC	N/A	----	VERO	320.00	----	11/ 7/88
AVS-3245	CPE	PT	----	----	VERO >	320.00	----	7/21/88
AVS-3245	CPE	SF	----	----	VERO	320.00	----	7/21/88
AVS-3245	CPE	VEE	----	----	VERO	100.00	----	7/21/88
AVS-3245	CPE	VSV	----	----	L929	100.00	----	8/25/87
AVS-3245	CPE	VV	----	----	VERO	320.00	----	9/ 4/87
AVS-3245	CPE	YFV	----	----	VERO >	320.00	----	7/21/88
AVS-3246	CPE	JE	----	----	VERO	32.00	----	8/ 4/88
AVS-3246	PR	PIC	N/A	----	VERO	10.00	----	11/15/88
AVS-3246	CPE	PT	----	----	VERO	32.00	----	8/ 4/88
AVS-3246	CPE	SF	0.85	21.20	VERO	32.00	1.50	8/ 4/88
AVS-3246	CPE	VEE	----	----	VERO	100.00	----	8/ 4/88
AVS-3246	CPE	YFV	0.05	----	VERO	32.00	----	8/ 4/88
AVS-3247	CPE	JE	----	----	VERO	32.00	----	8/ 4/88
AVS-3247	PR	PIC	N/A	63.00	VERO	32.00	0.51	11/15/88
AVS-3247	CPE	PT	0.2	----	VERO	100.00	----	8/ 4/88
AVS-3247	CPE	SF	1.9	26.80	VERO	100.00	3.72	8/ 4/88
AVS-3247	CPE	VEE	----	----	VERO	32.00	----	8/ 4/88
AVS-3247	CPE	YFV	----	----	VERO	100.00	----	8/ 4/88
AVS-3248	CPE	JE	----	----	VERO	3.20	----	8/ 4/88
AVS-3248	PR	PIC	N/A	----	VERO <	0.32	----	11/15/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-3248	CPE	PT	----	----	VERO	1.00	----	8/ 4/88
AVS-3248	CPE	SF	0.45	9.20	VERO	3.20	0.34	8/ 4/88
AVS-3248	CPE	VEE	----	----	VERO	10.00	----	8/ 4/88
AVS-3248	CPE	YFV	----	----	VERO	3.20	----	8/ 4/88
AVS-3250	CPE	JE	----	----	VERO	10.00	----	8/11/88
AVS-3250	PR	PIC	N/A	----	VERO	10.00	----	11/15/88
AVS-3250	CPE	PT	----	----	VERO	10.00	----	8/11/88
AVS-3250	CPE	SF	0.7	----	VERO	10.00	----	8/11/88
AVS-3250	CPE	VEE	----	----	VERO	32.00	----	8/11/88
AVS-3250	CPE	YFV	----	----	VERO	10.00	----	8/11/88
AVS-3251	CPE	JE	----	----	VERO	10.00	----	8/11/88
AVS-3251	PR	PIC	N/A	16.90	VERO	10.00	0.59	11/15/88
AVS-3251	CPE	PT	0.3	100.00	VERO	32.00	0.32	8/11/88
AVS-3251	CPE	SF	1.4	9.30	VERO	10.00	1.06	8/11/88
AVS-3251	CPE	VEE	----	----	VERO	32.00	----	8/11/88
AVS-3251	CPE	YFV	----	----	VERO	32.00	----	8/11/88
AVS-3252	CPE	JE	----	----	VERO	10.00	----	8/11/88
AVS-3252	PR	PIC	N/A	12.90	VERO	10.00	0.77	11/15/88
AVS-3252	CPE	PT	0.45	68.30	VERO	32.00	0.47	8/11/88
AVS-3252	CPE	SF	1.65	11.70	VERO	32.00	2.72	8/11/88
AVS-3252	CPE	VEE	----	----	VERO	32.00	----	8/11/88
AVS-3252	CPE	YFV	----	----	VERO	10.00	----	8/11/88
AVS-3254	CPE	JE	----	----	VERO	3.20	----	8/11/88
AVS-3254	PR	PIC	N/A	----	VERO	3.20	----	11/15/88
AVS-3254	CPE	PT	----	----	VERO	10.00	----	8/11/88
AVS-3254	CPE	SF	0.45	----	VERO	10.00	----	8/11/88
AVS-3254	CPE	VEE	----	----	VERO	10.00	----	8/11/88
AVS-3254	CPE	YFV	----	----	VERO	3.20	----	8/11/88
AVS-3256	CPE	JE	----	----	VERO	32.00	----	8/11/88
AVS-3256	PR	PIC	N/A	54.60	VERO	10.00	0.18	11/15/88
AVS-3256	CPE	PT	----	----	VERO	32.00	----	8/11/88
AVS-3256	CPE	SF	0.3	32.00	VERO	32.00	1.00	8/11/88
AVS-3256	CPE	VEE	----	----	VERO	32.00	----	8/11/88
AVS-3256	CPE	YFV	----	----	VERO	32.00	----	8/11/88
AVS-3263	CPE	JE	----	----	VERO	32.00	----	8/11/88
AVS-3263	PR	PIC	N/A	----	VERO	10.00	----	11/18/88
AVS-3263	CPE	PT	----	----	VERO	32.00	----	8/11/88
AVS-3263	CPE	SF	0.3	32.00	VERO	32.00	1.00	8/11/88
AVS-3263	CPE	VEE	----	----	VERO	10.00	----	8/11/88
AVS-3263	CPE	YFV	----	----	VERO	32.00	----	8/11/88
AVS-3265	CPE	JE	----	----	VERO	32.00	----	8/11/88
AVS-3265	PR	PIC	N/A	----	VERO	32.00	----	11/18/88
AVS-3265	CPE	PT	----	----	VERO	10.00	----	8/11/88
AVS-3265	CPE	SF	0.65	19.90	VERO	32.00	1.60	8/11/88
AVS-3265	CPE	VEE	----	----	VERO	32.00	----	8/11/88
AVS-3265	CPE	YFV	----	----	VERO	32.00	----	8/11/88
AVS-3269	CPE	JE	----	----	VERO	32.00	----	8/11/88
AVS-3269	PR	PIC	N/A	----	VERO	32.00	----	11/18/88
AVS-3269	CPE	PT	----	----	VERO	32.00	----	8/11/88
AVS-3269	CPE	SF	0.3	32.00	VERO	32.00	1.00	8/11/88
AVS-3269	CPE	VEE	----	----	VERO	10.00	----	8/11/88
AVS-3269	CPE	YFV	----	----	VERO	32.00	----	8/11/88
AVS-3270	CPE	JE	----	----	VERO	32.00	----	8/11/88
AVS-3270	PR	PIC	N/A	----	VERO	32.00	----	11/18/88
AVS-3270	CPE	PT	----	----	VERO	32.00	----	8/11/88
AVS-3270	CPE	SF	0.45	21.70	VERO	32.00	1.47	8/11/88
AVS-3270	CPE	VEE	----	----	VERO	32.00	----	8/11/88
AVS-3270	CPE	YFV	----	----	VERO	10.00	----	8/11/88
AVS-3271	CPE	JE	----	----	VERO	32.00	----	8/11/88
AVS-3271	PR	PIC	N/A	----	VERO	100.00	----	11/18/88
AVS-3271	CPE	PT	0.05	----	VERO	32.00	----	8/11/88
AVS-3271	CPE	SF	0.4	75.10	VERO	100.00	1.33	8/11/88
AVS-3271	CPE	VEE	----	----	VERO	100.00	----	8/11/88
AVS-3271	CPE	YFV	----	----	VERO	32.00	----	8/11/88
AVS-3272	CPE	JE	----	----	VERO	32.00	----	8/11/88

B-165

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3272	PR	PIC	N/A	----	VERO	32.00	----	11/18/88
AVS-3272	CPE	PT	----	----	VERO	10.00	----	8/11/88
AVS-3272	CPE	SF	0.45	68.30	VERO	100.00	1.46	8/11/88
AVS-3272	CPE	VEE	----	----	VERO	10.00	----	8/11/88
AVS-3272	CPE	YFV	----	----	VERO	32.00	----	8/11/88
AVS-3274	CPE	JE	----	----	VERO	10.00	----	8/11/88
AVS-3274	PR	PIC	N/A	30.00	VERO	10.00	0.33	11/18/88
AVS-3274	CPE	PT	----	----	VERO	32.00	----	8/11/88
AVS-3274	CPE	SF	0.25	----	VERO	32.00	----	8/11/88
AVS-3274	CPE	VEE	----	----	VERO	100.00	----	8/11/88
AVS-3274	CPE	YFV	----	----	VERO	10.00	----	8/11/88
AVS-3277	CPE	JE	----	----	VERO	100.00	----	8/11/88
AVS-3277	PR	PIC	N/A	62.80	VERO	32.00	0.51	11/18/88
AVS-3277	CPE	PT	----	----	VERO	100.00	----	8/11/88
AVS-3277	CPE	SF	0.6	94.20	VERO	100.00	1.06	8/11/88
AVS-3277	CPE	VEE	----	----	VERO	100.00	----	8/11/88
AVS-3277	CPE	YFV	----	----	VERO	32.00	----	8/11/88
AVS-3278	CPE	JE	----	----	VERO	32.00	----	8/11/88
AVS-3278	PR	PIC	N/A	11.10	VERO	3.20	0.29	11/18/88
AVS-3278	CPE	PT	----	----	VERO	32.00	----	8/11/88
AVS-3278	CPE	SF	0.45	21.70	VERO	32.00	1.47	8/11/88
AVS-3278	CPE	VEE	----	----	VERO	100.00	----	8/11/88
AVS-3278	CPE	YFV	----	----	VERO	10.00	----	8/11/88
AVS-3279	CPE	JE	----	----	VERO	100.00	----	8/11/88
AVS-3279	PR	PIC	N/A	204.00	VERO	3.20	0.02	11/18/88
AVS-3279	CPE	PT	----	----	VERO	100.00	----	8/11/88
AVS-3279	CPE	SF	0.15	----	VERO	100.00	----	8/11/88
AVS-3279	CPE	VEE	----	----	VERO	100.00	----	8/11/88
AVS-3279	CPE	YFV	----	----	VERO	100.00	----	8/11/88
AVS-3280	CPE	JE	----	----	VERO	10.00	----	8/18/88
AVS-3280	CPE	PT	----	----	VERO	100.00	----	8/18/88
AVS-3280	CPE	SF	0.7	42.90	VERO	32.00	0.75	8/18/88
AVS-3280	CPE	VEE	----	----	VERO	32.00	----	8/18/88
AVS-3284	CPE	JE	----	----	VERO	1.00	----	8/18/88
AVS-3284	CPE	PT	----	----	VERO	1.00	----	8/18/88
AVS-3284	CPE	SF	0.15	----	VERO	3.20	----	8/18/88
AVS-3284	CPE	VEE	----	----	VERO	10.00	----	8/18/88
AVS-3286	CPE	JE	----	----	VERO	10.00	----	8/18/88
AVS-3286	CPE	PT	----	----	VERO	32.00	----	8/18/88
AVS-3286	CPE	SF	0.3	32.00	VERO	32.00	1.00	8/18/88
AVS-3286	CPE	VEE	----	----	VERO	32.00	----	8/18/88
AVS-3288	CPE	JE	----	----	VERO	32.00	----	8/18/88
AVS-3288	CPE	PT	----	----	VERO	32.00	----	8/18/88
AVS-3288	CPE	SF	----	----	VERO	32.00	----	8/18/88
AVS-3288	CPE	VEE	----	----	VERO	32.00	----	8/18/88
AVS-3290	CPE	JE	----	----	VERO	32.00	----	8/18/88
AVS-3290	CPE	PT	----	----	VERO	100.00	----	8/18/88
AVS-3290	CPE	SF	0.6	56.30	VERO	10.00	0.18	8/18/88
AVS-3290	CPE	VEE	----	----	VERO	32.00	----	8/18/88
AVS-3292	CPE	JE	----	----	VERO	3.20	----	8/18/88
AVS-3292	CPE	PT	----	----	VERO	10.00	----	8/18/88
AVS-3292	CPE	SF	0.7	4.20	VERO	3.20	0.76	8/18/88
AVS-3292	CPE	VEE	----	----	VERO	3.20	----	8/18/88
AVS-3293	CPE	JE	----	----	VERO	3.20	----	8/18/88
AVS-3293	CPE	PT	----	----	VERO	10.00	----	8/18/88
AVS-3293	CPE	SF	0.6	17.70	VERO	3.20	0.18	8/18/88
AVS-3293	CPE	VEE	----	----	VERO	10.00	----	8/18/88
AVS-3294	CPE	JE	0.1	----	VERO	10.00	----	8/18/88
AVS-3294	CPE	PT	----	----	VERO	3.20	----	8/18/88
AVS-3294	CPE	SF	0.3	10.00	VERO	10.00	1.00	8/18/88
AVS-3294	CPE	VEE	----	----	VERO	10.00	----	8/18/88
AVS-3295	CPE	JE	----	----	VERO	3.20	----	8/18/88
AVS-3295	CPE	PT	----	----	VERO	3.20	----	8/18/88
AVS-3295	CPE	SF	0.45	6.80	VERO	3.20	0.47	8/18/88
AVS-3295	CPE	VEE	----	----	VERO	3.20	----	8/18/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3296	CPE	JE	----	----	VERO	10.00	----	8/18/88
AVS-3296	CPE	PT	----	----	VERO	32.00	----	8/18/88
AVS-3296	CPE	SF	0.5	22.10	VERO	10.00	0.45	8/18/88
AVS-3296	CPE	VEE	----	----	VERO	32.00	----	8/18/88
AVS-3297	CPE	JE	----	----	VERO	10.00	----	8/18/88
AVS-3297	CPE	PT	----	----	VERO	10.00	----	8/18/88
AVS-3297	CPE	SF	0.15	----	VERO	32.00	----	8/18/88
AVS-3297	CPE	VEE	----	----	VERO	10.00	----	8/18/88
AVS-3299	CPE	JE	----	----	VERO	10.00	----	8/18/88
AVS-3299	CPE	PT	0.3	100.00	VERO	10.00	0.10	8/18/88
AVS-3299	CPE	SF	0.9	31.70	VERO	32.00	1.00	8/18/88
AVS-3299	CPE	VEE	----	----	VERO	32.00	----	8/18/88
AVS-3303	CPE	JE	----	----	VERO	32.00	----	8/25/88
AVS-3303	CPE	SF	0.3	----	VERO	100.00	----	8/25/88
AVS-3303	CPE	YFV	0.2	----	VERO	32.00	----	8/25/88
AVS-3304	CPE	JE	----	----	VERO	3.20	----	8/25/88
AVS-3304	CPE	SF	----	----	VERO	3.20	----	8/25/88
AVS-3304	CPE	YFV	----	----	VERO	10.00	----	8/25/88
AVS-3305	CPE	SF	0.3	100.00	VERO	100.00	1.00	8/25/88
AVS-3306	CPE	JE	----	----	VERO	32.00	----	8/25/88
AVS-3306	CPE	SF	0.75	155.00	VERO	100.00	0.64	8/25/88
AVS-3306	CPE	YFV	0.2	----	VERO	32.00	----	8/25/88
AVS-3308	CPE	JE	----	----	VERO	10.00	----	8/25/88
AVS-3308	CPE	SF	----	----	VERO	10.00	----	8/25/88
AVS-3308	CPE	YFV	----	----	VERO	10.00	----	8/25/88
AVS-3309	CPE	JE	----	----	VERO	10.00	----	8/25/88
AVS-3309	CPE	SF	----	----	VERO	10.00	----	8/25/88
AVS-3309	CPE	YFV	----	----	VERO	10.00	----	8/25/88
AVS-3310	CPE	JE	----	----	VERO	100.00	----	8/25/88
AVS-3310	CPE	SF	----	----	VERO	100.00	----	8/25/88
AVS-3310	CPE	YFV	----	----	VERO	100.00	----	8/25/88
AVS-3314	CPE	JE	----	----	VERO	10.00	----	8/25/88
AVS-3314	CPE	SF	----	----	VERO	3.20	----	8/25/88
AVS-3314	CPE	YFV	----	----	VERO	10.00	----	8/25/88
AVS-3315	CPE	JE	----	----	VERO	3.20	----	8/25/88
AVS-3315	CPE	SF	0.15	----	VERO	3.20	----	8/25/88
AVS-3315	CPE	YFV	----	----	VERO	3.20	----	8/25/88
AVS-3316	CPE	JE	----	----	VERO	10.00	----	8/25/88
AVS-3316	CPE	SF	0.75	56.30	VERO	100.00	1.77	8/25/88
AVS-3316	CPE	YFV	----	----	VERO	10.00	----	8/25/88
AVS-3317	CPE	JE	----	----	VERO	32.00	----	8/25/88
AVS-3317	CPE	SF	0.15	----	VERO	32.00	----	8/25/88
AVS-3317	CPE	YFV	----	----	VERO	32.00	----	8/25/88
AVS-3348	CPE	AD2	----	----	HEP2	1.00	----	5/ 5/88
AVS-3348	CPE	JE	----	----	VERO <	100.00	----	10/21/87
AVS-3348	CPE	SF	0.05	----	VERO	10.00	----	8/25/88
AVS-3348	CPE	VSV	----	----	L929	1.00	----	3/29/88
AVS-3348	CPE	VV	----	----	VERO <	32.00	----	5/ 5/88
AVS-3348	CPE	YFV	----	----	VERO	10.00	----	8/25/88
AVS-3349	CPE	JE	----	----	VERO >	320.00	----	10/21/87
AVS-3349	CPE	SF	----	----	VERO	3.20	----	8/25/88
AVS-3349	CPE	VSV	----	----	L929	1.00	----	3/29/88
AVS-3349	CPE	VV	----	----	VERO <	32.00	----	5/ 5/88
AVS-3349	CPE	YFV	----	----	VERO	3.20	----	8/25/88
AVS-3350	CPE	JE	----	----	VERO >	320.00	----	10/21/87
AVS-3350	CPE	SF	----	----	VERO	32.00	----	8/25/88
AVS-3350	CPE	VSV	----	----	L929	3.20	----	3/29/88
AVS-3350	CPE	VV	----	----	VERO <	32.00	----	5/ 5/88
AVS-3350	CPE	YFV	----	----	VERO	32.00	----	8/25/88
AVS-3351	CPE	AD2	----	----	HEP2	3.20	----	5/ 5/88
AVS-3351	CPE	JE	----	----	VERO >	320.00	----	10/21/87
AVS-3351	CPE	SF	0.05	----	VERO	32.00	----	8/25/88
AVS-3351	CPE	VSV	----	----	L929	32.00	----	3/29/88
AVS-3351	CPE	VV	0.1	----	VERO	100.00	----	5/ 5/88
AVS-3351	CPE	YFV	----	----	VERO	100.00	----	8/25/88

S-167

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3352	CPE	AD2	----	----	HEP2 <	3.20	----	5/ 5/88
AVS-3352	CPE	JE	----	----	VERO	10.00	----	10/21/87
AVS-3352	CPE	PT	0.45	68.30	VERO	32.00	0.47	9/ 1/88
AVS-3352	CPE	SF	0.45	68.30	VERO	32.00	0.47	9/ 1/88
AVS-3352	CPE	VEE	----	----	VERO	32.00	----	9/ 1/88
AVS-3352	CPE	VSV	----	----	L929	3.20	----	3/29/88
AVS-3352	CPE	VV	0.1	----	VERO	32.00	----	5/ 5/88
AVS-3353	CPE	AD2	0.15	----	HEP2	1.00	----	11/ 5/87
AVS-3353	CPE	JE	----	----	VERO	10.00	----	10/21/87
AVS-3353	CPE	PT	----	----	VERO	100.00	----	9/ 1/88
AVS-3353	CPE	SF	----	----	VERO	100.00	----	9/ 1/88
AVS-3353	CPE	VEE	0.1	----	VERO	32.00	----	9/ 1/88
AVS-3353	CPE	VSV	----	----	L929	1.00	----	12/ 1/87
AVS-3353	CPE	VV	----	----	VERO <	32.00	----	10/22/87
AVS-3354	CPE	AD2	----	----	HEP2 <	10.00	----	10/22/87
AVS-3354	CPE	JE	----	----	VERO <	32.00	----	10/21/87
AVS-3354	CPE	PT	----	----	VERO	100.00	----	9/ 1/88
AVS-3354	CPE	SF	----	----	VERO	32.00	----	9/ 1/88
AVS-3354	CPE	VEE	----	----	VERO	100.00	----	9/ 1/88
AVS-3354	CPE	VSV	----	----	L929	1.00	----	12/ 1/87
AVS-3354	CPE	VV	----	----	VERO <	32.00	----	10/22/87
AVS-3355	CPE	AD2	----	----	HEP2 <	3.20	----	10/22/87
AVS-3355	CPE	JE	----	----	VERO	10.00	----	10/22/87
AVS-3355	CPE	PT	----	----	VERO	10.00	----	9/ 1/88
AVS-3355	CPE	SF	----	----	VERO	10.00	----	9/ 1/88
AVS-3355	CPE	VEE	0.45	81.80	VERO	10.00	0.12	9/ 1/88
AVS-3355	CPE	VSV	----	----	L929	1.00	----	3/29/88
AVS-3355	CPE	VV	----	----	VERO <	32.00	----	10/22/87
AVS-3356	CPE	AD2	----	----	HEP2 <	32.00	----	10/22/87
AVS-3356	CPE	JE	----	----	VERO	10.00	----	10/22/87
AVS-3356	CPE	PT	----	----	VERO <	100.00	----	9/ 1/88
AVS-3356	CPE	SF	----	----	VERO <	100.00	----	9/ 1/88
AVS-3356	CPE	VEE	----	----	VERO	32.00	----	9/ 1/88
AVS-3356	CPE	VSV	----	----	L929	3.20	----	12/ 1/87
AVS-3356	CPE	VV	----	----	VERO <	32.00	----	10/22/87
AVS-3357	CPE	AD2	----	----	HEP2 <	10.00	----	5/ 5/88
AVS-3357	CPE	JE	----	----	VERO	32.00	----	10/22/87
AVS-3357	CPE	PT	----	----	VERO	32.00	----	9/ 1/88
AVS-3357	CPE	SF	----	----	VERO	10.00	----	9/ 1/88
AVS-3357	CPE	VEE	----	----	VERO	3.20	----	9/ 1/88
AVS-3357	CPE	VSV	----	----	L929	32.00	----	3/29/88
AVS-3357	CPE	VV	----	----	VERO <	32.00	----	5/ 5/88
AVS-3358	CPE	AD2	0.2	----	HEP2 <	10.00	----	5/26/88
AVS-3358	CPE	JE	----	----	VERO <	100.00	----	10/22/87
AVS-3358	CPE	PT	----	----	VERO	320.00	----	9/ 1/88
AVS-3358	CPE	SF	----	----	VERO	100.00	----	9/ 1/88
AVS-3358	CPE	VEE	----	----	VERO	320.00	----	9/ 1/88
AVS-3358	CPE	VSV	----	----	L929 <	320.00	----	3/29/88
AVS-3358	CPE	VV	0.15	----	VERO	32.00	----	5/26/88
AVS-3359	CPE	AD2	----	----	HEP2 <	10.00	----	10/22/87
AVS-3359	CPE	JE	----	----	VERO >	320.00	----	10/22/87
AVS-3359	CPE	PT	0.05	----	VERO	100.00	----	9/ 1/88
AVS-3359	CPE	SF	0.25	----	VERO	100.00	----	9/ 1/88
AVS-3359	CPE	VEE	----	----	VERO	32.00	----	9/ 1/88
AVS-3359	CPE	VSV	----	----	L929	3.20	----	12/ 1/87
AVS-3359	CPE	VV	----	----	VERO	32.00	----	10/22/87
AVS-3360	CPE	AD2	0.3	----	HEP2 <	10.00	----	6/ 2/88
AVS-3360	CPE	JE	----	----	VERO <	32.00	----	10/22/87
AVS-3360	CPE	PT	----	----	VERO	100.00	----	9/ 1/88
AVS-3360	CPE	SF	----	----	VERO	100.00	----	9/ 1/88
AVS-3360	CPE	VEE	----	----	VERO	100.00	----	9/ 1/88
AVS-3360	CPE	VSV	0.05	----	L929	32.00	----	3/29/88
AVS-3360	CPE	VV	----	----	VERO	10.00	----	5/26/88
AVS-3361	CPE	AD2	----	----	HEP2	10.00	----	10/22/87
AVS-3361	CPE	JE	----	----	VERO <	100.00	----	10/22/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	T-RUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3361	CPE	PT	----	----	VERO	32.00	----	9/ 1/88
AVS-3361	CPE	SF	0.2	----	VERO	32.00	----	9/ 1/88
AVS-3361	CPE	VEE	----	----	VERO	32.00	----	9/ 1/88
AVS-3361	CPE	VSV	----	----	L929	10.00	----	12/ 1/87
AVS-3361	CPE	VV	----	----	VERO	32.00	----	10/22/87
AVS-3362	CPE	AD2	0.3	320.00	HEP2	320.00	1.00	11/12/87
AVS-3362	CPE	AD2	0.15	----	HEP2	320.00	----	12/10/87
AVS-3362	CPE	JE	----	----	VERO	10.00	----	10/23/87
AVS-3362	CPE	PT	----	----	VERO	100.00	----	9/ 1/88
AVS-3362	CPE	SF	----	----	VERO	10.00	----	9/ 1/88
AVS-3362	CPE	VEE	----	----	VERO	10.00	----	9/ 1/88
AVS-3362	CPE	VSV	----	----	L929	3.20	----	12/ 1/87
AVS-3362	CPE	VV	----	----	VERO	320.00	----	11/12/87
AVS-3362	CPE	VV	----	----	VERO	320.00	----	12/10/87
AVS-3363	CPE	AD2	----	----	HEP2	10.00	----	12/10/87
AVS-3363	CPE	JE	----	----	VERO	32.00	----	10/23/87
AVS-3363	CPE	PT	----	----	VERO	10.00	----	9/ 1/88
AVS-3363	CPE	SF	----	----	VERO	3.20	----	9/ 1/88
AVS-3363	CPE	VEE	----	----	VERO	32.00	----	9/ 1/88
AVS-3363	CPE	VSV	----	----	L929	3.20	----	12/ 1/87
AVS-3363	CPE	VV	0.15	----	VERO	32.00	----	12/10/87
AVS-3364	CPE	AD2	----	----	HEP2	1.00	----	12/10/87
AVS-3364	CPE	JE	----	----	VERO	10.00	----	10/23/87
AVS-3364	CPE	PT	----	----	VERO	10.00	----	9/ 1/88
AVS-3364	CPE	SF	0.25	----	VERO	10.00	----	9/ 1/88
AVS-3364	CPE	VEE	----	----	VERO	10.00	----	9/ 1/88
AVS-3364	CPE	VSV	----	----	L929	3.20	----	12/ 1/87
AVS-3364	CPE	VV	0.1	----	VERO	32.00	----	12/10/87
AVS-3365	CPE	AD2	0.05	----	HEP2	10.00	----	12/10/87
AVS-3365	CPE	JE	----	----	VERO	10.00	----	10/23/87
AVS-3365	CPE	SF	0.2	----	VERO	32.00	----	9/ 8/88
AVS-3365	CPE	VEE	----	----	VERO	32.00	----	9/ 8/88
AVS-3365	CPE	VSV	----	----	L929	10.00	----	12/ 4/87
AVS-3365	CPE	VV	----	----	VERO	32.00	----	12/10/87
AVS-3366	CPE	AD2	0.1	----	HEP2	10.00	----	12/10/87
AVS-3366	CPE	JE	----	----	VERO	32.00	----	10/23/87
AVS-3366	CPE	SF	----	----	VERO	10.00	----	9/ 8/88
AVS-3366	CPE	VEE	----	----	VERO	32.00	----	9/ 8/88
AVS-3366	CPE	VSV	----	----	L929	10.00	----	12/ 4/87
AVS-3366	CPE	VV	0.1	----	VERO	32.00	----	12/10/87
AVS-3367	CPE	AD2	----	----	HEP2	1.00	----	6/16/88
AVS-3367	CPE	SF	----	----	VERO	10.00	----	9/ 8/88
AVS-3367	CPE	VEE	----	----	VERO	10.00	----	9/ 8/88
AVS-3367	CPE	VSV	----	----	L929	0.32	----	4/ 5/88
AVS-3367	CPE	VV	----	----	VERO	10.00	----	5/26/88
AVS-3368	CPE	AD2	0.1	----	HEP2	10.00	----	12/10/87
AVS-3368	CPE	JE	----	----	VERO	100.00	----	10/23/87
AVS-3368	CPE	SF	0.8	13.30	VERO	10.00	0.75	9/ 8/88
AVS-3368	CPE	VEE	----	----	VERO	10.00	----	9/ 8/88
AVS-3368	CPE	VSV	----	----	L929	10.00	----	12/ 4/87
AVS-3368	CPE	VV	0.3	32.00	VERO	32.00	1.00	12/10/87
AVS-3369	CPE	AD2	0.4	----	HEP2	320.00	----	6/16/88
AVS-3369	CPE	JE	0.6	178.00	VERO	320.00	1.78	10/26/87
AVS-3369	CPE	SF	----	----	VERO	100.00	----	9/ 8/88
AVS-3369	CPE	VEE	----	----	VERO	320.00	----	9/ 8/88
AVS-3369	CPE	VSV	----	----	L929	320.00	----	4/ 5/88
AVS-3369	CPE	VV	0.1	----	VERO	32.00	----	5/26/88
AVS-3370	CPE	AD2	0.6	0.32	HEP2	1.00	3.12	6/ 2/88
AVS-3370	CPE	JE	----	----	VERO	32.00	----	10/26/87
AVS-3370	CPE	SF	----	----	VERO	32.00	----	9/ 8/88
AVS-3370	CPE	VEE	----	----	VERO	32.00	----	9/ 8/88
AVS-3370	CPE	VSV	----	----	L929	1.00	----	4/ 5/88
AVS-3370	CPE	VV	0.05	----	VERO	10.00	----	5/26/88
AVS-3371	CPE	AD2	----	----	HEP2	10.00	----	12/10/87
AVS-3371	CPE	JE	----	----	VERO	320.00	----	10/26/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3371	CPE	SF	1.1	7.90	VERO	10.00	1.25	9/ 8/88
AVS-3371	CPE	VEE	----	----	VERO	32.00	----	9/ 8/88
AVS-3371	CPE	VSV	----	----	L929	10.00	----	12/ 4/87
AVS-3371	CPE	VV	----	----	VERO <	100.00	----	12/10/87
AVS-3372	CPE	AD2	0.3	----	HEP2	10.00	----	12/10/87
AVS-3372	CPE	JE	----	----	VERO	100.00	----	10/26/87
AVS-3372	CPE	SF	0.7	10.00	VERO <	32.00 <	3.20	9/ 8/88
AVS-3372	CPE	VEE	----	----	VERO	10.00	----	9/ 8/88
AVS-3372	CPE	VSV	----	----	L929	32.00	----	12/ 4/87
AVS-3372	CPE	VV	0.1	----	VERO <	100.00	----	12/10/87
AVS-3373	CPE	AD2	0.5	----	HEP2 >	320.00	----	12/10/87
AVS-3373	CPE	JE	----	----	VERO >	320.00	----	10/26/87
AVS-3373	CPE	SF	0.6	178.00	VERO	32.00	0.18	9/ 8/88
AVS-3373	CPE	VEE	----	----	VERO	32.00	----	9/ 8/88
AVS-3373	CPE	VSV	----	----	L929	320.00	----	12/ 4/87
AVS-3373	CPE	VV	----	----	VERO >	320.00	----	12/10/87
AVS-3374	CPE	AD2	----	----	HEP2	100.00	----	12/10/87
AVS-3374	CPE	JE	----	----	VERO <	100.00	----	10/26/87
AVS-3374	CPE	SF	0.05	----	VERO	32.00	----	9/ 8/88
AVS-3374	CPE	VEE	----	----	VERO	10.00	----	9/ 8/88
AVS-3374	CPE	VSV	----	----	L929	100.00	----	12/ 4/87
AVS-3374	CPE	VV	----	----	VERO	100.00	----	12/10/87
AVS-3375	CPE	AD2	0.1	----	HEP2	1.00	----	5/26/88
AVS-3375	CPE	JE	----	----	VERO	10.00	----	10/26/87
AVS-3375	CPE	SF	----	----	VERO	10.00	----	9/ 8/88
AVS-3375	CPE	VEE	----	----	VERO	10.00	----	9/ 8/88
AVS-3375	CPE	VSV	----	----	L929	3.20	----	3/29/88
AVS-3375	CPE	VV	----	----	VERO <	32.00	----	5/26/88
AVS-3376	CPE	SF	----	----	VERO	32.00	----	9/ 8/88
AVS-3376	CPE	VEE	----	----	VERO	10.00	----	9/ 8/88
AVS-3377	CPE	SF	0.25	----	VERO	10.00	----	9/ 8/88
AVS-3377	CPE	VEE	----	----	VERO	32.00	----	9/ 8/88
AVS-3379	CPE	SF	1.05	24.60	VERO	10.00	0.41	9/ 8/88
AVS-3379	CPE	VEE	----	----	VERO	10.00	----	9/ 8/88
AVS-3380	CPE	SF	----	----	VERO	10.00	----	9/ 8/88
AVS-3380	CPE	VEE	----	----	VERO	10.00	----	9/ 8/88
AVS-3381	CPE	PT	0.30	320.00	VERO	10.00	0.03	9/15/88
AVS-3381	CPE	VEE	----	----	VERO	10.00	----	9/15/88
AVS-3382	CPE	PT	----	----	VERO	32.00	----	9/15/88
AVS-3382	CPE	VEE	----	----	VERO	10.00	----	9/15/88
AVS-3383	CPE	PT	0.15	----	VERO	100.00	----	9/15/88
AVS-3383	CPE	VEE	----	----	VERO	100.00	----	9/15/88
AVS-3384	CPE	PT	0.30	32.00	VERO	32.00	1.00	9/15/88
AVS-3384	CPE	VEE	----	----	VERO	10.00	----	9/15/88
AVS-3385	CPE	PT	----	----	VERO	32.00	----	9/15/88
AVS-3385	CPE	VEE	----	----	VERO	32.00	----	9/15/88
AVS-3386	CPE	PT	0.45	68.30	VERO	10.00	0.15	9/15/88
AVS-3386	CPE	VEE	----	----	VERO	10.00	----	9/15/88
AVS-3387	CPE	PT	0.80	23.70	VERO	10.00	0.42	9/15/88
AVS-3387	CPE	VEE	----	----	VERO	100.00	----	9/15/88
AVS-3393	CPE	PT	0.60	178.00	VERO	100.00	0.56	9/15/88
AVS-3393	CPE	VEE	----	----	VERO	100.00	----	9/15/88
AVS-3399	CPE	PT	0.20	----	VERO	32.00	----	9/15/88
AVS-3399	CPE	VEE	0.7	159.00	VERO	32.00	0.20	9/15/88
AVS-3400	CPE	PT	----	----	VERO	32.00	----	9/15/88
AVS-3400	CPE	VEE	----	----	VERO	100.00	----	9/15/88
AVS-3403	CPE	PT	0.45	217.00	VERO	100.00	0.46	9/15/88
AVS-3403	CPE	VEE	0.1	----	VERO	100.00	----	9/15/88
AVS-3412	CPE	PT	----	----	VERO	1.00	----	9/15/88
AVS-3412	CPE	VEE	----	----	VERO	3.20	----	9/15/88
AVS-3421	CPE	JE	----	----	VERO	320.00	----	12/ 4/87
AVS-3421	CPE	PT	----	----	VERO	320.00	----	10/13/88
AVS-3421	CPE	SF	----	----	VERO	100.00	----	10/13/88
AVS-3421	CPE	VEE	----	----	VERO	32.00	----	10/13/88
AVS-3422	CPE	JE	----	----	VERO <	0.32	----	10/13/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3422	CPE	PT	0.45	2.17	VERO	3.20	1.47	10/13/88
AVS-3422	CPE	SF	----	----	VERO	1.00	----	10/13/88
AVS-3422	CPE	VEE	----	----	VERO	1.00	----	10/13/88
AVS-3423	CPE	JE	0.1	----	VERO	3.20	----	10/13/88
AVS-3423	CPE	PT	----	----	VERO	100.00	----	10/13/88
AVS-3423	CPE	SF	----	----	VERO	100.00	----	10/13/88
AVS-3423	CPE	VEE	----	----	VERO	32.00	----	10/13/88
AVS-3424	CPE	JE	----	----	VERO	32.00	----	10/13/88
AVS-3424	CPE	PT	----	----	VERO	100.00	----	10/13/88
AVS-3424	CPE	SF	----	----	VERO	100.00	----	10/13/88
AVS-3424	CPE	VEE	----	----	VERO	100.00	----	10/13/88
AVS-3450	CPE	AD2	0.4	23.90	HEP2	32.00	1.33	3/ 3/88
AVS-3450	CPE	JE	----	----	VERO	320.00	----	12/ 8/87
AVS-3450	CPE	VSV	----	----	L929 <	32.00	----	2/23/88
AVS-3450	CPE	VV	0.1	----	VERO <	32.00	----	3/ 3/88
AVS-3462	CPE	AD2	0.15	----	HEP2	320.00	----	2/18/88
AVS-3462	CPE	JE	----	----	VERO	320.00	----	3/10/88
AVS-3462	CPE	VSV	----	----	L929	320.00	----	2/16/88
AVS-3462	CPE	VV	----	----	VERO	320.00	----	2/18/88
AVS-3482	CPE	AD2	0.35	27.00	HEP2	32.00	1.18	2/18/88
AVS-3482	CPE	VSV	----	----	L929	10.00	----	2/16/88
AVS-3482	CPE	VV	0.6	56.30	VERO	32.00	0.57	2/18/88
AVS-3485	CPE	JE	----	----	VERO	0.32	----	3/10/88
AVS-3486	CPE	JE	----	----	VERO	0.32	----	3/10/88
AVS-3487	CPE	JE	----	----	VERO	1.00	----	3/11/88
AVS-3488	CPE	JE	----	----	VERO	10.00	----	3/11/88
AVS-3489	CPE	JE	----	----	VERO	32.00	----	3/11/88
AVS-3490	CPE	JE	----	----	VERO	10.00	----	3/11/88
AVS-3491	CPE	JE	----	----	VERO	3.20	----	3/11/88
AVS-3513	CPE	AD2	0.25	----	HEP2	320.00	----	2/18/88
AVS-3513	CPE	VSV	----	----	L929	100.00	----	2/16/88
AVS-3513	CPE	VV	2.5	18.10	VERO	100.00	5.52	2/18/88
AVS-3513	CPE	VV	2.9	17.60	VERO	320.00	18.10	3/ 3/88
AVS-3513	PR	VV	N/A	4.69	VERO >	320.00 >	68.10	9/23/88
AVS-3520	CPE	AD2	0.15	----	HEP2	10.00	----	12/17/87
AVS-3520	CPE	JE	----	----	VERO	1.00	----	11/19/87
AVS-3520	CPE	PT	0.30	24.00	VERO	7.50	0.31	9/15/88
AVS-3520	CPE	VEE	0.05	----	VERO	10.00	----	9/15/88
AVS-3520	CPE	VSV	----	----	L929	10.00	----	12/ 4/87
AVS-3520	CPE	VV	0.45	20.30	VERO	32.00	1.57	12/17/87
AVS-3521	CPE	AD2	0.2	----	HEP2 <	320.00	----	10/29/87
AVS-3521	CPE	JE	0.1	----	VERO	100.00	----	11/19/87
AVS-3521	CPE	PT	0.90	21.70	VERO	10.00	0.46	9/15/88
AVS-3521	CPE	VEE	----	----	VERO	100.00	----	9/15/88
AVS-3521	CPE	VSV	----	----	L929 >	320.00	----	12/18/87
AVS-3521	CPE	VV	0.25	----	VERO	100.00	----	10/29/87
AVS-3522	CPE	AD2	0.1	----	HEP2	320.00	----	10/29/87
AVS-3522	CPE	JE	0.05	----	VERO	320.00	----	11/19/87
AVS-3522	CPE	PT	----	----	VERO	240.00	----	9/15/88
AVS-3522	CPE	VEE	----	----	VERO	320.00	----	9/15/88
AVS-3522	CPE	VSV	----	----	L929 >	320.00	----	12/18/87
AVS-3522	CPE	VV	----	----	VERO >	320.00	----	10/29/87
AVS-3523	CPE	AD2	0.7	270.00	HEP2 >	320.00 >	1.18	10/29/87
AVS-3523	CPE	JE	----	----	VERO >	320.00	----	11/19/87
AVS-3523	CPE	PT	----	----	VERO	75.00	----	9/22/88
AVS-3523	CPE	SF	----	----	VERO	240.00	----	9/22/88
AVS-3523	CPE	VEE	----	----	VERO	240.00	----	9/22/88
AVS-3523	CPE	VSV	----	----	L929	320.00	----	12/18/87
AVS-3523	CPE	VV	0.15	----	VERO	320.00	----	10/29/87
AVS-3523	CPE	YFV	0.80	202.00	VERO	75.00	0.37	9/22/88
AVS-3524	CPE	AD2	0.2	----	HEP2 >	320.00	----	10/29/87
AVS-3524	CPE	JE	0.8	----	VERO >	320.00	----	11/19/87
AVS-3524	CPE	PT	----	----	VERO	75.00	----	9/22/88
AVS-3524	CPE	SF	----	----	VERO	240.00	----	9/22/88
AVS-3524	CPE	VEE	----	----	VERO	75.00	----	9/22/88

B-171

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3524	CPE	VSV	----	----	L929	320.00	----	12/18/87
AVS-3524	CPE	VV	0.6	----	VERO >	320.00	----	10/29/87
AVS-3524	CPE	YFV	1.23	237.00	VERO	24.00	0.10	9/22/88
AVS-3525	CPE	AD2	----	----	HEP2 >	320.00	----	10/29/87
AVS-3525	CPE	JE	0.9	100.00	VERO	100.00	1.00	11/19/87
AVS-3525	CPE	PT	----	----	VERO	240.00	----	9/22/88
AVS-3525	CPE	SF	----	----	VERO	240.00	----	9/22/88
AVS-3525	CPE	VEE	----	----	VERO	75.00	----	9/22/88
AVS-3525	CPE	VSV	----	----	L929 >	320.00	----	12/18/87
AVS-3525	CPE	VV	----	----	VERO >	320.00	----	10/29/87
AVS-3525	CPE	YFV	0.73	----	VERO	75.00	----	9/22/88
AVS-3526	CPE	AD2	0.3	----	HEP2 >	320.00	----	12/17/87
AVS-3526	CPE	JE	----	----	VERO	32.00	----	11/19/87
AVS-3526	CPE	PT	----	----	VERO	10.00	----	9/22/88
AVS-3526	CPE	SF	----	----	VERO	32.00	----	9/22/88
AVS-3526	CPE	VEE	----	----	VERO	10.00	----	9/22/88
AVS-3526	CPE	VSV	----	----	L929	32.00	----	12/18/87
AVS-3526	CPE	VV	----	----	VERO >	320.00	----	12/17/87
AVS-3526	CPE	YFV	0.25	----	VERO	100.00	----	9/22/88
AVS-3527	CPE	AD2	1.	2.35	HEP2 <	10.00 <	4.25	12/17/87
AVS-3527	CPE	AD2	0.4	----	HEP2 <	100.00	----	5/12/88
AVS-3527	CPE	JE	----	----	VERO <	100.00	----	10/28/87
AVS-3527	CPE	PT	----	----	VERO >	100.00	----	9/22/88
AVS-3527	CPE	SF	----	----	VERO	100.00	----	9/22/88
AVS-3527	CPE	VEE	----	----	VERO >	100.00	----	9/22/88
AVS-3527	CPE	VSV	----	----	L929	32.00	----	12/18/87
AVS-3527	CPE	VV	0.25	----	VERO	100.00	----	12/17/87
AVS-3527	CPE	YFV	0.35	----	VERO	100.00	----	9/22/88
AVS-3528	CPE	AD2	0.4	----	HEP2 <	320.00	----	10/29/87
AVS-3528	CPE	JE	----	----	VERO <	320.00	----	10/28/87
AVS-3528	CPE	PT	----	----	VERO	24.00	----	9/22/88
AVS-3528	CPE	SF	----	----	VERO	75.00	----	9/22/88
AVS-3528	CPE	VEE	----	----	VERO	75.00	----	9/22/88
AVS-3528	CPE	VSV	----	----	L929	32.00	----	12/18/87
AVS-3528	CPE	VV	0.75	178.00	VERO	320.00	1.79	10/29/87
AVS-3529	CPE	AD2	1.35	1.59	HEP2	3.20	2.00	1/28/88
AVS-3529	CPE	AD2	1.6	1.80	HEP2	10.00	5.54	2/18/88
AVS-3529	CPE	JE	----	----	VERO	1.00	----	9/22/88
AVS-3529	CPE	PT	----	----	VERO	1.00	----	9/22/88
AVS-3529	CPE	SF	1.40	2.36	VERO	1.00	0.42	9/22/88
AVS-3529	CPE	VEE	0.25	----	VERO	3.20	----	9/22/88
AVS-3529	CPE	VSV	----	----	L929	1.00	----	12/18/87
AVS-3529	CPE	VV	0.55	69.80	VERO	100.00	1.43	1/28/88
AVS-3530	CPE	AD2	----	----	HEP2 >	320.00	----	12/10/87
AVS-3530	CPE	JE	----	----	VERO >	320.00	----	10/28/87
AVS-3530	CPE	PT	----	----	VERO	100.00	----	9/22/88
AVS-3530	CPE	SF	----	----	VERO	10.00	----	9/22/88
AVS-3530	CPE	VEE	----	----	VERO	32.00	----	9/22/88
AVS-3530	CPE	VSV	----	----	L929	320.00	----	12/18/87
AVS-3530	CPE	VV	0.3	----	VERO >	320.00	----	12/10/87
AVS-3531	CPE	AD2	----	----	HEP2	320.00	----	12/10/87
AVS-3531	CPE	JE	----	----	VERO >	320.00	----	10/28/87
AVS-3531	CPE	PT	0.05	----	VERO	24.00	----	9/22/88
AVS-3531	CPE	SF	0.05	----	VERO	7.50	----	9/22/88
AVS-3531	CPE	VEE	----	----	VERO	24.00	----	9/22/88
AVS-3531	CPE	VSV	----	----	L929	100.00	----	12/18/87
AVS-3531	CPE	VV	0.55	69.80	VERO	100.00	1.43	12/10/87
AVS-3531	CPE	YFV	----	----	VERO	24.00	----	9/22/88
AVS-3532	CPE	AD2	----	----	HEP2	320.00	----	10/29/87
AVS-3532	CPE	JE	----	----	VERO <	320.00	----	10/28/87
AVS-3532	CPE	PT	----	----	VERO	32.00	----	9/22/88
AVS-3532	CPE	SF	----	----	VERO	32.00	----	9/22/88
AVS-3532	CPE	VEE	----	----	VERO	32.00	----	9/22/88
AVS-3532	CPE	VSV	----	----	L929	32.00	----	12/18/87
AVS-3532	CPE	VV	----	----	VERO <	320.00	----	10/29/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3532	CPE	YFV	0.08	----	VERO	10.00	----	9/22/88
AVS-3533	CPE	AD2	0.15	----	HEP2	320.00	----	10/29/87
AVS-3533	CPE	JE	----	----	VERO >	320.00	----	10/28/87
AVS-3533	CPE	PT	----	----	VERO	240.00	----	9/22/88
AVS-3533	CPE	SF	----	----	VERO >	240.00	----	9/22/88
AVS-3533	CPE	VEE	----	----	VERO	240.00	----	9/22/88
AVS-3533	CPE	VSV	----	----	L929 >	320.00	----	12/18/87
AVS-3533	CPE	VV	7.1	0.49	VERO >	320.00 >	653.00	10/29/87
AVS-3533	CPE	VV	7.1	0.31	VERO >	320.00 >	1020.00	11/12/87
AVS-3533	PR	VV	N/A	0.15	VERO	320.00	2000.00	4/ 8/88
AVS-3533	CPE	YFV	----	----	VERO >	240.00	----	9/22/88
AVS-3534	CPE	AD2	0.3	----	HEP2 >	320.00	----	10/29/87
AVS-3534	CPE	JE	0.2	----	VERO >	320.00	----	10/29/87
AVS-3534	CPE	PT	----	----	VERO	240.00	----	9/22/88
AVS-3534	CPE	SF	----	----	VERO	240.00	----	9/22/88
AVS-3534	CPE	VEE	----	----	VERO	240.00	----	9/22/88
AVS-3534	CPE	VSV	----	----	L929 >	320.00	----	12/18/87
AVS-3534	CPE	VV	6.8	0.73	VERO >	320.00 >	433.00	10/29/87
AVS-3534	CPE	VV	7.	0.47	VERO >	320.00 >	671.00	11/12/87
AVS-3534	CPE	YFV	0.40	----	VERO	240.00	----	9/22/88
AVS-3535	CPE	AD2	0.15	----	HEP2	320.00	----	10/29/87
AVS-3535	CPE	JE	0.2	----	VERO >	320.00	----	10/29/87
AVS-3535	CPE	PT	----	----	VERO	75.00	----	9/22/88
AVS-3535	CPE	SF	----	----	VERO	240.00	----	9/22/88
AVS-3535	CPE	VEE	----	----	VERO	240.00	----	9/22/88
AVS-3535	CPE	VSV	----	----	L929	320.00	----	12/18/87
AVS-3535	CPE	VV	2.3	55.10	VERO >	320.00 >	5.80	10/29/87
AVS-3535	CPE	VV	2.5	49.00	VERO >	320.00 >	6.52	11/12/87
AVS-3535	CPE	YFV	----	----	VERO	240.00	----	9/22/88
AVS-3536	CPE	AD2	----	----	HEP2	100.00	----	10/29/87
AVS-3536	CPE	JE	----	----	VERO >	320.00	----	10/29/87
AVS-3536	CPE	PT	----	----	VERO	240.00	----	9/22/88
AVS-3536	CPE	SF	0.15	----	VERO	75.00	----	9/22/88
AVS-3536	CPE	VEE	----	----	VERO	240.00	----	9/22/88
AVS-3536	CPE	VSV	----	----	L929	320.00	----	12/18/87
AVS-3536	CPE	VV	1.2	178.00	VERO >	320.00 >	1.79	10/29/87
AVS-3536	CPE	YFV	0.30	----	VERO	240.00	----	9/22/88
AVS-3537	CPE	AD2	----	----	HEP2 <	32.00	----	10/29/87
AVS-3537	CPE	JE	----	----	VERO <	32.00	----	10/29/87
AVS-3537	CPE	PT	----	----	VERO	3.20	----	9/22/88
AVS-3537	CPE	SF	0.15	----	VERO	3.20	----	9/22/88
AVS-3537	CPE	VEE	0.35	7.80	VERO	3.20	0.41	9/22/88
AVS-3537	CPE	VSV	----	----	L929 <	32.00	----	12/18/87
AVS-3537	CPE	VV	----	----	VERO	10.00	----	10/29/87
AVS-3537	CPE	YFV	----	----	VERO	3.20	----	9/22/88
AVS-3538	CPE	AD2	----	----	HEP2	100.00	----	10/29/87
AVS-3538	CPE	JE	0.75	105.00	VERO	100.00	0.95	10/29/87
AVS-3538	CPE	PT	----	----	VERO	10.00	----	9/29/88
AVS-3538	CPE	SF	1.05	38.20	VERO	1.00	0.03	9/29/88
AVS-3538	CPE	VEE	----	----	VERO	10.00	----	9/29/88
AVS-3538	CPE	VSV	0.1	----	L929	320.00	----	1/ 5/88
AVS-3538	CPE	VV	----	----	VERO	100.00	----	10/29/87
AVS-3538	CPE	YFV	----	----	VERO	3.20	----	9/29/88
AVS-3539	CPE	AD2	----	----	HEP2 <	100.00	----	12/10/87
AVS-3539	CPE	JE	----	----	VERO <	32.00	----	10/29/87
AVS-3539	CPE	PT	----	----	VERO	10.00	----	9/29/88
AVS-3539	CPE	SF	0.50	23.90	VERO	10.00	0.42	9/29/88
AVS-3539	CPE	VEE	----	----	VERO	10.00	----	9/29/88
AVS-3539	CPE	VSV	----	----	L929	32.00	----	1/ 5/88
AVS-3539	CPE	VV	0.05	----	VERO	32.00	----	12/10/87
AVS-3539	CPE	YFV	----	----	VERO	10.00	----	9/29/88
AVS-3540	CPE	AD2	0.2	----	HEP2 >	320.00	----	12/10/87
AVS-3540	CPE	JE	0.2	----	VERO >	320.00	----	10/29/87
AVS-3540	CPE	PT	----	----	VERO >	320.00	----	9/29/88
AVS-3540	CPE	SF	0.20	----	VERO	320.00	----	9/29/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3540	CPE	VEE	----	----	VERO	320.00	----	9/29/88
AVS-3540	CPE	VSV	----	----	L929 >	320.00	----	1/ 5/88
AVS-3540	CPE	VV	----	----	VERO >	320.00	----	12/10/87
AVS-3540	CPE	YFV	----	----	VERO	32.00	----	9/29/88
AVS-3541	CPE	AD2	----	----	HEP2	320.00	----	12/10/87
AVS-3541	CPE	JE	----	----	VERO	3.20	----	11/ 2/87
AVS-3541	CPE	PT	----	----	VERO	32.00	----	9/29/88
AVS-3541	CPE	SF	0.50	----	VERO	32.00	----	9/29/88
AVS-3541	CPE	VEE	----	----	VERO	32.00	----	9/29/88
AVS-3541	CPE	VSV	0.05	----	L929	320.00	----	1/ 5/88
AVS-3541	CPE	VV	0.45	306.00	VERO	100.00	0.33	12/10/87
AVS-3541	CPE	YFV	----	----	VERO	32.00	----	9/29/88
AVS-3542	CPE	AD2	----	----	HEP2	10.00	----	12/10/87
AVS-3542	CPE	JE	----	----	VERO	3.20	----	11/ 2/87
AVS-3542	CPE	PT	0.15	----	VERO	3.20	----	9/29/88
AVS-3542	CPE	SF	1.50	5.00	VERO	3.20	0.64	9/29/88
AVS-3542	CPE	VEE	0.95	9.40	VERO	3.20	0.34	9/29/88
AVS-3542	CPE	VSV	0.05	----	L929	10.00	----	1/ 5/88
AVS-3542	CPE	VV	----	----	VERO	32.00	----	12/10/87
AVS-3542	CPE	YFV	----	----	VERO	10.00	----	9/29/88
AVS-3543	CPE	AD2	0.45	0.86	HEP2	1.00	1.15	12/17/87
AVS-3543	CPE	JE	----	----	VERO	0.32	----	11/ 2/87
AVS-3543	CPE	PT	----	----	VERO	0.10	----	9/29/88
AVS-3543	CPE	SF	----	----	VERO	0.10	----	9/29/88
AVS-3543	CPE	VEE	----	----	VERO	0.32	----	9/29/88
AVS-3543	CPE	VSV	----	----	L929	0.32	----	1/ 5/88
AVS-3543	CPE	VV	0.15	----	VERO	1.00	----	12/17/87
AVS-3543	CPE	YFV	----	----	VERO	0.10	----	9/29/88
AVS-3544	CPE	AD2	----	----	HEP2 >	320.00	----	12/10/87
AVS-3544	CPE	JE	----	----	VERO >	320.00	----	11/ 2/87
AVS-3544	CPE	PT	----	----	VERO >	320.00	----	9/29/88
AVS-3544	CPE	SF	0.25	----	VERO	32.00	----	9/29/88
AVS-3544	CPE	VEE	----	----	VERO >	320.00	----	9/29/88
AVS-3544	CPE	VSV	----	----	L929 >	320.00	----	1/ 5/88
AVS-3544	CPE	VV	----	----	VERO >	320.00	----	12/10/87
AVS-3544	CPE	YFV	----	----	VERO >	320.00	----	9/29/88
AVS-3545	CPE	AD2	----	----	HEP2 <	320.00	----	12/17/87
AVS-3545	CPE	JE	----	----	VERO	320.00	----	11/ 2/87
AVS-3545	CPE	PT	----	----	VERO	32.00	----	10/ 6/88
AVS-3545	CPE	SF	----	----	VERO	100.00	----	10/ 6/88
AVS-3545	CPE	VSV	----	----	L929	100.00	----	1/ 5/88
AVS-3545	CPE	VV	0.1	----	VERO	320.00	----	12/17/87
AVS-3546	CPE	AD2	0.35	----	HEP2	10.00	----	12/17/87
AVS-3546	CPE	JE	0.2	----	VERO	32.00	----	11/ 2/87
AVS-3546	CPE	PT	----	----	VERO >	32.00	----	10/ 6/88
AVS-3546	CPE	SF	----	----	VERO >	32.00	----	10/ 6/88
AVS-3546	CPE	VSV	0.1	----	L929	100.00	----	1/ 5/88
AVS-3546	CPE	VV	0.5	75.60	VERO	32.00	0.42	12/17/87
AVS-3547	CPE	AD2	----	----	HEP2	100.00	----	12/17/87
AVS-3547	CPE	JE	0.05	----	VERO	10.00	----	11/ 2/87
AVS-3547	CPE	PT	----	----	VERO	1.00	----	10/ 6/88
AVS-3547	CPE	SF	----	----	VERO	3.20	----	10/ 6/88
AVS-3547	CPE	VSV	0.1	----	L929	32.00	----	1/ 5/88
AVS-3547	CPE	VV	0.4	----	VERO >	100.00	----	12/17/87
AVS-3548	CPE	AD2	0.7	20.20	HEP2	32.00	1.57	12/17/87
AVS-3548	CPE	JE	----	----	VERO <	100.00	----	11/ 3/87
AVS-3548	CPE	PT	0.5	63.30	VERO	100.00	1.57	10/ 6/88
AVS-3548	CPE	SF	0.05	----	VERO	32.00	----	10/ 6/88
AVS-3548	CPE	VSV	0.05	----	L929	10.00	----	1/ 5/88
AVS-3548	CPE	VV	----	----	VERO	32.00	----	12/17/87
AVS-3549	CPE	AD2	1.	----	HEP2 <	32.00	----	12/17/87
AVS-3549	CPE	JE	----	----	VERO	10.00	----	11/ 3/87
AVS-3549	CPE	PT	----	----	VERO	10.00	----	10/ 6/88
AVS-3549	CPE	SF	----	----	VERO	3.20	----	10/ 6/88
AVS-3549	CPE	VSV	----	----	L929 <	32.00	----	1/ 5/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3549	CPE	VV	0.4	22.20	VERO	32.00	1.43	12/17/87
AVS-3550	CPE	AD2	----	----	HEP2 <	320.00	----	12/17/87
AVS-3550	CPE	JE	----	----	VERO	32.00	----	11/ 3/87
AVS-3550	CPE	PT	----	----	VERO	32.00	----	10/ 6/88
AVS-3550	CPE	SF	----	----	VERO	32.00	----	10/ 6/88
AVS-3550	CPE	VSV	----	----	L929	100.00	----	1/ 5/88
AVS-3550	CPE	VV	0.3	320.00	VERO	320.00	1.00	12/17/87
AVS-3551	CPE	AD2	0.05	----	HEP2	320.00	----	12/17/87
AVS-3551	CPE	JE	----	----	VERO <	320.00	----	11/ 3/87
AVS-3551	CPE	PT	0.15	----	VERO	10.00	----	10/ 6/88
AVS-3551	CPE	SF	0.55	204.00	VERO	10.00	0.05	10/ 6/88
AVS-3551	CPE	VSV	----	----	L929	10.00	----	1/19/88
AVS-3551	CPE	VV	----	----	VERO	320.00	----	12/17/87
AVS-3552	CPE	AD2	----	----	HEP2	10.00	----	12/17/87
AVS-3552	CPE	JE	----	----	VERO	10.00	----	11/ 3/87
AVS-3552	CPE	PT	----	----	VERO	10.00	----	10/ 6/88
AVS-3552	CPE	SF	----	----	VERO	10.00	----	10/ 6/88
AVS-3552	CPE	VSV	0.1	----	L929	10.00	----	1/ 5/88
AVS-3552	CPE	VV	0.1	----	VERO	32.00	----	12/17/87
AVS-3553	CPE	AD2	----	----	HEP2 <	100.00	----	12/17/87
AVS-3553	CPE	VSV	----	----	L929 <	100.00	----	1/ 5/88
AVS-3553	CPE	VV	0.1	----	VERO	100.00	----	12/17/87
AVS-3554	CPE	AD2	0.1	----	HEP2 <	320.00	----	9/ 4/87
AVS-3554	CPE	JE	----	----	VERO >	320.00	----	10/ 2/87
AVS-3554	CPE	JE	----	----	VERO	320.00	----	7/21/88
AVS-3554	PR	PIC	N/A	----	VERO	100.00	----	11/ 8/88
AVS-3554	CPE	PT	----	----	VERO	320.00	----	7/28/88
AVS-3554	CPE	SF	----	----	VERO	100.00	----	7/21/88
AVS-3554	CPE	VEE	----	----	VERO	320.00	----	7/28/88
AVS-3554	CPE	VSV	----	----	L929	320.00	----	8/25/87
AVS-3554	CPE	VV	0.3	----	VERO >	320.00	----	9/ 4/87
AVS-3554	CPE	YFV	----	----	VERO	100.00	----	7/28/88
AVS-3555	CPE	AD2	----	----	HEP2	320.00	----	9/ 4/87
AVS-3555	CPE	JE	0.08	----	VERO >	320.00	----	10/ 2/87
AVS-3555	CPE	JE	----	----	VERO	320.00	----	7/28/88
AVS-3555	PR	PIC	N/A	----	VERO	32.00	----	11/ 8/88
AVS-3555	CPE	PT	----	----	VERO >	320.00	----	7/21/88
AVS-3555	CPE	SF	----	----	VERO >	320.00	----	7/21/88
AVS-3555	CPE	VEE	----	----	VERO	320.00	----	7/21/88
AVS-3555	CPE	VSV	----	----	L929	320.00	----	8/25/87
AVS-3555	CPE	VV	----	----	VERO	320.00	----	9/ 4/87
AVS-3555	CPE	YFV	----	----	VERO >	320.00	----	7/21/88
AVS-3556	CPE	AD2	0.15	----	HEP2	100.00	----	12/17/87
AVS-3556	CPE	JE	----	----	VERO	100.00	----	11/ 3/87
AVS-3556	CPE	PT	----	----	VERO	32.00	----	10/ 6/88
AVS-3556	CPE	SF	----	----	VERO	32.00	----	10/ 6/88
AVS-3556	CPE	VSV	0.3	320.00	L929	32.00	0.10	1/19/88
AVS-3556	CPE	VV	0.4	99.00	VERO	100.00	1.00	12/17/87
AVS-3557	CPE	AD2	1.2	56.50	HEP2	100.00	1.76	12/17/87
AVS-3557	CPE	JE	0.6	----	VERO	100.00	----	11/ 3/87
AVS-3557	CPE	PT	----	----	VERO	100.00	----	10/ 6/88
AVS-3557	CPE	SF	0.45	68.30	VERO	32.00	0.47	10/ 6/88
AVS-3557	CPE	VSV	----	----	L929	32.00	----	1/ 5/88
AVS-3557	CPE	VV	1.05	56.50	VERO	100.00	1.76	12/17/87
AVS-3558	CPE	AD2	0.6	----	HEP2 <	320.00	----	12/17/87
AVS-3558	CPE	PT	0.45	68.30	VERO	32.00	0.47	10/ 6/88
AVS-3558	CPE	SF	0.45	68.30	VERO	32.00	0.47	10/ 6/88
AVS-3558	CPE	VSV	0.4	----	L929	320.00	----	1/ 5/88
AVS-3558	CPE	VV	0.6	----	VERO <	320.00	----	12/17/87
AVS-3559	CPE	AD2	0.5	----	HEP2 <	100.00	----	12/17/87
AVS-3559	CPE	PT	0.45	217.00	VERO	320.00	1.47	10/ 6/88
AVS-3559	CPE	SF	0.45	217.00	VERO	100.00	0.46	10/ 6/88
AVS-3559	CPE	VSV	----	----	L929	320.00	----	1/ 5/88
AVS-3559	CPE	VV	0.6	178.00	VERO	320.00	1.78	12/17/87
AVS-3560	CPE	AD2	0.7	99.00	HEP2 <	320.00 <	3.20	12/17/87

B-175

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3560	CPE	AD2	0.6	----	HEP2 <	320.00	----	5/12/88
AVS-3560	CPE	PT	----	----	VERO	32.00	----	10/ 6/88
AVS-3560	CPE	SF	0.15	----	VERO	32.00	----	10/ 6/88
AVS-3560	CPE	VSV	0.2	----	L929	100.00	----	1/19/88
AVS-3560	CPE	VV	0.35	270.00	VERO	320.00	1.18	12/17/87
AVS-3561	CPE	AD2	1.	242.00	HEP2 >	320.00 >	1.31	12/17/87
AVS-3561	CPE	PT	----	----	VERO	320.00	----	10/ 6/88
AVS-3561	CPE	SF	----	----	VERO	100.00	----	10/ 6/88
AVS-3561	CPE	VSV	----	----	L929	100.00	----	1/19/88
AVS-3561	CPE	VV	----	----	VERO >	320.00	----	12/17/87
AVS-3562	CPE	AD2	0.6	2.92	HEP2	3.20	1.09	12/17/87
AVS-3562	CPE	PT	0.1	----	VERO >	10.00	----	10/ 6/88
AVS-3562	CPE	SF	----	----	VERO	10.00	----	10/ 6/88
AVS-3562	CPE	VSV	----	----	L929	3.20	----	1/19/88
AVS-3562	CPE	VV	----	----	VERO <	10.00	----	12/17/87
AVS-3563	CPE	AD2	0.2	----	HEP2 >	320.00	----	12/17/87
AVS-3563	CPE	JE	----	----	VERO	320.00	----	10/13/88
AVS-3563	CPE	PT	----	----	VERO >	320.00	----	10/13/88
AVS-3563	CPE	SF	----	----	VERO	320.00	----	10/13/88
AVS-3563	CPE	VEE	----	----	VERO >	320.00	----	10/13/88
AVS-3563	CPE	VSV	----	----	L929	320.00	----	1/19/88
AVS-3563	CPE	VV	----	----	VERO >	320.00	----	12/17/87
AVS-3564	CPE	AD2	----	----	HEP2 <	100.00	----	4/14/88
AVS-3564	CPE	JE	----	----	VERO <	0.32	----	12/ 8/87
AVS-3564	CPE	VSV	----	----	L929	0.32	----	1/29/88
AVS-3564	CPE	VV	0.05	----	VERO	32.00	----	2/11/88
AVS-3565	CPE	AD2	0.45	----	HEP2	10.00	----	2/11/88
AVS-3565	CPE	JE	0.05	----	VERO	0.32	----	12/ 8/87
AVS-3565	CPE	VSV	1.	13.30	L929	32.00	2.39	1/29/88
AVS-3565	CPE	VSV	----	----	L929 <	32.00	----	3/11/88
AVS-3565	CPE	VV	----	----	VERO	32.00	----	2/11/88
AVS-3566	CPE	AD2	----	----	HEP2 <	0.10	----	3/17/88
AVS-3566	CPE	JE	----	----	VERO <	0.32	----	12/ 8/87
AVS-3566	CPE	VSV	----	----	L929	0.32	----	1/29/88
AVS-3566	CPE	VV	0.15	----	VERO	10.00	----	2/11/88
AVS-3567	CPE	AD2	----	----	HEP2 <	10.00	----	2/11/88
AVS-3567	CPE	JE	0.15	----	VERO	10.00	----	12/ 8/87
AVS-3567	CPE	VSV	----	----	L929	10.00	----	1/29/88
AVS-3567	CPE	VV	0.7	22.20	VERO	32.00	1.43	2/11/88
AVS-3568	CPE	AD2	----	----	HEP2 <	0.03	----	3/17/88
AVS-3568	CPE	JE	----	----	VERO <	0.32	----	12/ 8/87
AVS-3568	CPE	VSV	----	----	L929	0.32	----	1/29/88
AVS-3568	CPE	VV	0.45	20.30	VERO	1.00	0.05	2/11/88
AVS-3569	CPE	AD2	----	----	HEP2 <	32.00	----	2/11/88
AVS-3569	CPE	JE	----	----	VERO	3.20	----	12/ 8/87
AVS-3569	CPE	VSV	----	----	L929	32.00	----	1/29/88
AVS-3569	CPE	VV	0.95	74.00	VERO	10.00	0.14	2/11/88
AVS-3570	CPE	AD2	0.8	277.00	HEP2 >	320.00 >	1.15	2/11/88
AVS-3570	CPE	JE	----	----	VERO >	320.00	----	12/14/87
AVS-3570	CPE	VSV	----	----	L929 >	320.00	----	1/29/88
AVS-3570	CPE	VV	----	----	VERO	320.00	----	2/11/88
AVS-3571	CPE	AD2	----	----	HEP2 >	100.00	----	2/11/88
AVS-3571	CPE	JE	----	----	VERO	32.00	----	12/14/87
AVS-3571	CPE	VSV	----	----	L929	320.00	----	1/29/88
AVS-3571	CPE	VV	1.6	17.80	VERO	100.00	5.59	2/11/88
AVS-3572	CPE	AD2	----	----	HEP2	32.00	----	1/28/88
AVS-3572	CPE	JE	----	----	VERO <	100.00	----	12/14/87
AVS-3572	CPE	VSV	----	----	L929	32.00	----	1/22/88
AVS-3572	CPE	VV	0.3	100.00	VERO	100.00	1.00	1/28/88
AVS-3573	CPE	AD2	0.75	50.50	HEP2	100.00	1.97	1/14/88
AVS-3573	CPE	JE	0.15	----	VERO	32.00	----	12/14/87
AVS-3573	CPE	VSV	----	----	L929	32.00	----	1/22/88
AVS-3573	CPE	VV	0.65	62.90	VERO	100.00	1.58	1/14/88
AVS-3574	CPE	AD2	0.1	----	HEP2 <	32.00	----	1/14/88
AVS-3574	CPE	JE	----	----	VERO	100.00	----	12/14/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3574	CPE	VSV	----	----	L929	32.00	----	1/22/88
AVS-3574	CPE	VV	0.3	----	VERO	32.00	----	1/14/88
AVS-3575	CPE	AD2	0.8	7.50	HEP2 <	32.00 <	4.25	1/14/88
AVS-3575	CPE	AD2	0.1	----	HEP2	10.00	----	5/12/88
AVS-3575	CPE	JE	0.25	----	VERO	3.20	----	12/14/87
AVS-3575	CPE	VSV	----	----	L929	32.00	----	1/22/88
AVS-3575	CPE	VV	----	----	VERO	32.00	----	1/14/88
AVS-3576	CPE	AD2	0.3	----	HEP2 >	320.00	----	1/14/88
AVS-3576	CPE	JE	----	----	VERO >	320.00	----	12/14/87
AVS-3576	CPE	VSV	----	----	L929	100.00	----	1/22/88
AVS-3576	CPE	VV	----	----	VERO	320.00	----	1/14/88
AVS-3577	CPE	AD2	1.4	96.00	HEP2	320.00	3.31	1/28/88
AVS-3577	CPE	AD2	1.8	112.00	HEP2 >	320.00 >	2.83	2/18/88
AVS-3577	CPE	JE	0.55	----	VERO	100.00	----	12/14/87
AVS-3577	CPE	VSV	----	----	L929	32.00	----	1/22/88
AVS-3577	CPE	VV	0.1	----	VERO	320.00	----	1/28/88
AVS-3578	CPE	AD2	----	----	HEP2 >	320.00	----	12/31/87
AVS-3578	CPE	JE	----	----	VERO >	320.00	----	12/14/87
AVS-3578	CPE	VSV	----	----	L929 >	320.00	----	1/22/88
AVS-3578	CPE	VV	----	----	VERO >	320.00	----	12/31/87
AVS-3579	CPE	AD2	----	----	HEP2	10.00	----	12/31/87
AVS-3579	CPE	JE	----	----	VERO >	320.00	----	12/14/87
AVS-3579	CPE	VSV	0.05	----	L929	0.32	----	1/22/88
AVS-3579	CPE	VV	----	----	VERO <	10.00	----	12/31/87
AVS-3580	CPE	AD2	----	----	HEP2 <	10.00	----	12/31/87
AVS-3580	CPE	JE	----	----	VERO <	10.00	----	12/14/87
AVS-3580	CPE	VSV	----	----	L929	0.32	----	1/22/88
AVS-3580	CPE	VV	0.15	----	VERO	10.00	----	1/21/88
AVS-3581	CPE	AD2	----	----	HEP2	100.00	----	12/31/87
AVS-3581	CPE	JE	0.1	----	VERO	32.00	----	12/14/87
AVS-3581	CPE	VSV	----	----	L929	0.32	----	1/22/88
AVS-3581	CPE	VV	0.45	203.00	VERO	10.00	0.05	12/31/87
AVS-3582	CPE	AD2	0.3	----	HEP2 >	320.00	----	1/14/88
AVS-3582	CPE	JE	0.15	----	VERO	100.00	----	12/14/87
AVS-3582	CPE	VSV	----	----	L929	320.00	----	1/22/88
AVS-3582	CPE	VV	----	----	VERO >	320.00	----	1/14/88
AVS-3583	CPE	AD2	0.6	320.00	HEP2 >	320.00 >	1.00	12/31/87
AVS-3583	CPE	JE	0.35	319.00	VERO	32.00	0.10	12/14/87
AVS-3583	CPE	VSV	----	----	L929	320.00	----	1/22/88
AVS-3583	CPE	VV	----	----	VERO >	320.00	----	12/31/87
AVS-3584	CPE	AD2	----	----	HEP2 <	320.00	----	12/31/87
AVS-3584	CPE	VSV	----	----	L929	100.00	----	1/29/88
AVS-3584	CPE	VV	----	----	VERO	100.00	----	12/31/87
AVS-3586	CPE	AD2	1.35	320.00	HEP2	32.00	0.10	3/ 3/88
AVS-3586	CPE	AD2	1.1	320.00	HEP2	32.00	0.10	3/17/88
AVS-3586	CPE	VSV	3.75	1.80	L929	32.00	17.70	1/29/88
AVS-3586	CPE	VSV	4.25	1.59	L929	32.00	20.00	2/23/88
AVS-3586	CPE	VV	3.25	0.36	VERO	3.20	8.88	3/ 3/88
AVS-3586	CPE	VV	3.45	0.36	VERO	1.00	2.71	3/17/88
AVS-3587	CPE	AD2	----	----	HEP2 <	100.00	----	2/ 4/88
AVS-3587	CPE	VSV	----	----	L929	320.00	----	1/28/88
AVS-3587	CPE	VSV	----	----	L929 <	320.00	----	1/29/88
AVS-3587	CPE	VV	----	----	L929 <	320.00	----	2/ 4/88
AVS-3587	CPE	VV	0.25	----	VERO	100.00	----	2/ 4/88
AVS-3588	CPE	AD2	0.6	----	HEP2 <	100.00	----	2/ 4/88
AVS-3588	CPE	VSV	----	----	L929 <	320.00	----	1/28/88
AVS-3588	CPE	VSV	----	----	L929	100.00	----	1/29/88
AVS-3588	CPE	VV	0.3	100.00	L929	100.00	1.00	2/ 4/88
AVS-3588	CPE	VV	0.15	----	VERO	32.00	----	2/ 4/88
AVS-3589	CPE	AD2	----	----	HEP2	32.00	----	2/ 4/88
AVS-3589	CPE	VSV	----	----	L929	100.00	----	1/28/88
AVS-3589	CPE	VSV	----	----	L929	100.00	----	1/29/88
AVS-3589	CPE	VV	----	----	L929	100.00	----	2/ 4/88
AVS-3589	CPE	VV	0.25	----	VERO	100.00	----	2/ 4/88
AVS-3590	CPE	AD2	0.4	----	HEP2 >	320.00	----	1/28/88

B-177

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3590	CPE	VSV	----	----	L929	32.00	----	1/29/88
AVS-3590	CPE	VV	0.4	319.00	VERO	320.00	1.00	1/28/88
AVS-3593	CPE	AD2	2.7	3.69	HEP2	10.00	2.70	10/22/87
AVS-3593	CPE	AD2	1.9	1.74	HEP2	3.20	1.83	11/12/87
AVS-3593	CPE	AD2	1.1	2.45	HEP2	3.20	1.30	12/31/87
AVS-3593	CPE	AD2	1.2	1.78	HEP2	3.20	1.78	1/21/88
AVS-3593	PR	HTM	N/A	0.93	VERC	1.00	1.07	2/17/88
AVS-3593	CPE	JE	2.75	0.12	VERO	0.32	2.48	4/12/88
AVS-3593	LPE	PT	3.87	0.32	VERO	0.32	1.00	12/21/87
AVS-3593	CPE	PT	1.9	0.08	VERO	0.10	1.12	4/12/88
AVS-3593	CPE	SF	2.2	0.20	VERO	0.32	1.59	4/12/88
AVS-3593	CPE	VEE	1.75	0.63	VERO	0.32	0.51	4/12/88
AVS-3593	CPE	VSV	----	----	L929	100.00	----	11/ 6/87
AVS-3593	CPE	VSV	----	----	L929	32.00	----	11/20/87
AVS-3593	CPE	VSV	----	----	L929	320.00	----	1/29/88
AVS-3593	CPE	VV	4.2	0.25	VERO	10.00	39.40	10/22/87
AVS-3593	CPE	VV	4.1	0.32	VERO	1.00	3.12	11/12/87
AVS-3593	CPE	VV	3.95	0.35	VERO	1.00	2.80	1/21/88
AVS-3593	CPE	VV	4.15	0.35	VERO	1.00	2.79	5/26/88
AVS-3593	CPE	YFV	2.55	0.14	VERO	0.10	0.68	4/12/88
AVS-3602	CPE	AD2	----	----	HEP2	320.00	----	9/ 4/87
AVS-3602	CPE	JE	0.04	----	VERO	320.00	----	10/ 2/87
AVS-3602	CPE	JE	----	----	VERO	100.00	----	7/21/88
AVS-3602	PR	PIC	N/A	----	VERO	100.00	----	11/ 8/88
AVS-3602	CPE	PT	----	----	VERO	320.00	----	7/21/88
AVS-3602	CPE	SF	----	----	VERO	32.00	----	7/21/88
AVS-3602	CPE	VEE	----	----	VERO	320.00	----	7/21/88
AVS-3602	CPE	VSV	----	----	L929	320.00	----	8/25/87
AVS-3602	CPE	VV	0.15	----	VERO	320.00	----	9/ 4/87
AVS-3602	CPE	YFV	0.2	----	VERO	320.00	----	7/21/88
AVS-3603	CPE	AD2	----	----	HEP2	320.00	----	9/ 4/87
AVS-3603	CPE	JE	----	----	VERO	320.00	----	7/21/88
AVS-3603	PR	PIC	N/A	----	VERO	320.00	----	11/ 8/88
AVS-3603	CPE	PT	----	----	VERO	320.00	----	7/21/88
AVS-3603	CPE	SF	----	----	VERO	320.00	----	7/21/88
AVS-3603	CPE	VEE	----	----	VERO	32.00	----	7/21/88
AVS-3603	CPE	VSV	----	----	L929	100.00	----	8/25/87
AVS-3603	CPE	VV	----	----	VERO	320.00	----	9/ 4/87
AVS-3603	CPE	YFV	----	----	VERO	320.00	----	7/21/88
AVS-3604	CPE	AD2	----	----	HEP2	100.00	----	9/ 4/87
AVS-3604	CPE	JE	----	----	VERO	100.00	----	7/21/88
AVS-3604	PR	PIC	N/A	----	VERO	100.00	----	11/ 8/88
AVS-3604	CPE	PT	----	----	VERO	320.00	----	7/21/88
AVS-3604	CPE	SF	----	----	VERO	32.00	----	7/21/88
AVS-3604	CPE	VEE	----	----	VERO	10.00	----	7/21/88
AVS-3604	CPE	VSV	----	----	L929	320.00	----	8/25/87
AVS-3604	CPE	VV	----	----	VERO	100.00	----	9/ 4/87
AVS-3604	CPE	YFV	----	----	VERO	320.00	----	7/21/88
AVS-3605	CPE	AD2	0.3	----	HEP2	320.00	----	12/31/87
AVS-3605	CPE	VSV	----	----	L929	320.00	----	2/ 2/88
AVS-3605	CPE	VV	----	----	VERO	320.00	----	12/31/87
AVS-3606	CPE	AD2	0.3	----	HEP2	320.00	----	12/31/87
AVS-3606	CPE	VSV	----	----	L929	320.00	----	2/ 2/88
AVS-3606	CPE	VV	----	----	VERO	320.00	----	12/31/87
AVS-3607	CPE	AD2	0.75	159.00	HEP2	320.00	2.00	1/14/88
AVS-3607	CPE	VSV	----	----	L929	320.00	----	2/ 2/88
AVS-3607	CPE	VV	8. <	0.10	VERO	320.00	1000.00	1/14/88
AVS-3607	CPE	VV	7.2	0.32	VERO	100.00	306.00	2/ 4/88
AVS-3607	CPE	VV	7.2	0.32	VERO	320.00	991.00	2/18/88
AVS-3607	PR	VV	N/A	0.34	VERO	320.00	923.00	4/ 8/88
AVS-3608	CPE	AD2	0.35	84.90	HEP2	100.00	1.17	1/14/88
AVS-3608	CPE	VSV	----	----	L929	100.00	----	2/ 2/88
AVS-3608	CPE	VV	0.85	56.50	VERO	100.00	1.76	1/14/88
AVS-3609	CPE	AD2	0.3	----	HEP2	320.00	----	1/14/88
AVS-3609	CPE	VSV	----	----	L929	320.00	----	2/ 2/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-3609	CPE	VV	----	----	VERO >	320.00	----	1/14/88
AVS-3610	CPE	AD2	0.6	100.00	HEP2 <	320.00 <	3.20	12/31/87
AVS-3610	CPE	AD2	1.3	50.60	HEP2 <	320.00 <	6.31	5/12/88
AVS-3610	CPE	VSV	----	----	L929	100.00	----	2/ 2/88
AVS-3610	CPE	VV	0.4	75.10	VERO	100.00	1.33	12/31/87
AVS-3611	CPE	AD2	0.3	----	HEP2 >	320.00	----	12/31/87
AVS-3611	CPE	VSV	----	----	L929	320.00	----	2/ 2/88
AVS-3611	CPE	VV	----	----	VERO >	320.00	----	12/31/87
AVS-3612	CPE	AD2	----	----	HEP2 >	320.00	----	12/31/87
AVS-3612	CPE	VSV	----	----	L929	320.00	----	2/ 2/88
AVS-3612	CPE	VV	0.2	----	VERO >	320.00	----	12/31/87
AVS-3613	CPE	AD2	0.3	----	HEP2	10.00	----	1/21/88
AVS-3613	CPE	VSV	----	----	L929	32.00	----	2/ 2/88
AVS-3613	CPE	VV	----	----	VERO >	100.00	----	1/21/88
AVS-3614	CPE	AD2	0.3	----	HEP2 <	32.00	----	1/21/88
AVS-3614	CPE	VSV	----	----	L929	32.00	----	2/ 2/88
AVS-3614	CPE	VV	0.5	24.60	VERO	32.00	1.29	1/21/88
AVS-3615	CPE	AD2	0.3	----	HEP2 >	100.00	----	2/11/88
AVS-3615	CPE	VSV	----	----	L929	100.00	----	2/ 2/88
AVS-3615	CPE	VV	0.1	----	VERO >	100.00	----	2/11/88
AVS-3616	CPE	AD2	0.4	----	HEP2 >	320.00	----	2/11/88
AVS-3616	CPE	VSV	----	----	L929 >	320.00	----	2/ 2/88
AVS-3616	CPE	VV	----	----	VERO >	320.00	----	2/11/88
AVS-3617	CPE	AD2	1.1	204.00	HEP2 >	320.00 >	1.56	2/11/88
AVS-3617	CPE	VSV	----	----	L929	100.00	----	2/ 2/88
AVS-3617	CPE	VV	----	----	VERO	320.00	----	2/11/88
AVS-3618	CPE	AD2	0.4	----	HEP2 >	320.00	----	2/11/88
AVS-3618	CPE	VSV	----	----	L929	320.00	----	2/ 2/88
AVS-3618	CPE	VV	----	----	VERO >	320.00	----	2/11/88
AVS-3619	CPE	AD2	0.5	----	HEP2 >	320.00	----	2/11/88
AVS-3619	CPE	VSV	----	----	L929	320.00	----	2/ 2/88
AVS-3619	CPE	VV	0.1	----	VERO >	320.00	----	2/11/88
AVS-3620	CPE	AD2	0.3	----	HEP2 >	320.00	----	2/11/88
AVS-3620	CPE	VSV	----	----	L929	100.00	----	2/ 2/88
AVS-3620	CPE	VV	----	----	VERO >	320.00	----	2/11/88
AVS-3621	CPE	AD2	----	----	HEP2 <	320.00	----	2/11/88
AVS-3621	CPE	VSV	----	----	L929	320.00	----	2/ 2/88
AVS-3621	CPE	VV	0.4	320.00	VERO	320.00	1.00	2/11/88
AVS-3622	CPE	AD2	----	----	HEP2 <	10.00	----	2/11/88
AVS-3622	CPE	VSV	----	----	L929	32.00	----	2/ 2/88
AVS-3622	CPE	VV	1.2	56.50	VERO >	100.00 >	1.76	2/11/88
AVS-3623	CPE	AD2	0.3	----	HEP2 >	320.00	----	2/11/88
AVS-3623	CPE	VSV	----	----	L929	100.00	----	2/ 2/88
AVS-3623	CPE	VV	0.1	----	VERO >	320.00	----	2/11/88
AVS-3624	CPE	AD2	0.3	----	HEP2 >	320.00	----	2/11/88
AVS-3624	CPE	VSV	----	----	L929	100.00	----	2/ 2/88
AVS-3624	CPE	VV	----	----	VERO	320.00	----	2/11/88
AVS-3624	CPE	YFV	----	----	VERO	100.00	----	12/ 1/87
AVS-3625	CPE	AD2	----	----	HEP2	10.00	----	8/25/88
AVS-3625	CPE	JE	----	----	VERO	32.00	----	10/16/87
AVS-3625	CPE	VSV	----	----	L929	32.00	----	11/ 6/87
AVS-3625	CPE	VV	0.75	56.50	VERO	100.00	1.76	8/25/88
AVS-3626	CPE	YFV	----	----	VERO >	100.00	----	12/ 1/87
AVS-3627	CPE	YFV	----	----	VERO	100.00	----	12/ 1/87
AVS-3628	CPE	YFV	----	----	VERO	100.00	----	12/ 1/87
AVS-3629	CPE	YFV	----	----	VERO	100.00	----	12/ 1/87
AVS-3630	CPE	YFV	----	----	VERO	100.00	----	12/ 1/87
AVS-3631	CPE	YFV	----	----	VERO	32.00	----	12/ 1/87
AVS-3632	CPE	YFV	----	----	VERO	100.00	----	12/ 1/87
AVS-3633	CPE	YFV	----	----	VERO	100.00	----	12/ 2/87
AVS-3634	CPE	YFV	----	----	VERO >	100.00	----	12/ 2/87
AVS-3635	CPE	YFV	----	----	VERO	100.00	----	12/ 2/87
AVS-3636	CPE	YFV	----	----	VERO	100.00	----	12/ 2/87
AVS-3637	CPE	YFV	----	----	VERO	100.00	----	12/ 2/87
AVS-3638	CPE	YFV	----	----	VERO	100.00	----	12/ 2/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	T1	DATE
AVS-3639	CPE	YFV	----	----	VERO	100.00	----	12/ 2/87
AVS-3640	CPE	YFV	0.6	17.80	VERO	32.00	1.78	12/ 3/87
AVS-3641	CPE	YFV	----	----	VERO >	100.00	----	12/ 3/87
AVS-3642	CPE	YFV	----	----	VERO >	100.00	----	12/ 3/87
AVS-3643	CPE	YFV	----	----	VERO	100.00	----	12/ 3/87
AVS-3644	CPE	YFV	----	----	VERO >	100.00	----	12/ 3/87
AVS-3645	CPE	YFV	----	----	VERO >	100.00	----	12/ 3/87
AVS-3646	CPE	YFV	----	----	VERO	100.00	----	12/ 3/87
AVS-3647	CPE	YFV	----	----	VERO	100.00	----	12/ 3/87
AVS-3648	CPE	YFV	0.45	68.30	VERO	100.00	1.46	12/ 4/87
AVS-3649	CPE	YFV	----	----	VERO	100.00	----	12/ 4/87
AVS-3650	CPE	YFV	----	----	VERO	100.00	----	12/ 4/87
AVS-3651	CPE	YFV	----	----	VERO	100.00	----	12/ 4/87
AVS-3652	CPE	YFV	----	----	VERO	32.00	----	12/ 4/87
AVS-3653	CPE	YFV	----	----	VERO	100.00	----	12/ 4/87
AVS-3654	CPE	YFV	----	----	VERO	100.00	----	12/ 4/87
AVS-3655	CPE	YFV	----	----	VERO	100.00	----	12/ 7/87
AVS-3656	CPE	YFV	----	----	VERO	100.00	----	12/ 7/87
AVS-3657	CPE	YFV	----	----	VERO	10.00	----	12/ 7/87
AVS-3658	CPE	YFV	----	----	VERO	100.00	----	12/ 7/87
AVS-3659	CPE	YFV	----	----	VERO	32.00	----	12/ 7/87
AVS-3660	CPE	YFV	----	----	VERO	32.00	----	12/ 7/87
AVS-3661	CPE	YFV	----	----	VERO	10.00	----	12/ 7/87
AVS-3662	CPE	YFV	----	----	VERO	32.00	----	12/ 7/87
AVS-3663	CPE	YFV	----	----	VERO	3.20	----	12/ 8/87
AVS-3664	CPE	YFV	----	----	VERO	100.00	----	12/ 8/87
AVS-3665	CPE	YFV	----	----	VERO	10.00	----	12/ 8/87
AVS-3666	CPE	YFV	----	----	VERO	10.00	----	12/ 8/87
AVS-3667	CPE	YFV	0.1	----	VERO	100.00	----	12/ 8/87
AVS-3668	CPE	YFV	----	----	VERO	100.00	----	12/ 8/87
AVS-3669	CPE	YFV	----	----	VERO	10.00	----	12/ 8/87
AVS-3670	CPE	YFV	----	----	VERO	32.00	----	12/ 9/87
AVS-3671	CPE	YFV	----	----	VERO	100.00	----	12/ 9/87
AVS-3672	CPE	YFV	----	----	VERO	32.00	----	12/ 9/87
AVS-3673	CPE	YFV	----	----	VERO	32.00	----	12/ 9/87
AVS-3674	CPE	YFV	----	----	VERO	100.00	----	12/ 9/87
AVS-3675	CPE	YFV	0.1	----	VERO	100.00	----	12/ 9/87
AVS-3676	CPE	YFV	----	----	VERO >	100.00	----	12/ 9/87
AVS-3677	CPE	AD2	0.65	6.20	HEP2	10.00	1.59	1/14/88
AVS-3677	CPE	VSV	----	----	L929	10.00	----	2/ 2/88
AVS-3677	CPE	VV	1.5	2.57	VERO	3.20	1.24	1/14/88
AVS-3678	CPE	AD2	----	----	HEP2 <	3.20	----	1/14/88
AVS-3678	CPE	VSV	----	----	L929	3.20	----	2/ 2/88
AVS-3678	CPE	VV	----	----	VERO	3.20	----	1/14/88
AVS-3679	CPE	AD2	0.6	5.60	HEP2	10.00	1.76	12/31/87
AVS-3679	CPE	VSV	----	----	L929	10.00	----	2/ 5/88
AVS-3679	CPE	VV	9.8	0.01	VERO	32.00	3200.00	1/21/88
AVS-3679	CPE	VV	9.05	----	VERO >	10.00 >	1160.00	2/ 4/88
AVS-3679	CPE	VV	8.55	0.01	VERO	32.00	2800.00	2/18/88
AVS-3679	PR	VV	N/A	----	VERO >	3.20 >	427.00	7/15/88
AVS-3680	CPE	AD2	0.2	----	HEP2 >	320.00	----	12/31/87
AVS-3680	CPE	VSV	----	----	L929 >	320.00	----	2/ 5/88
AVS-3680	CPE	VV	----	----	VERO >	320.00	----	12/31/87
AVS-3681	CPE	AD2	----	----	HEP2 <	32.00	----	11/ 5/87
AVS-3681	CPE	JE	----	----	VERO	32.00	----	12/29/87
AVS-3681	PR	PIC	N/A	----	VERO >	32.00	----	2/12/88
AVS-3681	CPE	PT	0.1	----	VERO	32.00	----	12/14/87
AVS-3681	CPE	SF	1.1	12.80	VERO -	0.32 -	0.02	3/11/88
AVS-3681	CPE	VSV	----	----	L929	32.00	----	11/13/87
AVS-3681	CPE	VV	----	----	VERO	32.00	----	11/ 5/87
AVS-3682	CPE	AD2	----	----	HEP2	32.00	----	11/ 5/87
AVS-3682	CPE	JE	----	----	VERO	32.00	----	12/29/87
AVS-3682	PR	PIC	N/A	----	VERO >	32.00	----	1/29/88
AVS-3682	CPE	PT	0.05	----	VERO	32.00	----	12/16/87
AVS-3682	CPE	VSV	----	----	L929	32.00	----	11/13/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3682	CPE	VV	----	----	VERO	32.00	----	11/ 5/87
AVS-3683	CPE	AD2	----	----	HEP2 <	32.00	----	11/ 5/87
AVS-3683	CPE	JE	0.2	----	VERO >	320.00	----	2/ 1/87
AVS-3683	PR	PIC	N/A	----	VERO >	100.00	----	1/29/88
AVS-3683	CPE	PT	0.15	----	VERO	100.00	----	12/16/87
AVS-3683	CPE	VSV	----	----	L929	100.00	----	11/13/87
AVS-3683	CPE	VV	----	----	VERO	100.00	----	11/ 5/87
AVS-3684	CPE	AD2	----	----	HEP2 >	320.00	----	11/ 5/87
AVS-3684	CPE	JE	----	----	VERO	320.00	----	12/ 1/87
AVS-3684	PR	PIC	N/A	----	VERO	100.00	----	1/29/88
AVS-3684	CPE	PT	----	----	VERO	320.00	----	12/16/87
AVS-3684	CPE	VSV	----	----	L929	100.00	----	11/13/87
AVS-3684	CPE	VV	0.35	270.00	VERO	320.00	1.18	11/ 5/87
AVS-3685	CPE	AD2	0.15	----	HEP2	320.00	----	11/ 5/87
AVS-3685	CPE	JE	----	----	VERO	320.00	----	12/ 1/87
AVS-3685	PR	PIC	N/A	----	VERO >	320.00	----	1/29/88
AVS-3685	CPE	PT	----	----	VERO	320.00	----	12/16/87
AVS-3685	CPE	VSV	----	----	L929 <	320.00	----	11/13/87
AVS-3685	CPE	VV	----	----	VERO	320.00	----	11/ 5/87
AVS-3686	CPE	AD2	0.1	----	HEP2 <	100.00	----	11/ 5/87
AVS-3686	CPE	JE	----	----	VERO >	320.00	----	12/ 1/87
AVS-3686	PR	PIC	N/A	----	VERO >	100.00	----	1/29/88
AVS-3686	CPE	PT	----	----	VERO	320.00	----	12/16/87
AVS-3686	CPE	VSV	----	----	L929	32.00	----	11/13/87
AVS-3686	CPE	VV	----	----	VERO	100.00	----	11/ 5/87
AVS-3687	CPE	AD2	----	----	HEP2 >	320.00	----	11/ 5/87
AVS-3687	CPE	JE	----	----	VERO	320.00	----	12/ 1/87
AVS-3687	PR	PIC	N/A	----	VERO >	320.00	----	1/29/88
AVS-3687	CPE	PT	----	----	VERO	320.00	----	12/16/87
AVS-3687	CPE	VSV	----	----	L929	320.00	----	11/13/87
AVS-3687	CPE	VV	----	----	VERO >	320.00	----	11/ 5/87
AVS-3688	CPE	AD2	----	----	HEP2	100.00	----	11/ 5/87
AVS-3688	PR	PIC	N/A	----	VERO	100.00	----	1/29/88
AVS-3688	CPE	PT	----	----	VERO	320.00	----	12/16/87
AVS-3688	CPE	VSV	----	----	L929 <	100.00	----	11/13/87
AVS-3688	CPE	VV	----	----	VERO	100.00	----	11/ 5/87
AVS-3689	CPE	AD2	0.15	----	HEP2	100.00	----	11/ 5/87
AVS-3689	CPE	JE	----	----	VERO >	320.00	----	12/ 1/87
AVS-3689	PR	PIC	N/A	81.90	VERO	100.00	1.22	2/ 2/88
AVS-3689	CPE	PT	----	----	VERO	100.00	----	12/17/87
AVS-3689	CPE	VSV	----	----	L929	32.00	----	11/13/87
AVS-3689	CPE	VV	0.2	----	VERO	100.00	----	11/ 5/87
AVS-3690	CPE	AD2	----	----	HEP2 <	100.00	----	11/ 5/87
AVS-3690	CPE	JE	0.5	200.00	VERO	320.00	1.59	12/ 2/87
AVS-3690	PR	PIC	N/A	----	VERO >	100.00	----	2/ 5/88
AVS-3690	CPE	PT	----	----	VERO	100.00	----	12/17/87
AVS-3690	CPE	VSV	----	----	L929	32.00	----	11/20/87
AVS-3690	CPE	VV	----	----	VERO	100.00	----	11/ 5/87
AVS-3691	CPE	AD2	0.3	----	HEP2	100.00	----	11/ 5/87
AVS-3691	CPE	JE	0.8	317.00	VERO >	320.00 >	1.00	12/ 2/87
AVS-3691	PR	PIC	N/A	64.40	VERO >	100.00 >	1.55	2/ 5/88
AVS-3691	CPE	PT	----	----	VERO	100.00	----	12/17/87
AVS-3691	CPE	VSV	----	----	L929	10.00	----	11/20/87
AVS-3691	CPE	VV	0.55	23.90	VERO	32.00	1.33	11/ 5/87
AVS-3692	CPE	AD2	----	----	HEP2	10.00	----	11/ 5/87
AVS-3692	CPE	JE	----	----	VERO	10.00	----	12/ 2/87
AVS-3692	PR	PIC	N/A	----	VERO >	10.00	----	2/ 5/88
AVS-3692	CPE	PT	----	----	VERO	32.00	----	12/17/87
AVS-3692	CPE	VSV	----	----	L929	10.00	----	11/20/87
AVS-3692	CPE	VV	----	----	VERO	10.00	----	11/ 5/87
AVS-3693	CPE	AD2	----	----	HEP2	32.00	----	11/12/87
AVS-3693	CPE	JE	----	----	VERO	32.00	----	12/ 2/87
AVS-3693	PR	PIC	N/A	----	VERO	32.00	----	2/ 5/88
AVS-3693	CPE	PT	----	----	VERO	32.00	----	12/17/87
AVS-3693	CPE	VSV	----	----	L929	10.00	----	11/20/87

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3693	CPE	VV	0.15	----	VERO	32.00	----	11/12/87
AVS-3694	CPE	AD2	0.3	----	HEP2 <	320.00	----	11/12/87
AVS-3694	CPE	JE	0.05	----	VERO	320.00	----	12/ 2/87
AVS-3694	PR	PIC	N/A	----	VERO	100.00	----	2/ 5/88
AVS-3694	CPE	PT	----	----	VERO	100.00	----	12/17/87
AVS-3694	CPE	VSV	----	----	L929	10.00	----	11/20/87
AVS-3694	CPE	VV	----	----	VERO	100.00	----	11/12/87
AVS-3695	CPE	AD2	----	----	HEP2	320.00	----	11/12/87
AVS-3695	CPE	JE	----	----	VERO >	320.00	----	12/ 2/87
AVS-3695	PR	PIC	N/A	248.00	VERO	320.00	1.28	2/ 5/88
AVS-3695	CPE	PT	----	----	VERO	100.00	----	12/17/87
AVS-3695	CPE	VSV	----	----	L929	320.00	----	11/20/87
AVS-3695	CPE	VV	----	----	VERO	320.00	----	11/12/87
AVS-3696	CPE	AD2	0.7	319.00	HEP2 >	320.00 >	1.00	11/12/87
AVS-3696	CPE	JE	----	----	VERO >	320.00	----	12/ 2/87
AVS-3696	PR	PIC	N/A	314.00	VERO	100.00	0.32	2/ 5/88
AVS-3696	CPE	PT	0.55	161.00	VERO	100.00	0.62	12/21/87
AVS-3696	CPE	VSV	----	----	L929 >	320.00	----	11/20/87
AVS-3696	CPE	VV	----	----	VERO	320.00	----	11/12/87
AVS-3697	CPE	AD2	0.7	----	HEP2 <	320.00	----	11/12/87
AVS-3697	CPE	JE	0.35	----	VERO	100.00	----	12/30/87
AVS-3697	PR	PIC	N/A	316.00	VERO	320.00	1.00	2/12/88
AVS-3697	CPE	PT	0.65	157.00	VERO	100.00	0.63	12/21/87
AVS-3697	CPE	VSV	----	----	L929	100.00	----	11/20/87
AVS-3697	CPE	VV	0.53	222.00	VERO	320.00	1.44	11/12/87
AVS-3698	CPE	AD2	----	----	HEP2	100.00	----	11/12/87
AVS-3698	CPE	JE	----	----	VERO	10.00	----	12/30/87
AVS-3698	PR	PIC	N/A	----	VERO	100.00	----	2/15/88
AVS-3698	CPE	PT	----	----	VERO	10.00	----	12/21/87
AVS-3698	CPE	VSV	----	----	L929	10.00	----	11/20/87
AVS-3698	CPE	VV	----	----	VERO	32.00	----	11/12/87
AVS-3699	CPE	AD2	----	----	HEP2	100.00	----	11/12/87
AVS-3699	CPE	JE	----	----	VERO	32.00	----	12/30/87
AVS-3699	CPE	PT	----	----	VERO	10.00	----	12/21/87
AVS-3699	CPE	VSV	----	----	L929	10.00	----	11/20/87
AVS-3699	CPE	VV	----	----	VERO	100.00	----	11/12/87
AVS-3700	CPE	AD2	----	----	HEP2 <	320.00	----	11/12/87
AVS-3700	CPE	JE	0.1	----	VERO	100.00	----	12/30/87
AVS-3700	CPE	PT	0.05	----	VERO	100.00	----	12/21/87
AVS-3700	CPE	VSV	----	----	L929 <	100.00	----	11/20/87
AVS-3700	CPE	VV	0.05	----	VERO	320.00	----	11/12/87
AVS-3701	CPE	AD2	----	----	HEP2	100.00	----	11/12/87
AVS-3701	CPE	JE	----	----	VERO	320.00	----	1/13/88
AVS-3701	CPE	PT	----	----	VERO	32.00	----	12/21/87
AVS-3701	CPE	VSV	----	----	L929	32.00	----	11/20/87
AVS-3701	CPE	VV	----	----	VERO	100.00	----	11/12/87
AVS-3702	CPE	AD2	0.7	319.00	HEP2 >	320.00 >	1.00	11/12/87
AVS-3702	CPE	JE	----	----	VERO	320.00	----	1/13/88
AVS-3702	CPE	PT	0.4	----	VERO	100.00	----	12/21/87
AVS-3702	CPE	VSV	----	----	L929	10.00	----	11/20/87
AVS-3702	CPE	VV	----	----	VERO	320.00	----	11/12/87
AVS-3703	CPE	AD2	----	----	HEP2 <	320.00	----	1/14/88
AVS-3703	CPE	VSV	----	----	L929	32.00	----	2/ 5/88
AVS-3703	CPE	VV	----	----	VERO <	320.00	----	1/14/88
AVS-3704	CPE	AD2	----	----	HEP2	100.00	----	1/14/88
AVS-3704	CPE	VSV	----	----	L929	100.00	----	2/ 5/88
AVS-3704	CPE	VV	----	----	VERO	100.00	----	1/14/88
AVS-3705	CPE	AD2	1.7	73.00	HEP2	320.00	4.38	1/14/88
AVS-3705	CPE	AD2	1.1	118.00	HEP2	320.00	2.71	2/ 4/88
AVS-3705	CPE	AD2	0.9	147.00	HEP2	320.00	2.17	2/18/88
AVS-3705	CPE	AD2	0.6	320.00	HEP2 >	320.00 >	1.00	5/12/88
AVS-3705	CPE	VSV	----	----	L929	10.00	----	2/ 5/88
AVS-3705	CPE	VV	1.45	34.90	VERO	100.00	2.85	1/14/88
AVS-3705	CPE	VV	1.1	50.10	VERO	100.00	1.99	2/ 4/88
AVS-3706	CPE	AD2	0.6	320.00	HEP2 >	320.00 >	1.00	1/14/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3706	CPE	VSV	----	----	L929	10.00	----	2/ 5/88
AVS-3706	CPE	VV	0.2	----	VERO >	320.00	----	1/14/88
AVS-3707	CPE	AD2	----	----	HEP2	32.00	----	1/14/88
AVS-3707	CPE	VSV	----	----	L929	100.00	----	2/ 5/88
AVS-3707	CPE	VV	0.05	----	VERO	32.00	----	1/14/88
AVS-3708	CPE	AD2	----	----	HEP2 >	320.00	----	1/14/88
AVS-3708	CPE	VSV	----	----	L929 >	320.00	----	2/ 5/88
AVS-3708	CPE	VV	----	----	VERO	320.00	----	1/14/88
AVS-3709	CPE	AD2	0.15	----	HEP2	100.00	----	1/14/88
AVS-3709	CPE	VSV	----	----	L929	100.00	----	2/ 5/88
AVS-3709	CPE	VV	0.05	----	VERO	100.00	----	1/14/88
AVS-3710	CPE	AD2	----	----	HEP2	100.00	----	1/28/88
AVS-3710	CPE	VSV	----	----	L929	100.00	----	2/ 5/88
AVS-3710	CPE	VV	0.6	100.00	VERO >	100.00 >	1.00	1/28/88
AVS-3711	CPE	AD2	0.3	----	HEP2 >	320.00	----	1/21/88
AVS-3711	CPE	VSV	----	----	L929	320.00	----	2/ 5/88
AVS-3711	CPE	VV	----	----	VERO	320.00	----	1/21/88
AVS-3712	CPE	AD2	----	----	HEP2	100.00	----	1/21/88
AVS-3712	CPE	VSV	----	----	L929	100.00	----	2/ 5/88
AVS-3712	CPE	VV	----	----	VERO <	320.00	----	1/21/88
AVS-3713	CPE	AD2	----	----	HEP2 <	320.00	----	1/21/88
AVS-3713	CPE	VSV	----	----	L929	320.00	----	2/ 5/88
AVS-3713	CPE	VV	----	----	VERO	320.00	----	1/21/88
AVS-3714	CPE	AD2	0.3	----	HEP2	100.00	----	1/28/88
AVS-3714	CPE	VSV	----	----	L929	320.00	----	2/ 5/88
AVS-3714	CPE	VV	----	----	VERO >	100.00	----	1/28/88
AVS-3715	CPE	AD2	----	----	HEP2 >	320.00	----	2/ 4/88
AVS-3715	CPE	VSV	----	----	L929 >	320.00	----	2/ 5/88
AVS-3715	CPE	VV	----	----	VERO	100.00	----	2/ 4/88
AVS-3716	CPE	AD2	----	----	HEP2 <	320.00	----	2/ 4/88
AVS-3716	CPE	VSV	----	----	L929	320.00	----	2/ 5/88
AVS-3716	CPE	VV	0.2	----	VERO	320.00	----	2/ 4/88
AVS-3717	CPE	AD2	0.15	----	HEP2	32.00	----	2/ 4/88
AVS-3717	CPE	VSV	----	----	L929	10.00	----	2/ 5/88
AVS-3717	CPE	VV	0.1	----	VERO	32.00	----	2/ 4/88
AVS-3718	CPE	PT	----	----	VERO	32.00	----	9/ 1/88
AVS-3718	CPE	SF	----	----	VERO	32.00	----	9/ 1/88
AVS-3718	CPE	VEE	----	----	VERO	320.00	----	9/ 1/88
AVS-3719	CPE	PT	----	----	VERO	320.00	----	9/ 1/88
AVS-3719	CPE	SF	0.05	----	VERO	320.00	----	9/ 1/88
AVS-3719	CPE	VEE	----	----	VERO	100.00	----	9/ 1/88
AVS-3720	CPE	AD2	0.1	----	HEP2 >	320.00	----	1/14/88
AVS-3720	CPE	VSV	----	----	L929 >	320.00	----	2/ 5/88
AVS-3720	CPE	VV	----	----	VERO >	320.00	----	1/14/88
AVS-3721	CPE	AD2	0.15	----	HEP2	32.00	----	1/14/88
AVS-3721	CPE	VSV	----	----	L929	3.20	----	2/ 5/88
AVS-3721	CPE	VV	----	----	VERO	10.00	----	1/14/88
AVS-3722	CPE	AD2	0.2	----	HEP2 >	320.00	----	1/14/88
AVS-3722	CPE	VSV	----	----	L929	320.00	----	2/ 5/88
AVS-3722	CPE	VV	----	----	VERO >	320.00	----	1/14/88
AVS-3723	CPE	AD2	----	----	HEP2 >	320.00	----	1/14/88
AVS-3723	CPE	VSV	----	----	L929 >	320.00	----	2/ 5/88
AVS-3723	CPE	VV	----	----	VERO >	320.00	----	1/14/88
AVS-3724	CPE	AD2	0.5	----	HEP2 >	320.00	----	1/14/88
AVS-3724	CPE	VSV	----	----	L929	100.00	----	2/ 5/88
AVS-3724	CPE	VV	0.45	320.00	VERO	100.00	0.31	1/14/88
AVS-3725	CPE	AD2	----	----	HEP2	100.00	----	1/28/88
AVS-3725	CPE	VSV	----	----	L929	100.00	----	2/ 5/88
AVS-3725	CPE	VV	0.15	----	VERO	100.00	----	1/28/88
AVS-3726	CPE	AD2	0.3	----	HEP2 <	320.00	----	2/ 4/88
AVS-3726	CPE	VSV	----	----	L929 >	320.00	----	2/ 5/88
AVS-3726	CPE	VV	0.1	----	VERO	320.00	----	2/ 4/88
AVS-3727	CPE	JE	1.1	100.00	VERO	100.00	1.00	3/15/88
AVS-3727	CPE	PT	----	----	VERO	320.00	----	3/15/88
AVS-3727	CPE	VEE	----	----	VERO	100.00	----	3/15/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3727	CPE	YFV	0.5	222.00	VERO -	0.32 -	----	3/15/88
AVS-3728	CPE	JE	0.7	----	VERO	320.00	----	3/15/88
AVS-3728	CPE	PT	0.05	----	VERO >	320.00	----	3/15/88
AVS-3728	CPE	SF	0.55	320.00	VERO	100.00	0.31	3/15/88
AVS-3728	CPE	VEE	----	----	VERO	100.00	----	3/15/88
AVS-3728	CPE	YFV	----	----	VERO	100.00	----	3/15/88
AVS-3729	CPE	JE	----	----	VERO	32.00	----	3/15/88
AVS-3729	CPE	PT	0.3	----	VERO	100.00	----	3/15/88
AVS-3729	CPE	SF	0.6	100.00	VERO	32.00	0.32	3/15/88
AVS-3729	CPE	VEE	----	----	VERO	10.00	----	3/15/88
AVS-3729	CPE	YFV	----	----	VERO	32.00	----	3/15/88
AVS-3730	CPE	JE	0.6	247.00	VERO	32.00	0.13	3/15/88
AVS-3730	CPE	PT	0.43	225.00	VERO	320.00	1.41	3/15/88
AVS-3730	CPE	SF	1.55	30.20	VERO	32.00	1.05	3/15/88
AVS-3730	CPE	VEE	----	----	VERO	100.00	----	3/15/88
AVS-3730	CPE	YFV	0.95	86.00	VERO -	0.32 -	----	3/15/88
AVS-3731	CPE	JE	1.45	28.40	VERO	100.00	3.51	3/15/88
AVS-3731	CPE	PT	----	----	VERO >	100.00	----	3/15/88
AVS-3731	CPE	SF	0.5	69.80	VERO	32.00	0.46	3/15/88
AVS-3731	CPE	VEE	----	----	VERO	10.00	----	3/15/88
AVS-3731	CPE	YFV	0.75	63.00	VERO	32.00	0.51	3/15/88
AVS-3732	CPE	JE	0.65	242.00	VERO	320.00	1.31	3/15/88
AVS-3732	CPE	PT	----	----	VERO >	320.00	----	3/15/88
AVS-3732	CPE	SF	0.4	----	VERO >	320.00	----	3/15/88
AVS-3732	CPE	VEE	----	----	VERO	32.00	----	3/15/88
AVS-3732	CPE	YFV	0.2	----	VERO >	320.00	----	3/15/88
AVS-3733	CPE	JE	0.45	----	VERO	320.00	----	3/15/88
AVS-3733	CPE	PT	----	----	VERO	320.00	----	3/15/88
AVS-3733	CPE	SF	----	----	VERO	320.00	----	3/15/88
AVS-3733	CPE	VEE	----	----	VERO	32.00	----	3/15/88
AVS-3733	CPE	YFV	0.5	----	VERO >	320.00	----	3/15/88
AVS-3734	CPE	JE	2.55	3.18	VERO	10.00	3.13	3/15/88
AVS-3734	CPE	PT	0.85	40.90	VERO	100.00	2.44	3/15/88
AVS-3734	CPE	SF	1.4	6.40	VERO	10.00	1.54	3/15/88
AVS-3734	CPE	VEE	----	----	VERO	3.20	----	3/15/88
AVS-3734	CPE	YFV	1.9	4.36	VERO	3.20	0.73	3/15/88
AVS-3735	CPE	PT	----	----	VERO	100.00	----	3/15/88
AVS-3735	CPE	SF	0.25	----	VERO	3.20	----	3/15/88
AVS-3735	CPE	VEE	----	----	VERO	3.20	----	3/15/88
AVS-3735	CPE	YFV	0.15	----	VERO	32.00	----	3/15/88
AVS-3736	CPE	JE	1.35	25.50	VERO	10.00	0.39	3/15/88
AVS-3736	CPE	PT	----	----	VERO	32.00	----	3/15/88
AVS-3736	CPE	SF	0.8	50.30	VERO	10.00	0.20	3/15/88
AVS-3736	CPE	VEE	----	----	VERO	1.00	----	3/15/88
AVS-3736	CPE	YFV	1.2	70.40	VERO	32.00	0.45	3/15/88
AVS-3737	CPE	JE	----	----	VERO	10.00	----	3/15/88
AVS-3737	CPE	PT	0.05	----	VERO <	100.00	----	3/15/88
AVS-3737	CPE	SF	1.35	7.60	VERO	10.00	1.30	3/15/88
AVS-3737	CPE	VEE	----	----	VERO	32.00	----	3/15/88
AVS-3737	CPE	YFV	0.25	----	VERO	10.00	----	3/15/88
AVS-3738	CPE	JE	0.1	----	VERO -	0.32 -	----	3/15/88
AVS-3738	CPE	PT	----	----	VERO -	0.32 -	----	3/15/88
AVS-3738	CPE	SF	----	----	VERO -	0.32 -	----	3/15/88
AVS-3738	CPE	VEE	----	----	VERO -	0.32 -	----	3/15/88
AVS-3738	CPE	YFV	----	----	VERO -	0.32 -	----	3/15/88
AVS-3739	CPE	PT	----	----	VERO >	100.00	----	3/15/88
AVS-3739	CPE	SF	0.5	----	VERO	10.00	----	3/15/88
AVS-3739	CPE	VEE	----	----	VERO	1.00	----	3/15/88
AVS-3739	CPE	YFV	----	----	VERO	32.00	----	3/15/88
AVS-3740	CPE	PT	----	----	VERO	100.00	----	3/15/88
AVS-3740	CPE	VEE	----	----	VERO >	100.00	----	3/15/88
AVS-3740	CPE	YFV	----	----	VERO	100.00	----	3/15/88
AVS-3741	CPE	JE	----	----	VERO	100.00	----	3/15/88
AVS-3741	CPE	PT	----	----	VERO	320.00	----	3/15/88
AVS-3741	CPE	SF	0.55	199.00	VERO	100.00	0.50	3/15/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3741	CPE	VEE	----	----	VERO	32.00	----	3/15/88
AVS-3741	CPE	YFV	----	----	VERO	100.00	----	3/15/88
AVS-3742	CPE	JE	----	----	VERO	100.00	----	3/16/88
AVS-3742	CPE	PT	0.05	----	VERO	32.00	----	4/14/88
AVS-3742	CPE	SF	2.49	84.70	VERO	100.00	1.18	3/16/88
AVS-3742	CPE	VEE	----	----	VERO	32.00	----	3/16/88
AVS-3742	CPE	YFV	----	----	VERO	32.00	----	3/16/88
AVS-3743	CPE	JE	----	----	VERO	320.00	----	3/16/88
AVS-3743	CPE	PT	----	----	VERO	100.00	----	4/14/88
AVS-3743	CPE	SF	0.15	----	VERO	100.00	----	3/16/88
AVS-3743	CPE	VEE	----	----	VERO	32.00	----	3/16/88
AVS-3743	CPE	YFV	----	----	VERO	100.00	----	3/16/88
AVS-3744	CPE	JE	----	----	VERO	32.00	----	3/16/88
AVS-3744	CPE	PT	----	----	VERO	320.00	----	4/14/88
AVS-3744	CPE	VEE	----	----	VERO	320.00	----	3/16/88
AVS-3744	CPE	YFV	----	----	VERO	32.00	----	3/16/88
AVS-3745	CPE	JE	----	----	VERO	100.00	----	3/16/88
AVS-3745	CPE	PT	----	----	VERO	320.00	----	4/14/88
AVS-3745	CPE	VEE	----	----	VERO	32.00	----	3/16/88
AVS-3745	CPE	YFV	0.15	----	VERO	320.00	----	3/16/88
AVS-3746	CPE	JE	----	----	VERO	320.00	----	3/16/88
AVS-3746	CPE	PT	----	----	VERO	100.00	----	4/14/88
AVS-3746	CPE	VEE	----	----	VERO	320.00	----	3/16/88
AVS-3746	CPE	YFV	----	----	VERO	100.00	----	3/16/88
AVS-3747	CPE	JE	----	----	VERO	100.00	----	3/16/88
AVS-3747	CPE	PT	----	----	VERO	10.00	----	4/14/88
AVS-3747	CPE	SF	2.65	3.92	VERO	32.00	8.16	3/16/88
AVS-3747	CPE	VEE	----	----	VERO	100.00	----	3/16/88
AVS-3747	CPE	YFV	----	----	VERO	10.00	----	3/16/88
AVS-3748	CPE	JE	----	----	VERO	100.00	----	3/16/88
AVS-3748	CPE	PT	----	----	VERO	320.00	----	4/14/88
AVS-3748	CPE	VEE	----	----	VERO	320.00	----	3/16/88
AVS-3748	CPE	YFV	----	----	VERO	32.00	----	3/16/88
AVS-3749	CPE	JE	----	----	VERO	100.00	----	3/16/88
AVS-3749	CPE	PT	----	----	VERO	320.00	----	4/14/88
AVS-3749	CPE	VEE	----	----	VERO	320.00	----	3/16/88
AVS-3749	CPE	YFV	----	----	VERO	320.00	----	3/16/88
AVS-3750	CPE	JE	----	----	VERO	320.00	----	3/16/88
AVS-3750	CPE	PT	----	----	VERO	100.00	----	4/14/88
AVS-3750	CPE	VEE	----	----	VERO	100.00	----	3/16/88
AVS-3750	CPE	YFV	0.15	----	VERO	320.00	----	3/16/88
AVS-3751	CPE	JE	----	----	VERO	100.00	----	3/16/88
AVS-3751	CPE	PT	----	----	VERO	320.00	----	4/14/88
AVS-3751	CPE	SF	1.6	----	VERO	320.00	----	3/16/88
AVS-3751	CPE	VEE	----	----	VERO	320.00	----	3/16/88
AVS-3751	CPE	YFV	----	----	VERO	32.00	----	3/16/88
AVS-3752	CPE	JE	----	----	VERO	100.00	----	3/16/88
AVS-3752	CPE	PT	----	----	VERO	320.00	----	4/14/88
AVS-3752	CPE	VEE	----	----	VERO	100.00	----	3/16/88
AVS-3752	CPE	YFV	----	----	VERO	320.00	----	3/16/88
AVS-3753	CPE	JE	----	----	VERO	100.00	----	3/16/88
AVS-3753	CPE	PT	----	----	VERO	320.00	----	4/14/88
AVS-3753	CPE	VEE	----	----	VERO	1.00	----	3/16/88
AVS-3753	CPE	YFV	----	----	VERO	320.00	----	3/16/88
AVS-3754	CPE	JE	0.05	----	VERO	32.00	----	3/22/88
AVS-3754	CPE	PT	----	----	VERO	320.00	----	4/15/88
AVS-3754	CPE	SF	0.3	320.00	VERO	32.00	0.10	3/22/88
AVS-3754	CPE	VEE	----	----	VERO	32.00	----	3/22/88
AVS-3754	CPE	YFV	----	----	VERO	320.00	----	3/22/88
AVS-3755	CPE	JE	----	----	VERO	100.00	----	3/22/88
AVS-3755	CPE	PT	----	----	VERO	100.00	----	4/15/88
AVS-3755	CPE	SF	0.15	----	VERO	100.00	----	3/22/88
AVS-3755	CPE	VEE	----	----	VERO	10.00	----	3/22/88
AVS-3755	CPE	YFV	----	----	VERO	320.00	----	3/22/88
AVS-3756	CPE	JE	----	----	VERO	100.00	----	3/22/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3756	CPE	PT	----	----	VERO >	320.00	----	4/15/88
AVS-3756	CPE	SF	----	----	VERO	100.00	----	3/22/88
AVS-3756	CPE	VEE	----	----	VERO	3.20	----	3/22/88
AVS-3756	CPE	YFV	----	----	VERO	320.00	----	3/22/88
AVS-3757	CPE	JE	----	----	VERO	100.00	----	3/22/88
AVS-3757	CPE	PT	----	----	VERO >	320.00	----	4/15/88
AVS-3757	CPE	SF	0.25	----	VERO	100.00	----	3/22/88
AVS-3757	CPE	VEE	----	----	VERO	10.00	----	3/22/88
AVS-3757	CPE	YFV	----	----	VERO	320.00	----	3/22/88
AVS-3758	CPE	JE	----	----	VERO	100.00	----	3/22/88
AVS-3758	CPE	PT	----	----	VERO	100.00	----	4/15/88
AVS-3758	CPE	SF	0.15	----	VERO	32.00	----	3/22/88
AVS-3758	CPE	VEE	----	----	VERO	0.32	----	3/22/88
AVS-3758	CPE	YFV	----	----	VERO	100.00	----	3/22/88
AVS-3759	CPE	JE	----	----	VERO	100.00	----	3/22/88
AVS-3759	CPE	PT	----	----	VERO	100.00	----	4/15/88
AVS-3759	CPE	SF	0.25	----	VERO	32.00	----	3/22/88
AVS-3759	CPE	VEE	----	----	VERO	100.00	----	3/22/88
AVS-3759	CPE	YFV	----	----	VERO	32.00	----	3/22/88
AVS-3761	CPE	JE	0.25	----	VERO	32.00	----	3/22/88
AVS-3761	CPE	SF	0.3	320.00	VERO	32.00	0.10	3/22/88
AVS-3761	CPE	VEE	----	----	VERO	1.00	----	3/22/88
AVS-3761	CPE	YFV	----	----	VERO	32.00	----	3/22/88
AVS-3762	CPE	JE	0.2	----	VERO	3.20	----	3/22/88
AVS-3762	CPE	PT	----	----	VERO	10.00	----	4/15/88
AVS-3762	CPE	SF	1.1	7.70	VERO	10.00	1.28	3/22/88
AVS-3762	CPE	VEE	----	----	VERO	10.00	----	3/22/88
AVS-3762	CPE	YFV	----	----	VERO	10.00	----	3/22/88
AVS-3763	CPE	JE	----	----	VERO	100.00	----	3/22/88
AVS-3763	CPE	PT	----	----	VERO	320.00	----	4/15/88
AVS-3763	CPE	SF	0.35	----	VERO	100.00	----	3/22/88
AVS-3763	CPE	VEE	----	----	VERO	320.00	----	3/22/88
AVS-3763	CPE	YFV	----	----	VERO	320.00	----	3/22/88
AVS-3764	CPE	JE	0.6	178.00	VERO	100.00	0.56	3/22/88
AVS-3764	CPE	SF	0.85	118.00	VERO	32.00	0.27	3/22/88
AVS-3764	CPE	VEE	----	----	VERO	100.00	----	3/22/88
AVS-3764	CPE	YFV	0.6	178.00	VERO	100.00	0.56	3/22/88
AVS-3765	CPE	JE	----	----	VERO	100.00	----	3/30/88
AVS-3765	CPE	VEE	----	----	VERO >	100.00	----	3/30/88
AVS-3765	CPE	YFV	----	----	VERO	100.00	----	3/30/88
AVS-3766	CPE	JE	----	----	VERO	100.00	----	3/30/88
AVS-3766	CPE	VEE	----	----	VERO	100.00	----	3/30/88
AVS-3766	CPE	YFV	----	----	VERO	100.00	----	3/30/88
AVS-3767	CPE	JE	----	----	VERO	32.00	----	3/30/88
AVS-3767	CPE	VEE	----	----	VERO	32.00	----	3/30/88
AVS-3767	CPE	YFV	----	----	VERO	32.00	----	3/30/88
AVS-3769	CPE	JE	----	----	VERO	3.20	----	3/30/88
AVS-3769	CPE	VEE	----	----	VERO	1.00	----	3/30/88
AVS-3769	CPE	YFV	----	----	VERO	10.00	----	3/30/88
AVS-3770	CPE	JE	----	----	VERO >	320.00	----	3/30/88
AVS-3770	CPE	VEE	----	----	VERO >	320.00	----	3/30/88
AVS-3770	CPE	YFV	----	----	VERO >	320.00	----	3/30/88
AVS-3771	CPE	JE	----	----	VERO	100.00	----	3/30/88
AVS-3771	CPE	VEE	----	----	VERO	100.00	----	3/30/88
AVS-3771	CPE	YFV	----	----	VERO	32.00	----	3/30/88
AVS-3772	CPE	JE	----	----	VERO	10.00	----	3/30/88
AVS-3772	CPE	VEE	----	----	VERO	32.00	----	3/30/88
AVS-3772	CPE	YFV	----	----	VERO	3.20	----	3/30/88
AVS-3773	CPE	JE	----	----	VERO	10.00	----	3/30/88
AVS-3773	CPE	VEE	----	----	VERO	10.00	----	3/30/88
AVS-3773	CPE	YFV	----	----	VERO	32.00	----	3/30/88
AVS-3774	CPE	JE	----	----	VERO	3.20	----	3/30/88
AVS-3774	CPE	VEE	----	----	VERO	32.00	----	3/30/88
AVS-3774	CPE	YFV	----	----	VERO	3.20	----	3/30/88
AVS-3775	CPE	JE	----	----	VERO	100.00	----	3/30/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3775	CPE	VEE	----	----	VERO	100.00	----	3/30/88
AVS-3775	CPE	YFV	----	----	VERO	32.00	----	3/30/88
AVS-3776	CPE	JE	----	----	VERO	100.00	----	3/30/88
AVS-3776	CPE	VEE	----	----	VERO	320.00	----	3/30/88
AVS-3776	CPE	YFV	----	----	VERO	320.00	----	3/30/88
AVS-3777	CPE	JE	----	----	VERO	100.00	----	3/30/88
AVS-3777	CPE	VEE	----	----	VERO	320.00	----	3/30/88
AVS-3777	CPE	YFV	----	----	VERO	100.00	----	3/30/88
AVS-3778	CPE	JE	----	----	VERO	320.00	----	3/30/88
AVS-3778	CPE	VEE	----	----	VERO	320.00	----	3/30/88
AVS-3778	CPE	YFV	----	----	VERO	100.00	----	3/30/88
AVS-3779	CPE	JE	----	----	VERO	32.00	----	3/30/88
AVS-3779	CPE	VEE	----	----	VERO	32.00	----	3/30/88
AVS-3779	CPE	YFV	----	----	VERO	32.00	----	3/30/88
AVS-3780	CPE	JE	----	----	VERO	10.00	----	3/30/88
AVS-3780	CPE	VEE	----	----	VERO	3.20	----	3/30/88
AVS-3780	CPE	YFV	----	----	VERO	10.00	----	3/30/88
AVS-3781	CPE	JE	----	----	VERO	3.20	----	3/31/88
AVS-3781	CPE	SF	----	----	VERO	1.00	----	3/31/88
AVS-3781	CPE	VEE	----	----	VERO	3.20	----	3/31/88
AVS-3781	CPE	YFV	0.05	----	VERO	3.20	----	3/31/88
AVS-3782	CPE	JE	----	----	VERO	10.00	----	3/31/88
AVS-3782	CPE	SF	----	----	VERO	1.00	----	3/31/88
AVS-3782	CPE	VEE	----	----	VERO	3.20	----	3/31/88
AVS-3782	CPE	YFV	----	----	VERO	3.20	----	3/31/88
AVS-3783	CPE	JE	----	----	VERO	10.00	----	3/31/88
AVS-3783	CPE	SF	0.1	----	VERO	1.00	----	3/31/88
AVS-3783	CPE	VEE	----	----	VERO	3.20	----	3/31/88
AVS-3783	CPE	YFV	----	----	VERO	3.20	----	3/31/88
AVS-3784	CPE	JE	----	----	VERO	3.20	----	3/31/88
AVS-3784	CPE	SF	----	----	VERO	1.00	----	3/31/88
AVS-3784	CPE	VEE	----	----	VERO	3.20	----	3/31/88
AVS-3784	CPE	YFV	----	----	VERO	3.20	----	3/31/88
AVS-3785	CPE	JE	----	----	VERO	3.20	----	3/31/88
AVS-3785	CPE	SF	0.45	2.17	VERO	1.00	0.46	3/31/88
AVS-3785	CPE	VEE	----	----	VERO	3.20	----	3/31/88
AVS-3785	CPE	YFV	0.1	----	VERO	3.20	----	3/31/88
AVS-3786	CPE	JE	----	----	VERO	10.00	----	3/31/88
AVS-3786	CPE	SF	0.4	2.76	VERO	1.00	0.36	3/31/88
AVS-3786	CPE	VEE	----	----	VERO	3.20	----	3/31/88
AVS-3786	CPE	YFV	0.05	----	VERO	3.20	----	3/31/88
AVS-3787	CPE	JE	----	----	VERO	3.20	----	3/31/88
AVS-3787	CPE	SF	0.5	2.21	VERO	1.00	0.45	3/31/88
AVS-3787	CPE	VEE	----	----	VERO	3.20	----	3/31/88
AVS-3787	CPE	YFV	----	----	VERO	3.20	----	3/31/88
AVS-3788	CPE	JE	----	----	VERO	32.00	----	3/31/88
AVS-3788	CPE	SF	0.6	32.00	VERO	100.00	3.12	3/31/88
AVS-3788	CPE	VEE	----	----	VERO	32.00	----	3/31/88
AVS-3788	CPE	YFV	0.45	21.70	VERO	32.00	1.47	3/31/88
AVS-3789	CPE	JE	0.4	7.50	VERO	10.00	1.33	3/31/88
AVS-3789	CPE	SF	0.8	6.40	VERO	10.00	1.56	3/31/88
AVS-3789	CPE	VEE	----	----	VERO	10.00	----	3/31/88
AVS-3789	CPE	YFV	0.5	6.90	VERO	3.20	0.46	3/31/88
AVS-3790	CPE	JE	----	----	VERO	32.00	----	3/31/88
AVS-3790	CPE	SF	0.6	84.90	VERO	10.00	0.12	3/31/88
AVS-3790	CPE	VEE	----	----	VERO	100.00	----	3/31/88
AVS-3790	CPE	YFV	0.2	----	VERO	100.00	----	3/31/88
AVS-3791	CPE	JE	----	----	VERO	3.20	----	3/31/88
AVS-3791	CPE	SF	----	----	VERO	10.00	----	3/31/88
AVS-3791	CPE	VEE	----	----	VERO	1.00	----	3/31/88
AVS-3791	CPE	YFV	0.5	----	VERO	1.00	----	3/31/88
AVS-3792	CPE	JE	----	----	VERO	3.20	----	3/31/88
AVS-3792	CPE	SF	0.25	----	VERO	10.00	----	3/31/88
AVS-3792	CPE	VEE	----	----	VERO	1.00	----	3/31/88
AVS-3792	CPE	YFV	0.4	----	VERO	3.20	----	3/31/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3793	CPE	JE	----	----	VERO	32.00	----	3/31/88
AVS-3793	CPE	SF	----	----	VERO	32.00	----	3/31/88
AVS-3793	CPE	VEE	----	----	VERO	3.20	----	3/31/88
AVS-3793	CPE	YFV	0.45	----	VERO	10.00	----	3/31/88
AVS-3794	CPE	JE	----	----	VERO	1.00	----	3/31/88
AVS-3794	CPE	SF	----	----	VERO	1.00	----	3/31/88
AVS-3794	CPE	VEE	----	----	VERO	1.00	----	3/31/88
AVS-3794	CPE	YFV	0.35	----	VERO	1.00	----	3/31/88
AVS-3796	CPE	JE	----	----	VERO	10.00	----	3/31/88
AVS-3796	CPE	SF	----	----	VERO	10.00	----	3/31/88
AVS-3796	CPE	VEE	----	----	VERO	3.20	----	3/31/88
AVS-3796	CPE	YFV	0.1	----	VERO	3.20	----	3/31/88
AVS-3797	CPE	JE	----	----	VERO	3.20	----	4/ 5/88
AVS-3797	CPE	PT	----	----	VERO	10.00	----	4/ 5/88
AVS-3797	CPE	VEE	----	----	VERO	1.00	----	4/ 5/88
AVS-3797	CPE	YFV	----	----	VERO	10.00	----	4/ 5/88
AVS-3798	CPE	JE	0.2	----	VERO	3.20	----	4/ 5/88
AVS-3798	CPE	PT	----	----	VERO	3.20	----	4/ 5/88
AVS-3798	CPE	VEE	----	----	VERO	32.00	----	4/ 5/88
AVS-3798	CPE	YFV	----	----	VERO	320.00	----	4/ 5/88
AVS-3799	CPE	JE	1.75	5.60	VERO	3.20	0.57	4/ 5/88
AVS-3799	CPE	PT	0.6	21.70	VERO	3.20	0.15	4/ 5/88
AVS-3799	CPE	VEE	0.85	19.40	VERO	10.00	0.51	4/ 5/88
AVS-3799	CPE	YFV	----	----	VERO	10.00	----	4/ 5/88
AVS-3800	CPE	JE	1.6	0.97	VERO <	0.32 <	0.33	4/ 5/88
AVS-3800	CPE	PT	1.6	2.61	VERO	3.20	1.22	4/ 5/88
AVS-3800	CPE	VEE	2.25	0.96	VERO	10.00	10.30	4/ 5/88
AVS-3800	CPE	YFV	----	----	VERO	1.00	----	4/ 5/88
AVS-3801	CPE	JE	2.4	0.56	VERO <	0.32 <	0.57	4/ 5/88
AVS-3801	CPE	PT	1.7	2.79	VERO	1.00	0.36	4/ 5/88
AVS-3801	CPE	VEE	1.4	1.53	VERO	1.00	0.65	4/ 5/88
AVS-3801	CPE	YFV	----	----	VERO >	320.00	----	4/ 5/88
AVS-3802	CPE	JE	2.1	0.59	VERO <	0.32 <	0.54	4/ 5/88
AVS-3802	CPE	PT	1.7	1.88	VERO	1.00	0.53	4/ 5/88
AVS-3802	CPE	VEE	1.85	1.00	VERO	3.20	3.17	4/ 5/88
AVS-3802	CPE	YFV	----	----	VERO	320.00	----	4/ 5/88
AVS-3803	CPE	JE	1.2	1.78	VERO	1.00	0.56	4/ 5/88
AVS-3803	CPE	PT	0.55	5.90	VERO	10.00	1.67	4/ 5/88
AVS-3803	CPE	VEE	0.85	10.30	VERO	10.00	0.97	4/ 5/88
AVS-3803	CPE	YFV	----	----	VERO	32.00	----	4/ 5/88
AVS-3805	CPE	JE	0.05	----	VERO	3.20	----	4/ 5/88
AVS-3805	CPE	PT	----	----	VERO	10.00	----	4/ 5/88
AVS-3805	CPE	VEE	----	----	VERO	10.00	----	4/ 5/88
AVS-3805	CPE	YFV	----	----	VERO	3.20	----	4/ 5/88
AVS-3828	CPE	JE	----	----	VERO	3.20	----	6/ 7/88
AVS-3828	CPE	PT	----	----	VERO	10.00	----	6/ 7/88
AVS-3828	CPE	SF	0.2	----	VERO	3.20	----	6/ 7/88
AVS-3828	CPE	VEE	----	----	VERO	3.20	----	6/ 7/88
AVS-3829	CPE	JE	0.05	----	VERO	3.20	----	6/ 7/88
AVS-3829	CPE	PT	----	----	VERO	10.00	----	6/ 7/88
AVS-3829	CPE	SF	1.3	0.85	VERO	3.20	3.76	6/ 7/88
AVS-3829	CPE	VEE	----	----	VERO	32.00	----	6/ 7/88
AVS-3830	CPE	JE	----	----	VERO	1.00	----	6/ 7/88
AVS-3830	CPE	PT	----	----	VERO	3.20	----	6/ 7/88
AVS-3830	CPE	SF	1.05	21.70	VERO	10.00	0.46	6/ 7/88
AVS-3830	CPE	VEE	----	----	VERO	32.00	----	6/ 7/88
AVS-3832	CPE	JE	0.15	----	VERO	10.00	----	6/ 7/88
AVS-3832	CPE	PT	----	----	VERO	10.00	----	6/ 7/88
AVS-3832	CPE	SF	0.55	22.10	VERO	32.00	1.44	6/ 7/88
AVS-3832	CPE	VEE	----	----	VERO	32.00	----	6/ 7/88
AVS-3833	CPE	JE	----	----	VERO >	320.00	----	6/ 8/88
AVS-3833	CPE	PT	----	----	VERO	320.00	----	6/ 8/88
AVS-3833	CPE	VEE	----	----	VERO	320.00	----	6/ 8/88
AVS-3834	CPE	JE	----	----	VERO >	320.00	----	6/ 8/88
AVS-3834	CPE	PT	-0-	----	VERO >	320.00	----	6/ 8/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-3834	CPE	VEE	----	----	VERO	100.00	----	6/ 8/88
AVS-3835	CPE	JE	----	----	VERO	32.00	----	6/ 8/88
AVS-3835	CPE	PT	0.15	----	VERO	32.00	----	6/ 8/88
AVS-3835	CPE	VEE	----	----	VERO	100.00	----	6/ 8/88
AVS-3836	CPE	JE	----	----	VERO	10.00	----	6/ 8/88
AVS-3836	CPE	PT	0.65	49.80	VERO	10.00	0.20	6/ 8/88
AVS-3836	CPE	VEE	----	----	VERO	32.00	----	6/ 8/88
AVS-3837	CPE	JE	----	----	VERO	32.00	----	6/ 8/88
AVS-3837	CPE	PT	----	----	VERO	320.00	----	6/ 8/88
AVS-3837	CPE	VEE	----	----	VERO	320.00	----	6/ 8/88
AVS-3842	CPE	JE	----	----	VERO	3.20	----	6/ 8/88
AVS-3842	CPE	PT	----	----	VERO	10.00	----	6/ 8/88
AVS-3842	CPE	VEE	----	----	VERO	1.00	----	6/ 8/88
AVS-3843	CPE	AD2	----	----	HEP2 <	3.20	----	6/ 2/88
AVS-3843	CPE	VSV	----	----	L929 <	1.00	----	5/10/88
AVS-3843	CPE	VV	----	----	VERO <	1.00	----	6/ 2/88
AVS-3849	CPE	JE	----	----	VERO	10.00	----	6/ 8/88
AVS-3849	CPE	PT	----	----	VERO	10.00	----	6/ 8/88
AVS-3849	CPE	VEE	----	----	VERO	10.00	----	6/ 8/88
AVS-3850	CPE	JE	----	----	VERO	32.00	----	6/ 8/88
AVS-3850	CPE	PT	----	----	VERO	32.00	----	6/ 8/88
AVS-3850	CPE	VEE	----	----	VERO	10.00	----	6/ 8/88
AVS-3851	CPE	JE	0.2	----	VERO	1.00	----	6/ 8/88
AVS-3851	CPE	PT	0.25	----	VERO	10.00	----	6/ 8/88
AVS-3851	CPE	VEE	----	----	VERO	10.00	----	6/ 8/88
AVS-3852	CPE	JE	0.5	70.90	VERO	32.00	0.45	6/ 8/88
AVS-3852	CPE	PT	0.15	----	VERO	100.00	----	6/ 8/88
AVS-3852	CPE	VEE	----	----	VERO	32.00	----	6/ 8/88
AVS-3853	CPE	JE	----	----	VERO	100.00	----	6/ 8/88
AVS-3853	CPE	PT	----	----	VERO	100.00	----	6/ 8/88
AVS-3853	CPE	VEE	----	----	VERO	10.00	----	6/ 8/88
AVS-3854	CPE	JE	----	----	VERO	32.00	----	6/ 8/88
AVS-3854	CPE	PT	0.15	----	VERO	100.00	----	6/ 8/88
AVS-3854	CPE	VEE	----	----	VERO	32.00	----	6/ 8/88
AVS-3855	CPE	JE	----	----	VERO	32.00	----	6/ 8/88
AVS-3855	CPE	PT	----	----	VERO	100.00	----	6/ 8/88
AVS-3855	CPE	VEE	----	----	VERO	32.00	----	6/ 8/88
AVS-3856	CPE	JE	----	----	VERO	3.20	----	6/ 8/88
AVS-3856	CPE	PT	----	----	VERO <	32.00	----	6/ 8/88
AVS-3856	CPE	VEE	----	----	VERO	10.00	----	6/ 8/88
AVS-3857	CPE	JE	0.55	5.90	VERO	3.20	0.54	6/ 8/88
AVS-3857	CPE	PT	0.9	4.45	VERO	10.00	2.24	6/ 8/88
AVS-3857	CPE	VEE	1.2	5.60	VERO	10.00	1.76	6/ 8/88
AVS-3858	CPE	JE	----	----	VERO	0.32	----	6/14/88
AVS-3858	CPE	PT	----	----	VERO	1.00	----	6/14/88
AVS-3858	CPE	SF	0.75	0.69	VERO	0.32	0.46	6/14/88
AVS-3858	CPE	VEE	0.55	1.88	VERO	3.20	1.69	6/14/88
AVS-3859	CPE	JE	----	----	VERO	10.00	----	6/14/88
AVS-3859	CPE	PT	0.15	----	VERO	10.00	----	6/14/88
AVS-3859	CPE	SF	0.55	----	VERO	10.00	----	6/14/88
AVS-3859	CPE	VEE	----	----	VERO	32.00	----	6/14/88
AVS-3860	CPE	JE	----	----	VERO	10.00	----	6/14/88
AVS-3860	CPE	PT	0.15	----	VERO	10.00	----	6/14/88
AVS-3860	CPE	SF	0.45	81.90	VERO	32.00	0.39	6/14/88
AVS-3860	CPE	VEE	----	----	VERO	100.00	----	6/14/88
AVS-3861	CPE	JE	----	----	VERO	3.20	----	6/14/88
AVS-3861	CPE	PT	0.25	----	VERO	32.00	----	6/14/88
AVS-3861	CPE	SF	0.8	42.80	VERO	32.00	0.75	6/14/88
AVS-3861	CPE	VEE	----	----	VERO	100.00	----	6/14/88
AVS-3862	CPE	JE	----	----	VERO	3.20	----	6/14/88
AVS-3862	CPE	PT	----	----	VERO	10.00	----	6/14/88
AVS-3862	CPE	SF	0.2	----	VERO	32.00	----	6/14/88
AVS-3862	CPE	VEE	----	----	VERO >	100.00	----	6/14/88
AVS-3863	CPE	JE	----	----	VERO	32.00	----	6/14/88
AVS-3863	CPE	PT	0.35	84.90	VERO	100.00	1.17	6/14/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-3863	CPE	SF	0.3	----	VERO	32.00	----	6/14/88
AVS-3863	CPE	VEE	----	----	VERO	100.00	----	6/14/88
AVS-3864	CPE	JE	----	----	VERO	32.00	----	6/14/88
AVS-3864	CPE	PT	0.15	----	VERO	100.00	----	6/14/88
AVS-3864	CPE	SF	0.55	----	VERO	32.00	----	6/14/88
AVS-3864	CPE	VEE	----	----	VERO	100.00	----	6/14/88
AVS-3865	CPE	JE	----	----	VERO	3.20	----	6/14/88
AVS-3865	CPE	PT	0.2	----	VERO	10.00	----	6/14/88
AVS-3865	CPE	SF	1.15	63.20	VERO	10.00	0.16	6/14/88
AVS-3865	CPE	VEE	----	----	VERO	100.00	----	6/14/88
AVS-3866	CPE	JE	----	----	VERO	10.00	----	6/21/88
AVS-3866	CPE	PT	1.5	13.30	VERO	32.00	2.40	6/21/88
AVS-3866	CPE	SF	0.8	50.40	VERO	100.00	1.98	6/21/88
AVS-3867	CPE	JE	0.15	----	VERO	3.20	----	6/21/88
AVS-3867	CPE	PT	0.25	----	VERO	10.00	----	6/21/88
AVS-3867	CPE	SF	0.85	37.30	VERO	3.20	0.09	6/21/88
AVS-3868	CPE	JE	----	----	VERO	32.00	----	6/21/88
AVS-3868	CPE	PT	----	----	VERO	32.00	----	6/21/88
AVS-3868	CPE	SF	----	----	VERO	32.00	----	6/21/88
AVS-3869	CPE	JE	----	----	VERO	1.00	----	6/21/88
AVS-3869	CPE	PT	----	----	VERO	1.00	----	6/21/88
AVS-3869	CPE	SF	----	----	VERO	3.20	----	6/21/88
AVS-3870	CPE	JE	----	----	VERO	1.00	----	6/21/88
AVS-3870	CPE	PT	----	----	VERO	3.20	----	6/21/88
AVS-3870	CPE	SF	----	----	VERO	10.00	----	6/21/88
AVS-3871	CPE	JE	----	----	VERO	32.00	----	6/21/88
AVS-3871	CPE	PT	----	----	VERO	10.00	----	6/21/88
AVS-3871	CPE	SF	----	----	VERO	32.00	----	6/21/88
AVS-3872	CPE	JE	----	----	VERO	32.00	----	6/21/88
AVS-3872	CPE	PT	----	----	VERO	10.00	----	6/21/88
AVS-3872	CPE	SF	----	----	VERO	32.00	----	6/21/88
AVS-3873	CPE	JE	0.15	----	VERO	10.00	----	6/21/88
AVS-3873	CPE	PT	----	----	VERO	32.00	----	6/21/88
AVS-3873	CPE	SF	0.15	----	VERO	10.00	----	6/21/88
AVS-3874	CPE	JE	----	----	VERO	32.00	----	6/22/88
AVS-3874	CPE	PT	0.1	----	VERO	32.00	----	6/22/88
AVS-3874	CPE	SF	1.05	69.10	VERO	32.00	0.46	6/22/88
AVS-3874	CPE	VEE	----	----	VERO	32.00	----	6/22/88
AVS-3874	CPE	YFV	0.15	----	VERO	32.00	----	6/22/88
AVS-3875	CPE	JE	----	----	VERO	32.00	----	6/22/88
AVS-3875	CPE	PT	----	----	VERO	32.00	----	6/22/88
AVS-3875	CPE	SF	0.7	91.00	VERO	32.00	0.35	6/22/88
AVS-3875	CPE	VEE	----	----	VERO	32.00	----	6/22/88
AVS-3875	CPE	YFV	----	----	VERO	32.00	----	6/22/88
AVS-3876	CPE	JE	----	----	VERO	10.00	----	6/22/88
AVS-3876	CPE	PT	----	----	VERO	10.00	----	6/22/88
AVS-3876	CPE	SF	0.65	----	VERO	32.00	----	6/22/88
AVS-3876	CPE	VEE	----	----	VERO	32.00	----	6/22/88
AVS-3876	CPE	YFV	0.2	----	VERO	10.00	----	6/22/88
AVS-3877	CPE	JE	----	----	VERO	100.00	----	6/22/88
AVS-3877	CPE	PT	----	----	VERO	32.00	----	6/22/88
AVS-3877	CPE	SF	0.5	----	VERO	10.00	----	6/22/88
AVS-3877	CPE	VEE	----	----	VERO	32.00	----	6/22/88
AVS-3877	CPE	YFV	0.15	----	VERO	10.00	----	6/22/88
AVS-3878	CPE	JE	----	----	VERO	10.00	----	6/22/88
AVS-3878	CPE	PT	----	----	VERO	32.00	----	6/22/88
AVS-3878	CPE	SF	0.05	----	VERO	10.00	----	6/22/88
AVS-3878	CPE	VEE	----	----	VERO	100.00	----	6/22/88
AVS-3878	CPE	YFV	0.05	----	VERO	32.00	----	6/22/88
AVS-3879	CPE	JE	----	----	VERO	10.00	----	6/22/88
AVS-3879	CPE	PT	----	----	VERO	32.00	----	6/22/88
AVS-3879	CPE	SF	0.25	----	VERO	3.20	----	6/22/88
AVS-3879	CPE	VEE	----	----	VERO	10.00	----	6/22/88
AVS-3879	CPE	YFV	----	----	VERO	10.00	----	6/22/88
AVS-3880	CPE	JE	----	----	VERO	1.00	----	6/22/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-3880	CPE	PT	0.25	----	VERO	10.00	----	6/22/88
AVS-3880	CPE	SF	1.1	6.50	VERO	3.20	0.49	6/22/88
AVS-3880	CPE	VEE	----	----	VERO	3.20	----	6/22/88
AVS-3880	CPE	YFV	----	----	VERO	3.20	----	6/22/88
AVS-3881	CPE	JE	0.3	----	VERO	3.20	----	6/22/88
AVS-3881	CPE	PT	0.6	56.50	VERO	10.00	0.18	6/22/88
AVS-3881	CPE	SF	1.1	22.20	VERO	10.00	0.45	6/22/88
AVS-3881	CPE	VEE	----	----	VERO	10.00	----	6/22/88
AVS-3881	CPE	YFV	1.04	20.70	VERO	10.00	0.48	6/22/88
AVS-3882	CPE	JE	----	----	VERO	10.00	----	6/22/88
AVS-3882	CPE	PT	----	----	VERO	32.00	----	6/22/88
AVS-3882	CPE	SF	0.65	----	VERO	32.00	----	6/22/88
AVS-3882	CPE	VEE	----	----	VERO	10.00	----	6/22/88
AVS-3882	CPE	YFV	0.4	----	VERO	3.20	----	6/22/88
AVS-3883	CPE	JE	----	----	VERO	10.00	----	6/22/88
AVS-3883	CPE	PT	0.35	27.00	VERO	32.00	1.18	6/22/88
AVS-3883	CPE	SF	0.7	20.00	VERO	10.00	0.50	6/22/88
AVS-3883	CPE	VEE	----	----	VERO	10.00	----	6/22/88
AVS-3883	CPE	YFV	----	----	VERO	10.00	----	6/22/88
AVS-3884	CPE	JE	0.05	----	VERO	10.00	----	6/22/88
AVS-3884	CPE	PT	----	----	VERO	32.00	----	6/22/88
AVS-3884	CPE	SF	0.5	32.00	VERO	10.00	0.31	6/22/88
AVS-3884	CPE	VEE	----	----	VERO	32.00	----	6/22/88
AVS-3884	CPE	YFV	0.2	----	VERO	10.00	----	6/22/88
AVS-3885	CPE	JE	0.05	----	VERO	3.20	----	6/22/88
AVS-3885	CPE	PT	----	----	VERO	1.00	----	6/22/88
AVS-3885	CPE	SF	0.5	10.00	VERO	3.20	0.32	6/22/88
AVS-3885	CPE	VEE	----	----	VERO	10.00	----	6/22/88
AVS-3885	CPE	YFV	0.1	----	VERO	3.20	----	6/22/88
AVS-3886	CPE	JE	----	----	VERO	10.00	----	6/22/88
AVS-3886	CPE	PT	----	----	VERO	32.00	----	6/22/88
AVS-3886	CPE	SF	1.15	13.20	VERO	10.00	0.76	6/22/88
AVS-3886	CPE	VEE	----	----	VERO	10.00	----	6/22/88
AVS-3886	CPE	YFV	----	----	VERO	10.00	----	6/22/88
AVS-3887	CPE	JE	----	----	VERO	32.00	----	6/22/88
AVS-3887	CPE	PT	----	----	VERO	32.00	----	6/22/88
AVS-3887	CPE	SF	0.35	----	VERO	32.00	----	6/22/88
AVS-3887	CPE	VEE	----	----	VERO	32.00	----	6/22/88
AVS-3887	CPE	YFV	0.2	----	VERO	32.00	----	6/22/88
AVS-3888	CPE	JE	----	----	VERO	32.00	----	6/22/88
AVS-3888	CPE	PT	----	----	VERO	10.00	----	6/22/88
AVS-3888	CPE	SF	1.15	48.70	VERO	32.00	0.65	6/22/88
AVS-3888	CPE	VEE	----	----	VERO	32.00	----	6/22/88
AVS-3888	CPE	YFV	0.15	----	VERO	32.00	----	6/22/88
AVS-3889	CPE	SF	0.3	----	VERO	32.00	----	6/28/88
AVS-3889	CPE	VEE	----	----	VERO	32.00	----	6/28/88
AVS-3890	CPE	SF	0.1	----	VERO	32.00	----	6/28/88
AVS-3890	CPE	VEE	----	----	VERO	10.00	----	6/28/88
AVS-3891	CPE	SF	0.85	6.80	VERO	10.00	1.46	6/28/88
AVS-3891	CPE	VEE	----	----	VERO	3.20	----	6/28/88
AVS-3892	CPE	SF	0.15	----	VERO	10.00	----	6/28/88
AVS-3892	CPE	VEE	----	----	VERO	10.00	----	6/28/88
AVS-3893	CPE	SF	0.05	----	VERO	32.00	----	6/28/88
AVS-3893	CPE	VEE	----	----	VERO	3.20	----	6/28/88
AVS-3894	CPE	SF	----	----	VERO	100.00	----	6/28/88
AVS-3894	CPE	VEE	----	----	VERO	100.00	----	6/28/88
AVS-3895	CPE	SF	----	----	VERO	100.00	----	6/28/88
AVS-3895	CPE	VEE	----	----	VERO	100.00	----	6/28/88
AVS-3896	CPE	SF	----	----	VERO	32.00	----	6/28/88
AVS-3896	CPE	VEE	----	----	VERO	32.00	----	6/28/88
AVS-3897	CPE	SF	0.45	21.70	VERO	10.00	0.46	6/28/88
AVS-3897	CPE	VEE	----	----	VERO	32.00	----	6/28/88
AVS-3898	CPE	SF	----	----	VERO	100.00	----	6/28/88
AVS-3898	CPE	VEE	----	----	VERO	100.00	----	6/28/88
AVS-3899	CPE	SF	0.2	----	VERO	100.00	----	6/28/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3899	CPE	VEE	----	----	VERO	100.00	----	6/28/88
AVS-3902	CPE	AD2	----	----	HEP2	3.20	----	5/26/88
AVS-3902	CPE	SF	0.45	217.00	VERO	100.00	0.46	6/28/88
AVS-3902	CPE	VEE	----	----	VERO	100.00	----	4/28/88
AVS-3902	CPE	VSV	----	----	L929	10.00	----	5/24/88
AVS-3902	CPE	VV	----	----	VERO <	32.00	----	5/26/88
AVS-3905	CPE	AD2	0.3	----	HEP2 <	320.00	----	11/12/87
AVS-3905	CPE	AD2	0.3	----	HEP2 <	320.00	----	12/17/87
AVS-3905	CPE	JE	----	----	VERO	320.00	----	1/13/88
AVS-3905	CPE	PT	----	----	VERO	32.00	----	12/21/87
AVS-3905	CPE	VSV	----	----	L929	32.00	----	11/20/87
AVS-3905	CPE	VV	0.15	----	VERO	100.00	----	11/12/87
AVS-3905	CPE	VV	0.35	----	VERO	100.00	----	12/17/87
AVS-3906	CPE	AD2	0.2	----	HEP2 <	320.00	----	2/18/88
AVS-3906	CPE	JE	----	----	VERO	10.00	----	3/16/88
AVS-3906	CPE	PT	----	----	VERO	32.00	----	4/14/88
AVS-3906	CPE	SF	1.25	3.20	VERO	10.00	3.12	3/16/88
AVS-3906	CPE	VEE	----	----	VERO	1.00	----	3/16/88
AVS-3906	CPE	VSV	----	----	L929	32.00	----	2/16/88
AVS-3906	CPE	VV	----	----	VERO <	100.00	----	2/18/88
AVS-3906	CPE	YFV	----	----	VERO	32.00	----	3/16/88
AVS-3907	CPE	AD2	----	----	HEP2 >	320.00	----	2/18/88
AVS-3907	CPE	JE	----	----	VERO	320.00	----	3/16/88
AVS-3907	CPE	PT	----	----	VERO >	320.00	----	4/14/88
AVS-3907	CPE	SF	0.45	----	VERO	100.00	----	3/16/88
AVS-3907	CPE	VEE	----	----	VERO	100.00	----	3/16/88
AVS-3907	CPE	VSV	----	----	L929 >	320.00	----	2/16/88
AVS-3907	CPE	VV	----	----	VERO >	320.00	----	2/18/88
AVS-3907	CPE	YFV	----	----	VERO	320.00	----	3/16/88
AVS-3908	CPE	AD2	0.6	----	HEP2 >	320.00	----	2/18/88
AVS-3908	CPE	JE	----	----	VERO	320.00	----	3/16/88
AVS-3908	CPE	PT	----	----	VERO <	100.00	----	4/14/88
AVS-3908	CPE	SF	2.23	194.00	VERO	32.00	0.16	3/16/88
AVS-3908	CPE	VEE	----	----	VERO	32.00	----	3/16/88
AVS-3908	CPE	VSV	----	----	L929	100.00	----	2/16/88
AVS-3908	CPE	VV	0.3	----	VERO	100.00	----	2/18/88
AVS-3908	CPE	YFV	----	----	VERO <	320.00	----	3/16/88
AVS-3909	CPE	AD2	----	----	HEP2 >	320.00	----	2/11/88
AVS-3909	CPE	JE	----	----	VERO	100.00	----	3/21/88
AVS-3909	CPE	SF	----	----	VERO >	320.00	----	3/21/88
AVS-3909	CPE	VEE	----	----	VERO	100.00	----	3/21/88
AVS-3909	CPE	VSV	----	----	L929 >	320.00	----	2/16/88
AVS-3909	CPE	VV	----	----	VERO >	320.00	----	2/11/88
AVS-3909	CPE	YFV	----	----	VERO >	320.00	----	3/21/88
AVS-3910	CPE	AD2	1.2	56.50	HEP2 <	320.00 <	5.66	2/18/88
AVS-3910	CPE	AD2	1.1	204.00	HEP2 >	320.00 >	1.56	3/10/88
AVS-3910	CPE	JE	----	----	VERO	320.00	----	3/21/88
AVS-3910	CPE	SF	----	----	VERO	320.00	----	3/21/88
AVS-3910	CPE	VEE	----	----	VERO	100.00	----	3/21/88
AVS-3910	CPE	VSV	----	----	L929 >	320.00	----	2/16/88
AVS-3910	CPE	VV	0.3	----	VERO <	320.00	----	2/18/88
AVS-3910	CPE	YFV	----	----	VERO	320.00	----	3/21/88
AVS-3911	CPE	AD2	0.7	319.00	HEP2 >	320.00 >	1.00	2/18/88
AVS-3911	CPE	JE	----	----	VERO	320.00	----	3/21/88
AVS-3911	CPE	SF	----	----	VERO	320.00	----	3/21/88
AVS-3911	CPE	VEE	----	----	VERO	100.00	----	3/21/88
AVS-3911	CPE	VSV	----	----	L929 >	320.00	----	2/16/88
AVS-3911	CPE	VV	----	----	VERO >	320.00	----	2/18/88
AVS-3911	CPE	YFV	----	----	VERO	100.00	----	3/21/88
AVS-3912	CPE	AD2	0.75	178.00	HEP2	320.00	1.79	2/25/88
AVS-3912	CPE	JE	0.75	178.00	VERO	320.00	1.79	3/21/88
AVS-3912	CPE	SF	0.15	----	VERO	100.00	----	3/21/88
AVS-3912	CPE	VEE	----	----	VERO	32.00	----	3/21/88
AVS-3912	CPE	VSV	----	----	L929	100.00	----	2/16/88
AVS-3912	CPE	VV	7.9	0.29	VERO >	320.00 >	1070.00	3/10/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-3912	CPE	VV	8.3	0.19	VERO >	320.00	> 1600.00	3/31/88
AVS-3912	PR	VV	N/A	0.04	VERO	320.00	6920.00	7/15/88
AVS-3912	CPE	YFV	0.15	----	VERO	100.00	----	3/21/88
AVS-3913	CPE	AD2	0.7	320.00	HEP2	320.00	1.00	2/25/88
AVS-3913	CPE	JE	----	----	VERO	100.00	----	3/21/88
AVS-3913	CPE	SF	0.45	217.00	VERO	320.00	1.47	3/21/88
AVS-3913	CPE	VEE	----	----	VERO	100.00	----	3/21/88
AVS-3913	CPE	VSV	----	----	L929	320.00	----	2/16/88
AVS-3913	CPE	VV	2.1	67.10	VERO >	320.00	> 4.76	2/25/88
AVS-3913	CPE	VV	2.1	43.10	VERO	320.00	7.41	3/10/88
AVS-3913	CPE	YFV	----	----	VERO	100.00	----	3/21/88
AVS-3914	CPE	AD2	0.45	68.30	HEP2	100.00	1.46	2/25/88
AVS-3914	CPE	JE	----	----	VERO	3.20	----	3/21/88
AVS-3914	CPE	SF	0.7	17.80	VERO	10.00	0.56	3/21/88
AVS-3914	CPE	VEE	----	----	VERO	32.00	----	3/21/88
AVS-3914	CPE	VSV	----	----	L929	32.00	----	2/16/88
AVS-3914	CPE	VV	0.65	53.70	VERO	32.00	0.60	2/25/88
AVS-3914	CPE	YFV	----	----	VERO	3.20	----	3/21/88
AVS-3915	CPE	AD2	0.65	242.00	HEP2	320.00	1.31	2/25/88
AVS-3915	CPE	JE	0.3	----	VERO	32.00	----	3/21/88
AVS-3915	CPE	SF	0.85	77.90	VERO	100.00	1.28	3/21/88
AVS-3915	CPE	VEE	----	----	VERO	10.00	----	3/21/88
AVS-3915	CPE	VSV	----	----	L929	320.00	----	2/16/88
AVS-3915	CPE	VV	0.15	----	VERO	100.00	----	2/25/88
AVS-3915	CPE	YFV	0.2	----	VERO	100.00	----	3/21/88
AVS-3916	CPE	AD2	0.6	320.00	HEP2 >	320.00	> 1.00	2/25/88
AVS-3916	CPE	JE	----	----	VERO	320.00	----	3/21/88
AVS-3916	CPE	SF	----	----	VERO	320.00	----	3/21/88
AVS-3916	CPE	VEE	----	----	VERO >	320.00	----	3/21/88
AVS-3916	CPE	VSV	----	----	L929	320.00	----	2/16/88
AVS-3916	CPE	VV	----	----	VERO >	320.00	----	2/25/88
AVS-3916	CPE	YFV	----	----	VERO	320.00	----	3/21/88
AVS-3917	CPE	AD2	----	----	HEP2 <	100.00	----	2/25/88
AVS-3917	CPE	JE	----	----	VERO	10.00	----	3/21/88
AVS-3917	CPE	SF	0.2	----	VERO	10.00	----	3/21/88
AVS-3917	CPE	VEE	----	----	VERO	32.00	----	3/21/88
AVS-3917	CPE	VSV	----	----	L929 <	320.00	----	2/16/88
AVS-3917	CPE	VV	----	----	VERO	100.00	----	2/25/88
AVS-3917	CPE	YFV	----	----	VERO	32.00	----	3/21/88
AVS-3918	CPE	AD2	----	----	HEP2	100.00	----	2/25/88
AVS-3918	CPE	SF	0.95	29.70	VERO	10.00	0.34	3/21/88
AVS-3918	CPE	VEE	----	----	VERO	3.20	----	3/21/88
AVS-3918	CPE	VSV	----	----	L929 <	100.00	----	2/16/88
AVS-3918	CPE	VV	0.05	----	VERO	32.00	----	2/25/88
AVS-3918	CPE	YFV	----	----	VERO	32.00	----	3/21/88
AVS-3919	CPE	AD2	0.15	----	HEP2	10.00	----	2/25/88
AVS-3919	CPE	JE	0.15	----	VERO	3.20	----	3/21/88
AVS-3919	CPE	SF	0.45	6.80	VERO	10.00	1.46	3/21/88
AVS-3919	CPE	VEE	----	----	VERO	10.00	----	3/21/88
AVS-3919	CPE	VSV	----	----	L929	10.00	----	2/16/88
AVS-3919	CPE	VV	0.15	----	VERO	10.00	----	2/25/88
AVS-3919	CPE	YFV	----	----	VERO	10.00	----	3/21/88
AVS-3920	CPE	AD2	----	----	HEP2	10.00	----	2/25/88
AVS-3920	CPE	JE	0.1	----	VERO	3.20	----	3/21/88
AVS-3920	CPE	SF	0.1	----	VERO	3.20	----	3/21/88
AVS-3920	CPE	VEE	----	----	VERO	10.00	----	3/21/88
AVS-3920	CPE	VSV	----	----	L929 <	32.00	----	2/16/88
AVS-3920	CPE	VV	0.15	----	VERO	10.00	----	2/25/88
AVS-3920	CPE	YFV	----	----	VERO	3.20	----	3/21/88
AVS-3921	CPE	AD2	----	----	HEP2 >	320.00	----	2/25/88
AVS-3921	CPE	JE	----	----	VERO	320.00	----	3/21/88
AVS-3921	CPE	SF	----	----	VERO	320.00	----	3/21/88
AVS-3921	CPE	VEE	----	----	VERO	32.00	----	3/21/88
AVS-3921	CPE	VSV	----	----	L929 >	320.00	----	2/16/88
AVS-3921	CPE	VV	----	----	VERO >	320.00	----	2/25/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3921	CPE	YFV	----	----	VERO	320.00	----	3/21/88
AVS-3922	CPE	AD2	0.3	----	HEP2 >	320.00	----	2/25/88
AVS-3922	CPE	JE	----	----	VERO >	320.00	----	3/21/88
AVS-3922	CPE	SF	----	----	VERO	100.00	----	3/21/88
AVS-3922	CPE	VEE	----	----	VERO	100.00	----	3/21/88
AVS-3922	CPE	VSV	----	----	L929 >	320.00	----	2/16/88
AVS-3922	CPE	VV	----	----	VERO >	320.00	----	2/25/88
AVS-3922	CPE	YFV	----	----	VERO	100.00	----	3/21/88
AVS-3923	CPE	AD2	----	----	HEP2	320.00	----	2/25/88
AVS-3923	CPE	AD2	----	----	HEP2	320.00	----	3/ 3/88
AVS-3923	CPE	JE	----	----	VERO	32.00	----	3/21/88
AVS-3923	CPE	SF	0.15	----	VERO	32.00	----	3/21/88
AVS-3923	CPE	VEE	----	----	VERO	100.00	----	3/21/88
AVS-3923	CPE	VSV	----	----	L929	320.00	----	2/16/88
AVS-3923	CPE	VV	----	----	VERO >	320.00	----	2/25/88
AVS-3923	CPE	VV	----	----	VERO >	320.00	----	3/ 3/88
AVS-3923	CPE	YFV	----	----	VERO	32.00	----	3/21/88
AVS-3924	CPE	AD2	----	----	HEP2 >	320.00	----	2/25/88
AVS-3924	CPE	JE	0.65	----	VERO	320.00	----	3/22/88
AVS-3924	CPE	PT	----	----	VERO >	320.00	----	4/15/88
AVS-3924	CPE	SF	----	----	VERO	320.00	----	3/22/88
AVS-3924	CPE	VEE	----	----	VERO	10.00	----	3/22/88
AVS-3924	CPE	VSV	----	----	L929	320.00	----	2/16/88
AVS-3924	CPE	VV	----	----	VERO >	320.00	----	2/25/88
AVS-3924	CPE	YFV	0.1	----	VERO >	320.00	----	3/22/88
AVS-3935	CPE	AD2	----	----	HEP2	32.00	----	3/ 3/88
AVS-3935	CPE	JE	----	----	VERO >	320.00	----	4/ 5/88
AVS-3935	CPE	PT	----	----	VERO	32.00	----	4/ 5/88
AVS-3935	CPE	VEE	----	----	VERO <	320.00	----	4/ 5/88
AVS-3935	CPE	VSV	----	----	L929	3.20	----	2/19/88
AVS-3935	CPE	VV	----	----	VERO	100.00	----	3/ 3/88
AVS-3935	CPE	YFV	----	----	VERO	10.00	----	4/ 5/88
AVS-3936	CPE	AD2	0.65	199.00	HEP2	320.00	1.60	3/ 3/88
AVS-3936	CPE	JE	----	----	VERO >	320.00	----	4/ 5/88
AVS-3936	CPE	PT	----	----	VERO >	320.00	----	4/ 5/88
AVS-3936	CPE	VEE	----	----	VERO >	320.00	----	4/ 5/88
AVS-3936	CPE	VSV	----	----	L929	100.00	----	2/19/88
AVS-3936	CPE	VV	0.2	----	VERO >	320.00	----	3/ 3/88
AVS-3936	CPE	YFV	----	----	VERO	320.00	----	4/ 5/88
AVS-3937	CPE	AD2	0.4	----	HEP2 >	320.00	----	3/ 3/88
AVS-3937	CPE	JE	----	----	VERO	100.00	----	4/ 5/88
AVS-3937	CPE	PT	----	----	VERO >	320.00	----	4/ 5/88
AVS-3937	CPE	VEE	----	----	VERO >	320.00	----	4/ 5/88
AVS-3937	CPE	VSV	----	----	L929 >	320.00	----	2/19/88
AVS-3937	CPE	VV	0.2	----	VERO >	320.00	----	3/ 3/88
AVS-3937	CPE	YFV	----	----	VERO	320.00	----	4/ 5/88
AVS-3938	CPE	AD2	0.4	----	HEP2 >	320.00	----	3/ 3/88
AVS-3938	CPE	JE	----	----	VERO >	320.00	----	4/ 5/88
AVS-3938	CPE	PT	----	----	VERO >	320.00	----	4/ 5/88
AVS-3938	CPE	VEE	----	----	VERO >	320.00	----	4/ 5/88
AVS-3938	CPE	VSV	----	----	L929 >	320.00	----	2/19/88
AVS-3938	CPE	VV	----	----	VERO >	320.00	----	3/ 3/88
AVS-3938	CPE	YFV	----	----	VERO	10.00	----	4/ 5/88
AVS-3939	CPE	AD2	----	----	HEP2 <	320.00	----	3/ 3/88
AVS-3939	CPE	JE	----	----	VERO	100.00	----	4/ 5/88
AVS-3939	CPE	PT	----	----	VERO	100.00	----	4/ 5/88
AVS-3939	CPE	VEE	----	----	VERO	1.00	----	4/ 5/88
AVS-3939	CPE	VSV	----	----	L929	32.00	----	2/19/88
AVS-3939	CPE	VV	0.35	----	VERO	320.00	----	3/ 3/88
AVS-3939	CPE	YFV	----	----	VERO	10.00	----	4/ 5/88
AVS-3940	CPE	AD2	0.6	----	HEP2 >	320.00	----	3/ 3/88
AVS-3940	CPE	JE	----	----	VERO	320.00	----	4/ 5/88
AVS-3940	CPE	PT	----	----	VERO >	320.00	----	4/ 5/88
AVS-3940	CPE	VEE	----	----	VERO	100.00	----	4/ 5/88
AVS-3940	CPE	VSV	----	----	L929	100.00	----	2/19/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-3940	CPE	VV	5.	4.96	VERO >	320.00 >	64.30	3/ 3/88
AVS-3940	CPE	VV	4.4	9.40	VERO >	320.00 >	33.70	3/17/88
AVS-3940	PR	VV	N/A	0.48	VERO >	100.00 >	207.00	9/23/88
AVS-3940	CPE	YFV	----	----	VERO	100.00	----	4/ 5/88
AVS-3941	CPE	AD2	----	----	HEP2 >	320.00	----	3/ 3/88
AVS-3941	CPE	JE	----	----	VERO	320.00	----	4/ 5/88
AVS-3941	CPE	PT	----	----	VERO >	320.00	----	4/ 5/88
AVS-3941	CPE	VEE	----	----	VERO	3.20	----	4/ 5/88
AVS-3941	CPE	VSV	----	----	L929	320.00	----	2/19/88
AVS-3941	CPE	VV	6.3	0.98	VERO >	320.00 >	325.00	3/ 3/88
AVS-3941	CPE	VV	6.6	1.12	VERO >	320.00 >	265.00	3/17/88
AVS-3941	PR	VV	N/A	0.34	VERO	320.00	941.00	7/15/88
AVS-3941	CPE	YFV	----	----	VERO	100.00	----	4/ 5/88
AVS-3942	CPE	AD2	----	----	HEP2 >	320.00	----	3/ 3/88
AVS-3942	CPE	SF	----	----	VERO	100.00	----	4/ 6/88
AVS-3942	CPE	VEE	----	----	VERO	100.00	----	4/ 6/88
AVS-3942	CPE	VSV	----	----	L929	100.00	----	2/19/88
AVS-3942	CPE	VV	0.8	317.00	VERO >	320.00 >	1.00	3/ 3/88
AVS-3943	CPE	AD2	0.4	----	HEP2 >	320.00	----	3/ 3/88
AVS-3943	CPE	SF	----	----	VERO	320.00	----	4/ 6/88
AVS-3943	CPE	VEE	----	----	VERO	320.00	----	4/ 6/88
AVS-3943	CPE	VSV	----	----	L929	100.00	----	2/19/88
AVS-3943	CPE	VV	0.5	----	VERO >	320.00	----	3/ 3/88
AVS-3944	CPE	AD2	0.15	----	HEP2	320.00	----	3/ 3/88
AVS-3944	CPE	SF	----	----	VERO	100.00	----	4/ 6/88
AVS-3944	CPE	VEE	----	----	VERO	320.00	----	4/ 6/88
AVS-3944	CPE	VSV	----	----	L929	100.00	----	2/19/88
AVS-3944	CPE	VV	2.1	88.40	VERO >	320.00 >	3.61	3/ 3/88
AVS-3944	CPE	VV	1.8	99.00	VERO >	320.00 >	3.20	3/17/88
AVS-3945	CPE	AD2	----	----	HEP2 <	32.00	----	3/ 3/88
AVS-3945	CPE	SF	----	----	VERO	3.20	----	4/ 6/88
AVS-3945	CPE	VEE	----	----	VERO	10.00	----	4/ 6/88
AVS-3945	CPE	VSV	----	----	L929	32.00	----	2/19/88
AVS-3945	CPE	VV	0.4	32.00	VERO	32.00	1.00	3/ 3/88
AVS-3946	CPE	AD2	0.4	----	HEP2 >	320.00	----	3/ 3/88
AVS-3946	CPE	VEE	----	----	VERO	320.00	----	4/ 6/88
AVS-3946	CPE	VSV	----	----	L929	100.00	----	2/19/88
AVS-3946	CPE	VV	----	----	VERO >	320.00	----	3/ 3/88
AVS-3947	CPE	AD2	0.3	----	HEP2 >	320.00	----	3/ 3/88
AVS-3947	CPE	VEE	----	----	VERO >	320.00	----	4/ 6/88
AVS-3947	CPE	VSV	----	----	L929	320.00	----	2/19/88
AVS-3947	CPE	VV	----	----	VERO >	320.00	----	3/ 3/88
AVS-3962	CPE	AD2	0.8	277.00	HEP2 >	320.00 >	1.15	3/ 3/88
AVS-3962	CPE	VEE	----	----	VERO	320.00	----	4/ 6/88
AVS-3962	CPE	VSV	----	----	L929 >	320.00	----	2/19/88
AVS-3962	CPE	VV	0.2	----	VERO >	320.00	----	3/ 3/88
AVS-3963	CPE	AD2	0.6	----	HEP2 >	320.00	----	3/ 3/88
AVS-3963	CPE	SF	0.9	75.50	VERO	100.00	1.32	4/ 6/88
AVS-3963	CPE	VEE	----	----	VERO	320.00	----	4/ 6/88
AVS-3963	CPE	VSV	----	----	L929	100.00	----	2/19/88
AVS-3963	CPE	VV	2.1	50.40	VERO	320.00	6.33	3/ 3/88
AVS-3963	CPE	VV	2.4	17.80	VERO	100.00	5.59	3/17/88
AVS-3964	CPE	JE	----	----	VERO <	3.20	----	3/ 1/88
AVS-3964	PR	PIC	N/A	----	VERO	3.20	----	3/28/88
AVS-3964	CPE	PT	----	----	VERO >	0.03	----	12/22/87
AVS-3964	CPE	PT	0.75	14.70	VERO	10.00	0.68	3/ 1/88
AVS-3964	CPE	YFV	0.2	----	VERO	32.00	----	3/ 1/88
AVS-3964	CPE	YFV	1.	19.20	VERO	32.00	1.65	2/15/88
AVS-3965	CPE	JE	0.6	0.79	VERO	1.00	1.25	3/ 1/88
AVS-3965	PR	PIC	N/A	1.96	VERO	1.00	0.51	3/28/88
AVS-3965	CPE	PT	----	----	VERO >	100.00	----	12/22/87
AVS-3965	CPE	PT	0.7	0.50	VERO	0.32	0.63	3/ 1/88
AVS-3965	CPE	VEE	----	----	VERO <	10.00	----	3/ 1/88
AVS-3965	CPE	YFV	0.7	5.00	VERO	1.00	0.20	2/15/88
AVS-3967	CPE	AD2	0.9	320.00	HEP2 >	320.00 >	1.00	3/24/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-3967	CPE	JE	----	----	VERO >	320.00	----	4/12/88
AVS-3967	CPE	PT	0.3	----	VERO >	320.00	----	4/12/88
AVS-3967	CPE	SF	----	----	VERO	320.00	----	4/12/88
AVS-3967	CPE	VEE	----	----	VERO	320.00	----	4/12/88
AVS-3967	CPE	VSV	----	----	L929 >	320.00	----	3/18/88
AVS-3967	CPE	VV	0.4	----	VERO >	320.00	----	3/24/88
AVS-3967	CPE	YFV	----	----	VERO >	320.00	----	4/12/88
AVS-3968	CPE	AD2	0.9	320.00	HEP2	320.00	1.00	3/24/88
AVS-3968	CPE	JE	0.15	----	VERO	100.00	----	4/12/88
AVS-3968	CPE	PT	0.65	----	VERO	100.00	----	4/12/88
AVS-3968	CPE	SF	----	----	VERO	100.00	----	4/12/88
AVS-3968	CPE	VEE	----	----	VERO	320.00	----	4/12/88
AVS-3968	CPE	VSV	1.25	89.40	L929	320.00	3.57	3/18/88
AVS-3968	CPE	VV	1.65	56.50	VERO	100.00	1.76	3/24/88
AVS-3968	CPE	YFV	0.4	317.00	VERO	100.00	0.31	4/12/88
AVS-3969	CPE	AD2	0.4	----	HEP2 >	320.00	----	3/24/88
AVS-3969	CPE	JE	----	----	VERO	100.00	----	4/12/88
AVS-3969	CPE	PT	0.15	----	VERO	32.00	----	4/12/88
AVS-3969	CPE	SF	----	----	VERO	32.00	----	4/12/88
AVS-3969	CPE	VEE	----	----	VERO	32.00	----	4/12/88
AVS-3969	CPE	VSV	----	----	L929 >	320.00	----	3/18/88
AVS-3969	CPE	VV	----	----	VERO >	320.00	----	3/24/88
AVS-3969	CPE	YFV	----	----	VERO	100.00	----	4/12/88
AVS-3970	CPE	AD2	0.7	319.00	HEP2 >	320.00 >	1.00	3/24/88
AVS-3970	CPE	JE	0.05	----	VERO	100.00	----	4/12/88
AVS-3970	CPE	PT	0.25	----	VERO	100.00	----	4/12/88
AVS-3970	CPE	SF	0.1	----	VERO	100.00	----	4/12/88
AVS-3970	CPE	VEE	----	----	VERO	32.00	----	4/12/88
AVS-3970	CPE	VSV	----	----	L929 >	320.00	----	3/18/88
AVS-3970	CPE	VV	----	----	VERO >	320.00	----	3/24/88
AVS-3970	CPE	YFV	----	----	VERO	100.00	----	4/12/88
AVS-3971	CPE	AD2	0.6	----	HEP2 >	320.00	----	3/24/88
AVS-3971	CPE	JE	----	----	VERO	100.00	----	4/12/88
AVS-3971	CPE	PT	0.9	100.00	VERO	100.00	1.00	4/12/88
AVS-3971	CPE	SF	0.2	----	VERO	100.00	----	4/12/88
AVS-3971	CPE	VEE	----	----	VERO	100.00	----	4/12/88
AVS-3971	CPE	VSV	----	----	L929 >	320.00	----	3/18/88
AVS-3971	CPE	VV	0.45	----	VERO	320.00	----	3/24/88
AVS-3971	CPE	YFV	----	----	VERO	32.00	----	4/12/88
AVS-3972	CPE	AD2	0.8	----	HEP2 >	320.00	----	3/24/88
AVS-3972	CPE	JE	----	----	VERO	320.00	----	4/12/88
AVS-3972	CPE	PT	0.35	319.00	VERO	100.00	0.31	4/12/88
AVS-3972	CPE	SF	----	----	VERO	100.00	----	4/12/88
AVS-3972	CPE	VEE	----	----	VERO	100.00	----	4/12/88
AVS-3972	CPE	VSV	0.9	217.00	L929 >	320.00 >	1.47	3/18/88
AVS-3972	CPE	VV	0.6	----	VERO	320.00	----	3/24/88
AVS-3972	CPE	YFV	----	----	VERO	320.00	----	4/12/88
AVS-3973	CPE	AD2	0.5	----	HEP2 >	320.00	----	3/24/88
AVS-3973	CPE	JE	----	----	VERO >	320.00	----	4/13/88
AVS-3973	CPE	PT	----	----	VERO	32.00	----	4/13/88
AVS-3973	CPE	SF	----	----	VERO >	320.00	----	4/13/88
AVS-3973	CPE	VEE	----	----	VERO	100.00	----	4/13/88
AVS-3973	CPE	VSV	----	----	L929 >	320.00	----	3/18/88
AVS-3973	CPE	VV	----	----	VERO >	320.00	----	3/24/88
AVS-3973	CPE	YFV	----	----	VERO	32.00	----	4/13/88
AVS-3974	CPE	AD2	0.7	319.00	HEP2 >	320.00 >	1.00	3/24/88
AVS-3974	CPE	JE	----	----	VERO	320.00	----	4/13/88
AVS-3974	CPE	PT	----	----	VERO >	320.00	----	4/13/88
AVS-3974	CPE	SF	0.3	----	VERO	320.00	----	4/13/88
AVS-3974	CPE	VEE	----	----	VERO	32.00	----	4/13/88
AVS-3974	CPE	VSV	----	----	L929 >	320.00	----	3/18/88
AVS-3974	CPE	VV	----	----	VERO >	320.00	----	3/24/88
AVS-3974	CPE	YFV	----	----	VERO >	320.00	----	4/13/88
AVS-3975	CPE	AD2	0.3	----	HEP2 >	320.00	----	3/24/88
AVS-3975	CPE	JE	----	----	VERO	320.00	----	4/13/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-3975	CPE	PT	----	----	VERO	320.00	----	4/13/88
AVS-3975	CPE	SF	0.8	----	VERO	320.00	----	4/13/88
AVS-3975	CPE	VEE	----	----	VERO >	320.00	----	4/13/88
AVS-3975	CPE	VSV	----	----	L929 >	320.00	----	3/18/88
AVS-3975	CPE	VV	0.1	----	VERO >	320.00	----	3/24/88
AVS-3975	CPE	YFV	----	----	VERO >	320.00	----	4/13/88
AVS-3976	CPE	AD2	0.0	320.00	HEP2 >	320.00 >	1.00	3/24/88
AVS-3976	CPE	JE	----	----	VERO	320.00	----	4/13/88
AVS-3976	CPE	PT	----	----	VERO >	320.00	----	4/13/88
AVS-3976	CPE	SF	----	----	VERO >	320.00	----	4/13/88
AVS-3976	CPE	VEE	----	----	VERO	320.00	----	4/13/88
AVS-3976	CPE	VSV	----	----	L929 >	320.00	----	3/18/88
AVS-3976	CPE	VV	----	----	VERO >	320.00	----	3/24/88
AVS-3976	CPE	YFV	----	----	VERO >	320.00	----	4/13/88
AVS-3977	CPE	AD2	0.5	----	HEP2 >	320.00	----	3/31/88
AVS-3977	CPE	JE	----	----	VERO	320.00	----	4/13/88
AVS-3977	CPE	PT	----	----	VERO	320.00	----	4/13/88
AVS-3977	CPE	SF	0.7	----	VERO	320.00	----	4/13/88
AVS-3977	CPE	VEE	----	----	VERO	100.00	----	4/13/88
AVS-3977	CPE	VSV	----	----	L929 >	320.00	----	3/18/88
AVS-3977	CPE	VV	----	----	VERO >	320.00	----	3/31/88
AVS-3977	CPE	YFV	----	----	VERO	100.00	----	4/13/88
AVS-3978	CPE	AD2	----	----	HEP2 >	320.00	----	3/31/88
AVS-3978	CPE	JE	----	----	VERO	100.00	----	4/13/88
AVS-3978	CPE	PT	----	----	VERO	320.00	----	4/13/88
AVS-3978	CPE	SF	0.6	----	VERO	320.00	----	4/13/88
AVS-3978	CPE	VEE	----	----	VERO	32.00	----	4/13/88
AVS-3978	CPE	VSV	----	----	L929 >	320.00	----	3/18/88
AVS-3978	CPE	VV	----	----	VERO >	320.00	----	3/31/88
AVS-3978	CPE	YFV	----	----	VERO	100.00	----	4/13/88
AVS-3979	CPE	AD2	0.3	----	HEP2 >	320.00	----	3/31/88
AVS-3979	CPE	JE	----	----	VERO	320.00	----	4/13/88
AVS-3979	CPE	PT	----	----	VERO	320.00	----	4/13/88
AVS-3979	CPE	SF	----	----	VERO >	320.00	----	4/13/88
AVS-3979	CPE	VEE	----	----	VERO	320.00	----	4/13/88
AVS-3979	CPE	VSV	----	----	L929 >	320.00	----	3/18/88
AVS-3979	CPE	VV	----	----	VERO >	320.00	----	3/31/88
AVS-3979	CPE	YFV	----	----	VERO	100.00	----	4/13/88
AVS-3980	CPE	AD2	----	----	HEP2	10.00	----	3/ 3/88
AVS-3980	CPE	JE	----	----	VERO	32.00	----	4/13/88
AVS-3980	CPE	PT	----	----	VERO	10.00	----	4/13/88
AVS-3980	CPE	SF	1.85	18.30	VERO	100.00	5.43	4/13/88
AVS-3980	CPE	VEE	----	----	VERO	10.00	----	4/13/88
AVS-3980	CPE	VSV	----	----	L929	3.20	----	2/23/88
AVS-3980	CPE	VV	----	----	VERO	32.00	----	3/ 3/88
AVS-3980	CPE	YFV	----	----	VERO	32.00	----	4/13/88
AVS-3981	CPE	AD2	----	----	HEP2 <	320.00	----	3/ 3/88
AVS-3981	CPE	JE	----	----	VERO	320.00	----	4/13/88
AVS-3981	CPE	PT	----	----	VERO	32.00	----	4/13/88
AVS-3981	CPE	SF	1.5	294.00	VERO	320.00	1.08	4/13/88
AVS-3981	CPE	VEE	----	----	VERO	10.00	----	4/13/88
AVS-3981	CPE	VSV	----	----	L929	100.00	----	2/23/88
AVS-3981	CPE	VV	----	----	VERO >	320.00	----	3/ 3/88
AVS-3981	CPE	YFV	----	----	VERO >	320.00	----	4/13/88
AVS-3982	CPE	AD2	----	----	HEP2 <	320.00	----	3/ 3/88
AVS-3982	CPE	JE	----	----	VERO	32.00	----	4/13/88
AVS-3982	CPE	PT	0.2	----	VERO	10.00	----	4/13/88
AVS-3982	CPE	SF	0.35	270.00	VERO	320.00	1.18	4/13/88
AVS-3982	CPE	VEE	----	----	VERO	100.00	----	4/13/88
AVS-3982	CPE	VSV	----	----	L929 <	320.00	----	2/23/88
AVS-3982	CPE	VV	0.1	----	VERO	320.00	----	3/ 3/88
AVS-3982	CPE	YFV	0.35	----	VERO	100.00	----	4/13/88
AVS-3983	CPE	AD2	----	----	HEP2 >	320.00	----	3/ 3/88
AVS-3983	CPE	JE	----	----	VERO	100.00	----	4/13/88
AVS-3983	CPE	PT	----	----	VERO	100.00	----	4/13/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MYC50	TI	DATE
AVS-3983	CPE	SF	----	----	VERO >	320.00	----	4/13/88
AVS-3983	CPE	VEE	----	----	VERO	100.00	----	4/13/88
AVS-3983	CPE	VSV	----	----	L929 >	320.00	----	2/23/88
AVS-3983	CPE	VV	----	----	VERO >	320.00	----	3/ 3/88
AVS-3983	CPE	YFV	0.15	----	VERO	100.00	----	4/13/88
AVS-3984	CPE	AD2	----	----	HEP2	320.00	----	3/ 3/88
AVS-3984	CPE	JE	----	----	VERO	100.00	----	4/13/88
AVS-3984	CPE	PT	----	----	VERO	32.00	----	4/13/88
AVS-3984	CPE	SF	1.25	126.00	VERO	100.00	0.79	4/13/88
AVS-3984	CPE	VEE	----	----	VERO	32.00	----	4/13/88
AVS-3984	CPE	VSV	----	----	L929	100.00	----	2/23/88
AVS-3984	CPE	VV	----	----	VERO	320.00	----	3/ 3/88
AVS-3984	CPE	YFV	----	----	VERO	320.00	----	4/13/88
AVS-3985	CPE	AD2	----	----	HEP2 >	320.00	----	3/10/88
AVS-3985	CPE	JE	----	----	VERO	100.00	----	4/13/88
AVS-3985	CPE	PT	----	----	VERO >	320.00	----	4/13/88
AVS-3985	CPE	SF	----	----	VERO >	320.00	----	4/13/88
AVS-3985	CPE	VEE	----	----	VERO	1.00	----	4/13/88
AVS-3985	CPE	VSV	----	----	L929 >	320.00	----	2/23/88
AVS-3985	CPE	VV	----	----	VERO >	320.00	----	3 10/88
AVS-3985	CPE	YFV	----	----	VERO >	320.00	----	4/13/88
AVS-3986	CPE	AD2	----	----	HEP2	320.00	----	3/10/88
AVS-3986	CPE	JE	----	----	VERO	100.00	----	4/13/88
AVS-3986	CPE	PT	----	----	VERO	320.00	----	4/13/88
AVS-3986	CPE	SF	0.25	----	VERO >	320.00	----	4/13/88
AVS-3986	CPE	VEE	----	----	VERO	1.00	----	4/13/88
AVS-3986	CPE	VSV	----	----	L929	320.00	----	2/23/88
AVS-3986	CPE	VV	----	----	VERO >	320.00	----	3/10/88
AVS-3986	CPE	YFV	----	----	VERO >	320.00	----	4/13/88
AVS-3987	CPE	AD2	0.3	----	HEP2 <	320.00	----	3/10/88
AVS-3987	CPE	JE	----	----	VERO	100.00	----	4/19/88
AVS-3987	CPE	PT	----	----	VERO <	100.00	----	4/19/88
AVS-3987	CPE	SF	0.25	----	VERO	32.00	----	4/19/88
AVS-3987	CPE	VEE	----	----	VERO	100.00	----	4/19/88
AVS-3987	CPE	VSV	----	----	L929	32.00	----	2/23/88
AVS-3987	CPE	VV	0.15	----	VERO	100.00	----	3/10/88
AVS-3988	CPE	AD2	----	----	HEP2 <	100.00	----	3/10/88
AVS-3988	CPE	JE	0.45	68.30	VERO	10.00	0.15	4/19/88
AVS-3988	CPE	PT	0.55	59.50	VERO	32.00	0.54	4/19/88
AVS-3988	CPE	SF	0.45	68.30	VERO	32.00	0.47	4/19/88
AVS-3988	CPE	VEE	----	----	VERO	32.00	----	4/19/88
AVS-3988	CPE	VSV	----	----	L929	100.00	----	2/23/88
AVS-3988	CPE	VV	----	----	VERO	32.00	----	3/10/88
AVS-3989	CPE	AD2	----	----	HEP2 >	100.00	----	3/10/88
AVS-3989	CPE	JE	----	----	VERO >	320.00	----	4/19/88
AVS-3989	CPE	PT	----	----	VERO >	320.00	----	4/19/88
AVS-3989	CPE	SF	----	----	VERO >	320.00	----	4/19/88
AVS-3989	CPE	VEE	----	----	VERO >	320.00	----	4/19/88
AVS-3989	CPE	VSV	----	----	L929	100.00	----	2/23/88
AVS-3989	CPE	VV	----	----	VERO	100.00	----	3/10/88
AVS-3990	CPE	AD2	0.8	----	HEP2 <	32.00	----	3/10/88
AVS-3990	CPE	JE	----	----	VERO >	320.00	----	4/19/88
AVS-3990	CPE	PT	0.1	----	VERO	320.00	----	4/19/88
AVS-3990	CPE	SF	0.05	----	VERO	320.00	----	4/19/88
AVS-3990	CPE	VEE	----	----	VERO	100.00	----	4/19/88
AVS-3990	CPE	VSV	----	----	L929	100.00	----	2/23/88
AVS-3990	CPE	VV	----	----	VERO <	32.00	----	3/10/88
AVS-3991	CPE	AD2	----	----	HEP2 >	100.00	----	3/10/88
AVS-3991	CPE	JE	----	----	VERO >	320.00	----	4/19/88
AVS-3991	CPE	PT	----	----	VERO >	320.00	----	4/19/88
AVS-3991	CPE	SF	----	----	VERO	320.00	----	4/19/88
AVS-3991	CPE	VEE	----	----	VERC	320.00	----	4/19/88
AVS-3991	CPE	VSV	----	----	L929	320.00	----	2/23/88
AVS-3991	CPE	VV	----	----	VERO	100.00	----	3/10/88
AVS-3992	CPE	AD2	0.3	----	HEP2 >	320.00	----	3/10/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-3992	CPE	JE	----	----	VERO >	320.00	----	4/19/88
AVS-3992	CPE	PT	----	----	VERO	320.00	----	4/19/88
AVS-3992	CPE	SF	0.1	----	VERO	320.00	----	4/19/88
AVS-3992	CPE	VEE	----	----	VERO	320.00	----	4/19/88
AVS-3992	CPE	VSV	----	----	L929	320.00	----	2/23/88
AVS-3992	CPE	VV	----	----	VERO >	320.00	----	3/10/88
AVS-3993	CPE	AD2	0.2	----	HEP2 >	320.00	----	3/10/88
AVS-3993	CPE	JE	----	----	VERO >	320.00	----	4/19/88
AVS-3993	CPE	PT	----	----	VERO	320.00	----	4/19/88
AVS-3993	CPE	SF	0.05	----	VERO	100.00	----	4/19/88
AVS-3993	CPE	VEE	----	----	VERO	32.00	----	4/19/88
AVS-3993	CPE	VSV	----	----	L929	320.00	----	2/23/88
AVS-3993	CPE	VV	----	----	VERO >	320.00	----	3/10/88
AVS-3994	CPE	AD2	0.5	----	HEP2 >	320.00	----	3/10/88
AVS-3994	CPE	JE	----	----	VERO >	320.00	----	4/19/88
AVS-3994	CPE	PT	----	----	VERO >	320.00	----	4/19/88
AVS-3994	CPE	SF	0.1	----	VERO	320.00	----	4/19/88
AVS-3994	CPE	VEE	----	----	VERO	320.00	----	4/19/88
AVS-3994	CPE	VSV	----	----	L929	320.00	----	2/23/88
AVS-3994	CPE	VV	----	----	VERO	320.00	----	3/10/88
AVS-3995	CPE	AD2	----	----	HEP2 >	100.00	----	3/10/88
AVS-3995	CPE	JE	----	----	VERO	100.00	----	4/19/88
AVS-3995	CPE	PT	----	----	VERO	320.00	----	4/19/88
AVS-3995	CPE	SF	0.1	----	VERO	320.00	----	4/19/88
AVS-3995	CPE	VEE	----	----	VERO	320.00	----	4/19/88
AVS-3995	CPE	VSV	----	----	L929	32.00	----	2/23/88
AVS-3995	CPE	VV	----	----	VERO	100.00	----	3/10/88
AVS-3996	CPE	AD2	----	----	HEP2 <	100.00	----	3/10/88
AVS-3996	CPE	JE	----	----	VERO	32.00	----	4/19/88
AVS-3996	CPE	PT	----	----	VERO	32.00	----	4/19/88
AVS-3996	CPE	SF	0.9	31.70	VERO	10.00	0.31	4/19/88
AVS-3996	CPE	VEE	----	----	VERO	10.00	----	4/19/88
AVS-3996	CPE	VSV	----	----	L929	32.00	----	3/11/88
AVS-3996	CPE	VV	----	----	VERO	32.00	----	3/10/88
AVS-3997	CPE	AD2	0.1	----	HEP2 <	32.00	----	3/10/88
AVS-3997	CPE	JE	0.3	10.00	VERO	10.00	1.00	4/19/88
AVS-3997	CPE	PT	----	----	VERO	32.00	----	4/19/88
AVS-3997	CPE	SF	0.08	----	VERO	32.00	----	4/19/88
AVS-3997	CPE	VEE	----	----	VERO	10.00	----	4/19/88
AVS-3997	CPE	VSV	0.05	----	L929	32.00	----	3/11/88
AVS-3997	CPE	VV	----	----	VERO	10.00	----	3/10/88
AVS-3997	CPE	YFV	1.3	3.45	VERO	3.20	0.93	4/19/88
AVS-3998	CPE	AD2	----	----	HEP2 <	1.00	----	3/10/88
AVS-3998	CPE	JE	----	----	VERO	3.20	----	4/19/88
AVS-3998	CPE	PT	----	----	VERO	1.00	----	4/19/88
AVS-3998	CPE	SF	0.75	14.70	VERO	1.00	0.07	4/19/88
AVS-3998	CPE	VEE	----	----	VERO	3.20	----	4/19/88
AVS-3998	CPE	VSV	----	----	L929	10.00	----	3/11/88
AVS-3998	CPE	VV	0.45	6.80	VERO	3.20	0.47	3/10/88
AVS-3998	CPE	YFV	0.15	----	VERO	1.00	----	4/19/88
AVS-3999	CPE	AD2	----	----	HEP2 <	1.00	----	3/10/88
AVS-3999	CPE	JE	----	----	VERO	3.20	----	4/19/88
AVS-3999	CPE	PT	----	----	VERO	3.20	----	4/19/88
AVS-3999	CPE	SF	0.2	----	VERO	1.00	----	4/19/88
AVS-3999	CPE	VEE	----	----	VERO	3.20	----	4/19/88
AVS-3999	CPE	VSV	----	----	L929	1.00	----	3/11/88
AVS-3999	CPE	VV	0.15	----	VERO	3.20	----	3/10/88
AVS-3999	CPE	YFV	0.25	----	VERO	3.20	----	4/19/88
AVS-4000	CPE	AD2	----	----	HEP2 <	100.00	----	3/10/88
AVS-4000	CPE	JE	----	----	VERO	320.00	----	4/19/88
AVS-4000	CPE	PT	0.15	----	VERO	100.00	----	4/19/88
AVS-4000	CPE	SF	0.3	320.00	VERO	100.00	0.31	4/19/88
AVS-4000	CPE	VEE	----	----	VERO	32.00	----	4/19/88
AVS-4000	CPE	VSV	----	----	L929	100.00	----	3/11/88
AVS-4000	CPE	VV	0.3	320.00	VERO	100.00	0.31	3/10/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIP'S	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4001	CPE	AD2	1.1	204.00	HEP2 >	320.00 >	1.56	3/10/88
AVS-4001	CPE	AD2	1.	320.00	HEP2 >	320.00 >	1.00	3/31/88
AVS-4001	CPE	JE	----	----	VERO >	320.00	----	4/19/88
AVS-4001	CPE	PT	----	----	VERO >	320.00	----	4/19/88
AVS-4001	CPE	SF	0.05	----	VERO	32.00	----	4/19/88
AVS-4001	CPE	VEE	----	----	VERO	320.00	----	4/19/88
AVS-4001	CPE	VSV	----	----	L929 >	320.00	----	3/11/88
AVS-4001	CPE	VV	----	----	VERO >	320.00	----	3/10/88
AVS-4002	CPE	AD2	1.	320.00	HEP2 >	320.00 >	1.00	3/10/88
AVS-4002	CPE	AD2	0.8	----	HEP2 >	320.00	----	3/31/88
AVS-4002	CPE	AD2	0.3	----	HEP2 >	320.00	----	4/14/88
AVS-4002	CPE	JE	----	----	VERO	320.00	----	4/20/88
AVS-4002	CPE	PT	----	----	VERO >	320.00	----	4/20/88
AVS-4002	CPE	SF	0.5	----	VERO	320.00	----	4/20/88
AVS-4002	CPE	VEE	----	----	VERO	100.00	----	4/20/88
AVS-4002	CPE	VSV	----	----	L929 >	320.00	----	3/11/88
AVS-4002	CPE	VV	0.1	----	VERO >	320.00	----	3/10/88
AVS-4002	CPE	YFV	----	----	VERO	320.00	----	4/20/88
AVS-4003	CPE	AD2	0.3	----	HEP2 <	320.00	----	3/10/88
AVS-4003	CPE	JE	----	----	VERO	100.00	----	4/20/88
AVS-4003	CPE	PT	0.25	----	VERO	32.00	----	4/20/88
AVS-4003	CPE	SF	0.9	59.70	VERO	32.00	0.54	4/20/88
AVS-4003	CPE	VEE	----	----	VERO	100.00	----	4/20/88
AVS-4003	CPE	VSV	----	----	L929	100.00	----	3/11/88
AVS-4003	CPE	VV	0.6	100.00	VERO	100.00	1.00	3/10/88
AVS-4003	CPE	YFV	----	----	VERO	32.00	----	4/20/88
AVS-4004	CPE	AD2	1.2	193.00	HEP2 >	320.00 >	1.65	3/10/88
AVS-4004	CPE	AD2	0.8	----	HEP2 >	320.00	----	3/31/88
AVS-4004	CPE	AD2	0.5	----	HEP2 >	320.00	----	4/14/88
AVS-4004	CPE	JE	----	----	VERO	320.00	----	4/20/88
AVS-4004	CPE	PT	----	----	VERO	100.00	----	4/20/88
AVS-4004	CPE	SF	----	----	VERO	100.00	----	4/20/88
AVS-4004	CPE	VEE	----	----	VERO	320.00	----	4/20/88
AVS-4004	CPE	VSV	----	----	L929 >	320.00	----	3/11/88
AVS-4004	CPE	VV	0.2	----	VERO	320.00	----	3/10/88
AVS-4004	CPE	YFV	----	----	VERO	100.00	----	4/20/88
AVS-4005	CPE	AD2	0.6	56.50	HEP2	100.00	1.76	3/10/88
AVS-4005	CPE	JE	----	----	VERO	100.00	----	4/20/88
AVS-4005	CPE	PT	----	----	VERO	100.00	----	4/20/88
AVS-4005	CPE	SF	0.25	----	VERO	320.00	----	4/20/88
AVS-4005	CPE	VEE	----	----	VERO	100.00	----	4/20/88
AVS-4005	CPE	VSV	----	----	L929	100.00	----	3/11/88
AVS-4005	CPE	VV	0.65	62.90	VERO	100.00	1.58	3/10/88
AVS-4005	CPE	YFV	----	----	VERO	100.00	----	4/20/88
AVS-4006	CPE	AD2	0.4	75.10	HEP2	100.00	1.33	3/10/88
AVS-4006	CPE	JE	----	----	VERO	32.00	----	4/20/88
AVS-4006	CPE	PT	0.45	77.40	VERO	10.00	0.13	4/20/88
AVS-4006	CPE	SF	0.45	68.30	VERO	32.00	0.47	4/20/88
AVS-4006	CPE	VEE	----	----	VERO	100.00	----	4/20/88
AVS-4006	CPE	VSV	----	----	L929	100.00	----	3/11/88
AVS-4006	CPE	VV	0.45	68.30	VERO	32.00	0.47	3/10/88
AVS-4006	CPE	YFV	----	----	VERO	32.00	----	4/20/88
AVS-4015	CPE	JE	0.8	2.09	VERO	0.10	0.05	3/22/88
AVS-4015	CPE	PT	1.6	2.52	VERO	1.00	0.40	12/22/87
AVS-4015	CPE	PT	2.1	0.06	VERO <	0.10 <	1.64	4/15/88
AVS-4015	CPE	SF	0.15	----	VERO	0.10	----	12/15/87
AVS-4015	CPE	VEE	----	----	VERO	0.32	----	3/22/88
AVS-4015	CPE	YFV	----	----	VERO	0.10	----	12/15/87
AVS-4015	CPE	YFV	0.5	----	VERO	0.10	----	3/22/88
AVS-4016	CPE	JE	1.5	1.17	VERO	0.32	0.27	3/22/88
AVS-4016	CPE	PT	1.9	14.10	VERO	10.00	0.70	12/22/87
AVS-4016	CPE	PT	1.85	0.13	VERO <	0.10 <	0.73	4/15/88
AVS-4016	CPE	SF	0.7	7.50	VERO	1.00	0.13	12/15/87
AVS-4016	CPE	SF	1.7	0.70	VERO	0.32	0.46	3/22/88
AVS-4016	CPE	VEE	----	----	VERO	3.20	----	3/22/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4016	CPE	YFV	0.2	----	VERO	3.20	----	12/15/87
AVS-4016	CPE	YFV	0.65	----	VERO	1.00	----	3/22/88
AVS-4017	CPE	JE	0.25	----	VERO	10.00	----	3/22/88
AVS-4017	CPE	PT	----	----	VERO	32.00	----	12/22/87
AVS-4017	CPE	PT	----	----	VERO	10.00	----	4/15/88
AVS-4017	CPE	SF	----	----	VERO	100.00	----	12/15/87
AVS-4017	CPE	VSV	----	----	VERO	0.10	----	3/22/88
AVS-4017	CPE	YFV	----	----	VERO	100.00	----	12/15/87
AVS-4017	CPE	YFV	----	----	VERO	100.00	----	3/22/88
AVS-4018	CPE	JE	1.05	0.26	VERO <	0.10 <	0.38	4/20/88
AVS-4018	CPE	PT	1.15	0.22	VERO	0.32	1.43	4/20/88
AVS-4018	CPE	SF	0.85	0.37	VERO	0.32	0.85	4/20/88
AVS-4018	CPE	VEE	1.6	0.88	VERO <	0.10 <	0.11	4/20/88
AVS-4018	CPE	YFV	1.4	0.15	VERO	0.32	2.00	4/20/88
AVS-4019	CPE	JE	0.6	1.78	VERO	0.32	0.18	4/20/88
AVS-4019	CPE	PT	0.8	1.59	VERO	3.20	2.00	4/20/88
AVS-4019	CPE	SF	0.8	1.59	VERO	1.00	0.63	4/20/88
AVS-4019	CPE	VEE	0.85	9.80	VERO	3.20	0.32	4/20/88
AVS-4019	CPE	YFV	1.05	0.83	VERO	1.00	1.30	4/20/88
AVS-4020	CPE	JE	0.9	4.77	VERO	3.20	0.67	4/20/88
AVS-4020	CPE	PT	0.45	6.80	VERO	3.20	0.47	4/20/88
AVS-4020	CPE	SF	----	----	VERO	1.00	----	4/20/88
AVS-4020	CPE	VEE	0.45	21.70	VERO	1.00	0.05	4/20/88
AVS-4020	CPE	YFV	1.6	1.22	VERO	3.20	2.60	4/20/88
AVS-4021	CPE	AD2	----	----	HEP2	10.00	----	3/31/88
AVS-4021	CPE	JE	----	----	VERO	100.00	----	4/20/88
AVS-4021	CPE	PT	0.2	----	VERO	100.00	----	4/20/88
AVS-4021	CPE	SF	0.85	77.90	VERO	100.00	1.28	4/20/88
AVS-4021	CPE	VEE	----	----	VERO	32.00	----	4/20/88
AVS-4021	CPE	VSV	----	----	L929	32.00	----	3/29/88
AVS-4021	CPE	VV	----	----	VERO	32.00	----	3/31/88
AVS-4021	CPE	YFV	1.3	144.00	VERO	320.00	2.20	4/20/88
AVS-4022	CPE	AD2	0.3	----	HEP2	32.00	----	3/10/88
AVS-4022	CPE	JE	----	----	VERO	32.00	----	4/20/88
AVS-4022	CPE	PT	----	----	VERO	100.00	----	4/20/88
AVS-4022	CPE	SF	0.55	217.00	VERO	100.00	0.46	4/20/88
AVS-4022	CPE	VEE	----	----	VERO	32.00	----	4/20/88
AVS-4022	CPE	VSV	----	----	L929	32.00	----	3/11/88
AVS-4022	CPE	VV	----	----	VERO <	100.00	----	3/10/88
AVS-4022	CPE	YFV	----	----	VERO	32.00	----	4/20/88
AVS-4023	CPE	AD2	----	----	HEP2	320.00	----	3/17/88
AVS-4023	CPE	JE	----	----	VERO	320.00	----	4/20/88
AVS-4023	CPE	PT	----	----	VERO	320.00	----	4/20/88
AVS-4023	CPE	SF	----	----	VERO	320.00	----	4/20/88
AVS-4023	CPE	VEE	----	----	VERO	100.00	----	4/20/88
AVS-4023	CPE	VSV	----	----	L929 <	320.00	----	3/11/88
AVS-4023	CPE	VV	0.6	100.00	VERO	100.00	1.00	3/17/88
AVS-4023	CPE	YFV	----	----	VERO	32.00	----	4/20/88
AVS-4024	CPE	AD2	0.3	----	HEP2 <	32.00	----	3/17/88
AVS-4024	CPE	JE	----	----	VERO	32.00	----	4/20/88
AVS-4024	CPE	PT	----	----	VERO	32.00	----	4/20/88
AVS-4024	CPE	SF	----	----	VERO	32.00	----	4/20/88
AVS-4024	CPE	VEE	----	----	VERO	100.00	----	4/20/88
AVS-4024	CPE	VSV	----	----	L929	32.00	----	3/11/88
AVS-4024	CPE	VV	----	----	VERO <	32.00	----	3/17/88
AVS-4024	CPE	YFV	----	----	VERO <	320.00	----	4/20/88
AVS-4025	CPE	AD2	0.3	----	HEP2 <	100.00	----	3/17/88
AVS-4025	CPE	JE	----	----	VERO	100.00	----	4/20/88
AVS-4025	CPE	PT	----	----	VERO	320.00	----	4/20/88
AVS-4025	CPE	SF	0.45	261.00	VERO	100.00	0.38	4/20/88
AVS-4025	CPE	VEE	----	----	VERO >	320.00	----	4/20/88
AVS-4025	CPE	VSV	----	----	L929	100.00	----	3/11/88
AVS-4025	CPE	VV	----	----	VERO	32.00	----	3/17/88
AVS-4025	CPE	YFV	----	----	VERO	320.00	----	4/20/88
AVS-4027	CPE	VSV	----	----	L929	1.00	----	3/25/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-4028	CPE	AD2	----	----	HEP2	320.00	----	3/31/88
AVS-4028	CPE	VSV	----	----	L929	100.00	----	3/25/88
AVS-4028	CPE	VV	----	----	VERO >	320.00	----	3/31/88
AVS-4029	CPE	AD2	----	----	HEP2 >	320.00	----	3/31/88
AVS-4029	CPE	JE	----	----	VERO	320.00	----	4/20/88
AVS-4029	CPE	PT	----	----	VERO	320.00	----	4/20/88
AVS-4029	CPE	SF	----	----	VERO	320.00	----	4/20/88
AVS-4029	CPE	VEE	----	----	VERO >	320.00	----	4/20/88
AVS-4029	CPE	VSV	----	----	L929 >	320.00	----	3/25/88
AVS-4029	CPE	VV	----	----	VERO >	320.00	----	3/31/88
AVS-4029	CPE	YFV	----	----	VERO >	320.00	----	4/20/88
AVS-4029	CPE	AD2	----	----	HEP2 >	320.00	----	3/31/88
AVS-4030	CPE	JE	----	----	VERO	320.00	----	4/20/88
AVS-4030	CPE	PT	----	----	VERO	320.00	----	4/20/88
AVS-4030	CPE	SF	0.5	----	VERO >	320.00	----	4/20/88
AVS-4030	CPE	VEE	----	----	VERO	100.00	----	4/20/88
AVS-4030	CPE	VSV	----	----	L929 >	320.00	----	3/25/88
AVS-4030	CPE	VV	----	----	VERO >	320.00	----	3/31/88
AVS-4030	CPE	YFV	----	----	VERO >	320.00	----	4/20/88
AVS-4031	CPE	AD2	----	----	HEP2 <	100.00	----	3/17/88
AVS-4031	CPE	AD2	----	----	HEP2 <	100.00	----	3/31/88
AVS-4031	CPE	JE	----	----	VERO	10.00	----	4/26/88
AVS-4031	CPE	PT	----	----	VERO	100.00	----	4/26/88
AVS-4031	CPE	SF	2.05	19.50	VERO	10.00	0.51	4/26/88
AVS-4031	CPE	VEE	----	----	VERO	10.00	----	4/26/88
AVS-4031	CPE	VSV	----	----	L929	100.00	----	3/11/88
AVS-4031	CPE	VV	----	----	VERO	32.00	----	3/17/88
AVS-4031	CPE	VV	0.2	----	VERO	32.00	----	3/31/88
AVS-4031	CPE	YFV	----	----	VERO	3.20	----	4/26/88
AVS-4032	CPE	AD2	----	----	HEP2	320.00	----	3/17/88
AVS-4032	CPE	JE	0.1	----	VERO	10.00	----	4/26/88
AVS-4032	CPE	PT	1.15	63.30	VERO	10.00	0.16	4/26/88
AVS-4032	CPE	SF	1.6	29.10	VERO	32.00	1.09	4/26/88
AVS-4032	CPE	VEE	0.15	----	VERO	100.00	----	4/26/88
AVS-4032	CPE	VSV	----	----	L929	32.00	----	3/11/88
AVS-4032	CPE	VV	----	----	VERO	320.00	----	3/17/88
AVS-4032	CPE	YFV	0.75	112.00	VERO	10.00	0.09	4/26/88
AVS-4033	CPE	AD2	0.4	----	HEP2 >	320.00	----	3/17/88
AVS-4033	CPE	JE	----	----	VERO	100.00	----	4/26/88
AVS-4033	CPE	PT	----	----	VERO	320.00	----	4/26/88
AVS-4033	CPE	SF	0.7	0.32	VERO	1.00	3.12	4/26/88
AVS-4033	CPE	VEE	----	----	VERO	320.00	----	4/26/88
AVS-4033	CPE	VSV	----	----	L929 >	320.00	----	3/11/88
AVS-4033	CPE	VV	----	----	VERO >	320.00	----	3/17/88
AVS-4033	CPE	YFV	----	----	VERO	320.00	----	4/26/88
AVS-4034	CPE	JE	----	----	VERO	100.00	----	4/26/88
AVS-4034	CPE	PT	----	----	VERO	100.00	----	4/26/88
AVS-4034	CPE	SF	0.2	----	VERO	100.00	----	4/26/88
AVS-4034	CPE	VEE	----	----	VERO >	100.00	----	4/26/88
AVS-4034	CPE	VSV	0.3	----	L929 >	320.00	----	3/25/88
AVS-4034	CPE	YFV	----	----	VERO	100.00	----	4/26/88
AVS-4035	CPE	AD2	----	----	HEP2	100.00	----	3/31/88
AVS-4035	CPE	JE	----	----	VERO	3.20	----	4/26/88
AVS-4035	CPE	PT	0.15	----	VERO	3.20	----	4/26/88
AVS-4035	CPE	SF	1.85	8.60	VERO	10.00	1.16	4/26/88
AVS-4035	CPE	VEE	----	----	VERO	10.00	----	4/26/88
AVS-4035	CPE	VSV	----	----	L929	10.00	----	3/25/88
AVS-4035	CPE	VV	0.4	----	VERO	100.00	----	3/31/88
AVS-4035	CPE	YFV	----	----	VERO	3.20	----	4/26/88
AVS-4036	CPE	AD2	0.1	----	HEP2	100.00	----	3/17/88
AVS-4036	CPE	JE	0.15	----	VERO	10.00	----	4/26/88
AVS-4036	CPE	PT	0.25	----	VERO	32.00	----	4/26/88
AVS-4036	CPE	SF	1	55.00	VERO	32.00	0.58	4/26/88
AVS-4036	CPE	VEE	----	----	VERO	32.00	----	4/26/88
AVS-4036	CPE	VSV	----	----	L929	32.00	----	3/11/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-4036	CPE	VV	----	----	VERO	100.00	----	3/17/88
AVS-4036	CPE	YFV	0.3	320.00	VERO	100.00	0.31	4/26/88
AVS-4037	CPE	AD2	0.2	----	HEP2 >	320.00	----	3/31/88
AVS-4037	CPE	JE	----	----	VERO	100.00	----	4/26/88
AVS-4037	CPE	PT	----	----	VERO >	100.00	----	4/26/88
AVS-4037	CPE	SF	0.3	----	VERO	100.00	----	4/26/88
AVS-4037	CPE	VEE	----	----	VERO	100.00	----	4/26/88
AVS-4037	CPE	VSV	----	----	L929	320.00	----	3/25/88
AVS-4037	CPE	VV	----	----	VERO >	320.00	----	3/31/88
AVS-4037	CPE	YFV	----	----	VERO >	100.00	----	4/26/88
AVS-4038	CPE	AD2	0.6	----	HEP2 >	320.00	----	3/17/88
AVS-4038	CPE	JE	----	----	VERO	32.00	----	4/26/88
AVS-4038	CPE	PT	----	----	VERO	320.00	----	4/26/88
AVS-4038	CPE	SF	0.15	----	VERO	100.00	----	4/26/88
AVS-4038	CPE	VEE	----	----	VERO	100.00	----	4/26/88
AVS-4038	CPE	VSV	----	----	L929 >	320.00	----	3/11/88
AVS-4038	CPE	VV	----	----	VERO	320.00	----	3/17/88
AVS-4038	CPE	YFV	----	----	VERO	100.00	----	4/26/88
AVS-4039	CPE	AD2	----	----	HEP2 >	320.00	----	3/31/88
AVS-4039	CPE	JE	----	----	VERO	10.00	----	4/26/88
AVS-4039	CPE	PT	----	----	VERO	32.00	----	4/26/88
AVS-4039	CPE	SF	----	----	VERO	32.00	----	4/26/88
AVS-4039	CPE	VEE	----	----	VERO	32.00	----	4/26/88
AVS-4039	CPE	VSV	----	----	L929 >	320.00	----	3/25/88
AVS-4039	CPE	VV	----	----	VERO	320.00	----	3/31/88
AVS-4039	CPE	YFV	----	----	VERO	32.00	----	4/26/88
AVS-4040	CPE	AD2	0.7	----	HEP2 >	320.00	----	3/17/88
AVS-4040	CPE	JE	----	----	VERO	100.00	----	4/26/88
AVS-4040	CPE	PT	0.25	----	VERO	32.00	----	4/26/88
AVS-4040	CPE	SF	0.5	283.00	VERO	10.00	0.04	4/26/88
AVS-4040	CPE	VEE	----	----	VERO	100.00	----	4/26/88
AVS-4040	CPE	VSV	----	----	L929	320.00	----	3/11/88
AVS-4040	CPE	VV	----	----	VERO	320.00	----	3/17/88
AVS-4040	CPE	YFV	----	----	VERO	32.00	----	4/26/88
AVS-4041	CPE	AD2	1.1	320.00	HEP2 >	320.00 >	1.00	3/17/88
AVS-4041	CPE	AD2	1.1	320.00	HEP2 >	320.00 >	1.00	4/21/88
AVS-4041	CPE	JE	----	----	VERO	100.00	----	4/26/88
AVS-4041	CPE	PT	----	----	VERO	100.00	----	4/26/88
AVS-4041	CPE	SF	0.5	----	VERO	32.00	----	4/26/88
AVS-4041	CPE	VEE	----	----	VERO	100.00	----	4/26/88
AVS-4041	CPE	VSV	----	----	L929 >	320.00	----	3/11/88
AVS-4041	CPE	VV	----	----	VERO >	320.00	----	3/17/88
AVS-4041	CPE	YFV	----	----	VERO	32.00	----	4/26/88
AVS-4042	CPE	AD2	0.3	----	HEP2 >	320.00	----	3/31/88
AVS-4042	CPE	JE	----	----	VERO	100.00	----	4/26/88
AVS-4042	CPE	PT	0.3	320.00	VERO	100.00	0.31	4/26/88
AVS-4042	CPE	SF	----	----	VERO	100.00	----	4/26/88
AVS-4042	CPE	VEE	----	----	VERO	320.00	----	4/26/88
AVS-4042	CPE	VSV	----	----	L929 >	320.00	----	3/25/88
AVS-4042	CPE	VV	----	----	VERO >	320.00	----	3/31/88
AVS-4042	CPE	YFV	----	----	VERO	320.00	----	4/26/88
AVS-4043	CPE	AD2	0.2	----	HEP2 >	320.00	----	3/31/88
AVS-4043	CPE	JE	----	----	VERO	320.00	----	4/26/88
AVS-4043	CPE	PT	----	----	VERO >	320.00	----	4/26/88
AVS-4043	CPE	SF	----	----	VERO	100.00	----	4/26/88
AVS-4043	CPE	VEE	----	----	VERO	320.00	----	4/26/88
AVS-4043	CPE	VSV	0.2	----	L929 >	320.00	----	3/25/88
AVS-4043	CPE	VV	----	----	VERO >	320.00	----	3/31/88
AVS-4043	CPE	YFV	----	----	VERO	320.00	----	4/26/88
AVS-4044	CPE	AD2	0.1	----	HEP2 <	320.00	----	3/31/88
AVS-4044	CPE	JE	----	----	VERO	32.00	----	4/26/88
AVS-4044	CPE	PT	0.8	55.90	VERO	32.00	0.57	4/26/88
AVS-4044	CPE	SF	2.15	20.20	VERO	100.00	4.94	4/26/88
AVS-4044	CPE	VEE	----	----	VERO	320.00	----	4/26/88
AVS-4044	CPE	VSV	----	----	L929	320.00	----	3/25/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4044	CPE	VV	0.25	----	VERO	32.00	----	3/31/88
AVS-4044	CPE	YFV	----	----	VERO	32.00	----	4/26/88
AVS-4045	CPE	AD2	----	----	HEP2	3.20	----	3/31/88
AVS-4045	CPE	JE	----	----	VERO	320.00	----	4/27/88
AVS-4045	CPE	PT	----	----	VERO	320.00	----	4/27/88
AVS-4045	CPE	SF	----	----	VERO >	320.00	----	4/27/88
AVS-4045	CPE	VEE	----	----	VERO	100.00	----	4/27/88
AVS-4045	CPE	VSV	----	----	L929 >	320.00	----	3/25/88
AVS-4045	CPE	VV	----	----	VERO <	32.00	----	3/31/88
AVS-4045	CPE	YFV	----	----	VERO >	320.00	----	4/27/88
AVS-4046	CPE	JE	----	----	VERO	100.00	----	4/27/88
AVS-4046	CPE	PT	0.25	----	VERO	100.00	----	4/27/88
AVS-4046	CPE	SF	0.05	----	VERO	100.00	----	4/27/88
AVS-4046	CPE	VEE	----	----	VERO	32.00	----	4/27/88
AVS-4046	CPE	VSV	----	----	L929	100.00	----	3/25/88
AVS-4046	CPE	YFV	----	----	VERO	100.00	----	4/27/88
AVS-4047	CPE	AD2	----	----	HEP2	1.00	----	3/31/88
AVS-4047	CPE	JE	----	----	VERO	3.20	----	4/27/88
AVS-4047	CPE	PT	----	----	VERO	10.00	----	4/27/88
AVS-4047	CPE	SF	0.05	----	VERO	3.20	----	4/27/88
AVS-4047	CPE	VEE	----	----	VERO	3.20	----	4/27/88
AVS-4047	CPE	VSV	----	----	L929	10.00	----	3/25/88
AVS-4047	CPE	VV	0.4	----	VERO <	10.00	----	3/31/88
AVS-4047	CPE	YFV	----	----	VERO <	10.00	----	4/27/88
AVS-4048	CPE	AD2	0.2	----	HEP2	3.20	----	3/31/88
AVS-4048	CPE	JE	----	----	VERO	1.00	----	4/27/88
AVS-4048	CPE	PT	----	----	VERO <	0.32	----	4/27/88
AVS-4048	CPE	SF	0.2	----	VERO <	0.32	----	4/27/88
AVS-4048	CPE	VEE	----	----	VERO	3.20	----	4/27/88
AVS-4048	CPE	VSV	----	----	L929 <	1.00	----	3/29/88
AVS-4048	CPE	VV	0.15	----	VERO	1.00	----	3/31/88
AVS-4048	CPE	YFV	0.05	----	VERO <	0.32	----	4/27/88
AVS-4049	CPE	AD2	0.1	----	HEP2 <	32.00	----	4/14/88
AVS-4049	CPE	JE	----	----	VERO <	0.32	----	4/27/88
AVS-4049	CPE	PT	----	----	VERO <	0.32	----	4/27/88
AVS-4049	CPE	SF	1.05	3.22	VERO	1.00	0.31	4/27/88
AVS-4049	CPE	VEE	----	----	VERO	3.20	----	4/27/88
AVS-4049	CPE	VSV	----	----	L929	3.20	----	3/29/88
AVS-4049	CPE	VV	0.35	8.40	VERO	10.00	1.17	4/14/88
AVS-4049	CPE	YFV	0.05	----	VERO <	0.32	----	4/27/88
AVS-4050	CPE	AD2	----	----	HEP2 <	32.00	----	4/14/88
AVS-4050	CPE	JE	----	----	VERO	3.20	----	4/27/88
AVS-4050	CPE	PT	1.05	3.97	VERO	10.00	2.51	4/27/88
AVS-4050	CPE	SF	0.3	3.20	VERO	3.20	1.00	4/27/88
AVS-4050	CPE	VEE	----	----	VERO	3.20	----	4/27/88
AVS-4050	CPE	VSV	1.1	1.90	L929	10.00	5.24	4/1/88
AVS-4050	CPE	VSV	----	----	L929 <	10.00	----	5/3/88
AVS-4050	CPE	VSV	----	----	L929 <	10.00	----	5/10/88
AVS-4050	CPE	VV	1.	3.20	VERO	10.00	3.12	4/14/88
AVS-4050	CPE	VV	0.8	----	VERO <	32.00	----	6/16/88
AVS-4050	CPE	VV	0.4	----	VERO <	10.00	----	6/30/88
AVS-4050	CPE	YFV	----	----	VERO	10.00	----	4/27/88
AVS-4051	CPE	AD2	----	----	HEP2 <	10.00	----	3/31/88
AVS-4051	CPE	JE	----	----	VERO	3.20	----	4/27/88
AVS-4051	CPE	PT	0.7	2.70	VERO <	10.00	3.69	4/27/88
AVS-4051	CPE	SF	0.7	2.01	VERO	3.20	1.59	4/27/88
AVS-4051	CPE	VEE	----	----	VERO <	10.00	----	4/27/88
AVS-4051	CPE	VSV	0.2	----	L929	3.20	----	4/1/88
AVS-4051	CPE	VV	0.1	----	VERO <	32.00	----	3/31/88
AVS-4051	CPE	YFV	----	----	VERO <	10.00	----	4/27/88
AVS-4052	CPE	AD2	----	----	HEP2	10.00	----	4/14/88
AVS-4052	CPE	JE	0.15	----	VERO	3.20	----	4/27/88
AVS-4052	CPE	PT	0.95	4.10	VERO	10.00	2.43	4/27/88
AVS-4052	CPE	SF	0.4	2.39	VERO	1.00	0.42	4/27/88
AVS-4052	CPE	VEE	----	----	VERO	3.20	----	4/27/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-4052	CPE	VSV	0.4	2.39	L929	3.20	1.33	4/ 1/88
AVS-4052	CPE	VV	----	----	VERO <	10.00	----	4/14/88
AVS-4052	CPE	YFV	----	----	VERO	10.00	----	4/27/88
AVS-4053	CPE	JE	----	----	VERO	32.00	----	4/27/88
AVS-4053	CPE	PT	----	----	VERO	32.00	----	4/27/88
AVS-4053	CPE	SF	----	----	VERO	100.00	----	4/27/88
AVS-4053	CPE	VEE	----	----	VERO	100.00	----	4/27/88
AVS-4053	CPE	VSV	----	----	L929	100.00	----	4/ 1/88
AVS-4053	CPE	YFV	----	----	VERO	100.00	----	4/27/88
AVS-4055	CPE	AD2	----	----	HEP2	320.00	----	1/28/88
AVS-4055	CPE	SF	0.05	----	VERO	100.00	----	4/ 6/88
AVS-4055	CPE	VEE	----	----	VERO	100.00	----	4/ 6/88
AVS-4055	CPE	VSV	----	----	L929	100.00	----	1/19/88
AVS-4055	CPE	VV	----	----	VERO >	320.00	----	1/28/88
AVS-4056	CPE	SF	1.15	35.80	VERO	100.00	2.79	4/ 6/88
AVS-4056	CPE	VEE	----	----	VERO	100.00	----	4/ 6/88
AVS-4057	CPE	AD2	----	----	HEP2	320.00	----	1/28/88
AVS-4057	CPE	SF	----	----	VERO	320.00	----	4/ 6/88
AVS-4057	CPE	VEE	----	----	VERO	100.00	----	4/ 6/88
AVS-4057	CPE	VSV	----	----	L929	320.00	----	1/19/88
AVS-4057	CPE	VV	----	----	VERO >	320.00	----	1/28/88
AVS-4058	CPE	AD2	----	----	HEP2 >	320.00	----	1/28/88
AVS-4058	PR	PIC	N/A	----	VERO >	320.00	----	2/15/88
AVS-4058	CPE	SF	----	----	VERO	320.00	----	4/ 6/88
AVS-4058	CPE	VEE	----	----	VERO	320.00	----	4/ 6/88
AVS-4058	CPE	VSV	----	----	L929	100.00	----	1/19/88
AVS-4058	CPE	VV	----	----	VERO	320.00	----	1/28/88
AVS-4059	CPE	AD2	----	----	HEP2 >	320.00	----	1/28/88
AVS-4059	CPE	SF	----	----	VERO	32.00	----	4/ 6/88
AVS-4059	CPE	VEE	----	----	VERO >	320.00	----	4/ 6/88
AVS-4059	CPE	VSV	----	----	L929	320.00	----	1/19/88
AVS-4059	CPE	VV	----	----	VERO >	320.00	----	1/28/88
AVS-4060	CPE	SF	----	----	VERO	10.00	----	4/ 6/88
AVS-4060	CPE	VEE	----	----	VERO	32.00	----	4/ 6/88
AVS-4061	CPE	SF	----	----	VERO	32.00	----	4/ 6/88
AVS-4061	CPE	VEE	----	----	VERO	100.00	----	4/ 6/88
AVS-4062	CPE	JE	----	----	VERO	32.00	----	4/26/88
AVS-4062	CPE	PT	----	----	VERO	100.00	----	4/26/88
AVS-4062	CPE	SF	1.1	42.50	VERO	32.00	0.75	4/26/88
AVS-4062	CPE	VEE	----	----	VERO	100.00	----	4/26/88
AVS-4062	CPE	YFV	----	----	VERO	100.00	----	4/26/88
AVS-4063	CPE	AD2	0.3	----	HEP2 <	10.00	----	1/28/88
AVS-4063	CPE	JE	0.2	----	VERO	3.20	----	4/12/88
AVS-4063	CPE	PT	1.75	13.10	VERO	3.20	0.24	4/12/88
AVS-4063	CPE	SF	1.55	20.30	VERO	3.20	0.16	4/12/88
AVS-4063	CPE	VEE	----	----	VERO	3.20	----	4/12/88
AVS-4063	CPE	VSV	----	----	L929	3.20	----	1/19/88
AVS-4063	CPE	VV	0.2	----	VERO	100.00	----	1/28/88
AVS-4063	CPE	YFV	0.45	10.00	VERO	3.20	0.32	4/12/88
AVS-4064	CPE	AD2	0.3	----	HEP2 >	320.00	----	1/28/88
AVS-4064	CPE	JE	----	----	VERO >	320.00	----	4/12/88
AVS-4064	CPE	PT	----	----	VERO >	320.00	----	4/12/88
AVS-4064	CPE	SF	----	----	VERO	320.00	----	4/12/88
AVS-4064	CPE	VEE	----	----	VERO >	320.00	----	4/12/88
AVS-4064	CPE	VSV	----	----	L929	320.00	----	1/19/88
AVS-4064	CPE	VV	0.1	----	VERO >	320.00	----	1/28/88
AVS-4064	CPE	YFV	----	----	VERO >	320.00	----	4/12/88
AVS-4065	CPE	AD2	0.3	----	HEP2	32.00	----	1/28/88
AVS-4065	CPE	JE	----	----	VERO <	0.32	----	4/12/88
AVS-4065	CPE	PT	----	----	VERO <	0.32	----	4/12/88
AVS-4065	CPE	SF	----	----	VERO <	0.32	----	4/12/88
AVS-4065	CPE	VEE	----	----	VERO <	0.32	----	4/12/88
AVS-4065	CPE	VSV	----	----	L929	1.00	----	1/19/88
AVS-4065	CPE	VV	5.1	0.14	VERO	1.00	6.78	2/11/88
AVS-4065	CPE	YFV	0.7	----	VERO <	0.32	----	4/12/88

8-205

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4066	CPE	AD2	----	----	HEP2	100.00	----	1/28/88
AVS-4066	CPE	JE	----	----	VERO	100.00	----	4/12/88
AVS-4066	CPE	PT	----	----	VERO	10.00	----	4/12/88
AVS-4066	CPE	SF	----	----	VERO	32.00	----	4/12/88
AVS-4066	CPE	VEE	----	----	VERO	10.00	----	4/12/88
AVS-4066	CPE	VSV	----	----	L929	100.00	----	1/19/88
AVS-4066	CPE	VV	0.25	----	VERO	100.00	----	1/28/88
AVS-4066	CPE	YFV	----	----	VERO	10.00	----	4/12/88
AVS-4067	CPE	AD2	----	----	HEP2	320.00	----	1/28/88
AVS-4067	CPE	JE	----	----	VERO	100.00	----	4/12/88
AVS-4067	CPE	PT	----	----	VERO	100.00	----	4/12/88
AVS-4067	CPE	SF	----	----	VERO	320.00	----	4/12/88
AVS-4067	CPE	VEE	----	----	VERO	320.00	----	4/12/88
AVS-4067	CPE	VSV	----	----	L929	320.00	----	1/19/88
AVS-4067	CPE	VV	----	----	VERO	320.00	----	1/28/88
AVS-4067	CPE	YFV	----	----	VERO	32.00	----	4/12/88
AVS-4068	CPE	AD2	----	----	HEP2	320.00	----	1/28/88
AVS-4068	CPE	JE	----	----	VERO	10.00	----	4/12/88
AVS-4068	CPE	PT	0.05	----	VERO	32.00	----	4/12/88
AVS-4068	CPE	SF	----	----	VERO	10.00	----	4/12/88
AVS-4068	CPE	VEE	----	----	VERO	100.00	----	4/12/88
AVS-4068	CPE	VSV	0.15	----	L929	100.00	----	1/19/88
AVS-4068	CPE	VV	0.6	320.00	VERO	320.00	1.00	1/28/88
AVS-4068	CPE	YFV	----	----	VERO	100.00	----	4/12/88
AVS-4070	CPE	AD2	2.2	4.25	HEP2	10.00	2.35	1/28/88
AVS-4070	CPE	AD2	2.3	3.76	HEP2	32.00	8.49	2/18/88
AVS-4070	CPE	JE	1.5	0.68	VERO	1.00	1.46	4/12/88
AVS-4070	CPE	PT	1.85	1.50	VERO	3.20	2.13	4/12/88
AVS-4070	CPE	SF	1.55	1.34	VERO	3.20	2.37	4/12/88
AVS-4070	CPE	VEE	----	----	VERO	3.20	----	4/12/88
AVS-4070	CPE	VSV	0.65	16.90	L929	10.00	0.59	1/19/88
AVS-4070	CPE	VV	0.35	27.00	VERO	10.00	0.37	1/28/88
AVS-4070	CPE	YFV	1.35	1.78	VERO	3.20	1.78	4/12/88
AVS-4071	CPE	AD2	0.45	217.00	HEP2	320.00	1.47	1/28/88
AVS-4071	CPE	JE	0.15	----	VERO	320.00	----	4/12/88
AVS-4071	CPE	PT	1.4	133.00	VERO	320.00	2.39	4/12/88
AVS-4071	CPE	SF	0.55	222.00	VERO	320.00	1.44	4/12/88
AVS-4071	CPE	VEE	----	----	VERO	100.00	----	4/12/88
AVS-4071	CPE	VSV	0.55	188.00	L929	100.00	0.53	1/19/88
AVS-4071	CPE	VV	----	----	VERO	320.00	----	1/28/88
AVS-4071	CPE	YFV	0.15	----	VERO	320.00	----	4/12/88
AVS-4073	CPE	AD2	0.3	----	HEP2	320.00	----	3/31/88
AVS-4073	CPE	JE	----	----	VERO	100.00	----	4/27/88
AVS-4073	CPE	PT	----	----	VERO	320.00	----	4/27/88
AVS-4073	CPE	SF	----	----	VERO	320.00	----	4/27/88
AVS-4073	CPE	VEE	----	----	VERO	100.00	----	4/27/88
AVS-4073	CPE	VSV	----	----	L929	320.00	----	4/1/88
AVS-4073	CPE	VV	----	----	VERO	320.00	----	3/31/88
AVS-4073	CPE	YFV	----	----	VERO	320.00	----	4/27/88
AVS-4076	CPE	AD2	----	----	HEP2	320.00	----	4/14/88
AVS-4076	CPE	JE	----	----	VERO	1.00	----	4/27/88
AVS-4076	CPE	PT	----	----	VERO	1.00	----	4/27/88
AVS-4076	CPE	SF	----	----	VERO	1.00	----	4/27/88
AVS-4076	CPE	VEE	----	----	VERO	3.20	----	4/27/88
AVS-4076	CPE	VSV	----	----	L929	320.00	----	4/1/88
AVS-4076	CPE	VV	----	----	VERO	100.00	----	4/27/88
AVS-4076	CPE	YFV	0.35	----	VERO	3.20	----	4/27/88
AVS-4077	CPE	AD2	0.6	320.00	HEP2	320.00	1.00	3/31/88
AVS-4077	CPE	JE	----	----	VERO	320.00	----	4/27/88
AVS-4077	CPE	PT	----	----	VERO	320.00	----	4/27/88
AVS-4077	CPE	SF	----	----	VERO	320.00	----	4/27/88
AVS-4077	CPE	VEE	----	----	VERO	320.00	----	4/27/88
AVS-4077	CPE	VSV	----	----	L929	320.00	----	4/1/88
AVS-4077	CPE	VV	----	----	VERO	320.00	----	3/31/88
AVS-4077	CPE	YFV	----	----	VERO	320.00	----	4/27/88

B-206

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-4078	CPE	AD2	----	----	HEP2	320.00	----	3/31/88
AVS-4078	CPE	JE	----	----	VERO	100.00	----	4/27/88
AVS-4078	CPE	PT	----	----	VERO	320.00	----	4/27/88
AVS-4078	CPE	SF	0.05	----	VERO	100.00	----	4/27/88
AVS-4078	CPE	VEE	----	----	VERO	320.00	----	4/27/88
AVS-4078	CPE	VSV	----	----	L929	320.00	----	4/1/88
AVS-4078	CPE	VV	----	----	VERO	320.00	----	3/31/88
AVS-4078	CPE	YFV	----	----	VERO	320.00	----	4/27/88
AVS-4079	CPE	AD2	----	----	HEP2	320.00	----	3/31/88
AVS-4079	CPE	JE	----	----	VERO	10.00	----	4/27/88
AVS-4079	CPE	PT	----	----	VERO	10.00	----	4/27/88
AVS-4079	CPE	SF	----	----	VERO	100.00	----	4/27/88
AVS-4079	CPE	VEE	----	----	VERO	100.00	----	4/27/88
AVS-4079	CPE	VSV	----	----	L929	320.00	----	4/1/88
AVS-4079	CPE	VV	----	----	VERO	320.00	----	3/31/88
AVS-4079	CPE	YFV	----	----	VERO	320.00	----	4/27/88
AVS-4080	CPE	AD2	----	----	HEP2	320.00	----	4/14/88
AVS-4080	CPE	JE	----	----	VERO	320.00	----	4/27/88
AVS-4080	CPE	PT	----	----	VERO	320.00	----	4/27/88
AVS-4080	CPE	SF	----	----	VERO	320.00	----	4/27/88
AVS-4080	CPE	VEE	----	----	VERO	320.00	----	4/27/88
AVS-4080	CPE	VSV	----	----	L929	320.00	----	4/1/88
AVS-4080	CPE	VV	----	----	VERO	320.00	----	4/14/88
AVS-4080	CPE	YFV	----	----	VERO	320.00	----	4/27/88
AVS-4081	CPE	AD2	----	----	HEP2	320.00	----	4/14/88
AVS-4081	CPE	JE	----	----	VERO	100.00	----	5/3/88
AVS-4081	CPE	PT	----	----	VERO	320.00	----	5/3/88
AVS-4081	CPE	SF	----	----	VERO	320.00	----	5/3/88
AVS-4081	CPE	VEE	----	----	VERO	100.00	----	5/3/88
AVS-4081	CPE	VSV	----	----	L929	320.00	----	4/1/88
AVS-4081	CPE	VV	0.2	----	VERO	320.00	----	4/14/88
AVS-4081	CPE	YFV	----	----	VERO	320.00	----	5/3/88
AVS-4082	CPE	AD2	0.1	----	HEP2	320.00	----	4/14/88
AVS-4082	CPE	JE	----	----	VERO	320.00	----	5/3/88
AVS-4082	CPE	PT	----	----	VERO	320.00	----	5/3/88
AVS-4082	CPE	SF	----	----	VERO	320.00	----	5/3/88
AVS-4082	CPE	VEE	----	----	VERO	320.00	----	5/3/88
AVS-4082	CPE	VSV	----	----	L929	320.00	----	4/1/88
AVS-4082	CPE	VV	----	----	VERO	320.00	----	4/14/88
AVS-4082	CPE	YFV	----	----	VERO	320.00	----	5/3/88
AVS-4083	CPE	AD2	----	----	HEP2	100.00	----	4/14/88
AVS-4083	CPE	JE	----	----	VERO	100.00	----	5/3/88
AVS-4083	CPE	PT	----	----	VERO	32.00	----	5/3/88
AVS-4083	CPE	SF	0.05	----	VERO	320.00	----	5/3/88
AVS-4083	CPE	VEE	----	----	VERO	320.00	----	5/3/88
AVS-4083	CPE	VSV	----	----	L929	320.00	----	4/1/88
AVS-4083	CPE	VV	----	----	VERO	320.00	----	4/14/88
AVS-4083	CPE	YFV	----	----	VERO	320.00	----	5/3/88
AVS-4084	CPE	AD2	----	----	HEP2	10.00	----	4/14/88
AVS-4084	CPE	JE	----	----	VERO	32.00	----	5/3/88
AVS-4084	CPE	PT	----	----	VERO	32.00	----	5/3/88
AVS-4084	CPE	SF	----	----	VERO	100.00	----	5/3/88
AVS-4084	CPE	VEE	----	----	VERO	100.00	----	5/3/88
AVS-4084	CPE	VSV	----	----	L929	100.00	----	4/1/88
AVS-4084	CPE	VV	----	----	VERO	320.00	----	4/14/88
AVS-4084	CPE	YFV	----	----	VERO	10.00	----	5/3/88
AVS-4085	CPE	AD2	----	----	HEP2	320.00	----	4/14/88
AVS-4085	CPE	JE	----	----	VERO	10.00	----	5/3/88
AVS-4085	CPE	PT	----	----	VERO	10.00	----	5/3/88
AVS-4085	CPE	SF	----	----	VERO	10.00	----	5/3/88
AVS-4085	CPE	VEE	----	----	VERO	1.00	----	5/3/88
AVS-4085	CPE	VSV	----	----	L929	100.00	----	4/1/88
AVS-4085	CPE	VV	----	----	VERO	32.00	----	4/14/88
AVS-4085	CPE	YFV	0.45	217.00	VERO	32.00	0.15	5/3/88
AVS-4086	CPE	AD2	----	----	HEP2	32.00	----	4/14/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4086	CPE	JE	----	----	VERO	320.00	----	5/ 3/88
AVS-4086	CPE	PT	----	----	VERO	32.00	----	5/ 3/88
AVS-4086	CPE	SF	----	----	VERO	320.00	----	5/ 3/88
AVS-4086	CPE	VEE	----	----	VERO	10.00	----	5/ 3/88
AVS-4086	CPE	VSV	----	----	L929	320.00	----	4/ 1/88
AVS-4086	CPE	VV	----	----	VERO	320.00	----	4/14/88
AVS-4086	CPE	YFV	----	----	VERO	100.00	----	5/ 3/88
AVS-4087	CPE	AD2	----	----	HEP2	100.00	----	4/14/88
AVS-4087	CPE	JE	----	----	VERO	10.00	----	5/ 3/88
AVS-4087	CPE	PT	----	----	VERO	10.00	----	5/ 3/88
AVS-4087	CPE	SF	----	----	VERO	10.00	----	5/ 3/88
AVS-4087	CPE	VEE	----	----	VERO	320.00	----	5/ 3/88
AVS-4087	CPE	VSV	----	----	L929	100.00	----	4/ 1/88
AVS-4087	CPE	VV	----	----	VERO	10.00	----	4/14/88
AVS-4087	CPE	YFV	0.15	----	VERO	10.00	----	5/ 3/88
AVS-4088	CPE	AD2	----	----	HEP2	10.00	----	4/14/88
AVS-4088	CPE	JE	----	----	VERO	10.00	----	5/ 3/88
AVS-4088	CPE	PT	----	----	VERO	10.00	----	5/ 3/88
AVS-4088	CPE	SF	----	----	VERO	10.00	----	5/ 3/88
AVS-4088	CPE	VEE	----	----	VERO	3.20	----	5/ 3/88
AVS-4088	CPE	VSV	----	----	L929	100.00	----	4/ 1/88
AVS-4088	CPE	VV	----	----	VERO	320.00	----	4/14/88
AVS-4088	CPE	YFV	0.55	199.00	VERO	10.00	0.05	5/ 3/88
AVS-4089	CPE	AD2	----	----	HEP2	32.00	----	4/14/88
AVS-4089	CPE	JE	----	----	VERO	32.00	----	5/ 3/88
AVS-4089	CPE	PT	----	----	VERO	32.00	----	5/ 3/88
AVS-4089	CPE	SF	----	----	VERO	10.00	----	5/ 3/88
AVS-4089	CPE	VEE	----	----	VERO	10.00	----	5/ 3/88
AVS-4089	CPE	VSV	----	----	L929	100.00	----	4/ 1/88
AVS-4089	CPE	VV	----	----	VERO	320.00	----	4/14/88
AVS-4089	CPE	YFV	0.45	217.00	VERO	32.00	0.15	5/ 3/88
AVS-4090	CPE	AD2	----	----	HEP2	320.00	----	4/14/88
AVS-4090	CPE	JE	----	----	VERO	3.20	----	5/ 3/88
AVS-4090	CPE	PT	----	----	VERO	10.00	----	5/ 3/88
AVS-4090	CPE	SF	----	----	VERO	3.20	----	5/ 3/88
AVS-4090	CPE	VEE	----	----	VERO	320.00	----	5/ 3/88
AVS-4090	CPE	VSV	----	----	L929	320.00	----	4/ 1/88
AVS-4090	CPE	VV	----	----	VERO	10.00	----	4/14/88
AVS-4090	CPE	YFV	0.6	56.30	VERO	10.00	0.18	5/ 3/88
AVS-4091	CPE	AD2	----	----	HEP2	320.00	----	4/ 1/88
AVS-4091	CPE	JE	----	----	VERO	32.00	----	5/ 3/88
AVS-4091	CPE	PT	----	----	VERO	32.00	----	5/ 3/88
AVS-4091	CPE	SF	----	----	VERO	32.00	----	5/ 3/88
AVS-4091	CPE	VEE	----	----	VERO	32.00	----	5/ 3/88
AVS-4091	CPE	VSV	----	----	L929	320.00	----	4/ 1/88
AVS-4091	CPE	VV	----	----	VERO	32.00	----	4/14/88
AVS-4091	CPE	YFV	0.2	----	VERO	32.00	----	5/ 3/88
AVS-4092	CPE	AD2	----	----	HEP2	320.00	----	4/14/88
AVS-4092	CPE	JE	----	----	VERO	320.00	----	5/ 3/88
AVS-4092	CPE	PT	----	----	VERO	320.00	----	5/ 3/88
AVS-4092	CPE	SF	----	----	VERO	320.00	----	5/ 3/88
AVS-4092	CPE	VEE	----	----	VERO	100.00	----	5/ 3/88
AVS-4092	CPE	VSV	----	----	L929	320.00	----	4/ 5/88
AVS-4092	CPE	VV	----	----	VERO	320.00	----	4/14/88
AVS-4092	CPE	YFV	----	----	VERO	320.00	----	5/ 3/88
AVS-4093	CPE	AD2	----	----	HEP2	320.00	----	4/14/88
AVS-4093	CPE	JE	----	----	VERO	100.00	----	5/ 3/88
AVS-4093	CPE	PT	----	----	VERO	320.00	----	5/ 3/88
AVS-4093	CPE	SF	----	----	VERO	320.00	----	5/ 3/88
AVS-4093	CPE	VEE	----	----	VERO	10.00	----	5/ 3/88
AVS-4093	CPE	VSV	----	----	L929	100.00	----	4/ 5/88
AVS-4093	CPE	VV	----	----	VERO	320.00	----	4/14/88
AVS-4093	CPE	YFV	----	----	VERO	320.00	----	5/ 3/88
AVS-4094	CPE	AD2	0.9	68.30	HEP2	320.00	4.68	4/14/88
AVS-4094	CPE	JE	----	----	VERO	320.00	----	5/ 3/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4094	CPE	PT	----	----	VERO >	320.00	----	5/ 3/88
AVS-4094	CPE	SF	----	----	VERO >	320.00	----	5/ 3/88
AVS-4094	CPE	VEE	----	----	VERO >	320.00	----	5/ 3/88
AVS-4094	CPE	VSV	0.55	320.00	L929	100.00	0.31	4/ 5/88
AVS-4094	CPE	VV	0.4	----	VERO >	320.00	----	4/14/88
AVS-4094	CPE	YFV	----	----	VERO >	320.00	----	5/ 3/88
AVS-4095	CPE	AD2	----	----	HEP2 >	320.00	----	4/14/88
AVS-4095	CPE	JE	----	----	VERO	320.00	----	5/ 3/88
AVS-4095	CPE	PT	----	----	VERO	320.00	----	5/ 3/88
AVS-4095	CPE	SF	----	----	VERO >	320.00	----	5/ 3/88
AVS-4095	CPE	VEE	----	----	VERO >	320.00	----	5/ 3/88
AVS-4095	CPE	VSV	----	----	L929	320.00	----	4/ 5/88
AVS-4095	CPE	VV	----	----	VERO >	320.00	----	4/14/88
AVS-4095	CPE	YFV	----	----	VERO >	320.00	----	5/ 3/88
AVS-4096	CPE	JE	----	----	VERO	10.00	----	5/ 4/88
AVS-4096	CPE	PT	----	----	VERO	32.00	----	5/ 4/88
AVS-4096	CPE	SF	----	----	VERO	32.00	----	5/ 4/88
AVS-4096	CPE	VEE	----	----	VERO	100.00	----	5/ 4/88
AVS-4096	CPE	YFV	----	----	VERO	10.00	----	5/ 4/88
AVS-4103	CPE	AD2	0.3	----	HEP2 >	320.00	----	4/14/88
AVS-4103	CPE	JE	----	----	VERO	320.00	----	5/ 4/88
AVS-4103	CPE	PT	----	----	VERO	320.00	----	5/ 4/88
AVS-4103	CPE	SF	----	----	VERO	320.00	----	5/ 4/88
AVS-4103	CPE	VEE	----	----	VERO	100.00	----	5/ 4/88
AVS-4103	CPE	VSV	----	----	L929 >	320.00	----	4/ 5/88
AVS-4103	CPE	VV	----	----	VERO >	320.00	----	4/14/88
AVS-4103	CPE	YFV	----	----	VERO	100.00	----	5/ 4/88
AVS-4104	CPE	AD2	----	----	HEP2 >	320.00	----	4/14/88
AVS-4104	CPE	JE	----	----	VERO	320.00	----	5/ 4/88
AVS-4104	CPE	PT	----	----	VERO	320.00	----	5/ 4/88
AVS-4104	CPE	SF	----	----	VERO	100.00	----	5/ 4/88
AVS-4104	CPE	VEE	----	----	VERO	320.00	----	5/ 4/88
AVS-4104	CPE	VSV	----	----	L929 >	320.00	----	4/ 5/88
AVS-4104	CPE	VV	----	----	VERO >	320.00	----	4/14/88
AVS-4104	CPE	YFV	----	----	VERO >	320.00	----	5/ 4/88
AVS-4105	CPE	AD2	----	----	HEP2	320.00	----	4/21/88
AVS-4105	CPE	JE	----	----	VERO	100.00	----	5/ 4/88
AVS-4105	CPE	PT	0.1	----	VERO	320.00	----	5/ 4/88
AVS-4105	CPE	SF	----	----	VERO	100.00	----	5/ 4/88
AVS-4105	CPE	VEE	----	----	VERO	100.00	----	5/ 4/88
AVS-4105	CPE	VSV	----	----	L929	100.00	----	4/ 5/88
AVS-4105	CPE	VV	----	----	VERO	320.00	----	4/21/88
AVS-4105	CPE	YFV	----	----	VERO	100.00	----	5/ 4/88
AVS-4108	CPE	AD2	0.6	320.00	HEP2 >	320.00	1.00	4/21/88
AVS-4108	CPE	JE	----	----	VERO	320.00	----	5/ 4/88
AVS-4108	CPE	PT	----	----	VERO >	320.00	----	5/ 4/88
AVS-4108	CPE	SF	----	----	VERO	100.00	----	5/ 4/88
AVS-4108	CPE	VEE	----	----	VERO	100.00	----	5/ 4/88
AVS-4108	CPE	VSV	----	----	L929	320.00	----	4/ 5/88
AVS-4108	CPE	VV	0.2	----	VERO >	320.00	----	4/21/88
AVS-4108	CPE	YFV	----	----	VERO >	320.00	----	5/ 4/88
AVS-4109	CPE	AD2	0.3	----	HEP2 >	320.00	----	4/21/88
AVS-4109	CPE	JE	----	----	VERO	320.00	----	5/ 4/88
AVS-4109	CPE	PT	----	----	VERO >	320.00	----	5/ 4/88
AVS-4109	CPE	SF	0.05	----	VERO	320.00	----	5/ 4/88
AVS-4109	CPE	VEE	----	----	VERO	100.00	----	5/ 4/88
AVS-4109	CPE	VSV	----	----	L929	320.00	----	4/ 5/88
AVS-4109	CPE	VV	----	----	VERO >	320.00	----	4/21/88
AVS-4109	CPE	YFV	----	----	VERO >	320.00	----	5/ 4/88
AVS-4110	CPE	AD2	----	----	HEP2 <	100.00	----	5/19/88
AVS-4110	CPE	JE	----	----	VERO	32.00	----	6/14/88
AVS-4110	CPE	PT	0.35	319.00	VERO	100.00	0.31	6/14/88
AVS-4110	CPE	SF	0.3	----	VERO	32.00	----	6/14/88
AVS-4110	CPE	VEE	----	----	VERO >	320.00	----	6/14/88
AVS-4110	CPE	VSV	----	----	L929 >	320.00	----	5/ 3/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4110	CPE	VV	0.3	----	VERO >	320.00	----	5/19/88
AVS-4111	CPE	AD2	0.8	317.00	HEP2 >	320.00 >	1.00	5/19/88
AVS-4111	CPE	JE	----	----	VERO	100.00	----	6/14/88
AVS-4111	CPE	PT	----	----	VERO	320.00	----	6/14/88
AVS-4111	CPE	SF	0.3	----	VERO	320.00	----	6/14/88
AVS-4111	CPE	VEE	----	----	VERO >	320.00	----	6/14/88
AVS-4111	CPE	VSV	----	----	L929 >	320.00	----	5/ 3/88
AVS-4111	CPE	VV	----	----	VERO >	320.00	----	5/19/88
AVS-4112	CPE	AD2	0.7	319.00	HEP2 >	320.00 >	1.00	5/19/88
AVS-4112	CPE	JE	----	----	VERO	32.00	----	6/14/88
AVS-4112	CPE	PT	0.05	----	VERO	320.00	----	6/14/88
AVS-4112	CPE	SF	0.55	----	VERO	10.00	----	6/14/88
AVS-4112	CPE	VEE	----	----	VERO	320.00	----	6/14/88
AVS-4112	CPE	VSV	----	----	L929 >	320.00	----	5/ 3/88
AVS-4112	CPE	VV	----	----	VERO >	320.00	----	5/19/88
AVS-4113	CPE	AD2	----	----	HEP2	10.00	----	4/29/88
AVS-4113	CPE	JE	1.05	0.26	VERO	0.10	0.38	5/ 4/88
AVS-4113	CPE	JE	1.4	0.18	VERO	1.00	5.52	6/14/88
AVS-4113	CPE	PT	1.05	0.26	VERO	0.10	0.38	5/ 4/88
AVS-4113	CPE	PT	0.75	0.46	VERO <	0.32 <	0.68	6/14/88
AVS-4113	CPE	SF	0.45	0.21	VERO	0.32	1.47	5/ 4/88
AVS-4113	CPE	SF	0.75	0.36	VERO <	0.32 <	0.88	6/14/88
AVS-4113	CPE	VEE	----	----	VERO	0.10	----	5/ 4/88
AVS-4113	CPE	VEE	----	----	VERO <	0.32	----	6/14/88
AVS-4113	CPE	VSV	1.15	2.30	L929	1.00	0.43	4/ 5/88
AVS-4113	CPE	VV	0.6	10.00	VERO	10.00	1.00	4/29/88
AVS-4113	CPE	YFV	0.75	0.14	VERO	0.10	0.68	5/ 4/88
AVS-4114	CPE	AD2	----	----	HEP2 >	320.00	----	5/19/88
AVS-4114	CPE	JE	----	----	VERO	32.00	----	6/14/88
AVS-4114	CPE	PT	----	----	VERO	32.00	----	6/14/88
AVS-4114	CPE	SF	1.3	42.70	VERO	10.00	0.23	6/14/88
AVS-4114	CPE	VEE	----	----	VERO	100.00	----	6/14/88
AVS-4114	CPE	VSV	----	----	L929	100.00	----	5/ 3/88
AVS-4114	CPE	VV	----	----	VERO >	320.00	----	5/19/88
AVS-4115	CPE	AD2	----	----	HEP2 >	320.00	----	5/19/88
AVS-4115	CPE	JE	----	----	VERO	320.00	----	6/15/88
AVS-4115	CPE	PT	----	----	VERO >	320.00	----	6/15/88
AVS-4115	CPE	SF	0.2	----	VERO	320.00	----	6/15/88
AVS-4115	CPE	VEE	----	----	VERO	320.00	----	6/15/88
AVS-4115	CPE	VSV	----	----	L929 >	320.00	----	5/ 3/88
AVS-4115	CPE	VV	----	----	VERO >	320.00	----	5/19/88
AVS-4115	CPE	YFV	----	----	VERO >	320.00	----	6/15/88
AVS-4116	CPE	AD2	----	----	HEP2	320.00	----	5/19/88
AVS-4116	CPE	JE	----	----	VERO	320.00	----	6/15/88
AVS-4116	CPE	PT	----	----	VERO	100.00	----	6/15/88
AVS-4116	CPE	SF	----	----	VERO	32.00	----	6/15/88
AVS-4116	CPE	VEE	----	----	VERO	320.00	----	6/15/88
AVS-4116	CPE	VSV	----	----	L929	100.00	----	5/ 3/88
AVS-4116	CPE	VV	0.1	----	VERO >	320.00	----	5/19/88
AVS-4116	CPE	YFV	----	----	VERO	100.00	----	6/15/88
AVS-4117	CPE	AD2	0.4	----	HEP2 >	320.00	----	5/19/88
AVS-4117	CPE	JE	----	----	VERO	320.00	----	6/15/88
AVS-4117	CPE	PT	----	----	VERO >	320.00	----	6/15/88
AVS-4117	CPE	SF	----	----	VERO	320.00	----	6/15/88
AVS-4117	CPE	VEE	----	----	VERO	320.00	----	6/15/88
AVS-4117	CPE	VSV	----	----	L929 >	320.00	----	5/ 3/88
AVS-4117	CPE	VV	----	----	VERO >	320.00	----	5/19/88
AVS-4117	CPE	YFV	----	----	VERO >	320.00	----	6/15/88
AVS-4118	CPE	AD2	0.3	----	HEP2 >	320.00	----	5/19/88
AVS-4118	CPE	JE	----	----	VERO	320.00	----	6/15/88
AVS-4118	CPE	PT	----	----	VERO >	320.00	----	6/15/88
AVS-4118	CPE	SF	0.1	----	VERO	320.00	----	6/15/88
AVS-4118	CPE	VEE	----	----	VERO	320.00	----	6/15/88
AVS-4118	CPE	VSV	----	----	L929 >	320.00	----	5/ 3/88
AVS-4118	CPE	VV	----	----	VERO >	320.00	----	5/19/88

B-210

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	T _i	DATE
AVS-4118	CPE	YFV	----	----	VERO >	320.00	----	6/15/88
AVS-4119	CPE	AD2	0.6	320.00	HEP2 >	320.00	1.00	5/19/88
AVS-4119	CPE	IE	----	----	VERO	320.00	----	6/15/88
AVS-4119	CPE	VEE	----	----	VERO	100.00	----	6/15/88
AVS-4119	CPE	YFV	----	----	VERO	100.00	----	6/15/88
AVS-4119	CPE	VEE	----	----	VERO	320.00	----	6/15/88
AVS-4119	CPE	VSV	----	----	L929	320.00	----	5/ 3/88
AVS-4119	CPE	VV	----	----	VERO >	320.00	----	5/19/88
AVS-4119	CPE	YFV	----	----	VERO	100.00	----	6/15/88
AVS-4120	CPE	AD2	----	----	HEP2 <	320.00	----	5/19/88
AVS-4120	CPE	JE	----	----	VERO <	0.32	----	6/15/88
AVS-4120	CPE	PT	----	----	VERO	10.00	----	6/15/88
AVS-4120	CPE	SF	0.35	27.00	VERO	10.00	0.37	6/15/88
AVS-4120	CPE	VEE	----	----	VERO	32.00	----	6/15/88
AVS-4120	CPE	VSV	----	----	L929	320.00	----	5/ 3/88
AVS-4120	CPE	VV	----	----	VERO <	320.00	----	5/19/88
AVS-4120	CPE	YFV	----	----	VERO	10.00	----	6/15/88
AVS-4121	CPE	AD2	0.9	306.00	HEP2 >	320.00	1.04	5/19/88
AVS-4121	CPE	JE	----	----	VERO	100.00	----	6/15/88
AVS-4121	CPE	PT	----	----	VERO >	320.00	----	6/15/88
AVS-4121	CPE	SF	0.1	----	VERO	320.00	----	6/15/88
AVS-4121	CPE	VEE	----	----	VERO	100.00	----	6/15/88
AVS-4121	CPE	VSV	----	----	L929 >	320.00	----	5/ 3/88
AVS-4121	CPE	VV	----	----	VERO >	320.00	----	5/19/88
AVS-4121	CPE	YFV	----	----	VERO >	320.00	----	6/15/88
AVS-4122	CPE	AD2	0.45	----	HEP2	320.00	----	5/19/88
AVS-4122	CPE	JE	----	----	VERO	32.00	----	6/15/88
AVS-4122	CPE	PT	0.15	----	VERO	32.00	----	6/15/88
AVS-4122	CPE	SF	0.9	40.60	VERO	32.00	0.79	6/15/88
AVS-4122	CPE	VEE	----	----	VERO	32.00	----	6/15/88
AVS-4122	CPE	VSV	----	----	L929	320.00	----	5/ 3/88
AVS-4122	CPE	VV	0.3	----	VERO <	320.00	----	5/19/88
AVS-4122	CPE	YFV	----	----	VERO	100.00	----	6/15/88
AVS-4123	CPE	AD2	0.3	----	HEP2	320.00	----	5/19/88
AVS-4123	CPE	JE	----	----	VERO	32.00	----	6/15/88
AVS-4123	CPE	PT	0.85	118.00	VERO	32.00	0.27	6/15/88
AVS-4123	CPE	SF	0.7	42.90	VERO	32.00	0.75	6/15/88
AVS-4123	CPE	VEE	----	----	VERO	32.00	----	6/15/88
AVS-4123	CPE	VSV	----	----	L929	320.00	----	5/ 3/88
AVS-4123	CPE	VV	0.3	----	VERO <	320.00	----	5/19/88
AVS-4123	CPE	YFV	0.05	----	VERO	32.00	----	6/15/88
AVS-4124	CPE	AD2	----	----	HEP2 <	100.00	----	5/19/88
AVS-4124	CPE	JE	----	----	VERO	10.00	----	6/15/88
AVS-4124	CPE	PT	0.4	23.90	VERO	10.00	0.42	6/15/88
AVS-4124	CPE	SF	0.7	13.40	VERO	10.00	0.74	6/15/88
AVS-4124	CPE	VSV	----	----	L929	32.00	----	5/ 3/88
AVS-4124	CPE	VV	0.3	----	VERO <	100.00	----	5/19/88
AVS-4124	CPE	YFV	----	----	VERO	10.00	----	6/15/88
AVS-4125	CPE	AD2	0.2	----	HEP2 >	320.00	----	5/19/88
AVS-4125	CPE	JE	----	----	VERO	100.00	----	6/15/88
AVS-4125	CPE	PT	----	----	VERO	100.00	----	6/15/88
AVS-4125	CPE	SF	0.6	----	VERO	320.00	----	6/15/88
AVS-4125	CPE	VEE	----	----	VERO	320.00	----	6/15/88
AVS-4125	CPE	VSV	0.7	270.00	L929 >	320.00	1.18	5/10/88
AVS-4125	CPE	VV	----	----	VERO >	320.00	----	5/19/88
AVS-4125	CPE	YFV	----	----	VERO	320.00	----	6/15/88
AVS-4126	CPE	AD2	0.15	----	HEP2	100.00	----	5/12/88
AVS-4126	CPE	JE	----	----	VERO	100.00	----	6/15/88
AVS-4126	CPE	PT	----	----	VERO	100.00	----	6/15/88
AVS-4126	CPE	SF	0.4	----	VERO	100.00	----	6/15/88
AVS-4126	CPE	VEE	----	----	VERO	320.00	----	6/15/88
AVS-4126	CPE	VSV	----	----	L929	320.00	----	5/10/88
AVS-4126	CPE	VV	1.	222.00	VERO >	320.00	1.44	5/12/88
AVS-4126	CPE	YFV	----	----	VERO >	320.00	----	6/15/88
AVS-4127	CPE	AD2	----	----	HEP2 <	100.00	----	5/12/88

B-211

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4127	CPE	JE	----	----	VERO	32.00	----	6/15/88
AVS-4127	CPE	PT	0.25	----	VERO	100.00	----	6/15/88
AVS-4127	CPE	SF	0.65	----	VERO	32.00	----	6/15/88
AVS-4127	CPE	VEE	----	----	VERO	100.00	----	6/15/88
AVS-4127	CPE	VSV	----	----	L929 >	320.00	----	5/10/88
AVS-4127	CPE	VV	0.3	320.00	VERO	320.00	1.00	5/12/88
AVS-4127	CPE	YFV	----	----	VERO	100.00	----	6/15/88
AVS-4128	CPE	AD2	0.3	----	HEP2 >	320.00	----	5/19/88
AVS-4128	CPE	JE	----	----	VERO	320.00	----	6/15/88
AVS-4128	CPE	PT	----	----	VERO >	320.00	----	6/15/88
AVS-4128	CPE	SF	0.1	----	VERO	320.00	----	6/15/88
AVS-4128	CPE	VEE	----	----	VERO	100.00	----	6/15/88
AVS-4128	CPE	VSV	----	----	L929 >	320.00	----	5/10/88
AVS-4128	CPE	VV	----	----	VERO >	320.00	----	5/19/88
AVS-4128	CPE	YFV	----	----	VERO >	320.00	----	6/15/88
AVS-4129	CPE	AD2	----	----	HEP2 >	320.00	----	5/12/88
AVS-4129	CPE	JE	----	----	VERO	100.00	----	6/15/88
AVS-4129	CPE	PT	----	----	VERO	320.00	----	6/15/88
AVS-4129	CPE	SF	0.55	----	VERO	320.00	----	6/15/88
AVS-4129	CPE	VEE	----	----	VERO	320.00	----	6/15/88
AVS-4129	CPE	VSV	----	----	L929 >	320.00	----	5/10/88
AVS-4129	CPE	VV	----	----	VERO >	320.00	----	5/12/88
AVS-4129	CPE	YFV	----	----	VERO	320.00	----	6/15/88
AVS-4130	CPE	AD2	----	----	HEP2 >	320.00	----	5/12/88
AVS-4130	CPE	JE	----	----	VERO	32.00	----	6/14/88
AVS-4130	CPE	PT	0.3	----	VERO	32.00	----	6/14/88
AVS-4130	CPE	SF	1.65	54.20	VERO	32.00	0.18	6/14/88
AVS-4130	CPE	VEE	----	----	VERO	320.00	----	6/14/88
AVS-4130	CPE	VSV	----	----	L929 >	320.00	----	5/10/88
AVS-4130	CPE	VV	----	----	VERO	100.00	----	5/12/88
AVS-4131	CPE	AD2	----	----	HEP2 >	320.00	----	5/19/88
AVS-4131	CPE	JE	----	----	VERO	100.00	----	6/14/88
AVS-4131	CPE	PT	0.15	----	VERO	100.00	----	6/14/88
AVS-4131	CPE	SF	0.1	----	VERO	320.00	----	6/14/88
AVS-4131	CPE	VEE	----	----	VERO	320.00	----	6/14/88
AVS-4131	CPE	VSV	----	----	L929	100.00	----	5/10/88
AVS-4131	CPE	VV	----	----	VERO	100.00	----	5/19/88
AVS-4135	CPE	AD2	0.8	----	HEP2 >	320.00	----	5/19/88
AVS-4135	CPE	JE	----	----	VERO	320.00	----	6/21/88
AVS-4135	CPE	PT	----	----	VERO	100.00	----	6/21/88
AVS-4135	CPE	SF	----	----	VERO	320.00	----	6/21/88
AVS-4135	CPE	VSV	----	----	L929 >	320.00	----	5/10/88
AVS-4135	CPE	VV	----	----	VERO >	320.00	----	5/19/88
AVS-4136	CPE	AD2	0.3	----	HEP2 >	320.00	----	5/19/88
AVS-4136	CPE	JE	----	----	VERO >	320.00	----	6/21/88
AVS-4136	CPE	PT	----	----	VERO	320.00	----	6/21/88
AVS-4136	CPE	SF	----	----	VERO	320.00	----	6/21/88
AVS-4136	CPE	VSV	----	----	L929 >	320.00	----	5/10/88
AVS-4136	CPE	VV	----	----	VERO >	320.00	----	5/19/88
AVS-4137	CPE	AD2	----	----	HEP2 >	320.00	----	5/19/88
AVS-4137	CPE	JE	----	----	VERO	100.00	----	6/21/88
AVS-4137	CPE	PT	----	----	VERO >	320.00	----	6/21/88
AVS-4137	CPE	SF	----	----	VERO >	320.00	----	6/21/88
AVS-4137	CPE	VSV	----	----	L929 >	320.00	----	5/10/88
AVS-4137	CPE	VV	0.1	----	VERO >	320.00	----	5/19/88
AVS-4138	CPE	AD2	0.3	----	HEP2 >	320.00	----	5/19/88
AVS-4138	CPE	JE	----	----	VERO	100.00	----	6/21/88
AVS-4138	CPE	PT	----	----	VERO	320.00	----	6/21/88
AVS-4138	CPE	SF	----	----	VERO >	320.00	----	6/21/88
AVS-4138	CPE	VSV	----	----	L929 >	320.00	----	5/10/88
AVS-4138	CPE	VV	0.2	----	VERO >	320.00	----	5/19/88
AVS-4139	CPE	AD2	----	----	HEP2 <	100.00	----	5/19/88
AVS-4139	CPE	JE	----	----	VERO	32.00	----	6/21/88
AVS-4139	CPE	PT	----	----	VERO	32.00	----	6/21/88
AVS-4139	CPE	SF	----	----	VERO	32.00	----	6/21/88

B-212

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4139	CPE	VSV	----	----	L929 <	100.00	----	5/10/88
AVS-4139	CPE	VV	----	----	VERO	100.00	----	5/19/88
AVS-4140	CPE	AD2	----	----	HCP2 <	100.00	----	5/19/88
AVS-4140	CPE	JE	----	----	VERO	10.00	----	6/21/88
AVS-4140	CPE	PT	----	----	VERO	10.00	----	6/21/88
AVS-4140	CPE	SF	----	----	VERO	100.00	----	6/21/88
AVS-4140	CPE	VSV	----	----	L929 <	320.00	----	5/10/88
AVS-4140	CPE	VV	----	----	VERO <	100.00	----	5/19/88
AVS-4141	CPE	AD2	0.6	----	HEP2 <	320.00	----	5/19/88
AVS-4141	CPE	JE	----	----	VERO	3.20	----	6/21/88
AVS-4141	CPE	PT	0.1	----	VERO	32.00	----	6/21/88
AVS-4141	CPE	SF	----	----	VERO	100.00	----	6/21/88
AVS-4141	CPE	VSV	----	----	L929 >	320.00	----	5/10/88
AVS-4141	CPE	VV	----	----	VERO <	320.00	----	5/19/88
AVS-4149	CPE	AD2	----	----	HEP2 >	320.00	----	5/26/88
AVS-4149	CPE	SF	----	----	VERO	320.00	----	6/28/88
AVS-4149	CPE	VEE	----	----	VERO	100.00	----	6/28/88
AVS-4149	CPE	VSV	----	----	L929	320.00	----	5/24/88
AVS-4149	CPE	VV	0.4	----	VERO	320.00	----	5/26/88
AVS-4150	CPE	AD2	----	----	HEP2 >	320.00	----	6/ 2/88
AVS-4150	CPE	SF	----	----	VERO	320.00	----	6/28/88
AVS-4150	CPE	VEE	----	----	VERO	320.00	----	6/28/88
AVS-4150	CPE	VSV	----	----	L929	320.00	----	5/24/88
AVS-4150	CPE	VV	----	----	VERO >	320.00	----	6/ 2/88
AVS-4151	CPE	AD2	0.3	----	HEP2 >	320.00	----	6/ 2/88
AVS-4151	CPE	SF	----	----	VERO	32.00	----	6/28/88
AVS-4151	CPE	VEE	----	----	VERO	10.00	----	6/28/88
AVS-4151	CPE	VSV	----	----	L929	320.00	----	5/24/88
AVS-4151	CPE	VV	----	----	VERO >	320.00	----	6/ 2/88
AVS-4152	CPE	AD2	----	----	HEP2	100.00	----	6/ 2/88
AVS-4152	CPE	SF	----	----	VERO	320.00	----	6/29/88
AVS-4152	CPE	VEE	----	----	VERO	100.00	----	6/29/88
AVS-4152	CPE	VSV	----	----	L929	100.00	----	5/24/88
AVS-4152	CPE	VV	----	----	VERO	32.00	----	6/ 2/88
AVS-4153	CPE	AD2	----	----	HEP2 >	100.00	----	6/ 2/88
AVS-4153	CPE	SF	----	----	VERO	100.00	----	6/29/88
AVS-4153	CPE	VEE	----	----	VERO	32.00	----	6/29/88
AVS-4153	CPE	VSV	----	----	L929	100.00	----	5/24/88
AVS-4153	CPE	VV	----	----	VERO >	100.00	----	6/ 2/88
AVS-4154	CPE	AD2	----	----	HEP2 >	320.00	----	6/ 2/88
AVS-4154	CPE	SF	0.9	75.50	VERO	10.00	0.13	6/29/88
AVS-4154	CPE	VEE	----	----	VERO	32.00	----	6/29/88
AVS-4154	CPE	VSV	----	----	L929	32.00	----	5/24/88
AVS-4154	CPE	VV	----	----	VERO >	320.00	----	6/ 2/88
AVS-4155	CPE	AD2	----	----	AVS2 <	3.20	----	6/ 2/88
AVS-4155	CPE	SF	----	----	VERO	100.00	----	6/29/88
AVS-4155	CPE	VEE	----	----	VERO	32.00	----	6/ 2/88
AVS-4155	CPE	VSV	----	----	L929	1.00	----	5/24/88
AVS-4155	CPE	VV	----	----	VERO	3.20	----	6/ 2/88
AVS-4156	CPE	AD2	----	----	HEP2 <	320.00	----	6/ 2/88
AVS-4156	CPE	SF	----	----	VERO	100.00	----	6/29/88
AVS-4156	CPE	VEE	----	----	VERO	100.00	----	6/29/88
AVS-4156	CPE	VSV	----	----	L929	320.00	----	5/24/88
AVS-4156	CPE	VV	0.3	320.00	VERO	100.00	0.31	6/ 2/88
AVS-4159	CPE	AD2	0.3	----	HEP2 >	320.00	----	6/16/88
AVS-4159	CPE	SF	----	----	VERO	100.00	----	6/29/88
AVS-4159	CPE	VEE	----	----	VERO	10.00	----	6/29/88
AVS-4159	CPE	VSV	----	----	L929 >	320.00	----	5/24/88
AVS-4159	CPE	VV	0.4	----	VERO >	320.00	----	6/16/88
AVS-4160	CPE	SF	0.3	----	VERO	100.00	----	6/29/88
AVS-4160	CPE	VEE	----	----	VERO	100.00	----	6/29/88
AVS-4161	CPE	AD2	----	----	HEP2 >	320.00	----	6/ 2/88
AVS-4161	CPE	SF	----	----	VERO >	320.00	----	6/29/88
AVS-4161	CPE	VEE	----	----	VERO	320.00	----	6/29/88
AVS-4161	CPE	VSV	----	----	L929	320.00	----	5/24/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MT50	TI	DATE
AVS-4161	CPE	VV	----	----	VERO >	320.00	----	6/ 2/88
AVS-4162	CPE	AD2	----	----	HEP2 >	320.00	----	6/16/88
AVS-4162	CPE	SF	----	----	VERO	320.00	----	6/29/88
AVS-4162	CPE	VEE	----	----	VERO	100.00	----	6/29/88
AVS-4162	CPE	VSV	----	----	L929 >	320.00	----	5/24/88
AVS-4162	CPE	VV	----	----	VERO >	320.00	----	6/16/88
AVS-4163	CPE	AD2	0.3	----	HEP2 >	320.00	----	6/ 2/88
AVS-4163	CPE	SF	----	----	VERO	320.00	----	6/29/88
AVS-4163	CPE	VEE	----	----	VERO	32.00	----	6/29/88
AVS-4163	CPE	VSV	----	----	L929	100.00	----	5/24/88
AVS-4163	CPE	VV	1.3	64.20	VERO	100.00	1.55	6/ 2/88
AVS-4163	CPE	VV	1.45	118.00	VERO	320.00	2.69	6/16/88
AVS-4166	CPE	AD2	----	----	HEP2 >	320.00	----	6/16/88
AVS-4166	CPE	SF	----	----	VERO	100.00	----	6/29/88
AVS-4166	CPE	VEE	----	----	VERO	320.00	----	6/29/88
AVS-4166	CPE	VSV	----	----	L929 >	320.00	----	5/24/88
AVS-4166	CPE	VV	----	----	VERO >	320.00	----	6/16/88
AVS-4167	CPE	AD2	3.5	2.48	HEP2	32.00	12.80	6/16/88
AVS-4167	CPE	AD2	2.3	6.60	HEP2	32.00	4.82	6/30/88
AVS-4167	CPE	SF	----	----	VERO	3.20	----	6/29/88
AVS-4167	CPE	VEE	0.05	----	VERO	3.20	----	6/29/88
AVS-4167	CPE	VSV	----	----	L929	100.00	----	5/24/88
AVS-4167	CPE	VV	0.55	252.00	VERO	100.00	0.40	6/16/88
AVS-4168	CPE	AD2	----	----	HEP2	320.00	----	6/ 2/88
AVS-4168	CPE	SF	----	----	VERO >	320.00	----	6/29/88
AVS-4168	CPE	VEE	----	----	VERO >	320.00	----	6/29/88
AVS-4168	CPE	VSV	----	----	L929 >	320.00	----	5/24/88
AVS-4168	CPE	VV	----	----	VERO >	320.00	----	6/ 2/88
AVS-4169	CPE	AD2	----	----	HEP2 >	320.00	----	6/16/88
AVS-4169	CPE	SF	----	----	VERO >	320.00	----	6/29/88
AVS-4169	CPE	VEE	----	----	VERO	320.00	----	6/29/88
AVS-4169	CPE	VSV	----	----	L929	320.00	----	5/24/88
AVS-4169	CPE	VV	----	----	VERO >	320.00	----	6/16/88
AVS-4171	CPE	AD2	----	----	HEP2 >	320.00	----	6/16/88
AVS-4171	CPE	SF	----	----	VERO >	100.00	----	6/29/88
AVS-4171	CPE	VEE	----	----	VERO	32.00	----	6/29/88
AVS-4171	CPE	VSV	----	----	L929 >	320.00	----	6/ 7/88
AVS-4171	CPE	VV	0.1	----	VERO >	320.00	----	6/16/88
AVS-4172	CPE	AD2	----	----	HEP2 >	320.00	----	6/16/88
AVS-4172	CPE	JE	----	----	VERO >	100.00	----	7/ 5/88
AVS-4172	CPE	PT	0.1	----	VERO	100.00	----	7/ 5/88
AVS-4172	CPE	VEE	----	----	VERO	32.00	----	7/ 5/88
AVS-4172	CPE	VSV	----	----	L929 >	320.00	----	6/ 7/88
AVS-4172	CPE	VV	----	----	VERO >	320.00	----	6/16/88
AVS-4172	CPE	YFV	0.05	----	VERO >	100.00	----	7/ 5/88
AVS-4173	CPE	AD2	----	----	HEP2	100.00	----	4/21/88
AVS-4173	CPE	JE	----	----	VERO	320.00	----	5/ 4/88
AVS-4173	CPE	PT	----	----	VERO	32.00	----	5/ 4/88
AVS-4173	CPE	SF	----	----	VERO	320.00	----	5/ 4/88
AVS-4173	CPE	VEE	----	----	VERO	32.00	----	5/ 4/88
AVS-4173	CPE	VSV	----	----	L929	100.00	----	4/ 8/88
AVS-4173	CPE	VV	----	----	VERO	32.00	----	4/21/88
AVS-4173	CPE	YFV	----	----	VERO	320.00	----	5/ 4/88
AVS-4174	CPE	AD2	----	----	HEP2 <	320.00	----	4/21/88
AVS-4174	CPE	JE	----	----	VERO	320.00	----	5/ 4/88
AVS-4174	CPE	PT	----	----	VERO	320.00	----	5/ 4/88
AVS-4174	CPE	SF	0.45	217.00	VERO	320.00	1.47	5/ 4/88
AVS-4174	CPE	VEE	----	----	VERO	320.00	----	5/ 4/88
AVS-4174	CPE	VSV	----	----	L929	32.00	----	4/ 8/88
AVS-4174	CPE	VV	----	----	VERO	320.00	----	4/21/88
AVS-4174	CPE	YFV	----	----	VERO	320.00	----	5/ 4/88
AVS-4175	CPE	AD2	----	----	HEP2 <	10.00	----	4/21/88
AVS-4175	CPE	JE	----	----	VERO <	0.32	----	5/ 4/88
AVS-4175	CPE	PT	----	----	VERO	1.00	----	5/ 4/88
AVS-4175	CPE	SF	0.15	----	VERO	1.00	----	5/ 4/88

B-214

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4175	CPE	VEE	----	----	VERO	1.00	----	5/ 4/88
AVS-4175	CPE	VSV	0.1	----	L929	10.00	----	4/ 8/88
AVS-4175	CPE	VV	----	----	VERO <	10.00	----	4/21/88
AVS-4175	CPE	YFV	----	----	VERO	1.00	----	5/ 4/88
AVS-4176	CPE	AD2	----	----	HEP2 <	320.00	----	4/21/88
AVS-4176	CPE	JE	----	----	VERO	32.00	----	5/ 4/88
AVS-4176	CPE	PT	----	----	VERO	10.00	----	5/ 4/88
AVS-4176	CPE	SF	1.15	14.70	VERO	10.00	0.68	5/ 4/88
AVS-4176	CPE	VEE	----	----	VERO	10.00	----	5/ 4/88
AVS-4176	CPE	VV	----	----	L929	10.00	----	4/ 8/88
AVS-4176	CPE	VV	0.4	100.00	VERO	32.00	0.32	4/21/88
AVS-4176	CPE	YFV	----	----	VERO	10.00	----	5/ 4/88
AVS-4177	CPE	AD2	0.1	----	HEP2	3.20	----	4/29/88
AVS-4177	CPE	JE	----	----	VERO <	0.32	----	5/ 4/88
AVS-4177	CPE	PT	----	----	VERO <	0.32	----	5/ 4/88
AVS-4177	CPE	SF	0.1	----	VERO <	0.32	----	5/ 4/88
AVS-4177	CPE	VEE	----	----	VERO <	0.32	----	5/ 4/88
AVS-4177	CPE	VSV	----	----	L929	32.00	----	4/ 8/88
AVS-4177	CPE	VV	0.6	----	VERO <	10.00	----	4/29/88
AVS-4177	CPE	YFV	----	----	VERO <	0.32	----	5/ 4/88
AVS-4178	CPE	AD2	0.2	----	HEP2 >	320.00	----	4/21/88
AVS-4178	CPE	JE	----	----	VERO	320.00	----	5/10/88
AVS-4178	CPE	PT	0.05	----	VERO	32.00	----	5/10/88
AVS-4178	CPE	SF	0.25	----	VERO	100.00	----	5/10/88
AVS-4178	CPE	VEE	----	----	VERO	320.00	----	5/10/88
AVS-4178	CPE	VSV	----	----	L929 >	320.00	----	4/ 8/88
AVS-4178	CPE	VV	----	----	VERO >	320.00	----	4/21/88
AVS-4178	CPE	YFV	----	----	VERO	320.00	----	5/10/88
AVS-4179	CPE	AD2	0.9	----	HEP2 >	320.00	----	4/29/88
AVS-4179	CPE	JE	----	----	VERO	100.00	----	5/10/88
AVS-4179	CPE	PT	0.45	217.00	VERO	32.00	0.15	5/10/88
AVS-4179	CPE	SF	0.4	----	VERO	10.00	----	5/10/88
AVS-4179	CPE	VEE	----	----	VERO	100.00	----	5/10/88
AVS-4179	CPE	VSV	1.	200.00	L929 >	320.00 >	1.59	4/12/88
AVS-4179	CPE	VV	----	----	VERO >	320.00	----	4/21/88
AVS-4179	CPE	YFV	0.2	----	VERO	100.00	----	5/10/88
AVS-4180	CPE	AD2	0.5	----	HEP2 >	320.00	----	4/21/88
AVS-4180	CPE	JE	----	----	VERO	320.00	----	5/10/88
AVS-4180	CPE	PT	----	----	VERO	320.00	----	5/10/88
AVS-4180	CPE	SF	----	----	VERO	100.00	----	5/10/88
AVS-4180	CPE	VEE	----	----	VERO	320.00	----	5/10/88
AVS-4180	CPE	VSV	----	----	L929 >	320.00	----	4/12/88
AVS-4180	CPE	VV	0.05	----	VERO	320.00	----	4/21/88
AVS-4180	CPE	YFV	0.45	----	VERO	320.00	----	5/10/88
AVS-4181	CPE	AD2	----	----	HEP2 <	320.00	----	4/21/88
AVS-4181	CPE	JE	----	----	VERO	100.00	----	5/10/88
AVS-4181	CPE	PT	0.45	217.00	VERO	32.00	0.15	5/10/88
AVS-4181	CPE	SF	0.5	222.00	VERO	100.00	0.45	5/10/88
AVS-4181	CPE	VEE	----	----	VERO	100.00	----	5/10/88
AVS-4181	CPE	VSV	----	----	L929 <	320.00	----	4/12/88
AVS-4181	CPE	VV	0.15	----	VERO	320.00	----	4/21/88
AVS-4181	CPE	YFV	----	----	VERO	100.00	----	5/10/88
AVS-4182	CPE	AD2	----	----	HEP2	100.00	----	4/21/88
AVS-4182	CPE	JE	0.05	----	VERO	32.00	----	5/10/88
AVS-4182	CPE	PT	0.15	----	VERO	10.00	----	5/10/88
AVS-4182	CPE	SF	0.7	162.00	VERO	32.00	0.20	5/10/88
AVS-4182	CPE	VEE	----	----	VERO	100.00	----	5/10/88
AVS-4182	CPE	VSV	----	----	L929	32.00	----	4/12/88
AVS-4182	CPE	VV	1.	32.00	VERO >	100.00 >	3.12	4/21/88
AVS-4182	CPE	VV	1.5	50.00	VERO >	100.00 >	2.00	6/16/88
AVS-4182	CPE	YFV	----	----	VERO	32.00	----	5/10/88
AVS-4183	CPE	AD2	----	----	HEP2 <	32.00	----	4/21/88
AVS-4183	CPE	JE	----	----	VERO	10.00	----	5/10/88
AVS-4183	CPE	PT	----	----	VERO	10.00	----	5/10/88
AVS-4183	CPE	SF	0.3	10.00	VERO	3.20	0.32	5/10/88

B-215

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4183	CPE	VEE	----	----	VERO	3.20	----	5/10/88
AVS-4183	CPE	VSV	----	----	L929	10.00	----	4/12/88
AVS-4183	CPE	VV	----	----	VERO	3.20	----	4/21/88
AVS-4183	CPE	YFV	----	----	VERO	10.00	----	5/10/88
AVS-4184	CPE	AD2	----	----	HEP2 >	320.00	----	4/21/88
AVS-4184	CPE	JE	----	----	VERO	100.00	----	5/10/88
AVS-4184	CPE	PT	0.15	----	VERO	100.00	----	5/10/88
AVS-4184	CPE	SF	----	----	VERO	100.00	----	5/10/88
AVS-4184	CPE	VEE	----	----	VERO	320.00	----	5/10/88
AVS-4184	CPE	VSV	----	----	L929 >	320.00	----	4/12/88
AVS-4184	CPE	VV	0.7	----	VERO >	320.00	----	4/21/88
AVS-4184	CPE	YFV	----	----	VERO	320.00	----	5/10/88
AVS-4185	CPE	JE	----	----	VERO	10.00	----	5/10/88
AVS-4185	CPE	PT	0.25	----	VERO	3.20	----	5/10/88
AVS-4185	CPE	SF	0.35	8.40	VERO	10.00	1.17	5/10/88
AVS-4185	CPE	VEE	----	----	VERO	3.20	----	5/10/88
AVS-4185	CPE	VSV	----	----	L929	32.00	----	4/12/88
AVS-4185	CPE	YFV	----	----	VERO	10.00	----	5/10/88
AVS-4186	CPE	AD2	----	----	HEP2 >	32.00	----	4/21/88
AVS-4186	CPE	JE	----	----	VERO	10.00	----	5/10/88
AVS-4186	CPE	PT	0.3	32.00	VERO	3.20	0.10	5/10/88
AVS-4186	CPE	SF	0.95	19.20	VERO	10.00	0.52	5/10/88
AVS-4186	CPE	VEE	----	----	VERO	10.00	----	5/10/88
AVS-4186	CPE	VSV	----	----	L929	32.00	----	4/12/88
AVS-4186	CPE	VV	----	----	VERO	32.00	----	4/21/88
AVS-4186	CPE	YFV	----	----	VERO	10.00	----	5/10/88
AVS-4187	CPE	AD2	----	----	HEP2 <	320.00	----	4/21/88
AVS-4187	CPE	JE	----	----	VERO	320.00	----	5/10/88
AVS-4187	CPE	PT	----	----	VERO	100.00	----	5/10/88
AVS-4187	CPE	SF	0.25	----	VERO	100.00	----	5/10/88
AVS-4187	CPE	VEE	----	----	VERO	100.00	----	5/10/88
AVS-4187	CPE	VSV	----	----	L929	100.00	----	4/12/88
AVS-4187	CPE	VV	0.5	246.00	VERO	320.00	1.29	4/21/88
AVS-4187	CPE	YFV	----	----	VERO	320.00	----	5/10/88
AVS-4188	CPE	AD2	----	----	HEP2	100.00	----	4/21/88
AVS-4188	CPE	JE	----	----	VERO	10.00	----	5/10/88
AVS-4188	CPE	PT	----	----	VERO	10.00	----	5/10/88
AVS-4188	CPE	SF	0.15	----	VERO	32.00	----	5/10/88
AVS-4188	CPE	VEE	----	----	VERO	10.00	----	5/10/88
AVS-4188	CPE	VSV	----	----	L929	10.00	----	4/12/88
AVS-4188	CPE	VV	0.3	100.00	VERO	100.00	1.00	4/21/88
AVS-4188	CPE	YFV	----	----	VERO	100.00	----	5/10/88
AVS-4189	CPE	AD2	----	----	HEP2	320.00	----	4/21/88
AVS-4189	CPE	JE	----	----	VERO	100.00	----	5/10/88
AVS-4189	CPE	PT	----	----	VERO	32.00	----	5/10/88
AVS-4189	CPE	SF	0.25	----	VERO	320.00	----	5/10/88
AVS-4189	CPE	VEE	----	----	VERO	100.00	----	5/10/88
AVS-4189	CPE	VSV	----	----	L929	100.00	----	4/12/88
AVS-4189	CPE	VV	0.3	320.00	VERO	100.00	0.31	4/21/88
AVS-4189	CPE	YFV	----	----	VERO	100.00	----	5/10/88
AVS-4190	CPE	AD2	----	----	HEP2 <	10.00	----	4/21/88
AVS-4190	CPE	JE	----	----	VERO	10.00	----	5/10/88
AVS-4190	CPE	PT	0.1	----	VERO	3.20	----	5/10/88
AVS-4190	CPE	SF	----	----	VERO <	320.00	----	5/10/88
AVS-4190	CPE	VEE	----	----	VERO	10.00	----	5/10/88
AVS-4190	CPE	VSV	----	----	L929	10.00	----	4/12/88
AVS-4190	CPE	VV	----	----	VERO <	32.00	----	4/21/88
AVS-4190	CPE	YFV	----	----	VERO	10.00	----	5/10/88
AVS-4191	CPE	AD2	----	----	HEP2 >	100.00	----	4/21/88
AVS-4191	CPE	JE	0.2	----	VERO	3.20	----	5/10/88
AVS-4191	CPE	PT	0.45	68.30	VERO	10.00	0.15	5/10/88
AVS-4191	CPE	SF	0.6	178.00	VERO	320.00	1.78	5/10/88
AVS-4191	CPE	VEE	----	----	VERO	32.00	----	5/10/88
AVS-4191	CPE	VSV	----	----	L929	32.00	----	4/12/88
AVS-4191	CPE	VV	----	----	VERO	100.00	----	4/21/88

B-216

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4191	CPE	YFV	----	----	VERO	10.00	----	5/10/88
AVS-4192	CPE	AD2	----	----	HEP2	32.00	----	4/21/88
AVS-4192	CPE	JE	0.15	----	VERO	3.20	----	5/10/88
AVS-4192	CPE	PT	1.7	40.00	VERO	32.00	0.80	5/10/88
AVS-4192	CPE	SF	----	----	VERO <	320.00	----	5/10/88
AVS-4192	CPE	VEE	----	----	VERO	3.20	----	5/10/88
AVS-4192	CPE	VSV	----	----	L929	3.20	----	4/12/88
AVS-4192	CPE	VV	1.05	101.00	VERO	32.00	0.31	4/21/88
AVS-4192	CPE	VV	1.05	157.00	VERO	32.00	0.20	5/19/88
AVS-4192	CPE	YFV	0.4	----	VERO	10.00	----	5/10/88
AVS-4193	CPE	AD2	----	----	HEP2 >	320.00	----	4/21/88
AVS-4193	CPE	JE	----	----	VERO	100.00	----	5/11/88
AVS-4193	CPE	PT	----	----	VERO	320.00	----	5/11/88
AVS-4193	CPE	SF	----	----	VERO	32.00	----	5/11/88
AVS-4193	CPE	VEE	----	----	VERO	100.00	----	5/11/88
AVS-4193	CPE	VSV	----	----	L929	320.00	----	4/12/88
AVS-4193	CPE	VV	0.1	----	VERO >	320.00	----	4/21/88
AVS-4193	CPE	YFV	----	----	VERO	100.00	----	5/11/88
AVS-4194	CPE	AD2	0.4	----	HEP2 >	100.00	----	4/29/88
AVS-4194	CPE	JE	----	----	VERO	32.00	----	5/11/88
AVS-4194	CPE	PT	----	----	VERO	100.00	----	5/11/88
AVS-4194	CPE	SF	0.15	----	VERO	32.00	----	5/11/88
AVS-4194	CPE	VEE	----	----	VERO	10.00	----	5/11/88
AVS-4194	CPE	VSV	----	----	L929 <	320.00	----	4/12/88
AVS-4194	CPE	VV	0.1	----	VERO >	100.00	----	4/29/88
AVS-4194	CPE	YFV	----	----	VERO	100.00	----	5/11/88
AVS-4195	CPE	AD2	0.3	----	HEP2 <	320.00	----	4/21/88
AVS-4195	CPE	JE	----	----	VERO	10.00	----	5/11/88
AVS-4195	CPE	PT	----	----	VERO	320.00	----	5/11/88
AVS-4195	CPE	SF	0.15	----	VERO	32.00	----	5/11/88
AVS-4195	CPE	VEE	----	----	VERO	100.00	----	5/11/88
AVS-4195	CPE	VSV	----	----	L929	100.00	----	4/15/88
AVS-4195	CPE	VV	0.3	----	VERO >	320.00	----	4/21/88
AVS-4195	CPE	YFV	0.15	----	VERO	100.00	----	5/11/88
AVS-4196	CPE	AD2	0.15	----	HEP2	320.00	----	4/21/88
AVS-4196	CPE	JE	----	----	VERO	100.00	----	5/11/88
AVS-4196	CPE	PT	----	----	VERO >	320.00	----	5/11/88
AVS-4196	CPE	SF	----	----	VERO	320.00	----	5/11/88
AVS-4196	CPE	VEE	----	----	VERO	320.00	----	5/11/88
AVS-4196	CPE	VSV	----	----	L929	320.00	----	4/15/88
AVS-4196	CPE	VV	----	----	VERO >	320.00	----	4/21/88
AVS-4196	CPE	YFV	----	----	VERO >	320.00	----	5/11/88
AVS-4197	CPE	AD2	----	----	HEP2	100.00	----	4/29/88
AVS-4197	CPE	JE	----	----	VERO	32.00	----	5/11/88
AVS-4197	CPE	PT	0.15	----	VERO	32.00	----	5/11/88
AVS-4197	CPE	SF	1.2	57.10	VERO	32.00	0.56	5/11/88
AVS-4197	CPE	VEE	0.75	147.00	VERO	100.00	0.68	5/11/88
AVS-4197	CPE	VSV	----	----	L929	32.00	----	4/15/88
AVS-4197	CPE	VV	----	----	VERO	100.00	----	4/29/88
AVS-4197	CPE	YFV	0.5	222.00	VERO	10.00	0.04	5/11/88
AVS-4198	CPE	AD2	0.15	----	HEP2	100.00	----	4/29/88
AVS-4198	CPE	JE	----	----	VERO	32.00	----	5/11/88
AVS-4198	CPE	PT	0.3	320.00	VERO	100.00	0.31	5/11/88
AVS-4198	CPE	SF	0.4	239.00	VERO	100.00	0.42	5/11/88
AVS-4198	CPE	VEE	----	----	VERO	320.00	----	5/11/88
AVS-4198	CPE	VSV	----	----	L929	320.00	----	4/15/88
AVS-4198	CPE	VV	----	----	VERO	320.00	----	4/29/88
AVS-4198	CPE	YFV	0.2	----	VERO	100.00	----	5/11/88
AVS-4199	CPE	AD2	0.95	165.00	HEP2	320.00	1.93	4/29/88
AVS-4199	CPE	JE	----	----	VERO	32.00	----	5/11/88
AVS-4199	CPE	PT	----	----	VERO	32.00	----	5/11/88
AVS-4199	CPE	SF	----	----	VERO	32.00	----	5/11/88
AVS-4199	CPE	VEE	----	----	VERO	320.00	----	5/11/88
AVS-4199	CPE	VSV	----	----	L929 >	320.00	----	4/15/88
AVS-4199	CPE	VV	0.3	----	VERO >	320.00	----	4/29/88

B-217

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4199	CPE	YFV	----	----	VERO	100.00	----	5/11/88
AVS-4200	CPE	AD2	0.3	----	HEP2 <	320.00	----	4/29/88
AVS-4200	CPE	JE	----	----	VERO	32.00	----	5/11/88
AVS-4200	CPE	PT	0.5	222.00	VERO	100.00	0.45	5/11/88
AVS-4200	CPE	SF	0.7	159.00	VERO	32.00	0.20	5/11/88
AVS-4200	CPE	VEE	----	----	VERO	32.00	----	5/11/88
AVS-4200	CPE	VSV	----	----	L929	320.00	----	4/15/88
AVS-4200	CPE	VV	0.2	----	VERO	320.00	----	4/29/88
AVS-4200	CPE	YFV	----	----	VERO	32.00	----	5/11/88
AVS-4201	CPE	AD2	----	----	HEP2 >	320.00	----	4/29/88
AVS-4201	CPE	JE	----	----	VERO >	320.00	----	5/11/88
AVS-4201	CPE	PT	----	----	VERO	320.00	----	5/11/88
AVS-4201	CPE	SF	----	----	VERO	320.00	----	5/11/88
AVS-4201	CPE	VEE	----	----	VERO	320.00	----	5/11/88
AVS-4201	CPE	VSV	----	----	L929	320.00	----	4/15/88
AVS-4201	CPE	VV	----	----	VERO >	320.00	----	4/29/88
AVS-4201	CPE	YFV	----	----	VERO	320.00	----	5/11/88
AVS-4202	CPE	AD2	----	----	HEP2 <	100.00	----	4/29/88
AVS-4202	CPE	JE	----	----	VERO	10.00	----	5/11/88
AVS-4202	CPE	PT	1.1	70.10	VERO	10.00	0.14	5/11/88
AVS-4202	CPE	SF	1.15	63.40	VERO	32.00	0.50	5/11/88
AVS-4202	CPE	VEE	----	----	VERO	32.00	----	5/11/88
AVS-4202	CPE	VSV	----	----	L929	32.00	----	4/15/88
AVS-4202	CPE	VV	0.35	----	VERO	100.00	----	4/29/88
AVS-4202	CPE	YFV	----	----	VERO	3.20	----	5/11/88
AVS-4203	CPE	AD2	0.45	----	HEP2	320.00	----	4/29/88
AVS-4203	CPE	JE	----	----	VERO	100.00	----	5/11/88
AVS-4203	CPE	PT	----	----	VERO	100.00	----	5/11/88
AVS-4203	CPE	SF	----	----	VERO	100.00	----	5/11/88
AVS-4203	CPE	VEE	----	----	VERO	100.00	----	5/11/88
AVS-4203	CPE	VSV	----	----	L929	100.00	----	4/15/88
AVS-4203	CPE	VV	0.3	----	VERO >	320.00	----	4/29/88
AVS-4203	CPE	YFV	0.15	----	VERO	320.00	----	5/11/88
AVS-4204	CPE	AD2	0.3	----	HEP2 >	320.00	----	6/ 2/88
AVS-4204	CPE	JE	----	----	VERO	320.00	----	7/ 5/88
AVS-4204	CPE	PT	----	----	VERO	320.00	----	7/ 5/88
AVS-4204	CPE	VEE	----	----	VERO	320.00	----	7/ 5/88
AVS-4204	CPE	VSV	----	----	L929	320.00	----	6/ 7/88
AVS-4204	CPE	VV	----	----	VERO >	320.00	----	6/ 2/88
AVS-4204	CPE	YFV	0.1	----	VERO >	320.00	----	7/ 5/88
AVS-4205	CPE	AD2	----	----	HEP2 >	320.00	----	6/ 2/88
AVS-4205	CPE	JE	----	----	VERO >	320.00	----	7/ 5/88
AVS-4205	CPE	PT	----	----	VERO	320.00	----	7/ 5/88
AVS-4205	CPE	VEE	----	----	VERO	100.00	----	7/ 5/88
AVS-4205	CPE	VSV	----	----	L929 <	320.00	----	6/ 7/88
AVS-4205	CPE	VV	----	----	VERO >	320.00	----	6/ 2/88
AVS-4205	CPE	YFV	0.55	----	VERO >	320.00	----	7/ 5/88
AVS-4206	CPE	AD2	----	----	HEP2 >	320.00	----	6/ 2/88
AVS-4206	CPE	JE	----	----	VERO	320.00	----	7/ 5/88
AVS-4206	CPE	PT	----	----	VERO >	320.00	----	7/ 5/88
AVS-4206	CPE	SF	0.65	0.36	VERO >	320.00 >	877.00	7/ 5/88
AVS-4206	CPE	VEE	----	----	VERO >	320.00	----	7/ 5/88
AVS-4206	CPE	VSV	----	----	L929 >	320.00	----	6/ 7/88
AVS-4206	CPE	VV	----	----	VERO >	320.00	----	6/ 2/88
AVS-4206	CPE	YFV	0.1	----	VERO >	320.00	----	7/ 5/88
AVS-4207	CPE	AD2	0.4	----	HEP2 >	320.00	----	6/ 2/88
AVS-4207	CPE	JE	----	----	VERO	320.00	----	7/ 5/88
AVS-4207	CPE	PT	----	----	VERO	320.00	----	7/ 5/88
AVS-4207	CPE	SF	0.2	----	VERO	100.00	----	7/ 5/88
AVS-4207	CPE	VEE	----	----	VERO	320.00	----	7/ 5/88
AVS-4207	CPE	VSV	----	----	L929 >	320.00	----	6/ 7/88
AVS-4207	CPE	VV	0.6	320.00	VERO >	320.00 >	1.00	6/ 2/88
AVS-4207	CPE	YFV	0.29	----	VERO	320.00	----	7/ 5/88
AVS-4208	CPE	AD2	0.4	----	HEP2 >	320.00	----	6/ 2/88
AVS-4208	CPE	JE	----	----	VERO	32.00	----	7/ 5/88

B-218

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4208	CPE	PT	----	----	VERO	32.00	----	7/ 5/88
AVS-4208	CPE	SF	0.75	123.00	VERO	100.00	0.81	7/ 5/88
AVS-4208	CPE	VEE	----	----	VERO	100.00	----	7/ 5/88
AVS-4208	CPE	VSV	----	----	L929	320.00	----	6/ 7/88
AVS-4208	CPE	VV	----	----	VERO >	320.00	----	6/ 2/88
AVS-4208	CPE	YFV	0.3	----	VERO	32.00	----	7/ 5/88
AVS-4209	CPE	AD2	----	----	HEP2 >	320.00	----	6/16/88
AVS-4209	CPE	JE	----	----	VERO	100.00	----	7/ 5/88
AVS-4209	CPE	PT	0.35	270.00	VERO	10.00	0.04	7/ 5/88
AVS-4209	CPE	SF	0.85	264.00	VERO	32.00	0.12	7/ 5/88
AVS-4209	CPE	VEE	----	----	VERO	320.00	----	7/ 5/88
AVS-4209	CPE	VSV	----	----	L929 >	320.00	----	6/ 7/88
AVS-4209	CPE	VV	0.75	----	VERO	320.00	----	6/16/88
AVS-4209	CPE	YFV	0.05	----	VERO	32.00	----	7/ 5/88
AVS-4210	CPE	AD2	0.1	----	HEP2	100.00	----	6/30/88
AVS-4210	CPE	JE	----	----	VERO <	0.10	----	7/ 5/88
AVS-4210	CPE	PT	----	----	VERO <	0.10	----	7/ 5/88
AVS-4210	CPE	SF	----	----	VERO <	0.10	----	7/ 5/88
AVS-4210	CPE	VEE	----	----	VERO <	0.10	----	7/ 5/88
AVS-4210	CPE	VSV	----	----	L929 <	0.32	----	6/ 7/88
AVS-4210	CPE	VV	5.46	0.03	VERO	0.10	2.94	6/30/88
AVS-4210	CPE	VV	5.55	0.03	VERO	0.10	3.20	7/21/88
AVS-4210	CPE	YFV	1.3	0.30	VERO <	0.10 <	0.33	7/ 5/88
AVS-4211	CPE	AD2	----	----	HEP2 >	320.00	----	6/ 2/88
AVS-4211	CPE	JE	----	----	VERO	100.00	----	7/ 5/88
AVS-4211	CPE	PT	----	----	VERO	100.00	----	7/ 5/88
AVS-4211	CPE	SF	0.15	----	VERO	100.00	----	7/ 5/88
AVS-4211	CPE	VEE	----	----	VERO	320.00	----	7/ 5/88
AVS-4211	CPE	VSV	----	----	L929 >	320.00	----	6/ 7/88
AVS-4211	CPE	VV	0.5	----	VERO >	320.00	----	6/ 2/88
AVS-4211	CPE	YFV	0.05	----	VERO >	320.00	----	7/ 5/88
AVS-4213	CPE	AD2	----	----	HEP2 >	320.00	----	6/ 2/88
AVS-4213	CPE	JE	----	----	VERO	320.00	----	7/ 5/88
AVS-4213	CPE	PT	0.25	----	VERO	100.00	----	7/ 5/88
AVS-4213	CPE	SF	0.9	320.00	VERO	320.00	1.00	7/ 5/88
AVS-4213	CPE	VEE	----	----	VERO	100.00	----	7/ 5/88
AVS-4213	CPE	VSV	----	----	L929 >	320.00	----	6/ 7/88
AVS-4213	CPE	VV	----	----	VERO >	320.00	----	6/ 2/88
AVS-4213	CPE	YFV	0.25	----	VERO	320.00	----	7/ 5/88
AVS-4214	CPE	AD2	----	----	HEP2	320.00	----	6/ 2/88
AVS-4214	CPE	JE	----	----	VERO	320.00	----	7/ 5/88
AVS-4214	CPE	PT	----	----	VERO	32.00	----	7/ 5/88
AVS-4214	CPE	SF	0.38	225.00	VERO	100.00	0.44	7/ 5/88
AVS-4214	CPE	VEE	----	----	VERO	320.00	----	7/ 5/88
AVS-4214	CPE	VSV	----	----	L929 <	100.00	----	6/ 7/88
AVS-4214	CPE	VV	----	----	VERO >	320.00	----	6/ 2/88
AVS-4214	CPE	YFV	0.3	----	VERO	100.00	----	7/ 5/88
AVS-4215	CPE	AD2	----	----	HEP2 >	320.00	----	6/ 2/88
AVS-4215	CPE	JE	----	----	VERO >	320.00	----	7/ 5/88
AVS-4215	CPE	PT	----	----	VERO	320.00	----	7/ 5/88
AVS-4215	CPE	SF	----	----	VERO	100.00	----	7/ 5/88
AVS-4215	CPE	VEE	----	----	VERO	100.00	----	7/ 5/88
AVS-4215	CPE	VSV	----	----	L929 >	320.00	----	6/ 7/88
AVS-4215	CPE	VV	----	----	VERO >	320.00	----	6/ 2/88
AVS-4215	CPE	YFV	0.4	----	VERO	320.00	----	7/ 5/88
AVS-4216	CPE	AD2	----	----	HEP2 <	320.00	----	6/ 2/88
AVS-4216	CPE	JE	----	----	VERO	3.20	----	7/ 5/88
AVS-4216	CPE	PT	0.05	----	VERO	10.00	----	7/ 5/88
AVS-4216	CPE	SF	0.8	17.80	VERO	10.00	0.56	7/ 5/88
AVS-4216	CPE	VEE	----	----	VERO	3.20	----	7/ 5/88
AVS-4216	CPE	VSV	----	----	L929	32.00	----	6/ 7/88
AVS-4216	CPE	VV	0.15	----	VERO	100.00	----	6/ 2/88
AVS-4216	CPE	YFV	----	----	VERO	10.00	----	7/ 5/88
AVS-4217	CPE	AD2	----	----	HEP2	0.32	----	6/16/88
AVS-4217	CPE	JE	----	----	VERO	32.00	----	7/ 5/88

B-219

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4217	CPE	PT	0.5	----	VERO	32.00	----	7/ 5/88
AVS-4217	CPE	SF	1.85	9.50	VERO	32.00	3.36	7/ 5/88
AVS-4217	CPE	VEE	----	----	VERO	10.00	----	7/ 5/88
AVS-4217	CPE	VSV	----	----	L929	100.00	----	6/ 7/88
AVS-4217	CPE	VV	----	----	VERO	100.00	----	6/ 2/88
AVS-4217	CPE	YFV	0.8	----	VERO	32.00	----	7/ 5/88
AVS-4218	CPE	AD2	----	----	HEP2	32.00	----	6/ 2/88
AVS-4218	CPE	JE	----	----	VERO	100.00	----	7/ 5/88
AVS-4218	CPE	PT	0.05	----	VERO	100.00	----	7/ 5/88
AVS-4218	CPE	SF	0.45	68.30	VERO	100.00	1.46	7/ 5/88
AVS-4218	CPE	VEE	----	----	VERO	100.00	----	7/ 5/88
AVS-4218	CPE	VSV	0.55	59.50	L929	32.00	0.54	6/ 7/88
AVS-4218	CPE	VV	0.2	----	VERO	32.00	----	6/ 2/88
AVS-4218	CPE	YFV	0.3	----	VERO	100.00	----	7/ 5/88
AVS-4219	CPE	AD2	----	----	HEP2	10.00	----	6/ 2/88
AVS-4219	CPE	JE	----	----	VERO	3.20	----	7/ 6/88
AVS-4219	CPE	PT	0.3	10.00	VERO	3.20	0.32	7/ 6/88
AVS-4219	CPE	SF	1.25	8.30	VERO	10.00	1.20	7/ 6/88
AVS-4219	CPE	VSV	----	----	L929	32.00	----	6/ 7/88
AVS-4219	CPE	VV	0.45	21.70	VERO	32.00	1.47	6/ 2/88
AVS-4219	CPE	YFV	----	----	VERO	10.00	----	7/ 6/88
AVS-4220	CPE	AD2	----	----	HEP2	32.00	----	6/ 2/88
AVS-4220	CPE	JE	----	----	VERO	10.00	----	7/ 6/88
AVS-4220	CPE	PT	0.8	7.50	VERO	10.00	1.33	7/ 6/88
AVS-4220	CPE	SF	0.9	7.50	VERO	10.00	1.33	7/ 6/88
AVS-4220	CPE	VSV	----	----	L929	32.00	----	6/ 7/88
AVS-4220	CPE	VV	0.3	32.00	VERO	32.00	1.00	6/ 2/88
AVS-4220	CPE	YFV	----	----	VERO	32.00	----	7/ 6/88
AVS-4221	CPE	AD2	----	----	HEP2	100.00	----	6/16/88
AVS-4221	CPE	JE	----	----	VERO	10.00	----	7/ 6/88
AVS-4221	CPE	PT	0.1	----	VERO	3.20	----	7/ 6/88
AVS-4221	CPE	SF	1.45	6.80	VERO	10.00	1.46	7/ 6/88
AVS-4221	CPE	VSV	----	----	L929	1.00	----	6/ 7/88
AVS-4221	CPE	VV	----	----	VERO	10.00	----	6/16/88
AVS-4221	CPE	YFV	----	----	VERO	32.00	----	7/ 6/88
AVS-4222	CPE	AD2	0.35	----	HEP2	320.00	----	8/25/88
AVS-4222	CPE	PT	----	----	VERO	100.00	----	9/14/88
AVS-4224	CPE	AD2	----	----	HEP2	320.00	----	6/23/88
AVS-4224	CPE	JE	----	----	VERO	320.00	----	7/ 6/88
AVS-4224	CPE	PT	----	----	VERO	320.00	----	7/ 6/88
AVS-4224	CPE	SF	1.3	6.80	VERO	32.00	4.68	7/ 6/88
AVS-4224	CPE	VSV	----	----	L929	100.00	----	6/22/88
AVS-4224	CPE	VV	8.4	0.18	VERO	320.00	> 1760.00	7/ 7/88
AVS-4224	CPE	VV	7.7	0.32	VERO	320.00	> 996.00	7/21/88
AVS-4224	CPE	YFV	0.2	----	VERO	320.00	----	7/ 6/88
AVS-4225	CPE	AD2	----	----	HEP2	320.00	----	6/23/88
AVS-4225	CPE	JE	----	----	VERO	100.00	----	7/ 6/88
AVS-4225	CPE	PT	----	----	VERO	320.00	----	7/ 6/88
AVS-4225	CPE	SF	0.6	----	VERO	32.00	----	7/ 6/88
AVS-4225	CPE	VSV	----	----	L929	320.00	----	6/22/88
AVS-4225	CPE	VV	7.9	0.32	VERO	320.00	> 1000.00	7/ 7/88
AVS-4225	CPE	VV	7.5	0.45	VERO	320.00	> 707.00	7/21/88
AVS-4225	CPE	YFV	----	----	VERO	320.00	----	7/ 6/88
AVS-4226	CPE	AD2	0.45	217.00	HEP2	320.00	1.47	6/23/88
AVS-4226	CPE	JE	----	----	VERO	320.00	----	7/ 6/88
AVS-4226	CPE	PT	----	----	VERO	320.00	----	7/ 6/88
AVS-4226	CPE	SF	0.3	320.00	VERO	100.00	0.31	7/ 6/88
AVS-4226	CPE	VSV	----	----	L929	100.00	----	6/22/88
AVS-4226	CPE	VV	8.3	0.23	VERO	320.00	> 1340.00	7/ 7/88
AVS-4226	CPE	VV	7.7	0.37	VERO	320.00	> 849.00	7/21/88
AVS-4226	CPE	YFV	0.4	----	VERO	320.00	----	7/ 6/88
AVS-4227	CPE	AD2	----	----	HEP2	100.00	----	6/23/88
AVS-4227	CPE	JE	----	----	VERO	100.00	----	7/ 6/88
AVS-4227	CPE	PT	0.15	----	VERO	100.00	----	7/ 6/88
AVS-4227	CPE	SF	0.6	178.00	VERO	32.00	0.18	7/ 6/88

8-220

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4227	CPE	VSV	----	----	L929	100.00	----	6/22/88
AVS-4227	CPE	VV	8.7	0.08	VERO	320.00	3880.00	7/ 7/88
AVS-4227	CPE	VV	8.7	0.07	VERO	320.00	4100.00	7/21/88
AVS-4227	CPE	YFV	0.15	----	VERO	320.00	----	7/ 6/88
AVS-4228	CPE	AD2	----	----	HEP2 <	320.00	----	6/23/88
AVS-4228	CPE	JE	----	----	VERO	10.00	----	7/ 6/88
AVS-4228	CPE	PT	0.2	----	VERO	10.00	----	7/ 6/88
AVS-4228	CPE	SF	0.15	----	VERO	32.00	----	7/ 6/88
AVS-4228	CPE	VSV	----	----	L929	100.00	----	6/22/88
AVS-4228	CPE	VV	0.2	----	VERO <	320.00	----	6/23/88
AVS-4228	CPE	YFV	----	----	VERO	100.00	----	7/ 6/88
AVS-4229	CPE	AD2	----	----	HEP2 <	10.00	----	6/23/88
AVS-4229	CPE	JE	----	----	VERO <	1.00	----	7/ 6/88
AVS-4229	CPE	PT	----	----	VERO <	3.20	----	7/ 6/88
AVS-4229	CPE	SF	----	----	VERO	1.00	----	7/ 6/88
AVS-4229	CPE	VSV	----	----	L929	3.20	----	6/22/88
AVS-4229	CPE	VV	1.5	4.67	VERO	10.00	2.13	6/23/88
AVS-4229	CPE	VV	1.3	5.30	VERO	10.00	1.86	7/ 7/88
AVS-4229	CPE	YFV	----	----	VERO <	3.20	----	7/ 6/88
AVS-4230	CPE	AD2	----	----	HEP2	10.00	----	6/23/88
AVS-4230	CPE	JE	----	----	VERO <	3.20	----	7/ 6/88
AVS-4230	CPE	PT	----	----	VERO	1.00	----	7/ 6/88
AVS-4230	CPE	SF	----	----	VERO	1.00	----	7/ 6/88
AVS-4230	CPE	VSV	----	----	L929	3.20	----	6/22/88
AVS-4230	CPE	VV	1.15	8.10	VERO	3.20	0.39	6/23/88
AVS-4230	CPE	VV	1.8	5.60	VERO	10.00	1.76	7/ 7/88
AVS-4230	CPE	YFV	----	----	VERO	1.00	----	7/ 6/88
AVS-4231	CPE	AD2	----	----	HEP2 >	320.00	----	6/23/88
AVS-4231	CPE	JE	----	----	VERO	100.00	----	7/ 6/88
AVS-4231	CPE	PT	----	----	VERO	320.00	----	7/ 6/88
AVS-4231	CPE	SF	----	----	VERO	100.00	----	7/ 6/88
AVS-4231	CPE	VSV	----	----	L929 >	320.00	----	6/22/88
AVS-4231	CPE	VV	0.1	----	VERO >	320.00	----	6/23/88
AVS-4231	CPE	YFV	----	----	VERO	100.00	----	7/ 6/88
AVS-4232	CPE	AD2	----	----	HEP2 >	320.00	----	6/23/88
AVS-4232	CPE	JE	----	----	VERO	320.00	----	7/ 6/88
AVS-4232	CPE	PT	0.2	----	VERO	320.00	----	7/ 6/88
AVS-4232	CPE	SF	----	----	VERO	100.00	----	7/ 6/88
AVS-4232	CPE	VSV	----	----	L929	100.00	----	6/22/88
AVS-4232	CPE	VV	1.5	202.00	VERO >	320.00 >	1.57	6/23/88
AVS-4232	CPE	VV	1.4	176.00	VERO >	320.00 >	1.81	7/ 7/88
AVS-4232	CPE	YFV	----	----	VERO	320.00	----	7/ 6/88
AVS-4233	CPE	AD2	----	----	HEP2	320.00	----	6/23/88
AVS-4233	CPE	JE	----	----	VERO	320.00	----	7/ 6/88
AVS-4233	CPE	PT	0.45	217.00	VERO	320.00	1.47	7/ 6/88
AVS-4233	CPE	SF	0.35	319.00	VERO	100.00	0.31	7/ 6/88
AVS-4233	CPE	VSV	----	----	L929	100.00	----	6/22/88
AVS-4233	CPE	VV	0.4	----	VERO >	320.00	----	6/23/88
AVS-4233	CPE	YFV	0.35	270.00	VERO	320.00	1.18	7/ 6/88
AVS-4234	CPE	AD2	0.3	----	HEP2 <	320.00	----	6/30/88
AVS-4234	CPE	JE	----	----	VERO	100.00	----	7/19/88
AVS-4234	CPE	PT	----	----	VERO >	100.00	----	7/19/88
AVS-4234	CPE	SF	----	----	VERO	100.00	----	7/19/88
AVS-4234	CPE	VEE	----	----	VERO	100.00	----	7/19/88
AVS-4234	CPE	VSV	0.1	----	L929	320.00	----	6/22/88
AVS-4234	CPE	VV	0.15	----	VERO	320.00	----	6/30/88
AVS-4234	CPE	YFV	----	----	VERO	32.00	----	7/19/88
AVS-4235	CPE	AD2	0.3	----	HEP2 >	320.00	----	6/30/88
AVS-4235	CPE	JE	0.45	----	VERO	10.00	----	7/19/88
AVS-4235	CPE	PT	----	----	VERO	100.00	----	7/19/88
AVS-4235	CPE	SF	0.6	100.00	VERO	100.00	1.00	7/19/88
AVS-4235	CPE	VEL	----	----	VERO	320.00	----	7/19/88
AVS-4235	CPE	VSV	0.45	279.00	L929	32.00	0.11	6/22/88
AVS-4235	CPE	VV	1.5	83.00	VERO	320.00	3.85	6/30/88
AVS-4235	CPE	YFV	----	----	VERO	32.00	----	7/19/88

B-221

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MYC50	TI	DATE
AVS-4236	CPE	AD2	0.1	----	HEP2 >	320.00	----	6/30/88
AVS-4236	CPE	JE	----	----	VERO	32.00	----	7/19/88
AVS-4236	CPE	PT	0.15	----	VERO	100.00	----	7/19/88
AVS-4236	CPE	SF	0.2	----	VERO	100.00	----	7/19/88
AVS-4236	CPE	VEE	----	----	VERO	320.00	----	7/19/88
AVS-4236	CPE	VSV	0.4	239.00	L929	320.00	1.33	6/22/88
AVS-4236	CPE	VV	----	----	VERO >	320.00	----	6/30/88
AVS-4236	CPE	YFV	----	----	VERO	320.00	----	7/19/88
AVS-4237	CPE	AD2	----	----	HEP2	100.00	----	6/30/88
AVS-4237	CPE	JE	----	----	VERO	32.00	----	7/19/88
AVS-4237	CPE	PT	0.1	----	VERO	100.00	----	7/19/88
AVS-4237	CPE	SF	0.15	----	VERO	100.00	----	7/19/88
AVS-4237	CPE	VEE	----	----	VERO	320.00	----	7/19/88
AVS-4237	CPE	VSV	----	----	L929	320.00	----	6/22/88
AVS-4237	CPE	VV	----	----	VERO >	320.00	----	6/30/88
AVS-4237	CPE	YFV	----	----	VERO	100.00	----	7/19/88
AVS-4238	CPE	JE	----	----	VERO	32.00	----	7/19/88
AVS-4238	CPE	PT	----	----	VERO	100.00	----	7/19/88
AVS-4238	CPE	SF	----	----	VERO	32.00	----	7/19/88
AVS-4238	CPE	VEE	----	----	VERO	10.00	----	7/19/88
AVS-4238	CPE	YFV	----	----	VERO	32.00	----	7/19/88
AVS-4239	CPE	AD2	0.15	----	HEP2	32.00	----	4/29/88
AVS-4239	CPE	JE	----	----	VERO	1.00	----	5/11/88
AVS-4239	CPE	PT	1.1	2.39	VERO	10.00	4.18	5/11/88
AVS-4239	CPE	SF	0.45	8.60	VERO	10.00	1.15	5/11/88
AVS-4239	CPE	VEE	----	----	VERO	10.00	----	5/11/88
AVS-4239	CPE	VSV	1.8	17.80	L929	32.00	1.78	4/ 5/88
AVS-4239	CPE	VV	----	----	VERO <	10.00	----	4/29/88
AVS-4239	CPE	YFV	----	----	VERO	10.00	----	5/11/88
AVS-4240	CPE	AD2	0.3	32.00	HEP2	32.00	1.00	4/29/88
AVS-4240	CPE	JE	----	----	VERO	3.20	----	5/11/88
AVS-4240	CPE	PT	1.35	8.50	VERO	32.00	3.72	5/11/88
AVS-4240	CPE	SF	0.9	17.70	VERO	32.00	1.80	5/11/88
AVS-4240	CPE	VEE	----	----	VERO	32.00	----	5/11/88
AVS-4240	CPE	VSV	2.65	8.00	L929	32.00	3.98	4/ 5/88
AVS-4240	CPE	VSV	1.7	11.80	L929 <	100.00 <	8.46	5/10/88
AVS-4240	PR	VSV	N/A	18.90	L929	32.00	1.69	10/26/88
AVS-4240	CPE	VV	0.5	----	VERO <	32.00	----	4/29/88
AVS-4240	CPE	YFV	----	----	VERO	32.00	----	5/11/88
AVS-4241	CPE	AD2	0.6	70.80	HEP2	100.00	1.41	4/29/88
AVS-4241	CPE	AD2	0.1	----	HEP2 <	100.00	----	10/13/88
AVS-4241	CPE	JE	0.25	----	VERO	3.20	----	5/11/88
AVS-4241	CPE	PT	1.5	4.90	VERO	10.00	2.04	5/11/88
AVS-4241	CPE	SF	1.25	6.30	VERO	10.00	1.57	5/11/88
AVS-4241	CPE	VEE	----	----	VERO	10.00	----	5/11/88
AVS-4241	CPE	VSV	----	----	L929	32.00	----	4/ 5/88
AVS-4241	CPE	VSV	----	----	L929 <	100.00	----	11/18/88
AVS-4241	CPE	VV	0.8	31.40	VERO <	100.00 <	3.18	4/29/88
AVS-4241	CPE	VV	0.6	17.80	VERO	32.00	1.78	10/13/88
AVS-4241	CPE	YFV	0.85	7.70	VERO	10.00	1.29	5/11/88
AVS-4242	CPE	AD2	----	----	HEP2 <	32.00	----	4/29/88
AVS-4242	CPE	JE	----	----	VERO	320.00	----	5/11/88
AVS-4242	CPE	PT	----	----	VERO >	320.00	----	5/11/88
AVS-4242	CPE	SF	----	----	VERO	320.00	----	5/11/88
AVS-4242	CPE	VEE	----	----	VERO	320.00	----	5/11/88
AVS-4242	CPE	VSV	----	----	L929 <	100.00	----	4/ 5/88
AVS-4242	CPE	VV	----	----	VERO	10.00	----	4/29/88
AVS-4242	CPE	YFV	----	----	VERO >	320.00	----	5/11/88
AVS-4243	CPE	AD2	0.9	32.00	HEP2 <	100.00 <	3.12	4/29/88
AVS-4243	CPE	JE	0.4	23.90	VERO	32.00	1.33	6/ 1/88
AVS-4243	CPE	PT	0.3	32.00	VERO	10.00	0.31	6/ 1/88
AVS-4243	CPE	SF	0.65	19.90	VERO	32.00	1.60	6/ 1/88
AVS-4243	CPE	VEE	----	----	VERO	10.00	----	6/ 1/88
AVS-4243	CPE	VSV	----	----	L929	32.00	----	4/ 5/88
AVS-4243	CPE	VV	0.6	----	VERO <	100.00	----	4/29/88

8-222

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4244	CPE	AD2	0.8	23.90	HEP2 <	100.00 <	4.18	4/29/88
AVS-4244	CPE	JE	0.75	41.00	VERO	3.20	0.08	6/ 1/88
AVS-4244	CPE	PT	1.25	6.30	VERO	10.00	1.57	6/ 1/88
AVS-4244	CPE	SF	1.8	1.73	VERO	3.20	1.84	6/ 1/88
AVS-4244	CPE	VEE	----	----	VERO	100.00	----	6/ 1/88
AVS-4244	CPE	VSV	----	----	L929 <	100.00	----	4/ 5/88
AVS-4244	CPE	VV	0.3	----	VERO <	100.00	----	4/29/88
AVS-4245	CPE	AD2	----	----	HEP2 <	320.00	----	4/29/88
AVS-4245	CPE	JE	0.4	75.10	VERO	32.00	0.43	6/ 1/88
AVS-4245	CPE	PT	0.4	75.10	VERO	32.00	0.43	6/ 1/88
AVS-4245	CPE	SF	0.9	36.80	VERO	32.00	0.87	6/ 1/88
AVS-4245	CPE	VEE	----	----	VERO	32.00	----	6/ 1/88
AVS-4245	CPE	VSV	----	----	L929	32.00	----	4/ 5/88
AVS-4245	CPE	VV	0.2	----	VERO >	100.00	----	4/29/88
AVS-4246	CPE	AD2	----	----	HEP2 <	100.00	----	4/29/88
AVS-4246	CPE	JE	----	----	VERO	10.00	----	6/ 1/88
AVS-4246	CPE	PT	----	----	VERO	10.00	----	6/ 1/88
AVS-4246	CPE	SF	0.8	24.50	VERO	10.00	0.41	6/ 1/88
AVS-4246	CPE	VEE	----	----	VERO	32.00	----	6/ 1/88
AVS-4246	CPE	VSV	----	----	L929	32.00	----	4/ 5/88
AVS-4246	CPE	VV	----	----	VERO	100.00	----	4/29/88
AVS-4247	CPE	AD2	0.15	----	HEP2	32.00	----	4/29/88
AVS-4247	CPE	JE	0.45	68.30	VERO	32.00	0.47	6/ 1/88
AVS-4247	CPE	PT	0.25	----	VERO	100.00	----	6/ 1/88
AVS-4247	CPE	SF	1.5	58.40	VERO	100.00	1.71	6/ 1/88
AVS-4247	CPE	VEE	----	----	VERO	100.00	----	6/ 1/88
AVS-4247	CPE	VSV	0.3	320.00	L929	32.00	0.10	4/ 5/88
AVS-4247	CPE	VV	0.15	----	VERO	100.00	----	4/29/88
AVS-4248	CPE	AD2	----	----	HEP2 <	32.00	----	4/29/88
AVS-4248	CPE	JE	0.25	----	VERO	10.00	----	6/ 1/88
AVS-4248	CPE	PT	----	----	VERO	32.00	----	6/ 1/88
AVS-4248	CPE	SF	0.95	18.60	VERO	32.00	1.71	6/ 1/88
AVS-4248	CPE	VEE	----	----	VERO	32.00	----	6/ 1/88
AVS-4248	CPE	VSV	----	----	L929 <	100.00	----	4/ 5/88
AVS-4248	CPE	VV	----	----	VERO	10.00	----	4/29/88
AVS-4249	CPE	AD2	----	----	HEP2 >	320.00	----	4/29/88
AVS-4249	CPE	JE	0.6	56.50	VERO	100.00	1.76	6/ 2/88
AVS-4249	CPE	PT	0.35	84.90	VERO	32.00	0.38	6/ 2/88
AVS-4249	CPE	SF	0.45	68.30	VERO	32.00	0.47	6/ 2/88
AVS-4249	CPE	VEE	----	----	VERO	100.00	----	6/ 2/88
AVS-4249	CPE	VSV	----	----	L929	100.00	----	4/ 5/88
AVS-4249	CPE	VV	0.15	----	VERO	100.00	----	4/29/88
AVS-4250	CPE	AD2	0.5	----	HEP2 >	320.00	----	4/29/88
AVS-4250	CPE	JE	0.4	100.00	VERO	32.00	0.32	6/ 2/88
AVS-4250	CPE	PT	0.65	62.90	VERO	100.00	1.58	6/ 2/88
AVS-4250	CPE	SF	0.35	84.90	VERO	32.00	0.38	6/ 2/88
AVS-4250	CPE	VEE	----	----	VERO	32.00	----	6/ 2/88
AVS-4250	CPE	VSV	----	----	L929	10.00	----	4/15/88
AVS-4250	CPE	VV	----	----	VERO >	320.00	----	4/29/88
AVS-4251	CPE	AD2	----	----	HEP2 <	320.00	----	4/29/88
AVS-4251	CPE	JE	0.15	----	VERO	10.00	----	6/ 2/88
AVS-4251	CPE	PT	0.4	75.10	VERO	10.00	0.13	6/ 2/88
AVS-4251	CPE	SF	0.05	----	VERO	10.00	----	6/ 2/88
AVS-4251	CPE	VEE	----	----	VERO	1.00	----	6/ 2/88
AVS-4251	CPE	VSV	----	----	L929 <	320.00	----	4/15/88
AVS-4251	CPE	VV	----	----	VERO <	320.00	----	4/29/88
AVS-4252	CPE	AD2	0.45	----	HEP2	10.00	----	4/29/88
AVS-4252	CPE	JE	----	----	VERO	32.00	----	6/ 2/88
AVS-4252	CPE	PT	----	----	VERO <	100.00	----	6/ 2/88
AVS-4252	CPE	SF	----	----	VERO	32.00	----	6/ 2/88
AVS-4252	CPE	VEE	----	----	VERO <	100.00	----	6/ 2/88
AVS-4252	CPE	VSV	----	----	L929 <	32.00	----	4/15/88
AVS-4252	CPE	VV	----	----	VERO <	32.00	----	4/29/88
AVS-4253	CPE	AD2	----	----	HEP2	100.00	----	4/29/88
AVS-4253	CPE	JE	----	----	VERO <	32.00	----	6/ 2/88

B-223

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4253	CPE	PT	----	----	VERO	32.00	----	6/ 2/88
AVS-4253	CPE	SF	0.45	21.70	VERO	10.00	0.46	6/ 2/88
AVS-4253	CPE	VEE	----	----	VERO	10.00	----	6/ 2/88
AVS-4253	CPE	VSV	----	----	L929	32.00	----	4/15/88
AVS-4253	CPE	VV	----	----	VERO	100.00	----	4/29/88
AVS-4254	CPE	AD2	----	----	HEP2 <	10.00	----	4/29/88
AVS-4254	CPE	JE	----	----	VERO	32.00	----	6/ 2/88
AVS-4254	CPE	PT	1.15	47.70	VERO	32.00	0.67	6/ 2/88
AVS-4254	CPE	SF	1.3	22.70	VERO	32.00	1.40	6/ 2/88
AVS-4254	CPE	VEE	----	----	VERO	32.00	----	6/ 2/88
AVS-4254	CPE	VSV	----	----	L929	100.00	----	4/15/88
AVS-4254	CPE	VV	0.3	----	VERO <	320.00	----	4/29/88
AVS-4255	CPE	AD2	----	----	HEP2 <	100.00	----	5/ 5/88
AVS-4255	CPE	JE	----	----	VERO	3.20	----	6/ 2/88
AVS-4255	CPE	PT	0.82	7.00	VERO	3.20	0.46	6/ 2/88
AVS-4255	CPE	SF	1.1	1.73	VERO	3.20	1.84	6/ 2/88
AVS-4255	CPE	VEE	----	----	VERO	3.20	----	6/ 2/88
AVS-4255	CPE	VSV	----	----	L929	32.00	----	4/15/88
AVS-4255	CPE	VV	0.6	----	VERO <	32.00	----	5/ 5/88
AVS-4256	CPE	AD2	----	----	HEP2 >	320.00	----	5/ 5/88
AVS-4256	CPE	JE	0.15	----	VERO	32.00	----	6/ 2/88
AVS-4256	CPE	PT	----	----	VERO	10.00	----	6/ 2/88
AVS-4256	CPE	SF	----	----	VERO	10.00	----	6/ 2/88
AVS-4256	CPE	VEE	----	----	VERO	32.00	----	6/ 2/88
AVS-4256	CPE	VSV	----	----	L929	32.00	----	4/15/88
AVS-4256	CPE	VV	----	----	VERO >	320.00	----	5/ 5/88
AVS-4257	CPE	AD2	----	----	HEP2 >	320.00	----	5/ 5/88
AVS-4257	CPE	JE	0.6	179.00	VERO	32.00	0.18	6/ 2/88
AVS-4257	CPE	PT	0.15	----	VERO	32.00	----	6/ 2/88
AVS-4257	CPE	SF	0.85	77.90	VERO	100.00	1.28	6/ 2/88
AVS-4257	CPE	VEE	----	----	VERO	32.00	----	6/ 2/88
AVS-4257	CPE	VSV	----	----	L929	320.00	----	4/19/88
AVS-4257	CPE	VV	----	----	VERO >	320.00	----	5/ 5/88
AVS-4258	CPE	AD2	0.6	320.00	HEP2 >	320.00 >	1.00	5/ 5/88
AVS-4258	CPE	JE	0.05	----	VERO	32.00	----	6/ 2/88
AVS-4258	CPE	PT	1.	117.00	VERO	3.20	0.03	6/ 2/88
AVS-4258	CPE	SF	1.7	6.10	VERO	3.20	0.52	6/ 2/88
AVS-4258	CPE	VEE	----	----	VERO	10.00	----	6/ 2/88
AVS-4258	CPE	VSV	----	----	L929	100.00	----	4/19/88
AVS-4258	CPE	VV	0.4	----	VERO <	320.00	----	5/ 5/88
AVS-4259	CPE	AD2	----	----	HEP2 <	32.00	----	5/ 5/88
AVS-4259	CPE	JE	----	----	VERO <	32.00	----	6/ 2/88
AVS-4259	CPE	PT	0.7	2.70	VERO <	10.00 <	3.69	6/ 2/88
AVS-4259	CPE	SF	0.4	----	VERO <	10.00	----	6/ 2/88
AVS-4259	CPE	VEE	----	----	VERO	3.20	----	6/ 2/88
AVS-4259	CPE	VSV	----	----	L929	10.00	----	4/19/88
AVS-4259	CPE	VV	----	----	VERO <	10.00	----	5/ 5/88
AVS-4260	CPE	AD2	----	----	HEP2 <	32.00	----	5/ 5/88
AVS-4260	CPE	JE	----	----	VERO	10.00	----	6/ 2/88
AVS-4260	CPE	PT	0.5	----	VERO <	10.00	----	6/ 2/88
AVS-4260	CPE	SF	0.6	3.20	VERO <	10.00 <	3.12	6/ 2/88
AVS-4260	CPE	VEE	----	----	VERO	10.00	----	6/ 2/88
AVS-4260	CPE	VSV	----	----	L929 <	32.00	----	4/19/88
AVS-4260	CPE	VV	----	----	VERO <	10.00	----	5/ 5/88
AVS-4261	CPE	AD2	----	----	HEP2 <	100.00	----	5/ 5/88
AVS-4261	CPE	JE	----	----	VERO	3.20	----	6/ 2/88
AVS-4261	CPE	PT	0.25	----	VERO	10.00	----	6/ 2/88
AVS-4261	CPE	SF	0.6	7.00	VERO	10.00	1.41	6/ 2/88
AVS-4261	CPE	VEE	----	----	VERO	10.00	----	6/ 2/88
AVS-4261	CPE	VSV	0.45	6.80	L929	10.00	1.46	4/19/88
AVS-4261	CPE	VV	0.4	----	VERO <	100.00	----	5/ 5/88
AVS-4262	CPE	AD2	1.1	199.00	HEP2 >	320.00 >	1.60	5/ 5/88
AVS-4262	CPE	AD2	0.6	----	HEP2 >	320.00	----	5/26/88
AVS-4262	CPE	AD2	0.5	----	HEP2 >	320.00	----	6/16/88
AVS-4262	CPE	JE	----	----	VERO	320.00	----	6/ 2/88

B-224

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4262	CPE	PT	0.2	----	VERO	100.00	----	6/ 2/88
AVS-4262	CPE	SF	0.35	----	VERO	100.00	----	6/ 2/88
AVS-4262	CPE	VEE	----	----	VERO	100.00	----	6/ 2/88
AVS-4262	CPE	VSV	----	----	L929 >	320.00	----	4/19/88
AVS-4262	CPE	VV	----	----	VERO >	320.00	----	5/ 5/88
AVS-4263	CPE	AD2	0.6	56.50	HEP2	100.00	1.76	5/ 5/88
AVS-4263	CPE	JE	----	----	VERO	3.20	----	6/ 2/88
AVS-4263	CPE	PT	----	----	VERO	320.00	----	6/ 2/88
AVS-4263	CPE	SF	0.1	----	VERO	3.20	----	6/ 2/88
AVS-4263	CPE	VEE	----	----	VERO	1.00	----	6/ 2/88
AVS-4263	CPE	VSV	----	----	L929	32.00	----	4/19/88
AVS-4263	CPE	VV	0.05	----	VERO	10.00	----	5/ 5/88
AVS-4264	CPE	AD2	0.45	----	HEP2	100.00	----	5/ 5/88
AVS-4264	CPE	JE	----	----	VERO	10.00	----	6/ 7/88
AVS-4264	CPE	PT	----	----	VERO	32.00	----	6/ 7/88
AVS-4264	CPE	SF	----	----	VERO <	100.00	----	6/ 7/88
AVS-4264	CPE	VEE	----	----	VERO	32.00	----	6/ 7/88
AVS-4264	CPE	VSV	----	----	L929	32.00	----	4/19/88
AVS-4264	CPE	VV	----	----	VERO <	100.00	----	5/ 5/88
AVS-4265	CPE	AD2	0.6	320.00	HEP2 >	320.00 >	1.00	5/ 5/88
AVS-4265	CPE	JE	----	----	VERO	10.00	----	6/ 7/88
AVS-4265	CPE	PT	----	----	VERO <	100.00	----	6/ 7/88
AVS-4265	CPE	SF	0.3	----	VERO	10.00	----	6/ 7/88
AVS-4265	CPE	VEE	----	----	VERO	100.00	----	6/ 7/88
AVS-4265	CPE	VSV	----	----	L929	10.00	----	4/19/88
AVS-4265	CPE	VV	----	----	VERO	100.00	----	5/ 5/88
AVS-4266	CPE	AD2	----	----	HEP2 <	100.00	----	5/ 5/88
AVS-4266	CPE	PT	1.05	13.20	VERO	32.00	2.41	6/ 7/88
AVS-4266	CPE	SF	----	----	VERO	100.00	----	6/ 7/88
AVS-4266	CPE	VEE	----	----	VERO	100.00	----	6/ 7/88
AVS-4266	CPE	VSV	----	----	L929	32.00	----	4/19/88
AVS-4266	CPE	VV	----	----	VERO	100.00	----	5/ 5/88
AVS-4267	CPE	AD2	1.4	159.00	HEP2 >	320.00 >	2.00	5/ 5/88
AVS-4267	CPE	AD2	1.3	169.00	HEP2 >	320.00 >	1.88	5/26/88
AVS-4267	CPE	PT	0.65	16.90	VERO	10.00	0.59	6/ 7/88
AVS-4267	CPE	SF	0.6	----	VERO	320.00	----	6/ 7/88
AVS-4267	CPE	VEE	----	----	VERO	320.00	----	6/ 7/88
AVS-4267	CPE	VSV	----	----	L929	320.00	----	4/19/88
AVS-4267	CPE	VV	0.1	----	VERO	320.00	----	5/ 5/88
AVS-4268	CPE	AD2	0.3	----	HEP2 >	320.00	----	5/ 5/88
AVS-4268	CPE	JE	0.2	----	VERO	320.00	----	6/ 7/88
AVS-4268	CPE	PT	----	----	VERO >	320.00	----	6/ 7/88
AVS-4268	CPE	SF	0.4	----	VERO	100.00	----	6/ 7/88
AVS-4268	CPE	VEE	----	----	VERO	100.00	----	6/ 7/88
AVS-4268	CPE	VSV	----	----	L929	100.00	----	4/19/88
AVS-4268	CPE	VV	----	----	VERO	320.00	----	5/ 5/88
AVS-4269	CPE	AD2	0.3	----	HEP2 >	320.00	----	5/ 5/88
AVS-4269	CPE	JE	----	----	VERO	10.00	----	6/ 7/88
AVS-4269	CPE	PT	0.05	----	VERO	32.00	----	6/ 7/88
AVS-4269	CPE	SF	0.55	19.90	VERO	10.00	0.50	6/ 7/88
AVS-4269	CPE	VEE	----	----	VERO	32.00	----	6/ 7/88
AVS-4269	CPE	VSV	----	----	L929	100.00	----	4/19/88
AVS-4269	CPE	VV	----	----	VERO >	320.00	----	5/ 5/88
AVS-4270	CPE	AD2	0.9	320.00	HEP2 >	320.00 >	1.00	5/ 5/88
AVS-4270	CPE	JE	0.6	5.60	VERO	3.20	0.57	6/ 7/88
AVS-4270	CPE	PT	----	----	VERO	10.00	----	6/ 7/88
AVS-4270	CPE	SF	0.65	4.91	VERO	3.20	0.65	6/ 7/88
AVS-4270	CPE	VEE	----	----	VERO	32.00	----	6/ 7/88
AVS-4270	CPE	VSV	----	----	L929	32.00	----	4/19/88
AVS-4270	CPE	VV	0.35	270.00	VERO	320.00	1.18	5/ 5/88
AVS-4271	CPE	AD2	0.2	----	HEP2 <	100.00	----	5/ 5/88
AVS-4271	CPE	JE	0.65	17.80	VERO	3.20	0.18	6/ 7/88
AVS-4271	CPE	PT	0.6	17.80	VERO	32.00	1.78	6/ 7/88
AVS-4271	CPE	SF	2.55	0.96	VERO	10.00	10.30	6/ 7/88
AVS-4271	CPE	VEE	0.4	75.10	VERO	1.00	0.01	6/ 7/88

B-225

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-4271	CPE	VSV	----	----	L929 <	100.00	----	4/19/88
AVS-4271	CPE	VV	0.6	32.00	VERO	32.00	1.00	5/ 5/88
AVS-4272	CPE	AD2	----	----	HEP2 <	1.00	----	5/ 5/88
AVS-4272	CPE	JE	0.6	22.90	VERO	3.20	0.14	6/ 7/88
AVS-4272	CPE	PT	----	----	VERO	320.00	----	6/ 7/88
AVS-4272	CPE	SF	1.35	5.60	VERO	10.00	1.76	6/ 7/88
AVS-4272	CPE	VEE	----	----	VERO	10.00	----	6/ 7/88
AVS-4272	CPE	VSV	----	----	L929	32.00	----	4/19/88
AVS-4272	CPE	VV	0.4	----	VERO <	100.00	----	5/ 5/88
AVS-4273	CPE	AD2	0.45	68.30	HEP2	100.00	1.46	5/ 5/88
AVS-4273	CPE	JE	0.6	17.70	VERO	3.20	0.18	6/ 7/88
AVS-4273	CPE	PT	----	----	VERO	32.00	----	6/ 7/88
AVS-4273	CPE	SF	1.25	2.47	VERO	3.20	1.29	6/ 7/88
AVS-4273	CPE	VEE	0.1	----	VERO	3.20	----	6/ 7/88
AVS-4273	CPE	VSV	----	----	L929	32.00	----	4/19/88
AVS-4273	CPE	VV	0.6	----	VERO <	100.00	----	5/ 5/88
AVS-4274	CPE	AD2	----	----	HEP2 >	320.00	----	6/23/88
AVS-4274	CPE	JE	----	----	VERO	10.00	----	7/19/88
AVS-4274	CPE	PT	----	----	VERO >	320.00	----	7/19/88
AVS-4274	CPE	SF	----	----	VERO >	320.00	----	7/19/88
AVS-4274	CPE	VEE	----	----	VERO	320.00	----	7/19/88
AVS-4274	CPE	VSV	----	----	L929	100.00	----	6/22/88
AVS-4274	CPE	VV	----	----	VERO	100.00	----	6/23/88
AVS-4274	CPE	YFV	----	----	VERO >	320.00	----	7/19/88
AVS-4275	CPE	AD2	----	----	HEP2	3.20	----	4/21/88
AVS-4275	CPE	JE	2.8	0.49	VERO <	0.32 <	0.65	4/13/88
AVS-4275	CPE	JE	----	----	VERO	1.00	----	6/ 7/88
AVS-4275	PR	PIC	N/A	----	VERO >	320.00	----	4/11/88
AVS-4275	CPE	PT	1.25	320.00	VERO <	0.32 <	----	4/13/88
AVS-4275	CPE	PT	----	----	VERO >	32.00	----	6/ 7/88
AVS-4275	CPE	SF	0.15	----	VERO <	0.32	----	4/13/88
AVS-4275	CPE	SF	0.8	----	VERO	32.00	----	6/ 7/88
AVS-4275	CPE	VEE	----	----	VERO <	0.32	----	4/13/88
AVS-4275	CPE	VEE	----	----	VERO	32.00	----	6/ 7/88
AVS-4275	CPE	VSV	3.6	0.22	L929	1.00	4.49	4/ 8/88
AVS-4275	CPE	VSV	4.1	0.16	L929	0.32	1.95	4/19/88
AVS-4275	CPE	VV	5.3	0.01	VERO	0.32	19.30	4/21/88
AVS-4275	CPE	VV	4.45	0.03	VERO	0.32	10.00	4/29/88
AVS-4275	CPE	YFV	2.85	0.95	VERO <	0.32 <	0.34	4/13/88
AVS-4276	CPE	AD2	0.6	56.50	HEP2	100.00	1.76	6/23/88
AVS-4276	CPE	JE	1.05	2.81	VERO	3.20	1.13	7/19/88
AVS-4276	CPE	PT	0.55	6.90	VERO	10.00	1.43	7/19/88
AVS-4276	CPE	SF	0.45	6.80	VERO	10.00	1.46	7/19/88
AVS-4276	CPE	VEE	0.25	----	VERO	1.00	----	7/19/88
AVS-4276	CPE	VSV	0.15	----	L929	10.00	----	6/22/88
AVS-4276	CPE	VV	0.6	56.50	VERO	32.00	0.57	6/23/88
AVS-4276	CPE	YFV	0.7	6.40	VERO	10.00	1.54	7/19/88
AVS-4277	CPE	AD2	0.6	56.50	HEP2	100.00	1.76	6/23/88
AVS-4277	CPE	JE	1.15	2.06	VERO	1.00	0.49	7/19/88
AVS-4277	CPE	PT	0.45	6.80	VERO	10.00	1.46	7/19/88
AVS-4277	CPE	SF	0.45	6.80	VERO	10.00	1.46	7/19/88
AVS-4277	CPE	VEE	0.05	----	VERO	3.20	----	7/19/88
AVS-4277	CPE	VSV	0.3	32.00	L929	10.00	0.31	6/22/88
AVS-4277	CPE	VV	0.6	56.50	VERO	32.00	0.57	6/23/88
AVS-4277	CPE	YFV	1.4	2.81	VERO	10.00	3.54	7/19/88
AVS-4278	CPE	AD2	0.6	56.50	HEP2	100.00	1.76	6/23/88
AVS-4278	CPE	JE	0.95	2.97	VERO	0.32	0.11	7/19/88
AVS-4278	CPE	PT	1.05	8.30	VERO	10.00	1.20	7/19/88
AVS-4278	CPE	SF	0.75	11.20	VERO	3.20	0.28	7/19/88
AVS-4278	CPE	VEE	----	----	VERO	10.00	----	7/19/88
AVS-4278	CPE	VSV	----	----	L929	32.00	----	6/28/88
AVS-4278	CPE	VV	0.65	53.70	VERO	32.00	0.60	6/23/88
AVS-4278	CPE	YFV	1.94	3.22	VERO	32.00	0.92	7/19/88
AVS-4279	CPE	AD2	0.95	29.70	HEP2	32.00	1.07	6/23/88
AVS-4279	CPE	AD2	1.	40.30	HEP2	100.00	2.47	7/ 7/88

8-226

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4279	CPE	JE	1.05	2.49	VERO	1.00	0.40	7/19/88
AVS-4279	CPE	PT	1.	4.25	VERO	10.00	2.35	7/19/88
AVS-4279	CPE	SF	0.7	5.00	VERO	3.20	0.63	7/19/88
AVS-4279	CPE	VEE	0.45	21.70	VERO	10.00	0.46	7/19/88
AVS-4279	CPE	VSV	0.25	----	L929	32.00	----	6/28/88
AVS-4279	CPE	VV	0.45	21.70	VERO	32.00	1.47	6/23/88
AVS-4279	CPE	YFV	0.85	3.06	VERO	3.20	1.04	7/19/88
AVS-4280	CPE	AD2	0.45	68.30	HEP2	100.00	1.46	6/23/88
AVS-4280	CPE	JE	1.15	2.06	VERO	0.32	0.16	7/19/88
AVS-4280	CPE	PT	0.45	6.80	VERO	10.00	1.46	7/19/88
AVS-4280	CPE	SF	1.05	8.30	VERO	0.32	0.04	7/19/88
AVS-4280	CPE	VEE	----	----	VERO	10.00	----	7/19/88
AVS-4280	CPE	VSV	----	----	L929	32.00	----	6/28/88
AVS-4280	CPE	VV	0.6	56.50	VERO	32.00	0.57	6/23/88
AVS-4280	CPE	YFV	1.89	2.74	VERO	10.00	3.64	7/19/88
AVS-4281	CPE	AD2	1.05	26.10	HEP2	32.00	1.22	6/23/88
AVS-4281	CPE	AD2	1.1	37.60	HEP2	100.00	2.65	7/19/88
AVS-4281	CPE	JE	1.45	1.43	VERO	3.20	2.22	7/19/88
AVS-4281	CPE	PT	1.5	2.61	VERO	10.00	3.81	7/19/88
AVS-4281	CPE	SF	1.05	2.61	VERO	3.20	1.22	7/19/88
AVS-4281	CPE	VEE	0.6	17.80	VERO	3.20	0.18	7/19/88
AVS-4281	CPE	VSV	----	----	L929	10.00	----	6/28/88
AVS-4281	CPE	VV	0.6	17.80	VERO	10.00	0.56	6/23/88
AVS-4281	CPE	YFV	1.65	1.88	VERO	10.00	5.30	7/19/88
AVS-4288	CPE	JE	----	----	VERO	10.00	----	7/19/88
AVS-4288	CPE	PT	----	----	VERO >	100.00	----	7/19/88
AVS-4288	CPE	SF	0.15	----	VERO	10.00	----	7/19/88
AVS-4288	CPE	VEE	----	----	VERO	10.00	----	7/19/88
AVS-4288	CPE	YFV	----	----	VERO >	100.00	----	7/19/88
AVS-4289	CPE	JE	----	----	VERO >	100.00	----	7/19/88
AVS-4289	CPE	PT	----	----	VERO >	100.00	----	7/19/88
AVS-4289	CPE	SF	----	----	VERO	10.00	----	7/19/88
AVS-4289	CPE	VEE	----	----	VERO	32.00	----	7/19/88
AVS-4289	CPE	YFV	----	----	VERO >	100.00	----	7/19/88
AVS-4290	CPE	JE	----	----	VERO	32.00	----	7/19/88
AVS-4290	CPE	PT	----	----	VERO	32.00	----	7/19/88
AVS-4290	CPE	SF	----	----	VERO	32.00	----	7/19/88
AVS-4290	CPE	VEE	----	----	VERO	10.00	----	7/19/88
AVS-4290	CPE	YFV	----	----	VERO	100.00	----	7/19/88
AVS-4291	CPE	JE	----	----	VERO	100.00	----	7/20/88
AVS-4291	CPE	PT	----	----	VERO >	320.00	----	7/20/88
AVS-4291	CPE	SF	0.05	----	VERO	32.00	----	7/20/88
AVS-4291	CPE	VEE	----	----	VERO >	320.00	----	7/20/88
AVS-4291	CPE	YFV	0.2	----	VERO >	320.00	----	7/20/88
AVS-4292	CPE	JE	----	----	VERO <	0.32	----	7/20/88
AVS-4292	CPE	PT	----	----	VERO	3.20	----	7/20/88
AVS-4292	CPE	SF	0.3	3.20	VERO <	0.32 <	0.10	7/20/88
AVS-4292	CPE	VEE	----	----	VERO <	0.32	----	7/20/88
AVS-4292	CPE	YFV	----	----	VERO	3.20	----	7/20/88
AVS-4293	CPE	JE	----	----	VERO	10.00	----	7/20/88
AVS-4293	CPE	PT	----	----	VERO	100.00	----	7/20/88
AVS-4293	CPE	SF	0.05	----	VERO	10.00	----	7/20/88
AVS-4293	CPE	VEE	----	----	VERO	100.00	----	7/20/88
AVS-4293	CPE	YFV	----	----	VERO	100.00	----	7/20/88
AVS-4294	CPE	JE	----	----	VERO <	0.10	----	7/20/88
AVS-4294	CPE	PT	----	----	VERO	3.20	----	7/20/88
AVS-4294	CPE	SF	0.2	----	VERO	3.20	----	7/20/88
AVS-4294	CPE	VEE	----	----	VERO <	3.20	----	7/20/88
AVS-4294	CPE	YFV	----	----	VERO	1.00	----	7/20/88
AVS-4295	CPE	JE	----	----	VERO	32.00	----	7/20/88
AVS-4295	CPE	PT	0.3	----	VERO >	100.00	----	7/20/88
AVS-4295	CPE	SF	0.1	----	VERO	32.00	----	7/20/88
AVS-4295	CPE	VEE	----	----	VERO >	100.00	----	7/20/88
AVS-4295	CPE	YFV	----	----	VERO	100.00	----	7/20/88
AVS-4299	CPE	JE	----	----	VERO	32.00	----	7/20/88

B-227

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4299	CPE	PT	0.1	----	VERO >	100.00	----	7/20/88
AVS-4299	CPE	SF	0.05	----	VERO	32.00	----	7/20/88
AVS-4299	CPE	VEE	----	----	VERO	100.00	----	7/20/88
AVS-4299	CPE	YFV	----	----	VERO	100.00	----	7/20/88
AVS-4300	CPE	JE	----	----	VERO	10.00	----	7/20/88
AVS-4300	CPE	PT	----	----	VERO >	100.00	----	7/20/88
AVS-4300	CPE	SF	0.15	----	VERO	32.00	----	7/20/88
AVS-4300	CPE	VEE	----	----	VERO	32.00	----	7/20/88
AVS-4300	CPE	YFV	----	----	VERO	100.00	----	7/20/88
AVS-4302	CPE	JE	----	----	VERO	10.00	----	7/20/88
AVS-4302	CPE	PT	0.75	56.40	VERO	100.00	1.77	7/20/88
AVS-4302	CPE	SF	0.65	53.70	VERO	10.00	0.19	7/20/88
AVS-4302	CPE	VEE	----	----	VERO	10.00	----	7/20/88
AVS-4302	CPE	YFV	----	----	VERO	10.00	----	7/20/88
AVS-4303	CPE	JE	----	----	VERO	32.00	----	7/20/88
AVS-4303	CPE	PT	0.05	----	VERO	32.00	----	7/20/88
AVS-4303	CPE	SF	0.25	----	VERO	3.20	----	7/20/88
AVS-4303	CPE	VEE	----	----	VERO	32.00	----	7/20/88
AVS-4303	CPE	YFV	----	----	VERO	100.00	----	7/20/88
AVS-4304	CPE	JE	----	----	VERO	10.00	----	7/20/88
AVS-4304	CPE	PT	0.45	21.70	VERO	10.00	0.46	7/20/88
AVS-4304	CPE	SF	0.4	23.90	VERO	10.00	0.42	7/20/88
AVS-4304	CPE	VEE	----	----	VERO	32.00	----	7/20/88
AVS-4304	CPE	YFV	----	----	VERO	10.00	----	7/20/88
AVS-4305	CPE	JE	----	----	VERO	3.20	----	7/20/88
AVS-4305	CPE	PT	----	----	VERO	10.00	----	7/20/88
AVS-4305	CPE	SF	0.3	10.00	VERO	10.00	1.00	7/20/88
AVS-4305	CPE	VEE	----	----	VERO	3.20	----	7/20/88
AVS-4305	CPE	YFV	----	----	VERO	10.00	----	7/20/88
AVS-4306	CPE	JE	----	----	VERO	10.00	----	7/20/88
AVS-4306	CPE	PT	----	----	VERO	32.00	----	7/20/88
AVS-4306	CPE	SF	----	----	VERO	32.00	----	7/20/88
AVS-4306	CPE	VEE	----	----	VERO	32.00	----	7/20/88
AVS-4306	CPE	YFV	----	----	VERO <	100.00	----	7/20/88
AVS-4307	CPE	JE	----	----	VERO	32.00	----	7/20/88
AVS-4307	CPE	PT	----	----	VERO >	100.00	----	7/20/88
AVS-4307	CPE	SF	0.15	----	VERO	32.00	----	7/20/88
AVS-4307	CPE	VEE	----	----	VERO >	100.00	----	7/20/88
AVS-4307	CPE	YFV	----	----	VERO >	100.00	----	7/20/88
AVS-4308	CPE	JE	----	----	VERO	10.00	----	7/20/88
AVS-4308	CPE	PT	----	----	VERO	100.00	----	7/20/88
AVS-4308	CPE	SF	0.15	----	VERO	10.00	----	7/20/88
AVS-4308	CPE	VEE	----	----	VERO	100.00	----	7/20/88
AVS-4308	CPE	YFV	----	----	VERO >	100.00	----	7/20/88
AVS-4309	CPE	JE	----	----	VERO	10.00	----	7/20/88
AVS-4309	CPE	PT	0.05	----	VERO	32.00	----	7/20/88
AVS-4309	CPE	SF	0.3	100.00	VERO	32.00	0.32	7/20/88
AVS-4309	CPE	VEE	----	----	VERO	100.00	----	7/20/88
AVS-4309	CPE	YFV	----	----	VERO	100.00	----	7/20/88
AVS-4310	CPE	JE	----	----	VERO	10.00	----	7/26/88
AVS-4310	CPE	PT	0.55	19.90	VERO	3.20	0.16	7/26/88
AVS-4310	CPE	SF	1.05	12.50	VERO	10.00	0.79	7/26/88
AVS-4310	CPE	VEE	----	----	VERO	32.00	----	7/26/88
AVS-4310	CPE	YFV	0.25	----	VERO	10.00	----	7/26/88
AVS-4311	CPE	JE	----	----	VERO	100.00	----	7/26/88
AVS-4311	CPE	PT	----	----	VERO	32.00	----	7/26/88
AVS-4311	CPE	SF	0.55	217.00	VERO	100.00	0.46	7/26/88
AVS-4311	CPE	VEE	----	----	VERO	32.00	----	7/26/88
AVS-4311	CPE	YFV	----	----	VERO	320.00	----	7/26/88
AVS-4312	CPE	JE	----	----	VERO	320.00	----	7/26/88
AVS-4312	CPE	PT	----	----	VERO	100.00	----	7/26/88
AVS-4312	CPE	SF	----	----	VERO	100.00	----	7/26/88
AVS-4312	CPE	VEE	----	----	VERO	320.00	----	7/26/88
AVS-4312	CPE	YFV	0.1	----	VERO >	320.00	----	7/26/88
AVS-4313	CPE	JE	0.7	----	VERO	100.00	----	7/26/88

B-228

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

CONC/NO	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4313	CPE	PT	----	----	VERO	320.00	----	7/26/88
AVS-4313	CPE	SF	0.75	232.00	VERO	320.00	1.37	7/26/88
AVS-4313	CPE	VEE	----	----	VERO	320.00	----	7/26/88
AVS-4313	CPE	YFV	0.15	----	VERO	320.00	----	7/26/88
AVS-4314	CPE	JE	----	----	VERO	1.00	----	7/26/88
AVS-4314	CPE	PT	0.4	2.39	VERO	1.00	0.42	7/26/88
AVS-4314	CPE	SF	1.3	0.59	VERO	1.00	1.68	7/26/88
AVS-4314	CPE	VEE	----	----	VERO	1.00	----	7/26/88
AVS-4314	CPE	YFV	0.2	----	VERO	1.00	----	7/26/88
AVS-4315	CPE	JE	----	----	VERO	320.00	----	7/26/88
AVS-4315	CPE	PT	----	----	VERO	320.00	----	7/26/88
AVS-4315	CPE	SF	0.3	----	VERO	100.00	----	7/26/88
AVS-4315	CPE	VEE	----	----	VERO	32.00	----	7/26/88
AVS-4315	CPE	YFV	----	----	VERO	100.00	----	7/26/88
AVS-4316	CPE	JE	0.2	----	VERO	32.00	----	7/26/88
AVS-4316	CPE	PT	----	----	VERO	32.00	----	7/26/88
AVS-4316	CPE	SF	0.25	----	VERO	100.00	----	7/26/88
AVS-4316	CPE	VEE	----	----	VERO	100.00	----	7/26/88
AVS-4316	CPE	YFV	----	----	VERO	100.00	----	7/26/88
AVS-4329	CPE	JE	----	----	VERO	100.00	----	7/26/88
AVS-4329	CPE	PT	0.45	217.00	VERO	100.00	0.46	7/26/88
AVS-4329	CPE	SF	0.7	182.00	VERO	100.00	0.55	7/26/88
AVS-4329	CPE	VEE	----	----	VERO	32.00	----	7/26/88
AVS-4329	CPE	YFV	----	----	VERO	100.00	----	7/26/88
AVS-4337	CPE	AD2	----	----	HEP2 <	320.00	----	6/30/88
AVS-4337	CPE	JE	----	----	VERO	100.00	----	7/26/88
AVS-4337	CPE	PT	----	----	VERO	100.00	----	7/26/88
AVS-4337	CPE	SF	0.07	----	VERO	100.00	----	7/26/88
AVS-4337	CPE	VEE	----	----	VERO	100.00	----	7/26/88
AVS-4337	CPE	VSV	----	----	L929 <	320.00	----	6/28/88
AVS-4337	CPE	VV	0.45	217.00	VERO	320.00	1.47	6/30/88
AVS-4337	CPE	YFV	----	----	VERO	100.00	----	7/26/88
AVS-4339	CPE	AD2	0.15	----	HEP2	32.00	----	6/30/88
AVS-4339	CPE	JE	0.2	----	VERO	10.00	----	7/26/88
AVS-4339	CPE	PT	0.45	68.30	VERO	32.00	0.47	7/26/88
AVS-4339	CPE	SF	1.55	13.40	VERO	32.00	2.37	7/26/88
AVS-4339	CPE	VEE	----	----	VERO	10.00	----	7/26/88
AVS-4339	CPE	VSV	----	----	L929	32.00	----	6/28/88
AVS-4339	CPE	VV	0.25	----	VERO	10.00	----	6/30/88
AVS-4339	CPE	YFV	0.5	69.80	VERO	32.00	0.46	7/26/88
AVS-4340	CPE	AD2	----	----	HEP2 <	320.00	----	6/30/88
AVS-4340	CPE	JE	----	----	VERO	100.00	----	7/26/88
AVS-4340	CPE	PT	----	----	VERO	100.00	----	7/26/88
AVS-4340	CPE	SF	0.55	206.00	VERO	100.00	0.48	7/26/88
AVS-4340	CPE	VEE	----	----	VERO	32.00	----	7/26/88
AVS-4340	CPE	VSV	----	----	L929 <	320.00	----	6/28/88
AVS-4340	CPE	VV	----	----	VERO	100.00	----	6/30/88
AVS-4340	CPE	YFV	----	----	VERO	320.00	----	7/26/88
AVS-4342	CPE	AD2	0.8	9.70	HEP2 <	32.00 <	3.27	8/18/88
AVS-4342	CPE	JE	----	----	VERO	320.00	----	7/27/88
AVS-4342	CPE	PT	----	----	VERO	320.00	----	7/27/88
AVS-4342	CPE	SF	0.25	----	VERO	32.00	----	7/27/88
AVS-4342	CPE	VEE	----	----	VERO	320.00	----	7/27/88
AVS-4342	CPE	VSV	----	----	L929 <	32.00	----	7/20/88
AVS-4342	CPE	VV	0.15	----	VERO	10.00	----	8/18/88
AVS-4342	CPE	YFV	0.3	----	VERO	100.00	----	7/27/88
AVS-4343	CPE	AD2	----	----	HEP2 <	100.00	----	8/18/88
AVS-4343	CPE	JE	----	----	VERO	3.20	----	7/27/88
AVS-4343	CPE	PT	0.45	21.70	VERO	10.00	0.46	7/27/88
AVS-4343	CPE	SF	0.6	17.70	VERO	3.20	0.18	7/27/88
AVS-4343	CPE	VEE	----	----	VERO	10.00	----	7/27/88
AVS-4343	CPE	VSV	----	----	L929	100.00	----	7/20/88
AVS-4343	CPE	VV	1.9	4.83	VERO	10.00	2.06	8/18/88
AVS-4343	CPE	YFV	0.75	----	VERO	3.20	----	7/27/88
AVS-4359	CPE	JE	----	----	VERO	10.00	----	7/27/88

B-229

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4359	CPE	PT	----	----	VERO	32.00	----	7/27/88
AVS-4359	CPE	SF	0.15	----	VERO	32.00	----	7/27/88
AVS-4359	CPE	VEE	----	----	VERO	1.00	----	7/27/88
AVS-4359	CPE	YFV	1.1	20.50	VERO	10.00	0.49	7/27/88
AVS-4360	CPE	JE	0.05	----	VERO	100.00	----	7/27/88
AVS-4360	CPE	PT	----	----	VERO >	100.00	----	7/27/88
AVS-4360	CPE	SF	----	----	VERO >	100.00	----	7/27/88
AVS-4360	CPE	VEE	----	----	VERO	100.00	----	7/27/88
AVS-4360	CPE	YFV	0.7	----	VERO	100.00	----	7/27/88
AVS-4361	CPE	JE	----	----	VERO	10.00	----	7/27/88
AVS-4361	CPE	PT	----	----	VERO >	100.00	----	7/27/88
AVS-4361	CPE	SF	----	----	VERO	100.00	----	7/27/88
AVS-4361	CPE	VEE	----	----	VERO	10.00	----	7/27/88
AVS-4361	CPE	YFV	0.95	----	VERO	100.00	----	7/27/88
AVS-4362	CPE	JE	----	----	VERO >	100.00	----	7/27/88
AVS-4362	CPE	PT	----	----	VERO >	100.00	----	7/27/88
AVS-4362	CPE	SF	----	----	VERO	100.00	----	7/27/88
AVS-4362	CPE	VEE	----	----	VERO	10.00	----	7/27/88
AVS-4362	CPE	YFV	0.4	----	VERO >	100.00	----	7/27/88
AVS-4363	CPE	JE	----	----	VERO	100.00	----	8/ 2/88
AVS-4363	CPE	PT	----	----	VERO	320.00	----	8/ 2/88
AVS-4363	CPE	SF	0.15	----	VERO	100.00	----	8/ 2/88
AVS-4363	CPE	VEE	----	----	VERO	10.00	----	8/ 2/88
AVS-4363	CPE	YFV	----	----	VERO	320.00	----	8/ 2/88
AVS-4364	CPE	JE	----	----	VERO	3.20	----	8/ 2/88
AVS-4364	CPE	PT	0.15	----	VERO	10.00	----	8/ 2/88
AVS-4364	CPE	SF	0.3	32.00	VERO	32.00	1.00	8/ 2/88
AVS-4364	CPE	VEE	----	----	VERO	32.00	----	8/ 2/88
AVS-4364	CPE	YFV	----	----	VERO	10.00	----	8/ 2/88
AVS-4366	CPE	JE	----	----	VERO	10.00	----	8/ 2/88
AVS-4366	CPE	PT	----	----	VERO	32.00	----	8/ 2/88
AVS-4366	CPE	SF	0.9	10.00	VERO	32.00	3.20	8/ 2/88
AVS-4366	CPE	VEE	----	----	VERO	100.00	----	8/ 2/88
AVS-4366	CPE	YFV	----	----	VERO	10.00	----	8/ 2/88
AVS-4367	CPE	JE	----	----	VERO	100.00	----	8/ 2/88
AVS-4367	CPE	PT	0.35	270.00	VERO	320.00	1.18	8/ 2/88
AVS-4367	CPE	SF	0.35	319.00	VERO	32.00	0.10	8/ 2/88
AVS-4367	CPE	VEE	----	----	VERO	100.00	----	8/ 2/88
AVS-4367	CPE	YFV	----	----	VERO	100.00	----	8/ 2/88
AVS-4369	CPE	JE	----	----	VERO	100.00	----	8/ 2/88
AVS-4369	CPE	PT	----	----	VERO	320.00	----	8/ 2/88
AVS-4369	CPE	SF	----	----	VERO	320.00	----	8/ 2/88
AVS-4369	CPE	VEE	----	----	VERO	320.00	----	8/ 2/88
AVS-4369	CPE	YFV	----	----	VERO	320.00	----	8/ 2/88
AVS-4370	CPE	JE	----	----	VERO	32.00	----	8/ 2/88
AVS-4370	CPE	PT	----	----	VERO	32.00	----	8/ 2/88
AVS-4370	CPE	SF	0.9	68.30	VERO <	320.00 <	4.68	8/ 2/88
AVS-4370	CPE	VEE	----	----	VERO	100.00	----	8/ 2/88
AVS-4370	CPE	YFV	----	----	VERO	100.00	----	8/ 2/88
AVS-4371	CPE	JE	----	----	VERO	32.00	----	8/ 2/88
AVS-4371	CPE	PT	0.45	68.30	VERO	100.00	1.46	8/ 2/88
AVS-4371	CPE	SF	0.45	68.30	VERO	100.00	1.46	8/ 2/88
AVS-4371	CPE	VEE	----	----	VERO	100.00	----	8/ 2/88
AVS-4371	CPE	YFV	----	----	VERO	100.00	----	8/ 2/88
AVS-4372	CPE	JE	----	----	VERO	100.00	----	8/ 2/88
AVS-4372	CPE	PT	0.3	42.50	VERO	32.00	0.75	8/ 2/88
AVS-4372	CPE	SF	0.75	56.30	VERO	100.00	1.77	8/ 2/88
AVS-4372	CPE	VEE	----	----	VERO	32.00	----	8/ 2/88
AVS-4372	CPE	YFV	----	----	VERO	100.00	----	8/ 2/88
AVS-4373	CPE	JE	----	----	VERO	32.00	----	8/ 2/88
AVS-4373	CPE	PT	0.55	63.20	VERO	32.00	0.50	8/ 2/88
AVS-4373	CPE	SF	0.6	56.30	VERO	32.00	0.57	8/ 2/88
AVS-4373	CPE	VEE	----	----	VERO	10.00	----	8/ 2/88
AVS-4373	CPE	YFV	----	----	VERO	100.00	----	8/ 2/88
AVS-4374	CPE	JE	----	----	VERO	320.00	----	8/ 2/88

B-230

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4374	CPE	PT	----	----	VERO	320.00	----	8/ 2/88
AVS-4374	CPE	SF	----	----	VERO	320.00	----	8/ 2/88
AVS-4374	CPE	VEE	----	----	VERO >	320.00	----	8/ 2/88
AVS-4374	CPE	YFV	----	----	VERO	320.00	----	8/ 2/88
AVS-4375	CPE	JE	----	----	VERO	32.00	----	8/ 2/88
AVS-4375	CPE	PT	----	----	VERO <	100.00	----	8/ 2/88
AVS-4375	CPE	SF	----	----	VERO	32.00	----	8/ 2/88
AVS-4375	CPE	VEE	----	----	VERO <	0.32	----	8/ 2/88
AVS-4375	CPE	YFV	----	----	VERO <	100.00	----	8/ 2/88
AVS-4376	CPE	JE	----	----	VERO	10.00	----	8/ 2/88
AVS-4376	CPE	PT	0.15	----	VERO	32.00	----	8/ 2/88
AVS-4376	CPE	SF	0.8	82.90	VERO	100.00	1.20	8/ 2/88
AVS-4376	CPE	VEE	----	----	VERO	100.00	----	8/ 2/88
AVS-4376	CPE	YFV	0.6	178.00	VERO	100.00	0.56	8/ 2/88
AVS-4377	CPE	JE	----	----	VERO	10.00	----	8/ 2/88
AVS-4377	CPE	PT	0.1	----	VERO	32.00	----	8/ 2/88
AVS-4377	CPE	SF	0.75	17.70	VERO	32.00	1.80	8/ 2/88
AVS-4377	CPE	VEE	----	----	VERO	32.00	----	8/ 2/88
AVS-4377	CPE	YFV	----	----	VERO	32.00	----	8/ 2/88
AVS-4379	CPE	JE	----	----	VERO	100.00	----	8/ 2/88
AVS-4379	CPE	PT	----	----	VERO	100.00	----	8/ 2/88
AVS-4379	CPE	SF	0.15	----	VERO	100.00	----	8/ 2/88
AVS-4379	CPE	VEE	----	----	VERO	100.00	----	8/ 2/88
AVS-4379	CPE	YFV	----	----	VERO	320.00	----	8/ 2/88
AVS-4380	CPE	JE	----	----	VERO	100.00	----	8/ 2/88
AVS-4380	CPE	PT	----	----	VERO >	320.00	----	8/ 2/88
AVS-4380	CPE	SF	0.3	----	VERO >	320.00	----	8/ 2/88
AVS-4380	CPE	VEE	----	----	VERO	320.00	----	8/ 2/88
AVS-4380	CPE	YFV	----	----	VERO >	320.00	----	8/ 2/88
AVS-4381	CPE	JE	----	----	VERO	10.00	----	8/ 3/88
AVS-4381	CPE	SF	0.85	11.00	VERO	10.00	0.90	8/ 3/88
AVS-4381	CPE	VEE	----	----	VERO	10.00	----	8/ 3/88
AVS-4382	CPE	JE	----	----	VERO	100.00	----	8/ 3/88
AVS-4382	CPE	SF	0.25	----	VERO	320.00	----	8/ 3/88
AVS-4382	CPE	VEE	----	----	VERO	32.00	----	8/ 3/88
AVS-4383	CPE	JE	----	----	VERO	32.00	----	8/ 3/88
AVS-4383	CPE	SF	0.6	178.00	VERO	100.00	0.56	8/ 3/88
AVS-4383	CPE	VEE	----	----	VERO	100.00	----	8/ 3/88
AVS-4384	CPE	JE	----	----	VERO	32.00	----	8/ 3/88
AVS-4384	CPE	SF	0.55	69.80	VERO	100.00	1.43	8/ 3/88
AVS-4384	CPE	VEE	----	----	VERO	10.00	----	8/ 3/88
AVS-4385	CPE	JE	----	----	VERO	100.00	----	8/ 3/88
AVS-4385	CPE	SF	1.35	33.60	VERO	32.00	0.95	8/ 3/88
AVS-4385	CPE	VEE	----	----	VERO	100.00	----	8/ 3/88
AVS-4386	CPE	JE	----	----	VERO	32.00	----	8/ 3/88
AVS-4386	CPE	SF	0.55	69.80	VERO	100.00	1.43	8/ 3/88
AVS-4386	CPE	VEE	----	----	VERO	32.00	----	8/ 3/88
AVS-4388	CPE	JE	----	----	VERO	32.00	----	8/ 3/88
AVS-4388	CPE	SF	0.55	62.90	VERO	32.00	0.51	8/ 3/88
AVS-4388	CPE	VEE	----	----	VERO	32.00	----	8/ 3/88
AVS-4389	CPE	JE	----	----	VERO	10.00	----	8/ 3/88
AVS-4389	CPE	SF	1.35	18.00	VERO	32.00	1.77	8/ 3/88
AVS-4389	CPE	VEE	----	----	VERO	32.00	----	8/ 3/88
AVS-4390	CPE	JE	----	----	VERO	32.00	----	8/ 3/88
AVS-4390	CPE	SF	0.3	24.60	VERO	32.00	1.29	8/ 3/88
AVS-4390	CPE	VEE	----	----	VERO	32.00	----	8/ 3/88
AVS-4391	CPE	JE	----	----	VERO	32.00	----	8/ 3/88
AVS-4391	CPE	SF	1.8	31.10	VERO <	320.00 <	10.20	8/ 3/88
AVS-4391	CPE	VEE	----	----	VERO	32.00	----	8/ 3/88
AVS-4392	CPE	JE	----	----	VERO	100.00	----	8/ 3/88
AVS-4392	CPE	SF	0.25	----	VERO	320.00	----	8/ 3/88
AVS-4392	CPE	VEE	----	----	VERO	100.00	----	8/ 3/88
AVS-4393	CPE	JE	----	----	VERO	10.00	----	8/ 3/88
AVS-4393	CPE	SF	0.15	----	VERO	3.20	----	8/ 3/88
AVS-4393	CPE	VEE	----	----	VERO	3.20	----	8/ 3/88

B-231

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4394	CPE	JE	----	----	VERO <	32.00	----	8/ 3/88
AVS-4394	CPE	SF	0.15	----	VERO	10.00	----	8/ 3/88
AVS-4394	CPE	VEE	----	----	VERO	3.20	----	8/ 3/88
AVS-4395	CPE	JE	----	----	VERO	320.00	----	8/ 3/88
AVS-4395	CPE	SF	0.4	319.00	VERO	320.00	1.00	8/ 3/88
AVS-4395	CPE	VEE	----	----	VERO	32.00	----	8/ 3/88
AVS-4396	CPE	JE	----	----	VERO	32.00	----	8/ 3/88
AVS-4396	CPE	SF	1.35	87.70	VERO	100.00	1.13	8/ 3/88
AVS-4396	CPE	VEE	----	----	VERO	32.00	----	8/ 3/88
AVS-4397	CPE	JE	0.15	----	VERO	3.20	----	9/20/88
AVS-4397	CPE	PT	0.20	----	VERO	10.00	----	9/20/88
AVS-4397	CPE	SF	1.00	24.10	VERO	3.20	0.13	9/20/88
AVS-4397	CPE	VEE	----	----	VERO	10.00	----	9/20/88
AVS-4397	CPE	YFV	0.10	----	VERO	10.00	----	9/20/88
AVS-4398	CPE	JE	----	----	VERO	3.20	----	9/20/88
AVS-4398	CPE	PT	0.15	----	VERO	10.00	----	9/20/88
AVS-4398	CPE	SF	0.40	----	VERO <	1.00	----	9/20/88
AVS-4398	CPE	VEE	----	----	VERO	10.00	----	9/20/88
AVS-4398	CPE	YFV	0.65	----	VERO	32.00	----	9/20/88
AVS-4399	CPE	JE	----	----	VERO	3.20	----	9/20/88
AVS-4399	CPE	PT	0.55	27.40	VERO	3.20	0.12	9/20/88
AVS-4399	CPE	SF	0.20	----	VERO <	1.00	----	9/20/88
AVS-4399	CPE	VEE	0.40	----	VERO	3.20	----	9/20/88
AVS-4399	CPE	YFV	0.40	----	VERO <	10.00	----	9/20/88
AVS-4400	CPE	JE	----	----	VERO	3.20	----	9/20/88
AVS-4400	CPE	PT	0.75	5.50	VERO	10.00	1.79	9/20/88
AVS-4400	CPE	SF	0.80	2.67	VERO	3.20	1.20	9/20/88
AVS-4400	CPE	VEE	----	----	VERO	10.00	----	9/20/88
AVS-4400	CPE	YFV	0.10	----	VERO	10.00	----	9/20/88
AVS-4401	CPE	JE	0.40	23.90	VERO	10.00	0.42	9/20/88
AVS-4401	CPE	PT	----	----	VERO	32.00	----	9/20/88
AVS-4401	CPE	SF	0.40	31.90	VERO	32.00	1.00	9/20/88
AVS-4401	CPE	VEE	----	----	VERO	32.00	----	9/20/88
AVS-4401	CPE	YFV	0.40	----	VERO	32.00	----	9/20/88
AVS-4402	CPE	JE	0.12	----	VERO	10.00	----	9/21/88
AVS-4402	CPE	PT	0.45	21.70	VERO	32.00	1.47	9/21/88
AVS-4402	CPE	SF	0.45	21.70	VERO	32.00	1.47	9/21/88
AVS-4402	CPE	VEE	0.40	----	VERO	32.00	----	9/21/88
AVS-4402	CPE	YFV	0.78	----	VERO	32.00	----	9/21/88
AVS-4403	CPE	JE	0.52	18.90	VERO	3.20	0.17	9/21/88
AVS-4403	CPE	PT	----	----	VERO	10.00	----	9/21/88
AVS-4403	CPE	SF	0.25	----	VERO <	1.00	----	9/21/88
AVS-4403	CPE	VEE	0.80	----	VERO	10.00	----	9/21/88
AVS-4403	CPE	YFV	0.76	----	VERO	10.00	----	9/21/88
AVS-4404	CPE	JE	----	----	VERO	10.00	----	9/21/88
AVS-4404	CPE	PT	----	----	VERO	10.00	----	9/21/88
AVS-4404	CPE	SF	0.90	28.40	VERO	32.00	1.13	9/21/88
AVS-4404	CPE	VEE	----	----	VERO	10.00	----	9/21/88
AVS-4404	CPE	YFV	0.30	----	VERO	32.00	----	9/21/88
AVS-4405	CPE	PT	3.60	----	VERO <	1.00	----	9/21/88
AVS-4405	CPE	SF	3.60	----	VERO <	1.00	----	9/21/88
AVS-4405	CPE	VEE	2.82	1.78	VERO <	1.00	0.56	9/21/88
AVS-4405	CPE	YFV	3.00	----	VERO <	1.00	----	9/21/88
AVS-4406	CPE	JE	----	----	VERO	10.00	----	9/27/88
AVS-4406	CPE	PT	----	----	VERO	10.00	----	9/27/88
AVS-4406	CPE	YFV	0.10	----	VERO <	32.00	----	9/27/88
AVS-4407	CPE	JE	0.20	----	VERO	24.00	----	9/27/88
AVS-4407	CPE	PT	0.60	42.40	VERO	24.00	0.57	9/27/88
AVS-4407	CPE	YFV	0.35	----	VERO	24.00	----	9/27/88
AVS-4408	CPE	JE	0.87	13.60	VERO	32.00	2.34	9/27/88
AVS-4408	CPE	PT	0.30	32.00	VERO	10.00	0.31	9/27/88
AVS-4408	CPE	YFV	0.30	----	VERO	32.00	----	9/27/88
AVS-4409	CPE	JE	----	----	VERO <	1.00	----	9/27/88
AVS-4409	CPE	PT	----	----	VERO	3.20	----	9/27/88
AVS-4409	CPE	YFV	----	----	VERO	10.00	----	9/27/88

8-232

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4410	CPE	JE	0.42	6.90	VERO	3.20	0.46	9/28/88
AVS-4410	CPE	PT	0.45	21.70	VERO	10.00	0.46	9/28/88
AVS-4410	CPE	SF	0.45	21.70	VERO	32.00	1.47	9/28/88
AVS-4410	CPE	VEE	----	----	VERO	10.00	----	9/28/88
AVS-4410	CPE	YFV	----	----	VERO	32.00	----	9/28/88
AVS-4411	CPE	JE	0.42	21.90	VERO	32.00	1.46	9/28/88
AVS-4411	CPE	PT	----	----	VERO	32.00	----	9/28/88
AVS-4411	CPE	SF	----	----	VERO	10.00	----	9/28/88
AVS-4411	CPE	VEE	1.00	----	VERO	100.00	----	9/28/88
AVS-4411	CPE	YFV	----	----	VERO	100.00	----	9/28/88
AVS-4413	CPE	JE	----	----	VERO	100.00	----	9/28/88
AVS-4413	CPE	PT	----	----	VERO	100.00	----	9/28/88
AVS-4413	CPE	SF	0.45	270.00	VERO	100.00	0.37	9/28/88
AVS-4413	CPE	VEE	----	----	VERO	32.00	----	9/28/88
AVS-4413	CPE	YFV	----	----	VERO	32.00	----	9/28/88
AVS-4414	CPE	JE	----	----	VERO	10.00	----	9/28/88
AVS-4414	CPE	PT	----	----	VERO	32.00	----	9/28/88
AVS-4414	CPE	SF	0.85	17.90	VERO	32.00	1.78	9/28/88
AVS-4414	CPE	VEE	0.15	----	VERO	32.00	----	9/28/88
AVS-4414	CPE	YFV	----	----	VERO	3.20	----	9/28/88
AVS-4415	CPE	JE	----	----	VERO	3.20	----	10/ 4/88
AVS-4415	CPE	PT	0.3	32.00	VERO	10.00	0.31	10/ 4/88
AVS-4415	CPE	SF	----	----	VERO	32.00	----	10/ 4/88
AVS-4415	CPE	VEE	----	----	VERO	10.00	----	10/ 4/88
AVS-4415	CPE	YFV	----	----	VERO	32.00	----	10/ 4/88
AVS-4416	CPE	JE	----	----	VERO	0.32	----	10/ 4/88
AVS-4416	CPE	PT	----	----	VERO	3.20	----	10/ 4/88
AVS-4416	CPE	SF	----	----	VERO	1.00	----	10/ 4/88
AVS-4416	CPE	VEE	----	----	VERO	1.00	----	10/ 4/88
AVS-4416	CPE	YFV	----	----	VERO	1.00	----	10/ 4/88
AVS-4417	CPE	JE	----	----	VERO	10.00	----	10/ 4/88
AVS-4417	CPE	PT	0.45	68.30	VERO	100.00	1.46	10/ 4/88
AVS-4417	CPE	SF	----	----	VERO	32.00	----	10/ 4/88
AVS-4417	CPE	VEE	----	----	VERO	32.00	----	10/ 4/88
AVS-4417	CPE	YFV	----	----	VERO	10.00	----	10/ 4/88
AVS-4418	CPE	JE	----	----	VERO	10.00	----	10/ 4/88
AVS-4418	CPE	PT	0.45	217.00	VERO	100.00	0.46	10/ 4/88
AVS-4418	CPE	SF	----	----	VERO	32.00	----	10/ 4/88
AVS-4418	CPE	VEE	----	----	VERO	32.00	----	10/ 4/88
AVS-4418	CPE	YFV	----	----	VERO	100.00	----	10/ 4/88
AVS-4419	CPE	JE	----	----	VERO	3.20	----	10/ 5/88
AVS-4419	CPE	PT	----	----	VERO	10.00	----	10/ 5/88
AVS-4419	CPE	SF	----	----	VERO	10.00	----	10/ 5/88
AVS-4419	CPE	VEE	----	----	VERO	10.00	----	10/ 5/88
AVS-4419	CPE	YFV	----	----	VERO	10.00	----	10/ 5/88
AVS-4420	CPE	JE	----	----	VERO	10.00	----	10/ 5/88
AVS-4420	CPE	PT	----	----	VERO	32.00	----	10/ 5/88
AVS-4420	CPE	SF	1.05	26.10	VERO	32.00	1.22	10/ 5/88
AVS-4420	CPE	VEE	----	----	VERO	100.00	----	10/ 5/88
AVS-4420	CPE	YFV	----	----	VERO	10.00	----	10/ 5/88
AVS-4422	CPE	JE	----	----	VERO	32.00	----	10/ 5/88
AVS-4422	CPE	PT	----	----	VERO	100.00	----	10/ 5/88
AVS-4422	CPE	SF	----	----	VERO	100.00	----	10/ 5/88
AVS-4422	CPE	VEE	----	----	VERO	320.00	----	10/ 5/88
AVS-4422	CPE	YFV	----	----	VERO	100.00	----	10/ 5/88
AVS-4423	CPE	JE	----	----	VERO	10.00	----	10/ 5/88
AVS-4423	CPE	PT	0.05	----	VERO	32.00	----	10/ 5/88
AVS-4423	CPE	SF	0.5	69.80	VERO	32.00	0.46	10/ 5/88
AVS-4423	CPE	VEE	----	----	VERO	32.00	----	10/ 5/88
AVS-4423	CPE	YFV	----	----	VERO	32.00	----	10/ 5/88
AVS-4424	CPE	JE	----	----	VERO	32.00	----	10/11/88
AVS-4424	CPE	PT	1.05	68.80	VERO	100.00	1.45	10/11/88
AVS-4424	CPE	VEE	----	----	VERO	100.00	----	10/11/88
AVS-4424	CPE	YFV	0.2	----	VERO	32.00	----	10/11/88
AVS-4425	CPE	JE	0.15	----	VERO	3.20	----	10/11/88

B-233

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4425	CPE	PT	0.15	----	VERO <	1.00	----	10/11/88
AVS-4425	CPE	VEE	----	----	VERO	10.00	----	10/11/88
AVS-4425	CPE	YFV	----	----	VERO	10.00	----	10/11/88
AVS-4426	CPE	JE	0.1	----	VERO	32.00	----	10/11/88
AVS-4426	CPE	PT	0.65	178.00	VERO	100.00	0.56	10/11/88
AVS-4426	CPE	VEE	0.3	----	VERO	100.00	----	10/11/88
AVS-4426	CPE	YFV	----	----	VERO	100.00	----	10/11/88
AVS-4427	CPE	JE	0.2	----	VERO	3.20	----	10/11/88
AVS-4427	CPE	PT	----	----	VERO	10.00	----	10/11/88
AVS-4427	CPE	VEE	----	----	VERO	10.00	----	10/11/88
AVS-4427	CPE	YFV	----	----	VERO	10.00	----	10/11/88
AVS-4428	CPE	JE	----	----	VERO	10.00	----	10/12/88
AVS-4428	CPE	PT	----	----	VERO	10.00	----	10/12/88
AVS-4428	CPE	SF	1.5	5.90	VERO	10.00	1.68	10/12/88
AVS-4428	CPE	VEE	----	----	VERO	10.00	----	10/12/88
AVS-4429	CPE	JE	----	----	VERO	10.00	----	10/12/88
AVS-4429	CPE	PT	0.45	6.80	VERO	10.00	1.46	10/12/88
AVS-4429	CPE	SF	0.55	5.90	VERO	3.20	0.54	10/12/88
AVS-4429	CPE	VEE	----	----	VERO	10.00	----	10/12/88
AVS-4430	CPE	JE	----	----	VERO	100.00	----	10/12/88
AVS-4430	CPE	PT	----	----	VERO	320.00	----	10/12/88
AVS-4430	CPE	SF	----	----	VERO	100.00	----	10/12/88
AVS-4430	CPE	VEE	----	----	VERO	100.00	----	10/12/88
AVS-4431	CPE	JE	----	----	VERO	32.00	----	10/12/88
AVS-4431	CPE	PT	0.05	----	VERO	32.00	----	10/12/88
AVS-4431	CPE	SF	0.8	71.40	VERO	32.00	0.45	10/12/88
AVS-4431	CPE	VEE	----	----	VERO	100.00	----	10/12/88
AVS-4511	CPE	AD2	0.3	----	HEP2	32.00	----	10/ 6/88
AVS-4526	CPE	AD2	0.2	----	HEP2 >	320.00	----	6/23/88
AVS-4526	CPE	JE	0.15	----	VERO	100.00	----	7/26/88
AVS-4526	CPE	PT	----	----	VERO	320.00	----	7/26/88
AVS-4526	CPE	SF	----	----	VERO	320.00	----	7/26/88
AVS-4526	CPE	VEE	----	----	VERO	32.00	----	7/26/88
AVS-4526	CPE	VSV	----	----	L929 >	320.00	----	6/28/88
AVS-4526	CPE	VV	----	----	VERO >	320.00	----	6/23/88
AVS-4526	CPE	YFV	----	----	VERO >	320.00	----	7/26/88
AVS-4528	CPE	AD2	----	----	HEP2 >	320.00	----	6/23/88
AVS-4528	CPE	JE	----	----	VERO	320.00	----	7/26/88
AVS-4528	CPE	PT	----	----	VERO >	320.00	----	7/26/88
AVS-4528	CPE	SF	0.1	----	VERO >	320.00	----	7/26/88
AVS-4528	CPE	VEE	----	----	VERO	32.00	----	7/26/88
AVS-4528	CPE	VSV	----	----	L929 >	320.00	----	6/28/88
AVS-4528	CPE	VV	----	----	VERO >	320.00	----	6/23/88
AVS-4528	CPE	YFV	0.1	----	VERO >	320.00	----	7/26/88
AVS-4529	CPE	AD2	----	----	HEP2 <	320.00	----	6/23/88
AVS-4529	CPE	JE	0.1	----	VERO	100.00	----	7/26/88
AVS-4529	CPE	PT	0.05	----	VERO	100.00	----	7/26/88
AVS-4529	CPE	SF	0.85	117.00	VERO	100.00	0.85	7/26/88
AVS-4529	CPE	VEE	----	----	VERO	32.00	----	7/26/88
AVS-4529	CPE	VSV	----	----	L929	320.00	----	6/28/88
AVS-4529	CPE	VV	0.65	200.00	VERO	100.00	0.50	6/23/88
AVS-4529	CPE	YFV	----	----	VERO	320.00	----	7/26/88
AVS-4530	CPE	AD2	1.8	27.00	HEP2 <	320.00 <	11.80	6/23/88
AVS-4530	CPE	AD2	1.6	94.50	HEP2	100.00	1.05	6/30/88
AVS-4530	CPE	JE	1.2	----	VERO	100.00	----	7/26/88
AVS-4530	CPE	PT	----	----	VERO	100.00	----	7/26/88
AVS-4530	CPE	SF	0.6	----	VERO	320.00	----	7/26/88
AVS-4530	CPE	VEE	----	----	VERO	100.00	----	7/26/88
AVS-4530	CPE	VSV	----	----	L929	32.00	----	6/28/88
AVS-4530	CPE	VV	5.9	1.21	VERO	320.00	263.00	6/23/88
AVS-4530	CPE	VV	7.2	0.45	VERO >	320.00 >	708.00	6/30/88
AVS-4530	CPE	YFV	----	----	VERO	320.00	----	7/26/88
AVS-4531	CPE	AD2	----	----	HEP2 >	320.00	----	6/23/88
AVS-4531	CPE	JE	0.5	----	VERO	100.00	----	7/27/88
AVS-4531	CPE	PT	----	----	VERO >	320.00	----	7/27/88

8-234

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4531	CPE	SF	----	----	VERO >	320.00	----	7/27/88
AVS-4531	CPE	VEE	----	----	VERO	320.00	----	7/27/88
AVS-4531	CPE	VSV	----	----	L929 >	320.00	----	6/28/88
AVS-4531	CPE	VV	1.35	110.00	VERO	320.00	2.90	6/23/88
AVS-4531	CPE	VV	2.	88.60	VERO >	320.00 >	3.61	7/ 7/88
AVS-4531	CPE	YFV	0.85	----	VERO >	320.00	----	7/27/88
AVS-4532	CPE	AD2	----	----	HEP2	320.00	----	6/23/88
AVS-4532	CPE	JE	----	----	VERO	320.00	----	7/27/88
AVS-4532	CPE	PT	----	----	VERO >	320.00	----	7/27/88
AVS-4532	CPE	SF	0.35	270.00	VERO	100.00	0.37	7/27/88
AVS-4532	CPE	VEE	----	----	VERO	100.00	----	7/27/88
AVS-4532	CPE	VSV	----	----	L929	320.00	----	6/28/88
AVS-4532	CPE	VV	1.65	103.00	VERO	320.00	3.09	6/23/88
AVS-4532	CPE	VV	1.35	100.00	VERO	320.00	3.19	7/ 7/88
AVS-4532	CPE	YFV	0.4	----	VERO	100.00	----	7/27/88
AVS-4533	CPE	AD2	0.15	----	HEP2	100.00	----	6/23/88
AVS-4533	CPE	JE	1.	60.80	VERO	100.00	1.64	7/27/88
AVS-4533	CPE	PT	0.15	----	VERO	100.00	----	7/27/88
AVS-4533	CPE	SF	0.45	217.00	VERO	32.00	0.15	7/27/88
AVS-4533	CPE	VEE	----	----	VERO	32.00	----	7/27/88
AVS-4533	CPE	VSV	----	----	L929	320.00	----	6/28/88
AVS-4533	CPE	VV	9.2	0.10	VERO >	320.00 >	3010.00	7/ 7/88
AVS-4533	CPE	VV	8.	0.16	VERO	320.00	1930.00	7/21/88
AVS-4533	CPE	YFV	1.8	94.60	VERO	320.00	3.38	7/27/88
AVS-4534	CPE	JE	----	----	VERO	10.00	----	8/ 9/88
AVS-4534	CPE	PT	----	----	VERO	10.00	----	8/ 9/88
AVS-4534	CPE	SF	0.4	31.40	VERO	3.20	0.10	8/ 9/88
AVS-4536	CPE	JE	----	----	VERO	10.00	----	8/ 9/88
AVS-4536	CPE	PT	----	----	VERO	10.00	----	8/ 9/88
AVS-4536	CPE	SF	----	----	VERO	10.00	----	8/ 9/88
AVS-4537	CPE	JE	----	----	VERO	32.00	----	8/ 9/88
AVS-4537	CPE	PT	----	----	VERO	100.00	----	8/ 9/88
AVS-4537	CPE	SF	----	----	VERO	100.00	----	8/ 9/88
AVS-4550	CPE	JE	----	----	VERO	320.00	----	8/ 9/88
AVS-4550	CPE	PT	----	----	VERO	320.00	----	8/ 9/88
AVS-4550	CPE	SF	----	----	VERO	320.00	----	8/ 9/88
AVS-4551	CPE	JE	----	----	VERO	100.00	----	8/ 9/88
AVS-4551	CPE	PT	----	----	VERO	100.00	----	8/ 9/88
AVS-4551	CPE	SF	----	----	VERO	10.00	----	8/ 9/88
AVS-4553	CPE	JE	----	----	VERO	100.00	----	8/ 9/88
AVS-4553	CPE	PT	----	----	VERO	100.00	----	8/ 9/88
AVS-4553	CPE	SF	0.05	----	VERO	100.00	----	8/ 9/88
AVS-4554	CPE	JE	0.1	----	VERO	32.00	----	8/ 9/88
AVS-4554	CPE	PT	0.6	70.80	VERO	100.00	1.41	8/ 9/88
AVS-4554	CPE	SF	0.05	----	VERO	32.00	----	8/ 9/88
AVS-4561	CPE	JE	0.05	----	VERO	100.00	----	8/ 9/88
AVS-4561	CPE	PT	----	----	VERO	100.00	----	8/ 9/88
AVS-4561	CPE	SF	----	----	VERO	320.00	----	8/ 9/88
AVS-4569	CPE	JE	0.04	----	VERO	32.00	----	8/ 9/88
AVS-4569	CPE	PT	----	----	VERO	32.00	----	8/ 9/88
AVS-4569	CPE	SF	----	----	VERO	32.00	----	8/ 9/88
AVS-4573	CPE	JE	0.71	152.00	VERO	10.00	0.07	8/ 9/88
AVS-4573	CPE	PT	1.05	26.10	VERO	3.20	0.12	8/ 9/88
AVS-4573	CPE	SF	0.85	24.50	VERO	1.00	0.04	8/ 9/88
AVS-4574	CPE	JE	0.02	----	VERO	3.20	----	8/ 9/88
AVS-4574	CPE	PT	----	----	VERO	1.00	----	8/ 9/88
AVS-4574	CPE	SF	0.25	----	VERO <	0.32	----	8/ 9/88
AVS-4575	CPE	JE	----	----	VERO	10.00	----	8/ 9/88
AVS-4575	CPE	PT	----	----	VERO	32.00	----	8/ 9/88
AVS-4575	CPE	SF	0.2	----	VERO	100.00	----	8/ 9/88
AVS-4576	CPE	JE	----	----	VERO	32.00	----	8/ 9/88
AVS-4576	CPE	PT	1.7	17.10	VERO	32.00	1.86	8/ 9/88
AVS-4576	CPE	SF	0.7	100.00	VERO	10.00	0.10	8/ 9/88
AVS-4582	CPE	JE	----	----	VERO	32.00	----	8/ 9/88
AVS-4582	CPE	PT	----	----	VERO	100.00	----	8/ 9/88

B-235

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4582	CPE	SF	----	----	VERO	32.00	----	8/ 9/88
AVS-4585	CPE	JE	----	----	VERO	100.00	----	8/ 9/88
AVS-4585	CPE	PT	----	----	VERO	100.00	----	8/ 9/88
AVS-4585	CPE	SF	0.55	222.00	VERO	320.00	1.44	8/ 9/88
AVS-4586	CPE	JE	----	----	VERO	10.00	----	8/ 9/88
AVS-4586	CPE	PT	----	----	VERO	32.00	----	8/ 9/88
AVS-4586	CPE	SF	----	----	VERO	32.00	----	8/ 9/88
AVS-4587	CPE	AD2	----	----	HEP2 >	320.00	----	6/23/88
AVS-4587	CPE	JE	----	----	VERO >	320.00	----	7/27/88
AVS-4587	CPE	PT	----	----	VERO >	320.00	----	7/27/88
AVS-4587	CPE	SF	----	----	VERO	100.00	----	7/27/88
AVS-4587	CPE	VEE	----	----	VERO >	320.00	----	7/27/88
AVS-4587	CPE	VSV	----	----	L929 >	320.00	----	6/28/88
AVS-4587	CPE	VV	----	----	VERO >	320.00	----	6/23/88
AVS-4587	CPE	YFV	1.	----	VERO >	320.00	----	7/27/88
AVS-4588	CPE	AD2	----	----	HEP2 <	100.00	----	6/23/88
AVS-4588	CPE	JE	0.3	----	VERO	32.00	----	7/27/88
AVS-4588	CPE	PT	0.45	68.30	VERO	32.00	0.47	7/27/88
AVS-4588	CPE	SF	0.45	68.30	VERO	32.00	0.47	7/27/88
AVS-4588	CPE	VEE	----	----	VERO	32.00	----	7/27/88
AVS-4588	CPE	VSV	----	----	L929 >	320.00	----	6/28/88
AVS-4588	CPE	VV	1.	59.50	VERO	32.00	0.54	6/23/88
AVS-4588	CPE	VV	1.1	96.00	VERO	100.00	1.03	7/ 7/88
AVS-4588	CPE	YFV	0.4	----	VERO	32.00	----	7/27/88
AVS-4589	CPE	AD2	----	----	HEP2	32.00	----	6/23/88
AVS-4589	CPE	JE	----	----	VERO	32.00	----	7/27/88
AVS-4589	CPE	PT	----	----	VERO	100.00	----	7/27/88
AVS-4589	CPE	SF	----	----	VERO	100.00	----	7/27/88
AVS-4589	CPE	VEE	----	----	VERO	32.00	----	7/27/88
AVS-4589	CPE	VSV	----	----	L929	100.00	----	6/28/88
AVS-4589	CPE	VV	----	----	VERO <	10.00	----	6/23/88
AVS-4589	CPE	YFV	0.3	----	VERO	100.00	----	7/27/88
AVS-4590	CPE	JE	1.88	0.89	VERO	3.20	3.56	7/27/88
AVS-4590	CPE	PT	0.45	6.80	VERO	3.20	0.47	7/27/88
AVS-4590	CPE	SF	0.65	5.30	VERO	3.20	0.60	7/27/88
AVS-4590	CPE	YFV	1.9	1.40	VERO	3.20	2.28	7/27/88
AVS-4592	CPE	AD2	----	----	HEP2 <	32.00	----	6/30/88
AVS-4592	CPE	JE	2.05	3.39	VERO	32.00	9.43	7/27/88
AVS-4592	CPE	PT	0.45	21.70	VERO	32.00	1.47	7/27/88
AVS-4592	CPE	SF	1.05	26.10	VERO	10.00	0.38	7/27/88
AVS-4592	CPE	VEE	----	----	VERO	10.00	----	7/27/88
AVS-4592	CPE	VSV	----	----	L929 >	10.00	----	6/28/88
AVS-4592	CPE	VV	0.5	70.90	VERO	32.00	0.45	6/30/88
AVS-4592	CPE	YFV	2.4	3.15	VERO	32.00	10.10	7/27/88
AVS-4598	CPE	AD2	----	----	HEP2 <	1.00	----	6/23/88
AVS-4598	CPE	JE	----	----	VERO <	1.00	----	7/27/88
AVS-4598	CPE	PT	----	----	VERO <	0.32	----	7/27/88
AVS-4598	CPE	VEE	----	----	VERO	1.00	----	7/27/88
AVS-4598	CPE	VSV	----	----	L929	10.00	----	6/28/88
AVS-4598	CPE	VV	----	----	VERO <	0.32	----	6/23/88
AVS-4600	CPE	AD2	0.3	----	HEP2 <	100.00	----	7/21/88
AVS-4600	CPE	JE	----	----	VERO	10.00	----	8/10/88
AVS-4600	CPE	PT	1.	27.90	VERO	32.00	1.14	8/10/88
AVS-4600	CPE	SF	1.55	5.00	VERO	10.00	1.98	8/10/88
AVS-4600	CPE	VEE	----	----	VERO	32.00	----	8/10/88
AVS-4600	CPE	VSV	----	----	L929	100.00	----	7/20/88
AVS-4600	CPE	VV	1.15	35.60	VERO	100.00	2.80	7/21/88
AVS-4600	CPE	YFV	0.5	72.80	VERO	10.00	0.14	8/10/88
AVS-4600	CPE	YFV	0.5	72.80	VERO	10.00	0.14	8/10/88
AVS-4601	CPE	AD2	----	----	HEP2 >	320.00	----	7/21/88
AVS-4601	CPE	JE	----	----	VERO >	320.00	----	8/10/88
AVS-4601	CPE	PT	----	----	VERO >	320.00	----	8/10/88
AVS-4601	CPE	SF	----	----	VERO >	320.00	----	8/10/88
AVS-4601	CPE	VEE	----	----	VERO	100.00	----	8/10/88
AVS-4601	CPE	VSV	----	----	L929	320.00	----	7/20/88

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4601	CPE	VV	----	----	VERO >	320.00	----	7/21/88
AVS-4601	CPE	YFV	0.4	----	VERO >	320.00	----	8/10/88
AVS-4602	CPE	AD2	----	----	HEP2 >	320.00	----	7/21/88
AVS-4602	CPE	JE	----	----	VERO	320.00	----	8/10/88
AVS-4602	CPE	PT	----	----	VERO >	320.00	----	8/10/88
AVS-4602	CPE	SF	----	----	VERO >	320.00	----	8/10/88
AVS-4602	CPE	VEE	----	----	VERO	32.00	----	8/10/88
AVS-4602	CPE	VSV	----	----	L929 >	320.00	----	7/20/88
AVS-4602	CPE	VV	----	----	VERO >	320.00	----	7/21/88
AVS-4602	CPE	YFV	0.1	----	VERO >	320.00	----	8/10/88
AVS-4603	CPE	AD2	----	----	HEP2 >	320.00	----	7/21/88
AVS-4603	CPE	JE	----	----	VERO >	320.00	----	8/10/88
AVS-4603	CPE	PT	----	----	VERO	320.00	----	8/10/88
AVS-4603	CPE	SF	----	----	VERO >	320.00	----	8/10/88
AVS-4603	CPE	VEE	----	----	VERO	320.00	----	8/10/88
AVS-4603	CPE	VSV	----	----	L929 >	320.00	----	7/20/88
AVS-4603	CPE	VV	----	----	VERO >	320.00	----	7/21/88
AVS-4603	CPE	YFV	----	----	VERO >	320.00	----	8/10/88
AVS-4604	CPE	AD2	----	----	HEP2 >	320.00	----	7/21/88
AVS-4604	CPE	JE	----	----	VERO >	320.00	----	8/10/88
AVS-4604	CPE	PT	----	----	VERO	320.00	----	8/10/88
AVS-4604	CPE	SF	----	----	VERO	320.00	----	8/10/88
AVS-4604	CPE	VEE	----	----	VERO	10.00	----	8/10/88
AVS-4604	CPE	VSV	----	----	L929 >	320.00	----	7/20/88
AVS-4604	CPE	VV	----	----	VERO >	320.00	----	7/21/88
AVS-4604	CPE	YFV	0.2	----	VERO >	320.00	----	8/10/88
AVS-4605	CPE	AD2	----	----	HEP2	100.00	----	8/18/88
AVS-4605	CPE	JE	----	----	VERO	100.00	----	8/10/88
AVS-4605	CPE	PT	----	----	VERO	320.00	----	8/10/88
AVS-4605	CPE	SF	----	----	VERO	320.00	----	8/10/88
AVS-4605	CPE	VEE	----	----	VERO	32.00	----	8/10/88
AVS-4605	CPE	VSV	----	----	L929	320.00	----	7/20/88
AVS-4605	CPE	VV	----	----	VERO	320.00	----	8/18/88
AVS-4605	CPE	YFV	----	----	VERO	100.00	----	8/10/88
AVS-4606	CPE	AD2	----	----	HEP2 >	320.00	----	8/18/88
AVS-4606	CPE	JE	----	----	VERO	100.00	----	8/10/88
AVS-4606	CPE	PT	----	----	VERO	32.00	----	8/10/88
AVS-4606	CPE	SF	0.15	----	VERO	100.00	----	8/10/88
AVS-4606	CPE	VEE	----	----	VEDR	100.00	----	8/10/88
AVS-4606	CPE	VSV	----	----	L929 >	320.00	----	7/20/88
AVS-4606	CPE	VV	----	----	VERO >	320.00	----	8/18/88
AVS-4606	CPE	YFV	0.2	----	VERO	320.00	----	8/10/88
AVS-4607	CPE	AD2	----	----	HEP2 <	32.00	----	7/21/88
AVS-4607	CPE	JE	----	----	VERO	3.20	----	8/10/88
AVS-4607	CPE	PT	0.15	----	VERO	10.00	----	8/10/88
AVS-4607	CPE	SF	0.55	3.20	VERO	3.20	1.00	8/10/88
AVS-4607	CPE	VEE	----	----	VERO	10.00	----	8/10/88
AVS-4607	CPE	VSV	0.2	----	L929	32.00	----	7/20/88
AVS-4607	CPE	VV	----	----	VERO <	32.00	----	7/21/88
AVS-4607	CPE	YFV	0.1	----	VERO	10.00	----	8/10/88
AVS-4608	CPE	AD2	----	----	HEP2 <	100.00	----	7/21/88
AVS-4608	CPE	JE	----	----	VERO	10.00	----	8/10/88
AVS-4608	CPE	PT	0.65	15.70	VERO	10.00	0.63	8/10/88
AVS-4608	CPE	SF	0.95	8.70	VERO	10.00	1.14	8/10/88
AVS-4608	CPE	VEE	----	----	VERO	10.00	----	8/10/88
AVS-4608	CPE	VSV	0.25	----	L929	32.00	----	7/20/88
AVS-4608	CPE	VV	----	----	VERO	32.00	----	7/21/88
AVS-4608	CPE	YFV	0.65	----	VERO	32.00	----	8/10/88
AVS-4609	CPE	AD2	1.	0.40	HEP2	1.00	2.48	7/21/88
AVS-4610	CPE	AD2	----	----	HEP2 >	320.00	----	7/21/88
AVS-4610	CPE	JE	----	----	VERO	3.20	----	8/10/88
AVS-4610	CPE	PT	----	----	VERO	3.20	----	8/10/88
AVS-4610	CPE	SF	----	----	VERO	3.20	----	8/10/88
AVS-4610	CPE	VEE	----	----	VERO	100.00	----	8/10/88
AVS-4610	CPE	VSV	----	----	L929	320.00	----	7/20/88

B-237

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-4610	CPE	VV	----	----	VERO >	320.00	----	7/21/88
AVS-4611	CPE	AD2	0.3	----	HEP2 >	320.00	----	7/21/88
AVS-4611	CPE	JE	----	----	VERO	10.00	----	8/10/88
AVS-4611	CPE	PT	2.1	8.90	VERO	10.00	1.11	8/10/88
AVS-4611	CPE	SF	1.75	7.70	VERO	10.00	1.28	8/10/88
AVS-4611	CPE	VEE	----	----	VERO	32.00	----	8/10/88
AVS-4611	CPE	VSV	----	----	L929	10.00	----	7/20/88
AVS-4611	CPE	VV	----	----	VERO	100.00	----	7/21/88
AVS-4611	CPE	YFV	1.95	3.17	VERO	3.20	1.00	8/10/88
AVS-4612	CPE	AD2	0.3	----	HEP2 <	320.00	----	8/18/88
AVS-4612	CPE	JE	----	----	VERO	100.00	----	8/10/88
AVS-4612	CPE	PT	----	----	VERO	100.00	----	8/10/88
AVS-4612	CPE	SF	0.25	----	VERO	100.00	----	8/10/88
AVS-4612	CPE	VEE	----	----	VERO	100.00	----	8/10/88
AVS-4612	CPE	VSV	----	----	L929	100.00	----	7/20/88
AVS-4612	CPE	VV	0.6	178.00	VERO	320.00	1.78	8/18/88
AVS-4612	CPE	YFV	----	----	VERO	320.00	----	8/10/88
AVS-4613	CPE	AD2	----	----	HEP2	32.00	----	8/18/88
AVS-4613	CPE	JE	----	----	VERO	100.00	----	8/10/88
AVS-4613	CPE	PT	0.6	178.00	VERO	32.00	0.18	8/10/88
AVS-4613	CPE	SF	0.55	62.90	VERO	32.00	0.51	8/10/88
AVS-4613	CPE	VEE	0.15	----	VERO	32.00	----	8/10/88
AVS-4613	CPE	VSV	----	----	L929	100.00	----	7/20/88
AVS-4613	CPE	VV	0.55	69.80	VERO	100.00	1.43	8/18/88
AVS-4613	CPE	YFV	----	----	VERO	32.00	----	8/10/88
AVS-4614	CPE	AD2	----	----	HEP2	100.00	----	7/21/83
AVS-4614	CPE	JE	----	----	VERO	100.00	----	8/10/88
AVS-4614	CPE	PT	----	----	VERO	100.00	----	8/10/88
AVS-4614	CPE	SF	0.3	320.00	VERO	100.00	0.31	8/10/88
AVS-4614	CPE	VEE	----	----	VERO	32.00	----	8/1/88
AVS-4614	CPE	VSV	----	----	L929	320.00	----	7/20/88
AVS-4614	CPE	VV	0.1	----	VERO	100.00	----	7/21/88
AVS-4614	CPE	YFV	----	----	VERO	100.00	----	8/10/88
AVS-4615	CPE	AD2	----	----	HEP2 >	320.00	----	7/21/88
AVS-4615	CPE	JE	----	----	VERO	32.00	----	8/16/88
AVS-4615	CPE	PT	0.6	178.00	VERO	320.00	1.78	8/16/88
AVS-4615	CPE	SF	0.6	178.00	VERO	100.00	0.56	8/16/88
AVS-4615	CPE	VEE	----	----	VERO	320.00	----	8/16/88
AVS-4615	CPE	VSV	----	----	L929	320.00	----	7/20/88
AVS-4615	CPE	VV	0.6	----	VERO <	320.00	----	7/21/88
AVS-4615	CPE	YFV	0.62	----	VERO	320.00	----	8/16/88
AVS-4617	CPE	AD2	----	----	HEP2 >	320.00	----	7/21/88
AVS-4617	CPE	JE	----	----	VERO >	240.00	----	8/16/88
AVS-4617	CPE	PT	----	----	VERO >	240.00	----	8/16/88
AVS-4617	CPE	SF	----	----	VERO	240.00	----	8/16/88
AVS-4617	CPE	VEE	----	----	VERO >	240.00	----	8/16/88
AVS-4617	CPE	VSV	----	----	L929 >	320.00	----	7/20/88
AVS-4617	CPE	VV	----	----	VERO >	320.00	----	7/21/88
AVS-4617	CPE	YFV	0.12	----	VERO	240.00	----	8/16/88
AVS-4618	CPE	AD2	----	----	HEP2 <	100.00	----	7/21/88
AVS-4618	CPE	JE	----	----	VERO	240.00	----	8/16/88
AVS-4618	CPE	PT	----	----	VERO	240.00	----	8/16/88
AVS-4618	CPE	SF	0.2	----	VERO	75.00	----	8/16/88
AVS-4618	CPE	VEE	----	----	VERO	240.00	----	8/16/88
AVS-4618	CPE	VSV	0.4	239.00	L929	320.00	1.33	7/20/88
AVS-4618	CPE	VV	0.45	306.00	VERO	100.00	0.33	7/21/88
AVS-4618	CPE	YFV	----	----	VERO	240.00	----	8/16/88
AVS-4619	CPE	AD2	----	----	HEP2 >	320.00	----	7/21/88
AVS-4619	CPE	JE	----	----	VERO	240.00	----	8/16/88
AVS-4619	CPE	PT	----	----	VERO	240.00	----	8/16/88
AVS-4619	CPE	SF	----	----	VERO >	240.00	----	8/16/88
AVS-4619	CPE	VEE	----	----	VERO >	240.00	----	8/16/88
AVS-4619	CPE	VSV	----	----	L929 >	320.00	----	7/20/88
AVS-4619	CPE	VV	6.	1.76	VERO >	320.00 >	180.00	7/21/88
AVS-4619	CPE	VV	6.	1.76	VERO >	320.00 >	180.00	8/18/88

B-238

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4619	CPE	YFV	----	----	VERO	75.00	----	8/16/88
AVS-4620	CPE	AD2	----	----	HEP2 >	320.00	----	7/21/88
AVS-4620	CPE	JE	----	----	VERO >	240.00	----	8/16/88
AVS-4620	CPE	PT	----	----	VERO	240.00	----	8/16/88
AVS-4620	CPE	SF	----	----	VERO >	240.00	----	8/16/88
AVS-4620	CPE	VEE	----	----	VERO >	240.00	----	8/16/88
AVS-4620	CPE	VSV	----	----	L929 >	320.00	----	7/20/88
AVS-4620	CPE	VV	6.1	1.54	VERO >	320.00 >	206.00	7/21/88
AVS-4620	CPE	VV	6.1	1.83	VERO >	320.00 >	174.00	8/18/88
AVS-4620	CPE	YFV	----	----	VERO >	240.00	----	8/16/88
AVS-4621	CPE	AD2	----	----	HEP2 >	320.00	----	7/21/88
AVS-4621	CPE	JE	----	----	VERO	240.00	----	8/16/88
AVS-4621	CPE	PT	----	----	VERO >	240.00	----	8/16/88
AVS-4621	CPE	SF	----	----	VERO >	240.00	----	8/16/88
AVS-4621	CPE	VEE	----	----	VERO >	240.00	----	8/16/88
AVS-4621	CPE	VSV	----	----	L929 >	320.00	----	7/20/88
AVS-4621	CPE	VV	5.9	1.99	VERO >	320.00 >	160.00	7/21/88
AVS-4621	CPE	VV	6.	1.76	VERO >	320.00 >	180.00	8/18/88
AVS-4621	CPE	YFV	----	----	VERO >	240.00	----	8/16/88
AVS-4622	CPE	AD2	----	----	HEP2 >	320.00	----	7/21/88
AVS-4622	CPE	JE	----	----	VERO	240.00	----	8/16/88
AVS-4622	CPE	PT	----	----	VERO	240.00	----	8/16/88
AVS-4622	CPE	SF	----	----	VERO >	240.00	----	8/16/88
AVS-4622	CPE	VEE	----	----	VERO >	240.00	----	8/16/88
AVS-4622	CPE	VSV	----	----	L929 >	320.00	----	7/20/88
AVS-4622	CPE	VV	5.6	2.79	VERO >	320.00 >	114.00	7/21/88
AVS-4622	CPE	VV	6.	1.76	VERO >	320.00 >	180.00	8/18/88
AVS-4622	CPE	YFV	----	----	VERO >	240.00	----	8/16/88
AVS-4623	CPE	AD2	----	----	HEP2 <	320.00	----	7/21/88
AVS-4623	CPE	JE	0.2	----	VERO	75.00	----	8/16/88
AVS-4623	CPE	PT	----	----	VERO	75.00	----	8/16/88
AVS-4623	CPE	SF	----	----	VERO	75.00	----	8/16/88
AVS-4623	CPE	VEE	----	----	VERO	240.00	----	8/16/88
AVS-4623	CPE	VSV	----	----	L929	320.00	----	7/20/88
AVS-4623	CPE	VV	0.6	178.00	VERO	100.00	0.56	7/21/88
AVS-4623	CPE	YFV	0.2	----	VERO >	240.00	----	8/16/88
AVS-4624	CPE	AD2	----	----	HEP2	32.00	----	7/21/88
AVS-4624	CPE	JE	0.05	----	VERO	24.00	----	8/16/88
AVS-4624	CPE	PT	0.6	42.40	VERO	24.00	0.57	8/16/88
AVS-4624	CPE	SF	0.45	51.20	VERO	24.00	0.47	8/16/88
AVS-4624	CPE	VEE	0.15	----	VERO	24.00	----	8/16/88
AVS-4624	CPE	VSV	0.15	----	L929	100.00	----	7/20/88
AVS-4624	CPE	VV	0.2	----	VERO	32.00	----	7/21/88
AVS-4624	CPE	YFV	0.6	42.40	VERO	24.00	0.56	8/16/88
AVS-4627	CPE	JE	----	----	VERO	320.00	----	8/17/88
AVS-4627	CPE	PT	----	----	VERO >	320.00	----	8/17/88
AVS-4627	CPE	SF	----	----	VERO	320.00	----	8/17/88
AVS-4628	CPE	JE	----	----	VERO	3.20	----	8/17/88
AVS-4628	CPE	PT	0.3	320.00	VERO	100.00	0.31	8/17/88
AVS-4628	CPE	SF	0.45	217.00	VERO	100.00	0.46	8/17/88
AVS-4634	CPE	JE	----	----	VERO <	0.32	----	8/17/88
AVS-4634	CPE	PT	0.55	2.21	VERO	3.20	1.44	8/17/88
AVS-4634	CPE	SF	0.65	0.76	VERO	1.00	1.30	8/17/88
AVS-4636	CPE	JE	----	----	VERO	32.00	----	8/17/88
AVS-4636	CPE	PT	1.	55.00	VERO	10.00	0.18	8/17/88
AVS-4636	CPE	SF	0.45	217.00	VERO	3.20	0.01	8/17/88
AVS-4637	CPE	JE	0.15	----	VERO	3.20	----	8/17/88
AVS-4637	CPE	PT	0.1	----	VERO	3.20	----	8/17/88
AVS-4637	CPE	SF	0.8	13.30	VERO	10.00	0.75	8/17/88
AVS-4638	CPE	JE	----	----	VERO >	320.00	----	8/17/88
AVS-4638	CPE	PT	----	----	VERO	100.00	----	8/17/88
AVS-4638	CPE	SF	0.2	----	VERO	320.00	----	8/17/88
AVS-4639	CPE	JE	0.4	----	VERO	32.00	----	8/17/88
AVS-4639	CPE	PT	----	----	VERO	3.20	----	8/17/88
AVS-4639	CPE	SF	0.75	35.90	VERO	32.00	0.89	8/17/88

8-239

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4640	CPE	JE	----	----	VERO	320.00	----	8/17/88
AVS-4640	CPE	PT	----	----	VERO	100.00	----	8/17/88
AVS-4640	CPE	SF	----	----	VERO	320.00	----	8/17/88
AVS-4641	CPE	JE	----	----	VERO	320.00	----	8/17/88
AVS-4641	CPE	PT	----	----	VERO	320.00	----	8/17/88
AVS-4641	CPE	SF	0.3	320.00	VERO	320.00	1.00	8/17/88
AVS-4642	CPE	JE	----	----	VERO	32.00	----	8/17/88
AVS-4642	CPE	PT	----	----	VERO	100.00	----	8/17/88
AVS-4642	CPE	SF	----	----	VERO	100.00	----	8/17/88
AVS-4643	CPE	JE	----	----	VERO	100.00	----	8/17/88
AVS-4643	CPE	PT	----	----	VERO	100.00	----	8/17/88
AVS-4643	CPE	SF	----	----	VERO	32.00	----	8/17/88
AVS-4645	CPE	JE	----	----	VERO	100.00	----	8/17/88
AVS-4645	CPE	PT	----	----	VERO	32.00	----	8/17/88
AVS-4645	CPE	SF	----	----	VERO	100.00	----	8/17/88
AVS-4647	CPE	JE	----	----	VERO	1.00	----	8/17/88
AVS-4647	CPE	PT	----	----	VERO	10.00	----	8/17/88
AVS-4647	CPE	SF	----	----	VERO	3.20	----	8/17/88
AVS-4648	CPE	JE	0.15	----	VERO	10.00	----	8/17/88
AVS-4648	CPE	PT	----	----	VERO	10.00	----	8/17/88
AVS-4648	CPE	SF	----	----	VERO	10.00	----	8/17/88
AVS-4649	CPE	JE	----	----	VERO	320.00	----	8/17/88
AVS-4649	CPE	PT	----	----	VERO >	320.00	----	8/17/88
AVS-4649	CPE	SF	----	----	VERO >	320.00	----	8/17/88
AVS-4651	CPE	JE	----	----	VERO	24.00	----	8/23/88
AVS-4651	CPE	PT	----	----	VERO	24.00	----	8/23/88
AVS-4651	CPE	SF	0.75	84.50	VERO	75.00	0.89	8/23/88
AVS-4652	CPE	JE	----	----	VERO	32.00	----	8/23/88
AVS-4652	CPE	PT	----	----	VERO	100.00	----	8/23/88
AVS-4652	CPE	SF	0.15	----	VERO	32.00	----	8/23/88
AVS-4654	CPE	JE	----	----	VERO	240.00	----	8/23/88
AVS-4654	CPE	PT	----	----	VERO	240.00	----	8/23/88
AVS-4654	CPE	SF	----	----	VERO	75.00	----	8/23/88
AVS-4655	CPE	JE	----	----	VERO >	240.00	----	8/23/88
AVS-4655	CPE	PT	----	----	VERO	240.00	----	8/23/88
AVS-4655	CPE	SF	0.15	----	VERO	75.00	----	8/23/88
AVS-4656	CPE	JE	----	----	VERO	240.00	----	8/23/88
AVS-4656	CPE	PT	----	----	VERO	240.00	----	8/23/88
AVS-4656	CPE	SF	----	----	VERO	240.00	----	8/23/88
AVS-4657	CPE	JE	----	----	VERO	75.00	----	8/23/88
AVS-4657	CPE	PT	0.15	----	VERO	24.00	----	8/23/88
AVS-4657	CPE	SF	0.55	166.00	VERO	240.00	1.44	8/23/88
AVS-4659	CPE	JE	----	----	VERO	240.00	----	8/23/88
AVS-4659	CPE	PT	----	----	VERO	75.00	----	8/23/88
AVS-4659	CPE	SF	----	----	VERO	75.00	----	8/23/88
AVS-4661	CPE	JE	----	----	VERO >	240.00	----	8/23/88
AVS-4661	CPE	PT	----	----	VERO >	240.00	----	8/23/88
AVS-4661	CPE	SF	----	----	VERO >	240.00	----	8/23/88
AVS-4662	CPE	JE	----	----	VERO	32.00	----	8/23/88
AVS-4662	CPE	PT	0.45	217.00	VERO	32.00	0.15	8/23/88
AVS-4662	CPE	SF	0.9	75.50	VERO	32.00	0.42	8/23/88
AVS-4663	CPE	JE	----	----	VERO	10.00	----	8/23/88
AVS-4663	CPE	PT	----	----	VERO	32.00	----	8/23/88
AVS-4663	CPE	SF	----	----	VERO	32.00	----	8/23/88
AVS-4664	CPE	JE	----	----	VERO	7.50	----	8/23/88
AVS-4664	CPE	PT	----	----	VERO	24.00	----	8/23/88
AVS-4664	CPE	SF	----	----	VERO	7.50	----	8/23/88
AVS-4665	CPE	JE	----	----	VERO	32.00	----	8/23/88
AVS-4665	CPE	PT	0.3	100.00	VERO	10.00	0.10	8/23/88
AVS-4665	CPE	SF	0.45	68.30	VERO	10.00	0.15	8/23/88
AVS-4666	CPE	JE	----	----	VERO	10.00	----	8/23/88
AVS-4666	CPE	PT	----	----	VERO	10.00	----	8/23/88
AVS-4666	CPE	SF	0.45	21.70	VERO	10.00	0.46	8/23/88
AVS-4667	CPE	JE	0.05	----	VERO	3.20	----	8/23/88
AVS-4667	CPE	PT	----	----	VERO	3.20	----	8/23/88

B-240

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4667	CPE	SF	0.5	6.90	VERO	3.20	0.46	8/23/88
AVS-4668	CPE	JE	----	----	VERO	10.00	----	8/23/88
AVS-4668	CPE	PT	----	----	VERO	10.00	----	8/23/88
AVS-4668	CPE	SF	----	----	VERO	10.00	----	8/23/88
AVS-4669	CPE	JE	----	----	VERO	100.00	----	8/24/88
AVS-4669	CPE	PT	----	----	VERO	100.00	----	8/24/88
AVS-4669	CPE	SF	0.15	----	VERO	100.00	----	8/24/88
AVS-4685	CPE	JE	----	----	VERO	100.00	----	8/24/88
AVS-4685	CPE	PT	----	----	VERO	320.00	----	8/24/88
AVS-4685	CPE	SF	----	----	VERO	100.00	----	8/24/88
AVS-4691	CPE	JE	----	----	VERO	24.00	----	8/24/88
AVS-4691	CPE	PT	----	----	VERO	24.00	----	8/24/88
AVS-4691	CPE	SF	----	----	VERO	24.00	----	8/24/88
AVS-4692	CPE	JE	0.15	----	VERO	240.00	----	8/24/88
AVS-4692	CPE	PT	----	----	VERO	75.00	----	8/24/88
AVS-4692	CPE	SF	----	----	VERO	75.00	----	8/24/88
AVS-4693	CPE	JE	0.15	----	VERO	24.00	----	8/24/88
AVS-4693	CPE	PT	----	----	VERO	75.00	----	8/24/88
AVS-4693	CPE	SF	----	----	VERO	24.00	----	8/24/88
AVS-4694	CPE	JE	----	----	VERO	240.00	----	8/24/88
AVS-4694	CPE	PT	----	----	VERO	240.00	----	8/24/88
AVS-4694	CPE	SF	----	----	VERO	240.00	----	8/24/88
AVS-4695	CPE	JE	----	----	VERO	240.00	----	8/24/88
AVS-4695	CPE	PT	----	----	VERO	240.00	----	8/24/88
AVS-4695	CPE	SF	----	----	VERO	240.00	----	8/24/88
AVS-4697	CPE	JE	----	----	VERO	32.00	----	8/24/88
AVS-4697	CPE	PT	0.1	----	VERO	100.00	----	8/24/88
AVS-4697	CPE	SF	0.75	46.70	VERO	72.00	0.68	8/24/88
AVS-4698	CPE	JE	----	----	VERO	320.00	----	8/24/88
AVS-4698	CPE	PT	----	----	VERO	320.00	----	8/24/88
AVS-4698	CPE	SF	0.2	----	VERO	320.00	----	8/24/88
AVS-4700	CPE	JE	----	----	VERO	240.00	----	8/24/88
AVS-4700	CPE	PT	----	----	VERO	240.00	----	8/24/88
AVS-4700	CPE	SF	----	----	VERO	240.00	----	8/24/88
AVS-4701	CPE	JE	----	----	VERO	75.00	----	8/24/88
AVS-4701	CPE	PT	----	----	VERO	240.00	----	8/24/88
AVS-4701	CPE	SF	0.1	----	VERO	75.00	----	8/24/88
AVS-4702	CPE	JE	----	----	VERO	24.00	----	8/24/88
AVS-4702	CPE	PT	----	----	VERO	24.00	----	8/24/88
AVS-4702	CPE	SF	0.42	164.00	VERO	7.50	0.05	8/24/88
AVS-4703	CPE	JE	----	----	VERO	32.00	----	8/24/88
AVS-4703	CPE	PT	----	----	VERO	100.00	----	8/24/88
AVS-4703	CPE	SF	0.7	114.00	VERO	100.00	0.88	8/24/88
AVS-4704	CPE	JE	----	----	VERO	32.00	----	8/24/88
AVS-4704	CPE	PT	----	----	VERO	100.00	----	8/24/88
AVS-4704	CPE	SF	0.55	180.00	VERO	100.00	0.55	8/24/88
AVS-4705	CPE	JE	----	----	VERO	75.00	----	8/24/88
AVS-4705	CPE	PT	----	----	VERO	240.00	----	8/24/88
AVS-4705	CPE	SF	----	----	VERO	24.00	----	8/24/88
AVS-4706	CPE	SF	0.35	270.00	VERO	320.00	1.18	8/30/88
AVS-4707	CPE	SF	----	----	VERO	32.00	----	8/30/88
AVS-4708	CPE	SF	0.45	217.00	VERO	100.00	0.46	8/30/88
AVS-4709	CPE	SF	1.05	83.00	VERO	32.00	0.38	8/30/88
AVS-4710	CPE	SF	----	----	VERO	100.00	----	8/31/88
AVS-4711	CPE	SF	0.9	75.20	VERO	100.00	1.32	8/31/88
AVS-4712	CPE	SF	----	----	VERO	32.00	----	8/31/88
AVS-4713	CPE	SF	----	----	VERO	10.00	----	8/31/88
AVS-4714	CPE	SF	0.45	217.00	VERO	32.00	0.15	9/ 7/88
AVS-4715	CPE	SF	0.75	112.00	VERO	32.00	0.28	9/ 7/88
AVS-4716	CPE	SF	0.15	----	VERO	10.00	----	9/ 7/88
AVS-4717	CPE	SF	----	----	VERO	320.00	----	9/ 7/88
AVS-4720	CPE	AD2	----	----	HEP2	320.00	----	8/18/88
AVS-4720	CPE	JE	----	----	VERO	32.00	----	8/16/88
AVS-4720	CPE	PT	0.1	----	VERO	100.00	----	8/16/88
AVS-4720	CPE	PT	0.15	----	VERO	32.00	----	9/13/88

B-241

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4720	CPE	SF	1.	121.00	VERO	100.00	0.82	8/16/88
AVS-4720	CPE	SF	2.95	1.84	VERO	10.00	5.41	9/13/88
AVS-4720	CPE	VEE	----	----	VERO >	320.00	----	8/16/88
AVS-4720	CPE	VEE	----	----	VERO	32.00	----	9/13/88
AVS-4720	CPE	VSV	----	----	L929	10.00	----	7/20/88
AVS-4720	CPE	VV	----	----	VERO	100.00	----	8/18/88
AVS-4720	CPE	YFV	----	----	VERO	100.00	----	8/16/88
AVS-4721	CPE	AD2	----	----	HEP2 <	100.00	----	8/18/88
AVS-4721	CPE	JE	----	----	VERO	10.00	----	8/16/88
AVS-4721	CPE	PT	----	----	VERO	32.00	----	8/16/88
AVS-4721	CPE	PT	----	----	VERO	3.20	----	9/13/88
AVS-4721	CPE	SF	0.2	----	VERO	32.00	----	8/16/88
AVS-4721	CPE	SF	1.1	26.10	VERO	3.20	0.12	9/13/88
AVS-4721	CPE	VEE	----	----	VERO	32.00	----	8/16/88
AVS-4721	CPE	VEE	----	----	VERO	10.00	----	9/13/88
AVS-4721	CPE	VSV	----	----	L929	10.00	----	7/20/88
AVS-4721	CPE	VV	0.65	56.50	VERO	100.00	1.76	8/18/88
AVS-4721	CPE	YFV	0.05	----	VERO	10.00	----	8/16/88
AVS-4722	CPE	AD2	----	----	HEP2 <	320.00	----	8/18/88
AVS-4722	CPE	JE	----	----	VERO	320.00	----	8/16/88
AVS-4722	CPE	PT	----	----	VERO	320.00	----	8/16/88
AVS-4722	CPE	PT	0.05	----	VERO	100.00	----	9/13/88
AVS-4722	CPE	SF	0.25	----	VERO	320.00	----	8/16/88
AVS-4722	CPE	SF	0.3	100.00	VERO	32.00	0.32	9/13/88
AVS-4722	CPE	VEE	----	----	VERO	320.00	----	8/16/88
AVS-4722	CPE	VEE	----	----	VERO	100.00	----	9/13/88
AVS-4722	CPE	VSV	----	----	L929	320.00	----	7/20/88
AVS-4722	CPE	VV	0.15	----	VERO	320.00	----	8/18/88
AVS-4722	CPE	YFV	----	----	VERO	320.00	----	8/16/88
AVS-4723	CPE	AD2	----	----	HEP2 <	100.00	----	8/18/88
AVS-4723	CPE	JE	----	----	VERO	100.00	----	8/16/88
AVS-4723	CPE	PT	----	----	VERO	100.00	----	8/16/88
AVS-4723	CPE	PT	----	----	VERO	32.00	----	9/13/88
AVS-4723	CPE	SF	----	----	VERO	100.00	----	8/16/88
AVS-4723	CPE	SF	0.75	241.00	VERO	32.00	0.13	9/13/88
AVS-4723	CPE	VEE	----	----	VERO	100.00	----	8/16/88
AVS-4723	CPE	VEE	----	----	VERO	100.00	----	9/13/88
AVS-4723	CPE	VSV	----	----	L929	100.00	----	7/20/88
AVS-4723	CPE	VV	0.3	----	VERO <	320.00	----	8/18/88
AVS-4723	CPE	YFV	----	----	VERO	100.00	----	8/16/88
AVS-4724	CPE	AD2	0.3	----	HEP2 <	320.00	----	8/18/88
AVS-4724	CPE	JE	----	----	VERO	100.00	----	8/16/88
AVS-4724	CPE	PT	----	----	VERO <	320.00	----	8/16/88
AVS-4724	CPE	PT	0.20	----	VERO	100.00	----	9/14/88
AVS-4724	CPE	SF	----	----	VERO	100.00	----	8/16/88
AVS-4724	CPE	VEE	----	----	VERO	320.00	----	8/16/88
AVS-4724	CPE	VEE	----	----	VERO	100.00	----	9/14/88
AVS-4724	CPE	VSV	0.3	----	L929	100.00	----	7/20/88
AVS-4724	CPE	VV	0.3	----	VERO <	320.00	----	8/18/88
AVS-4724	CPE	YFV	----	----	VERO	32.00	----	8/16/88
AVS-4725	CPE	AD2	0.1	----	HEP2 <	320.00	----	8/18/88
AVS-4725	CPE	JE	0.15	----	VERO	10.00	----	8/16/88
AVS-4725	CPE	PT	0.15	----	VERO	100.00	----	8/16/88
AVS-4725	CPE	PT	----	----	VERO <	320.00	----	9/14/88
AVS-4725	CPE	SF	0.15	----	VERO	320.00	----	8/16/88
AVS-4725	CPE	VEE	----	----	VERO	320.00	----	8/16/88
AVS-4725	CPE	VEE	----	----	VERO	100.00	----	9/14/88
AVS-4725	CPE	VSV	----	----	L929	320.00	----	7/20/88
AVS-4725	CPE	VV	0.3	----	VERO <	100.00	----	8/18/88
AVS-4725	CPE	YFV	----	----	VERO	320.00	----	8/16/88
AVS-4727	CPE	AD2	----	----	HEP2 >	320.00	----	7/21/88
AVS-4727	CPE	PT	0.45	217.00	VERO	100.00	0.46	9/14/88
AVS-4727	CPE	VEE	0.1	----	VERO	100.00	----	9/14/88
AVS-4727	CPE	VV	----	----	VERO >	320.00	----	7/21/88
AVS-4737	CPE	AD2	0.25	----	HEP2	100.00	----	8/25/88

B-242

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4737	CPE	VSV	----	----	L929 <	32.00	----	8/30/88
AVS-4737	CPE	VV	0.3	----	VERO <	320.00	----	8/25/88
AVS-4738	CPE	AD2	0.5	----	HEP2 >	320.00	----	8/25/88
AVS-4738	CPE	VSV	0.1	----	L929 >	320.00	----	8/30/88
AVS-4738	CPE	VV	----	----	VERO >	320.00	----	8/25/88
AVS-4739	CPE	AD2	----	----	HEP2 <	32.00	----	8/25/88
AVS-4739	CPE	VSV	----	----	L929	32.00	----	8/30/88
AVS-4739	CPE	VV	----	----	VERO	32.00	----	8/25/88
AVS-4740	CPE	AD2	0.1	----	HEP2 <	320.00	----	8/25/88
AVS-4740	CPE	VSV	0.25	----	L929	100.00	----	8/30/88
AVS-4740	CPE	VV	----	----	VERO	100.00	----	8/25/88
AVS-4741	CPE	AD2	----	----	HEP2 <	10.00	----	8/25/88
AVS-4741	CPE	VSV	----	----	L929	32.00	----	8/30/88
AVS-4741	CPE	VV	----	----	VERO >	320.00	----	8/25/88
AVS-4742	CPE	AD2	0.15	----	HEP2	32.00	----	8/25/88
AVS-4742	CPE	VSV	----	----	L929	10.00	----	8/30/88
AVS-4742	CPE	VV	0.15	----	VERO	100.00	----	8/25/88
AVS-4743	CPE	AD2	0.3	----	HEP2 <	32.00	----	8/25/88
AVS-4743	CPE	VSV	----	----	L929 <	10.00	----	8/30/88
AVS-4743	CPE	VV	----	----	VERO	10.00	----	8/25/88
AVS-4744	CPE	AD2	----	----	HEP2 <	10.00	----	8/25/88
AVS-4744	CPE	VSV	----	----	L929 <	32.00	----	8/30/88
AVS-4744	CPE	VV	----	----	VERO	32.00	----	8/25/88
AVS-4745	CPE	AD2	----	----	HEP2	100.00	----	8/25/88
AVS-4745	CPE	VSV	----	----	L929	32.00	----	8/30/88
AVS-4745	CPE	VV	----	----	VERO	100.00	----	8/25/88
AVS-4746	CPE	AD2	----	----	HEP2 <	100.00	----	8/25/88
AVS-4746	CPE	VSV	----	----	L929	100.00	----	8/30/88
AVS-4746	CPE	VV	----	----	VERO <	320.00	----	8/25/88
AVS-4747	CPE	AD2	----	----	HEP2	10.00	----	8/25/88
AVS-4747	CPE	VSV	----	----	L929	10.00	----	8/30/88
AVS-4747	CPE	VV	0.4	31.90	VERO	32.00	1.00	8/25/88
AVS-4748	CPE	AD2	----	----	HEP2 <	320.00	----	8/25/88
AVS-4748	CPE	VSV	----	----	L929 <	100.00	----	8/30/88
AVS-4748	CPE	VV	----	----	VERO	320.00	----	8/25/88
AVS-4749	CPE	AD2	0.15	----	HEP2	100.00	----	8/25/88
AVS-4749	CPE	VSV	----	----	L929	32.00	----	8/30/88
AVS-4749	CPE	VV	----	----	VERO	100.00	----	8/25/88
AVS-4750	CPE	AD2	1.05	11.10	HEP2	32.00	2.86	8/25/88
AVS-4750	CPE	AD2	0.35	8.40	HEP2	10.00	1.17	9/ 1/88
AVS-4750	CPE	VSV	0.25	----	L929	10.00	----	8/30/88
AVS-4750	CPE	VV	0.15	----	VERO	32.00	----	8/25/88
AVS-4751	CPE	AD2	0.1	----	HEP2	10.00	----	8/25/88
AVS-4751	CPE	VSV	----	----	L929	10.00	----	8/30/88
AVS-4751	CPE	VV	----	----	VERO	32.00	----	8/25/88
AVS-4752	CPE	AD2	----	----	HEP2	32.00	----	8/25/88
AVS-4752	CPE	VSV	----	----	L929	10.00	----	8/30/88
AVS-4752	CPE	VV	----	----	VERO	32.00	----	8/25/88
AVS-4753	CPE	AD2	----	----	HEP2	32.00	----	8/25/88
AVS-4753	CPE	VSV	----	----	L929	32.00	----	8/30/88
AVS-4753	CPE	VV	----	----	VERO	1.00	----	8/25/88
AVS-4754	CPE	AD2	----	----	HEP2 <	32.00	----	8/25/88
AVS-4754	CPE	VSV	----	----	L929	3.20	----	8/30/88
AVS-4754	CPE	VV	----	----	VERO	3.20	----	8/25/88
AVS-4755	CPE	AD2	----	----	HEP2 >	320.00	----	8/25/88
AVS-4755	CPE	VSV	----	----	L929	100.00	----	8/30/88
AVS-4755	CPE	VV	----	----	VERO >	320.00	----	8/25/88
AVS-4756	CPE	AD2	0.55	----	HEP2	32.00	----	8/25/88
AVS-4756	CPE	VSV	0.3	10.00	L929	10.00	1.00	8/30/88
AVS-4756	CPE	VV	----	----	VERO	10.00	----	8/25/88
AVS-4757	CPE	AD2	0.05	----	HEP2	100.00	----	8/25/88
AVS-4757	CPE	VSV	----	----	L929	32.00	----	8/30/88
AVS-4757	CPE	VV	----	----	VERO	32.00	----	8/25/88
AVS-4758	CPE	AD2	----	----	HEP2 <	3.20	----	9/ 1/88
AVS-4758	CPE	VSV	----	----	L929	10.00	----	8/30/88

8-243

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTCSO	TI	DATE
AVS-4758	CPE	VV	----	----	VERO	32.00	----	9/ 1/88
AVS-4759	CPE	AD2	0.3	----	HEP2	100.00	----	9/ 1/88
AVS-4759	CPE	VSV	0.1	----	L929	3.20	----	8/30/88
AVS-4759	CPE	VV	0.6	----	VERO	32.00	----	9/ 1/88
AVS-4760	CPE	AD2	0.3	----	HEP2	32.00	----	9/ 1/88
AVS-4760	CPE	VSV	----	----	L929	32.00	----	8/30/88
AVS-4760	CPE	VV	----	----	VERO <	10.00	----	9/ 1/88
AVS-4761	CPE	AD2	----	----	HEP2 <	100.00	----	9/ 1/88
AVS-4761	CPE	VSV	----	----	L929	100.00	----	8/30/88
AVS-4761	CPE	VV	----	----	VERO <	320.00	----	9/ 1/88
AVS-4762	CPE	AD2	----	----	HEP2 <	3.20	----	9/ 1/88
AVS-4762	CPE	VSV	----	----	L929	32.00	----	8/30/88
AVS-4762	CPE	VV	----	----	VERO	32.00	----	9/ 1/88
AVS-4763	CPE	AD2	----	----	HEP2	32.00	----	9/ 1/88
AVS-4763	CPE	VSV	----	----	L929	3.20	----	8/30/88
AVS-4763	CPE	VV	0.3	----	VERO	32.00	----	9/ 1/88
AVS-4764	CPE	AD2	----	----	HEP2 <	100.00	----	9/ 1/88
AVS-4764	CPE	VSV	----	----	L929	320.00	----	8/30/88
AVS-4764	CPE	VV	----	----	VERO	320.00	----	9/ 1/88
AVS-4765	CPE	AD2	0.3	----	HEP2 <	32.00	----	9/ 1/88
AVS-4765	CPE	VSV	----	----	L929	32.00	----	8/30/88
AVS-4765	CPE	VV	0.1	----	VERO	32.00	----	9/ 1/88
AVS-4767	CPE	AD2	----	----	HEP2	320.00	----	9/ 1/88
AVS-4767	CPE	VSV	----	----	L929	10.00	----	8/30/88
AVS-4767	CPE	VV	0.1	----	VERO	100.00	----	9/ 1/88
AVS-4768	CPE	AD2	----	----	HEP2 <	100.00	----	9/ 1/88
AVS-4768	CPE	VSV	----	----	L929	32.00	----	8/30/88
AVS-4768	CPE	VV	0.1	----	VERO	32.00	----	9/ 1/88
AVS-4769	CPE	AD2	----	----	HEP2 <	100.00	----	9/ 1/88
AVS-4769	CPE	VSV	----	----	L929	10.00	----	8/30/88
AVS-4769	CPE	VV	0.1	----	VERO	32.00	----	9/ 1/88
AVS-4770	CPE	AD2	----	----	HEP2	32.00	----	9/ 1/88
AVS-4770	CPE	VSV	----	----	L929	10.00	----	8/30/88
AVS-4770	CPE	VV	0.25	----	VERO	10.00	----	9/ 1/88
AVS-4771	CPE	AD2	----	----	HEP2 <	100.00	----	10/27/88
AVS-4771	CPE	VSV	----	----	L929	32.00	----	11/18/88
AVS-4771	CPE	VV	0.05	----	VERO	32.00	----	10/27/88
AVS-4772	CPE	AD2	----	----	HEP2 >	320.00	----	10/27/88
AVS-4772	CPE	VSV	----	----	L929 >	320.00	----	11/18/88
AVS-4772	CPE	VV	----	----	VERO >	320.00	----	10/27/88
AVS-4773	CPE	AD2	----	----	HEP2 >	320.00	----	10/27/88
AVS-4773	CPE	VSV	----	----	L929 >	320.00	----	11/18/88
AVS-4773	CPE	VV	----	----	VERO >	320.00	----	10/27/88
AVS-4774	CPE	AD2	----	----	HEP2 >	320.00	----	10/27/88
AVS-4774	CPE	VSV	----	----	L929 >	320.00	----	11/18/88
AVS-4774	CPE	VV	----	----	VERO >	320.00	----	10/27/88
AVS-4775	CPE	AD2	----	----	HEP2 >	320.00	----	10/27/88
AVS-4775	CPE	VSV	----	----	L929 >	320.00	----	11/18/88
AVS-4775	CPE	VV	----	----	VERO >	320.00	----	10/27/88
AVS-4776	CPE	AD2	----	----	HEP2 <	32.00	----	10/27/88
AVS-4776	CPE	VSV	0.1	----	L929	320.00	----	11/18/88
AVS-4776	CPE	VV	0.1	----	VERO	32.00	----	10/27/88
AVS-4777	CPE	AD2	----	----	HEP2 <	100.00	----	10/27/88
AVS-4777	CPE	VSV	----	----	L929	100.00	----	11/18/88
AVS-4777	CPE	VV	0.3	----	VERO	100.00	----	10/27/88
AVS-4778	CPE	AD2	----	----	HEP2	320.00	----	10/27/88
AVS-4778	CPE	VSV	----	----	L929 >	320.00	----	11/18/88
AVS-4778	CPE	VV	0.4	----	VERO	320.00	----	10/27/88
AVS-4779	CPE	AD2	0.2	----	HEP2 >	320.00	----	10/27/88
AVS-4779	CPE	VSV	----	----	L929 >	320.00	----	11/18/88
AVS-4779	CPE	VV	----	----	VERO >	320.00	----	10/27/88
AVS-4780	CPE	AD2	----	----	HEP2 >	320.00	----	10/27/88
AVS-4780	CPE	VSV	----	----	L929	100.00	----	11/18/88
AVS-4780	CPE	VV	----	----	VERO >	320.00	----	10/27/88
AVS-4781	CPE	AD2	0.3	----	HEP2 <	100.00	----	11/ 3/88

B-244

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MTC50	TI	DATE
AVS-4781	CPE	VSV	----	----	L929	10.00	----	11/18/88
AVS-4781	CPE	VV	0.3	----	VERO	100.00	----	11/ 3/88
AVS-4782	CPE	AD2	----	----	HEP2 >	320.00	----	11/ 3/88
AVS-4782	CPE	VSV	----	----	L929	320.00	----	11/18/88
AVS-4782	CPE	VV	----	----	VERO >	320.00	----	11/ 3/88
AVS-4783	CPE	AD2	----	----	HEP2 >	320.00	----	11/ 3/88
AVS-4783	CPE	VSV	----	----	L929	100.00	----	11/18/88
AVS-4783	CPE	VV	0.4	----	VERO >	320.00	----	11/ 3/88
AVS-4784	CPE	AD2	0.3	----	HEP2 >	320.00	----	11/ 3/88
AVS-4784	CPE	VSV	----	----	L929 >	320.00	----	11/18/88
AVS-4784	CPE	VV	0.1	----	VERO >	320.00	----	11/ 3/88
AVS-4785	CPE	AD2	3.4	4.25	HEP2	32.00	7.52	11/ 3/88
AVS-4785	CPE	AD2	3.15	3.82	HEP2	32.00	8.36	11/17/88
AVS-4785	CPE	VSV	0.55	71.30	L929	10.00	0.14	11/18/88
AVS-4785	CPE	VV	1.2	18.00	VERO	10.00	0.55	11/ 3/88
AVS-4785	CPE	VV	0.85	122.00	VERO	10.00	0.08	11/17/88
AVS-4786	CPE	AD2	----	----	HEP2	32.00	----	11/ 3/88
AVS-4786	CPE	VSV	----	----	L929	3.20	----	11/18/88
AVS-4786	CPE	VV	----	----	VERO	100.00	----	11/ 3/88
AVS-4787	CPE	AD2	0.3	----	HEP2 <	100.00	----	11/ 3/88
AVS-4787	CPE	VSV	----	----	L929	100.00	----	11/18/88
AVS-4787	CPE	VV	0.55	59.50	VERO	100.00	1.67	11/ 3/88
AVS-4788	CPE	AD2	----	----	HEP2 <	3.20	----	11/ 3/88
AVS-4788	CPE	VV	0.1	----	VERO	32.00	----	11/ 3/88
AVS-4789	CPE	AD2	0.1	----	HEP2 <	32.00	----	11/ 3/88
AVS-4789	CPE	VV	0.1	----	VERO	32.00	----	11/ 3/88
AVS-4790	CPE	AD2	----	----	HEP2 >	320.00	----	11/ 3/88
AVS-4790	CPE	VV	----	----	VERO	320.00	----	11/ 3/88
AVS-4791	CPE	AD2	----	----	HEP2 >	320.00	----	11/ 3/88
AVS-4791	CPE	VV	----	----	VERO >	320.00	----	11/ 3/88
AVS-4792	CPE	AD2	----	----	HEP2 <	320.00	----	11/ 3/88
AVS-4792	CPE	VV	0.45	68.30	VERO	100.00	1.46	11/ 3/88
AVS-4793	CPE	AD2	----	----	HEP2 <	0.03	----	11/17/88
AVS-4793	CPE	VV	----	----	VERO	0.03	----	11/17/88
AVS-4794	CPE	AD2	0.15	----	HEP2	100.00	----	11/ 3/88
AVS-4794	CPE	VV	0.1	----	VERO	320.00	----	11/ 3/88
AVS-4795	CPE	AD2	----	----	HEP2 <	100.00	----	11/ 3/88
AVS-4795	CPE	VV	0.15	----	VERO	100.00	----	11/ 3/88
AVS-4796	CPE	AD2	2.4	17.90	HEP2	100.00	5.56	11/ 3/88
AVS-4796	CPE	AD2	2.4	32.00	HEP2	320.00	10.00	11/17/88
AVS-4796	CPE	VV	0.8	127.00	VERO	32.00	0.25	11/ 3/88
AVS-4798	CPE	AD2	2.4	0.56	HEP2	3.20	5.64	11/ 3/88
AVS-4798	CPE	AD2	2.25	0.56	HEP2	3.20	5.62	11/17/88
AVS-4798	CPE	VV	1.2	0.93	VERO	1.00	1.06	11/ 3/88
AVS-4798	CPE	VV	1.	1.00	VERO	1.00	1.00	11/17/88
AVS-4799	CPE	AD2	----	----	HEP2	100.00	----	11/ 3/88
AVS-4799	CPE	VV	----	----	VERO <	100.00	----	11/ 3/88
AVS-4800	CPE	AD2	----	----	HEP2 >	320.00	----	11/ 3/88
AVS-4800	CPE	VV	----	----	VERO >	320.00	----	11/ 3/88
AVS-4801	CPE	AD2	----	----	HEP2	320.00	----	11/ 3/88
AVS-4801	CPE	VV	----	----	VERO >	320.00	----	11/ 3/88
AVS-4802	CPE	AD2	----	----	HEP2 <	100.00	----	11/ 3/88
AVS-4802	CPE	VV	----	----	VERO	100.00	----	11/ 3/88
AVS-4803	CPE	AD2	----	----	HEP2 <	10.00	----	11/ 3/88
AVS-4803	CPE	VV	----	----	VERO	10.00	----	11/ 3/88
AVS-4804	CPE	AD2	----	----	HEP2 >	320.00	----	11/10/88
AVS-4804	CPE	VV	----	----	VERO >	320.00	----	11/10/88
AVS-4805	CPE	AD2	----	----	HEP2 <	32.00	----	11/10/88
AVS-4805	CPE	VV	----	----	VERO	320.00	----	11/10/88
AVS-4806	CPE	AD2	----	----	HEP2 >	320.00	----	11/10/88
AVS-4806	CPE	VV	----	----	VERO <	320.00	----	11/10/88
AVS-4807	CPE	AD2	----	----	HEP2	320.00	----	11/10/88
AVS-4807	CPE	VV	0.2	----	VERO >	320.00	----	11/10/88
AVS-4808	CPE	AD2	----	----	HEP2 >	320.00	----	11/10/88
AVS-4808	CPE	VV	0.1	----	VERO	320.00	----	11/10/88

8-245

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	NTC50	TI	DATE
AVS-4809	CPE	AD2	----	----	HEP2 <	10.00	----	11/10/88
AVS-4809	CPE	VV	----	----	VERO	320.00	----	11/10/88
AVS-4811	CPE	AD2	----	----	HEP2	32.00	----	11/10/88
AVS-4811	CPE	VV	0.4	239.00	VERO	320.00	1.33	11/10/88
AVS-4812	CPE	AD2	0.4	----	HEP2 >	320.00	----	11/10/88
AVS-4812	CPE	VV	0.15	----	VERO	320.00	----	11/10/88
AVS-4813	CPE	AD2	----	----	HEP2 >	320.00	----	11/10/88
AVS-4813	CPE	VV	----	----	VERO >	320.00	----	11/10/88
AVS-4864	CPE	AD2	0.3	----	HEP2 >	320.00	----	6/16/88
AVS-4864	CPE	AD2	0.4	----	HEP2 >	320.00	----	10/13/88
AVS-4864	CPE	JE	----	----	VERO	32.00	----	7/ 6/88
AVS-4864	CPE	PT	0.15	----	VERO	10.00	----	7/ 6/88
AVS-4864	CPE	SF	----	----	VERO	32.00	----	7/ 6/88
AVS-4864	CPE	VSV	0.3	320.00	L929	100.00	0.31	6/22/88
AVS-4864	CPE	VV	1.1	320.00	VERO >	320.00 >	1.00	6/16/88
AVS-4864	CPE	VV	1.	----	VERO >	320.00	----	6/30/88
AVS-4864	CPE	VV	2.05	32.00	VERO	320.00	10.00	10/13/88
AVS-4864	CPE	VV	1.9	57.00	VERO	320.00	5.61	10/27/88
AVS-4864	CPE	YFV	----	----	VERO	100.00	----	7/ 6/88
AVS-4865	CPE	AD2	----	----	HEP2 >	320.00	----	11/10/88
AVS-4865	CPE	VV	0.6	----	VERO >	320.00	----	11/10/88
AVS-4866	CPE	AD2	----	----	HEP2 >	320.00	----	11/17/88
AVS-4866	CPE	VV	----	----	VERO >	320.00	----	11/17/88
AVS-4871	CPE	AD2	2.05	32.00	HEP2	320.00	10.00	11/10/88
AVS-4871	CPE	VV	1.65	100.00	VERO	320.00	3.20	11/10/88
AVS-4872	CPE	AD2	0.5	----	HEP2 >	320.00	----	11/10/88
AVS-4872	CPE	VV	1.3	180.00	VERO >	320.00 >	1.77	11/10/88
AVS-4873	CPE	AD2	0.3	----	HEP2 >	320.00	----	11/10/88
AVS-4873	CPE	VV	0.9	320.00	VERO >	320.00 >	1.00	11/10/88
AVS-4874	CPE	AD2	0.3	----	HEP2 >	320.00	----	11/10/88
AVS-4874	CPE	VV	4.8	5.60	VERO >	320.00 >	56.70	11/10/88
AVS-4875	CPE	AD2	0.1	----	HEP2 >	320.00	----	11/10/88
AVS-4875	CPE	VV	1.5	82.80	VERO	320.00	3.86	11/10/88
AVS-4876	CPE	AD2	----	----	HEP2 >	320.00	----	11/10/88
AVS-4876	CPE	VV	----	----	VERO >	320.00	----	11/10/88
AVS-4877	CPE	AD2	----	----	HEP2 <	100.00	----	11/10/88
AVS-4877	CPE	VV	0.3	----	VERO	100.00	----	11/10/88
AVS-4878	CPE	AD2	----	----	HEP2	32.00	----	11/10/88
AVS-4878	CPE	VV	----	----	VERO	32.00	----	11/10/88
AVS-4879	CPE	AD2	----	----	HEP2 >	320.00	----	10/13/88
AVS-4879	CPE	AD2	----	----	HEP2 >	320.00	----	11/10/88
AVS-4879	CPE	VV	----	----	VERO >	320.00	----	10/13/88
AVS-4879	CPE	VV	----	----	VERO >	320.00	----	11/10/88
AVS-4880	CPE	AD2	----	----	HEP2	32.00	----	11/10/88
AVS-4880	CPE	VV	0.6	100.00	VERO	100.00	1.00	11/10/88
AVS-4881	CPE	AD2	0.05	----	HEP2	10.00	----	11/10/88
AVS-4881	CPE	VV	0.45	100.00	VERO	32.00	0.32	11/10/88
AVS-4882	CPC	AD2	----	----	HEP2	100.00	----	11/10/88
AVS-4882	CPE	VV	----	----	VERO >	320.00	----	11/10/88
AVS-4883	CPE	AD2	----	----	HEP2 >	320.00	----	10/13/88
AVS-4883	CPE	VV	----	----	VERO >	320.00	----	10/13/88
AVS-4884	CPE	AD2	----	----	HEP2	100.00	----	10/13/88
AVS-4884	CPE	VV	----	----	VERO >	320.00	----	10/13/88
AVS-4885	CPE	AD2	0.4	----	HEP2 <	100.00	----	11/10/88
AVS-4885	CPE	VV	----	----	VERO <	100.00	----	11/10/88
AVS-4886	CPE	AD2	0.6	100.00	HEP2 <	320.00 <	3.20	11/10/88
AVS-4886	CPE	VV	0.1	----	VERO <	320.00	----	11/10/88
AVS-4887	CPE	AD2	----	----	HEP2 <	32.00	----	11/17/88
AVS-4887	CPE	VV	1.15	----	VERO	10.00	----	11/17/88
AVS-4888	CPE	AD2	----	----	HEP2 >	320.00	----	11/17/88
AVS-4888	CPE	VV	0.2	----	VERO >	320.00	----	11/17/88
AVS-4890	CPE	AD2	----	----	HEP2 <	100.00	----	11/17/88
AVS-4890	CPE	VV	0.05	----	VERO	32.00	----	11/17/88
AVS-4897	CPE	AD2	----	----	HEP2	32.00	----	11/17/88
AVS-4897	CPE	VV	----	----	VERO	10.00	----	11/17/88

B-246

CUMULATIVE SUMMARY OF ANTIVIRAL TEST RESULTS

COMPOUND	PROTOCOL	VIRUS	VR	ID50	CELL	MT50	TI	DATE
AVS-4898	CPE	AD2	0.15	----	HEP2	1.00	----	11/17/88
AVS-4899	CPE	AD2	0.3	----	HEP2	1.00	----	11/17/88
AVS-4900	CPE	AD2	0.3	----	HEP2 <	3.20	----	11/17/88
AVS-4900	CPE	VV	----	----	VERO	1.00	----	11/17/88
AVS-4901	CPE	AD2	0.65	6.20	HEP2	10.00	1.59	11/17/88
AVS-4901	CPE	VV	----	----	VERO	3.20	----	11/17/88
AVS-4902	CPE	AD2	0.6	1.00	HEP2 <	3.20 <	3.20	11/17/88
AVS-4902	CPE	VV	----	----	VERO <	1.00	----	11/17/88
AVS-4903	CPE	AD2	----	----	HEP2 <	3.20	----	11/17/88
AVS-4903	CPE	VV	----	----	VERO <	1.00	----	11/17/88
AVS-4904	CPE	AD2	0.35	----	HEP2	3.20	----	11/17/88
AVS-4904	CPE	VV	0.65	23.80	VERO	32.00	1.34	11/17/88
AVS-4906	CPE	AD2	0.3	----	HEP2 <	32.00	----	11/17/88
AVS-4906	CPE	VV	0.3	10.00	VERO	10.00	1.00	11/17/88
AVS-4908	CPE	AD2	0.3	----	HEP2	3.20	----	11/17/88
AVS-4910	CPE	AD2	0.2	----	HEP2 <	320.00	----	11/17/88
AVS-4910	CPE	VV	0.1	----	VERO	100.00	----	11/17/88
AVS-4911	CPE	AD2	0.85	14.30	HEP2	32.00	2.22	11/17/88
AVS-4911	CPE	VV	----	----	VERO	10.00	----	11/17/88
AVS-4912	CPE	AD2	----	----	HEP2 >	320.00	----	11/17/88
AVS-4912	CPE	VV	0.2	----	VERO	100.00	----	11/17/88
AVS-4913	CPE	AD2	0.3	----	HEP2 <	320.00	----	11/17/88
AVS-4913	CPE	VV	0.6	225.00	VERO	320.00	1.41	11/17/88
AVS-4914	CPE	AD2	0.25	----	HEP2	32.00	----	11/17/88
AVS-4914	CPE	VV	0.25	----	VERO	32.00	----	11/17/88
AVS-4915	CPE	AD2	0.4	100.00	HEP2	100.00	1.00	11/17/88
AVS-4915	CPE	VV	0.45	320.00	VERO	100.00	0.31	11/17/88
AVS-4925	CPE	AD2	----	----	HEP2	10.00	----	11/17/88
AVS-4925	CPE	VV	----	----	VERO <	32.00	----	11/17/88
AVS-4926	CPE	AD2	0.3	----	HEP2 >	320.00	----	11/17/88
AVS-4926	CPE	VV	0.15	----	VERO	100.00	----	11/17/88
AVS-4928	CPE	AD2	0.1	----	HEP2 >	320.00	----	11/17/88
AVS-4928	CPE	VV	0.3	----	VERO >	320.00	----	11/17/88
AVS-5040	CPE	AD2	0.3	----	HEP2	320.00	----	10/13/88
AVS-5040	CPE	VSV	0.5	200.00	L929	320.00	1.59	10/18/88
AVS-5040	CPE	VV	0.9	320.00	VERO >	320.00 >	1.00	10/13/88
AVS-5041	CPE	AD2	0.15	----	HEP2	320.00	----	10/13/88
AVS-5041	CPE	VSV	0.1	----	L929 >	320.00	----	10/18/88
AVS-5041	CPE	VV	0.1	----	VERO >	320.00	----	10/13/88
AVS-5042	CPE	AD2	----	----	HEP2 >	320.00	----	10/13/88
AVS-5042	CPE	VSV	0.4	320.00	L929	320.00	1.00	10/18/88
AVS-5042	CPE	VV	----	----	VERO >	320.00	----	10/13/88

B-247

APPENDIX C

Cumulative Summary of *In Vivo* Antiviral Test Results

CUMULATIVE SUMMARY OF IN VIVO TEST RESULTS
-VENEZUELAN EQUINE ENCEPHALOMYELITIS (VEE) VIRUS IN CD-1 MICE-

EXP. NO.	CMPD #	DOSE (MG/KG)	RX RTE & SCHEDULE	UNINFECTED		INFECTED			
				DEAD/ TOTAL	ADD	DEAD/ TOTAL	ADD	GMTD	VR
18	AVS-0079	320	SC; Q1D X 7, DAY-1	5/5	3.0	10/10	3.3	3.3	0.3
18		100		0/5	--	8/10	6.3	8.3	0.7
18		32		0/5	--	9/10	8.6	9.5	0.8
18		10		0/5	--	9/10	7.0	8.0	0.6
18		3.2		0/5	--	10/10	8.0	7.9	0.6
20	AVS-0079	32	SC; Q1D X10, DAY-1	0/5	--	6/10	8.8	12.4	1.3
22	AVS-0079	32	SC; Q1D X10, DAY-1	0/5	--	9/10	8.5	8.5	1.0
20	AVS-0079	16	SC; Q1D X10, DAY-1	0/5	--	5/5	9.2	8.8	0.9*
22	AVS-0079	16	SC; 2XD X10, DAY-1	ND	ND	10/10	7.8	7.8	1.0
9	AVS-0206	1000	SC; Q1D X 7, DAY-1	0/5	--	8/10	7.1	9.2	1.2
9		320		0/5	--	8/10	8.3	10.5	1.3
9		100		0/5	--	5/5	8.0	7.8	1.0
9		32		0/5	--	10/10	7.8	7.8	1.0
9		10		0/5	--	7/10	8.1	11.7	1.5
18	AVS-0272	100	SC; Q1D X 7, DAY-1	0/5	--	9/10	6.9	7.8	0.6
18		32		0/5	--	10/10	8.6	8.4	0.7
18		10		0/5	--	7/10	8.3	11.9	1.0
18		3.2		0/5	--	9/10	7.9	8.9	0.7
18		1.0		0/5	--	9/10	8.1	9.1	0.7
20	AVS-0272	10	SC; Q1D X10, DAY-1	0/5	--	10/10	8.3	8.2	0.9
20	AVS-0272	5	SC; Q1D X10, DAY-1	0/5	--	10/10	7.8	7.7	0.8*
19	AVS-0347	32	SC; Q1D X 7, DAY-1	0/4	--	8/10	7.5	9.2	1.1
19		10		0/5	--	9/10	9.8	10.5	1.2
19		3.2		0/5	--	9/10	9.0	10.0	1.2
19		1.0		0/5	--	9/10	7.6	8.5	1.0
19		0.32		0/5	--	7/10	9.4	13.0	1.5
20	AVS-0347	5	SC; Q1D X10, DAY-1	0/5	--	10/10	8.4	8.3	0.9*
20	AVS-0347	0.32	SC; Q1D X10, DAY-1	0/5	--	10/10	8.2	8.1	0.9
20	AVS-0347	0.16	SC; Q1D X10, DAY-1	0/5	--	8/10	9.3	10.7	1.1*
9	AVS-0360	100	SC; Q1D X 7, DAY 0	0/5	--	7/10	8.0	11.2	1.4
5		32		0/5	--	7/10	7.4	10.6	1.3
5		10		0/5	--	9/10	8.0	8.8	1.1
5		3.2		0/5	--	6/10	8.7	13.2	1.6
13	AVS-0360	100	SC; Q1D X 7, DAY-1	0/5	--	8/10	8.4	10.6	1.1
13		32		0/4	--	10/10	8.0	7.9	0.8
13		10		0/4	--	8/10	9.6	11.6	1.2
13		3.2		0/4	--	8/10	9.5	11.6	1.2
13		1.0		0/4	--	8/10	8.5	10.7	1.1
13	AVS-0360	3.2	SC; Q1D X12, DAY-1	0/5	--	9/10	8.8	9.8	0.9
13		1.0		0/5	--	9/10	8.4	9.5	0.9

9	AVS-0646	100	SC; Q1D X 7, DAY-1	0/5	--	7/7	6.7	5.9	0.7
9		32		0/5	--	8/10	8.3	10.4	1.3
9		10		0/5	--	9/10	8.3	9.4	1.2
9		3.2		0/5	--	7/7	8.6	8.4	1.1
9		1.0		0/5	--	8/10	7.9	10.1	1.3
13	AVS-0646	32	SC; Q1D X12, DAY-1	0/5	--	10/10	8.2	8.2	0.8
13		10		0/5	--	8/10	8.1	10.4	1.0
13		3.2		0/5	--	9/10	8.1	9.1	0.9
13		1.0		0/5	--	8/10	8.8	11.0	1.1
13		0.5		0/5	--	9/10	9.1	10.0	1.0
9	UNTREATED CONTROL	--		0/4	--	3/5	10.0	--	--
5	UNTREATED CONTROL	--		0/10	--	7/10	8.4	11.6	1.4
13	UNTREATED CONTROL	--		0/4	--	9/10	9.0	9.5	0.9
18	UNTREATED CONTROL	--		0/5	--	7/10	7.7	11.2	0.9
19	UNTREATED CONTROL	--		0/5	--	6/10	8.7	13.7	1.6
20	UNTREATED CONTROL	--		0/5	--	9/9	8.9	--	--
22	UNTREATED CONTROL	--		0/5	--	7.7	7.6	--	--
9	SHAM-INFECTED	--		0/5	--	--	--	--	--
5	SHAM-INFECTED	--		0/10	--	--	--	--	--
9	PBS CONTROL	SC; Q1D X 7, DAY-1	0/5	--	10/10	8.1	--	--	--
18	PBS CONTROL	SC; Q1D X 7, DAY-1	0/5	--	6/10	7.3	12.5	1.0	
20	PBS CONTROL	SC; Q1D X10, DAY-1	0/5	--	9/10	8.4	9.2	1.0	
20	PBS CONTROL	SC; Q1D X10, DAY-1	0/5	--	9/10	8.8	9.5	1.0*	
22	PBS CONTROL	SC; Q1D X10, DAY-1	0/5	--	9/10	7.0	8.0	--	
22	PBS CONTROL	SC; 2XD X10, DAY-1	0/5	--	9/10	7.4	8.2	--	
5	CMC + PBS CONTROL	SC; Q1D X 7, DAY 0	0/5	--	10/10	8.2	8.1	1.0	
13	CMC + PBS CONTROL	SC; Q1D X12, DAY-1	0/5	--	8/10	8.3	10.4	1.0	
19	CMC CONTROL	SC; Q1D X 7, DAY-1	0/5	--	10/10	8.7	8.5	1.0	

ADD= AVERAGE DAY OF DEATH(SURVIVORS NOT INCLUDED IN CALCULATIONS).
GMTD= GEOMETRIC MEAN TIME TO DEATH = (d1 X d2 Xdn where dn is the day of death for each animal and surviving animals are assigned a value of 28 days).
VR= GMTD of experimental treated/ GMTD of DILUENT treated controls.
* DOSE LISTED WAS DIVIDED IN HALF AND ADMINISTERED TWICE EACH DAY.

CONTRACT DAMD17-86-C-6013
SOUTHERN RESEARCH INSTITUTE
FILENAME: VEE.SUM
UPDATED: 12/14/87 : ADB

CUMULATIVE SUMMARY OF IN VIVO TEST RESULTS
-VACCINIA VIPUS INFECTED IV: TAILPOX MODEL-

EXPT NO.	AVS NO.	DOSE (MG/KG)	RTE & SCHEDULE	TOX.	INFECTED				PERCENT REDUCT. (T/C)
				DEAD/ TOTAL	NO.	MED	POX COUNTS MEAN	SD	
12	0001	150	IP: Q1D X 7, DAY-1	0/5	18	23.5	29.9	30.0	50
11	1752	400	SC: Q1D X 7, DAY-1	0/5	20	7.5	24.4	29.8	57
11	1752	400	IP: Q1D X 7, DAY-1	0/5	18	30.0	46.2	52.3	20*
8	1752	300	SC: Q1D X 7, DAY-1	0/5	20	13.0	24.3	31.8	58
10	1752	300	IP: Q1D X 7, DAY-1	0/5	19	6.0	20.1	29.5	52
12	1752	300	IP: Q1D X 7, DAY-1	0/5	20	34.5	33.1	19.1	44
16	1752	300	IP: Q1D X 7, DAY-1	0/5	18	36.5	41.9	36.4	44
8	1985	293	IP: Q1D X 7, DAY-1	0/5	20	24.5	26.1	23.0	55
10	1985	325	IP: Q1D X 7, DAY-1	0/5	19	20.0	42.2	48.5	5
11	1985	325	IP: Q1D X 7, DAY-1	0/5	19	30.0	36.0	24.1	37*
10	1986	300	IP: Q1D X 7, DAY-1	2/5	11	5.0	19.5	26.1	54**
8	1986	250	IP: Q1D X 7, DAY-1	0/5	18	21.0	35.7	36.3	38
11	1986	100	SC: Q1D X 7, DAY-1	0/5	20	14.0	18.5	19.8	69
16	2875	300	IP: Q1D X 7, DAY-1	0/5	19	47.5	47.3	22.5	50
16	4225	300	IP: Q1D X 7, DAY-1	0/5	19	31.0	41.0	32.4	43
8	H2O CONTROL		IP: Q1D X 7, DAY-1	0/5	19	54.0	58.3	24.1	-
10	H2O CONTROL		IP: Q1D X 7, DAY-1	0/5	17	36.0	42.2	30.4	-
11	H2O CONTROL		IP: Q1D X 7, DAY-1	0/5	19	57.0	57.4	28.1	-
11	H2O CONTROL		SC: Q1D X 7, DAY-1	0/5	15	60.0	60.3	26.8	-
12	H2O CONTROL		IP: Q1D X 7, DAY-1	0/5	17	62.0	59.5	20.7	-
16	DMSO CONTROL		IP: Q1D X 7, DAY-1	0/5	18	95.0	94.6	19.5	-
16	UNTREATED		IP: Q1D X 7, DAY-1	0/5	19	104.0	101.0	37.0	-

TOX = TOXICITY; NUMBER DEAD/TOTAL NUMBER OF UNINFECTED ANIMALS AT START OF RX.

NO. = NUMBER OF ANIMALS ALIVE ON DAY OF EVALUATION(i.e. 24hrs POST RX)--TEST ROUTINELY BEGINS WITH 20 ANIMALS.

MED = MEDIAN POX COUNT PER ANIMAL.

SD = STANDARD DEVIATION.

MEAN POX CT OF TEST(T) - MEAN POX CT OF DILUENT CONTROL(C)
PERCENT REDUCTION = -----
MEAN POX CT OF DILUENT CONTROL

(EXPRESS T/C REDUCTION IN PERCENT.)

* = COMPOUND FOR IP TREATMENT WAS PREPARED AND ADMINISTERED AS 0.2ML/10 GM. OF BODY WEIGHT.

** = DOSE OF 350 WAS TOXIC AND REDUCED TO 300 MG/KG ON DAY 0.

CONTRACT DAMD17-86-C-6013
SOUTHERN RESEARCH INSTITUTE
FILENAME: VVPOX.SUM
UPDATED: 03/28/89 : ADB

CUMULATIVE SUMMARY OF IN VIVO TEST RESULTS
-PICHINDE VIRUS IN MHA HAMSTERS-

EXP. NO.	CMPD #	DOSE (MG/KG)	RX RTE & SCHEDULE	UNINFECTED		INFECTED				
				DEAD/ TOTAL	ADD	DEAD/ TOTAL	ADD	GMTD	VR	
15	AVS-0001	100	SC; Q1D X 7, DAY 0	0/5	--	0/10	--	21.0	1.3	
18	AVS-0001	100	SC; Q1D X 7, DAY 0	0/5	--	4/10	17.3	19.4	2.1	
19	AVS-0001	100	SC; Q1D X 7, DAY 0	0/5	--	6/10	16.7	18.1	1.7	
20	AVS-0001	100	SC; Q1D X 7, DAY 0	0/5	--	8/10	16.9	18.5	1.7	
21	AVS-0001	100	SC; Q1D X 7, DAY 0	0/5	--	7/10	16.3	19.1	1.8	
23	AVS-0001	100	SC; Q1D X 7, DAY 0	0/5	--	8/10	18.4	19.9	2.0	
24	AVS-0001	100	SC; Q1D X 7, DAY 0	0/5	--	7/9	15.9	17.7	1.7	
28	AVS-0001	100	SC; Q1D X 7, DAY 0	0/5	--	5/10	16.2	21.2	1.8	
29	AVS-0001	100	SC; Q1D X 7, DAY 0	0/5	--	7/10	18.7	20.5	1.9	
35	AVS-0001	100	SC; Q1D X 7, DAY -1	0/6	--	2/6	13.5	22.2	2.2	
35	AVS-0001	100	SC; Q1D X 7, DAY 4	0/6	--	0/6	--	28.0	2.9	
35	AVS-0001	100	SC; Q1D X 7, DAY 5	0/6	--	6/6	15.7	16.3	1.8	
35	AVS-0001	100	SC; Q1D X 7, DAY 6	0/6	--	5/6	11.2	13.0	1.3	
38	AVS-0001	100	SC; Q1D X 7, DAY 0	0/5	--	6/10	17.8	P=0.001		
39	AVS-0001	125	SC; Q1D X 7, DAY 0	0/5	--	3/10	22.7	P=0.043		
33	AVS-0001	150	SC; Q1D X 8, DAY 0	0/5	--	1/10	13.0	25.9	2.8	
33	AVS-0001	100	SC; Q1D X 8, DAY 0	0/5	--	6/10	18.5	21.5	2.3	
33	AVS-0001	50	SC; Q1D X 8, DAY 0	0/5	--	8/10	14.5	16.4	1.7	
33	AVS-0001	25	SC; Q1D X 8, DAY 0	0/5	--	10/10	13.6	13.6	1.4	
31	AVS-0001	1000	SC; Q1D X10, DAY-1	5/5	3.6	--	--	--	--	
31	AVS-0001	500	SC; Q1D X10, DAY-1	5/5	5.2	10/10	5.7	5.6	0.6	
31	AVS-0001	250	SC; Q1D X10, DAY-1	5/5	7.6	--	--	--	--	
31	AVS-0001	200	SC; Q1D X10, DAY-1	3/5	10.7	8/10	12.8	14.4	1.6	
31	AVS-0001	100	SC; Q1D X10, DAY-1	0/5	--	3/10	18.7	24.4	2.7	
32	AVS-0001	100	SC; Q1D X10, DAY-1	0/5	--	2/10	20.5	26.1	2.1	
30	AVS-0001	50	SC; Q1D X10, DAY-1	0/5	--	8/10	14.5	16.4	1.3	
27	AVS-0001	50	SC; Q1D X10, DAY-1	0/5	--	9/10	16.4	17.1	1.7	
33	AVS-0001	150	SC; Q1D X11, DAY-3	1/5	14.0	3/10	16.0	23.7	2.6	
33	AVS-0001	100	SC; Q1D X11, DAY-3	0/5	--	1/10	14.0	26.1	2.9	
34	AVS-0001	100	SC; Q1D X11, DAY 0	0/5	--	4/10	20.8	24.8	2.4	
33	AVS-0001	50	SC; Q1D X11, DAY-3	0/3	--	10/10	16.2	15.9	1.8	
34	AVS-0001	50	SC; Q1D X11, DAY 0	0/5	--	9/10	19.2	19.4	1.9	
33	AVS-0001	25	SC; Q1D X11, DAY-3	0/5	--	10/10	13.0	13.0	1.4	
25	AVS-0001	100	SC; Q1D X12, DAY-1	1/5	18.0	3/10	21.7	25.8	2.7	
26	AVS-0001	100	SC; Q1D X12, DAY-1	0/5	--	10/10	12.5	12.3	1.3	
34	AVS-0001	100	SC; Q1D X18, DAY-1	0/5	--	3/10	17.0	24.1	2.3	
34	AVS-0001	50	SC; Q1D X18, DAY-1	0/5	--	7/10	18.3	20.7	2.0	
18	AVS-0052	100	SC; Q1D X 7, DAY 0	5/5	4.2	10/10	4.2	4.2	0.5	
18		32		5/5	6.8	10/10	6.6	6.6	0.7	
18		10		0/5	--	10/10	8.9	8.6	0.9	
18		3.2		0/5	--	9/10	10.6	10.9	1.2	
25		3.2	SC; Q1D X12, DAY-1	0/5	--	10/10	7.0	7.0	0.7	
25		1.0	SC; Q1D X12, DAY-1	0/5	--	10/10	9.2	9.2	0.9	
27		3.2	SC; Q1D X10, DAY-1	0/5	--	10/10	7.7	7.7	0.8	
27		1.0	SC; Q1D X10, DAY-1	0/5	--	10/10	10.5	10.2	1.0	

27	1)AVS-0052	1)	3.2	SC; Q1D X10, DAY-1	0/5	--	10/10	17.0	16.9	1.7
	2)AVS-0001	2)	50	SC; Q1D X10, DAY-1						
27		1)	1.0		0/5	--	9/10	17.6	18.1	1.8
		2)	50							
15	AVS-0079		100	SC; Q1D X 7, DAY 0	0/5	--	8/8	14.0	13.5	0.9
15			32		0/5	--	1/10	11.0	19.7	1.2
18			32		--	--	10/10	8.6	7.0	0.8
15			10		0/5	--	5/10	9.8	14.3	0.9
15			3.2		0/5	--	7/10	13.0	14.5	0.9
38	AVS-0094		100	SC; Q1D X 7, DAY 0	0/5	--	9/10	10.4	P=0.408	
38			32		0/5	--	10/10	10.3	P=0.458	
38			10		0/5	--	10/10	10.1	P=0.713	
38			3.2		0/5	--	10/10	9.9	P=1.0	
19	AVS-0111		100	SC; Q1D X 7, DAY 0	0/5	--	9/10	11.9	12.5	1.2
19			32		0/5	--	9/10	10.7	11.4	1.1
19			10		0/5	--	8/10	11.4	12.6	1.2
19			3.2		0/5	--	9/10	9.0	9.7	0.9
32	AVS-0111		150	SC; Q1D X10, DAY 0	0/3	--	5/05	14.0	14.0	1.1
32			32		0/5	--	10/10	13.0	12.3	1.2
32			10		0/5	--	10/10	10.8	10.6	0.8
19	AVS-0148		10	SC; Q1D X 7, DAY 0	0/5	--	10/10	12.0	11.7	1.1
19			3.2		0/5	--	10/10	11.2	11.1	1.1
19			1.0		0/5	--	10/10	10.4	10.3	1.0
19			0.32		0/5	--	10/10	11.7	11.5	1.1
19			0.1		0/5	--	10/10	11.3	10.9	1.1
27	AVS-0148		3.2	SC; Q1D X10, DAY-1	0/5	--	10/10	10.3	10.3	1.1
27			1.0		0/5	--	10/10	11.3	11.1	1.1
30			0.5		0/5	--	10/10	12.2	12.0	1.0
30			0.25		0/5	--	10/10	12.1	11.9	1.0
25	AVS-0148		20	SC; Q1D X12, DAY-1	5/5	8.8	10/10	7.0	6.9	0.7
25			10		5/5	20.0	10/10	9.5	9.5	1.0
25			3.2		2/5	14.0	10/10	9.8	9.8	1.0
27	1)AVS-0148	1)	3.2	SC; Q1D X10, DAY-1	0/5	--	10/10	16.6	16.5	1.7
	2)AVS-0001	2)	50.0	SC; Q1D X10, DAY-1						
27		1)	1.0		0/5	--	9/9	16.2	17.1	1.7
		2)	50.0							
30		1)	0.5		0/5	--	10/10	16.5	16.3	1.3
		2)	50.0							
30		1)	0.25		0/5	--	10/10	16.5	16.4	1.3
		2)	50.0							
20	AVS-0167		32	SC; Q1D X 7, DAY 0	0/5	--	10/10	10.0	10.0	0.9
20			10		0/5	--	9/10	9.8	10.8	1.0
20			3.2		0/5	--	9/10	10.4	11.5	1.0
20			1.0		0/5	--	10/10	11.4	10.9	1.0
26	AVS-0167		10	SC; Q1D X12, DAY-1	0/5	--	10/10	11.3	10.8	1.2
26			3.2		0/5	--	10/10	9.6	9.6	1.0
26			1.0		0/5	--	10/10	10.3	10.1	1.1
21	AVS-0206		100	SC; Q1D X 7, DAY 0	0/5	--	8/10	15.3	17.1	1.6
21			32		0/5	--	9/10	14.0	14.9	1.4

21		10		0/5	--	9/10	13.1	13.9	1.3
21		3.2		0/5	--	10/10	10.4	10.3	1.0
31	AVS-0206	1000	SC; Q1D X10, DAY-1	4/4	5.0	10/10	5.0	4.9	0.6
31		500	SC; Q1D X10, DAY-1	4/4	8.5	10/10	8.4	8.3	0.9
31		250	SC; Q1D X10, DAY-1	0/5	--	1/10	23.0	27.5	3.1
31		200	SC; Q1D X10, DAY-1	0/5	--	2/10	25.0	27.4	3.1
25	AVS-0206	200	SC; Q1D X12, DAY-1	0/5	--	4/10	18.8	23.8	2.5
37	AVS-0215	100	SC; Q1D X 7, DAY 0	5/5	6.2	10/10	10.0	5.9	0.6
37		50		3/4	13.0	10/10	10.4	10.3	1.0
24		32		0/5	--	10/10	9.7	9.6	0.9
37		25		0/5	--	10/10	9.4	9.2	0.9
24		10		0/5	--	10/10	9.7	9.7	0.9
24		3.2		0/5	--	10/10	11.1	10.8	1.0
24		1.0		0/5	--	10/10	9.5	9.5	0.9
15	AVS-0253	100	SC; Q1D X 7, DAY 0	2/5	9.5	9/10	9.3	10.1	0.6
15	AVS-0253	32		0/5	--	1/10	11.0	19.7	1.2
18	AVS-0253	32		0/5	--	10/10	10.1	9.9	1.1
21	AVS-0253	32		0/5	--	8/10	8.3	10.4	1.3
39	AVS-0253	32		0/5	--	10/10	10.8	P=0.277	
39	AVS-0253	16		1/5	8.0	10/10	14.9	P=0.447	
15	AVS-0253	10		0/5	--	5/10	11.2	15.3	0.9
15	AVS-0253	3.2		0/5	--	8/10	11.3	12.6	0.8
39	AVS-0253	32	SC; Q2D X 10, DAY 0	5/5	10.6	10/10	8.7	P=0.04	
39	AVS-0253	16		0/5	--	10/10	12.6	P=0.809	
28	AVS-0272	100	SC; Q1D X 7, DAY 0	4/5	10.5	10/10	10.5	10.3	0.9
28		32		0/5	--	10/10	9.8	9.7	0.8
28		10		1/5	16.0	10/10	11.6	11.2	0.9
28		3.2		0/5	--	10/10	11.5	11.2	0.9
20	AVS-0332	100	SC; Q1D X 7, DAY 0	0/5	--	10/10	11.5	11.1	1.0
20		32		0/5	--	10/10	11.1	10.8	1.0
20		10		0/5	--	10/10	9.9	9.7	0.9
20		3.2		0/5	--	9/10	11.2	11.8	1.1
26	AVS-0332	3.2	SC; Q1D X12, DAY-1	0/5	--	10/10	9.3	9.2	1.0
26		1.0		0/5	--	10/10	11.1	10.9	1.2
28	AVS-0346	60	SC; Q1D X 7, DAY 0	0/5	--	10/10	11.1	10.7	0.9
28		30		0/5	--	10/10	11.9	11.4	0.9
28		15		0/5	--	9/10	11.8	12.7	1.1
28		7.5		0/5	--	8/10	14.4	15.7	1.3
32	AVS-0346	7.5	SC; Q1D X10, DAY 0	0/5	--	10/10	10.7	10.6	0.8
32		5.0		0/5	--	9/10	10.4	11.4	0.9
32		2.5		0/5	--	10/10	11.2	11.1	0.9
32		1.0		0/5	--	9/10	10.9	11.3	0.9
38	AVS-0347	100	SC; Q1D X 7, DAY 0	5/5	1.0	10/10	1.0	P<10-6	
38		32		5/5	1.2	10/10	1.3	P<10-6	
39		20		5/5	1.4	10/10	1.1	P=0.000008	
39		10		5/5	1.8	10/10	2.0	P=0.00002	
39		5		5/5	2.6	10/10	2.8	P=0.00006	

23	AVS-0360	100	SC; Q1D X 7, DAY 0	5/5*	--	10/10	8.2	8.2	0.8
23		32		5/5**	--	9/10***	9.9	10.8	1.1
23		10		0/5	--	10/10	11.1	10.6	1.1
23		3.2		0/5	--	10/10	10.3	10.2	1.0
21	AVS-0646	100	SC; Q1D X 7, DAY 0	5/5	6.4	10/10	6.1	6.1	0.6
21		32		1/5	11.0	10/10	7.0	6.7	0.6
21		10		0/5	--	9/10	7.8	8.4	0.8
21		3.2		0/5	--	10/10	12.6	11.8	1.1
26	AVS-0646	3.2	SC; Q1D X 7, DAY-1	0/5	--	10/10	7.9	8.0	0.9
26		1.0		0/5	--	10/10	9.5	9.5	1.0
29	AVS-0925	100	SC; Q1D X 7, DAY 0	0/5	--	10/10	8.0	7.6	0.7
29		32		0/5	--	10/10	9.2	9.1	0.9
29		10		0/5	--	10/10	10.3	10.2	1.0
29		3.2		0/5	--	10/10	9.9	9.8	0.9
24	AVS-1046	100	SC; Q1D X 7, DAY 0	0/5	--	10/10	13.7	13.4	1.3
24		32		0/5	--	9/10	12.3	13.1	1.3
24		10		0/5	--	10/10	12.4	11.8	1.1
24		3.2		0/5	--	9/10	10.9	11.8	1.1
23	AVS-1250	100	SC; Q1D X 7, DAY 0	0/5	--	10/10	10.2	9.8	1.0
23		32		0/5	--	10/10	9.2	9.2	0.9
23		10		0/5	--	9/10	9.6	10.6	1.1
23		3.2		0/5	--	10/10	9.7	9.7	1.0
9	UNTREATED	CONTROL	--	0/4	--	3/5	10.0	--	--
15	UNTREATED	CONTROL	--	0/5	--	4/10	10.0	15.6	1.0
18	UNTREATED	CONTROL	--	0/5	--	8/10	9.9	11.4	1.2
19	UNTREATED	CONTROL	--	0/5	--	9/10	10.2	10.7	1.0
20	UNTREATED	CONTROL	--	0/5	--	9/10	9.0	10.1	0.9
21	UNTREATED	CONTROL	--	0/5	--	10/10	10.1	10.1	0.9
23	UNTREATED	CONTROL	--	0/5	--	10/10	10.9	10.6	1.1
24	UNTREATED	CONTROL	--	0/5	--	10/10	10.5	10.4	1.0
25	UNTREATED	CONTROL	--	0/5	--	10/10	9.5	9.4	1.0
26	UNTREATED	CONTROL	--	0/5	--	10/10	8.9	8.9	1.0
27	UNTREATED	CONTROL	--	0/5	--	10/10	10.0	--	--
28	UNTREATED	CONTROL	--	0/5	--	10/10	10.2	10.1	0.8
29	UNTREATED	CONTROL	--	0/5	--	10/10	13.4	12.4	1.2
30	UNTREATED	CONTROL	--	0/5	--	8/10	9.0	11.2	0.9
31	UNTREATED	CONTROL	--	0/10	--	10/10	9.8	9.8	1.1
32	UNTREATED	CONTROL	--	0/5	--	7/10	10.9	14.1	1.3
33	UNTREATED	CONTROL	--	0/5	--	10/10	10.3	10.2	1.0
34	UNTREATED	CONTROL	--	0/5	--	10/10	10.1	9.8	--
35	UNTREATED	CONTROL	--	0/3	--	3/3	9.7	9.6	--
37	UNTREATED	CONTROL	--	0/5	--	10/10	10.0	9.9	--
38	UNTREATED	CONTROL	--	0/5	--	9/9	--	--	--
39	UNTREATED	CONTROL	--	0/5	--	10/10	9.8	P=0.105	--
9	SHAM-INFECTED	--	--	0/5	--	--	--	--	--
18	SHAM-INFECTED	--	--	0/5	--	--	--	--	--
24	SHAM-INFECTED	--	--	0/5	--	--	--	--	--
38	0.9% SALINE	--	--	0/5	--	10/10	9.9	--	--
38	2% ETHANOL SALINE	--	--	0/5	--	10/10	10.4	--	--
39	0.4% CMC/PBS	--	--	0/5	--	10/10	13.2	--	--

9	PBS CONTROL	SC; Q1D X 7, DAY 0	0/5	--	10/10	8.1	--	--
15	PBS CONTROL	SC; Q1D X 7, DAY 0	0/5	--	5/10	12.2	15.6	1.0
18	PBS CONTROL	SC; Q1D X 7, DAY 0	0/5	--	10/10	9.1	9.2	1.0
19	PBS CONTROL	SC; Q1D X 7, DAY 0	0/5	--	10/10	10.5	10.4	1.0
20	CMC + PBS CONTROL	SC; Q1D X 7, DAY 0	0/5	--	10/10	11.0	10.7	1.0
21	PBS CONTROL	SC; Q1D X 7, DAY 0	0/5	--	10/10	10.8	10.4	1.0
23	PBS CONTROL	SC; Q1D X 7, DAY 0	0/5	--	10/10	10.1	9.9	1.0
24	CMC + PBS CONTROL	SC; Q1D X 7, DAY 0	0/5	--	10/10	10.8	10.4	1.0
28	CMC + PBS CONTROL	SC; Q1D X 7, DAY 0	0/5	--	9/10	11.4	12.1	1.0
29	CMC + PBS CONTROL	SC; Q1D X 7, DAY 0	0/5	--	10/10	11.3	10.7	1.0
35	PBS CONTROL	SC; Q1D X 7, DAY-1	0/3	--	3/3	10.3	10.3	1.0
35	PBS CONTROL	SC; Q1D X 7, DAY 4	0/3	--	3/3	9.7	9.6	1.0
35	PBS CONTROL	SC; Q1D X 7, DAY 5	0/3	--	3/3	9.3	9.3	1.0
35	PBS CONTROL	SC; Q1D X 7, DAY 6	0/3	--	3/3	10.3	10.3	1.0
33	PBS CONTROL	SC; Q1D X 8, DAY 0	0/5	--	10/10	9.3	9.4	1.0
27	PBS CONTROL	SC; Q1D X10, DAY-1	0/5	--	10/10	9.9	9.8	1.0
30	PBS CONTROL	SC; Q1D X10, DAY-1	0/5	--	10/10	13.0	12.3	1.0
31	PBS CONTROL	SC; Q1D X10, DAY-1	0/10	--	10/10	9.0	8.9	1.0
33	PBS CONTROL	SC; Q1D X11, DAY-3	0/5	--	10/10	9.0	9.0	1.0
34	PBS CONTROL	SC; Q1D X11, DAY-7	0/5	--	10/10	10.5	10.3	--
32	CMC CONTROL	SC; Q1D X10, DAY 0	0/5	--	10/10	12.6	12.5	1.0
25	PBS CONTROL	SC; Q1D X12, DAY-1	0/5	--	10/10	9.7	9.7	1.0
26	CMC + PBS CONTROL	SC; Q1D X12, DAY-1	0/5	--	10/10	9.3	9.2	1.0
34	PBS CONTROL	SC; Q1D X18, DAY 0	0/5	--	10/10	10.5	10.4	--
37	PBS CONTROL	SC; Q1D X 7, DAY 0	0/5	--	9/10	9.7	10.7	--

ADD= AVERAGE DAY OF DEATH(SURVIVORS NOT INCLUDED IN CALCULATIONS).

GMTD=GEOMETRIC MEAN TIME TO DEATH = (d1 X d2 Xdn where dn is the day of death for each animal and surviving animals are assigned a value of 28 days).

VR= GMTD of experimental treated/ GMTD of PBS treated controls.

* = FOUR ANIMALS SACRIFICED DUE TO SEVERE ULCERATIONS AT THE INJECTION SITE.

**= FIVE ANIMALS SACRIFICED DUE TO SEVERE ULCERATIONS AT THE INJECTION SITE.

***= ONE ANIMAL SACRIFICED DUE TO SEVERE ULCERATION AT THE INJECTION SITE.

NOTE: EXPT. #26. DUE TO THE INCONSISTENT RESULTS OBTAINED WITH RIBAVIRIN CONTROL, WE SUSPECT THAT THE COMPOUND WAS IMPROPERLY PREPARED FOR USE.

EXPT. #31. DUE TO SKIN LESIONS, THE ROUTE OF INJECTION WAS CHANGED FROM SC TO IP ON DAY 3 (POSTINFECTION). BLOOD WAS COLLECTED FOR HEMATOCRIT DETERMINATIONS FOR AVS-0206.RESULTS: DECREASE IN HEMATOCRITS FOR AVS-0206 BUT NOT AS SEVERE AS THAT INDUCED BY RIBAVIRIN.

CONTRACT DAMD17-86-C-6013
SOUTHERN RESEARCH INSTITUTE
FILENAME: PIC.SUM
UPDATED: 03/28/89:ADB

CUMULATIVE SUMMARY OF IN VIVO TEST RESULTS
-JAPANESE ENCEPHALITIS(JE) VIRUS IN C57BL/6 MICE-

EXP. NO.	CMPD #	DOSE (MG/KG)	RX RTE & SCHEDULE	UNINFECTED		INFECTED				
				DEAD/ TOTAL	ADD	DEAD/ TOTAL	ADD	GMTD	VR	
30	AVS-0111	320	SC; Q1D X 7, DAY-1	0/5	--	10/10	10.5	10.5	0.8	
30		100	SC; Q1D X 7, DAY-1	0/5	--	10/10	11.4	11.4	0.9	
30		32	SC; Q1D X 7, DAY-1	0/5	--	9/10	12.1	13.1	1.0	
30	AVS-0111	320	IP; Q1D X 7, DAY-1	0/5	--	10/10	10.7	10.7	0.8	
30		100	IP; Q1D X 7, DAY-1	0/5	--	10/10	10.5	10.4	0.8	
30		32	IP; Q1D X 7, DAY-1	0/5	--	10/10	10.7	10.5	0.8	
34	AVS-0215	100	SC; Q1D X 7, DAY-1	2/5	15.0	10/10	12.1	12.0	0.8	
34		64	SC; Q1D X 7, DAY-1	0/5	--	10/10	11.9	11.7	0.8	
34		32	SC; Q1D X 7, DAY-1	0/5	--	9/10	13.3	14.3	0.9	
30	AVS-0257	320	SC; Q1D X 7, DAY-1	0/5	--	10/10	10.9	10.9	0.8	
30		100	SC; Q1D X 7, DAY-1	0/5	--	10/10	10.4	10.4	0.8	
30		32	SC; Q1D X 7, DAY-1	0/5	--	10/10	12.9	12.7	1.0	
34	AVS-0272	53	SC; Q1D X 7, DAY-1	0/5	--	9/10	11.8	12.7	0.8	
34		34	SC; Q1D X 7, DAY-1	0/5	--	10/10	12.6	12.5	0.8	
34		17	SC; Q1D X 7, DAY-1	0/5	--	9/10	14.0	15.0	1.0	
34	AVS-0360	300	SC; Q1D X 7, DAY-1	0/5	--	7/10	13.6	16.8	1.1	
32		250	SC; Q1D X 7, DAY-1	0/5	--	7/10	12.0	15.2	1.3	
34		150	SC; Q1D X 7, DAY-1	0/5	--	8/10	13.5	15.6	1.0	
26	AVS-0361	6	SC; Q1D X 7, DAY-1	3/5	2.7	7/10	4.0	6.5	0.5	
33		6	SC; Q1D X 7, DAY-1	0/5	--	1/10	15.0	26.3	2.2	
26		4	SC; Q1D X 7, DAY-1	0/5	--	0/10	--	28.0	2.2	
33		4	SC; Q1D X 7, DAY-1	0/5	--	7/10	15.4	18.4	1.5	
26		2	SC; Q1D X 7, DAY-1	0/5	--	8/10	16.3	18.0	1.4	
33		2	SC; Q1D X 7, DAY-1	1/5	28.0	9/10	11.6	12.5	1.0	
34	AVS-2563	45	IP; Q1D X 7, DAY-1	0/5	--	7/10	13.9	17.0	1.3	
34		30	IP; Q1D X 7, DAY-1	0/5	--	10/10	13.1	13.0	1.0	
34		15	IP; Q1D X 7, DAY-1	0/5	--	9/10	13.0	13.8	1.1	
26		12	SC; Q1D X 7, DAY-1	0/5	--	10/10	13.6	13.4	1.1	
26		6	SC; Q1D X 7, DAY-1	0/5	--	9/10	13.7	14.6	1.2	
26		3	SC; Q1D X 7, DAY-1	0/5	--	9/10	12.0	12.7	1.0	
26	AVS-2811	25	SC; Q1D X 7, DAY-1	4/5	4.8	4/10	10.5	16.1	1.3	
33		20	SC; Q1D X 7, DAY-1	5/5	2.6	10/10	3.5	2.8	0.2	
26		12.5	SC; Q1D X 7, DAY-1	0/5	--	8/10	14.0	16.0	1.3	
33		10	SC; Q1D X 7, DAY-1	0/5	--	4/10	13.3	20.7	1.6	
26		6.25	SC; Q1D X 7, DAY-1	0/5	--	8/10	13.5	15.6	1.2	
33		5	SC; Q1D X 7, DAY-1	0/5	--	9/10	13.4	14.4	1.1	
26	AVS-2812	6	SC; Q1D X 7, DAY-1	4/5	6.0	5/9	6.4	15.8	1.2	
33		6	SC; Q1D X 7, DAY-1	3/5	7.0	10/10	6.9	6.3	0.5	
26		3	SC; Q1D X 7, DAY-1	0/5	--	2/10	17.5	25.2	2.0	
33		3	SC; Q1D X 7, DAY-1	0/5	--	1/10	15.0	26.3	2.2	
26		1	SC; Q1D X 7, DAY-1	0/5	--	6/10	15.7	19.5	1.5	
33		1	SC; Q1D X 7, DAY-1	0/5	--	9/10	15.1	16.0	1.3	

34	AVS-2979	200	SC; Q1D X 7, DAY-1	5/5	1.2	10/10	1.4	1.3	0.08
34		100	SC; Q1D X 7, DAY-1	5/5	1.8	10/10	2.0	1.9	0.1
34		50	SC; Q1D X 7, DAY-1	4/4	6.0	8/10	5.9	7.8	0.5
33	AVS-2980	40	SC; Q1D X 7, DAY-1	0/5	--	2/10	9.5	22.2	1.8
33		20	SC; Q1D X 7, DAY-1	0/5	--	4/10	15.0	21.7	1.7
33		10	SC; Q1D X 7, DAY-1	0/5	--	9/10	13.6	14.4	1.1
33	AVS-4113	32	SC; Q1D X 7, DAY-1	N/A	--	9/10	13.6	14.4	1.2
33		16	SC; Q1D X 7, DAY-1	0/5	--	9/10	11.8	12.6	1.0
33		8	SC; Q1D X 7, DAY-1	0/5	--	9/10	13.3	13.2	1.1
26	UNTREATED CONTROL	--		0/5	--	10/10	14.0	13.9	--
30	UNTREATED CONTROL	--		0/5	--	7/10	13.6	16.7	--
32	UNTREATED CONTROL	--		0/5	--	10/10	13.6	13.5	--
33	UNTREATED CONTROL	--		0/5	--	10/10	12.2	11.9	--
34	UNTREATED CONTROL	--		0/5	--	10/10	12.1	11.4	--
26	SHAM-INFECTED	--		0/10	--	--	--	--	--
26	ALC-SALINE CONTROL	SC; Q1D X 7, DAY-1	0/5	--	10/10	12.8	12.7	--	--
33	ALC-SALINE CONTROL	SC; Q1D X 7, DAY-1	0/5	--	10/10	12.4	12.1	--	--
30	PBS	SC; Q1D X 7, DAY-1	0/5	--	10/10	13.5	13.3	--	--
30	PBS	IP; Q1D X 7, DAY-1	0/5	--	10/10	13.7	13.1	--	--
32	0.4%CMC + PBS	SC; Q1D X 7, DAY-1	0/5	--	10/10	12.3	12.1	--	--
34	0.4%CMC + PBS	SC; Q1D X 7, DAY-1	0/5	--	9/10	14.3	15.3	--	--
34	0.4%CMC + PBS	IP; Q1D X 7, DAY-1	0/5	--	10/10	13.4	13.2	--	--
33	H ₂ O ₂ (FROM NCI)	SC; Q1D X 7, DAY-1	0/5	--	10/10	12.6	12.6	--	--

ADD= AVERAGE DAY OF DEATH (SURVIORS NOT INCLUDED IN CALCULATIONS)

GMTD= GEOMETRIC MEAN TIME TO DEATH = $(d_1 \times d_2 \dots d_n)$ where d_n is the day of death for each animal and surviving animals are assigned a value of 28 days).

VR= GMTD of experimental treated/ GMTD of PBS treated controls.

CONTRACT DAMD17-86-C-6013
SOUTHERN RESEARCH INSTITUTE
FILENAME: JE.SUM
UPDATED: 03/28/89:AJB

DISTRIBUTION LIST

4 copies	Commander U.S. Army Medical Research Institute of Infectious Diseases ATTN: SGRD-UIZ-M Fort Detrick, Frederick, MD 21702-5011
1 copy	Commander U.S. Army Medical Research and Development Command ATTN: SGRD-RMI-S Fort Detrick, Frederick, MD 21702-5012
2 copies	Defense Technical Information Center (DTIC) ATTN: DTIC-FDAC Cameron Station Alexandria, VA 22304-6145
1 copy	Dean School of Medicine Uniformed Services University of Health Sciences 4301 Jones Bridge Road Bethesda, MD 20814-4799
1 copy	Commandant Academy of Health Sciences, U.S. Army ATTN: AHS-CDM Fort Sam Houston, TX 78234-6100

**THIS REPORT HAS BEEN DELIMITED
AND CLEARED FOR PUBLIC RELEASE
UNDER DOD DIRECTIVE 5200.20 AND
NO RESTRICTIONS ARE IMPOSED UPON
ITS USE AND DISCLOSURE.**

DISTRIBUTION STATEMENT A

**APPROVED FOR PUBLIC RELEASE,
DISTRIBUTION UNLIMITED.**